data_1onb_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1onb _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.31 0.576 . . . . 0.0 109.974 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.49 ' CD1' HG21 ' A' ' 122' ' ' THR . 9.0 mt -106.0 133.3 50.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.043 -1.036 . . . . 0.0 109.901 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -85.67 128.41 34.77 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.383 -0.823 . . . . 0.0 108.946 178.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -89.21 139.24 30.69 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.026 . . . . 0.0 110.328 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.67 155.63 41.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.46 -0.775 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.09 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 110.064 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.401 HD22 ' CG2' ' A' ' 133' ' ' VAL . 9.6 tp -54.35 140.0 34.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.324 -0.86 . . . . 0.0 109.889 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.48 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 110.249 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.274 -0.891 . . . . 0.0 110.033 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.432 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 31.3 m -146.15 109.29 4.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 110.555 -179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.462 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.91 -173.9 28.7 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.294 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -107.87 -22.75 12.33 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.794 -0.827 . . . . 0.0 110.428 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.468 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -95.11 102.45 9.43 Favored Pre-proline 0 N--CA 1.486 1.345 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.695 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -61.97 139.97 82.21 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 O-C-N 123.558 1.293 . . . . 0.0 110.603 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.87 -164.08 1.45 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 111.028 -178.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.517 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.4 m-85 -58.07 81.61 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.527 -0.733 . . . . 0.0 111.221 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.05 4.99 38.2 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.406 ' O ' ' N ' ' A' ' 23' ' ' PHE . 12.5 mmtm -131.05 155.91 46.08 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.295 . . . . 0.0 109.432 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.422 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.92 107.34 16.31 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.063 -1.023 . . . . 0.0 108.918 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.468 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -68.04 114.57 21.51 Favored Pre-proline 0 C--N 1.3 -1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 110.895 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.462 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.0 Cg_endo -70.2 128.28 15.41 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 N-CA-C 106.91 -1.996 . . . . 0.0 106.91 175.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.44 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 9.8 mt -56.22 -18.51 10.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.785 -1.197 . . . . 0.0 110.867 -177.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -59.5 -16.13 22.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.632 -1.293 . . . . 0.0 110.466 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.43 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 9.3 m -91.8 -25.17 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.021 -1.049 . . . . 0.0 110.869 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.536 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 38.0 pt -118.31 -17.15 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.011 -1.056 . . . . 0.0 110.602 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.475 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 6.1 tptm -98.66 148.39 23.88 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.987 -1.07 . . . . 0.0 109.847 179.229 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.58 -6.1 33.41 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.98 -136.81 2.97 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.305 -1.426 . . . . 0.0 110.307 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -117.65 132.54 56.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -1.124 . . . . 0.0 110.43 -179.56 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.536 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.83 150.25 44.45 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.244 -0.91 . . . . 0.0 110.806 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.404 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 24.3 tp -112.16 114.73 27.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.503 -0.748 . . . . 0.0 110.023 179.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 83' ' ' VAL . 43.8 mt -97.6 127.93 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.325 -0.859 . . . . 0.0 109.972 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.418 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.34 123.03 38.65 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.217 -0.927 . . . . 0.0 109.907 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.12 21.68 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.275 -0.891 . . . . 0.0 110.702 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.517 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.7 p80 -107.12 0.46 23.47 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.483 -0.761 . . . . 0.0 110.371 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.24 137.42 44.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.944 -1.098 . . . . 0.0 110.865 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.508 ' CG ' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.51 -39.69 70.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.722 -0.611 . . . . 0.0 110.787 -179.753 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -58.6 -36.71 74.42 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 110.369 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -73.8 -34.4 64.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 109.59 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.438 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.95 73.43 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.46 -0.775 . . . . 0.0 109.461 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.48 -49.58 53.43 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.216 -0.928 . . . . 0.0 110.295 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.421 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.93 -44.38 63.72 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.288 -0.883 . . . . 0.0 110.353 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.44 ' CD1' HG13 ' A' ' 83' ' ' VAL . 2.0 tm? -56.86 -43.05 80.8 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.441 -0.787 . . . . 0.0 110.773 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.19 -51.84 14.28 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.9 -1.125 . . . . 0.0 110.656 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.69 -38.77 86.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.854 -1.154 . . . . 0.0 109.413 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.421 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 2.5 ttmm -59.38 -45.98 89.93 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.36 -0.838 . . . . 0.0 109.493 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.35 -40.28 71.05 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.418 -0.801 . . . . 0.0 109.763 179.833 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -56.41 -34.49 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.109 -0.995 . . . . 0.0 108.786 178.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.48 -31.2 60.15 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.558 -0.714 . . . . 0.0 110.093 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.466 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.0 mm? -71.22 -26.13 62.8 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.63 4.77 9.56 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.484 HG22 HG23 ' A' ' 81' ' ' VAL . 58.2 mt -108.09 143.34 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.283 -1.128 . . . . 0.0 110.034 -179.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.449 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 52.4 t30 -86.28 107.6 18.02 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 178.326 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.496 ' HB2' HD21 ' A' ' 55' ' ' LEU . . . -120.9 149.79 42.07 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.947 -1.101 . . . . 0.0 112.095 -176.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.479 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.5 t -138.3 152.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.429 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.481 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -114.45 130.81 56.74 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.076 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.444 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.51 122.24 40.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.29 -0.881 . . . . 0.0 110.441 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.508 ' CG ' ' CG ' ' A' ' 45' ' ' LYS . 3.5 p90 -156.23 176.76 12.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.592 -0.692 . . . . 0.0 109.62 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.31 125.1 16.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.064 -1.023 . . . . 0.0 110.505 -179.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.95 38.57 15.34 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.491 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -117.5 156.06 28.66 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.152 -1.205 . . . . 0.0 110.147 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.456 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 15.5 m-20 -96.68 148.96 22.34 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.322 -0.862 . . . . 0.0 110.565 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.417 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 32.4 m -62.23 110.95 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.054 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.443 ' CB ' HG12 ' A' ' 63' ' ' VAL . 12.4 m -132.62 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.398 -0.814 . . . . 0.0 110.523 -179.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.479 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 58.7 t -52.25 128.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -0.904 . . . . 0.0 110.053 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.446 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 2.0 pp . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.274 -0.891 . . . . 0.0 110.487 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 121.925 0.869 . . . . 0.0 110.176 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.1 p -116.98 134.46 60.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 122.054 0.93 . . . . 0.0 110.698 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.484 HG23 HG22 ' A' ' 60' ' ' ILE . 13.4 m -112.9 122.3 66.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.092 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.465 ' CG2' HG13 ' A' ' 73' ' ' VAL . 4.3 t -96.99 119.62 45.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.009 -1.057 . . . . 0.0 110.326 -177.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.485 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 4.5 m -111.36 100.4 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 120.997 -1.065 . . . . 0.0 108.627 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.444 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.45 162.78 34.65 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.731 -1.231 . . . . 0.0 111.602 -177.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -93.28 -136.0 0.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.524 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -86.42 46.69 1.37 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.734 -1.228 . . . . 0.0 110.623 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.13 -23.09 8.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.931 -1.106 . . . . 0.0 110.405 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.698 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.053 0.454 . . . . 0.0 111.095 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -119.69 146.66 45.39 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.086 -1.008 . . . . 0.0 109.855 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.06 -33.33 67.88 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.352 -0.843 . . . . 0.0 109.856 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -162.78 163.7 26.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.887 . . . . 0.0 111.078 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.528 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 114.56 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.312 -0.868 . . . . 0.0 109.994 178.811 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.433 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.2 114.7 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.227 -0.92 . . . . 0.0 108.608 179.061 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.418 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.11 160.17 25.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.125 -0.984 . . . . 0.0 111.798 -178.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.94 -7.39 52.24 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.86 18.79 0.55 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 112.247 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.305 -1.368 0 O-C-N 120.746 -1.221 . . . . 0.0 109.366 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 121.489 0.662 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -108.01 161.61 14.79 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.6 -0.687 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.417 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.52 -55.13 2.95 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.605 -0.684 . . . . 0.0 112.629 -178.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 11.6 m -66.31 -29.79 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 120.663 -1.273 . . . . 0.0 111.499 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.43 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.78 -57.58 5.41 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.093 -1.005 . . . . 0.0 110.555 -179.037 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.417 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.53 -33.94 77.09 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.198 -0.939 . . . . 0.0 108.819 178.631 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.1 m -60.23 -49.25 78.35 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -41.03 63.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.427 -0.796 . . . . 0.0 110.288 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.43 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.2 mpt_? -69.96 -44.13 70.12 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.049 -1.032 . . . . 0.0 110.732 -179.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.482 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 0.9 OUTLIER -54.18 -38.51 65.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.044 -1.035 . . . . 0.0 110.243 -179.863 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.93 0.06 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.466 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.9 mmt-85 -151.38 -43.55 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.952 . . . . 0.0 108.848 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.49 HG21 ' CD1' ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.49 39.25 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.522 -0.736 . . . . 0.0 109.345 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 121.76 19.86 3.28 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.622 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.462 ' N ' ' CD ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.42 81.85 4.42 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.033 -1.275 . . . . 0.0 110.034 179.821 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.49 5.39 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.473 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.611 -0.935 . . . . 0.0 108.573 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.473 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.0 Cg_endo -84.08 111.78 1.67 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.12 1.063 . . . . 0.0 109.913 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.46 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.64 168.96 54.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.5 mt -127.15 142.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.366 -1.079 . . . . 0.0 109.231 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.528 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.04 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.585 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.421 ' NE ' HG12 ' A' ' 32' ' ' VAL . 6.8 mtt85 -106.47 123.23 47.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.524 -0.735 . . . . 0.0 109.372 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.426 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.93 155.43 31.32 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.167 -0.958 . . . . 0.0 110.559 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.401 ' CG2' HD22 ' A' ' 15' ' ' LEU . 50.1 t . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.17 -0.956 . . . . 0.0 109.322 179.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 4.9 m120 . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.188 0.518 . . . . 0.0 110.399 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.449 HD12 ' CG2' ' A' ' 122' ' ' THR . 19.9 mt -107.82 135.4 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 120.946 -1.096 . . . . 0.0 110.383 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.91 128.71 34.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.519 179.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.16 131.82 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.095 -1.003 . . . . 0.0 110.099 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.444 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.7 t -126.62 158.13 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.368 -0.832 . . . . 0.0 110.258 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 108.55 20.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.253 -0.904 . . . . 0.0 109.693 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.426 ' CD2' ' HB3' ' A' ' 26' ' ' LYS . 9.7 tp -55.22 138.69 44.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.348 -0.845 . . . . 0.0 109.883 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.0 p -136.41 -179.68 5.83 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.301 -0.874 . . . . 0.0 110.55 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.306 -0.871 . . . . 0.0 109.862 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.436 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 2.6 m -147.66 113.13 5.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.334 -0.854 . . . . 0.0 110.373 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.479 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.45 -162.26 27.95 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.889 -1.624 . . . . 0.0 110.625 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.16 -22.64 7.67 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.78 -0.835 . . . . 0.0 110.497 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.465 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 10.0 tt -97.22 100.46 7.83 Favored Pre-proline 0 N--CA 1.485 1.324 0 C-N-CA 118.641 -1.224 . . . . 0.0 110.264 -179.317 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.411 ' HD2' ' HE3' ' A' ' 54' ' ' LYS . 37.0 Cg_endo -62.34 147.29 95.19 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.384 1.202 . . . . 0.0 109.649 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.587 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.8 t80 -160.84 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.189 -0.944 . . . . 0.0 111.487 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.587 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 25.9 m-85 59.13 67.32 0.93 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.425 -0.797 . . . . 0.0 111.609 178.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.48 14.35 13.54 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 41.3 mmtm -130.63 156.4 44.95 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.069 -1.254 . . . . 0.0 109.192 179.647 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.43 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.16 107.1 13.54 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.921 -1.112 . . . . 0.0 109.487 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.465 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.2 mt -71.22 113.79 22.16 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.29 -0.881 . . . . 0.0 110.156 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.479 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 39.8 Cg_endo -68.69 129.59 19.05 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 N-CA-C 106.877 -2.009 . . . . 0.0 106.877 176.363 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.435 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 8.7 mt -55.58 -19.36 9.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.867 -1.146 . . . . 0.0 110.762 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.438 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.06 24.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.753 -1.217 . . . . 0.0 110.434 179.682 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.451 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.5 m -91.99 -25.01 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.997 -1.064 . . . . 0.0 111.049 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.528 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 6.2 pt -117.6 -21.09 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.917 -1.115 . . . . 0.0 110.764 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.469 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 4.0 tptt -94.29 148.44 22.2 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.1 -1.0 . . . . 0.0 110.175 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.38 33.39 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.24 -140.43 4.85 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.113 -1.518 . . . . 0.0 110.266 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.421 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.78 131.57 55.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.319 -1.106 . . . . 0.0 110.399 -179.609 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.528 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 86.5 m-70 -139.32 151.89 46.77 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.289 -0.882 . . . . 0.0 110.701 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.464 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.3 tp -114.32 122.07 45.56 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.273 -0.892 . . . . 0.0 110.224 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.441 ' CD1' HG13 ' A' ' 83' ' ' VAL . 37.5 mt -104.23 129.51 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.248 -0.907 . . . . 0.0 109.451 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.48 123.92 38.2 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.452 -0.78 . . . . 0.0 109.934 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.81 159.18 22.73 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.198 -0.939 . . . . 0.0 110.732 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -108.25 0.4 21.36 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.394 -0.816 . . . . 0.0 110.15 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 30.2 p -136.37 141.39 43.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.523 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.83 -40.2 69.25 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.538 -0.726 . . . . 0.0 110.6 -179.842 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.88 -34.14 71.29 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.353 -0.842 . . . . 0.0 110.663 -179.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.18 -35.08 68.89 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 1.8 m -61.3 -33.9 74.34 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.455 -0.778 . . . . 0.0 109.464 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -69.15 -50.59 46.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.273 -0.892 . . . . 0.0 110.874 -179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.71 -47.11 49.88 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.133 -0.979 . . . . 0.0 110.56 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.441 ' CD1' HG11 ' A' ' 83' ' ' VAL . 2.6 tm? -56.74 -37.64 71.29 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.585 -0.697 . . . . 0.0 111.256 -178.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.23 -51.36 12.22 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.793 -1.192 . . . . 0.0 110.381 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.57 92.71 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.149 -0.969 . . . . 0.0 110.008 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.411 ' HE3' ' HD2' ' A' ' 22' ' ' PRO . 0.3 OUTLIER -57.3 -44.56 84.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.362 -0.836 . . . . 0.0 109.347 179.598 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.475 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.38 -42.91 74.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.647 -0.658 . . . . 0.0 110.12 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.2 -33.16 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.052 -1.03 . . . . 0.0 108.983 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.7 -31.48 59.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.458 -0.776 . . . . 0.0 110.057 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.465 HD23 ' N ' ' A' ' 58' ' ' LEU . 3.9 mm? -71.65 -26.36 62.51 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.302 -0.874 . . . . 0.0 109.329 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.77 5.47 9.09 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.495 HG23 HG21 ' A' ' 81' ' ' VAL . 37.6 mt -108.23 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.261 -1.14 . . . . 0.0 110.314 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.431 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.4 t30 -88.05 107.08 18.56 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.475 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.03 143.9 45.22 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.912 -1.115 . . . . 0.0 111.893 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.485 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 94.8 t -125.05 147.46 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.713 -0.617 . . . . 0.0 109.767 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.44 123.0 49.0 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.46 -0.896 . . . . 0.0 109.519 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.428 ' HB3' ' HB2' ' A' ' 84' ' ' ALA . 2.3 t80 -117.67 136.36 53.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.124 -0.985 . . . . 0.0 110.743 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.483 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.9 p90 -169.14 176.25 5.35 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.454 -0.779 . . . . 0.0 109.819 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -50.95 122.93 8.2 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 110.876 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.4 38.78 16.7 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.483 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.01 154.82 30.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.06 -1.259 . . . . 0.0 109.923 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.451 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 10.1 m-20 -94.09 149.12 21.52 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.292 -0.88 . . . . 0.0 110.557 -179.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.407 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.8 m -62.58 110.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.212 -0.995 . . . . 0.0 109.501 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.7 m -132.56 -17.54 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.561 -0.712 . . . . 0.0 110.903 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.485 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 61.2 t -65.38 141.85 17.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.146 -0.971 . . . . 0.0 109.744 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 6.0 pt . . . . . 0 N--CA 1.493 1.703 0 O-C-N 121.239 -0.913 . . . . 0.0 110.436 -179.565 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 122.072 0.939 . . . . 0.0 109.933 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.2 p -116.93 134.29 60.95 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 CA-C-O 122.125 0.964 . . . . 0.0 110.339 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.495 HG21 HG23 ' A' ' 60' ' ' ILE . 13.9 m -113.44 124.69 70.34 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.45 ' CG2' HG11 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.865 -1.147 . . . . 0.0 110.58 -177.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.494 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.4 m -112.7 100.6 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.862 -1.149 . . . . 0.0 108.305 179.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.428 ' HB2' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.73 34.7 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.886 -1.134 . . . . 0.0 111.541 -177.527 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.3 t -84.17 -126.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -101.37 40.27 1.32 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.474 -1.391 . . . . 0.0 110.211 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.444 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.72 -34.67 7.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.87 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.722 0 O-C-N 121.279 -0.888 . . . . 0.0 109.841 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 121.008 0.432 . . . . 0.0 110.567 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.498 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.15 145.71 46.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.039 -1.038 . . . . 0.0 110.161 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.495 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.53 -31.5 42.08 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.725 179.532 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.436 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 4.1 p -161.56 163.95 29.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.176 -0.953 . . . . 0.0 111.33 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.479 HG22 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.89 115.54 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.494 -0.754 . . . . 0.0 110.017 179.291 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.6 mp -93.42 112.56 26.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.165 -0.96 . . . . 0.0 108.859 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.8 161.07 19.86 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.125 -0.985 . . . . 0.0 111.765 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.441 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 15.0 t -102.98 8.31 39.0 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.735 -0.603 . . . . 0.0 109.482 178.19 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 47.09 26.16 0.6 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.155 -0.966 . . . . 0.0 111.09 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.492 1.672 0 O-C-N 121.114 -0.991 . . . . 0.0 110.516 179.633 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.421 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 121.293 0.568 . . . . 0.0 110.78 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.42 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.0 p30 -89.06 161.57 16.48 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.402 -0.811 . . . . 0.0 110.442 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.7 -53.87 3.47 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.469 -0.769 . . . . 0.0 112.375 -178.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.42 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 12.1 m -68.66 -29.5 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.608 -1.307 . . . . 0.0 111.264 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.421 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.66 -56.48 7.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.078 -1.014 . . . . 0.0 110.549 -179.268 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.415 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -67.6 -34.89 77.92 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.15 -0.969 . . . . 0.0 108.605 178.758 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 13.3 m -59.56 -49.79 76.42 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -74.02 -35.89 64.4 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.592 -0.693 . . . . 0.0 109.871 178.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.404 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 3.3 mtt85 -71.13 -44.83 64.81 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.028 -1.045 . . . . 0.0 110.71 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.482 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 2.7 ttm105 -60.42 -42.56 96.26 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.978 -1.076 . . . . 0.0 110.455 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.58 86.16 0.09 OUTLIER Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.7 -45.4 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.5 -1.0 . . . . 0.0 108.652 179.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.459 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.57 30.03 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.09 10.45 12.04 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.117 -1.516 . . . . 0.0 110.567 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 5.8 mtt180 -84.88 83.99 7.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.043 -1.269 . . . . 0.0 109.842 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.49 9.46 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 108.916 -1.674 . . . . 0.0 108.916 -179.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.503 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.74 -169.63 0.22 Allowed Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.892 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.503 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.8 Cg_endo -88.0 111.06 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 122.883 0.938 . . . . 0.0 110.047 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.459 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -76.57 150.93 38.95 Favored Glycine 0 N--CA 1.494 2.563 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.173 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.436 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.43 141.46 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -1.202 . . . . 0.0 109.139 179.251 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.482 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.89 116.46 17.2 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.882 -1.136 . . . . 0.0 110.725 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.444 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 9.6 mtt-85 -105.81 125.78 51.39 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.405 -0.809 . . . . 0.0 109.635 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.7 p90 -114.61 157.92 22.42 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.979 -1.076 . . . . 0.0 110.192 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.42 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t . . . . . 0 N--CA 1.491 1.603 0 O-C-N 121.119 -0.988 . . . . 0.0 109.984 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.35 0.595 . . . . 0.0 109.561 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.483 HD11 HG22 ' A' ' 10' ' ' ILE . 13.7 mt -96.24 130.21 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.095 -1.003 . . . . 0.0 110.153 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -84.93 129.44 34.8 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.454 -0.778 . . . . 0.0 109.686 179.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -88.42 133.04 34.22 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.024 -1.047 . . . . 0.0 109.946 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.4 HG23 HG22 ' A' ' 129' ' ' ILE . 12.0 t -126.72 158.0 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.433 -0.792 . . . . 0.0 110.469 -179.016 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.74 110.74 23.0 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.312 -0.867 . . . . 0.0 109.906 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.7 tp -56.49 140.1 47.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.766 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.9 p -135.36 170.53 15.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.17 -0.956 . . . . 0.0 110.236 -179.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.73 63.6 0.29 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.08 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.443 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.3 m -133.91 111.67 10.64 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.35 -0.844 . . . . 0.0 110.399 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.479 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.912 -1.613 . . . . 0.0 110.815 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.4 -19.15 8.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.763 -0.845 . . . . 0.0 110.366 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.504 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -96.56 113.2 62.21 Favored Pre-proline 0 N--CA 1.485 1.322 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.421 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -65.48 144.22 78.63 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.596 1.314 . . . . 0.0 109.648 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.498 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.07 98.65 1.06 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.078 -1.049 . . . . 0.0 111.634 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CD1' ' N ' ' A' ' 24' ' ' TYR . 22.7 m-85 55.45 65.24 1.53 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.292 -0.88 . . . . 0.0 111.59 178.424 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.86 14.59 10.37 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.91 156.2 45.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.075 -1.25 . . . . 0.0 108.93 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.443 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.39 106.55 14.13 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.916 -1.115 . . . . 0.0 109.465 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.504 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.9 mt -68.7 114.9 25.48 Favored Pre-proline 0 C--N 1.298 -1.663 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.018 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.479 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.3 Cg_endo -69.54 128.68 16.59 Favored 'Trans proline' 0 C--N 1.303 -1.825 0 N-CA-C 106.587 -2.12 . . . . 0.0 106.587 176.235 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.439 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 14.0 mt -55.57 -18.85 8.36 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.469 -177.375 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -59.06 -16.52 19.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.721 -1.237 . . . . 0.0 110.574 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.482 ' O ' ' CD2' ' A' ' 38' ' ' HIS . 11.0 m -92.57 -24.1 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 120.921 -1.112 . . . . 0.0 110.925 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.495 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 6.9 pt -119.44 -20.27 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.936 -1.103 . . . . 0.0 110.983 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.455 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.41 22.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.935 -1.103 . . . . 0.0 110.403 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.86 -2.85 66.96 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.66 18.0 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.025 -1.56 . . . . 0.0 110.69 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.61 132.79 52.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.479 -1.012 . . . . 0.0 110.162 -179.622 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.495 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.14 45.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 110.933 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.431 ' CD2' ' HG2' ' A' ' 121' ' ' ARG . 50.2 tp -113.29 114.44 26.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.411 -0.806 . . . . 0.0 110.241 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 83' ' ' VAL . 29.2 mt -97.31 128.79 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.021 . . . . 0.0 109.549 179.367 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -97.54 123.28 41.36 Favored 'General case' 0 C--N 1.292 -1.893 0 O-C-N 121.108 -0.995 . . . . 0.0 110.448 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.39 159.86 22.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.342 -0.849 . . . . 0.0 110.382 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.42 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 18.6 p-80 -104.73 -5.61 21.13 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.31 -0.869 . . . . 0.0 110.06 179.172 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.7 p -128.15 139.85 52.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.98 -1.075 . . . . 0.0 110.863 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.86 -39.51 69.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.636 -0.665 . . . . 0.0 110.475 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.08 -33.44 70.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.399 -0.813 . . . . 0.0 110.648 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.408 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.67 -37.08 68.02 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.349 -0.844 . . . . 0.0 109.914 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.438 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 69.7 m -62.16 -36.38 81.68 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.364 -0.835 . . . . 0.0 109.651 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.35 -50.28 64.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.027 -1.046 . . . . 0.0 110.231 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.63 -44.81 61.43 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.312 -0.867 . . . . 0.0 110.415 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.408 ' CB ' ' O ' ' A' ' 47' ' ' LYS . 3.4 tm? -61.29 -36.82 81.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.479 -0.763 . . . . 0.0 111.583 -178.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.77 -51.68 12.1 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.843 -1.161 . . . . 0.0 110.776 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.78 -38.22 78.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.036 -1.04 . . . . 0.0 109.563 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.444 ' CD ' HD11 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.11 -46.46 82.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.661 -0.649 . . . . 0.0 109.464 179.287 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.49 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.7 -40.23 72.1 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.355 -0.841 . . . . 0.0 110.131 179.897 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.5 t -59.08 -30.91 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.173 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.77 60.17 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.456 -0.778 . . . . 0.0 110.0 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.456 HD22 ' N ' ' A' ' 58' ' ' LEU . 4.4 mm? -71.27 -25.52 62.49 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.845 0.831 . . . . 0.0 109.739 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.79 7.05 8.97 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.467 HG22 HG21 ' A' ' 81' ' ' VAL . 39.4 mt -107.77 142.78 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.31 -1.112 . . . . 0.0 109.821 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.409 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 28.5 t30 -88.87 106.52 18.45 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 177.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.523 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -115.95 141.76 47.68 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.521 -177.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.462 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.97 143.17 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.704 -0.622 . . . . 0.0 110.007 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -111.34 117.82 34.17 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.366 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.435 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.28 127.12 53.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.197 -0.939 . . . . 0.0 111.07 -179.235 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.457 ' CE1' HD21 ' A' ' 69' ' ' LEU . 7.3 p90 -157.59 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.684 -0.635 . . . . 0.0 109.642 179.417 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.19 126.99 25.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.08 -1.012 . . . . 0.0 111.007 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.75 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.457 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.3 tm? -116.59 154.92 29.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.09 -1.241 . . . . 0.0 109.896 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.436 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 1.7 m-20 -94.84 149.57 21.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.345 -0.847 . . . . 0.0 110.517 -179.201 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.422 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 31.1 m -61.75 110.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 118.969 -1.092 . . . . 0.0 108.817 179.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.3 m -130.66 -34.72 1.52 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.438 -0.789 . . . . 0.0 110.283 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.462 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 90.9 t -46.86 129.83 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.457 -0.777 . . . . 0.0 109.883 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 111.18 -179.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.898 0.856 . . . . 0.0 110.343 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.5 p -117.25 133.95 62.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 CA-C-O 121.978 0.894 . . . . 0.0 110.452 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 12.6 m -112.59 122.01 65.99 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.107 0 O-C-N 121.355 -0.841 . . . . 0.0 109.01 179.118 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.421 HG21 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.54 45.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.911 -1.118 . . . . 0.0 110.726 -177.685 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.498 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.4 m -110.16 99.58 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.91 -1.116 . . . . 0.0 108.974 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.435 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -132.41 162.09 32.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.698 -1.251 . . . . 0.0 110.326 -178.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.445 HG22 ' N ' ' A' ' 86' ' ' ASP . 7.2 t -99.1 -27.91 13.62 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.161 -0.962 . . . . 0.0 110.689 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.445 ' N ' HG22 ' A' ' 85' ' ' THR . 1.3 p30 177.93 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.376 -0.827 . . . . 0.0 110.257 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.405 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -46.35 -25.57 0.67 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.266 -0.896 . . . . 0.0 110.936 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.426 ' CD1' ' CD2' ' A' ' 65' ' ' TYR . 14.7 tp . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.184 -0.948 . . . . 0.0 109.791 179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.126 0.488 . . . . 0.0 110.781 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -119.25 149.47 41.72 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -0.988 . . . . 0.0 110.01 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.416 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.6 -30.74 46.78 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.354 -0.841 . . . . 0.0 109.61 179.528 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 p -161.65 163.22 30.02 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.231 -0.918 . . . . 0.0 110.925 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.487 HG21 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.2 114.37 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.999 0 O-C-N 121.417 -0.802 . . . . 0.0 110.154 179.189 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.8 mp -93.06 112.41 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 108.523 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.416 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.82 21.2 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.103 -0.998 . . . . 0.0 111.722 -177.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.455 ' SG ' ' CE1' ' A' ' 24' ' ' TYR . 57.0 m -98.45 2.31 47.61 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.658 -0.651 . . . . 0.0 109.293 177.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 53.86 24.84 4.78 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.149 -0.97 . . . . 0.0 111.172 179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.489 1.48 0 O-C-N 121.026 -1.046 . . . . 0.0 110.923 179.907 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.403 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 4.2 pt20 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.272 0.558 . . . . 0.0 110.935 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -85.28 161.46 19.53 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.245 -0.909 . . . . 0.0 110.286 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.67 -57.94 2.13 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.605 -0.685 . . . . 0.0 112.519 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.411 HG22 ' N ' ' A' ' 114' ' ' SER . 8.1 m -67.36 -29.6 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 120.68 -1.263 . . . . 0.0 111.532 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.411 ' N ' HG22 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.54 -56.09 7.83 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.111 -0.993 . . . . 0.0 110.437 -179.286 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.44 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.16 -34.06 76.74 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.537 178.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.6 m -59.28 -48.89 79.92 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.049 -1.032 . . . . 0.0 108.404 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.1 -35.7 66.64 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.746 -0.782 . . . . 0.0 109.812 178.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.406 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.58 -45.06 66.1 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.058 -1.026 . . . . 0.0 110.463 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.482 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.1 ttm180 -59.45 -40.79 88.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.003 -1.06 . . . . 0.0 110.004 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.28 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.437 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -149.07 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.515 -0.991 . . . . 0.0 108.625 179.365 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.456 ' CG2' HD13 ' A' ' 10' ' ' ILE . 11.8 t -98.16 143.35 28.78 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.445 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 12.5 10.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.4 -1.381 . . . . 0.0 110.515 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.5 85.07 5.3 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.009 -1.289 . . . . 0.0 109.877 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.406 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 98.74 17.2 28.94 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.453 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 4.5 pttt -176.98 -177.02 0.25 Allowed Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.453 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 45.7 Cg_endo -89.01 106.93 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.118 1.062 . . . . 0.0 109.488 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.445 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.01 174.0 49.73 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.321 -179.131 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.432 HG21 HD11 ' A' ' 129' ' ' ILE . 20.3 mt -130.22 141.86 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 108.839 179.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.487 ' CD2' HG21 ' A' ' 99' ' ' VAL . 12.8 t80 -132.18 115.95 16.35 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.061 -1.024 . . . . 0.0 110.858 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.42 ' CZ ' HG12 ' A' ' 32' ' ' VAL . 0.3 OUTLIER -102.67 122.15 43.86 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -115.17 158.1 22.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.015 -1.053 . . . . 0.0 110.254 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.4 t . . . . . 0 N--CA 1.493 1.681 0 O-C-N 121.156 -0.965 . . . . 0.0 110.37 -179.881 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.12 0.486 . . . . 0.0 110.618 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.494 ' CD1' HG23 ' A' ' 122' ' ' THR . 45.0 mt -103.45 128.24 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.919 -1.113 . . . . 0.0 110.218 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.36 127.98 34.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.147 179.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.63 142.02 28.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.049 -1.032 . . . . 0.0 110.365 -179.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.418 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 4.8 t -128.97 157.7 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.481 -0.762 . . . . 0.0 109.878 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.66 112.32 25.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.248 -0.907 . . . . 0.0 110.317 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.5 tp -62.9 135.58 57.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -0.922 . . . . 0.0 109.326 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.5 p -137.15 -178.15 5.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.029 -1.045 . . . . 0.0 110.623 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.29 4.28 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.371 -0.83 . . . . 0.0 109.741 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.432 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 3.6 m -156.68 113.55 3.1 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.898 . . . . 0.0 110.589 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.468 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -168.18 28.25 Favored Glycine 0 N--CA 1.488 2.125 0 C-N-CA 118.836 -1.649 . . . . 0.0 111.081 179.18 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.42 -20.92 10.06 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.844 -0.798 . . . . 0.0 110.289 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.461 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 9.0 tt -96.78 107.76 38.92 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 118.794 -1.163 . . . . 0.0 109.757 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -64.62 126.97 17.79 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 123.353 1.186 . . . . 0.0 110.887 -178.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.3 -169.82 1.69 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.564 -0.71 . . . . 0.0 110.345 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.3 m-85 -57.4 81.15 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.488 -0.757 . . . . 0.0 111.6 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.84 -1.29 59.23 Favored Glycine 0 N--CA 1.494 2.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.757 179.427 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -129.59 156.89 43.46 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.881 -1.364 . . . . 0.0 110.047 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -104.79 106.86 17.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.062 -1.024 . . . . 0.0 108.868 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.461 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 4.8 mt -68.34 113.14 13.54 Favored Pre-proline 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 110.677 -179.169 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.468 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.5 Cg_endo -68.97 130.65 20.72 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 107.216 -1.879 . . . . 0.0 107.216 175.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.446 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 13.0 mt -56.3 -18.99 12.34 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.816 -1.178 . . . . 0.0 110.137 -178.09 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.427 ' OE2' ' CG1' ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.69 -16.15 24.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.681 -1.262 . . . . 0.0 110.437 179.687 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.447 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 17.0 m -91.76 -25.02 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.949 -1.094 . . . . 0.0 110.836 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.528 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 38.6 pt -119.4 -20.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.058 -1.026 . . . . 0.0 111.134 -178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.469 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 1.2 tptm -92.93 148.33 22.1 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.984 -1.072 . . . . 0.0 110.073 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.93 -5.32 46.44 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 -179.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.87 21.88 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.205 -1.474 . . . . 0.0 110.341 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.1 mtt-85 -97.85 133.01 42.93 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -1.028 . . . . 0.0 110.305 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.528 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.5 m-70 -140.29 149.21 42.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.21 -0.931 . . . . 0.0 110.799 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.462 HD22 ' CE2' ' A' ' 41' ' ' PHE . 26.8 tp -111.41 114.09 26.99 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.371 -0.831 . . . . 0.0 110.061 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.45 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 35.3 mt -96.68 127.76 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.192 -0.943 . . . . 0.0 109.776 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.462 ' CE2' HD22 ' A' ' 39' ' ' LEU . 14.0 m-85 -95.36 123.46 38.9 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.574 -0.704 . . . . 0.0 109.873 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.8 157.07 27.25 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.2 -0.937 . . . . 0.0 110.755 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.2 p80 -104.44 0.92 29.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.374 -0.829 . . . . 0.0 109.976 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 110.255 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 7.7 ttpt -71.63 -41.9 68.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.513 -0.742 . . . . 0.0 110.907 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.86 -33.79 72.27 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.251 -0.906 . . . . 0.0 110.812 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.48 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.27 -39.6 82.11 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.926 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.42 ' O ' ' HB1' ' A' ' 64' ' ' ALA . 66.6 m -61.16 -34.68 75.41 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.253 -0.904 . . . . 0.0 109.768 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.63 -50.36 65.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.241 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.17 53.85 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.213 -0.929 . . . . 0.0 110.377 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.441 HD21 ' CD1' ' A' ' 21' ' ' ILE . 2.6 tm? -57.03 -36.51 70.55 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.719 -0.613 . . . . 0.0 111.386 -178.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.84 -51.09 13.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.9 -1.125 . . . . 0.0 110.722 -179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.14 -39.34 89.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.072 -1.017 . . . . 0.0 109.846 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.417 ' O ' HD22 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.26 -45.77 83.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.332 -0.855 . . . . 0.0 109.586 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.32 -39.95 70.57 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.513 -0.742 . . . . 0.0 110.088 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.93 -34.84 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.118 -0.989 . . . . 0.0 108.958 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -30.81 60.64 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.435 -0.79 . . . . 0.0 110.238 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.442 HD23 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -71.6 -25.88 62.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.345 -0.847 . . . . 0.0 109.815 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.11 4.71 10.03 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.469 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 45.9 mt -107.57 143.4 18.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.362 -1.081 . . . . 0.0 109.919 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.426 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 55.6 t30 -89.46 106.85 18.72 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 106.476 -1.675 . . . . 0.0 106.476 178.065 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -117.21 143.48 45.82 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.728 -1.189 . . . . 0.0 112.316 -176.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.469 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.25 151.88 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -121.27 118.34 29.31 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.715 178.554 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.469 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -108.81 133.83 52.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.317 -0.865 . . . . 0.0 110.552 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.529 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 6.5 p90 -165.81 -173.25 2.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.473 -0.767 . . . . 0.0 110.162 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.91 125.44 23.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.224 -0.923 . . . . 0.0 110.702 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.55 29.2 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.529 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -1.167 . . . . 0.0 109.997 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.434 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.4 m-20 -97.24 149.13 22.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 110.731 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.415 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 32.9 m -62.9 110.99 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.254 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 72.8 m -131.4 -32.53 1.54 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.426 -0.796 . . . . 0.0 110.752 -179.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.469 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 99.0 t -47.83 134.55 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.44 -0.787 . . . . 0.0 110.19 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.137 -0.977 . . . . 0.0 111.12 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 121.973 0.892 . . . . 0.0 110.381 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -116.52 134.69 59.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 122.038 0.923 . . . . 0.0 109.858 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.49 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 16.5 m -112.83 123.53 68.59 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.317 -0.864 . . . . 0.0 109.555 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.462 HG23 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.95 116.46 40.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.842 -1.161 . . . . 0.0 110.595 -178.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.497 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 2.8 m -107.87 100.38 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 0.0 108.559 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.469 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -135.63 162.2 33.37 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.732 -1.23 . . . . 0.0 111.335 -177.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.3 t -91.61 -132.83 0.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.673 -0.642 . . . . 0.0 109.649 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.15 21.35 3.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.752 -1.217 . . . . 0.0 110.59 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.429 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.25 -34.91 15.59 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -0.949 . . . . 0.0 109.646 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp . . . . . 0 N--CA 1.489 1.508 0 O-C-N 121.375 -0.828 . . . . 0.0 109.592 179.461 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.157 0.503 . . . . 0.0 110.717 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -119.21 148.51 43.03 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.112 -0.993 . . . . 0.0 109.964 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.23 59.8 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.351 -0.843 . . . . 0.0 109.237 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.417 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.323 -0.861 . . . . 0.0 111.003 179.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.548 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.03 117.54 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.355 -0.841 . . . . 0.0 110.685 179.799 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.409 HG22 ' CD1' ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.12 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.74 160.71 22.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.174 -0.954 . . . . 0.0 111.517 -178.154 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.415 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 13.7 t -100.01 8.27 44.13 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.649 -0.657 . . . . 0.0 109.588 178.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.5 m120 46.89 25.95 0.52 Allowed 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.272 -0.893 . . . . 0.0 110.725 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.235 -0.915 . . . . 0.0 110.062 179.53 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.382 0.61 . . . . 0.0 110.797 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.441 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.9 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.243 -0.911 . . . . 0.0 110.294 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.16 -53.19 5.15 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.554 -0.716 . . . . 0.0 112.239 -178.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.441 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.46 -29.07 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.68 -1.263 . . . . 0.0 111.432 -178.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.427 ' N ' HG23 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.36 -56.46 6.85 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.124 -0.985 . . . . 0.0 110.486 -179.067 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.434 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 16.4 ptp180 -68.9 -35.17 76.54 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.218 -0.926 . . . . 0.0 108.635 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.9 m -59.32 -49.89 76.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.072 -1.017 . . . . 0.0 108.608 178.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -73.75 -38.54 64.7 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.498 -0.752 . . . . 0.0 110.064 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.421 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.43 -44.71 67.31 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.263 -0.898 . . . . 0.0 110.838 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.496 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 1.3 ttp180 -55.28 -48.73 73.63 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.27 -0.893 . . . . 0.0 110.507 -179.552 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.18 -18.89 1.41 Allowed Glycine 0 N--CA 1.499 2.834 0 O-C-N 121.526 -0.734 . . . . 0.0 112.343 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -56.61 -35.55 68.41 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.501 -1.588 . . . . 0.0 112.014 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.494 HG23 ' CD1' ' A' ' 10' ' ' ILE . 13.3 t -100.06 144.67 28.82 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.696 -1.252 . . . . 0.0 111.495 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.432 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.63 8.06 62.62 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.578 178.659 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.09 86.83 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.065 -1.256 . . . . 0.0 109.006 179.502 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.8 -21.44 34.2 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -178.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.488 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -138.99 -168.87 0.2 Allowed Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.386 -1.067 . . . . 0.0 109.09 179.924 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.488 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.1 Cg_endo -87.87 107.98 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.147 1.077 . . . . 0.0 110.564 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.441 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -84.52 168.36 43.92 Favored Glycine 0 N--CA 1.498 2.777 0 O-C-N 121.047 -1.033 . . . . 0.0 110.973 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.2 mt -124.87 143.24 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.548 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 10.0 t80 -130.22 121.94 27.15 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.693 -1.254 . . . . 0.0 111.771 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.418 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.25 124.38 49.67 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -123.27 155.97 36.15 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.954 -1.091 . . . . 0.0 110.888 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.415 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 16.7 t . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.369 -0.832 . . . . 0.0 109.173 178.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 18.3 m120 . . . . . 0 N--CA 1.494 1.725 0 CA-C-O 121.142 0.496 . . . . 0.0 110.316 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.465 HD11 HG22 ' A' ' 10' ' ' ILE . 25.1 mt -106.2 135.78 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.072 -1.018 . . . . 0.0 110.223 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.42 128.5 34.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.323 -0.86 . . . . 0.0 109.451 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.38 125.51 35.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.063 -1.023 . . . . 0.0 110.047 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.451 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.06 155.01 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 110.322 -179.385 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.6 110.48 22.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.603 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.416 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 11.4 tp -56.5 135.38 54.41 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.269 -0.894 . . . . 0.0 109.976 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.414 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.3 p -134.58 167.47 20.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 110.378 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.05 79.72 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.302 -0.874 . . . . 0.0 109.993 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.448 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 35.8 m -154.14 109.7 3.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.457 -0.777 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.46 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.68 -170.69 29.83 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 118.928 -1.606 . . . . 0.0 111.103 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.33 -22.14 11.5 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.716 -0.873 . . . . 0.0 110.207 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.445 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.83 25.67 Favored Pre-proline 0 N--CA 1.49 1.532 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.738 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.443 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.3 Cg_endo -64.49 131.88 31.36 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.317 1.167 . . . . 0.0 110.805 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.1 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.586 -0.696 . . . . 0.0 110.646 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.512 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 36.6 m-85 -58.04 81.46 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.397 -0.814 . . . . 0.0 111.342 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.46 47.71 Favored Glycine 0 N--CA 1.493 2.434 0 O-C-N 121.084 -1.01 . . . . 0.0 110.6 179.718 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.416 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 16.7 mmtp -130.45 156.8 44.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.957 -1.32 . . . . 0.0 109.309 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.433 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -110.43 107.77 17.56 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.94 -1.1 . . . . 0.0 109.653 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.445 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -67.76 113.57 15.25 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.388 -0.82 . . . . 0.0 110.987 -179.25 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.46 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.8 Cg_endo -69.55 127.49 14.84 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 N-CA-C 106.9 -2.0 . . . . 0.0 106.9 175.674 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.445 HD21 ' CD1' ' A' ' 60' ' ' ILE . 7.7 mt -55.84 -19.1 10.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.816 -1.178 . . . . 0.0 110.819 -177.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.406 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 15.1 pt-20 -59.86 -16.07 26.06 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.761 -1.212 . . . . 0.0 110.499 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.424 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.3 m -91.1 -25.29 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.952 -1.093 . . . . 0.0 110.967 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.55 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 41.3 pt -117.28 -16.48 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.019 -1.051 . . . . 0.0 110.616 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.464 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 3.5 tptm -96.33 148.24 22.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.873 -1.142 . . . . 0.0 110.226 179.358 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.43 -3.23 56.41 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.25 -161.35 26.61 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.934 -1.603 . . . . 0.0 110.906 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.15 128.48 44.09 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.531 -0.982 . . . . 0.0 110.521 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.55 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.56 145.11 44.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.035 -1.04 . . . . 0.0 110.771 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.487 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.6 tp -107.19 113.56 27.07 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.369 -0.832 . . . . 0.0 109.979 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.444 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 36.0 mt -96.37 129.28 46.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.251 -0.906 . . . . 0.0 109.452 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.91 123.75 38.56 Favored 'General case' 0 C--N 1.292 -1.917 0 O-C-N 121.136 -0.977 . . . . 0.0 109.74 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.69 159.74 21.79 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.193 -0.942 . . . . 0.0 111.029 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.512 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -112.3 6.83 19.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.482 -0.761 . . . . 0.0 110.057 179.002 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.9 p -138.18 137.17 37.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.028 -1.045 . . . . 0.0 110.68 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.462 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.58 -40.6 69.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.381 -0.824 . . . . 0.0 110.194 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -36.77 79.43 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 110.247 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.24 -35.64 68.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.412 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 5.5 m -60.29 -33.78 72.82 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.434 -0.791 . . . . 0.0 109.55 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.87 -49.05 61.58 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.201 -0.937 . . . . 0.0 110.432 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.64 -43.32 66.32 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.342 -0.849 . . . . 0.0 110.538 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.425 ' CD1' HG13 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.5 -41.58 76.89 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.392 -0.818 . . . . 0.0 111.008 -179.047 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.96 -51.33 12.64 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.988 -1.07 . . . . 0.0 110.58 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.59 -42.05 98.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.87 -1.144 . . . . 0.0 109.594 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.443 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.8 OUTLIER -57.68 -46.08 84.77 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.86 . . . . 0.0 109.882 179.71 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.494 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.04 -41.51 71.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.473 -0.767 . . . . 0.0 109.607 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.4 t -56.08 -31.19 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.068 -1.02 . . . . 0.0 108.61 178.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.55 -32.92 60.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.561 -0.712 . . . . 0.0 109.97 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.458 HD22 ' N ' ' A' ' 58' ' ' LEU . 4.2 mm? -71.92 -25.87 62.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.313 -0.867 . . . . 0.0 109.512 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.0 7.32 8.62 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.464 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 34.6 mt -108.83 143.25 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.416 -1.05 . . . . 0.0 110.303 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.432 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.0 t-20 -86.43 107.0 17.85 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.018 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.494 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.52 143.91 48.32 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.428 -177.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.49 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.5 t -132.11 150.8 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.848 -0.741 . . . . 0.0 109.176 179.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.41 126.51 55.42 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.102 179.37 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.454 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 7.4 t80 -118.26 122.56 43.25 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.231 -0.918 . . . . 0.0 110.401 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.478 ' CE1' HD22 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.76 8.19 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.628 179.643 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.93 125.24 14.73 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.167 -0.958 . . . . 0.0 110.985 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.11 44.69 22.52 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.32 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.478 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.72 156.48 28.19 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.089 -1.242 . . . . 0.0 110.127 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.453 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 6.7 m-20 -94.51 148.98 21.7 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.283 -0.886 . . . . 0.0 110.723 -179.361 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.421 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.9 m -62.42 111.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.229 -0.989 . . . . 0.0 109.288 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.44 ' CB ' HG11 ' A' ' 63' ' ' VAL . 6.9 m -133.65 -32.63 1.12 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.988 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.49 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 30.3 t -56.01 138.73 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.194 -0.941 . . . . 0.0 109.949 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.406 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.2 pp . . . . . 0 N--CA 1.496 1.829 0 O-C-N 121.108 -0.995 . . . . 0.0 111.131 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.938 0.875 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.446 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -117.3 133.92 62.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-O 121.961 0.886 . . . . 0.0 110.351 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.471 HG23 ' CB ' ' A' ' 62' ' ' ALA . 7.8 m -112.67 123.82 68.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 178.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG2' HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.76 116.46 38.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.1 -1.0 . . . . 0.0 110.353 -177.766 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.483 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.8 m -108.97 100.22 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.771 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.454 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.78 162.98 34.13 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.732 -1.23 . . . . 0.0 111.114 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.3 t -92.04 -130.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.537 -0.727 . . . . 0.0 109.47 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.98 34.83 0.91 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.713 -1.242 . . . . 0.0 110.226 179.534 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.405 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 0.0 110.356 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.132 -0.98 . . . . 0.0 109.099 179.401 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 120.761 0.315 . . . . 0.0 110.489 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.487 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.51 152.19 38.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.872 -1.143 . . . . 0.0 110.778 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.421 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.56 -28.79 19.35 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.567 -0.708 . . . . 0.0 109.363 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.3 p -161.0 163.77 31.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.34 -0.85 . . . . 0.0 110.758 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.75 119.18 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.251 -0.905 . . . . 0.0 110.292 179.578 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 131' ' ' ARG . 37.9 mm -95.9 111.26 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 108.859 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -118.89 161.06 20.81 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.913 -1.117 . . . . 0.0 111.73 -178.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.454 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.3 p -99.96 -0.33 39.6 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 50.52 18.63 0.47 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.341 -0.85 . . . . 0.0 112.175 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.305 -1.349 0 O-C-N 120.729 -1.232 . . . . 0.0 109.407 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.644 0.735 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.405 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.8 p30 -102.68 161.56 13.63 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.544 -0.723 . . . . 0.0 110.327 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.28 -56.55 2.9 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.576 -0.702 . . . . 0.0 112.376 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.405 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -64.21 -29.87 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.702 -1.249 . . . . 0.0 111.255 -178.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.404 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -47.73 -56.32 7.61 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.116 -0.99 . . . . 0.0 110.505 -179.209 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.76 -33.77 76.36 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.159 -0.963 . . . . 0.0 108.851 178.91 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.5 m -60.93 -50.16 74.54 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.061 -1.025 . . . . 0.0 108.357 178.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.96 -38.71 64.13 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 114' ' ' SER . 45.1 mtt-85 -71.85 -44.37 63.94 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.258 -0.901 . . . . 0.0 111.321 -179.181 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.468 ' O ' ' N ' ' A' ' 121' ' ' ARG . 6.9 ttp180 -62.12 -40.42 95.85 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.917 -1.114 . . . . 0.0 110.244 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.4 75.26 0.04 OUTLIER Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.468 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -149.05 -47.35 0.14 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.43 -1.041 . . . . 0.0 108.76 179.599 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.445 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.1 t -96.19 143.47 27.27 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.437 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.76 17.82 4.55 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.409 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -91.75 82.8 5.22 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.117 -1.225 . . . . 0.0 109.986 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.92 -31.74 4.84 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.477 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.18 -169.74 0.22 Allowed Pre-proline 0 C--N 1.301 -1.514 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 179.509 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.477 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.5 Cg_endo -85.31 115.0 1.59 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 122.916 0.956 . . . . 0.0 110.466 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.445 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.29 51.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 98' ' ' SER . 5.1 mt -119.99 140.13 45.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.039 -1.271 . . . . 0.0 109.051 179.267 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -122.7 114.49 20.65 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 118.965 -1.094 . . . . 0.0 110.218 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.445 ' HB2' ' CD1' ' A' ' 100' ' ' ILE . 24.2 mtt180 -108.12 126.87 53.27 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.594 -0.692 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.451 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.8 p90 -126.95 156.94 40.72 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.078 -1.014 . . . . 0.0 110.847 -179.131 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 7.0 t . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.319 -0.863 . . . . 0.0 108.978 178.81 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 . . . . . 0 N--CA 1.496 1.851 0 CA-C-O 121.574 0.702 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.449 HD13 ' CG2' ' A' ' 122' ' ' THR . 20.0 mt -105.8 132.99 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.442 -0.786 . . . . 0.0 109.117 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.5 33.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.054 -1.028 . . . . 0.0 109.302 179.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.54 126.43 35.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.176 -0.952 . . . . 0.0 110.021 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.461 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 6.4 t -116.14 154.52 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.334 -0.853 . . . . 0.0 110.4 -179.221 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.88 105.04 15.34 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.339 -0.851 . . . . 0.0 109.639 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.434 HD22 ' CB ' ' A' ' 26' ' ' LYS . 12.1 tp -55.43 132.34 48.08 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.412 -0.805 . . . . 0.0 109.82 -179.828 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.408 ' O ' ' N ' ' A' ' 18' ' ' THR . 70.5 p -135.83 172.29 13.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.212 -0.93 . . . . 0.0 110.314 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.91 78.28 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.22 -0.925 . . . . 0.0 110.202 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.435 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 26.0 m -151.31 108.54 3.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.206 -0.934 . . . . 0.0 110.687 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.451 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.037 -1.554 . . . . 0.0 110.747 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.32 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.649 -0.912 . . . . 0.0 110.326 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.487 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.8 tt -100.53 104.24 29.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.314 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.417 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -62.94 148.7 93.17 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.338 1.178 . . . . 0.0 109.894 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.533 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.26 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.174 -0.954 . . . . 0.0 111.127 -178.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.5 m-85 59.15 66.78 0.99 Allowed 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.406 -0.809 . . . . 0.0 111.332 179.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.87 15.0 11.11 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.448 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.62 156.98 43.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.057 -1.261 . . . . 0.0 109.121 179.524 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.2 107.28 14.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.883 -1.135 . . . . 0.0 109.69 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.487 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.6 mt -69.98 114.33 24.4 Favored Pre-proline 0 C--N 1.3 -1.553 0 C-N-CA 119.614 -0.835 . . . . 0.0 109.926 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.451 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.6 Cg_endo -69.01 129.72 18.92 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 N-CA-C 107.047 -1.943 . . . . 0.0 107.047 176.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.447 HD22 HG21 ' A' ' 21' ' ' ILE . 12.9 mt -56.52 -16.92 6.8 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.78 -1.2 . . . . 0.0 110.976 -177.495 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.442 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.03 -15.89 47.83 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.799 -1.188 . . . . 0.0 110.242 179.427 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.437 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 12.8 m -92.6 -25.14 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.986 -1.071 . . . . 0.0 111.212 -179.215 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.524 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 12.0 pt -120.47 -23.25 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.99 -1.069 . . . . 0.0 110.804 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.476 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.04 147.9 22.6 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.954 -1.092 . . . . 0.0 110.692 -179.872 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.413 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.63 -3.48 57.65 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.95 -155.73 13.6 Favored Glycine 0 N--CA 1.494 2.542 0 C-N-CA 119.008 -1.567 . . . . 0.0 110.705 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.415 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.98 131.12 52.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.413 -1.051 . . . . 0.0 110.092 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.524 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.4 m-70 -140.83 152.38 45.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 111.07 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.0 tp -112.27 115.67 29.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.361 -0.837 . . . . 0.0 110.321 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' A' ' 83' ' ' VAL . 29.6 mt -100.34 128.59 52.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 109.823 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.46 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.04 123.66 40.84 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.098 -1.001 . . . . 0.0 110.054 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.52 159.59 21.03 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.278 -0.889 . . . . 0.0 110.55 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.577 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.63 5.11 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.362 -0.836 . . . . 0.0 110.006 179.076 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.08 135.95 37.93 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.127 -0.983 . . . . 0.0 110.607 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.486 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.51 -31.31 66.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.546 -0.721 . . . . 0.0 110.395 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.06 -30.0 66.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.357 -0.84 . . . . 0.0 110.198 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.1 -36.98 66.87 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.394 -0.816 . . . . 0.0 109.649 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.455 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.3 82.33 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.53 -49.9 73.5 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.103 -0.998 . . . . 0.0 109.955 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.65 -47.01 51.09 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.328 -0.858 . . . . 0.0 110.348 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.42 ' CD1' HG11 ' A' ' 83' ' ' VAL . 1.9 tm? -56.53 -40.08 74.48 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.51 -0.744 . . . . 0.0 110.772 -179.298 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.36 13.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.078 -1.014 . . . . 0.0 110.179 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.34 -42.21 98.31 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 109.798 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.417 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -57.42 -45.25 84.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.459 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.466 HD21 HG22 ' A' ' 81' ' ' VAL . 0.2 OUTLIER -55.08 -42.12 72.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.541 -0.725 . . . . 0.0 109.614 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.5 t -56.08 -33.33 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 109.097 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.64 -31.36 59.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.408 -0.807 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.446 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.1 mm? -71.21 -26.39 62.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.339 -0.85 . . . . 0.0 109.456 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.24 5.39 8.75 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.476 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 67.9 mt -108.15 143.83 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -1.106 . . . . 0.0 110.358 -179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.413 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.72 106.48 18.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 177.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -116.47 142.87 46.3 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.883 -177.029 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.472 ' CG1' ' CG2' ' A' ' 73' ' ' VAL . 84.0 t -122.97 148.81 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -115.48 117.17 29.63 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.256 178.226 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.437 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.88 135.37 49.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.294 -0.878 . . . . 0.0 111.02 -179.235 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.53 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 15.4 p90 -167.95 177.36 5.69 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.522 -0.736 . . . . 0.0 109.853 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.1 ttp-105 -51.56 126.06 16.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.07 -1.018 . . . . 0.0 110.683 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.88 45.11 22.44 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.53 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.28 153.61 32.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.04 -1.271 . . . . 0.0 109.836 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.445 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 15.9 m-20 -91.2 149.46 21.77 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.297 -0.877 . . . . 0.0 110.608 -179.242 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.419 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 33.9 m -62.42 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.125 179.096 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 15.0 m -133.9 -34.37 1.01 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.445 -0.785 . . . . 0.0 110.843 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.472 ' CG2' ' CG1' ' A' ' 63' ' ' VAL . 92.4 t -49.43 129.47 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.098 -1.001 . . . . 0.0 110.106 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.1 pp . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.11 -0.994 . . . . 0.0 110.996 -179.899 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 122.103 0.954 . . . . 0.0 110.241 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.425 ' O ' HG12 ' A' ' 80' ' ' VAL . 7.2 p -116.89 135.23 57.91 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 CA-C-O 121.966 0.889 . . . . 0.0 109.912 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.49 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 13.7 m -112.62 124.6 69.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 O-C-N 121.282 -0.886 . . . . 0.0 109.373 179.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.45 HG21 ' CG1' ' A' ' 73' ' ' VAL . 13.1 t -97.19 119.14 44.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 O-C-N 120.955 -1.091 . . . . 0.0 110.383 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.493 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.3 m -111.9 99.27 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.015 -1.074 . . . . 0.0 108.771 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.431 ' HB1' ' CB ' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.22 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.587 -1.321 . . . . 0.0 110.811 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.05 -28.56 17.88 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.345 -0.847 . . . . 0.0 110.71 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.89 -31.3 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.079 -1.013 . . . . 0.0 110.762 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.411 ' CB ' ' CA ' ' A' ' 66' ' ' TYR . . . -46.95 -37.55 9.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.259 -0.901 . . . . 0.0 111.099 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.45 ' CD1' HG22 ' A' ' 73' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.738 0 O-C-N 121.145 -0.972 . . . . 0.0 110.7 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.217 0.532 . . . . 0.0 110.186 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -119.77 152.75 36.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.208 -0.932 . . . . 0.0 110.167 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -84.83 -29.26 25.48 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.505 -0.747 . . . . 0.0 109.735 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.7 p -161.18 163.47 31.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.166 -0.959 . . . . 0.0 110.843 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.29 116.32 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.298 -0.876 . . . . 0.0 109.963 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.43 ' CD1' HG21 ' A' ' 33' ' ' ILE . 4.2 mp -94.61 111.3 25.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.07 -1.019 . . . . 0.0 108.974 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -114.4 161.07 18.42 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.149 -0.97 . . . . 0.0 111.732 -178.369 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.32 9.65 35.81 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.406 ' O ' ' HG2' ' A' ' 110' ' ' GLN . 2.7 m120 46.19 27.29 0.53 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.279 -0.888 . . . . 0.0 110.963 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.488 1.446 0 O-C-N 121.188 -0.945 . . . . 0.0 110.469 179.864 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.406 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.571 0.701 . . . . 0.0 111.205 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -100.52 161.78 13.37 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.556 -0.715 . . . . 0.0 110.111 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.433 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.46 -61.56 1.03 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.476 -0.765 . . . . 0.0 112.108 -178.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.406 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.79 -28.87 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.71 -1.244 . . . . 0.0 111.435 -178.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.423 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -47.69 -57.19 5.83 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.893 -1.13 . . . . 0.0 110.932 -178.732 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.433 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.46 -34.63 78.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.02 -1.05 . . . . 0.0 108.525 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 49.6 m -59.84 -48.87 79.95 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.28 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.59 -40.1 64.13 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.513 -0.742 . . . . 0.0 110.126 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.46 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.48 -44.61 70.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.984 -1.073 . . . . 0.0 110.31 -179.687 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.449 ' O ' ' N ' ' A' ' 121' ' ' ARG . 41.9 ttp180 -61.54 -36.08 79.58 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.047 -1.033 . . . . 0.0 109.315 179.184 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.05 66.67 0.34 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.7 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.462 -1.022 . . . . 0.0 108.848 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.455 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 12.3 t -92.12 142.45 27.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.335 -0.853 . . . . 0.0 108.931 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.58 17.07 2.95 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.269 -1.444 . . . . 0.0 110.605 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -95.11 82.37 3.77 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.986 -1.303 . . . . 0.0 110.002 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.39 -51.46 0.76 Allowed Glycine 0 N--CA 1.493 2.483 0 N-CA-C 108.412 -1.875 . . . . 0.0 108.412 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.449 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.84 166.36 21.72 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.3 Cg_endo -63.59 117.73 4.68 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.299 1.157 . . . . 0.0 110.128 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.455 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.85 172.24 54.78 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.447 ' N ' HG23 ' A' ' 122' ' ' THR . 5.1 mt -126.15 142.06 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.301 -1.117 . . . . 0.0 108.989 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 10.5 t80 -131.13 115.19 16.06 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.292 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.406 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 5.9 mtp180 -99.78 147.71 25.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.497 -0.752 . . . . 0.0 109.365 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.47 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 25.1 p90 -138.14 150.36 46.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.085 -1.01 . . . . 0.0 110.212 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 34.5 t . . . . . 0 N--CA 1.492 1.666 0 O-C-N 121.129 -0.982 . . . . 0.0 109.448 179.454 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.442 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.9 t-20 . . . . . 0 N--CA 1.493 1.682 0 CA-C-O 121.461 0.648 . . . . 0.0 109.627 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.454 HD12 ' NH1' ' A' ' 119' ' ' ARG . 16.5 mt -106.81 132.43 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.001 -1.062 . . . . 0.0 109.518 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.87 127.26 33.71 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.134 -0.979 . . . . 0.0 109.278 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.66 128.5 36.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.16 -0.962 . . . . 0.0 110.003 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.418 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.49 158.04 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.404 -0.81 . . . . 0.0 110.176 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.98 110.94 21.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.752 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.412 ' O ' ' NZ ' ' A' ' 26' ' ' LYS . 12.7 tp -53.45 134.5 40.44 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.319 -0.863 . . . . 0.0 110.329 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.6 p -135.49 177.76 7.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 110.142 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.33 65.31 0.42 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.225 -0.922 . . . . 0.0 109.951 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.444 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 22.1 m -137.1 110.57 7.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.339 -0.851 . . . . 0.0 110.353 -179.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.455 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.0 -163.89 27.98 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.76 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.72 -21.02 7.43 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.675 -0.897 . . . . 0.0 110.327 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.464 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.3 tt -96.79 108.66 44.44 Favored Pre-proline 0 N--CA 1.488 1.458 0 C-N-CA 118.668 -1.213 . . . . 0.0 110.204 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.411 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.6 Cg_endo -65.48 149.77 87.49 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 O-C-N 123.444 1.234 . . . . 0.0 110.296 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.517 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.3 t80 -169.04 108.21 0.45 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 110.977 -178.778 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.478 ' OH ' ' CE1' ' A' ' 43' ' ' HIS . 17.6 m-85 56.25 60.69 3.05 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.234 -0.916 . . . . 0.0 111.171 179.209 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.97 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.517 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.49 157.28 43.1 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.128 -1.219 . . . . 0.0 109.064 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -115.79 107.27 14.83 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.811 -1.181 . . . . 0.0 110.239 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.464 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.4 mt -68.29 114.5 21.77 Favored Pre-proline 0 C--N 1.301 -1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.455 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.6 Cg_endo -69.16 128.39 16.5 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 N-CA-C 106.579 -2.123 . . . . 0.0 106.579 175.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.429 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 11.0 mt -55.82 -17.62 6.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.673 -1.267 . . . . 0.0 111.09 -177.216 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -59.63 -15.98 22.83 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.677 -1.264 . . . . 0.0 110.667 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.4 m -91.37 -25.38 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.024 -1.048 . . . . 0.0 111.187 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.501 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 25.0 pt -119.84 -16.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.96 -1.087 . . . . 0.0 110.65 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.468 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 1.9 tptt -98.8 147.86 24.49 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.769 -1.207 . . . . 0.0 110.046 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.84 -5.39 50.63 Favored Glycine 0 N--CA 1.485 1.911 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.35 -151.17 9.52 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.081 -1.533 . . . . 0.0 110.561 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.03 131.92 53.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.43 -1.041 . . . . 0.0 110.371 -179.409 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.501 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 95.6 m-70 -138.44 151.53 47.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.172 -0.955 . . . . 0.0 110.95 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 45.9 tp -111.58 119.29 38.24 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.766 . . . . 0.0 110.025 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.457 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 31.6 mt -103.86 126.26 58.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.295 -0.878 . . . . 0.0 109.155 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.96 123.79 38.63 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.177 -0.952 . . . . 0.0 110.329 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.28 160.13 21.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.425 -0.797 . . . . 0.0 110.668 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.478 ' CE1' ' OH ' ' A' ' 24' ' ' TYR . 5.4 p-80 -105.16 -4.73 21.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.337 -0.852 . . . . 0.0 110.426 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.423 ' HB3' ' CD2' ' A' ' 43' ' ' HIS . 66.4 p -136.14 145.8 46.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.01 -1.056 . . . . 0.0 111.235 -179.413 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 23.7 tttt -72.08 -40.92 67.91 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.673 -0.642 . . . . 0.0 110.669 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.77 -34.98 72.04 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.139 -0.976 . . . . 0.0 110.684 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.403 ' HA ' ' HD3' ' A' ' 47' ' ' LYS . 12.3 tppt? -71.6 -40.42 69.86 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.077 -1.014 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.453 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 67.3 m -61.83 -37.15 83.37 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 110.06 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.98 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.949 -1.094 . . . . 0.0 110.577 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.28 -44.2 63.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.174 -0.954 . . . . 0.0 110.229 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.452 ' CD1' HG12 ' A' ' 83' ' ' VAL . 1.7 tm? -56.58 -42.12 78.1 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.489 -0.757 . . . . 0.0 111.198 -179.102 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.35 -50.88 16.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.897 -1.127 . . . . 0.0 110.375 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.38 -42.09 98.15 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.118 -0.989 . . . . 0.0 109.798 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.432 ' O ' HD21 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.98 -45.78 86.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.901 . . . . 0.0 109.788 179.703 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.493 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -54.54 -42.31 70.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.453 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.5 t -56.79 -30.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.122 -0.986 . . . . 0.0 108.591 178.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.56 -33.93 60.67 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.597 -0.689 . . . . 0.0 110.021 179.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.44 HD22 ' N ' ' A' ' 58' ' ' LEU . 4.4 mm? -71.48 -25.73 62.4 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.82 0.819 . . . . 0.0 109.556 179.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.56 7.34 9.0 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.468 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 40.1 mt -108.01 143.31 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.324 -1.103 . . . . 0.0 109.977 -179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.415 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 38.2 t30 -87.2 107.08 18.32 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.493 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.91 145.11 48.02 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.409 -177.576 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.499 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 6.7 t -133.02 143.1 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.589 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -107.16 123.45 48.28 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.824 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.473 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.17 119.06 36.47 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.335 -0.853 . . . . 0.0 110.387 -179.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.516 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 6.8 p90 -146.74 174.48 11.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.608 -0.683 . . . . 0.0 109.753 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.6 5.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.161 -0.962 . . . . 0.0 110.803 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.02 35.73 9.58 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.516 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.0 tm? -117.17 155.84 28.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 110.079 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.457 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 37.1 m-20 -95.37 149.42 21.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.333 -0.854 . . . . 0.0 110.248 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.408 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 27.2 m -61.81 110.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.176 179.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 m -132.04 -20.82 2.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.486 -0.759 . . . . 0.0 111.068 -179.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.499 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.88 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 109.302 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.422 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.496 1.85 0 O-C-N 121.241 -0.912 . . . . 0.0 110.969 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.965 0.888 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.6 p -117.47 134.58 60.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.074 0.94 . . . . 0.0 110.359 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.466 HG22 ' CB ' ' A' ' 62' ' ' ALA . 5.7 m -113.28 124.67 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 O-C-N 121.413 -0.805 . . . . 0.0 108.901 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.495 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.91 45.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 121.159 -0.963 . . . . 0.0 110.049 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.8 m -114.48 100.98 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.07 -1.019 . . . . 0.0 108.594 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.473 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.37 164.22 32.16 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.725 -1.234 . . . . 0.0 111.796 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.4 t -94.28 -147.2 0.26 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.671 -0.643 . . . . 0.0 109.42 179.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.15 -15.3 56.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.964 -1.085 . . . . 0.0 110.235 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -49.32 -44.64 44.49 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.038 -1.039 . . . . 0.0 110.257 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 108.985 179.101 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.11 0.481 . . . . 0.0 110.492 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -119.92 147.93 44.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.937 -1.102 . . . . 0.0 110.303 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.459 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.43 -28.77 56.75 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.409 -0.807 . . . . 0.0 110.127 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.428 ' OG ' ' ND1' ' A' ' 38' ' ' HIS . 5.2 p -160.38 163.58 33.05 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.256 -0.903 . . . . 0.0 110.752 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.9 117.86 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.332 -0.855 . . . . 0.0 110.563 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.444 HD12 ' N ' ' A' ' 100' ' ' ILE . 4.6 mp -98.24 110.86 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.16 158.88 25.05 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.992 . . . . 0.0 111.773 -178.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.84 3.67 53.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.423 ' CA ' ' OE1' ' A' ' 110' ' ' GLN . 3.2 m-20 52.88 27.72 5.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.239 -0.913 . . . . 0.0 111.087 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.488 1.455 0 O-C-N 121.11 -0.994 . . . . 0.0 110.24 179.361 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.46 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.195 0.522 . . . . 0.0 110.998 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.427 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.8 p30 -99.7 160.77 14.05 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.28 179.674 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.31 -53.47 5.21 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.438 -0.789 . . . . 0.0 112.286 -178.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.427 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.8 m -69.75 -29.42 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 120.83 -1.169 . . . . 0.0 111.525 -178.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.427 ' N ' HG22 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.31 -56.52 6.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.07 -1.019 . . . . 0.0 110.625 -179.114 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 ptm180 -69.07 -34.69 75.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.296 -0.877 . . . . 0.0 108.819 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.402 ' O ' ' NH2' ' A' ' 119' ' ' ARG . 25.8 m -59.52 -49.79 76.42 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.68 -37.53 65.2 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.451 -0.781 . . . . 0.0 110.056 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.409 ' HB2' ' O ' ' A' ' 114' ' ' SER . 36.3 mtt-85 -71.89 -45.63 60.61 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.209 -0.932 . . . . 0.0 111.719 -179.234 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.454 ' NH1' HD12 ' A' ' 10' ' ' ILE . 27.6 ttp85 -59.34 -51.65 69.02 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.091 -1.006 . . . . 0.0 109.917 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.429 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.4 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -179.265 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -45.73 -33.21 2.87 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.283 -1.128 . . . . 0.0 111.632 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.441 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.9 t -100.65 144.12 30.01 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.884 -1.135 . . . . 0.0 110.884 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.97 14.54 24.51 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.389 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.429 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.59 84.23 0.61 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -1.201 . . . . 0.0 109.794 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.53 -26.34 13.34 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.903 -1.679 . . . . 0.0 108.903 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.497 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.96 -168.7 0.19 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.495 -1.003 . . . . 0.0 108.669 179.653 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.497 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.0 Cg_endo -87.32 110.95 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.14 1.074 . . . . 0.0 110.7 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.441 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -82.42 170.57 50.7 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 49.1 mt -126.48 142.64 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.516 -0.991 . . . . 0.0 108.416 178.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -128.77 114.75 16.97 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.721 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.418 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 18.2 mtp180 -105.27 122.88 46.86 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.41 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 32.0 p90 -121.72 158.06 29.58 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 110.662 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 32.1 t . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.238 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.409 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 . . . . . 0 N--CA 1.496 1.827 0 CA-C-O 120.971 0.415 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.434 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 30.3 mt -129.0 137.28 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.867 -1.146 . . . . 0.0 109.707 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -82.75 127.81 33.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.056 -1.028 . . . . 0.0 109.207 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.89 139.32 30.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.3 -0.875 . . . . 0.0 110.553 -179.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.471 ' CG1' ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.75 156.55 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.215 -0.928 . . . . 0.0 110.14 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.34 109.86 21.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -0.889 . . . . 0.0 110.109 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.469 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.77 141.88 36.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 109.311 179.456 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.33 174.57 10.62 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 110.548 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.58 0.99 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.325 -0.86 . . . . 0.0 110.276 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.432 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 26.9 m -155.68 109.32 2.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.174 -0.954 . . . . 0.0 110.482 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.462 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.49 -171.35 28.89 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.891 -1.623 . . . . 0.0 111.181 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.54 -22.59 11.57 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.722 -0.87 . . . . 0.0 110.45 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.462 ' O ' HG23 ' A' ' 21' ' ' ILE . 9.9 tt -95.26 107.12 30.31 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 118.872 -1.131 . . . . 0.0 109.455 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.84 144.67 89.15 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.249 1.131 . . . . 0.0 111.34 -178.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.421 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.73 -166.37 1.85 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.522 -0.736 . . . . 0.0 110.318 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.572 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.8 m-85 -59.92 82.03 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.403 -0.811 . . . . 0.0 111.051 -179.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.4 5.85 51.49 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.469 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 14.4 mmtm -130.64 156.68 44.47 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.941 -1.329 . . . . 0.0 109.778 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.432 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.64 16.77 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.062 -1.024 . . . . 0.0 109.106 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.462 ' O ' HG23 ' A' ' 21' ' ' ILE . 6.2 mt -69.12 114.16 21.57 Favored Pre-proline 0 C--N 1.299 -1.596 0 O-C-N 121.367 -0.833 . . . . 0.0 110.798 -179.081 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.462 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.2 Cg_endo -69.73 132.12 22.72 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.13 -1.912 . . . . 0.0 107.13 176.164 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.446 HD22 ' CD1' ' A' ' 60' ' ' ILE . 13.2 mt -56.95 -14.95 4.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.961 -1.087 . . . . 0.0 111.219 -177.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -63.31 -16.16 59.5 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.539 -1.351 . . . . 0.0 110.51 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.43 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 10.6 m -93.86 -24.44 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.052 -1.03 . . . . 0.0 110.87 -179.406 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.512 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 48.3 pt -117.16 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.035 -1.041 . . . . 0.0 110.493 -179.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.455 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.98 148.41 24.56 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -0.903 . . . . 0.0 110.501 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.74 -5.17 46.99 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.27 -147.68 7.79 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.428 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.8 132.5 53.93 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.406 -1.055 . . . . 0.0 110.473 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.2 m-70 -140.77 149.0 41.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 0.0 110.603 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.51 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 57.3 tp -111.0 113.59 26.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.441 -0.787 . . . . 0.0 109.803 179.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.433 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 29.2 mt -96.41 127.38 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.882 . . . . 0.0 109.662 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.51 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.2 m-85 -95.08 122.72 38.03 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.295 -0.878 . . . . 0.0 110.251 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.04 160.16 21.98 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.339 -0.85 . . . . 0.0 110.733 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.572 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p-80 -110.01 4.65 21.55 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.396 -0.815 . . . . 0.0 109.964 178.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.52 136.41 49.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 110.987 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.84 69.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.645 -0.66 . . . . 0.0 110.861 -179.866 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.74 -36.75 73.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.28 -0.888 . . . . 0.0 110.917 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.13 -35.39 80.36 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.313 -0.867 . . . . 0.0 109.574 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.419 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 53.2 m -61.48 -33.83 74.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.511 -0.743 . . . . 0.0 109.764 179.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.19 -50.22 61.77 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.283 -0.886 . . . . 0.0 110.967 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.22 -44.11 63.44 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.119 -0.988 . . . . 0.0 110.569 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.442 ' CD1' HG12 ' A' ' 83' ' ' VAL . 2.6 tm? -56.99 -38.35 72.91 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.562 -0.711 . . . . 0.0 111.242 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.62 -51.15 13.49 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.871 -1.143 . . . . 0.0 110.633 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.46 -40.04 85.58 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.146 -0.971 . . . . 0.0 110.145 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.458 ' CE ' HD22 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.04 82.99 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.318 -0.864 . . . . 0.0 109.788 179.739 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.484 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.07 -38.92 71.29 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.643 -0.661 . . . . 0.0 110.093 179.818 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.3 t -58.62 -34.38 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.185 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.29 -30.66 60.47 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.436 -0.79 . . . . 0.0 109.965 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.508 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.1 mm? -72.01 -25.71 61.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.437 -0.789 . . . . 0.0 109.773 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.9 10.3 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.468 HG22 HG22 ' A' ' 81' ' ' VAL . 45.9 mt -108.03 143.23 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.298 -1.119 . . . . 0.0 109.75 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.413 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 51.8 t30 -89.84 106.39 18.44 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -116.18 142.59 46.62 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.729 -177.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.488 ' HB ' HG22 ' A' ' 73' ' ' VAL . 57.4 t -125.56 149.41 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 120.139 -0.624 . . . . 0.0 109.701 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.476 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -116.69 119.05 34.25 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.433 178.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.457 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.42 132.72 55.52 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.216 -0.927 . . . . 0.0 110.839 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.482 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 3.5 p90 -166.93 176.85 6.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.569 -0.707 . . . . 0.0 109.719 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.15 125.35 15.44 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.069 -1.02 . . . . 0.0 110.707 -179.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.7 37.4 19.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.432 ' CD1' ' O ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.44 157.24 26.57 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.031 -1.276 . . . . 0.0 110.12 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.432 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.8 m-20 -96.53 149.23 21.98 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.29 -0.881 . . . . 0.0 110.555 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.427 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 30.3 m -62.66 111.37 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.193 -0.942 . . . . 0.0 109.121 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.82 -35.39 1.09 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.389 -0.819 . . . . 0.0 110.733 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.488 HG22 ' HB ' ' A' ' 63' ' ' VAL . 59.6 t -48.41 120.37 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.391 -0.818 . . . . 0.0 110.294 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.454 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.494 1.762 0 O-C-N 121.235 -0.916 . . . . 0.0 110.608 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.813 0.816 . . . . 0.0 110.182 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.2 p -116.92 135.56 56.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-O 122.151 0.977 . . . . 0.0 110.568 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 11.9 m -112.88 119.94 61.72 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.072 0 O-C-N 121.228 -0.92 . . . . 0.0 108.844 178.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.435 ' CG2' HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.84 45.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 120.886 -1.134 . . . . 0.0 110.265 -178.041 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.501 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.2 m -109.06 100.53 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.146 -0.971 . . . . 0.0 108.691 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.36 162.24 35.49 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.765 -1.21 . . . . 0.0 110.979 -178.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.8 t -88.26 -131.34 0.07 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.347 -0.846 . . . . 0.0 109.612 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 44.9 p30 -91.4 29.28 1.49 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.694 -1.254 . . . . 0.0 110.55 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.62 -29.06 12.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.052 -1.03 . . . . 0.0 110.231 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.144 -0.973 . . . . 0.0 109.742 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.0 t0 . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.055 0.455 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -119.77 147.98 43.97 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.111 -0.993 . . . . 0.0 110.115 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.493 ' CB ' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -71.11 -35.1 71.65 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.385 -0.822 . . . . 0.0 109.383 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.3 p -162.04 163.65 28.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.225 -0.922 . . . . 0.0 111.128 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.535 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 1.3 m -129.36 118.1 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.52 -0.737 . . . . 0.0 110.091 179.378 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.438 HG23 ' CD1' ' A' ' 28' ' ' ILE . 2.7 mp -92.6 111.98 25.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.14 160.26 21.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 111.718 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.502 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.23 6.26 38.08 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.159 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.428 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.04 25.43 0.49 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.294 -0.879 . . . . 0.0 110.396 179.641 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.428 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.341 0.591 . . . . 0.0 110.713 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 114' ' ' SER . 1.7 p30 -90.73 160.78 15.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.342 -0.849 . . . . 0.0 110.285 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -42.37 -52.26 4.63 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.544 -0.722 . . . . 0.0 112.34 -178.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.427 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.79 -29.27 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.855 -1.153 . . . . 0.0 111.214 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.43 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.39 -56.21 7.37 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.112 -0.993 . . . . 0.0 110.509 -179.377 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.408 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.4 OUTLIER -68.84 -34.5 75.59 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.168 -0.957 . . . . 0.0 108.789 178.685 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.3 m -60.02 -49.92 75.76 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.183 -0.948 . . . . 0.0 108.533 178.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.64 -39.93 64.13 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.546 -0.721 . . . . 0.0 109.671 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.408 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 4.1 mtt180 -66.21 -44.75 83.01 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 110.018 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.486 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 13.5 ttm180 -64.06 -34.08 77.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.221 -0.925 . . . . 0.0 110.279 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.455 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.33 12.07 1.96 Allowed Glycine 0 N--CA 1.497 2.73 0 O-C-N 121.055 -1.028 . . . . 0.0 112.3 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 1.2 mmt85 -101.32 -5.19 25.76 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.296 -1.708 . . . . 0.0 109.461 178.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.491 ' CG2' ' CG2' ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.44 142.15 50.31 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.224 -0.923 . . . . 0.0 109.424 179.782 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 78.48 26.5 59.12 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.455 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.3 82.62 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.134 -1.215 . . . . 0.0 110.109 179.908 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.59 24.92 5.45 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.474 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.5 -1.0 . . . . 0.0 109.105 -179.628 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 45.8 Cg_endo -84.47 99.58 0.75 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.187 1.099 . . . . 0.0 109.551 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.434 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.82 176.58 52.18 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.48 143.95 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.45 -1.03 . . . . 0.0 109.968 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.535 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 9.6 t80 -129.4 116.9 19.73 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.176 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.471 ' NE ' ' CG1' ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.21 137.9 37.07 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.541 -0.725 . . . . 0.0 109.215 179.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.458 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.6 p90 -137.8 153.98 49.6 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 110.719 -179.58 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.323 -0.861 . . . . 0.0 109.422 179.315 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.419 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 . . . . . 0 N--CA 1.494 1.771 0 CA-C-O 121.112 0.482 . . . . 0.0 110.436 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 31.1 mt -111.86 135.2 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.973 -1.079 . . . . 0.0 110.277 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.19 129.07 34.87 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.188 -0.945 . . . . 0.0 109.726 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.44 33.57 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.077 -1.014 . . . . 0.0 110.501 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.439 HG12 ' CZ ' ' A' ' 131' ' ' ARG . 17.2 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.91 114.93 29.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.15 -0.968 . . . . 0.0 110.371 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.444 HD21 ' CB ' ' A' ' 26' ' ' LYS . 12.3 tp -63.2 135.65 57.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 109.607 179.561 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.3 p -134.78 171.58 14.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.093 -1.004 . . . . 0.0 110.602 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.447 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.4 m -149.21 112.68 5.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.353 -0.842 . . . . 0.0 110.349 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.33 -161.68 27.28 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.674 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -122.05 -22.35 5.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.724 -0.868 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.488 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -93.51 112.82 58.28 Favored Pre-proline 0 N--CA 1.488 1.426 0 C-N-CA 118.598 -1.241 . . . . 0.0 110.335 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -64.85 141.26 70.66 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.597 1.314 . . . . 0.0 109.977 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.453 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.91 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.101 -0.999 . . . . 0.0 111.732 -178.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.574 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.08 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.534 -0.729 . . . . 0.0 111.558 178.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 12.07 25.88 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.2 mmtt -129.91 156.63 44.1 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.055 -1.262 . . . . 0.0 109.235 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.445 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.93 15.11 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.873 -1.142 . . . . 0.0 108.891 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.488 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 4.4 mt -70.88 114.97 31.3 Favored Pre-proline 0 C--N 1.296 -1.733 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.045 -179.412 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.494 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 38.9 Cg_endo -67.51 130.32 22.01 Favored 'Trans proline' 0 C--N 1.302 -1.878 0 N-CA-C 107.465 -1.783 . . . . 0.0 107.465 176.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.413 ' O ' ' N ' ' A' ' 34' ' ' LYS . 12.4 mt -56.32 -16.41 5.5 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.939 -1.101 . . . . 0.0 110.628 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.21 -16.22 59.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.671 -1.268 . . . . 0.0 110.576 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.427 ' CG2' HG23 ' A' ' 28' ' ' ILE . 15.4 m -92.68 -25.21 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 120.934 -1.104 . . . . 0.0 111.074 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.502 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 30.7 pt -116.41 -29.73 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.467 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.35 148.15 24.4 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.294 -0.879 . . . . 0.0 110.385 179.404 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.12 -5.21 49.46 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.09 -152.52 11.25 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.122 -1.514 . . . . 0.0 110.533 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.408 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.18 128.61 50.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.469 -1.018 . . . . 0.0 110.436 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.502 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 54.6 m80 -139.47 149.93 44.58 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 110.474 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.479 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 19.9 tp -111.85 117.26 32.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.403 -0.811 . . . . 0.0 110.403 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.443 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.307 -0.871 . . . . 0.0 108.997 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.479 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 5.8 m-85 -94.84 122.0 37.02 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.98 -1.075 . . . . 0.0 110.059 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.35 159.37 23.53 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.409 -0.807 . . . . 0.0 110.442 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.574 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.69 18.17 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.413 -0.805 . . . . 0.0 109.617 178.465 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.53 141.35 47.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.093 -1.005 . . . . 0.0 110.476 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.49 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.09 -35.69 69.3 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.535 -0.728 . . . . 0.0 110.549 -179.912 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.17 -45.38 88.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.303 -0.873 . . . . 0.0 110.591 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.14 -38.32 85.98 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.409 -0.807 . . . . 0.0 109.613 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.434 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 1.7 m -61.2 -34.19 74.68 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.488 -0.757 . . . . 0.0 109.56 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.24 -48.68 69.75 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.208 -0.933 . . . . 0.0 110.784 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.408 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.26 -44.61 64.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.204 -0.935 . . . . 0.0 110.472 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.436 ' CD1' HG13 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.64 77.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.319 -0.863 . . . . 0.0 111.002 -179.058 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.401 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.16 -51.41 21.43 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.059 -1.026 . . . . 0.0 110.484 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.09 -43.46 98.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.93 . . . . 0.0 110.039 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.412 ' O ' HD22 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.2 -46.16 83.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.171 -0.956 . . . . 0.0 109.526 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.484 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.76 -40.96 73.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.537 -0.727 . . . . 0.0 110.176 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.0 t -57.33 -35.34 48.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.984 -1.073 . . . . 0.0 108.978 179.425 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -31.26 59.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.352 -0.842 . . . . 0.0 110.243 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.509 HD23 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -71.32 -25.8 62.56 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.94 0.876 . . . . 0.0 109.75 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.41 5.77 10.11 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.474 HG23 HG23 ' A' ' 81' ' ' VAL . 37.7 mt -108.03 143.29 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.468 -1.019 . . . . 0.0 110.08 -179.532 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 45.9 t30 -89.52 106.64 18.59 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.484 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.77 144.4 46.31 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.708 -177.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.498 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 48.8 t -127.84 145.91 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.881 -0.727 . . . . 0.0 109.646 179.243 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -110.09 119.42 39.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.877 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.463 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 4.1 t80 -116.45 127.26 54.43 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.229 -0.92 . . . . 0.0 110.655 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.495 ' CE1' HD21 ' A' ' 69' ' ' LEU . 1.2 p90 -153.22 -171.4 3.91 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.402 -0.811 . . . . 0.0 110.013 179.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.56 126.9 21.03 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.308 -0.87 . . . . 0.0 111.276 -179.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.85 48.63 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.495 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.73 155.0 30.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.978 -1.307 . . . . 0.0 109.958 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.448 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.3 m-20 -90.75 149.49 21.99 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.37 -0.832 . . . . 0.0 110.694 -179.18 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.426 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.4 m -62.54 110.94 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.145 -0.972 . . . . 0.0 109.586 179.423 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 34.5 m -132.11 -23.82 2.16 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.383 -0.823 . . . . 0.0 111.178 -179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.498 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 22.6 t -60.1 138.73 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.133 -0.979 . . . . 0.0 110.082 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.495 1.797 0 O-C-N 121.203 -0.935 . . . . 0.0 110.541 179.86 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 122.036 0.922 . . . . 0.0 110.379 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.1 p -116.88 133.75 62.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.039 0.923 . . . . 0.0 110.425 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.474 HG23 HG23 ' A' ' 60' ' ' ILE . 6.1 m -113.54 123.56 69.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 O-C-N 121.502 -0.749 . . . . 0.0 109.021 179.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.421 ' CG2' HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.51 118.04 43.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.958 -1.089 . . . . 0.0 110.649 -177.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.498 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.4 m -106.64 100.45 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.009 -1.057 . . . . 0.0 108.634 179.037 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.463 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -144.19 162.39 36.45 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.667 -1.27 . . . . 0.0 111.239 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.8 t -92.9 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.476 -0.765 . . . . 0.0 108.988 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.36 50.06 1.92 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.72 -1.237 . . . . 0.0 109.931 179.416 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.68 -18.63 9.61 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.22 -0.925 . . . . 0.0 110.583 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 14.2 tp . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.031 -1.043 . . . . 0.0 109.71 179.972 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 121.007 0.432 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -119.66 146.6 45.43 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.015 -1.053 . . . . 0.0 110.345 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.33 -34.81 58.98 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.516 -0.74 . . . . 0.0 109.508 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -160.89 163.02 32.26 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.249 -0.907 . . . . 0.0 110.778 179.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.529 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.29 118.15 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.21 -0.931 . . . . 0.0 110.131 179.375 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.438 HD13 ' CD1' ' A' ' 40' ' ' ILE . 3.2 mp -95.96 117.73 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.462 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.413 ' OD1' ' CB ' ' A' ' 41' ' ' PHE . 18.8 t0 -124.46 161.36 26.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.137 -0.977 . . . . 0.0 111.851 -178.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.454 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.91 -6.81 34.84 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 55.7 15.36 1.56 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.319 -0.863 . . . . 0.0 111.654 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.308 -1.221 0 O-C-N 120.731 -1.231 . . . . 0.0 109.535 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.832 0 CA-C-O 121.357 0.598 . . . . 0.0 111.163 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.425 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 3.0 p30 -87.77 160.98 17.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.333 -0.854 . . . . 0.0 110.292 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.15 3.75 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.339 -0.851 . . . . 0.0 111.832 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.425 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.66 -29.76 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.932 -1.105 . . . . 0.0 111.794 -178.345 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.408 ' N ' HG21 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.27 -56.1 7.42 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.083 -1.011 . . . . 0.0 110.426 -179.142 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.451 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.35 -32.87 72.22 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.224 -0.922 . . . . 0.0 108.848 178.808 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.451 ' N ' ' HG2' ' A' ' 115' ' ' ARG . 25.3 m -61.11 -49.8 75.81 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.109 -0.994 . . . . 0.0 108.409 178.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.97 -36.3 64.56 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.918 -0.713 . . . . 0.0 109.807 178.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.426 ' HG2' ' CZ ' ' A' ' 41' ' ' PHE . 49.1 mtt-85 -71.68 -44.47 64.19 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.255 -0.903 . . . . 0.0 111.117 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.458 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 19.5 ttm180 -56.7 -41.03 76.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.891 -1.131 . . . . 0.0 109.93 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.06 71.43 0.19 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.456 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.72 -45.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.593 -0.945 . . . . 0.0 108.836 179.488 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.456 ' CG2' HD13 ' A' ' 10' ' ' ILE . 9.2 t -101.14 143.01 31.76 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.598 -0.689 . . . . 0.0 109.393 178.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.451 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 4.0 22.02 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.184 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.01 85.38 0.71 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.995 -1.297 . . . . 0.0 109.822 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.406 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 104.08 9.79 35.99 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.467 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 3.6 pttt -174.96 -173.76 0.22 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.318 -1.107 . . . . 0.0 108.659 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.467 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 50.0 Cg_endo -88.15 105.33 0.51 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.22 1.116 . . . . 0.0 110.297 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.444 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.42 170.45 53.61 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.706 -1.235 . . . . 0.0 110.102 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.411 HG21 HG22 ' A' ' 13' ' ' VAL . 1.5 mp -126.79 142.55 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.535 -0.979 . . . . 0.0 108.862 179.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.529 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.3 t80 -129.33 115.18 17.18 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.982 -1.073 . . . . 0.0 110.578 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.439 ' CZ ' HG12 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.68 122.85 42.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.47 -0.768 . . . . 0.0 109.273 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 24.0 p90 -121.41 148.7 44.05 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.05 -1.031 . . . . 0.0 110.262 -179.495 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.454 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 46.1 t . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.524 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.5 m120 . . . . . 0 N--CA 1.494 1.749 0 CA-C-O 121.135 0.493 . . . . 0.0 110.19 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.45 HD11 ' CG2' ' A' ' 122' ' ' THR . 40.8 mt -117.52 136.39 54.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 110.533 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.164 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 110.382 -179.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.49 156.3 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.439 -0.788 . . . . 0.0 110.05 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.01 111.49 24.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.276 -0.89 . . . . 0.0 110.169 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.421 HD21 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.16 136.17 48.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.358 -0.839 . . . . 0.0 109.877 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.97 173.83 11.28 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.132 -0.98 . . . . 0.0 110.22 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.9 p -67.57 74.32 0.16 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 109.814 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.455 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 17.8 m -145.59 109.55 4.84 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.379 -0.826 . . . . 0.0 110.388 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.471 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.7 27.93 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.671 179.567 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.04 -25.01 5.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.696 -0.884 . . . . 0.0 110.561 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.457 HG21 ' O ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.34 52.55 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.172 -179.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.412 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.1 Cg_endo -64.79 143.01 78.8 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.5 1.263 . . . . 0.0 110.158 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.448 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.5 t80 -155.23 94.84 1.66 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 111.286 -178.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.433 ' CZ ' ' CE1' ' A' ' 43' ' ' HIS . 23.7 m-85 57.66 67.07 1.01 Allowed 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.535 -0.728 . . . . 0.0 111.611 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.5 13.33 16.4 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.448 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 22.2 mmtm -130.6 156.99 43.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.142 -1.211 . . . . 0.0 109.185 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.411 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.6 107.52 16.26 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.906 -1.121 . . . . 0.0 109.827 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.457 ' O ' HG21 ' A' ' 21' ' ' ILE . 3.5 mt -69.97 113.39 17.28 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 121.372 -0.83 . . . . 0.0 109.894 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.471 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.8 Cg_endo -68.99 128.88 17.41 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 N-CA-C 106.993 -1.964 . . . . 0.0 106.993 176.463 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.421 HD23 HD12 ' A' ' 60' ' ' ILE . 6.2 mt -56.61 -15.98 5.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.854 -1.154 . . . . 0.0 111.137 -177.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.424 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.43 62.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.65 -1.281 . . . . 0.0 110.869 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.431 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.1 m -89.68 -26.5 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.922 -1.111 . . . . 0.0 111.134 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.524 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 43.3 pt -116.94 -23.68 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.165 -0.96 . . . . 0.0 110.048 -179.626 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.457 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.59 148.35 22.15 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.174 -0.954 . . . . 0.0 110.596 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.23 51.73 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.18 -151.61 9.86 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.211 -1.471 . . . . 0.0 110.208 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.428 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.57 130.72 54.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -1.078 . . . . 0.0 110.208 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.524 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.9 m80 -140.81 148.81 41.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.117 -0.99 . . . . 0.0 110.983 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.496 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 20.2 tp -109.76 123.18 49.09 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.924 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.469 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 37.8 mt -104.78 128.73 58.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.286 -0.883 . . . . 0.0 108.876 179.225 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.496 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.3 122.86 37.28 Favored 'General case' 0 C--N 1.294 -1.844 0 O-C-N 121.241 -0.912 . . . . 0.0 110.348 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.83 160.05 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.335 -0.853 . . . . 0.0 110.8 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.433 ' CE1' ' CZ ' ' A' ' 24' ' ' TYR . 3.9 p-80 -115.51 5.23 14.39 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.575 -0.703 . . . . 0.0 109.799 178.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.74 138.14 45.61 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.007 . . . . 0.0 110.878 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.488 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.69 -43.35 66.11 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.709 -0.619 . . . . 0.0 110.53 -179.931 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.66 -34.5 74.4 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.325 -0.859 . . . . 0.0 110.564 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.21 -38.19 66.18 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.233 -0.917 . . . . 0.0 109.911 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.419 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 61.5 m -61.4 -34.48 75.43 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.521 -0.737 . . . . 0.0 109.892 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.24 -49.72 58.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 110.381 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.01 -46.38 57.41 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.246 -0.909 . . . . 0.0 110.274 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.436 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.3 tm? -56.92 -42.65 80.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.976 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.38 -50.85 19.74 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.01 -1.056 . . . . 0.0 110.651 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -40.5 97.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.038 -1.039 . . . . 0.0 109.733 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.416 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.24 -43.1 82.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.315 -0.866 . . . . 0.0 109.434 179.394 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.478 HD21 HG22 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -55.34 -42.87 74.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.39 -0.819 . . . . 0.0 109.749 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.14 -32.58 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -0.966 . . . . 0.0 108.716 179.043 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.52 -32.08 60.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.571 -0.706 . . . . 0.0 110.013 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.463 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.1 mm? -71.52 -26.26 62.58 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.298 -0.876 . . . . 0.0 109.595 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 5.47 9.45 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.483 HG22 HG21 ' A' ' 81' ' ' VAL . 51.8 mt -108.26 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.303 -1.116 . . . . 0.0 110.069 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.415 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 36.7 t30 -86.65 107.04 18.02 Favored 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.481 ' CB ' HG23 ' A' ' 81' ' ' VAL . . . -122.03 147.74 45.71 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.541 -177.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.481 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 2.8 t -135.73 142.43 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.518 179.278 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -105.35 135.05 47.44 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.244 -0.983 . . . . 0.0 109.871 179.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.433 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.62 131.29 49.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.12 -0.987 . . . . 0.0 110.792 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.488 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 5.6 p90 -166.25 175.33 8.39 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.66 -0.65 . . . . 0.0 109.515 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.74 114.89 1.41 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.249 -0.907 . . . . 0.0 110.799 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.77 31.45 7.77 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.439 ' CD1' ' O ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.53 157.31 26.55 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.064 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.439 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 5.3 m-20 -96.91 149.45 21.86 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.195 -0.941 . . . . 0.0 110.508 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.43 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.3 m -62.64 111.25 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.189 -0.945 . . . . 0.0 109.162 179.224 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.45 ' CB ' HG13 ' A' ' 63' ' ' VAL . 4.6 m -133.63 -32.19 1.15 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.337 -0.852 . . . . 0.0 111.08 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.481 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 20.4 t -53.73 137.94 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.193 -0.942 . . . . 0.0 109.825 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.223 -0.923 . . . . 0.0 111.169 -179.453 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 122.109 0.957 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 12.0 p -117.86 133.16 65.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.089 0.947 . . . . 0.0 110.111 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.483 HG21 HG22 ' A' ' 60' ' ' ILE . 4.7 m -113.87 125.45 71.16 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.369 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.088 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 39' ' ' LEU . 9.1 t -97.18 121.17 47.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 121.008 -1.058 . . . . 0.0 110.133 -178.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 5.2 m -114.88 100.07 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.706 -1.246 . . . . 0.0 108.586 179.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.433 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.27 163.99 33.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.667 -1.271 . . . . 0.0 111.659 -177.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -84.11 -138.56 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.597 -0.689 . . . . 0.0 109.6 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -87.53 14.4 8.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.799 -1.188 . . . . 0.0 110.613 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -86.54 -21.82 26.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.989 -1.069 . . . . 0.0 110.181 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.128 -0.983 . . . . 0.0 110.143 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.3 t0 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.158 0.504 . . . . 0.0 110.201 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -119.38 144.36 46.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.23 -0.919 . . . . 0.0 110.339 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -78.95 -31.66 45.18 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.694 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -161.56 163.15 30.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.294 -0.879 . . . . 0.0 110.768 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.523 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.45 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.271 -0.893 . . . . 0.0 110.08 179.27 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.427 ' CD1' HG22 ' A' ' 33' ' ' ILE . 3.0 mp -93.41 119.18 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.276 -0.89 . . . . 0.0 109.14 179.349 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -128.47 160.58 31.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.121 -0.987 . . . . 0.0 111.599 -178.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.438 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.96 -5.14 31.14 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 177.452 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.15 14.02 1.38 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.285 -0.884 . . . . 0.0 111.723 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 C--N 1.307 -1.242 0 O-C-N 120.678 -1.264 . . . . 0.0 109.043 179.585 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.476 0.655 . . . . 0.0 110.99 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.428 ' OD2' ' CG2' ' A' ' 113' ' ' VAL . 6.8 p-10 -73.82 162.88 28.65 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.558 -0.714 . . . . 0.0 110.287 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.429 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.24 -44.8 92.33 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.877 -1.14 . . . . 0.0 111.6 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.428 ' CG2' ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.76 -30.66 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.716 -1.24 . . . . 0.0 112.74 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.482 ' O ' ' N ' ' A' ' 118' ' ' ARG . 2.6 p -53.6 -55.25 27.39 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.449 -1.407 . . . . 0.0 110.162 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.429 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.64 -35.33 75.92 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.048 178.435 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.405 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 26.2 m -62.07 -50.35 72.32 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 119.369 -0.932 . . . . 0.0 108.581 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.25 -46.83 39.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.322 -0.861 . . . . 0.0 109.982 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.482 ' N ' ' O ' ' A' ' 114' ' ' SER . 60.2 mtt180 -61.3 -45.29 95.06 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.268 -0.895 . . . . 0.0 110.967 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.482 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.9 ttm180 -55.55 -38.68 69.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.694 -1.254 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.78 0.28 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.61 -50.81 0.24 Allowed 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.468 -1.019 . . . . 0.0 108.632 179.666 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.45 ' CG2' HD11 ' A' ' 10' ' ' ILE . 11.9 t -94.79 142.35 27.57 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.484 1.891 0 C-N-CA 119.335 -1.412 . . . . 0.0 110.574 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.2 86.19 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.883 -1.363 . . . . 0.0 109.931 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.89 -43.01 1.75 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.457 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 12.9 mttt -111.0 -171.68 0.22 Allowed Pre-proline 0 N--CA 1.487 1.392 0 O-C-N 121.611 -0.935 . . . . 0.0 109.454 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.457 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.9 Cg_endo -90.75 107.79 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.61 1.321 . . . . 0.0 109.786 179.044 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.442 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.33 166.07 50.92 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 4.0 mt -119.55 140.49 43.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.227 179.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.523 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.6 t80 -128.73 114.93 17.21 Favored 'General case' 0 C--N 1.3 -1.585 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.139 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.8 mtt180 -99.38 134.28 42.48 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 109.665 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.474 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.16 148.26 50.59 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.157 -0.964 . . . . 0.0 109.803 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.438 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.1 t . . . . . 0 N--CA 1.493 1.682 0 O-C-N 121.068 -1.02 . . . . 0.0 110.042 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 31.8 m120 . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 121.307 0.575 . . . . 0.0 110.29 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.518 HD12 ' O ' ' A' ' 122' ' ' THR . 62.2 mt -108.75 136.64 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.044 -1.035 . . . . 0.0 110.141 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.43 127.94 34.1 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.188 -0.945 . . . . 0.0 109.25 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.72 135.66 33.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.159 -0.963 . . . . 0.0 110.185 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.8 t -137.22 156.41 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.286 -0.884 . . . . 0.0 110.423 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.33 113.83 26.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 0.0 109.83 179.529 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.4 ' CD2' ' HB3' ' A' ' 26' ' ' LYS . 8.8 tp -52.78 142.58 18.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.161 -0.962 . . . . 0.0 110.111 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 p -138.22 174.36 10.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.262 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.2 71.91 1.71 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.289 -0.882 . . . . 0.0 109.969 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.435 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.4 m -144.19 110.15 5.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 110.513 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.451 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.77 -171.44 26.75 Favored Glycine 0 N--CA 1.488 2.145 0 C-N-CA 118.876 -1.631 . . . . 0.0 110.859 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -108.95 -26.18 10.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.65 -0.912 . . . . 0.0 110.394 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.499 HG22 ' O ' ' A' ' 28' ' ' ILE . 8.0 tt -95.27 101.53 7.69 Favored Pre-proline 0 N--CA 1.487 1.403 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.357 -179.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.403 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 36.5 Cg_endo -61.29 155.29 52.6 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.516 1.272 . . . . 0.0 110.228 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.589 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.75 94.48 0.5 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.091 -1.005 . . . . 0.0 111.309 -178.024 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.589 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 60.0 68.28 0.79 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.407 -0.808 . . . . 0.0 111.673 178.808 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 14.6 11.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 21.4 mmtt -130.73 156.69 44.52 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.082 -1.246 . . . . 0.0 109.2 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.413 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.24 108.07 16.11 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.986 -1.071 . . . . 0.0 109.086 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.499 ' O ' HG22 ' A' ' 21' ' ' ILE . 5.1 mt -71.31 113.33 18.47 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.117 -179.384 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.451 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 43.0 Cg_endo -71.04 129.69 16.64 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.053 -1.941 . . . . 0.0 107.053 176.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.445 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 7.8 mt -55.77 -18.82 9.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.808 -1.182 . . . . 0.0 110.545 -177.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -15.97 23.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.628 -1.295 . . . . 0.0 110.332 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.435 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 16.2 m -93.36 -25.36 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.882 -1.136 . . . . 0.0 111.057 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.532 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 21.4 pt -117.9 -16.17 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.01 -1.056 . . . . 0.0 110.923 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.445 ' HB3' ' O ' ' A' ' 30' ' ' LEU . 0.4 OUTLIER -97.82 148.49 23.34 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.844 -1.16 . . . . 0.0 110.083 179.534 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.17 -4.14 51.81 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.65 -159.08 23.37 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.347 -1.406 . . . . 0.0 110.082 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.89 133.45 44.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.275 -1.132 . . . . 0.0 110.547 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.532 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.76 147.01 40.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.098 -1.001 . . . . 0.0 110.703 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.459 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 60.2 tp -108.54 113.74 27.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.417 -0.802 . . . . 0.0 109.998 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.467 HG23 HD11 ' A' ' 40' ' ' ILE . 25.9 mt -96.54 126.89 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.341 -0.85 . . . . 0.0 109.409 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.459 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 34.0 m-85 -95.23 123.75 38.9 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.41 -0.806 . . . . 0.0 109.978 -179.587 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.01 160.23 21.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.192 -0.943 . . . . 0.0 110.606 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.545 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 4.3 p-80 -107.18 -3.81 19.46 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.439 -0.788 . . . . 0.0 110.175 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.65 50.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.066 -1.021 . . . . 0.0 110.779 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.496 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.53 -41.38 69.24 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.81 -0.556 . . . . 0.0 110.646 -179.765 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mttp -58.79 -35.27 72.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.195 -0.941 . . . . 0.0 110.109 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.401 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.26 -34.86 66.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.347 -0.846 . . . . 0.0 109.427 179.656 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.407 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 91.9 m -60.7 -34.23 74.05 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.511 -0.743 . . . . 0.0 109.58 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.06 -49.16 63.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.17 -0.956 . . . . 0.0 110.246 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.7 -42.68 67.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.258 -0.901 . . . . 0.0 110.599 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.401 ' HB2' ' O ' ' A' ' 47' ' ' LYS . 1.1 tm? -57.23 -41.1 78.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.427 -0.796 . . . . 0.0 111.295 -179.018 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.95 -51.48 12.33 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.874 -1.141 . . . . 0.0 110.528 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.6 89.78 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.996 -1.065 . . . . 0.0 109.48 179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.43 ' CD ' HG13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.98 -45.77 86.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.475 -0.766 . . . . 0.0 109.559 179.337 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.494 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.83 -42.0 75.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 109.898 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.8 t -56.35 -33.71 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.091 -1.006 . . . . 0.0 109.181 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -32.05 61.01 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.32 -0.862 . . . . 0.0 109.863 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.457 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.0 mm? -71.69 -26.2 62.41 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.379 -0.826 . . . . 0.0 109.529 179.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.52 6.09 8.94 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.474 HG22 HG23 ' A' ' 81' ' ' VAL . 30.6 mt -108.25 143.72 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.254 -1.145 . . . . 0.0 110.143 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.423 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.3 t30 -87.07 107.3 18.38 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.302 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.494 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -121.22 147.33 45.76 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.744 -177.274 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.479 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -134.75 150.0 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.916 -0.714 . . . . 0.0 109.326 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.47 136.4 52.83 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.011 179.078 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.461 ' CG ' HD13 ' A' ' 88' ' ' LEU . 7.1 t80 -123.47 128.12 49.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.911 . . . . 0.0 110.742 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.502 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.12 -179.94 8.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.515 -0.741 . . . . 0.0 109.858 179.63 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.73 11.0 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.238 -0.913 . . . . 0.0 111.012 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.76 47.73 19.39 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.502 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.9 tm? -116.96 153.02 33.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.058 -1.26 . . . . 0.0 109.608 179.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.453 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 5.4 m-20 -89.55 148.25 23.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.219 -0.925 . . . . 0.0 110.994 -178.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.415 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.5 m -63.2 111.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.102 -0.999 . . . . 0.0 109.235 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.404 ' CB ' HG12 ' A' ' 63' ' ' VAL . 18.1 m -132.58 -38.31 1.03 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.266 -0.896 . . . . 0.0 110.488 -179.486 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.479 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 64.6 t -48.19 137.3 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.388 -0.82 . . . . 0.0 110.464 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.627 0 O-C-N 121.305 -0.872 . . . . 0.0 110.298 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.944 0.878 . . . . 0.0 110.024 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.44 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.1 p -117.06 134.8 59.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 122.014 0.911 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.474 HG23 HG22 ' A' ' 60' ' ' ILE . 11.4 m -112.6 125.76 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.334 -0.854 . . . . 0.0 109.02 179.127 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.453 HG21 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -97.39 118.34 43.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 120.935 -1.103 . . . . 0.0 110.037 -178.282 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.4 m -112.64 100.09 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.027 -1.046 . . . . 0.0 108.806 179.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.0 162.23 36.0 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.613 -1.304 . . . . 0.0 111.521 -178.079 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -87.01 -143.95 0.12 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.678 -0.639 . . . . 0.0 109.353 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -73.9 -4.62 36.12 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.926 -1.109 . . . . 0.0 110.782 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.405 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -61.65 -40.05 93.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.144 . . . . 0.0 110.502 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.461 HD13 ' CG ' ' A' ' 65' ' ' TYR . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.107 -0.996 . . . . 0.0 109.844 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.198 0.523 . . . . 0.0 110.421 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.419 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 21.9 m-85 -119.42 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.109 -0.994 . . . . 0.0 109.726 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.422 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.99 -35.59 80.7 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.142 -0.973 . . . . 0.0 109.067 179.538 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.59 31.79 Favored 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.741 -0.784 . . . . 0.0 110.863 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.493 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.12 117.6 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.453 -0.78 . . . . 0.0 110.571 179.837 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.444 ' CD1' ' N ' ' A' ' 100' ' ' ILE . 2.9 mp -93.1 112.59 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.29 161.1 21.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.115 -0.99 . . . . 0.0 111.912 -178.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.485 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.1 p -102.83 6.57 39.29 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.068 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m120 45.86 25.4 0.29 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.238 -0.913 . . . . 0.0 111.349 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.921 . . . . 0.0 110.028 179.506 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.421 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 121.147 0.499 . . . . 0.0 110.709 . . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.435 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.7 p30 -96.36 160.29 14.5 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.298 -0.876 . . . . 0.0 110.397 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.409 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.44 -48.26 37.5 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.418 -0.801 . . . . 0.0 112.001 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.435 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -71.17 -29.56 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.769 -1.207 . . . . 0.0 110.836 -178.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.48 -56.31 7.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.217 -0.927 . . . . 0.0 110.387 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.426 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.66 -34.82 76.35 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.279 -0.888 . . . . 0.0 108.715 178.705 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 42.7 m -59.79 -49.82 76.24 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.064 -1.022 . . . . 0.0 108.608 178.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -73.82 -38.89 64.42 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.43 -0.794 . . . . 0.0 109.951 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 114' ' ' SER . 82.8 mtt180 -70.18 -44.29 69.05 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.262 -0.899 . . . . 0.0 110.586 -179.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.436 ' O ' HD12 ' A' ' 10' ' ' ILE . 34.5 ttm180 -54.45 -36.58 64.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.222 -0.924 . . . . 0.0 110.577 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.94 -15.85 11.1 Favored Glycine 0 N--CA 1.494 2.527 0 O-C-N 120.959 -1.088 . . . . 0.0 111.524 -179.205 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -71.73 -3.58 22.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.651 -1.5 . . . . 0.0 111.485 -179.252 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.518 ' O ' HD12 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.98 143.53 48.97 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.76 -1.213 . . . . 0.0 110.9 -179.685 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 74.93 12.25 83.32 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.846 178.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.2 mtt180 -61.3 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.048 -1.266 . . . . 0.0 109.022 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.4 16.64 39.46 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -178.516 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.458 ' O ' ' CA ' ' A' ' 123' ' ' GLY . 0.2 OUTLIER -175.48 -176.48 0.26 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.472 -1.016 . . . . 0.0 108.779 -179.615 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.451 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -88.27 105.39 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.133 1.07 . . . . 0.0 109.983 179.452 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.456 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.23 173.82 25.63 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.529 -1.32 . . . . 0.0 110.198 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.468 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.28 142.94 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.486 -1.008 . . . . 0.0 109.572 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.493 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.44 114.93 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.757 -1.215 . . . . 0.0 110.389 179.4 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.427 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.55 145.68 27.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.495 -0.753 . . . . 0.0 109.484 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.7 p90 -137.89 157.08 47.14 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.906 -1.121 . . . . 0.0 110.306 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 N--CA 1.494 1.752 0 O-C-N 121.142 -0.974 . . . . 0.0 109.656 179.451 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.279 0.561 . . . . 0.0 109.898 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.464 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 19.8 mt -105.28 134.83 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.856 -1.153 . . . . 0.0 110.027 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -84.93 128.28 34.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.328 -0.857 . . . . 0.0 108.893 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.43 142.74 27.39 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.043 -1.036 . . . . 0.0 110.245 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.439 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 13.3 t -136.53 157.29 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.943 -179.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.35 108.7 19.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.869 179.418 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.418 ' CD2' ' HB3' ' A' ' 26' ' ' LYS . 11.2 tp -54.98 134.35 48.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.798 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.0 p -137.97 -179.32 5.7 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.323 -0.861 . . . . 0.0 110.176 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.2 p -74.56 60.78 0.91 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -0.909 . . . . 0.0 109.988 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.452 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.8 m -131.73 111.41 11.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.892 . . . . 0.0 110.227 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.53 -162.61 27.97 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.977 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.32 -21.63 7.42 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.724 -0.868 . . . . 0.0 110.474 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.475 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.0 tt -97.39 107.1 36.8 Favored Pre-proline 0 N--CA 1.489 1.517 0 C-N-CA 118.796 -1.162 . . . . 0.0 110.24 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.426 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -63.64 155.01 65.62 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 O-C-N 123.385 1.203 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.7 t80 -169.13 91.6 0.25 Allowed 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.056 -1.027 . . . . 0.0 111.563 -178.123 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.501 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.82 67.27 0.89 Allowed 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.473 -0.767 . . . . 0.0 111.38 178.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.68 13.56 18.33 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 6.5 mmtt -130.8 156.23 45.34 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.14 -1.212 . . . . 0.0 109.08 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.452 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.81 106.92 12.56 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.896 -1.127 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.475 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.0 mt -68.47 115.1 26.44 Favored Pre-proline 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.61 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.487 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.1 Cg_endo -68.42 126.74 14.63 Favored 'Trans proline' 0 C--N 1.304 -1.813 0 N-CA-C 107.382 -1.815 . . . . 0.0 107.382 176.261 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.437 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 5.6 mt -56.08 -20.72 18.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.962 -1.086 . . . . 0.0 110.846 -177.474 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.4 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 5.2 pt-20 -59.95 -16.05 26.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.674 -1.266 . . . . 0.0 110.467 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.462 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 15.4 m -91.58 -25.33 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.005 -1.059 . . . . 0.0 110.955 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.532 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 14.7 pt -117.86 -15.49 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.963 -1.085 . . . . 0.0 110.951 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.456 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.5 tptm -98.22 147.77 24.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.809 -1.182 . . . . 0.0 110.507 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.35 -3.14 61.43 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.09 -159.45 21.29 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.23 -1.462 . . . . 0.0 110.374 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.428 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.375 -1.074 . . . . 0.0 110.543 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.532 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.11 147.86 39.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.225 -0.922 . . . . 0.0 110.918 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.4 tp -109.14 116.24 31.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.38 -0.825 . . . . 0.0 110.291 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.447 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 34.4 mt -99.89 127.77 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.132 -0.98 . . . . 0.0 109.687 179.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.05 39.55 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.327 -0.858 . . . . 0.0 109.891 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.71 159.72 21.82 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.821 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.501 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.43 -8.58 19.05 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.557 -0.714 . . . . 0.0 109.942 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.13 138.98 53.27 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.031 -1.043 . . . . 0.0 110.96 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.455 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.95 -40.37 68.73 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.315 0.579 . . . . 0.0 110.774 -179.79 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mttp -59.93 -36.49 77.13 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.369 -0.832 . . . . 0.0 111.028 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.28 71.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 -179.48 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.438 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 84.8 m -61.2 -36.36 79.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.284 -0.885 . . . . 0.0 109.302 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.45 66.85 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.267 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -73.01 -45.99 54.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.234 -0.916 . . . . 0.0 110.283 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.413 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.2 tm? -57.01 -39.72 75.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.591 -0.693 . . . . 0.0 111.267 -179.002 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.88 -51.17 13.1 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.929 -1.107 . . . . 0.0 110.54 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.127 -0.983 . . . . 0.0 109.677 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.427 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.68 83.89 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.372 -0.83 . . . . 0.0 109.526 179.379 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.473 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -54.94 -42.59 72.49 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.491 -0.756 . . . . 0.0 109.489 179.683 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.5 t -56.14 -31.02 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.99 -1.068 . . . . 0.0 108.725 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.03 -32.73 61.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.521 -0.737 . . . . 0.0 109.899 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.463 HD23 ' N ' ' A' ' 58' ' ' LEU . 4.3 mm? -72.1 -26.11 62.01 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-O 121.851 0.834 . . . . 0.0 109.728 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.0 9.17 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.465 HG23 HG23 ' A' ' 81' ' ' VAL . 44.7 mt -107.55 143.24 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.247 -1.149 . . . . 0.0 109.861 -179.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.423 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 50.0 t30 -87.56 106.83 18.27 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.348 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 118.774 -1.17 . . . . 0.0 111.831 -177.079 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.473 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 92.2 t -126.01 148.12 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.697 -0.627 . . . . 0.0 109.828 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -117.77 117.63 29.85 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.495 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.455 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.5 t80 -108.14 131.25 54.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 110.878 -179.264 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.505 ' CE1' HD22 ' A' ' 69' ' ' LEU . 3.0 p90 -155.34 -168.72 2.93 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.62 -0.675 . . . . 0.0 109.958 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -55.92 123.66 15.04 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.319 -0.863 . . . . 0.0 111.266 -179.256 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.56 59.02 8.76 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.505 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.66 152.05 35.98 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.074 -1.25 . . . . 0.0 109.712 179.397 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.457 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 5.2 m-20 -85.88 149.03 25.51 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.209 -0.932 . . . . 0.0 110.592 -179.276 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.431 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.0 m -62.5 110.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.133 179.178 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.9 m -131.33 -32.09 1.58 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.372 -0.83 . . . . 0.0 110.656 -179.403 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.473 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 94.9 t -53.0 131.25 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.153 -0.967 . . . . 0.0 109.441 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 O-C-N 121.125 -0.984 . . . . 0.0 110.779 -179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 122.018 0.914 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -117.43 132.44 67.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 CA-C-O 122.087 0.946 . . . . 0.0 110.456 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 11.4 m -112.45 122.05 65.95 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 121.356 -0.84 . . . . 0.0 108.96 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.436 ' CG2' HG13 ' A' ' 73' ' ' VAL . 16.1 t -97.01 120.94 46.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.684 0 O-C-N 121.054 -1.029 . . . . 0.0 110.611 -177.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.3 m -112.39 100.39 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.044 -1.035 . . . . 0.0 108.667 179.321 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.455 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.7 34.44 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -177.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -93.19 -136.68 0.18 Allowed 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -77.04 -6.16 51.63 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.679 -1.263 . . . . 0.0 111.068 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.456 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -60.71 -41.52 95.4 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.849 -1.157 . . . . 0.0 110.066 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.444 HD11 ' CB ' ' A' ' 65' ' ' TYR . 3.4 tp . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 108.577 179.161 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.274 0.559 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -120.26 152.81 37.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.214 -0.929 . . . . 0.0 110.294 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.457 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.6 -28.35 30.88 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.425 -0.797 . . . . 0.0 109.831 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.6 p -160.7 163.58 32.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.283 -0.886 . . . . 0.0 110.712 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.91 128.12 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.345 -0.847 . . . . 0.0 110.138 179.441 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.1 mp -105.95 111.11 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.195 -0.94 . . . . 0.0 108.666 178.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -115.85 161.29 18.99 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.052 -1.03 . . . . 0.0 111.96 -178.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.468 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.84 -2.91 43.04 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.023 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 53.89 21.48 2.82 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.007 . . . . 0.0 110.183 -179.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.323 -0.86 . . . . 0.0 110.153 179.662 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.408 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.474 0.654 . . . . 0.0 110.873 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.411 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -105.55 161.85 14.0 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.478 -0.764 . . . . 0.0 110.323 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.404 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.8 -59.85 1.8 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.315 -0.865 . . . . 0.0 112.156 -178.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 11.4 m -64.31 -29.32 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.788 -1.195 . . . . 0.0 111.764 -178.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.411 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.34 -56.5 6.73 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.009 -1.057 . . . . 0.0 110.63 -179.015 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.446 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.58 -34.75 76.35 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.719 178.933 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 29.5 m -59.13 -49.22 78.69 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.984 -1.072 . . . . 0.0 108.301 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . 0.418 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -36.99 65.87 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.508 -0.745 . . . . 0.0 109.9 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.407 ' HB2' ' O ' ' A' ' 114' ' ' SER . 5.1 mtt180 -71.8 -44.59 63.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.042 -1.036 . . . . 0.0 111.193 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.476 ' HG3' ' CD2' ' A' ' 130' ' ' TYR . 12.2 ttm180 -57.35 -41.64 80.48 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.848 -1.158 . . . . 0.0 109.834 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.421 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.05 63.88 0.21 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.443 ' N ' ' O ' ' A' ' 119' ' ' ARG . 10.9 mmp_? -135.38 -44.69 0.69 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.43 -1.041 . . . . 0.0 108.524 178.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.438 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 12.0 t -93.58 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.677 -0.639 . . . . 0.0 109.732 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.08 3.23 36.13 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.617 179.058 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.8 mmt180 -62.71 87.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.965 -1.315 . . . . 0.0 109.511 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.51 19.13 33.29 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -178.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.454 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 16.4 ptpt -176.23 -178.31 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.491 -1.005 . . . . 0.0 108.503 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.5 Cg_endo -89.16 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.254 1.134 . . . . 0.0 110.428 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.438 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.85 176.72 54.59 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.772 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.434 ' N ' HG22 ' A' ' 122' ' ' THR . 3.5 mp -132.52 143.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.764 -0.845 . . . . 0.0 109.043 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.476 ' CD2' ' HG3' ' A' ' 119' ' ' ARG . 9.6 t80 -129.95 115.52 17.28 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.24 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.439 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 6.5 mtt180 -105.98 131.42 53.29 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.522 -0.736 . . . . 0.0 109.435 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -129.63 157.29 42.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.042 -1.036 . . . . 0.0 110.376 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.104 -0.997 . . . . 0.0 109.923 179.757 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.0 m-80 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.142 0.496 . . . . 0.0 110.346 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.431 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 36.2 mt -128.05 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.187 -0.945 . . . . 0.0 109.413 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.97 128.45 34.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.139 -0.976 . . . . 0.0 109.305 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.06 133.09 34.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.206 -0.933 . . . . 0.0 110.429 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.459 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 16.5 t -128.66 156.11 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.403 -0.811 . . . . 0.0 110.021 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.61 110.9 21.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.252 -0.905 . . . . 0.0 109.968 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.424 HD21 ' CG2' ' A' ' 133' ' ' VAL . 11.7 tp -58.84 134.21 56.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.275 -0.891 . . . . 0.0 109.581 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.9 p -138.78 -175.19 4.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.24 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.5 p -77.75 81.3 4.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.264 -0.897 . . . . 0.0 109.896 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.436 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 27.8 m -153.64 109.5 3.27 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.297 -0.877 . . . . 0.0 110.656 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.469 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.74 -165.08 28.07 Favored Glycine 0 N--CA 1.487 2.044 0 C-N-CA 119.072 -1.537 . . . . 0.0 110.567 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.7 -21.83 8.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.647 -0.914 . . . . 0.0 110.275 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.485 HG22 HD12 ' A' ' 21' ' ' ILE . 6.6 tt -96.19 110.69 53.55 Favored Pre-proline 0 N--CA 1.487 1.407 0 C-N-CA 118.8 -1.16 . . . . 0.0 109.91 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.63 155.39 67.07 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.684 1.36 . . . . 0.0 110.285 -179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.4 t80 -169.5 94.06 0.28 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.112 -0.993 . . . . 0.0 111.508 -178.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.583 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 24.9 m-85 58.38 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.393 -0.817 . . . . 0.0 111.497 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.44 14.76 9.61 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.431 -1.067 . . . . 0.0 110.431 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.8 156.8 44.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.041 -1.27 . . . . 0.0 109.418 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.7 107.35 15.34 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 120.967 -1.083 . . . . 0.0 109.5 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.475 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.3 mt -69.56 113.9 20.46 Favored Pre-proline 0 C--N 1.299 -1.6 0 O-C-N 121.383 -0.823 . . . . 0.0 110.215 -179.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.469 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 42.8 Cg_endo -70.27 129.73 17.54 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 N-CA-C 107.189 -1.889 . . . . 0.0 107.189 176.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.431 ' CD2' HD12 ' A' ' 33' ' ' ILE . 17.6 mt -56.33 -18.19 10.07 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.874 -1.141 . . . . 0.0 110.94 -177.659 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.49 -16.47 24.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.636 -1.29 . . . . 0.0 110.087 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.431 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 14.4 m -93.96 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.155 -0.966 . . . . 0.0 110.981 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.537 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 40.9 pt -118.15 -22.79 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.934 -1.104 . . . . 0.0 110.872 -178.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.476 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.26 22.16 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.506 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.02 -5.27 59.35 Favored Glycine 0 N--CA 1.483 1.82 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.22 -162.58 27.81 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.678 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.22 129.38 44.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.468 -1.019 . . . . 0.0 110.351 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.537 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.5 m-70 -138.93 145.59 40.01 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.222 -0.924 . . . . 0.0 110.607 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.476 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 38.3 tp -108.06 117.17 33.43 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.431 ' CD1' HG22 ' A' ' 33' ' ' ILE . 10.5 mm -94.03 125.69 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.275 -0.891 . . . . 0.0 108.601 179.26 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.476 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 11.4 m-85 -94.21 121.81 36.11 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.089 -1.007 . . . . 0.0 109.637 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.46 150.69 39.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.271 -0.893 . . . . 0.0 110.83 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.583 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 2.4 p-80 -103.74 3.59 34.33 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 109.682 178.442 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.55 135.39 45.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.186 -0.946 . . . . 0.0 110.199 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.428 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.4 ttpt -71.28 -37.2 71.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.609 -0.682 . . . . 0.0 110.735 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.7 -37.03 80.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.315 -0.866 . . . . 0.0 110.775 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 4.3 tptm -72.6 -36.33 68.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 110.015 -179.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.441 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 71.1 m -60.4 -34.23 73.63 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.475 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.72 -49.15 56.07 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 110.538 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.429 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.43 -41.71 69.17 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.147 -0.971 . . . . 0.0 110.583 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.448 ' CD1' HG13 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.9 80.41 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 111.282 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.11 -51.0 43.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.934 -1.104 . . . . 0.0 110.175 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.88 -31.76 65.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.209 -0.932 . . . . 0.0 109.123 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.479 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.83 -47.06 85.05 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 179.358 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.496 ' CB ' ' HB3' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -60.99 -41.42 96.46 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.279 -0.888 . . . . 0.0 111.053 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.0 t -56.38 -33.93 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.868 -1.145 . . . . 0.0 109.227 179.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -34.83 60.3 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.318 -0.864 . . . . 0.0 110.482 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.479 HD22 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.32 -25.57 62.47 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.409 -0.807 . . . . 0.0 109.833 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.31 8.9 8.25 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.476 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 36.5 mt -108.34 143.73 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.338 -1.095 . . . . 0.0 109.666 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.413 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.6 t30 -90.07 106.75 18.69 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.23 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.496 ' HB3' ' CB ' ' A' ' 55' ' ' LEU . . . -119.59 145.96 45.94 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.508 -176.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.474 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.64 149.36 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.52 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.43 128.29 56.4 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.711 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.461 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 12.9 t80 -119.96 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.384 -0.823 . . . . 0.0 110.094 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.477 ' CZ ' HD22 ' A' ' 69' ' ' LEU . 2.7 p90 -167.76 -178.27 3.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.521 -0.737 . . . . 0.0 109.776 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.13 116.78 3.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.175 -0.953 . . . . 0.0 110.617 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.69 36.12 7.5 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.477 HD22 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.68 156.88 27.44 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.191 -1.182 . . . . 0.0 110.122 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.436 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 33.7 m-20 -97.41 149.01 22.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.284 -0.885 . . . . 0.0 110.088 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.422 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 33.7 m -62.45 111.28 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 C-N-CA 119.261 -0.976 . . . . 0.0 109.207 179.245 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.466 ' CB ' HG13 ' A' ' 63' ' ' VAL . 27.4 m -130.16 -34.39 1.66 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.366 -0.834 . . . . 0.0 110.731 -179.459 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.474 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 50.7 t -49.88 151.77 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.225 -0.922 . . . . 0.0 109.459 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.406 ' CG1' ' O ' ' A' ' 74' ' ' ILE . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.78 0 O-C-N 120.781 -1.199 . . . . 0.0 111.523 -178.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 122.059 0.933 . . . . 0.0 110.242 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.432 ' O ' HG12 ' A' ' 80' ' ' VAL . 4.9 p -117.25 131.07 71.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 122.062 0.935 . . . . 0.0 110.057 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.478 HG23 ' CB ' ' A' ' 62' ' ' ALA . 6.2 m -112.95 121.36 65.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.418 HG21 ' CG1' ' A' ' 73' ' ' VAL . 11.1 t -96.76 118.52 43.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.148 -0.97 . . . . 0.0 110.414 -177.647 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.513 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 2.9 m -109.44 100.34 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.063 -1.023 . . . . 0.0 108.79 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.461 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -143.0 161.6 37.69 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.6 -1.313 . . . . 0.0 111.108 -178.31 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.8 t -85.37 -136.97 0.07 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.493 -0.755 . . . . 0.0 109.147 179.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -82.54 -13.64 56.26 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.723 -1.235 . . . . 0.0 110.404 179.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.442 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -52.65 -41.96 64.26 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.072 -1.017 . . . . 0.0 110.339 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.421 HD13 ' CB ' ' A' ' 65' ' ' TYR . 2.4 tp . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.081 -1.012 . . . . 0.0 109.769 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.314 0.578 . . . . 0.0 110.611 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -116.64 151.69 35.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.331 -0.855 . . . . 0.0 109.494 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.49 -32.98 72.19 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.342 -0.943 . . . . 0.0 109.327 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.7 p -162.37 163.56 27.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.274 -0.891 . . . . 0.0 111.084 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.549 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.3 OUTLIER -130.83 112.98 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.52 -0.738 . . . . 0.0 109.886 179.343 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.2 mp -94.48 115.32 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.217 -0.927 . . . . 0.0 109.166 179.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -127.99 161.12 29.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 111.504 -178.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.434 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.7 t -90.94 -9.1 47.36 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 57.35 13.74 1.88 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.293 -0.879 . . . . 0.0 111.662 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.2 m . . . . . 0 C--N 1.306 -1.31 0 O-C-N 120.777 -1.202 . . . . 0.0 108.992 179.541 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.906 0 CA-C-O 121.591 0.71 . . . . 0.0 111.239 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.442 ' O ' ' OG ' ' A' ' 114' ' ' SER . 4.4 p-10 -73.25 162.49 29.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.501 -0.749 . . . . 0.0 109.971 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.16 -42.61 91.15 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.884 -1.135 . . . . 0.0 111.62 -178.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.433 ' CG2' ' OD2' ' A' ' 111' ' ' ASP . 6.7 m -72.59 -30.86 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 120.784 -1.198 . . . . 0.0 113.031 -178.001 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.74 -55.76 20.44 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.474 -1.391 . . . . 0.0 110.3 -178.766 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -62.88 -34.71 77.97 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 118.695 -1.202 . . . . 0.0 108.225 178.327 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 24.6 m -61.46 -50.7 71.72 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.89 41.91 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.832 . . . . 0.0 109.6 178.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 25.2 mtt180 -59.59 -45.14 92.78 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.287 -0.883 . . . . 0.0 110.405 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.496 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 20.1 ttm180 -62.68 -34.59 77.41 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.734 -1.229 . . . . 0.0 110.071 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.427 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.78 -5.36 31.06 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 119.998 -1.096 . . . . 0.0 111.12 -179.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.95 -4.96 58.77 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.656 -1.496 . . . . 0.0 110.96 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.47 ' CG2' ' CG2' ' A' ' 99' ' ' VAL . 0.5 OUTLIER -118.72 140.36 50.06 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.859 -1.151 . . . . 0.0 109.442 179.535 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.01 19.6 39.17 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.427 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 10.2 mmt85 -69.39 85.98 0.42 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.033 -1.275 . . . . 0.0 109.806 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.05 57.82 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.437 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.41 -174.8 0.39 Allowed Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.202 -1.175 . . . . 0.0 109.016 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -85.22 103.33 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.36 1.19 . . . . 0.0 109.438 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.406 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -86.98 173.25 44.72 Favored Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.046 -179.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.4 mt -122.18 142.92 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -1.056 . . . . 0.0 109.54 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.7 t80 -127.02 115.34 19.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.166 -0.959 . . . . 0.0 110.178 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.431 ' CZ ' HG13 ' A' ' 32' ' ' VAL . 10.6 mtt85 -105.65 135.26 47.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.353 -0.842 . . . . 0.0 109.476 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.2 147.0 45.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.153 -0.967 . . . . 0.0 110.552 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.434 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 54.4 t . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.829 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.465 ' ND2' ' N ' ' A' ' 9' ' ' ASN . 0.1 OUTLIER . . . . . 0 N--CA 1.507 2.382 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.465 HD11 HG23 ' A' ' 10' ' ' ILE . 12.7 mt -124.32 135.62 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.131 -1.606 . . . . 0.0 109.562 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.88 128.74 34.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.316 -0.865 . . . . 0.0 109.801 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.36 140.93 29.01 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.194 -0.941 . . . . 0.0 109.882 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.426 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 6.5 t -134.78 153.97 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.224 -0.923 . . . . 0.0 110.467 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.59 18.6 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.325 -0.859 . . . . 0.0 109.552 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.8 tp -56.08 136.63 52.29 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.29 -0.881 . . . . 0.0 109.778 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.42 -167.58 1.99 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 110.288 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.2 p -88.3 73.24 8.88 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' HB1' ' A' ' 27' ' ' ALA . 7.3 m -146.04 112.37 5.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 110.48 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.34 -165.35 27.87 Favored Glycine 0 N--CA 1.489 2.204 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.831 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.59 -21.57 9.08 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.61 -0.936 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.466 HG21 ' O ' ' A' ' 28' ' ' ILE . 9.1 tt -98.85 105.69 32.76 Favored Pre-proline 0 N--CA 1.488 1.46 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.179 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -62.95 155.0 63.13 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.225 1.118 . . . . 0.0 109.66 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.457 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.2 t80 -167.55 93.61 0.41 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.062 -1.024 . . . . 0.0 111.576 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.479 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 25.5 m-85 59.38 67.04 0.94 Allowed 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.571 -0.705 . . . . 0.0 111.554 179.06 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.09 13.81 15.82 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.84 156.89 44.25 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.105 -1.233 . . . . 0.0 109.039 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.44 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -118.06 107.92 14.59 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.789 -1.194 . . . . 0.0 109.675 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.466 ' O ' HG21 ' A' ' 21' ' ' ILE . 4.5 mt -70.89 114.15 24.6 Favored Pre-proline 0 C--N 1.299 -1.62 0 O-C-N 121.411 -0.806 . . . . 0.0 110.637 -179.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.453 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 39.3 Cg_endo -68.91 128.42 16.79 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 N-CA-C 106.906 -1.998 . . . . 0.0 106.906 176.181 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.439 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 6.9 mt -55.91 -18.94 10.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.914 -1.116 . . . . 0.0 110.678 -177.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.51 -16.29 23.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.714 -1.241 . . . . 0.0 110.296 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.432 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 13.1 m -92.24 -25.43 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 120.968 -1.082 . . . . 0.0 111.228 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.534 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 8.9 pt -117.9 -18.53 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.985 -1.072 . . . . 0.0 110.662 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.453 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 9.7 tptt -96.24 148.92 22.22 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.931 -1.106 . . . . 0.0 110.417 179.534 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.84 56.7 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.8 -159.22 21.81 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.239 -1.457 . . . . 0.0 110.091 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.6 mtt85 -100.61 130.65 46.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.404 -1.057 . . . . 0.0 110.603 -179.571 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.534 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.2 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 110.505 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.418 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 14.0 tp -109.49 120.96 44.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 110.301 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.438 ' CG1' HG13 ' A' ' 83' ' ' VAL . 12.3 mm -99.72 125.58 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.194 -0.941 . . . . 0.0 109.283 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.481 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.3 123.05 38.62 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.098 -1.001 . . . . 0.0 109.709 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.24 157.89 25.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.239 -0.913 . . . . 0.0 110.857 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.479 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 0.7 OUTLIER -105.75 8.14 32.79 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.412 -0.805 . . . . 0.0 109.967 178.939 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.46 139.65 40.75 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.172 -0.955 . . . . 0.0 110.346 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.93 -38.11 69.92 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 110.783 -179.683 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.93 -37.26 86.74 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.759 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.91 -35.98 82.9 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.765 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.431 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 66.2 m -60.2 -34.34 73.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.407 -0.808 . . . . 0.0 109.039 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.03 -48.83 64.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.191 -0.943 . . . . 0.0 110.25 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.0 mt-10 -71.46 -45.59 62.18 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.198 -0.939 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.422 ' CD1' HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.42 -41.38 76.27 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.373 -0.83 . . . . 0.0 111.338 -178.926 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.415 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.36 -50.92 14.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 110.363 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.73 -41.62 99.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 109.446 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.434 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 0.0 OUTLIER -58.4 -46.16 86.95 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.346 -0.846 . . . . 0.0 109.433 179.341 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.41 -42.93 78.81 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.487 -0.758 . . . . 0.0 110.236 179.853 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.9 -33.43 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.073 -1.017 . . . . 0.0 109.166 179.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.61 -31.48 59.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.323 -0.861 . . . . 0.0 110.004 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.467 HD23 ' N ' ' A' ' 58' ' ' LEU . 3.9 mm? -72.07 -26.54 62.21 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.893 0.854 . . . . 0.0 109.601 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.03 6.3 8.45 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.46 HG22 HG21 ' A' ' 81' ' ' VAL . 35.1 mt -107.86 143.87 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -1.14 . . . . 0.0 110.144 -179.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.415 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 15.8 t30 -88.02 106.45 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.364 -1.717 . . . . 0.0 106.364 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -116.69 141.67 47.9 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.671 -177.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.495 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 87.4 t -124.27 147.9 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.998 -0.681 . . . . 0.0 109.69 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -115.47 127.04 55.04 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.822 178.503 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.448 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.71 31.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 110.57 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.481 ' CE1' HD22 ' A' ' 69' ' ' LEU . 4.7 p90 -147.78 175.08 11.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.619 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.69 5.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 110.766 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.9 37.18 10.43 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.481 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.31 155.93 28.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.115 -1.227 . . . . 0.0 109.969 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.453 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 32.3 m-20 -95.61 149.25 21.66 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.225 -0.922 . . . . 0.0 110.462 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.423 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 33.4 m -61.81 110.08 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 120.939 -1.101 . . . . 0.0 108.969 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.7 m -132.13 -9.69 3.38 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.508 -0.745 . . . . 0.0 110.953 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.495 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 40.1 t -72.27 135.12 28.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.082 -1.012 . . . . 0.0 109.305 -179.582 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.3 pp . . . . . 0 N--CA 1.493 1.722 0 O-C-N 121.155 -0.965 . . . . 0.0 111.235 -178.979 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.965 0.888 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -116.06 135.42 56.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 121.966 0.889 . . . . 0.0 110.302 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.485 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 19.0 m -111.88 126.88 69.31 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 O-C-N 121.464 -0.773 . . . . 0.0 109.236 179.567 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.418 HG22 HG12 ' A' ' 73' ' ' VAL . 7.6 t -97.63 116.91 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.793 -1.192 . . . . 0.0 110.502 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.503 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.9 m -110.67 100.07 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.884 -1.135 . . . . 0.0 108.691 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.448 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.53 162.48 34.96 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.568 -1.332 . . . . 0.0 111.195 -178.109 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.3 t -90.8 -133.36 0.12 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.524 -0.735 . . . . 0.0 109.112 179.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 49.4 p-10 -90.02 41.74 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.583 -1.323 . . . . 0.0 110.147 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.91 -32.09 6.5 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.92 . . . . 0.0 108.907 178.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.052 0.453 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -119.39 151.06 39.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.955 -1.09 . . . . 0.0 110.255 179.366 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.87 -28.4 20.38 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.348 -0.845 . . . . 0.0 109.417 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 p -160.87 163.33 32.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.397 -0.815 . . . . 0.0 110.675 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.15 115.39 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 110.093 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.421 HG22 ' CD1' ' A' ' 28' ' ' ILE . 3.4 mp -95.52 111.29 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.16 -0.962 . . . . 0.0 108.579 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -119.65 161.17 21.13 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.159 -0.963 . . . . 0.0 111.786 -178.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.441 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.1 t -101.84 8.5 41.28 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.715 -0.616 . . . . 0.0 109.502 178.191 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 51.66 23.75 2.09 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.113 -0.992 . . . . 0.0 111.293 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.492 1.634 0 O-C-N 121.17 -0.956 . . . . 0.0 109.972 179.141 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.475 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.308 0.575 . . . . 0.0 111.053 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -88.45 161.12 17.21 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.298 -0.876 . . . . 0.0 110.345 179.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -46.01 -54.97 7.49 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -178.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.417 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.67 -31.89 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 120.585 -1.322 . . . . 0.0 112.685 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.475 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.41 -56.22 8.77 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.96 -1.088 . . . . 0.0 110.434 -179.266 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.463 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.74 -35.54 80.35 Favored 'General case' 0 C--O 1.205 -1.284 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.265 178.781 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.417 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.0 m -58.38 -49.2 78.08 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.541 178.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.08 -35.54 71.9 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.376 -0.827 . . . . 0.0 109.571 178.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.481 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.2 -45.18 61.41 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.239 -0.913 . . . . 0.0 110.931 -179.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.463 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 14.4 ttt180 -54.03 -45.17 71.52 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.045 -1.035 . . . . 0.0 109.995 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.58 64.19 0.29 Allowed Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.225 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.42 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.78 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.562 -0.964 . . . . 0.0 108.438 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.449 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 10.9 t -96.12 142.87 27.79 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.621 -0.674 . . . . 0.0 109.478 178.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.433 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.68 33.25 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.47 -1.348 . . . . 0.0 110.94 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.29 87.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.047 -1.266 . . . . 0.0 109.397 179.607 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.87 -8.33 70.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -178.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.47 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.03 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.18 -1.188 . . . . 0.0 109.265 -179.799 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.47 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -89.04 97.46 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.379 1.199 . . . . 0.0 110.601 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.449 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.24 171.09 53.01 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.7 mp -126.85 142.15 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.488 -1.007 . . . . 0.0 109.305 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -128.65 115.27 17.78 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.0 . . . . 0.0 110.314 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.426 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 4.1 mtp180 -104.73 122.8 46.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.433 -0.792 . . . . 0.0 109.17 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -121.53 157.5 30.55 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 110.415 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.341 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.508 2.446 0 CA-C-O 120.666 0.27 . . . . 0.0 111.055 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.46 HD12 ' CG2' ' A' ' 122' ' ' THR . 12.5 mt -95.79 124.92 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.574 -1.329 . . . . 0.0 109.892 179.53 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.57 128.02 34.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.138 -0.976 . . . . 0.0 109.554 179.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.97 132.95 35.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -0.943 . . . . 0.0 110.005 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.434 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 16.7 t -122.08 149.94 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.24 -0.912 . . . . 0.0 110.419 -179.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.85 21.65 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.268 -0.895 . . . . 0.0 109.706 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.457 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 9.0 tp -53.52 141.1 26.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.278 -0.889 . . . . 0.0 109.881 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.3 p -136.09 -178.49 5.17 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.253 -0.905 . . . . 0.0 110.526 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.8 p -79.74 71.19 6.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.887 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.429 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 5.9 m -146.12 112.71 5.94 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.317 -0.865 . . . . 0.0 110.424 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.47 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.81 28.42 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 118.731 -1.7 . . . . 0.0 111.173 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.62 10.4 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.783 -0.834 . . . . 0.0 110.306 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.462 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.14 107.94 41.06 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.666 -1.214 . . . . 0.0 110.098 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.413 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.5 Cg_endo -65.05 117.4 4.51 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 O-C-N 123.478 1.251 . . . . 0.0 110.645 -179.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.5 -170.79 1.8 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.649 -0.657 . . . . 0.0 110.592 -179.489 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.53 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.5 m-85 -57.73 82.26 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.552 -0.718 . . . . 0.0 111.634 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.15 -1.84 54.16 Favored Glycine 0 N--CA 1.493 2.437 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.684 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.457 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 12.1 mmtm -130.1 156.18 44.96 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.858 -1.378 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.429 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -105.83 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.94 -1.1 . . . . 0.0 109.427 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.462 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 3.9 mt -68.38 112.95 12.55 Favored Pre-proline 0 C--N 1.301 -1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 110.779 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.47 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 40.0 Cg_endo -68.26 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 N-CA-C 106.96 -1.977 . . . . 0.0 106.96 175.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.417 HD22 HD11 ' A' ' 60' ' ' ILE . 12.4 mt -56.72 -16.65 6.81 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.826 -1.171 . . . . 0.0 110.652 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.83 -15.97 36.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.686 -1.259 . . . . 0.0 110.268 179.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.477 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.1 m -91.77 -25.71 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.011 -1.056 . . . . 0.0 111.213 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.512 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 27.7 pt -118.48 -25.33 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.938 -1.101 . . . . 0.0 110.199 -179.496 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.454 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.41 148.18 22.5 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 110.648 179.828 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.87 57.77 Favored Glycine 0 N--CA 1.484 1.891 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.42 -151.27 8.74 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.127 -1.511 . . . . 0.0 110.278 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.3 mtt85 -109.74 132.37 54.21 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.53 -0.982 . . . . 0.0 110.1 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 90.9 m-70 -140.81 152.94 45.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.087 -1.008 . . . . 0.0 110.993 -179.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 54.9 tp -112.03 114.17 26.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.4 -0.812 . . . . 0.0 109.994 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.44 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 32.8 mt -98.37 129.2 48.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.594 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.4 123.82 38.04 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.304 -0.873 . . . . 0.0 109.751 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.86 158.83 23.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 110.801 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.53 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.17 4.28 20.91 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.439 -0.788 . . . . 0.0 110.023 179.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.11 137.05 38.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.058 -1.026 . . . . 0.0 110.618 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.59 -42.82 67.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.485 -0.76 . . . . 0.0 110.219 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.83 -39.21 84.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.882 . . . . 0.0 110.45 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.74 -35.11 76.69 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.404 ' O ' ' CB ' ' A' ' 64' ' ' ALA . 1.7 m -61.14 -34.1 74.47 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.537 -0.727 . . . . 0.0 109.501 179.212 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.76 -49.43 62.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.235 -0.916 . . . . 0.0 110.255 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.79 -44.64 63.64 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -0.951 . . . . 0.0 110.146 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.412 ' CD2' HD12 ' A' ' 21' ' ' ILE . 2.6 tm? -57.17 -41.65 79.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.819 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.0 -51.16 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.03 -1.044 . . . . 0.0 110.382 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.08 96.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.12 -0.988 . . . . 0.0 109.675 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.43 ' CE ' HG13 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -57.15 -44.91 83.86 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 179.485 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.468 HD22 HG22 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -55.1 -42.68 73.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.517 -0.739 . . . . 0.0 109.885 179.956 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.4 -32.09 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.007 -1.058 . . . . 0.0 108.807 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.4 -30.87 60.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.389 -0.82 . . . . 0.0 109.608 179.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.451 HD22 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -71.66 -26.17 62.43 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.833 0.825 . . . . 0.0 109.467 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.04 7.44 10.27 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.143 -1.583 . . . . 0.0 109.143 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.476 HG22 HG21 ' A' ' 81' ' ' VAL . 56.4 mt -108.26 143.24 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.277 -1.131 . . . . 0.0 110.349 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.93 107.56 17.78 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.924 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -122.01 144.62 48.78 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.019 -1.072 . . . . 0.0 111.643 -177.558 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.483 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 45.2 t -130.3 143.58 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 C-N-CA 119.976 -0.69 . . . . 0.0 109.512 179.083 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -109.49 118.36 36.41 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.95 179.094 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.445 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.65 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.26 -0.9 . . . . 0.0 110.574 -179.59 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.485 ' CD1' ' HD2' ' A' ' 45' ' ' LYS . 2.2 p90 -167.31 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.544 -0.723 . . . . 0.0 109.757 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.24 127.14 30.6 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.165 -0.96 . . . . 0.0 110.764 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.32 37.77 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.475 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.4 tm? -117.09 155.81 28.64 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.156 -1.203 . . . . 0.0 110.101 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.454 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.24 22.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.366 -0.834 . . . . 0.0 110.545 -179.351 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.42 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 29.5 m -62.1 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 119.061 -1.055 . . . . 0.0 109.002 179.229 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.72 -15.45 2.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.507 -0.746 . . . . 0.0 111.413 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.483 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.06 23.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.072 -1.017 . . . . 0.0 109.471 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.432 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.6 pp . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.261 -0.899 . . . . 0.0 111.004 -179.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.41 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.7 m-20 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.873 0.845 . . . . 0.0 109.998 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 8.2 p -115.06 130.91 68.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 122.152 0.977 . . . . 0.0 110.414 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.476 HG21 HG22 ' A' ' 60' ' ' ILE . 6.9 m -113.0 123.04 68.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 O-C-N 121.351 -0.843 . . . . 0.0 109.104 179.052 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.441 ' CG2' HG11 ' A' ' 73' ' ' VAL . 4.7 t -97.06 118.07 42.82 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 O-C-N 121.056 -1.028 . . . . 0.0 110.149 -177.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.498 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.9 m -111.19 100.3 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.809 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.445 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.46 162.64 34.99 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.765 -1.209 . . . . 0.0 111.122 -178.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -90.17 -139.26 0.14 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.598 -0.689 . . . . 0.0 109.4 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.41 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -86.01 48.05 1.55 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.806 -1.184 . . . . 0.0 109.99 179.706 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.425 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.24 -19.22 7.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.173 -0.955 . . . . 0.0 110.646 -179.671 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp . . . . . 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.671 179.821 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.104 0.478 . . . . 0.0 110.965 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -119.74 144.86 47.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.075 -1.016 . . . . 0.0 109.918 178.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.485 ' CB ' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.21 -33.44 63.39 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.502 179.334 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.0 p -162.88 163.56 26.35 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.272 -0.892 . . . . 0.0 110.913 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.494 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.19 116.58 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.331 -0.855 . . . . 0.0 110.078 179.062 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.428 HG22 ' CD1' ' A' ' 28' ' ' ILE . 4.1 mp -93.37 118.41 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.178 -0.951 . . . . 0.0 109.031 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -126.85 160.87 29.66 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.119 -0.988 . . . . 0.0 111.454 -178.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 37.0 t -101.59 7.26 42.26 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.685 -0.634 . . . . 0.0 109.393 178.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 49.07 33.2 4.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 111.111 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.415 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p . . . . . 0 N--CA 1.492 1.627 0 O-C-N 120.877 -1.139 . . . . 0.0 110.819 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.42 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.511 0.672 . . . . 0.0 110.837 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.446 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.7 p30 -80.74 161.49 24.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -0.954 . . . . 0.0 109.664 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.419 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.32 -57.05 4.29 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.847 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.446 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -66.17 -28.34 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 120.823 -1.173 . . . . 0.0 111.729 -178.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.421 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.12 -56.27 6.89 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.994 -1.066 . . . . 0.0 110.715 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.437 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.55 -35.91 78.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.108 -0.995 . . . . 0.0 108.836 178.931 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.1 m -59.27 -49.48 77.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.066 -1.021 . . . . 0.0 108.598 178.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.74 -35.52 65.07 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.493 -0.755 . . . . 0.0 109.754 178.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.419 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.58 -44.81 63.81 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 110.844 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.437 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 2.8 ttm180 -55.01 -37.97 67.29 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.9 -1.125 . . . . 0.0 109.721 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.53 77.21 0.13 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -153.38 -49.08 0.1 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.462 -1.022 . . . . 0.0 108.522 179.51 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.462 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.7 t -93.14 143.3 26.38 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.369 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.446 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.25 15.96 5.85 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.263 -1.446 . . . . 0.0 110.405 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 25.4 mmt180 -92.9 83.02 4.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.065 -1.256 . . . . 0.0 110.106 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.12 -26.83 6.01 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.49 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.29 -166.51 0.15 Allowed Pre-proline 0 N--CA 1.488 1.456 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.61 115.02 2.44 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.025 1.013 . . . . 0.0 110.545 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.462 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -78.99 172.09 55.22 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.437 ' N ' HG22 ' A' ' 122' ' ' THR . 1.8 mp -132.76 142.6 41.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.283 -1.128 . . . . 0.0 109.432 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.494 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.24 115.21 17.29 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.316 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.434 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.67 122.54 43.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.814 . . . . 0.0 109.213 179.505 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -117.44 149.71 40.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.036 -1.04 . . . . 0.0 110.228 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.207 -0.933 . . . . 0.0 110.079 179.919 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.422 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.2 m120 . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.054 0.454 . . . . 0.0 110.406 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.463 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 34.0 mt -119.62 136.17 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.906 -1.121 . . . . 0.0 110.436 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.79 128.89 34.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.319 -0.863 . . . . 0.0 109.543 179.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.24 132.42 34.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.226 -0.921 . . . . 0.0 110.339 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.471 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 29.5 t -122.64 157.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.45 -0.781 . . . . 0.0 110.246 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.04 110.64 22.82 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.209 -0.932 . . . . 0.0 109.851 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.431 ' O ' ' CD ' ' A' ' 26' ' ' LYS . 12.1 tp -62.63 134.77 56.82 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.279 -0.888 . . . . 0.0 109.68 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.68 179.52 6.18 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.911 . . . . 0.0 110.176 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.92 74.47 2.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 109.631 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.428 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.5 m -144.55 111.61 5.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 110.576 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.48 -159.35 27.18 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.561 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.94 -24.78 5.99 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.602 -0.94 . . . . 0.0 110.522 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.468 HG22 ' O ' ' A' ' 28' ' ' ILE . 8.9 tt -95.86 108.76 42.6 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.618 -1.233 . . . . 0.0 110.492 -179.399 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.33 154.56 70.61 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.341 1.18 . . . . 0.0 109.897 179.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.496 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.3 t80 -167.79 95.02 0.42 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 110.891 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.439 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 66.8 m-85 60.33 65.48 1.07 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.5 -0.75 . . . . 0.0 111.188 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 15.87 16.53 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.496 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 3.6 mmtt -130.54 157.26 43.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.182 -1.187 . . . . 0.0 109.389 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -115.98 107.39 14.91 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.77 -1.206 . . . . 0.0 109.719 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.468 ' O ' HG22 ' A' ' 21' ' ' ILE . 3.9 mt -69.84 114.03 21.85 Favored Pre-proline 0 C--N 1.301 -1.523 0 O-C-N 121.294 -0.879 . . . . 0.0 110.461 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.468 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.3 Cg_endo -69.14 130.09 19.45 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 N-CA-C 106.586 -2.121 . . . . 0.0 106.586 175.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.445 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 7.6 mt -56.16 -18.32 9.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.734 -1.228 . . . . 0.0 110.528 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.33 -15.91 19.08 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.662 -1.274 . . . . 0.0 110.693 179.68 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.443 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.3 m -92.46 -25.14 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 120.884 -1.135 . . . . 0.0 110.995 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.523 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 10.3 pt -116.89 -22.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 -179.403 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.468 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.0 tptt -92.67 148.46 22.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.001 -1.062 . . . . 0.0 109.97 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.71 -5.68 43.76 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.6 -152.66 11.2 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.086 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.435 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.46 131.41 52.91 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.314 -1.109 . . . . 0.0 110.292 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.523 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.41 153.73 51.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.154 -0.966 . . . . 0.0 110.943 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.42 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 65.5 tp -114.45 118.27 33.33 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.371 -0.83 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.429 ' CG1' HG13 ' A' ' 83' ' ' VAL . 30.2 mt -104.39 127.92 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.127 -0.983 . . . . 0.0 109.673 179.395 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.42 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 24.9 m-85 -95.74 122.73 38.82 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.242 -0.911 . . . . 0.0 110.097 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.79 159.01 23.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.523 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.429 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.31 26.84 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 110.375 179.18 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.74 136.34 37.24 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.09 -1.007 . . . . 0.0 110.916 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.469 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.0 69.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.557 -0.714 . . . . 0.0 110.232 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.31 -36.48 84.26 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.282 -0.886 . . . . 0.0 110.421 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.82 -36.48 75.66 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.233 -0.917 . . . . 0.0 109.513 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.442 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 98.7 m -61.65 -34.05 75.03 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.439 -0.788 . . . . 0.0 109.684 179.465 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.35 -49.42 64.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.175 -0.953 . . . . 0.0 109.957 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.79 -45.66 60.87 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.097 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.419 ' CD1' HG11 ' A' ' 83' ' ' VAL . 2.1 tm? -56.49 -41.67 77.01 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.446 -0.784 . . . . 0.0 110.567 -179.411 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.411 ' O ' ' HB2' ' A' ' 62' ' ' ALA . . . -76.0 -51.43 12.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.092 -1.005 . . . . 0.0 110.236 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.44 -42.04 98.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.985 -1.072 . . . . 0.0 109.652 179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.44 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -57.09 -44.39 83.09 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.167 -0.958 . . . . 0.0 109.644 179.614 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.11 -41.58 71.84 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.345 -0.847 . . . . 0.0 109.612 179.735 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.6 t -56.27 -33.18 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.146 -0.971 . . . . 0.0 108.815 179.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.0 -32.05 59.23 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.5 -0.75 . . . . 0.0 110.131 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.456 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.0 mm? -71.62 -26.42 62.57 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.332 -0.855 . . . . 0.0 109.712 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.09 8.36 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.47 HG23 HG23 ' A' ' 81' ' ' VAL . 49.4 mt -108.15 143.94 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.202 -1.175 . . . . 0.0 110.32 -179.677 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.422 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.3 t30 -86.84 107.1 18.16 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 178.121 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.482 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.86 147.71 45.03 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.62 -177.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.504 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 2.9 t -136.11 148.71 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.507 179.308 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -111.32 126.95 55.45 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.095 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 5.4 t80 -117.48 125.9 51.69 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 110.713 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.473 ' CE1' HD22 ' A' ' 69' ' ' LEU . 5.5 p90 -157.76 -174.85 5.05 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.63 123.64 11.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 0.0 111.26 -179.212 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.65 47.73 32.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.473 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.27 155.7 29.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.07 -1.253 . . . . 0.0 109.807 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.454 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 7.7 m-20 -92.12 148.6 22.04 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.201 -0.937 . . . . 0.0 110.825 -179.18 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.412 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 30.4 m -62.8 111.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.055 -1.028 . . . . 0.0 109.336 179.068 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.443 ' CB ' HG12 ' A' ' 63' ' ' VAL . 10.6 m -134.58 -35.96 0.88 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.375 -0.828 . . . . 0.0 110.849 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.504 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 24.9 t -51.38 135.85 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.032 -1.043 . . . . 0.0 110.055 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.419 ' O ' ' CG1' ' A' ' 74' ' ' ILE . 1.4 pp . . . . . 0 N--CA 1.495 1.776 0 O-C-N 121.263 -0.898 . . . . 0.0 110.724 -179.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 m-20 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.973 0.892 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.435 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.6 p -117.33 133.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 122.003 0.906 . . . . 0.0 110.347 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.48 HG21 ' CB ' ' A' ' 62' ' ' ALA . 9.5 m -111.93 124.2 68.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.202 0 O-C-N 121.311 -0.868 . . . . 0.0 108.773 178.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.45 ' CG2' HG12 ' A' ' 73' ' ' VAL . 5.7 t -97.24 120.99 47.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 110.306 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.6 m -116.47 100.48 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.971 -1.081 . . . . 0.0 108.7 179.592 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -138.4 162.22 35.0 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.683 -1.261 . . . . 0.0 111.454 -177.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.1 t -87.24 -132.27 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.612 -0.68 . . . . 0.0 109.708 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -91.5 32.83 1.04 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.803 -1.186 . . . . 0.0 110.594 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.443 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.49 -32.96 9.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.095 -1.003 . . . . 0.0 109.887 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.85 . . . . 0.0 109.254 179.213 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.129 0.49 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -119.07 148.16 43.34 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.18 -0.95 . . . . 0.0 109.906 178.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.407 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.95 -32.25 61.68 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.272 -0.893 . . . . 0.0 109.486 179.294 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.406 ' OG ' ' ND1' ' A' ' 38' ' ' HIS . 4.0 p -162.51 163.79 27.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.218 -0.927 . . . . 0.0 111.207 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.531 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.47 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.452 -0.78 . . . . 0.0 110.3 179.347 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.407 ' CD1' HG23 ' A' ' 33' ' ' ILE . 3.1 mp -92.88 117.78 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.893 . . . . 0.0 108.795 179.145 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.19 20.5 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.07 -1.019 . . . . 0.0 112.107 -178.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.22 -11.66 34.81 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.434 ' HB3' ' NE2' ' A' ' 110' ' ' GLN . 3.7 m120 55.58 12.37 0.78 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.294 -0.879 . . . . 0.0 112.487 179.091 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.306 -1.295 0 O-C-N 120.491 -1.38 . . . . 0.0 109.495 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.434 ' NE2' ' HB3' ' A' ' 103' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 121.332 0.587 . . . . 0.0 110.851 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 114' ' ' SER . 1.6 p30 -88.92 160.36 17.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.9 . . . . 0.0 109.85 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.85 -51.13 7.66 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.424 -0.798 . . . . 0.0 112.317 -178.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.427 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.44 -29.7 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.795 -1.19 . . . . 0.0 111.447 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.443 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.08 -56.47 6.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.08 -1.013 . . . . 0.0 110.402 -179.204 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -69.49 -34.38 74.24 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.301 -0.874 . . . . 0.0 108.688 178.756 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 22.5 m -59.22 -50.02 75.6 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.164 -0.96 . . . . 0.0 108.454 178.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.93 -39.52 63.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.763 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.401 ' HB2' ' O ' ' A' ' 114' ' ' SER . 2.2 mtt180 -67.47 -44.32 78.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.168 -0.958 . . . . 0.0 110.557 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.484 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 7.0 ttm180 -60.47 -39.06 86.25 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.026 -1.046 . . . . 0.0 110.057 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.74 66.69 0.44 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.06 -46.6 0.3 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.514 -0.992 . . . . 0.0 108.602 179.471 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.45 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 15.0 t -94.45 142.13 27.79 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.375 -0.828 . . . . 0.0 109.136 178.657 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.89 10.03 19.45 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.556 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.0 mmt85 -69.3 86.96 0.42 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.011 -1.288 . . . . 0.0 109.69 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.2 22.17 33.19 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.463 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.85 -178.31 0.29 Allowed Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.514 -0.992 . . . . 0.0 108.717 -179.515 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.463 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.3 Cg_endo -89.65 103.94 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.258 1.136 . . . . 0.0 110.126 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.45 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -77.61 156.84 45.09 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.605 -179.303 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 38.8 mt -111.05 142.06 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.479 -1.012 . . . . 0.0 109.046 178.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.531 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 5.4 t80 -132.09 118.91 20.27 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.09 -1.006 . . . . 0.0 110.785 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -101.51 124.04 46.52 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.454 -0.779 . . . . 0.0 109.477 179.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.471 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.6 p90 -118.04 155.87 29.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 110.229 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.1 t . . . . . 0 N--CA 1.493 1.722 0 O-C-N 121.168 -0.958 . . . . 0.0 109.869 179.602 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.8 t-20 . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.512 0.672 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.453 HD13 HG21 ' A' ' 10' ' ' ILE . 33.0 mt -103.48 136.34 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.011 -1.056 . . . . 0.0 110.094 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.9 129.46 35.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 109.322 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.75 34.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.173 -0.954 . . . . 0.0 110.294 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.41 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 20.4 t -117.84 155.0 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.641 -0.662 . . . . 0.0 110.026 -179.422 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.19 106.89 17.58 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.439 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 12.5 tp -57.6 132.16 52.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.593 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.8 p -135.84 -166.95 1.94 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.192 -0.942 . . . . 0.0 110.587 -179.516 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.41 ' HA ' ' HB1' ' A' ' 27' ' ' ALA . 5.1 p -82.49 83.45 7.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.436 -0.79 . . . . 0.0 109.917 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.421 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 11.0 m -156.9 110.04 2.58 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.302 -0.874 . . . . 0.0 110.541 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.38 28.52 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 118.895 -1.622 . . . . 0.0 110.956 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -117.49 -24.68 7.23 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.78 -0.835 . . . . 0.0 110.404 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.464 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -93.86 103.48 10.4 Favored Pre-proline 0 N--CA 1.485 1.303 0 C-N-CA 118.496 -1.281 . . . . 0.0 109.99 -179.342 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -61.61 118.76 5.66 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 O-C-N 123.682 1.359 . . . . 0.0 110.558 -179.564 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.62 -168.74 1.39 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.736 -0.602 . . . . 0.0 110.718 -178.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.435 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.09 81.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.592 -0.693 . . . . 0.0 111.71 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.4 -1.68 49.53 Favored Glycine 0 N--CA 1.495 2.625 0 C-N-CA 120.148 -1.025 . . . . 0.0 110.809 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.439 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.13 156.41 44.6 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.899 -1.353 . . . . 0.0 109.304 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.41 ' HB1' ' HA ' ' A' ' 17' ' ' THR . . . -105.22 107.09 17.89 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.837 -1.164 . . . . 0.0 108.993 179.401 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.464 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 4.0 mt -67.37 113.58 14.65 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.487 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.3 Cg_endo -68.85 127.36 15.21 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 N-CA-C 106.828 -2.028 . . . . 0.0 106.828 175.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.423 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 8.7 mt -55.93 -17.98 7.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.897 -1.127 . . . . 0.0 110.791 -177.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.69 -16.36 26.27 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.639 -1.288 . . . . 0.0 110.26 179.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.428 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 12.4 m -90.97 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.008 -1.058 . . . . 0.0 110.884 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.512 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 20.3 pt -117.46 -18.64 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.996 -1.065 . . . . 0.0 110.633 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.483 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.65 148.24 23.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.867 -1.146 . . . . 0.0 110.169 179.537 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.97 36.67 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.375 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.2 -143.63 6.08 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.153 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.9 mtt85 -111.25 134.57 52.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.396 -1.061 . . . . 0.0 110.313 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 66.4 m80 -141.14 150.73 43.19 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.089 -1.007 . . . . 0.0 111.077 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.491 HD23 ' CZ ' ' A' ' 41' ' ' PHE . 60.7 tp -110.01 115.07 29.11 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.478 -0.764 . . . . 0.0 110.013 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.438 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 26.6 mt -98.79 127.27 51.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.113 -0.992 . . . . 0.0 109.821 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.491 ' CZ ' HD23 ' A' ' 39' ' ' LEU . 29.5 m-85 -95.35 124.67 39.5 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.453 -0.78 . . . . 0.0 110.084 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.66 157.77 24.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.163 -0.961 . . . . 0.0 110.642 -179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.435 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 15.0 p80 -101.96 -2.95 28.61 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 110.29 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.55 46.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.111 -0.993 . . . . 0.0 110.288 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.406 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 19.6 tttt -70.59 -37.49 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.47 -0.769 . . . . 0.0 110.757 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.57 -36.06 77.57 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.172 -0.955 . . . . 0.0 110.291 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.63 -32.75 68.3 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.424 -0.798 . . . . 0.0 109.253 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.438 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.74 74.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.35 -0.844 . . . . 0.0 109.095 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.88 -48.86 64.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.379 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.86 -44.39 63.89 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.236 -0.915 . . . . 0.0 110.631 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -56.81 -38.94 73.28 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.459 -0.776 . . . . 0.0 111.235 -178.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.84 -51.36 12.72 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.868 -1.145 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -40.78 97.26 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.01 -1.056 . . . . 0.0 109.672 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.42 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.94 83.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.522 179.447 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.37 -40.99 72.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.478 -0.764 . . . . 0.0 109.978 179.937 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.3 -33.81 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.135 -0.978 . . . . 0.0 108.899 179.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.88 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.333 -0.854 . . . . 0.0 110.078 179.357 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.459 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.0 mm? -71.47 -25.94 62.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.426 179.609 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.0 5.67 10.59 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.523 HG21 HG21 ' A' ' 81' ' ' VAL . 33.7 mt -108.42 143.46 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.475 -1.015 . . . . 0.0 110.235 -179.572 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.446 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -87.98 106.92 18.45 Favored 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.056 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.482 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.56 146.97 44.18 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.748 -1.181 . . . . 0.0 111.922 -177.163 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.507 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 19.6 t -129.32 149.34 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.706 -0.621 . . . . 0.0 109.884 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -114.03 123.84 50.67 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.261 -0.975 . . . . 0.0 109.861 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.46 ' CB ' ' HB3' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -114.04 134.68 54.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.923 . . . . 0.0 111.013 -179.31 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.517 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 5.1 p90 -171.01 -179.82 2.86 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.381 -0.825 . . . . 0.0 110.174 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.24 126.27 18.39 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.209 -0.932 . . . . 0.0 111.02 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.1 46.5 35.31 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.338 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.517 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.49 154.74 30.91 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.127 -1.219 . . . . 0.0 109.891 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.454 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.1 m-20 -93.16 149.83 20.95 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.271 -0.893 . . . . 0.0 110.651 -179.229 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.433 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 34.1 m -61.69 111.15 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 119.041 -1.064 . . . . 0.0 108.829 179.104 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.479 ' CB ' HG12 ' A' ' 63' ' ' VAL . 74.1 m -132.42 -34.71 1.19 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 110.749 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.507 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 58.7 t -47.69 125.18 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.246 -0.909 . . . . 0.0 109.612 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.1 pp . . . . . 0 N--CA 1.497 1.894 0 O-C-N 121.098 -1.001 . . . . 0.0 111.751 -178.373 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 121.995 0.903 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.446 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.9 p -117.2 134.96 59.13 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 CA-C-O 122.124 0.964 . . . . 0.0 110.084 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.523 HG21 HG21 ' A' ' 60' ' ' ILE . 5.3 m -113.99 122.05 67.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 O-C-N 121.296 -0.877 . . . . 0.0 109.229 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.7 t -96.84 117.87 42.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 120.916 -1.115 . . . . 0.0 110.308 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.503 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.7 m -108.81 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.244 -0.982 . . . . 0.0 108.916 179.548 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.46 ' HB3' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.23 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.658 -1.276 . . . . 0.0 110.656 -178.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.04 -34.48 15.09 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 110.679 -179.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -178.01 -29.57 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.114 -0.991 . . . . 0.0 111.066 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.437 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -44.88 -34.09 2.22 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.178 -0.951 . . . . 0.0 111.073 -179.553 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 tp . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.087 -1.008 . . . . 0.0 109.772 179.469 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.157 0.503 . . . . 0.0 110.776 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 22.1 m-85 -119.83 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.055 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.425 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.68 -29.32 27.69 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.492 -0.755 . . . . 0.0 109.976 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.66 163.66 29.71 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -0.975 . . . . 0.0 111.351 -179.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.519 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.22 114.4 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.439 -0.788 . . . . 0.0 109.922 179.141 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.409 ' CG2' ' CD1' ' A' ' 28' ' ' ILE . 3.7 mp -93.0 115.64 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.244 -0.91 . . . . 0.0 109.297 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.95 160.94 25.17 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.169 -0.957 . . . . 0.0 111.53 -178.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.418 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.64 3.75 42.74 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.628 -0.67 . . . . 0.0 109.504 178.15 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.48 23.88 0.66 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.266 -0.896 . . . . 0.0 111.254 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.451 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 O-C-N 120.959 -1.088 . . . . 0.0 110.476 179.283 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.481 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 13.9 tt0 . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 121.62 0.724 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -88.27 161.5 17.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.567 -0.708 . . . . 0.0 110.092 179.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.4 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -52.31 -61.79 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.346 -0.846 . . . . 0.0 112.29 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 7.2 m -58.1 -29.79 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.765 -1.209 . . . . 0.0 112.004 -177.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.481 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.82 -56.22 7.95 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.011 -1.055 . . . . 0.0 110.489 -179.293 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.41 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.49 -33.9 76.73 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.207 -0.933 . . . . 0.0 108.941 178.94 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.0 m -60.29 -49.82 76.1 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 120.999 -1.063 . . . . 0.0 108.452 178.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -73.93 -38.02 64.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 178.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.406 ' HB2' ' O ' ' A' ' 114' ' ' SER . 40.6 mtt85 -72.16 -44.85 62.43 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.222 -0.924 . . . . 0.0 111.477 -179.245 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.487 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.2 ttm180 -54.59 -45.38 73.58 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.787 -1.195 . . . . 0.0 109.495 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.28 81.71 0.03 OUTLIER Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.73 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 179.606 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.456 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 8.7 t -93.13 143.47 26.22 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.56 1.7 19.74 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.646 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.24 85.9 0.57 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.978 -1.307 . . . . 0.0 110.13 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.1 -38.04 2.89 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.87 -166.87 0.13 Allowed Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.508 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -86.31 114.81 1.31 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.086 1.045 . . . . 0.0 109.647 179.202 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.456 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.4 167.88 54.81 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.504 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.83 138.74 49.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.451 -1.029 . . . . 0.0 108.62 178.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.519 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.26 118.78 22.88 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.218 -0.993 . . . . 0.0 110.581 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.428 ' CZ ' HG13 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.31 127.14 53.03 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.487 -0.758 . . . . 0.0 109.879 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.439 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 10.4 p90 -118.84 158.5 25.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.17 -0.956 . . . . 0.0 109.81 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 7.2 t . . . . . 0 N--CA 1.493 1.68 0 O-C-N 121.085 -1.009 . . . . 0.0 110.263 179.76 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.5 m120 . . . . . 0 N--CA 1.508 2.462 0 CA-C-O 120.547 0.213 . . . . 0.0 111.239 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.449 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.1 mt -116.59 135.38 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.664 -1.273 . . . . 0.0 109.488 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.417 ' N ' ' O ' ' A' ' 128' ' ' GLY . 1.5 tm-20 -86.1 127.15 34.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.8 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -90.43 136.65 32.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.104 -0.997 . . . . 0.0 110.03 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.439 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.2 157.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.193 -0.942 . . . . 0.0 110.044 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.63 112.21 25.2 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.188 -0.945 . . . . 0.0 110.044 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.441 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 8.5 tp -54.81 147.36 15.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.873 . . . . 0.0 109.282 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.53 7.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.122 -0.987 . . . . 0.0 110.533 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.13 74.62 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.345 -0.847 . . . . 0.0 109.976 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.43 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 9.4 m -152.41 108.8 3.42 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.322 -0.862 . . . . 0.0 110.741 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.57 -167.16 29.2 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.922 -1.608 . . . . 0.0 110.818 179.214 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.41 ' CB ' HD13 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.26 -24.85 9.58 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.664 -0.904 . . . . 0.0 110.482 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.458 HG22 ' O ' ' A' ' 28' ' ' ILE . 9.4 tt -95.12 101.89 8.27 Favored Pre-proline 0 C--N 1.305 -1.334 0 C-N-CA 118.734 -1.187 . . . . 0.0 109.743 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.405 ' HD3' ' O ' ' A' ' 20' ' ' GLU . 37.0 Cg_endo -61.44 127.39 21.73 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.534 1.281 . . . . 0.0 111.074 -178.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.432 ' N ' ' O ' ' A' ' 26' ' ' LYS . 6.3 t80 -117.19 -171.91 2.12 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.541 0.686 . . . . 0.0 110.695 -179.062 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.565 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.4 m-85 -57.58 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.434 -0.791 . . . . 0.0 111.688 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.02 -4.62 53.47 Favored Glycine 0 N--CA 1.493 2.495 0 O-C-N 121.229 -0.919 . . . . 0.0 110.911 178.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.441 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 28.3 mmtt -130.05 156.34 44.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.826 -1.397 . . . . 0.0 109.908 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.43 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -106.26 108.07 19.39 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.064 -1.023 . . . . 0.0 108.864 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.458 ' O ' HG22 ' A' ' 21' ' ' ILE . 5.1 mt -68.24 112.99 12.54 Favored Pre-proline 0 C--N 1.3 -1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 110.732 -179.056 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.446 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.3 Cg_endo -68.43 130.05 20.26 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.125 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.443 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.8 mt -56.64 -17.13 7.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.772 -1.205 . . . . 0.0 110.801 -177.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.416 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.32 -16.05 19.87 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.739 -1.226 . . . . 0.0 110.476 179.955 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.442 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 9.9 m -95.16 -24.24 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.008 -1.057 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.534 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 46.2 pt -116.58 -12.17 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.919 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.46 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 8.9 tptm -102.12 148.29 25.57 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.831 -1.168 . . . . 0.0 110.193 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.03 -5.3 36.24 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.74 3.89 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.407 -1.377 . . . . 0.0 110.08 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.424 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.54 135.96 53.38 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.313 -1.11 . . . . 0.0 110.363 -179.736 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.534 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.6 m-70 -140.01 153.42 46.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.254 -0.904 . . . . 0.0 111.196 -179.427 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.404 ' HB3' ' CG1' ' A' ' 99' ' ' VAL . 60.4 tp -113.5 116.47 29.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.419 -0.801 . . . . 0.0 110.285 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.451 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 33.7 mt -100.93 128.1 53.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.194 -0.942 . . . . 0.0 109.568 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -95.08 123.75 38.74 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.441 -0.787 . . . . 0.0 110.238 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.94 159.92 21.71 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.217 -0.927 . . . . 0.0 110.679 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.565 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.2 p80 -105.55 -4.48 21.15 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.381 -0.824 . . . . 0.0 110.395 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.5 p -132.13 138.53 48.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.973 -1.08 . . . . 0.0 110.702 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.498 ' HD2' ' CE1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.25 -41.19 70.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.483 -0.761 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.77 72.1 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.221 -0.924 . . . . 0.0 110.59 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.41 -37.36 65.95 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.379 -0.826 . . . . 0.0 109.949 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.452 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 73.9 m -61.14 -34.35 74.87 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.273 -0.892 . . . . 0.0 109.857 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.413 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.67 -50.08 59.54 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.229 -0.919 . . . . 0.0 110.592 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -72.37 -40.54 67.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.191 -0.943 . . . . 0.0 110.374 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.444 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.92 -42.67 98.55 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.616 -0.678 . . . . 0.0 111.567 -178.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.64 -51.16 45.13 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.8 -1.188 . . . . 0.0 110.271 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.15 -34.43 68.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.032 -1.043 . . . . 0.0 109.183 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.527 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.24 -47.95 80.08 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.208 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.505 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -57.02 -42.45 80.43 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.531 -0.731 . . . . 0.0 110.955 -179.994 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -55.67 -28.32 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.925 -1.11 . . . . 0.0 108.753 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.62 -35.37 60.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.516 -0.74 . . . . 0.0 110.266 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.33 -26.11 61.81 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.06 7.96 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.461 HG21 HG23 ' A' ' 81' ' ' VAL . 50.4 mt -106.39 143.0 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.282 -1.128 . . . . 0.0 109.633 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.402 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.7 t30 -87.41 106.56 18.04 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.024 -1.472 . . . . 0.0 107.024 178.401 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.505 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -119.5 146.07 45.77 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.23 -0.988 . . . . 0.0 111.008 -177.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.469 ' CG2' HG12 ' A' ' 73' ' ' VAL . 6.1 t -138.7 149.97 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.823 -0.751 . . . . 0.0 109.303 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -112.01 134.84 53.32 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.713 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.463 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 20.4 t80 -124.96 129.27 50.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.382 -0.824 . . . . 0.0 110.274 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.503 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 3.0 p90 -154.73 -171.3 3.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.595 -0.691 . . . . 0.0 109.634 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.8 124.88 22.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.125 -0.984 . . . . 0.0 110.731 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.35 34.02 30.27 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.503 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.7 tm? -117.35 157.13 26.67 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.143 -1.21 . . . . 0.0 110.035 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.452 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.15 22.77 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.188 -0.945 . . . . 0.0 110.815 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.44 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 27.8 m -62.97 111.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.121 -0.987 . . . . 0.0 109.067 178.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.433 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.0 m -131.19 -11.73 3.64 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.166 -0.959 . . . . 0.0 111.494 -179.322 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.489 ' CG1' ' CG2' ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.34 136.2 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.737 -1.227 . . . . 0.0 109.509 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.447 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.497 1.883 0 O-C-N 121.12 -0.987 . . . . 0.0 110.513 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.953 0.882 . . . . 0.0 110.181 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 5.8 p -117.06 135.11 58.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 121.904 0.859 . . . . 0.0 110.359 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.483 HG22 ' CB ' ' A' ' 62' ' ' ALA . 7.1 m -112.95 122.5 67.2 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.489 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.6 t -96.83 117.65 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.019 -1.051 . . . . 0.0 110.097 -177.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 5.3 m -111.43 99.74 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.075 -1.016 . . . . 0.0 108.828 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.463 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.13 159.84 41.2 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.646 -1.283 . . . . 0.0 111.27 -178.189 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.8 t -82.33 -130.45 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.618 -0.676 . . . . 0.0 109.515 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.82 27.82 2.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.595 -1.315 . . . . 0.0 110.225 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.45 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.11 -35.76 12.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 110.133 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.3 tp . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.644 179.643 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.7 t0 . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 120.974 0.416 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -120.05 151.57 38.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.079 -1.013 . . . . 0.0 110.315 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.418 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.42 -30.96 33.36 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.33 178.983 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.444 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.9 163.94 28.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.377 -0.827 . . . . 0.0 111.197 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.53 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.44 115.38 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.557 -0.714 . . . . 0.0 109.796 179.002 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 2.7 mp -93.11 117.62 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.241 -0.912 . . . . 0.0 109.113 179.495 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -122.5 161.18 24.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.937 . . . . 0.0 111.559 -178.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 20.7 t -103.47 8.42 37.87 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.257 -0.902 . . . . 0.0 110.713 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.73 -179.83 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.454 0.645 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.464 ' O ' ' OG ' ' A' ' 114' ' ' SER . 3.6 p-10 -92.73 162.57 14.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.479 -0.763 . . . . 0.0 110.382 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.405 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -50.55 -49.38 56.17 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.831 -1.168 . . . . 0.0 111.868 -178.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.42 ' CG2' ' OD2' ' A' ' 111' ' ' ASP . 5.8 m -72.63 -30.62 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.601 -1.312 . . . . 0.0 113.283 -177.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.88 -54.7 34.95 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.293 -1.504 . . . . 0.0 110.096 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.27 -35.97 78.76 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 118.363 -1.335 . . . . 0.0 108.164 178.363 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.4 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 83.0 m -60.79 -49.97 75.34 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . 0.413 ' NE2' ' HA ' ' A' ' 117' ' ' GLN . 7.7 tp60 -73.68 -46.45 46.32 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.86 178.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.0 mtt-85 -58.25 -46.08 86.63 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 110.466 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.484 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.1 ttm180 -58.21 -39.85 80.1 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.847 -1.158 . . . . 0.0 109.485 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.56 68.81 0.4 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -146.22 -45.95 0.2 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.425 -1.044 . . . . 0.0 108.743 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.448 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.9 t -94.34 142.33 27.54 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.4 5.7 11.17 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.547 179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.403 ' CD ' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -76.2 84.53 3.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.947 -1.325 . . . . 0.0 110.171 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.93 -43.58 1.66 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.475 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.22 -169.31 0.17 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.499 -1.001 . . . . 0.0 108.662 179.565 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.475 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -87.72 110.67 0.73 Allowed 'Trans proline' 0 C--N 1.309 -1.529 0 O-C-N 123.274 1.144 . . . . 0.0 109.452 178.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.449 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -76.62 146.58 32.89 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.444 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 2.9 mp -106.35 141.15 22.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.859 -1.377 . . . . 0.0 109.301 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.53 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 4.4 t80 -127.87 115.35 18.46 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.105 -0.997 . . . . 0.0 110.41 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.442 ' CZ ' HG11 ' A' ' 32' ' ' VAL . 6.5 mmt180 -102.06 123.39 45.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.498 -0.752 . . . . 0.0 109.632 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 25.7 p90 -115.23 157.84 23.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.022 -1.049 . . . . 0.0 110.059 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.09 -1.006 . . . . 0.0 109.76 179.507 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.43 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 19.6 m-80 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.159 0.504 . . . . 0.0 109.931 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.462 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 11.7 mt -128.44 137.64 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.952 -1.093 . . . . 0.0 109.343 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.67 128.24 34.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.102 -0.999 . . . . 0.0 109.39 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.59 127.99 35.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.109 -0.994 . . . . 0.0 110.198 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 t -122.93 155.4 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.286 -0.884 . . . . 0.0 110.206 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.05 110.46 22.59 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.295 -0.878 . . . . 0.0 109.925 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.403 HD21 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.67 134.72 54.89 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 110.005 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 17.7 p -135.37 171.5 14.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.256 -0.902 . . . . 0.0 110.214 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.53 69.96 0.17 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 110.153 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.439 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.4 m -140.54 112.29 7.53 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.28 -0.887 . . . . 0.0 110.392 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.74 -163.28 26.94 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.542 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.2 -22.33 7.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.666 -0.902 . . . . 0.0 110.518 179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.471 HG21 ' O ' ' A' ' 28' ' ' ILE . 9.0 tt -97.41 107.06 36.64 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 120.839 -1.163 . . . . 0.0 110.28 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.467 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.91 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.318 1.167 . . . . 0.0 110.088 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.55 93.73 0.2 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.191 -0.943 . . . . 0.0 110.96 -178.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.25 68.56 0.76 Allowed 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.526 -0.733 . . . . 0.0 111.251 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.76 15.38 9.15 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 5.2 mmpt? -130.67 156.21 45.29 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.028 -1.278 . . . . 0.0 109.243 179.638 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.439 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.79 107.51 15.14 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 109.348 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.471 ' O ' HG21 ' A' ' 21' ' ' ILE . 4.2 mt -69.83 113.91 20.95 Favored Pre-proline 0 C--N 1.298 -1.654 0 O-C-N 121.474 -0.766 . . . . 0.0 110.688 -179.235 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.468 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.9 Cg_endo -70.18 130.81 19.45 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 106.443 -2.176 . . . . 0.0 106.443 175.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.418 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 8.1 mt -55.92 -18.41 8.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.718 -1.238 . . . . 0.0 110.518 -177.716 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.75 -16.16 25.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.771 -1.205 . . . . 0.0 110.484 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.433 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 13.3 m -92.03 -25.04 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.976 -1.078 . . . . 0.0 110.93 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.551 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 42.2 pt -117.06 -17.48 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.079 -1.013 . . . . 0.0 110.622 -179.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.451 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.49 22.84 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.947 -1.095 . . . . 0.0 110.262 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.05 -7.56 27.24 Favored Glycine 0 N--CA 1.485 1.947 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.02 3.21 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.149 -1.5 . . . . 0.0 110.342 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.42 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -111.99 129.95 56.02 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.353 -1.086 . . . . 0.0 110.232 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.551 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.63 146.94 46.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.06 -1.025 . . . . 0.0 110.953 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.8 tp -109.65 115.66 30.3 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.475 -0.765 . . . . 0.0 110.216 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.473 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 35.8 mt -98.96 127.67 51.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.15 -0.969 . . . . 0.0 109.465 179.284 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -94.88 122.62 37.7 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.556 -0.715 . . . . 0.0 110.518 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.2 31.24 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.344 -0.847 . . . . 0.0 110.581 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.3 p80 -109.31 8.17 25.48 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.245 -0.91 . . . . 0.0 109.478 178.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.93 135.95 41.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.13 -0.981 . . . . 0.0 110.316 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.51 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.94 -42.37 66.7 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.55 -0.719 . . . . 0.0 110.818 -179.687 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.63 -36.51 74.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.345 -0.847 . . . . 0.0 110.428 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.29 -36.28 68.9 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.482 -0.761 . . . . 0.0 109.809 -179.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.4 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 2.2 m -60.89 -34.04 74.03 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.359 -0.838 . . . . 0.0 109.77 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.34 -49.31 56.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.268 -0.895 . . . . 0.0 110.672 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.56 -43.85 65.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.208 -0.933 . . . . 0.0 110.383 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.422 ' CD1' HG13 ' A' ' 83' ' ' VAL . 1.5 tm? -56.34 -41.14 75.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.422 -0.799 . . . . 0.0 110.909 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.21 -51.41 13.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 110.372 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.75 -43.86 98.02 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.055 -1.028 . . . . 0.0 109.582 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.467 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -56.83 -43.84 81.45 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.309 -0.87 . . . . 0.0 109.549 179.528 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.485 ' HB3' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.46 -42.89 74.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.444 -0.785 . . . . 0.0 109.704 179.592 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.8 t -55.84 -30.78 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.133 -0.98 . . . . 0.0 108.71 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.15 -33.32 59.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.574 -0.703 . . . . 0.0 110.121 179.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.466 HD23 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -71.74 -26.37 62.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 109.614 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.97 5.64 8.05 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.452 HG23 HG21 ' A' ' 81' ' ' VAL . 19.8 mt -108.29 143.57 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.199 -1.177 . . . . 0.0 110.235 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.414 ' ND2' HD13 ' A' ' 74' ' ' ILE . 19.5 t30 -86.12 107.34 17.8 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.199 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.485 ' CB ' ' HB3' ' A' ' 55' ' ' LEU . . . -121.96 146.92 46.67 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.002 -1.079 . . . . 0.0 112.064 -177.151 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.499 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -135.92 150.29 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.66 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -112.69 131.82 55.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.222 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.464 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -120.82 123.42 42.54 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.933 . . . . 0.0 110.731 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.51 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 4.1 p90 -155.2 178.43 10.22 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.641 179.546 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -52.36 128.17 24.58 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.071 -1.018 . . . . 0.0 110.63 -179.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.25 39.27 31.99 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.48 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -117.02 155.63 28.88 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.124 -1.221 . . . . 0.0 109.777 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.463 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 27.0 m-20 -95.39 149.15 21.7 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.272 -0.893 . . . . 0.0 110.884 -179.125 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.421 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 34.7 m -62.21 111.4 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.061 -1.024 . . . . 0.0 108.873 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.401 ' CB ' HG13 ' A' ' 63' ' ' VAL . 4.2 m -134.33 -36.06 0.9 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.895 . . . . 0.0 110.888 -179.11 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.499 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 20.6 t -50.91 134.7 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.195 -0.941 . . . . 0.0 109.851 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.429 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.8 pp . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.219 -0.926 . . . . 0.0 110.905 -179.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 122.033 0.921 . . . . 0.0 110.072 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.42 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.6 p -116.85 134.94 58.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 CA-C-O 121.969 0.89 . . . . 0.0 109.855 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.48 HG23 ' CB ' ' A' ' 62' ' ' ALA . 16.0 m -113.34 124.45 69.99 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.341 0 O-C-N 121.422 -0.799 . . . . 0.0 109.484 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.472 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.4 117.25 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.096 -1.003 . . . . 0.0 109.934 -178.61 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.499 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.7 m -112.08 100.07 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.986 -1.071 . . . . 0.0 108.625 179.697 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.464 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.9 162.24 35.64 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.752 -1.218 . . . . 0.0 110.943 -178.149 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -91.35 -133.15 0.12 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.627 -0.671 . . . . 0.0 109.24 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.403 ' N ' ' OD1' ' A' ' 86' ' ' ASP . 46.5 p-10 -88.42 43.33 1.12 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.663 -1.273 . . . . 0.0 110.342 179.709 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.446 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.79 -30.29 6.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 110.144 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.041 -1.037 . . . . 0.0 109.28 179.421 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 120.902 0.382 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -119.74 153.18 36.04 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.066 . . . . 0.0 110.139 178.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.91 -26.99 25.26 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.386 -0.821 . . . . 0.0 109.551 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 p -162.52 163.63 27.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 111.432 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.0 126.21 49.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.479 -0.763 . . . . 0.0 109.718 179.114 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.414 ' CG2' HD13 ' A' ' 28' ' ' ILE . 2.8 mp -105.51 111.54 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.088 -1.007 . . . . 0.0 109.117 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -121.58 161.0 23.17 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.249 -0.907 . . . . 0.0 111.565 -178.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.1 t -96.26 -6.91 36.86 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 177.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.76 11.01 1.21 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.37 -0.831 . . . . 0.0 112.225 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.31 -1.123 0 O-C-N 120.537 -1.352 . . . . 0.0 109.509 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.403 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.315 0.579 . . . . 0.0 110.956 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.421 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.2 p30 -83.53 161.4 21.23 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.298 -0.876 . . . . 0.0 110.062 179.69 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.431 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.53 -61.88 1.25 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.435 -0.791 . . . . 0.0 112.172 -178.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.421 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.1 m -60.41 -29.31 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.742 -1.224 . . . . 0.0 111.692 -178.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.407 ' N ' HG21 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.21 -56.49 6.6 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.01 -1.056 . . . . 0.0 110.749 -178.812 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.431 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.03 76.88 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.124 -0.985 . . . . 0.0 108.668 178.947 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.2 m -60.49 -50.03 75.18 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.109 -0.995 . . . . 0.0 108.368 178.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.24 63.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.477 -0.764 . . . . 0.0 110.184 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.402 ' HB2' ' O ' ' A' ' 114' ' ' SER . 10.8 mtt85 -71.2 -44.31 65.68 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.119 -0.988 . . . . 0.0 111.138 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.462 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 11.8 ttp180 -70.46 -40.0 73.96 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.999 -1.063 . . . . 0.0 109.975 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.96 63.33 0.71 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -137.12 -45.93 0.57 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.144 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.439 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.1 t -95.16 142.29 27.78 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.316 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.2 17.33 51.01 Favored Glycine 0 N--CA 1.484 1.887 0 C-N-CA 119.528 -1.32 . . . . 0.0 110.356 178.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.07 -37.86 55.21 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.059 -1.26 . . . . 0.0 109.705 179.666 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.0 28.59 2.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.478 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.6 -168.25 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.694 -0.886 . . . . 0.0 109.123 -179.415 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.478 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.6 Cg_endo -86.66 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.167 1.088 . . . . 0.0 110.556 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.439 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.09 157.67 41.35 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.1 mt -106.85 141.59 21.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.041 -1.27 . . . . 0.0 109.105 178.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -130.07 114.81 16.23 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.07 -1.052 . . . . 0.0 110.227 179.392 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.8 mtt180 -101.5 122.15 43.27 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.428 -0.795 . . . . 0.0 109.656 179.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.417 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 14.3 p90 -120.24 154.54 34.74 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.896 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.4 t . . . . . 0 N--CA 1.492 1.66 0 O-C-N 121.205 -0.934 . . . . 0.0 110.235 179.916 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.5 m120 . . . . . 0 N--CA 1.501 2.108 0 CA-C-O 120.8 0.333 . . . . 0.0 111.221 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.474 ' CD1' HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.55 126.23 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.674 -1.266 . . . . 0.0 109.313 179.136 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.78 127.59 34.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.942 179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.47 136.18 33.22 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.209 -0.932 . . . . 0.0 110.104 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.455 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.2 t -129.71 154.95 41.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.368 -0.832 . . . . 0.0 109.925 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.5 112.87 25.98 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.109 -0.994 . . . . 0.0 110.389 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.8 tp -59.31 140.52 55.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.368 -0.833 . . . . 0.0 109.19 179.308 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.33 -178.24 5.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 110.508 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 72.0 p -76.99 59.9 1.73 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.077 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.436 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 10.0 m -132.45 109.34 9.74 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.269 -0.895 . . . . 0.0 110.714 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.439 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.17 -167.2 28.98 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 118.85 -1.643 . . . . 0.0 110.687 179.204 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.54 -18.86 10.83 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.667 -0.902 . . . . 0.0 110.304 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.485 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.2 tt -99.34 104.51 27.25 Favored Pre-proline 0 N--CA 1.49 1.533 0 C-N-CA 118.771 -1.172 . . . . 0.0 109.876 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.423 ' HD2' ' HE3' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -63.55 128.51 22.54 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.336 1.177 . . . . 0.0 111.009 -179.109 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.442 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.95 1.17 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.779 -0.576 . . . . 0.0 109.882 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.1 m-85 -58.11 82.21 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.219 -0.926 . . . . 0.0 111.605 -179.236 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.12 0.52 52.7 Favored Glycine 0 N--CA 1.494 2.566 0 O-C-N 121.156 -0.965 . . . . 0.0 110.888 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.416 ' O ' ' N ' ' A' ' 23' ' ' PHE . 27.3 mmtp -130.51 156.99 43.88 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.877 -1.367 . . . . 0.0 109.538 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.413 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -108.23 107.64 18.34 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 120.977 -1.077 . . . . 0.0 109.474 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.485 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -67.08 113.43 13.42 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.34 -0.85 . . . . 0.0 110.757 -179.344 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.439 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.4 Cg_endo -68.52 130.99 22.01 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 N-CA-C 106.874 -2.01 . . . . 0.0 106.874 176.012 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.419 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 10.7 mt -56.24 -17.61 8.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.816 -1.178 . . . . 0.0 110.728 -177.815 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -59.9 -16.41 29.25 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.64 -1.287 . . . . 0.0 110.518 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG2' HG22 ' A' ' 33' ' ' ILE . 13.6 m -93.09 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.005 -1.059 . . . . 0.0 111.213 -179.552 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.493 ' HA ' ' CD2' ' A' ' 38' ' ' HIS . 18.9 pt -119.45 -21.45 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.031 -1.043 . . . . 0.0 110.639 -179.288 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.443 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.79 148.28 22.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.89 -1.131 . . . . 0.0 110.317 179.46 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.14 -3.9 60.38 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.579 -1.409 . . . . 0.0 109.579 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.3 -158.65 21.45 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.447 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.75 132.38 50.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -1.069 . . . . 0.0 110.654 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.493 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.82 147.02 40.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.181 -0.949 . . . . 0.0 110.523 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.419 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.08 122.22 46.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.341 -0.849 . . . . 0.0 110.08 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.443 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 10.3 mm -100.56 126.08 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.271 -0.893 . . . . 0.0 109.186 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -96.5 121.41 38.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.105 -0.997 . . . . 0.0 110.025 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.36 28.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.277 -0.889 . . . . 0.0 110.511 179.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.1 37.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.284 -0.885 . . . . 0.0 110.079 178.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.97 135.39 46.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.067 -1.021 . . . . 0.0 110.459 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.489 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.43 65.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.662 -0.649 . . . . 0.0 110.906 -179.761 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.31 -32.77 73.13 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.36 -0.837 . . . . 0.0 110.843 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.33 65.71 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.399 -0.813 . . . . 0.0 109.9 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.439 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 94.6 m -61.13 -38.52 86.66 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.592 179.154 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.4 -49.16 70.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.128 -0.983 . . . . 0.0 110.531 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.409 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -72.05 -46.29 57.54 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.239 -0.913 . . . . 0.0 110.608 -179.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.44 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.0 tm? -56.73 -41.09 76.87 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.459 -0.776 . . . . 0.0 111.42 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.36 -51.08 60.81 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.851 -1.156 . . . . 0.0 109.759 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.8 -32.5 69.4 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.236 -0.915 . . . . 0.0 109.347 179.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.442 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -61.72 -33.67 74.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.573 -0.704 . . . . 0.0 109.352 179.63 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.504 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -74.91 -42.44 57.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.423 -0.798 . . . . 0.0 110.397 -179.911 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.07 -33.03 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.048 -1.033 . . . . 0.0 109.189 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.43 -32.95 60.87 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.502 -0.749 . . . . 0.0 109.918 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.512 HD23 ' N ' ' A' ' 58' ' ' LEU . 3.5 mm? -71.96 -26.37 62.24 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.947 0.88 . . . . 0.0 109.981 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.81 3.06 10.21 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.289 -1.525 . . . . 0.0 109.289 -179.251 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.453 ' CG2' HG21 ' A' ' 81' ' ' VAL . 31.2 mt -103.88 143.96 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.356 -1.085 . . . . 0.0 109.955 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 35.1 t30 -88.68 106.87 18.62 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.178 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.504 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.92 145.28 44.77 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 118.868 -1.133 . . . . 0.0 111.739 -177.2 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.492 ' HB ' HG22 ' A' ' 73' ' ' VAL . 70.5 t -129.22 152.74 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.084 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -118.67 117.33 28.66 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.156 -1.018 . . . . 0.0 109.237 177.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.436 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -105.76 127.48 53.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.172 -0.955 . . . . 0.0 110.826 -179.256 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.537 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 10.0 p90 -155.58 -178.66 7.44 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.503 -0.748 . . . . 0.0 110.096 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.35 127.41 22.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.171 -0.956 . . . . 0.0 110.834 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.23 53.1 23.6 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.537 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.42 154.44 31.35 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.211 -1.17 . . . . 0.0 109.794 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.462 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.7 m-20 -91.21 149.37 21.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.229 -0.919 . . . . 0.0 110.427 -179.297 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.422 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.2 m -61.69 110.65 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.024 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 72.5 m -132.2 -38.72 1.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.759 . . . . 0.0 109.973 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.492 HG22 ' HB ' ' A' ' 63' ' ' VAL . 95.3 t -49.5 133.32 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.39 -0.819 . . . . 0.0 109.484 179.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.417 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.1 pp . . . . . 0 N--CA 1.493 1.7 0 O-C-N 120.99 -1.069 . . . . 0.0 110.398 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.878 0.846 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.461 ' O ' HG12 ' A' ' 80' ' ' VAL . 6.3 p -116.68 135.13 57.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 122.013 0.911 . . . . 0.0 110.286 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.485 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 9.9 m -113.0 121.23 64.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 O-C-N 121.242 -0.911 . . . . 0.0 108.877 179.2 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 39' ' ' LEU . 15.1 t -97.82 120.04 46.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 O-C-N 120.788 -1.195 . . . . 0.0 111.257 -177.612 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 2.8 m -111.26 99.0 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 122.361 1.077 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.436 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.45 155.04 46.35 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 120.514 -1.366 . . . . 0.0 110.526 -178.775 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.432 ' CG2' ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.87 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.222 -0.923 . . . . 0.0 110.663 -179.322 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.432 ' N ' ' CG2' ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.77 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.123 -0.986 . . . . 0.0 110.608 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.04 -33.92 9.96 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.039 179.362 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.41 HD11 ' CD2' ' A' ' 65' ' ' TYR . 5.3 tp . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.597 -0.689 . . . . 0.0 109.341 178.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.163 0.506 . . . . 0.0 110.643 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -113.43 150.89 32.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.172 -0.955 . . . . 0.0 109.81 179.489 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.479 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.2 -32.58 56.07 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.369 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.45 163.06 30.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.203 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.506 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.29 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.389 -0.819 . . . . 0.0 110.031 179.264 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.427 HD12 HG23 ' A' ' 33' ' ' ILE . 3.3 mp -93.44 112.82 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.264 -0.898 . . . . 0.0 108.584 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.424 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.93 161.35 20.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 111.52 -178.269 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.453 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 58.5 m -88.86 -13.32 39.51 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.15 10.63 1.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.295 -0.878 . . . . 0.0 112.073 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.306 -1.297 0 O-C-N 120.755 -1.216 . . . . 0.0 109.133 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.434 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 121.366 0.603 . . . . 0.0 111.544 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -87.47 160.78 18.15 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.466 -0.771 . . . . 0.0 110.359 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -42.02 -55.34 3.21 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.647 -0.658 . . . . 0.0 112.553 -178.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.438 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 9.3 m -70.62 -29.64 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.705 -1.247 . . . . 0.0 111.838 -178.197 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.434 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.49 -56.28 7.37 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.129 -0.982 . . . . 0.0 110.553 -179.243 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.406 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.2 -35.08 77.43 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.465 -0.894 . . . . 0.0 108.786 178.905 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.438 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 99.6 m -59.14 -49.8 76.47 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.537 178.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -73.28 -36.04 66.24 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.494 -0.754 . . . . 0.0 109.98 179.022 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 8.8 mtt85 -71.9 -44.98 62.81 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.262 -0.899 . . . . 0.0 111.118 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.483 ' HA ' ' CE2' ' A' ' 130' ' ' TYR . 0.8 OUTLIER -64.36 -36.62 84.71 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.984 -1.072 . . . . 0.0 110.318 -179.873 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.43 0.76 Allowed Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.418 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -135.51 -43.02 0.69 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.411 -1.053 . . . . 0.0 109.206 179.489 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.474 HG23 ' CD1' ' A' ' 10' ' ' ILE . 14.8 t -102.32 141.77 34.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.561 -0.712 . . . . 0.0 109.632 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.432 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.16 10.81 14.8 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.502 -1.332 . . . . 0.0 110.15 179.761 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.11 84.71 1.82 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.956 -1.32 . . . . 0.0 109.876 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 96.33 16.13 38.66 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.469 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.89 0.22 Allowed Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.259 -1.142 . . . . 0.0 109.378 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.469 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.2 Cg_endo -88.06 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 O-C-N 123.349 1.183 . . . . 0.0 110.412 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.455 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.26 160.05 45.64 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.49 142.75 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.417 -1.049 . . . . 0.0 108.779 178.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.506 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 8.4 t80 -129.91 117.27 19.87 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 120.953 -1.092 . . . . 0.0 111.016 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.455 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 22.2 mtt180 -101.42 123.5 45.58 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.548 -0.72 . . . . 0.0 109.331 179.22 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.415 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.19 156.24 26.87 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.041 -1.037 . . . . 0.0 110.533 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 4.6 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.171 -0.956 . . . . 0.0 109.392 179.451 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.454 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.554 0.692 . . . . 0.0 109.365 . . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.467 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 14.6 mt -96.73 133.73 37.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.935 -1.103 . . . . 0.0 110.203 179.816 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -84.2 128.14 34.38 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.35 -0.844 . . . . 0.0 109.541 179.19 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -89.4 121.5 31.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.069 -1.02 . . . . 0.0 109.9 -179.573 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.446 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 4.8 t -115.69 156.63 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.368 -0.833 . . . . 0.0 110.222 -179.34 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.77 105.07 15.17 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.281 -0.887 . . . . 0.0 109.625 179.078 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 12.7 tp -54.15 132.51 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.35 -0.844 . . . . 0.0 109.658 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.51 -174.7 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 110.256 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.94 63.43 3.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 110.041 179.835 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.431 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 5.0 m -132.07 112.08 12.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.337 -0.852 . . . . 0.0 110.244 -179.834 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.486 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.21 -163.41 26.72 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 119.158 -1.496 . . . . 0.0 110.455 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.39 -22.5 5.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.525 -0.985 . . . . 0.0 110.729 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.487 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 6.6 tt -93.94 113.24 60.04 Favored Pre-proline 0 N--CA 1.487 1.417 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.064 -179.5 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.23 150.76 87.68 Favored 'Trans proline' 0 C--N 1.313 -1.309 0 O-C-N 123.519 1.273 . . . . 0.0 110.026 -179.824 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.475 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.95 88.84 0.62 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.137 -0.977 . . . . 0.0 111.374 -178.477 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.514 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.14 67.18 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.349 -0.845 . . . . 0.0 111.26 179.146 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.03 13.75 21.29 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.708 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.475 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.36 156.16 45.17 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.063 -1.257 . . . . 0.0 109.366 179.738 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -112.47 106.97 15.57 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.918 -1.114 . . . . 0.0 109.279 179.74 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.487 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.2 mt -69.47 114.11 21.83 Favored Pre-proline 0 C--N 1.3 -1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 110.384 -179.307 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.486 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.7 Cg_endo -70.67 129.98 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 N-CA-C 107.024 -1.952 . . . . 0.0 107.024 176.364 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.435 HD22 HG22 ' A' ' 21' ' ' ILE . 15.7 mt -56.62 -17.49 8.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.939 -1.101 . . . . 0.0 110.744 -177.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.423 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -60.86 -16.19 38.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.817 -1.177 . . . . 0.0 110.347 179.503 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.438 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.4 m -93.77 -25.35 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.003 -1.061 . . . . 0.0 111.15 -179.348 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.533 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 46.0 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 110.472 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.444 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.03 147.86 24.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.256 -0.902 . . . . 0.0 110.429 179.898 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.36 -5.63 38.49 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.95 -145.62 7.11 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.198 -1.477 . . . . 0.0 110.44 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.1 mtt85 -108.53 132.67 53.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.415 -1.05 . . . . 0.0 110.264 -179.696 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.533 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -140.71 150.56 43.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.023 -1.048 . . . . 0.0 111.031 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.412 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 62.1 tp -110.98 114.29 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.447 -0.783 . . . . 0.0 109.947 179.565 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.465 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 29.2 mt -98.75 127.15 51.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.131 -0.981 . . . . 0.0 109.493 179.689 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -95.44 124.01 39.26 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.172 -0.955 . . . . 0.0 110.143 -179.78 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.76 21.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.202 -0.936 . . . . 0.0 110.494 -179.688 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.514 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.2 p80 -107.02 -1.41 22.17 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.352 -0.843 . . . . 0.0 110.073 179.03 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.91 136.8 42.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.1 -1.0 . . . . 0.0 110.465 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.47 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.72 -38.27 70.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.466 -0.771 . . . . 0.0 110.663 -179.848 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.86 -35.6 73.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.333 -0.854 . . . . 0.0 110.453 -179.636 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.421 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.68 -35.83 65.24 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.79 -179.958 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.431 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 76.3 m -61.2 -34.01 74.4 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.415 -0.803 . . . . 0.0 109.757 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.7 -50.17 53.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 110.245 -179.841 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.406 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.32 -43.5 64.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.288 -0.882 . . . . 0.0 110.065 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.429 HD11 HG11 ' A' ' 83' ' ' VAL . 3.3 tm? -57.12 -42.51 81.03 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.602 -0.686 . . . . 0.0 111.248 -178.994 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.03 -51.09 42.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.796 -1.19 . . . . 0.0 110.013 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.24 -34.62 68.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.272 -0.893 . . . . 0.0 109.25 179.462 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.472 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.81 -46.39 84.74 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.274 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.483 ' CB ' ' HB2' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -59.78 -43.35 94.43 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.39 -0.819 . . . . 0.0 110.999 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.4 t -56.11 -34.14 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.966 -1.084 . . . . 0.0 109.375 179.617 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.51 -34.46 60.82 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.297 -0.877 . . . . 0.0 110.315 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.472 HD22 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.35 -25.84 62.56 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.285 -0.884 . . . . 0.0 109.699 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.2 7.86 8.18 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.633 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.456 HG22 HG23 ' A' ' 81' ' ' VAL . 47.0 mt -108.47 143.48 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.254 -1.145 . . . . 0.0 110.119 -179.756 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.418 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 16.7 t30 -89.25 106.53 18.5 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.168 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.483 ' HB2' ' CB ' ' A' ' 55' ' ' LEU . . . -118.48 145.21 45.45 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.977 -1.089 . . . . 0.0 111.629 -177.244 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.472 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.95 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.066 -0.653 . . . . 0.0 109.454 179.719 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.514 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -108.2 122.52 47.09 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.585 178.818 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.435 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.4 OUTLIER -109.52 131.35 55.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.262 -0.899 . . . . 0.0 110.809 -179.534 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.483 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.24 178.32 5.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.563 -0.711 . . . . 0.0 109.905 179.644 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.55 125.52 20.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.045 -1.035 . . . . 0.0 110.814 -179.366 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.83 40.93 13.44 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.743 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.483 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.38 157.02 26.89 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -1.14 . . . . 0.0 110.322 -179.831 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.442 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 21.8 m-20 -98.48 149.33 22.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.281 -0.887 . . . . 0.0 110.571 -179.378 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 31.5 m -62.33 111.36 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.036 . . . . 0.0 109.311 179.123 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.437 ' CB ' HG11 ' A' ' 63' ' ' VAL . 43.8 m -134.31 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.52 -0.737 . . . . 0.0 110.368 -179.415 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.472 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 76.9 t -46.47 131.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.489 -0.757 . . . . 0.0 110.685 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.408 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.3 pp . . . . . 0 N--CA 1.495 1.802 0 O-C-N 121.166 -0.958 . . . . 0.0 110.659 179.408 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 122.083 0.944 . . . . 0.0 109.954 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.6 p -116.39 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-O 121.899 0.857 . . . . 0.0 110.199 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 10.1 m -111.91 123.35 67.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.159 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.426 HG11 HG12 ' A' ' 73' ' ' VAL . 33.2 t -96.62 118.11 42.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.061 -1.025 . . . . 0.0 110.612 -178.062 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.514 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.2 m -111.75 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 118.93 -1.108 . . . . 0.0 108.756 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.435 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -131.44 156.46 45.58 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 120.69 -1.256 . . . . 0.0 110.339 -178.606 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.446 HG22 ' N ' ' A' ' 86' ' ' ASP . 9.0 t -94.07 -30.46 14.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.367 -0.833 . . . . 0.0 111.471 -178.583 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.446 ' N ' HG22 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.56 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.931 -1.106 . . . . 0.0 111.529 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.446 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -46.79 -39.95 12.76 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.958 -1.089 . . . . 0.0 110.163 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.9 tp . . . . . 0 N--CA 1.488 1.45 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.213 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 120.964 0.411 . . . . 0.0 110.344 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -120.22 135.55 54.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.04 -1.037 . . . . 0.0 110.381 179.868 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.482 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.14 -27.75 57.15 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.556 179.22 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -160.38 163.0 33.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.29 -0.881 . . . . 0.0 110.54 179.501 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.479 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.82 115.9 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.228 -0.92 . . . . 0.0 110.336 179.66 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.4 ' CG2' HD12 ' A' ' 28' ' ' ILE . 3.2 mp -93.44 114.63 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.6 161.31 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.09 -1.006 . . . . 0.0 111.829 -178.151 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.26 9.09 38.28 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.946 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 52.35 23.18 2.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.194 -0.941 . . . . 0.0 110.97 179.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 110.657 179.584 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.449 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.199 0.523 . . . . 0.0 110.722 . . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.409 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -84.96 161.0 19.96 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.154 -0.966 . . . . 0.0 110.085 179.605 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.401 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.26 -57.45 2.98 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.517 -0.74 . . . . 0.0 112.433 -178.531 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.417 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.2 m -68.6 -29.39 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 120.688 -1.257 . . . . 0.0 111.847 -178.143 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.449 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.21 -56.23 7.07 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.039 -1.038 . . . . 0.0 110.545 -179.263 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.445 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.7 ptm180 -70.43 -35.15 73.22 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.377 -0.929 . . . . 0.0 108.873 179.073 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.417 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.9 m -58.98 -49.55 77.47 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.04 -1.037 . . . . 0.0 108.371 178.637 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.78 -35.85 64.98 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.394 -0.816 . . . . 0.0 109.863 178.704 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.445 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.69 -44.54 64.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.08 -1.013 . . . . 0.0 110.934 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.467 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 17.2 ttm180 -53.12 -41.82 65.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.896 -1.127 . . . . 0.0 109.713 179.587 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.37 63.28 0.26 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.433 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -132.57 -42.71 0.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.449 -1.03 . . . . 0.0 108.658 179.152 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.444 ' CG2' HG23 ' A' ' 10' ' ' ILE . 10.9 t -98.17 144.05 28.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.653 -0.654 . . . . 0.0 109.576 179.148 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.431 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.24 9.25 36.85 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.692 -1.242 . . . . 0.0 110.32 179.35 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -66.29 87.5 0.11 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.99 -1.3 . . . . 0.0 109.52 179.709 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.74 23.27 28.65 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -178.772 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.452 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.43 -179.81 0.3 Allowed Pre-proline 0 N--CA 1.492 1.646 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.454 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.7 Cg_endo -88.93 105.97 0.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.09 1.047 . . . . 0.0 110.882 -179.939 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.438 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.64 179.47 53.47 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.409 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.51 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.468 -1.019 . . . . 0.0 108.951 179.033 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.479 ' CD2' HG23 ' A' ' 99' ' ' VAL . 11.7 t80 -129.71 115.83 17.9 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.897 -1.121 . . . . 0.0 111.063 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.429 ' HD2' ' CG1' ' A' ' 32' ' ' VAL . 1.7 mtt180 -100.58 134.33 43.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.515 -0.74 . . . . 0.0 109.029 179.366 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.4 p90 -126.28 156.73 39.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.931 -1.105 . . . . 0.0 110.582 -179.456 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 55.9 t . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.287 -0.883 . . . . 0.0 109.9 179.561 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 . . . . . 0 N--CA 1.494 1.761 0 CA-C-O 120.806 0.336 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.469 ' CD1' ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.08 137.39 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.832 -1.168 . . . . 0.0 110.62 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.6 128.43 34.51 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 108.866 178.312 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -89.53 142.68 27.45 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.055 -1.028 . . . . 0.0 110.62 -179.007 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.444 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.2 t -137.73 158.02 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.418 -0.802 . . . . 0.0 110.434 -179.694 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.88 109.41 17.58 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.442 -0.786 . . . . 0.0 109.56 179.104 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.44 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 10.1 tp -53.5 136.85 37.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.279 -0.888 . . . . 0.0 109.964 -179.878 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.1 p -137.38 174.49 10.54 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 110.285 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.407 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . 25.8 p -71.63 80.09 0.82 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.196 -0.94 . . . . 0.0 110.067 179.856 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.434 ' N ' ' HB1' ' A' ' 27' ' ' ALA . 17.8 m -155.53 109.05 2.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.176 -0.953 . . . . 0.0 110.799 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.459 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.33 -170.22 29.6 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.833 -1.651 . . . . 0.0 110.942 179.136 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.22 -20.39 12.34 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.755 -0.85 . . . . 0.0 110.417 -179.792 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.461 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.2 tt -98.85 103.88 21.95 Favored Pre-proline 0 N--CA 1.491 1.592 0 C-N-CA 118.906 -1.118 . . . . 0.0 109.86 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.417 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.4 Cg_endo -62.63 124.96 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.32 1.168 . . . . 0.0 110.84 -179.369 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.426 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.49 -166.85 1.13 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.737 -0.602 . . . . 0.0 110.433 -179.239 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.527 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.17 81.77 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.465 -0.772 . . . . 0.0 111.514 -179.451 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.1 2.25 52.27 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.607 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.44 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 15.1 mmtp -130.18 156.3 44.81 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.973 -1.31 . . . . 0.0 109.355 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.434 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -106.69 107.43 18.44 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.961 -1.087 . . . . 0.0 109.078 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.461 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.2 mt -69.33 112.92 13.42 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.312 -0.867 . . . . 0.0 110.521 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.459 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.1 Cg_endo -68.54 129.62 19.28 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 N-CA-C 107.161 -1.9 . . . . 0.0 107.161 176.282 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.432 HD21 HG21 ' A' ' 21' ' ' ILE . 10.9 mt -56.27 -17.78 8.61 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.83 -1.169 . . . . 0.0 110.69 -177.803 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -59.88 -16.05 26.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.677 -1.265 . . . . 0.0 110.575 179.898 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.454 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 10.6 m -93.99 -25.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.982 -1.074 . . . . 0.0 110.775 -179.727 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.512 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 12.3 pt -114.62 -23.27 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.094 -1.004 . . . . 0.0 110.57 -179.508 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.486 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.0 tptm -93.81 147.96 22.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.803 -1.185 . . . . 0.0 110.2 179.381 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.77 -3.42 52.85 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.799 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.64 -150.63 8.64 Favored Glycine 0 N--CA 1.494 2.533 0 C-N-CA 118.927 -1.606 . . . . 0.0 110.626 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.42 129.41 55.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.435 -1.038 . . . . 0.0 109.968 -179.793 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.1 m-70 -137.8 149.42 46.35 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.982 -1.074 . . . . 0.0 110.963 -179.635 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.483 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 34.1 tp -110.82 117.27 32.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.419 -0.8 . . . . 0.0 110.21 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.442 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 12.1 mm -97.92 125.42 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.293 -0.88 . . . . 0.0 109.471 179.792 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.48 ' CE2' HD23 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.67 123.38 42.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.093 -1.004 . . . . 0.0 109.882 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.21 159.39 22.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.545 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.527 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.56 23.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.161 179.373 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.35 141.12 51.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.11 -0.994 . . . . 0.0 110.382 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.426 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.63 -31.82 67.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.478 -0.764 . . . . 0.0 110.58 -179.762 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.47 75.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.183 -0.948 . . . . 0.0 110.54 -179.861 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.411 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.2 OUTLIER -73.83 -34.26 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.873 . . . . 0.0 109.622 179.803 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.465 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.7 m -60.52 -35.05 75.04 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.398 -0.814 . . . . 0.0 109.177 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.56 -49.06 65.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 110.304 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.437 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.56 -43.16 66.84 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.165 -0.959 . . . . 0.0 110.778 -179.615 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.432 ' CD1' HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.46 73.92 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.248 -0.907 . . . . 0.0 110.909 -179.057 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.432 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.74 -51.37 12.83 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.974 -1.079 . . . . 0.0 110.281 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.43 99.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.025 -1.047 . . . . 0.0 109.696 179.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.437 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 0.0 OUTLIER -57.42 -47.41 81.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.422 -0.799 . . . . 0.0 109.468 179.649 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.469 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.89 -43.02 76.83 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.604 -0.685 . . . . 0.0 110.365 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.38 -34.6 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.084 -1.01 . . . . 0.0 109.217 179.614 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.0 59.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.316 -0.865 . . . . 0.0 109.74 179.271 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.427 ' N ' HD21 ' A' ' 58' ' ' LEU . 3.7 mm? -71.52 -26.36 62.63 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-O 121.924 0.869 . . . . 0.0 109.575 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.15 6.3 10.03 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.486 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 37.8 mt -108.1 143.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.293 -1.122 . . . . 0.0 110.104 -179.776 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.415 ' ND2' HG23 ' A' ' 80' ' ' VAL . 21.0 t30 -87.89 106.56 18.19 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 177.953 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.469 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.33 144.26 46.0 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.086 -1.045 . . . . 0.0 111.397 -177.288 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.476 HG13 ' N ' ' A' ' 73' ' ' VAL . 2.5 t -131.03 142.63 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.807 179.551 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.519 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -105.84 118.33 36.31 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.81 178.984 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.437 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.7 OUTLIER -105.27 118.43 36.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.857 . . . . 0.0 110.706 -179.43 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.481 ' CE1' HD22 ' A' ' 69' ' ' LEU . 4.6 p90 -149.69 -179.88 7.46 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 179.32 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.66 129.37 40.79 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.069 -1.019 . . . . 0.0 110.687 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.96 23.68 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.481 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.9 tm? -117.22 154.71 30.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.321 -1.105 . . . . 0.0 110.014 -179.765 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.477 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 23.9 m-20 -94.9 149.78 20.89 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.338 -0.851 . . . . 0.0 110.39 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.419 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 118.934 -1.107 . . . . 0.0 108.99 179.338 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.427 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 36.7 m -133.09 -33.51 1.14 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.485 -0.759 . . . . 0.0 110.708 -179.234 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.476 ' N ' HG13 ' A' ' 63' ' ' VAL . 89.6 t -56.49 134.67 20.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.154 -0.966 . . . . 0.0 109.782 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.495 1.818 0 O-C-N 121.194 -0.941 . . . . 0.0 110.696 179.873 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 121.838 0.828 . . . . 0.0 110.313 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.431 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -117.6 134.22 61.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 122.052 0.929 . . . . 0.0 110.351 179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.477 HG22 HG23 ' A' ' 60' ' ' ILE . 8.0 m -113.16 124.55 69.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.249 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.009 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.465 ' CG2' HG12 ' A' ' 73' ' ' VAL . 8.8 t -97.7 118.78 44.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.019 -1.051 . . . . 0.0 110.778 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.519 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.1 m -111.87 98.54 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 120.78 -1.2 . . . . 0.0 108.81 179.135 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.437 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.92 29.24 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.626 -1.296 . . . . 0.0 110.077 -178.813 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.401 HG21 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -103.36 -24.73 13.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 111.296 -178.544 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.401 ' N ' HG21 ' A' ' 85' ' ' THR . 0.7 OUTLIER 179.92 -29.37 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.996 -1.065 . . . . 0.0 111.059 -179.943 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.95 -38.98 24.58 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.013 -1.055 . . . . 0.0 110.278 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.9 tp . . . . . 0 N--CA 1.49 1.532 0 O-C-N 121.135 -0.978 . . . . 0.0 108.705 178.552 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.02 0.438 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.483 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.2 m-85 -119.7 150.67 39.98 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.953 -1.092 . . . . 0.0 110.265 179.284 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.433 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.6 m-20 -76.86 -31.92 57.15 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.459 -0.776 . . . . 0.0 109.898 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.408 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.61 163.97 26.92 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.256 -0.977 . . . . 0.0 111.788 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.48 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.98 113.77 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.504 -0.748 . . . . 0.0 110.069 179.064 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.449 ' CG2' ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -92.74 116.16 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.093 -1.004 . . . . 0.0 108.387 178.863 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.05 31.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.083 -1.011 . . . . 0.0 112.039 -177.895 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.482 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.5 t -95.77 -1.04 50.56 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 177.84 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.402 ' ND2' ' OE1' ' A' ' 110' ' ' GLN . 2.4 m120 54.89 20.92 3.34 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -0.974 . . . . 0.0 111.168 179.737 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.492 1.635 0 O-C-N 120.974 -1.079 . . . . 0.0 110.659 179.669 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.402 ' OE1' ' ND2' ' A' ' 103' ' ' ASN . 5.7 pt20 . . . . . 0 N--CA 1.494 1.762 0 CA-C-O 121.34 0.59 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.435 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.6 p30 -98.1 160.81 14.06 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.43 -0.794 . . . . 0.0 110.141 179.741 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.51 -50.67 7.06 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.522 -0.736 . . . . 0.0 112.298 -178.681 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.435 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 16.2 m -71.25 -29.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 120.699 -1.251 . . . . 0.0 111.446 -178.564 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.418 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.32 -56.01 7.67 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.059 -1.026 . . . . 0.0 110.449 -179.375 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.428 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.17 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.401 -0.92 . . . . 0.0 108.888 178.683 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.412 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.495 -0.882 . . . . 0.0 108.698 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . 0.42 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.27 66.42 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.608 -0.683 . . . . 0.0 109.528 178.984 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.432 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 21.3 mtt85 -68.42 -44.97 73.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.164 -0.96 . . . . 0.0 110.499 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.432 ' HG2' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -59.94 -46.45 89.36 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.23 -0.919 . . . . 0.0 110.332 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.0 -26.37 1.2 Allowed Glycine 0 N--CA 1.499 2.85 0 O-C-N 121.474 -0.766 . . . . 0.0 111.396 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.465 ' NE ' ' HA ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -48.83 -55.39 11.76 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.882 -1.363 . . . . 0.0 110.858 -179.394 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.472 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 1.3 t -91.62 142.59 27.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.66 12.54 16.4 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.303 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 6.2 mtt180 -102.47 76.56 1.55 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.953 -1.322 . . . . 0.0 109.951 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.671 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.429 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -145.14 167.11 15.38 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.58 -0.953 . . . . 0.0 108.79 179.779 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.95 111.98 1.71 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.202 1.106 . . . . 0.0 109.637 179.582 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.472 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -87.24 166.16 36.44 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -178.854 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.441 ' N ' HG22 ' A' ' 122' ' ' THR . 2.7 mt -124.3 141.79 43.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.514 -0.992 . . . . 0.0 108.54 178.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.48 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.59 115.44 19.5 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.927 179.827 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.444 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.35 121.82 45.34 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.536 -0.728 . . . . 0.0 109.183 179.276 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 24.5 p90 -119.52 157.75 27.69 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -0.987 . . . . 0.0 109.991 -179.694 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.7 t . . . . . 0 N--CA 1.493 1.711 0 O-C-N 121.189 -0.944 . . . . 0.0 110.005 179.751 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.114 0.483 . . . . 0.0 110.449 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.475 ' CD1' HG22 ' A' ' 122' ' ' THR . 1.9 mt -112.8 135.49 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.03 -1.044 . . . . 0.0 109.811 179.898 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.94 125.14 33.13 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.256 -0.902 . . . . 0.0 108.741 178.311 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -89.33 129.53 35.85 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.031 -1.043 . . . . 0.0 110.276 -179.245 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.439 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 12.0 t -125.35 157.88 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.472 -0.767 . . . . 0.0 110.42 -179.193 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.485 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.46 114.15 27.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.292 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.6 tp -52.21 143.87 13.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.231 -0.918 . . . . 0.0 109.878 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.8 p -142.06 -178.2 5.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.196 -0.94 . . . . 0.0 110.226 -179.663 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.4 p -80.33 59.16 3.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.302 -0.873 . . . . 0.0 110.097 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.445 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 23.8 m -132.75 109.22 9.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.436 -0.79 . . . . 0.0 110.597 -179.829 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.459 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.35 -171.63 28.73 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 118.81 -1.662 . . . . 0.0 111.139 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.7 -22.82 10.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.703 -0.88 . . . . 0.0 110.473 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.466 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.8 tt -93.48 109.5 41.01 Favored Pre-proline 0 N--CA 1.49 1.538 0 C-N-CA 118.749 -1.18 . . . . 0.0 109.226 -179.923 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -63.14 145.54 93.73 Favored 'Trans proline' 0 C--N 1.312 -1.354 0 O-C-N 123.423 1.223 . . . . 0.0 111.491 -178.284 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.438 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.83 -165.12 1.68 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.624 -0.673 . . . . 0.0 110.403 -179.311 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.52 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.3 m-85 -60.65 79.76 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.507 -0.745 . . . . 0.0 110.688 -179.879 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.99 57.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.485 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.405 ' O ' ' N ' ' A' ' 23' ' ' PHE . 1.3 mmtp -130.19 156.08 45.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.027 -1.278 . . . . 0.0 109.547 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.431 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.08 106.91 16.11 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.989 -1.069 . . . . 0.0 109.054 179.38 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.466 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.32 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 110.819 -179.173 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.459 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.4 Cg_endo -70.31 130.57 18.88 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 N-CA-C 106.668 -2.089 . . . . 0.0 106.668 175.869 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.428 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 14.3 mt -55.99 -17.98 8.16 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.809 -1.182 . . . . 0.0 110.581 -177.784 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.404 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 13.2 pt-20 -59.35 -16.49 22.85 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.525 -1.359 . . . . 0.0 110.515 179.729 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.409 HG21 ' N ' ' A' ' 33' ' ' ILE . 13.4 m -92.73 -24.33 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.002 -1.061 . . . . 0.0 111.038 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.525 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 37.9 pt -117.45 -26.28 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.921 -1.112 . . . . 0.0 110.358 -179.413 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.449 ' HG3' ' N ' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -90.32 148.79 22.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.057 -1.027 . . . . 0.0 110.058 179.057 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.449 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.81 -4.86 25.92 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.577 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.5 -130.95 2.18 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 119.214 -1.469 . . . . 0.0 110.268 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.412 ' C ' ' CD2' ' A' ' 38' ' ' HIS . 3.2 mtt-85 -115.59 131.0 57.07 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.33 -1.1 . . . . 0.0 110.234 -179.69 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.525 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 74.4 m-70 -140.83 146.4 37.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.111 -0.993 . . . . 0.0 110.879 -179.762 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.463 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 20.4 tp -106.79 127.59 53.53 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.534 -0.729 . . . . 0.0 109.942 179.593 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.445 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 35.1 mt -109.76 128.22 66.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.515 179.388 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.463 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 12.7 m-85 -95.09 124.11 38.95 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 109.99 -179.754 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.56 159.9 21.44 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.347 -0.845 . . . . 0.0 110.739 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.52 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.5 OUTLIER -106.81 3.1 26.07 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.492 -0.755 . . . . 0.0 110.206 179.26 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.0 p -136.7 136.74 39.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.957 -1.089 . . . . 0.0 110.834 -179.661 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.49 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.91 -36.98 70.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.551 -0.718 . . . . 0.0 110.628 179.907 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.29 -33.67 76.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.416 -179.738 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.54 -35.51 65.53 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.51 -0.744 . . . . 0.0 109.712 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.427 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 93.1 m -61.11 -36.06 78.68 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.357 -0.839 . . . . 0.0 109.418 179.498 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.54 -49.95 60.92 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.197 -0.939 . . . . 0.0 110.519 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -72.22 -44.81 62.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.209 -0.932 . . . . 0.0 110.267 179.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.401 HD13 HG11 ' A' ' 83' ' ' VAL . 3.4 tm? -56.79 -43.57 81.04 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.661 . . . . 0.0 111.154 -179.12 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.72 -51.16 52.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.872 -1.142 . . . . 0.0 109.821 179.894 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -35.5 69.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.195 -0.941 . . . . 0.0 109.27 179.323 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.48 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.765 . . . . 0.0 108.978 179.235 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.508 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -58.15 -41.95 84.86 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 110.794 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.5 t -56.15 -32.87 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.07 -1.019 . . . . 0.0 109.156 179.664 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.38 60.15 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.392 -0.818 . . . . 0.0 110.491 179.68 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.48 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.31 -25.44 62.42 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.146 -0.971 . . . . 0.0 109.918 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.78 4.61 9.51 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.329 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.47 HG23 HG22 ' A' ' 81' ' ' VAL . 44.7 mt -105.71 143.37 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 121.376 -1.073 . . . . 0.0 109.845 -179.729 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.445 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.9 t30 -88.58 106.99 18.67 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 178.173 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.508 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.57 146.31 44.69 Favored 'General case' 0 C--N 1.294 -1.812 0 C-N-CA 118.706 -1.197 . . . . 0.0 111.728 -177.084 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.477 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 89.8 t -128.2 149.75 33.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -116.29 117.74 30.83 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.549 178.412 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.451 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.5 142.36 45.16 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.337 -0.852 . . . . 0.0 110.354 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.495 ' CE1' HD23 ' A' ' 69' ' ' LEU . 2.9 p90 -175.32 -177.27 1.01 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.399 -0.813 . . . . 0.0 110.034 179.888 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.52 119.8 5.76 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.176 -0.952 . . . . 0.0 111.234 -179.232 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 40.97 11.8 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.13 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.495 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.3 tm? -117.59 155.37 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.052 -1.264 . . . . 0.0 110.223 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.442 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.8 m-20 -93.56 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.282 -0.886 . . . . 0.0 110.416 -179.541 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.409 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 28.2 m -62.55 110.61 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.411 179.384 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.59 -20.95 2.27 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.536 -0.728 . . . . 0.0 111.046 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.477 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 54.5 t -63.99 128.15 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.022 -1.049 . . . . 0.0 109.53 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.454 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.4 pp . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.028 -1.045 . . . . 0.0 110.926 -179.647 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.873 0.844 . . . . 0.0 110.146 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.445 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.8 p -116.65 135.38 57.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-O 122.006 0.908 . . . . 0.0 110.721 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.476 HG23 ' CB ' ' A' ' 62' ' ' ALA . 9.6 m -113.2 122.81 68.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.611 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.421 ' CG2' HG13 ' A' ' 73' ' ' VAL . 4.1 t -97.29 118.81 44.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 120.833 -1.167 . . . . 0.0 110.5 -178.118 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.494 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.5 m -109.8 100.64 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.018 -1.051 . . . . 0.0 108.947 179.699 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.451 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.21 163.83 31.9 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.602 -1.311 . . . . 0.0 111.38 -177.859 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 11.2 t -91.38 -140.76 0.17 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.423 -0.798 . . . . 0.0 109.332 179.757 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -84.43 52.12 2.28 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.806 -1.184 . . . . 0.0 110.248 179.633 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.437 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.43 -19.58 6.36 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.202 -0.936 . . . . 0.0 110.936 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 O-C-N 121.012 -1.055 . . . . 0.0 109.548 179.922 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.199 0.523 . . . . 0.0 110.392 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -119.45 153.1 35.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.205 -0.934 . . . . 0.0 110.167 179.433 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.86 -29.24 25.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.396 -0.815 . . . . 0.0 109.513 179.393 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.4 p -161.88 163.7 29.07 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.244 -0.91 . . . . 0.0 111.161 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.53 125.85 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.389 -0.819 . . . . 0.0 110.094 179.24 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.422 HD12 ' CG2' ' A' ' 33' ' ' ILE . 3.2 mp -102.86 112.15 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.231 -0.918 . . . . 0.0 109.003 179.265 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -118.09 162.01 18.91 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.184 -0.948 . . . . 0.0 111.869 -178.485 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.494 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.26 9.38 38.13 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.75 -0.594 . . . . 0.0 109.744 178.556 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.433 ' ND2' ' NE2' ' A' ' 110' ' ' GLN . 2.8 m-20 46.58 25.16 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.091 -1.006 . . . . 0.0 111.481 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 110.454 179.629 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.433 ' NE2' ' ND2' ' A' ' 103' ' ' ASN . 13.9 pt20 . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.465 0.65 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.439 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.5 p30 -93.21 161.09 14.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.384 -0.822 . . . . 0.0 109.719 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.13 -51.75 5.78 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.375 -0.828 . . . . 0.0 112.316 -178.629 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.439 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 12.6 m -69.74 -29.15 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.76 -1.213 . . . . 0.0 111.382 -178.81 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.47 -56.13 7.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.122 -0.986 . . . . 0.0 110.522 -179.091 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -68.08 -34.86 77.22 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.066 -1.021 . . . . 0.0 108.658 178.927 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.402 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.95 -49.91 75.83 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.14 -0.975 . . . . 0.0 108.427 178.623 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.8 -36.85 65.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.584 -0.697 . . . . 0.0 109.888 179.078 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 13.6 mtt180 -71.23 -44.61 65.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.163 -0.96 . . . . 0.0 110.502 -179.727 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.438 ' HG2' ' CD1' ' A' ' 10' ' ' ILE . 0.5 OUTLIER -58.6 -42.19 87.55 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.109 -0.994 . . . . 0.0 109.903 179.734 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.97 89.41 0.02 OUTLIER Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.435 ' HG2' ' CD2' ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.66 -44.06 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.55 -0.971 . . . . 0.0 108.616 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.48 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.6 t -102.07 132.54 47.88 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 178.663 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.44 8.18 3.67 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.015 -1.564 . . . . 0.0 110.845 179.596 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -85.39 82.48 8.3 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.853 -1.381 . . . . 0.0 110.269 -179.791 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.67 -52.08 0.71 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.448 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.92 178.74 0.91 Allowed Pre-proline 0 C--N 1.302 -1.489 0 O-C-N 121.579 -0.954 . . . . 0.0 109.332 179.403 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.53 109.53 2.79 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 123.57 1.3 . . . . 0.0 109.39 179.127 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.48 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.57 161.8 52.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.261 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.5 mt -119.64 142.66 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.427 -1.043 . . . . 0.0 109.389 179.491 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 5.5 t80 -130.34 115.47 16.96 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.18 -0.95 . . . . 0.0 110.387 179.899 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.406 ' CZ ' HG12 ' A' ' 32' ' ' VAL . 2.0 mtt180 -103.27 133.95 47.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.432 -0.793 . . . . 0.0 109.892 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.485 ' CE1' ' HA ' ' A' ' 14' ' ' ALA . 8.2 p90 -127.12 152.44 47.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 110.205 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.4 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t . . . . . 0 N--CA 1.493 1.687 0 O-C-N 121.183 -0.948 . . . . 0.0 109.859 179.568 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.441 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.639 0.733 . . . . 0.0 109.433 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.445 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 28.4 mt -102.09 136.68 33.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.116 -0.99 . . . . 0.0 109.772 179.452 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.11 34.99 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.132 -0.98 . . . . 0.0 109.576 179.838 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.93 121.54 31.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.237 -0.915 . . . . 0.0 110.206 -179.291 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.449 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 10.8 t -116.45 157.16 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.432 -0.793 . . . . 0.0 110.113 -179.521 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.86 111.29 23.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.165 -0.959 . . . . 0.0 109.91 179.483 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.433 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 9.9 tp -55.65 139.62 44.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.935 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.72 3.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 110.34 -179.825 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.56 84.38 7.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.17 -0.957 . . . . 0.0 109.867 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.43 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 25.2 m -158.99 109.78 2.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.186 -0.946 . . . . 0.0 110.906 -179.482 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.463 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.32 -174.47 29.71 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.212 178.922 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.02 -19.57 13.46 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.834 -0.803 . . . . 0.0 110.284 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.47 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.3 tt -98.26 106.31 34.56 Favored Pre-proline 0 N--CA 1.489 1.516 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.421 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -62.91 123.38 12.16 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 O-C-N 123.347 1.182 . . . . 0.0 110.776 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.0 t80 -111.5 -167.81 1.23 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.686 -0.634 . . . . 0.0 110.336 -179.185 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.8 m-85 -58.93 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.479 -0.763 . . . . 0.0 111.117 -179.595 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.73 3.83 56.14 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 179.831 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.433 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.43 44.28 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.019 -1.283 . . . . 0.0 109.224 179.733 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.43 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -106.21 106.49 17.02 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.971 -1.08 . . . . 0.0 108.546 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.47 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.0 mt -69.8 113.44 17.38 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.337 -0.852 . . . . 0.0 110.52 -178.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.463 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.5 Cg_endo -69.75 130.77 19.94 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 N-CA-C 107.159 -1.9 . . . . 0.0 107.159 176.347 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.424 HD23 ' CD1' ' A' ' 60' ' ' ILE . 10.5 mt -56.74 -16.43 6.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.802 -1.186 . . . . 0.0 110.521 -178.313 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.435 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.05 -16.14 49.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.555 -1.341 . . . . 0.0 110.532 179.516 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.424 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 12.8 m -93.39 -25.77 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 120.935 -1.103 . . . . 0.0 111.125 -179.313 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.511 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 25.0 pt -115.98 -26.04 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.061 . . . . 0.0 109.954 -179.658 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.458 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.21 147.99 22.67 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.224 -0.923 . . . . 0.0 110.435 179.945 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.22 -4.77 41.19 Favored Glycine 0 N--CA 1.484 1.872 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.352 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.63 -149.44 9.32 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.185 -1.483 . . . . 0.0 110.376 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.65 129.95 54.47 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.336 -1.097 . . . . 0.0 110.323 -179.621 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.511 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.2 m80 -138.43 153.59 48.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.067 -1.02 . . . . 0.0 111.087 -179.508 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.424 ' CD2' ' HG2' ' A' ' 121' ' ' ARG . 24.9 tp -113.23 114.05 26.19 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.41 -0.806 . . . . 0.0 109.81 179.613 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.476 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 38.6 mt -97.14 126.75 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.28 -0.887 . . . . 0.0 109.539 179.427 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -95.0 123.73 38.65 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.402 -0.811 . . . . 0.0 110.196 -179.797 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.2 -0.938 . . . . 0.0 110.885 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.499 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.7 p80 -104.42 -5.47 21.63 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.834 . . . . 0.0 110.128 179.148 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.63 137.4 53.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 110.637 -179.741 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.495 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.8 -43.28 65.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.677 -0.64 . . . . 0.0 110.679 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.17 -36.94 81.18 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.266 -0.896 . . . . 0.0 110.71 -179.632 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.68 -35.38 78.74 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.37 -0.831 . . . . 0.0 109.485 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.421 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 94.3 m -61.45 -34.84 76.11 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.439 -0.788 . . . . 0.0 109.385 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.61 -49.02 74.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 110.459 179.86 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.76 -40.38 69.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.228 -0.92 . . . . 0.0 110.494 -179.734 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -57.11 -39.96 76.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.47 -0.769 . . . . 0.0 110.958 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.43 -51.36 13.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 110.377 -179.784 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.32 -41.21 93.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.096 -1.002 . . . . 0.0 109.517 179.619 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.424 ' O ' HD21 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.67 -46.88 83.69 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.423 -0.798 . . . . 0.0 109.664 179.47 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.485 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.17 -43.32 78.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.552 -0.718 . . . . 0.0 110.326 179.931 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.3 t -55.7 -33.16 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.04 -1.037 . . . . 0.0 109.166 179.611 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.9 60.85 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.272 -0.892 . . . . 0.0 109.79 179.088 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.463 HD22 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -72.05 -26.2 62.09 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.312 -0.867 . . . . 0.0 109.703 179.634 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.46 9.51 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.343 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.465 HG23 HG21 ' A' ' 81' ' ' VAL . 48.6 mt -108.3 143.09 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.308 -1.113 . . . . 0.0 110.239 -179.626 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.418 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 17.0 t30 -86.69 106.66 17.79 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 178.232 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.485 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.84 144.59 48.28 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.506 -177.432 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.473 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 2.7 t -134.56 145.1 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -108.79 128.79 55.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.976 -1.09 . . . . 0.0 109.996 179.308 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.1 53.19 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 110.376 -179.839 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.497 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.4 p90 -170.57 174.62 4.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.473 -0.767 . . . . 0.0 109.655 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.78 120.84 5.68 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 110.766 -179.179 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.27 34.36 14.65 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.531 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.497 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -116.97 156.24 27.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.134 -1.215 . . . . 0.0 110.021 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.469 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 2.0 m-20 -93.96 148.32 22.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.186 -0.946 . . . . 0.0 110.91 -179.189 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 27.8 m -63.26 111.45 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.343 178.884 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.439 ' CB ' HG12 ' A' ' 63' ' ' VAL . 5.4 m -134.76 -33.18 0.96 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.419 -0.801 . . . . 0.0 110.921 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.473 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 20.8 t -53.96 140.1 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.109 -0.995 . . . . 0.0 110.308 -179.418 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.3 -0.875 . . . . 0.0 110.832 179.814 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 122.019 0.914 . . . . 0.0 109.791 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -110.98 134.47 53.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-O 121.928 0.87 . . . . 0.0 110.042 -179.779 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.481 HG21 HD23 ' A' ' 55' ' ' LEU . 6.3 m -112.04 125.9 69.38 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.397 -0.814 . . . . 0.0 109.248 179.495 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.468 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.8 t -97.57 116.14 39.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 O-C-N 121.117 -0.99 . . . . 0.0 110.12 -178.303 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.4 m -110.65 100.21 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.048 -1.032 . . . . 0.0 108.763 179.723 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.16 33.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.545 -1.347 . . . . 0.0 111.552 -177.891 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -86.9 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.595 -0.691 . . . . 0.0 109.412 179.6 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -90.1 42.87 1.12 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.693 -1.255 . . . . 0.0 110.484 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.423 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.96 -26.04 8.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.122 -0.987 . . . . 0.0 110.351 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.405 HD11 ' CG1' ' A' ' 82' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.701 0 O-C-N 121.089 -1.007 . . . . 0.0 109.977 179.538 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.049 0.452 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -119.79 152.85 36.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.08 -1.012 . . . . 0.0 110.507 179.636 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.19 17.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.504 -0.747 . . . . 0.0 109.356 179.213 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.8 p -160.82 163.04 32.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.421 -0.799 . . . . 0.0 110.294 179.779 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.479 HG22 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.36 122.67 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.066 -1.021 . . . . 0.0 110.421 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.7 mp -97.99 112.68 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.429 -0.795 . . . . 0.0 109.121 179.266 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -121.01 160.74 22.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.114 -0.991 . . . . 0.0 111.589 -178.72 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.66 5.55 43.82 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.688 -0.633 . . . . 0.0 109.47 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 49.21 24.44 0.98 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 111.064 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.081 -1.012 . . . . 0.0 110.316 179.55 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 . . . . . 0 N--CA 1.493 1.703 0 CA-C-O 121.35 0.595 . . . . 0.0 111.253 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.429 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.4 p30 -77.4 160.57 28.65 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.429 -0.794 . . . . 0.0 110.174 179.85 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -46.62 -52.83 12.78 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.348 -0.845 . . . . 0.0 112.058 -178.794 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.429 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.51 -28.95 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 120.838 -1.164 . . . . 0.0 111.466 -178.583 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.05 -56.47 6.43 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.071 -1.018 . . . . 0.0 110.593 -179.289 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.41 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.7 OUTLIER -68.95 -34.61 75.63 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.231 -0.918 . . . . 0.0 108.723 178.961 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 41.0 m -59.61 -49.98 75.65 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.174 -0.954 . . . . 0.0 108.482 178.781 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.72 -36.25 65.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.464 -0.772 . . . . 0.0 109.9 178.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.41 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.1 mtt180 -71.22 -44.58 65.09 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.179 -0.951 . . . . 0.0 110.723 -179.585 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.489 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 14.1 ttm180 -56.15 -43.38 78.23 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.912 -1.117 . . . . 0.0 110.415 -179.757 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.69 79.55 0.06 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.433 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -152.08 -43.96 0.11 Allowed 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.296 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.441 ' CG2' HD11 ' A' ' 10' ' ' ILE . 8.8 t -100.27 144.06 29.73 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.297 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.466 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.69 14.63 46.13 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.192 -1.48 . . . . 0.0 110.444 179.425 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.67 -31.79 68.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.127 -1.219 . . . . 0.0 110.032 -179.916 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.89 20.75 4.03 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.333 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.494 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -165.46 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.427 -1.043 . . . . 0.0 108.506 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.494 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 50.2 Cg_endo -85.32 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 122.85 0.921 . . . . 0.0 110.607 179.365 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.429 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.53 176.61 50.25 Favored Glycine 0 N--CA 1.497 2.759 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.8 mt -131.35 142.87 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.466 -1.02 . . . . 0.0 109.075 179.296 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.489 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 18.6 t80 -131.3 116.03 17.06 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.034 -1.041 . . . . 0.0 110.934 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -101.83 134.86 44.35 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.536 -0.727 . . . . 0.0 109.461 179.391 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.449 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.91 148.93 50.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.055 -1.028 . . . . 0.0 110.042 -179.79 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 N--CA 1.493 1.677 0 O-C-N 121.188 -0.945 . . . . 0.0 109.902 179.75 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 . . . . . 0 N--CA 1.493 1.682 0 CA-C-O 121.245 0.545 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.501 ' CD1' HG22 ' A' ' 122' ' ' THR . 20.8 mt -95.15 128.19 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.428 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.12 128.14 34.37 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.263 -0.898 . . . . 0.0 108.951 178.868 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.3 134.67 33.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.109 -0.994 . . . . 0.0 110.128 -179.303 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.405 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 5.5 t -128.66 157.73 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.396 -0.815 . . . . 0.0 110.183 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.43 113.79 27.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.356 -0.84 . . . . 0.0 110.068 179.718 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.433 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.78 143.97 19.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 110.027 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.42 170.17 16.41 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.977 . . . . 0.0 110.397 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.86 81.59 1.18 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.201 -0.937 . . . . 0.0 109.754 179.651 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.434 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 9.4 m -158.31 111.44 2.39 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.872 -179.502 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.459 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.27 -170.39 30.24 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.139 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.75 -19.08 12.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.787 -0.831 . . . . 0.0 110.0 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.452 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.3 tt -99.92 104.05 26.18 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.833 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.403 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -63.16 125.92 16.8 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.231 1.122 . . . . 0.0 111.008 -179.18 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.0 t80 -112.93 -169.57 1.51 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.738 -0.601 . . . . 0.0 110.352 -179.499 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.524 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.0 m-85 -59.46 82.3 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.269 -0.894 . . . . 0.0 111.377 -179.433 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.19 61.69 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.627 179.274 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.433 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 26.6 mmtt -129.86 156.54 44.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.884 -1.362 . . . . 0.0 109.638 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.429 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.34 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.98 -1.075 . . . . 0.0 108.993 179.56 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.452 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.4 mt -70.28 113.17 15.95 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.375 -0.828 . . . . 0.0 110.729 -179.122 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.459 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.4 Cg_endo -69.63 130.77 20.09 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 N-CA-C 106.849 -2.02 . . . . 0.0 106.849 175.754 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.435 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 9.7 mt -55.99 -18.68 9.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.784 -1.198 . . . . 0.0 110.507 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.433 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.01 15.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.861 -1.149 . . . . 0.0 110.589 179.728 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.404 HG11 ' HG2' ' A' ' 29' ' ' PRO . 9.6 m -93.96 -25.3 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.926 -1.109 . . . . 0.0 110.951 -179.735 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.538 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 27.1 pt -117.95 -14.86 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.934 -1.104 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.462 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.64 148.06 24.2 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.849 -1.157 . . . . 0.0 110.383 179.683 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.7 -4.4 50.17 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.629 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.01 7.23 Favored Glycine 0 N--CA 1.492 2.393 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.589 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.416 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.05 132.54 54.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -1.018 . . . . 0.0 110.213 -179.602 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.538 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -139.93 150.46 44.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.197 -0.939 . . . . 0.0 110.863 -179.759 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.488 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 51.3 tp -110.99 115.26 29.17 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.466 -0.771 . . . . 0.0 109.996 179.836 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.435 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.4 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.231 -0.918 . . . . 0.0 109.041 179.503 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.488 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.76 37.98 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.866 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.63 159.36 23.06 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.363 -0.836 . . . . 0.0 110.422 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.59 20.31 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.388 -0.82 . . . . 0.0 110.024 179.069 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.2 p -132.8 139.21 47.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.403 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.57 -34.09 71.81 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.464 -0.773 . . . . 0.0 110.465 -179.932 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.46 -34.14 76.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.249 -0.907 . . . . 0.0 110.333 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.433 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.09 -36.34 64.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.206 -0.934 . . . . 0.0 109.636 179.818 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 64.9 m -60.98 -39.2 88.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.563 -0.71 . . . . 0.0 109.469 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.52 -46.59 87.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.915 . . . . 0.0 110.035 179.699 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.439 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.43 -45.47 62.59 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.395 -0.815 . . . . 0.0 110.454 -179.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.439 ' CD1' HG12 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.36 -45.07 80.66 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.36 -0.838 . . . . 0.0 111.149 -178.997 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.429 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.75 -51.57 22.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.001 -1.062 . . . . 0.0 110.366 -179.467 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.16 99.33 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 109.762 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.439 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 0.0 OUTLIER -58.54 -46.81 86.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.24 -0.912 . . . . 0.0 109.606 179.591 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.491 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.2 -43.52 78.56 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.636 -0.665 . . . . 0.0 110.147 179.86 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.2 t -55.48 -32.67 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.21 -0.931 . . . . 0.0 109.029 179.7 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.56 -31.05 59.89 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.251 -0.906 . . . . 0.0 109.832 179.071 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.458 HD23 ' N ' ' A' ' 58' ' ' LEU . 3.9 mm? -72.19 -26.36 62.03 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.864 0.84 . . . . 0.0 109.837 179.844 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.9 4.58 10.29 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.16 -1.576 . . . . 0.0 109.16 -179.113 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.466 HG22 HG23 ' A' ' 81' ' ' VAL . 28.1 mt -105.48 143.34 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.352 -1.087 . . . . 0.0 110.096 -179.748 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.402 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.7 t-20 -88.06 106.07 17.91 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 178.031 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.491 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.288 -177.502 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.478 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.33 139.55 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.806 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -101.26 122.77 44.27 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.214 178.758 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.429 ' CB ' ' HB3' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.1 134.88 54.78 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.313 -0.867 . . . . 0.0 111.153 -178.925 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.496 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.5 p90 -168.89 170.65 8.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.574 -0.704 . . . . 0.0 109.641 179.506 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.67 118.3 3.27 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.242 -0.912 . . . . 0.0 110.845 -179.439 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.82 37.35 6.44 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.496 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.42 30.03 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -1.142 . . . . 0.0 110.168 -179.724 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.46 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 6.3 m-20 -91.84 149.58 21.51 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.36 -0.837 . . . . 0.0 110.596 -179.48 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.417 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 34.7 m -62.15 110.88 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 119.128 -1.029 . . . . 0.0 109.426 179.326 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.456 ' CB ' HG11 ' A' ' 63' ' ' VAL . 19.7 m -133.19 -39.33 0.93 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.447 -0.783 . . . . 0.0 110.233 -179.656 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.478 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 79.0 t -47.61 133.09 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.42 -0.8 . . . . 0.0 109.993 179.822 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.776 0 O-C-N 121.138 -0.976 . . . . 0.0 110.842 -179.51 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.925 0.869 . . . . 0.0 110.39 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -117.75 134.0 62.73 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 CA-C-O 122.095 0.95 . . . . 0.0 110.05 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 16.8 m -113.24 122.71 67.89 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.466 -0.771 . . . . 0.0 108.984 179.348 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.443 HG23 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -96.95 118.59 43.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.723 -1.235 . . . . 0.0 111.106 -177.686 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.502 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 4.3 m -108.7 99.68 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.034 -1.041 . . . . 0.0 108.852 178.838 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.429 ' HB3' ' CB ' ' A' ' 65' ' ' TYR . . . -135.79 155.93 49.59 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.446 -1.409 . . . . 0.0 110.912 -178.488 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.436 ' CG2' ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.17 -42.43 15.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.369 -0.832 . . . . 0.0 110.385 -179.5 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.436 ' N ' ' CG2' ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.22 32.54 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.432 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -103.16 -30.99 10.35 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.009 . . . . 0.0 110.067 -179.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 110.067 179.415 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.1 0.476 . . . . 0.0 110.478 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.479 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 16.9 m-85 -119.9 149.75 41.6 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.103 -0.998 . . . . 0.0 110.078 179.399 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.402 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.85 -31.54 25.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.812 . . . . 0.0 109.619 179.554 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.5 p -162.26 163.43 28.15 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.417 -0.913 . . . . 0.0 111.466 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.497 HG21 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 117.74 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.455 -0.778 . . . . 0.0 109.614 178.798 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.433 HG21 ' CD1' ' A' ' 28' ' ' ILE . 4.2 mp -97.59 117.18 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.224 -0.923 . . . . 0.0 109.456 179.876 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -129.84 161.32 31.04 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.107 -0.995 . . . . 0.0 111.634 -178.716 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 52.8 t -92.03 -7.41 48.87 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.641 -0.662 . . . . 0.0 109.534 178.017 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.2 13.44 1.66 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.255 -0.903 . . . . 0.0 111.87 179.704 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 m . . . . . 0 C--N 1.306 -1.31 0 O-C-N 120.725 -1.234 . . . . 0.0 109.39 -179.888 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.369 0.604 . . . . 0.0 110.794 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.44 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.0 p30 -80.88 159.06 25.12 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.272 -0.892 . . . . 0.0 109.84 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -46.63 -50.92 16.88 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.282 -0.886 . . . . 0.0 111.893 -178.787 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.44 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.41 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.792 -1.193 . . . . 0.0 111.444 -178.727 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.423 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.27 -56.6 6.47 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.987 -1.071 . . . . 0.0 110.426 -179.131 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.422 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.73 -35.03 76.61 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.264 -0.898 . . . . 0.0 108.918 178.718 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.2 m -59.9 -46.69 88.53 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 178.709 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.61 -40.43 63.82 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.671 -0.643 . . . . 0.0 109.767 178.905 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -69.65 -44.23 70.99 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.273 -0.892 . . . . 0.0 110.344 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.457 ' O ' ' N ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -56.54 -43.74 80.16 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.362 -0.836 . . . . 0.0 110.004 179.678 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.01 0.11 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.682 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.457 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.77 -46.41 0.13 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.563 -0.963 . . . . 0.0 108.76 179.622 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.501 HG22 ' CD1' ' A' ' 10' ' ' ILE . 15.3 t -97.19 141.89 29.77 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.466 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.26 17.17 3.34 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.594 179.787 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.499 ' N ' ' CD ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.15 81.71 6.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.889 -1.359 . . . . 0.0 109.986 -179.731 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.52 -52.08 0.71 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.466 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.96 176.61 1.49 Allowed Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 121.765 -0.844 . . . . 0.0 109.123 179.308 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.21 112.89 3.64 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 N-CA-C 108.806 -1.267 . . . . 0.0 108.806 178.484 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.473 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.01 177.87 41.45 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -178.927 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.2 mt -135.23 142.8 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.239 -1.154 . . . . 0.0 109.652 179.502 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.497 ' CD1' HG21 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.87 114.5 19.29 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.051 178.721 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.405 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 3.8 mtt85 -105.97 122.77 46.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.515 -0.741 . . . . 0.0 109.297 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 11.0 p90 -122.94 157.81 31.8 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.058 -1.026 . . . . 0.0 110.464 -179.576 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 37.8 t . . . . . 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.751 179.555 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.78 135.42 34.13 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.174 -1.192 . . . . 0.0 110.104 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.436 ' CG1' ' O ' ' A' ' 3' ' ' VAL . 13.6 p -113.01 104.56 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.154 -0.966 . . . . 0.0 109.929 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 79.1 p -72.28 144.68 48.29 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.31 -0.869 . . . . 0.0 110.5 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.426 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.45 147.96 98.14 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.295 -0.878 . . . . 0.0 109.683 179.673 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.426 ' HD2' HG21 ' A' ' 5' ' ' VAL . 49.3 Cg_endo -73.37 -173.76 1.4 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 124.116 1.588 . . . . 0.0 111.006 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.497 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 1.0 OUTLIER 170.67 76.6 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.782 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.576 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -68.22 -17.38 45.05 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 O-C-N 123.879 1.462 . . . . 0.0 111.022 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 -57.0 -24.56 54.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.104 -0.997 . . . . 0.0 109.974 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.49 ' CD1' HG21 ' A' ' 122' ' ' THR . 9.0 mt -106.0 133.3 50.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.043 -1.036 . . . . 0.0 109.901 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -85.67 128.41 34.77 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.383 -0.823 . . . . 0.0 108.946 178.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -89.21 139.24 30.69 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.026 . . . . 0.0 110.328 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.67 155.63 41.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.46 -0.775 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.09 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 110.064 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.401 HD22 ' CG2' ' A' ' 133' ' ' VAL . 9.6 tp -54.35 140.0 34.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.324 -0.86 . . . . 0.0 109.889 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.48 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 110.249 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.274 -0.891 . . . . 0.0 110.033 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.432 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 31.3 m -146.15 109.29 4.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 110.555 -179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.462 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.91 -173.9 28.7 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.294 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -107.87 -22.75 12.33 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.794 -0.827 . . . . 0.0 110.428 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.468 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -95.11 102.45 9.43 Favored Pre-proline 0 N--CA 1.486 1.345 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.695 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -61.97 139.97 82.21 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 O-C-N 123.558 1.293 . . . . 0.0 110.603 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.87 -164.08 1.45 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 111.028 -178.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.517 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.4 m-85 -58.07 81.61 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.527 -0.733 . . . . 0.0 111.221 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.05 4.99 38.2 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.406 ' O ' ' N ' ' A' ' 23' ' ' PHE . 12.5 mmtm -131.05 155.91 46.08 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.295 . . . . 0.0 109.432 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.422 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.92 107.34 16.31 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.063 -1.023 . . . . 0.0 108.918 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.468 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -68.04 114.57 21.51 Favored Pre-proline 0 C--N 1.3 -1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 110.895 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.462 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.0 Cg_endo -70.2 128.28 15.41 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 N-CA-C 106.91 -1.996 . . . . 0.0 106.91 175.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.44 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 9.8 mt -56.22 -18.51 10.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.785 -1.197 . . . . 0.0 110.867 -177.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -59.5 -16.13 22.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.632 -1.293 . . . . 0.0 110.466 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.43 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 9.3 m -91.8 -25.17 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.021 -1.049 . . . . 0.0 110.869 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.536 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 38.0 pt -118.31 -17.15 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.011 -1.056 . . . . 0.0 110.602 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.475 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 6.1 tptm -98.66 148.39 23.88 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.987 -1.07 . . . . 0.0 109.847 179.229 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.58 -6.1 33.41 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.98 -136.81 2.97 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.305 -1.426 . . . . 0.0 110.307 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -117.65 132.54 56.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -1.124 . . . . 0.0 110.43 -179.56 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.536 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.83 150.25 44.45 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.244 -0.91 . . . . 0.0 110.806 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.404 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 24.3 tp -112.16 114.73 27.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.503 -0.748 . . . . 0.0 110.023 179.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 83' ' ' VAL . 43.8 mt -97.6 127.93 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.325 -0.859 . . . . 0.0 109.972 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.418 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.34 123.03 38.65 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.217 -0.927 . . . . 0.0 109.907 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.12 21.68 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.275 -0.891 . . . . 0.0 110.702 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.517 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.7 p80 -107.12 0.46 23.47 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.483 -0.761 . . . . 0.0 110.371 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.24 137.42 44.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.944 -1.098 . . . . 0.0 110.865 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.508 ' CG ' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.51 -39.69 70.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.722 -0.611 . . . . 0.0 110.787 -179.753 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -58.6 -36.71 74.42 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 110.369 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -73.8 -34.4 64.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 109.59 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.438 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.95 73.43 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.46 -0.775 . . . . 0.0 109.461 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.48 -49.58 53.43 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.216 -0.928 . . . . 0.0 110.295 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.421 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.93 -44.38 63.72 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.288 -0.883 . . . . 0.0 110.353 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.44 ' CD1' HG13 ' A' ' 83' ' ' VAL . 2.0 tm? -56.86 -43.05 80.8 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.441 -0.787 . . . . 0.0 110.773 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.19 -51.84 14.28 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.9 -1.125 . . . . 0.0 110.656 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.69 -38.77 86.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.854 -1.154 . . . . 0.0 109.413 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.421 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 2.5 ttmm -59.38 -45.98 89.93 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.36 -0.838 . . . . 0.0 109.493 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.35 -40.28 71.05 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.418 -0.801 . . . . 0.0 109.763 179.833 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -56.41 -34.49 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.109 -0.995 . . . . 0.0 108.786 178.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.48 -31.2 60.15 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.558 -0.714 . . . . 0.0 110.093 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.466 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.0 mm? -71.22 -26.13 62.8 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.63 4.77 9.56 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.484 HG22 HG23 ' A' ' 81' ' ' VAL . 58.2 mt -108.09 143.34 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.283 -1.128 . . . . 0.0 110.034 -179.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.449 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 52.4 t30 -86.28 107.6 18.02 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 178.326 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.496 ' HB2' HD21 ' A' ' 55' ' ' LEU . . . -120.9 149.79 42.07 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.947 -1.101 . . . . 0.0 112.095 -176.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.479 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.5 t -138.3 152.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.429 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.481 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -114.45 130.81 56.74 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.076 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.444 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.51 122.24 40.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.29 -0.881 . . . . 0.0 110.441 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.508 ' CG ' ' CG ' ' A' ' 45' ' ' LYS . 3.5 p90 -156.23 176.76 12.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.592 -0.692 . . . . 0.0 109.62 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.31 125.1 16.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.064 -1.023 . . . . 0.0 110.505 -179.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.95 38.57 15.34 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.491 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -117.5 156.06 28.66 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.152 -1.205 . . . . 0.0 110.147 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.456 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 15.5 m-20 -96.68 148.96 22.34 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.322 -0.862 . . . . 0.0 110.565 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.417 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 32.4 m -62.23 110.95 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.054 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.443 ' CB ' HG12 ' A' ' 63' ' ' VAL . 12.4 m -132.62 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.398 -0.814 . . . . 0.0 110.523 -179.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.479 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 58.7 t -52.25 128.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -0.904 . . . . 0.0 110.053 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.446 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 2.0 pp -137.96 115.73 9.52 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.274 -0.891 . . . . 0.0 110.487 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.405 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.1 Cg_endo -87.35 39.15 0.56 Allowed 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 123.251 1.132 . . . . 0.0 110.952 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.5 p -144.2 46.9 1.42 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.904 -1.122 . . . . 0.0 110.528 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.437 ' HB2' ' CD1' ' A' ' 74' ' ' ILE . 3.8 m-80 -142.25 26.89 1.79 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.173 -0.954 . . . . 0.0 110.164 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.99 -94.95 1.12 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -128.77 109.04 10.95 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.174 -1.192 . . . . 0.0 110.176 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.1 p -116.98 134.46 60.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 122.054 0.93 . . . . 0.0 110.698 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.484 HG23 HG22 ' A' ' 60' ' ' ILE . 13.4 m -112.9 122.3 66.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.092 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.465 ' CG2' HG13 ' A' ' 73' ' ' VAL . 4.3 t -96.99 119.62 45.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.009 -1.057 . . . . 0.0 110.326 -177.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.485 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 4.5 m -111.36 100.4 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 120.997 -1.065 . . . . 0.0 108.627 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.444 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.45 162.78 34.65 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.731 -1.231 . . . . 0.0 111.602 -177.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -93.28 -136.0 0.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.524 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -86.42 46.69 1.37 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.734 -1.228 . . . . 0.0 110.623 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.13 -23.09 8.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.931 -1.106 . . . . 0.0 110.405 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -65.79 -29.35 69.83 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.698 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.47 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 48.68 44.93 21.69 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.455 -0.778 . . . . 0.0 111.074 179.791 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.468 ' CB ' HG23 ' A' ' 93' ' ' THR . 2.6 t 33.94 -118.86 0.09 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 112.03 0.381 . . . . 0.0 112.03 179.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 86.47 -63.66 4.1 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -119.88 1.83 11.0 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.43 -1.041 . . . . 0.0 110.134 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.468 HG23 ' CB ' ' A' ' 90' ' ' THR . 12.3 t -67.65 -154.43 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.016 -1.052 . . . . 0.0 110.278 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.402 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 90.11 -41.52 2.97 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 179.428 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -84.05 57.54 4.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.188 -1.183 . . . . 0.0 111.095 -179.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -119.69 146.66 45.39 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.086 -1.008 . . . . 0.0 109.855 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.06 -33.33 67.88 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.352 -0.843 . . . . 0.0 109.856 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -162.78 163.7 26.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.887 . . . . 0.0 111.078 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.528 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 114.56 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.312 -0.868 . . . . 0.0 109.994 178.811 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.433 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.2 114.7 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.227 -0.92 . . . . 0.0 108.608 179.061 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.418 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.11 160.17 25.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.125 -0.984 . . . . 0.0 111.798 -178.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.94 -7.39 52.24 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.86 18.79 0.55 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 112.247 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.422 ' CA ' ' O ' ' A' ' 108' ' ' LYS . 0.8 OUTLIER -147.4 113.76 5.93 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.746 -1.221 . . . . 0.0 109.366 179.565 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.443 ' N ' ' O ' ' A' ' 108' ' ' LYS . 58.9 p -88.01 140.17 29.76 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.155 -0.966 . . . . 0.0 110.625 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 52.41 28.26 5.68 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.382 -0.823 . . . . 0.0 110.675 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.62 -14.86 57.19 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.151 -1.179 . . . . 0.0 110.151 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.443 ' O ' ' N ' ' A' ' 105' ' ' SER . 8.5 mmtt -96.6 156.65 36.44 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.059 -1.26 . . . . 0.0 109.757 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.65 133.79 41.16 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.661 1.348 . . . . 0.0 110.107 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -57.64 -177.18 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.412 -0.805 . . . . 0.0 111.168 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -108.01 161.61 14.79 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.6 -0.687 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.417 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.52 -55.13 2.95 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.605 -0.684 . . . . 0.0 112.629 -178.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 11.6 m -66.31 -29.79 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 120.663 -1.273 . . . . 0.0 111.499 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.43 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.78 -57.58 5.41 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.093 -1.005 . . . . 0.0 110.555 -179.037 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.417 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.53 -33.94 77.09 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.198 -0.939 . . . . 0.0 108.819 178.631 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.1 m -60.23 -49.25 78.35 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -41.03 63.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.427 -0.796 . . . . 0.0 110.288 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.43 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.2 mpt_? -69.96 -44.13 70.12 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.049 -1.032 . . . . 0.0 110.732 -179.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.497 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.9 OUTLIER -54.18 -38.51 65.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.044 -1.035 . . . . 0.0 110.243 -179.863 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.93 0.06 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.466 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.9 mmt-85 -151.38 -43.55 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.952 . . . . 0.0 108.848 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.49 HG21 ' CD1' ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.49 39.25 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.522 -0.736 . . . . 0.0 109.345 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 121.76 19.86 3.28 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.622 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.462 ' N ' ' CD ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.42 81.85 4.42 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.033 -1.275 . . . . 0.0 110.034 179.821 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.49 5.39 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.473 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.611 -0.935 . . . . 0.0 108.573 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.473 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.0 Cg_endo -84.08 111.78 1.67 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.12 1.063 . . . . 0.0 109.913 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.46 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.64 168.96 54.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.5 mt -127.15 142.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.366 -1.079 . . . . 0.0 109.231 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.528 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.04 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.585 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.421 ' NE ' HG12 ' A' ' 32' ' ' VAL . 6.8 mtt85 -106.47 123.23 47.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.524 -0.735 . . . . 0.0 109.372 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.426 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.93 155.43 31.32 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.167 -0.958 . . . . 0.0 110.559 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.401 ' CG2' HD22 ' A' ' 15' ' ' LEU . 50.1 t -72.28 -61.48 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.17 -0.956 . . . . 0.0 109.322 179.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -98.95 147.82 33.74 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.822 . . . . 0.0 109.936 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.33 -47.02 0.43 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.655 1.345 . . . . 0.0 110.494 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.19 -124.4 0.82 Allowed Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -110.71 -62.07 1.58 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.229 -1.16 . . . . 0.0 110.252 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 32.7 ttt85 . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.314 179.975 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.88 125.5 51.08 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.291 -1.123 . . . . 0.0 110.245 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 27.4 m -113.3 104.26 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.37 -0.831 . . . . 0.0 110.006 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 13.9 p -78.33 142.97 37.33 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.335 -0.853 . . . . 0.0 110.379 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.432 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -74.63 148.72 85.61 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.29 -0.881 . . . . 0.0 109.506 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.433 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 43.8 Cg_endo -69.13 -169.24 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 124.132 1.596 . . . . 0.0 110.762 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.521 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.2 OUTLIER 175.72 79.5 0.08 OUTLIER Pre-proline 0 N--CA 1.499 1.995 0 O-C-N 121.299 -0.876 . . . . 0.0 110.11 -179.549 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.52 -15.35 27.65 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.595 1.313 . . . . 0.0 110.547 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -65.24 -25.8 67.83 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.086 -1.009 . . . . 0.0 110.399 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.449 HD12 ' CG2' ' A' ' 122' ' ' THR . 19.9 mt -107.82 135.4 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 120.946 -1.096 . . . . 0.0 110.383 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.91 128.71 34.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.519 179.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.16 131.82 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.095 -1.003 . . . . 0.0 110.099 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.444 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.7 t -126.62 158.13 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.368 -0.832 . . . . 0.0 110.258 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 108.55 20.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.253 -0.904 . . . . 0.0 109.693 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.426 ' CD2' ' HB3' ' A' ' 26' ' ' LYS . 9.7 tp -55.22 138.69 44.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.348 -0.845 . . . . 0.0 109.883 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.0 p -136.41 -179.68 5.83 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.301 -0.874 . . . . 0.0 110.55 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.306 -0.871 . . . . 0.0 109.862 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.436 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 2.6 m -147.66 113.13 5.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.334 -0.854 . . . . 0.0 110.373 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.479 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.45 -162.26 27.95 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.889 -1.624 . . . . 0.0 110.625 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.16 -22.64 7.67 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.78 -0.835 . . . . 0.0 110.497 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.465 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 10.0 tt -97.22 100.46 7.83 Favored Pre-proline 0 N--CA 1.485 1.324 0 C-N-CA 118.641 -1.224 . . . . 0.0 110.264 -179.317 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.411 ' HD2' ' HE3' ' A' ' 54' ' ' LYS . 37.0 Cg_endo -62.34 147.29 95.19 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.384 1.202 . . . . 0.0 109.649 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.587 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.8 t80 -160.84 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.189 -0.944 . . . . 0.0 111.487 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.587 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 25.9 m-85 59.13 67.32 0.93 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.425 -0.797 . . . . 0.0 111.609 178.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.48 14.35 13.54 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 41.3 mmtm -130.63 156.4 44.95 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.069 -1.254 . . . . 0.0 109.192 179.647 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.43 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.16 107.1 13.54 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.921 -1.112 . . . . 0.0 109.487 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.465 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.2 mt -71.22 113.79 22.16 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.29 -0.881 . . . . 0.0 110.156 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.479 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 39.8 Cg_endo -68.69 129.59 19.05 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 N-CA-C 106.877 -2.009 . . . . 0.0 106.877 176.363 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.435 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 8.7 mt -55.58 -19.36 9.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.867 -1.146 . . . . 0.0 110.762 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.438 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.06 24.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.753 -1.217 . . . . 0.0 110.434 179.682 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.451 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.5 m -91.99 -25.01 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.997 -1.064 . . . . 0.0 111.049 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.528 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 6.2 pt -117.6 -21.09 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.917 -1.115 . . . . 0.0 110.764 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.469 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 4.0 tptt -94.29 148.44 22.2 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.1 -1.0 . . . . 0.0 110.175 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.38 33.39 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.24 -140.43 4.85 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.113 -1.518 . . . . 0.0 110.266 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.421 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.78 131.57 55.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.319 -1.106 . . . . 0.0 110.399 -179.609 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.528 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 86.5 m-70 -139.32 151.89 46.77 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.289 -0.882 . . . . 0.0 110.701 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.464 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.3 tp -114.32 122.07 45.56 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.273 -0.892 . . . . 0.0 110.224 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.441 ' CD1' HG13 ' A' ' 83' ' ' VAL . 37.5 mt -104.23 129.51 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.248 -0.907 . . . . 0.0 109.451 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.48 123.92 38.2 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.452 -0.78 . . . . 0.0 109.934 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.81 159.18 22.73 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.198 -0.939 . . . . 0.0 110.732 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -108.25 0.4 21.36 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.394 -0.816 . . . . 0.0 110.15 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 30.2 p -136.37 141.39 43.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.523 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.83 -40.2 69.25 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.538 -0.726 . . . . 0.0 110.6 -179.842 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.88 -34.14 71.29 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.353 -0.842 . . . . 0.0 110.663 -179.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.18 -35.08 68.89 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 1.8 m -61.3 -33.9 74.34 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.455 -0.778 . . . . 0.0 109.464 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -69.15 -50.59 46.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.273 -0.892 . . . . 0.0 110.874 -179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.71 -47.11 49.88 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.133 -0.979 . . . . 0.0 110.56 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.441 ' CD1' HG11 ' A' ' 83' ' ' VAL . 2.6 tm? -56.74 -37.64 71.29 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.585 -0.697 . . . . 0.0 111.256 -178.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.23 -51.36 12.22 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.793 -1.192 . . . . 0.0 110.381 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.57 92.71 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.149 -0.969 . . . . 0.0 110.008 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.411 ' HE3' ' HD2' ' A' ' 22' ' ' PRO . 0.3 OUTLIER -57.3 -44.56 84.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.362 -0.836 . . . . 0.0 109.347 179.598 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.475 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.38 -42.91 74.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.647 -0.658 . . . . 0.0 110.12 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.2 -33.16 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.052 -1.03 . . . . 0.0 108.983 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.7 -31.48 59.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.458 -0.776 . . . . 0.0 110.057 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.465 HD23 ' N ' ' A' ' 58' ' ' LEU . 3.9 mm? -71.65 -26.36 62.51 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.302 -0.874 . . . . 0.0 109.329 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.77 5.47 9.09 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.495 HG23 HG21 ' A' ' 81' ' ' VAL . 37.6 mt -108.23 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.261 -1.14 . . . . 0.0 110.314 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.431 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.4 t30 -88.05 107.08 18.56 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.475 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.03 143.9 45.22 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.912 -1.115 . . . . 0.0 111.893 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.485 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 94.8 t -125.05 147.46 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.713 -0.617 . . . . 0.0 109.767 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.44 123.0 49.0 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.46 -0.896 . . . . 0.0 109.519 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.428 ' HB3' ' HB2' ' A' ' 84' ' ' ALA . 2.3 t80 -117.67 136.36 53.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.124 -0.985 . . . . 0.0 110.743 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.483 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.9 p90 -169.14 176.25 5.35 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.454 -0.779 . . . . 0.0 109.819 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -50.95 122.93 8.2 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 110.876 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.4 38.78 16.7 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.483 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.01 154.82 30.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.06 -1.259 . . . . 0.0 109.923 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.451 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 10.1 m-20 -94.09 149.12 21.52 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.292 -0.88 . . . . 0.0 110.557 -179.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.407 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.8 m -62.58 110.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.212 -0.995 . . . . 0.0 109.501 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.7 m -132.56 -17.54 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.561 -0.712 . . . . 0.0 110.903 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.485 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 61.2 t -65.38 141.85 17.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.146 -0.971 . . . . 0.0 109.744 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 6.0 pt -136.41 91.3 16.49 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.239 -0.913 . . . . 0.0 110.436 -179.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -92.57 42.19 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.71 1.373 . . . . 0.0 110.413 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.6 t -120.32 -24.77 5.82 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.157 -0.964 . . . . 0.0 110.668 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -162.98 162.22 25.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.176 -0.953 . . . . 0.0 110.407 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 64.63 134.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -61.27 106.75 0.66 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.074 -1.251 . . . . 0.0 109.933 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.2 p -116.93 134.29 60.95 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 CA-C-O 122.125 0.964 . . . . 0.0 110.339 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.495 HG21 HG23 ' A' ' 60' ' ' ILE . 13.9 m -113.44 124.69 70.34 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.45 ' CG2' HG11 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.865 -1.147 . . . . 0.0 110.58 -177.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.494 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.4 m -112.7 100.6 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.862 -1.149 . . . . 0.0 108.305 179.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.428 ' HB2' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.73 34.7 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.886 -1.134 . . . . 0.0 111.541 -177.527 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.3 t -84.17 -126.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -101.37 40.27 1.32 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.474 -1.391 . . . . 0.0 110.211 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.444 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.72 -34.67 7.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.87 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -68.99 -19.89 64.15 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.279 -0.888 . . . . 0.0 109.841 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.423 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.2 OUTLIER 53.68 -150.5 0.37 Allowed 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.251 -0.906 . . . . 0.0 109.871 -179.788 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.455 ' OG1' ' CG2' ' A' ' 93' ' ' THR . 0.1 OUTLIER -150.62 31.51 0.64 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.272 -0.893 . . . . 0.0 109.975 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.33 -29.44 73.15 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -131.95 19.15 4.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.119 -1.224 . . . . 0.0 110.787 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.478 ' OG1' ' CE1' ' A' ' 96' ' ' PHE . 14.5 t -90.56 -154.78 0.36 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.051 -1.031 . . . . 0.0 110.302 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.434 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 103.24 -32.46 7.56 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.443 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -84.05 53.96 2.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.962 -1.317 . . . . 0.0 110.567 -179.597 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.498 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.15 145.71 46.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.039 -1.038 . . . . 0.0 110.161 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.495 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.53 -31.5 42.08 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.725 179.532 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.436 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 4.1 p -161.56 163.95 29.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.176 -0.953 . . . . 0.0 111.33 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.479 HG22 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.89 115.54 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.494 -0.754 . . . . 0.0 110.017 179.291 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.6 mp -93.42 112.56 26.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.165 -0.96 . . . . 0.0 108.859 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.8 161.07 19.86 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.125 -0.985 . . . . 0.0 111.765 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.441 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 15.0 t -102.98 8.31 39.0 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.735 -0.603 . . . . 0.0 109.482 178.19 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 47.09 26.16 0.6 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.155 -0.966 . . . . 0.0 111.09 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.8 p -146.53 132.52 19.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.114 -0.991 . . . . 0.0 110.516 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.446 ' N ' ' O ' ' A' ' 108' ' ' LYS . 80.6 p -112.81 134.36 54.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.326 -0.859 . . . . 0.0 109.941 179.536 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.4 t0 49.36 29.1 2.62 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.172 -0.955 . . . . 0.0 110.632 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.03 -33.01 5.47 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.66 157.3 82.3 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.287 -1.125 . . . . 0.0 110.127 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.13 133.74 36.69 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.565 1.297 . . . . 0.0 110.135 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.421 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 -49.21 150.2 1.79 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.254 -0.904 . . . . 0.0 110.78 -179.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.42 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.0 p30 -89.06 161.57 16.48 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.402 -0.811 . . . . 0.0 110.442 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.7 -53.87 3.47 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.469 -0.769 . . . . 0.0 112.375 -178.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.42 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 12.1 m -68.66 -29.5 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.608 -1.307 . . . . 0.0 111.264 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.421 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.66 -56.48 7.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.078 -1.014 . . . . 0.0 110.549 -179.268 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.415 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -67.6 -34.89 77.92 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.15 -0.969 . . . . 0.0 108.605 178.758 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 13.3 m -59.56 -49.79 76.42 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -74.02 -35.89 64.4 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.592 -0.693 . . . . 0.0 109.871 178.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.404 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 3.3 mtt85 -71.13 -44.83 64.81 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.028 -1.045 . . . . 0.0 110.71 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.521 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 2.7 ttm105 -60.42 -42.56 96.26 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.978 -1.076 . . . . 0.0 110.455 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.58 86.16 0.09 OUTLIER Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.423 ' NH1' ' O ' ' A' ' 89' ' ' MET . 0.0 OUTLIER -164.7 -45.4 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.5 -1.0 . . . . 0.0 108.652 179.502 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.459 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.57 30.03 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.09 10.45 12.04 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.117 -1.516 . . . . 0.0 110.567 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.434 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 5.8 mtt180 -84.88 83.99 7.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.043 -1.269 . . . . 0.0 109.842 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.49 9.46 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 108.916 -1.674 . . . . 0.0 108.916 -179.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.503 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.74 -169.63 0.22 Allowed Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.892 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.503 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.8 Cg_endo -88.0 111.06 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 122.883 0.938 . . . . 0.0 110.047 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.459 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -76.57 150.93 38.95 Favored Glycine 0 N--CA 1.494 2.563 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.173 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.436 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.43 141.46 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -1.202 . . . . 0.0 109.139 179.251 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.482 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.89 116.46 17.2 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.882 -1.136 . . . . 0.0 110.725 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.444 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 9.6 mtt-85 -105.81 125.78 51.39 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.405 -0.809 . . . . 0.0 109.635 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.7 p90 -114.61 157.92 22.42 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.979 -1.076 . . . . 0.0 110.192 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.42 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t -89.94 -65.76 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.119 -0.988 . . . . 0.0 109.984 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 54.29 96.73 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.594 -0.691 . . . . 0.0 109.952 -179.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.03 -49.51 0.3 Allowed 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.669 1.352 . . . . 0.0 110.408 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -131.21 23.67 4.31 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -110.61 167.14 10.45 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -1.103 . . . . 0.0 110.209 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.027 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.9 p -81.35 106.77 13.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.339 -1.094 . . . . 0.0 110.091 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.429 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 9.2 p -113.01 104.04 16.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.229 -0.92 . . . . 0.0 110.018 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 7.8 p -73.1 145.28 46.58 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 110.176 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.419 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -81.04 147.04 60.32 Favored Pre-proline 0 C--N 1.302 -1.498 0 O-C-N 121.364 -0.835 . . . . 0.0 109.712 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.419 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.7 Cg_endo -73.19 -165.06 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 124.038 1.546 . . . . 0.0 110.949 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.535 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 1.7 p80 -177.62 82.18 0.24 Allowed Pre-proline 0 C--N 1.302 -1.472 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -64.85 81.32 0.18 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 123.891 1.469 . . . . 0.0 110.74 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 -172.16 -37.4 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 CA-C-O 121.35 0.595 . . . . 0.0 109.561 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.489 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 13.7 mt -96.24 130.21 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.095 -1.003 . . . . 0.0 110.153 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -84.93 129.44 34.8 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.454 -0.778 . . . . 0.0 109.686 179.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -88.42 133.04 34.22 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.024 -1.047 . . . . 0.0 109.946 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.4 HG23 HG22 ' A' ' 129' ' ' ILE . 12.0 t -126.72 158.0 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.433 -0.792 . . . . 0.0 110.469 -179.016 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.74 110.74 23.0 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.312 -0.867 . . . . 0.0 109.906 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.7 tp -56.49 140.1 47.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.766 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.9 p -135.36 170.53 15.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.17 -0.956 . . . . 0.0 110.236 -179.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.73 63.6 0.29 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.08 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.443 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.3 m -133.91 111.67 10.64 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.35 -0.844 . . . . 0.0 110.399 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.479 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.912 -1.613 . . . . 0.0 110.815 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.4 -19.15 8.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.763 -0.845 . . . . 0.0 110.366 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.504 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -96.56 113.2 62.21 Favored Pre-proline 0 N--CA 1.485 1.322 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.421 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -65.48 144.22 78.63 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.596 1.314 . . . . 0.0 109.648 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.498 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.07 98.65 1.06 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.078 -1.049 . . . . 0.0 111.634 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CD1' ' N ' ' A' ' 24' ' ' TYR . 22.7 m-85 55.45 65.24 1.53 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.292 -0.88 . . . . 0.0 111.59 178.424 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.86 14.59 10.37 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.91 156.2 45.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.075 -1.25 . . . . 0.0 108.93 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.443 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.39 106.55 14.13 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.916 -1.115 . . . . 0.0 109.465 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.504 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.9 mt -68.7 114.9 25.48 Favored Pre-proline 0 C--N 1.298 -1.663 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.018 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.479 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.3 Cg_endo -69.54 128.68 16.59 Favored 'Trans proline' 0 C--N 1.303 -1.825 0 N-CA-C 106.587 -2.12 . . . . 0.0 106.587 176.235 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.439 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 14.0 mt -55.57 -18.85 8.36 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.469 -177.375 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -59.06 -16.52 19.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.721 -1.237 . . . . 0.0 110.574 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.482 ' O ' ' CD2' ' A' ' 38' ' ' HIS . 11.0 m -92.57 -24.1 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 120.921 -1.112 . . . . 0.0 110.925 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.495 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 6.9 pt -119.44 -20.27 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.936 -1.103 . . . . 0.0 110.983 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.455 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.41 22.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.935 -1.103 . . . . 0.0 110.403 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.86 -2.85 66.96 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.66 18.0 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.025 -1.56 . . . . 0.0 110.69 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.61 132.79 52.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.479 -1.012 . . . . 0.0 110.162 -179.622 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.495 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.14 45.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 110.933 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.431 ' CD2' ' HG2' ' A' ' 121' ' ' ARG . 50.2 tp -113.29 114.44 26.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.411 -0.806 . . . . 0.0 110.241 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 83' ' ' VAL . 29.2 mt -97.31 128.79 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.021 . . . . 0.0 109.549 179.367 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -97.54 123.28 41.36 Favored 'General case' 0 C--N 1.292 -1.893 0 O-C-N 121.108 -0.995 . . . . 0.0 110.448 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.39 159.86 22.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.342 -0.849 . . . . 0.0 110.382 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.42 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 18.6 p-80 -104.73 -5.61 21.13 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.31 -0.869 . . . . 0.0 110.06 179.172 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.7 p -128.15 139.85 52.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.98 -1.075 . . . . 0.0 110.863 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.86 -39.51 69.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.636 -0.665 . . . . 0.0 110.475 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.08 -33.44 70.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.399 -0.813 . . . . 0.0 110.648 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.408 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.67 -37.08 68.02 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.349 -0.844 . . . . 0.0 109.914 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.438 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 69.7 m -62.16 -36.38 81.68 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.364 -0.835 . . . . 0.0 109.651 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.35 -50.28 64.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.027 -1.046 . . . . 0.0 110.231 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.63 -44.81 61.43 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.312 -0.867 . . . . 0.0 110.415 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.408 ' CB ' ' O ' ' A' ' 47' ' ' LYS . 3.4 tm? -61.29 -36.82 81.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.479 -0.763 . . . . 0.0 111.583 -178.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.77 -51.68 12.1 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.843 -1.161 . . . . 0.0 110.776 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.78 -38.22 78.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.036 -1.04 . . . . 0.0 109.563 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.444 ' CD ' HD11 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.11 -46.46 82.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.661 -0.649 . . . . 0.0 109.464 179.287 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.49 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.7 -40.23 72.1 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.355 -0.841 . . . . 0.0 110.131 179.897 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.5 t -59.08 -30.91 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.173 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.77 60.17 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.456 -0.778 . . . . 0.0 110.0 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.456 HD22 ' N ' ' A' ' 58' ' ' LEU . 4.4 mm? -71.27 -25.52 62.49 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.845 0.831 . . . . 0.0 109.739 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.79 7.05 8.97 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.467 HG22 HG21 ' A' ' 81' ' ' VAL . 39.4 mt -107.77 142.78 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.31 -1.112 . . . . 0.0 109.821 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.409 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 28.5 t30 -88.87 106.52 18.45 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 177.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.523 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -115.95 141.76 47.68 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.521 -177.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.462 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.97 143.17 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.704 -0.622 . . . . 0.0 110.007 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -111.34 117.82 34.17 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.366 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.435 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.28 127.12 53.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.197 -0.939 . . . . 0.0 111.07 -179.235 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.457 ' CE1' HD21 ' A' ' 69' ' ' LEU . 7.3 p90 -157.59 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.684 -0.635 . . . . 0.0 109.642 179.417 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.19 126.99 25.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.08 -1.012 . . . . 0.0 111.007 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.75 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.457 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.3 tm? -116.59 154.92 29.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.09 -1.241 . . . . 0.0 109.896 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.436 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 1.7 m-20 -94.84 149.57 21.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.345 -0.847 . . . . 0.0 110.517 -179.201 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.422 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 31.1 m -61.75 110.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 118.969 -1.092 . . . . 0.0 108.817 179.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.3 m -130.66 -34.72 1.52 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.438 -0.789 . . . . 0.0 110.283 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.462 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 90.9 t -46.86 129.83 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.457 -0.777 . . . . 0.0 109.883 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -136.14 92.99 15.44 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 111.18 -179.186 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -82.81 53.35 4.38 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 O-C-N 123.731 1.385 . . . . 0.0 109.589 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.9 p -147.05 19.44 1.25 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.332 -0.855 . . . . 0.0 110.435 -179.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -123.39 -164.49 1.22 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.281 -0.887 . . . . 0.0 109.933 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.79 -77.83 0.11 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -146.79 113.39 6.0 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.111 -1.229 . . . . 0.0 110.343 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.5 p -117.25 133.95 62.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 CA-C-O 121.978 0.894 . . . . 0.0 110.452 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 12.6 m -112.59 122.01 65.99 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.107 0 O-C-N 121.355 -0.841 . . . . 0.0 109.01 179.118 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.421 HG21 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.54 45.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.911 -1.118 . . . . 0.0 110.726 -177.685 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.498 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.4 m -110.16 99.58 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.91 -1.116 . . . . 0.0 108.974 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.435 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -132.41 162.09 32.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.698 -1.251 . . . . 0.0 110.326 -178.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.445 HG22 ' N ' ' A' ' 86' ' ' ASP . 7.2 t -99.1 -27.91 13.62 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.161 -0.962 . . . . 0.0 110.689 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.445 ' N ' HG22 ' A' ' 85' ' ' THR . 1.3 p30 177.93 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.376 -0.827 . . . . 0.0 110.257 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.405 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -46.35 -25.57 0.67 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.266 -0.896 . . . . 0.0 110.936 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.426 ' CD1' ' CD2' ' A' ' 65' ' ' TYR . 14.7 tp -62.01 -34.44 76.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.184 -0.948 . . . . 0.0 109.791 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.442 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 14.7 mmt 48.24 46.95 19.9 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.482 -0.762 . . . . 0.0 110.877 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.45 ' OG1' ' CG2' ' A' ' 93' ' ' THR . 2.6 t 34.8 -128.05 0.09 Allowed 'General case' 0 N--CA 1.505 2.32 0 O-C-N 122.03 -0.419 . . . . 0.0 112.012 179.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.429 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 93.63 -61.48 2.05 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 108.383 -1.887 . . . . 0.0 108.383 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 33.3 p90 -122.0 3.48 9.92 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.457 -1.025 . . . . 0.0 109.923 178.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.45 ' CG2' ' OG1' ' A' ' 90' ' ' THR . 13.1 t -67.41 -160.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.058 -1.026 . . . . 0.0 109.78 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.404 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 91.32 -39.38 3.07 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -84.25 57.01 4.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.144 -1.209 . . . . 0.0 110.781 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -119.25 149.47 41.72 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -0.988 . . . . 0.0 110.01 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.416 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.6 -30.74 46.78 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.354 -0.841 . . . . 0.0 109.61 179.528 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 p -161.65 163.22 30.02 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.231 -0.918 . . . . 0.0 110.925 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.487 HG21 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.2 114.37 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.999 0 O-C-N 121.417 -0.802 . . . . 0.0 110.154 179.189 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.8 mp -93.06 112.41 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 108.523 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.416 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.82 21.2 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.103 -0.998 . . . . 0.0 111.722 -177.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.455 ' SG ' ' CE1' ' A' ' 24' ' ' TYR . 57.0 m -98.45 2.31 47.61 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.658 -0.651 . . . . 0.0 109.293 177.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 53.86 24.84 4.78 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.149 -0.97 . . . . 0.0 111.172 179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -147.16 129.58 15.82 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.026 -1.046 . . . . 0.0 110.923 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.9 p -103.35 134.06 47.37 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.361 -0.837 . . . . 0.0 109.336 179.128 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 49.09 27.22 1.65 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.146 -0.971 . . . . 0.0 110.455 -179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.18 -32.72 5.71 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 105' ' ' SER . 9.8 mmpt? -76.68 157.31 82.25 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.318 -1.107 . . . . 0.0 110.142 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -64.44 130.12 25.85 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 123.587 1.309 . . . . 0.0 110.168 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.403 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 4.2 pt20 -51.7 154.0 2.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.478 -0.764 . . . . 0.0 110.935 -179.041 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -85.28 161.46 19.53 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.245 -0.909 . . . . 0.0 110.286 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.67 -57.94 2.13 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.605 -0.685 . . . . 0.0 112.519 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.411 HG22 ' N ' ' A' ' 114' ' ' SER . 8.1 m -67.36 -29.6 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 120.68 -1.263 . . . . 0.0 111.532 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.411 ' N ' HG22 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.54 -56.09 7.83 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.111 -0.993 . . . . 0.0 110.437 -179.286 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.44 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.16 -34.06 76.74 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.537 178.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.6 m -59.28 -48.89 79.92 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.049 -1.032 . . . . 0.0 108.404 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.1 -35.7 66.64 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.746 -0.782 . . . . 0.0 109.812 178.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.406 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.58 -45.06 66.1 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.058 -1.026 . . . . 0.0 110.463 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.535 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.1 ttm180 -59.45 -40.79 88.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.003 -1.06 . . . . 0.0 110.004 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.28 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.437 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -149.07 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.515 -0.991 . . . . 0.0 108.625 179.365 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.456 ' CG2' HD13 ' A' ' 10' ' ' ILE . 11.8 t -98.16 143.35 28.78 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.445 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 12.5 10.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.4 -1.381 . . . . 0.0 110.515 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 0.7 OUTLIER -79.5 85.07 5.3 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.009 -1.289 . . . . 0.0 109.877 179.797 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.406 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 98.74 17.2 28.94 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.453 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 4.5 pttt -176.98 -177.02 0.25 Allowed Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.453 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 45.7 Cg_endo -89.01 106.93 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.118 1.062 . . . . 0.0 109.488 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.445 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.01 174.0 49.73 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.321 -179.131 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.432 HG21 HD11 ' A' ' 129' ' ' ILE . 20.3 mt -130.22 141.86 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 108.839 179.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.487 ' CD2' HG21 ' A' ' 99' ' ' VAL . 12.8 t80 -132.18 115.95 16.35 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.061 -1.024 . . . . 0.0 110.858 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.42 ' CZ ' HG12 ' A' ' 32' ' ' VAL . 0.3 OUTLIER -102.67 122.15 43.86 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -115.17 158.1 22.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.015 -1.053 . . . . 0.0 110.254 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.4 t -98.01 -30.78 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.156 -0.965 . . . . 0.0 110.37 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -95.75 117.76 66.29 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.156 -0.965 . . . . 0.0 110.51 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -85.15 47.31 2.02 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.573 1.302 . . . . 0.0 110.375 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -66.02 -136.46 0.03 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 55.56 34.77 23.82 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.335 -1.097 . . . . 0.0 110.212 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 29.5 ttt85 . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.997 179.834 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 p -77.2 143.42 39.03 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.213 -1.169 . . . . 0.0 110.093 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 31.3 m -112.95 103.9 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.2 -0.937 . . . . 0.0 110.009 179.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 62.5 p -103.39 143.13 33.09 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.352 -0.843 . . . . 0.0 110.353 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.422 HG22 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.17 149.43 98.47 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.45 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.422 ' HD2' HG22 ' A' ' 5' ' ' VAL . 40.7 Cg_endo -68.51 -165.35 0.12 Allowed 'Trans proline' 0 C--N 1.307 -1.635 0 O-C-N 123.993 1.523 . . . . 0.0 110.608 179.213 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.551 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER 173.42 82.42 0.05 OUTLIER Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.46 -0.775 . . . . 0.0 109.979 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -69.34 66.47 1.52 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.631 1.332 . . . . 0.0 109.858 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -153.62 -34.84 0.11 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.564 -0.71 . . . . 0.0 110.618 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.494 ' CD1' HG23 ' A' ' 122' ' ' THR . 45.0 mt -103.45 128.24 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.919 -1.113 . . . . 0.0 110.218 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.36 127.98 34.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.147 179.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.63 142.02 28.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.049 -1.032 . . . . 0.0 110.365 -179.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.418 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 4.8 t -128.97 157.7 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.481 -0.762 . . . . 0.0 109.878 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.66 112.32 25.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.248 -0.907 . . . . 0.0 110.317 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.5 tp -62.9 135.58 57.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -0.922 . . . . 0.0 109.326 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.5 p -137.15 -178.15 5.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.029 -1.045 . . . . 0.0 110.623 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.29 4.28 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.371 -0.83 . . . . 0.0 109.741 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.432 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 3.6 m -156.68 113.55 3.1 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.898 . . . . 0.0 110.589 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.468 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -168.18 28.25 Favored Glycine 0 N--CA 1.488 2.125 0 C-N-CA 118.836 -1.649 . . . . 0.0 111.081 179.18 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.42 -20.92 10.06 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.844 -0.798 . . . . 0.0 110.289 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.461 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 9.0 tt -96.78 107.76 38.92 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 118.794 -1.163 . . . . 0.0 109.757 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -64.62 126.97 17.79 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 123.353 1.186 . . . . 0.0 110.887 -178.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.3 -169.82 1.69 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.564 -0.71 . . . . 0.0 110.345 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.3 m-85 -57.4 81.15 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.488 -0.757 . . . . 0.0 111.6 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.84 -1.29 59.23 Favored Glycine 0 N--CA 1.494 2.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.757 179.427 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -129.59 156.89 43.46 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.881 -1.364 . . . . 0.0 110.047 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -104.79 106.86 17.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.062 -1.024 . . . . 0.0 108.868 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.461 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 4.8 mt -68.34 113.14 13.54 Favored Pre-proline 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 110.677 -179.169 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.468 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.5 Cg_endo -68.97 130.65 20.72 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 107.216 -1.879 . . . . 0.0 107.216 175.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.446 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 13.0 mt -56.3 -18.99 12.34 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.816 -1.178 . . . . 0.0 110.137 -178.09 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.427 ' OE2' ' CG1' ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.69 -16.15 24.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.681 -1.262 . . . . 0.0 110.437 179.687 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.447 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 17.0 m -91.76 -25.02 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.949 -1.094 . . . . 0.0 110.836 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.528 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 38.6 pt -119.4 -20.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.058 -1.026 . . . . 0.0 111.134 -178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.469 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 1.2 tptm -92.93 148.33 22.1 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.984 -1.072 . . . . 0.0 110.073 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.93 -5.32 46.44 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 -179.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.87 21.88 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.205 -1.474 . . . . 0.0 110.341 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.1 mtt-85 -97.85 133.01 42.93 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -1.028 . . . . 0.0 110.305 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.528 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.5 m-70 -140.29 149.21 42.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.21 -0.931 . . . . 0.0 110.799 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.462 HD22 ' CE2' ' A' ' 41' ' ' PHE . 26.8 tp -111.41 114.09 26.99 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.371 -0.831 . . . . 0.0 110.061 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.45 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 35.3 mt -96.68 127.76 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.192 -0.943 . . . . 0.0 109.776 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.462 ' CE2' HD22 ' A' ' 39' ' ' LEU . 14.0 m-85 -95.36 123.46 38.9 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.574 -0.704 . . . . 0.0 109.873 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.8 157.07 27.25 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.2 -0.937 . . . . 0.0 110.755 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.2 p80 -104.44 0.92 29.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.374 -0.829 . . . . 0.0 109.976 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 110.255 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 7.7 ttpt -71.63 -41.9 68.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.513 -0.742 . . . . 0.0 110.907 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.86 -33.79 72.27 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.251 -0.906 . . . . 0.0 110.812 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.48 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.27 -39.6 82.11 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.926 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.42 ' O ' ' HB1' ' A' ' 64' ' ' ALA . 66.6 m -61.16 -34.68 75.41 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.253 -0.904 . . . . 0.0 109.768 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.63 -50.36 65.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.241 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.17 53.85 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.213 -0.929 . . . . 0.0 110.377 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.441 HD21 ' CD1' ' A' ' 21' ' ' ILE . 2.6 tm? -57.03 -36.51 70.55 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.719 -0.613 . . . . 0.0 111.386 -178.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.84 -51.09 13.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.9 -1.125 . . . . 0.0 110.722 -179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.14 -39.34 89.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.072 -1.017 . . . . 0.0 109.846 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.417 ' O ' HD22 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.26 -45.77 83.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.332 -0.855 . . . . 0.0 109.586 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.32 -39.95 70.57 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.513 -0.742 . . . . 0.0 110.088 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.93 -34.84 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.118 -0.989 . . . . 0.0 108.958 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -30.81 60.64 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.435 -0.79 . . . . 0.0 110.238 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.442 HD23 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -71.6 -25.88 62.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.345 -0.847 . . . . 0.0 109.815 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.11 4.71 10.03 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.469 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 45.9 mt -107.57 143.4 18.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.362 -1.081 . . . . 0.0 109.919 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.426 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 55.6 t30 -89.46 106.85 18.72 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 106.476 -1.675 . . . . 0.0 106.476 178.065 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -117.21 143.48 45.82 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.728 -1.189 . . . . 0.0 112.316 -176.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.469 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.25 151.88 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -121.27 118.34 29.31 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.715 178.554 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.469 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -108.81 133.83 52.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.317 -0.865 . . . . 0.0 110.552 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.529 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 6.5 p90 -165.81 -173.25 2.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.473 -0.767 . . . . 0.0 110.162 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.91 125.44 23.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.224 -0.923 . . . . 0.0 110.702 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.55 29.2 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.529 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -1.167 . . . . 0.0 109.997 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.434 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.4 m-20 -97.24 149.13 22.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 110.731 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.415 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 32.9 m -62.9 110.99 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.254 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 72.8 m -131.4 -32.53 1.54 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.426 -0.796 . . . . 0.0 110.752 -179.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.469 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 99.0 t -47.83 134.55 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.44 -0.787 . . . . 0.0 110.19 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -137.0 92.53 14.09 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.137 -0.977 . . . . 0.0 111.12 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -83.21 51.47 3.63 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.626 1.329 . . . . 0.0 109.719 178.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -146.25 13.88 1.27 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.213 -0.93 . . . . 0.0 111.04 -178.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -135.85 -149.94 0.35 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.021 -1.049 . . . . 0.0 109.856 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.21 174.64 0.1 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -56.5 114.99 2.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.201 -1.176 . . . . 0.0 110.381 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -116.52 134.69 59.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 122.038 0.923 . . . . 0.0 109.858 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.49 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 16.5 m -112.83 123.53 68.59 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.317 -0.864 . . . . 0.0 109.555 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.462 HG23 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.95 116.46 40.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.842 -1.161 . . . . 0.0 110.595 -178.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.497 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 2.8 m -107.87 100.38 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 0.0 108.559 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.469 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -135.63 162.2 33.37 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.732 -1.23 . . . . 0.0 111.335 -177.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.3 t -91.61 -132.83 0.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.673 -0.642 . . . . 0.0 109.649 179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.15 21.35 3.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.752 -1.217 . . . . 0.0 110.59 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.429 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.25 -34.91 15.59 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -0.949 . . . . 0.0 109.646 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp -69.72 -46.5 65.81 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.375 -0.828 . . . . 0.0 109.592 179.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.431 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 1.2 mmt 53.32 21.04 2.15 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.361 -0.837 . . . . 0.0 110.204 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.445 HG23 ' N ' ' A' ' 94' ' ' GLY . 0.3 OUTLIER 45.42 36.25 2.31 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.514 -0.741 . . . . 0.0 110.861 179.826 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.79 -70.88 0.78 Allowed Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -99.54 41.61 1.15 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.251 -1.146 . . . . 0.0 108.908 178.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.472 HG21 ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -139.23 -156.66 0.7 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.575 -0.703 . . . . 0.0 110.017 -179.337 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.445 ' N ' HG23 ' A' ' 90' ' ' THR . . . 126.71 -25.92 5.23 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -89.49 80.3 6.75 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.119 -1.224 . . . . 0.0 110.717 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.472 ' CE2' HG21 ' A' ' 93' ' ' THR . 46.3 m-85 -119.21 148.51 43.03 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.112 -0.993 . . . . 0.0 109.964 179.228 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.23 59.8 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.351 -0.843 . . . . 0.0 109.237 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.417 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.323 -0.861 . . . . 0.0 111.003 179.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.548 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.03 117.54 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.355 -0.841 . . . . 0.0 110.685 179.799 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.409 HG22 ' CD1' ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.12 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.74 160.71 22.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.174 -0.954 . . . . 0.0 111.517 -178.154 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.415 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 13.7 t -100.01 8.27 44.13 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.649 -0.657 . . . . 0.0 109.588 178.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.5 m120 46.89 25.95 0.52 Allowed 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.272 -0.893 . . . . 0.0 110.725 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.6 p -147.31 129.73 15.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.235 -0.915 . . . . 0.0 110.062 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.434 ' N ' ' O ' ' A' ' 108' ' ' LYS . 5.7 p -114.01 133.7 55.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.163 -0.96 . . . . 0.0 110.147 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.19 28.76 7.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.192 -0.942 . . . . 0.0 110.472 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.06 -35.04 4.25 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.434 ' O ' ' N ' ' A' ' 105' ' ' SER . 1.9 mttm -79.47 156.45 75.83 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.168 -1.195 . . . . 0.0 110.061 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -66.18 135.51 40.53 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 O-C-N 123.622 1.327 . . . . 0.0 110.187 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -49.53 165.74 0.06 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.276 -0.89 . . . . 0.0 110.797 -179.067 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.441 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.9 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.243 -0.911 . . . . 0.0 110.294 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.16 -53.19 5.15 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.554 -0.716 . . . . 0.0 112.239 -178.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.441 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.46 -29.07 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.68 -1.263 . . . . 0.0 111.432 -178.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.427 ' N ' HG23 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.36 -56.46 6.85 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.124 -0.985 . . . . 0.0 110.486 -179.067 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.434 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 16.4 ptp180 -68.9 -35.17 76.54 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.218 -0.926 . . . . 0.0 108.635 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.9 m -59.32 -49.89 76.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.072 -1.017 . . . . 0.0 108.608 178.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -73.75 -38.54 64.7 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.498 -0.752 . . . . 0.0 110.064 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.421 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.43 -44.71 67.31 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.263 -0.898 . . . . 0.0 110.838 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.551 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 1.3 ttp180 -55.28 -48.73 73.63 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.27 -0.893 . . . . 0.0 110.507 -179.552 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.18 -18.89 1.41 Allowed Glycine 0 N--CA 1.499 2.834 0 O-C-N 121.526 -0.734 . . . . 0.0 112.343 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -56.61 -35.55 68.41 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.501 -1.588 . . . . 0.0 112.014 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.494 HG23 ' CD1' ' A' ' 10' ' ' ILE . 13.3 t -100.06 144.67 28.82 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.696 -1.252 . . . . 0.0 111.495 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.432 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.63 8.06 62.62 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.578 178.659 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.09 86.83 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.065 -1.256 . . . . 0.0 109.006 179.502 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.8 -21.44 34.2 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -178.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.488 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -138.99 -168.87 0.2 Allowed Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.386 -1.067 . . . . 0.0 109.09 179.924 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.488 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.1 Cg_endo -87.87 107.98 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.147 1.077 . . . . 0.0 110.564 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.441 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -84.52 168.36 43.92 Favored Glycine 0 N--CA 1.498 2.777 0 O-C-N 121.047 -1.033 . . . . 0.0 110.973 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.2 mt -124.87 143.24 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.548 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 10.0 t80 -130.22 121.94 27.15 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.693 -1.254 . . . . 0.0 111.771 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.418 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.25 124.38 49.67 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -123.27 155.97 36.15 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.954 -1.091 . . . . 0.0 110.888 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.415 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 16.7 t -84.01 -68.77 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.369 -0.832 . . . . 0.0 109.173 178.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 52.12 83.04 0.23 Allowed Pre-proline 0 N--CA 1.487 1.387 0 O-C-N 121.744 -0.598 . . . . 0.0 110.225 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.81 -53.26 0.14 Allowed 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.725 1.381 . . . . 0.0 110.536 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 110.37 135.76 7.1 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.99 -68.2 0.83 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.195 -1.179 . . . . 0.0 110.257 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.6 ttt-85 . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.253 -179.934 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.9 p -91.92 138.01 31.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.241 -1.152 . . . . 0.0 110.212 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.7 m -113.08 104.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.944 179.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.427 ' CG2' ' HB3' ' A' ' 112' ' ' ALA . 34.9 p -92.62 144.87 24.89 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.474 -0.766 . . . . 0.0 110.097 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.424 HG22 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.3 147.03 98.97 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.184 -0.948 . . . . 0.0 109.744 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.424 ' HD2' HG22 ' A' ' 5' ' ' VAL . 46.9 Cg_endo -71.0 -167.63 0.28 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 124.092 1.575 . . . . 0.0 110.461 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.5 ' CE1' ' HD3' ' A' ' 119' ' ' ARG . 0.5 OUTLIER 173.73 83.11 0.06 OUTLIER Pre-proline 0 N--CA 1.496 1.861 0 O-C-N 121.513 -0.742 . . . . 0.0 109.571 179.621 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.22 -13.6 28.36 Favored 'Trans proline' 0 C--N 1.312 -1.36 0 O-C-N 123.903 1.475 . . . . 0.0 111.126 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -64.99 -31.21 72.34 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.063 -1.023 . . . . 0.0 110.316 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.465 HD11 HG22 ' A' ' 10' ' ' ILE . 25.1 mt -106.2 135.78 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.072 -1.018 . . . . 0.0 110.223 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.42 128.5 34.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.323 -0.86 . . . . 0.0 109.451 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.38 125.51 35.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.063 -1.023 . . . . 0.0 110.047 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.451 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.06 155.01 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 110.322 -179.385 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.6 110.48 22.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.603 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.416 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 11.4 tp -56.5 135.38 54.41 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.269 -0.894 . . . . 0.0 109.976 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.414 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.3 p -134.58 167.47 20.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 110.378 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.05 79.72 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.302 -0.874 . . . . 0.0 109.993 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.448 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 35.8 m -154.14 109.7 3.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.457 -0.777 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.46 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.68 -170.69 29.83 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 118.928 -1.606 . . . . 0.0 111.103 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.33 -22.14 11.5 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.716 -0.873 . . . . 0.0 110.207 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.445 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.83 25.67 Favored Pre-proline 0 N--CA 1.49 1.532 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.738 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.443 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.3 Cg_endo -64.49 131.88 31.36 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.317 1.167 . . . . 0.0 110.805 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.1 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.586 -0.696 . . . . 0.0 110.646 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.512 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 36.6 m-85 -58.04 81.46 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.397 -0.814 . . . . 0.0 111.342 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.46 47.71 Favored Glycine 0 N--CA 1.493 2.434 0 O-C-N 121.084 -1.01 . . . . 0.0 110.6 179.718 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.416 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 16.7 mmtp -130.45 156.8 44.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.957 -1.32 . . . . 0.0 109.309 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.433 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -110.43 107.77 17.56 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.94 -1.1 . . . . 0.0 109.653 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.445 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -67.76 113.57 15.25 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.388 -0.82 . . . . 0.0 110.987 -179.25 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.46 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.8 Cg_endo -69.55 127.49 14.84 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 N-CA-C 106.9 -2.0 . . . . 0.0 106.9 175.674 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.445 HD21 ' CD1' ' A' ' 60' ' ' ILE . 7.7 mt -55.84 -19.1 10.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.816 -1.178 . . . . 0.0 110.819 -177.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.406 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 15.1 pt-20 -59.86 -16.07 26.06 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.761 -1.212 . . . . 0.0 110.499 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.424 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.3 m -91.1 -25.29 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.952 -1.093 . . . . 0.0 110.967 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.55 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 41.3 pt -117.28 -16.48 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.019 -1.051 . . . . 0.0 110.616 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.464 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 3.5 tptm -96.33 148.24 22.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.873 -1.142 . . . . 0.0 110.226 179.358 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.43 -3.23 56.41 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.25 -161.35 26.61 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.934 -1.603 . . . . 0.0 110.906 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.15 128.48 44.09 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.531 -0.982 . . . . 0.0 110.521 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.55 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.56 145.11 44.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.035 -1.04 . . . . 0.0 110.771 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.487 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.6 tp -107.19 113.56 27.07 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.369 -0.832 . . . . 0.0 109.979 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.444 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 36.0 mt -96.37 129.28 46.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.251 -0.906 . . . . 0.0 109.452 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.91 123.75 38.56 Favored 'General case' 0 C--N 1.292 -1.917 0 O-C-N 121.136 -0.977 . . . . 0.0 109.74 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.69 159.74 21.79 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.193 -0.942 . . . . 0.0 111.029 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.512 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -112.3 6.83 19.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.482 -0.761 . . . . 0.0 110.057 179.002 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.9 p -138.18 137.17 37.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.028 -1.045 . . . . 0.0 110.68 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.462 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.58 -40.6 69.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.381 -0.824 . . . . 0.0 110.194 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -36.77 79.43 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 110.247 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.24 -35.64 68.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.412 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 5.5 m -60.29 -33.78 72.82 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.434 -0.791 . . . . 0.0 109.55 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.87 -49.05 61.58 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.201 -0.937 . . . . 0.0 110.432 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.64 -43.32 66.32 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.342 -0.849 . . . . 0.0 110.538 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.425 ' CD1' HG13 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.5 -41.58 76.89 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.392 -0.818 . . . . 0.0 111.008 -179.047 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.96 -51.33 12.64 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.988 -1.07 . . . . 0.0 110.58 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.59 -42.05 98.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.87 -1.144 . . . . 0.0 109.594 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.443 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.8 OUTLIER -57.68 -46.08 84.77 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.86 . . . . 0.0 109.882 179.71 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.494 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.04 -41.51 71.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.473 -0.767 . . . . 0.0 109.607 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.4 t -56.08 -31.19 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.068 -1.02 . . . . 0.0 108.61 178.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.55 -32.92 60.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.561 -0.712 . . . . 0.0 109.97 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.458 HD22 ' N ' ' A' ' 58' ' ' LEU . 4.2 mm? -71.92 -25.87 62.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.313 -0.867 . . . . 0.0 109.512 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.0 7.32 8.62 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.464 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 34.6 mt -108.83 143.25 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.416 -1.05 . . . . 0.0 110.303 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.432 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.0 t-20 -86.43 107.0 17.85 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.018 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.494 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.52 143.91 48.32 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.428 -177.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.49 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.5 t -132.11 150.8 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.848 -0.741 . . . . 0.0 109.176 179.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.41 126.51 55.42 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.102 179.37 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.454 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 7.4 t80 -118.26 122.56 43.25 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.231 -0.918 . . . . 0.0 110.401 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.478 ' CE1' HD22 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.76 8.19 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.628 179.643 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.93 125.24 14.73 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.167 -0.958 . . . . 0.0 110.985 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.11 44.69 22.52 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.32 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.478 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.72 156.48 28.19 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.089 -1.242 . . . . 0.0 110.127 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.453 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 6.7 m-20 -94.51 148.98 21.7 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.283 -0.886 . . . . 0.0 110.723 -179.361 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.421 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.9 m -62.42 111.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.229 -0.989 . . . . 0.0 109.288 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.44 ' CB ' HG11 ' A' ' 63' ' ' VAL . 6.9 m -133.65 -32.63 1.12 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.988 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.49 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 30.3 t -56.01 138.73 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.194 -0.941 . . . . 0.0 109.949 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.406 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.2 pp -137.06 92.12 14.32 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.108 -0.995 . . . . 0.0 111.131 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -87.69 50.91 2.0 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 O-C-N 123.586 1.308 . . . . 0.0 109.738 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -122.47 -25.59 4.74 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.124 -0.985 . . . . 0.0 111.272 -179.026 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.7 m-20 -158.08 160.38 37.3 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.851 -1.156 . . . . 0.0 110.729 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 60.0 160.47 0.07 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -78.26 111.09 13.87 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.058 -1.26 . . . . 0.0 110.097 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.446 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -117.3 133.92 62.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-O 121.961 0.886 . . . . 0.0 110.351 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.471 HG23 ' CB ' ' A' ' 62' ' ' ALA . 7.8 m -112.67 123.82 68.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 178.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG2' HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.76 116.46 38.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.1 -1.0 . . . . 0.0 110.353 -177.766 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.483 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.8 m -108.97 100.22 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.771 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.454 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.78 162.98 34.13 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.732 -1.23 . . . . 0.0 111.114 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.3 t -92.04 -130.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.537 -0.727 . . . . 0.0 109.47 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.98 34.83 0.91 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.713 -1.242 . . . . 0.0 110.226 179.534 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.405 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 0.0 110.356 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp -62.68 -36.57 83.32 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.132 -0.98 . . . . 0.0 109.099 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.443 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.6 OUTLIER 46.07 43.93 11.22 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.538 -0.726 . . . . 0.0 110.664 179.727 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.481 ' CB ' HG23 ' A' ' 93' ' ' THR . 1.8 t 35.39 -119.08 0.11 Allowed 'General case' 0 N--CA 1.504 2.242 0 O-C-N 122.138 -0.351 . . . . 0.0 111.661 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.404 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 79.94 -58.47 4.55 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -179.664 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.3 p90 -122.1 20.18 10.69 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.229 -1.159 . . . . 0.0 110.156 179.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.481 HG23 ' CB ' ' A' ' 90' ' ' THR . 8.3 t -94.37 -171.41 2.51 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.217 -0.927 . . . . 0.0 110.204 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.418 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 119.58 5.62 11.04 Favored Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.833 -1.175 . . . . 0.0 110.527 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -125.77 58.62 1.32 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.742 -1.446 . . . . 0.0 110.489 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.487 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.51 152.19 38.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.872 -1.143 . . . . 0.0 110.778 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.421 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.56 -28.79 19.35 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.567 -0.708 . . . . 0.0 109.363 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.3 p -161.0 163.77 31.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.34 -0.85 . . . . 0.0 110.758 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.75 119.18 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.251 -0.905 . . . . 0.0 110.292 179.578 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 131' ' ' ARG . 37.9 mm -95.9 111.26 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 108.859 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -118.89 161.06 20.81 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.913 -1.117 . . . . 0.0 111.73 -178.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.454 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.3 p -99.96 -0.33 39.6 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 50.52 18.63 0.47 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.341 -0.85 . . . . 0.0 112.175 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -144.7 120.86 10.81 Favored 'General case' 0 C--N 1.305 -1.349 0 O-C-N 120.729 -1.232 . . . . 0.0 109.407 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' LYS . 10.3 p -102.45 141.58 35.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 110.277 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t70 52.3 28.32 5.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.263 -0.898 . . . . 0.0 110.536 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.21 -13.26 58.02 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.201 -1.159 . . . . 0.0 110.201 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.431 ' O ' ' N ' ' A' ' 105' ' ' SER . 14.6 mttt -96.64 156.66 36.4 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 120.952 -1.323 . . . . 0.0 109.973 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.44 130.0 27.01 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.542 1.285 . . . . 0.0 110.639 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -49.24 168.1 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.644 0.735 . . . . 0.0 111.183 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.405 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.8 p30 -102.68 161.56 13.63 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.544 -0.723 . . . . 0.0 110.327 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.427 ' HB3' ' CG2' ' A' ' 4' ' ' THR . . . -42.28 -56.55 2.9 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.576 -0.702 . . . . 0.0 112.376 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.405 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -64.21 -29.87 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.702 -1.249 . . . . 0.0 111.255 -178.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.404 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -47.73 -56.32 7.61 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.116 -0.99 . . . . 0.0 110.505 -179.209 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.76 -33.77 76.36 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.159 -0.963 . . . . 0.0 108.851 178.91 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.5 m -60.93 -50.16 74.54 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.061 -1.025 . . . . 0.0 108.357 178.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.96 -38.71 64.13 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 114' ' ' SER . 45.1 mtt-85 -71.85 -44.37 63.94 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.258 -0.901 . . . . 0.0 111.321 -179.181 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.5 ' HD3' ' CE1' ' A' ' 7' ' ' HIS . 6.9 ttp180 -62.12 -40.42 95.85 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.917 -1.114 . . . . 0.0 110.244 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.4 75.26 0.04 OUTLIER Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.468 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -149.05 -47.35 0.14 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.43 -1.041 . . . . 0.0 108.76 179.599 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.445 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.1 t -96.19 143.47 27.27 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.437 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.76 17.82 4.55 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.409 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.418 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 10.8 mmt180 -91.75 82.8 5.22 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.117 -1.225 . . . . 0.0 109.986 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.92 -31.74 4.84 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.477 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.18 -169.74 0.22 Allowed Pre-proline 0 C--N 1.301 -1.514 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 179.509 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.477 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.5 Cg_endo -85.31 115.0 1.59 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 122.916 0.956 . . . . 0.0 110.466 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.445 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.29 51.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 98' ' ' SER . 5.1 mt -119.99 140.13 45.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.039 -1.271 . . . . 0.0 109.051 179.267 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -122.7 114.49 20.65 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 118.965 -1.094 . . . . 0.0 110.218 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.445 ' HB2' ' CD1' ' A' ' 100' ' ' ILE . 24.2 mtt180 -108.12 126.87 53.27 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.594 -0.692 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.451 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.8 p90 -126.95 156.94 40.72 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.078 -1.014 . . . . 0.0 110.847 -179.131 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.421 HG12 ' N ' ' A' ' 134' ' ' ALA . 7.0 t -78.05 -69.31 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.319 -0.863 . . . . 0.0 108.978 178.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.421 ' N ' HG12 ' A' ' 133' ' ' VAL . . . 54.49 83.29 0.23 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.71 -0.619 . . . . 0.0 110.853 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -83.41 7.85 4.96 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.714 1.376 . . . . 0.0 110.609 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 132.03 -124.66 4.03 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -161.05 155.23 22.84 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.261 -1.141 . . . . 0.0 110.127 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.265 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.0 t -109.34 141.76 41.23 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.405 -1.056 . . . . 0.0 110.33 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.422 ' CG1' ' O ' ' A' ' 3' ' ' VAL . 10.6 p -113.46 104.61 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.373 -0.83 . . . . 0.0 109.717 179.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.1 p -66.54 145.51 55.54 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.306 -0.871 . . . . 0.0 110.792 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.42 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -72.64 149.9 90.87 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.275 -0.891 . . . . 0.0 109.81 179.599 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.516 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 40.2 Cg_endo -79.59 -64.86 0.02 OUTLIER 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 124.222 1.643 . . . . 0.0 112.547 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.524 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 15.3 p80 42.85 88.8 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.62 0 CA-C-O 121.578 0.704 . . . . 0.0 110.404 -177.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.43 2.41 5.14 Favored 'Trans proline' 0 C--N 1.316 -1.165 0 O-C-N 123.511 1.269 . . . . 0.0 112.326 -178.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -51.54 -25.07 6.03 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.647 -1.283 . . . . 0.0 109.302 179.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.449 HD13 ' CG2' ' A' ' 122' ' ' THR . 20.0 mt -105.8 132.99 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.442 -0.786 . . . . 0.0 109.117 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.5 33.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.054 -1.028 . . . . 0.0 109.302 179.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.54 126.43 35.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.176 -0.952 . . . . 0.0 110.021 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.461 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 6.4 t -116.14 154.52 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.334 -0.853 . . . . 0.0 110.4 -179.221 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.88 105.04 15.34 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.339 -0.851 . . . . 0.0 109.639 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.434 HD22 ' CB ' ' A' ' 26' ' ' LYS . 12.1 tp -55.43 132.34 48.08 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.412 -0.805 . . . . 0.0 109.82 -179.828 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.408 ' O ' ' N ' ' A' ' 18' ' ' THR . 70.5 p -135.83 172.29 13.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.212 -0.93 . . . . 0.0 110.314 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.91 78.28 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.22 -0.925 . . . . 0.0 110.202 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.435 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 26.0 m -151.31 108.54 3.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.206 -0.934 . . . . 0.0 110.687 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.451 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.037 -1.554 . . . . 0.0 110.747 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.32 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.649 -0.912 . . . . 0.0 110.326 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.487 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.8 tt -100.53 104.24 29.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.314 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.417 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -62.94 148.7 93.17 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.338 1.178 . . . . 0.0 109.894 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.533 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.26 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.174 -0.954 . . . . 0.0 111.127 -178.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.5 m-85 59.15 66.78 0.99 Allowed 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.406 -0.809 . . . . 0.0 111.332 179.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.87 15.0 11.11 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.448 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.62 156.98 43.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.057 -1.261 . . . . 0.0 109.121 179.524 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.2 107.28 14.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.883 -1.135 . . . . 0.0 109.69 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.487 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.6 mt -69.98 114.33 24.4 Favored Pre-proline 0 C--N 1.3 -1.553 0 C-N-CA 119.614 -0.835 . . . . 0.0 109.926 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.451 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.6 Cg_endo -69.01 129.72 18.92 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 N-CA-C 107.047 -1.943 . . . . 0.0 107.047 176.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.447 HD22 HG21 ' A' ' 21' ' ' ILE . 12.9 mt -56.52 -16.92 6.8 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.78 -1.2 . . . . 0.0 110.976 -177.495 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.442 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.03 -15.89 47.83 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.799 -1.188 . . . . 0.0 110.242 179.427 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.437 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 12.8 m -92.6 -25.14 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.986 -1.071 . . . . 0.0 111.212 -179.215 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.524 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 12.0 pt -120.47 -23.25 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.99 -1.069 . . . . 0.0 110.804 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.476 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.04 147.9 22.6 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.954 -1.092 . . . . 0.0 110.692 -179.872 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.413 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.63 -3.48 57.65 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.95 -155.73 13.6 Favored Glycine 0 N--CA 1.494 2.542 0 C-N-CA 119.008 -1.567 . . . . 0.0 110.705 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.415 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.98 131.12 52.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.413 -1.051 . . . . 0.0 110.092 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.524 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.4 m-70 -140.83 152.38 45.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 111.07 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.0 tp -112.27 115.67 29.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.361 -0.837 . . . . 0.0 110.321 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' A' ' 83' ' ' VAL . 29.6 mt -100.34 128.59 52.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 109.823 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.46 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.04 123.66 40.84 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.098 -1.001 . . . . 0.0 110.054 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.52 159.59 21.03 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.278 -0.889 . . . . 0.0 110.55 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.577 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.63 5.11 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.362 -0.836 . . . . 0.0 110.006 179.076 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.08 135.95 37.93 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.127 -0.983 . . . . 0.0 110.607 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.486 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.51 -31.31 66.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.546 -0.721 . . . . 0.0 110.395 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.06 -30.0 66.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.357 -0.84 . . . . 0.0 110.198 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.1 -36.98 66.87 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.394 -0.816 . . . . 0.0 109.649 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.455 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.3 82.33 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.53 -49.9 73.5 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.103 -0.998 . . . . 0.0 109.955 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.65 -47.01 51.09 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.328 -0.858 . . . . 0.0 110.348 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.42 ' CD1' HG11 ' A' ' 83' ' ' VAL . 1.9 tm? -56.53 -40.08 74.48 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.51 -0.744 . . . . 0.0 110.772 -179.298 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.36 13.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.078 -1.014 . . . . 0.0 110.179 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.34 -42.21 98.31 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 109.798 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.417 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -57.42 -45.25 84.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.459 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.466 HD21 HG22 ' A' ' 81' ' ' VAL . 0.2 OUTLIER -55.08 -42.12 72.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.541 -0.725 . . . . 0.0 109.614 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.5 t -56.08 -33.33 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 109.097 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.64 -31.36 59.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.408 -0.807 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.446 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.1 mm? -71.21 -26.39 62.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.339 -0.85 . . . . 0.0 109.456 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.24 5.39 8.75 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.476 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 67.9 mt -108.15 143.83 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -1.106 . . . . 0.0 110.358 -179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.413 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.72 106.48 18.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 177.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -116.47 142.87 46.3 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.883 -177.029 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.472 ' CG1' ' CG2' ' A' ' 73' ' ' VAL . 84.0 t -122.97 148.81 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -115.48 117.17 29.63 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.256 178.226 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.437 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.88 135.37 49.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.294 -0.878 . . . . 0.0 111.02 -179.235 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.53 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 15.4 p90 -167.95 177.36 5.69 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.522 -0.736 . . . . 0.0 109.853 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.1 ttp-105 -51.56 126.06 16.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.07 -1.018 . . . . 0.0 110.683 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.88 45.11 22.44 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.53 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.28 153.61 32.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.04 -1.271 . . . . 0.0 109.836 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.445 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 15.9 m-20 -91.2 149.46 21.77 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.297 -0.877 . . . . 0.0 110.608 -179.242 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.419 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 33.9 m -62.42 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.125 179.096 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 15.0 m -133.9 -34.37 1.01 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.445 -0.785 . . . . 0.0 110.843 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.472 ' CG2' ' CG1' ' A' ' 63' ' ' VAL . 92.4 t -49.43 129.47 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.098 -1.001 . . . . 0.0 110.106 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.1 pp -138.41 94.75 10.58 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.11 -0.994 . . . . 0.0 110.996 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.432 ' HA ' ' CG1' ' A' ' 80' ' ' VAL . 48.3 Cg_endo -78.75 58.05 6.66 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.675 1.355 . . . . 0.0 110.012 179.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.9 t -165.3 41.87 0.07 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.354 -0.841 . . . . 0.0 110.42 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -140.99 29.33 1.86 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.171 -0.956 . . . . 0.0 110.41 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 106.74 -89.0 0.57 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -140.56 102.81 4.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.11 -1.23 . . . . 0.0 110.241 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.432 ' CG1' ' HA ' ' A' ' 75' ' ' PRO . 7.2 p -116.89 135.23 57.91 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 CA-C-O 121.966 0.889 . . . . 0.0 109.912 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.49 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 13.7 m -112.62 124.6 69.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 O-C-N 121.282 -0.886 . . . . 0.0 109.373 179.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.45 HG21 ' CG1' ' A' ' 73' ' ' VAL . 13.1 t -97.19 119.14 44.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 O-C-N 120.955 -1.091 . . . . 0.0 110.383 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.493 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.3 m -111.9 99.27 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.015 -1.074 . . . . 0.0 108.771 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.431 ' HB1' ' CB ' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.22 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.587 -1.321 . . . . 0.0 110.811 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.05 -28.56 17.88 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.345 -0.847 . . . . 0.0 110.71 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.89 -31.3 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.079 -1.013 . . . . 0.0 110.762 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.411 ' CB ' ' CA ' ' A' ' 66' ' ' TYR . . . -46.95 -37.55 9.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.259 -0.901 . . . . 0.0 111.099 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.45 ' CD1' HG22 ' A' ' 73' ' ' VAL . 0.6 OUTLIER -70.22 -33.44 71.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.145 -0.972 . . . . 0.0 110.7 -179.708 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' MET . . . . . . . . . . . . . 2.3 tpt 53.43 -144.12 0.68 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.088 -1.007 . . . . 0.0 109.337 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.401 ' HA ' ' OG1' ' A' ' 93' ' ' THR . 0.5 OUTLIER -155.54 24.84 0.4 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.863 -1.148 . . . . 0.0 110.44 179.463 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.03 -62.41 5.98 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -101.21 36.24 2.05 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.354 -1.086 . . . . 0.0 108.609 178.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.478 HG22 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -133.8 -167.58 1.97 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.742 -0.599 . . . . 0.0 110.063 -179.433 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 120.68 -24.2 7.65 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.599 -1.401 . . . . 0.0 109.599 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -84.43 73.26 10.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.981 -1.305 . . . . 0.0 110.186 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.478 ' CZ ' HG22 ' A' ' 93' ' ' THR . 38.6 m-85 -119.77 152.75 36.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.208 -0.932 . . . . 0.0 110.167 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -84.83 -29.26 25.48 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.505 -0.747 . . . . 0.0 109.735 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.7 p -161.18 163.47 31.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.166 -0.959 . . . . 0.0 110.843 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.29 116.32 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.298 -0.876 . . . . 0.0 109.963 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.43 ' CD1' HG21 ' A' ' 33' ' ' ILE . 4.2 mp -94.61 111.3 25.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.07 -1.019 . . . . 0.0 108.974 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -114.4 161.07 18.42 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.149 -0.97 . . . . 0.0 111.732 -178.369 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.32 9.65 35.81 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.406 ' O ' ' HG2' ' A' ' 110' ' ' GLN . 2.7 m120 46.19 27.29 0.53 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.279 -0.888 . . . . 0.0 110.963 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p -144.29 133.45 22.93 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.188 -0.945 . . . . 0.0 110.469 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 62.0 p -113.42 128.66 56.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.323 -0.861 . . . . 0.0 109.394 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.0 t70 55.65 -141.55 0.84 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.037 -1.039 . . . . 0.0 109.555 -179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -88.35 18.46 41.52 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -134.82 156.98 78.1 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.115 -1.227 . . . . 0.0 109.569 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -63.26 158.37 44.91 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.53 1.279 . . . . 0.0 110.443 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.406 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER -64.85 164.77 11.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.278 -0.889 . . . . 0.0 111.205 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -100.52 161.78 13.37 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.556 -0.715 . . . . 0.0 110.111 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.433 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.46 -61.56 1.03 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.476 -0.765 . . . . 0.0 112.108 -178.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.406 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.79 -28.87 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.71 -1.244 . . . . 0.0 111.435 -178.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.423 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -47.69 -57.19 5.83 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.893 -1.13 . . . . 0.0 110.932 -178.732 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.433 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.46 -34.63 78.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.02 -1.05 . . . . 0.0 108.525 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 49.6 m -59.84 -48.87 79.95 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.28 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.59 -40.1 64.13 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.513 -0.742 . . . . 0.0 110.126 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.46 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.48 -44.61 70.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.984 -1.073 . . . . 0.0 110.31 -179.687 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.482 ' NE ' ' NE2' ' A' ' 7' ' ' HIS . 41.9 ttp180 -61.54 -36.08 79.58 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.047 -1.033 . . . . 0.0 109.315 179.184 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.05 66.67 0.34 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.7 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.462 -1.022 . . . . 0.0 108.848 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.455 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 12.3 t -92.12 142.45 27.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.335 -0.853 . . . . 0.0 108.931 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.58 17.07 2.95 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.269 -1.444 . . . . 0.0 110.605 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -95.11 82.37 3.77 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.986 -1.303 . . . . 0.0 110.002 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.39 -51.46 0.76 Allowed Glycine 0 N--CA 1.493 2.483 0 N-CA-C 108.412 -1.875 . . . . 0.0 108.412 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.449 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.84 166.36 21.72 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.3 Cg_endo -63.59 117.73 4.68 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.299 1.157 . . . . 0.0 110.128 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.455 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.85 172.24 54.78 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.447 ' N ' HG23 ' A' ' 122' ' ' THR . 5.1 mt -126.15 142.06 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.301 -1.117 . . . . 0.0 108.989 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 10.5 t80 -131.13 115.19 16.06 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.292 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.406 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 5.9 mtp180 -99.78 147.71 25.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.497 -0.752 . . . . 0.0 109.365 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.475 ' CE1' ' HA ' ' A' ' 135' ' ' PRO . 25.1 p90 -138.14 150.36 46.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.085 -1.01 . . . . 0.0 110.212 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 34.5 t -87.01 -41.07 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.129 -0.982 . . . . 0.0 109.448 179.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -91.17 113.1 57.18 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.357 -0.839 . . . . 0.0 109.947 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.475 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 45.4 Cg_endo -71.52 -22.96 23.94 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.456 1.24 . . . . 0.0 110.756 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 157.31 148.14 5.01 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -90.63 -32.44 16.24 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.272 -1.134 . . . . 0.0 110.223 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.677 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.143 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.376 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.2 m -89.89 105.98 18.16 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.195 -1.179 . . . . 0.0 110.154 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.42 ' O ' ' CG2' ' A' ' 3' ' ' VAL . 31.3 m -112.87 104.4 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.357 -0.84 . . . . 0.0 109.629 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.8 p -90.02 143.35 26.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.202 -0.936 . . . . 0.0 110.785 -179.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.439 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.67 148.5 98.05 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.34 -0.85 . . . . 0.0 109.477 179.434 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.442 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 39.4 Cg_endo -67.65 -167.01 0.14 Allowed 'Trans proline' 0 C--N 1.307 -1.622 0 O-C-N 124.045 1.55 . . . . 0.0 111.11 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.562 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 176.33 83.23 0.1 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.681 -0.637 . . . . 0.0 109.332 -179.736 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.72 -9.61 26.05 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 O-C-N 123.861 1.453 . . . . 0.0 111.059 -179.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.442 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.9 t-20 -77.96 -29.41 49.82 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.94 -1.1 . . . . 0.0 109.627 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.454 HD12 ' NH1' ' A' ' 119' ' ' ARG . 16.5 mt -106.81 132.43 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.001 -1.062 . . . . 0.0 109.518 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.87 127.26 33.71 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.134 -0.979 . . . . 0.0 109.278 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.66 128.5 36.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.16 -0.962 . . . . 0.0 110.003 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.418 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.49 158.04 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.404 -0.81 . . . . 0.0 110.176 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.98 110.94 21.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.752 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.412 ' O ' ' NZ ' ' A' ' 26' ' ' LYS . 12.7 tp -53.45 134.5 40.44 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.319 -0.863 . . . . 0.0 110.329 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.6 p -135.49 177.76 7.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 110.142 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.33 65.31 0.42 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.225 -0.922 . . . . 0.0 109.951 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.444 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 22.1 m -137.1 110.57 7.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.339 -0.851 . . . . 0.0 110.353 -179.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.455 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.0 -163.89 27.98 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.76 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.72 -21.02 7.43 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.675 -0.897 . . . . 0.0 110.327 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.464 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.3 tt -96.79 108.66 44.44 Favored Pre-proline 0 N--CA 1.488 1.458 0 C-N-CA 118.668 -1.213 . . . . 0.0 110.204 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.411 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.6 Cg_endo -65.48 149.77 87.49 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 O-C-N 123.444 1.234 . . . . 0.0 110.296 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.517 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.3 t80 -169.04 108.21 0.45 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 110.977 -178.778 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.478 ' OH ' ' CE1' ' A' ' 43' ' ' HIS . 17.6 m-85 56.25 60.69 3.05 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.234 -0.916 . . . . 0.0 111.171 179.209 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.97 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.517 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.49 157.28 43.1 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.128 -1.219 . . . . 0.0 109.064 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -115.79 107.27 14.83 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.811 -1.181 . . . . 0.0 110.239 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.464 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.4 mt -68.29 114.5 21.77 Favored Pre-proline 0 C--N 1.301 -1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.455 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.6 Cg_endo -69.16 128.39 16.5 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 N-CA-C 106.579 -2.123 . . . . 0.0 106.579 175.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.429 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 11.0 mt -55.82 -17.62 6.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.673 -1.267 . . . . 0.0 111.09 -177.216 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -59.63 -15.98 22.83 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.677 -1.264 . . . . 0.0 110.667 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.4 m -91.37 -25.38 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.024 -1.048 . . . . 0.0 111.187 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.501 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 25.0 pt -119.84 -16.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.96 -1.087 . . . . 0.0 110.65 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.468 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 1.9 tptt -98.8 147.86 24.49 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.769 -1.207 . . . . 0.0 110.046 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.84 -5.39 50.63 Favored Glycine 0 N--CA 1.485 1.911 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.35 -151.17 9.52 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.081 -1.533 . . . . 0.0 110.561 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.03 131.92 53.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.43 -1.041 . . . . 0.0 110.371 -179.409 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.501 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 95.6 m-70 -138.44 151.53 47.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.172 -0.955 . . . . 0.0 110.95 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 45.9 tp -111.58 119.29 38.24 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.766 . . . . 0.0 110.025 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.457 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 31.6 mt -103.86 126.26 58.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.295 -0.878 . . . . 0.0 109.155 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.96 123.79 38.63 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.177 -0.952 . . . . 0.0 110.329 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.28 160.13 21.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.425 -0.797 . . . . 0.0 110.668 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.478 ' CE1' ' OH ' ' A' ' 24' ' ' TYR . 5.4 p-80 -105.16 -4.73 21.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.337 -0.852 . . . . 0.0 110.426 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.423 ' HB3' ' CD2' ' A' ' 43' ' ' HIS . 66.4 p -136.14 145.8 46.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.01 -1.056 . . . . 0.0 111.235 -179.413 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 23.7 tttt -72.08 -40.92 67.91 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.673 -0.642 . . . . 0.0 110.669 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.77 -34.98 72.04 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.139 -0.976 . . . . 0.0 110.684 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.403 ' HA ' ' HD3' ' A' ' 47' ' ' LYS . 12.3 tppt? -71.6 -40.42 69.86 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.077 -1.014 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.453 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 67.3 m -61.83 -37.15 83.37 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 110.06 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.98 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.949 -1.094 . . . . 0.0 110.577 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.28 -44.2 63.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.174 -0.954 . . . . 0.0 110.229 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.452 ' CD1' HG12 ' A' ' 83' ' ' VAL . 1.7 tm? -56.58 -42.12 78.1 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.489 -0.757 . . . . 0.0 111.198 -179.102 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.35 -50.88 16.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.897 -1.127 . . . . 0.0 110.375 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.38 -42.09 98.15 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.118 -0.989 . . . . 0.0 109.798 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.432 ' O ' HD21 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.98 -45.78 86.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.901 . . . . 0.0 109.788 179.703 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.493 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -54.54 -42.31 70.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.453 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.5 t -56.79 -30.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.122 -0.986 . . . . 0.0 108.591 178.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.56 -33.93 60.67 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.597 -0.689 . . . . 0.0 110.021 179.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.44 HD22 ' N ' ' A' ' 58' ' ' LEU . 4.4 mm? -71.48 -25.73 62.4 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.82 0.819 . . . . 0.0 109.556 179.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.56 7.34 9.0 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.468 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 40.1 mt -108.01 143.31 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.324 -1.103 . . . . 0.0 109.977 -179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.415 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 38.2 t30 -87.2 107.08 18.32 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.493 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.91 145.11 48.02 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.409 -177.576 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.499 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 6.7 t -133.02 143.1 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.589 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -107.16 123.45 48.28 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.824 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.473 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.17 119.06 36.47 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.335 -0.853 . . . . 0.0 110.387 -179.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.516 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 6.8 p90 -146.74 174.48 11.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.608 -0.683 . . . . 0.0 109.753 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.6 5.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.161 -0.962 . . . . 0.0 110.803 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.02 35.73 9.58 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.516 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.0 tm? -117.17 155.84 28.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 110.079 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.457 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 37.1 m-20 -95.37 149.42 21.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.333 -0.854 . . . . 0.0 110.248 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.408 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 27.2 m -61.81 110.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.176 179.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 m -132.04 -20.82 2.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.486 -0.759 . . . . 0.0 111.068 -179.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.499 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.88 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 109.302 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.422 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.5 pp -126.25 96.91 35.54 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.241 -0.912 . . . . 0.0 110.969 -179.496 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -82.26 54.0 4.77 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.689 1.362 . . . . 0.0 109.95 179.164 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.4 t -156.95 42.44 0.35 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.259 -0.901 . . . . 0.0 110.537 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -141.5 -164.94 1.87 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.171 -0.956 . . . . 0.0 110.149 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.43 -73.36 0.36 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 -149.93 111.66 4.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.303 -1.116 . . . . 0.0 110.097 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.6 p -117.47 134.58 60.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.074 0.94 . . . . 0.0 110.359 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.466 HG22 ' CB ' ' A' ' 62' ' ' ALA . 5.7 m -113.28 124.67 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 O-C-N 121.413 -0.805 . . . . 0.0 108.901 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.495 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.91 45.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 121.159 -0.963 . . . . 0.0 110.049 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.8 m -114.48 100.98 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.07 -1.019 . . . . 0.0 108.594 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.473 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.37 164.22 32.16 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.725 -1.234 . . . . 0.0 111.796 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.4 t -94.28 -147.2 0.26 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.671 -0.643 . . . . 0.0 109.42 179.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.15 -15.3 56.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.964 -1.085 . . . . 0.0 110.235 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -49.32 -44.64 44.49 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.038 -1.039 . . . . 0.0 110.257 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp -63.56 -26.86 68.89 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 108.985 179.101 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.473 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 5.6 tpt 45.2 32.42 0.95 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.71 -0.619 . . . . 0.0 111.207 179.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.433 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 48.1 p 44.13 36.77 1.59 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.706 -0.621 . . . . 0.0 111.22 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.06 -63.98 4.67 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -122.31 41.13 3.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.307 -1.114 . . . . 0.0 109.879 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.433 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 15.3 t -91.13 -159.38 0.63 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.342 -0.849 . . . . 0.0 110.777 -179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.47 -36.9 3.63 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -84.45 55.05 3.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.966 -1.314 . . . . 0.0 110.492 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -119.92 147.93 44.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.937 -1.102 . . . . 0.0 110.303 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.459 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.43 -28.77 56.75 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.409 -0.807 . . . . 0.0 110.127 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.428 ' OG ' ' ND1' ' A' ' 38' ' ' HIS . 5.2 p -160.38 163.58 33.05 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.256 -0.903 . . . . 0.0 110.752 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.9 117.86 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.332 -0.855 . . . . 0.0 110.563 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.444 HD12 ' N ' ' A' ' 100' ' ' ILE . 4.6 mp -98.24 110.86 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.16 158.88 25.05 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.992 . . . . 0.0 111.773 -178.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.84 3.67 53.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.423 ' CA ' ' OE1' ' A' ' 110' ' ' GLN . 3.2 m-20 52.88 27.72 5.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.239 -0.913 . . . . 0.0 111.087 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p -147.23 130.78 16.8 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.11 -0.994 . . . . 0.0 110.24 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.407 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.1 p -112.86 127.88 56.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.324 -0.86 . . . . 0.0 109.837 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 55.43 26.96 9.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.316 -0.865 . . . . 0.0 110.553 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.15 -37.83 3.31 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.407 ' O ' ' N ' ' A' ' 105' ' ' SER . 15.8 mttt -77.05 156.56 82.06 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.325 -1.103 . . . . 0.0 110.121 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -65.94 132.61 30.78 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.612 1.322 . . . . 0.0 109.887 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.46 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER -49.66 171.15 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.275 -0.891 . . . . 0.0 110.998 -179.046 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.427 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.8 p30 -99.7 160.77 14.05 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.28 179.674 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.31 -53.47 5.21 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.438 -0.789 . . . . 0.0 112.286 -178.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.427 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.8 m -69.75 -29.42 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 120.83 -1.169 . . . . 0.0 111.525 -178.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.427 ' N ' HG22 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.31 -56.52 6.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.07 -1.019 . . . . 0.0 110.625 -179.114 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 ptm180 -69.07 -34.69 75.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.296 -0.877 . . . . 0.0 108.819 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.402 ' O ' ' NH2' ' A' ' 119' ' ' ARG . 25.8 m -59.52 -49.79 76.42 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.68 -37.53 65.2 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.451 -0.781 . . . . 0.0 110.056 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.409 ' HB2' ' O ' ' A' ' 114' ' ' SER . 36.3 mtt-85 -71.89 -45.63 60.61 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.209 -0.932 . . . . 0.0 111.719 -179.234 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.562 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 27.6 ttp85 -59.34 -51.65 69.02 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.091 -1.006 . . . . 0.0 109.917 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.429 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.4 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -179.265 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -45.73 -33.21 2.87 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.283 -1.128 . . . . 0.0 111.632 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.441 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.9 t -100.65 144.12 30.01 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.884 -1.135 . . . . 0.0 110.884 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.97 14.54 24.51 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.389 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.429 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.59 84.23 0.61 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -1.201 . . . . 0.0 109.794 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.53 -26.34 13.34 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.903 -1.679 . . . . 0.0 108.903 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.497 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.96 -168.7 0.19 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.495 -1.003 . . . . 0.0 108.669 179.653 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.497 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.0 Cg_endo -87.32 110.95 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.14 1.074 . . . . 0.0 110.7 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.441 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -82.42 170.57 50.7 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 49.1 mt -126.48 142.64 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.516 -0.991 . . . . 0.0 108.416 178.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -128.77 114.75 16.97 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.721 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.418 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 18.2 mtp180 -105.27 122.88 46.86 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.41 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 32.0 p90 -121.72 158.06 29.58 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 110.662 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.418 ' O ' ' CB ' ' A' ' 134' ' ' ALA . 32.1 t -94.69 -56.97 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.418 ' CB ' ' O ' ' A' ' 133' ' ' VAL . . . 69.08 145.19 0.1 Allowed Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.749 -0.594 . . . . 0.0 110.343 -179.576 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -78.32 -56.02 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.726 1.382 . . . . 0.0 110.506 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 136.85 -32.53 2.43 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.24 -161.12 1.26 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.257 -1.143 . . . . 0.0 110.317 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 9.8 ttt-85 . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 118.049 -0.977 . . . . 0.0 110.149 179.886 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 t -77.36 108.29 10.39 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.204 -1.174 . . . . 0.0 110.302 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 19.2 m -113.32 104.26 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.278 -0.889 . . . . 0.0 109.878 179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.2 p -63.59 139.87 58.81 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.382 -0.824 . . . . 0.0 110.497 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.417 HG22 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.81 148.38 96.47 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.361 -0.837 . . . . 0.0 109.717 179.677 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.423 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 45.6 Cg_endo -71.99 -165.72 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 124.136 1.598 . . . . 0.0 110.887 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.491 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 174.65 80.64 0.06 OUTLIER Pre-proline 0 N--CA 1.499 1.982 0 O-C-N 121.508 -0.745 . . . . 0.0 109.523 -179.617 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -75.18 55.23 3.98 Favored 'Trans proline' 0 C--N 1.313 -1.325 0 O-C-N 123.681 1.359 . . . . 0.0 111.427 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.409 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 -139.04 4.66 2.28 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.028 -1.045 . . . . 0.0 110.968 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.434 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 30.3 mt -129.0 137.28 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.867 -1.146 . . . . 0.0 109.707 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -82.75 127.81 33.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.056 -1.028 . . . . 0.0 109.207 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.89 139.32 30.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.3 -0.875 . . . . 0.0 110.553 -179.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.471 ' CG1' ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.75 156.55 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.215 -0.928 . . . . 0.0 110.14 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.34 109.86 21.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -0.889 . . . . 0.0 110.109 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.469 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.77 141.88 36.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 109.311 179.456 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.33 174.57 10.62 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 110.548 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.58 0.99 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.325 -0.86 . . . . 0.0 110.276 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.432 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 26.9 m -155.68 109.32 2.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.174 -0.954 . . . . 0.0 110.482 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.462 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.49 -171.35 28.89 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.891 -1.623 . . . . 0.0 111.181 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.54 -22.59 11.57 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.722 -0.87 . . . . 0.0 110.45 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.462 ' O ' HG23 ' A' ' 21' ' ' ILE . 9.9 tt -95.26 107.12 30.31 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 118.872 -1.131 . . . . 0.0 109.455 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.84 144.67 89.15 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.249 1.131 . . . . 0.0 111.34 -178.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.421 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.73 -166.37 1.85 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.522 -0.736 . . . . 0.0 110.318 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.572 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.8 m-85 -59.92 82.03 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.403 -0.811 . . . . 0.0 111.051 -179.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.4 5.85 51.49 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.469 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 14.4 mmtm -130.64 156.68 44.47 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.941 -1.329 . . . . 0.0 109.778 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.432 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.64 16.77 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.062 -1.024 . . . . 0.0 109.106 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.462 ' O ' HG23 ' A' ' 21' ' ' ILE . 6.2 mt -69.12 114.16 21.57 Favored Pre-proline 0 C--N 1.299 -1.596 0 O-C-N 121.367 -0.833 . . . . 0.0 110.798 -179.081 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.462 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.2 Cg_endo -69.73 132.12 22.72 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.13 -1.912 . . . . 0.0 107.13 176.164 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.446 HD22 ' CD1' ' A' ' 60' ' ' ILE . 13.2 mt -56.95 -14.95 4.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.961 -1.087 . . . . 0.0 111.219 -177.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -63.31 -16.16 59.5 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.539 -1.351 . . . . 0.0 110.51 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.43 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 10.6 m -93.86 -24.44 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.052 -1.03 . . . . 0.0 110.87 -179.406 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.512 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 48.3 pt -117.16 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.035 -1.041 . . . . 0.0 110.493 -179.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.455 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.98 148.41 24.56 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -0.903 . . . . 0.0 110.501 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.74 -5.17 46.99 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.27 -147.68 7.79 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.428 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.8 132.5 53.93 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.406 -1.055 . . . . 0.0 110.473 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.2 m-70 -140.77 149.0 41.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 0.0 110.603 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.51 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 57.3 tp -111.0 113.59 26.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.441 -0.787 . . . . 0.0 109.803 179.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.433 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 29.2 mt -96.41 127.38 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.882 . . . . 0.0 109.662 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.51 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.2 m-85 -95.08 122.72 38.03 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.295 -0.878 . . . . 0.0 110.251 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.04 160.16 21.98 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.339 -0.85 . . . . 0.0 110.733 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.572 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p-80 -110.01 4.65 21.55 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.396 -0.815 . . . . 0.0 109.964 178.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.52 136.41 49.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 110.987 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.84 69.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.645 -0.66 . . . . 0.0 110.861 -179.866 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.74 -36.75 73.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.28 -0.888 . . . . 0.0 110.917 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.13 -35.39 80.36 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.313 -0.867 . . . . 0.0 109.574 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.419 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 53.2 m -61.48 -33.83 74.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.511 -0.743 . . . . 0.0 109.764 179.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.19 -50.22 61.77 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.283 -0.886 . . . . 0.0 110.967 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.22 -44.11 63.44 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.119 -0.988 . . . . 0.0 110.569 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.442 ' CD1' HG12 ' A' ' 83' ' ' VAL . 2.6 tm? -56.99 -38.35 72.91 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.562 -0.711 . . . . 0.0 111.242 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.62 -51.15 13.49 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.871 -1.143 . . . . 0.0 110.633 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.46 -40.04 85.58 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.146 -0.971 . . . . 0.0 110.145 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.458 ' CE ' HD22 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.04 82.99 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.318 -0.864 . . . . 0.0 109.788 179.739 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.484 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.07 -38.92 71.29 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.643 -0.661 . . . . 0.0 110.093 179.818 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.3 t -58.62 -34.38 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.185 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.29 -30.66 60.47 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.436 -0.79 . . . . 0.0 109.965 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.508 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.1 mm? -72.01 -25.71 61.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.437 -0.789 . . . . 0.0 109.773 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.9 10.3 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.468 HG22 HG22 ' A' ' 81' ' ' VAL . 45.9 mt -108.03 143.23 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.298 -1.119 . . . . 0.0 109.75 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.413 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 51.8 t30 -89.84 106.39 18.44 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -116.18 142.59 46.62 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.729 -177.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.488 ' HB ' HG22 ' A' ' 73' ' ' VAL . 57.4 t -125.56 149.41 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 120.139 -0.624 . . . . 0.0 109.701 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.476 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -116.69 119.05 34.25 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.433 178.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.457 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.42 132.72 55.52 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.216 -0.927 . . . . 0.0 110.839 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.482 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 3.5 p90 -166.93 176.85 6.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.569 -0.707 . . . . 0.0 109.719 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.15 125.35 15.44 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.069 -1.02 . . . . 0.0 110.707 -179.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.7 37.4 19.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.432 ' CD1' ' O ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.44 157.24 26.57 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.031 -1.276 . . . . 0.0 110.12 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.432 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.8 m-20 -96.53 149.23 21.98 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.29 -0.881 . . . . 0.0 110.555 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.427 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 30.3 m -62.66 111.37 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.193 -0.942 . . . . 0.0 109.121 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.82 -35.39 1.09 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.389 -0.819 . . . . 0.0 110.733 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.488 HG22 ' HB ' ' A' ' 63' ' ' VAL . 59.6 t -48.41 120.37 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.391 -0.818 . . . . 0.0 110.294 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.454 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.5 pp -137.53 109.99 8.79 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.235 -0.916 . . . . 0.0 110.608 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.422 ' HA ' HG13 ' A' ' 80' ' ' VAL . 50.3 Cg_endo -87.31 40.14 0.63 Allowed 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 123.327 1.172 . . . . 0.0 110.666 179.559 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.3 p -136.42 26.27 3.16 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.081 -1.012 . . . . 0.0 110.143 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.7 m-20 -135.44 27.27 3.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.216 -0.927 . . . . 0.0 110.172 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 111.4 -156.5 15.52 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.369 -1.492 . . . . 0.0 109.369 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.67 112.59 15.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.113 -1.228 . . . . 0.0 110.182 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.2 p -116.92 135.56 56.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-O 122.151 0.977 . . . . 0.0 110.568 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 11.9 m -112.88 119.94 61.72 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.072 0 O-C-N 121.228 -0.92 . . . . 0.0 108.844 178.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.435 ' CG2' HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.84 45.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 120.886 -1.134 . . . . 0.0 110.265 -178.041 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.501 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.2 m -109.06 100.53 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.146 -0.971 . . . . 0.0 108.691 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.36 162.24 35.49 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.765 -1.21 . . . . 0.0 110.979 -178.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.8 t -88.26 -131.34 0.07 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.347 -0.846 . . . . 0.0 109.612 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 44.9 p30 -91.4 29.28 1.49 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.694 -1.254 . . . . 0.0 110.55 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.62 -29.06 12.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.052 -1.03 . . . . 0.0 110.231 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -75.19 -33.49 61.43 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.144 -0.973 . . . . 0.0 109.742 179.674 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.42 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 1.6 mmt 51.1 -106.76 0.26 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.305 -0.872 . . . . 0.0 109.958 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.443 ' CB ' HG21 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.75 41.58 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.831 0 O-C-N 120.668 -1.27 . . . . 0.0 110.419 179.739 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.25 -32.4 51.08 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 108.639 -1.784 . . . . 0.0 108.639 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.481 ' CD1' ' N ' ' A' ' 92' ' ' PHE . 14.2 p90 -145.47 38.26 1.13 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.684 -0.892 . . . . 0.0 109.803 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.492 ' OG1' ' CZ ' ' A' ' 96' ' ' PHE . 0.5 OUTLIER -126.86 -162.4 1.15 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.323 -0.861 . . . . 0.0 110.209 -179.633 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.48 ' N ' ' CG2' ' A' ' 93' ' ' THR . . . 123.48 -40.47 1.97 Allowed Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.331 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -84.42 81.05 9.01 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.132 -1.217 . . . . 0.0 110.844 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.492 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 15.1 m-85 -119.77 147.98 43.97 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.111 -0.993 . . . . 0.0 110.115 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.493 ' CB ' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -71.11 -35.1 71.65 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.385 -0.822 . . . . 0.0 109.383 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.3 p -162.04 163.65 28.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.225 -0.922 . . . . 0.0 111.128 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.535 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 1.3 m -129.36 118.1 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.52 -0.737 . . . . 0.0 110.091 179.378 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.438 HG23 ' CD1' ' A' ' 28' ' ' ILE . 2.7 mp -92.6 111.98 25.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.14 160.26 21.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 111.718 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.502 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.23 6.26 38.08 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.159 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.428 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.04 25.43 0.49 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.411 HG23 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -147.75 129.38 15.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.294 -0.879 . . . . 0.0 110.396 179.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 24.4 p -113.34 132.17 55.69 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.266 -0.896 . . . . 0.0 109.636 179.403 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.404 ' OD1' ' N ' ' A' ' 106' ' ' ASP . 1.5 m-20 54.5 -141.87 0.83 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.053 -1.03 . . . . 0.0 109.669 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.76 17.99 41.88 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.0 mmtp -133.74 156.28 79.59 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.05 -1.264 . . . . 0.0 109.749 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.411 ' HA ' HG23 ' A' ' 104' ' ' THR . 38.4 Cg_endo -64.61 159.82 43.03 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 O-C-N 123.662 1.348 . . . . 0.0 110.198 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.428 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 -57.16 153.33 11.97 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.22 -0.925 . . . . 0.0 110.713 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 114' ' ' SER . 1.7 p30 -90.73 160.78 15.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.342 -0.849 . . . . 0.0 110.285 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -42.37 -52.26 4.63 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.544 -0.722 . . . . 0.0 112.34 -178.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.427 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.79 -29.27 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.855 -1.153 . . . . 0.0 111.214 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.43 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.39 -56.21 7.37 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.112 -0.993 . . . . 0.0 110.509 -179.377 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.408 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.4 OUTLIER -68.84 -34.5 75.59 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.168 -0.957 . . . . 0.0 108.789 178.685 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.3 m -60.02 -49.92 75.76 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.183 -0.948 . . . . 0.0 108.533 178.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.64 -39.93 64.13 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.546 -0.721 . . . . 0.0 109.671 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.408 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 4.1 mtt180 -66.21 -44.75 83.01 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 110.018 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.491 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 13.5 ttm180 -64.06 -34.08 77.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.221 -0.925 . . . . 0.0 110.279 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.455 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.33 12.07 1.96 Allowed Glycine 0 N--CA 1.497 2.73 0 O-C-N 121.055 -1.028 . . . . 0.0 112.3 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.423 ' CZ ' HG21 ' A' ' 90' ' ' THR . 1.2 mmt85 -101.32 -5.19 25.76 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.296 -1.708 . . . . 0.0 109.461 178.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.491 ' CG2' ' CG2' ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.44 142.15 50.31 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.224 -0.923 . . . . 0.0 109.424 179.782 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 78.48 26.5 59.12 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.455 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.3 82.62 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.134 -1.215 . . . . 0.0 110.109 179.908 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.59 24.92 5.45 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.474 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.5 -1.0 . . . . 0.0 109.105 -179.628 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 45.8 Cg_endo -84.47 99.58 0.75 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.187 1.099 . . . . 0.0 109.551 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.434 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.82 176.58 52.18 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.48 143.95 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.45 -1.03 . . . . 0.0 109.968 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.535 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 9.6 t80 -129.4 116.9 19.73 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.176 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.471 ' NE ' ' CG1' ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.21 137.9 37.07 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.541 -0.725 . . . . 0.0 109.215 179.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.458 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.6 p90 -137.8 153.98 49.6 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 110.719 -179.58 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.85 -46.7 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.323 -0.861 . . . . 0.0 109.422 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.2 161.01 38.99 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 110.271 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.45 -27.37 15.94 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 O-C-N 123.776 1.409 . . . . 0.0 110.572 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 137.47 79.84 0.08 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -175.91 143.36 0.57 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.291 -1.123 . . . . 0.0 110.182 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.191 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.5 m -93.04 150.96 20.17 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.232 -1.158 . . . . 0.0 110.382 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.409 ' O ' HG21 ' A' ' 3' ' ' VAL . 21.0 m -113.37 104.73 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.388 -0.82 . . . . 0.0 110.013 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 6.1 p -66.09 145.07 56.26 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.358 -0.839 . . . . 0.0 110.331 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.437 HG22 ' N ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -70.2 147.82 95.58 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.215 -0.928 . . . . 0.0 109.819 179.841 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.473 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 38.8 Cg_endo -73.11 -64.67 0.03 OUTLIER 'Trans proline' 0 C--N 1.309 -1.517 0 O-C-N 124.096 1.577 . . . . 0.0 112.445 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.508 ' CD2' ' O ' ' A' ' 7' ' ' HIS . 47.8 p-80 41.26 87.24 0.12 Allowed Pre-proline 0 N--CA 1.492 1.652 0 CA-C-O 121.231 0.539 . . . . 0.0 111.294 -178.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.9 0.72 8.51 Favored 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.463 1.244 . . . . 0.0 111.556 -179.211 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.419 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 -52.41 -22.13 4.37 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.803 -1.186 . . . . 0.0 110.436 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 31.1 mt -111.86 135.2 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.973 -1.079 . . . . 0.0 110.277 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.19 129.07 34.87 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.188 -0.945 . . . . 0.0 109.726 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.44 33.57 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.077 -1.014 . . . . 0.0 110.501 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.439 HG12 ' CZ ' ' A' ' 131' ' ' ARG . 17.2 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.91 114.93 29.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.15 -0.968 . . . . 0.0 110.371 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.444 HD21 ' CB ' ' A' ' 26' ' ' LYS . 12.3 tp -63.2 135.65 57.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 109.607 179.561 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.3 p -134.78 171.58 14.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.093 -1.004 . . . . 0.0 110.602 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.447 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.4 m -149.21 112.68 5.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.353 -0.842 . . . . 0.0 110.349 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.33 -161.68 27.28 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.674 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -122.05 -22.35 5.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.724 -0.868 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.488 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -93.51 112.82 58.28 Favored Pre-proline 0 N--CA 1.488 1.426 0 C-N-CA 118.598 -1.241 . . . . 0.0 110.335 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -64.85 141.26 70.66 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.597 1.314 . . . . 0.0 109.977 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.453 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.91 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.101 -0.999 . . . . 0.0 111.732 -178.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.574 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.08 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.534 -0.729 . . . . 0.0 111.558 178.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 12.07 25.88 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.2 mmtt -129.91 156.63 44.1 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.055 -1.262 . . . . 0.0 109.235 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.445 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.93 15.11 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.873 -1.142 . . . . 0.0 108.891 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.488 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 4.4 mt -70.88 114.97 31.3 Favored Pre-proline 0 C--N 1.296 -1.733 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.045 -179.412 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.494 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 38.9 Cg_endo -67.51 130.32 22.01 Favored 'Trans proline' 0 C--N 1.302 -1.878 0 N-CA-C 107.465 -1.783 . . . . 0.0 107.465 176.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.413 ' O ' ' N ' ' A' ' 34' ' ' LYS . 12.4 mt -56.32 -16.41 5.5 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.939 -1.101 . . . . 0.0 110.628 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.21 -16.22 59.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.671 -1.268 . . . . 0.0 110.576 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.427 ' CG2' HG23 ' A' ' 28' ' ' ILE . 15.4 m -92.68 -25.21 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 120.934 -1.104 . . . . 0.0 111.074 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.502 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 30.7 pt -116.41 -29.73 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.467 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.35 148.15 24.4 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.294 -0.879 . . . . 0.0 110.385 179.404 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.12 -5.21 49.46 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.09 -152.52 11.25 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.122 -1.514 . . . . 0.0 110.533 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.408 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.18 128.61 50.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.469 -1.018 . . . . 0.0 110.436 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.502 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 54.6 m80 -139.47 149.93 44.58 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 110.474 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.479 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 19.9 tp -111.85 117.26 32.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.403 -0.811 . . . . 0.0 110.403 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.443 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.307 -0.871 . . . . 0.0 108.997 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.479 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 5.8 m-85 -94.84 122.0 37.02 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.98 -1.075 . . . . 0.0 110.059 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.35 159.37 23.53 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.409 -0.807 . . . . 0.0 110.442 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.574 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.69 18.17 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.413 -0.805 . . . . 0.0 109.617 178.465 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.53 141.35 47.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.093 -1.005 . . . . 0.0 110.476 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.49 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.09 -35.69 69.3 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.535 -0.728 . . . . 0.0 110.549 -179.912 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.17 -45.38 88.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.303 -0.873 . . . . 0.0 110.591 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.14 -38.32 85.98 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.409 -0.807 . . . . 0.0 109.613 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.434 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 1.7 m -61.2 -34.19 74.68 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.488 -0.757 . . . . 0.0 109.56 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.24 -48.68 69.75 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.208 -0.933 . . . . 0.0 110.784 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.408 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.26 -44.61 64.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.204 -0.935 . . . . 0.0 110.472 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.436 ' CD1' HG13 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.64 77.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.319 -0.863 . . . . 0.0 111.002 -179.058 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.401 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.16 -51.41 21.43 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.059 -1.026 . . . . 0.0 110.484 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.09 -43.46 98.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.93 . . . . 0.0 110.039 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.412 ' O ' HD22 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.2 -46.16 83.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.171 -0.956 . . . . 0.0 109.526 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.484 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.76 -40.96 73.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.537 -0.727 . . . . 0.0 110.176 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.0 t -57.33 -35.34 48.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.984 -1.073 . . . . 0.0 108.978 179.425 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -31.26 59.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.352 -0.842 . . . . 0.0 110.243 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.509 HD23 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -71.32 -25.8 62.56 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.94 0.876 . . . . 0.0 109.75 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.41 5.77 10.11 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.474 HG23 HG23 ' A' ' 81' ' ' VAL . 37.7 mt -108.03 143.29 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.468 -1.019 . . . . 0.0 110.08 -179.532 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 45.9 t30 -89.52 106.64 18.59 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.484 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.77 144.4 46.31 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.708 -177.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.498 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 48.8 t -127.84 145.91 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.881 -0.727 . . . . 0.0 109.646 179.243 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -110.09 119.42 39.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.877 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.463 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 4.1 t80 -116.45 127.26 54.43 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.229 -0.92 . . . . 0.0 110.655 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.495 ' CE1' HD21 ' A' ' 69' ' ' LEU . 1.2 p90 -153.22 -171.4 3.91 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.402 -0.811 . . . . 0.0 110.013 179.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.56 126.9 21.03 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.308 -0.87 . . . . 0.0 111.276 -179.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.85 48.63 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.495 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.73 155.0 30.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.978 -1.307 . . . . 0.0 109.958 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.448 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.3 m-20 -90.75 149.49 21.99 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.37 -0.832 . . . . 0.0 110.694 -179.18 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.426 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.4 m -62.54 110.94 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.145 -0.972 . . . . 0.0 109.586 179.423 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 34.5 m -132.11 -23.82 2.16 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.383 -0.823 . . . . 0.0 111.178 -179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.498 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 22.6 t -60.1 138.73 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.133 -0.979 . . . . 0.0 110.082 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp -137.11 100.49 9.59 Favored Pre-proline 0 N--CA 1.495 1.797 0 O-C-N 121.203 -0.935 . . . . 0.0 110.541 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -88.19 36.92 0.43 Allowed 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.608 1.32 . . . . 0.0 110.537 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.47 16.43 6.52 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.099 -1.001 . . . . 0.0 110.655 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -116.18 -165.37 1.04 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.023 -1.048 . . . . 0.0 110.042 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.83 -87.56 0.01 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -131.85 115.02 15.39 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.192 -1.181 . . . . 0.0 110.379 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.1 p -116.88 133.75 62.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.039 0.923 . . . . 0.0 110.425 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.474 HG23 HG23 ' A' ' 60' ' ' ILE . 6.1 m -113.54 123.56 69.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 O-C-N 121.502 -0.749 . . . . 0.0 109.021 179.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.421 ' CG2' HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.51 118.04 43.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.958 -1.089 . . . . 0.0 110.649 -177.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.498 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.4 m -106.64 100.45 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.009 -1.057 . . . . 0.0 108.634 179.037 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.463 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -144.19 162.39 36.45 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.667 -1.27 . . . . 0.0 111.239 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.8 t -92.9 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.476 -0.765 . . . . 0.0 108.988 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.36 50.06 1.92 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.72 -1.237 . . . . 0.0 109.931 179.416 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.68 -18.63 9.61 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.22 -0.925 . . . . 0.0 110.583 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 14.2 tp -62.43 -23.55 66.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.031 -1.043 . . . . 0.0 109.71 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.477 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.4 OUTLIER 46.29 28.35 0.68 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.42 -0.8 . . . . 0.0 110.733 179.736 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.472 ' CB ' HG22 ' A' ' 93' ' ' THR . 5.8 t 35.11 -126.34 0.11 Allowed 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 178.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.414 ' N ' HG23 ' A' ' 90' ' ' THR . . . 90.75 -51.25 3.24 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 -178.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -133.19 23.68 4.15 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.552 -0.97 . . . . 0.0 109.432 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.493 ' OG1' ' CE2' ' A' ' 96' ' ' PHE . 3.7 t -98.95 -156.33 0.54 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.433 -0.792 . . . . 0.0 110.695 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 94.12 -24.99 24.34 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.196 -1.162 . . . . 0.0 110.196 179.25 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -87.15 60.92 6.44 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.024 -1.28 . . . . 0.0 110.844 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.493 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 20.8 m-85 -119.66 146.6 45.43 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.015 -1.053 . . . . 0.0 110.345 179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.33 -34.81 58.98 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.516 -0.74 . . . . 0.0 109.508 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -160.89 163.02 32.26 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.249 -0.907 . . . . 0.0 110.778 179.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.529 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.29 118.15 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.21 -0.931 . . . . 0.0 110.131 179.375 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.438 HD13 ' CD1' ' A' ' 40' ' ' ILE . 3.2 mp -95.96 117.73 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.462 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.413 ' OD1' ' CB ' ' A' ' 41' ' ' PHE . 18.8 t0 -124.46 161.36 26.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.137 -0.977 . . . . 0.0 111.851 -178.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.454 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.91 -6.81 34.84 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 55.7 15.36 1.56 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.319 -0.863 . . . . 0.0 111.654 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.407 HG21 ' O ' ' A' ' 108' ' ' LYS . 1.1 m -143.4 120.15 11.19 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 120.731 -1.231 . . . . 0.0 109.535 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.479 ' N ' ' O ' ' A' ' 108' ' ' LYS . 8.9 p -96.92 121.74 39.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.312 -0.868 . . . . 0.0 110.348 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 13.5 t0 60.78 32.84 20.19 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.311 -0.868 . . . . 0.0 110.736 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.34 -28.27 9.23 Favored Glycine 0 N--CA 1.492 2.394 0 C-N-CA 119.907 -1.14 . . . . 0.0 110.262 179.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -88.36 155.78 51.37 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.044 -1.268 . . . . 0.0 110.109 -179.765 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.88 128.47 22.07 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.506 1.266 . . . . 0.0 110.777 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -46.36 168.73 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.588 -0.695 . . . . 0.0 111.163 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.425 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 3.0 p30 -87.77 160.98 17.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.333 -0.854 . . . . 0.0 110.292 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.15 3.75 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.339 -0.851 . . . . 0.0 111.832 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.425 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.66 -29.76 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.932 -1.105 . . . . 0.0 111.794 -178.345 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.408 ' N ' HG21 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.27 -56.1 7.42 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.083 -1.011 . . . . 0.0 110.426 -179.142 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.451 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.35 -32.87 72.22 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.224 -0.922 . . . . 0.0 108.848 178.808 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.451 ' N ' ' HG2' ' A' ' 115' ' ' ARG . 25.3 m -61.11 -49.8 75.81 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.109 -0.994 . . . . 0.0 108.409 178.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.97 -36.3 64.56 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.918 -0.713 . . . . 0.0 109.807 178.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.426 ' HG2' ' CZ ' ' A' ' 41' ' ' PHE . 49.1 mtt-85 -71.68 -44.47 64.19 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.255 -0.903 . . . . 0.0 111.117 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.483 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 19.5 ttm180 -56.7 -41.03 76.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.891 -1.131 . . . . 0.0 109.93 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.06 71.43 0.19 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.456 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.72 -45.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.593 -0.945 . . . . 0.0 108.836 179.488 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.456 ' CG2' HD13 ' A' ' 10' ' ' ILE . 9.2 t -101.14 143.01 31.76 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.598 -0.689 . . . . 0.0 109.393 178.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.451 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 4.0 22.02 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.184 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.01 85.38 0.71 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.995 -1.297 . . . . 0.0 109.822 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.406 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 104.08 9.79 35.99 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.467 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 3.6 pttt -174.96 -173.76 0.22 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.318 -1.107 . . . . 0.0 108.659 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.467 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 50.0 Cg_endo -88.15 105.33 0.51 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.22 1.116 . . . . 0.0 110.297 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.444 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.42 170.45 53.61 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.706 -1.235 . . . . 0.0 110.102 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.411 HG21 HG22 ' A' ' 13' ' ' VAL . 1.5 mp -126.79 142.55 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.535 -0.979 . . . . 0.0 108.862 179.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.529 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.3 t80 -129.33 115.18 17.18 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.982 -1.073 . . . . 0.0 110.578 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.439 ' CZ ' HG12 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.68 122.85 42.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.47 -0.768 . . . . 0.0 109.273 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 24.0 p90 -121.41 148.7 44.05 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.05 -1.031 . . . . 0.0 110.262 -179.495 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.454 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 46.1 t -74.65 -31.69 27.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.524 179.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -127.69 134.0 25.71 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.142 -0.974 . . . . 0.0 110.076 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -74.45 -18.79 19.93 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.529 1.278 . . . . 0.0 110.707 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . 0.425 ' O ' ' N ' ' A' ' 138' ' ' ARG . . . 108.03 -42.59 1.9 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 55.1 -88.22 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.531 -0.981 . . . . 0.0 110.564 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.425 ' N ' ' O ' ' A' ' 136' ' ' GLY . 9.8 ptt85 . . . . . 0 N--CA 1.492 1.63 0 O-C-N 120.996 -1.065 . . . . 0.0 110.312 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.8 m -117.09 140.1 49.92 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.243 -1.151 . . . . 0.0 110.303 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.407 ' O ' HG12 ' A' ' 3' ' ' VAL . 7.1 p -112.84 104.83 17.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.285 -0.885 . . . . 0.0 109.761 179.657 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 71.7 p -62.87 141.79 58.53 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.336 -0.852 . . . . 0.0 110.337 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.428 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -66.9 148.84 98.74 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.326 -0.859 . . . . 0.0 109.303 179.79 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.436 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 43.2 Cg_endo -69.07 -172.01 0.47 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 124.057 1.556 . . . . 0.0 110.883 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.506 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.2 OUTLIER 175.68 75.09 0.07 OUTLIER Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.513 -0.742 . . . . 0.0 109.54 -179.718 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.65 -13.51 32.5 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.827 1.436 . . . . 0.0 110.687 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -59.86 -18.08 41.55 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.062 -1.024 . . . . 0.0 110.19 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.45 HD11 ' CG2' ' A' ' 122' ' ' THR . 40.8 mt -117.52 136.39 54.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 110.533 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.164 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 110.382 -179.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.49 156.3 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.439 -0.788 . . . . 0.0 110.05 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.01 111.49 24.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.276 -0.89 . . . . 0.0 110.169 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.421 HD21 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.16 136.17 48.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.358 -0.839 . . . . 0.0 109.877 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.97 173.83 11.28 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.132 -0.98 . . . . 0.0 110.22 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.9 p -67.57 74.32 0.16 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 109.814 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.455 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 17.8 m -145.59 109.55 4.84 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.379 -0.826 . . . . 0.0 110.388 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.471 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.7 27.93 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.671 179.567 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.04 -25.01 5.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.696 -0.884 . . . . 0.0 110.561 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.457 HG21 ' O ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.34 52.55 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.172 -179.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.412 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.1 Cg_endo -64.79 143.01 78.8 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.5 1.263 . . . . 0.0 110.158 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.448 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.5 t80 -155.23 94.84 1.66 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 111.286 -178.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.433 ' CZ ' ' CE1' ' A' ' 43' ' ' HIS . 23.7 m-85 57.66 67.07 1.01 Allowed 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.535 -0.728 . . . . 0.0 111.611 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.5 13.33 16.4 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.448 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 22.2 mmtm -130.6 156.99 43.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.142 -1.211 . . . . 0.0 109.185 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.411 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.6 107.52 16.26 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.906 -1.121 . . . . 0.0 109.827 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.457 ' O ' HG21 ' A' ' 21' ' ' ILE . 3.5 mt -69.97 113.39 17.28 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 121.372 -0.83 . . . . 0.0 109.894 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.471 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.8 Cg_endo -68.99 128.88 17.41 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 N-CA-C 106.993 -1.964 . . . . 0.0 106.993 176.463 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.421 HD23 HD12 ' A' ' 60' ' ' ILE . 6.2 mt -56.61 -15.98 5.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.854 -1.154 . . . . 0.0 111.137 -177.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.424 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.43 62.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.65 -1.281 . . . . 0.0 110.869 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.431 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.1 m -89.68 -26.5 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.922 -1.111 . . . . 0.0 111.134 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.524 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 43.3 pt -116.94 -23.68 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.165 -0.96 . . . . 0.0 110.048 -179.626 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.457 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.59 148.35 22.15 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.174 -0.954 . . . . 0.0 110.596 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.23 51.73 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.18 -151.61 9.86 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.211 -1.471 . . . . 0.0 110.208 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.428 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.57 130.72 54.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -1.078 . . . . 0.0 110.208 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.524 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.9 m80 -140.81 148.81 41.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.117 -0.99 . . . . 0.0 110.983 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.496 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 20.2 tp -109.76 123.18 49.09 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.924 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.469 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 37.8 mt -104.78 128.73 58.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.286 -0.883 . . . . 0.0 108.876 179.225 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.496 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.3 122.86 37.28 Favored 'General case' 0 C--N 1.294 -1.844 0 O-C-N 121.241 -0.912 . . . . 0.0 110.348 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.83 160.05 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.335 -0.853 . . . . 0.0 110.8 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.433 ' CE1' ' CZ ' ' A' ' 24' ' ' TYR . 3.9 p-80 -115.51 5.23 14.39 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.575 -0.703 . . . . 0.0 109.799 178.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.74 138.14 45.61 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.007 . . . . 0.0 110.878 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.488 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.69 -43.35 66.11 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.709 -0.619 . . . . 0.0 110.53 -179.931 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.66 -34.5 74.4 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.325 -0.859 . . . . 0.0 110.564 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.21 -38.19 66.18 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.233 -0.917 . . . . 0.0 109.911 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.419 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 61.5 m -61.4 -34.48 75.43 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.521 -0.737 . . . . 0.0 109.892 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.24 -49.72 58.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 110.381 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.01 -46.38 57.41 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.246 -0.909 . . . . 0.0 110.274 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.436 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.3 tm? -56.92 -42.65 80.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.976 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.38 -50.85 19.74 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.01 -1.056 . . . . 0.0 110.651 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -40.5 97.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.038 -1.039 . . . . 0.0 109.733 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.416 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.24 -43.1 82.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.315 -0.866 . . . . 0.0 109.434 179.394 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.478 HD21 HG22 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -55.34 -42.87 74.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.39 -0.819 . . . . 0.0 109.749 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.14 -32.58 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -0.966 . . . . 0.0 108.716 179.043 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.52 -32.08 60.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.571 -0.706 . . . . 0.0 110.013 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.463 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.1 mm? -71.52 -26.26 62.58 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.298 -0.876 . . . . 0.0 109.595 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 5.47 9.45 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.483 HG22 HG21 ' A' ' 81' ' ' VAL . 51.8 mt -108.26 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.303 -1.116 . . . . 0.0 110.069 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.415 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 36.7 t30 -86.65 107.04 18.02 Favored 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.481 ' CB ' HG23 ' A' ' 81' ' ' VAL . . . -122.03 147.74 45.71 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.541 -177.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.481 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 2.8 t -135.73 142.43 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.518 179.278 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -105.35 135.05 47.44 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.244 -0.983 . . . . 0.0 109.871 179.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.433 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.62 131.29 49.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.12 -0.987 . . . . 0.0 110.792 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.488 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 5.6 p90 -166.25 175.33 8.39 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.66 -0.65 . . . . 0.0 109.515 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.74 114.89 1.41 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.249 -0.907 . . . . 0.0 110.799 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.77 31.45 7.77 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.439 ' CD1' ' O ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.53 157.31 26.55 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.064 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.439 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 5.3 m-20 -96.91 149.45 21.86 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.195 -0.941 . . . . 0.0 110.508 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.43 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.3 m -62.64 111.25 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.189 -0.945 . . . . 0.0 109.162 179.224 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.45 ' CB ' HG13 ' A' ' 63' ' ' VAL . 4.6 m -133.63 -32.19 1.15 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.337 -0.852 . . . . 0.0 111.08 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.481 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 20.4 t -53.73 137.94 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.193 -0.942 . . . . 0.0 109.825 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp -137.76 101.0 8.87 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.223 -0.923 . . . . 0.0 111.169 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -82.1 53.45 4.56 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.462 1.243 . . . . 0.0 110.109 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.8 p -149.63 22.36 0.91 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.047 -1.033 . . . . 0.0 110.918 -179.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -123.18 -165.85 1.38 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.021 -1.049 . . . . 0.0 110.135 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.67 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -126.36 113.04 16.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.159 -1.201 . . . . 0.0 110.153 179.561 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 12.0 p -117.86 133.16 65.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.089 0.947 . . . . 0.0 110.111 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.483 HG21 HG22 ' A' ' 60' ' ' ILE . 4.7 m -113.87 125.45 71.16 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.369 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.088 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 39' ' ' LEU . 9.1 t -97.18 121.17 47.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 121.008 -1.058 . . . . 0.0 110.133 -178.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 5.2 m -114.88 100.07 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.706 -1.246 . . . . 0.0 108.586 179.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.433 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.27 163.99 33.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.667 -1.271 . . . . 0.0 111.659 -177.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -84.11 -138.56 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.597 -0.689 . . . . 0.0 109.6 179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -87.53 14.4 8.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.799 -1.188 . . . . 0.0 110.613 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -86.54 -21.82 26.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.989 -1.069 . . . . 0.0 110.181 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.55 -24.55 53.61 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.128 -0.983 . . . . 0.0 110.143 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.43 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 52.56 -157.03 0.15 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.354 -179.198 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.44 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.1 OUTLIER -147.72 29.16 0.93 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.035 -1.041 . . . . 0.0 110.071 179.717 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.64 -39.54 61.1 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -130.03 25.16 5.27 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.43 -1.041 . . . . 0.0 110.463 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.481 ' OG1' ' CZ ' ' A' ' 96' ' ' PHE . 0.5 OUTLIER -108.31 -171.08 1.79 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.146 -0.971 . . . . 0.0 109.81 179.684 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.448 ' O ' ' CD ' ' A' ' 124' ' ' ARG . . . 121.77 -26.87 6.4 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.964 -1.255 . . . . 0.0 109.964 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -83.94 65.8 8.84 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.927 -1.337 . . . . 0.0 110.201 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.481 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 24.1 m-85 -119.38 144.36 46.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.23 -0.919 . . . . 0.0 110.339 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -78.95 -31.66 45.18 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.694 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -161.56 163.15 30.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.294 -0.879 . . . . 0.0 110.768 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.523 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.45 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.271 -0.893 . . . . 0.0 110.08 179.27 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.427 ' CD1' HG22 ' A' ' 33' ' ' ILE . 3.0 mp -93.41 119.18 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.276 -0.89 . . . . 0.0 109.14 179.349 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -128.47 160.58 31.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.121 -0.987 . . . . 0.0 111.599 -178.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.438 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.96 -5.14 31.14 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 177.452 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.15 14.02 1.38 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.285 -0.884 . . . . 0.0 111.723 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m -141.61 127.94 19.91 Favored 'General case' 0 C--N 1.307 -1.242 0 O-C-N 120.678 -1.264 . . . . 0.0 109.043 179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.478 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -109.18 124.43 50.83 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.304 -0.873 . . . . 0.0 110.657 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 58.23 34.73 24.38 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.348 -0.845 . . . . 0.0 111.262 179.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.85 -33.94 4.78 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.841 -1.171 . . . . 0.0 110.342 179.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -86.21 155.29 57.6 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.158 -1.201 . . . . 0.0 110.067 -179.858 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -64.91 138.49 57.76 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 123.366 1.193 . . . . 0.0 110.747 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -50.32 156.7 0.8 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.545 -0.722 . . . . 0.0 110.99 -179.439 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.428 ' OD2' ' CG2' ' A' ' 113' ' ' VAL . 6.8 p-10 -73.82 162.88 28.65 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.558 -0.714 . . . . 0.0 110.287 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.429 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.24 -44.8 92.33 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.877 -1.14 . . . . 0.0 111.6 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.428 ' CG2' ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.76 -30.66 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.716 -1.24 . . . . 0.0 112.74 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.482 ' O ' ' N ' ' A' ' 118' ' ' ARG . 2.6 p -53.6 -55.25 27.39 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.449 -1.407 . . . . 0.0 110.162 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.429 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.64 -35.33 75.92 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.048 178.435 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.405 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 26.2 m -62.07 -50.35 72.32 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 119.369 -0.932 . . . . 0.0 108.581 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.25 -46.83 39.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.322 -0.861 . . . . 0.0 109.982 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.482 ' N ' ' O ' ' A' ' 114' ' ' SER . 60.2 mtt180 -61.3 -45.29 95.06 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.268 -0.895 . . . . 0.0 110.967 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.506 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 11.9 ttm180 -55.55 -38.68 69.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.694 -1.254 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.78 0.28 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.61 -50.81 0.24 Allowed 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.468 -1.019 . . . . 0.0 108.632 179.666 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.45 ' CG2' HD11 ' A' ' 10' ' ' ILE . 11.9 t -94.79 142.35 27.57 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.484 1.891 0 C-N-CA 119.335 -1.412 . . . . 0.0 110.574 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.448 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -62.2 86.19 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.883 -1.363 . . . . 0.0 109.931 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.89 -43.01 1.75 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.457 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 12.9 mttt -111.0 -171.68 0.22 Allowed Pre-proline 0 N--CA 1.487 1.392 0 O-C-N 121.611 -0.935 . . . . 0.0 109.454 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.457 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.9 Cg_endo -90.75 107.79 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.61 1.321 . . . . 0.0 109.786 179.044 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.442 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.33 166.07 50.92 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 4.0 mt -119.55 140.49 43.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.227 179.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.523 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.6 t80 -128.73 114.93 17.21 Favored 'General case' 0 C--N 1.3 -1.585 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.139 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.8 mtt180 -99.38 134.28 42.48 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 109.665 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.474 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.16 148.26 50.59 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.157 -0.964 . . . . 0.0 109.803 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.438 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.1 t -79.89 -54.16 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.068 -1.02 . . . . 0.0 110.042 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -89.5 134.98 31.52 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.218 -0.926 . . . . 0.0 110.121 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.23 -51.87 0.13 Allowed 'Trans proline' 0 C--N 1.311 -1.398 0 O-C-N 123.533 1.28 . . . . 0.0 110.373 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.31 -69.34 0.42 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 53.47 96.32 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.25 -1.147 . . . . 0.0 110.077 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 117.925 -1.036 . . . . 0.0 110.195 -179.885 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.2 m -115.02 128.33 56.2 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -1.155 . . . . 0.0 110.239 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 63.6 t -113.19 104.21 16.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.262 -0.899 . . . . 0.0 110.174 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.404 ' CG2' ' OG1' ' A' ' 116' ' ' THR . 69.1 p -72.16 146.1 47.63 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.497 -0.752 . . . . 0.0 110.108 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.433 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -66.47 148.42 98.61 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.18 -0.95 . . . . 0.0 109.75 -179.867 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.536 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 41.9 Cg_endo -80.3 -59.74 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.442 0 O-C-N 124.21 1.637 . . . . 0.0 112.392 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.536 ' CD2' ' O ' ' A' ' 6' ' ' PRO . 20.4 p80 39.3 89.28 0.08 OUTLIER Pre-proline 0 N--CA 1.492 1.655 0 CA-C-O 121.063 0.458 . . . . 0.0 111.466 -178.347 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -74.7 57.26 4.31 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.289 1.152 . . . . 0.0 110.925 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 31.8 m120 -119.95 -18.82 8.09 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.264 -0.897 . . . . 0.0 110.29 179.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.518 HD12 ' O ' ' A' ' 122' ' ' THR . 62.2 mt -108.75 136.64 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.044 -1.035 . . . . 0.0 110.141 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.43 127.94 34.1 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.188 -0.945 . . . . 0.0 109.25 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.72 135.66 33.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.159 -0.963 . . . . 0.0 110.185 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.8 t -137.22 156.41 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.286 -0.884 . . . . 0.0 110.423 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.33 113.83 26.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 0.0 109.83 179.529 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.4 ' CD2' ' HB3' ' A' ' 26' ' ' LYS . 8.8 tp -52.78 142.58 18.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.161 -0.962 . . . . 0.0 110.111 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 p -138.22 174.36 10.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.262 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.2 71.91 1.71 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.289 -0.882 . . . . 0.0 109.969 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.435 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.4 m -144.19 110.15 5.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 110.513 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.451 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.77 -171.44 26.75 Favored Glycine 0 N--CA 1.488 2.145 0 C-N-CA 118.876 -1.631 . . . . 0.0 110.859 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -108.95 -26.18 10.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.65 -0.912 . . . . 0.0 110.394 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.499 HG22 ' O ' ' A' ' 28' ' ' ILE . 8.0 tt -95.27 101.53 7.69 Favored Pre-proline 0 N--CA 1.487 1.403 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.357 -179.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.403 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 36.5 Cg_endo -61.29 155.29 52.6 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.516 1.272 . . . . 0.0 110.228 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.589 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.75 94.48 0.5 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.091 -1.005 . . . . 0.0 111.309 -178.024 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.589 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 60.0 68.28 0.79 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.407 -0.808 . . . . 0.0 111.673 178.808 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 14.6 11.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 21.4 mmtt -130.73 156.69 44.52 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.082 -1.246 . . . . 0.0 109.2 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.413 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.24 108.07 16.11 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.986 -1.071 . . . . 0.0 109.086 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.499 ' O ' HG22 ' A' ' 21' ' ' ILE . 5.1 mt -71.31 113.33 18.47 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.117 -179.384 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.451 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 43.0 Cg_endo -71.04 129.69 16.64 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.053 -1.941 . . . . 0.0 107.053 176.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.445 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 7.8 mt -55.77 -18.82 9.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.808 -1.182 . . . . 0.0 110.545 -177.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -15.97 23.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.628 -1.295 . . . . 0.0 110.332 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.435 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 16.2 m -93.36 -25.36 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.882 -1.136 . . . . 0.0 111.057 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.532 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 21.4 pt -117.9 -16.17 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.01 -1.056 . . . . 0.0 110.923 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.445 ' HB3' ' O ' ' A' ' 30' ' ' LEU . 0.4 OUTLIER -97.82 148.49 23.34 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.844 -1.16 . . . . 0.0 110.083 179.534 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.17 -4.14 51.81 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.65 -159.08 23.37 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.347 -1.406 . . . . 0.0 110.082 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.89 133.45 44.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.275 -1.132 . . . . 0.0 110.547 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.532 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.76 147.01 40.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.098 -1.001 . . . . 0.0 110.703 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.459 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 60.2 tp -108.54 113.74 27.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.417 -0.802 . . . . 0.0 109.998 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.467 HG23 HD11 ' A' ' 40' ' ' ILE . 25.9 mt -96.54 126.89 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.341 -0.85 . . . . 0.0 109.409 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.459 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 34.0 m-85 -95.23 123.75 38.9 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.41 -0.806 . . . . 0.0 109.978 -179.587 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.01 160.23 21.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.192 -0.943 . . . . 0.0 110.606 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.545 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 4.3 p-80 -107.18 -3.81 19.46 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.439 -0.788 . . . . 0.0 110.175 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.65 50.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.066 -1.021 . . . . 0.0 110.779 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.496 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.53 -41.38 69.24 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.81 -0.556 . . . . 0.0 110.646 -179.765 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mttp -58.79 -35.27 72.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.195 -0.941 . . . . 0.0 110.109 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.401 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.26 -34.86 66.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.347 -0.846 . . . . 0.0 109.427 179.656 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.407 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 91.9 m -60.7 -34.23 74.05 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.511 -0.743 . . . . 0.0 109.58 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.06 -49.16 63.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.17 -0.956 . . . . 0.0 110.246 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.7 -42.68 67.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.258 -0.901 . . . . 0.0 110.599 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.401 ' HB2' ' O ' ' A' ' 47' ' ' LYS . 1.1 tm? -57.23 -41.1 78.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.427 -0.796 . . . . 0.0 111.295 -179.018 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.95 -51.48 12.33 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.874 -1.141 . . . . 0.0 110.528 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.6 89.78 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.996 -1.065 . . . . 0.0 109.48 179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.43 ' CD ' HG13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.98 -45.77 86.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.475 -0.766 . . . . 0.0 109.559 179.337 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.494 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.83 -42.0 75.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 109.898 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.8 t -56.35 -33.71 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.091 -1.006 . . . . 0.0 109.181 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -32.05 61.01 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.32 -0.862 . . . . 0.0 109.863 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.457 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.0 mm? -71.69 -26.2 62.41 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.379 -0.826 . . . . 0.0 109.529 179.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.52 6.09 8.94 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.474 HG22 HG23 ' A' ' 81' ' ' VAL . 30.6 mt -108.25 143.72 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.254 -1.145 . . . . 0.0 110.143 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.423 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.3 t30 -87.07 107.3 18.38 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.302 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.494 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -121.22 147.33 45.76 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.744 -177.274 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.479 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -134.75 150.0 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.916 -0.714 . . . . 0.0 109.326 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.47 136.4 52.83 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.011 179.078 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.461 ' CG ' HD13 ' A' ' 88' ' ' LEU . 7.1 t80 -123.47 128.12 49.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.911 . . . . 0.0 110.742 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.502 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.12 -179.94 8.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.515 -0.741 . . . . 0.0 109.858 179.63 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.73 11.0 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.238 -0.913 . . . . 0.0 111.012 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.76 47.73 19.39 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.502 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.9 tm? -116.96 153.02 33.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.058 -1.26 . . . . 0.0 109.608 179.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.453 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 5.4 m-20 -89.55 148.25 23.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.219 -0.925 . . . . 0.0 110.994 -178.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.415 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.5 m -63.2 111.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.102 -0.999 . . . . 0.0 109.235 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.404 ' CB ' HG12 ' A' ' 63' ' ' VAL . 18.1 m -132.58 -38.31 1.03 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.266 -0.896 . . . . 0.0 110.488 -179.486 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.479 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 64.6 t -48.19 137.3 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.388 -0.82 . . . . 0.0 110.464 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -137.0 91.77 14.7 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.305 -0.872 . . . . 0.0 110.298 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -79.83 55.69 5.74 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 O-C-N 123.707 1.372 . . . . 0.0 110.387 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.8 t -156.13 31.91 0.34 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.171 -0.956 . . . . 0.0 110.46 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -128.95 -164.75 1.43 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.179 -0.95 . . . . 0.0 110.075 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.57 -73.65 0.34 Allowed Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -149.26 109.36 4.12 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.212 -1.169 . . . . 0.0 110.024 179.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.44 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.1 p -117.06 134.8 59.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 122.014 0.911 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.474 HG23 HG22 ' A' ' 60' ' ' ILE . 11.4 m -112.6 125.76 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.334 -0.854 . . . . 0.0 109.02 179.127 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.453 HG21 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -97.39 118.34 43.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 120.935 -1.103 . . . . 0.0 110.037 -178.282 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.4 m -112.64 100.09 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.027 -1.046 . . . . 0.0 108.806 179.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.0 162.23 36.0 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.613 -1.304 . . . . 0.0 111.521 -178.079 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -87.01 -143.95 0.12 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.678 -0.639 . . . . 0.0 109.353 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -73.9 -4.62 36.12 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.926 -1.109 . . . . 0.0 110.782 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.405 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -61.65 -40.05 93.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.144 . . . . 0.0 110.502 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.461 HD13 ' CG ' ' A' ' 65' ' ' TYR . 0.8 OUTLIER -69.67 -46.98 64.86 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.107 -0.996 . . . . 0.0 109.844 179.921 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.457 ' O ' ' N ' ' A' ' 91' ' ' GLY . 0.4 OUTLIER 53.1 21.91 2.33 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.356 -0.84 . . . . 0.0 110.088 -179.744 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 62.35 -72.75 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.581 -0.699 . . . . 0.0 110.709 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 54.63 -98.65 0.05 OUTLIER Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.529 ' O ' ' CD2' ' A' ' 92' ' ' PHE . 46.6 p90 -88.98 48.43 1.63 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.258 -1.143 . . . . 0.0 109.592 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.482 HG23 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -151.65 -146.16 0.19 Allowed 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.375 -0.828 . . . . 0.0 109.951 -179.628 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 111.51 -30.64 7.71 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 179.574 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.17 80.99 9.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.211 -1.17 . . . . 0.0 110.421 -179.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.482 ' CZ ' HG23 ' A' ' 93' ' ' THR . 21.9 m-85 -119.42 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.109 -0.994 . . . . 0.0 109.726 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.422 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.99 -35.59 80.7 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.142 -0.973 . . . . 0.0 109.067 179.538 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.59 31.79 Favored 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.741 -0.784 . . . . 0.0 110.863 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.493 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.12 117.6 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.453 -0.78 . . . . 0.0 110.571 179.837 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.444 ' CD1' ' N ' ' A' ' 100' ' ' ILE . 2.9 mp -93.1 112.59 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.29 161.1 21.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.115 -0.99 . . . . 0.0 111.912 -178.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.485 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.1 p -102.83 6.57 39.29 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.068 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m120 45.86 25.4 0.29 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.238 -0.913 . . . . 0.0 111.349 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.9 p -146.91 128.89 15.47 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.921 . . . . 0.0 110.028 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.4 p -114.4 134.6 54.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.073 -1.017 . . . . 0.0 110.381 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 29.0 t0 54.07 26.98 7.01 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.243 -0.911 . . . . 0.0 110.385 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.41 -31.51 6.36 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.73 155.91 77.96 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.136 -1.214 . . . . 0.0 110.115 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -66.63 133.52 32.23 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 O-C-N 123.637 1.335 . . . . 0.0 110.319 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.421 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER -47.91 163.98 0.05 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.318 -0.864 . . . . 0.0 110.709 -179.483 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.435 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.7 p30 -96.36 160.29 14.5 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.298 -0.876 . . . . 0.0 110.397 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.409 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.44 -48.26 37.5 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.418 -0.801 . . . . 0.0 112.001 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.435 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -71.17 -29.56 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.769 -1.207 . . . . 0.0 110.836 -178.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.48 -56.31 7.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.217 -0.927 . . . . 0.0 110.387 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.426 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.66 -34.82 76.35 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.279 -0.888 . . . . 0.0 108.715 178.705 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.404 ' OG1' ' CG2' ' A' ' 4' ' ' THR . 42.7 m -59.79 -49.82 76.24 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.064 -1.022 . . . . 0.0 108.608 178.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -73.82 -38.89 64.42 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.43 -0.794 . . . . 0.0 109.951 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 114' ' ' SER . 82.8 mtt180 -70.18 -44.29 69.05 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.262 -0.899 . . . . 0.0 110.586 -179.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.441 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 34.5 ttm180 -54.45 -36.58 64.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.222 -0.924 . . . . 0.0 110.577 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.94 -15.85 11.1 Favored Glycine 0 N--CA 1.494 2.527 0 O-C-N 120.959 -1.088 . . . . 0.0 111.524 -179.205 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -71.73 -3.58 22.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.651 -1.5 . . . . 0.0 111.485 -179.252 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.518 ' O ' HD12 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.98 143.53 48.97 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.76 -1.213 . . . . 0.0 110.9 -179.685 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 74.93 12.25 83.32 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.846 178.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.2 mtt180 -61.3 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.048 -1.266 . . . . 0.0 109.022 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.4 16.64 39.46 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -178.516 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.458 ' O ' ' CA ' ' A' ' 123' ' ' GLY . 0.2 OUTLIER -175.48 -176.48 0.26 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.472 -1.016 . . . . 0.0 108.779 -179.615 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.451 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -88.27 105.39 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.133 1.07 . . . . 0.0 109.983 179.452 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.456 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.23 173.82 25.63 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.529 -1.32 . . . . 0.0 110.198 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.468 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.28 142.94 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.486 -1.008 . . . . 0.0 109.572 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.493 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.44 114.93 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.757 -1.215 . . . . 0.0 110.389 179.4 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.427 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.55 145.68 27.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.495 -0.753 . . . . 0.0 109.484 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.7 p90 -137.89 157.08 47.14 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.906 -1.121 . . . . 0.0 110.306 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t -87.03 -34.77 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.142 -0.974 . . . . 0.0 109.656 179.451 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -128.11 159.81 64.97 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.208 -0.932 . . . . 0.0 110.32 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -73.71 -41.0 1.22 Allowed 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.778 1.409 . . . . 0.0 110.415 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 67.09 88.78 0.06 OUTLIER Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -78.47 130.79 36.45 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.242 -1.152 . . . . 0.0 110.307 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.4 mtt-85 . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.293 179.884 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.4 m -111.57 155.35 23.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.3 -1.118 . . . . 0.0 110.189 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.4 HG22 ' O ' ' A' ' 3' ' ' VAL . 27.6 m -113.34 104.01 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.221 -0.924 . . . . 0.0 109.877 179.638 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.429 ' CG2' ' OG1' ' A' ' 116' ' ' THR . 10.5 p -64.23 138.14 58.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.406 -0.809 . . . . 0.0 110.605 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.409 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.61 147.83 98.66 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.556 179.62 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.409 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.3 Cg_endo -69.91 -169.29 0.33 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 124.089 1.573 . . . . 0.0 111.057 179.512 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.542 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 6.9 p80 -177.42 82.48 0.24 Allowed Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.568 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -63.81 89.25 0.15 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 O-C-N 123.67 1.353 . . . . 0.0 110.471 -179.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 -177.24 -33.94 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.753 -0.592 . . . . 0.0 109.898 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.464 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 19.8 mt -105.28 134.83 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.856 -1.153 . . . . 0.0 110.027 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -84.93 128.28 34.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.328 -0.857 . . . . 0.0 108.893 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.43 142.74 27.39 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.043 -1.036 . . . . 0.0 110.245 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.439 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 13.3 t -136.53 157.29 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.943 -179.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.35 108.7 19.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.869 179.418 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.418 ' CD2' ' HB3' ' A' ' 26' ' ' LYS . 11.2 tp -54.98 134.35 48.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.798 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.0 p -137.97 -179.32 5.7 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.323 -0.861 . . . . 0.0 110.176 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.2 p -74.56 60.78 0.91 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -0.909 . . . . 0.0 109.988 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.452 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.8 m -131.73 111.41 11.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.892 . . . . 0.0 110.227 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.53 -162.61 27.97 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.977 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.32 -21.63 7.42 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.724 -0.868 . . . . 0.0 110.474 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.475 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.0 tt -97.39 107.1 36.8 Favored Pre-proline 0 N--CA 1.489 1.517 0 C-N-CA 118.796 -1.162 . . . . 0.0 110.24 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.426 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -63.64 155.01 65.62 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 O-C-N 123.385 1.203 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.7 t80 -169.13 91.6 0.25 Allowed 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.056 -1.027 . . . . 0.0 111.563 -178.123 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.501 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.82 67.27 0.89 Allowed 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.473 -0.767 . . . . 0.0 111.38 178.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.68 13.56 18.33 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 6.5 mmtt -130.8 156.23 45.34 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.14 -1.212 . . . . 0.0 109.08 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.452 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.81 106.92 12.56 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.896 -1.127 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.475 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.0 mt -68.47 115.1 26.44 Favored Pre-proline 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.61 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.487 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.1 Cg_endo -68.42 126.74 14.63 Favored 'Trans proline' 0 C--N 1.304 -1.813 0 N-CA-C 107.382 -1.815 . . . . 0.0 107.382 176.261 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.437 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 5.6 mt -56.08 -20.72 18.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.962 -1.086 . . . . 0.0 110.846 -177.474 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.4 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 5.2 pt-20 -59.95 -16.05 26.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.674 -1.266 . . . . 0.0 110.467 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.462 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 15.4 m -91.58 -25.33 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.005 -1.059 . . . . 0.0 110.955 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.532 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 14.7 pt -117.86 -15.49 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.963 -1.085 . . . . 0.0 110.951 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.456 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.5 tptm -98.22 147.77 24.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.809 -1.182 . . . . 0.0 110.507 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.35 -3.14 61.43 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.09 -159.45 21.29 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.23 -1.462 . . . . 0.0 110.374 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.428 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.375 -1.074 . . . . 0.0 110.543 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.532 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.11 147.86 39.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.225 -0.922 . . . . 0.0 110.918 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.4 tp -109.14 116.24 31.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.38 -0.825 . . . . 0.0 110.291 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.447 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 34.4 mt -99.89 127.77 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.132 -0.98 . . . . 0.0 109.687 179.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.05 39.55 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.327 -0.858 . . . . 0.0 109.891 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.71 159.72 21.82 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.821 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.501 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.43 -8.58 19.05 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.557 -0.714 . . . . 0.0 109.942 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.13 138.98 53.27 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.031 -1.043 . . . . 0.0 110.96 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.455 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.95 -40.37 68.73 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.315 0.579 . . . . 0.0 110.774 -179.79 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mttp -59.93 -36.49 77.13 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.369 -0.832 . . . . 0.0 111.028 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.28 71.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 -179.48 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.438 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 84.8 m -61.2 -36.36 79.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.284 -0.885 . . . . 0.0 109.302 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.45 66.85 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.267 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -73.01 -45.99 54.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.234 -0.916 . . . . 0.0 110.283 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.413 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.2 tm? -57.01 -39.72 75.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.591 -0.693 . . . . 0.0 111.267 -179.002 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.88 -51.17 13.1 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.929 -1.107 . . . . 0.0 110.54 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.127 -0.983 . . . . 0.0 109.677 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.427 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.68 83.89 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.372 -0.83 . . . . 0.0 109.526 179.379 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.473 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -54.94 -42.59 72.49 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.491 -0.756 . . . . 0.0 109.489 179.683 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.5 t -56.14 -31.02 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.99 -1.068 . . . . 0.0 108.725 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.03 -32.73 61.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.521 -0.737 . . . . 0.0 109.899 179.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.463 HD23 ' N ' ' A' ' 58' ' ' LEU . 4.3 mm? -72.1 -26.11 62.01 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-O 121.851 0.834 . . . . 0.0 109.728 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.0 9.17 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.465 HG23 HG23 ' A' ' 81' ' ' VAL . 44.7 mt -107.55 143.24 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.247 -1.149 . . . . 0.0 109.861 -179.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.423 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 50.0 t30 -87.56 106.83 18.27 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.348 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 118.774 -1.17 . . . . 0.0 111.831 -177.079 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.473 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 92.2 t -126.01 148.12 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.697 -0.627 . . . . 0.0 109.828 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -117.77 117.63 29.85 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.495 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.455 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.5 t80 -108.14 131.25 54.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 110.878 -179.264 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.505 ' CE1' HD22 ' A' ' 69' ' ' LEU . 3.0 p90 -155.34 -168.72 2.93 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.62 -0.675 . . . . 0.0 109.958 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -55.92 123.66 15.04 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.319 -0.863 . . . . 0.0 111.266 -179.256 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.56 59.02 8.76 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.505 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.66 152.05 35.98 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.074 -1.25 . . . . 0.0 109.712 179.397 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.457 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 5.2 m-20 -85.88 149.03 25.51 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.209 -0.932 . . . . 0.0 110.592 -179.276 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.431 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.0 m -62.5 110.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.133 179.178 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.9 m -131.33 -32.09 1.58 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.372 -0.83 . . . . 0.0 110.656 -179.403 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.473 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 94.9 t -53.0 131.25 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.153 -0.967 . . . . 0.0 109.441 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.431 ' CD1' ' HB2' ' A' ' 77' ' ' ASN . 1.0 OUTLIER -134.04 103.8 11.72 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.125 -0.984 . . . . 0.0 110.779 -179.263 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -87.05 43.68 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 O-C-N 123.457 1.241 . . . . 0.0 110.294 179.214 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.5 p -136.64 4.52 2.84 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.018 -1.051 . . . . 0.0 111.114 -179.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.431 ' HB2' ' CD1' ' A' ' 74' ' ' ILE . 1.6 m-80 -100.74 -169.11 1.66 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.915 -1.116 . . . . 0.0 110.291 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -54.47 -70.47 0.94 Allowed Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -144.85 113.67 6.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.202 -1.175 . . . . 0.0 110.297 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -117.43 132.44 67.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 CA-C-O 122.087 0.946 . . . . 0.0 110.456 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 11.4 m -112.45 122.05 65.95 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 121.356 -0.84 . . . . 0.0 108.96 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.436 ' CG2' HG13 ' A' ' 73' ' ' VAL . 16.1 t -97.01 120.94 46.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.684 0 O-C-N 121.054 -1.029 . . . . 0.0 110.611 -177.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.3 m -112.39 100.39 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.044 -1.035 . . . . 0.0 108.667 179.321 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.455 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.7 34.44 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -177.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -93.19 -136.68 0.18 Allowed 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -77.04 -6.16 51.63 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.679 -1.263 . . . . 0.0 111.068 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.456 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -60.71 -41.52 95.4 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.849 -1.157 . . . . 0.0 110.066 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.444 HD11 ' CB ' ' A' ' 65' ' ' TYR . 3.4 tp -64.43 -32.25 73.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 108.577 179.161 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.465 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 43.82 34.82 0.94 Allowed 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 121.244 0.545 . . . . 0.0 110.953 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.461 HG21 ' NH1' ' A' ' 121' ' ' ARG . 22.6 p 47.28 -130.31 1.49 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.708 -0.62 . . . . 0.0 110.392 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 92.98 -85.17 1.13 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 27.0 p90 -94.44 17.06 13.7 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -1.167 . . . . 0.0 109.781 179.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.435 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 14.9 t -92.53 -151.22 0.28 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.319 -0.863 . . . . 0.0 110.264 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.439 ' O ' ' CG ' ' A' ' 124' ' ' ARG . . . 94.08 -31.92 6.28 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.59 57.3 3.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.977 -1.307 . . . . 0.0 110.304 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.421 ' CE1' ' OG1' ' A' ' 93' ' ' THR . 64.0 m-85 -120.26 152.81 37.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.214 -0.929 . . . . 0.0 110.294 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.457 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.6 -28.35 30.88 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.425 -0.797 . . . . 0.0 109.831 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.6 p -160.7 163.58 32.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.283 -0.886 . . . . 0.0 110.712 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.91 128.12 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.345 -0.847 . . . . 0.0 110.138 179.441 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.1 mp -105.95 111.11 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.195 -0.94 . . . . 0.0 108.666 178.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -115.85 161.29 18.99 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.052 -1.03 . . . . 0.0 111.96 -178.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.468 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.84 -2.91 43.04 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.023 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.423 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 53.89 21.48 2.82 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.007 . . . . 0.0 110.183 -179.098 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -144.13 125.94 15.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.323 -0.86 . . . . 0.0 110.153 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.1 p -112.59 139.23 48.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.154 -0.966 . . . . 0.0 109.61 179.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.5 t70 54.74 -143.54 0.73 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.047 -1.033 . . . . 0.0 109.605 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.76 26.45 12.54 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.11 156.79 67.92 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.175 -1.191 . . . . 0.0 109.843 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -65.84 162.1 36.36 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.654 1.344 . . . . 0.0 110.523 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.408 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER -64.86 168.1 6.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.308 -0.87 . . . . 0.0 110.873 -179.329 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.411 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -105.55 161.85 14.0 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.478 -0.764 . . . . 0.0 110.323 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.404 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.8 -59.85 1.8 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.315 -0.865 . . . . 0.0 112.156 -178.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 11.4 m -64.31 -29.32 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.788 -1.195 . . . . 0.0 111.764 -178.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.411 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.34 -56.5 6.73 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.009 -1.057 . . . . 0.0 110.63 -179.015 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.446 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.58 -34.75 76.35 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.719 178.933 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.429 ' OG1' ' CG2' ' A' ' 4' ' ' THR . 29.5 m -59.13 -49.22 78.69 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.984 -1.072 . . . . 0.0 108.301 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.418 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -36.99 65.87 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.508 -0.745 . . . . 0.0 109.9 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.407 ' HB2' ' O ' ' A' ' 114' ' ' SER . 5.1 mtt180 -71.8 -44.59 63.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.042 -1.036 . . . . 0.0 111.193 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.542 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -57.35 -41.64 80.48 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.848 -1.158 . . . . 0.0 109.834 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.421 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.05 63.88 0.21 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.461 ' NH1' HG21 ' A' ' 90' ' ' THR . 10.9 mmp_? -135.38 -44.69 0.69 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.43 -1.041 . . . . 0.0 108.524 178.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.438 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 12.0 t -93.58 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.677 -0.639 . . . . 0.0 109.732 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.08 3.23 36.13 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.617 179.058 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.439 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 2.8 mmt180 -62.71 87.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.965 -1.315 . . . . 0.0 109.511 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.51 19.13 33.29 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -178.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.454 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 16.4 ptpt -176.23 -178.31 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.491 -1.005 . . . . 0.0 108.503 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.5 Cg_endo -89.16 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.254 1.134 . . . . 0.0 110.428 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.438 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.85 176.72 54.59 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.772 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.434 ' N ' HG22 ' A' ' 122' ' ' THR . 3.5 mp -132.52 143.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.764 -0.845 . . . . 0.0 109.043 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.476 ' CD2' ' HG3' ' A' ' 119' ' ' ARG . 9.6 t80 -129.95 115.52 17.28 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.24 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.439 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 6.5 mtt180 -105.98 131.42 53.29 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.522 -0.736 . . . . 0.0 109.435 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -129.63 157.29 42.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.042 -1.036 . . . . 0.0 110.376 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 42.8 t -76.08 -60.39 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.104 -0.997 . . . . 0.0 109.923 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.423 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -111.14 146.81 35.29 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.154 -0.967 . . . . 0.0 110.317 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.99 -51.05 0.15 Allowed 'Trans proline' 0 C--N 1.311 -1.4 0 O-C-N 123.81 1.426 . . . . 0.0 110.432 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 62.7 85.6 0.05 OUTLIER Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -94.93 81.99 3.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.23 -1.159 . . . . 0.0 110.326 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.3 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.2 139.3 50.09 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -1.155 . . . . 0.0 110.24 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 59.6 t -112.83 104.28 16.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.239 -0.913 . . . . 0.0 109.822 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.1 p -69.12 138.23 54.07 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.479 -0.763 . . . . 0.0 110.185 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.414 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.82 146.25 98.3 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.257 -0.902 . . . . 0.0 109.523 179.72 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.429 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 46.2 Cg_endo -72.69 -174.28 1.44 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.978 1.515 . . . . 0.0 110.51 179.204 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.485 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 175.85 76.79 0.08 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.481 -0.762 . . . . 0.0 109.887 -179.61 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -75.25 53.98 3.61 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.76 1.4 . . . . 0.0 111.1 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.0 m-80 -138.45 8.31 2.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.002 -1.061 . . . . 0.0 110.346 179.562 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.431 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 36.2 mt -128.05 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.187 -0.945 . . . . 0.0 109.413 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.97 128.45 34.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.139 -0.976 . . . . 0.0 109.305 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.06 133.09 34.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.206 -0.933 . . . . 0.0 110.429 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.459 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 16.5 t -128.66 156.11 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.403 -0.811 . . . . 0.0 110.021 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.61 110.9 21.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.252 -0.905 . . . . 0.0 109.968 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.424 HD21 ' CG2' ' A' ' 133' ' ' VAL . 11.7 tp -58.84 134.21 56.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.275 -0.891 . . . . 0.0 109.581 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.9 p -138.78 -175.19 4.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.24 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.5 p -77.75 81.3 4.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.264 -0.897 . . . . 0.0 109.896 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.436 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 27.8 m -153.64 109.5 3.27 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.297 -0.877 . . . . 0.0 110.656 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.469 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.74 -165.08 28.07 Favored Glycine 0 N--CA 1.487 2.044 0 C-N-CA 119.072 -1.537 . . . . 0.0 110.567 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.7 -21.83 8.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.647 -0.914 . . . . 0.0 110.275 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.485 HG22 HD12 ' A' ' 21' ' ' ILE . 6.6 tt -96.19 110.69 53.55 Favored Pre-proline 0 N--CA 1.487 1.407 0 C-N-CA 118.8 -1.16 . . . . 0.0 109.91 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.63 155.39 67.07 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.684 1.36 . . . . 0.0 110.285 -179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.4 t80 -169.5 94.06 0.28 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.112 -0.993 . . . . 0.0 111.508 -178.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.583 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 24.9 m-85 58.38 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.393 -0.817 . . . . 0.0 111.497 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.44 14.76 9.61 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.431 -1.067 . . . . 0.0 110.431 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.8 156.8 44.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.041 -1.27 . . . . 0.0 109.418 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.7 107.35 15.34 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 120.967 -1.083 . . . . 0.0 109.5 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.475 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.3 mt -69.56 113.9 20.46 Favored Pre-proline 0 C--N 1.299 -1.6 0 O-C-N 121.383 -0.823 . . . . 0.0 110.215 -179.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.469 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 42.8 Cg_endo -70.27 129.73 17.54 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 N-CA-C 107.189 -1.889 . . . . 0.0 107.189 176.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.431 ' CD2' HD12 ' A' ' 33' ' ' ILE . 17.6 mt -56.33 -18.19 10.07 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.874 -1.141 . . . . 0.0 110.94 -177.659 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.49 -16.47 24.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.636 -1.29 . . . . 0.0 110.087 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.431 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 14.4 m -93.96 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.155 -0.966 . . . . 0.0 110.981 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.537 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 40.9 pt -118.15 -22.79 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.934 -1.104 . . . . 0.0 110.872 -178.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.476 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.26 22.16 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.506 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.02 -5.27 59.35 Favored Glycine 0 N--CA 1.483 1.82 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.22 -162.58 27.81 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.678 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.22 129.38 44.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.468 -1.019 . . . . 0.0 110.351 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.537 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.5 m-70 -138.93 145.59 40.01 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.222 -0.924 . . . . 0.0 110.607 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.476 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 38.3 tp -108.06 117.17 33.43 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.431 ' CD1' HG22 ' A' ' 33' ' ' ILE . 10.5 mm -94.03 125.69 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.275 -0.891 . . . . 0.0 108.601 179.26 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.476 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 11.4 m-85 -94.21 121.81 36.11 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.089 -1.007 . . . . 0.0 109.637 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.46 150.69 39.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.271 -0.893 . . . . 0.0 110.83 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.583 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 2.4 p-80 -103.74 3.59 34.33 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 109.682 178.442 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.55 135.39 45.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.186 -0.946 . . . . 0.0 110.199 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.428 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.4 ttpt -71.28 -37.2 71.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.609 -0.682 . . . . 0.0 110.735 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.7 -37.03 80.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.315 -0.866 . . . . 0.0 110.775 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 4.3 tptm -72.6 -36.33 68.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 110.015 -179.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.441 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 71.1 m -60.4 -34.23 73.63 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.475 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.72 -49.15 56.07 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 110.538 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.429 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.43 -41.71 69.17 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.147 -0.971 . . . . 0.0 110.583 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.448 ' CD1' HG13 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.9 80.41 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 111.282 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.11 -51.0 43.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.934 -1.104 . . . . 0.0 110.175 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.88 -31.76 65.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.209 -0.932 . . . . 0.0 109.123 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.479 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.83 -47.06 85.05 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 179.358 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.496 ' CB ' ' HB3' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -60.99 -41.42 96.46 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.279 -0.888 . . . . 0.0 111.053 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.0 t -56.38 -33.93 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.868 -1.145 . . . . 0.0 109.227 179.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -34.83 60.3 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.318 -0.864 . . . . 0.0 110.482 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.479 HD22 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.32 -25.57 62.47 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.409 -0.807 . . . . 0.0 109.833 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.31 8.9 8.25 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.476 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 36.5 mt -108.34 143.73 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.338 -1.095 . . . . 0.0 109.666 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.413 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.6 t30 -90.07 106.75 18.69 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.23 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.496 ' HB3' ' CB ' ' A' ' 55' ' ' LEU . . . -119.59 145.96 45.94 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.508 -176.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.474 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.64 149.36 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.52 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.43 128.29 56.4 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.711 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.461 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 12.9 t80 -119.96 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.384 -0.823 . . . . 0.0 110.094 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.477 ' CZ ' HD22 ' A' ' 69' ' ' LEU . 2.7 p90 -167.76 -178.27 3.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.521 -0.737 . . . . 0.0 109.776 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.13 116.78 3.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.175 -0.953 . . . . 0.0 110.617 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.69 36.12 7.5 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.477 HD22 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.68 156.88 27.44 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.191 -1.182 . . . . 0.0 110.122 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.436 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 33.7 m-20 -97.41 149.01 22.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.284 -0.885 . . . . 0.0 110.088 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.422 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 33.7 m -62.45 111.28 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 C-N-CA 119.261 -0.976 . . . . 0.0 109.207 179.245 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.466 ' CB ' HG13 ' A' ' 63' ' ' VAL . 27.4 m -130.16 -34.39 1.66 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.366 -0.834 . . . . 0.0 110.731 -179.459 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.474 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 50.7 t -49.88 151.77 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.225 -0.922 . . . . 0.0 109.459 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.406 ' CG1' ' O ' ' A' ' 74' ' ' ILE . 1.0 OUTLIER -131.31 100.29 16.91 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 120.781 -1.199 . . . . 0.0 111.523 -178.945 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -81.7 59.83 7.36 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.632 1.332 . . . . 0.0 109.889 179.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.425 ' O ' ' HB2' ' A' ' 77' ' ' ASN . 4.7 t -135.88 61.78 1.64 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.463 -0.773 . . . . 0.0 109.311 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.428 ' N ' ' OD1' ' A' ' 77' ' ' ASN . 3.2 m-20 62.74 -154.13 0.34 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.831 -0.543 . . . . 0.0 110.033 -179.33 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 63.68 151.36 0.05 OUTLIER Glycine 0 N--CA 1.489 2.227 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.44 94.04 6.12 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.95 -1.324 . . . . 0.0 110.242 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.432 ' O ' HG12 ' A' ' 80' ' ' VAL . 4.9 p -117.25 131.07 71.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 122.062 0.935 . . . . 0.0 110.057 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.478 HG23 ' CB ' ' A' ' 62' ' ' ALA . 6.2 m -112.95 121.36 65.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.418 HG21 ' CG1' ' A' ' 73' ' ' VAL . 11.1 t -96.76 118.52 43.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.148 -0.97 . . . . 0.0 110.414 -177.647 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.513 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 2.9 m -109.44 100.34 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.063 -1.023 . . . . 0.0 108.79 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.461 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -143.0 161.6 37.69 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.6 -1.313 . . . . 0.0 111.108 -178.31 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.8 t -85.37 -136.97 0.07 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.493 -0.755 . . . . 0.0 109.147 179.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -82.54 -13.64 56.26 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.723 -1.235 . . . . 0.0 110.404 179.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.442 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -52.65 -41.96 64.26 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.072 -1.017 . . . . 0.0 110.339 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.421 HD13 ' CB ' ' A' ' 65' ' ' TYR . 2.4 tp -64.07 -47.87 78.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.081 -1.012 . . . . 0.0 109.769 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.418 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 54.21 20.61 2.67 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.287 -0.883 . . . . 0.0 109.937 -179.744 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.481 HG23 ' N ' ' A' ' 94' ' ' GLY . 0.1 OUTLIER 46.85 54.69 8.77 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.37 -0.831 . . . . 0.0 110.777 179.834 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.6 -67.92 1.83 Allowed Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -93.1 21.73 5.61 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.322 -1.105 . . . . 0.0 109.643 178.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.456 HG21 ' CZ ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -127.98 -167.69 1.79 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.446 -0.784 . . . . 0.0 109.817 -179.91 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.481 ' N ' HG23 ' A' ' 90' ' ' THR . . . 150.74 -51.0 0.53 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -87.3 97.36 10.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -1.154 . . . . 0.0 110.611 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.456 ' CZ ' HG21 ' A' ' 93' ' ' THR . 10.6 m-85 -116.64 151.69 35.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.331 -0.855 . . . . 0.0 109.494 179.198 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.49 -32.98 72.19 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.342 -0.943 . . . . 0.0 109.327 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.7 p -162.37 163.56 27.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.274 -0.891 . . . . 0.0 111.084 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.549 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.3 OUTLIER -130.83 112.98 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.52 -0.738 . . . . 0.0 109.886 179.343 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.2 mp -94.48 115.32 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.217 -0.927 . . . . 0.0 109.166 179.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -127.99 161.12 29.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 111.504 -178.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.434 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.7 t -90.94 -9.1 47.36 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 57.35 13.74 1.88 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.293 -0.879 . . . . 0.0 111.662 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.2 m -144.06 109.95 5.31 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 120.777 -1.202 . . . . 0.0 108.992 179.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.459 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -86.82 128.76 35.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.316 -0.865 . . . . 0.0 111.093 -179.307 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.9 t70 54.34 34.34 20.43 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.425 -0.797 . . . . 0.0 111.272 179.208 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.6 -14.9 54.21 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.314 179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 105' ' ' SER . 10.6 mttt -98.08 156.58 35.74 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 120.929 -1.336 . . . . 0.0 109.743 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -62.51 127.3 20.45 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.524 1.276 . . . . 0.0 110.473 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.48 157.42 0.06 Allowed 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.591 0.71 . . . . 0.0 111.239 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.442 ' O ' ' OG ' ' A' ' 114' ' ' SER . 4.4 p-10 -73.25 162.49 29.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.501 -0.749 . . . . 0.0 109.971 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.16 -42.61 91.15 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.884 -1.135 . . . . 0.0 111.62 -178.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.433 ' CG2' ' OD2' ' A' ' 111' ' ' ASP . 6.7 m -72.59 -30.86 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 120.784 -1.198 . . . . 0.0 113.031 -178.001 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.74 -55.76 20.44 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.474 -1.391 . . . . 0.0 110.3 -178.766 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -62.88 -34.71 77.97 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 118.695 -1.202 . . . . 0.0 108.225 178.327 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 24.6 m -61.46 -50.7 71.72 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.89 41.91 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.832 . . . . 0.0 109.6 178.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 25.2 mtt180 -59.59 -45.14 92.78 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.287 -0.883 . . . . 0.0 110.405 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.496 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 20.1 ttm180 -62.68 -34.59 77.41 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.734 -1.229 . . . . 0.0 110.071 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.427 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.78 -5.36 31.06 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 119.998 -1.096 . . . . 0.0 111.12 -179.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.449 ' CG ' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -87.95 -4.96 58.77 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.656 -1.496 . . . . 0.0 110.96 -179.823 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.47 ' CG2' ' CG2' ' A' ' 99' ' ' VAL . 0.5 OUTLIER -118.72 140.36 50.06 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.859 -1.151 . . . . 0.0 109.442 179.535 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.01 19.6 39.17 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.427 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 10.2 mmt85 -69.39 85.98 0.42 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.033 -1.275 . . . . 0.0 109.806 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.05 57.82 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.437 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.41 -174.8 0.39 Allowed Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.202 -1.175 . . . . 0.0 109.016 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -85.22 103.33 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.36 1.19 . . . . 0.0 109.438 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.406 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -86.98 173.25 44.72 Favored Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.046 -179.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.4 mt -122.18 142.92 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -1.056 . . . . 0.0 109.54 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.7 t80 -127.02 115.34 19.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.166 -0.959 . . . . 0.0 110.178 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.431 ' CZ ' HG13 ' A' ' 32' ' ' VAL . 10.6 mtt85 -105.65 135.26 47.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.353 -0.842 . . . . 0.0 109.476 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.2 147.0 45.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.153 -0.967 . . . . 0.0 110.552 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.434 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 54.4 t -69.22 -55.59 14.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.829 179.735 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -118.85 159.26 45.23 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.217 -0.927 . . . . 0.0 110.312 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.423 ' HG2' ' CB ' ' A' ' 138' ' ' ARG . 44.6 Cg_endo -72.17 -23.11 21.57 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 O-C-N 123.719 1.378 . . . . 0.0 110.374 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 115.47 -64.58 0.31 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -83.65 -48.95 9.65 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.188 -1.184 . . . . 0.0 110.169 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.423 ' CB ' ' HG2' ' A' ' 135' ' ' PRO . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.141 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.3 p -104.04 106.88 17.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 0.0 110.279 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.7 p -113.32 103.92 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 O-C-N 121.29 -0.881 . . . . 0.0 109.881 179.627 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.1 p -75.19 142.68 43.45 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.222 -0.924 . . . . 0.0 110.324 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.427 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.8 146.91 97.8 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.21 -0.932 . . . . 0.0 109.635 179.604 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.427 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.4 Cg_endo -71.97 -168.58 0.38 Allowed 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.17 1.616 . . . . 0.0 110.456 179.167 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.549 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.6 OUTLIER -173.67 81.87 0.38 Allowed Pre-proline 0 C--N 1.302 -1.457 0 O-C-N 121.531 -0.731 . . . . 0.0 109.547 179.565 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.415 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 39.8 Cg_endo -67.05 87.83 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.387 1.204 . . . . 0.0 110.999 -179.138 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.465 ' ND2' ' N ' ' A' ' 9' ' ' ASN . 0.1 OUTLIER 171.79 -5.76 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.382 0 O-C-N 121.45 -0.781 . . . . 0.0 112.448 179.251 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.511 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 12.7 mt -124.32 135.62 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.131 -1.606 . . . . 0.0 109.562 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.88 128.74 34.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.316 -0.865 . . . . 0.0 109.801 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.36 140.93 29.01 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.194 -0.941 . . . . 0.0 109.882 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.426 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 6.5 t -134.78 153.97 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.224 -0.923 . . . . 0.0 110.467 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.59 18.6 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.325 -0.859 . . . . 0.0 109.552 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.8 tp -56.08 136.63 52.29 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.29 -0.881 . . . . 0.0 109.778 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.42 -167.58 1.99 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 110.288 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.2 p -88.3 73.24 8.88 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' HB1' ' A' ' 27' ' ' ALA . 7.3 m -146.04 112.37 5.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 110.48 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.34 -165.35 27.87 Favored Glycine 0 N--CA 1.489 2.204 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.831 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.59 -21.57 9.08 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.61 -0.936 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.466 HG21 ' O ' ' A' ' 28' ' ' ILE . 9.1 tt -98.85 105.69 32.76 Favored Pre-proline 0 N--CA 1.488 1.46 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.179 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -62.95 155.0 63.13 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.225 1.118 . . . . 0.0 109.66 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.457 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.2 t80 -167.55 93.61 0.41 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.062 -1.024 . . . . 0.0 111.576 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.479 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 25.5 m-85 59.38 67.04 0.94 Allowed 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.571 -0.705 . . . . 0.0 111.554 179.06 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.09 13.81 15.82 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.84 156.89 44.25 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.105 -1.233 . . . . 0.0 109.039 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.44 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -118.06 107.92 14.59 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.789 -1.194 . . . . 0.0 109.675 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.466 ' O ' HG21 ' A' ' 21' ' ' ILE . 4.5 mt -70.89 114.15 24.6 Favored Pre-proline 0 C--N 1.299 -1.62 0 O-C-N 121.411 -0.806 . . . . 0.0 110.637 -179.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.453 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 39.3 Cg_endo -68.91 128.42 16.79 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 N-CA-C 106.906 -1.998 . . . . 0.0 106.906 176.181 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.439 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 6.9 mt -55.91 -18.94 10.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.914 -1.116 . . . . 0.0 110.678 -177.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.51 -16.29 23.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.714 -1.241 . . . . 0.0 110.296 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.432 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 13.1 m -92.24 -25.43 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 120.968 -1.082 . . . . 0.0 111.228 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.534 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 8.9 pt -117.9 -18.53 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.985 -1.072 . . . . 0.0 110.662 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.453 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 9.7 tptt -96.24 148.92 22.22 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.931 -1.106 . . . . 0.0 110.417 179.534 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.84 56.7 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.8 -159.22 21.81 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.239 -1.457 . . . . 0.0 110.091 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.6 mtt85 -100.61 130.65 46.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.404 -1.057 . . . . 0.0 110.603 -179.571 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.534 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.2 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 110.505 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.418 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 14.0 tp -109.49 120.96 44.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 110.301 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.438 ' CG1' HG13 ' A' ' 83' ' ' VAL . 12.3 mm -99.72 125.58 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.194 -0.941 . . . . 0.0 109.283 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.481 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.3 123.05 38.62 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.098 -1.001 . . . . 0.0 109.709 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.24 157.89 25.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.239 -0.913 . . . . 0.0 110.857 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.479 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 0.7 OUTLIER -105.75 8.14 32.79 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.412 -0.805 . . . . 0.0 109.967 178.939 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.46 139.65 40.75 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.172 -0.955 . . . . 0.0 110.346 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.93 -38.11 69.92 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 110.783 -179.683 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.93 -37.26 86.74 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.759 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.91 -35.98 82.9 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.765 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.431 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 66.2 m -60.2 -34.34 73.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.407 -0.808 . . . . 0.0 109.039 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.03 -48.83 64.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.191 -0.943 . . . . 0.0 110.25 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.0 mt-10 -71.46 -45.59 62.18 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.198 -0.939 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.422 ' CD1' HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.42 -41.38 76.27 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.373 -0.83 . . . . 0.0 111.338 -178.926 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.415 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.36 -50.92 14.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 110.363 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.73 -41.62 99.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 109.446 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.434 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 0.0 OUTLIER -58.4 -46.16 86.95 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.346 -0.846 . . . . 0.0 109.433 179.341 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.41 -42.93 78.81 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.487 -0.758 . . . . 0.0 110.236 179.853 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.9 -33.43 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.073 -1.017 . . . . 0.0 109.166 179.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.61 -31.48 59.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.323 -0.861 . . . . 0.0 110.004 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.467 HD23 ' N ' ' A' ' 58' ' ' LEU . 3.9 mm? -72.07 -26.54 62.21 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.893 0.854 . . . . 0.0 109.601 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.03 6.3 8.45 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.46 HG22 HG21 ' A' ' 81' ' ' VAL . 35.1 mt -107.86 143.87 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -1.14 . . . . 0.0 110.144 -179.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.415 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 15.8 t30 -88.02 106.45 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.364 -1.717 . . . . 0.0 106.364 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -116.69 141.67 47.9 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.671 -177.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.495 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 87.4 t -124.27 147.9 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.998 -0.681 . . . . 0.0 109.69 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -115.47 127.04 55.04 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.822 178.503 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.448 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.71 31.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 110.57 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.481 ' CE1' HD22 ' A' ' 69' ' ' LEU . 4.7 p90 -147.78 175.08 11.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.619 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.69 5.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 110.766 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.9 37.18 10.43 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.481 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.31 155.93 28.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.115 -1.227 . . . . 0.0 109.969 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.453 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 32.3 m-20 -95.61 149.25 21.66 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.225 -0.922 . . . . 0.0 110.462 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.423 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 33.4 m -61.81 110.08 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 120.939 -1.101 . . . . 0.0 108.969 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.7 m -132.13 -9.69 3.38 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.508 -0.745 . . . . 0.0 110.953 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.495 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 40.1 t -72.27 135.12 28.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.082 -1.012 . . . . 0.0 109.305 -179.582 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.448 ' CD1' ' HB2' ' A' ' 77' ' ' ASN . 1.3 pp -137.14 104.1 8.79 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.155 -0.965 . . . . 0.0 111.235 -178.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -89.35 35.57 0.36 Allowed 'Trans proline' 0 C--N 1.312 -1.378 0 O-C-N 123.7 1.369 . . . . 0.0 110.606 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.9 t -127.8 -11.16 5.49 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.908 -1.12 . . . . 0.0 111.5 -179.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.448 ' HB2' ' CD1' ' A' ' 74' ' ' ILE . 8.1 m120 -104.82 -150.37 0.43 Allowed 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.853 -1.154 . . . . 0.0 110.37 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -53.05 174.98 0.23 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -54.86 115.81 2.39 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.133 -1.216 . . . . 0.0 110.141 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -116.06 135.42 56.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 121.966 0.889 . . . . 0.0 110.302 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.485 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 19.0 m -111.88 126.88 69.31 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 O-C-N 121.464 -0.773 . . . . 0.0 109.236 179.567 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.418 HG22 HG12 ' A' ' 73' ' ' VAL . 7.6 t -97.63 116.91 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.793 -1.192 . . . . 0.0 110.502 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.503 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.9 m -110.67 100.07 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.884 -1.135 . . . . 0.0 108.691 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.448 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.53 162.48 34.96 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.568 -1.332 . . . . 0.0 111.195 -178.109 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.3 t -90.8 -133.36 0.12 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.524 -0.735 . . . . 0.0 109.112 179.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 49.4 p-10 -90.02 41.74 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.583 -1.323 . . . . 0.0 110.147 179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.91 -32.09 6.5 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.62 -34.29 46.72 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.92 . . . . 0.0 108.907 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.433 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 46.44 -96.19 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.767 -0.583 . . . . 0.0 110.526 179.71 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.452 ' CB ' HG23 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.09 57.02 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.807 -1.183 . . . . 0.0 110.745 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.05 -50.14 68.39 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 108.459 -1.856 . . . . 0.0 108.459 179.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.419 ' O ' ' CD2' ' A' ' 92' ' ' PHE . 51.8 p90 -137.51 38.69 2.45 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.597 -0.943 . . . . 0.0 109.918 179.715 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.505 ' OG1' ' CZ ' ' A' ' 96' ' ' PHE . 1.3 t -98.4 -153.77 0.44 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.938 . . . . 0.0 110.634 -179.402 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' A' ' 93' ' ' THR . . . 109.75 7.56 27.39 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.74 68.87 1.1 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.783 -1.422 . . . . 0.0 110.785 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.505 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 22.6 m-85 -119.39 151.06 39.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.955 -1.09 . . . . 0.0 110.255 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.87 -28.4 20.38 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.348 -0.845 . . . . 0.0 109.417 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 p -160.87 163.33 32.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.397 -0.815 . . . . 0.0 110.675 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.15 115.39 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 110.093 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.421 HG22 ' CD1' ' A' ' 28' ' ' ILE . 3.4 mp -95.52 111.29 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.16 -0.962 . . . . 0.0 108.579 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -119.65 161.17 21.13 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.159 -0.963 . . . . 0.0 111.786 -178.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.441 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.1 t -101.84 8.5 41.28 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.715 -0.616 . . . . 0.0 109.502 178.191 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 51.66 23.75 2.09 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.113 -0.992 . . . . 0.0 111.293 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -145.13 128.71 17.09 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.17 -0.956 . . . . 0.0 109.972 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 3.8 p -113.07 134.49 54.51 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.316 -0.865 . . . . 0.0 110.189 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 54.16 41.5 31.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.182 -0.949 . . . . 0.0 110.297 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 65.15 19.77 66.41 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.409 ' HB2' ' O ' ' A' ' 105' ' ' SER . 0.9 OUTLIER -126.56 157.58 70.38 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.245 -1.15 . . . . 0.0 109.694 179.82 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -62.61 123.72 12.87 Favored 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.64 1.337 . . . . 0.0 110.196 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.475 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 -48.71 147.35 2.64 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.488 -0.757 . . . . 0.0 111.053 -179.163 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -88.45 161.12 17.21 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.298 -0.876 . . . . 0.0 110.345 179.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -46.01 -54.97 7.49 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -178.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.417 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.67 -31.89 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 120.585 -1.322 . . . . 0.0 112.685 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.475 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.41 -56.22 8.77 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.96 -1.088 . . . . 0.0 110.434 -179.266 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.463 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.74 -35.54 80.35 Favored 'General case' 0 C--O 1.205 -1.284 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.265 178.781 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.417 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.0 m -58.38 -49.2 78.08 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.541 178.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.08 -35.54 71.9 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.376 -0.827 . . . . 0.0 109.571 178.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.481 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.2 -45.18 61.41 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.239 -0.913 . . . . 0.0 110.931 -179.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.549 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 14.4 ttt180 -54.03 -45.17 71.52 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.045 -1.035 . . . . 0.0 109.995 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.58 64.19 0.29 Allowed Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.225 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.42 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.78 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.562 -0.964 . . . . 0.0 108.438 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.449 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 10.9 t -96.12 142.87 27.79 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.621 -0.674 . . . . 0.0 109.478 178.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.433 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.68 33.25 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.47 -1.348 . . . . 0.0 110.94 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.422 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -61.29 87.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.047 -1.266 . . . . 0.0 109.397 179.607 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.87 -8.33 70.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -178.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.47 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.03 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.18 -1.188 . . . . 0.0 109.265 -179.799 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.47 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -89.04 97.46 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.379 1.199 . . . . 0.0 110.601 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.449 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.24 171.09 53.01 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.7 mp -126.85 142.15 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.488 -1.007 . . . . 0.0 109.305 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -128.65 115.27 17.78 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.0 . . . . 0.0 110.314 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.426 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 4.1 mtp180 -104.73 122.8 46.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.433 -0.792 . . . . 0.0 109.17 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -121.53 157.5 30.55 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 110.415 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t -95.0 -56.01 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 63.34 146.85 0.09 OUTLIER Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.662 -0.649 . . . . 0.0 110.188 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.22 -52.08 0.19 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 123.768 1.404 . . . . 0.0 110.467 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 160.18 -151.69 22.35 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -86.42 159.19 19.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.268 -1.137 . . . . 0.0 110.173 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.176 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.3 t -83.87 146.48 28.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.199 -1.177 . . . . 0.0 110.368 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.444 ' CG1' ' O ' ' A' ' 3' ' ' VAL . 12.9 p -113.16 104.63 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.293 -0.879 . . . . 0.0 109.571 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 16.4 p -80.11 145.61 32.3 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.32 -0.863 . . . . 0.0 110.775 -179.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.478 ' O ' ' CE1' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -74.98 148.99 85.02 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.383 -0.823 . . . . 0.0 109.452 179.366 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.525 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 40.3 Cg_endo -71.16 -43.61 1.49 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 124.169 1.616 . . . . 0.0 112.839 -179.613 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.525 ' CG ' ' O ' ' A' ' 6' ' ' PRO . 13.5 p-80 41.26 85.39 0.16 Allowed Pre-proline 0 N--CA 1.498 1.94 0 O-C-N 122.128 -0.357 . . . . 0.0 110.774 -177.204 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.466 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 41.6 Cg_endo -68.3 -161.18 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.791 1.416 . . . . 0.0 110.157 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.466 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER 78.11 -35.91 0.2 Allowed 'General case' 0 N--CA 1.508 2.446 0 O-C-N 121.636 -0.665 . . . . 0.0 111.055 -179.192 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.46 HD12 ' CG2' ' A' ' 122' ' ' THR . 12.5 mt -95.79 124.92 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.574 -1.329 . . . . 0.0 109.892 179.53 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.57 128.02 34.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.138 -0.976 . . . . 0.0 109.554 179.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.97 132.95 35.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -0.943 . . . . 0.0 110.005 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.434 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 16.7 t -122.08 149.94 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.24 -0.912 . . . . 0.0 110.419 -179.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.85 21.65 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.268 -0.895 . . . . 0.0 109.706 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.457 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 9.0 tp -53.52 141.1 26.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.278 -0.889 . . . . 0.0 109.881 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.3 p -136.09 -178.49 5.17 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.253 -0.905 . . . . 0.0 110.526 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.8 p -79.74 71.19 6.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.887 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.429 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 5.9 m -146.12 112.71 5.94 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.317 -0.865 . . . . 0.0 110.424 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.47 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.81 28.42 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 118.731 -1.7 . . . . 0.0 111.173 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.62 10.4 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.783 -0.834 . . . . 0.0 110.306 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.462 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.14 107.94 41.06 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.666 -1.214 . . . . 0.0 110.098 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.413 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.5 Cg_endo -65.05 117.4 4.51 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 O-C-N 123.478 1.251 . . . . 0.0 110.645 -179.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.5 -170.79 1.8 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.649 -0.657 . . . . 0.0 110.592 -179.489 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.53 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.5 m-85 -57.73 82.26 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.552 -0.718 . . . . 0.0 111.634 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.15 -1.84 54.16 Favored Glycine 0 N--CA 1.493 2.437 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.684 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.457 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 12.1 mmtm -130.1 156.18 44.96 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.858 -1.378 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.429 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -105.83 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.94 -1.1 . . . . 0.0 109.427 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.462 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 3.9 mt -68.38 112.95 12.55 Favored Pre-proline 0 C--N 1.301 -1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 110.779 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.47 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 40.0 Cg_endo -68.26 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 N-CA-C 106.96 -1.977 . . . . 0.0 106.96 175.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.417 HD22 HD11 ' A' ' 60' ' ' ILE . 12.4 mt -56.72 -16.65 6.81 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.826 -1.171 . . . . 0.0 110.652 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.83 -15.97 36.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.686 -1.259 . . . . 0.0 110.268 179.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.477 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.1 m -91.77 -25.71 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.011 -1.056 . . . . 0.0 111.213 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.512 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 27.7 pt -118.48 -25.33 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.938 -1.101 . . . . 0.0 110.199 -179.496 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.454 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.41 148.18 22.5 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 110.648 179.828 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.87 57.77 Favored Glycine 0 N--CA 1.484 1.891 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.42 -151.27 8.74 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.127 -1.511 . . . . 0.0 110.278 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.3 mtt85 -109.74 132.37 54.21 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.53 -0.982 . . . . 0.0 110.1 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 90.9 m-70 -140.81 152.94 45.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.087 -1.008 . . . . 0.0 110.993 -179.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 54.9 tp -112.03 114.17 26.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.4 -0.812 . . . . 0.0 109.994 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.44 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 32.8 mt -98.37 129.2 48.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.594 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.4 123.82 38.04 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.304 -0.873 . . . . 0.0 109.751 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.86 158.83 23.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 110.801 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.53 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.17 4.28 20.91 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.439 -0.788 . . . . 0.0 110.023 179.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.11 137.05 38.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.058 -1.026 . . . . 0.0 110.618 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.59 -42.82 67.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.485 -0.76 . . . . 0.0 110.219 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.83 -39.21 84.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.882 . . . . 0.0 110.45 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.74 -35.11 76.69 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.404 ' O ' ' CB ' ' A' ' 64' ' ' ALA . 1.7 m -61.14 -34.1 74.47 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.537 -0.727 . . . . 0.0 109.501 179.212 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.76 -49.43 62.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.235 -0.916 . . . . 0.0 110.255 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.79 -44.64 63.64 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -0.951 . . . . 0.0 110.146 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.412 ' CD2' HD12 ' A' ' 21' ' ' ILE . 2.6 tm? -57.17 -41.65 79.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.819 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.0 -51.16 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.03 -1.044 . . . . 0.0 110.382 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.08 96.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.12 -0.988 . . . . 0.0 109.675 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.43 ' CE ' HG13 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -57.15 -44.91 83.86 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 179.485 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.468 HD22 HG22 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -55.1 -42.68 73.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.517 -0.739 . . . . 0.0 109.885 179.956 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.4 -32.09 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.007 -1.058 . . . . 0.0 108.807 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.4 -30.87 60.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.389 -0.82 . . . . 0.0 109.608 179.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.451 HD22 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -71.66 -26.17 62.43 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.833 0.825 . . . . 0.0 109.467 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.04 7.44 10.27 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.143 -1.583 . . . . 0.0 109.143 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.476 HG22 HG21 ' A' ' 81' ' ' VAL . 56.4 mt -108.26 143.24 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.277 -1.131 . . . . 0.0 110.349 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.93 107.56 17.78 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.924 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -122.01 144.62 48.78 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.019 -1.072 . . . . 0.0 111.643 -177.558 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.483 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 45.2 t -130.3 143.58 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 C-N-CA 119.976 -0.69 . . . . 0.0 109.512 179.083 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -109.49 118.36 36.41 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.95 179.094 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.445 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.65 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.26 -0.9 . . . . 0.0 110.574 -179.59 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.485 ' CD1' ' HD2' ' A' ' 45' ' ' LYS . 2.2 p90 -167.31 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.544 -0.723 . . . . 0.0 109.757 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.24 127.14 30.6 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.165 -0.96 . . . . 0.0 110.764 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.32 37.77 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.475 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.4 tm? -117.09 155.81 28.64 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.156 -1.203 . . . . 0.0 110.101 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.454 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.24 22.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.366 -0.834 . . . . 0.0 110.545 -179.351 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.42 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 29.5 m -62.1 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 119.061 -1.055 . . . . 0.0 109.002 179.229 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.72 -15.45 2.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.507 -0.746 . . . . 0.0 111.413 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.483 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.06 23.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.072 -1.017 . . . . 0.0 109.471 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.432 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.6 pp -137.33 98.8 9.98 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.261 -0.899 . . . . 0.0 111.004 -179.362 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -81.55 51.57 3.92 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 O-C-N 123.583 1.307 . . . . 0.0 110.44 179.24 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.9 p -141.89 8.97 1.92 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.943 -1.098 . . . . 0.0 111.089 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -108.64 -165.51 1.04 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.898 -1.126 . . . . 0.0 109.906 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.08 -91.86 0.01 OUTLIER Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.41 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.7 m-20 -124.23 113.67 18.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.171 -1.193 . . . . 0.0 109.998 179.475 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 8.2 p -115.06 130.91 68.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 122.152 0.977 . . . . 0.0 110.414 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.476 HG21 HG22 ' A' ' 60' ' ' ILE . 6.9 m -113.0 123.04 68.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 O-C-N 121.351 -0.843 . . . . 0.0 109.104 179.052 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.441 ' CG2' HG11 ' A' ' 73' ' ' VAL . 4.7 t -97.06 118.07 42.82 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 O-C-N 121.056 -1.028 . . . . 0.0 110.149 -177.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.498 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.9 m -111.19 100.3 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.809 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.445 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.46 162.64 34.99 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.765 -1.209 . . . . 0.0 111.122 -178.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -90.17 -139.26 0.14 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.598 -0.689 . . . . 0.0 109.4 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.41 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -86.01 48.05 1.55 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.806 -1.184 . . . . 0.0 109.99 179.706 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.425 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.24 -19.22 7.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.173 -0.955 . . . . 0.0 110.646 -179.671 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp -62.48 -23.54 66.97 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.671 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.497 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 32.4 mmt 49.89 37.23 13.13 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.412 -0.805 . . . . 0.0 110.923 179.548 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.479 ' OG1' ' CG2' ' A' ' 93' ' ' THR . 3.1 t 32.68 42.7 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.189 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 178.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.09 -38.55 88.38 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -136.24 12.42 3.29 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.489 -1.007 . . . . 0.0 110.758 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.479 ' CG2' ' OG1' ' A' ' 90' ' ' THR . 14.9 t -67.41 -158.98 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.981 -1.074 . . . . 0.0 110.478 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.432 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 90.35 -50.95 3.34 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.06 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -84.2 60.21 5.79 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.993 -1.298 . . . . 0.0 110.965 -179.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.479 ' CE2' ' HA ' ' A' ' 93' ' ' THR . 20.3 m-85 -119.74 144.86 47.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.075 -1.016 . . . . 0.0 109.918 178.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.485 ' CB ' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.21 -33.44 63.39 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.502 179.334 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.0 p -162.88 163.56 26.35 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.272 -0.892 . . . . 0.0 110.913 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.494 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.19 116.58 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.331 -0.855 . . . . 0.0 110.078 179.062 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.428 HG22 ' CD1' ' A' ' 28' ' ' ILE . 4.1 mp -93.37 118.41 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.178 -0.951 . . . . 0.0 109.031 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -126.85 160.87 29.66 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.119 -0.988 . . . . 0.0 111.454 -178.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 37.0 t -101.59 7.26 42.26 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.685 -0.634 . . . . 0.0 109.393 178.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 49.07 33.2 4.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 111.111 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.415 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p -147.52 130.36 16.14 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.877 -1.139 . . . . 0.0 110.819 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.446 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.6 p -114.0 127.69 56.06 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.253 -0.905 . . . . 0.0 109.907 179.321 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 26.9 t70 54.95 28.99 11.38 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.172 -0.955 . . . . 0.0 110.487 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.92 -36.18 3.91 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.85 156.6 82.48 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.32 -1.106 . . . . 0.0 109.966 179.873 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -64.75 138.96 60.77 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 O-C-N 123.469 1.247 . . . . 0.0 109.962 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.42 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 -49.77 150.64 2.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.276 -0.89 . . . . 0.0 110.837 -179.018 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.446 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.7 p30 -80.74 161.49 24.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -0.954 . . . . 0.0 109.664 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.419 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.32 -57.05 4.29 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.847 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.446 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -66.17 -28.34 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 120.823 -1.173 . . . . 0.0 111.729 -178.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.421 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.12 -56.27 6.89 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.994 -1.066 . . . . 0.0 110.715 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.437 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.55 -35.91 78.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.108 -0.995 . . . . 0.0 108.836 178.931 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.1 m -59.27 -49.48 77.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.066 -1.021 . . . . 0.0 108.598 178.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.74 -35.52 65.07 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.493 -0.755 . . . . 0.0 109.754 178.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.419 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.58 -44.81 63.81 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 110.844 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.497 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 2.8 ttm180 -55.01 -37.97 67.29 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.9 -1.125 . . . . 0.0 109.721 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.53 77.21 0.13 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -153.38 -49.08 0.1 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.462 -1.022 . . . . 0.0 108.522 179.51 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.462 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.7 t -93.14 143.3 26.38 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.369 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.446 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.25 15.96 5.85 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.263 -1.446 . . . . 0.0 110.405 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.432 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 25.4 mmt180 -92.9 83.02 4.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.065 -1.256 . . . . 0.0 110.106 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.12 -26.83 6.01 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.49 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.29 -166.51 0.15 Allowed Pre-proline 0 N--CA 1.488 1.456 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.61 115.02 2.44 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.025 1.013 . . . . 0.0 110.545 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.462 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -78.99 172.09 55.22 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.437 ' N ' HG22 ' A' ' 122' ' ' THR . 1.8 mp -132.76 142.6 41.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.283 -1.128 . . . . 0.0 109.432 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.494 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.24 115.21 17.29 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.316 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.434 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.67 122.54 43.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.814 . . . . 0.0 109.213 179.505 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -117.44 149.71 40.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.036 -1.04 . . . . 0.0 110.228 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.8 t -78.43 -61.08 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.207 -0.933 . . . . 0.0 110.079 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -115.97 170.76 5.35 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.295 -0.878 . . . . 0.0 110.425 -179.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -74.72 -50.33 0.14 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.776 1.408 . . . . 0.0 110.317 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 112.02 87.09 1.67 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -85.08 -164.72 1.03 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.247 -1.149 . . . . 0.0 110.339 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.257 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.27 138.0 31.93 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.245 -1.15 . . . . 0.0 110.0 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.403 ' O ' HG21 ' A' ' 3' ' ' VAL . 8.9 m -113.13 104.09 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.179 -0.95 . . . . 0.0 109.943 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.0 p -73.45 135.81 44.16 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.332 -0.855 . . . . 0.0 110.224 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.12 147.5 99.02 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.297 -0.877 . . . . 0.0 109.146 179.623 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.442 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 49.9 Cg_endo -73.6 -168.87 0.48 Allowed 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 124.053 1.554 . . . . 0.0 110.644 179.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.498 ' CD2' ' HD3' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 173.67 81.27 0.05 OUTLIER Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.644 -0.66 . . . . 0.0 109.226 -179.758 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.52 -5.87 17.95 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.788 1.415 . . . . 0.0 111.187 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.422 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.2 m120 -69.56 -14.32 62.79 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.908 -1.12 . . . . 0.0 110.406 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.463 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 34.0 mt -119.62 136.17 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.906 -1.121 . . . . 0.0 110.436 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.79 128.89 34.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.319 -0.863 . . . . 0.0 109.543 179.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.24 132.42 34.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.226 -0.921 . . . . 0.0 110.339 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.471 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 29.5 t -122.64 157.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.45 -0.781 . . . . 0.0 110.246 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.04 110.64 22.82 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.209 -0.932 . . . . 0.0 109.851 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.431 ' O ' ' CD ' ' A' ' 26' ' ' LYS . 12.1 tp -62.63 134.77 56.82 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.279 -0.888 . . . . 0.0 109.68 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.68 179.52 6.18 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.911 . . . . 0.0 110.176 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.92 74.47 2.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 109.631 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.428 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.5 m -144.55 111.61 5.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 110.576 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.48 -159.35 27.18 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.561 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.94 -24.78 5.99 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.602 -0.94 . . . . 0.0 110.522 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.468 HG22 ' O ' ' A' ' 28' ' ' ILE . 8.9 tt -95.86 108.76 42.6 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.618 -1.233 . . . . 0.0 110.492 -179.399 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.33 154.56 70.61 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.341 1.18 . . . . 0.0 109.897 179.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.496 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.3 t80 -167.79 95.02 0.42 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 110.891 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.439 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 66.8 m-85 60.33 65.48 1.07 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.5 -0.75 . . . . 0.0 111.188 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 15.87 16.53 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.496 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 3.6 mmtt -130.54 157.26 43.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.182 -1.187 . . . . 0.0 109.389 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -115.98 107.39 14.91 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.77 -1.206 . . . . 0.0 109.719 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.468 ' O ' HG22 ' A' ' 21' ' ' ILE . 3.9 mt -69.84 114.03 21.85 Favored Pre-proline 0 C--N 1.301 -1.523 0 O-C-N 121.294 -0.879 . . . . 0.0 110.461 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.468 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.3 Cg_endo -69.14 130.09 19.45 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 N-CA-C 106.586 -2.121 . . . . 0.0 106.586 175.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.445 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 7.6 mt -56.16 -18.32 9.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.734 -1.228 . . . . 0.0 110.528 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.33 -15.91 19.08 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.662 -1.274 . . . . 0.0 110.693 179.68 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.443 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.3 m -92.46 -25.14 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 120.884 -1.135 . . . . 0.0 110.995 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.523 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 10.3 pt -116.89 -22.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 -179.403 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.468 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.0 tptt -92.67 148.46 22.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.001 -1.062 . . . . 0.0 109.97 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.71 -5.68 43.76 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.6 -152.66 11.2 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.086 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.435 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.46 131.41 52.91 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.314 -1.109 . . . . 0.0 110.292 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.523 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.41 153.73 51.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.154 -0.966 . . . . 0.0 110.943 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.42 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 65.5 tp -114.45 118.27 33.33 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.371 -0.83 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.429 ' CG1' HG13 ' A' ' 83' ' ' VAL . 30.2 mt -104.39 127.92 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.127 -0.983 . . . . 0.0 109.673 179.395 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.42 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 24.9 m-85 -95.74 122.73 38.82 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.242 -0.911 . . . . 0.0 110.097 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.79 159.01 23.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.523 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.429 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.31 26.84 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 110.375 179.18 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.74 136.34 37.24 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.09 -1.007 . . . . 0.0 110.916 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.469 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.0 69.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.557 -0.714 . . . . 0.0 110.232 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.31 -36.48 84.26 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.282 -0.886 . . . . 0.0 110.421 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.82 -36.48 75.66 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.233 -0.917 . . . . 0.0 109.513 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.442 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 98.7 m -61.65 -34.05 75.03 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.439 -0.788 . . . . 0.0 109.684 179.465 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.35 -49.42 64.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.175 -0.953 . . . . 0.0 109.957 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.79 -45.66 60.87 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.097 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.419 ' CD1' HG11 ' A' ' 83' ' ' VAL . 2.1 tm? -56.49 -41.67 77.01 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.446 -0.784 . . . . 0.0 110.567 -179.411 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.411 ' O ' ' HB2' ' A' ' 62' ' ' ALA . . . -76.0 -51.43 12.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.092 -1.005 . . . . 0.0 110.236 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.44 -42.04 98.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.985 -1.072 . . . . 0.0 109.652 179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.44 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -57.09 -44.39 83.09 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.167 -0.958 . . . . 0.0 109.644 179.614 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.11 -41.58 71.84 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.345 -0.847 . . . . 0.0 109.612 179.735 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.6 t -56.27 -33.18 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.146 -0.971 . . . . 0.0 108.815 179.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.0 -32.05 59.23 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.5 -0.75 . . . . 0.0 110.131 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.456 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.0 mm? -71.62 -26.42 62.57 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.332 -0.855 . . . . 0.0 109.712 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.09 8.36 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.47 HG23 HG23 ' A' ' 81' ' ' VAL . 49.4 mt -108.15 143.94 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.202 -1.175 . . . . 0.0 110.32 -179.677 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.422 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.3 t30 -86.84 107.1 18.16 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 178.121 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.482 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.86 147.71 45.03 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.62 -177.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.504 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 2.9 t -136.11 148.71 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.507 179.308 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -111.32 126.95 55.45 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.095 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 5.4 t80 -117.48 125.9 51.69 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 110.713 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.473 ' CE1' HD22 ' A' ' 69' ' ' LEU . 5.5 p90 -157.76 -174.85 5.05 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.63 123.64 11.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 0.0 111.26 -179.212 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.65 47.73 32.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.473 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.27 155.7 29.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.07 -1.253 . . . . 0.0 109.807 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.454 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 7.7 m-20 -92.12 148.6 22.04 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.201 -0.937 . . . . 0.0 110.825 -179.18 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.412 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 30.4 m -62.8 111.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.055 -1.028 . . . . 0.0 109.336 179.068 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.443 ' CB ' HG12 ' A' ' 63' ' ' VAL . 10.6 m -134.58 -35.96 0.88 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.375 -0.828 . . . . 0.0 110.849 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.504 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 24.9 t -51.38 135.85 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.032 -1.043 . . . . 0.0 110.055 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.419 ' O ' ' CG1' ' A' ' 74' ' ' ILE . 1.4 pp -136.16 95.06 13.62 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.263 -0.898 . . . . 0.0 110.724 -179.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.413 ' HA ' ' CG1' ' A' ' 80' ' ' VAL . 52.3 Cg_endo -81.42 52.83 4.44 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.622 1.327 . . . . 0.0 110.88 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.7 t -149.98 17.73 0.87 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.968 -1.082 . . . . 0.0 110.689 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -112.6 -165.84 1.03 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.099 -1.001 . . . . 0.0 110.169 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.09 -66.29 2.7 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 m-20 -151.84 110.92 3.88 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -1.165 . . . . 0.0 110.211 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.435 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.6 p -117.33 133.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 122.003 0.906 . . . . 0.0 110.347 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.48 HG21 ' CB ' ' A' ' 62' ' ' ALA . 9.5 m -111.93 124.2 68.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.202 0 O-C-N 121.311 -0.868 . . . . 0.0 108.773 178.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.45 ' CG2' HG12 ' A' ' 73' ' ' VAL . 5.7 t -97.24 120.99 47.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 110.306 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.6 m -116.47 100.48 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.971 -1.081 . . . . 0.0 108.7 179.592 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -138.4 162.22 35.0 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.683 -1.261 . . . . 0.0 111.454 -177.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.1 t -87.24 -132.27 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.612 -0.68 . . . . 0.0 109.708 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -91.5 32.83 1.04 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.803 -1.186 . . . . 0.0 110.594 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.443 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.49 -32.96 9.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.095 -1.003 . . . . 0.0 109.887 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp -76.23 -45.49 32.65 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.85 . . . . 0.0 109.254 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.434 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.6 OUTLIER 53.23 20.72 1.96 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.563 -0.71 . . . . 0.0 110.717 179.644 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.442 ' CG2' ' HB ' ' A' ' 93' ' ' THR . 0.7 OUTLIER 48.08 32.67 3.06 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.184 -0.947 . . . . 0.0 110.578 179.584 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.83 -67.85 1.9 Allowed Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.433 ' CD1' ' O ' ' A' ' 92' ' ' PHE . 53.3 p90 -96.72 34.01 1.75 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -1.145 . . . . 0.0 109.136 179.077 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.487 HG23 ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -131.23 -151.67 0.47 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.579 -0.701 . . . . 0.0 110.281 -179.351 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.401 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 124.42 -35.8 3.09 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.556 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -84.6 80.15 9.34 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.928 -1.337 . . . . 0.0 110.839 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.487 ' CE2' HG23 ' A' ' 93' ' ' THR . 27.1 m-85 -119.07 148.16 43.34 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.18 -0.95 . . . . 0.0 109.906 178.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.407 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.95 -32.25 61.68 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.272 -0.893 . . . . 0.0 109.486 179.294 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.406 ' OG ' ' ND1' ' A' ' 38' ' ' HIS . 4.0 p -162.51 163.79 27.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.218 -0.927 . . . . 0.0 111.207 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.531 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.47 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.452 -0.78 . . . . 0.0 110.3 179.347 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.407 ' CD1' HG23 ' A' ' 33' ' ' ILE . 3.1 mp -92.88 117.78 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.893 . . . . 0.0 108.795 179.145 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.19 20.5 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.07 -1.019 . . . . 0.0 112.107 -178.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.22 -11.66 34.81 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.434 ' HB3' ' NE2' ' A' ' 110' ' ' GLN . 3.7 m120 55.58 12.37 0.78 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.294 -0.879 . . . . 0.0 112.487 179.091 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.402 HG22 ' O ' ' A' ' 108' ' ' LYS . 1.0 OUTLIER -147.5 122.16 9.85 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 120.491 -1.38 . . . . 0.0 109.495 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.466 ' N ' ' O ' ' A' ' 108' ' ' LYS . 32.7 p -102.59 131.47 49.32 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.296 -0.877 . . . . 0.0 110.248 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 56.04 30.69 16.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.334 -0.854 . . . . 0.0 111.0 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.39 -29.71 8.02 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.338 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.466 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -85.29 154.42 59.91 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.005 -1.291 . . . . 0.0 110.131 -179.937 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.83 139.26 56.45 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.584 1.307 . . . . 0.0 110.256 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.434 ' NE2' ' HB3' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -48.14 164.69 0.05 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.304 -0.872 . . . . 0.0 110.851 -179.434 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 114' ' ' SER . 1.6 p30 -88.92 160.36 17.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.9 . . . . 0.0 109.85 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.85 -51.13 7.66 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.424 -0.798 . . . . 0.0 112.317 -178.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.427 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.44 -29.7 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.795 -1.19 . . . . 0.0 111.447 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.443 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.08 -56.47 6.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.08 -1.013 . . . . 0.0 110.402 -179.204 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -69.49 -34.38 74.24 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.301 -0.874 . . . . 0.0 108.688 178.756 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 22.5 m -59.22 -50.02 75.6 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.164 -0.96 . . . . 0.0 108.454 178.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.93 -39.52 63.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.763 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.401 ' HB2' ' O ' ' A' ' 114' ' ' SER . 2.2 mtt180 -67.47 -44.32 78.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.168 -0.958 . . . . 0.0 110.557 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.498 ' HD3' ' CD2' ' A' ' 7' ' ' HIS . 7.0 ttm180 -60.47 -39.06 86.25 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.026 -1.046 . . . . 0.0 110.057 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.74 66.69 0.44 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.06 -46.6 0.3 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.514 -0.992 . . . . 0.0 108.602 179.471 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.45 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 15.0 t -94.45 142.13 27.79 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.375 -0.828 . . . . 0.0 109.136 178.657 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.89 10.03 19.45 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.556 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.0 mmt85 -69.3 86.96 0.42 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.011 -1.288 . . . . 0.0 109.69 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.2 22.17 33.19 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.463 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.85 -178.31 0.29 Allowed Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.514 -0.992 . . . . 0.0 108.717 -179.515 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.463 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.3 Cg_endo -89.65 103.94 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.258 1.136 . . . . 0.0 110.126 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.45 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -77.61 156.84 45.09 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.605 -179.303 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 38.8 mt -111.05 142.06 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.479 -1.012 . . . . 0.0 109.046 178.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.531 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 5.4 t80 -132.09 118.91 20.27 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.09 -1.006 . . . . 0.0 110.785 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -101.51 124.04 46.52 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.454 -0.779 . . . . 0.0 109.477 179.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.471 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.6 p90 -118.04 155.87 29.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 110.229 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.1 t -95.36 -24.11 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.168 -0.958 . . . . 0.0 109.869 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -148.03 124.64 5.48 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.295 -0.878 . . . . 0.0 110.164 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -76.46 -50.76 0.1 Allowed 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.484 1.255 . . . . 0.0 110.358 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 66.73 113.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -100.73 83.89 2.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.188 -1.183 . . . . 0.0 110.295 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 69.5 ttt180 . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.167 -179.931 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.5 t -84.11 106.31 15.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.197 -1.178 . . . . 0.0 110.313 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 19.3 m -113.16 104.36 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.314 -0.866 . . . . 0.0 110.059 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.8 p -88.5 136.34 33.04 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.333 -0.855 . . . . 0.0 110.232 179.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.67 147.25 98.68 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.306 -0.871 . . . . 0.0 109.647 179.639 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.415 ' O ' ' CB ' ' A' ' 7' ' ' HIS . 55.9 Cg_endo -81.96 -169.34 0.74 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 124.102 1.58 . . . . 0.0 110.909 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.534 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 169.75 80.84 0.03 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 N-CA-C 109.074 -0.714 . . . . 0.0 109.074 179.14 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -65.7 108.81 1.31 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.826 1.435 . . . . 0.0 110.875 -179.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.8 t-20 179.69 -32.48 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.789 0 CA-C-O 121.512 0.672 . . . . 0.0 109.424 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.453 HD13 HG21 ' A' ' 10' ' ' ILE . 33.0 mt -103.48 136.34 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.011 -1.056 . . . . 0.0 110.094 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.9 129.46 35.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 109.322 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.75 34.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.173 -0.954 . . . . 0.0 110.294 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.41 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 20.4 t -117.84 155.0 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.641 -0.662 . . . . 0.0 110.026 -179.422 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.19 106.89 17.58 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.439 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 12.5 tp -57.6 132.16 52.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.593 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.8 p -135.84 -166.95 1.94 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.192 -0.942 . . . . 0.0 110.587 -179.516 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.41 ' HA ' ' HB1' ' A' ' 27' ' ' ALA . 5.1 p -82.49 83.45 7.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.436 -0.79 . . . . 0.0 109.917 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.421 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 11.0 m -156.9 110.04 2.58 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.302 -0.874 . . . . 0.0 110.541 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.38 28.52 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 118.895 -1.622 . . . . 0.0 110.956 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -117.49 -24.68 7.23 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.78 -0.835 . . . . 0.0 110.404 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.464 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -93.86 103.48 10.4 Favored Pre-proline 0 N--CA 1.485 1.303 0 C-N-CA 118.496 -1.281 . . . . 0.0 109.99 -179.342 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -61.61 118.76 5.66 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 O-C-N 123.682 1.359 . . . . 0.0 110.558 -179.564 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.62 -168.74 1.39 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.736 -0.602 . . . . 0.0 110.718 -178.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.435 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.09 81.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.592 -0.693 . . . . 0.0 111.71 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.4 -1.68 49.53 Favored Glycine 0 N--CA 1.495 2.625 0 C-N-CA 120.148 -1.025 . . . . 0.0 110.809 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.439 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.13 156.41 44.6 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.899 -1.353 . . . . 0.0 109.304 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.41 ' HB1' ' HA ' ' A' ' 17' ' ' THR . . . -105.22 107.09 17.89 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.837 -1.164 . . . . 0.0 108.993 179.401 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.464 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 4.0 mt -67.37 113.58 14.65 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.487 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.3 Cg_endo -68.85 127.36 15.21 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 N-CA-C 106.828 -2.028 . . . . 0.0 106.828 175.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.423 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 8.7 mt -55.93 -17.98 7.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.897 -1.127 . . . . 0.0 110.791 -177.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.69 -16.36 26.27 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.639 -1.288 . . . . 0.0 110.26 179.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.428 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 12.4 m -90.97 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.008 -1.058 . . . . 0.0 110.884 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.512 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 20.3 pt -117.46 -18.64 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.996 -1.065 . . . . 0.0 110.633 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.483 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.65 148.24 23.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.867 -1.146 . . . . 0.0 110.169 179.537 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.97 36.67 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.375 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.2 -143.63 6.08 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.153 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.9 mtt85 -111.25 134.57 52.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.396 -1.061 . . . . 0.0 110.313 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 66.4 m80 -141.14 150.73 43.19 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.089 -1.007 . . . . 0.0 111.077 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.491 HD23 ' CZ ' ' A' ' 41' ' ' PHE . 60.7 tp -110.01 115.07 29.11 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.478 -0.764 . . . . 0.0 110.013 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.438 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 26.6 mt -98.79 127.27 51.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.113 -0.992 . . . . 0.0 109.821 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.491 ' CZ ' HD23 ' A' ' 39' ' ' LEU . 29.5 m-85 -95.35 124.67 39.5 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.453 -0.78 . . . . 0.0 110.084 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.66 157.77 24.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.163 -0.961 . . . . 0.0 110.642 -179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.435 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 15.0 p80 -101.96 -2.95 28.61 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 110.29 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.55 46.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.111 -0.993 . . . . 0.0 110.288 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.406 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 19.6 tttt -70.59 -37.49 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.47 -0.769 . . . . 0.0 110.757 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.57 -36.06 77.57 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.172 -0.955 . . . . 0.0 110.291 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.63 -32.75 68.3 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.424 -0.798 . . . . 0.0 109.253 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.438 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.74 74.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.35 -0.844 . . . . 0.0 109.095 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.88 -48.86 64.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.379 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.86 -44.39 63.89 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.236 -0.915 . . . . 0.0 110.631 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -56.81 -38.94 73.28 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.459 -0.776 . . . . 0.0 111.235 -178.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.84 -51.36 12.72 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.868 -1.145 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -40.78 97.26 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.01 -1.056 . . . . 0.0 109.672 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.42 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.94 83.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.522 179.447 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.37 -40.99 72.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.478 -0.764 . . . . 0.0 109.978 179.937 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.3 -33.81 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.135 -0.978 . . . . 0.0 108.899 179.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.88 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.333 -0.854 . . . . 0.0 110.078 179.357 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.459 ' N ' HD21 ' A' ' 58' ' ' LEU . 4.0 mm? -71.47 -25.94 62.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.426 179.609 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.0 5.67 10.59 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.523 HG21 HG21 ' A' ' 81' ' ' VAL . 33.7 mt -108.42 143.46 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.475 -1.015 . . . . 0.0 110.235 -179.572 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.446 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -87.98 106.92 18.45 Favored 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.056 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.482 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.56 146.97 44.18 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.748 -1.181 . . . . 0.0 111.922 -177.163 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.507 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 19.6 t -129.32 149.34 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.706 -0.621 . . . . 0.0 109.884 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -114.03 123.84 50.67 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.261 -0.975 . . . . 0.0 109.861 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.46 ' CB ' ' HB3' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -114.04 134.68 54.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.923 . . . . 0.0 111.013 -179.31 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.517 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 5.1 p90 -171.01 -179.82 2.86 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.381 -0.825 . . . . 0.0 110.174 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.24 126.27 18.39 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.209 -0.932 . . . . 0.0 111.02 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.1 46.5 35.31 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.338 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.517 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.49 154.74 30.91 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.127 -1.219 . . . . 0.0 109.891 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.454 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.1 m-20 -93.16 149.83 20.95 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.271 -0.893 . . . . 0.0 110.651 -179.229 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.433 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 34.1 m -61.69 111.15 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 119.041 -1.064 . . . . 0.0 108.829 179.104 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.479 ' CB ' HG12 ' A' ' 63' ' ' VAL . 74.1 m -132.42 -34.71 1.19 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 110.749 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.507 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 58.7 t -47.69 125.18 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.246 -0.909 . . . . 0.0 109.612 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.442 HD13 ' ND2' ' A' ' 77' ' ' ASN . 1.1 pp -136.7 113.33 10.0 Favored Pre-proline 0 N--CA 1.497 1.894 0 O-C-N 121.098 -1.001 . . . . 0.0 111.751 -178.373 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.419 ' HA ' HG13 ' A' ' 80' ' ' VAL . 51.1 Cg_endo -89.29 40.96 0.51 Allowed 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.575 1.303 . . . . 0.0 110.343 178.705 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.0 p -142.59 47.7 1.56 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.015 -1.053 . . . . 0.0 110.704 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.442 ' ND2' HD13 ' A' ' 74' ' ' ILE . 5.5 m-80 -148.46 27.38 0.92 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.159 -0.963 . . . . 0.0 110.253 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.7 -94.55 1.39 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -128.31 111.67 13.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.153 -1.204 . . . . 0.0 110.087 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.446 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.9 p -117.2 134.96 59.13 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 CA-C-O 122.124 0.964 . . . . 0.0 110.084 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.523 HG21 HG21 ' A' ' 60' ' ' ILE . 5.3 m -113.99 122.05 67.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 O-C-N 121.296 -0.877 . . . . 0.0 109.229 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.7 t -96.84 117.87 42.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 120.916 -1.115 . . . . 0.0 110.308 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.503 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.7 m -108.81 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.244 -0.982 . . . . 0.0 108.916 179.548 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.46 ' HB3' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.23 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.658 -1.276 . . . . 0.0 110.656 -178.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.04 -34.48 15.09 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 110.679 -179.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -178.01 -29.57 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.114 -0.991 . . . . 0.0 111.066 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.437 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -44.88 -34.09 2.22 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.178 -0.951 . . . . 0.0 111.073 -179.553 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.445 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.7 tp -66.99 -33.87 76.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.087 -1.008 . . . . 0.0 109.772 179.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' MET . . . . . . . . . . . . . 4.4 mmt 55.1 -87.47 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.585 -0.697 . . . . 0.0 110.526 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.445 ' N ' ' O ' ' A' ' 88' ' ' LEU . 0.0 OUTLIER -179.54 -91.76 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.006 -1.059 . . . . 0.0 110.438 -179.853 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.402 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 70.14 -65.42 0.72 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -128.2 13.94 6.69 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.073 -1.251 . . . . 0.0 110.881 -179.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.483 ' OG1' ' CE1' ' A' ' 96' ' ' PHE . 14.6 t -75.49 -167.23 0.63 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.11 -0.994 . . . . 0.0 110.398 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.437 ' O ' ' CD ' ' A' ' 124' ' ' ARG . . . 113.11 -37.58 3.57 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.339 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -84.42 65.4 8.9 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.95 -1.323 . . . . 0.0 110.776 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.483 ' CE1' ' OG1' ' A' ' 93' ' ' THR . 22.1 m-85 -119.83 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.055 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.425 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.68 -29.32 27.69 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.492 -0.755 . . . . 0.0 109.976 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.66 163.66 29.71 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -0.975 . . . . 0.0 111.351 -179.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.519 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.22 114.4 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.439 -0.788 . . . . 0.0 109.922 179.141 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.409 ' CG2' ' CD1' ' A' ' 28' ' ' ILE . 3.7 mp -93.0 115.64 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.244 -0.91 . . . . 0.0 109.297 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.95 160.94 25.17 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.169 -0.957 . . . . 0.0 111.53 -178.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.418 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.64 3.75 42.74 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.628 -0.67 . . . . 0.0 109.504 178.15 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.48 23.88 0.66 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.266 -0.896 . . . . 0.0 111.254 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.451 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 0.8 OUTLIER -146.76 135.77 22.45 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.959 -1.088 . . . . 0.0 110.476 179.283 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.7 p -114.76 132.69 56.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.262 -0.899 . . . . 0.0 109.908 179.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t0 52.55 -142.65 0.75 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.008 -1.058 . . . . 0.0 109.826 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.19 17.29 43.38 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 179.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 5.6 mmtp -129.43 156.26 78.82 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.101 -1.235 . . . . 0.0 109.432 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.431 ' HA ' ' CG2' ' A' ' 104' ' ' THR . 39.0 Cg_endo -64.29 167.07 15.37 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 123.581 1.306 . . . . 0.0 110.48 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.481 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 13.9 tt0 -70.8 154.84 41.47 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.417 -0.802 . . . . 0.0 110.902 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -88.27 161.5 17.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.567 -0.708 . . . . 0.0 110.092 179.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.4 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -52.31 -61.79 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.346 -0.846 . . . . 0.0 112.29 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 7.2 m -58.1 -29.79 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.765 -1.209 . . . . 0.0 112.004 -177.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.481 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.82 -56.22 7.95 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.011 -1.055 . . . . 0.0 110.489 -179.293 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.41 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.49 -33.9 76.73 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.207 -0.933 . . . . 0.0 108.941 178.94 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.0 m -60.29 -49.82 76.1 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 120.999 -1.063 . . . . 0.0 108.452 178.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -73.93 -38.02 64.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 178.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.406 ' HB2' ' O ' ' A' ' 114' ' ' SER . 40.6 mtt85 -72.16 -44.85 62.43 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.222 -0.924 . . . . 0.0 111.477 -179.245 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.534 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -54.59 -45.38 73.58 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.787 -1.195 . . . . 0.0 109.495 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.28 81.71 0.03 OUTLIER Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.73 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 179.606 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.456 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 8.7 t -93.13 143.47 26.22 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.56 1.7 19.74 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.646 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.437 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -70.24 85.9 0.57 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.978 -1.307 . . . . 0.0 110.13 -179.801 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.1 -38.04 2.89 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.87 -166.87 0.13 Allowed Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.508 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -86.31 114.81 1.31 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.086 1.045 . . . . 0.0 109.647 179.202 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.456 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.4 167.88 54.81 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.504 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.83 138.74 49.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.451 -1.029 . . . . 0.0 108.62 178.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.519 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.26 118.78 22.88 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.218 -0.993 . . . . 0.0 110.581 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.428 ' CZ ' HG13 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.31 127.14 53.03 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.487 -0.758 . . . . 0.0 109.879 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' A' ' 134' ' ' ALA . 10.4 p90 -118.84 158.5 25.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.17 -0.956 . . . . 0.0 109.81 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 7.2 t -82.93 -50.55 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.085 -1.009 . . . . 0.0 110.263 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.465 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -49.51 162.61 0.42 Allowed Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.35 -0.844 . . . . 0.0 111.553 -178.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -76.38 -53.82 0.08 OUTLIER 'Trans proline' 0 C--N 1.311 -1.4 0 O-C-N 123.617 1.325 . . . . 0.0 110.184 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 117.87 177.68 17.28 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -74.24 -34.41 63.64 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.353 -1.086 . . . . 0.0 110.205 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.215 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.01 106.37 6.48 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.214 -1.168 . . . . 0.0 110.093 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 27.5 m -112.97 104.16 16.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.271 -0.893 . . . . 0.0 110.024 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.486 ' CG2' ' CB ' ' A' ' 112' ' ' ALA . 17.9 p -66.94 141.21 57.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.317 -0.865 . . . . 0.0 109.922 179.788 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.431 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -66.68 147.59 98.97 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.19 -0.944 . . . . 0.0 109.403 179.839 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.431 ' HD2' HG23 ' A' ' 5' ' ' VAL . 42.3 Cg_endo -67.85 -168.31 0.19 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 124.169 1.615 . . . . 0.0 110.654 179.683 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.503 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -179.83 81.21 0.19 Allowed Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.522 -0.736 . . . . 0.0 109.998 -179.82 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.456 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 42.5 Cg_endo -69.73 -170.74 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.697 1.367 . . . . 0.0 109.821 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.456 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 6.5 m120 76.83 -14.05 0.87 Allowed 'General case' 0 N--CA 1.508 2.462 0 O-C-N 121.816 -0.553 . . . . 0.0 111.239 -179.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.449 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.1 mt -116.59 135.38 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.664 -1.273 . . . . 0.0 109.488 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.417 ' N ' ' O ' ' A' ' 128' ' ' GLY . 1.5 tm-20 -86.1 127.15 34.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.8 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -90.43 136.65 32.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.104 -0.997 . . . . 0.0 110.03 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.439 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.2 157.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.193 -0.942 . . . . 0.0 110.044 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.63 112.21 25.2 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.188 -0.945 . . . . 0.0 110.044 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.441 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 8.5 tp -54.81 147.36 15.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.873 . . . . 0.0 109.282 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.53 7.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.122 -0.987 . . . . 0.0 110.533 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.13 74.62 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.345 -0.847 . . . . 0.0 109.976 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.43 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 9.4 m -152.41 108.8 3.42 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.322 -0.862 . . . . 0.0 110.741 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.57 -167.16 29.2 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.922 -1.608 . . . . 0.0 110.818 179.214 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.41 ' CB ' HD13 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.26 -24.85 9.58 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.664 -0.904 . . . . 0.0 110.482 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.458 HG22 ' O ' ' A' ' 28' ' ' ILE . 9.4 tt -95.12 101.89 8.27 Favored Pre-proline 0 C--N 1.305 -1.334 0 C-N-CA 118.734 -1.187 . . . . 0.0 109.743 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.405 ' HD3' ' O ' ' A' ' 20' ' ' GLU . 37.0 Cg_endo -61.44 127.39 21.73 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.534 1.281 . . . . 0.0 111.074 -178.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.432 ' N ' ' O ' ' A' ' 26' ' ' LYS . 6.3 t80 -117.19 -171.91 2.12 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.541 0.686 . . . . 0.0 110.695 -179.062 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.565 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.4 m-85 -57.58 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.434 -0.791 . . . . 0.0 111.688 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.02 -4.62 53.47 Favored Glycine 0 N--CA 1.493 2.495 0 O-C-N 121.229 -0.919 . . . . 0.0 110.911 178.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.441 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 28.3 mmtt -130.05 156.34 44.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.826 -1.397 . . . . 0.0 109.908 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.43 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -106.26 108.07 19.39 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.064 -1.023 . . . . 0.0 108.864 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.458 ' O ' HG22 ' A' ' 21' ' ' ILE . 5.1 mt -68.24 112.99 12.54 Favored Pre-proline 0 C--N 1.3 -1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 110.732 -179.056 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.446 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.3 Cg_endo -68.43 130.05 20.26 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.125 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.443 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.8 mt -56.64 -17.13 7.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.772 -1.205 . . . . 0.0 110.801 -177.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.416 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.32 -16.05 19.87 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.739 -1.226 . . . . 0.0 110.476 179.955 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.442 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 9.9 m -95.16 -24.24 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.008 -1.057 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.534 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 46.2 pt -116.58 -12.17 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.919 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.46 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 8.9 tptm -102.12 148.29 25.57 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.831 -1.168 . . . . 0.0 110.193 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.03 -5.3 36.24 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.74 3.89 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.407 -1.377 . . . . 0.0 110.08 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.424 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.54 135.96 53.38 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.313 -1.11 . . . . 0.0 110.363 -179.736 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.534 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.6 m-70 -140.01 153.42 46.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.254 -0.904 . . . . 0.0 111.196 -179.427 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.404 ' HB3' ' CG1' ' A' ' 99' ' ' VAL . 60.4 tp -113.5 116.47 29.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.419 -0.801 . . . . 0.0 110.285 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.451 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 33.7 mt -100.93 128.1 53.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.194 -0.942 . . . . 0.0 109.568 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -95.08 123.75 38.74 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.441 -0.787 . . . . 0.0 110.238 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.94 159.92 21.71 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.217 -0.927 . . . . 0.0 110.679 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.565 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.2 p80 -105.55 -4.48 21.15 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.381 -0.824 . . . . 0.0 110.395 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.5 p -132.13 138.53 48.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.973 -1.08 . . . . 0.0 110.702 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.498 ' HD2' ' CE1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.25 -41.19 70.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.483 -0.761 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.77 72.1 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.221 -0.924 . . . . 0.0 110.59 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.41 -37.36 65.95 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.379 -0.826 . . . . 0.0 109.949 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.452 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 73.9 m -61.14 -34.35 74.87 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.273 -0.892 . . . . 0.0 109.857 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.413 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.67 -50.08 59.54 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.229 -0.919 . . . . 0.0 110.592 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -72.37 -40.54 67.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.191 -0.943 . . . . 0.0 110.374 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.444 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.92 -42.67 98.55 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.616 -0.678 . . . . 0.0 111.567 -178.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.64 -51.16 45.13 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.8 -1.188 . . . . 0.0 110.271 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.15 -34.43 68.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.032 -1.043 . . . . 0.0 109.183 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.527 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.24 -47.95 80.08 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.208 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.505 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -57.02 -42.45 80.43 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.531 -0.731 . . . . 0.0 110.955 -179.994 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -55.67 -28.32 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.925 -1.11 . . . . 0.0 108.753 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.62 -35.37 60.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.516 -0.74 . . . . 0.0 110.266 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.33 -26.11 61.81 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.06 7.96 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.461 HG21 HG23 ' A' ' 81' ' ' VAL . 50.4 mt -106.39 143.0 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.282 -1.128 . . . . 0.0 109.633 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.402 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.7 t30 -87.41 106.56 18.04 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.024 -1.472 . . . . 0.0 107.024 178.401 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.505 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -119.5 146.07 45.77 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.23 -0.988 . . . . 0.0 111.008 -177.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.469 ' CG2' HG12 ' A' ' 73' ' ' VAL . 6.1 t -138.7 149.97 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.823 -0.751 . . . . 0.0 109.303 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -112.01 134.84 53.32 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.713 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.463 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 20.4 t80 -124.96 129.27 50.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.382 -0.824 . . . . 0.0 110.274 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.503 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 3.0 p90 -154.73 -171.3 3.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.595 -0.691 . . . . 0.0 109.634 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.8 124.88 22.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.125 -0.984 . . . . 0.0 110.731 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.35 34.02 30.27 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.503 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.7 tm? -117.35 157.13 26.67 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.143 -1.21 . . . . 0.0 110.035 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.452 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.15 22.77 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.188 -0.945 . . . . 0.0 110.815 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.44 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 27.8 m -62.97 111.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.121 -0.987 . . . . 0.0 109.067 178.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.433 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.0 m -131.19 -11.73 3.64 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.166 -0.959 . . . . 0.0 111.494 -179.322 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.489 ' CG1' ' CG2' ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.34 136.2 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.737 -1.227 . . . . 0.0 109.509 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.447 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.2 pp -136.91 92.09 14.65 Favored Pre-proline 0 N--CA 1.497 1.883 0 O-C-N 121.12 -0.987 . . . . 0.0 110.513 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -77.01 58.1 6.02 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 123.456 1.24 . . . . 0.0 110.491 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.5 p -119.43 -31.99 4.47 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.189 -0.944 . . . . 0.0 110.361 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.7 m-80 -150.81 160.67 43.72 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.229 -0.919 . . . . 0.0 110.179 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 64.99 166.69 1.38 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -89.11 102.95 15.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.042 -1.27 . . . . 0.0 110.181 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 5.8 p -117.06 135.11 58.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 121.904 0.859 . . . . 0.0 110.359 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.483 HG22 ' CB ' ' A' ' 62' ' ' ALA . 7.1 m -112.95 122.5 67.2 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.489 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.6 t -96.83 117.65 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.019 -1.051 . . . . 0.0 110.097 -177.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 5.3 m -111.43 99.74 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.075 -1.016 . . . . 0.0 108.828 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.463 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.13 159.84 41.2 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.646 -1.283 . . . . 0.0 111.27 -178.189 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.8 t -82.33 -130.45 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.618 -0.676 . . . . 0.0 109.515 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.82 27.82 2.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.595 -1.315 . . . . 0.0 110.225 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.45 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.11 -35.76 12.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 110.133 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.3 tp -69.37 -32.96 72.34 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.644 179.643 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' MET . . . . . . . . . . . . . 4.2 mmt 54.06 -89.98 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.575 -0.703 . . . . 0.0 110.134 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.444 ' CB ' HG21 ' A' ' 93' ' ' THR . 0.4 OUTLIER 177.84 41.73 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 O-C-N 120.912 -1.118 . . . . 0.0 110.066 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.81 -48.6 79.73 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -128.57 32.63 4.79 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.481 -1.011 . . . . 0.0 110.502 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.444 HG21 ' CB ' ' A' ' 90' ' ' THR . 5.6 t -95.07 -152.91 0.37 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.097 -1.002 . . . . 0.0 110.219 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.438 ' N ' HG22 ' A' ' 93' ' ' THR . . . 97.34 -10.32 65.21 Favored Glycine 0 N--CA 1.49 2.247 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.618 179.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.7 t0 -124.93 64.95 1.12 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.802 -1.41 . . . . 0.0 110.871 -179.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -120.05 151.57 38.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.079 -1.013 . . . . 0.0 110.315 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.418 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.42 -30.96 33.36 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.33 178.983 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.444 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.9 163.94 28.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.377 -0.827 . . . . 0.0 111.197 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.53 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.44 115.38 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.557 -0.714 . . . . 0.0 109.796 179.002 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 2.7 mp -93.11 117.62 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.241 -0.912 . . . . 0.0 109.113 179.495 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -122.5 161.18 24.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.937 . . . . 0.0 111.559 -178.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 20.7 t -103.47 8.42 37.87 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.257 -0.902 . . . . 0.0 110.713 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -142.9 133.65 25.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.73 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.4 p -113.83 132.42 55.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.325 -0.86 . . . . 0.0 109.441 179.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 54.47 -141.92 0.83 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.991 -1.068 . . . . 0.0 109.513 -179.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -90.36 24.69 15.38 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.87 157.2 70.07 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.301 -1.117 . . . . 0.0 109.617 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -64.61 166.3 18.14 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.547 1.288 . . . . 0.0 110.248 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.04 162.91 28.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.186 -0.946 . . . . 0.0 110.826 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.464 ' O ' ' OG ' ' A' ' 114' ' ' SER . 3.6 p-10 -92.73 162.57 14.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.479 -0.763 . . . . 0.0 110.382 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.486 ' CB ' ' CG2' ' A' ' 4' ' ' THR . . . -50.55 -49.38 56.17 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.831 -1.168 . . . . 0.0 111.868 -178.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.42 ' CG2' ' OD2' ' A' ' 111' ' ' ASP . 5.8 m -72.63 -30.62 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.601 -1.312 . . . . 0.0 113.283 -177.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.88 -54.7 34.95 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.293 -1.504 . . . . 0.0 110.096 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.27 -35.97 78.76 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 118.363 -1.335 . . . . 0.0 108.164 178.363 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.424 ' CG2' HG11 ' A' ' 5' ' ' VAL . 83.0 m -60.79 -49.97 75.34 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.413 ' NE2' ' HA ' ' A' ' 117' ' ' GLN . 7.7 tp60 -73.68 -46.45 46.32 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.86 178.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.0 mtt-85 -58.25 -46.08 86.63 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 110.466 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.503 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 11.1 ttm180 -58.21 -39.85 80.1 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.847 -1.158 . . . . 0.0 109.485 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.56 68.81 0.4 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -146.22 -45.95 0.2 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.425 -1.044 . . . . 0.0 108.743 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.448 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.9 t -94.34 142.33 27.54 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.4 5.7 11.17 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.547 179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.428 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -76.2 84.53 3.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.947 -1.325 . . . . 0.0 110.171 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.93 -43.58 1.66 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.475 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.22 -169.31 0.17 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.499 -1.001 . . . . 0.0 108.662 179.565 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.475 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -87.72 110.67 0.73 Allowed 'Trans proline' 0 C--N 1.309 -1.529 0 O-C-N 123.274 1.144 . . . . 0.0 109.452 178.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.449 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -76.62 146.58 32.89 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.444 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 2.9 mp -106.35 141.15 22.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.859 -1.377 . . . . 0.0 109.301 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.53 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 4.4 t80 -127.87 115.35 18.46 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.105 -0.997 . . . . 0.0 110.41 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.442 ' CZ ' HG11 ' A' ' 32' ' ' VAL . 6.5 mmt180 -102.06 123.39 45.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.498 -0.752 . . . . 0.0 109.632 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.481 ' CE1' ' HA ' ' A' ' 135' ' ' PRO . 25.7 p90 -115.23 157.84 23.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.022 -1.049 . . . . 0.0 110.059 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t -89.01 -38.98 12.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.09 -1.006 . . . . 0.0 109.76 179.507 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.422 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -96.17 131.71 28.23 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.178 -0.952 . . . . 0.0 110.198 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.481 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 50.0 Cg_endo -76.88 -19.66 13.89 Favored 'Trans proline' 0 C--N 1.314 -1.263 0 O-C-N 123.519 1.273 . . . . 0.0 110.657 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -52.21 105.36 0.24 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -135.02 -166.32 1.81 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.252 -1.146 . . . . 0.0 110.214 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 118.124 -0.941 . . . . 0.0 110.262 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.3 p -115.19 157.2 24.0 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.204 -1.174 . . . . 0.0 110.19 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.94 104.47 17.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.303 -0.873 . . . . 0.0 109.665 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.7 p -66.68 137.0 56.38 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.4 -0.813 . . . . 0.0 110.535 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.401 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -73.04 149.05 89.53 Favored Pre-proline 0 C--N 1.303 -1.432 0 O-C-N 121.315 -0.865 . . . . 0.0 109.297 179.225 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.401 ' HD2' HG21 ' A' ' 5' ' ' VAL . 50.6 Cg_endo -80.28 -165.55 0.35 Allowed 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.992 1.522 . . . . 0.0 111.377 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.495 ' NE2' ' NE ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.07 83.35 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.824 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.14 60.69 0.47 Allowed 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.906 1.477 . . . . 0.0 111.937 -178.337 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.43 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 19.6 m-80 -131.88 2.57 4.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.49 -0.756 . . . . 0.0 109.931 178.37 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.462 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 11.7 mt -128.44 137.64 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.952 -1.093 . . . . 0.0 109.343 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.67 128.24 34.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.102 -0.999 . . . . 0.0 109.39 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.59 127.99 35.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.109 -0.994 . . . . 0.0 110.198 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 t -122.93 155.4 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.286 -0.884 . . . . 0.0 110.206 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.05 110.46 22.59 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.295 -0.878 . . . . 0.0 109.925 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.403 HD21 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.67 134.72 54.89 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 110.005 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 17.7 p -135.37 171.5 14.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.256 -0.902 . . . . 0.0 110.214 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.53 69.96 0.17 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 110.153 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.439 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.4 m -140.54 112.29 7.53 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.28 -0.887 . . . . 0.0 110.392 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.74 -163.28 26.94 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.542 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.2 -22.33 7.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.666 -0.902 . . . . 0.0 110.518 179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.471 HG21 ' O ' ' A' ' 28' ' ' ILE . 9.0 tt -97.41 107.06 36.64 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 120.839 -1.163 . . . . 0.0 110.28 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.467 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.91 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.318 1.167 . . . . 0.0 110.088 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.55 93.73 0.2 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.191 -0.943 . . . . 0.0 110.96 -178.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.25 68.56 0.76 Allowed 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.526 -0.733 . . . . 0.0 111.251 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.76 15.38 9.15 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 5.2 mmpt? -130.67 156.21 45.29 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.028 -1.278 . . . . 0.0 109.243 179.638 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.439 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.79 107.51 15.14 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 109.348 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.471 ' O ' HG21 ' A' ' 21' ' ' ILE . 4.2 mt -69.83 113.91 20.95 Favored Pre-proline 0 C--N 1.298 -1.654 0 O-C-N 121.474 -0.766 . . . . 0.0 110.688 -179.235 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.468 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.9 Cg_endo -70.18 130.81 19.45 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 106.443 -2.176 . . . . 0.0 106.443 175.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.418 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 8.1 mt -55.92 -18.41 8.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.718 -1.238 . . . . 0.0 110.518 -177.716 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.75 -16.16 25.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.771 -1.205 . . . . 0.0 110.484 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.433 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 13.3 m -92.03 -25.04 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.976 -1.078 . . . . 0.0 110.93 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.551 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 42.2 pt -117.06 -17.48 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.079 -1.013 . . . . 0.0 110.622 -179.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.451 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.49 22.84 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.947 -1.095 . . . . 0.0 110.262 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.05 -7.56 27.24 Favored Glycine 0 N--CA 1.485 1.947 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.02 3.21 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.149 -1.5 . . . . 0.0 110.342 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.42 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -111.99 129.95 56.02 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.353 -1.086 . . . . 0.0 110.232 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.551 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.63 146.94 46.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.06 -1.025 . . . . 0.0 110.953 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.8 tp -109.65 115.66 30.3 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.475 -0.765 . . . . 0.0 110.216 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.473 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 35.8 mt -98.96 127.67 51.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.15 -0.969 . . . . 0.0 109.465 179.284 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -94.88 122.62 37.7 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.556 -0.715 . . . . 0.0 110.518 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.2 31.24 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.344 -0.847 . . . . 0.0 110.581 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.3 p80 -109.31 8.17 25.48 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.245 -0.91 . . . . 0.0 109.478 178.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.93 135.95 41.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.13 -0.981 . . . . 0.0 110.316 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.51 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.94 -42.37 66.7 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.55 -0.719 . . . . 0.0 110.818 -179.687 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.63 -36.51 74.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.345 -0.847 . . . . 0.0 110.428 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.29 -36.28 68.9 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.482 -0.761 . . . . 0.0 109.809 -179.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.4 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 2.2 m -60.89 -34.04 74.03 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.359 -0.838 . . . . 0.0 109.77 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.34 -49.31 56.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.268 -0.895 . . . . 0.0 110.672 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.56 -43.85 65.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.208 -0.933 . . . . 0.0 110.383 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.422 ' CD1' HG13 ' A' ' 83' ' ' VAL . 1.5 tm? -56.34 -41.14 75.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.422 -0.799 . . . . 0.0 110.909 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.21 -51.41 13.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 110.372 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.75 -43.86 98.02 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.055 -1.028 . . . . 0.0 109.582 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.467 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -56.83 -43.84 81.45 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.309 -0.87 . . . . 0.0 109.549 179.528 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.485 ' HB3' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.46 -42.89 74.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.444 -0.785 . . . . 0.0 109.704 179.592 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.8 t -55.84 -30.78 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.133 -0.98 . . . . 0.0 108.71 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.15 -33.32 59.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.574 -0.703 . . . . 0.0 110.121 179.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.466 HD23 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -71.74 -26.37 62.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 109.614 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.97 5.64 8.05 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.452 HG23 HG21 ' A' ' 81' ' ' VAL . 19.8 mt -108.29 143.57 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.199 -1.177 . . . . 0.0 110.235 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.414 ' ND2' HD13 ' A' ' 74' ' ' ILE . 19.5 t30 -86.12 107.34 17.8 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.199 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.485 ' CB ' ' HB3' ' A' ' 55' ' ' LEU . . . -121.96 146.92 46.67 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.002 -1.079 . . . . 0.0 112.064 -177.151 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.499 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -135.92 150.29 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.66 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -112.69 131.82 55.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.222 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.464 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -120.82 123.42 42.54 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.933 . . . . 0.0 110.731 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.51 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 4.1 p90 -155.2 178.43 10.22 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.641 179.546 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -52.36 128.17 24.58 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.071 -1.018 . . . . 0.0 110.63 -179.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.25 39.27 31.99 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.48 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -117.02 155.63 28.88 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.124 -1.221 . . . . 0.0 109.777 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.463 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 27.0 m-20 -95.39 149.15 21.7 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.272 -0.893 . . . . 0.0 110.884 -179.125 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.421 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 34.7 m -62.21 111.4 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.061 -1.024 . . . . 0.0 108.873 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.401 ' CB ' HG13 ' A' ' 63' ' ' VAL . 4.2 m -134.33 -36.06 0.9 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.895 . . . . 0.0 110.888 -179.11 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.499 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 20.6 t -50.91 134.7 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.195 -0.941 . . . . 0.0 109.851 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.429 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.8 pp -136.91 109.52 9.17 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.219 -0.926 . . . . 0.0 110.905 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -86.93 46.79 1.51 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.485 1.255 . . . . 0.0 110.245 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.5 p -129.87 -9.49 4.42 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.068 -1.02 . . . . 0.0 111.424 -179.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -88.9 -171.94 3.49 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.933 -1.104 . . . . 0.0 110.366 -179.74 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.11 -80.19 0.07 OUTLIER Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 -130.8 114.44 15.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.174 -1.192 . . . . 0.0 110.072 179.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.42 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.6 p -116.85 134.94 58.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 CA-C-O 121.969 0.89 . . . . 0.0 109.855 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.48 HG23 ' CB ' ' A' ' 62' ' ' ALA . 16.0 m -113.34 124.45 69.99 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.341 0 O-C-N 121.422 -0.799 . . . . 0.0 109.484 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.472 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.4 117.25 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.096 -1.003 . . . . 0.0 109.934 -178.61 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.499 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.7 m -112.08 100.07 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.986 -1.071 . . . . 0.0 108.625 179.697 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.464 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.9 162.24 35.64 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.752 -1.218 . . . . 0.0 110.943 -178.149 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -91.35 -133.15 0.12 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.627 -0.671 . . . . 0.0 109.24 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.403 ' N ' ' OD1' ' A' ' 86' ' ' ASP . 46.5 p-10 -88.42 43.33 1.12 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.663 -1.273 . . . . 0.0 110.342 179.709 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.446 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.79 -30.29 6.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 110.144 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.446 ' O ' ' N ' ' A' ' 90' ' ' THR . 2.2 tp -68.9 -29.13 67.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.041 -1.037 . . . . 0.0 109.28 179.421 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.454 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.8 OUTLIER 55.61 -85.9 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.833 -0.542 . . . . 0.0 110.418 179.872 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.446 ' N ' ' O ' ' A' ' 88' ' ' LEU . 0.3 OUTLIER 173.61 43.14 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.023 -1.048 . . . . 0.0 110.22 -179.928 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -56.85 -46.87 89.87 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 179.412 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -138.17 28.15 2.57 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.453 -1.028 . . . . 0.0 110.128 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.425 HG21 ' HA ' ' A' ' 90' ' ' THR . 3.1 t -86.26 -160.41 0.55 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.16 -0.963 . . . . 0.0 110.42 -179.656 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.437 ' O ' ' CG ' ' A' ' 124' ' ' ARG . . . 100.53 -31.83 8.08 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 -107.46 73.89 0.94 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.815 -1.403 . . . . 0.0 111.163 -179.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -119.74 153.18 36.04 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.066 . . . . 0.0 110.139 178.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.91 -26.99 25.26 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.386 -0.821 . . . . 0.0 109.551 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.8 p -162.52 163.63 27.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 111.432 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.0 126.21 49.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.479 -0.763 . . . . 0.0 109.718 179.114 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.414 ' CG2' HD13 ' A' ' 28' ' ' ILE . 2.8 mp -105.51 111.54 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.088 -1.007 . . . . 0.0 109.117 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -121.58 161.0 23.17 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.249 -0.907 . . . . 0.0 111.565 -178.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.1 t -96.26 -6.91 36.86 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 177.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.76 11.01 1.21 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.37 -0.831 . . . . 0.0 112.225 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.35 126.26 12.75 Favored 'General case' 0 C--N 1.31 -1.123 0 O-C-N 120.537 -1.352 . . . . 0.0 109.509 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 108' ' ' LYS . 24.6 p -100.54 129.27 46.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.918 . . . . 0.0 110.189 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 57.3 29.1 16.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.223 -0.923 . . . . 0.0 110.552 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.75 -30.56 7.78 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -82.51 155.36 68.83 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.175 -1.191 . . . . 0.0 110.206 -179.885 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -64.69 137.41 54.08 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 123.552 1.291 . . . . 0.0 110.503 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.403 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 -51.29 163.62 0.24 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.475 -0.766 . . . . 0.0 110.956 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.421 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.2 p30 -83.53 161.4 21.23 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.298 -0.876 . . . . 0.0 110.062 179.69 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.431 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.53 -61.88 1.25 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.435 -0.791 . . . . 0.0 112.172 -178.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.421 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.1 m -60.41 -29.31 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.742 -1.224 . . . . 0.0 111.692 -178.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.407 ' N ' HG21 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.21 -56.49 6.6 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.01 -1.056 . . . . 0.0 110.749 -178.812 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.431 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.03 76.88 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.124 -0.985 . . . . 0.0 108.668 178.947 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.2 m -60.49 -50.03 75.18 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.109 -0.995 . . . . 0.0 108.368 178.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.24 63.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.477 -0.764 . . . . 0.0 110.184 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.402 ' HB2' ' O ' ' A' ' 114' ' ' SER . 10.8 mtt85 -71.2 -44.31 65.68 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.119 -0.988 . . . . 0.0 111.138 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.495 ' NE ' ' NE2' ' A' ' 7' ' ' HIS . 11.8 ttp180 -70.46 -40.0 73.96 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.999 -1.063 . . . . 0.0 109.975 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.96 63.33 0.71 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -137.12 -45.93 0.57 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.144 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.439 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.1 t -95.16 142.29 27.78 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.316 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.2 17.33 51.01 Favored Glycine 0 N--CA 1.484 1.887 0 C-N-CA 119.528 -1.32 . . . . 0.0 110.356 178.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.437 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -52.07 -37.86 55.21 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.059 -1.26 . . . . 0.0 109.705 179.666 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.0 28.59 2.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.478 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.6 -168.25 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.694 -0.886 . . . . 0.0 109.123 -179.415 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.478 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.6 Cg_endo -86.66 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.167 1.088 . . . . 0.0 110.556 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.439 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.09 157.67 41.35 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.1 mt -106.85 141.59 21.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.041 -1.27 . . . . 0.0 109.105 178.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -130.07 114.81 16.23 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.07 -1.052 . . . . 0.0 110.227 179.392 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.8 mtt180 -101.5 122.15 43.27 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.428 -0.795 . . . . 0.0 109.656 179.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.417 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 14.3 p90 -120.24 154.54 34.74 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.896 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 75.4 t -86.67 -41.3 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.205 -0.934 . . . . 0.0 110.235 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -101.45 111.57 63.93 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.16 -0.962 . . . . 0.0 110.336 -179.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.404 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 44.6 Cg_endo -71.5 -46.74 0.58 Allowed 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.529 1.279 . . . . 0.0 110.311 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 97.31 129.72 6.38 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 51.8 82.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.245 -1.15 . . . . 0.0 110.407 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.306 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.19 102.59 14.41 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.217 -1.166 . . . . 0.0 110.154 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.43 ' CG1' ' O ' ' A' ' 3' ' ' VAL . 10.4 p -113.32 104.32 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.283 -0.886 . . . . 0.0 109.689 179.474 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.2 p -100.41 140.44 34.66 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.339 -0.85 . . . . 0.0 110.41 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.483 ' O ' ' CE1' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -67.21 147.38 98.98 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.343 -0.848 . . . . 0.0 109.101 179.589 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.527 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 45.9 Cg_endo -73.93 -19.54 20.56 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 O-C-N 124.054 1.555 . . . . 0.0 113.113 -178.541 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.527 ' CG ' ' C ' ' A' ' 6' ' ' PRO . 1.8 p-80 42.73 75.8 0.59 Allowed Pre-proline 0 N--CA 1.502 2.146 0 O-C-N 121.375 -0.828 . . . . 0.0 110.715 -178.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.43 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 43.6 Cg_endo -71.02 -175.11 1.34 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.735 1.387 . . . . 0.0 110.145 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.43 ' HB2' ' O ' ' A' ' 8' ' ' PRO . 8.5 m120 65.77 7.15 4.34 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.685 -0.634 . . . . 0.0 111.221 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.474 ' CD1' HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.55 126.23 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.674 -1.266 . . . . 0.0 109.313 179.136 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.78 127.59 34.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.942 179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.47 136.18 33.22 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.209 -0.932 . . . . 0.0 110.104 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.455 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.2 t -129.71 154.95 41.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.368 -0.832 . . . . 0.0 109.925 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.5 112.87 25.98 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.109 -0.994 . . . . 0.0 110.389 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.8 tp -59.31 140.52 55.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.368 -0.833 . . . . 0.0 109.19 179.308 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.33 -178.24 5.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 110.508 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 72.0 p -76.99 59.9 1.73 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.077 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.436 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 10.0 m -132.45 109.34 9.74 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.269 -0.895 . . . . 0.0 110.714 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.439 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.17 -167.2 28.98 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 118.85 -1.643 . . . . 0.0 110.687 179.204 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.54 -18.86 10.83 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.667 -0.902 . . . . 0.0 110.304 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.485 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.2 tt -99.34 104.51 27.25 Favored Pre-proline 0 N--CA 1.49 1.533 0 C-N-CA 118.771 -1.172 . . . . 0.0 109.876 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.423 ' HD2' ' HE3' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -63.55 128.51 22.54 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.336 1.177 . . . . 0.0 111.009 -179.109 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.442 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.95 1.17 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.779 -0.576 . . . . 0.0 109.882 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.1 m-85 -58.11 82.21 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.219 -0.926 . . . . 0.0 111.605 -179.236 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.12 0.52 52.7 Favored Glycine 0 N--CA 1.494 2.566 0 O-C-N 121.156 -0.965 . . . . 0.0 110.888 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.416 ' O ' ' N ' ' A' ' 23' ' ' PHE . 27.3 mmtp -130.51 156.99 43.88 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.877 -1.367 . . . . 0.0 109.538 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.413 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -108.23 107.64 18.34 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 120.977 -1.077 . . . . 0.0 109.474 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.485 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -67.08 113.43 13.42 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.34 -0.85 . . . . 0.0 110.757 -179.344 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.439 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.4 Cg_endo -68.52 130.99 22.01 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 N-CA-C 106.874 -2.01 . . . . 0.0 106.874 176.012 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.419 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 10.7 mt -56.24 -17.61 8.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.816 -1.178 . . . . 0.0 110.728 -177.815 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -59.9 -16.41 29.25 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.64 -1.287 . . . . 0.0 110.518 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG2' HG22 ' A' ' 33' ' ' ILE . 13.6 m -93.09 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.005 -1.059 . . . . 0.0 111.213 -179.552 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.493 ' HA ' ' CD2' ' A' ' 38' ' ' HIS . 18.9 pt -119.45 -21.45 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.031 -1.043 . . . . 0.0 110.639 -179.288 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.443 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.79 148.28 22.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.89 -1.131 . . . . 0.0 110.317 179.46 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.14 -3.9 60.38 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.579 -1.409 . . . . 0.0 109.579 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.3 -158.65 21.45 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.447 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.75 132.38 50.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -1.069 . . . . 0.0 110.654 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.493 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.82 147.02 40.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.181 -0.949 . . . . 0.0 110.523 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.419 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.08 122.22 46.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.341 -0.849 . . . . 0.0 110.08 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.443 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 10.3 mm -100.56 126.08 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.271 -0.893 . . . . 0.0 109.186 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -96.5 121.41 38.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.105 -0.997 . . . . 0.0 110.025 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.36 28.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.277 -0.889 . . . . 0.0 110.511 179.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.1 37.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.284 -0.885 . . . . 0.0 110.079 178.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.97 135.39 46.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.067 -1.021 . . . . 0.0 110.459 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.489 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.43 65.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.662 -0.649 . . . . 0.0 110.906 -179.761 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.31 -32.77 73.13 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.36 -0.837 . . . . 0.0 110.843 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.33 65.71 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.399 -0.813 . . . . 0.0 109.9 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.439 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 94.6 m -61.13 -38.52 86.66 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.592 179.154 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.4 -49.16 70.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.128 -0.983 . . . . 0.0 110.531 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.409 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -72.05 -46.29 57.54 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.239 -0.913 . . . . 0.0 110.608 -179.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.44 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.0 tm? -56.73 -41.09 76.87 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.459 -0.776 . . . . 0.0 111.42 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.36 -51.08 60.81 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.851 -1.156 . . . . 0.0 109.759 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.8 -32.5 69.4 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.236 -0.915 . . . . 0.0 109.347 179.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.442 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -61.72 -33.67 74.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.573 -0.704 . . . . 0.0 109.352 179.63 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.504 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -74.91 -42.44 57.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.423 -0.798 . . . . 0.0 110.397 -179.911 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.07 -33.03 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.048 -1.033 . . . . 0.0 109.189 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.43 -32.95 60.87 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.502 -0.749 . . . . 0.0 109.918 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.512 HD23 ' N ' ' A' ' 58' ' ' LEU . 3.5 mm? -71.96 -26.37 62.24 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.947 0.88 . . . . 0.0 109.981 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.81 3.06 10.21 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.289 -1.525 . . . . 0.0 109.289 -179.251 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.453 ' CG2' HG21 ' A' ' 81' ' ' VAL . 31.2 mt -103.88 143.96 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.356 -1.085 . . . . 0.0 109.955 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 35.1 t30 -88.68 106.87 18.62 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.178 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.504 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.92 145.28 44.77 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 118.868 -1.133 . . . . 0.0 111.739 -177.2 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.492 ' HB ' HG22 ' A' ' 73' ' ' VAL . 70.5 t -129.22 152.74 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.084 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -118.67 117.33 28.66 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.156 -1.018 . . . . 0.0 109.237 177.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.436 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -105.76 127.48 53.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.172 -0.955 . . . . 0.0 110.826 -179.256 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.537 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 10.0 p90 -155.58 -178.66 7.44 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.503 -0.748 . . . . 0.0 110.096 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.35 127.41 22.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.171 -0.956 . . . . 0.0 110.834 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.23 53.1 23.6 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.537 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.42 154.44 31.35 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.211 -1.17 . . . . 0.0 109.794 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.462 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.7 m-20 -91.21 149.37 21.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.229 -0.919 . . . . 0.0 110.427 -179.297 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.422 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.2 m -61.69 110.65 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.024 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 72.5 m -132.2 -38.72 1.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.759 . . . . 0.0 109.973 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.492 HG22 ' HB ' ' A' ' 63' ' ' VAL . 95.3 t -49.5 133.32 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.39 -0.819 . . . . 0.0 109.484 179.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.417 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.1 pp -133.76 89.95 29.0 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 120.99 -1.069 . . . . 0.0 110.398 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -90.61 53.5 1.11 Allowed 'Trans proline' 0 C--N 1.311 -1.404 0 O-C-N 124.04 1.547 . . . . 0.0 110.584 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.418 HG23 ' N ' ' A' ' 77' ' ' ASN . 5.1 t -125.68 -25.98 3.59 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.114 -0.991 . . . . 0.0 111.031 -179.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.418 ' N ' HG23 ' A' ' 76' ' ' THR . 56.4 m-80 -155.23 167.69 29.54 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.988 -1.07 . . . . 0.0 110.608 -179.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 54.54 174.72 0.09 OUTLIER Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -94.71 110.16 22.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.058 -1.26 . . . . 0.0 110.206 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.461 ' O ' HG12 ' A' ' 80' ' ' VAL . 6.3 p -116.68 135.13 57.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 122.013 0.911 . . . . 0.0 110.286 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.485 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 9.9 m -113.0 121.23 64.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 O-C-N 121.242 -0.911 . . . . 0.0 108.877 179.2 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 39' ' ' LEU . 15.1 t -97.82 120.04 46.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 O-C-N 120.788 -1.195 . . . . 0.0 111.257 -177.612 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 2.8 m -111.26 99.0 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 122.361 1.077 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.436 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.45 155.04 46.35 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 120.514 -1.366 . . . . 0.0 110.526 -178.775 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.432 ' CG2' ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.87 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.222 -0.923 . . . . 0.0 110.663 -179.322 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.432 ' N ' ' CG2' ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.77 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.123 -0.986 . . . . 0.0 110.608 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.04 -33.92 9.96 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.039 179.362 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.41 HD11 ' CD2' ' A' ' 65' ' ' TYR . 5.3 tp -67.48 -42.27 83.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.597 -0.689 . . . . 0.0 109.341 178.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.466 ' O ' ' N ' ' A' ' 91' ' ' GLY . 0.5 OUTLIER 49.74 23.41 0.99 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.55 -0.719 . . . . 0.0 110.462 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.458 ' CG2' ' HB ' ' A' ' 93' ' ' THR . 89.8 m 53.91 -85.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.445 -0.784 . . . . 0.0 110.719 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 65.11 -83.41 0.07 OUTLIER Glycine 0 N--CA 1.492 2.381 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.42 ' N ' ' O ' ' A' ' 90' ' ' THR . 29.6 p90 -97.87 37.85 1.36 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.371 -1.076 . . . . 0.0 108.587 178.144 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.473 HG22 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -137.75 -168.74 2.39 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.714 -0.617 . . . . 0.0 110.311 -179.284 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 133.01 -17.92 4.55 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.34 75.92 3.92 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -1.19 . . . . 0.0 110.643 -179.8 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.473 ' CZ ' HG22 ' A' ' 93' ' ' THR . 27.3 m-85 -113.43 150.89 32.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.172 -0.955 . . . . 0.0 109.81 179.489 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.479 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.2 -32.58 56.07 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.369 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.45 163.06 30.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.203 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.506 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.29 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.389 -0.819 . . . . 0.0 110.031 179.264 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.427 HD12 HG23 ' A' ' 33' ' ' ILE . 3.3 mp -93.44 112.82 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.264 -0.898 . . . . 0.0 108.584 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.424 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.93 161.35 20.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 111.52 -178.269 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.453 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 58.5 m -88.86 -13.32 39.51 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.15 10.63 1.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.295 -0.878 . . . . 0.0 112.073 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.42 ' CA ' ' O ' ' A' ' 108' ' ' LYS . 0.9 OUTLIER -147.47 130.55 16.36 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 120.755 -1.216 . . . . 0.0 109.133 179.598 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.44 ' N ' ' O ' ' A' ' 108' ' ' LYS . 86.2 p -107.58 134.97 49.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.159 -0.963 . . . . 0.0 110.546 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.6 t0 55.95 32.85 20.6 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.304 -0.873 . . . . 0.0 110.959 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 79.4 12.44 83.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.44 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -123.41 156.06 64.47 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.056 -1.261 . . . . 0.0 109.604 179.705 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -62.88 127.71 21.18 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.543 1.286 . . . . 0.0 110.726 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.434 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 -44.02 160.93 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 CA-C-O 121.366 0.603 . . . . 0.0 111.544 -179.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -87.47 160.78 18.15 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.466 -0.771 . . . . 0.0 110.359 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -42.02 -55.34 3.21 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.647 -0.658 . . . . 0.0 112.553 -178.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.438 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 9.3 m -70.62 -29.64 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.705 -1.247 . . . . 0.0 111.838 -178.197 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.434 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.49 -56.28 7.37 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.129 -0.982 . . . . 0.0 110.553 -179.243 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.406 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.2 -35.08 77.43 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.465 -0.894 . . . . 0.0 108.786 178.905 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.438 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 99.6 m -59.14 -49.8 76.47 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.537 178.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.406 ' OE1' ' CE ' ' A' ' 89' ' ' MET . 7.7 tt0 -73.28 -36.04 66.24 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.494 -0.754 . . . . 0.0 109.98 179.022 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 8.8 mtt85 -71.9 -44.98 62.81 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.262 -0.899 . . . . 0.0 111.118 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.527 ' CD ' ' CD2' ' A' ' 7' ' ' HIS . 0.8 OUTLIER -64.36 -36.62 84.71 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.984 -1.072 . . . . 0.0 110.318 -179.873 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.43 0.76 Allowed Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.418 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -135.51 -43.02 0.69 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.411 -1.053 . . . . 0.0 109.206 179.489 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.474 HG23 ' CD1' ' A' ' 10' ' ' ILE . 14.8 t -102.32 141.77 34.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.561 -0.712 . . . . 0.0 109.632 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.432 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.16 10.81 14.8 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.502 -1.332 . . . . 0.0 110.15 179.761 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.11 84.71 1.82 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.956 -1.32 . . . . 0.0 109.876 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 96.33 16.13 38.66 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.469 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.89 0.22 Allowed Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.259 -1.142 . . . . 0.0 109.378 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.469 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.2 Cg_endo -88.06 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 O-C-N 123.349 1.183 . . . . 0.0 110.412 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.455 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.26 160.05 45.64 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.49 142.75 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.417 -1.049 . . . . 0.0 108.779 178.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.506 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 8.4 t80 -129.91 117.27 19.87 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 120.953 -1.092 . . . . 0.0 111.016 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.455 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 22.2 mtt180 -101.42 123.5 45.58 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.548 -0.72 . . . . 0.0 109.331 179.22 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.415 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.19 156.24 26.87 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.041 -1.037 . . . . 0.0 110.533 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 4.6 t -84.78 -67.44 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.171 -0.956 . . . . 0.0 109.392 179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 52.77 95.24 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.551 -0.718 . . . . 0.0 110.37 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.27 -35.0 7.18 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 O-C-N 123.644 1.339 . . . . 0.0 110.401 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 63.38 -170.03 17.25 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -62.08 121.98 14.4 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.287 -1.126 . . . . 0.0 110.258 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.281 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.454 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.28 133.05 43.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.215 -1.168 . . . . 0.0 110.3 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.42 104.45 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.25 -0.906 . . . . 0.0 110.175 179.662 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.3 p -65.95 145.07 56.34 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.368 -0.832 . . . . 0.0 110.235 179.813 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.436 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.28 147.22 98.96 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.265 -0.897 . . . . 0.0 109.851 179.926 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.436 ' HD2' HG21 ' A' ' 5' ' ' VAL . 44.8 Cg_endo -71.73 -169.02 0.39 Allowed 'Trans proline' 0 C--N 1.307 -1.634 0 O-C-N 124.15 1.605 . . . . 0.0 111.066 179.248 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.54 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 3.3 p80 -178.89 82.99 0.21 Allowed Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 179.464 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -65.79 89.64 0.23 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.756 1.398 . . . . 0.0 110.905 -179.17 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.454 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -179.98 -35.62 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.554 0.692 . . . . 0.0 109.365 179.859 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.481 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 14.6 mt -96.73 133.73 37.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.935 -1.103 . . . . 0.0 110.203 179.816 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -84.2 128.14 34.38 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.35 -0.844 . . . . 0.0 109.541 179.19 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -89.4 121.5 31.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.069 -1.02 . . . . 0.0 109.9 -179.573 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.446 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 4.8 t -115.69 156.63 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.368 -0.833 . . . . 0.0 110.222 -179.34 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.77 105.07 15.17 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.281 -0.887 . . . . 0.0 109.625 179.078 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 12.7 tp -54.15 132.51 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.35 -0.844 . . . . 0.0 109.658 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.51 -174.7 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 110.256 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.94 63.43 3.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 110.041 179.835 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.431 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 5.0 m -132.07 112.08 12.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.337 -0.852 . . . . 0.0 110.244 -179.834 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.486 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.21 -163.41 26.72 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 119.158 -1.496 . . . . 0.0 110.455 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.39 -22.5 5.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.525 -0.985 . . . . 0.0 110.729 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.487 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 6.6 tt -93.94 113.24 60.04 Favored Pre-proline 0 N--CA 1.487 1.417 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.064 -179.5 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.23 150.76 87.68 Favored 'Trans proline' 0 C--N 1.313 -1.309 0 O-C-N 123.519 1.273 . . . . 0.0 110.026 -179.824 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.475 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.95 88.84 0.62 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.137 -0.977 . . . . 0.0 111.374 -178.477 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.514 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.14 67.18 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.349 -0.845 . . . . 0.0 111.26 179.146 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.03 13.75 21.29 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.708 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.475 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.36 156.16 45.17 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.063 -1.257 . . . . 0.0 109.366 179.738 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -112.47 106.97 15.57 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.918 -1.114 . . . . 0.0 109.279 179.74 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.487 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.2 mt -69.47 114.11 21.83 Favored Pre-proline 0 C--N 1.3 -1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 110.384 -179.307 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.486 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.7 Cg_endo -70.67 129.98 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 N-CA-C 107.024 -1.952 . . . . 0.0 107.024 176.364 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.435 HD22 HG22 ' A' ' 21' ' ' ILE . 15.7 mt -56.62 -17.49 8.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.939 -1.101 . . . . 0.0 110.744 -177.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.423 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -60.86 -16.19 38.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.817 -1.177 . . . . 0.0 110.347 179.503 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.438 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.4 m -93.77 -25.35 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.003 -1.061 . . . . 0.0 111.15 -179.348 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.533 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 46.0 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 110.472 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.444 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.03 147.86 24.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.256 -0.902 . . . . 0.0 110.429 179.898 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.36 -5.63 38.49 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.95 -145.62 7.11 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.198 -1.477 . . . . 0.0 110.44 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.1 mtt85 -108.53 132.67 53.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.415 -1.05 . . . . 0.0 110.264 -179.696 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.533 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -140.71 150.56 43.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.023 -1.048 . . . . 0.0 111.031 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.412 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 62.1 tp -110.98 114.29 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.447 -0.783 . . . . 0.0 109.947 179.565 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.465 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 29.2 mt -98.75 127.15 51.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.131 -0.981 . . . . 0.0 109.493 179.689 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -95.44 124.01 39.26 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.172 -0.955 . . . . 0.0 110.143 -179.78 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.76 21.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.202 -0.936 . . . . 0.0 110.494 -179.688 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.514 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.2 p80 -107.02 -1.41 22.17 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.352 -0.843 . . . . 0.0 110.073 179.03 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.91 136.8 42.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.1 -1.0 . . . . 0.0 110.465 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.47 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.72 -38.27 70.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.466 -0.771 . . . . 0.0 110.663 -179.848 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.86 -35.6 73.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.333 -0.854 . . . . 0.0 110.453 -179.636 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.421 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.68 -35.83 65.24 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.79 -179.958 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.431 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 76.3 m -61.2 -34.01 74.4 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.415 -0.803 . . . . 0.0 109.757 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.7 -50.17 53.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 110.245 -179.841 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.406 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.32 -43.5 64.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.288 -0.882 . . . . 0.0 110.065 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.429 HD11 HG11 ' A' ' 83' ' ' VAL . 3.3 tm? -57.12 -42.51 81.03 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.602 -0.686 . . . . 0.0 111.248 -178.994 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.03 -51.09 42.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.796 -1.19 . . . . 0.0 110.013 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.24 -34.62 68.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.272 -0.893 . . . . 0.0 109.25 179.462 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.472 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.81 -46.39 84.74 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.274 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.483 ' CB ' ' HB2' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -59.78 -43.35 94.43 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.39 -0.819 . . . . 0.0 110.999 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.4 t -56.11 -34.14 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.966 -1.084 . . . . 0.0 109.375 179.617 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.51 -34.46 60.82 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.297 -0.877 . . . . 0.0 110.315 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.472 HD22 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.35 -25.84 62.56 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.285 -0.884 . . . . 0.0 109.699 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.2 7.86 8.18 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.633 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.456 HG22 HG23 ' A' ' 81' ' ' VAL . 47.0 mt -108.47 143.48 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.254 -1.145 . . . . 0.0 110.119 -179.756 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.418 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 16.7 t30 -89.25 106.53 18.5 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.168 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.483 ' HB2' ' CB ' ' A' ' 55' ' ' LEU . . . -118.48 145.21 45.45 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.977 -1.089 . . . . 0.0 111.629 -177.244 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.472 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.95 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.066 -0.653 . . . . 0.0 109.454 179.719 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.514 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -108.2 122.52 47.09 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.585 178.818 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.435 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.4 OUTLIER -109.52 131.35 55.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.262 -0.899 . . . . 0.0 110.809 -179.534 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.483 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.24 178.32 5.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.563 -0.711 . . . . 0.0 109.905 179.644 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.55 125.52 20.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.045 -1.035 . . . . 0.0 110.814 -179.366 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.83 40.93 13.44 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.743 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.483 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.38 157.02 26.89 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -1.14 . . . . 0.0 110.322 -179.831 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.442 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 21.8 m-20 -98.48 149.33 22.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.281 -0.887 . . . . 0.0 110.571 -179.378 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 31.5 m -62.33 111.36 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.036 . . . . 0.0 109.311 179.123 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.437 ' CB ' HG11 ' A' ' 63' ' ' VAL . 43.8 m -134.31 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.52 -0.737 . . . . 0.0 110.368 -179.415 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.472 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 76.9 t -46.47 131.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.489 -0.757 . . . . 0.0 110.685 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.408 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.3 pp -137.75 91.61 13.55 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.166 -0.958 . . . . 0.0 110.659 179.408 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.44 ' HA ' ' CG1' ' A' ' 80' ' ' VAL . 49.7 Cg_endo -89.32 44.9 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.608 1.32 . . . . 0.0 109.947 178.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -124.38 -21.94 4.81 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.285 -0.884 . . . . 0.0 111.255 -179.097 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.6 m-20 -139.8 150.12 44.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.941 -1.099 . . . . 0.0 110.855 -179.385 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 51.79 -177.78 0.08 OUTLIER Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.66 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -94.55 112.31 24.07 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.342 -1.093 . . . . 0.0 109.954 179.848 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.44 ' CG1' ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -116.39 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-O 121.899 0.857 . . . . 0.0 110.199 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 10.1 m -111.91 123.35 67.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.159 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.426 HG11 HG12 ' A' ' 73' ' ' VAL . 33.2 t -96.62 118.11 42.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.061 -1.025 . . . . 0.0 110.612 -178.062 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.514 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.2 m -111.75 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 118.93 -1.108 . . . . 0.0 108.756 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.435 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -131.44 156.46 45.58 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 120.69 -1.256 . . . . 0.0 110.339 -178.606 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.446 HG22 ' N ' ' A' ' 86' ' ' ASP . 9.0 t -94.07 -30.46 14.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.367 -0.833 . . . . 0.0 111.471 -178.583 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.446 ' N ' HG22 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.56 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.931 -1.106 . . . . 0.0 111.529 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.446 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -46.79 -39.95 12.76 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.958 -1.089 . . . . 0.0 110.163 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.9 tp -64.59 -40.34 95.35 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.213 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.456 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 45.09 26.79 0.25 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.864 -0.523 . . . . 0.0 111.219 179.378 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.417 HG21 ' NE ' ' A' ' 121' ' ' ARG . 63.8 p 43.41 -133.45 0.56 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.551 -0.718 . . . . 0.0 110.988 179.616 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.87 -78.07 0.79 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.675 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -95.52 18.34 12.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.275 -1.133 . . . . 0.0 109.812 179.27 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.48 ' OG1' ' CE2' ' A' ' 96' ' ' PHE . 13.3 t -98.88 -148.55 0.34 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.363 -0.836 . . . . 0.0 110.199 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.44 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 115.12 18.57 6.25 Favored Glycine 0 N--CA 1.491 2.3 0 C-N-CA 119.835 -1.174 . . . . 0.0 110.171 179.462 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -125.32 59.62 1.25 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.945 -1.326 . . . . 0.0 110.344 179.761 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.48 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 25.2 m-85 -120.22 135.55 54.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.04 -1.037 . . . . 0.0 110.381 179.868 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.482 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.14 -27.75 57.15 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.556 179.22 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -160.38 163.0 33.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.29 -0.881 . . . . 0.0 110.54 179.501 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.479 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.82 115.9 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.228 -0.92 . . . . 0.0 110.336 179.66 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.4 ' CG2' HD12 ' A' ' 28' ' ' ILE . 3.2 mp -93.44 114.63 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.6 161.31 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.09 -1.006 . . . . 0.0 111.829 -178.151 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.26 9.09 38.28 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.946 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.42 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 52.35 23.18 2.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.194 -0.941 . . . . 0.0 110.97 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p -144.25 137.94 27.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 110.657 179.584 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.403 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.7 p -111.09 121.91 46.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.369 -0.832 . . . . 0.0 109.495 179.622 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 55.06 -141.61 0.85 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.096 -1.003 . . . . 0.0 109.426 -179.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.25 9.6 57.19 Favored Glycine 0 N--CA 1.49 2.288 0 C-N-CA 119.813 -1.185 . . . . 0.0 110.234 179.776 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.403 ' O ' ' N ' ' A' ' 105' ' ' SER . 11.3 mmtt -126.16 155.47 73.62 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 120.857 -1.378 . . . . 0.0 109.868 -179.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.48 160.7 46.68 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 O-C-N 123.505 1.266 . . . . 0.0 110.519 179.912 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.449 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER -68.12 147.6 52.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.356 -0.84 . . . . 0.0 110.722 -179.473 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.409 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -84.96 161.0 19.96 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.154 -0.966 . . . . 0.0 110.085 179.605 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.401 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.26 -57.45 2.98 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.517 -0.74 . . . . 0.0 112.433 -178.531 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.417 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.2 m -68.6 -29.39 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 120.688 -1.257 . . . . 0.0 111.847 -178.143 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.449 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.21 -56.23 7.07 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.039 -1.038 . . . . 0.0 110.545 -179.263 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.445 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.7 ptm180 -70.43 -35.15 73.22 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.377 -0.929 . . . . 0.0 108.873 179.073 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.417 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.9 m -58.98 -49.55 77.47 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.04 -1.037 . . . . 0.0 108.371 178.637 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.78 -35.85 64.98 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.394 -0.816 . . . . 0.0 109.863 178.704 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.445 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.69 -44.54 64.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.08 -1.013 . . . . 0.0 110.934 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.54 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 17.2 ttm180 -53.12 -41.82 65.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.896 -1.127 . . . . 0.0 109.713 179.587 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.37 63.28 0.26 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.433 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -132.57 -42.71 0.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.449 -1.03 . . . . 0.0 108.658 179.152 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.444 ' CG2' HG23 ' A' ' 10' ' ' ILE . 10.9 t -98.17 144.05 28.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.653 -0.654 . . . . 0.0 109.576 179.148 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.431 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.24 9.25 36.85 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.692 -1.242 . . . . 0.0 110.32 179.35 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.44 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 2.9 mmt180 -66.29 87.5 0.11 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.99 -1.3 . . . . 0.0 109.52 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.74 23.27 28.65 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -178.772 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.452 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.43 -179.81 0.3 Allowed Pre-proline 0 N--CA 1.492 1.646 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.454 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.7 Cg_endo -88.93 105.97 0.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.09 1.047 . . . . 0.0 110.882 -179.939 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.438 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.64 179.47 53.47 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.409 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.51 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.468 -1.019 . . . . 0.0 108.951 179.033 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.479 ' CD2' HG23 ' A' ' 99' ' ' VAL . 11.7 t80 -129.71 115.83 17.9 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.897 -1.121 . . . . 0.0 111.063 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.429 ' HD2' ' CG1' ' A' ' 32' ' ' VAL . 1.7 mtt180 -100.58 134.33 43.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.515 -0.74 . . . . 0.0 109.029 179.366 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.4 p90 -126.28 156.73 39.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.931 -1.105 . . . . 0.0 110.582 -179.456 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 55.9 t -94.28 -46.02 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.287 -0.883 . . . . 0.0 109.9 179.561 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.42 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -119.79 103.77 45.45 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.207 -0.933 . . . . 0.0 110.279 -179.79 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.39 -21.37 22.97 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 O-C-N 123.542 1.285 . . . . 0.0 110.711 -179.733 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -117.45 140.54 15.81 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 -179.966 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -69.56 -29.33 66.88 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.267 -1.137 . . . . 0.0 110.282 179.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.231 179.878 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.37 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.8 108.09 4.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -1.131 . . . . 0.0 110.259 -179.984 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.429 ' O ' ' CG2' ' A' ' 3' ' ' VAL . 31.3 m -113.37 105.22 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.973 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.7 p -63.22 144.89 56.54 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.328 -0.858 . . . . 0.0 110.32 -179.846 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.414 HG22 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -70.39 147.23 94.98 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.3 -0.875 . . . . 0.0 110.248 -179.885 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.414 ' HD2' HG22 ' A' ' 5' ' ' VAL . 52.1 Cg_endo -76.4 -173.61 1.78 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 124.203 1.633 . . . . 0.0 110.962 179.609 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.51 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 3.9 p80 -177.97 83.66 0.23 Allowed Pre-proline 0 N--CA 1.489 1.499 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.325 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.85 58.54 1.61 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 O-C-N 123.446 1.235 . . . . 0.0 111.6 -178.989 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -148.59 7.98 0.77 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.095 -1.003 . . . . 0.0 111.18 179.475 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.469 ' CD1' ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.08 137.39 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.832 -1.168 . . . . 0.0 110.62 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.6 128.43 34.51 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 108.866 178.312 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -89.53 142.68 27.45 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.055 -1.028 . . . . 0.0 110.62 -179.007 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.444 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.2 t -137.73 158.02 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.418 -0.802 . . . . 0.0 110.434 -179.694 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.88 109.41 17.58 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.442 -0.786 . . . . 0.0 109.56 179.104 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.44 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 10.1 tp -53.5 136.85 37.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.279 -0.888 . . . . 0.0 109.964 -179.878 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.1 p -137.38 174.49 10.54 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 110.285 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.407 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . 25.8 p -71.63 80.09 0.82 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.196 -0.94 . . . . 0.0 110.067 179.856 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.434 ' N ' ' HB1' ' A' ' 27' ' ' ALA . 17.8 m -155.53 109.05 2.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.176 -0.953 . . . . 0.0 110.799 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.459 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.33 -170.22 29.6 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.833 -1.651 . . . . 0.0 110.942 179.136 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.22 -20.39 12.34 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.755 -0.85 . . . . 0.0 110.417 -179.792 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.461 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.2 tt -98.85 103.88 21.95 Favored Pre-proline 0 N--CA 1.491 1.592 0 C-N-CA 118.906 -1.118 . . . . 0.0 109.86 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.417 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.4 Cg_endo -62.63 124.96 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.32 1.168 . . . . 0.0 110.84 -179.369 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.426 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.49 -166.85 1.13 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.737 -0.602 . . . . 0.0 110.433 -179.239 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.527 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.17 81.77 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.465 -0.772 . . . . 0.0 111.514 -179.451 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.1 2.25 52.27 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.607 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.44 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 15.1 mmtp -130.18 156.3 44.81 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.973 -1.31 . . . . 0.0 109.355 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.434 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -106.69 107.43 18.44 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.961 -1.087 . . . . 0.0 109.078 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.461 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.2 mt -69.33 112.92 13.42 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.312 -0.867 . . . . 0.0 110.521 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.459 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.1 Cg_endo -68.54 129.62 19.28 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 N-CA-C 107.161 -1.9 . . . . 0.0 107.161 176.282 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.432 HD21 HG21 ' A' ' 21' ' ' ILE . 10.9 mt -56.27 -17.78 8.61 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.83 -1.169 . . . . 0.0 110.69 -177.803 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -59.88 -16.05 26.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.677 -1.265 . . . . 0.0 110.575 179.898 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.454 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 10.6 m -93.99 -25.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.982 -1.074 . . . . 0.0 110.775 -179.727 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.512 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 12.3 pt -114.62 -23.27 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.094 -1.004 . . . . 0.0 110.57 -179.508 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.486 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.0 tptm -93.81 147.96 22.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.803 -1.185 . . . . 0.0 110.2 179.381 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.77 -3.42 52.85 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.799 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.64 -150.63 8.64 Favored Glycine 0 N--CA 1.494 2.533 0 C-N-CA 118.927 -1.606 . . . . 0.0 110.626 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.42 129.41 55.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.435 -1.038 . . . . 0.0 109.968 -179.793 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.1 m-70 -137.8 149.42 46.35 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.982 -1.074 . . . . 0.0 110.963 -179.635 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.483 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 34.1 tp -110.82 117.27 32.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.419 -0.8 . . . . 0.0 110.21 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.442 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 12.1 mm -97.92 125.42 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.293 -0.88 . . . . 0.0 109.471 179.792 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.48 ' CE2' HD23 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.67 123.38 42.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.093 -1.004 . . . . 0.0 109.882 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.21 159.39 22.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.545 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.527 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.56 23.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.161 179.373 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.35 141.12 51.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.11 -0.994 . . . . 0.0 110.382 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.426 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.63 -31.82 67.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.478 -0.764 . . . . 0.0 110.58 -179.762 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.47 75.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.183 -0.948 . . . . 0.0 110.54 -179.861 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.411 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.2 OUTLIER -73.83 -34.26 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.873 . . . . 0.0 109.622 179.803 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.465 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.7 m -60.52 -35.05 75.04 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.398 -0.814 . . . . 0.0 109.177 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.56 -49.06 65.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 110.304 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.437 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.56 -43.16 66.84 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.165 -0.959 . . . . 0.0 110.778 -179.615 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.432 ' CD1' HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.46 73.92 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.248 -0.907 . . . . 0.0 110.909 -179.057 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.432 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.74 -51.37 12.83 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.974 -1.079 . . . . 0.0 110.281 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.43 99.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.025 -1.047 . . . . 0.0 109.696 179.636 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.437 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 0.0 OUTLIER -57.42 -47.41 81.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.422 -0.799 . . . . 0.0 109.468 179.649 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.469 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.89 -43.02 76.83 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.604 -0.685 . . . . 0.0 110.365 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.38 -34.6 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.084 -1.01 . . . . 0.0 109.217 179.614 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.0 59.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.316 -0.865 . . . . 0.0 109.74 179.271 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.427 ' N ' HD21 ' A' ' 58' ' ' LEU . 3.7 mm? -71.52 -26.36 62.63 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-O 121.924 0.869 . . . . 0.0 109.575 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.15 6.3 10.03 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.486 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 37.8 mt -108.1 143.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.293 -1.122 . . . . 0.0 110.104 -179.776 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.415 ' ND2' HG23 ' A' ' 80' ' ' VAL . 21.0 t30 -87.89 106.56 18.19 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 177.953 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.469 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.33 144.26 46.0 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.086 -1.045 . . . . 0.0 111.397 -177.288 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.476 HG13 ' N ' ' A' ' 73' ' ' VAL . 2.5 t -131.03 142.63 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.807 179.551 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.519 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -105.84 118.33 36.31 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.81 178.984 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.437 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.7 OUTLIER -105.27 118.43 36.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.857 . . . . 0.0 110.706 -179.43 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.481 ' CE1' HD22 ' A' ' 69' ' ' LEU . 4.6 p90 -149.69 -179.88 7.46 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 179.32 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.66 129.37 40.79 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.069 -1.019 . . . . 0.0 110.687 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.96 23.68 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.481 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.9 tm? -117.22 154.71 30.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.321 -1.105 . . . . 0.0 110.014 -179.765 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.477 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 23.9 m-20 -94.9 149.78 20.89 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.338 -0.851 . . . . 0.0 110.39 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.419 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 118.934 -1.107 . . . . 0.0 108.99 179.338 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.427 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 36.7 m -133.09 -33.51 1.14 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.485 -0.759 . . . . 0.0 110.708 -179.234 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.476 ' N ' HG13 ' A' ' 63' ' ' VAL . 89.6 t -56.49 134.67 20.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.154 -0.966 . . . . 0.0 109.782 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp -137.61 93.61 12.37 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.194 -0.941 . . . . 0.0 110.696 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -79.63 60.95 8.03 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.784 1.412 . . . . 0.0 110.236 179.436 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.0 t -162.75 40.25 0.11 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.039 -1.038 . . . . 0.0 110.52 -179.743 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -141.53 -163.48 1.57 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.204 -0.935 . . . . 0.0 109.82 179.891 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.37 -73.93 0.31 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -152.26 111.75 3.93 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.156 -1.202 . . . . 0.0 110.313 179.654 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.431 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -117.6 134.22 61.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 122.052 0.929 . . . . 0.0 110.351 179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.477 HG22 HG23 ' A' ' 60' ' ' ILE . 8.0 m -113.16 124.55 69.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.249 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.009 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.465 ' CG2' HG12 ' A' ' 73' ' ' VAL . 8.8 t -97.7 118.78 44.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.019 -1.051 . . . . 0.0 110.778 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.519 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.1 m -111.87 98.54 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 120.78 -1.2 . . . . 0.0 108.81 179.135 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.437 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.92 29.24 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.626 -1.296 . . . . 0.0 110.077 -178.813 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.401 HG21 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -103.36 -24.73 13.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 111.296 -178.544 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.425 ' O ' ' N ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 179.92 -29.37 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.996 -1.065 . . . . 0.0 111.059 -179.943 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.95 -38.98 24.58 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.013 -1.055 . . . . 0.0 110.278 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.9 tp -63.6 -29.85 71.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.135 -0.978 . . . . 0.0 108.705 178.552 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.487 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 44.19 27.31 0.2 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.754 -0.591 . . . . 0.0 111.426 179.578 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.458 ' HB ' ' CG2' ' A' ' 93' ' ' THR . 60.8 p 42.06 52.59 4.35 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.785 -0.572 . . . . 0.0 111.423 179.304 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.53 -66.44 2.29 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -179.834 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -110.15 22.96 14.94 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.246 -1.149 . . . . 0.0 110.269 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.481 ' OG1' ' CE1' ' A' ' 96' ' ' PHE . 14.6 t -78.81 -148.42 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.344 -0.847 . . . . 0.0 110.143 179.974 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.43 ' N ' HG22 ' A' ' 93' ' ' THR . . . 103.54 -43.14 1.73 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.344 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -86.75 66.63 9.54 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.914 -1.345 . . . . 0.0 110.838 -179.354 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.483 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.2 m-85 -119.7 150.67 39.98 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.953 -1.092 . . . . 0.0 110.265 179.284 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.433 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.6 m-20 -76.86 -31.92 57.15 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.459 -0.776 . . . . 0.0 109.898 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.408 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.61 163.97 26.92 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.256 -0.977 . . . . 0.0 111.788 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.48 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.98 113.77 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.504 -0.748 . . . . 0.0 110.069 179.064 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.449 ' CG2' ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -92.74 116.16 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.093 -1.004 . . . . 0.0 108.387 178.863 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.05 31.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.083 -1.011 . . . . 0.0 112.039 -177.895 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.482 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.5 t -95.77 -1.04 50.56 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 177.84 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.402 ' ND2' ' OE1' ' A' ' 110' ' ' GLN . 2.4 m120 54.89 20.92 3.34 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -0.974 . . . . 0.0 111.168 179.737 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p -143.17 140.54 30.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.974 -1.079 . . . . 0.0 110.659 179.669 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.406 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.5 p -114.32 127.72 56.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.319 -0.863 . . . . 0.0 109.918 179.561 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.0 t0 51.42 30.12 5.9 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.274 -0.891 . . . . 0.0 110.552 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.12 -33.0 5.5 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.406 ' O ' ' N ' ' A' ' 105' ' ' SER . 7.3 mtmt -76.66 156.53 82.88 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.277 -1.131 . . . . 0.0 109.998 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -65.7 133.27 33.51 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.657 1.346 . . . . 0.0 110.339 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.402 ' OE1' ' ND2' ' A' ' 103' ' ' ASN . 5.7 pt20 -47.94 167.02 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.426 -0.796 . . . . 0.0 110.942 -179.301 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.435 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.6 p30 -98.1 160.81 14.06 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.43 -0.794 . . . . 0.0 110.141 179.741 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.51 -50.67 7.06 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.522 -0.736 . . . . 0.0 112.298 -178.681 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.435 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 16.2 m -71.25 -29.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 120.699 -1.251 . . . . 0.0 111.446 -178.564 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.418 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.32 -56.01 7.67 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.059 -1.026 . . . . 0.0 110.449 -179.375 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.428 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.17 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.401 -0.92 . . . . 0.0 108.888 178.683 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.412 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.495 -0.882 . . . . 0.0 108.698 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.42 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.27 66.42 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.608 -0.683 . . . . 0.0 109.528 178.984 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.432 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 21.3 mtt85 -68.42 -44.97 73.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.164 -0.96 . . . . 0.0 110.499 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.51 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -59.94 -46.45 89.36 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.23 -0.919 . . . . 0.0 110.332 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.0 -26.37 1.2 Allowed Glycine 0 N--CA 1.499 2.85 0 O-C-N 121.474 -0.766 . . . . 0.0 111.396 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.465 ' NE ' ' HA ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -48.83 -55.39 11.76 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.882 -1.363 . . . . 0.0 110.858 -179.394 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.472 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 1.3 t -91.62 142.59 27.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.66 12.54 16.4 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.303 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 6.2 mtt180 -102.47 76.56 1.55 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.953 -1.322 . . . . 0.0 109.951 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.671 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.429 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -145.14 167.11 15.38 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.58 -0.953 . . . . 0.0 108.79 179.779 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.95 111.98 1.71 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.202 1.106 . . . . 0.0 109.637 179.582 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.472 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -87.24 166.16 36.44 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -178.854 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.441 ' N ' HG22 ' A' ' 122' ' ' THR . 2.7 mt -124.3 141.79 43.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.514 -0.992 . . . . 0.0 108.54 178.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.48 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.59 115.44 19.5 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.927 179.827 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.444 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.35 121.82 45.34 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.536 -0.728 . . . . 0.0 109.183 179.276 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 24.5 p90 -119.52 157.75 27.69 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -0.987 . . . . 0.0 109.991 -179.694 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.7 t -85.92 -42.47 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.189 -0.944 . . . . 0.0 110.005 179.751 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.71 155.1 55.01 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.168 -0.957 . . . . 0.0 110.503 -179.714 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -77.06 -57.32 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.369 0 O-C-N 123.713 1.375 . . . . 0.0 110.542 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 162.64 74.41 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.913 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -78.55 81.35 4.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.221 -1.164 . . . . 0.0 110.306 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 51.8 ttt180 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.274 -179.988 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 39.2 m -87.96 150.69 23.3 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.237 -1.155 . . . . 0.0 110.339 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.403 ' O ' HG21 ' A' ' 3' ' ' VAL . 17.3 m -113.2 104.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 109.831 179.57 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.412 ' CG2' ' O ' ' A' ' 112' ' ' ALA . 16.8 p -68.87 138.5 54.76 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.341 -0.85 . . . . 0.0 110.343 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.417 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.17 147.81 98.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.498 179.69 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.417 ' HD2' HG21 ' A' ' 5' ' ' VAL . 45.7 Cg_endo -71.5 -169.3 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 124.082 1.569 . . . . 0.0 111.083 179.793 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.491 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.43 77.62 0.04 OUTLIER Pre-proline 0 N--CA 1.498 1.948 0 O-C-N 121.564 -0.71 . . . . 0.0 109.682 -179.901 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -70.47 -10.64 28.42 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 O-C-N 123.695 1.366 . . . . 0.0 111.178 -179.437 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -74.91 -11.3 60.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.934 -1.104 . . . . 0.0 110.449 179.823 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.475 ' CD1' HG22 ' A' ' 122' ' ' THR . 1.9 mt -112.8 135.49 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.03 -1.044 . . . . 0.0 109.811 179.898 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.94 125.14 33.13 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.256 -0.902 . . . . 0.0 108.741 178.311 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -89.33 129.53 35.85 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.031 -1.043 . . . . 0.0 110.276 -179.245 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.439 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 12.0 t -125.35 157.88 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.472 -0.767 . . . . 0.0 110.42 -179.193 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.485 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.46 114.15 27.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.292 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.6 tp -52.21 143.87 13.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.231 -0.918 . . . . 0.0 109.878 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.8 p -142.06 -178.2 5.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.196 -0.94 . . . . 0.0 110.226 -179.663 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.4 p -80.33 59.16 3.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.302 -0.873 . . . . 0.0 110.097 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.445 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 23.8 m -132.75 109.22 9.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.436 -0.79 . . . . 0.0 110.597 -179.829 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.459 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.35 -171.63 28.73 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 118.81 -1.662 . . . . 0.0 111.139 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.7 -22.82 10.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.703 -0.88 . . . . 0.0 110.473 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.466 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.8 tt -93.48 109.5 41.01 Favored Pre-proline 0 N--CA 1.49 1.538 0 C-N-CA 118.749 -1.18 . . . . 0.0 109.226 -179.923 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -63.14 145.54 93.73 Favored 'Trans proline' 0 C--N 1.312 -1.354 0 O-C-N 123.423 1.223 . . . . 0.0 111.491 -178.284 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.438 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.83 -165.12 1.68 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.624 -0.673 . . . . 0.0 110.403 -179.311 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.52 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.3 m-85 -60.65 79.76 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.507 -0.745 . . . . 0.0 110.688 -179.879 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.99 57.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.485 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.405 ' O ' ' N ' ' A' ' 23' ' ' PHE . 1.3 mmtp -130.19 156.08 45.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.027 -1.278 . . . . 0.0 109.547 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.431 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.08 106.91 16.11 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.989 -1.069 . . . . 0.0 109.054 179.38 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.466 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.32 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 110.819 -179.173 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.459 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.4 Cg_endo -70.31 130.57 18.88 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 N-CA-C 106.668 -2.089 . . . . 0.0 106.668 175.869 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.428 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 14.3 mt -55.99 -17.98 8.16 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.809 -1.182 . . . . 0.0 110.581 -177.784 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.404 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 13.2 pt-20 -59.35 -16.49 22.85 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.525 -1.359 . . . . 0.0 110.515 179.729 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.409 HG21 ' N ' ' A' ' 33' ' ' ILE . 13.4 m -92.73 -24.33 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.002 -1.061 . . . . 0.0 111.038 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.525 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 37.9 pt -117.45 -26.28 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.921 -1.112 . . . . 0.0 110.358 -179.413 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.449 ' HG3' ' N ' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -90.32 148.79 22.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.057 -1.027 . . . . 0.0 110.058 179.057 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.449 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.81 -4.86 25.92 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.577 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.5 -130.95 2.18 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 119.214 -1.469 . . . . 0.0 110.268 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.412 ' C ' ' CD2' ' A' ' 38' ' ' HIS . 3.2 mtt-85 -115.59 131.0 57.07 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.33 -1.1 . . . . 0.0 110.234 -179.69 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.525 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 74.4 m-70 -140.83 146.4 37.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.111 -0.993 . . . . 0.0 110.879 -179.762 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.463 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 20.4 tp -106.79 127.59 53.53 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.534 -0.729 . . . . 0.0 109.942 179.593 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.445 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 35.1 mt -109.76 128.22 66.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.515 179.388 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.463 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 12.7 m-85 -95.09 124.11 38.95 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 109.99 -179.754 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.56 159.9 21.44 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.347 -0.845 . . . . 0.0 110.739 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.52 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.5 OUTLIER -106.81 3.1 26.07 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.492 -0.755 . . . . 0.0 110.206 179.26 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.0 p -136.7 136.74 39.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.957 -1.089 . . . . 0.0 110.834 -179.661 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.49 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.91 -36.98 70.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.551 -0.718 . . . . 0.0 110.628 179.907 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.29 -33.67 76.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.416 -179.738 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.54 -35.51 65.53 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.51 -0.744 . . . . 0.0 109.712 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.427 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 93.1 m -61.11 -36.06 78.68 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.357 -0.839 . . . . 0.0 109.418 179.498 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.54 -49.95 60.92 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.197 -0.939 . . . . 0.0 110.519 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -72.22 -44.81 62.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.209 -0.932 . . . . 0.0 110.267 179.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.401 HD13 HG11 ' A' ' 83' ' ' VAL . 3.4 tm? -56.79 -43.57 81.04 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.661 . . . . 0.0 111.154 -179.12 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.72 -51.16 52.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.872 -1.142 . . . . 0.0 109.821 179.894 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -35.5 69.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.195 -0.941 . . . . 0.0 109.27 179.323 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.48 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.765 . . . . 0.0 108.978 179.235 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.508 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -58.15 -41.95 84.86 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 110.794 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.5 t -56.15 -32.87 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.07 -1.019 . . . . 0.0 109.156 179.664 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.38 60.15 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.392 -0.818 . . . . 0.0 110.491 179.68 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.48 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.31 -25.44 62.42 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.146 -0.971 . . . . 0.0 109.918 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.78 4.61 9.51 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.329 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.47 HG23 HG22 ' A' ' 81' ' ' VAL . 44.7 mt -105.71 143.37 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 121.376 -1.073 . . . . 0.0 109.845 -179.729 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.445 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.9 t30 -88.58 106.99 18.67 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 178.173 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.508 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.57 146.31 44.69 Favored 'General case' 0 C--N 1.294 -1.812 0 C-N-CA 118.706 -1.197 . . . . 0.0 111.728 -177.084 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.477 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 89.8 t -128.2 149.75 33.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -116.29 117.74 30.83 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.549 178.412 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.451 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.5 142.36 45.16 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.337 -0.852 . . . . 0.0 110.354 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.495 ' CE1' HD23 ' A' ' 69' ' ' LEU . 2.9 p90 -175.32 -177.27 1.01 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.399 -0.813 . . . . 0.0 110.034 179.888 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.52 119.8 5.76 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.176 -0.952 . . . . 0.0 111.234 -179.232 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 40.97 11.8 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.13 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.495 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.3 tm? -117.59 155.37 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.052 -1.264 . . . . 0.0 110.223 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.442 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.8 m-20 -93.56 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.282 -0.886 . . . . 0.0 110.416 -179.541 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.409 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 28.2 m -62.55 110.61 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.411 179.384 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.59 -20.95 2.27 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.536 -0.728 . . . . 0.0 111.046 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.477 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 54.5 t -63.99 128.15 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.022 -1.049 . . . . 0.0 109.53 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.454 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.4 pp -136.33 98.31 11.39 Favored Pre-proline 0 N--CA 1.495 1.777 0 O-C-N 121.028 -1.045 . . . . 0.0 110.926 -179.647 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.43 ' O ' ' CG2' ' A' ' 76' ' ' THR . 50.7 Cg_endo -78.93 53.27 4.61 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.328 1.173 . . . . 0.0 110.207 179.238 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.43 ' CG2' ' O ' ' A' ' 75' ' ' PRO . 5.6 p -157.21 40.05 0.31 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.24 -0.913 . . . . 0.0 110.385 -179.471 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -145.21 31.67 1.11 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.171 -0.956 . . . . 0.0 110.343 -179.888 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 108.52 -116.2 4.64 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.812 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -115.86 109.48 17.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -1.144 . . . . 0.0 110.146 179.841 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.445 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.8 p -116.65 135.38 57.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-O 122.006 0.908 . . . . 0.0 110.721 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.476 HG23 ' CB ' ' A' ' 62' ' ' ALA . 9.6 m -113.2 122.81 68.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.611 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.421 ' CG2' HG13 ' A' ' 73' ' ' VAL . 4.1 t -97.29 118.81 44.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 120.833 -1.167 . . . . 0.0 110.5 -178.118 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.494 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 3.5 m -109.8 100.64 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.018 -1.051 . . . . 0.0 108.947 179.699 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.451 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.21 163.83 31.9 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.602 -1.311 . . . . 0.0 111.38 -177.859 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 11.2 t -91.38 -140.76 0.17 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.423 -0.798 . . . . 0.0 109.332 179.757 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -84.43 52.12 2.28 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.806 -1.184 . . . . 0.0 110.248 179.633 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.437 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.43 -19.58 6.36 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.202 -0.936 . . . . 0.0 110.936 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -62.43 -26.97 68.78 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.012 -1.055 . . . . 0.0 109.548 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.496 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 27.4 mmt 47.25 30.82 1.55 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.372 -0.83 . . . . 0.0 110.731 179.61 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.459 ' CB ' HG22 ' A' ' 93' ' ' THR . 5.5 t 35.11 -134.98 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 178.889 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 93.1 -49.61 2.46 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 107.99 -2.044 . . . . 0.0 107.99 -178.786 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -125.27 21.01 8.05 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.632 -0.922 . . . . 0.0 109.374 179.001 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.459 HG22 ' CB ' ' A' ' 90' ' ' THR . 4.9 t -102.82 -155.49 0.53 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.326 -0.859 . . . . 0.0 110.343 -179.702 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.433 ' O ' ' CG ' ' A' ' 124' ' ' ARG . . . 92.39 -33.94 4.7 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.467 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -84.26 59.04 5.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.939 -1.33 . . . . 0.0 110.392 -179.588 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -119.45 153.1 35.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.205 -0.934 . . . . 0.0 110.167 179.433 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.86 -29.24 25.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.396 -0.815 . . . . 0.0 109.513 179.393 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.4 p -161.88 163.7 29.07 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.244 -0.91 . . . . 0.0 111.161 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.53 125.85 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.389 -0.819 . . . . 0.0 110.094 179.24 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.422 HD12 ' CG2' ' A' ' 33' ' ' ILE . 3.2 mp -102.86 112.15 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.231 -0.918 . . . . 0.0 109.003 179.265 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -118.09 162.01 18.91 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.184 -0.948 . . . . 0.0 111.869 -178.485 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.494 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.26 9.38 38.13 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.75 -0.594 . . . . 0.0 109.744 178.556 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.433 ' ND2' ' NE2' ' A' ' 110' ' ' GLN . 2.8 m-20 46.58 25.16 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.091 -1.006 . . . . 0.0 111.481 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -147.04 136.43 22.73 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 110.454 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.42 ' N ' ' O ' ' A' ' 108' ' ' LYS . 60.2 p -113.13 126.66 55.69 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.367 -0.833 . . . . 0.0 110.122 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 52.76 35.63 19.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.279 -0.888 . . . . 0.0 110.762 179.951 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 84.26 -6.02 77.89 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.004 -1.093 . . . . 0.0 110.429 179.573 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.42 ' O ' ' N ' ' A' ' 105' ' ' SER . 72.1 mmtt -100.4 156.35 35.33 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.0 -1.294 . . . . 0.0 110.076 -179.77 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -65.49 129.2 21.91 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 O-C-N 123.74 1.389 . . . . 0.0 110.497 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.433 ' NE2' ' ND2' ' A' ' 103' ' ' ASN . 13.9 pt20 -51.12 152.85 2.14 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.554 -0.716 . . . . 0.0 110.892 -179.5 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.439 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.5 p30 -93.21 161.09 14.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.384 -0.822 . . . . 0.0 109.719 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -43.13 -51.75 5.78 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.375 -0.828 . . . . 0.0 112.316 -178.629 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.439 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 12.6 m -69.74 -29.15 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.76 -1.213 . . . . 0.0 111.382 -178.81 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.47 -56.13 7.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.122 -0.986 . . . . 0.0 110.522 -179.091 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -68.08 -34.86 77.22 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.066 -1.021 . . . . 0.0 108.658 178.927 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.402 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.95 -49.91 75.83 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.14 -0.975 . . . . 0.0 108.427 178.623 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.8 -36.85 65.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.584 -0.697 . . . . 0.0 109.888 179.078 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 13.6 mtt180 -71.23 -44.61 65.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.163 -0.96 . . . . 0.0 110.502 -179.727 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.491 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.5 OUTLIER -58.6 -42.19 87.55 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.109 -0.994 . . . . 0.0 109.903 179.734 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.97 89.41 0.02 OUTLIER Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.435 ' HG2' ' CD2' ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.66 -44.06 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.55 -0.971 . . . . 0.0 108.616 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.48 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.6 t -102.07 132.54 47.88 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 178.663 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.44 8.18 3.67 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.015 -1.564 . . . . 0.0 110.845 179.596 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.433 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 18.0 mmt180 -85.39 82.48 8.3 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.853 -1.381 . . . . 0.0 110.269 -179.791 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.67 -52.08 0.71 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.448 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.92 178.74 0.91 Allowed Pre-proline 0 C--N 1.302 -1.489 0 O-C-N 121.579 -0.954 . . . . 0.0 109.332 179.403 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.53 109.53 2.79 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 123.57 1.3 . . . . 0.0 109.39 179.127 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.48 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.57 161.8 52.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.261 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.5 mt -119.64 142.66 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.427 -1.043 . . . . 0.0 109.389 179.491 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 5.5 t80 -130.34 115.47 16.96 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.18 -0.95 . . . . 0.0 110.387 179.899 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.406 ' CZ ' HG12 ' A' ' 32' ' ' VAL . 2.0 mtt180 -103.27 133.95 47.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.432 -0.793 . . . . 0.0 109.892 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.485 ' CE1' ' HA ' ' A' ' 14' ' ' ALA . 8.2 p90 -127.12 152.44 47.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 110.205 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.4 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t -77.46 -46.89 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.183 -0.948 . . . . 0.0 109.859 179.568 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.427 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -65.69 116.38 31.34 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.365 -0.834 . . . . 0.0 110.715 -179.328 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.25 -23.77 15.19 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 O-C-N 123.531 1.28 . . . . 0.0 110.711 179.841 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.59 147.07 29.24 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.979 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -72.53 -51.49 19.7 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.146 -1.208 . . . . 0.0 110.143 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 117.91 -1.043 . . . . 0.0 110.285 179.97 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.04 153.62 22.33 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.336 -1.097 . . . . 0.0 110.308 -179.951 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.419 ' O ' ' CG2' ' A' ' 3' ' ' VAL . 33.8 m -113.38 104.54 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.278 -0.889 . . . . 0.0 110.037 179.678 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.424 ' CG2' ' OG1' ' A' ' 116' ' ' THR . 40.6 p -66.05 143.73 57.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 110.026 179.781 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.442 HG23 ' N ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -74.28 149.06 86.68 Favored Pre-proline 0 C--N 1.302 -1.498 0 O-C-N 121.293 -0.879 . . . . 0.0 109.566 179.673 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.522 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 41.6 Cg_endo -80.82 -57.95 0.03 OUTLIER 'Trans proline' 0 C--N 1.309 -1.5 0 O-C-N 124.261 1.664 . . . . 0.0 111.681 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.522 ' CD2' ' O ' ' A' ' 6' ' ' PRO . 17.3 p80 38.37 83.02 0.21 Allowed Pre-proline 0 N--CA 1.491 1.624 0 CA-C-O 121.098 0.475 . . . . 0.0 111.781 -178.796 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.22 58.11 2.88 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.375 1.198 . . . . 0.0 110.876 -179.938 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.441 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 -114.22 -28.02 7.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.178 -0.951 . . . . 0.0 109.433 179.315 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.445 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 28.4 mt -102.09 136.68 33.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.116 -0.99 . . . . 0.0 109.772 179.452 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.11 34.99 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.132 -0.98 . . . . 0.0 109.576 179.838 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.93 121.54 31.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.237 -0.915 . . . . 0.0 110.206 -179.291 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.449 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 10.8 t -116.45 157.16 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.432 -0.793 . . . . 0.0 110.113 -179.521 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.86 111.29 23.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.165 -0.959 . . . . 0.0 109.91 179.483 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.433 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 9.9 tp -55.65 139.62 44.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.935 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.72 3.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 110.34 -179.825 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.56 84.38 7.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.17 -0.957 . . . . 0.0 109.867 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.43 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 25.2 m -158.99 109.78 2.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.186 -0.946 . . . . 0.0 110.906 -179.482 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.463 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.32 -174.47 29.71 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.212 178.922 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.02 -19.57 13.46 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.834 -0.803 . . . . 0.0 110.284 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.47 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.3 tt -98.26 106.31 34.56 Favored Pre-proline 0 N--CA 1.489 1.516 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.421 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -62.91 123.38 12.16 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 O-C-N 123.347 1.182 . . . . 0.0 110.776 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.0 t80 -111.5 -167.81 1.23 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.686 -0.634 . . . . 0.0 110.336 -179.185 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.8 m-85 -58.93 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.479 -0.763 . . . . 0.0 111.117 -179.595 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.73 3.83 56.14 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 179.831 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.433 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.43 44.28 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.019 -1.283 . . . . 0.0 109.224 179.733 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.43 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -106.21 106.49 17.02 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.971 -1.08 . . . . 0.0 108.546 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.47 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.0 mt -69.8 113.44 17.38 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.337 -0.852 . . . . 0.0 110.52 -178.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.463 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.5 Cg_endo -69.75 130.77 19.94 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 N-CA-C 107.159 -1.9 . . . . 0.0 107.159 176.347 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.424 HD23 ' CD1' ' A' ' 60' ' ' ILE . 10.5 mt -56.74 -16.43 6.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.802 -1.186 . . . . 0.0 110.521 -178.313 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.435 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.05 -16.14 49.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.555 -1.341 . . . . 0.0 110.532 179.516 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.424 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 12.8 m -93.39 -25.77 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 120.935 -1.103 . . . . 0.0 111.125 -179.313 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.511 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 25.0 pt -115.98 -26.04 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.061 . . . . 0.0 109.954 -179.658 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.458 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.21 147.99 22.67 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.224 -0.923 . . . . 0.0 110.435 179.945 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.22 -4.77 41.19 Favored Glycine 0 N--CA 1.484 1.872 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.352 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.63 -149.44 9.32 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.185 -1.483 . . . . 0.0 110.376 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.65 129.95 54.47 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.336 -1.097 . . . . 0.0 110.323 -179.621 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.511 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.2 m80 -138.43 153.59 48.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.067 -1.02 . . . . 0.0 111.087 -179.508 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.424 ' CD2' ' HG2' ' A' ' 121' ' ' ARG . 24.9 tp -113.23 114.05 26.19 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.41 -0.806 . . . . 0.0 109.81 179.613 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.476 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 38.6 mt -97.14 126.75 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.28 -0.887 . . . . 0.0 109.539 179.427 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -95.0 123.73 38.65 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.402 -0.811 . . . . 0.0 110.196 -179.797 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.2 -0.938 . . . . 0.0 110.885 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.499 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.7 p80 -104.42 -5.47 21.63 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.834 . . . . 0.0 110.128 179.148 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.63 137.4 53.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 110.637 -179.741 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.495 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.8 -43.28 65.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.677 -0.64 . . . . 0.0 110.679 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.17 -36.94 81.18 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.266 -0.896 . . . . 0.0 110.71 -179.632 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.68 -35.38 78.74 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.37 -0.831 . . . . 0.0 109.485 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.421 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 94.3 m -61.45 -34.84 76.11 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.439 -0.788 . . . . 0.0 109.385 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.61 -49.02 74.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 110.459 179.86 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.76 -40.38 69.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.228 -0.92 . . . . 0.0 110.494 -179.734 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -57.11 -39.96 76.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.47 -0.769 . . . . 0.0 110.958 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.43 -51.36 13.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 110.377 -179.784 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.32 -41.21 93.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.096 -1.002 . . . . 0.0 109.517 179.619 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.424 ' O ' HD21 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.67 -46.88 83.69 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.423 -0.798 . . . . 0.0 109.664 179.47 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.485 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.17 -43.32 78.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.552 -0.718 . . . . 0.0 110.326 179.931 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.3 t -55.7 -33.16 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.04 -1.037 . . . . 0.0 109.166 179.611 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.9 60.85 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.272 -0.892 . . . . 0.0 109.79 179.088 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.463 HD22 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -72.05 -26.2 62.09 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.312 -0.867 . . . . 0.0 109.703 179.634 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.46 9.51 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.343 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.465 HG23 HG21 ' A' ' 81' ' ' VAL . 48.6 mt -108.3 143.09 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.308 -1.113 . . . . 0.0 110.239 -179.626 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.418 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 17.0 t30 -86.69 106.66 17.79 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 178.232 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.485 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.84 144.59 48.28 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.506 -177.432 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.473 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 2.7 t -134.56 145.1 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -108.79 128.79 55.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.976 -1.09 . . . . 0.0 109.996 179.308 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.1 53.19 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 110.376 -179.839 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.497 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.4 p90 -170.57 174.62 4.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.473 -0.767 . . . . 0.0 109.655 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.78 120.84 5.68 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 110.766 -179.179 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.27 34.36 14.65 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.531 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.497 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -116.97 156.24 27.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.134 -1.215 . . . . 0.0 110.021 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.469 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 2.0 m-20 -93.96 148.32 22.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.186 -0.946 . . . . 0.0 110.91 -179.189 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 27.8 m -63.26 111.45 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.343 178.884 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.439 ' CB ' HG12 ' A' ' 63' ' ' VAL . 5.4 m -134.76 -33.18 0.96 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.419 -0.801 . . . . 0.0 110.921 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.473 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 20.8 t -53.96 140.1 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.109 -0.995 . . . . 0.0 110.308 -179.418 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -137.8 91.79 13.33 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.3 -0.875 . . . . 0.0 110.832 179.814 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -86.73 55.51 3.29 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.616 1.324 . . . . 0.0 109.763 179.046 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -129.72 -24.69 2.68 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.207 -0.933 . . . . 0.0 111.547 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -154.39 158.57 40.23 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.842 -1.161 . . . . 0.0 110.894 -179.519 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 59.1 162.33 0.07 OUTLIER Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -80.47 102.92 9.98 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.141 -1.211 . . . . 0.0 109.791 179.704 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -110.98 134.47 53.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-O 121.928 0.87 . . . . 0.0 110.042 -179.779 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.481 HG21 HD23 ' A' ' 55' ' ' LEU . 6.3 m -112.04 125.9 69.38 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.397 -0.814 . . . . 0.0 109.248 179.495 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.468 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.8 t -97.57 116.14 39.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 O-C-N 121.117 -0.99 . . . . 0.0 110.12 -178.303 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.4 m -110.65 100.21 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.048 -1.032 . . . . 0.0 108.763 179.723 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.16 33.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.545 -1.347 . . . . 0.0 111.552 -177.891 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -86.9 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.595 -0.691 . . . . 0.0 109.412 179.6 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -90.1 42.87 1.12 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.693 -1.255 . . . . 0.0 110.484 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.423 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.96 -26.04 8.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.122 -0.987 . . . . 0.0 110.351 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.405 HD11 ' CG1' ' A' ' 82' ' ' VAL . 0.5 OUTLIER -76.28 -30.08 57.66 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.089 -1.007 . . . . 0.0 109.977 179.538 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.42 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 5.7 mmt 50.87 -115.49 0.87 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.344 -0.847 . . . . 0.0 109.737 -179.767 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.428 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.05 42.94 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.962 0 O-C-N 120.54 -1.35 . . . . 0.0 110.022 179.806 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -67.27 -29.86 74.81 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.789 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.425 ' CD1' ' N ' ' A' ' 92' ' ' PHE . 36.3 p90 -137.8 21.19 2.87 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.379 -1.071 . . . . 0.0 110.661 -179.742 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.474 ' OG1' ' CE2' ' A' ' 96' ' ' PHE . 0.6 OUTLIER -100.91 -162.39 0.94 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.103 -0.998 . . . . 0.0 110.281 -179.831 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.42 ' O ' ' CB ' ' A' ' 124' ' ' ARG . . . 118.94 11.97 7.34 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.956 -1.116 . . . . 0.0 110.315 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -124.9 65.6 1.11 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.714 -1.462 . . . . 0.0 110.448 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.474 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 51.0 m-85 -119.79 152.85 36.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.08 -1.012 . . . . 0.0 110.507 179.636 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.19 17.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.504 -0.747 . . . . 0.0 109.356 179.213 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.8 p -160.82 163.04 32.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.421 -0.799 . . . . 0.0 110.294 179.779 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.479 HG22 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.36 122.67 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.066 -1.021 . . . . 0.0 110.421 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.7 mp -97.99 112.68 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.429 -0.795 . . . . 0.0 109.121 179.266 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -121.01 160.74 22.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.114 -0.991 . . . . 0.0 111.589 -178.72 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.66 5.55 43.82 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.688 -0.633 . . . . 0.0 109.47 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.417 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 49.21 24.44 0.98 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 111.064 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -145.41 127.1 15.23 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.081 -1.012 . . . . 0.0 110.316 179.55 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 108' ' ' LYS . 96.2 p -107.66 130.95 54.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.305 -0.872 . . . . 0.0 110.167 179.964 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 25.2 t70 53.79 26.67 6.24 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.184 -0.947 . . . . 0.0 110.131 -179.889 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.8 -33.11 5.38 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.416 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.2 OUTLIER -78.07 157.26 78.81 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.291 -1.123 . . . . 0.0 110.089 179.946 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -62.69 128.69 24.03 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 O-C-N 123.649 1.342 . . . . 0.0 110.304 -179.586 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -46.55 146.69 1.41 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.648 -0.657 . . . . 0.0 111.253 -179.193 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.429 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.4 p30 -77.4 160.57 28.65 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.429 -0.794 . . . . 0.0 110.174 179.85 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -46.62 -52.83 12.78 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.348 -0.845 . . . . 0.0 112.058 -178.794 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.429 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.51 -28.95 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 120.838 -1.164 . . . . 0.0 111.466 -178.583 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.05 -56.47 6.43 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.071 -1.018 . . . . 0.0 110.593 -179.289 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.41 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.7 OUTLIER -68.95 -34.61 75.63 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.231 -0.918 . . . . 0.0 108.723 178.961 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.424 ' OG1' ' CG2' ' A' ' 4' ' ' THR . 41.0 m -59.61 -49.98 75.65 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.174 -0.954 . . . . 0.0 108.482 178.781 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.72 -36.25 65.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.464 -0.772 . . . . 0.0 109.9 178.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.41 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.1 mtt180 -71.22 -44.58 65.09 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.179 -0.951 . . . . 0.0 110.723 -179.585 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.489 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 14.1 ttm180 -56.15 -43.38 78.23 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.912 -1.117 . . . . 0.0 110.415 -179.757 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.69 79.55 0.06 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.433 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -152.08 -43.96 0.11 Allowed 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.296 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.441 ' CG2' HD11 ' A' ' 10' ' ' ILE . 8.8 t -100.27 144.06 29.73 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.297 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.466 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.69 14.63 46.13 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.192 -1.48 . . . . 0.0 110.444 179.425 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.42 ' CB ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -58.67 -31.79 68.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.127 -1.219 . . . . 0.0 110.032 -179.916 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.89 20.75 4.03 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.333 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.494 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -165.46 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.427 -1.043 . . . . 0.0 108.506 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.494 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 50.2 Cg_endo -85.32 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 122.85 0.921 . . . . 0.0 110.607 179.365 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.429 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.53 176.61 50.25 Favored Glycine 0 N--CA 1.497 2.759 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.8 mt -131.35 142.87 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.466 -1.02 . . . . 0.0 109.075 179.296 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.489 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 18.6 t80 -131.3 116.03 17.06 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.034 -1.041 . . . . 0.0 110.934 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -101.83 134.86 44.35 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.536 -0.727 . . . . 0.0 109.461 179.391 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.449 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.91 148.93 50.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.055 -1.028 . . . . 0.0 110.042 -179.79 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 54.4 t -73.22 -37.72 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.188 -0.945 . . . . 0.0 109.902 179.75 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.417 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -132.18 143.62 49.69 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.168 -0.958 . . . . 0.0 110.298 -179.799 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -73.59 -50.23 0.19 Allowed 'Trans proline' 0 C--N 1.312 -1.373 0 O-C-N 123.685 1.361 . . . . 0.0 110.251 179.939 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.46 -54.46 0.65 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -90.98 -55.79 3.42 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -1.147 . . . . 0.0 110.258 -179.914 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 23.7 mtt180 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.133 179.971 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.2 p -94.64 109.97 21.84 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.251 -1.146 . . . . 0.0 110.31 -179.778 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.4 HG11 ' O ' ' A' ' 3' ' ' VAL . 7.6 p -113.29 104.05 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.192 -0.942 . . . . 0.0 110.018 179.609 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.3 p -63.85 145.19 56.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.367 -0.833 . . . . 0.0 110.256 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.425 HG22 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.99 146.42 98.21 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.269 -0.895 . . . . 0.0 110.173 -179.9 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.425 ' HD2' HG22 ' A' ' 5' ' ' VAL . 43.6 Cg_endo -70.83 -175.86 1.57 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 124.163 1.612 . . . . 0.0 111.05 179.291 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.508 ' CE1' ' HG3' ' A' ' 119' ' ' ARG . 1.7 p80 -176.55 84.25 0.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.746 -0.596 . . . . 0.0 109.601 179.02 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -66.99 83.21 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.529 0 O-C-N 123.658 1.346 . . . . 0.0 110.604 -179.723 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -172.74 -37.05 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.647 -0.658 . . . . 0.0 109.736 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.501 ' CD1' HG22 ' A' ' 122' ' ' THR . 20.8 mt -95.15 128.19 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.428 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.12 128.14 34.37 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.263 -0.898 . . . . 0.0 108.951 178.868 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.3 134.67 33.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.109 -0.994 . . . . 0.0 110.128 -179.303 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.405 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 5.5 t -128.66 157.73 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.396 -0.815 . . . . 0.0 110.183 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.43 113.79 27.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.356 -0.84 . . . . 0.0 110.068 179.718 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.433 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.78 143.97 19.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 110.027 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.42 170.17 16.41 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.977 . . . . 0.0 110.397 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.86 81.59 1.18 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.201 -0.937 . . . . 0.0 109.754 179.651 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.434 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 9.4 m -158.31 111.44 2.39 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.872 -179.502 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.459 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.27 -170.39 30.24 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.139 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.75 -19.08 12.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.787 -0.831 . . . . 0.0 110.0 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.452 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.3 tt -99.92 104.05 26.18 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.833 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.403 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -63.16 125.92 16.8 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.231 1.122 . . . . 0.0 111.008 -179.18 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.0 t80 -112.93 -169.57 1.51 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.738 -0.601 . . . . 0.0 110.352 -179.499 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.524 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.0 m-85 -59.46 82.3 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.269 -0.894 . . . . 0.0 111.377 -179.433 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.19 61.69 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.627 179.274 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.433 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 26.6 mmtt -129.86 156.54 44.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.884 -1.362 . . . . 0.0 109.638 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.429 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.34 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.98 -1.075 . . . . 0.0 108.993 179.56 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.452 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.4 mt -70.28 113.17 15.95 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.375 -0.828 . . . . 0.0 110.729 -179.122 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.459 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.4 Cg_endo -69.63 130.77 20.09 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 N-CA-C 106.849 -2.02 . . . . 0.0 106.849 175.754 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.435 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 9.7 mt -55.99 -18.68 9.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.784 -1.198 . . . . 0.0 110.507 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.433 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.01 15.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.861 -1.149 . . . . 0.0 110.589 179.728 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.404 HG11 ' HG2' ' A' ' 29' ' ' PRO . 9.6 m -93.96 -25.3 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.926 -1.109 . . . . 0.0 110.951 -179.735 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.538 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 27.1 pt -117.95 -14.86 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.934 -1.104 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.462 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.64 148.06 24.2 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.849 -1.157 . . . . 0.0 110.383 179.683 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.7 -4.4 50.17 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.629 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.01 7.23 Favored Glycine 0 N--CA 1.492 2.393 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.589 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.42 ' NH1' ' O ' ' A' ' 78' ' ' GLY . 5.2 mtt85 -110.05 132.54 54.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -1.018 . . . . 0.0 110.213 -179.602 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.538 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -139.93 150.46 44.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.197 -0.939 . . . . 0.0 110.863 -179.759 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.488 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 51.3 tp -110.99 115.26 29.17 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.466 -0.771 . . . . 0.0 109.996 179.836 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.435 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.4 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.231 -0.918 . . . . 0.0 109.041 179.503 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.488 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.76 37.98 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.866 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.63 159.36 23.06 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.363 -0.836 . . . . 0.0 110.422 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.59 20.31 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.388 -0.82 . . . . 0.0 110.024 179.069 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.2 p -132.8 139.21 47.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.403 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.57 -34.09 71.81 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.464 -0.773 . . . . 0.0 110.465 -179.932 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.46 -34.14 76.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.249 -0.907 . . . . 0.0 110.333 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.433 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.09 -36.34 64.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.206 -0.934 . . . . 0.0 109.636 179.818 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 64.9 m -60.98 -39.2 88.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.563 -0.71 . . . . 0.0 109.469 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.52 -46.59 87.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.915 . . . . 0.0 110.035 179.699 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.439 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.43 -45.47 62.59 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.395 -0.815 . . . . 0.0 110.454 -179.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.439 ' CD1' HG12 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.36 -45.07 80.66 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.36 -0.838 . . . . 0.0 111.149 -178.997 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.429 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.75 -51.57 22.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.001 -1.062 . . . . 0.0 110.366 -179.467 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.16 99.33 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 109.762 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.439 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 0.0 OUTLIER -58.54 -46.81 86.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.24 -0.912 . . . . 0.0 109.606 179.591 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.491 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.2 -43.52 78.56 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.636 -0.665 . . . . 0.0 110.147 179.86 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.2 t -55.48 -32.67 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.21 -0.931 . . . . 0.0 109.029 179.7 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.56 -31.05 59.89 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.251 -0.906 . . . . 0.0 109.832 179.071 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.458 HD23 ' N ' ' A' ' 58' ' ' LEU . 3.9 mm? -72.19 -26.36 62.03 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.864 0.84 . . . . 0.0 109.837 179.844 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.9 4.58 10.29 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.16 -1.576 . . . . 0.0 109.16 -179.113 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.466 HG22 HG23 ' A' ' 81' ' ' VAL . 28.1 mt -105.48 143.34 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.352 -1.087 . . . . 0.0 110.096 -179.748 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.402 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.7 t-20 -88.06 106.07 17.91 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 178.031 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.491 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.288 -177.502 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.478 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.33 139.55 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.806 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -101.26 122.77 44.27 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.214 178.758 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.429 ' CB ' ' HB3' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.1 134.88 54.78 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.313 -0.867 . . . . 0.0 111.153 -178.925 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.496 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.5 p90 -168.89 170.65 8.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.574 -0.704 . . . . 0.0 109.641 179.506 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.67 118.3 3.27 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.242 -0.912 . . . . 0.0 110.845 -179.439 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.82 37.35 6.44 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.496 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.42 30.03 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -1.142 . . . . 0.0 110.168 -179.724 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.46 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 6.3 m-20 -91.84 149.58 21.51 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.36 -0.837 . . . . 0.0 110.596 -179.48 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.417 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 34.7 m -62.15 110.88 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 119.128 -1.029 . . . . 0.0 109.426 179.326 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.456 ' CB ' HG11 ' A' ' 63' ' ' VAL . 19.7 m -133.19 -39.33 0.93 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.447 -0.783 . . . . 0.0 110.233 -179.656 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.478 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 79.0 t -47.61 133.09 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.42 -0.8 . . . . 0.0 109.993 179.822 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -136.08 99.09 11.27 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.138 -0.976 . . . . 0.0 110.842 -179.51 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -84.45 48.04 2.34 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 O-C-N 123.788 1.415 . . . . 0.0 109.981 179.056 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.6 p -148.11 40.36 0.96 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.259 -0.901 . . . . 0.0 110.372 -179.218 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -143.74 -165.46 2.11 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.109 -0.994 . . . . 0.0 110.298 -179.794 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.42 ' O ' ' NH1' ' A' ' 37' ' ' ARG . . . -50.33 -77.04 0.14 Allowed Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -147.94 113.41 5.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.186 -1.185 . . . . 0.0 110.39 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -117.75 134.0 62.73 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 CA-C-O 122.095 0.95 . . . . 0.0 110.05 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 16.8 m -113.24 122.71 67.89 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.466 -0.771 . . . . 0.0 108.984 179.348 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.443 HG23 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -96.95 118.59 43.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.723 -1.235 . . . . 0.0 111.106 -177.686 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.502 ' O ' ' CG2' ' A' ' 83' ' ' VAL . 4.3 m -108.7 99.68 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.034 -1.041 . . . . 0.0 108.852 178.838 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.429 ' HB3' ' CB ' ' A' ' 65' ' ' TYR . . . -135.79 155.93 49.59 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.446 -1.409 . . . . 0.0 110.912 -178.488 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.436 ' CG2' ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.17 -42.43 15.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.369 -0.832 . . . . 0.0 110.385 -179.5 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.436 ' N ' ' CG2' ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.22 32.54 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.432 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -103.16 -30.99 10.35 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.009 . . . . 0.0 110.067 -179.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.61 -16.13 63.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 110.067 179.415 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.458 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 16.8 mmt 53.25 -165.07 0.08 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.311 -0.868 . . . . 0.0 109.894 -179.636 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.457 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 0.7 OUTLIER -136.47 30.13 2.93 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.193 -0.942 . . . . 0.0 110.042 179.939 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.4 -42.04 94.09 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.979 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -121.29 14.94 11.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.218 -1.166 . . . . 0.0 110.667 -179.825 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.482 ' OG1' ' CE1' ' A' ' 96' ' ' PHE . 6.6 t -80.39 -157.62 0.16 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.062 -1.024 . . . . 0.0 110.174 -179.731 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 102.76 -32.87 7.08 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.306 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.83 56.76 3.8 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.133 -1.216 . . . . 0.0 110.478 -179.528 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.482 ' CE1' ' OG1' ' A' ' 93' ' ' THR . 16.9 m-85 -119.9 149.75 41.6 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.103 -0.998 . . . . 0.0 110.078 179.399 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.402 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.85 -31.54 25.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.812 . . . . 0.0 109.619 179.554 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.5 p -162.26 163.43 28.15 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.417 -0.913 . . . . 0.0 111.466 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.497 HG21 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 117.74 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.455 -0.778 . . . . 0.0 109.614 178.798 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.433 HG21 ' CD1' ' A' ' 28' ' ' ILE . 4.2 mp -97.59 117.18 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.224 -0.923 . . . . 0.0 109.456 179.876 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -129.84 161.32 31.04 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.107 -0.995 . . . . 0.0 111.634 -178.716 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 52.8 t -92.03 -7.41 48.87 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.641 -0.662 . . . . 0.0 109.534 178.017 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.2 13.44 1.66 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.255 -0.903 . . . . 0.0 111.87 179.704 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 m -143.83 121.72 12.01 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 120.725 -1.234 . . . . 0.0 109.39 -179.888 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.447 ' N ' ' O ' ' A' ' 108' ' ' LYS . 12.5 p -98.85 132.85 43.88 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.184 -0.947 . . . . 0.0 110.416 -179.879 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 t0 51.08 30.24 5.33 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.293 -0.879 . . . . 0.0 110.604 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.91 -28.81 8.76 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.447 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -80.89 155.43 72.95 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.024 -1.28 . . . . 0.0 109.99 179.824 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -66.12 136.78 45.63 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.598 1.315 . . . . 0.0 110.666 -179.786 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -49.99 154.87 1.01 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.52 -0.737 . . . . 0.0 110.794 -179.588 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.44 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.0 p30 -80.88 159.06 25.12 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.272 -0.892 . . . . 0.0 109.84 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -46.63 -50.92 16.88 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.282 -0.886 . . . . 0.0 111.893 -178.787 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.44 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.41 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.792 -1.193 . . . . 0.0 111.444 -178.727 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.423 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.27 -56.6 6.47 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.987 -1.071 . . . . 0.0 110.426 -179.131 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.422 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.73 -35.03 76.61 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.264 -0.898 . . . . 0.0 108.918 178.718 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.2 m -59.9 -46.69 88.53 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 178.709 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.61 -40.43 63.82 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.671 -0.643 . . . . 0.0 109.767 178.905 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -69.65 -44.23 70.99 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.273 -0.892 . . . . 0.0 110.344 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.508 ' HG3' ' CE1' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -56.54 -43.74 80.16 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.362 -0.836 . . . . 0.0 110.004 179.678 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.01 0.11 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.682 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.457 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.77 -46.41 0.13 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.563 -0.963 . . . . 0.0 108.76 179.622 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.501 HG22 ' CD1' ' A' ' 10' ' ' ILE . 15.3 t -97.19 141.89 29.77 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.466 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.26 17.17 3.34 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.594 179.787 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.499 ' N ' ' CD ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.15 81.71 6.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.889 -1.359 . . . . 0.0 109.986 -179.731 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.52 -52.08 0.71 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.466 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.96 176.61 1.49 Allowed Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 121.765 -0.844 . . . . 0.0 109.123 179.308 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.21 112.89 3.64 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 N-CA-C 108.806 -1.267 . . . . 0.0 108.806 178.484 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.473 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.01 177.87 41.45 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -178.927 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.2 mt -135.23 142.8 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.239 -1.154 . . . . 0.0 109.652 179.502 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.497 ' CD1' HG21 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.87 114.5 19.29 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.051 178.721 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.405 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 3.8 mtt85 -105.97 122.77 46.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.515 -0.741 . . . . 0.0 109.297 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 11.0 p90 -122.94 157.81 31.8 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.058 -1.026 . . . . 0.0 110.464 -179.576 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 37.8 t -77.15 -40.9 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.751 179.555 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -131.37 144.04 51.77 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.317 -0.864 . . . . 0.0 110.07 179.886 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -75.45 -55.7 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.531 1.279 . . . . 0.0 110.612 -179.785 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 124.67 -91.35 0.42 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 54.03 68.12 0.9 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.244 -1.15 . . . . 0.0 110.161 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.173 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.447 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.31 0.576 . . . . 0.0 109.974 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.749 HG12 HG23 ' A' ' 122' ' ' THR . 9.0 mt -106.0 133.3 50.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.043 -1.036 . . . . 0.0 109.901 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.422 ' HB3' HG12 ' A' ' 129' ' ' ILE . 6.4 tp10 -85.67 128.41 34.77 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.383 -0.823 . . . . 0.0 108.946 178.75 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -89.21 139.24 30.69 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.026 . . . . 0.0 110.328 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.67 155.63 41.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.46 -0.775 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.09 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 110.064 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.68 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.6 tp -54.35 140.0 34.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.324 -0.86 . . . . 0.0 109.889 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.48 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 110.249 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.274 -0.891 . . . . 0.0 110.033 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 31.3 m -146.15 109.29 4.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 110.555 -179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.91 -173.9 28.7 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.294 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.42 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -107.87 -22.75 12.33 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.794 -0.827 . . . . 0.0 110.428 179.994 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -95.11 102.45 9.43 Favored Pre-proline 0 N--CA 1.486 1.345 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.695 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.442 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -61.97 139.97 82.21 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 O-C-N 123.558 1.293 . . . . 0.0 110.603 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.87 -164.08 1.45 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 111.028 -178.673 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.517 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.4 m-85 -58.07 81.61 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.527 -0.733 . . . . 0.0 111.221 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.05 4.99 38.2 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.68 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.5 mmtm -131.05 155.91 46.08 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.295 . . . . 0.0 109.432 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.92 107.34 16.31 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.063 -1.023 . . . . 0.0 108.918 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.898 ' CD1' HG21 ' A' ' 100' ' ' ILE . 4.5 mt -68.04 114.57 21.51 Favored Pre-proline 0 C--N 1.3 -1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 110.895 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.772 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.0 Cg_endo -70.2 128.28 15.41 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 N-CA-C 106.91 -1.996 . . . . 0.0 106.91 175.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.597 HD11 HD12 ' A' ' 58' ' ' LEU . 9.8 mt -56.22 -18.51 10.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.785 -1.197 . . . . 0.0 110.867 -177.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -59.5 -16.13 22.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.632 -1.293 . . . . 0.0 110.466 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.077 HG23 HG23 ' A' ' 33' ' ' ILE . 9.3 m -91.8 -25.17 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.021 -1.049 . . . . 0.0 110.869 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.077 HG23 HG23 ' A' ' 32' ' ' VAL . 38.0 pt -118.31 -17.15 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.011 -1.056 . . . . 0.0 110.602 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.628 ' HB2' HD11 ' A' ' 60' ' ' ILE . 6.1 tptm -98.66 148.39 23.88 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.987 -1.07 . . . . 0.0 109.847 179.229 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.58 -6.1 33.41 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.446 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.98 -136.81 2.97 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.305 -1.426 . . . . 0.0 110.307 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -117.65 132.54 56.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -1.124 . . . . 0.0 110.43 -179.56 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.574 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.83 150.25 44.45 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.244 -0.91 . . . . 0.0 110.806 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.58 HD12 ' HB ' ' A' ' 82' ' ' VAL . 24.3 tp -112.16 114.73 27.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.503 -0.748 . . . . 0.0 110.023 179.664 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.824 HD12 HG12 ' A' ' 83' ' ' VAL . 43.8 mt -97.6 127.93 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.325 -0.859 . . . . 0.0 109.972 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.418 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.34 123.03 38.65 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.217 -0.927 . . . . 0.0 109.907 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.12 21.68 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.275 -0.891 . . . . 0.0 110.702 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.517 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.7 p80 -107.12 0.46 23.47 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.483 -0.761 . . . . 0.0 110.371 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.24 137.42 44.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.944 -1.098 . . . . 0.0 110.865 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.512 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.51 -39.69 70.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.722 -0.611 . . . . 0.0 110.787 -179.753 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -58.6 -36.71 74.42 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 110.369 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.417 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.4 OUTLIER -73.8 -34.4 64.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 109.59 -179.941 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.888 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.95 73.43 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.46 -0.775 . . . . 0.0 109.461 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.48 -49.58 53.43 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.216 -0.928 . . . . 0.0 110.295 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.421 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.93 -44.38 63.72 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.288 -0.883 . . . . 0.0 110.353 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.749 HD12 HG11 ' A' ' 83' ' ' VAL . 2.0 tm? -56.86 -43.05 80.8 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.441 -0.787 . . . . 0.0 110.773 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.411 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -74.19 -51.84 14.28 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.9 -1.125 . . . . 0.0 110.656 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.69 -38.77 86.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.854 -1.154 . . . . 0.0 109.413 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.57 ' HE3' HD22 ' A' ' 51' ' ' LEU . 2.5 ttmm -59.38 -45.98 89.93 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.36 -0.838 . . . . 0.0 109.493 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.702 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.35 -40.28 71.05 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.418 -0.801 . . . . 0.0 109.763 179.833 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -56.41 -34.49 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.109 -0.995 . . . . 0.0 108.786 178.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.48 -31.2 60.15 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.558 -0.714 . . . . 0.0 110.093 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.597 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.22 -26.13 62.8 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.63 4.77 9.56 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.49 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.63 HG22 HG22 ' A' ' 81' ' ' VAL . 58.2 mt -108.09 143.34 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.283 -1.128 . . . . 0.0 110.034 -179.68 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.495 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 14.7 t-20 -86.28 107.6 18.02 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 178.326 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.534 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . . . -120.9 149.79 42.07 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.947 -1.101 . . . . 0.0 112.095 -176.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.911 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -138.3 152.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.429 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.888 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.45 130.81 56.74 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.076 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.465 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.51 122.24 40.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.29 -0.881 . . . . 0.0 110.441 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.949 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -156.23 176.76 12.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.592 -0.692 . . . . 0.0 109.62 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.31 125.1 16.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.064 -1.023 . . . . 0.0 110.505 -179.499 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.95 38.57 15.34 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.949 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.5 156.06 28.66 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.152 -1.205 . . . . 0.0 110.147 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.878 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.5 m-20 -96.68 148.96 22.34 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.322 -0.862 . . . . 0.0 110.565 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.23 110.95 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.054 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.4 m -132.62 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.398 -0.814 . . . . 0.0 110.523 -179.245 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.911 HG22 ' HB ' ' A' ' 63' ' ' VAL . 58.7 t -52.25 128.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -0.904 . . . . 0.0 110.053 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.874 ' O ' HD12 ' A' ' 74' ' ' ILE . 2.0 pp . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.274 -0.891 . . . . 0.0 110.487 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 121.925 0.869 . . . . 0.0 110.176 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.1 p -116.98 134.46 60.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 122.054 0.93 . . . . 0.0 110.698 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.63 HG22 HG22 ' A' ' 60' ' ' ILE . 13.4 m -112.9 122.3 66.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.092 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.705 HG22 HG13 ' A' ' 73' ' ' VAL . 4.3 t -96.99 119.62 45.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.009 -1.057 . . . . 0.0 110.326 -177.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.824 HG12 HD12 ' A' ' 40' ' ' ILE . 4.5 m -111.36 100.4 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 120.997 -1.065 . . . . 0.0 108.627 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.465 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.45 162.78 34.65 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.731 -1.231 . . . . 0.0 111.602 -177.68 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.54 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -93.28 -136.0 0.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.524 179.65 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.54 ' N ' HG23 ' A' ' 85' ' ' THR . 12.3 p-10 -86.42 46.69 1.37 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.734 -1.228 . . . . 0.0 110.623 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.13 -23.09 8.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.931 -1.106 . . . . 0.0 110.405 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.698 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.053 0.454 . . . . 0.0 111.095 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -119.69 146.66 45.39 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.086 -1.008 . . . . 0.0 109.855 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.06 -33.33 67.88 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.352 -0.843 . . . . 0.0 109.856 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.78 163.7 26.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.887 . . . . 0.0 111.078 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.528 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 114.56 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.312 -0.868 . . . . 0.0 109.994 178.811 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.898 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.2 114.7 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.227 -0.92 . . . . 0.0 108.608 179.061 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.418 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.11 160.17 25.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.125 -0.984 . . . . 0.0 111.798 -178.186 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.94 -7.39 52.24 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.86 18.79 0.55 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 112.247 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.482 ' O ' HG22 ' A' ' 104' ' ' THR . 0.8 OUTLIER . . . . . 0 C--N 1.305 -1.368 0 O-C-N 120.746 -1.221 . . . . 0.0 109.366 179.565 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 121.489 0.662 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -108.01 161.61 14.79 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.6 -0.687 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.52 -55.13 2.95 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.605 -0.684 . . . . 0.0 112.629 -178.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.31 -29.79 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 120.663 -1.273 . . . . 0.0 111.499 -178.458 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.426 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.78 -57.58 5.41 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.093 -1.005 . . . . 0.0 110.555 -179.037 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.428 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.53 -33.94 77.09 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.198 -0.939 . . . . 0.0 108.819 178.631 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.1 m -60.23 -49.25 78.35 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.531 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -41.03 63.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.427 -0.796 . . . . 0.0 110.288 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.426 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.2 mpt_? -69.96 -44.13 70.12 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.049 -1.032 . . . . 0.0 110.732 -179.594 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.477 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 0.9 OUTLIER -54.18 -38.51 65.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.044 -1.035 . . . . 0.0 110.243 -179.863 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.93 0.06 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.466 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.9 mmt-85 -151.38 -43.55 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.952 . . . . 0.0 108.848 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.749 HG23 HG12 ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.49 39.25 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.522 -0.736 . . . . 0.0 109.345 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.407 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 121.76 19.86 3.28 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.622 179.51 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.462 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.42 81.85 4.42 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.033 -1.275 . . . . 0.0 110.034 179.821 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.49 5.39 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.473 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.611 -0.935 . . . . 0.0 108.573 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.473 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.0 Cg_endo -84.08 111.78 1.67 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.12 1.063 . . . . 0.0 109.913 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.46 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.64 168.96 54.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.422 HG12 ' HB3' ' A' ' 11' ' ' GLU . 41.5 mt -127.15 142.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.366 -1.079 . . . . 0.0 109.231 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.528 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.04 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.585 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.403 ' NH2' HG21 ' A' ' 129' ' ' ILE . 6.8 mtt85 -106.47 123.23 47.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.524 -0.735 . . . . 0.0 109.372 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.426 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.93 155.43 31.32 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.167 -0.958 . . . . 0.0 110.559 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.499 HG22 HD23 ' A' ' 15' ' ' LEU . 50.1 t . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.17 -0.956 . . . . 0.0 109.322 179.119 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.435 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.9 m120 . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.188 0.518 . . . . 0.0 110.399 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.498 HD11 ' O ' ' A' ' 122' ' ' THR . 19.9 mt -107.82 135.4 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 120.946 -1.096 . . . . 0.0 110.383 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.91 128.71 34.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.519 179.15 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.16 131.82 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.095 -1.003 . . . . 0.0 110.099 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.449 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.7 t -126.62 158.13 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.368 -0.832 . . . . 0.0 110.258 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 108.55 20.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.253 -0.904 . . . . 0.0 109.693 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.555 HD11 HG12 ' A' ' 28' ' ' ILE . 9.7 tp -55.22 138.69 44.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.348 -0.845 . . . . 0.0 109.883 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.0 p -136.41 -179.68 5.83 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.301 -0.874 . . . . 0.0 110.55 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.306 -0.871 . . . . 0.0 109.862 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.742 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 2.6 m -147.66 113.13 5.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.334 -0.854 . . . . 0.0 110.373 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.442 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.45 -162.26 27.95 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.889 -1.624 . . . . 0.0 110.625 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.408 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -118.16 -22.64 7.67 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.78 -0.835 . . . . 0.0 110.497 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.911 HG23 ' HB ' ' A' ' 28' ' ' ILE . 10.0 tt -97.22 100.46 7.83 Favored Pre-proline 0 N--CA 1.485 1.324 0 C-N-CA 118.641 -1.224 . . . . 0.0 110.264 -179.317 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -62.34 147.29 95.19 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.384 1.202 . . . . 0.0 109.649 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.587 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.8 t80 -160.84 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.189 -0.944 . . . . 0.0 111.487 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.587 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 25.9 m-85 59.13 67.32 0.93 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.425 -0.797 . . . . 0.0 111.609 178.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.48 14.35 13.54 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.545 ' CB ' HD23 ' A' ' 15' ' ' LEU . 41.3 mmtm -130.63 156.4 44.95 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.069 -1.254 . . . . 0.0 109.192 179.647 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.742 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.16 107.1 13.54 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.921 -1.112 . . . . 0.0 109.487 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -71.22 113.79 22.16 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.29 -0.881 . . . . 0.0 110.156 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.834 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.8 Cg_endo -68.69 129.59 19.05 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 N-CA-C 106.877 -2.009 . . . . 0.0 106.877 176.363 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.635 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.7 mt -55.58 -19.36 9.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.867 -1.146 . . . . 0.0 110.762 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.448 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.06 24.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.753 -1.217 . . . . 0.0 110.434 179.682 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.027 HG23 HG23 ' A' ' 33' ' ' ILE . 12.5 m -91.99 -25.01 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.997 -1.064 . . . . 0.0 111.049 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.027 HG23 HG23 ' A' ' 32' ' ' VAL . 6.2 pt -117.6 -21.09 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.917 -1.115 . . . . 0.0 110.764 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.565 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.0 tptt -94.29 148.44 22.2 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.1 -1.0 . . . . 0.0 110.175 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.38 33.39 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.24 -140.43 4.85 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.113 -1.518 . . . . 0.0 110.266 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.78 131.57 55.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.319 -1.106 . . . . 0.0 110.399 -179.609 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.565 ' HB2' HG12 ' A' ' 81' ' ' VAL . 86.5 m-70 -139.32 151.89 46.77 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.289 -0.882 . . . . 0.0 110.701 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.48 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.3 tp -114.32 122.07 45.56 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.273 -0.892 . . . . 0.0 110.224 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.848 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.5 mt -104.23 129.51 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.248 -0.907 . . . . 0.0 109.451 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.48 123.92 38.2 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.452 -0.78 . . . . 0.0 109.934 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.81 159.18 22.73 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.198 -0.939 . . . . 0.0 110.732 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -108.25 0.4 21.36 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.394 -0.816 . . . . 0.0 110.15 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 30.2 p -136.37 141.39 43.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.523 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.491 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.83 -40.2 69.25 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.538 -0.726 . . . . 0.0 110.6 -179.842 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.88 -34.14 71.29 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.353 -0.842 . . . . 0.0 110.663 -179.557 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.18 -35.08 68.89 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.891 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -61.3 -33.9 74.34 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.455 -0.778 . . . . 0.0 109.464 179.409 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -69.15 -50.59 46.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.273 -0.892 . . . . 0.0 110.874 -179.622 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.71 -47.11 49.88 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.133 -0.979 . . . . 0.0 110.56 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.723 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.6 tm? -56.74 -37.64 71.29 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.585 -0.697 . . . . 0.0 111.256 -178.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.416 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -76.23 -51.36 12.22 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.793 -1.192 . . . . 0.0 110.381 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.57 92.71 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.149 -0.969 . . . . 0.0 110.008 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.561 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.3 OUTLIER -57.3 -44.56 84.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.362 -0.836 . . . . 0.0 109.347 179.598 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.839 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.38 -42.91 74.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.647 -0.658 . . . . 0.0 110.12 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.2 -33.16 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.052 -1.03 . . . . 0.0 108.983 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.7 -31.48 59.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.458 -0.776 . . . . 0.0 110.057 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.561 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -71.65 -26.36 62.51 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.302 -0.874 . . . . 0.0 109.329 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.77 5.47 9.09 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.635 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.6 mt -108.23 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.261 -1.14 . . . . 0.0 110.314 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.482 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 22.0 t-20 -88.05 107.08 18.56 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.74 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.03 143.9 45.22 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.912 -1.115 . . . . 0.0 111.893 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.937 HG21 ' HA ' ' A' ' 73' ' ' VAL . 94.8 t -125.05 147.46 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.713 -0.617 . . . . 0.0 109.767 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.891 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.44 123.0 49.0 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.46 -0.896 . . . . 0.0 109.519 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.45 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.3 t80 -117.67 136.36 53.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.124 -0.985 . . . . 0.0 110.743 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.869 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -169.14 176.25 5.35 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.454 -0.779 . . . . 0.0 109.819 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -50.95 122.93 8.2 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 110.876 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.4 38.78 16.7 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.869 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.01 154.82 30.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.06 -1.259 . . . . 0.0 109.923 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.848 ' N ' HD13 ' A' ' 69' ' ' LEU . 10.1 m-20 -94.09 149.12 21.52 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.292 -0.88 . . . . 0.0 110.557 -179.176 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.671 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.58 110.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.212 -0.995 . . . . 0.0 109.501 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.7 m -132.56 -17.54 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.561 -0.712 . . . . 0.0 110.903 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.937 ' HA ' HG21 ' A' ' 63' ' ' VAL . 61.2 t -65.38 141.85 17.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.146 -0.971 . . . . 0.0 109.744 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.756 ' O ' HG11 ' A' ' 80' ' ' VAL . 6.0 pt . . . . . 0 N--CA 1.493 1.703 0 O-C-N 121.239 -0.913 . . . . 0.0 110.436 -179.565 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 122.072 0.939 . . . . 0.0 109.933 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.756 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.2 p -116.93 134.29 60.95 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 CA-C-O 122.125 0.964 . . . . 0.0 110.339 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.572 HG22 HG22 ' A' ' 60' ' ' ILE . 13.9 m -113.44 124.69 70.34 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.856 HG22 HG13 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.865 -1.147 . . . . 0.0 110.58 -177.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.848 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -112.7 100.6 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.862 -1.149 . . . . 0.0 108.305 179.271 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.45 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.73 34.7 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.886 -1.134 . . . . 0.0 111.541 -177.527 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.522 HG23 ' N ' ' A' ' 86' ' ' ASP . 6.3 t -84.17 -126.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.522 ' N ' HG23 ' A' ' 85' ' ' THR . 1.0 OUTLIER -101.37 40.27 1.32 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.474 -1.391 . . . . 0.0 110.211 179.691 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.469 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.72 -34.67 7.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.87 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.663 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.722 0 O-C-N 121.279 -0.888 . . . . 0.0 109.841 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 121.008 0.432 . . . . 0.0 110.567 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.498 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.15 145.71 46.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.039 -1.038 . . . . 0.0 110.161 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.521 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.53 -31.5 42.08 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.725 179.532 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.475 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.1 p -161.56 163.95 29.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.176 -0.953 . . . . 0.0 111.33 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.462 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.89 115.54 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.494 -0.754 . . . . 0.0 110.017 179.291 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.946 HG21 HD11 ' A' ' 28' ' ' ILE . 3.6 mp -93.42 112.56 26.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.165 -0.96 . . . . 0.0 108.859 179.36 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.8 161.07 19.86 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.125 -0.985 . . . . 0.0 111.765 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.471 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 15.0 t -102.98 8.31 39.0 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.735 -0.603 . . . . 0.0 109.482 178.19 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 47.09 26.16 0.6 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.155 -0.966 . . . . 0.0 111.09 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.492 1.672 0 O-C-N 121.114 -0.991 . . . . 0.0 110.516 179.633 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.447 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 121.293 0.568 . . . . 0.0 110.78 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.555 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -89.06 161.57 16.48 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.402 -0.811 . . . . 0.0 110.442 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.434 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.7 -53.87 3.47 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.469 -0.769 . . . . 0.0 112.375 -178.633 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.555 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.1 m -68.66 -29.5 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.608 -1.307 . . . . 0.0 111.264 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.447 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.66 -56.48 7.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.078 -1.014 . . . . 0.0 110.549 -179.268 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.44 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.3 OUTLIER -67.6 -34.89 77.92 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.15 -0.969 . . . . 0.0 108.605 178.758 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 13.3 m -59.56 -49.79 76.42 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -74.02 -35.89 64.4 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.592 -0.693 . . . . 0.0 109.871 178.849 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.44 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 3.3 mtt85 -71.13 -44.83 64.81 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.028 -1.045 . . . . 0.0 110.71 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.476 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 2.7 ttm105 -60.42 -42.56 96.26 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.978 -1.076 . . . . 0.0 110.455 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.58 86.16 0.09 OUTLIER Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.7 -45.4 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.5 -1.0 . . . . 0.0 108.652 179.502 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.526 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.57 30.03 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.119 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.48 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.09 10.45 12.04 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.117 -1.516 . . . . 0.0 110.567 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 5.8 mtt180 -84.88 83.99 7.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.043 -1.269 . . . . 0.0 109.842 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.49 9.46 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 108.916 -1.674 . . . . 0.0 108.916 -179.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.508 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.74 -169.63 0.22 Allowed Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.892 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.508 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.8 Cg_endo -88.0 111.06 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 122.883 0.938 . . . . 0.0 110.047 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.526 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.57 150.93 38.95 Favored Glycine 0 N--CA 1.494 2.563 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.173 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.454 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.43 141.46 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -1.202 . . . . 0.0 109.139 179.251 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.476 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.89 116.46 17.2 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.882 -1.136 . . . . 0.0 110.725 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.486 ' NH1' HG11 ' A' ' 32' ' ' VAL . 9.6 mtt-85 -105.81 125.78 51.39 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.405 -0.809 . . . . 0.0 109.635 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.7 p90 -114.61 157.92 22.42 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.979 -1.076 . . . . 0.0 110.192 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.471 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t . . . . . 0 N--CA 1.491 1.603 0 O-C-N 121.119 -0.988 . . . . 0.0 109.984 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.35 0.595 . . . . 0.0 109.561 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.503 HD13 HG22 ' A' ' 122' ' ' THR . 13.7 mt -96.24 130.21 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.095 -1.003 . . . . 0.0 110.153 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.416 ' HB3' HG12 ' A' ' 129' ' ' ILE . 18.4 tt0 -84.93 129.44 34.8 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.454 -0.778 . . . . 0.0 109.686 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -88.42 133.04 34.22 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.024 -1.047 . . . . 0.0 109.946 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.557 HG11 ' NE ' ' A' ' 131' ' ' ARG . 12.0 t -126.72 158.0 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.433 -0.792 . . . . 0.0 110.469 -179.016 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.74 110.74 23.0 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.312 -0.867 . . . . 0.0 109.906 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.417 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.7 tp -56.49 140.1 47.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.766 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.9 p -135.36 170.53 15.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.17 -0.956 . . . . 0.0 110.236 -179.682 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.73 63.6 0.29 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.08 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.47 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.3 m -133.91 111.67 10.64 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.35 -0.844 . . . . 0.0 110.399 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.445 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.912 -1.613 . . . . 0.0 110.815 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.4 -19.15 8.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.763 -0.845 . . . . 0.0 110.366 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.904 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.56 113.2 62.21 Favored Pre-proline 0 N--CA 1.485 1.322 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.421 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -65.48 144.22 78.63 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.596 1.314 . . . . 0.0 109.648 179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.506 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.07 98.65 1.06 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.078 -1.049 . . . . 0.0 111.634 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.499 ' N ' ' CD1' ' A' ' 24' ' ' TYR . 22.7 m-85 55.45 65.24 1.53 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.292 -0.88 . . . . 0.0 111.59 178.424 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.86 14.59 10.37 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.506 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.91 156.2 45.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.075 -1.25 . . . . 0.0 108.93 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.47 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.39 106.55 14.13 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.916 -1.115 . . . . 0.0 109.465 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.935 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -68.7 114.9 25.48 Favored Pre-proline 0 C--N 1.298 -1.663 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.018 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.766 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.3 Cg_endo -69.54 128.68 16.59 Favored 'Trans proline' 0 C--N 1.303 -1.825 0 N-CA-C 106.587 -2.12 . . . . 0.0 106.587 176.235 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.756 HD11 HD12 ' A' ' 58' ' ' LEU . 14.0 mt -55.57 -18.85 8.36 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.469 -177.375 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -59.06 -16.52 19.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.721 -1.237 . . . . 0.0 110.574 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.034 HG23 HG23 ' A' ' 33' ' ' ILE . 11.0 m -92.57 -24.1 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 120.921 -1.112 . . . . 0.0 110.925 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.034 HG23 HG23 ' A' ' 32' ' ' VAL . 6.9 pt -119.44 -20.27 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.936 -1.103 . . . . 0.0 110.983 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.556 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.41 22.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.935 -1.103 . . . . 0.0 110.403 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.86 -2.85 66.96 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.66 18.0 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.025 -1.56 . . . . 0.0 110.69 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.46 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.61 132.79 52.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.479 -1.012 . . . . 0.0 110.162 -179.622 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.518 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.14 45.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 110.933 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.621 HD12 ' O ' ' A' ' 82' ' ' VAL . 50.2 tp -113.29 114.44 26.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.411 -0.806 . . . . 0.0 110.241 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.755 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.2 mt -97.31 128.79 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.021 . . . . 0.0 109.549 179.367 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.401 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 8.0 m-85 -97.54 123.28 41.36 Favored 'General case' 0 C--N 1.292 -1.893 0 O-C-N 121.108 -0.995 . . . . 0.0 110.448 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.39 159.86 22.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.342 -0.849 . . . . 0.0 110.382 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 18.6 p-80 -104.73 -5.61 21.13 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.31 -0.869 . . . . 0.0 110.06 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.7 p -128.15 139.85 52.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.98 -1.075 . . . . 0.0 110.863 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.86 -39.51 69.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.636 -0.665 . . . . 0.0 110.475 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.08 -33.44 70.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.399 -0.813 . . . . 0.0 110.648 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.408 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.67 -37.08 68.02 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.349 -0.844 . . . . 0.0 109.914 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.883 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 69.7 m -62.16 -36.38 81.68 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.364 -0.835 . . . . 0.0 109.651 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.35 -50.28 64.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.027 -1.046 . . . . 0.0 110.231 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.63 -44.81 61.43 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.312 -0.867 . . . . 0.0 110.415 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.897 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -61.29 -36.82 81.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.479 -0.763 . . . . 0.0 111.583 -178.872 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.417 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.77 -51.68 12.1 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.843 -1.161 . . . . 0.0 110.776 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.78 -38.22 78.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.036 -1.04 . . . . 0.0 109.563 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.806 ' HE2' HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.11 -46.46 82.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.661 -0.649 . . . . 0.0 109.464 179.287 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.742 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.7 -40.23 72.1 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.355 -0.841 . . . . 0.0 110.131 179.897 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.5 t -59.08 -30.91 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.173 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.77 60.17 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.456 -0.778 . . . . 0.0 110.0 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.756 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.27 -25.52 62.49 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.845 0.831 . . . . 0.0 109.739 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.79 7.05 8.97 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.709 ' CD1' HD22 ' A' ' 30' ' ' LEU . 39.4 mt -107.77 142.78 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.31 -1.112 . . . . 0.0 109.821 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.507 ' OD1' HD11 ' A' ' 74' ' ' ILE . 2.4 t-20 -88.87 106.52 18.45 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 177.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.679 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -115.95 141.76 47.68 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.521 -177.37 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.898 HG21 ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.97 143.17 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.704 -0.622 . . . . 0.0 110.007 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.883 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.34 117.82 34.17 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.366 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.28 127.12 53.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.197 -0.939 . . . . 0.0 111.07 -179.235 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.866 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 7.3 p90 -157.59 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.684 -0.635 . . . . 0.0 109.642 179.417 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.19 126.99 25.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.08 -1.012 . . . . 0.0 111.007 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.75 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.866 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -116.59 154.92 29.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.09 -1.241 . . . . 0.0 109.896 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.831 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.7 m-20 -94.84 149.57 21.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.345 -0.847 . . . . 0.0 110.517 -179.201 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.1 m -61.75 110.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 118.969 -1.092 . . . . 0.0 108.817 179.194 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.855 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.3 m -130.66 -34.72 1.52 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.438 -0.789 . . . . 0.0 110.283 -179.401 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.898 ' HA ' HG21 ' A' ' 63' ' ' VAL . 90.9 t -46.86 129.83 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.457 -0.777 . . . . 0.0 109.883 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.855 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 111.18 -179.186 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.898 0.856 . . . . 0.0 110.343 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.618 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.5 p -117.25 133.95 62.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 CA-C-O 121.978 0.894 . . . . 0.0 110.452 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.671 HG11 ' HB ' ' A' ' 33' ' ' ILE . 12.6 m -112.59 122.01 65.99 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.107 0 O-C-N 121.355 -0.841 . . . . 0.0 109.01 179.118 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.763 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.54 45.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.911 -1.118 . . . . 0.0 110.726 -177.685 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.755 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -110.16 99.58 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.91 -1.116 . . . . 0.0 108.974 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -132.41 162.09 32.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.698 -1.251 . . . . 0.0 110.326 -178.811 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.601 HG23 ' OD2' ' A' ' 86' ' ' ASP . 7.2 t -99.1 -27.91 13.62 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.161 -0.962 . . . . 0.0 110.689 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.601 ' OD2' HG23 ' A' ' 85' ' ' THR . 1.3 p30 177.93 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.376 -0.827 . . . . 0.0 110.257 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.499 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.35 -25.57 0.67 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.266 -0.896 . . . . 0.0 110.936 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.441 HD12 ' HA ' ' A' ' 88' ' ' LEU . 14.7 tp . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.184 -0.948 . . . . 0.0 109.791 179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.126 0.488 . . . . 0.0 110.781 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -119.25 149.47 41.72 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -0.988 . . . . 0.0 110.01 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.439 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.6 -30.74 46.78 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.354 -0.841 . . . . 0.0 109.61 179.528 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -161.65 163.22 30.02 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.231 -0.918 . . . . 0.0 110.925 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.459 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.2 114.37 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.999 0 O-C-N 121.417 -0.802 . . . . 0.0 110.154 179.189 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.935 HG21 HD11 ' A' ' 28' ' ' ILE . 3.8 mp -93.06 112.41 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 108.523 179.023 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.416 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.82 21.2 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.103 -0.998 . . . . 0.0 111.722 -177.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.447 ' SG ' ' CE1' ' A' ' 24' ' ' TYR . 57.0 m -98.45 2.31 47.61 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.658 -0.651 . . . . 0.0 109.293 177.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.415 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 53.86 24.84 4.78 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.149 -0.97 . . . . 0.0 111.172 179.739 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.489 1.48 0 O-C-N 121.026 -1.046 . . . . 0.0 110.923 179.907 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.428 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 4.2 pt20 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.272 0.558 . . . . 0.0 110.935 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.519 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -85.28 161.46 19.53 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.245 -0.909 . . . . 0.0 110.286 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.67 -57.94 2.13 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.605 -0.685 . . . . 0.0 112.519 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.519 HG22 ' OD1' ' A' ' 111' ' ' ASP . 8.1 m -67.36 -29.6 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 120.68 -1.263 . . . . 0.0 111.532 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.428 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.54 -56.09 7.83 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.111 -0.993 . . . . 0.0 110.437 -179.286 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.463 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.16 -34.06 76.74 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.537 178.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.6 m -59.28 -48.89 79.92 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.049 -1.032 . . . . 0.0 108.404 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.1 -35.7 66.64 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.746 -0.782 . . . . 0.0 109.812 178.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.432 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.58 -45.06 66.1 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.058 -1.026 . . . . 0.0 110.463 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.473 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.1 ttm180 -59.45 -40.79 88.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.003 -1.06 . . . . 0.0 110.004 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.28 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.437 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -149.07 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.515 -0.991 . . . . 0.0 108.625 179.365 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.543 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.8 t -98.16 143.35 28.78 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 12.5 10.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.4 -1.381 . . . . 0.0 110.515 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.5 85.07 5.3 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.009 -1.289 . . . . 0.0 109.877 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 98.74 17.2 28.94 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.463 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 4.5 pttt -176.98 -177.02 0.25 Allowed Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.48 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.7 Cg_endo -89.01 106.93 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.118 1.062 . . . . 0.0 109.488 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.543 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.01 174.0 49.73 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.321 -179.131 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 20.3 mt -130.22 141.86 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 108.839 179.137 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 12.8 t80 -132.18 115.95 16.35 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.061 -1.024 . . . . 0.0 110.858 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.557 ' NE ' HG11 ' A' ' 13' ' ' VAL . 0.3 OUTLIER -102.67 122.15 43.86 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.415 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 39.1 p90 -115.17 158.1 22.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.015 -1.053 . . . . 0.0 110.254 -179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.4 t . . . . . 0 N--CA 1.493 1.681 0 O-C-N 121.156 -0.965 . . . . 0.0 110.37 -179.881 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.5 t-20 . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.12 0.486 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.536 HD12 ' HG2' ' A' ' 119' ' ' ARG . 45.0 mt -103.45 128.24 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.919 -1.113 . . . . 0.0 110.218 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.36 127.98 34.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.147 179.188 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.63 142.02 28.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.049 -1.032 . . . . 0.0 110.365 -179.162 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.53 HG11 ' NE ' ' A' ' 131' ' ' ARG . 4.8 t -128.97 157.7 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.481 -0.762 . . . . 0.0 109.878 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.66 112.32 25.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.248 -0.907 . . . . 0.0 110.317 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.584 HD23 HG22 ' A' ' 133' ' ' VAL . 13.5 tp -62.9 135.58 57.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -0.922 . . . . 0.0 109.326 179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.5 p -137.15 -178.15 5.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.029 -1.045 . . . . 0.0 110.623 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.29 4.28 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.371 -0.83 . . . . 0.0 109.741 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.673 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 3.6 m -156.68 113.55 3.1 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.898 . . . . 0.0 110.589 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.429 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -168.18 28.25 Favored Glycine 0 N--CA 1.488 2.125 0 C-N-CA 118.836 -1.649 . . . . 0.0 111.081 179.18 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.42 -20.92 10.06 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.844 -0.798 . . . . 0.0 110.289 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.901 HD12 HD13 ' A' ' 55' ' ' LEU . 9.0 tt -96.78 107.76 38.92 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 118.794 -1.163 . . . . 0.0 109.757 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.2 Cg_endo -64.62 126.97 17.79 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 123.353 1.186 . . . . 0.0 110.887 -178.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.3 -169.82 1.69 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.564 -0.71 . . . . 0.0 110.345 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.3 m-85 -57.4 81.15 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.488 -0.757 . . . . 0.0 111.6 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.84 -1.29 59.23 Favored Glycine 0 N--CA 1.494 2.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.757 179.427 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.404 ' HD2' ' O ' ' A' ' 15' ' ' LEU . 0.5 OUTLIER -129.59 156.89 43.46 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.881 -1.364 . . . . 0.0 110.047 -179.903 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.673 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -104.79 106.86 17.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.062 -1.024 . . . . 0.0 108.868 179.448 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.8 mt -68.34 113.14 13.54 Favored Pre-proline 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 110.677 -179.169 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.893 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -68.97 130.65 20.72 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 107.216 -1.879 . . . . 0.0 107.216 175.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.682 HD11 HD12 ' A' ' 58' ' ' LEU . 13.0 mt -56.3 -18.99 12.34 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.816 -1.178 . . . . 0.0 110.137 -178.09 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.466 ' OE2' HG12 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.69 -16.15 24.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.681 -1.262 . . . . 0.0 110.437 179.687 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.025 HG23 HG23 ' A' ' 33' ' ' ILE . 17.0 m -91.76 -25.02 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.949 -1.094 . . . . 0.0 110.836 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.025 HG23 HG23 ' A' ' 32' ' ' VAL . 38.6 pt -119.4 -20.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.058 -1.026 . . . . 0.0 111.134 -178.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.592 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.2 tptm -92.93 148.33 22.1 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.984 -1.072 . . . . 0.0 110.073 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.93 -5.32 46.44 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 -179.542 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.87 21.88 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.205 -1.474 . . . . 0.0 110.341 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.1 mtt-85 -97.85 133.01 42.93 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -1.028 . . . . 0.0 110.305 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.572 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.5 m-70 -140.29 149.21 42.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.21 -0.931 . . . . 0.0 110.799 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.464 ' HB3' HG12 ' A' ' 99' ' ' VAL . 26.8 tp -111.41 114.09 26.99 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.371 -0.831 . . . . 0.0 110.061 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.821 HD12 HG12 ' A' ' 83' ' ' VAL . 35.3 mt -96.68 127.76 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.192 -0.943 . . . . 0.0 109.776 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -95.36 123.46 38.9 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.574 -0.704 . . . . 0.0 109.873 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.8 157.07 27.25 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.2 -0.937 . . . . 0.0 110.755 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.2 p80 -104.44 0.92 29.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.374 -0.829 . . . . 0.0 109.976 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 110.255 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.416 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.7 ttpt -71.63 -41.9 68.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.513 -0.742 . . . . 0.0 110.907 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.86 -33.79 72.27 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.251 -0.906 . . . . 0.0 110.812 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.506 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.27 -39.6 82.11 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.926 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.864 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.6 m -61.16 -34.68 75.41 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.253 -0.904 . . . . 0.0 109.768 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.63 -50.36 65.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.241 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.17 53.85 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.213 -0.929 . . . . 0.0 110.377 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.769 ' CD2' HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.03 -36.51 70.55 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.719 -0.613 . . . . 0.0 111.386 -178.809 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.487 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.84 -51.09 13.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.9 -1.125 . . . . 0.0 110.722 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.14 -39.34 89.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.072 -1.017 . . . . 0.0 109.846 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.545 ' HE3' HD21 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.26 -45.77 83.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.332 -0.855 . . . . 0.0 109.586 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.901 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.32 -39.95 70.57 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.513 -0.742 . . . . 0.0 110.088 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.93 -34.84 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.118 -0.989 . . . . 0.0 108.958 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -30.81 60.64 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.435 -0.79 . . . . 0.0 110.238 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.682 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.6 -25.88 62.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.345 -0.847 . . . . 0.0 109.815 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.11 4.71 10.03 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.669 ' CD1' HD22 ' A' ' 30' ' ' LEU . 45.9 mt -107.57 143.4 18.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.362 -1.081 . . . . 0.0 109.919 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.476 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 11.1 t-20 -89.46 106.85 18.72 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 106.476 -1.675 . . . . 0.0 106.476 178.065 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.676 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.21 143.48 45.82 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.728 -1.189 . . . . 0.0 112.316 -176.705 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.918 HG21 ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.25 151.88 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.864 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -121.27 118.34 29.31 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.715 178.554 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.493 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -108.81 133.83 52.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.317 -0.865 . . . . 0.0 110.552 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.977 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.5 p90 -165.81 -173.25 2.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.473 -0.767 . . . . 0.0 110.162 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.91 125.44 23.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.224 -0.923 . . . . 0.0 110.702 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.55 29.2 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.977 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -1.167 . . . . 0.0 109.997 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.826 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.4 m-20 -97.24 149.13 22.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 110.731 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.672 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.9 m -62.9 110.99 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.254 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.7 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.8 m -131.4 -32.53 1.54 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.426 -0.796 . . . . 0.0 110.752 -179.346 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.918 ' HA ' HG21 ' A' ' 63' ' ' VAL . 99.0 t -47.83 134.55 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.44 -0.787 . . . . 0.0 110.19 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.7 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.137 -0.977 . . . . 0.0 111.12 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 121.973 0.892 . . . . 0.0 110.381 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.3 p -116.52 134.69 59.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 122.038 0.923 . . . . 0.0 109.858 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.588 HG22 HG22 ' A' ' 60' ' ' ILE . 16.5 m -112.83 123.53 68.59 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.317 -0.864 . . . . 0.0 109.555 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.762 HG22 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.95 116.46 40.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.842 -1.161 . . . . 0.0 110.595 -178.136 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.821 HG12 HD12 ' A' ' 40' ' ' ILE . 2.8 m -107.87 100.38 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 0.0 108.559 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.493 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -135.63 162.2 33.37 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.732 -1.23 . . . . 0.0 111.335 -177.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.422 ' H ' HG22 ' A' ' 85' ' ' THR . 5.3 t -91.61 -132.83 0.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.673 -0.642 . . . . 0.0 109.649 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.15 21.35 3.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.752 -1.217 . . . . 0.0 110.59 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.46 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.25 -34.91 15.59 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -0.949 . . . . 0.0 109.646 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp . . . . . 0 N--CA 1.489 1.508 0 O-C-N 121.375 -0.828 . . . . 0.0 109.592 179.461 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.157 0.503 . . . . 0.0 110.717 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -119.21 148.51 43.03 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.112 -0.993 . . . . 0.0 109.964 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.23 59.8 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.351 -0.843 . . . . 0.0 109.237 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.323 -0.861 . . . . 0.0 111.003 179.634 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.58 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.03 117.54 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.355 -0.841 . . . . 0.0 110.685 179.799 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.868 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.12 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.74 160.71 22.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.174 -0.954 . . . . 0.0 111.517 -178.154 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.475 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 13.7 t -100.01 8.27 44.13 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.649 -0.657 . . . . 0.0 109.588 178.367 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.402 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.5 m120 46.89 25.95 0.52 Allowed 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.272 -0.893 . . . . 0.0 110.725 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.235 -0.915 . . . . 0.0 110.062 179.53 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.382 0.61 . . . . 0.0 110.797 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.9 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.243 -0.911 . . . . 0.0 110.294 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.16 -53.19 5.15 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.554 -0.716 . . . . 0.0 112.239 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.46 -29.07 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.68 -1.263 . . . . 0.0 111.432 -178.707 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.404 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.36 -56.46 6.85 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.124 -0.985 . . . . 0.0 110.486 -179.067 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.434 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 16.4 ptp180 -68.9 -35.17 76.54 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.218 -0.926 . . . . 0.0 108.635 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.434 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 26.9 m -59.32 -49.89 76.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.072 -1.017 . . . . 0.0 108.608 178.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -73.75 -38.54 64.7 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.498 -0.752 . . . . 0.0 110.064 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.425 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.43 -44.71 67.31 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.263 -0.898 . . . . 0.0 110.838 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.536 ' HG2' HD12 ' A' ' 10' ' ' ILE . 1.3 ttp180 -55.28 -48.73 73.63 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.27 -0.893 . . . . 0.0 110.507 -179.552 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.18 -18.89 1.41 Allowed Glycine 0 N--CA 1.499 2.834 0 O-C-N 121.526 -0.734 . . . . 0.0 112.343 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.425 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -56.61 -35.55 68.41 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.501 -1.588 . . . . 0.0 112.014 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.481 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.3 t -100.06 144.67 28.82 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.696 -1.252 . . . . 0.0 111.495 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.432 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.63 8.06 62.62 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.578 178.659 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.09 86.83 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.065 -1.256 . . . . 0.0 109.006 179.502 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.8 -21.44 34.2 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -178.596 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.489 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -138.99 -168.87 0.2 Allowed Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.386 -1.067 . . . . 0.0 109.09 179.924 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.1 Cg_endo -87.87 107.98 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.147 1.077 . . . . 0.0 110.564 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.481 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -84.52 168.36 43.92 Favored Glycine 0 N--CA 1.498 2.777 0 O-C-N 121.047 -1.033 . . . . 0.0 110.973 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.445 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.2 mt -124.87 143.24 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.618 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.58 ' CD2' HG23 ' A' ' 99' ' ' VAL . 10.0 t80 -130.22 121.94 27.15 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.693 -1.254 . . . . 0.0 111.771 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.53 ' NE ' HG11 ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.25 124.38 49.67 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.402 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 45.8 p90 -123.27 155.97 36.15 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.954 -1.091 . . . . 0.0 110.888 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.584 HG22 HD23 ' A' ' 15' ' ' LEU . 16.7 t . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.369 -0.832 . . . . 0.0 109.173 178.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.427 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 18.3 m120 . . . . . 0 N--CA 1.494 1.725 0 CA-C-O 121.142 0.496 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.491 HD11 ' O ' ' A' ' 122' ' ' THR . 25.1 mt -106.2 135.78 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.072 -1.018 . . . . 0.0 110.223 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.42 128.5 34.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.323 -0.86 . . . . 0.0 109.451 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.38 125.51 35.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.063 -1.023 . . . . 0.0 110.047 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.451 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.06 155.01 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 110.322 -179.385 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.6 110.48 22.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.603 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.683 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.4 tp -56.5 135.38 54.41 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.269 -0.894 . . . . 0.0 109.976 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.414 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.3 p -134.58 167.47 20.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 110.378 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.05 79.72 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.302 -0.874 . . . . 0.0 109.993 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.621 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 35.8 m -154.14 109.7 3.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.457 -0.777 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.43 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.68 -170.69 29.83 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 118.928 -1.606 . . . . 0.0 111.103 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.33 -22.14 11.5 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.716 -0.873 . . . . 0.0 110.207 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.895 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.83 25.67 Favored Pre-proline 0 N--CA 1.49 1.532 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.738 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.474 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.3 Cg_endo -64.49 131.88 31.36 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.317 1.167 . . . . 0.0 110.805 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.1 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.586 -0.696 . . . . 0.0 110.646 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.703 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.6 m-85 -58.04 81.46 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.397 -0.814 . . . . 0.0 111.342 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.46 47.71 Favored Glycine 0 N--CA 1.493 2.434 0 O-C-N 121.084 -1.01 . . . . 0.0 110.6 179.718 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.683 ' CB ' HD23 ' A' ' 15' ' ' LEU . 16.7 mmtp -130.45 156.8 44.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.957 -1.32 . . . . 0.0 109.309 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.621 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -110.43 107.77 17.56 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.94 -1.1 . . . . 0.0 109.653 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -67.76 113.57 15.25 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.388 -0.82 . . . . 0.0 110.987 -179.25 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.864 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.8 Cg_endo -69.55 127.49 14.84 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 N-CA-C 106.9 -2.0 . . . . 0.0 106.9 175.674 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.608 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.7 mt -55.84 -19.1 10.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.816 -1.178 . . . . 0.0 110.819 -177.49 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -59.86 -16.07 26.06 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.761 -1.212 . . . . 0.0 110.499 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.111 HG23 HG23 ' A' ' 33' ' ' ILE . 15.3 m -91.1 -25.29 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.952 -1.093 . . . . 0.0 110.967 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.111 HG23 HG23 ' A' ' 32' ' ' VAL . 41.3 pt -117.28 -16.48 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.019 -1.051 . . . . 0.0 110.616 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.575 ' HB2' HD11 ' A' ' 60' ' ' ILE . 3.5 tptm -96.33 148.24 22.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.873 -1.142 . . . . 0.0 110.226 179.358 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.43 -3.23 56.41 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.25 -161.35 26.61 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.934 -1.603 . . . . 0.0 110.906 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.15 128.48 44.09 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.531 -0.982 . . . . 0.0 110.521 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.59 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.56 145.11 44.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.035 -1.04 . . . . 0.0 110.771 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.506 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.6 tp -107.19 113.56 27.07 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.369 -0.832 . . . . 0.0 109.979 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.919 HD12 HG12 ' A' ' 83' ' ' VAL . 36.0 mt -96.37 129.28 46.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.251 -0.906 . . . . 0.0 109.452 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.91 123.75 38.56 Favored 'General case' 0 C--N 1.292 -1.917 0 O-C-N 121.136 -0.977 . . . . 0.0 109.74 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.69 159.74 21.79 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.193 -0.942 . . . . 0.0 111.029 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.703 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -112.3 6.83 19.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.482 -0.761 . . . . 0.0 110.057 179.002 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.407 ' OG ' ' HB3' ' A' ' 47' ' ' LYS . 3.9 p -138.18 137.17 37.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.028 -1.045 . . . . 0.0 110.68 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.58 -40.6 69.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.381 -0.824 . . . . 0.0 110.194 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -36.77 79.43 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 110.247 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.421 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -72.24 -35.64 68.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 179.975 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.869 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 5.5 m -60.29 -33.78 72.82 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.434 -0.791 . . . . 0.0 109.55 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.87 -49.05 61.58 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.201 -0.937 . . . . 0.0 110.432 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.64 -43.32 66.32 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.342 -0.849 . . . . 0.0 110.538 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.826 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.5 -41.58 76.89 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.392 -0.818 . . . . 0.0 111.008 -179.047 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.96 -51.33 12.64 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.988 -1.07 . . . . 0.0 110.58 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.59 -42.05 98.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.87 -1.144 . . . . 0.0 109.594 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -57.68 -46.08 84.77 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.86 . . . . 0.0 109.882 179.71 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.741 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.04 -41.51 71.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.473 -0.767 . . . . 0.0 109.607 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.4 t -56.08 -31.19 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.068 -1.02 . . . . 0.0 108.61 178.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.55 -32.92 60.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.561 -0.712 . . . . 0.0 109.97 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.479 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.92 -25.87 62.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.313 -0.867 . . . . 0.0 109.512 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.0 7.32 8.62 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.404 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.608 ' CD1' HD22 ' A' ' 30' ' ' LEU . 34.6 mt -108.83 143.25 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.416 -1.05 . . . . 0.0 110.303 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.586 ' ND2' HD11 ' A' ' 74' ' ' ILE . 24.0 t-20 -86.43 107.0 17.85 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.018 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.619 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.52 143.91 48.32 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.428 -177.589 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.931 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -132.11 150.8 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.848 -0.741 . . . . 0.0 109.176 179.346 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.41 126.51 55.42 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.102 179.37 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.588 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.4 t80 -118.26 122.56 43.25 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.231 -0.918 . . . . 0.0 110.401 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.92 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.76 8.19 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.628 179.643 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.93 125.24 14.73 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.167 -0.958 . . . . 0.0 110.985 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.11 44.69 22.52 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.32 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.926 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.5 tm? -117.72 156.48 28.19 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.089 -1.242 . . . . 0.0 110.127 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.926 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.7 m-20 -94.51 148.98 21.7 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.283 -0.886 . . . . 0.0 110.723 -179.361 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.9 m -62.42 111.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.229 -0.989 . . . . 0.0 109.288 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.507 ' O ' HG23 ' A' ' 74' ' ' ILE . 6.9 m -133.65 -32.63 1.12 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.988 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.931 HG22 ' HB ' ' A' ' 63' ' ' VAL . 30.3 t -56.01 138.73 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.194 -0.941 . . . . 0.0 109.949 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.636 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.496 1.829 0 O-C-N 121.108 -0.995 . . . . 0.0 111.131 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.938 0.875 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.4 p -117.3 133.92 62.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-O 121.961 0.886 . . . . 0.0 110.351 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.591 HG22 HG22 ' A' ' 60' ' ' ILE . 7.8 m -112.67 123.82 68.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 178.818 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.736 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.76 116.46 38.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.1 -1.0 . . . . 0.0 110.353 -177.766 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.919 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -108.97 100.22 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.771 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.475 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.78 162.98 34.13 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.732 -1.23 . . . . 0.0 111.114 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.525 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -92.04 -130.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.537 -0.727 . . . . 0.0 109.47 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.525 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -90.98 34.83 0.91 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.713 -1.242 . . . . 0.0 110.226 179.534 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.43 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 0.0 110.356 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.132 -0.98 . . . . 0.0 109.099 179.401 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 120.761 0.315 . . . . 0.0 110.489 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.506 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.51 152.19 38.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.872 -1.143 . . . . 0.0 110.778 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.444 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.56 -28.79 19.35 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.567 -0.708 . . . . 0.0 109.363 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.3 p -161.0 163.77 31.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.34 -0.85 . . . . 0.0 110.758 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.489 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -125.75 119.18 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.251 -0.905 . . . . 0.0 110.292 179.578 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.769 HG21 ' CD1' ' A' ' 28' ' ' ILE . 37.9 mm -95.9 111.26 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 108.859 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.44 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -118.89 161.06 20.81 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.913 -1.117 . . . . 0.0 111.73 -178.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.48 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.3 p -99.96 -0.33 39.6 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 50.52 18.63 0.47 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.341 -0.85 . . . . 0.0 112.175 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.305 -1.349 0 O-C-N 120.729 -1.232 . . . . 0.0 109.407 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.644 0.735 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.539 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -102.68 161.56 13.63 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.544 -0.723 . . . . 0.0 110.327 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.433 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.28 -56.55 2.9 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.576 -0.702 . . . . 0.0 112.376 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.539 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -64.21 -29.87 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.702 -1.249 . . . . 0.0 111.255 -178.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.403 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.73 -56.32 7.61 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.116 -0.99 . . . . 0.0 110.505 -179.209 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.76 -33.77 76.36 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.159 -0.963 . . . . 0.0 108.851 178.91 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.5 m -60.93 -50.16 74.54 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.061 -1.025 . . . . 0.0 108.357 178.473 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.96 -38.71 64.13 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 mtt-85 -71.85 -44.37 63.94 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.258 -0.901 . . . . 0.0 111.321 -179.181 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.474 ' O ' ' N ' ' A' ' 121' ' ' ARG . 6.9 ttp180 -62.12 -40.42 95.85 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.917 -1.114 . . . . 0.0 110.244 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.4 75.26 0.04 OUTLIER Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -149.05 -47.35 0.14 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.43 -1.041 . . . . 0.0 108.76 179.599 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.555 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.1 t -96.19 143.47 27.27 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.76 17.82 4.55 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.409 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -91.75 82.8 5.22 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.117 -1.225 . . . . 0.0 109.986 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.92 -31.74 4.84 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.482 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.18 -169.74 0.22 Allowed Pre-proline 0 C--N 1.301 -1.514 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 179.509 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.482 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.5 Cg_endo -85.31 115.0 1.59 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 122.916 0.956 . . . . 0.0 110.466 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.555 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.29 51.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.567 HG21 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 mt -119.99 140.13 45.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.039 -1.271 . . . . 0.0 109.051 179.267 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.489 ' HD1' HG23 ' A' ' 99' ' ' VAL . 6.8 t80 -122.7 114.49 20.65 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 118.965 -1.094 . . . . 0.0 110.218 179.547 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.601 ' HB2' HD13 ' A' ' 100' ' ' ILE . 24.2 mtt180 -108.12 126.87 53.27 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.594 -0.692 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.451 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.8 p90 -126.95 156.94 40.72 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.078 -1.014 . . . . 0.0 110.847 -179.131 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.509 HG21 ' HB2' ' A' ' 24' ' ' TYR . 7.0 t . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.319 -0.863 . . . . 0.0 108.978 178.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 24.4 t-20 . . . . . 0 N--CA 1.496 1.851 0 CA-C-O 121.574 0.702 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.548 HD12 ' HG2' ' A' ' 119' ' ' ARG . 20.0 mt -105.8 132.99 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.442 -0.786 . . . . 0.0 109.117 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.5 33.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.054 -1.028 . . . . 0.0 109.302 179.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.54 126.43 35.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.176 -0.952 . . . . 0.0 110.021 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.559 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 6.4 t -116.14 154.52 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.334 -0.853 . . . . 0.0 110.4 -179.221 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.88 105.04 15.34 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.339 -0.851 . . . . 0.0 109.639 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.506 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -55.43 132.34 48.08 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.412 -0.805 . . . . 0.0 109.82 -179.828 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.408 ' O ' ' N ' ' A' ' 18' ' ' THR . 70.5 p -135.83 172.29 13.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.212 -0.93 . . . . 0.0 110.314 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.91 78.28 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.22 -0.925 . . . . 0.0 110.202 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.682 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.0 m -151.31 108.54 3.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.206 -0.934 . . . . 0.0 110.687 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.037 -1.554 . . . . 0.0 110.747 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.32 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.649 -0.912 . . . . 0.0 110.326 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.867 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.8 tt -100.53 104.24 29.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.314 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.3 Cg_endo -62.94 148.7 93.17 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.338 1.178 . . . . 0.0 109.894 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.533 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.26 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.174 -0.954 . . . . 0.0 111.127 -178.164 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.5 m-85 59.15 66.78 0.99 Allowed 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.406 -0.809 . . . . 0.0 111.332 179.393 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.87 15.0 11.11 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.62 156.98 43.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.057 -1.261 . . . . 0.0 109.121 179.524 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.682 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -117.2 107.28 14.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.883 -1.135 . . . . 0.0 109.69 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.867 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.6 mt -69.98 114.33 24.4 Favored Pre-proline 0 C--N 1.3 -1.553 0 C-N-CA 119.614 -0.835 . . . . 0.0 109.926 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -69.01 129.72 18.92 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 N-CA-C 107.047 -1.943 . . . . 0.0 107.047 176.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.666 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.9 mt -56.52 -16.92 6.8 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.78 -1.2 . . . . 0.0 110.976 -177.495 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.443 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.03 -15.89 47.83 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.799 -1.188 . . . . 0.0 110.242 179.427 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.053 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -92.6 -25.14 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.986 -1.071 . . . . 0.0 111.212 -179.215 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.053 HG23 HG23 ' A' ' 32' ' ' VAL . 12.0 pt -120.47 -23.25 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.99 -1.069 . . . . 0.0 110.804 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.652 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.04 147.9 22.6 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.954 -1.092 . . . . 0.0 110.692 -179.872 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.413 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.63 -3.48 57.65 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.95 -155.73 13.6 Favored Glycine 0 N--CA 1.494 2.542 0 C-N-CA 119.008 -1.567 . . . . 0.0 110.705 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.98 131.12 52.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.413 -1.051 . . . . 0.0 110.092 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.4 m-70 -140.83 152.38 45.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 111.07 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.459 HD12 ' O ' ' A' ' 82' ' ' VAL . 43.0 tp -112.27 115.67 29.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.361 -0.837 . . . . 0.0 110.321 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.836 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.6 mt -100.34 128.59 52.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 109.823 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.467 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.04 123.66 40.84 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.098 -1.001 . . . . 0.0 110.054 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.52 159.59 21.03 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.278 -0.889 . . . . 0.0 110.55 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.577 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.63 5.11 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.362 -0.836 . . . . 0.0 110.006 179.076 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.08 135.95 37.93 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.127 -0.983 . . . . 0.0 110.607 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.486 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.51 -31.31 66.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.546 -0.721 . . . . 0.0 110.395 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.06 -30.0 66.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.357 -0.84 . . . . 0.0 110.198 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.4 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.1 -36.98 66.87 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.394 -0.816 . . . . 0.0 109.649 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.909 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.3 82.33 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.53 -49.9 73.5 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.103 -0.998 . . . . 0.0 109.955 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.65 -47.01 51.09 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.328 -0.858 . . . . 0.0 110.348 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.684 ' O ' HD13 ' A' ' 51' ' ' LEU . 1.9 tm? -56.53 -40.08 74.48 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.51 -0.744 . . . . 0.0 110.772 -179.298 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.36 13.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.078 -1.014 . . . . 0.0 110.179 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.34 -42.21 98.31 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 109.798 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.523 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.42 -45.25 84.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.459 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.834 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.08 -42.12 72.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.541 -0.725 . . . . 0.0 109.614 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.5 t -56.08 -33.33 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 109.097 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.64 -31.36 59.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.408 -0.807 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.21 -26.39 62.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.339 -0.85 . . . . 0.0 109.456 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.24 5.39 8.75 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.666 ' CD1' HD22 ' A' ' 30' ' ' LEU . 67.9 mt -108.15 143.83 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -1.106 . . . . 0.0 110.358 -179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.72 106.48 18.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 177.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.687 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.47 142.87 46.3 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.883 -177.029 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.88 HG21 ' HA ' ' A' ' 73' ' ' VAL . 84.0 t -122.97 148.81 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.909 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.48 117.17 29.63 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.256 178.226 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.473 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.88 135.37 49.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.294 -0.878 . . . . 0.0 111.02 -179.235 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.977 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 15.4 p90 -167.95 177.36 5.69 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.522 -0.736 . . . . 0.0 109.853 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.1 ttp-105 -51.56 126.06 16.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.07 -1.018 . . . . 0.0 110.683 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.88 45.11 22.44 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.977 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.28 153.61 32.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.04 -1.271 . . . . 0.0 109.836 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.783 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.9 m-20 -91.2 149.46 21.77 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.297 -0.877 . . . . 0.0 110.608 -179.242 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.663 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.9 m -62.42 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.125 179.096 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.674 ' O ' HG23 ' A' ' 74' ' ' ILE . 15.0 m -133.9 -34.37 1.01 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.445 -0.785 . . . . 0.0 110.843 -179.345 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.88 ' HA ' HG21 ' A' ' 63' ' ' VAL . 92.4 t -49.43 129.47 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.098 -1.001 . . . . 0.0 110.106 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.674 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.11 -0.994 . . . . 0.0 110.996 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 122.103 0.954 . . . . 0.0 110.241 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.485 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.2 p -116.89 135.23 57.91 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 CA-C-O 121.966 0.889 . . . . 0.0 109.912 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 13.7 m -112.62 124.6 69.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 O-C-N 121.282 -0.886 . . . . 0.0 109.373 179.568 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.839 HG11 HD13 ' A' ' 88' ' ' LEU . 13.1 t -97.19 119.14 44.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 O-C-N 120.955 -1.091 . . . . 0.0 110.383 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.836 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.3 m -111.9 99.27 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.015 -1.074 . . . . 0.0 108.771 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.426 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.22 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.587 -1.321 . . . . 0.0 110.811 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.05 -28.56 17.88 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.345 -0.847 . . . . 0.0 110.71 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.89 -31.3 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.079 -1.013 . . . . 0.0 110.762 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.473 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.95 -37.55 9.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.259 -0.901 . . . . 0.0 111.099 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.839 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.738 0 O-C-N 121.145 -0.972 . . . . 0.0 110.7 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.217 0.532 . . . . 0.0 110.186 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -119.77 152.75 36.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.208 -0.932 . . . . 0.0 110.167 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -84.83 -29.26 25.48 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.505 -0.747 . . . . 0.0 109.735 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.452 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.7 p -161.18 163.47 31.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.166 -0.959 . . . . 0.0 110.843 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.414 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.29 116.32 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.298 -0.876 . . . . 0.0 109.963 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.842 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -94.61 111.3 25.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.07 -1.019 . . . . 0.0 108.974 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.416 ' HB2' ' CE1' ' A' ' 130' ' ' TYR . 3.5 t0 -114.4 161.07 18.42 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.149 -0.97 . . . . 0.0 111.732 -178.369 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.32 9.65 35.81 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.079 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.416 ' O ' ' HG2' ' A' ' 110' ' ' GLN . 2.7 m120 46.19 27.29 0.53 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.279 -0.888 . . . . 0.0 110.963 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.4 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.1 p . . . . . 0 N--CA 1.488 1.446 0 O-C-N 121.188 -0.945 . . . . 0.0 110.469 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.416 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.571 0.701 . . . . 0.0 111.205 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.506 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -100.52 161.78 13.37 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.556 -0.715 . . . . 0.0 110.111 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.465 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.46 -61.56 1.03 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.476 -0.765 . . . . 0.0 112.108 -178.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.506 HG22 ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.79 -28.87 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.71 -1.244 . . . . 0.0 111.435 -178.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.69 -57.19 5.83 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.893 -1.13 . . . . 0.0 110.932 -178.732 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.465 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.46 -34.63 78.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.02 -1.05 . . . . 0.0 108.525 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 49.6 m -59.84 -48.87 79.95 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.28 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.59 -40.1 64.13 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.513 -0.742 . . . . 0.0 110.126 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.467 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.48 -44.61 70.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.984 -1.073 . . . . 0.0 110.31 -179.687 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.548 ' HG2' HD12 ' A' ' 10' ' ' ILE . 41.9 ttp180 -61.54 -36.08 79.58 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.047 -1.033 . . . . 0.0 109.315 179.184 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.05 66.67 0.34 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.7 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.462 -1.022 . . . . 0.0 108.848 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.538 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.3 t -92.12 142.45 27.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.335 -0.853 . . . . 0.0 108.931 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.58 17.07 2.95 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.269 -1.444 . . . . 0.0 110.605 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -95.11 82.37 3.77 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.986 -1.303 . . . . 0.0 110.002 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.39 -51.46 0.76 Allowed Glycine 0 N--CA 1.493 2.483 0 N-CA-C 108.412 -1.875 . . . . 0.0 108.412 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.455 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.84 166.36 21.72 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.3 Cg_endo -63.59 117.73 4.68 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.299 1.157 . . . . 0.0 110.128 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.538 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.85 172.24 54.78 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.424 HG23 ' CG2' ' A' ' 13' ' ' VAL . 5.1 mt -126.15 142.06 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.301 -1.117 . . . . 0.0 108.989 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.416 ' CE1' ' HB2' ' A' ' 101' ' ' ASP . 10.5 t80 -131.13 115.19 16.06 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.292 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.559 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 5.9 mtp180 -99.78 147.71 25.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.497 -0.752 . . . . 0.0 109.365 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.47 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 25.1 p90 -138.14 150.36 46.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.085 -1.01 . . . . 0.0 110.212 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.506 HG22 HD23 ' A' ' 15' ' ' LEU . 34.5 t . . . . . 0 N--CA 1.492 1.666 0 O-C-N 121.129 -0.982 . . . . 0.0 109.448 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 50.7 t30 . . . . . 0 N--CA 1.493 1.682 0 CA-C-O 121.461 0.648 . . . . 0.0 109.627 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.519 HD13 HG22 ' A' ' 122' ' ' THR . 16.5 mt -106.81 132.43 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.001 -1.062 . . . . 0.0 109.518 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.87 127.26 33.71 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.134 -0.979 . . . . 0.0 109.278 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.66 128.5 36.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.16 -0.962 . . . . 0.0 110.003 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.42 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.49 158.04 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.404 -0.81 . . . . 0.0 110.176 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.98 110.94 21.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.752 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.451 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -53.45 134.5 40.44 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.319 -0.863 . . . . 0.0 110.329 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.6 p -135.49 177.76 7.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 110.142 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.33 65.31 0.42 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.225 -0.922 . . . . 0.0 109.951 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.474 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 22.1 m -137.1 110.57 7.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.339 -0.851 . . . . 0.0 110.353 -179.721 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.0 -163.89 27.98 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.76 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.72 -21.02 7.43 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.675 -0.897 . . . . 0.0 110.327 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.893 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -96.79 108.66 44.44 Favored Pre-proline 0 N--CA 1.488 1.458 0 C-N-CA 118.668 -1.213 . . . . 0.0 110.204 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.437 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.6 Cg_endo -65.48 149.77 87.49 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 O-C-N 123.444 1.234 . . . . 0.0 110.296 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.523 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.3 t80 -169.04 108.21 0.45 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 110.977 -178.778 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.545 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 17.6 m-85 56.25 60.69 3.05 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.234 -0.916 . . . . 0.0 111.171 179.209 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.97 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.523 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.49 157.28 43.1 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.128 -1.219 . . . . 0.0 109.064 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.474 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.79 107.27 14.83 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.811 -1.181 . . . . 0.0 110.239 -179.517 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.893 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.4 mt -68.29 114.5 21.77 Favored Pre-proline 0 C--N 1.301 -1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.8 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -69.16 128.39 16.5 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 N-CA-C 106.579 -2.123 . . . . 0.0 106.579 175.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.64 HD22 ' CD1' ' A' ' 60' ' ' ILE . 11.0 mt -55.82 -17.62 6.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.673 -1.267 . . . . 0.0 111.09 -177.216 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -59.63 -15.98 22.83 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.677 -1.264 . . . . 0.0 110.667 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.084 HG23 HG23 ' A' ' 33' ' ' ILE . 16.4 m -91.37 -25.38 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.024 -1.048 . . . . 0.0 111.187 -179.432 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.084 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -119.84 -16.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.96 -1.087 . . . . 0.0 110.65 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.6 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.9 tptt -98.8 147.86 24.49 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.769 -1.207 . . . . 0.0 110.046 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.84 -5.39 50.63 Favored Glycine 0 N--CA 1.485 1.911 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.576 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.35 -151.17 9.52 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.081 -1.533 . . . . 0.0 110.561 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.442 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.03 131.92 53.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.43 -1.041 . . . . 0.0 110.371 -179.409 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.572 ' HB2' HG12 ' A' ' 81' ' ' VAL . 95.6 m-70 -138.44 151.53 47.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.172 -0.955 . . . . 0.0 110.95 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.578 HD12 ' O ' ' A' ' 82' ' ' VAL . 45.9 tp -111.58 119.29 38.24 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.766 . . . . 0.0 110.025 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.921 HD12 ' CG1' ' A' ' 83' ' ' VAL . 31.6 mt -103.86 126.26 58.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.295 -0.878 . . . . 0.0 109.155 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.96 123.79 38.63 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.177 -0.952 . . . . 0.0 110.329 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.28 160.13 21.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.425 -0.797 . . . . 0.0 110.668 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.545 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 10.6 p80 -105.16 -4.73 21.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.337 -0.852 . . . . 0.0 110.426 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 66.4 p -136.14 145.8 46.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.01 -1.056 . . . . 0.0 111.235 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.477 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 23.7 tttt -72.08 -40.92 67.91 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.673 -0.642 . . . . 0.0 110.669 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.77 -34.98 72.04 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.139 -0.976 . . . . 0.0 110.684 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HA ' ' HD3' ' A' ' 47' ' ' LYS . 12.3 tppt? -71.6 -40.42 69.86 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.077 -1.014 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.888 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 67.3 m -61.83 -37.15 83.37 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 110.06 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.98 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.949 -1.094 . . . . 0.0 110.577 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.414 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -72.28 -44.2 63.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.174 -0.954 . . . . 0.0 110.229 179.908 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.728 HD12 HG11 ' A' ' 83' ' ' VAL . 1.7 tm? -56.58 -42.12 78.1 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.489 -0.757 . . . . 0.0 111.198 -179.102 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.35 -50.88 16.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.897 -1.127 . . . . 0.0 110.375 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.38 -42.09 98.15 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.118 -0.989 . . . . 0.0 109.798 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.504 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.98 -45.78 86.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.901 . . . . 0.0 109.788 179.703 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.644 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -54.54 -42.31 70.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.453 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.5 t -56.79 -30.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.122 -0.986 . . . . 0.0 108.591 178.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.503 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.56 -33.93 60.67 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.597 -0.689 . . . . 0.0 110.021 179.23 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.536 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.48 -25.73 62.4 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.82 0.819 . . . . 0.0 109.556 179.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.56 7.34 9.0 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.64 ' CD1' HD22 ' A' ' 30' ' ' LEU . 40.1 mt -108.01 143.31 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.324 -1.103 . . . . 0.0 109.977 -179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 4.1 t-20 -87.2 107.08 18.32 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.272 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.637 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.91 145.11 48.02 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.409 -177.576 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.887 HG21 ' HA ' ' A' ' 73' ' ' VAL . 6.7 t -133.02 143.1 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.589 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.888 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -107.16 123.45 48.28 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.824 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.492 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.17 119.06 36.47 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.335 -0.853 . . . . 0.0 110.387 -179.754 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.922 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.8 p90 -146.74 174.48 11.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.608 -0.683 . . . . 0.0 109.753 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.6 5.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.161 -0.962 . . . . 0.0 110.803 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.02 35.73 9.58 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.948 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.0 tm? -117.17 155.84 28.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 110.079 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.948 ' N ' HD13 ' A' ' 69' ' ' LEU . 37.1 m-20 -95.37 149.42 21.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.333 -0.854 . . . . 0.0 110.248 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.672 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.2 m -61.81 110.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.176 179.455 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.401 ' O ' HG23 ' A' ' 74' ' ' ILE . 7.3 m -132.04 -20.82 2.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.486 -0.759 . . . . 0.0 111.068 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.887 ' HA ' HG21 ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.88 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 109.302 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.629 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.496 1.85 0 O-C-N 121.241 -0.912 . . . . 0.0 110.969 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.965 0.888 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.523 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -117.47 134.58 60.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.074 0.94 . . . . 0.0 110.359 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.647 HG11 ' HB ' ' A' ' 33' ' ' ILE . 5.7 m -113.28 124.67 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 O-C-N 121.413 -0.805 . . . . 0.0 108.901 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.784 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.91 45.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 121.159 -0.963 . . . . 0.0 110.049 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.921 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.8 m -114.48 100.98 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.07 -1.019 . . . . 0.0 108.594 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.492 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.37 164.22 32.16 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.725 -1.234 . . . . 0.0 111.796 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.706 HG23 ' H ' ' A' ' 87' ' ' ALA . 6.4 t -94.28 -147.2 0.26 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.671 -0.643 . . . . 0.0 109.42 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.15 -15.3 56.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.964 -1.085 . . . . 0.0 110.235 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.706 ' H ' HG23 ' A' ' 85' ' ' THR . . . -49.32 -44.64 44.49 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.038 -1.039 . . . . 0.0 110.257 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 108.985 179.101 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.11 0.481 . . . . 0.0 110.492 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -119.92 147.93 44.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.937 -1.102 . . . . 0.0 110.303 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.481 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.43 -28.77 56.75 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.409 -0.807 . . . . 0.0 110.127 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.2 p -160.38 163.58 33.05 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.256 -0.903 . . . . 0.0 110.752 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.505 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.9 117.86 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.332 -0.855 . . . . 0.0 110.563 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.798 HG21 HD11 ' A' ' 28' ' ' ILE . 4.6 mp -98.24 110.86 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.16 158.88 25.05 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.992 . . . . 0.0 111.773 -178.19 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.84 3.67 53.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.004 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.423 ' CA ' ' OE1' ' A' ' 110' ' ' GLN . 3.2 m-20 52.88 27.72 5.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.239 -0.913 . . . . 0.0 111.087 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.488 1.455 0 O-C-N 121.11 -0.994 . . . . 0.0 110.24 179.361 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.46 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.195 0.522 . . . . 0.0 110.998 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.535 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -99.7 160.77 14.05 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.28 179.674 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.31 -53.47 5.21 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.438 -0.789 . . . . 0.0 112.286 -178.76 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.535 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.8 m -69.75 -29.42 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 120.83 -1.169 . . . . 0.0 111.525 -178.683 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.402 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.31 -56.52 6.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.07 -1.019 . . . . 0.0 110.625 -179.114 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.408 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 1.8 ptm180 -69.07 -34.69 75.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.296 -0.877 . . . . 0.0 108.819 178.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.431 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.8 m -59.52 -49.79 76.42 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.68 -37.53 65.2 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.451 -0.781 . . . . 0.0 110.056 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 36.3 mtt-85 -71.89 -45.63 60.61 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.209 -0.932 . . . . 0.0 111.719 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' NH1' HD12 ' A' ' 10' ' ' ILE . 27.6 ttp85 -59.34 -51.65 69.02 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.091 -1.006 . . . . 0.0 109.917 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.429 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.4 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -179.265 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -45.73 -33.21 2.87 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.283 -1.128 . . . . 0.0 111.632 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.519 HG22 HD13 ' A' ' 10' ' ' ILE . 14.9 t -100.65 144.12 30.01 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.884 -1.135 . . . . 0.0 110.884 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.97 14.54 24.51 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.389 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.429 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.59 84.23 0.61 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -1.201 . . . . 0.0 109.794 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.53 -26.34 13.34 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.903 -1.679 . . . . 0.0 108.903 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.499 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.96 -168.7 0.19 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.495 -1.003 . . . . 0.0 108.669 179.653 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.499 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.0 Cg_endo -87.32 110.95 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.14 1.074 . . . . 0.0 110.7 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.48 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -82.42 170.57 50.7 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 49.1 mt -126.48 142.64 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.516 -0.991 . . . . 0.0 108.416 178.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.505 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -128.77 114.75 16.97 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.721 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.444 ' HD3' HG11 ' A' ' 32' ' ' VAL . 18.2 mtp180 -105.27 122.88 46.86 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.437 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.423 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 32.0 p90 -121.72 158.06 29.58 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 110.662 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.451 HG22 HD23 ' A' ' 15' ' ' LEU . 32.1 t . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.238 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.466 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 . . . . . 0 N--CA 1.496 1.827 0 CA-C-O 120.971 0.415 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.68 HD11 ' O ' ' A' ' 122' ' ' THR . 30.3 mt -129.0 137.28 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.867 -1.146 . . . . 0.0 109.707 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -82.75 127.81 33.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.056 -1.028 . . . . 0.0 109.207 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.89 139.32 30.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.3 -0.875 . . . . 0.0 110.553 -179.089 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.78 HG11 ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.75 156.55 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.215 -0.928 . . . . 0.0 110.14 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.34 109.86 21.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -0.889 . . . . 0.0 110.109 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.708 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.77 141.88 36.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 109.311 179.456 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.33 174.57 10.62 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 110.548 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.58 0.99 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.325 -0.86 . . . . 0.0 110.276 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.732 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.9 m -155.68 109.32 2.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.174 -0.954 . . . . 0.0 110.482 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.421 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.49 -171.35 28.89 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.891 -1.623 . . . . 0.0 111.181 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.54 -22.59 11.57 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.722 -0.87 . . . . 0.0 110.45 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.943 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -95.26 107.12 30.31 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 118.872 -1.131 . . . . 0.0 109.455 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.43 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -63.84 144.67 89.15 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.249 1.131 . . . . 0.0 111.34 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.421 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.73 -166.37 1.85 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.522 -0.736 . . . . 0.0 110.318 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.533 ' CD2' ' HB3' ' A' ' 102' ' ' CYS . 36.8 m-85 -59.92 82.03 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.403 -0.811 . . . . 0.0 111.051 -179.564 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.4 5.85 51.49 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.708 ' CB ' HD23 ' A' ' 15' ' ' LEU . 14.4 mmtm -130.64 156.68 44.47 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.941 -1.329 . . . . 0.0 109.778 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.732 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.64 16.77 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.062 -1.024 . . . . 0.0 109.106 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 1.051 HD11 HG21 ' A' ' 100' ' ' ILE . 6.2 mt -69.12 114.16 21.57 Favored Pre-proline 0 C--N 1.299 -1.596 0 O-C-N 121.367 -0.833 . . . . 0.0 110.798 -179.081 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.736 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.2 Cg_endo -69.73 132.12 22.72 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.13 -1.912 . . . . 0.0 107.13 176.164 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.78 HD11 HD12 ' A' ' 58' ' ' LEU . 13.2 mt -56.95 -14.95 4.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.961 -1.087 . . . . 0.0 111.219 -177.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -63.31 -16.16 59.5 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.539 -1.351 . . . . 0.0 110.51 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 10.6 m -93.86 -24.44 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.052 -1.03 . . . . 0.0 110.87 -179.406 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 48.3 pt -117.16 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.035 -1.041 . . . . 0.0 110.493 -179.328 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.635 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.98 148.41 24.56 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -0.903 . . . . 0.0 110.501 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.74 -5.17 46.99 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.27 -147.68 7.79 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.428 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.8 132.5 53.93 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.406 -1.055 . . . . 0.0 110.473 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.546 ' HB2' HG12 ' A' ' 81' ' ' VAL . 88.2 m-70 -140.77 149.0 41.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 0.0 110.603 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.583 HD12 ' O ' ' A' ' 82' ' ' VAL . 57.3 tp -111.0 113.59 26.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.441 -0.787 . . . . 0.0 109.803 179.548 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.891 HD12 HG12 ' A' ' 83' ' ' VAL . 29.2 mt -96.41 127.38 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.882 . . . . 0.0 109.662 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.51 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.2 m-85 -95.08 122.72 38.03 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.295 -0.878 . . . . 0.0 110.251 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.04 160.16 21.98 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.339 -0.85 . . . . 0.0 110.733 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 5.4 p80 -110.01 4.65 21.55 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.396 -0.815 . . . . 0.0 109.964 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.52 136.41 49.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 110.987 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.498 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.84 69.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.645 -0.66 . . . . 0.0 110.861 -179.866 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.74 -36.75 73.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.28 -0.888 . . . . 0.0 110.917 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.13 -35.39 80.36 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.313 -0.867 . . . . 0.0 109.574 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.923 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 53.2 m -61.48 -33.83 74.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.511 -0.743 . . . . 0.0 109.764 179.231 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.19 -50.22 61.77 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.283 -0.886 . . . . 0.0 110.967 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.22 -44.11 63.44 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.119 -0.988 . . . . 0.0 110.569 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.638 ' CD2' HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -56.99 -38.35 72.91 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.562 -0.711 . . . . 0.0 111.242 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.62 -51.15 13.49 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.871 -1.143 . . . . 0.0 110.633 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.46 -40.04 85.58 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.146 -0.971 . . . . 0.0 110.145 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.695 ' CE ' HD21 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.04 82.99 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.318 -0.864 . . . . 0.0 109.788 179.739 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.902 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.07 -38.92 71.29 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.643 -0.661 . . . . 0.0 110.093 179.818 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.3 t -58.62 -34.38 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.185 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.29 -30.66 60.47 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.436 -0.79 . . . . 0.0 109.965 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.78 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -72.01 -25.71 61.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.437 -0.789 . . . . 0.0 109.773 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.9 10.3 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.323 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.635 HD11 ' HB2' ' A' ' 34' ' ' LYS . 45.9 mt -108.03 143.23 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.298 -1.119 . . . . 0.0 109.75 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 15.2 t-20 -89.84 106.39 18.44 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.698 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.18 142.59 46.62 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.729 -177.07 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.927 HG21 ' HA ' ' A' ' 73' ' ' VAL . 57.4 t -125.56 149.41 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 120.139 -0.624 . . . . 0.0 109.701 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.923 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.69 119.05 34.25 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.433 178.341 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.475 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.42 132.72 55.52 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.216 -0.927 . . . . 0.0 110.839 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.75 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -166.93 176.85 6.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.569 -0.707 . . . . 0.0 109.719 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.15 125.35 15.44 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.069 -1.02 . . . . 0.0 110.707 -179.265 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.7 37.4 19.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.838 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.44 157.24 26.57 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.031 -1.276 . . . . 0.0 110.12 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.838 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -96.53 149.23 21.98 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.29 -0.881 . . . . 0.0 110.555 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 71' ' ' VAL . 30.3 m -62.66 111.37 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.193 -0.942 . . . . 0.0 109.121 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.82 -35.39 1.09 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.389 -0.819 . . . . 0.0 110.733 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.927 ' HA ' HG21 ' A' ' 63' ' ' VAL . 59.6 t -48.41 120.37 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.391 -0.818 . . . . 0.0 110.294 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.826 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.494 1.762 0 O-C-N 121.235 -0.916 . . . . 0.0 110.608 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.813 0.816 . . . . 0.0 110.182 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 5.2 p -116.92 135.56 56.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-O 122.151 0.977 . . . . 0.0 110.568 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 11.9 m -112.88 119.94 61.72 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.072 0 O-C-N 121.228 -0.92 . . . . 0.0 108.844 178.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.662 HG22 HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.84 45.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 120.886 -1.134 . . . . 0.0 110.265 -178.041 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.891 HG12 HD12 ' A' ' 40' ' ' ILE . 3.2 m -109.06 100.53 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.146 -0.971 . . . . 0.0 108.691 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.475 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.36 162.24 35.49 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.765 -1.21 . . . . 0.0 110.979 -178.172 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.513 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -88.26 -131.34 0.07 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.347 -0.846 . . . . 0.0 109.612 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.513 ' N ' HG23 ' A' ' 85' ' ' THR . 44.9 p30 -91.4 29.28 1.49 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.694 -1.254 . . . . 0.0 110.55 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.62 -29.06 12.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.052 -1.03 . . . . 0.0 110.231 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.144 -0.973 . . . . 0.0 109.742 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.0 t0 . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.055 0.455 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -119.77 147.98 43.97 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.111 -0.993 . . . . 0.0 110.115 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.495 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -71.11 -35.1 71.65 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.385 -0.822 . . . . 0.0 109.383 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.434 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.3 p -162.04 163.65 28.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.225 -0.922 . . . . 0.0 111.128 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.713 HG22 HG21 ' A' ' 122' ' ' THR . 1.3 m -129.36 118.1 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.52 -0.737 . . . . 0.0 110.091 179.378 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 1.051 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -92.6 111.98 25.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.481 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.14 160.26 21.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 111.718 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.533 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.23 6.26 38.08 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.159 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.442 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.04 25.43 0.49 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.406 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 1.3 p . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.294 -0.879 . . . . 0.0 110.396 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.442 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.341 0.591 . . . . 0.0 110.713 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.543 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -90.73 160.78 15.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.342 -0.849 . . . . 0.0 110.285 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.37 -52.26 4.63 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.544 -0.722 . . . . 0.0 112.34 -178.728 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.543 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.79 -29.27 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.855 -1.153 . . . . 0.0 111.214 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.43 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.39 -56.21 7.37 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.112 -0.993 . . . . 0.0 110.509 -179.377 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.439 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.4 OUTLIER -68.84 -34.5 75.59 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.168 -0.957 . . . . 0.0 108.789 178.685 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.446 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 31.3 m -60.02 -49.92 75.76 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.183 -0.948 . . . . 0.0 108.533 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.64 -39.93 64.13 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.546 -0.721 . . . . 0.0 109.671 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.439 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 4.1 mtt180 -66.21 -44.75 83.01 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 110.018 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.47 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 13.5 ttm180 -64.06 -34.08 77.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.221 -0.925 . . . . 0.0 110.279 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.455 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.33 12.07 1.96 Allowed Glycine 0 N--CA 1.497 2.73 0 O-C-N 121.055 -1.028 . . . . 0.0 112.3 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 1.2 mmt85 -101.32 -5.19 25.76 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.296 -1.708 . . . . 0.0 109.461 178.617 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.713 HG21 HG22 ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.44 142.15 50.31 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.224 -0.923 . . . . 0.0 109.424 179.782 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 78.48 26.5 59.12 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.455 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.3 82.62 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.134 -1.215 . . . . 0.0 110.109 179.908 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.59 24.92 5.45 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.474 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.5 -1.0 . . . . 0.0 109.105 -179.628 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 45.8 Cg_endo -84.47 99.58 0.75 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.187 1.099 . . . . 0.0 109.551 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.436 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.82 176.58 52.18 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.48 143.95 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.45 -1.03 . . . . 0.0 109.968 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.535 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 9.6 t80 -129.4 116.9 19.73 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.176 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.78 ' NE ' HG11 ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.21 137.9 37.07 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.541 -0.725 . . . . 0.0 109.215 179.018 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.458 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.6 p90 -137.8 153.98 49.6 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 110.719 -179.58 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.323 -0.861 . . . . 0.0 109.422 179.315 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 . . . . . 0 N--CA 1.494 1.771 0 CA-C-O 121.112 0.482 . . . . 0.0 110.436 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 31.1 mt -111.86 135.2 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.973 -1.079 . . . . 0.0 110.277 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.19 129.07 34.87 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.188 -0.945 . . . . 0.0 109.726 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.44 33.57 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.077 -1.014 . . . . 0.0 110.501 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.7 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 17.2 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.91 114.93 29.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.15 -0.968 . . . . 0.0 110.371 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.54 HD23 HG22 ' A' ' 133' ' ' VAL . 12.3 tp -63.2 135.65 57.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 109.607 179.561 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.3 p -134.78 171.58 14.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.093 -1.004 . . . . 0.0 110.602 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.532 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -149.21 112.68 5.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.353 -0.842 . . . . 0.0 110.349 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.33 -161.68 27.28 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.674 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -122.05 -22.35 5.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.724 -0.868 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.931 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -93.51 112.82 58.28 Favored Pre-proline 0 N--CA 1.488 1.426 0 C-N-CA 118.598 -1.241 . . . . 0.0 110.335 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -64.85 141.26 70.66 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.597 1.314 . . . . 0.0 109.977 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.459 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.91 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.101 -0.999 . . . . 0.0 111.732 -178.618 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.574 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.08 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.534 -0.729 . . . . 0.0 111.558 178.769 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 12.07 25.88 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.468 ' CB ' HD23 ' A' ' 15' ' ' LEU . 10.2 mmtt -129.91 156.63 44.1 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.055 -1.262 . . . . 0.0 109.235 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.532 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.93 15.11 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.873 -1.142 . . . . 0.0 108.891 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.931 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -70.88 114.97 31.3 Favored Pre-proline 0 C--N 1.296 -1.733 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.045 -179.412 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.845 ' O ' HG22 ' A' ' 32' ' ' VAL . 38.9 Cg_endo -67.51 130.32 22.01 Favored 'Trans proline' 0 C--N 1.302 -1.878 0 N-CA-C 107.465 -1.783 . . . . 0.0 107.465 176.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.769 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.32 -16.41 5.5 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.939 -1.101 . . . . 0.0 110.628 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.21 -16.22 59.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.671 -1.268 . . . . 0.0 110.576 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -92.68 -25.21 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 120.934 -1.104 . . . . 0.0 111.074 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 30.7 pt -116.41 -29.73 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.622 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.35 148.15 24.4 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.294 -0.879 . . . . 0.0 110.385 179.404 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.12 -5.21 49.46 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.09 -152.52 11.25 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.122 -1.514 . . . . 0.0 110.533 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.18 128.61 50.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.469 -1.018 . . . . 0.0 110.436 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.628 ' HB2' HG12 ' A' ' 81' ' ' VAL . 54.6 m80 -139.47 149.93 44.58 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 110.474 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.577 HD12 ' HB ' ' A' ' 82' ' ' VAL . 19.9 tp -111.85 117.26 32.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.403 -0.811 . . . . 0.0 110.403 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.893 ' CG1' HG12 ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.307 -0.871 . . . . 0.0 108.997 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.433 ' CZ ' ' HG2' ' A' ' 118' ' ' ARG . 5.8 m-85 -94.84 122.0 37.02 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.98 -1.075 . . . . 0.0 110.059 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.35 159.37 23.53 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.409 -0.807 . . . . 0.0 110.442 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.574 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.69 18.17 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.413 -0.805 . . . . 0.0 109.617 178.465 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.53 141.35 47.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.093 -1.005 . . . . 0.0 110.476 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.09 -35.69 69.3 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.535 -0.728 . . . . 0.0 110.549 -179.912 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.17 -45.38 88.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.303 -0.873 . . . . 0.0 110.591 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.14 -38.32 85.98 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.409 -0.807 . . . . 0.0 109.613 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.934 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.2 -34.19 74.68 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.488 -0.757 . . . . 0.0 109.56 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.24 -48.68 69.75 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.208 -0.933 . . . . 0.0 110.784 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.427 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.26 -44.61 64.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.204 -0.935 . . . . 0.0 110.472 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 1.044 HD12 HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.64 77.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.319 -0.863 . . . . 0.0 111.002 -179.058 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.434 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.16 -51.41 21.43 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.059 -1.026 . . . . 0.0 110.484 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.09 -43.46 98.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.93 . . . . 0.0 110.039 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.623 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.2 -46.16 83.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.171 -0.956 . . . . 0.0 109.526 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.747 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.76 -40.96 73.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.537 -0.727 . . . . 0.0 110.176 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.0 t -57.33 -35.34 48.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.984 -1.073 . . . . 0.0 108.978 179.425 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -31.26 59.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.352 -0.842 . . . . 0.0 110.243 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.769 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.32 -25.8 62.56 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.94 0.876 . . . . 0.0 109.75 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.41 5.77 10.11 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.321 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.662 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.7 mt -108.03 143.29 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.468 -1.019 . . . . 0.0 110.08 -179.532 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.467 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 14.8 t-20 -89.52 106.64 18.59 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.741 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.77 144.4 46.31 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.708 -177.292 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.928 HG21 ' HA ' ' A' ' 73' ' ' VAL . 48.8 t -127.84 145.91 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.881 -0.727 . . . . 0.0 109.646 179.243 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.934 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -110.09 119.42 39.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.877 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.518 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 4.1 t80 -116.45 127.26 54.43 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.229 -0.92 . . . . 0.0 110.655 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.835 ' CE1' HD23 ' A' ' 69' ' ' LEU . 1.2 p90 -153.22 -171.4 3.91 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.402 -0.811 . . . . 0.0 110.013 179.669 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.56 126.9 21.03 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.308 -0.87 . . . . 0.0 111.276 -179.129 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.85 48.63 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.835 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.73 155.0 30.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.978 -1.307 . . . . 0.0 109.958 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.818 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.3 m-20 -90.75 149.49 21.99 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.37 -0.832 . . . . 0.0 110.694 -179.18 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.4 m -62.54 110.94 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.145 -0.972 . . . . 0.0 109.586 179.423 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.44 ' O ' HG23 ' A' ' 74' ' ' ILE . 34.5 m -132.11 -23.82 2.16 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.383 -0.823 . . . . 0.0 111.178 -179.552 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.928 ' HA ' HG21 ' A' ' 63' ' ' VAL . 22.6 t -60.1 138.73 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.133 -0.979 . . . . 0.0 110.082 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.447 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.495 1.797 0 O-C-N 121.203 -0.935 . . . . 0.0 110.541 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 122.036 0.922 . . . . 0.0 110.379 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.1 p -116.88 133.75 62.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.039 0.923 . . . . 0.0 110.425 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.628 HG12 ' HB2' ' A' ' 38' ' ' HIS . 6.1 m -113.54 123.56 69.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 O-C-N 121.502 -0.749 . . . . 0.0 109.021 179.095 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.721 HG22 HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.51 118.04 43.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.958 -1.089 . . . . 0.0 110.649 -177.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.044 HG11 HD12 ' A' ' 51' ' ' LEU . 3.4 m -106.64 100.45 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.009 -1.057 . . . . 0.0 108.634 179.037 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.518 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -144.19 162.39 36.45 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.667 -1.27 . . . . 0.0 111.239 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -92.9 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.476 -0.765 . . . . 0.0 108.988 179.223 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.443 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -86.36 50.06 1.92 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.72 -1.237 . . . . 0.0 109.931 179.416 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.68 -18.63 9.61 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.22 -0.925 . . . . 0.0 110.583 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.462 HD12 ' HA ' ' A' ' 88' ' ' LEU . 14.2 tp . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.031 -1.043 . . . . 0.0 109.71 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 121.007 0.432 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -119.66 146.6 45.43 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.015 -1.053 . . . . 0.0 110.345 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.33 -34.81 58.98 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.516 -0.74 . . . . 0.0 109.508 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.441 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -160.89 163.02 32.26 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.249 -0.907 . . . . 0.0 110.778 179.784 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.554 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.29 118.15 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.21 -0.931 . . . . 0.0 110.131 179.375 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.71 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -95.96 117.73 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.462 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.427 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 18.8 t0 -124.46 161.36 26.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.137 -0.977 . . . . 0.0 111.851 -178.796 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.91 -6.81 34.84 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.695 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 55.7 15.36 1.56 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.319 -0.863 . . . . 0.0 111.654 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.308 -1.221 0 O-C-N 120.731 -1.231 . . . . 0.0 109.535 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.832 0 CA-C-O 121.357 0.598 . . . . 0.0 111.163 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.523 ' OD1' HG22 ' A' ' 113' ' ' VAL . 3.0 p30 -87.77 160.98 17.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.333 -0.854 . . . . 0.0 110.292 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.15 3.75 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.339 -0.851 . . . . 0.0 111.832 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.523 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.66 -29.76 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.932 -1.105 . . . . 0.0 111.794 -178.345 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.408 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.27 -56.1 7.42 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.083 -1.011 . . . . 0.0 110.426 -179.142 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.471 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.35 -32.87 72.22 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.224 -0.922 . . . . 0.0 108.848 178.808 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.471 ' N ' ' HG2' ' A' ' 115' ' ' ARG . 25.3 m -61.11 -49.8 75.81 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.109 -0.994 . . . . 0.0 108.409 178.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.97 -36.3 64.56 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.918 -0.713 . . . . 0.0 109.807 178.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HG2' ' CZ ' ' A' ' 41' ' ' PHE . 49.1 mtt-85 -71.68 -44.47 64.19 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.255 -0.903 . . . . 0.0 111.117 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.458 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 19.5 ttm180 -56.7 -41.03 76.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.891 -1.131 . . . . 0.0 109.93 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.06 71.43 0.19 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.456 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.72 -45.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.593 -0.945 . . . . 0.0 108.836 179.488 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.518 HG23 ' HA3' ' A' ' 128' ' ' GLY . 9.2 t -101.14 143.01 31.76 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.598 -0.689 . . . . 0.0 109.393 178.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 4.0 22.02 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.184 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.01 85.38 0.71 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.995 -1.297 . . . . 0.0 109.822 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 104.08 9.79 35.99 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 3.6 pttt -174.96 -173.76 0.22 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.318 -1.107 . . . . 0.0 108.659 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.469 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.0 Cg_endo -88.15 105.33 0.51 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.22 1.116 . . . . 0.0 110.297 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.518 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.42 170.45 53.61 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.706 -1.235 . . . . 0.0 110.102 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -126.79 142.55 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.535 -0.979 . . . . 0.0 108.862 179.167 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.554 ' CD2' HG23 ' A' ' 99' ' ' VAL . 6.3 t80 -129.33 115.18 17.18 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.982 -1.073 . . . . 0.0 110.578 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.7 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.68 122.85 42.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.47 -0.768 . . . . 0.0 109.273 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 24.0 p90 -121.41 148.7 44.05 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.05 -1.031 . . . . 0.0 110.262 -179.495 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.54 HG22 HD23 ' A' ' 15' ' ' LEU . 46.1 t . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.524 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.446 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 40.8 m-20 . . . . . 0 N--CA 1.494 1.749 0 CA-C-O 121.135 0.493 . . . . 0.0 110.19 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.445 HD11 ' O ' ' A' ' 122' ' ' THR . 40.8 mt -117.52 136.39 54.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 110.533 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.164 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 110.382 -179.013 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.49 156.3 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.439 -0.788 . . . . 0.0 110.05 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.01 111.49 24.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.276 -0.89 . . . . 0.0 110.169 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.438 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.16 136.17 48.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.358 -0.839 . . . . 0.0 109.877 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.97 173.83 11.28 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.132 -0.98 . . . . 0.0 110.22 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.9 p -67.57 74.32 0.16 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 109.814 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.634 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.8 m -145.59 109.55 4.84 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.379 -0.826 . . . . 0.0 110.388 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.7 27.93 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.671 179.567 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.04 -25.01 5.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.696 -0.884 . . . . 0.0 110.561 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.34 52.55 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.172 -179.535 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.438 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -64.79 143.01 78.8 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.5 1.263 . . . . 0.0 110.158 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.5 t80 -155.23 94.84 1.66 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 111.286 -178.602 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.415 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 23.7 m-85 57.66 67.07 1.01 Allowed 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.535 -0.728 . . . . 0.0 111.611 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.5 13.33 16.4 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 22.2 mmtm -130.6 156.99 43.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.142 -1.211 . . . . 0.0 109.185 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.634 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.6 107.52 16.26 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.906 -1.121 . . . . 0.0 109.827 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.5 mt -69.97 113.39 17.28 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 121.372 -0.83 . . . . 0.0 109.894 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.781 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.8 Cg_endo -68.99 128.88 17.41 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 N-CA-C 106.993 -1.964 . . . . 0.0 106.993 176.463 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.59 HD11 HD12 ' A' ' 58' ' ' LEU . 6.2 mt -56.61 -15.98 5.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.854 -1.154 . . . . 0.0 111.137 -177.599 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.425 ' OE2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.43 62.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.65 -1.281 . . . . 0.0 110.869 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.069 HG23 HG23 ' A' ' 33' ' ' ILE . 15.1 m -89.68 -26.5 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.922 -1.111 . . . . 0.0 111.134 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.069 HG23 HG23 ' A' ' 32' ' ' VAL . 43.3 pt -116.94 -23.68 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.165 -0.96 . . . . 0.0 110.048 -179.626 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.597 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.59 148.35 22.15 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.174 -0.954 . . . . 0.0 110.596 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.23 51.73 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.18 -151.61 9.86 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.211 -1.471 . . . . 0.0 110.208 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.57 130.72 54.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -1.078 . . . . 0.0 110.208 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.56 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.9 m80 -140.81 148.81 41.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.117 -0.99 . . . . 0.0 110.983 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 20.2 tp -109.76 123.18 49.09 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.924 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.94 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.8 mt -104.78 128.73 58.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.286 -0.883 . . . . 0.0 108.876 179.225 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.424 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.3 122.86 37.28 Favored 'General case' 0 C--N 1.294 -1.844 0 O-C-N 121.241 -0.912 . . . . 0.0 110.348 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.83 160.05 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.335 -0.853 . . . . 0.0 110.8 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -115.51 5.23 14.39 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.575 -0.703 . . . . 0.0 109.799 178.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.74 138.14 45.61 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.007 . . . . 0.0 110.878 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.509 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.69 -43.35 66.11 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.709 -0.619 . . . . 0.0 110.53 -179.931 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.66 -34.5 74.4 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.325 -0.859 . . . . 0.0 110.564 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.21 -38.19 66.18 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.233 -0.917 . . . . 0.0 109.911 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.942 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 61.5 m -61.4 -34.48 75.43 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.521 -0.737 . . . . 0.0 109.892 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.24 -49.72 58.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 110.381 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.01 -46.38 57.41 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.246 -0.909 . . . . 0.0 110.274 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.798 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -56.92 -42.65 80.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.976 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.475 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -73.38 -50.85 19.74 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.01 -1.056 . . . . 0.0 110.651 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -40.5 97.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.038 -1.039 . . . . 0.0 109.733 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.541 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.24 -43.1 82.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.315 -0.866 . . . . 0.0 109.434 179.394 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.727 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -55.34 -42.87 74.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.39 -0.819 . . . . 0.0 109.749 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.14 -32.58 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -0.966 . . . . 0.0 108.716 179.043 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.52 -32.08 60.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.571 -0.706 . . . . 0.0 110.013 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.59 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.52 -26.26 62.58 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.298 -0.876 . . . . 0.0 109.595 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 5.47 9.45 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.597 HD11 ' HB2' ' A' ' 34' ' ' LYS . 51.8 mt -108.26 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.303 -1.116 . . . . 0.0 110.069 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 7.9 t-20 -86.65 107.04 18.02 Favored 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.387 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.727 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.03 147.74 45.71 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.541 -177.571 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.952 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.8 t -135.73 142.43 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.518 179.278 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.942 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -105.35 135.05 47.44 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.244 -0.983 . . . . 0.0 109.871 179.324 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.447 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.62 131.29 49.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.12 -0.987 . . . . 0.0 110.792 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.685 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.6 p90 -166.25 175.33 8.39 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.66 -0.65 . . . . 0.0 109.515 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.74 114.89 1.41 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.249 -0.907 . . . . 0.0 110.799 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.77 31.45 7.77 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.916 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.53 157.31 26.55 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.064 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.916 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.3 m-20 -96.91 149.45 21.86 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.195 -0.941 . . . . 0.0 110.508 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.677 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.3 m -62.64 111.25 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.189 -0.945 . . . . 0.0 109.162 179.224 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.638 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.6 m -133.63 -32.19 1.15 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.337 -0.852 . . . . 0.0 111.08 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.952 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.4 t -53.73 137.94 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.193 -0.942 . . . . 0.0 109.825 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.638 HG23 ' O ' ' A' ' 72' ' ' SER . 1.2 pp . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.223 -0.923 . . . . 0.0 111.169 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 122.109 0.957 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 12.0 p -117.86 133.16 65.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.089 0.947 . . . . 0.0 110.111 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.59 HG22 HG22 ' A' ' 60' ' ' ILE . 4.7 m -113.87 125.45 71.16 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.369 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.088 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.681 HG22 HG13 ' A' ' 73' ' ' VAL . 9.1 t -97.18 121.17 47.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 121.008 -1.058 . . . . 0.0 110.133 -178.482 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.94 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.2 m -114.88 100.07 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.706 -1.246 . . . . 0.0 108.586 179.412 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.447 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.27 163.99 33.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.667 -1.271 . . . . 0.0 111.659 -177.64 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.481 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -84.11 -138.56 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.597 -0.689 . . . . 0.0 109.6 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.481 ' N ' HG23 ' A' ' 85' ' ' THR . 0.7 OUTLIER -87.53 14.4 8.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.799 -1.188 . . . . 0.0 110.613 179.817 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.476 ' H ' HG23 ' A' ' 85' ' ' THR . . . -86.54 -21.82 26.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.989 -1.069 . . . . 0.0 110.181 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.128 -0.983 . . . . 0.0 110.143 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.3 t0 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.158 0.504 . . . . 0.0 110.201 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -119.38 144.36 46.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.23 -0.919 . . . . 0.0 110.339 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.424 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 6.5 m-20 -78.95 -31.66 45.18 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.694 179.372 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -161.56 163.15 30.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.294 -0.879 . . . . 0.0 110.768 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.523 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.45 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.271 -0.893 . . . . 0.0 110.08 179.27 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.887 HG21 HD11 ' A' ' 28' ' ' ILE . 3.0 mp -93.41 119.18 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.276 -0.89 . . . . 0.0 109.14 179.349 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' A' ' 41' ' ' PHE . 2.4 t70 -128.47 160.58 31.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.121 -0.987 . . . . 0.0 111.599 -178.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.45 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.96 -5.14 31.14 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 177.452 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.15 14.02 1.38 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.285 -0.884 . . . . 0.0 111.723 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 C--N 1.307 -1.242 0 O-C-N 120.678 -1.264 . . . . 0.0 109.043 179.585 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.476 0.655 . . . . 0.0 110.99 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.506 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.8 p-10 -73.82 162.88 28.65 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.558 -0.714 . . . . 0.0 110.287 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.449 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.24 -44.8 92.33 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.877 -1.14 . . . . 0.0 111.6 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.506 HG22 ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.76 -30.66 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.716 -1.24 . . . . 0.0 112.74 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 2.6 p -53.6 -55.25 27.39 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.449 -1.407 . . . . 0.0 110.162 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.449 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.64 -35.33 75.92 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.048 178.435 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.415 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 26.2 m -62.07 -50.35 72.32 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 119.369 -0.932 . . . . 0.0 108.581 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.25 -46.83 39.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.322 -0.861 . . . . 0.0 109.982 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 114' ' ' SER . 60.2 mtt180 -61.3 -45.29 95.06 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.268 -0.895 . . . . 0.0 110.967 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.478 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.9 ttm180 -55.55 -38.68 69.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.694 -1.254 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.78 0.28 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.61 -50.81 0.24 Allowed 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.468 -1.019 . . . . 0.0 108.632 179.666 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.487 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -94.79 142.35 27.57 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.484 1.891 0 C-N-CA 119.335 -1.412 . . . . 0.0 110.574 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.2 86.19 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.883 -1.363 . . . . 0.0 109.931 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.89 -43.01 1.75 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.344 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.472 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 12.9 mttt -111.0 -171.68 0.22 Allowed Pre-proline 0 N--CA 1.487 1.392 0 O-C-N 121.611 -0.935 . . . . 0.0 109.454 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.457 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.9 Cg_endo -90.75 107.79 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.61 1.321 . . . . 0.0 109.786 179.044 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.487 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.33 166.07 50.92 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.429 ' O ' ' HA ' ' A' ' 98' ' ' SER . 4.0 mt -119.55 140.49 43.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.227 179.2 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.523 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.6 t80 -128.73 114.93 17.21 Favored 'General case' 0 C--N 1.3 -1.585 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.139 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.418 ' NE ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -99.38 134.28 42.48 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 109.665 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.474 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.16 148.26 50.59 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.157 -0.964 . . . . 0.0 109.803 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.45 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.1 t . . . . . 0 N--CA 1.493 1.682 0 O-C-N 121.068 -1.02 . . . . 0.0 110.042 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.8 m120 . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 121.307 0.575 . . . . 0.0 110.29 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.832 HD13 HG23 ' A' ' 122' ' ' THR . 62.2 mt -108.75 136.64 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.044 -1.035 . . . . 0.0 110.141 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.43 127.94 34.1 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.188 -0.945 . . . . 0.0 109.25 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.72 135.66 33.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.159 -0.963 . . . . 0.0 110.185 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.8 t -137.22 156.41 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.286 -0.884 . . . . 0.0 110.423 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.33 113.83 26.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 0.0 109.83 179.529 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.647 HD23 ' CB ' ' A' ' 26' ' ' LYS . 8.8 tp -52.78 142.58 18.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.161 -0.962 . . . . 0.0 110.111 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 p -138.22 174.36 10.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.262 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.2 71.91 1.71 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.289 -0.882 . . . . 0.0 109.969 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.753 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -144.19 110.15 5.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 110.513 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.77 -171.44 26.75 Favored Glycine 0 N--CA 1.488 2.145 0 C-N-CA 118.876 -1.631 . . . . 0.0 110.859 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -108.95 -26.18 10.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.65 -0.912 . . . . 0.0 110.394 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.979 HD12 HD13 ' A' ' 55' ' ' LEU . 8.0 tt -95.27 101.53 7.69 Favored Pre-proline 0 N--CA 1.487 1.403 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.357 -179.38 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 36.5 Cg_endo -61.29 155.29 52.6 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.516 1.272 . . . . 0.0 110.228 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.589 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.75 94.48 0.5 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.091 -1.005 . . . . 0.0 111.309 -178.024 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.589 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 60.0 68.28 0.79 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.407 -0.808 . . . . 0.0 111.673 178.808 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 14.6 11.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.647 ' CB ' HD23 ' A' ' 15' ' ' LEU . 21.4 mmtt -130.73 156.69 44.52 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.082 -1.246 . . . . 0.0 109.2 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.753 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.24 108.07 16.11 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.986 -1.071 . . . . 0.0 109.086 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 1.088 HD11 HG21 ' A' ' 100' ' ' ILE . 5.1 mt -71.31 113.33 18.47 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.117 -179.384 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.89 ' O ' HG22 ' A' ' 32' ' ' VAL . 43.0 Cg_endo -71.04 129.69 16.64 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.053 -1.941 . . . . 0.0 107.053 176.71 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.489 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.8 mt -55.77 -18.82 9.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.808 -1.182 . . . . 0.0 110.545 -177.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -15.97 23.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.628 -1.295 . . . . 0.0 110.332 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.069 HG23 HG23 ' A' ' 33' ' ' ILE . 16.2 m -93.36 -25.36 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.882 -1.136 . . . . 0.0 111.057 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.069 HG23 HG23 ' A' ' 32' ' ' VAL . 21.4 pt -117.9 -16.17 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.01 -1.056 . . . . 0.0 110.923 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.566 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -97.82 148.49 23.34 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.844 -1.16 . . . . 0.0 110.083 179.534 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.17 -4.14 51.81 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.65 -159.08 23.37 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.347 -1.406 . . . . 0.0 110.082 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.89 133.45 44.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.275 -1.132 . . . . 0.0 110.547 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.76 147.01 40.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.098 -1.001 . . . . 0.0 110.703 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.592 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.2 tp -108.54 113.74 27.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.417 -0.802 . . . . 0.0 109.998 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.784 HD12 HG12 ' A' ' 83' ' ' VAL . 25.9 mt -96.54 126.89 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.341 -0.85 . . . . 0.0 109.409 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.504 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 34.0 m-85 -95.23 123.75 38.9 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.41 -0.806 . . . . 0.0 109.978 -179.587 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.01 160.23 21.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.192 -0.943 . . . . 0.0 110.606 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.422 ' HB3' ' O ' ' A' ' 104' ' ' THR . 7.8 p80 -107.18 -3.81 19.46 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.439 -0.788 . . . . 0.0 110.175 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.65 50.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.066 -1.021 . . . . 0.0 110.779 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.516 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.53 -41.38 69.24 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.81 -0.556 . . . . 0.0 110.646 -179.765 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mttp -58.79 -35.27 72.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.195 -0.941 . . . . 0.0 110.109 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.26 -34.86 66.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.347 -0.846 . . . . 0.0 109.427 179.656 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.811 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 91.9 m -60.7 -34.23 74.05 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.511 -0.743 . . . . 0.0 109.58 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.06 -49.16 63.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.17 -0.956 . . . . 0.0 110.246 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.7 -42.68 67.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.258 -0.901 . . . . 0.0 110.599 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.775 HD12 HG11 ' A' ' 83' ' ' VAL . 1.1 tm? -57.23 -41.1 78.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.427 -0.796 . . . . 0.0 111.295 -179.018 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.95 -51.48 12.33 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.874 -1.141 . . . . 0.0 110.528 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.6 89.78 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.996 -1.065 . . . . 0.0 109.48 179.583 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.531 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.98 -45.77 86.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.475 -0.766 . . . . 0.0 109.559 179.337 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.979 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.83 -42.0 75.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 109.898 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.8 t -56.35 -33.71 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.091 -1.006 . . . . 0.0 109.181 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -32.05 61.01 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.32 -0.862 . . . . 0.0 109.863 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.531 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.69 -26.2 62.41 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.379 -0.826 . . . . 0.0 109.529 179.637 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.52 6.09 8.94 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.618 HG22 HG22 ' A' ' 81' ' ' VAL . 30.6 mt -108.25 143.72 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.254 -1.145 . . . . 0.0 110.143 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.471 ' OD1' HD11 ' A' ' 74' ' ' ILE . 1.5 t-20 -87.07 107.3 18.38 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.302 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.608 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.22 147.33 45.76 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.744 -177.274 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.88 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.6 t -134.75 150.0 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.916 -0.714 . . . . 0.0 109.326 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.811 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.47 136.4 52.83 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.011 179.078 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.577 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.1 t80 -123.47 128.12 49.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.911 . . . . 0.0 110.742 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.849 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.12 -179.94 8.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.515 -0.741 . . . . 0.0 109.858 179.63 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.73 11.0 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.238 -0.913 . . . . 0.0 111.012 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.76 47.73 19.39 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.849 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -116.96 153.02 33.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.058 -1.26 . . . . 0.0 109.608 179.549 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.4 m-20 -89.55 148.25 23.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.219 -0.925 . . . . 0.0 110.994 -178.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.677 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -63.2 111.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.102 -0.999 . . . . 0.0 109.235 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.712 ' O ' HG23 ' A' ' 74' ' ' ILE . 18.1 m -132.58 -38.31 1.03 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.266 -0.896 . . . . 0.0 110.488 -179.486 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.88 HG22 ' HB ' ' A' ' 63' ' ' VAL . 64.6 t -48.19 137.3 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.388 -0.82 . . . . 0.0 110.464 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.712 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.627 0 O-C-N 121.305 -0.872 . . . . 0.0 110.298 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.944 0.878 . . . . 0.0 110.024 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.555 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -117.06 134.8 59.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 122.014 0.911 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.618 HG22 HG22 ' A' ' 60' ' ' ILE . 11.4 m -112.6 125.76 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.334 -0.854 . . . . 0.0 109.02 179.127 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.795 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -97.39 118.34 43.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 120.935 -1.103 . . . . 0.0 110.037 -178.282 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.784 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -112.64 100.09 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.027 -1.046 . . . . 0.0 108.806 179.571 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.51 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -142.0 162.23 36.0 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.613 -1.304 . . . . 0.0 111.521 -178.079 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.699 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -87.01 -143.95 0.12 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.678 -0.639 . . . . 0.0 109.353 179.39 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.409 ' N ' HG23 ' A' ' 85' ' ' THR . 3.1 p30 -73.9 -4.62 36.12 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.926 -1.109 . . . . 0.0 110.782 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.699 ' H ' HG23 ' A' ' 85' ' ' THR . . . -61.65 -40.05 93.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.144 . . . . 0.0 110.502 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.107 -0.996 . . . . 0.0 109.844 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.198 0.523 . . . . 0.0 110.421 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.441 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 21.9 m-85 -119.42 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.109 -0.994 . . . . 0.0 109.726 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.445 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.99 -35.59 80.7 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.142 -0.973 . . . . 0.0 109.067 179.538 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.485 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.59 31.79 Favored 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.741 -0.784 . . . . 0.0 110.863 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.741 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.12 117.6 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.453 -0.78 . . . . 0.0 110.571 179.837 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 1.088 HG21 HD11 ' A' ' 28' ' ' ILE . 2.9 mp -93.1 112.59 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.29 161.1 21.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.115 -0.99 . . . . 0.0 111.912 -178.059 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.506 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.1 p -102.83 6.57 39.29 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.068 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.409 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.2 m120 45.86 25.4 0.29 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.238 -0.913 . . . . 0.0 111.349 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.9 p . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.921 . . . . 0.0 110.028 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.7 pp0? . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 121.147 0.499 . . . . 0.0 110.709 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.512 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -96.36 160.29 14.5 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.298 -0.876 . . . . 0.0 110.397 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.44 -48.26 37.5 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.418 -0.801 . . . . 0.0 112.001 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.512 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -71.17 -29.56 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.769 -1.207 . . . . 0.0 110.836 -178.781 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.48 -56.31 7.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.217 -0.927 . . . . 0.0 110.387 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.426 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.66 -34.82 76.35 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.279 -0.888 . . . . 0.0 108.715 178.705 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.459 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 42.7 m -59.79 -49.82 76.24 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.064 -1.022 . . . . 0.0 108.608 178.792 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -73.82 -38.89 64.42 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.43 -0.794 . . . . 0.0 109.951 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 82.8 mtt180 -70.18 -44.29 69.05 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.262 -0.899 . . . . 0.0 110.586 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.571 ' O ' HG23 ' A' ' 122' ' ' THR . 34.5 ttm180 -54.45 -36.58 64.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.222 -0.924 . . . . 0.0 110.577 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.94 -15.85 11.1 Favored Glycine 0 N--CA 1.494 2.527 0 O-C-N 120.959 -1.088 . . . . 0.0 111.524 -179.205 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.73 -3.58 22.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.651 -1.5 . . . . 0.0 111.485 -179.252 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.832 HG23 HD13 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.98 143.53 48.97 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.76 -1.213 . . . . 0.0 110.9 -179.685 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.469 ' N ' ' HA3' ' A' ' 128' ' ' GLY . . . 74.93 12.25 83.32 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.846 178.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.2 mtt180 -61.3 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.048 -1.266 . . . . 0.0 109.022 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.4 16.64 39.46 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -178.516 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.459 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.2 OUTLIER -175.48 -176.48 0.26 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.472 -1.016 . . . . 0.0 108.779 -179.615 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.459 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -88.27 105.39 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.133 1.07 . . . . 0.0 109.983 179.452 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.469 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.23 173.82 25.63 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.529 -1.32 . . . . 0.0 110.198 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.28 142.94 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.486 -1.008 . . . . 0.0 109.572 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.741 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.44 114.93 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.757 -1.215 . . . . 0.0 110.389 179.4 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.441 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.55 145.68 27.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.495 -0.753 . . . . 0.0 109.484 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.7 p90 -137.89 157.08 47.14 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.906 -1.121 . . . . 0.0 110.306 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 N--CA 1.494 1.752 0 O-C-N 121.142 -0.974 . . . . 0.0 109.656 179.451 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.509 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.279 0.561 . . . . 0.0 109.898 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.488 HD13 HG22 ' A' ' 122' ' ' THR . 19.8 mt -105.28 134.83 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.856 -1.153 . . . . 0.0 110.027 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -84.93 128.28 34.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.328 -0.857 . . . . 0.0 108.893 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.43 142.74 27.39 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.043 -1.036 . . . . 0.0 110.245 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.611 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 13.3 t -136.53 157.29 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.943 -179.448 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.35 108.7 19.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.869 179.418 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.586 HD23 HG22 ' A' ' 133' ' ' VAL . 11.2 tp -54.98 134.35 48.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.798 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.0 p -137.97 -179.32 5.7 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.323 -0.861 . . . . 0.0 110.176 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.2 p -74.56 60.78 0.91 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -0.909 . . . . 0.0 109.988 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.456 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.8 m -131.73 111.41 11.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.892 . . . . 0.0 110.227 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.454 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.53 -162.61 27.97 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.977 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.32 -21.63 7.42 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.724 -0.868 . . . . 0.0 110.474 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.896 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.0 tt -97.39 107.1 36.8 Favored Pre-proline 0 N--CA 1.489 1.517 0 C-N-CA 118.796 -1.162 . . . . 0.0 110.24 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.448 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -63.64 155.01 65.62 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 O-C-N 123.385 1.203 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.7 t80 -169.13 91.6 0.25 Allowed 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.056 -1.027 . . . . 0.0 111.563 -178.123 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.501 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.82 67.27 0.89 Allowed 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.473 -0.767 . . . . 0.0 111.38 178.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.68 13.56 18.33 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.632 ' HG3' HG13 ' A' ' 133' ' ' VAL . 6.5 mmtt -130.8 156.23 45.34 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.14 -1.212 . . . . 0.0 109.08 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.456 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.81 106.92 12.56 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.896 -1.127 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.896 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.0 mt -68.47 115.1 26.44 Favored Pre-proline 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.61 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.911 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.1 Cg_endo -68.42 126.74 14.63 Favored 'Trans proline' 0 C--N 1.304 -1.813 0 N-CA-C 107.382 -1.815 . . . . 0.0 107.382 176.261 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.565 HD11 HD12 ' A' ' 58' ' ' LEU . 5.6 mt -56.08 -20.72 18.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.962 -1.086 . . . . 0.0 110.846 -177.474 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -59.95 -16.05 26.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.674 -1.266 . . . . 0.0 110.467 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.109 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.58 -25.33 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.005 -1.059 . . . . 0.0 110.955 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.109 HG23 HG23 ' A' ' 32' ' ' VAL . 14.7 pt -117.86 -15.49 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.963 -1.085 . . . . 0.0 110.951 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.597 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.5 tptm -98.22 147.77 24.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.809 -1.182 . . . . 0.0 110.507 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.35 -3.14 61.43 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.09 -159.45 21.29 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.23 -1.462 . . . . 0.0 110.374 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.375 -1.074 . . . . 0.0 110.543 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.563 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.11 147.86 39.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.225 -0.922 . . . . 0.0 110.918 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.429 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 40.4 tp -109.14 116.24 31.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.38 -0.825 . . . . 0.0 110.291 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.907 HD12 HG12 ' A' ' 83' ' ' VAL . 34.4 mt -99.89 127.77 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.132 -0.98 . . . . 0.0 109.687 179.465 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.05 39.55 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.327 -0.858 . . . . 0.0 109.891 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.71 159.72 21.82 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.821 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.501 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.43 -8.58 19.05 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.557 -0.714 . . . . 0.0 109.942 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.13 138.98 53.27 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.031 -1.043 . . . . 0.0 110.96 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.471 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.95 -40.37 68.73 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.315 0.579 . . . . 0.0 110.774 -179.79 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mttp -59.93 -36.49 77.13 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.369 -0.832 . . . . 0.0 111.028 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.28 71.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 -179.48 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.916 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 84.8 m -61.2 -36.36 79.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.284 -0.885 . . . . 0.0 109.302 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.45 66.85 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.267 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -73.01 -45.99 54.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.234 -0.916 . . . . 0.0 110.283 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.61 ' O ' HD13 ' A' ' 51' ' ' LEU . 3.2 tm? -57.01 -39.72 75.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.591 -0.693 . . . . 0.0 111.267 -179.002 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.477 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.88 -51.17 13.1 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.929 -1.107 . . . . 0.0 110.54 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.127 -0.983 . . . . 0.0 109.677 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.498 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.68 83.89 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.372 -0.83 . . . . 0.0 109.526 179.379 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.873 HD13 HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -54.94 -42.59 72.49 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.491 -0.756 . . . . 0.0 109.489 179.683 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.5 t -56.14 -31.02 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.99 -1.068 . . . . 0.0 108.725 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.03 -32.73 61.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.521 -0.737 . . . . 0.0 109.899 179.35 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.565 HD12 HD11 ' A' ' 30' ' ' LEU . 4.3 mm? -72.1 -26.11 62.01 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-O 121.851 0.834 . . . . 0.0 109.728 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.0 9.17 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.599 HG22 HG22 ' A' ' 81' ' ' VAL . 44.7 mt -107.55 143.24 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.247 -1.149 . . . . 0.0 109.861 -179.818 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.7 t-20 -87.56 106.83 18.27 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.348 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.642 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 118.774 -1.17 . . . . 0.0 111.831 -177.079 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.896 HG21 ' HA ' ' A' ' 73' ' ' VAL . 92.2 t -126.01 148.12 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.697 -0.627 . . . . 0.0 109.828 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.916 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -117.77 117.63 29.85 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.495 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.485 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 3.5 t80 -108.14 131.25 54.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 110.878 -179.264 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.857 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -155.34 -168.72 2.93 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.62 -0.675 . . . . 0.0 109.958 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -55.92 123.66 15.04 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.319 -0.863 . . . . 0.0 111.266 -179.256 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.56 59.02 8.76 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.857 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.66 152.05 35.98 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.074 -1.25 . . . . 0.0 109.712 179.397 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.738 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -85.88 149.03 25.51 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.209 -0.932 . . . . 0.0 110.592 -179.276 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.0 m -62.5 110.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.133 179.178 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.707 ' O ' HG23 ' A' ' 74' ' ' ILE . 68.9 m -131.33 -32.09 1.58 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.372 -0.83 . . . . 0.0 110.656 -179.403 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.896 ' HA ' HG21 ' A' ' 63' ' ' VAL . 94.9 t -53.0 131.25 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.153 -0.967 . . . . 0.0 109.441 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 O-C-N 121.125 -0.984 . . . . 0.0 110.779 -179.263 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 122.018 0.914 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.619 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.43 132.44 67.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 CA-C-O 122.087 0.946 . . . . 0.0 110.456 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.614 HG11 ' HB ' ' A' ' 33' ' ' ILE . 11.4 m -112.45 122.05 65.95 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 121.356 -0.84 . . . . 0.0 108.96 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.839 HG22 HG13 ' A' ' 73' ' ' VAL . 16.1 t -97.01 120.94 46.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.684 0 O-C-N 121.054 -1.029 . . . . 0.0 110.611 -177.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.907 HG12 HD12 ' A' ' 40' ' ' ILE . 3.3 m -112.39 100.39 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.044 -1.035 . . . . 0.0 108.667 179.321 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.485 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.7 34.44 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -177.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.574 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -93.19 -136.68 0.18 Allowed 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.203 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.525 ' N ' HG23 ' A' ' 85' ' ' THR . 3.3 p30 -77.04 -6.16 51.63 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.679 -1.263 . . . . 0.0 111.068 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.574 ' H ' HG23 ' A' ' 85' ' ' THR . . . -60.71 -41.52 95.4 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.849 -1.157 . . . . 0.0 110.066 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.4 tp . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 108.577 179.161 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.274 0.559 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -120.26 152.81 37.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.214 -0.929 . . . . 0.0 110.294 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.478 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.6 -28.35 30.88 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.425 -0.797 . . . . 0.0 109.831 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.503 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.6 p -160.7 163.58 32.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.283 -0.886 . . . . 0.0 110.712 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.503 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.91 128.12 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.345 -0.847 . . . . 0.0 110.138 179.441 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.86 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -105.95 111.11 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.195 -0.94 . . . . 0.0 108.666 178.778 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.418 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.7 t0 -115.85 161.29 18.99 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.052 -1.03 . . . . 0.0 111.96 -178.277 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.468 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.84 -2.91 43.04 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.023 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.411 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 53.89 21.48 2.82 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.007 . . . . 0.0 110.183 -179.098 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.323 -0.86 . . . . 0.0 110.153 179.662 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.9 pp0? . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.474 0.654 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.482 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -105.55 161.85 14.0 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.478 -0.764 . . . . 0.0 110.323 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.8 -59.85 1.8 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.315 -0.865 . . . . 0.0 112.156 -178.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.482 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.4 m -64.31 -29.32 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.788 -1.195 . . . . 0.0 111.764 -178.57 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.34 -56.5 6.73 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.009 -1.057 . . . . 0.0 110.63 -179.015 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.47 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.58 -34.75 76.35 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.719 178.933 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.401 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 29.5 m -59.13 -49.22 78.69 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.984 -1.072 . . . . 0.0 108.301 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' GLN . . . . . 0.418 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -36.99 65.87 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.508 -0.745 . . . . 0.0 109.9 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.425 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 5.1 mtt180 -71.8 -44.59 63.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.042 -1.036 . . . . 0.0 111.193 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.47 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 12.2 ttm180 -57.35 -41.64 80.48 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.848 -1.158 . . . . 0.0 109.834 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.421 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.05 63.88 0.21 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.443 ' N ' ' O ' ' A' ' 119' ' ' ARG . 10.9 mmp_? -135.38 -44.69 0.69 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.43 -1.041 . . . . 0.0 108.524 178.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.507 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.0 t -93.58 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.677 -0.639 . . . . 0.0 109.732 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.08 3.23 36.13 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.617 179.058 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.8 mmt180 -62.71 87.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.965 -1.315 . . . . 0.0 109.511 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.51 19.13 33.29 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -178.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.462 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 16.4 ptpt -176.23 -178.31 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.491 -1.005 . . . . 0.0 108.503 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.5 Cg_endo -89.16 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.254 1.134 . . . . 0.0 110.428 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.588 ' C ' HD12 ' A' ' 129' ' ' ILE . . . -80.85 176.72 54.59 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.772 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.588 HD12 ' C ' ' A' ' 128' ' ' GLY . 3.5 mp -132.52 143.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.764 -0.845 . . . . 0.0 109.043 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.503 ' HD1' HG23 ' A' ' 99' ' ' VAL . 9.6 t80 -129.95 115.52 17.28 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.24 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.611 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mtt180 -105.98 131.42 53.29 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.522 -0.736 . . . . 0.0 109.435 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.418 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 46.0 p90 -129.63 157.29 42.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.042 -1.036 . . . . 0.0 110.376 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.632 HG13 ' HG3' ' A' ' 26' ' ' LYS . 42.8 t . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.104 -0.997 . . . . 0.0 109.923 179.757 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.436 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.0 m-80 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.142 0.496 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.64 HD11 ' O ' ' A' ' 122' ' ' THR . 36.2 mt -128.05 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.187 -0.945 . . . . 0.0 109.413 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.97 128.45 34.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.139 -0.976 . . . . 0.0 109.305 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.06 133.09 34.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.206 -0.933 . . . . 0.0 110.429 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.522 HG11 ' HE ' ' A' ' 131' ' ' ARG . 16.5 t -128.66 156.11 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.403 -0.811 . . . . 0.0 110.021 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.61 110.9 21.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.252 -0.905 . . . . 0.0 109.968 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.718 HD23 HG22 ' A' ' 133' ' ' VAL . 11.7 tp -58.84 134.21 56.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.275 -0.891 . . . . 0.0 109.581 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.9 p -138.78 -175.19 4.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.24 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.5 p -77.75 81.3 4.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.264 -0.897 . . . . 0.0 109.896 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.625 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.8 m -153.64 109.5 3.27 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.297 -0.877 . . . . 0.0 110.656 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.74 -165.08 28.07 Favored Glycine 0 N--CA 1.487 2.044 0 C-N-CA 119.072 -1.537 . . . . 0.0 110.567 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.7 -21.83 8.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.647 -0.914 . . . . 0.0 110.275 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.876 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -96.19 110.69 53.55 Favored Pre-proline 0 N--CA 1.487 1.407 0 C-N-CA 118.8 -1.16 . . . . 0.0 109.91 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.462 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.3 Cg_endo -64.63 155.39 67.07 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.684 1.36 . . . . 0.0 110.285 -179.515 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.4 t80 -169.5 94.06 0.28 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.112 -0.993 . . . . 0.0 111.508 -178.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 24.9 m-85 58.38 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.393 -0.817 . . . . 0.0 111.497 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.44 14.76 9.61 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.431 -1.067 . . . . 0.0 110.431 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.473 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.8 156.8 44.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.041 -1.27 . . . . 0.0 109.418 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.625 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -114.7 107.35 15.34 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 120.967 -1.083 . . . . 0.0 109.5 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.865 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.3 mt -69.56 113.9 20.46 Favored Pre-proline 0 C--N 1.299 -1.6 0 O-C-N 121.383 -0.823 . . . . 0.0 110.215 -179.517 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.917 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.8 Cg_endo -70.27 129.73 17.54 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 N-CA-C 107.189 -1.889 . . . . 0.0 107.189 176.858 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.818 HD11 HD12 ' A' ' 58' ' ' LEU . 17.6 mt -56.33 -18.19 10.07 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.874 -1.141 . . . . 0.0 110.94 -177.659 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.49 -16.47 24.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.636 -1.29 . . . . 0.0 110.087 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.025 HG23 HG23 ' A' ' 33' ' ' ILE . 14.4 m -93.96 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.155 -0.966 . . . . 0.0 110.981 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.025 HG23 HG23 ' A' ' 32' ' ' VAL . 40.9 pt -118.15 -22.79 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.934 -1.104 . . . . 0.0 110.872 -178.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.596 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.26 22.16 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.506 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.02 -5.27 59.35 Favored Glycine 0 N--CA 1.483 1.82 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.22 -162.58 27.81 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.678 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.22 129.38 44.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.468 -1.019 . . . . 0.0 110.351 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.5 m-70 -138.93 145.59 40.01 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.222 -0.924 . . . . 0.0 110.607 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.593 HD12 ' O ' ' A' ' 82' ' ' VAL . 38.3 tp -108.06 117.17 33.43 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.922 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.5 mm -94.03 125.69 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.275 -0.891 . . . . 0.0 108.601 179.26 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.471 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 11.4 m-85 -94.21 121.81 36.11 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.089 -1.007 . . . . 0.0 109.637 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.46 150.69 39.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.271 -0.893 . . . . 0.0 110.83 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.42 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p80 -103.74 3.59 34.33 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 109.682 178.442 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.55 135.39 45.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.186 -0.946 . . . . 0.0 110.199 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.454 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.4 ttpt -71.28 -37.2 71.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.609 -0.682 . . . . 0.0 110.735 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.7 -37.03 80.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.315 -0.866 . . . . 0.0 110.775 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 4.3 tptm -72.6 -36.33 68.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 110.015 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.725 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 71.1 m -60.4 -34.23 73.63 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.475 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.72 -49.15 56.07 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 110.538 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.445 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.43 -41.71 69.17 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.147 -0.971 . . . . 0.0 110.583 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.919 HD12 HG11 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.9 80.41 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 111.282 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.11 -51.0 43.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.934 -1.104 . . . . 0.0 110.175 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.88 -31.76 65.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.209 -0.932 . . . . 0.0 109.123 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.596 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.83 -47.06 85.05 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 179.358 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.876 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -60.99 -41.42 96.46 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.279 -0.888 . . . . 0.0 111.053 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.0 t -56.38 -33.93 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.868 -1.145 . . . . 0.0 109.227 179.519 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -34.83 60.3 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.318 -0.864 . . . . 0.0 110.482 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.818 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.32 -25.57 62.47 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.409 -0.807 . . . . 0.0 109.833 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.31 8.9 8.25 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.758 ' CD1' HD22 ' A' ' 30' ' ' LEU . 36.5 mt -108.34 143.73 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.338 -1.095 . . . . 0.0 109.666 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 17.1 t-20 -90.07 106.75 18.69 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.23 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.569 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.59 145.96 45.94 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.508 -176.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.877 HG21 ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.64 149.36 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.52 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.725 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.43 128.29 56.4 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.711 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.603 ' CD1' HD12 ' A' ' 69' ' ' LEU . 12.9 t80 -119.96 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.384 -0.823 . . . . 0.0 110.094 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.898 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.7 p90 -167.76 -178.27 3.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.521 -0.737 . . . . 0.0 109.776 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.13 116.78 3.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.175 -0.953 . . . . 0.0 110.617 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.69 36.12 7.5 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.898 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.68 156.88 27.44 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.191 -1.182 . . . . 0.0 110.122 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.782 ' N ' HD13 ' A' ' 69' ' ' LEU . 33.7 m-20 -97.41 149.01 22.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.284 -0.885 . . . . 0.0 110.088 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.681 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.7 m -62.45 111.28 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 C-N-CA 119.261 -0.976 . . . . 0.0 109.207 179.245 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.446 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 27.4 m -130.16 -34.39 1.66 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.366 -0.834 . . . . 0.0 110.731 -179.459 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.877 ' HA ' HG21 ' A' ' 63' ' ' VAL . 50.7 t -49.88 151.77 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.225 -0.922 . . . . 0.0 109.459 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.426 HG13 HG21 ' A' ' 80' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.78 0 O-C-N 120.781 -1.199 . . . . 0.0 111.523 -178.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 122.059 0.933 . . . . 0.0 110.242 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 4.9 p -117.25 131.07 71.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 122.062 0.935 . . . . 0.0 110.057 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.622 HG11 ' HB ' ' A' ' 33' ' ' ILE . 6.2 m -112.95 121.36 65.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.328 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.725 HG22 HG13 ' A' ' 73' ' ' VAL . 11.1 t -96.76 118.52 43.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.148 -0.97 . . . . 0.0 110.414 -177.647 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.922 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.9 m -109.44 100.34 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.063 -1.023 . . . . 0.0 108.79 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -143.0 161.6 37.69 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.6 -1.313 . . . . 0.0 111.108 -178.31 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.789 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.8 t -85.37 -136.97 0.07 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.493 -0.755 . . . . 0.0 109.147 179.532 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.509 ' N ' HG23 ' A' ' 85' ' ' THR . 6.1 m-20 -82.54 -13.64 56.26 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.723 -1.235 . . . . 0.0 110.404 179.764 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.789 ' H ' HG23 ' A' ' 85' ' ' THR . . . -52.65 -41.96 64.26 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.072 -1.017 . . . . 0.0 110.339 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.434 HD12 ' CD2' ' A' ' 65' ' ' TYR . 2.4 tp . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.081 -1.012 . . . . 0.0 109.769 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.314 0.578 . . . . 0.0 110.611 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -116.64 151.69 35.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.331 -0.855 . . . . 0.0 109.494 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.49 -32.98 72.19 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.342 -0.943 . . . . 0.0 109.327 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.7 p -162.37 163.56 27.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.274 -0.891 . . . . 0.0 111.084 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.604 HG22 HG21 ' A' ' 122' ' ' THR . 0.3 OUTLIER -130.83 112.98 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.52 -0.738 . . . . 0.0 109.886 179.343 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.601 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -94.48 115.32 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.217 -0.927 . . . . 0.0 109.166 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -127.99 161.12 29.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 111.504 -178.484 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 42.7 t -90.94 -9.1 47.36 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.824 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 57.35 13.74 1.88 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.293 -0.879 . . . . 0.0 111.662 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.2 m . . . . . 0 C--N 1.306 -1.31 0 O-C-N 120.777 -1.202 . . . . 0.0 108.992 179.541 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.906 0 CA-C-O 121.591 0.71 . . . . 0.0 111.239 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.537 ' OD2' HG22 ' A' ' 113' ' ' VAL . 4.4 p-10 -73.25 162.49 29.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.501 -0.749 . . . . 0.0 109.971 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.16 -42.61 91.15 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.884 -1.135 . . . . 0.0 111.62 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.537 HG22 ' OD2' ' A' ' 111' ' ' ASP . 6.7 m -72.59 -30.86 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 120.784 -1.198 . . . . 0.0 113.031 -178.001 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.74 -55.76 20.44 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.474 -1.391 . . . . 0.0 110.3 -178.766 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.411 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -62.88 -34.71 77.97 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 118.695 -1.202 . . . . 0.0 108.225 178.327 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.408 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 24.6 m -61.46 -50.7 71.72 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.825 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.89 41.91 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.832 . . . . 0.0 109.6 178.778 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.422 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 25.2 mtt180 -59.59 -45.14 92.78 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.287 -0.883 . . . . 0.0 110.405 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.481 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 20.1 ttm180 -62.68 -34.59 77.41 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.734 -1.229 . . . . 0.0 110.071 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.427 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.78 -5.36 31.06 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 119.998 -1.096 . . . . 0.0 111.12 -179.236 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.95 -4.96 58.77 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.656 -1.496 . . . . 0.0 110.96 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.64 ' O ' HD11 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -118.72 140.36 50.06 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.859 -1.151 . . . . 0.0 109.442 179.535 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.01 19.6 39.17 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.427 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 10.2 mmt85 -69.39 85.98 0.42 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.033 -1.275 . . . . 0.0 109.806 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.05 57.82 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.469 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.41 -174.8 0.39 Allowed Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.202 -1.175 . . . . 0.0 109.016 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.469 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -85.22 103.33 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.36 1.19 . . . . 0.0 109.438 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -86.98 173.25 44.72 Favored Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.046 -179.107 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.4 mt -122.18 142.92 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -1.056 . . . . 0.0 109.54 179.778 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.7 t80 -127.02 115.34 19.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.166 -0.959 . . . . 0.0 110.178 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.522 ' HE ' HG11 ' A' ' 13' ' ' VAL . 10.6 mtt85 -105.65 135.26 47.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.353 -0.842 . . . . 0.0 109.476 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.2 147.0 45.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.153 -0.967 . . . . 0.0 110.552 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.718 HG22 HD23 ' A' ' 15' ' ' LEU . 54.4 t . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.829 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.459 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.8 p30 . . . . . 0 N--CA 1.507 2.382 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.508 HD11 ' O ' ' A' ' 122' ' ' THR . 12.7 mt -124.32 135.62 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.131 -1.606 . . . . 0.0 109.562 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.88 128.74 34.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.316 -0.865 . . . . 0.0 109.801 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.36 140.93 29.01 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.194 -0.941 . . . . 0.0 109.882 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.408 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 6.5 t -134.78 153.97 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.224 -0.923 . . . . 0.0 110.467 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.59 18.6 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.325 -0.859 . . . . 0.0 109.552 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.501 HD11 HG12 ' A' ' 28' ' ' ILE . 10.8 tp -56.08 136.63 52.29 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.29 -0.881 . . . . 0.0 109.778 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.42 -167.58 1.99 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 110.288 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.2 p -88.3 73.24 8.88 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.636 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.3 m -146.04 112.37 5.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 110.48 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.34 -165.35 27.87 Favored Glycine 0 N--CA 1.489 2.204 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.831 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.59 -21.57 9.08 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.61 -0.936 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.907 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.1 tt -98.85 105.69 32.76 Favored Pre-proline 0 N--CA 1.488 1.46 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.179 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.474 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -62.95 155.0 63.13 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.225 1.118 . . . . 0.0 109.66 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.463 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.2 t80 -167.55 93.61 0.41 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.062 -1.024 . . . . 0.0 111.576 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.427 ' CD2' ' SG ' ' A' ' 102' ' ' CYS . 25.5 m-85 59.38 67.04 0.94 Allowed 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.571 -0.705 . . . . 0.0 111.554 179.06 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.09 13.81 15.82 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.84 156.89 44.25 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.105 -1.233 . . . . 0.0 109.039 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.636 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.06 107.92 14.59 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.789 -1.194 . . . . 0.0 109.675 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.975 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -70.89 114.15 24.6 Favored Pre-proline 0 C--N 1.299 -1.62 0 O-C-N 121.411 -0.806 . . . . 0.0 110.637 -179.415 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.833 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.3 Cg_endo -68.91 128.42 16.79 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 N-CA-C 106.906 -1.998 . . . . 0.0 106.906 176.181 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.55 HD11 HD12 ' A' ' 58' ' ' LEU . 6.9 mt -55.91 -18.94 10.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.914 -1.116 . . . . 0.0 110.678 -177.587 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.51 -16.29 23.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.714 -1.241 . . . . 0.0 110.296 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.121 HG23 HG23 ' A' ' 33' ' ' ILE . 13.1 m -92.24 -25.43 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 120.968 -1.082 . . . . 0.0 111.228 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.121 HG23 HG23 ' A' ' 32' ' ' VAL . 8.9 pt -117.9 -18.53 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.985 -1.072 . . . . 0.0 110.662 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.511 ' HB2' HD11 ' A' ' 60' ' ' ILE . 9.7 tptt -96.24 148.92 22.22 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.931 -1.106 . . . . 0.0 110.417 179.534 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.84 56.7 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.8 -159.22 21.81 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.239 -1.457 . . . . 0.0 110.091 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.447 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.6 mtt85 -100.61 130.65 46.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.404 -1.057 . . . . 0.0 110.603 -179.571 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.2 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 110.505 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.626 HD12 ' HB ' ' A' ' 82' ' ' VAL . 14.0 tp -109.49 120.96 44.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 110.301 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.918 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.3 mm -99.72 125.58 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.194 -0.941 . . . . 0.0 109.283 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.5 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.3 123.05 38.62 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.098 -1.001 . . . . 0.0 109.709 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.24 157.89 25.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.239 -0.913 . . . . 0.0 110.857 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.411 ' HB3' ' O ' ' A' ' 104' ' ' THR . 0.0 OUTLIER -105.75 8.14 32.79 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.412 -0.805 . . . . 0.0 109.967 178.939 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.46 139.65 40.75 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.172 -0.955 . . . . 0.0 110.346 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.459 ' HG2' ' CB ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.93 -38.11 69.92 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 110.783 -179.683 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.93 -37.26 86.74 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.759 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.412 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -64.91 -35.98 82.9 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.765 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.774 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.2 m -60.2 -34.34 73.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.407 -0.808 . . . . 0.0 109.039 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.03 -48.83 64.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.191 -0.943 . . . . 0.0 110.25 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.0 mt-10 -71.46 -45.59 62.18 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.198 -0.939 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.972 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.42 -41.38 76.27 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.373 -0.83 . . . . 0.0 111.338 -178.926 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.443 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.36 -50.92 14.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 110.363 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.73 -41.62 99.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 109.446 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.573 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.4 -46.16 86.95 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.346 -0.846 . . . . 0.0 109.433 179.341 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.41 -42.93 78.81 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.487 -0.758 . . . . 0.0 110.236 179.853 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.9 -33.43 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.073 -1.017 . . . . 0.0 109.166 179.504 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.61 -31.48 59.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.323 -0.861 . . . . 0.0 110.004 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.573 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -72.07 -26.54 62.21 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.893 0.854 . . . . 0.0 109.601 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.03 6.3 8.45 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.603 HG22 HG22 ' A' ' 81' ' ' VAL . 35.1 mt -107.86 143.87 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -1.14 . . . . 0.0 110.144 -179.802 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.625 ' ND2' HD11 ' A' ' 74' ' ' ILE . 15.8 t30 -88.02 106.45 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.364 -1.717 . . . . 0.0 106.364 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.588 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.69 141.67 47.9 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.671 -177.203 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.951 HG21 ' HA ' ' A' ' 73' ' ' VAL . 87.4 t -124.27 147.9 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.998 -0.681 . . . . 0.0 109.69 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.774 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.47 127.04 55.04 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.822 178.503 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.71 31.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 110.57 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.879 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.7 p90 -147.78 175.08 11.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.619 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.69 5.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 110.766 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.9 37.18 10.43 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.879 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.31 155.93 28.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.115 -1.227 . . . . 0.0 109.969 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.856 ' N ' HD13 ' A' ' 69' ' ' LEU . 32.3 m-20 -95.61 149.25 21.66 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.225 -0.922 . . . . 0.0 110.462 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.4 m -61.81 110.08 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 120.939 -1.101 . . . . 0.0 108.969 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.7 m -132.13 -9.69 3.38 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.508 -0.745 . . . . 0.0 110.953 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.951 ' HA ' HG21 ' A' ' 63' ' ' VAL . 40.1 t -72.27 135.12 28.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.082 -1.012 . . . . 0.0 109.305 -179.582 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.687 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.3 pp . . . . . 0 N--CA 1.493 1.722 0 O-C-N 121.155 -0.965 . . . . 0.0 111.235 -178.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.965 0.888 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.687 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -116.06 135.42 56.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 121.966 0.889 . . . . 0.0 110.302 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.603 HG22 HG22 ' A' ' 60' ' ' ILE . 19.0 m -111.88 126.88 69.31 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 O-C-N 121.464 -0.773 . . . . 0.0 109.236 179.567 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.778 HG22 HG13 ' A' ' 73' ' ' VAL . 7.6 t -97.63 116.91 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.793 -1.192 . . . . 0.0 110.502 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.972 HG11 HD12 ' A' ' 51' ' ' LEU . 3.9 m -110.67 100.07 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.884 -1.135 . . . . 0.0 108.691 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.53 162.48 34.96 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.568 -1.332 . . . . 0.0 111.195 -178.109 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.505 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -90.8 -133.36 0.12 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.524 -0.735 . . . . 0.0 109.112 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.505 ' N ' HG23 ' A' ' 85' ' ' THR . 49.4 p-10 -90.02 41.74 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.583 -1.323 . . . . 0.0 110.147 179.457 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.91 -32.09 6.5 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.92 . . . . 0.0 108.907 178.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.052 0.453 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -119.39 151.06 39.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.955 -1.09 . . . . 0.0 110.255 179.366 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.87 -28.4 20.38 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.348 -0.845 . . . . 0.0 109.417 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.553 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 5.8 p -160.87 163.33 32.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.397 -0.815 . . . . 0.0 110.675 179.795 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.415 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.15 115.39 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 110.093 179.72 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.975 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -95.52 111.29 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.16 -0.962 . . . . 0.0 108.579 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.7 t0 -119.65 161.17 21.13 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.159 -0.963 . . . . 0.0 111.786 -178.48 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.427 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.1 t -101.84 8.5 41.28 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.715 -0.616 . . . . 0.0 109.502 178.191 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.417 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.5 m-20 51.66 23.75 2.09 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.113 -0.992 . . . . 0.0 111.293 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.411 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p . . . . . 0 N--CA 1.492 1.634 0 O-C-N 121.17 -0.956 . . . . 0.0 109.972 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.51 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.308 0.575 . . . . 0.0 111.053 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.436 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.9 p-10 -88.45 161.12 17.21 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.298 -0.876 . . . . 0.0 110.345 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.01 -54.97 7.49 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -178.248 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.476 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.67 -31.89 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 120.585 -1.322 . . . . 0.0 112.685 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.51 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.41 -56.22 8.77 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.96 -1.088 . . . . 0.0 110.434 -179.266 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.485 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.74 -35.54 80.35 Favored 'General case' 0 C--O 1.205 -1.284 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.265 178.781 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.476 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.0 m -58.38 -49.2 78.08 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.541 178.804 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.08 -35.54 71.9 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.376 -0.827 . . . . 0.0 109.571 178.815 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.5 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.2 -45.18 61.41 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.239 -0.913 . . . . 0.0 110.931 -179.778 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.485 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 14.4 ttt180 -54.03 -45.17 71.52 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.045 -1.035 . . . . 0.0 109.995 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.58 64.19 0.29 Allowed Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.225 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.434 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.78 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.562 -0.964 . . . . 0.0 108.438 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.508 ' O ' HD11 ' A' ' 10' ' ' ILE . 10.9 t -96.12 142.87 27.79 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.621 -0.674 . . . . 0.0 109.478 178.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.68 33.25 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.47 -1.348 . . . . 0.0 110.94 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.29 87.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.047 -1.266 . . . . 0.0 109.397 179.607 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.87 -8.33 70.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -178.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.471 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.03 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.18 -1.188 . . . . 0.0 109.265 -179.799 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.471 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -89.04 97.46 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.379 1.199 . . . . 0.0 110.601 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.489 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.24 171.09 53.01 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -126.85 142.15 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.488 -1.007 . . . . 0.0 109.305 179.356 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.415 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.4 t80 -128.65 115.27 17.78 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.0 . . . . 0.0 110.314 179.683 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.428 ' HD2' ' HB ' ' A' ' 32' ' ' VAL . 4.1 mtp180 -104.73 122.8 46.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.433 -0.792 . . . . 0.0 109.17 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 29.8 p90 -121.53 157.5 30.55 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 110.415 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.341 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.508 2.446 0 CA-C-O 120.666 0.27 . . . . 0.0 111.055 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.491 HD13 HG22 ' A' ' 122' ' ' THR . 12.5 mt -95.79 124.92 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.574 -1.329 . . . . 0.0 109.892 179.53 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.57 128.02 34.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.138 -0.976 . . . . 0.0 109.554 179.325 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.97 132.95 35.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -0.943 . . . . 0.0 110.005 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.726 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 16.7 t -122.08 149.94 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.24 -0.912 . . . . 0.0 110.419 -179.304 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.85 21.65 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.268 -0.895 . . . . 0.0 109.706 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.885 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.0 tp -53.52 141.1 26.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.278 -0.889 . . . . 0.0 109.881 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.452 ' HA ' ' HD2' ' A' ' 26' ' ' LYS . 28.3 p -136.09 -178.49 5.17 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.253 -0.905 . . . . 0.0 110.526 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.8 p -79.74 71.19 6.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.887 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.689 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.9 m -146.12 112.71 5.94 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.317 -0.865 . . . . 0.0 110.424 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.441 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.81 28.42 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 118.731 -1.7 . . . . 0.0 111.173 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.62 10.4 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.783 -0.834 . . . . 0.0 110.306 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.14 107.94 41.06 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.666 -1.214 . . . . 0.0 110.098 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.446 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.5 Cg_endo -65.05 117.4 4.51 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 O-C-N 123.478 1.251 . . . . 0.0 110.645 -179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.5 -170.79 1.8 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.649 -0.657 . . . . 0.0 110.592 -179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.507 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.5 m-85 -57.73 82.26 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.552 -0.718 . . . . 0.0 111.634 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.15 -1.84 54.16 Favored Glycine 0 N--CA 1.493 2.437 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.684 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.885 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.1 mmtm -130.1 156.18 44.96 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.858 -1.378 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.689 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.83 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.94 -1.1 . . . . 0.0 109.427 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.9 mt -68.38 112.95 12.55 Favored Pre-proline 0 C--N 1.301 -1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 110.779 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.761 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.0 Cg_endo -68.26 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 N-CA-C 106.96 -1.977 . . . . 0.0 106.96 175.718 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.838 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.72 -16.65 6.81 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.826 -1.171 . . . . 0.0 110.652 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.83 -15.97 36.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.686 -1.259 . . . . 0.0 110.268 179.348 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.129 HG23 HG23 ' A' ' 33' ' ' ILE . 12.1 m -91.77 -25.71 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.011 -1.056 . . . . 0.0 111.213 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.129 HG23 HG23 ' A' ' 32' ' ' VAL . 27.7 pt -118.48 -25.33 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.938 -1.101 . . . . 0.0 110.199 -179.496 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.602 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.41 148.18 22.5 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 110.648 179.828 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.87 57.77 Favored Glycine 0 N--CA 1.484 1.891 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.42 -151.27 8.74 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.127 -1.511 . . . . 0.0 110.278 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.45 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.3 mtt85 -109.74 132.37 54.21 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.53 -0.982 . . . . 0.0 110.1 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.551 ' HB2' HG12 ' A' ' 81' ' ' VAL . 90.9 m-70 -140.81 152.94 45.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.087 -1.008 . . . . 0.0 110.993 -179.766 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 54.9 tp -112.03 114.17 26.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.4 -0.812 . . . . 0.0 109.994 179.622 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.85 HD12 ' CG1' ' A' ' 83' ' ' VAL . 32.8 mt -98.37 129.2 48.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.594 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.4 123.82 38.04 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.304 -0.873 . . . . 0.0 109.751 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.86 158.83 23.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 110.801 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.507 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.17 4.28 20.91 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.439 -0.788 . . . . 0.0 110.023 179.203 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.11 137.05 38.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.058 -1.026 . . . . 0.0 110.618 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.481 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.59 -42.82 67.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.485 -0.76 . . . . 0.0 110.219 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.83 -39.21 84.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.882 . . . . 0.0 110.45 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.74 -35.11 76.69 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.906 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.14 -34.1 74.47 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.537 -0.727 . . . . 0.0 109.501 179.212 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.76 -49.43 62.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.235 -0.916 . . . . 0.0 110.255 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.79 -44.64 63.64 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -0.951 . . . . 0.0 110.146 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.716 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.17 -41.65 79.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.819 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.521 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.0 -51.16 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.03 -1.044 . . . . 0.0 110.382 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.08 96.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.12 -0.988 . . . . 0.0 109.675 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.553 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.15 -44.91 83.86 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 179.485 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.7 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -55.1 -42.68 73.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.517 -0.739 . . . . 0.0 109.885 179.956 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.4 -32.09 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.007 -1.058 . . . . 0.0 108.807 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.4 -30.87 60.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.389 -0.82 . . . . 0.0 109.608 179.026 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.838 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.66 -26.17 62.43 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.833 0.825 . . . . 0.0 109.467 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.04 7.44 10.27 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.143 -1.583 . . . . 0.0 109.143 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.602 HD11 ' HB2' ' A' ' 34' ' ' LYS . 56.4 mt -108.26 143.24 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.277 -1.131 . . . . 0.0 110.349 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.93 107.56 17.78 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.924 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.655 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -122.01 144.62 48.78 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.019 -1.072 . . . . 0.0 111.643 -177.558 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.932 HG21 ' HA ' ' A' ' 73' ' ' VAL . 45.2 t -130.3 143.58 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 C-N-CA 119.976 -0.69 . . . . 0.0 109.512 179.083 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.906 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -109.49 118.36 36.41 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.95 179.094 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.462 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.65 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.26 -0.9 . . . . 0.0 110.574 -179.59 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.748 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.2 p90 -167.31 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.544 -0.723 . . . . 0.0 109.757 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.24 127.14 30.6 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.165 -0.96 . . . . 0.0 110.764 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.32 37.77 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.4 tm? -117.09 155.81 28.64 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.156 -1.203 . . . . 0.0 110.101 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.895 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.24 22.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.366 -0.834 . . . . 0.0 110.545 -179.351 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 29.5 m -62.1 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 119.061 -1.055 . . . . 0.0 109.002 179.229 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.72 -15.45 2.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.507 -0.746 . . . . 0.0 111.413 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.932 ' HA ' HG21 ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.06 23.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.072 -1.017 . . . . 0.0 109.471 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.676 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.6 pp . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.261 -0.899 . . . . 0.0 111.004 -179.362 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.422 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.7 m-20 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.873 0.845 . . . . 0.0 109.998 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 80' ' ' VAL . 8.2 p -115.06 130.91 68.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 122.152 0.977 . . . . 0.0 110.414 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 60' ' ' ILE . 6.9 m -113.0 123.04 68.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 O-C-N 121.351 -0.843 . . . . 0.0 109.104 179.052 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.661 ' O ' HD12 ' A' ' 39' ' ' LEU . 4.7 t -97.06 118.07 42.82 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 O-C-N 121.056 -1.028 . . . . 0.0 110.149 -177.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.85 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.9 m -111.19 100.3 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.809 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.462 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.46 162.64 34.99 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.765 -1.209 . . . . 0.0 111.122 -178.23 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -90.17 -139.26 0.14 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.598 -0.689 . . . . 0.0 109.4 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.41 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -86.01 48.05 1.55 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.806 -1.184 . . . . 0.0 109.99 179.706 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.454 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.24 -19.22 7.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.173 -0.955 . . . . 0.0 110.646 -179.671 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp . . . . . 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.671 179.821 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.104 0.478 . . . . 0.0 110.965 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -119.74 144.86 47.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.075 -1.016 . . . . 0.0 109.918 178.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.49 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.21 -33.44 63.39 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.502 179.334 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -162.88 163.56 26.35 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.272 -0.892 . . . . 0.0 110.913 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.19 116.58 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.331 -0.855 . . . . 0.0 110.078 179.062 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.865 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -93.37 118.41 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.178 -0.951 . . . . 0.0 109.031 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.402 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.3 t0 -126.85 160.87 29.66 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.119 -0.988 . . . . 0.0 111.454 -178.66 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.412 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 37.0 t -101.59 7.26 42.26 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.685 -0.634 . . . . 0.0 109.393 178.213 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.406 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 49.07 33.2 4.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 111.111 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.441 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p . . . . . 0 N--CA 1.492 1.627 0 O-C-N 120.877 -1.139 . . . . 0.0 110.819 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.42 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.511 0.672 . . . . 0.0 110.837 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.5 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.7 p30 -80.74 161.49 24.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -0.954 . . . . 0.0 109.664 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.44 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.32 -57.05 4.29 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.847 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.5 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -66.17 -28.34 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 120.823 -1.173 . . . . 0.0 111.729 -178.77 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.12 -56.27 6.89 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.994 -1.066 . . . . 0.0 110.715 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.457 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.55 -35.91 78.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.108 -0.995 . . . . 0.0 108.836 178.931 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.467 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.1 m -59.27 -49.48 77.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.066 -1.021 . . . . 0.0 108.598 178.815 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.74 -35.52 65.07 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.493 -0.755 . . . . 0.0 109.754 178.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.447 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.58 -44.81 63.81 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 110.844 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.457 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 2.8 ttm180 -55.01 -37.97 67.29 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.9 -1.125 . . . . 0.0 109.721 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.53 77.21 0.13 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -153.38 -49.08 0.1 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.462 -1.022 . . . . 0.0 108.522 179.51 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.542 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.7 t -93.14 143.3 26.38 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.369 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.25 15.96 5.85 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.263 -1.446 . . . . 0.0 110.405 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 25.4 mmt180 -92.9 83.02 4.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.065 -1.256 . . . . 0.0 110.106 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.12 -26.83 6.01 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.49 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.29 -166.51 0.15 Allowed Pre-proline 0 N--CA 1.488 1.456 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.61 115.02 2.44 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.025 1.013 . . . . 0.0 110.545 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.542 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.99 172.09 55.22 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.409 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mp -132.76 142.6 41.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.283 -1.128 . . . . 0.0 109.432 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.501 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.24 115.21 17.29 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.316 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.726 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.67 122.54 43.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.814 . . . . 0.0 109.213 179.505 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.406 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 50.3 p90 -117.44 149.71 40.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.036 -1.04 . . . . 0.0 110.228 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.412 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 48.8 t . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.207 -0.933 . . . . 0.0 110.079 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.661 ' N ' HD21 ' A' ' 9' ' ' ASN . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.054 0.454 . . . . 0.0 110.406 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.476 HD13 HG22 ' A' ' 122' ' ' THR . 34.0 mt -119.62 136.17 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.906 -1.121 . . . . 0.0 110.436 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.79 128.89 34.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.319 -0.863 . . . . 0.0 109.543 179.449 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.24 132.42 34.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.226 -0.921 . . . . 0.0 110.339 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.792 HG11 ' NH1' ' A' ' 131' ' ' ARG . 29.5 t -122.64 157.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.45 -0.781 . . . . 0.0 110.246 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.04 110.64 22.82 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.209 -0.932 . . . . 0.0 109.851 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.564 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -62.63 134.77 56.82 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.279 -0.888 . . . . 0.0 109.68 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.68 179.52 6.18 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.911 . . . . 0.0 110.176 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.92 74.47 2.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 109.631 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.692 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -144.55 111.61 5.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 110.576 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.48 -159.35 27.18 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.561 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.94 -24.78 5.99 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.602 -0.94 . . . . 0.0 110.522 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.921 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -95.86 108.76 42.6 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.618 -1.233 . . . . 0.0 110.492 -179.399 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.475 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.33 154.56 70.61 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.341 1.18 . . . . 0.0 109.897 179.79 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.501 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.3 t80 -167.79 95.02 0.42 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 110.891 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.463 ' HH ' ' CE1' ' A' ' 43' ' ' HIS . 66.8 m-85 60.33 65.48 1.07 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.5 -0.75 . . . . 0.0 111.188 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 15.87 16.53 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.56 ' HG3' HG13 ' A' ' 133' ' ' VAL . 3.6 mmtt -130.54 157.26 43.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.182 -1.187 . . . . 0.0 109.389 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.692 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.98 107.39 14.91 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.77 -1.206 . . . . 0.0 109.719 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.989 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -69.84 114.03 21.85 Favored Pre-proline 0 C--N 1.301 -1.523 0 O-C-N 121.294 -0.879 . . . . 0.0 110.461 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.764 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.3 Cg_endo -69.14 130.09 19.45 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 N-CA-C 106.586 -2.121 . . . . 0.0 106.586 175.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.486 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -56.16 -18.32 9.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.734 -1.228 . . . . 0.0 110.528 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.429 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.33 -15.91 19.08 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.662 -1.274 . . . . 0.0 110.693 179.68 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.079 HG23 HG23 ' A' ' 33' ' ' ILE . 12.3 m -92.46 -25.14 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 120.884 -1.135 . . . . 0.0 110.995 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.079 HG23 HG23 ' A' ' 32' ' ' VAL . 10.3 pt -116.89 -22.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 -179.403 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.53 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptt -92.67 148.46 22.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.001 -1.062 . . . . 0.0 109.97 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.71 -5.68 43.76 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.6 -152.66 11.2 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.086 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.46 131.41 52.91 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.314 -1.109 . . . . 0.0 110.292 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.55 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.41 153.73 51.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.154 -0.966 . . . . 0.0 110.943 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.526 ' HB3' HG12 ' A' ' 99' ' ' VAL . 65.5 tp -114.45 118.27 33.33 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.371 -0.83 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.865 HD12 ' CG1' ' A' ' 83' ' ' VAL . 30.2 mt -104.39 127.92 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.127 -0.983 . . . . 0.0 109.673 179.395 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -95.74 122.73 38.82 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.242 -0.911 . . . . 0.0 110.097 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.79 159.01 23.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.523 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.463 ' CE1' ' HH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.31 26.84 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 110.375 179.18 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.74 136.34 37.24 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.09 -1.007 . . . . 0.0 110.916 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.46 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.0 69.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.557 -0.714 . . . . 0.0 110.232 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.31 -36.48 84.26 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.282 -0.886 . . . . 0.0 110.421 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.82 -36.48 75.66 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.233 -0.917 . . . . 0.0 109.513 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.936 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 98.7 m -61.65 -34.05 75.03 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.439 -0.788 . . . . 0.0 109.684 179.465 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.35 -49.42 64.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.175 -0.953 . . . . 0.0 109.957 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.79 -45.66 60.87 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.097 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.668 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.1 tm? -56.49 -41.67 77.01 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.446 -0.784 . . . . 0.0 110.567 -179.411 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.416 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -76.0 -51.43 12.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.092 -1.005 . . . . 0.0 110.236 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.402 ' O ' ' HB ' ' A' ' 56' ' ' VAL . . . -61.44 -42.04 98.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.985 -1.072 . . . . 0.0 109.652 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.528 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.09 -44.39 83.09 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.167 -0.958 . . . . 0.0 109.644 179.614 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.772 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.11 -41.58 71.84 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.345 -0.847 . . . . 0.0 109.612 179.735 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 53' ' ' ALA . 78.6 t -56.27 -33.18 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.146 -0.971 . . . . 0.0 108.815 179.054 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.0 -32.05 59.23 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.5 -0.75 . . . . 0.0 110.131 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.528 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.62 -26.42 62.57 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.332 -0.855 . . . . 0.0 109.712 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.09 8.36 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.702 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.608 HG22 HG22 ' A' ' 81' ' ' VAL . 49.4 mt -108.15 143.94 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.202 -1.175 . . . . 0.0 110.32 -179.677 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 22.2 t-20 -86.84 107.1 18.16 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 178.121 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.577 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.86 147.71 45.03 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.62 -177.274 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.94 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.9 t -136.11 148.71 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.507 179.308 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.936 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.32 126.95 55.45 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.095 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.48 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 5.4 t80 -117.48 125.9 51.69 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 110.713 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.906 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.5 p90 -157.76 -174.85 5.05 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.63 123.64 11.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 0.0 111.26 -179.212 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.65 47.73 32.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.931 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.27 155.7 29.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.07 -1.253 . . . . 0.0 109.807 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.931 ' N ' HD13 ' A' ' 69' ' ' LEU . 7.7 m-20 -92.12 148.6 22.04 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.201 -0.937 . . . . 0.0 110.825 -179.18 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 71' ' ' VAL . 30.4 m -62.8 111.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.055 -1.028 . . . . 0.0 109.336 179.068 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.756 ' O ' HG23 ' A' ' 74' ' ' ILE . 10.6 m -134.58 -35.96 0.88 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.375 -0.828 . . . . 0.0 110.849 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.94 HG22 ' HB ' ' A' ' 63' ' ' VAL . 24.9 t -51.38 135.85 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.032 -1.043 . . . . 0.0 110.055 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.756 HG23 ' O ' ' A' ' 72' ' ' SER . 1.4 pp . . . . . 0 N--CA 1.495 1.776 0 O-C-N 121.263 -0.898 . . . . 0.0 110.724 -179.447 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 m-20 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.973 0.892 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.548 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -117.33 133.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 122.003 0.906 . . . . 0.0 110.347 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 60' ' ' ILE . 9.5 m -111.93 124.2 68.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.202 0 O-C-N 121.311 -0.868 . . . . 0.0 108.773 178.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.735 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -97.24 120.99 47.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 110.306 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.865 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.6 m -116.47 100.48 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.971 -1.081 . . . . 0.0 108.7 179.592 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.48 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -138.4 162.22 35.0 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.683 -1.261 . . . . 0.0 111.454 -177.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.605 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.1 t -87.24 -132.27 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.612 -0.68 . . . . 0.0 109.708 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.605 ' N ' HG23 ' A' ' 85' ' ' THR . 3.7 p30 -91.5 32.83 1.04 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.803 -1.186 . . . . 0.0 110.594 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.475 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.49 -32.96 9.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.095 -1.003 . . . . 0.0 109.887 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.85 . . . . 0.0 109.254 179.213 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.129 0.49 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -119.07 148.16 43.34 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.18 -0.95 . . . . 0.0 109.906 178.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.432 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.95 -32.25 61.68 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.272 -0.893 . . . . 0.0 109.486 179.294 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.463 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.0 p -162.51 163.79 27.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.218 -0.927 . . . . 0.0 111.207 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.564 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.47 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.452 -0.78 . . . . 0.0 110.3 179.347 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.989 HG21 HD11 ' A' ' 28' ' ' ILE . 3.1 mp -92.88 117.78 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.893 . . . . 0.0 108.795 179.145 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.19 20.5 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.07 -1.019 . . . . 0.0 112.107 -178.424 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.22 -11.66 34.81 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.412 ' ND2' ' HB2' ' A' ' 132' ' ' PHE . 3.7 m120 55.58 12.37 0.78 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.294 -0.879 . . . . 0.0 112.487 179.091 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.306 -1.295 0 O-C-N 120.491 -1.38 . . . . 0.0 109.495 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.566 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 121.332 0.587 . . . . 0.0 110.851 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.547 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -88.92 160.36 17.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.9 . . . . 0.0 109.85 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.403 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.85 -51.13 7.66 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.424 -0.798 . . . . 0.0 112.317 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.547 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.44 -29.7 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.795 -1.19 . . . . 0.0 111.447 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.443 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.08 -56.47 6.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.08 -1.013 . . . . 0.0 110.402 -179.204 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.9 OUTLIER -69.49 -34.38 74.24 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.301 -0.874 . . . . 0.0 108.688 178.756 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.458 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 22.5 m -59.22 -50.02 75.6 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.164 -0.96 . . . . 0.0 108.454 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.93 -39.52 63.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.763 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.405 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 2.2 mtt180 -67.47 -44.32 78.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.168 -0.958 . . . . 0.0 110.557 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.485 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 7.0 ttm180 -60.47 -39.06 86.25 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.026 -1.046 . . . . 0.0 110.057 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.74 66.69 0.44 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.06 -46.6 0.3 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.514 -0.992 . . . . 0.0 108.602 179.471 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.518 HG23 ' HA3' ' A' ' 128' ' ' GLY . 15.0 t -94.45 142.13 27.79 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.375 -0.828 . . . . 0.0 109.136 178.657 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.89 10.03 19.45 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.556 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.0 mmt85 -69.3 86.96 0.42 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.011 -1.288 . . . . 0.0 109.69 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.2 22.17 33.19 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.479 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.85 -178.31 0.29 Allowed Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.514 -0.992 . . . . 0.0 108.717 -179.515 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.3 Cg_endo -89.65 103.94 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.258 1.136 . . . . 0.0 110.126 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.518 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -77.61 156.84 45.09 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.605 -179.303 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 38.8 mt -111.05 142.06 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.479 -1.012 . . . . 0.0 109.046 178.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.564 ' CD2' HG23 ' A' ' 99' ' ' VAL . 5.4 t80 -132.09 118.91 20.27 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.09 -1.006 . . . . 0.0 110.785 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.792 ' NH1' HG11 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -101.51 124.04 46.52 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.454 -0.779 . . . . 0.0 109.477 179.158 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.471 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.6 p90 -118.04 155.87 29.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 110.229 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.564 HG22 HD23 ' A' ' 15' ' ' LEU . 71.1 t . . . . . 0 N--CA 1.493 1.722 0 O-C-N 121.168 -0.958 . . . . 0.0 109.869 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.454 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.8 t-20 . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.512 0.672 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.528 HD13 ' CG2' ' A' ' 122' ' ' THR . 33.0 mt -103.48 136.34 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.011 -1.056 . . . . 0.0 110.094 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.9 129.46 35.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 109.322 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.75 34.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.173 -0.954 . . . . 0.0 110.294 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.465 HG11 ' NE ' ' A' ' 131' ' ' ARG . 20.4 t -117.84 155.0 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.641 -0.662 . . . . 0.0 110.026 -179.422 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.19 106.89 17.58 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.669 HD23 HG22 ' A' ' 133' ' ' VAL . 12.5 tp -57.6 132.16 52.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.593 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.8 p -135.84 -166.95 1.94 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.192 -0.942 . . . . 0.0 110.587 -179.516 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.1 p -82.49 83.45 7.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.436 -0.79 . . . . 0.0 109.917 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.701 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 11.0 m -156.9 110.04 2.58 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.302 -0.874 . . . . 0.0 110.541 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.38 28.52 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 118.895 -1.622 . . . . 0.0 110.956 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.417 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -117.49 -24.68 7.23 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.78 -0.835 . . . . 0.0 110.404 -179.906 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.882 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -93.86 103.48 10.4 Favored Pre-proline 0 N--CA 1.485 1.303 0 C-N-CA 118.496 -1.281 . . . . 0.0 109.99 -179.342 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.61 118.76 5.66 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 O-C-N 123.682 1.359 . . . . 0.0 110.558 -179.564 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.62 -168.74 1.39 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.736 -0.602 . . . . 0.0 110.718 -178.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.435 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.09 81.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.592 -0.693 . . . . 0.0 111.71 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.4 -1.68 49.53 Favored Glycine 0 N--CA 1.495 2.625 0 C-N-CA 120.148 -1.025 . . . . 0.0 110.809 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.463 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.13 156.41 44.6 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.899 -1.353 . . . . 0.0 109.304 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.701 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.22 107.09 17.89 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.837 -1.164 . . . . 0.0 108.993 179.401 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.931 HD11 HG21 ' A' ' 100' ' ' ILE . 4.0 mt -67.37 113.58 14.65 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.798 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.3 Cg_endo -68.85 127.36 15.21 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 N-CA-C 106.828 -2.028 . . . . 0.0 106.828 175.819 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.556 HD11 HD12 ' A' ' 58' ' ' LEU . 8.7 mt -55.93 -17.98 7.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.897 -1.127 . . . . 0.0 110.791 -177.538 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.69 -16.36 26.27 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.639 -1.288 . . . . 0.0 110.26 179.666 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.035 HG23 HG23 ' A' ' 33' ' ' ILE . 12.4 m -90.97 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.008 -1.058 . . . . 0.0 110.884 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.035 HG23 HG23 ' A' ' 32' ' ' VAL . 20.3 pt -117.46 -18.64 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.996 -1.065 . . . . 0.0 110.633 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.606 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.65 148.24 23.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.867 -1.146 . . . . 0.0 110.169 179.537 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.97 36.67 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.375 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.2 -143.63 6.08 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.153 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.465 ' HG2' HG12 ' A' ' 80' ' ' VAL . 8.9 mtt85 -111.25 134.57 52.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.396 -1.061 . . . . 0.0 110.313 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.572 ' HB2' HG12 ' A' ' 81' ' ' VAL . 66.4 m80 -141.14 150.73 43.19 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.089 -1.007 . . . . 0.0 111.077 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.7 tp -110.01 115.07 29.11 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.478 -0.764 . . . . 0.0 110.013 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.824 HD12 ' CG1' ' A' ' 83' ' ' VAL . 26.6 mt -98.79 127.27 51.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.113 -0.992 . . . . 0.0 109.821 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.428 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 29.5 m-85 -95.35 124.67 39.5 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.453 -0.78 . . . . 0.0 110.084 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.66 157.77 24.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.163 -0.961 . . . . 0.0 110.642 -179.708 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.435 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 15.0 p80 -101.96 -2.95 28.61 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 110.29 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.55 46.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.111 -0.993 . . . . 0.0 110.288 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -70.59 -37.49 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.47 -0.769 . . . . 0.0 110.757 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.57 -36.06 77.57 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.172 -0.955 . . . . 0.0 110.291 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.42 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -71.63 -32.75 68.3 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.424 -0.798 . . . . 0.0 109.253 179.835 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.703 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.74 74.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.35 -0.844 . . . . 0.0 109.095 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.88 -48.86 64.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.379 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.86 -44.39 63.89 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.236 -0.915 . . . . 0.0 110.631 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.751 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -56.81 -38.94 73.28 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.459 -0.776 . . . . 0.0 111.235 -178.937 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.84 -51.36 12.72 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.868 -1.145 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -40.78 97.26 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.01 -1.056 . . . . 0.0 109.672 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.545 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.94 83.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.522 179.447 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.741 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.37 -40.99 72.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.478 -0.764 . . . . 0.0 109.978 179.937 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.3 -33.81 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.135 -0.978 . . . . 0.0 108.899 179.04 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.88 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.333 -0.854 . . . . 0.0 110.078 179.357 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.556 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.47 -25.94 62.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.426 179.609 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.0 5.67 10.59 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.606 HD11 ' HB2' ' A' ' 34' ' ' LYS . 33.7 mt -108.42 143.46 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.475 -1.015 . . . . 0.0 110.235 -179.572 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 20.3 t-20 -87.98 106.92 18.45 Favored 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.056 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.693 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -118.56 146.97 44.18 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.748 -1.181 . . . . 0.0 111.922 -177.163 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.939 HG21 ' HA ' ' A' ' 73' ' ' VAL . 19.6 t -129.32 149.34 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.706 -0.621 . . . . 0.0 109.884 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.703 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.03 123.84 50.67 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.261 -0.975 . . . . 0.0 109.861 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.45 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -114.04 134.68 54.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.923 . . . . 0.0 111.013 -179.31 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.986 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.1 p90 -171.01 -179.82 2.86 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.381 -0.825 . . . . 0.0 110.174 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.24 126.27 18.39 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.209 -0.932 . . . . 0.0 111.02 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.1 46.5 35.31 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.338 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.986 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.49 154.74 30.91 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.127 -1.219 . . . . 0.0 109.891 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.836 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.1 m-20 -93.16 149.83 20.95 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.271 -0.893 . . . . 0.0 110.651 -179.229 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.69 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.1 m -61.69 111.15 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 119.041 -1.064 . . . . 0.0 108.829 179.104 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.933 ' O ' HG23 ' A' ' 74' ' ' ILE . 74.1 m -132.42 -34.71 1.19 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 110.749 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.939 ' HA ' HG21 ' A' ' 63' ' ' VAL . 58.7 t -47.69 125.18 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.246 -0.909 . . . . 0.0 109.612 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.933 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.497 1.894 0 O-C-N 121.098 -1.001 . . . . 0.0 111.751 -178.373 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 121.995 0.903 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.9 p -117.2 134.96 59.13 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 CA-C-O 122.124 0.964 . . . . 0.0 110.084 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.596 HG22 HG22 ' A' ' 60' ' ' ILE . 5.3 m -113.99 122.05 67.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 O-C-N 121.296 -0.877 . . . . 0.0 109.229 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.766 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -96.84 117.87 42.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 120.916 -1.115 . . . . 0.0 110.308 -178.054 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.824 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -108.81 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.244 -0.982 . . . . 0.0 108.916 179.548 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.444 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.23 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.658 -1.276 . . . . 0.0 110.656 -178.744 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.04 -34.48 15.09 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 110.679 -179.151 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -178.01 -29.57 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.114 -0.991 . . . . 0.0 111.066 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.518 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -44.88 -34.09 2.22 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.178 -0.951 . . . . 0.0 111.073 -179.553 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 tp . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.087 -1.008 . . . . 0.0 109.772 179.469 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.157 0.503 . . . . 0.0 110.776 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 22.1 m-85 -119.83 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.055 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.448 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.68 -29.32 27.69 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.492 -0.755 . . . . 0.0 109.976 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.66 163.66 29.71 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -0.975 . . . . 0.0 111.351 -179.643 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.519 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.22 114.4 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.439 -0.788 . . . . 0.0 109.922 179.141 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.931 HG21 HD11 ' A' ' 28' ' ' ILE . 3.7 mp -93.0 115.64 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.244 -0.91 . . . . 0.0 109.297 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.95 160.94 25.17 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.169 -0.957 . . . . 0.0 111.53 -178.582 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.418 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.64 3.75 42.74 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.628 -0.67 . . . . 0.0 109.504 178.15 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.48 23.88 0.66 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.266 -0.896 . . . . 0.0 111.254 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.467 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 O-C-N 120.959 -1.088 . . . . 0.0 110.476 179.283 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.512 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 13.9 tt0 . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 121.62 0.724 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.416 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.3 p-10 -88.27 161.5 17.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.567 -0.708 . . . . 0.0 110.092 179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.404 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -52.31 -61.79 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.346 -0.846 . . . . 0.0 112.29 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.432 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 7.2 m -58.1 -29.79 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.765 -1.209 . . . . 0.0 112.004 -177.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.512 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.82 -56.22 7.95 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.011 -1.055 . . . . 0.0 110.489 -179.293 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.436 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.49 -33.9 76.73 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.207 -0.933 . . . . 0.0 108.941 178.94 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.432 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.0 m -60.29 -49.82 76.1 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 120.999 -1.063 . . . . 0.0 108.452 178.462 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -73.93 -38.02 64.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 178.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 40.6 mtt85 -72.16 -44.85 62.43 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.222 -0.924 . . . . 0.0 111.477 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.483 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.2 ttm180 -54.59 -45.38 73.58 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.787 -1.195 . . . . 0.0 109.495 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.28 81.71 0.03 OUTLIER Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.73 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 179.606 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.528 ' CG2' HD13 ' A' ' 10' ' ' ILE . 8.7 t -93.13 143.47 26.22 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.56 1.7 19.74 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.646 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.24 85.9 0.57 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.978 -1.307 . . . . 0.0 110.13 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.1 -38.04 2.89 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.87 -166.87 0.13 Allowed Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.508 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -86.31 114.81 1.31 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.086 1.045 . . . . 0.0 109.647 179.202 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.522 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.4 167.88 54.81 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.504 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.83 138.74 49.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.451 -1.029 . . . . 0.0 108.62 178.699 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.519 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.26 118.78 22.88 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.218 -0.993 . . . . 0.0 110.581 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.5 ' HD2' HG11 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.31 127.14 53.03 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.487 -0.758 . . . . 0.0 109.879 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.439 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 10.4 p90 -118.84 158.5 25.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.17 -0.956 . . . . 0.0 109.81 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.669 HG22 HD23 ' A' ' 15' ' ' LEU . 7.2 t . . . . . 0 N--CA 1.493 1.68 0 O-C-N 121.085 -1.009 . . . . 0.0 110.263 179.76 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.419 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.5 m120 . . . . . 0 N--CA 1.508 2.462 0 CA-C-O 120.547 0.213 . . . . 0.0 111.239 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.499 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.1 mt -116.59 135.38 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.664 -1.273 . . . . 0.0 109.488 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.417 ' N ' ' O ' ' A' ' 128' ' ' GLY . 1.5 tm-20 -86.1 127.15 34.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.8 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.407 ' HG2' ' NH2' ' A' ' 119' ' ' ARG . 47.6 mt-10 -90.43 136.65 32.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.104 -0.997 . . . . 0.0 110.03 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.493 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.2 157.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.193 -0.942 . . . . 0.0 110.044 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.63 112.21 25.2 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.188 -0.945 . . . . 0.0 110.044 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.778 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.5 tp -54.81 147.36 15.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.873 . . . . 0.0 109.282 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.53 7.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.122 -0.987 . . . . 0.0 110.533 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.13 74.62 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.345 -0.847 . . . . 0.0 109.976 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.803 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.4 m -152.41 108.8 3.42 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.322 -0.862 . . . . 0.0 110.741 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.57 -167.16 29.2 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.922 -1.608 . . . . 0.0 110.818 179.214 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.46 ' HB3' HD11 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.26 -24.85 9.58 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.664 -0.904 . . . . 0.0 110.482 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 1.018 HD12 HD13 ' A' ' 55' ' ' LEU . 9.4 tt -95.12 101.89 8.27 Favored Pre-proline 0 C--N 1.305 -1.334 0 C-N-CA 118.734 -1.187 . . . . 0.0 109.743 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.44 127.39 21.73 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.534 1.281 . . . . 0.0 111.074 -178.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 25' ' ' GLY . 6.3 t80 -117.19 -171.91 2.12 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.541 0.686 . . . . 0.0 110.695 -179.062 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.565 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.4 m-85 -57.58 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.434 -0.791 . . . . 0.0 111.688 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.02 -4.62 53.47 Favored Glycine 0 N--CA 1.493 2.495 0 O-C-N 121.229 -0.919 . . . . 0.0 110.911 178.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.778 ' HB2' HD23 ' A' ' 15' ' ' LEU . 28.3 mmtt -130.05 156.34 44.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.826 -1.397 . . . . 0.0 109.908 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.803 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.26 108.07 19.39 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.064 -1.023 . . . . 0.0 108.864 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.917 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.1 mt -68.24 112.99 12.54 Favored Pre-proline 0 C--N 1.3 -1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 110.732 -179.056 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.714 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.3 Cg_endo -68.43 130.05 20.26 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.125 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.576 ' CD2' HD11 ' A' ' 33' ' ' ILE . 12.8 mt -56.64 -17.13 7.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.772 -1.205 . . . . 0.0 110.801 -177.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.438 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.32 -16.05 19.87 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.739 -1.226 . . . . 0.0 110.476 179.955 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.064 HG23 HG23 ' A' ' 33' ' ' ILE . 9.9 m -95.16 -24.24 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.008 -1.057 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.064 HG23 HG23 ' A' ' 32' ' ' VAL . 46.2 pt -116.58 -12.17 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.919 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.643 ' HB2' HD11 ' A' ' 60' ' ' ILE . 8.9 tptm -102.12 148.29 25.57 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.831 -1.168 . . . . 0.0 110.193 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.03 -5.3 36.24 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.74 3.89 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.407 -1.377 . . . . 0.0 110.08 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.54 135.96 53.38 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.313 -1.11 . . . . 0.0 110.363 -179.736 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.576 ' HB2' HG12 ' A' ' 81' ' ' VAL . 93.6 m-70 -140.01 153.42 46.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.254 -0.904 . . . . 0.0 111.196 -179.427 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.622 ' HB3' HG12 ' A' ' 99' ' ' VAL . 60.4 tp -113.5 116.47 29.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.419 -0.801 . . . . 0.0 110.285 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.906 HD12 ' CG1' ' A' ' 83' ' ' VAL . 33.7 mt -100.93 128.1 53.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.194 -0.942 . . . . 0.0 109.568 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -95.08 123.75 38.74 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.441 -0.787 . . . . 0.0 110.238 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.94 159.92 21.71 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.217 -0.927 . . . . 0.0 110.679 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.565 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.2 p80 -105.55 -4.48 21.15 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.381 -0.824 . . . . 0.0 110.395 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.5 p -132.13 138.53 48.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.973 -1.08 . . . . 0.0 110.702 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.509 ' HD2' ' CE1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.25 -41.19 70.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.483 -0.761 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.77 72.1 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.221 -0.924 . . . . 0.0 110.59 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.41 -37.36 65.95 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.379 -0.826 . . . . 0.0 109.949 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.875 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 73.9 m -61.14 -34.35 74.87 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.273 -0.892 . . . . 0.0 109.857 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.413 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.67 -50.08 59.54 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.229 -0.919 . . . . 0.0 110.592 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.404 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 11.7 mt-10 -72.37 -40.54 67.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.191 -0.943 . . . . 0.0 110.374 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.814 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.92 -42.67 98.55 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.616 -0.678 . . . . 0.0 111.567 -178.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.64 -51.16 45.13 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.8 -1.188 . . . . 0.0 110.271 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.15 -34.43 68.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.032 -1.043 . . . . 0.0 109.183 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.532 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.24 -47.95 80.08 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.208 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 1.018 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.02 -42.45 80.43 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.531 -0.731 . . . . 0.0 110.955 -179.994 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -55.67 -28.32 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.925 -1.11 . . . . 0.0 108.753 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.62 -35.37 60.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.516 -0.74 . . . . 0.0 110.266 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.532 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.33 -26.11 61.81 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.06 7.96 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.643 HD11 ' HB2' ' A' ' 34' ' ' LYS . 50.4 mt -106.39 143.0 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.282 -1.128 . . . . 0.0 109.633 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.442 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.7 t30 -87.41 106.56 18.04 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.024 -1.472 . . . . 0.0 107.024 178.401 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.576 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.5 146.07 45.77 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.23 -0.988 . . . . 0.0 111.008 -177.704 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.698 ' HB ' HG13 ' A' ' 73' ' ' VAL . 6.1 t -138.7 149.97 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.823 -0.751 . . . . 0.0 109.303 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.875 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.01 134.84 53.32 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.713 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.657 ' CD1' HD12 ' A' ' 69' ' ' LEU . 20.4 t80 -124.96 129.27 50.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.382 -0.824 . . . . 0.0 110.274 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.814 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -154.73 -171.3 3.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.595 -0.691 . . . . 0.0 109.634 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.8 124.88 22.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.125 -0.984 . . . . 0.0 110.731 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.35 34.02 30.27 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.794 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.937 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.35 157.13 26.67 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.143 -1.21 . . . . 0.0 110.035 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.937 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.15 22.77 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.188 -0.945 . . . . 0.0 110.815 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.8 m -62.97 111.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.121 -0.987 . . . . 0.0 109.067 178.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.437 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.0 m -131.19 -11.73 3.64 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.166 -0.959 . . . . 0.0 111.494 -179.322 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.955 ' CG1' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.34 136.2 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.737 -1.227 . . . . 0.0 109.509 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.515 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.497 1.883 0 O-C-N 121.12 -0.987 . . . . 0.0 110.513 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.953 0.882 . . . . 0.0 110.181 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 5.8 p -117.06 135.11 58.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 121.904 0.859 . . . . 0.0 110.359 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.593 HG22 HG22 ' A' ' 60' ' ' ILE . 7.1 m -112.95 122.5 67.2 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.955 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.6 t -96.83 117.65 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.019 -1.051 . . . . 0.0 110.097 -177.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.906 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.3 m -111.43 99.74 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.075 -1.016 . . . . 0.0 108.828 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.479 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.13 159.84 41.2 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.646 -1.283 . . . . 0.0 111.27 -178.189 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.509 HG23 ' N ' ' A' ' 86' ' ' ASP . 7.8 t -82.33 -130.45 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.618 -0.676 . . . . 0.0 109.515 179.746 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.509 ' N ' HG23 ' A' ' 85' ' ' THR . 0.3 OUTLIER -93.82 27.82 2.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.595 -1.315 . . . . 0.0 110.225 179.94 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.476 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.11 -35.76 12.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 110.133 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.3 tp . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.644 179.643 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.7 t0 . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 120.974 0.416 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -120.05 151.57 38.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.079 -1.013 . . . . 0.0 110.315 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.443 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.42 -30.96 33.36 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.33 178.983 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.457 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.9 163.94 28.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.377 -0.827 . . . . 0.0 111.197 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.628 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.44 115.38 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.557 -0.714 . . . . 0.0 109.796 179.002 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.859 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -93.11 117.62 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.241 -0.912 . . . . 0.0 109.113 179.495 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.439 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.9 t0 -122.5 161.18 24.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.937 . . . . 0.0 111.559 -178.499 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.423 ' HG ' ' CB ' ' A' ' 24' ' ' TYR . 20.7 t -103.47 8.42 37.87 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.257 -0.902 . . . . 0.0 110.713 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.4 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.73 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.454 0.645 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.578 ' OD2' HG22 ' A' ' 113' ' ' VAL . 3.6 p-10 -92.73 162.57 14.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.479 -0.763 . . . . 0.0 110.382 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -50.55 -49.38 56.17 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.831 -1.168 . . . . 0.0 111.868 -178.675 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.578 HG22 ' OD2' ' A' ' 111' ' ' ASP . 5.8 m -72.63 -30.62 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.601 -1.312 . . . . 0.0 113.283 -177.825 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.88 -54.7 34.95 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.293 -1.504 . . . . 0.0 110.096 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.27 -35.97 78.76 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 118.363 -1.335 . . . . 0.0 108.164 178.363 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.411 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 83.0 m -60.79 -49.97 75.34 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.77 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.8 tp-100 -73.68 -46.45 46.32 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.86 178.826 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.0 mtt-85 -58.25 -46.08 86.63 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 110.466 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.478 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.1 ttm180 -58.21 -39.85 80.1 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.847 -1.158 . . . . 0.0 109.485 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.56 68.81 0.4 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -146.22 -45.95 0.2 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.425 -1.044 . . . . 0.0 108.743 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.563 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.9 t -94.34 142.33 27.54 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.4 5.7 11.17 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.547 179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.403 ' CD ' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -76.2 84.53 3.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.947 -1.325 . . . . 0.0 110.171 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.93 -43.58 1.66 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.474 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.22 -169.31 0.17 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.499 -1.001 . . . . 0.0 108.662 179.565 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -87.72 110.67 0.73 Allowed 'Trans proline' 0 C--N 1.309 -1.529 0 O-C-N 123.274 1.144 . . . . 0.0 109.452 178.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.563 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.62 146.58 32.89 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.483 HD12 ' N ' ' A' ' 129' ' ' ILE . 2.9 mp -106.35 141.15 22.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.859 -1.377 . . . . 0.0 109.301 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.628 ' CD2' HG23 ' A' ' 99' ' ' VAL . 4.4 t80 -127.87 115.35 18.46 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.105 -0.997 . . . . 0.0 110.41 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.493 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mmt180 -102.06 123.39 45.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.498 -0.752 . . . . 0.0 109.632 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.439 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 25.7 p90 -115.23 157.84 23.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.022 -1.049 . . . . 0.0 110.059 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.09 -1.006 . . . . 0.0 109.76 179.507 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 19.6 m-80 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.159 0.504 . . . . 0.0 109.931 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.482 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 11.7 mt -128.44 137.64 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.952 -1.093 . . . . 0.0 109.343 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.67 128.24 34.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.102 -0.999 . . . . 0.0 109.39 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.59 127.99 35.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.109 -0.994 . . . . 0.0 110.198 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.818 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 15.7 t -122.93 155.4 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.286 -0.884 . . . . 0.0 110.206 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.05 110.46 22.59 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.295 -0.878 . . . . 0.0 109.925 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.538 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.67 134.72 54.89 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 110.005 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 17.7 p -135.37 171.5 14.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.256 -0.902 . . . . 0.0 110.214 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.53 69.96 0.17 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 110.153 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.577 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.4 m -140.54 112.29 7.53 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.28 -0.887 . . . . 0.0 110.392 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.74 -163.28 26.94 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.542 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.2 -22.33 7.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.666 -0.902 . . . . 0.0 110.518 179.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.914 HD12 HD13 ' A' ' 55' ' ' LEU . 9.0 tt -97.41 107.06 36.64 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 120.839 -1.163 . . . . 0.0 110.28 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.511 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.91 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.318 1.167 . . . . 0.0 110.088 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.55 93.73 0.2 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.191 -0.943 . . . . 0.0 110.96 -178.522 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.25 68.56 0.76 Allowed 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.526 -0.733 . . . . 0.0 111.251 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.76 15.38 9.15 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.538 ' CB ' HD23 ' A' ' 15' ' ' LEU . 5.2 mmpt? -130.67 156.21 45.29 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.028 -1.278 . . . . 0.0 109.243 179.638 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.577 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.79 107.51 15.14 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 109.348 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.913 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -69.83 113.91 20.95 Favored Pre-proline 0 C--N 1.298 -1.654 0 O-C-N 121.474 -0.766 . . . . 0.0 110.688 -179.235 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.8 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.9 Cg_endo -70.18 130.81 19.45 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 106.443 -2.176 . . . . 0.0 106.443 175.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.673 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.1 mt -55.92 -18.41 8.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.718 -1.238 . . . . 0.0 110.518 -177.716 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.489 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -59.75 -16.16 25.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.771 -1.205 . . . . 0.0 110.484 179.655 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.051 HG23 HG23 ' A' ' 33' ' ' ILE . 13.3 m -92.03 -25.04 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.976 -1.078 . . . . 0.0 110.93 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.051 HG23 HG23 ' A' ' 32' ' ' VAL . 42.2 pt -117.06 -17.48 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.079 -1.013 . . . . 0.0 110.622 -179.391 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.569 ' HB2' HD11 ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.49 22.84 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.947 -1.095 . . . . 0.0 110.262 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.05 -7.56 27.24 Favored Glycine 0 N--CA 1.485 1.947 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.02 3.21 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.149 -1.5 . . . . 0.0 110.342 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.435 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -111.99 129.95 56.02 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.353 -1.086 . . . . 0.0 110.232 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.603 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.63 146.94 46.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.06 -1.025 . . . . 0.0 110.953 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 36.8 tp -109.65 115.66 30.3 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.475 -0.765 . . . . 0.0 110.216 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.94 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.8 mt -98.96 127.67 51.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.15 -0.969 . . . . 0.0 109.465 179.284 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.401 ' CE2' ' HA ' ' A' ' 118' ' ' ARG . 4.2 m-85 -94.88 122.62 37.7 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.556 -0.715 . . . . 0.0 110.518 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.2 31.24 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.344 -0.847 . . . . 0.0 110.581 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.3 p80 -109.31 8.17 25.48 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.245 -0.91 . . . . 0.0 109.478 178.363 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.93 135.95 41.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.13 -0.981 . . . . 0.0 110.316 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.531 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.94 -42.37 66.7 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.55 -0.719 . . . . 0.0 110.818 -179.687 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.63 -36.51 74.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.345 -0.847 . . . . 0.0 110.428 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.413 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -72.29 -36.28 68.9 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.482 -0.761 . . . . 0.0 109.809 -179.781 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.83 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 2.2 m -60.89 -34.04 74.03 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.359 -0.838 . . . . 0.0 109.77 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.34 -49.31 56.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.268 -0.895 . . . . 0.0 110.672 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.56 -43.85 65.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.208 -0.933 . . . . 0.0 110.383 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.702 HD12 HG11 ' A' ' 83' ' ' VAL . 1.5 tm? -56.34 -41.14 75.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.422 -0.799 . . . . 0.0 110.909 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.21 -51.41 13.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 110.372 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.75 -43.86 98.02 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.055 -1.028 . . . . 0.0 109.582 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.516 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -56.83 -43.84 81.45 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.309 -0.87 . . . . 0.0 109.549 179.528 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.914 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.46 -42.89 74.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.444 -0.785 . . . . 0.0 109.704 179.592 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.8 t -55.84 -30.78 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.133 -0.98 . . . . 0.0 108.71 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -76.15 -33.32 59.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.574 -0.703 . . . . 0.0 110.121 179.126 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.558 ' HB3' HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.74 -26.37 62.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 109.614 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.97 5.64 8.05 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.673 ' CD1' HD22 ' A' ' 30' ' ' LEU . 19.8 mt -108.29 143.57 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.199 -1.177 . . . . 0.0 110.235 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.5 t30 -86.12 107.34 17.8 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.199 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.628 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.96 146.92 46.67 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.002 -1.079 . . . . 0.0 112.064 -177.151 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.943 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.2 t -135.92 150.29 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.66 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.83 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.69 131.82 55.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.222 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.483 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -120.82 123.42 42.54 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.933 . . . . 0.0 110.731 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.855 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.1 p90 -155.2 178.43 10.22 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.641 179.546 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -52.36 128.17 24.58 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.071 -1.018 . . . . 0.0 110.63 -179.357 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.25 39.27 31.99 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.951 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -117.02 155.63 28.88 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.124 -1.221 . . . . 0.0 109.777 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.951 ' N ' HD13 ' A' ' 69' ' ' LEU . 27.0 m-20 -95.39 149.15 21.7 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.272 -0.893 . . . . 0.0 110.884 -179.125 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.677 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.7 m -62.21 111.4 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.061 -1.024 . . . . 0.0 108.873 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.78 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.2 m -134.33 -36.06 0.9 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.895 . . . . 0.0 110.888 -179.11 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.943 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.6 t -50.91 134.7 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.195 -0.941 . . . . 0.0 109.851 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.78 HG23 ' O ' ' A' ' 72' ' ' SER . 1.8 pp . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.219 -0.926 . . . . 0.0 110.905 -179.363 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 122.033 0.921 . . . . 0.0 110.072 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.45 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.6 p -116.85 134.94 58.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 CA-C-O 121.969 0.89 . . . . 0.0 109.855 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 60' ' ' ILE . 16.0 m -113.34 124.45 69.99 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.341 0 O-C-N 121.422 -0.799 . . . . 0.0 109.484 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.742 HG22 ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.4 117.25 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.096 -1.003 . . . . 0.0 109.934 -178.61 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.94 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -112.08 100.07 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.986 -1.071 . . . . 0.0 108.625 179.697 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.9 162.24 35.64 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.752 -1.218 . . . . 0.0 110.943 -178.149 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.513 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -91.35 -133.15 0.12 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.627 -0.671 . . . . 0.0 109.24 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.513 ' N ' HG23 ' A' ' 85' ' ' THR . 46.5 p-10 -88.42 43.33 1.12 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.663 -1.273 . . . . 0.0 110.342 179.709 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.473 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.79 -30.29 6.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 110.144 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.041 -1.037 . . . . 0.0 109.28 179.421 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 120.902 0.382 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -119.74 153.18 36.04 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.066 . . . . 0.0 110.139 178.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.91 -26.99 25.26 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.386 -0.821 . . . . 0.0 109.551 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.8 p -162.52 163.63 27.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 111.432 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.485 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -134.0 126.21 49.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.479 -0.763 . . . . 0.0 109.718 179.114 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.913 HG21 HD11 ' A' ' 28' ' ' ILE . 2.8 mp -105.51 111.54 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.088 -1.007 . . . . 0.0 109.117 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.422 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -121.58 161.0 23.17 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.249 -0.907 . . . . 0.0 111.565 -178.864 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.1 t -96.26 -6.91 36.86 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 177.781 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.76 11.01 1.21 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.37 -0.831 . . . . 0.0 112.225 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.31 -1.123 0 O-C-N 120.537 -1.352 . . . . 0.0 109.509 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.427 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.315 0.579 . . . . 0.0 110.956 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.54 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -83.53 161.4 21.23 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.298 -0.876 . . . . 0.0 110.062 179.69 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.442 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.53 -61.88 1.25 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.435 -0.791 . . . . 0.0 112.172 -178.822 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.54 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.1 m -60.41 -29.31 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.742 -1.224 . . . . 0.0 111.692 -178.652 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.21 -56.49 6.6 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.01 -1.056 . . . . 0.0 110.749 -178.812 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.03 76.88 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.124 -0.985 . . . . 0.0 108.668 178.947 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.2 m -60.49 -50.03 75.18 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.109 -0.995 . . . . 0.0 108.368 178.576 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.24 63.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.477 -0.764 . . . . 0.0 110.184 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.401 ' HA ' ' CE2' ' A' ' 41' ' ' PHE . 10.8 mtt85 -71.2 -44.31 65.68 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.119 -0.988 . . . . 0.0 111.138 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.462 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 11.8 ttp180 -70.46 -40.0 73.96 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.999 -1.063 . . . . 0.0 109.975 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.96 63.33 0.71 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -137.12 -45.93 0.57 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.144 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.452 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.1 t -95.16 142.29 27.78 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.316 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.467 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.2 17.33 51.01 Favored Glycine 0 N--CA 1.484 1.887 0 C-N-CA 119.528 -1.32 . . . . 0.0 110.356 178.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.07 -37.86 55.21 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.059 -1.26 . . . . 0.0 109.705 179.666 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.0 28.59 2.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.475 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.6 -168.25 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.694 -0.886 . . . . 0.0 109.123 -179.415 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.48 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 49.6 Cg_endo -86.66 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.167 1.088 . . . . 0.0 110.556 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -80.09 157.67 41.35 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -106.85 141.59 21.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.041 -1.27 . . . . 0.0 109.105 178.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.485 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.9 t80 -130.07 114.81 16.23 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.07 -1.052 . . . . 0.0 110.227 179.392 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.818 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -101.5 122.15 43.27 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.428 -0.795 . . . . 0.0 109.656 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.422 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 14.3 p90 -120.24 154.54 34.74 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.896 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.432 HG13 ' HG3' ' A' ' 26' ' ' LYS . 75.4 t . . . . . 0 N--CA 1.492 1.66 0 O-C-N 121.205 -0.934 . . . . 0.0 110.235 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 . . . . . 0 N--CA 1.501 2.108 0 CA-C-O 120.8 0.333 . . . . 0.0 111.221 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.729 HG12 HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.55 126.23 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.674 -1.266 . . . . 0.0 109.313 179.136 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.78 127.59 34.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.942 179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.47 136.18 33.22 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.209 -0.932 . . . . 0.0 110.104 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.462 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.2 t -129.71 154.95 41.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.368 -0.832 . . . . 0.0 109.925 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.5 112.87 25.98 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.109 -0.994 . . . . 0.0 110.389 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.614 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.8 tp -59.31 140.52 55.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.368 -0.833 . . . . 0.0 109.19 179.308 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.33 -178.24 5.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 110.508 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 72.0 p -76.99 59.9 1.73 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.077 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 10.0 m -132.45 109.34 9.74 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.269 -0.895 . . . . 0.0 110.714 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.17 -167.2 28.98 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 118.85 -1.643 . . . . 0.0 110.687 179.204 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.54 -18.86 10.83 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.667 -0.902 . . . . 0.0 110.304 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -99.34 104.51 27.25 Favored Pre-proline 0 N--CA 1.49 1.533 0 C-N-CA 118.771 -1.172 . . . . 0.0 109.876 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.449 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.2 Cg_endo -63.55 128.51 22.54 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.336 1.177 . . . . 0.0 111.009 -179.109 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.442 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.95 1.17 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.779 -0.576 . . . . 0.0 109.882 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.1 m-85 -58.11 82.21 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.219 -0.926 . . . . 0.0 111.605 -179.236 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.12 0.52 52.7 Favored Glycine 0 N--CA 1.494 2.566 0 O-C-N 121.156 -0.965 . . . . 0.0 110.888 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.614 ' HB2' HD23 ' A' ' 15' ' ' LEU . 27.3 mmtp -130.51 156.99 43.88 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.877 -1.367 . . . . 0.0 109.538 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -108.23 107.64 18.34 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 120.977 -1.077 . . . . 0.0 109.474 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.893 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -67.08 113.43 13.42 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.34 -0.85 . . . . 0.0 110.757 -179.344 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.817 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.4 Cg_endo -68.52 130.99 22.01 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 N-CA-C 106.874 -2.01 . . . . 0.0 106.874 176.012 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.747 HD11 HD12 ' A' ' 58' ' ' LEU . 10.7 mt -56.24 -17.61 8.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.816 -1.178 . . . . 0.0 110.728 -177.815 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -59.9 -16.41 29.25 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.64 -1.287 . . . . 0.0 110.518 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.051 HG23 HG23 ' A' ' 33' ' ' ILE . 13.6 m -93.09 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.005 -1.059 . . . . 0.0 111.213 -179.552 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.051 HG23 HG23 ' A' ' 32' ' ' VAL . 18.9 pt -119.45 -21.45 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.031 -1.043 . . . . 0.0 110.639 -179.288 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.566 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.79 148.28 22.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.89 -1.131 . . . . 0.0 110.317 179.46 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.14 -3.9 60.38 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.579 -1.409 . . . . 0.0 109.579 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.3 -158.65 21.45 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.465 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.75 132.38 50.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -1.069 . . . . 0.0 110.654 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.82 147.02 40.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.181 -0.949 . . . . 0.0 110.523 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.08 122.22 46.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.341 -0.849 . . . . 0.0 110.08 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.894 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.3 mm -100.56 126.08 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.271 -0.893 . . . . 0.0 109.186 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.454 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.2 m-85 -96.5 121.41 38.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.105 -0.997 . . . . 0.0 110.025 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.36 28.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.277 -0.889 . . . . 0.0 110.511 179.527 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.1 37.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.284 -0.885 . . . . 0.0 110.079 178.71 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.97 135.39 46.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.067 -1.021 . . . . 0.0 110.459 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.474 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.43 65.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.662 -0.649 . . . . 0.0 110.906 -179.761 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.31 -32.77 73.13 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.36 -0.837 . . . . 0.0 110.843 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.33 65.71 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.399 -0.813 . . . . 0.0 109.9 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.876 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.6 m -61.13 -38.52 86.66 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.592 179.154 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.4 -49.16 70.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.128 -0.983 . . . . 0.0 110.531 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.416 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -72.05 -46.29 57.54 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.239 -0.913 . . . . 0.0 110.608 -179.701 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.776 HD21 HD11 ' A' ' 21' ' ' ILE . 3.0 tm? -56.73 -41.09 76.87 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.459 -0.776 . . . . 0.0 111.42 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.36 -51.08 60.81 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.851 -1.156 . . . . 0.0 109.759 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.8 -32.5 69.4 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.236 -0.915 . . . . 0.0 109.347 179.253 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.849 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -61.72 -33.67 74.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.573 -0.704 . . . . 0.0 109.352 179.63 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.822 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.91 -42.44 57.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.423 -0.798 . . . . 0.0 110.397 -179.911 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.07 -33.03 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.048 -1.033 . . . . 0.0 109.189 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.43 -32.95 60.87 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.502 -0.749 . . . . 0.0 109.918 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.849 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.5 mm? -71.96 -26.37 62.24 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.947 0.88 . . . . 0.0 109.981 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.81 3.06 10.21 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.289 -1.525 . . . . 0.0 109.289 -179.251 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.619 HG22 HG22 ' A' ' 81' ' ' VAL . 31.2 mt -103.88 143.96 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.356 -1.085 . . . . 0.0 109.955 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.477 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 2.2 t-20 -88.68 106.87 18.62 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.178 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.544 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.92 145.28 44.77 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 118.868 -1.133 . . . . 0.0 111.739 -177.2 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.888 HG21 ' HA ' ' A' ' 73' ' ' VAL . 70.5 t -129.22 152.74 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.084 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.876 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -118.67 117.33 28.66 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.156 -1.018 . . . . 0.0 109.237 177.67 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -105.76 127.48 53.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.172 -0.955 . . . . 0.0 110.826 -179.256 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.925 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 10.0 p90 -155.58 -178.66 7.44 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.503 -0.748 . . . . 0.0 110.096 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.35 127.41 22.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.171 -0.956 . . . . 0.0 110.834 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.23 53.1 23.6 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.925 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.42 154.44 31.35 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.211 -1.17 . . . . 0.0 109.794 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.7 m-20 -91.21 149.37 21.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.229 -0.919 . . . . 0.0 110.427 -179.297 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.685 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.2 m -61.69 110.65 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.024 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.771 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.5 m -132.2 -38.72 1.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.759 . . . . 0.0 109.973 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.888 ' HA ' HG21 ' A' ' 63' ' ' VAL . 95.3 t -49.5 133.32 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.39 -0.819 . . . . 0.0 109.484 179.642 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.771 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.493 1.7 0 O-C-N 120.99 -1.069 . . . . 0.0 110.398 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.878 0.846 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 74' ' ' ILE . 6.3 p -116.68 135.13 57.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 122.013 0.911 . . . . 0.0 110.286 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.83 HG11 ' HB ' ' A' ' 33' ' ' ILE . 9.9 m -113.0 121.23 64.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 O-C-N 121.242 -0.911 . . . . 0.0 108.877 179.2 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.753 HG22 HG13 ' A' ' 73' ' ' VAL . 15.1 t -97.82 120.04 46.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 O-C-N 120.788 -1.195 . . . . 0.0 111.257 -177.612 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.894 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.8 m -111.26 99.0 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 122.361 1.077 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.45 155.04 46.35 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 120.514 -1.366 . . . . 0.0 110.526 -178.775 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.53 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.87 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.222 -0.923 . . . . 0.0 110.663 -179.322 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.53 ' N ' HG23 ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.77 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.123 -0.986 . . . . 0.0 110.608 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.587 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -101.04 -33.92 9.96 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.039 179.362 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 5.3 tp . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.597 -0.689 . . . . 0.0 109.341 178.805 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.163 0.506 . . . . 0.0 110.643 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -113.43 150.89 32.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.172 -0.955 . . . . 0.0 109.81 179.489 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.502 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.2 -32.58 56.07 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.369 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.465 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.2 p -161.45 163.06 30.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.203 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.561 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.29 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.389 -0.819 . . . . 0.0 110.031 179.264 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.893 HG21 HD11 ' A' ' 28' ' ' ILE . 3.3 mp -93.44 112.82 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.264 -0.898 . . . . 0.0 108.584 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.424 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.93 161.35 20.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 111.52 -178.269 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.452 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 58.5 m -88.86 -13.32 39.51 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.15 10.63 1.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.295 -0.878 . . . . 0.0 112.073 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.306 -1.297 0 O-C-N 120.755 -1.216 . . . . 0.0 109.133 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.472 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 121.366 0.603 . . . . 0.0 111.544 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.523 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -87.47 160.78 18.15 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.466 -0.771 . . . . 0.0 110.359 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.02 -55.34 3.21 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.647 -0.658 . . . . 0.0 112.553 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.523 HG22 ' OD1' ' A' ' 111' ' ' ASP . 9.3 m -70.62 -29.64 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.705 -1.247 . . . . 0.0 111.838 -178.197 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.472 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.49 -56.28 7.37 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.129 -0.982 . . . . 0.0 110.553 -179.243 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.426 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.2 -35.08 77.43 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.465 -0.894 . . . . 0.0 108.786 178.905 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.507 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 99.6 m -59.14 -49.8 76.47 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.537 178.832 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -73.28 -36.04 66.24 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.494 -0.754 . . . . 0.0 109.98 179.022 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.414 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 8.8 mtt85 -71.9 -44.98 62.81 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.262 -0.899 . . . . 0.0 111.118 -179.494 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 0.8 OUTLIER -64.36 -36.62 84.71 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.984 -1.072 . . . . 0.0 110.318 -179.873 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.43 0.76 Allowed Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.443 ' HB3' HG11 ' A' ' 99' ' ' VAL . 0.0 OUTLIER -135.51 -43.02 0.69 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.411 -1.053 . . . . 0.0 109.206 179.489 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.729 HG23 HG12 ' A' ' 10' ' ' ILE . 14.8 t -102.32 141.77 34.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.561 -0.712 . . . . 0.0 109.632 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.451 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.16 10.81 14.8 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.502 -1.332 . . . . 0.0 110.15 179.761 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.11 84.71 1.82 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.956 -1.32 . . . . 0.0 109.876 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 96.33 16.13 38.66 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.468 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.89 0.22 Allowed Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.259 -1.142 . . . . 0.0 109.378 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.468 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.2 Cg_endo -88.06 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 O-C-N 123.349 1.183 . . . . 0.0 110.412 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -79.26 160.05 45.64 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.49 142.75 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.417 -1.049 . . . . 0.0 108.779 178.883 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.561 ' CD2' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -129.91 117.27 19.87 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 120.953 -1.092 . . . . 0.0 111.016 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.462 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 22.2 mtt180 -101.42 123.5 45.58 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.548 -0.72 . . . . 0.0 109.331 179.22 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.415 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.19 156.24 26.87 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.041 -1.037 . . . . 0.0 110.533 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.437 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 4.6 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.171 -0.956 . . . . 0.0 109.392 179.451 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.554 0.692 . . . . 0.0 109.365 . . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.485 HD13 HG22 ' A' ' 122' ' ' THR . 14.6 mt -96.73 133.73 37.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.935 -1.103 . . . . 0.0 110.203 179.816 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -84.2 128.14 34.38 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.35 -0.844 . . . . 0.0 109.541 179.19 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -89.4 121.5 31.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.069 -1.02 . . . . 0.0 109.9 -179.573 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.783 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 4.8 t -115.69 156.63 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.368 -0.833 . . . . 0.0 110.222 -179.34 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.77 105.07 15.17 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.281 -0.887 . . . . 0.0 109.625 179.078 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.651 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -54.15 132.51 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.35 -0.844 . . . . 0.0 109.658 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.51 -174.7 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 110.256 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.94 63.43 3.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 110.041 179.835 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.501 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.0 m -132.07 112.08 12.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.337 -0.852 . . . . 0.0 110.244 -179.834 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.21 -163.41 26.72 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 119.158 -1.496 . . . . 0.0 110.455 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.39 -22.5 5.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.525 -0.985 . . . . 0.0 110.729 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.9 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -93.94 113.24 60.04 Favored Pre-proline 0 N--CA 1.487 1.417 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.064 -179.5 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.9 Cg_endo -64.23 150.76 87.68 Favored 'Trans proline' 0 C--N 1.313 -1.309 0 O-C-N 123.519 1.273 . . . . 0.0 110.026 -179.824 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.479 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.95 88.84 0.62 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.137 -0.977 . . . . 0.0 111.374 -178.477 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.514 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.14 67.18 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.349 -0.845 . . . . 0.0 111.26 179.146 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.03 13.75 21.29 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.708 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.36 156.16 45.17 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.063 -1.257 . . . . 0.0 109.366 179.738 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.501 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.47 106.97 15.57 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.918 -1.114 . . . . 0.0 109.279 179.74 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.898 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.47 114.11 21.83 Favored Pre-proline 0 C--N 1.3 -1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 110.384 -179.307 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.881 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.7 Cg_endo -70.67 129.98 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 N-CA-C 107.024 -1.952 . . . . 0.0 107.024 176.364 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.862 HD11 HD12 ' A' ' 58' ' ' LEU . 15.7 mt -56.62 -17.49 8.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.939 -1.101 . . . . 0.0 110.744 -177.942 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.477 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -60.86 -16.19 38.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.817 -1.177 . . . . 0.0 110.347 179.503 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.1 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -93.77 -25.35 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.003 -1.061 . . . . 0.0 111.15 -179.348 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.1 HG23 HG23 ' A' ' 32' ' ' VAL . 46.0 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 110.472 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.03 147.86 24.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.256 -0.902 . . . . 0.0 110.429 179.898 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.36 -5.63 38.49 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.95 -145.62 7.11 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.198 -1.477 . . . . 0.0 110.44 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.1 mtt85 -108.53 132.67 53.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.415 -1.05 . . . . 0.0 110.264 -179.696 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -140.71 150.56 43.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.023 -1.048 . . . . 0.0 111.031 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.591 HD12 ' O ' ' A' ' 82' ' ' VAL . 62.1 tp -110.98 114.29 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.447 -0.783 . . . . 0.0 109.947 179.565 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.919 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.2 mt -98.75 127.15 51.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.131 -0.981 . . . . 0.0 109.493 179.689 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.403 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 6.9 m-85 -95.44 124.01 39.26 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.172 -0.955 . . . . 0.0 110.143 -179.78 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.76 21.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.202 -0.936 . . . . 0.0 110.494 -179.688 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.514 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.2 p80 -107.02 -1.41 22.17 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.352 -0.843 . . . . 0.0 110.073 179.03 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.91 136.8 42.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.1 -1.0 . . . . 0.0 110.465 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.469 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.72 -38.27 70.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.466 -0.771 . . . . 0.0 110.663 -179.848 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.86 -35.6 73.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.333 -0.854 . . . . 0.0 110.453 -179.636 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.43 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.68 -35.83 65.24 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.79 -179.958 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.904 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 76.3 m -61.2 -34.01 74.4 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.415 -0.803 . . . . 0.0 109.757 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.7 -50.17 53.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 110.245 -179.841 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.32 -43.5 64.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.288 -0.882 . . . . 0.0 110.065 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.694 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -57.12 -42.51 81.03 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.602 -0.686 . . . . 0.0 111.248 -178.994 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.03 -51.09 42.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.796 -1.19 . . . . 0.0 110.013 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.24 -34.62 68.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.272 -0.893 . . . . 0.0 109.25 179.462 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.587 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.81 -46.39 84.74 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.274 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.9 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.78 -43.35 94.43 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.39 -0.819 . . . . 0.0 110.999 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.4 t -56.11 -34.14 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.966 -1.084 . . . . 0.0 109.375 179.617 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.51 -34.46 60.82 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.297 -0.877 . . . . 0.0 110.315 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.862 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.35 -25.84 62.56 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.285 -0.884 . . . . 0.0 109.699 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.2 7.86 8.18 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.633 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.622 ' CD1' HD22 ' A' ' 30' ' ' LEU . 47.0 mt -108.47 143.48 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.254 -1.145 . . . . 0.0 110.119 -179.756 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.504 ' OD1' HD11 ' A' ' 74' ' ' ILE . 1.0 OUTLIER -89.25 106.53 18.5 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.168 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.656 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.48 145.21 45.45 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.977 -1.089 . . . . 0.0 111.629 -177.244 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.893 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.95 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.066 -0.653 . . . . 0.0 109.454 179.719 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.904 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.2 122.52 47.09 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.585 178.818 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.475 ' CD1' HD12 ' A' ' 69' ' ' LEU . 0.4 OUTLIER -109.52 131.35 55.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.262 -0.899 . . . . 0.0 110.809 -179.534 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.907 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.24 178.32 5.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.563 -0.711 . . . . 0.0 109.905 179.644 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.55 125.52 20.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.045 -1.035 . . . . 0.0 110.814 -179.366 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.83 40.93 13.44 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.743 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.907 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.38 157.02 26.89 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -1.14 . . . . 0.0 110.322 -179.831 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.884 ' N ' HD13 ' A' ' 69' ' ' LEU . 21.8 m-20 -98.48 149.33 22.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.281 -0.887 . . . . 0.0 110.571 -179.378 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.5 m -62.33 111.36 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.036 . . . . 0.0 109.311 179.123 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.72 ' O ' HG23 ' A' ' 74' ' ' ILE . 43.8 m -134.31 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.52 -0.737 . . . . 0.0 110.368 -179.415 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.909 HG13 HG22 ' A' ' 82' ' ' VAL . 76.9 t -46.47 131.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.489 -0.757 . . . . 0.0 110.685 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.721 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.3 pp . . . . . 0 N--CA 1.495 1.802 0 O-C-N 121.166 -0.958 . . . . 0.0 110.659 179.408 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 122.083 0.944 . . . . 0.0 109.954 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.721 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -116.39 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-O 121.899 0.857 . . . . 0.0 110.199 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.613 HG22 HG22 ' A' ' 60' ' ' ILE . 10.1 m -111.91 123.35 67.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.159 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.909 HG22 HG13 ' A' ' 73' ' ' VAL . 33.2 t -96.62 118.11 42.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.061 -1.025 . . . . 0.0 110.612 -178.062 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.919 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.2 m -111.75 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 118.93 -1.108 . . . . 0.0 108.756 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.434 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -131.44 156.46 45.58 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 120.69 -1.256 . . . . 0.0 110.339 -178.606 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.551 HG23 ' OD2' ' A' ' 86' ' ' ASP . 9.0 t -94.07 -30.46 14.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.367 -0.833 . . . . 0.0 111.471 -178.583 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.551 ' OD2' HG23 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.56 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.931 -1.106 . . . . 0.0 111.529 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.616 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.79 -39.95 12.76 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.958 -1.089 . . . . 0.0 110.163 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.9 tp . . . . . 0 N--CA 1.488 1.45 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.213 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 120.964 0.411 . . . . 0.0 110.344 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -120.22 135.55 54.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.04 -1.037 . . . . 0.0 110.381 179.868 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.508 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.14 -27.75 57.15 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.556 179.22 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.514 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.0 p -160.38 163.0 33.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.29 -0.881 . . . . 0.0 110.54 179.501 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.415 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.82 115.9 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.228 -0.92 . . . . 0.0 110.336 179.66 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.823 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -93.44 114.63 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.6 161.31 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.09 -1.006 . . . . 0.0 111.829 -178.151 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.26 9.09 38.28 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.946 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.421 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 52.35 23.18 2.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.194 -0.941 . . . . 0.0 110.97 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 110.657 179.584 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.468 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.199 0.523 . . . . 0.0 110.722 . . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.414 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -84.96 161.0 19.96 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.154 -0.966 . . . . 0.0 110.085 179.605 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.417 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.26 -57.45 2.98 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.517 -0.74 . . . . 0.0 112.433 -178.531 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.474 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.2 m -68.6 -29.39 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 120.688 -1.257 . . . . 0.0 111.847 -178.143 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.468 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.21 -56.23 7.07 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.039 -1.038 . . . . 0.0 110.545 -179.263 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.476 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.7 ptm180 -70.43 -35.15 73.22 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.377 -0.929 . . . . 0.0 108.873 179.073 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.474 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.9 m -58.98 -49.55 77.47 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.04 -1.037 . . . . 0.0 108.371 178.637 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.78 -35.85 64.98 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.394 -0.816 . . . . 0.0 109.863 178.704 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.476 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.69 -44.54 64.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.08 -1.013 . . . . 0.0 110.934 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.467 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 17.2 ttm180 -53.12 -41.82 65.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.896 -1.127 . . . . 0.0 109.713 179.587 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.37 63.28 0.26 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.452 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -132.57 -42.71 0.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.449 -1.03 . . . . 0.0 108.658 179.152 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.486 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.9 t -98.17 144.05 28.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.653 -0.654 . . . . 0.0 109.576 179.148 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.24 9.25 36.85 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.692 -1.242 . . . . 0.0 110.32 179.35 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -66.29 87.5 0.11 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.99 -1.3 . . . . 0.0 109.52 179.709 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.74 23.27 28.65 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -178.772 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.478 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.43 -179.81 0.3 Allowed Pre-proline 0 N--CA 1.492 1.646 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.7 Cg_endo -88.93 105.97 0.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.09 1.047 . . . . 0.0 110.882 -179.939 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.486 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.64 179.47 53.47 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.51 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.468 -1.019 . . . . 0.0 108.951 179.033 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.447 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 11.7 t80 -129.71 115.83 17.9 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.897 -1.121 . . . . 0.0 111.063 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.783 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 1.7 mtt180 -100.58 134.33 43.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.515 -0.74 . . . . 0.0 109.029 179.366 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.4 p90 -126.28 156.73 39.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.931 -1.105 . . . . 0.0 110.582 -179.456 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.651 HG22 HD23 ' A' ' 15' ' ' LEU . 55.9 t . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.287 -0.883 . . . . 0.0 109.9 179.561 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 . . . . . 0 N--CA 1.494 1.761 0 CA-C-O 120.806 0.336 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.711 HD11 ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.08 137.39 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.832 -1.168 . . . . 0.0 110.62 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.6 128.43 34.51 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 108.866 178.312 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -89.53 142.68 27.45 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.055 -1.028 . . . . 0.0 110.62 -179.007 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.45 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.2 t -137.73 158.02 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.418 -0.802 . . . . 0.0 110.434 -179.694 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.88 109.41 17.58 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.442 -0.786 . . . . 0.0 109.56 179.104 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.732 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.1 tp -53.5 136.85 37.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.279 -0.888 . . . . 0.0 109.964 -179.878 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.1 p -137.38 174.49 10.54 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 110.285 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.8 p -71.63 80.09 0.82 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.196 -0.94 . . . . 0.0 110.067 179.856 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.826 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.8 m -155.53 109.05 2.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.176 -0.953 . . . . 0.0 110.799 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.416 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.33 -170.22 29.6 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.833 -1.651 . . . . 0.0 110.942 179.136 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.22 -20.39 12.34 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.755 -0.85 . . . . 0.0 110.417 -179.792 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -98.85 103.88 21.95 Favored Pre-proline 0 N--CA 1.491 1.592 0 C-N-CA 118.906 -1.118 . . . . 0.0 109.86 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -62.63 124.96 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.32 1.168 . . . . 0.0 110.84 -179.369 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.426 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.49 -166.85 1.13 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.737 -0.602 . . . . 0.0 110.433 -179.239 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.527 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.17 81.77 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.465 -0.772 . . . . 0.0 111.514 -179.451 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.1 2.25 52.27 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.607 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.732 ' HB2' HD23 ' A' ' 15' ' ' LEU . 15.1 mmtp -130.18 156.3 44.81 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.973 -1.31 . . . . 0.0 109.355 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.826 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.69 107.43 18.44 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.961 -1.087 . . . . 0.0 109.078 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 1.007 HD11 HG21 ' A' ' 100' ' ' ILE . 5.2 mt -69.33 112.92 13.42 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.312 -0.867 . . . . 0.0 110.521 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.745 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.1 Cg_endo -68.54 129.62 19.28 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 N-CA-C 107.161 -1.9 . . . . 0.0 107.161 176.282 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.746 HD22 ' CD1' ' A' ' 60' ' ' ILE . 10.9 mt -56.27 -17.78 8.61 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.83 -1.169 . . . . 0.0 110.69 -177.803 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -59.88 -16.05 26.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.677 -1.265 . . . . 0.0 110.575 179.898 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.131 HG23 HG23 ' A' ' 33' ' ' ILE . 10.6 m -93.99 -25.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.982 -1.074 . . . . 0.0 110.775 -179.727 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.131 HG23 HG23 ' A' ' 32' ' ' VAL . 12.3 pt -114.62 -23.27 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.094 -1.004 . . . . 0.0 110.57 -179.508 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.578 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptm -93.81 147.96 22.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.803 -1.185 . . . . 0.0 110.2 179.381 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.77 -3.42 52.85 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.799 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.64 -150.63 8.64 Favored Glycine 0 N--CA 1.494 2.533 0 C-N-CA 118.927 -1.606 . . . . 0.0 110.626 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.451 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.42 129.41 55.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.435 -1.038 . . . . 0.0 109.968 -179.793 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.536 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.1 m-70 -137.8 149.42 46.35 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.982 -1.074 . . . . 0.0 110.963 -179.635 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.656 HD23 ' HG2' ' A' ' 121' ' ' ARG . 34.1 tp -110.82 117.27 32.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.419 -0.8 . . . . 0.0 110.21 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.943 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.1 mm -97.92 125.42 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.293 -0.88 . . . . 0.0 109.471 179.792 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.429 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.67 123.38 42.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.093 -1.004 . . . . 0.0 109.882 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.21 159.39 22.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.545 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.527 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.56 23.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.161 179.373 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.35 141.12 51.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.11 -0.994 . . . . 0.0 110.382 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.445 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.63 -31.82 67.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.478 -0.764 . . . . 0.0 110.58 -179.762 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.47 75.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.183 -0.948 . . . . 0.0 110.54 -179.861 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.434 ' HE2' ' CE1' ' A' ' 24' ' ' TYR . 0.2 OUTLIER -73.83 -34.26 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.873 . . . . 0.0 109.622 179.803 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.707 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 62.7 m -60.52 -35.05 75.04 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.398 -0.814 . . . . 0.0 109.177 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.56 -49.06 65.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 110.304 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.437 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.56 -43.16 66.84 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.165 -0.959 . . . . 0.0 110.778 -179.615 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 1.028 HD12 HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.46 73.92 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.248 -0.907 . . . . 0.0 110.909 -179.057 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.462 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.74 -51.37 12.83 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.974 -1.079 . . . . 0.0 110.281 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.43 99.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.025 -1.047 . . . . 0.0 109.696 179.636 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.568 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.42 -47.41 81.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.422 -0.799 . . . . 0.0 109.468 179.649 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.78 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.89 -43.02 76.83 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.604 -0.685 . . . . 0.0 110.365 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.38 -34.6 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.084 -1.01 . . . . 0.0 109.217 179.614 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.0 59.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.316 -0.865 . . . . 0.0 109.74 179.271 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.568 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.7 mm? -71.52 -26.36 62.63 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-O 121.924 0.869 . . . . 0.0 109.575 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.15 6.3 10.03 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.235 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.746 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.8 mt -108.1 143.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.293 -1.122 . . . . 0.0 110.104 -179.776 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 2.4 t-20 -87.89 106.56 18.19 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 177.953 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.644 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.33 144.26 46.0 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.086 -1.045 . . . . 0.0 111.397 -177.288 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.878 HG21 ' HA ' ' A' ' 73' ' ' VAL . 2.5 t -131.03 142.63 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.807 179.551 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.707 ' HB2' ' O ' ' A' ' 48' ' ' CYS . . . -105.84 118.33 36.31 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.81 178.984 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.7 OUTLIER -105.27 118.43 36.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.857 . . . . 0.0 110.706 -179.43 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.909 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -149.69 -179.88 7.46 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 179.32 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.66 129.37 40.79 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.069 -1.019 . . . . 0.0 110.687 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.96 23.68 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.909 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.22 154.71 30.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.321 -1.105 . . . . 0.0 110.014 -179.765 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.844 ' N ' HD13 ' A' ' 69' ' ' LEU . 23.9 m-20 -94.9 149.78 20.89 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.338 -0.851 . . . . 0.0 110.39 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.674 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 118.934 -1.107 . . . . 0.0 108.99 179.338 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.509 ' O ' HG23 ' A' ' 74' ' ' ILE . 36.7 m -133.09 -33.51 1.14 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.485 -0.759 . . . . 0.0 110.708 -179.234 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.878 ' HA ' HG21 ' A' ' 63' ' ' VAL . 89.6 t -56.49 134.67 20.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.154 -0.966 . . . . 0.0 109.782 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.577 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.495 1.818 0 O-C-N 121.194 -0.941 . . . . 0.0 110.696 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 121.838 0.828 . . . . 0.0 110.313 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.526 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.6 134.22 61.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 122.052 0.929 . . . . 0.0 110.351 179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.626 HG22 HG22 ' A' ' 60' ' ' ILE . 8.0 m -113.16 124.55 69.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.249 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.009 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.758 HG22 HG13 ' A' ' 73' ' ' VAL . 8.8 t -97.7 118.78 44.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.019 -1.051 . . . . 0.0 110.778 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.028 HG11 HD12 ' A' ' 51' ' ' LEU . 4.1 m -111.87 98.54 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 120.78 -1.2 . . . . 0.0 108.81 179.135 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.92 29.24 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.626 -1.296 . . . . 0.0 110.077 -178.813 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -103.36 -24.73 13.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 111.296 -178.544 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 179.92 -29.37 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.996 -1.065 . . . . 0.0 111.059 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.95 -38.98 24.58 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.013 -1.055 . . . . 0.0 110.278 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.9 tp . . . . . 0 N--CA 1.49 1.532 0 O-C-N 121.135 -0.978 . . . . 0.0 108.705 178.552 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.02 0.438 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.503 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.2 m-85 -119.7 150.67 39.98 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.953 -1.092 . . . . 0.0 110.265 179.284 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.458 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.6 m-20 -76.86 -31.92 57.15 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.459 -0.776 . . . . 0.0 109.898 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.61 163.97 26.92 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.256 -0.977 . . . . 0.0 111.788 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.698 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.98 113.77 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.504 -0.748 . . . . 0.0 110.069 179.064 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 1.007 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -92.74 116.16 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.093 -1.004 . . . . 0.0 108.387 178.863 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.05 31.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.083 -1.011 . . . . 0.0 112.039 -177.895 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.479 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.5 t -95.77 -1.04 50.56 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 177.84 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.403 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 54.89 20.92 3.34 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -0.974 . . . . 0.0 111.168 179.737 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.492 1.635 0 O-C-N 120.974 -1.079 . . . . 0.0 110.659 179.669 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.402 ' OE1' ' ND2' ' A' ' 103' ' ' ASN . 5.7 pt20 . . . . . 0 N--CA 1.494 1.762 0 CA-C-O 121.34 0.59 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.513 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -98.1 160.81 14.06 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.43 -0.794 . . . . 0.0 110.141 179.741 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.51 -50.67 7.06 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.522 -0.736 . . . . 0.0 112.298 -178.681 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.513 HG22 ' OD1' ' A' ' 111' ' ' ASP . 16.2 m -71.25 -29.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 120.699 -1.251 . . . . 0.0 111.446 -178.564 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.418 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.32 -56.01 7.67 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.059 -1.026 . . . . 0.0 110.449 -179.375 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.469 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.17 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.401 -0.92 . . . . 0.0 108.888 178.683 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.468 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.495 -0.882 . . . . 0.0 108.698 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 117' ' ' GLN . . . . . 0.42 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.27 66.42 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.608 -0.683 . . . . 0.0 109.528 178.984 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.469 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 21.3 mtt85 -68.42 -44.97 73.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.164 -0.96 . . . . 0.0 110.499 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.48 ' HE ' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -59.94 -46.45 89.36 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.23 -0.919 . . . . 0.0 110.332 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.0 -26.37 1.2 Allowed Glycine 0 N--CA 1.499 2.85 0 O-C-N 121.474 -0.766 . . . . 0.0 111.396 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.656 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -48.83 -55.39 11.76 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.882 -1.363 . . . . 0.0 110.858 -179.394 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.711 ' O ' HD11 ' A' ' 10' ' ' ILE . 1.3 t -91.62 142.59 27.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.66 12.54 16.4 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.303 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 6.2 mtt180 -102.47 76.56 1.55 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.953 -1.322 . . . . 0.0 109.951 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.671 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.44 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -145.14 167.11 15.38 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.58 -0.953 . . . . 0.0 108.79 179.779 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.95 111.98 1.71 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.202 1.106 . . . . 0.0 109.637 179.582 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.493 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -87.24 166.16 36.44 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -178.854 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 98' ' ' SER . 2.7 mt -124.3 141.79 43.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.514 -0.992 . . . . 0.0 108.54 178.946 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.698 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.59 115.44 19.5 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.927 179.827 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.45 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.35 121.82 45.34 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.536 -0.728 . . . . 0.0 109.183 179.276 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.403 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 24.5 p90 -119.52 157.75 27.69 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -0.987 . . . . 0.0 109.991 -179.694 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.7 t . . . . . 0 N--CA 1.493 1.711 0 O-C-N 121.189 -0.944 . . . . 0.0 110.005 179.751 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.4 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 41.6 m-80 . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.114 0.483 . . . . 0.0 110.449 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.659 HG12 HG23 ' A' ' 122' ' ' THR . 1.9 mt -112.8 135.49 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.03 -1.044 . . . . 0.0 109.811 179.898 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.94 125.14 33.13 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.256 -0.902 . . . . 0.0 108.741 178.311 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -89.33 129.53 35.85 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.031 -1.043 . . . . 0.0 110.276 -179.245 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.625 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 12.0 t -125.35 157.88 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.472 -0.767 . . . . 0.0 110.42 -179.193 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.46 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.46 114.15 27.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.292 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.677 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -52.21 143.87 13.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.231 -0.918 . . . . 0.0 109.878 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.8 p -142.06 -178.2 5.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.196 -0.94 . . . . 0.0 110.226 -179.663 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.4 p -80.33 59.16 3.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.302 -0.873 . . . . 0.0 110.097 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.454 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 23.8 m -132.75 109.22 9.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.436 -0.79 . . . . 0.0 110.597 -179.829 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.414 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.35 -171.63 28.73 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 118.81 -1.662 . . . . 0.0 111.139 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.7 -22.82 10.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.703 -0.88 . . . . 0.0 110.473 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.893 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.8 tt -93.48 109.5 41.01 Favored Pre-proline 0 N--CA 1.49 1.538 0 C-N-CA 118.749 -1.18 . . . . 0.0 109.226 -179.923 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.14 145.54 93.73 Favored 'Trans proline' 0 C--N 1.312 -1.354 0 O-C-N 123.423 1.223 . . . . 0.0 111.491 -178.284 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.438 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.83 -165.12 1.68 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.624 -0.673 . . . . 0.0 110.403 -179.311 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.714 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 38.3 m-85 -60.65 79.76 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.507 -0.745 . . . . 0.0 110.688 -179.879 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.99 57.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.485 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.677 ' HB2' HD23 ' A' ' 15' ' ' LEU . 1.3 mmtp -130.19 156.08 45.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.027 -1.278 . . . . 0.0 109.547 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.454 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.08 106.91 16.11 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.989 -1.069 . . . . 0.0 109.054 179.38 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.893 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.32 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 110.819 -179.173 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.799 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.4 Cg_endo -70.31 130.57 18.88 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 N-CA-C 106.668 -2.089 . . . . 0.0 106.668 175.869 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.736 HD11 HD12 ' A' ' 58' ' ' LEU . 14.3 mt -55.99 -17.98 8.16 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.809 -1.182 . . . . 0.0 110.581 -177.784 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -59.35 -16.49 22.85 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.525 -1.359 . . . . 0.0 110.515 179.729 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.02 HG23 HG23 ' A' ' 33' ' ' ILE . 13.4 m -92.73 -24.33 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.002 -1.061 . . . . 0.0 111.038 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.02 HG23 HG23 ' A' ' 32' ' ' VAL . 37.9 pt -117.45 -26.28 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.921 -1.112 . . . . 0.0 110.358 -179.413 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.621 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -90.32 148.79 22.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.057 -1.027 . . . . 0.0 110.058 179.057 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.457 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.81 -4.86 25.92 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.577 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.5 -130.95 2.18 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 119.214 -1.469 . . . . 0.0 110.268 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.2 mtt-85 -115.59 131.0 57.07 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.33 -1.1 . . . . 0.0 110.234 -179.69 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.57 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 74.4 m-70 -140.83 146.4 37.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.111 -0.993 . . . . 0.0 110.879 -179.762 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.517 HD22 ' HG2' ' A' ' 121' ' ' ARG . 20.4 tp -106.79 127.59 53.53 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.534 -0.729 . . . . 0.0 109.942 179.593 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.916 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.1 mt -109.76 128.22 66.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.515 179.388 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -95.09 124.11 38.95 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 109.99 -179.754 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.56 159.9 21.44 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.347 -0.845 . . . . 0.0 110.739 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.714 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -106.81 3.1 26.07 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.492 -0.755 . . . . 0.0 110.206 179.26 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.0 p -136.7 136.74 39.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.957 -1.089 . . . . 0.0 110.834 -179.661 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.483 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.91 -36.98 70.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.551 -0.718 . . . . 0.0 110.628 179.907 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.29 -33.67 76.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.416 -179.738 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.54 -35.51 65.53 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.51 -0.744 . . . . 0.0 109.712 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.784 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 93.1 m -61.11 -36.06 78.68 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.357 -0.839 . . . . 0.0 109.418 179.498 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.54 -49.95 60.92 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.197 -0.939 . . . . 0.0 110.519 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.407 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.4 mm-40 -72.22 -44.81 62.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.209 -0.932 . . . . 0.0 110.267 179.828 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.634 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -56.79 -43.57 81.04 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.661 . . . . 0.0 111.154 -179.12 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.455 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -67.72 -51.16 52.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.872 -1.142 . . . . 0.0 109.821 179.894 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -35.5 69.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.195 -0.941 . . . . 0.0 109.27 179.323 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.668 ' HD3' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.765 . . . . 0.0 108.978 179.235 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.867 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.15 -41.95 84.86 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 110.794 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.5 t -56.15 -32.87 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.07 -1.019 . . . . 0.0 109.156 179.664 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.38 60.15 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.392 -0.818 . . . . 0.0 110.491 179.68 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.736 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.31 -25.44 62.42 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.146 -0.971 . . . . 0.0 109.918 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.78 4.61 9.51 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.329 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.668 ' CD1' HD22 ' A' ' 30' ' ' LEU . 44.7 mt -105.71 143.37 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 121.376 -1.073 . . . . 0.0 109.845 -179.729 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.486 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.9 t-20 -88.58 106.99 18.67 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 178.173 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.572 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.57 146.31 44.69 Favored 'General case' 0 C--N 1.294 -1.812 0 C-N-CA 118.706 -1.197 . . . . 0.0 111.728 -177.084 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.928 HG21 ' HA ' ' A' ' 73' ' ' VAL . 89.8 t -128.2 149.75 33.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.784 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.29 117.74 30.83 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.549 178.412 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.5 142.36 45.16 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.337 -0.852 . . . . 0.0 110.354 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.886 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.9 p90 -175.32 -177.27 1.01 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.399 -0.813 . . . . 0.0 110.034 179.888 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.52 119.8 5.76 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.176 -0.952 . . . . 0.0 111.234 -179.232 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 40.97 11.8 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.13 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.886 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -117.59 155.37 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.052 -1.264 . . . . 0.0 110.223 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.813 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -93.56 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.282 -0.886 . . . . 0.0 110.416 -179.541 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.656 HG23 ' O ' ' A' ' 71' ' ' VAL . 28.2 m -62.55 110.61 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.411 179.384 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.59 -20.95 2.27 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.536 -0.728 . . . . 0.0 111.046 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.928 ' HA ' HG21 ' A' ' 63' ' ' VAL . 54.5 t -63.99 128.15 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.022 -1.049 . . . . 0.0 109.53 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.703 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.4 pp . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.028 -1.045 . . . . 0.0 110.926 -179.647 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.873 0.844 . . . . 0.0 110.146 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.8 p -116.65 135.38 57.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-O 122.006 0.908 . . . . 0.0 110.721 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 60' ' ' ILE . 9.6 m -113.2 122.81 68.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.611 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.702 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -97.29 118.81 44.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 120.833 -1.167 . . . . 0.0 110.5 -178.118 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.916 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.5 m -109.8 100.64 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.018 -1.051 . . . . 0.0 108.947 179.699 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.21 163.83 31.9 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.602 -1.311 . . . . 0.0 111.38 -177.859 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.494 HG23 ' N ' ' A' ' 86' ' ' ASP . 11.2 t -91.38 -140.76 0.17 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.423 -0.798 . . . . 0.0 109.332 179.757 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.494 ' N ' HG23 ' A' ' 85' ' ' THR . 3.8 p30 -84.43 52.12 2.28 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.806 -1.184 . . . . 0.0 110.248 179.633 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.471 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.43 -19.58 6.36 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.202 -0.936 . . . . 0.0 110.936 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 O-C-N 121.012 -1.055 . . . . 0.0 109.548 179.922 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.199 0.523 . . . . 0.0 110.392 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -119.45 153.1 35.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.205 -0.934 . . . . 0.0 110.167 179.433 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.86 -29.24 25.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.396 -0.815 . . . . 0.0 109.513 179.393 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.4 p -161.88 163.7 29.07 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.244 -0.91 . . . . 0.0 111.161 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.492 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.53 125.85 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.389 -0.819 . . . . 0.0 110.094 179.24 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.742 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -102.86 112.15 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.231 -0.918 . . . . 0.0 109.003 179.265 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.417 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.0 t0 -118.09 162.01 18.91 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.184 -0.948 . . . . 0.0 111.869 -178.485 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.523 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.26 9.38 38.13 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.75 -0.594 . . . . 0.0 109.744 178.556 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.433 ' ND2' ' NE2' ' A' ' 110' ' ' GLN . 2.8 m-20 46.58 25.16 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.091 -1.006 . . . . 0.0 111.481 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 110.454 179.629 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.433 ' NE2' ' ND2' ' A' ' 103' ' ' ASN . 13.9 pt20 . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.465 0.65 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.532 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.5 p30 -93.21 161.09 14.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.384 -0.822 . . . . 0.0 109.719 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.41 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.13 -51.75 5.78 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.375 -0.828 . . . . 0.0 112.316 -178.629 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.532 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.6 m -69.74 -29.15 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.76 -1.213 . . . . 0.0 111.382 -178.81 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.47 -56.13 7.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.122 -0.986 . . . . 0.0 110.522 -179.091 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.419 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.3 OUTLIER -68.08 -34.86 77.22 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.066 -1.021 . . . . 0.0 108.658 178.927 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.462 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.95 -49.91 75.83 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.14 -0.975 . . . . 0.0 108.427 178.623 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.8 -36.85 65.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.584 -0.697 . . . . 0.0 109.888 179.078 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.419 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 13.6 mtt180 -71.23 -44.61 65.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.163 -0.96 . . . . 0.0 110.502 -179.727 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.448 ' HG2' ' CD1' ' A' ' 10' ' ' ILE . 0.5 OUTLIER -58.6 -42.19 87.55 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.109 -0.994 . . . . 0.0 109.903 179.734 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.97 89.41 0.02 OUTLIER Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.517 ' HG2' HD22 ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.66 -44.06 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.55 -0.971 . . . . 0.0 108.616 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.659 HG23 HG12 ' A' ' 10' ' ' ILE . 14.6 t -102.07 132.54 47.88 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 178.663 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.44 8.18 3.67 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.015 -1.564 . . . . 0.0 110.845 179.596 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -85.39 82.48 8.3 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.853 -1.381 . . . . 0.0 110.269 -179.791 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.67 -52.08 0.71 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.458 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.92 178.74 0.91 Allowed Pre-proline 0 C--N 1.302 -1.489 0 O-C-N 121.579 -0.954 . . . . 0.0 109.332 179.403 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.4 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.8 Cg_endo -77.53 109.53 2.79 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 123.57 1.3 . . . . 0.0 109.39 179.127 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.48 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.57 161.8 52.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.261 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.5 mt -119.64 142.66 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.427 -1.043 . . . . 0.0 109.389 179.491 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.492 ' CD1' HG23 ' A' ' 99' ' ' VAL . 5.5 t80 -130.34 115.47 16.96 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.18 -0.95 . . . . 0.0 110.387 179.899 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.625 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 2.0 mtt180 -103.27 133.95 47.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.432 -0.793 . . . . 0.0 109.892 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.46 ' CE1' ' HA ' ' A' ' 14' ' ' ALA . 8.2 p90 -127.12 152.44 47.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 110.205 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.402 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t . . . . . 0 N--CA 1.493 1.687 0 O-C-N 121.183 -0.948 . . . . 0.0 109.859 179.568 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.639 0.733 . . . . 0.0 109.433 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.608 HD12 ' HG2' ' A' ' 119' ' ' ARG . 28.4 mt -102.09 136.68 33.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.116 -0.99 . . . . 0.0 109.772 179.452 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.11 34.99 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.132 -0.98 . . . . 0.0 109.576 179.838 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.93 121.54 31.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.237 -0.915 . . . . 0.0 110.206 -179.291 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.537 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 10.8 t -116.45 157.16 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.432 -0.793 . . . . 0.0 110.113 -179.521 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.86 111.29 23.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.165 -0.959 . . . . 0.0 109.91 179.483 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.686 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.9 tp -55.65 139.62 44.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.935 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.72 3.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 110.34 -179.825 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.56 84.38 7.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.17 -0.957 . . . . 0.0 109.867 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.785 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 25.2 m -158.99 109.78 2.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.186 -0.946 . . . . 0.0 110.906 -179.482 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.419 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.32 -174.47 29.71 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.212 178.922 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.02 -19.57 13.46 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.834 -0.803 . . . . 0.0 110.284 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.863 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.3 tt -98.26 106.31 34.56 Favored Pre-proline 0 N--CA 1.489 1.516 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.443 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -62.91 123.38 12.16 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 O-C-N 123.347 1.182 . . . . 0.0 110.776 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.0 t80 -111.5 -167.81 1.23 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.686 -0.634 . . . . 0.0 110.336 -179.185 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.8 m-85 -58.93 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.479 -0.763 . . . . 0.0 111.117 -179.595 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.73 3.83 56.14 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 179.831 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.686 ' CB ' HD23 ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.43 44.28 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.019 -1.283 . . . . 0.0 109.224 179.733 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.785 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.21 106.49 17.02 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.971 -1.08 . . . . 0.0 108.546 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.863 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -69.8 113.44 17.38 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.337 -0.852 . . . . 0.0 110.52 -178.991 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.787 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -69.75 130.77 19.94 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 N-CA-C 107.159 -1.9 . . . . 0.0 107.159 176.347 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.666 HD11 HD12 ' A' ' 58' ' ' LEU . 10.5 mt -56.74 -16.43 6.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.802 -1.186 . . . . 0.0 110.521 -178.313 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.435 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.05 -16.14 49.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.555 -1.341 . . . . 0.0 110.532 179.516 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.042 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -93.39 -25.77 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 120.935 -1.103 . . . . 0.0 111.125 -179.313 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.042 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -115.98 -26.04 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.061 . . . . 0.0 109.954 -179.658 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.21 147.99 22.67 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.224 -0.923 . . . . 0.0 110.435 179.945 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.22 -4.77 41.19 Favored Glycine 0 N--CA 1.484 1.872 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.352 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.63 -149.44 9.32 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.185 -1.483 . . . . 0.0 110.376 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.65 129.95 54.47 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.336 -1.097 . . . . 0.0 110.323 -179.621 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.544 ' HB2' HG12 ' A' ' 81' ' ' VAL . 70.2 m80 -138.43 153.59 48.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.067 -1.02 . . . . 0.0 111.087 -179.508 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.639 HD12 ' O ' ' A' ' 82' ' ' VAL . 24.9 tp -113.23 114.05 26.19 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.41 -0.806 . . . . 0.0 109.81 179.613 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.96 HD12 ' CG1' ' A' ' 83' ' ' VAL . 38.6 mt -97.14 126.75 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.28 -0.887 . . . . 0.0 109.539 179.427 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.465 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 10.5 m-85 -95.0 123.73 38.65 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.402 -0.811 . . . . 0.0 110.196 -179.797 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.2 -0.938 . . . . 0.0 110.885 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.499 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.7 p80 -104.42 -5.47 21.63 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.834 . . . . 0.0 110.128 179.148 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.63 137.4 53.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 110.637 -179.741 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.52 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.8 -43.28 65.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.677 -0.64 . . . . 0.0 110.679 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.17 -36.94 81.18 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.266 -0.896 . . . . 0.0 110.71 -179.632 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.68 -35.38 78.74 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.37 -0.831 . . . . 0.0 109.485 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.869 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.3 m -61.45 -34.84 76.11 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.439 -0.788 . . . . 0.0 109.385 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.61 -49.02 74.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 110.459 179.86 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.76 -40.38 69.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.228 -0.92 . . . . 0.0 110.494 -179.734 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.742 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -57.11 -39.96 76.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.47 -0.769 . . . . 0.0 110.958 -179.354 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.43 -51.36 13.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 110.377 -179.784 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.32 -41.21 93.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.096 -1.002 . . . . 0.0 109.517 179.619 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.553 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.67 -46.88 83.69 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.423 -0.798 . . . . 0.0 109.664 179.47 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.815 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.17 -43.32 78.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.552 -0.718 . . . . 0.0 110.326 179.931 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.3 t -55.7 -33.16 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.04 -1.037 . . . . 0.0 109.166 179.611 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.9 60.85 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.272 -0.892 . . . . 0.0 109.79 179.088 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.666 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -72.05 -26.2 62.09 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.312 -0.867 . . . . 0.0 109.703 179.634 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.46 9.51 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.343 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.62 HD11 ' HB2' ' A' ' 34' ' ' LYS . 48.6 mt -108.3 143.09 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.308 -1.113 . . . . 0.0 110.239 -179.626 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.1 t-20 -86.69 106.66 17.79 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 178.232 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.66 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.84 144.59 48.28 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.506 -177.432 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.974 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.7 t -134.56 145.1 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.79 128.79 55.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.976 -1.09 . . . . 0.0 109.996 179.308 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.474 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.1 53.19 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 110.376 -179.839 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.937 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.4 p90 -170.57 174.62 4.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.473 -0.767 . . . . 0.0 109.655 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.78 120.84 5.68 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 110.766 -179.179 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.27 34.36 14.65 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.531 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.949 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -116.97 156.24 27.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.134 -1.215 . . . . 0.0 110.021 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.949 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.0 m-20 -93.96 148.32 22.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.186 -0.946 . . . . 0.0 110.91 -179.189 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.648 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.8 m -63.26 111.45 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.343 178.884 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.454 ' O ' HG23 ' A' ' 74' ' ' ILE . 5.4 m -134.76 -33.18 0.96 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.419 -0.801 . . . . 0.0 110.921 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.974 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.8 t -53.96 140.1 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.109 -0.995 . . . . 0.0 110.308 -179.418 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.55 ' O ' HG11 ' A' ' 80' ' ' VAL . 0.9 OUTLIER . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.3 -0.875 . . . . 0.0 110.832 179.814 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 122.019 0.914 . . . . 0.0 109.791 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.55 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -110.98 134.47 53.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-O 121.928 0.87 . . . . 0.0 110.042 -179.779 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 6.3 m -112.04 125.9 69.38 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.397 -0.814 . . . . 0.0 109.248 179.495 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.721 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.8 t -97.57 116.14 39.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 O-C-N 121.117 -0.99 . . . . 0.0 110.12 -178.303 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.96 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.4 m -110.65 100.21 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.048 -1.032 . . . . 0.0 108.763 179.723 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.474 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.16 33.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.545 -1.347 . . . . 0.0 111.552 -177.891 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.534 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -86.9 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.595 -0.691 . . . . 0.0 109.412 179.6 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.534 ' N ' HG23 ' A' ' 85' ' ' THR . 9.9 p-10 -90.1 42.87 1.12 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.693 -1.255 . . . . 0.0 110.484 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.443 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.96 -26.04 8.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.122 -0.987 . . . . 0.0 110.351 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.701 0 O-C-N 121.089 -1.007 . . . . 0.0 109.977 179.538 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.049 0.452 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -119.79 152.85 36.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.08 -1.012 . . . . 0.0 110.507 179.636 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.19 17.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.504 -0.747 . . . . 0.0 109.356 179.213 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.439 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.8 p -160.82 163.04 32.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.421 -0.799 . . . . 0.0 110.294 179.779 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.456 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.36 122.67 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.066 -1.021 . . . . 0.0 110.421 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.827 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.7 mp -97.99 112.68 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.429 -0.795 . . . . 0.0 109.121 179.266 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.419 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 5.2 t0 -121.01 160.74 22.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.114 -0.991 . . . . 0.0 111.589 -178.72 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.66 5.55 43.82 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.688 -0.633 . . . . 0.0 109.47 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.413 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 49.21 24.44 0.98 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 111.064 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.081 -1.012 . . . . 0.0 110.316 179.55 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 . . . . . 0 N--CA 1.493 1.703 0 CA-C-O 121.35 0.595 . . . . 0.0 111.253 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.528 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -77.4 160.57 28.65 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.429 -0.794 . . . . 0.0 110.174 179.85 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.406 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.62 -52.83 12.78 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.348 -0.845 . . . . 0.0 112.058 -178.794 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.528 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.51 -28.95 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 120.838 -1.164 . . . . 0.0 111.466 -178.583 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.05 -56.47 6.43 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.071 -1.018 . . . . 0.0 110.593 -179.289 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.439 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.7 OUTLIER -68.95 -34.61 75.63 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.231 -0.918 . . . . 0.0 108.723 178.961 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.442 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 41.0 m -59.61 -49.98 75.65 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.174 -0.954 . . . . 0.0 108.482 178.781 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.72 -36.25 65.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.464 -0.772 . . . . 0.0 109.9 178.926 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.439 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.1 mtt180 -71.22 -44.58 65.09 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.179 -0.951 . . . . 0.0 110.723 -179.585 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.608 ' HG2' HD12 ' A' ' 10' ' ' ILE . 14.1 ttm180 -56.15 -43.38 78.23 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.912 -1.117 . . . . 0.0 110.415 -179.757 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.69 79.55 0.06 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.478 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -152.08 -43.96 0.11 Allowed 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.296 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.519 HG22 HD13 ' A' ' 10' ' ' ILE . 8.8 t -100.27 144.06 29.73 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.297 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.69 14.63 46.13 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.192 -1.48 . . . . 0.0 110.444 179.425 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.421 ' HD3' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -58.67 -31.79 68.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.127 -1.219 . . . . 0.0 110.032 -179.916 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.89 20.75 4.03 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.333 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.494 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -165.46 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.427 -1.043 . . . . 0.0 108.506 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.494 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 50.2 Cg_endo -85.32 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 122.85 0.921 . . . . 0.0 110.607 179.365 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.503 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.53 176.61 50.25 Favored Glycine 0 N--CA 1.497 2.759 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.439 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mt -131.35 142.87 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.466 -1.02 . . . . 0.0 109.075 179.296 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.476 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 18.6 t80 -131.3 116.03 17.06 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.034 -1.041 . . . . 0.0 110.934 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.537 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.9 mtt180 -101.83 134.86 44.35 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.536 -0.727 . . . . 0.0 109.461 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.449 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.91 148.93 50.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.055 -1.028 . . . . 0.0 110.042 -179.79 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.442 HG22 HD23 ' A' ' 15' ' ' LEU . 54.4 t . . . . . 0 N--CA 1.493 1.677 0 O-C-N 121.188 -0.945 . . . . 0.0 109.902 179.75 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.3 m-80 . . . . . 0 N--CA 1.493 1.682 0 CA-C-O 121.245 0.545 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.839 HG12 HG23 ' A' ' 122' ' ' THR . 20.8 mt -95.15 128.19 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.428 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.12 128.14 34.37 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.263 -0.898 . . . . 0.0 108.951 178.868 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.3 134.67 33.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.109 -0.994 . . . . 0.0 110.128 -179.303 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.548 HG11 ' HE ' ' A' ' 131' ' ' ARG . 5.5 t -128.66 157.73 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.396 -0.815 . . . . 0.0 110.183 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.43 113.79 27.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.356 -0.84 . . . . 0.0 110.068 179.718 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.746 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.78 143.97 19.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 110.027 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.42 170.17 16.41 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.977 . . . . 0.0 110.397 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.86 81.59 1.18 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.201 -0.937 . . . . 0.0 109.754 179.651 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.829 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.4 m -158.31 111.44 2.39 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.872 -179.502 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.416 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.27 -170.39 30.24 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.139 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.75 -19.08 12.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.787 -0.831 . . . . 0.0 110.0 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -99.92 104.05 26.18 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.833 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.16 125.92 16.8 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.231 1.122 . . . . 0.0 111.008 -179.18 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.0 t80 -112.93 -169.57 1.51 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.738 -0.601 . . . . 0.0 110.352 -179.499 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.524 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.0 m-85 -59.46 82.3 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.269 -0.894 . . . . 0.0 111.377 -179.433 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.19 61.69 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.627 179.274 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.746 ' CB ' HD23 ' A' ' 15' ' ' LEU . 26.6 mmtt -129.86 156.54 44.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.884 -1.362 . . . . 0.0 109.638 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.829 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.34 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.98 -1.075 . . . . 0.0 108.993 179.56 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.4 mt -70.28 113.17 15.95 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.375 -0.828 . . . . 0.0 110.729 -179.122 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.72 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.4 Cg_endo -69.63 130.77 20.09 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 N-CA-C 106.849 -2.02 . . . . 0.0 106.849 175.754 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.577 HD11 HD12 ' A' ' 58' ' ' LEU . 9.7 mt -55.99 -18.68 9.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.784 -1.198 . . . . 0.0 110.507 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.433 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.01 15.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.861 -1.149 . . . . 0.0 110.589 179.728 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.024 HG23 HG23 ' A' ' 33' ' ' ILE . 9.6 m -93.96 -25.3 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.926 -1.109 . . . . 0.0 110.951 -179.735 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.024 HG23 HG23 ' A' ' 32' ' ' VAL . 27.1 pt -117.95 -14.86 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.934 -1.104 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.557 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.64 148.06 24.2 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.849 -1.157 . . . . 0.0 110.383 179.683 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.7 -4.4 50.17 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.629 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.01 7.23 Favored Glycine 0 N--CA 1.492 2.393 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.589 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.05 132.54 54.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -1.018 . . . . 0.0 110.213 -179.602 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -139.93 150.46 44.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.197 -0.939 . . . . 0.0 110.863 -179.759 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.645 HD12 ' O ' ' A' ' 82' ' ' VAL . 51.3 tp -110.99 115.26 29.17 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.466 -0.771 . . . . 0.0 109.996 179.836 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.944 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.4 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.231 -0.918 . . . . 0.0 109.041 179.503 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.55 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.76 37.98 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.866 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.63 159.36 23.06 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.363 -0.836 . . . . 0.0 110.422 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.59 20.31 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.388 -0.82 . . . . 0.0 110.024 179.069 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.2 p -132.8 139.21 47.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.42 ' HE3' ' CE1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.57 -34.09 71.81 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.464 -0.773 . . . . 0.0 110.465 -179.932 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.46 -34.14 76.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.249 -0.907 . . . . 0.0 110.333 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.457 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.09 -36.34 64.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.206 -0.934 . . . . 0.0 109.636 179.818 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.805 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 64.9 m -60.98 -39.2 88.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.563 -0.71 . . . . 0.0 109.469 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.52 -46.59 87.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.915 . . . . 0.0 110.035 179.699 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.439 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.43 -45.47 62.59 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.395 -0.815 . . . . 0.0 110.454 -179.875 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 1.05 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.36 -45.07 80.66 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.36 -0.838 . . . . 0.0 111.149 -178.997 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.47 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.75 -51.57 22.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.001 -1.062 . . . . 0.0 110.366 -179.467 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.16 99.33 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 109.762 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.548 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.54 -46.81 86.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.24 -0.912 . . . . 0.0 109.606 179.591 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.847 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.2 -43.52 78.56 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.636 -0.665 . . . . 0.0 110.147 179.86 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.2 t -55.48 -32.67 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.21 -0.931 . . . . 0.0 109.029 179.7 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.56 -31.05 59.89 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.251 -0.906 . . . . 0.0 109.832 179.071 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.577 HD12 HD11 ' A' ' 30' ' ' LEU . 3.9 mm? -72.19 -26.36 62.03 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.864 0.84 . . . . 0.0 109.837 179.844 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.9 4.58 10.29 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.16 -1.576 . . . . 0.0 109.16 -179.113 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.557 HD11 ' HB2' ' A' ' 34' ' ' LYS . 28.1 mt -105.48 143.34 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.352 -1.087 . . . . 0.0 110.096 -179.748 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.771 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.7 t-20 -88.06 106.07 17.91 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 178.031 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.713 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.288 -177.502 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.924 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.33 139.55 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.806 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.805 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -101.26 122.77 44.27 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.214 178.758 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.496 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.1 134.88 54.78 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.313 -0.867 . . . . 0.0 111.153 -178.925 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.896 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -168.89 170.65 8.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.574 -0.704 . . . . 0.0 109.641 179.506 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.67 118.3 3.27 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.242 -0.912 . . . . 0.0 110.845 -179.439 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.82 37.35 6.44 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.969 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.896 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.42 30.03 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -1.142 . . . . 0.0 110.168 -179.724 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.848 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.3 m-20 -91.84 149.58 21.51 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.36 -0.837 . . . . 0.0 110.596 -179.48 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.7 m -62.15 110.88 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 119.128 -1.029 . . . . 0.0 109.426 179.326 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.715 ' O ' HG23 ' A' ' 74' ' ' ILE . 19.7 m -133.19 -39.33 0.93 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.447 -0.783 . . . . 0.0 110.233 -179.656 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.924 ' HA ' HG21 ' A' ' 63' ' ' VAL . 79.0 t -47.61 133.09 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.42 -0.8 . . . . 0.0 109.993 179.822 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.771 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.776 0 O-C-N 121.138 -0.976 . . . . 0.0 110.842 -179.51 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.925 0.869 . . . . 0.0 110.39 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.644 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.75 134.0 62.73 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 CA-C-O 122.095 0.95 . . . . 0.0 110.05 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.546 HG22 HG22 ' A' ' 60' ' ' ILE . 16.8 m -113.24 122.71 67.89 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.466 -0.771 . . . . 0.0 108.984 179.348 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.998 HG11 HD13 ' A' ' 88' ' ' LEU . 12.2 t -96.95 118.59 43.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.723 -1.235 . . . . 0.0 111.106 -177.686 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.05 HG11 HD12 ' A' ' 51' ' ' LEU . 4.3 m -108.7 99.68 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.034 -1.041 . . . . 0.0 108.852 178.838 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.496 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -135.79 155.93 49.59 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.446 -1.409 . . . . 0.0 110.912 -178.488 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.517 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.17 -42.43 15.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.369 -0.832 . . . . 0.0 110.385 -179.5 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.517 ' N ' HG23 ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.22 32.54 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.69 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -103.16 -30.99 10.35 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.009 . . . . 0.0 110.067 -179.929 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.998 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 110.067 179.415 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.1 0.476 . . . . 0.0 110.478 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.484 ' CE2' ' HB2' ' A' ' 39' ' ' LEU . 16.9 m-85 -119.9 149.75 41.6 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.103 -0.998 . . . . 0.0 110.078 179.399 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.424 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.85 -31.54 25.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.812 . . . . 0.0 109.619 179.554 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.5 p -162.26 163.43 28.15 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.417 -0.913 . . . . 0.0 111.466 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.47 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 117.74 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.455 -0.778 . . . . 0.0 109.614 178.798 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.878 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -97.59 117.18 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.224 -0.923 . . . . 0.0 109.456 179.876 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.429 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.8 t0 -129.84 161.32 31.04 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.107 -0.995 . . . . 0.0 111.634 -178.716 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.436 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 52.8 t -92.03 -7.41 48.87 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.641 -0.662 . . . . 0.0 109.534 178.017 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.2 13.44 1.66 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.255 -0.903 . . . . 0.0 111.87 179.704 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 m . . . . . 0 C--N 1.306 -1.31 0 O-C-N 120.725 -1.234 . . . . 0.0 109.39 -179.888 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.369 0.604 . . . . 0.0 110.794 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -80.88 159.06 25.12 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.272 -0.892 . . . . 0.0 109.84 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -46.63 -50.92 16.88 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.282 -0.886 . . . . 0.0 111.893 -178.787 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.41 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.792 -1.193 . . . . 0.0 111.444 -178.727 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.423 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.27 -56.6 6.47 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.987 -1.071 . . . . 0.0 110.426 -179.131 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.422 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.73 -35.03 76.61 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.264 -0.898 . . . . 0.0 108.918 178.718 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.431 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.2 m -59.9 -46.69 88.53 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 178.709 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.61 -40.43 63.82 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.671 -0.643 . . . . 0.0 109.767 178.905 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -69.65 -44.23 70.99 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.273 -0.892 . . . . 0.0 110.344 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.47 ' HG2' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -56.54 -43.74 80.16 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.362 -0.836 . . . . 0.0 110.004 179.678 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.01 0.11 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.682 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.457 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.77 -46.41 0.13 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.563 -0.963 . . . . 0.0 108.76 179.622 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.839 HG23 HG12 ' A' ' 10' ' ' ILE . 15.3 t -97.19 141.89 29.77 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.26 17.17 3.34 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.594 179.787 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.499 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.15 81.71 6.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.889 -1.359 . . . . 0.0 109.986 -179.731 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.52 -52.08 0.71 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.477 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.96 176.61 1.49 Allowed Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 121.765 -0.844 . . . . 0.0 109.123 179.308 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.6 Cg_endo -73.21 112.89 3.64 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 N-CA-C 108.806 -1.267 . . . . 0.0 108.806 178.484 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.473 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.01 177.87 41.45 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -178.927 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.2 mt -135.23 142.8 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.239 -1.154 . . . . 0.0 109.652 179.502 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.47 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.87 114.5 19.29 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.051 178.721 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.548 ' HE ' HG11 ' A' ' 13' ' ' VAL . 3.8 mtt85 -105.97 122.77 46.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.515 -0.741 . . . . 0.0 109.297 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 11.0 p90 -122.94 157.81 31.8 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.058 -1.026 . . . . 0.0 110.464 -179.576 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.444 HG22 HD23 ' A' ' 15' ' ' LEU . 37.8 t . . . . . 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.751 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.78 135.42 34.13 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.174 -1.192 . . . . 0.0 110.104 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.675 ' O ' HG13 ' A' ' 3' ' ' VAL . 13.6 p -113.01 104.56 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.154 -0.966 . . . . 0.0 109.929 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.521 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 79.1 p -72.28 144.68 48.29 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.31 -0.869 . . . . 0.0 110.5 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.476 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.45 147.96 98.14 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.295 -0.878 . . . . 0.0 109.683 179.673 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.476 ' HD2' HG23 ' A' ' 5' ' ' VAL . 49.3 Cg_endo -73.37 -173.76 1.4 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 124.116 1.588 . . . . 0.0 111.006 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.529 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 1.0 OUTLIER 170.67 76.6 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.782 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.576 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -68.22 -17.38 45.05 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 O-C-N 123.879 1.462 . . . . 0.0 111.022 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.447 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 -57.0 -24.56 54.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.104 -0.997 . . . . 0.0 109.974 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.749 HG12 HG23 ' A' ' 122' ' ' THR . 9.0 mt -106.0 133.3 50.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.043 -1.036 . . . . 0.0 109.901 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.422 ' HB3' HG12 ' A' ' 129' ' ' ILE . 6.4 tp10 -85.67 128.41 34.77 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.383 -0.823 . . . . 0.0 108.946 178.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -89.21 139.24 30.69 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.026 . . . . 0.0 110.328 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.67 155.63 41.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.46 -0.775 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.09 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 110.064 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.68 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.6 tp -54.35 140.0 34.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.324 -0.86 . . . . 0.0 109.889 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.48 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 110.249 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.274 -0.891 . . . . 0.0 110.033 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 31.3 m -146.15 109.29 4.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 110.555 -179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.91 -173.9 28.7 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.294 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.42 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -107.87 -22.75 12.33 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.794 -0.827 . . . . 0.0 110.428 179.994 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -95.11 102.45 9.43 Favored Pre-proline 0 N--CA 1.486 1.345 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.695 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.442 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -61.97 139.97 82.21 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 O-C-N 123.558 1.293 . . . . 0.0 110.603 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.87 -164.08 1.45 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 111.028 -178.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.517 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.4 m-85 -58.07 81.61 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.527 -0.733 . . . . 0.0 111.221 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.05 4.99 38.2 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.68 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.5 mmtm -131.05 155.91 46.08 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.295 . . . . 0.0 109.432 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.92 107.34 16.31 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.063 -1.023 . . . . 0.0 108.918 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.898 ' CD1' HG21 ' A' ' 100' ' ' ILE . 4.5 mt -68.04 114.57 21.51 Favored Pre-proline 0 C--N 1.3 -1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 110.895 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.772 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.0 Cg_endo -70.2 128.28 15.41 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 N-CA-C 106.91 -1.996 . . . . 0.0 106.91 175.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.597 HD11 HD12 ' A' ' 58' ' ' LEU . 9.8 mt -56.22 -18.51 10.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.785 -1.197 . . . . 0.0 110.867 -177.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -59.5 -16.13 22.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.632 -1.293 . . . . 0.0 110.466 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.077 HG23 HG23 ' A' ' 33' ' ' ILE . 9.3 m -91.8 -25.17 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.021 -1.049 . . . . 0.0 110.869 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.077 HG23 HG23 ' A' ' 32' ' ' VAL . 38.0 pt -118.31 -17.15 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.011 -1.056 . . . . 0.0 110.602 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.628 ' HB2' HD11 ' A' ' 60' ' ' ILE . 6.1 tptm -98.66 148.39 23.88 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.987 -1.07 . . . . 0.0 109.847 179.229 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.58 -6.1 33.41 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.446 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.98 -136.81 2.97 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.305 -1.426 . . . . 0.0 110.307 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -117.65 132.54 56.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -1.124 . . . . 0.0 110.43 -179.56 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.574 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.83 150.25 44.45 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.244 -0.91 . . . . 0.0 110.806 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.58 HD12 ' HB ' ' A' ' 82' ' ' VAL . 24.3 tp -112.16 114.73 27.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.503 -0.748 . . . . 0.0 110.023 179.664 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.824 HD12 HG12 ' A' ' 83' ' ' VAL . 43.8 mt -97.6 127.93 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.325 -0.859 . . . . 0.0 109.972 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.418 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.34 123.03 38.65 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.217 -0.927 . . . . 0.0 109.907 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.12 21.68 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.275 -0.891 . . . . 0.0 110.702 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.517 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.7 p80 -107.12 0.46 23.47 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.483 -0.761 . . . . 0.0 110.371 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.24 137.42 44.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.944 -1.098 . . . . 0.0 110.865 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.512 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.51 -39.69 70.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.722 -0.611 . . . . 0.0 110.787 -179.753 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -58.6 -36.71 74.42 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 110.369 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.417 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.4 OUTLIER -73.8 -34.4 64.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 109.59 -179.941 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.888 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.95 73.43 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.46 -0.775 . . . . 0.0 109.461 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.48 -49.58 53.43 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.216 -0.928 . . . . 0.0 110.295 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.421 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.93 -44.38 63.72 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.288 -0.883 . . . . 0.0 110.353 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.749 HD12 HG11 ' A' ' 83' ' ' VAL . 2.0 tm? -56.86 -43.05 80.8 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.441 -0.787 . . . . 0.0 110.773 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.411 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -74.19 -51.84 14.28 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.9 -1.125 . . . . 0.0 110.656 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.69 -38.77 86.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.854 -1.154 . . . . 0.0 109.413 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.57 ' HE3' HD22 ' A' ' 51' ' ' LEU . 2.5 ttmm -59.38 -45.98 89.93 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.36 -0.838 . . . . 0.0 109.493 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.702 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.35 -40.28 71.05 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.418 -0.801 . . . . 0.0 109.763 179.833 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -56.41 -34.49 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.109 -0.995 . . . . 0.0 108.786 178.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.48 -31.2 60.15 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.558 -0.714 . . . . 0.0 110.093 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.597 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.22 -26.13 62.8 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.63 4.77 9.56 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.63 HG22 HG22 ' A' ' 81' ' ' VAL . 58.2 mt -108.09 143.34 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.283 -1.128 . . . . 0.0 110.034 -179.68 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.495 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 14.7 t-20 -86.28 107.6 18.02 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 178.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.534 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . . . -120.9 149.79 42.07 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.947 -1.101 . . . . 0.0 112.095 -176.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.911 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -138.3 152.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.429 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.888 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.45 130.81 56.74 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.076 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.465 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.51 122.24 40.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.29 -0.881 . . . . 0.0 110.441 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.949 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -156.23 176.76 12.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.592 -0.692 . . . . 0.0 109.62 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.31 125.1 16.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.064 -1.023 . . . . 0.0 110.505 -179.499 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.95 38.57 15.34 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.949 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.5 156.06 28.66 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.152 -1.205 . . . . 0.0 110.147 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.878 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.5 m-20 -96.68 148.96 22.34 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.322 -0.862 . . . . 0.0 110.565 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.23 110.95 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.054 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.4 m -132.62 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.398 -0.814 . . . . 0.0 110.523 -179.245 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.911 HG22 ' HB ' ' A' ' 63' ' ' VAL . 58.7 t -52.25 128.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -0.904 . . . . 0.0 110.053 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.874 ' O ' HD12 ' A' ' 74' ' ' ILE . 2.0 pp -137.96 115.73 9.52 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.274 -0.891 . . . . 0.0 110.487 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.735 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.1 Cg_endo -87.35 39.15 0.56 Allowed 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 123.251 1.132 . . . . 0.0 110.952 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.5 p -144.2 46.9 1.42 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.904 -1.122 . . . . 0.0 110.528 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.651 ' OD1' HD13 ' A' ' 74' ' ' ILE . 3.6 m120 -142.25 26.89 1.79 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.173 -0.954 . . . . 0.0 110.164 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.99 -94.95 1.12 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -128.77 109.04 10.95 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.174 -1.192 . . . . 0.0 110.176 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.735 HG11 ' HA ' ' A' ' 75' ' ' PRO . 6.1 p -116.98 134.46 60.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 122.054 0.93 . . . . 0.0 110.698 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.63 HG22 HG22 ' A' ' 60' ' ' ILE . 13.4 m -112.9 122.3 66.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.092 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.705 HG22 HG13 ' A' ' 73' ' ' VAL . 4.3 t -96.99 119.62 45.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.009 -1.057 . . . . 0.0 110.326 -177.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.824 HG12 HD12 ' A' ' 40' ' ' ILE . 4.5 m -111.36 100.4 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 120.997 -1.065 . . . . 0.0 108.627 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.465 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.45 162.78 34.65 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.731 -1.231 . . . . 0.0 111.602 -177.68 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.54 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -93.28 -136.0 0.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.524 179.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.54 ' N ' HG23 ' A' ' 85' ' ' THR . 12.3 p-10 -86.42 46.69 1.37 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.734 -1.228 . . . . 0.0 110.623 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.13 -23.09 8.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.931 -1.106 . . . . 0.0 110.405 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -65.79 -29.35 69.83 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.698 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.503 ' C ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER 48.68 44.93 21.69 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.455 -0.778 . . . . 0.0 111.074 179.791 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.642 ' OG1' HG22 ' A' ' 93' ' ' THR . 2.6 t 33.94 -118.86 0.09 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 112.03 0.381 . . . . 0.0 112.03 179.178 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 86.47 -63.66 4.1 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -119.88 1.83 11.0 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.43 -1.041 . . . . 0.0 110.134 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.642 HG22 ' OG1' ' A' ' 90' ' ' THR . 12.3 t -67.65 -154.43 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.016 -1.052 . . . . 0.0 110.278 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.426 ' N ' HG23 ' A' ' 93' ' ' THR . . . 90.11 -41.52 2.97 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 179.428 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -84.05 57.54 4.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.188 -1.183 . . . . 0.0 111.095 -179.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.459 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 29.8 m-85 -119.69 146.66 45.39 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.086 -1.008 . . . . 0.0 109.855 178.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.06 -33.33 67.88 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.352 -0.843 . . . . 0.0 109.856 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.78 163.7 26.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.887 . . . . 0.0 111.078 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.528 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 114.56 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.312 -0.868 . . . . 0.0 109.994 178.811 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.898 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.2 114.7 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.227 -0.92 . . . . 0.0 108.608 179.061 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.418 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.11 160.17 25.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.125 -0.984 . . . . 0.0 111.798 -178.186 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.94 -7.39 52.24 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.86 18.79 0.55 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 112.247 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.526 HG23 ' C ' ' A' ' 107' ' ' GLY . 0.8 OUTLIER -147.4 113.76 5.93 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.746 -1.221 . . . . 0.0 109.366 179.565 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.443 ' N ' ' O ' ' A' ' 108' ' ' LYS . 58.9 p -88.01 140.17 29.76 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.155 -0.966 . . . . 0.0 110.625 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 52.41 28.26 5.68 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.382 -0.823 . . . . 0.0 110.675 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.526 ' C ' HG23 ' A' ' 104' ' ' THR . . . 87.62 -14.86 57.19 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.151 -1.179 . . . . 0.0 110.151 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.496 ' O ' ' HA ' ' A' ' 104' ' ' THR . 8.5 mmtt -96.6 156.65 36.44 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.059 -1.26 . . . . 0.0 109.757 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.65 133.79 41.16 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.661 1.348 . . . . 0.0 110.107 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -57.64 -177.18 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.412 -0.805 . . . . 0.0 111.168 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -108.01 161.61 14.79 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.6 -0.687 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.521 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -41.52 -55.13 2.95 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.605 -0.684 . . . . 0.0 112.629 -178.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.31 -29.79 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 120.663 -1.273 . . . . 0.0 111.499 -178.458 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.426 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.78 -57.58 5.41 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.093 -1.005 . . . . 0.0 110.555 -179.037 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.428 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.53 -33.94 77.09 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.198 -0.939 . . . . 0.0 108.819 178.631 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.1 m -60.23 -49.25 78.35 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.531 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -41.03 63.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.427 -0.796 . . . . 0.0 110.288 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.426 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.2 mpt_? -69.96 -44.13 70.12 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.049 -1.032 . . . . 0.0 110.732 -179.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.529 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.9 OUTLIER -54.18 -38.51 65.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.044 -1.035 . . . . 0.0 110.243 -179.863 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.93 0.06 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.466 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.9 mmt-85 -151.38 -43.55 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.952 . . . . 0.0 108.848 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.749 HG23 HG12 ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.49 39.25 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.522 -0.736 . . . . 0.0 109.345 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.407 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 121.76 19.86 3.28 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.622 179.51 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.462 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.42 81.85 4.42 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.033 -1.275 . . . . 0.0 110.034 179.821 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.49 5.39 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.473 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.611 -0.935 . . . . 0.0 108.573 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.473 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.0 Cg_endo -84.08 111.78 1.67 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.12 1.063 . . . . 0.0 109.913 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.46 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.64 168.96 54.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.422 HG12 ' HB3' ' A' ' 11' ' ' GLU . 41.5 mt -127.15 142.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.366 -1.079 . . . . 0.0 109.231 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.528 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.04 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.585 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.403 ' NH2' HG21 ' A' ' 129' ' ' ILE . 6.8 mtt85 -106.47 123.23 47.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.524 -0.735 . . . . 0.0 109.372 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.426 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.93 155.43 31.32 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.167 -0.958 . . . . 0.0 110.559 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.499 HG22 HD23 ' A' ' 15' ' ' LEU . 50.1 t -72.28 -61.48 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.17 -0.956 . . . . 0.0 109.322 179.119 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -98.95 147.82 33.74 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.822 . . . . 0.0 109.936 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.33 -47.02 0.43 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.655 1.345 . . . . 0.0 110.494 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.19 -124.4 0.82 Allowed Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -110.71 -62.07 1.58 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.229 -1.16 . . . . 0.0 110.252 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 32.7 ttt85 . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.314 179.975 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.41 ' HB3' ' CB ' ' A' ' 112' ' ' ALA . 0.5 OUTLIER -106.88 125.5 51.08 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.291 -1.123 . . . . 0.0 110.245 179.847 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 3' ' ' VAL . 27.4 m -113.3 104.26 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.37 -0.831 . . . . 0.0 110.006 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.455 HG22 ' OG1' ' A' ' 116' ' ' THR . 13.9 p -78.33 142.97 37.33 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.335 -0.853 . . . . 0.0 110.379 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.471 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -74.63 148.72 85.61 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.29 -0.881 . . . . 0.0 109.506 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.471 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.8 Cg_endo -69.13 -169.24 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 124.132 1.596 . . . . 0.0 110.762 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.46 ' CG ' ' HD3' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 175.72 79.5 0.08 OUTLIER Pre-proline 0 N--CA 1.499 1.995 0 O-C-N 121.299 -0.876 . . . . 0.0 110.11 -179.549 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.52 -15.35 27.65 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.595 1.313 . . . . 0.0 110.547 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.435 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.9 m120 -65.24 -25.8 67.83 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.086 -1.009 . . . . 0.0 110.399 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.498 HD11 ' O ' ' A' ' 122' ' ' THR . 19.9 mt -107.82 135.4 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 120.946 -1.096 . . . . 0.0 110.383 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.91 128.71 34.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.519 179.15 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.16 131.82 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.095 -1.003 . . . . 0.0 110.099 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.449 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.7 t -126.62 158.13 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.368 -0.832 . . . . 0.0 110.258 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 108.55 20.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.253 -0.904 . . . . 0.0 109.693 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.555 HD11 HG12 ' A' ' 28' ' ' ILE . 9.7 tp -55.22 138.69 44.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.348 -0.845 . . . . 0.0 109.883 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.0 p -136.41 -179.68 5.83 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.301 -0.874 . . . . 0.0 110.55 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.306 -0.871 . . . . 0.0 109.862 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.742 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 2.6 m -147.66 113.13 5.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.334 -0.854 . . . . 0.0 110.373 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.442 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.45 -162.26 27.95 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.889 -1.624 . . . . 0.0 110.625 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.408 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -118.16 -22.64 7.67 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.78 -0.835 . . . . 0.0 110.497 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.911 HG23 ' HB ' ' A' ' 28' ' ' ILE . 10.0 tt -97.22 100.46 7.83 Favored Pre-proline 0 N--CA 1.485 1.324 0 C-N-CA 118.641 -1.224 . . . . 0.0 110.264 -179.317 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -62.34 147.29 95.19 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.384 1.202 . . . . 0.0 109.649 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.587 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.8 t80 -160.84 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.189 -0.944 . . . . 0.0 111.487 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.587 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 25.9 m-85 59.13 67.32 0.93 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.425 -0.797 . . . . 0.0 111.609 178.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.48 14.35 13.54 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.545 ' CB ' HD23 ' A' ' 15' ' ' LEU . 41.3 mmtm -130.63 156.4 44.95 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.069 -1.254 . . . . 0.0 109.192 179.647 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.742 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.16 107.1 13.54 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.921 -1.112 . . . . 0.0 109.487 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -71.22 113.79 22.16 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.29 -0.881 . . . . 0.0 110.156 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.834 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.8 Cg_endo -68.69 129.59 19.05 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 N-CA-C 106.877 -2.009 . . . . 0.0 106.877 176.363 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.635 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.7 mt -55.58 -19.36 9.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.867 -1.146 . . . . 0.0 110.762 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.448 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.06 24.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.753 -1.217 . . . . 0.0 110.434 179.682 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.027 HG23 HG23 ' A' ' 33' ' ' ILE . 12.5 m -91.99 -25.01 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.997 -1.064 . . . . 0.0 111.049 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.027 HG23 HG23 ' A' ' 32' ' ' VAL . 6.2 pt -117.6 -21.09 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.917 -1.115 . . . . 0.0 110.764 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.565 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.0 tptt -94.29 148.44 22.2 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.1 -1.0 . . . . 0.0 110.175 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.38 33.39 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.24 -140.43 4.85 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.113 -1.518 . . . . 0.0 110.266 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.78 131.57 55.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.319 -1.106 . . . . 0.0 110.399 -179.609 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.565 ' HB2' HG12 ' A' ' 81' ' ' VAL . 86.5 m-70 -139.32 151.89 46.77 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.289 -0.882 . . . . 0.0 110.701 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.48 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.3 tp -114.32 122.07 45.56 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.273 -0.892 . . . . 0.0 110.224 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.848 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.5 mt -104.23 129.51 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.248 -0.907 . . . . 0.0 109.451 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.48 123.92 38.2 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.452 -0.78 . . . . 0.0 109.934 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.81 159.18 22.73 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.198 -0.939 . . . . 0.0 110.732 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -108.25 0.4 21.36 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.394 -0.816 . . . . 0.0 110.15 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 30.2 p -136.37 141.39 43.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.523 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.491 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.83 -40.2 69.25 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.538 -0.726 . . . . 0.0 110.6 -179.842 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.88 -34.14 71.29 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.353 -0.842 . . . . 0.0 110.663 -179.557 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.18 -35.08 68.89 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.891 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -61.3 -33.9 74.34 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.455 -0.778 . . . . 0.0 109.464 179.409 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -69.15 -50.59 46.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.273 -0.892 . . . . 0.0 110.874 -179.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.71 -47.11 49.88 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.133 -0.979 . . . . 0.0 110.56 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.723 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.6 tm? -56.74 -37.64 71.29 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.585 -0.697 . . . . 0.0 111.256 -178.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.416 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -76.23 -51.36 12.22 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.793 -1.192 . . . . 0.0 110.381 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.57 92.71 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.149 -0.969 . . . . 0.0 110.008 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.561 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.3 OUTLIER -57.3 -44.56 84.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.362 -0.836 . . . . 0.0 109.347 179.598 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.839 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.38 -42.91 74.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.647 -0.658 . . . . 0.0 110.12 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.2 -33.16 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.052 -1.03 . . . . 0.0 108.983 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.7 -31.48 59.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.458 -0.776 . . . . 0.0 110.057 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.561 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -71.65 -26.36 62.51 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.302 -0.874 . . . . 0.0 109.329 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.77 5.47 9.09 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.635 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.6 mt -108.23 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.261 -1.14 . . . . 0.0 110.314 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.482 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 22.0 t-20 -88.05 107.08 18.56 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.74 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.03 143.9 45.22 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.912 -1.115 . . . . 0.0 111.893 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.937 HG21 ' HA ' ' A' ' 73' ' ' VAL . 94.8 t -125.05 147.46 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.713 -0.617 . . . . 0.0 109.767 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.891 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.44 123.0 49.0 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.46 -0.896 . . . . 0.0 109.519 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.45 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.3 t80 -117.67 136.36 53.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.124 -0.985 . . . . 0.0 110.743 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.869 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -169.14 176.25 5.35 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.454 -0.779 . . . . 0.0 109.819 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -50.95 122.93 8.2 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 110.876 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.4 38.78 16.7 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.869 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.01 154.82 30.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.06 -1.259 . . . . 0.0 109.923 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.848 ' N ' HD13 ' A' ' 69' ' ' LEU . 10.1 m-20 -94.09 149.12 21.52 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.292 -0.88 . . . . 0.0 110.557 -179.176 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.671 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.58 110.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.212 -0.995 . . . . 0.0 109.501 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.7 m -132.56 -17.54 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.561 -0.712 . . . . 0.0 110.903 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.937 ' HA ' HG21 ' A' ' 63' ' ' VAL . 61.2 t -65.38 141.85 17.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.146 -0.971 . . . . 0.0 109.744 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.756 ' O ' HG11 ' A' ' 80' ' ' VAL . 6.0 pt -136.41 91.3 16.49 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.239 -0.913 . . . . 0.0 110.436 -179.565 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -92.57 42.19 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.71 1.373 . . . . 0.0 110.413 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.6 t -120.32 -24.77 5.82 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.157 -0.964 . . . . 0.0 110.668 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -162.98 162.22 25.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.176 -0.953 . . . . 0.0 110.407 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 64.63 134.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -61.27 106.75 0.66 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.074 -1.251 . . . . 0.0 109.933 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.756 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.2 p -116.93 134.29 60.95 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 CA-C-O 122.125 0.964 . . . . 0.0 110.339 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.572 HG22 HG22 ' A' ' 60' ' ' ILE . 13.9 m -113.44 124.69 70.34 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.856 HG22 HG13 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.865 -1.147 . . . . 0.0 110.58 -177.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.848 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -112.7 100.6 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.862 -1.149 . . . . 0.0 108.305 179.271 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.45 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.73 34.7 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.886 -1.134 . . . . 0.0 111.541 -177.527 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.522 HG23 ' N ' ' A' ' 86' ' ' ASP . 6.3 t -84.17 -126.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.522 ' N ' HG23 ' A' ' 85' ' ' THR . 1.0 OUTLIER -101.37 40.27 1.32 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.474 -1.391 . . . . 0.0 110.211 179.691 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.469 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.72 -34.67 7.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.87 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.663 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -68.99 -19.89 64.15 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.279 -0.888 . . . . 0.0 109.841 179.518 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.423 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.2 OUTLIER 53.68 -150.5 0.37 Allowed 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.251 -0.906 . . . . 0.0 109.871 -179.788 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.457 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 0.1 OUTLIER -150.62 31.51 0.64 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.272 -0.893 . . . . 0.0 109.975 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.33 -29.44 73.15 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -131.95 19.15 4.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.119 -1.224 . . . . 0.0 110.787 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.457 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 14.5 t -90.56 -154.78 0.36 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.051 -1.031 . . . . 0.0 110.302 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.432 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 103.24 -32.46 7.56 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.443 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -84.05 53.96 2.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.962 -1.317 . . . . 0.0 110.567 -179.597 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.498 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.15 145.71 46.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.039 -1.038 . . . . 0.0 110.161 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.521 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.53 -31.5 42.08 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.725 179.532 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.475 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.1 p -161.56 163.95 29.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.176 -0.953 . . . . 0.0 111.33 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.462 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.89 115.54 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.494 -0.754 . . . . 0.0 110.017 179.291 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.946 HG21 HD11 ' A' ' 28' ' ' ILE . 3.6 mp -93.42 112.56 26.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.165 -0.96 . . . . 0.0 108.859 179.36 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.8 161.07 19.86 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.125 -0.985 . . . . 0.0 111.765 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.471 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 15.0 t -102.98 8.31 39.0 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.735 -0.603 . . . . 0.0 109.482 178.19 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 47.09 26.16 0.6 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.155 -0.966 . . . . 0.0 111.09 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.451 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.8 p -146.53 132.52 19.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.114 -0.991 . . . . 0.0 110.516 179.633 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.446 ' N ' ' O ' ' A' ' 108' ' ' LYS . 80.6 p -112.81 134.36 54.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.326 -0.859 . . . . 0.0 109.941 179.536 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.4 t0 49.36 29.1 2.62 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.172 -0.955 . . . . 0.0 110.632 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.03 -33.01 5.47 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.66 157.3 82.3 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.287 -1.125 . . . . 0.0 110.127 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.451 ' HA ' HG22 ' A' ' 104' ' ' THR . 39.7 Cg_endo -65.13 133.74 36.69 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.565 1.297 . . . . 0.0 110.135 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.447 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 -49.21 150.2 1.79 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.254 -0.904 . . . . 0.0 110.78 -179.457 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.555 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -89.06 161.57 16.48 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.402 -0.811 . . . . 0.0 110.442 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.434 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.7 -53.87 3.47 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.469 -0.769 . . . . 0.0 112.375 -178.633 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.555 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.1 m -68.66 -29.5 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.608 -1.307 . . . . 0.0 111.264 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.447 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.66 -56.48 7.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.078 -1.014 . . . . 0.0 110.549 -179.268 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.44 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.3 OUTLIER -67.6 -34.89 77.92 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.15 -0.969 . . . . 0.0 108.605 178.758 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.455 ' OG1' HG22 ' A' ' 4' ' ' THR . 13.3 m -59.56 -49.79 76.42 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -74.02 -35.89 64.4 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.592 -0.693 . . . . 0.0 109.871 178.849 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.44 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 3.3 mtt85 -71.13 -44.83 64.81 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.028 -1.045 . . . . 0.0 110.71 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.476 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 2.7 ttm105 -60.42 -42.56 96.26 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.978 -1.076 . . . . 0.0 110.455 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.58 86.16 0.09 OUTLIER Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.423 ' NH1' ' O ' ' A' ' 89' ' ' MET . 0.0 OUTLIER -164.7 -45.4 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.5 -1.0 . . . . 0.0 108.652 179.502 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.526 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.57 30.03 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.119 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.48 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.09 10.45 12.04 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.117 -1.516 . . . . 0.0 110.567 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.432 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 5.8 mtt180 -84.88 83.99 7.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.043 -1.269 . . . . 0.0 109.842 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.49 9.46 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 108.916 -1.674 . . . . 0.0 108.916 -179.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.508 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.74 -169.63 0.22 Allowed Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.892 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.508 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.8 Cg_endo -88.0 111.06 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 122.883 0.938 . . . . 0.0 110.047 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.526 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.57 150.93 38.95 Favored Glycine 0 N--CA 1.494 2.563 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.173 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.454 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.43 141.46 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -1.202 . . . . 0.0 109.139 179.251 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.476 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.89 116.46 17.2 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.882 -1.136 . . . . 0.0 110.725 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.486 ' NH1' HG11 ' A' ' 32' ' ' VAL . 9.6 mtt-85 -105.81 125.78 51.39 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.405 -0.809 . . . . 0.0 109.635 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.7 p90 -114.61 157.92 22.42 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.979 -1.076 . . . . 0.0 110.192 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.471 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t -89.94 -65.76 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.119 -0.988 . . . . 0.0 109.984 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 54.29 96.73 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.594 -0.691 . . . . 0.0 109.952 -179.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.03 -49.51 0.3 Allowed 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.669 1.352 . . . . 0.0 110.408 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -131.21 23.67 4.31 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -110.61 167.14 10.45 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -1.103 . . . . 0.0 110.209 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.027 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.9 p -81.35 106.77 13.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.339 -1.094 . . . . 0.0 110.091 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.675 ' O ' HG13 ' A' ' 3' ' ' VAL . 9.2 p -113.01 104.04 16.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.229 -0.92 . . . . 0.0 110.018 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 7.8 p -73.1 145.28 46.58 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 110.176 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.408 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -81.04 147.04 60.32 Favored Pre-proline 0 C--N 1.302 -1.498 0 O-C-N 121.364 -0.835 . . . . 0.0 109.712 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.408 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.7 Cg_endo -73.19 -165.06 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 124.038 1.546 . . . . 0.0 110.949 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.531 ' CD2' ' HB ' ' A' ' 10' ' ' ILE . 7.0 p-80 -177.62 82.18 0.24 Allowed Pre-proline 0 C--N 1.302 -1.472 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -64.85 81.32 0.18 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 123.891 1.469 . . . . 0.0 110.74 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 -172.16 -37.4 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 CA-C-O 121.35 0.595 . . . . 0.0 109.561 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.531 ' HB ' ' CD2' ' A' ' 7' ' ' HIS . 13.7 mt -96.24 130.21 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.095 -1.003 . . . . 0.0 110.153 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.416 ' HB3' HG12 ' A' ' 129' ' ' ILE . 18.4 tt0 -84.93 129.44 34.8 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.454 -0.778 . . . . 0.0 109.686 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -88.42 133.04 34.22 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.024 -1.047 . . . . 0.0 109.946 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.557 HG11 ' NE ' ' A' ' 131' ' ' ARG . 12.0 t -126.72 158.0 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.433 -0.792 . . . . 0.0 110.469 -179.016 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.74 110.74 23.0 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.312 -0.867 . . . . 0.0 109.906 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.417 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.7 tp -56.49 140.1 47.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.766 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.9 p -135.36 170.53 15.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.17 -0.956 . . . . 0.0 110.236 -179.682 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.73 63.6 0.29 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.08 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.47 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.3 m -133.91 111.67 10.64 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.35 -0.844 . . . . 0.0 110.399 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.445 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.912 -1.613 . . . . 0.0 110.815 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.4 -19.15 8.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.763 -0.845 . . . . 0.0 110.366 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.904 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.56 113.2 62.21 Favored Pre-proline 0 N--CA 1.485 1.322 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.421 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -65.48 144.22 78.63 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.596 1.314 . . . . 0.0 109.648 179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.506 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.07 98.65 1.06 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.078 -1.049 . . . . 0.0 111.634 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.499 ' N ' ' CD1' ' A' ' 24' ' ' TYR . 22.7 m-85 55.45 65.24 1.53 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.292 -0.88 . . . . 0.0 111.59 178.424 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.86 14.59 10.37 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.506 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.91 156.2 45.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.075 -1.25 . . . . 0.0 108.93 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.47 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.39 106.55 14.13 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.916 -1.115 . . . . 0.0 109.465 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.935 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -68.7 114.9 25.48 Favored Pre-proline 0 C--N 1.298 -1.663 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.018 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.766 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.3 Cg_endo -69.54 128.68 16.59 Favored 'Trans proline' 0 C--N 1.303 -1.825 0 N-CA-C 106.587 -2.12 . . . . 0.0 106.587 176.235 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.756 HD11 HD12 ' A' ' 58' ' ' LEU . 14.0 mt -55.57 -18.85 8.36 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.469 -177.375 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -59.06 -16.52 19.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.721 -1.237 . . . . 0.0 110.574 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.034 HG23 HG23 ' A' ' 33' ' ' ILE . 11.0 m -92.57 -24.1 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 120.921 -1.112 . . . . 0.0 110.925 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.034 HG23 HG23 ' A' ' 32' ' ' VAL . 6.9 pt -119.44 -20.27 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.936 -1.103 . . . . 0.0 110.983 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.556 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.41 22.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.935 -1.103 . . . . 0.0 110.403 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.86 -2.85 66.96 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.66 18.0 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.025 -1.56 . . . . 0.0 110.69 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.46 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.61 132.79 52.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.479 -1.012 . . . . 0.0 110.162 -179.622 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.518 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.14 45.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 110.933 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.621 HD12 ' O ' ' A' ' 82' ' ' VAL . 50.2 tp -113.29 114.44 26.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.411 -0.806 . . . . 0.0 110.241 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.755 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.2 mt -97.31 128.79 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.021 . . . . 0.0 109.549 179.367 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.401 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 8.0 m-85 -97.54 123.28 41.36 Favored 'General case' 0 C--N 1.292 -1.893 0 O-C-N 121.108 -0.995 . . . . 0.0 110.448 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.39 159.86 22.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.342 -0.849 . . . . 0.0 110.382 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 18.6 p-80 -104.73 -5.61 21.13 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.31 -0.869 . . . . 0.0 110.06 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.7 p -128.15 139.85 52.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.98 -1.075 . . . . 0.0 110.863 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.86 -39.51 69.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.636 -0.665 . . . . 0.0 110.475 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.08 -33.44 70.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.399 -0.813 . . . . 0.0 110.648 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.408 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.67 -37.08 68.02 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.349 -0.844 . . . . 0.0 109.914 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.883 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 69.7 m -62.16 -36.38 81.68 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.364 -0.835 . . . . 0.0 109.651 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.35 -50.28 64.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.027 -1.046 . . . . 0.0 110.231 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.63 -44.81 61.43 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.312 -0.867 . . . . 0.0 110.415 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.897 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -61.29 -36.82 81.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.479 -0.763 . . . . 0.0 111.583 -178.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.417 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.77 -51.68 12.1 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.843 -1.161 . . . . 0.0 110.776 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.78 -38.22 78.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.036 -1.04 . . . . 0.0 109.563 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.806 ' HE2' HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.11 -46.46 82.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.661 -0.649 . . . . 0.0 109.464 179.287 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.742 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.7 -40.23 72.1 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.355 -0.841 . . . . 0.0 110.131 179.897 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.5 t -59.08 -30.91 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.173 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.77 60.17 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.456 -0.778 . . . . 0.0 110.0 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.756 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.27 -25.52 62.49 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.845 0.831 . . . . 0.0 109.739 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.79 7.05 8.97 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.709 ' CD1' HD22 ' A' ' 30' ' ' LEU . 39.4 mt -107.77 142.78 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.31 -1.112 . . . . 0.0 109.821 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.507 ' OD1' HD11 ' A' ' 74' ' ' ILE . 2.4 t-20 -88.87 106.52 18.45 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 177.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.679 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -115.95 141.76 47.68 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.521 -177.37 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.898 HG21 ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.97 143.17 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.704 -0.622 . . . . 0.0 110.007 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.883 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.34 117.82 34.17 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.366 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.28 127.12 53.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.197 -0.939 . . . . 0.0 111.07 -179.235 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.866 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 7.3 p90 -157.59 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.684 -0.635 . . . . 0.0 109.642 179.417 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.19 126.99 25.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.08 -1.012 . . . . 0.0 111.007 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.75 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.866 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -116.59 154.92 29.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.09 -1.241 . . . . 0.0 109.896 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.831 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.7 m-20 -94.84 149.57 21.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.345 -0.847 . . . . 0.0 110.517 -179.201 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.1 m -61.75 110.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 118.969 -1.092 . . . . 0.0 108.817 179.194 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.855 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.3 m -130.66 -34.72 1.52 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.438 -0.789 . . . . 0.0 110.283 -179.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.898 ' HA ' HG21 ' A' ' 63' ' ' VAL . 90.9 t -46.86 129.83 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.457 -0.777 . . . . 0.0 109.883 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.855 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -136.14 92.99 15.44 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 111.18 -179.186 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -82.81 53.35 4.38 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 O-C-N 123.731 1.385 . . . . 0.0 109.589 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.9 p -147.05 19.44 1.25 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.332 -0.855 . . . . 0.0 110.435 -179.31 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -123.39 -164.49 1.22 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.281 -0.887 . . . . 0.0 109.933 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.79 -77.83 0.11 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -146.79 113.39 6.0 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.111 -1.229 . . . . 0.0 110.343 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.618 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.5 p -117.25 133.95 62.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 CA-C-O 121.978 0.894 . . . . 0.0 110.452 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.671 HG11 ' HB ' ' A' ' 33' ' ' ILE . 12.6 m -112.59 122.01 65.99 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.107 0 O-C-N 121.355 -0.841 . . . . 0.0 109.01 179.118 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.763 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.54 45.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.911 -1.118 . . . . 0.0 110.726 -177.685 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.755 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -110.16 99.58 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.91 -1.116 . . . . 0.0 108.974 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -132.41 162.09 32.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.698 -1.251 . . . . 0.0 110.326 -178.811 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.601 HG23 ' OD2' ' A' ' 86' ' ' ASP . 7.2 t -99.1 -27.91 13.62 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.161 -0.962 . . . . 0.0 110.689 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.601 ' OD2' HG23 ' A' ' 85' ' ' THR . 1.3 p30 177.93 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.376 -0.827 . . . . 0.0 110.257 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.499 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.35 -25.57 0.67 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.266 -0.896 . . . . 0.0 110.936 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.462 HD11 ' HZ ' ' A' ' 92' ' ' PHE . 14.7 tp -62.01 -34.44 76.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.184 -0.948 . . . . 0.0 109.791 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.499 ' C ' HG22 ' A' ' 90' ' ' THR . 14.7 mmt 48.24 46.95 19.9 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.482 -0.762 . . . . 0.0 110.877 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.572 ' OG1' HG22 ' A' ' 93' ' ' THR . 2.6 t 34.8 -128.05 0.09 Allowed 'General case' 0 N--CA 1.505 2.32 0 O-C-N 122.03 -0.419 . . . . 0.0 112.012 179.342 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.429 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 93.63 -61.48 2.05 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 108.383 -1.887 . . . . 0.0 108.383 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.462 ' HZ ' HD11 ' A' ' 88' ' ' LEU . 33.3 p90 -122.0 3.48 9.92 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.457 -1.025 . . . . 0.0 109.923 178.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.572 HG22 ' OG1' ' A' ' 90' ' ' THR . 13.1 t -67.41 -160.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.058 -1.026 . . . . 0.0 109.78 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 91.32 -39.38 3.07 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -84.25 57.01 4.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.144 -1.209 . . . . 0.0 110.781 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.497 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 28.4 m-85 -119.25 149.47 41.72 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -0.988 . . . . 0.0 110.01 179.276 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.439 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.6 -30.74 46.78 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.354 -0.841 . . . . 0.0 109.61 179.528 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -161.65 163.22 30.02 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.231 -0.918 . . . . 0.0 110.925 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.459 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.2 114.37 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.999 0 O-C-N 121.417 -0.802 . . . . 0.0 110.154 179.189 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.935 HG21 HD11 ' A' ' 28' ' ' ILE . 3.8 mp -93.06 112.41 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 108.523 179.023 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.416 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.82 21.2 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.103 -0.998 . . . . 0.0 111.722 -177.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.447 ' SG ' ' CE1' ' A' ' 24' ' ' TYR . 57.0 m -98.45 2.31 47.61 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.658 -0.651 . . . . 0.0 109.293 177.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.668 ' HB3' ' HB3' ' A' ' 134' ' ' ALA . 2.4 m120 53.86 24.84 4.78 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.149 -0.97 . . . . 0.0 111.172 179.739 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -147.16 129.58 15.82 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.026 -1.046 . . . . 0.0 110.923 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.9 p -103.35 134.06 47.37 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.361 -0.837 . . . . 0.0 109.336 179.128 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 49.09 27.22 1.65 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.146 -0.971 . . . . 0.0 110.455 -179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.18 -32.72 5.71 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 105' ' ' SER . 9.8 mmpt? -76.68 157.31 82.25 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.318 -1.107 . . . . 0.0 110.142 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -64.44 130.12 25.85 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 123.587 1.309 . . . . 0.0 110.168 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.428 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 4.2 pt20 -51.7 154.0 2.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.478 -0.764 . . . . 0.0 110.935 -179.041 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.519 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -85.28 161.46 19.53 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.245 -0.909 . . . . 0.0 110.286 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.67 -57.94 2.13 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.605 -0.685 . . . . 0.0 112.519 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.519 HG22 ' OD1' ' A' ' 111' ' ' ASP . 8.1 m -67.36 -29.6 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 120.68 -1.263 . . . . 0.0 111.532 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.428 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.54 -56.09 7.83 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.111 -0.993 . . . . 0.0 110.437 -179.286 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.463 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.16 -34.06 76.74 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.537 178.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.6 m -59.28 -48.89 79.92 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.049 -1.032 . . . . 0.0 108.404 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.1 -35.7 66.64 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.746 -0.782 . . . . 0.0 109.812 178.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.432 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.58 -45.06 66.1 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.058 -1.026 . . . . 0.0 110.463 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.473 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.1 ttm180 -59.45 -40.79 88.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.003 -1.06 . . . . 0.0 110.004 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.28 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.437 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -149.07 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.515 -0.991 . . . . 0.0 108.625 179.365 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.543 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.8 t -98.16 143.35 28.78 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 12.5 10.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.4 -1.381 . . . . 0.0 110.515 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.406 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 0.7 OUTLIER -79.5 85.07 5.3 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.009 -1.289 . . . . 0.0 109.877 179.797 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 98.74 17.2 28.94 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.463 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 4.5 pttt -176.98 -177.02 0.25 Allowed Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.48 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.7 Cg_endo -89.01 106.93 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.118 1.062 . . . . 0.0 109.488 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.543 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.01 174.0 49.73 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.321 -179.131 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 20.3 mt -130.22 141.86 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 108.839 179.137 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 12.8 t80 -132.18 115.95 16.35 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.061 -1.024 . . . . 0.0 110.858 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.557 ' NE ' HG11 ' A' ' 13' ' ' VAL . 0.3 OUTLIER -102.67 122.15 43.86 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.415 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 39.1 p90 -115.17 158.1 22.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.015 -1.053 . . . . 0.0 110.254 -179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.4 t -98.01 -30.78 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.156 -0.965 . . . . 0.0 110.37 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.668 ' HB3' ' HB3' ' A' ' 103' ' ' ASN . . . -95.75 117.76 66.29 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.156 -0.965 . . . . 0.0 110.51 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -85.15 47.31 2.02 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.573 1.302 . . . . 0.0 110.375 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -66.02 -136.46 0.03 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 55.56 34.77 23.82 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.335 -1.097 . . . . 0.0 110.212 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 29.5 ttt85 . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.997 179.834 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 p -77.2 143.42 39.03 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.213 -1.169 . . . . 0.0 110.093 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 3' ' ' VAL . 31.3 m -112.95 103.9 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.2 -0.937 . . . . 0.0 110.009 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.49 HG21 ' HD2' ' A' ' 115' ' ' ARG . 62.5 p -103.39 143.13 33.09 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.352 -0.843 . . . . 0.0 110.353 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.445 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.17 149.43 98.47 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.45 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.445 ' HD2' HG23 ' A' ' 5' ' ' VAL . 40.7 Cg_endo -68.51 -165.35 0.12 Allowed 'Trans proline' 0 C--N 1.307 -1.635 0 O-C-N 123.993 1.523 . . . . 0.0 110.608 179.213 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.563 ' CE1' ' HD3' ' A' ' 119' ' ' ARG . 0.4 OUTLIER 173.42 82.42 0.05 OUTLIER Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.46 -0.775 . . . . 0.0 109.979 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -69.34 66.47 1.52 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.631 1.332 . . . . 0.0 109.858 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.5 t-20 -153.62 -34.84 0.11 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.564 -0.71 . . . . 0.0 110.618 -179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.536 HD12 ' HG2' ' A' ' 119' ' ' ARG . 45.0 mt -103.45 128.24 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.919 -1.113 . . . . 0.0 110.218 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.36 127.98 34.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.147 179.188 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.63 142.02 28.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.049 -1.032 . . . . 0.0 110.365 -179.162 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.53 HG11 ' NE ' ' A' ' 131' ' ' ARG . 4.8 t -128.97 157.7 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.481 -0.762 . . . . 0.0 109.878 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.66 112.32 25.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.248 -0.907 . . . . 0.0 110.317 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.584 HD23 HG22 ' A' ' 133' ' ' VAL . 13.5 tp -62.9 135.58 57.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -0.922 . . . . 0.0 109.326 179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.5 p -137.15 -178.15 5.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.029 -1.045 . . . . 0.0 110.623 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.29 4.28 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.371 -0.83 . . . . 0.0 109.741 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.673 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 3.6 m -156.68 113.55 3.1 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.898 . . . . 0.0 110.589 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.429 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -168.18 28.25 Favored Glycine 0 N--CA 1.488 2.125 0 C-N-CA 118.836 -1.649 . . . . 0.0 111.081 179.18 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.42 -20.92 10.06 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.844 -0.798 . . . . 0.0 110.289 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.901 HD12 HD13 ' A' ' 55' ' ' LEU . 9.0 tt -96.78 107.76 38.92 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 118.794 -1.163 . . . . 0.0 109.757 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.2 Cg_endo -64.62 126.97 17.79 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 123.353 1.186 . . . . 0.0 110.887 -178.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.3 -169.82 1.69 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.564 -0.71 . . . . 0.0 110.345 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.3 m-85 -57.4 81.15 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.488 -0.757 . . . . 0.0 111.6 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.84 -1.29 59.23 Favored Glycine 0 N--CA 1.494 2.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.757 179.427 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.404 ' HD2' ' O ' ' A' ' 15' ' ' LEU . 0.5 OUTLIER -129.59 156.89 43.46 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.881 -1.364 . . . . 0.0 110.047 -179.903 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.673 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -104.79 106.86 17.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.062 -1.024 . . . . 0.0 108.868 179.448 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.8 mt -68.34 113.14 13.54 Favored Pre-proline 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 110.677 -179.169 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.893 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -68.97 130.65 20.72 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 107.216 -1.879 . . . . 0.0 107.216 175.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.682 HD11 HD12 ' A' ' 58' ' ' LEU . 13.0 mt -56.3 -18.99 12.34 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.816 -1.178 . . . . 0.0 110.137 -178.09 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.466 ' OE2' HG12 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.69 -16.15 24.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.681 -1.262 . . . . 0.0 110.437 179.687 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.025 HG23 HG23 ' A' ' 33' ' ' ILE . 17.0 m -91.76 -25.02 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.949 -1.094 . . . . 0.0 110.836 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.025 HG23 HG23 ' A' ' 32' ' ' VAL . 38.6 pt -119.4 -20.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.058 -1.026 . . . . 0.0 111.134 -178.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.592 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.2 tptm -92.93 148.33 22.1 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.984 -1.072 . . . . 0.0 110.073 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.93 -5.32 46.44 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 -179.542 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.87 21.88 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.205 -1.474 . . . . 0.0 110.341 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.1 mtt-85 -97.85 133.01 42.93 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -1.028 . . . . 0.0 110.305 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.572 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.5 m-70 -140.29 149.21 42.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.21 -0.931 . . . . 0.0 110.799 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.464 ' HB3' HG12 ' A' ' 99' ' ' VAL . 26.8 tp -111.41 114.09 26.99 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.371 -0.831 . . . . 0.0 110.061 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.821 HD12 HG12 ' A' ' 83' ' ' VAL . 35.3 mt -96.68 127.76 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.192 -0.943 . . . . 0.0 109.776 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -95.36 123.46 38.9 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.574 -0.704 . . . . 0.0 109.873 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.8 157.07 27.25 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.2 -0.937 . . . . 0.0 110.755 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.2 p80 -104.44 0.92 29.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.374 -0.829 . . . . 0.0 109.976 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 110.255 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.416 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.7 ttpt -71.63 -41.9 68.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.513 -0.742 . . . . 0.0 110.907 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.86 -33.79 72.27 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.251 -0.906 . . . . 0.0 110.812 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.506 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.27 -39.6 82.11 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.926 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.864 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.6 m -61.16 -34.68 75.41 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.253 -0.904 . . . . 0.0 109.768 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.63 -50.36 65.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.241 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.17 53.85 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.213 -0.929 . . . . 0.0 110.377 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.769 ' CD2' HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.03 -36.51 70.55 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.719 -0.613 . . . . 0.0 111.386 -178.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.487 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.84 -51.09 13.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.9 -1.125 . . . . 0.0 110.722 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.14 -39.34 89.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.072 -1.017 . . . . 0.0 109.846 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.545 ' HE3' HD21 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.26 -45.77 83.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.332 -0.855 . . . . 0.0 109.586 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.901 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.32 -39.95 70.57 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.513 -0.742 . . . . 0.0 110.088 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.93 -34.84 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.118 -0.989 . . . . 0.0 108.958 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -30.81 60.64 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.435 -0.79 . . . . 0.0 110.238 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.682 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.6 -25.88 62.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.345 -0.847 . . . . 0.0 109.815 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.11 4.71 10.03 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.669 ' CD1' HD22 ' A' ' 30' ' ' LEU . 45.9 mt -107.57 143.4 18.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.362 -1.081 . . . . 0.0 109.919 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.476 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 11.1 t-20 -89.46 106.85 18.72 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 106.476 -1.675 . . . . 0.0 106.476 178.065 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.676 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.21 143.48 45.82 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.728 -1.189 . . . . 0.0 112.316 -176.705 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.918 HG21 ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.25 151.88 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.864 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -121.27 118.34 29.31 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.715 178.554 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.493 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -108.81 133.83 52.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.317 -0.865 . . . . 0.0 110.552 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.977 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.5 p90 -165.81 -173.25 2.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.473 -0.767 . . . . 0.0 110.162 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.91 125.44 23.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.224 -0.923 . . . . 0.0 110.702 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.55 29.2 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.977 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -1.167 . . . . 0.0 109.997 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.826 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.4 m-20 -97.24 149.13 22.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 110.731 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.672 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.9 m -62.9 110.99 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.254 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.7 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.8 m -131.4 -32.53 1.54 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.426 -0.796 . . . . 0.0 110.752 -179.346 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.918 ' HA ' HG21 ' A' ' 63' ' ' VAL . 99.0 t -47.83 134.55 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.44 -0.787 . . . . 0.0 110.19 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.7 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -137.0 92.53 14.09 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.137 -0.977 . . . . 0.0 111.12 -179.797 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -83.21 51.47 3.63 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.626 1.329 . . . . 0.0 109.719 178.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -146.25 13.88 1.27 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.213 -0.93 . . . . 0.0 111.04 -178.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -135.85 -149.94 0.35 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.021 -1.049 . . . . 0.0 109.856 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.21 174.64 0.1 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -56.5 114.99 2.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.201 -1.176 . . . . 0.0 110.381 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.3 p -116.52 134.69 59.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 122.038 0.923 . . . . 0.0 109.858 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.588 HG22 HG22 ' A' ' 60' ' ' ILE . 16.5 m -112.83 123.53 68.59 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.317 -0.864 . . . . 0.0 109.555 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.762 HG22 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.95 116.46 40.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.842 -1.161 . . . . 0.0 110.595 -178.136 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.821 HG12 HD12 ' A' ' 40' ' ' ILE . 2.8 m -107.87 100.38 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 0.0 108.559 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.493 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -135.63 162.2 33.37 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.732 -1.23 . . . . 0.0 111.335 -177.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.422 ' H ' HG22 ' A' ' 85' ' ' THR . 5.3 t -91.61 -132.83 0.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.673 -0.642 . . . . 0.0 109.649 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.15 21.35 3.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.752 -1.217 . . . . 0.0 110.59 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.46 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.25 -34.91 15.59 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -0.949 . . . . 0.0 109.646 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp -69.72 -46.5 65.81 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.375 -0.828 . . . . 0.0 109.592 179.461 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.427 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 1.2 mmt 53.32 21.04 2.15 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.361 -0.837 . . . . 0.0 110.204 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.487 HG21 ' HG3' ' A' ' 121' ' ' ARG . 0.3 OUTLIER 45.42 36.25 2.31 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.514 -0.741 . . . . 0.0 110.861 179.826 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.79 -70.88 0.78 Allowed Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -99.54 41.61 1.15 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.251 -1.146 . . . . 0.0 108.908 178.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.425 HG21 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -139.23 -156.66 0.7 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.575 -0.703 . . . . 0.0 110.017 -179.337 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.463 ' N ' HG22 ' A' ' 90' ' ' THR . . . 126.71 -25.92 5.23 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -89.49 80.3 6.75 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.119 -1.224 . . . . 0.0 110.717 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.425 ' CZ ' HG21 ' A' ' 93' ' ' THR . 46.3 m-85 -119.21 148.51 43.03 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.112 -0.993 . . . . 0.0 109.964 179.228 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.23 59.8 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.351 -0.843 . . . . 0.0 109.237 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.323 -0.861 . . . . 0.0 111.003 179.634 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.58 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.03 117.54 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.355 -0.841 . . . . 0.0 110.685 179.799 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.868 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.12 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.74 160.71 22.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.174 -0.954 . . . . 0.0 111.517 -178.154 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.475 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 13.7 t -100.01 8.27 44.13 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.649 -0.657 . . . . 0.0 109.588 178.367 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.402 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.5 m120 46.89 25.95 0.52 Allowed 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.272 -0.893 . . . . 0.0 110.725 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.6 p -147.31 129.73 15.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.235 -0.915 . . . . 0.0 110.062 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.434 ' N ' ' O ' ' A' ' 108' ' ' LYS . 5.7 p -114.01 133.7 55.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.163 -0.96 . . . . 0.0 110.147 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.19 28.76 7.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.192 -0.942 . . . . 0.0 110.472 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.06 -35.04 4.25 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.434 ' O ' ' N ' ' A' ' 105' ' ' SER . 1.9 mttm -79.47 156.45 75.83 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.168 -1.195 . . . . 0.0 110.061 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -66.18 135.51 40.53 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 O-C-N 123.622 1.327 . . . . 0.0 110.187 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -49.53 165.74 0.06 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.276 -0.89 . . . . 0.0 110.797 -179.067 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.9 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.243 -0.911 . . . . 0.0 110.294 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.16 -53.19 5.15 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.554 -0.716 . . . . 0.0 112.239 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.46 -29.07 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.68 -1.263 . . . . 0.0 111.432 -178.707 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.404 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.36 -56.46 6.85 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.124 -0.985 . . . . 0.0 110.486 -179.067 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.49 ' HD2' HG21 ' A' ' 4' ' ' THR . 16.4 ptp180 -68.9 -35.17 76.54 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.218 -0.926 . . . . 0.0 108.635 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.434 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 26.9 m -59.32 -49.89 76.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.072 -1.017 . . . . 0.0 108.608 178.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -73.75 -38.54 64.7 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.498 -0.752 . . . . 0.0 110.064 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.425 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.43 -44.71 67.31 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.263 -0.898 . . . . 0.0 110.838 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.563 ' HD3' ' CE1' ' A' ' 7' ' ' HIS . 1.3 ttp180 -55.28 -48.73 73.63 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.27 -0.893 . . . . 0.0 110.507 -179.552 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.18 -18.89 1.41 Allowed Glycine 0 N--CA 1.499 2.834 0 O-C-N 121.526 -0.734 . . . . 0.0 112.343 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.487 ' HG3' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -56.61 -35.55 68.41 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.501 -1.588 . . . . 0.0 112.014 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.481 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.3 t -100.06 144.67 28.82 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.696 -1.252 . . . . 0.0 111.495 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.432 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.63 8.06 62.62 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.578 178.659 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.419 ' HD2' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -62.09 86.83 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.065 -1.256 . . . . 0.0 109.006 179.502 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.8 -21.44 34.2 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -178.596 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.489 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -138.99 -168.87 0.2 Allowed Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.386 -1.067 . . . . 0.0 109.09 179.924 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.1 Cg_endo -87.87 107.98 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.147 1.077 . . . . 0.0 110.564 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.481 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -84.52 168.36 43.92 Favored Glycine 0 N--CA 1.498 2.777 0 O-C-N 121.047 -1.033 . . . . 0.0 110.973 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.445 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.2 mt -124.87 143.24 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.618 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.58 ' CD2' HG23 ' A' ' 99' ' ' VAL . 10.0 t80 -130.22 121.94 27.15 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.693 -1.254 . . . . 0.0 111.771 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.53 ' NE ' HG11 ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.25 124.38 49.67 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.402 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 45.8 p90 -123.27 155.97 36.15 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.954 -1.091 . . . . 0.0 110.888 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.584 HG22 HD23 ' A' ' 15' ' ' LEU . 16.7 t -84.01 -68.77 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.369 -0.832 . . . . 0.0 109.173 178.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 52.12 83.04 0.23 Allowed Pre-proline 0 N--CA 1.487 1.387 0 O-C-N 121.744 -0.598 . . . . 0.0 110.225 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.81 -53.26 0.14 Allowed 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.725 1.381 . . . . 0.0 110.536 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 110.37 135.76 7.1 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.99 -68.2 0.83 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.195 -1.179 . . . . 0.0 110.257 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.6 ttt-85 . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.253 -179.934 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.9 p -91.92 138.01 31.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.241 -1.152 . . . . 0.0 110.212 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 3' ' ' VAL . 14.7 m -113.08 104.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.944 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.644 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 34.9 p -92.62 144.87 24.89 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.474 -0.766 . . . . 0.0 110.097 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.448 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.3 147.03 98.97 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.184 -0.948 . . . . 0.0 109.744 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.448 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.9 Cg_endo -71.0 -167.63 0.28 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 124.092 1.575 . . . . 0.0 110.461 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.536 ' CE1' ' HD3' ' A' ' 119' ' ' ARG . 0.5 OUTLIER 173.73 83.11 0.06 OUTLIER Pre-proline 0 N--CA 1.496 1.861 0 O-C-N 121.513 -0.742 . . . . 0.0 109.571 179.621 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.22 -13.6 28.36 Favored 'Trans proline' 0 C--N 1.312 -1.36 0 O-C-N 123.903 1.475 . . . . 0.0 111.126 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.427 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 18.3 m120 -64.99 -31.21 72.34 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.063 -1.023 . . . . 0.0 110.316 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.491 HD11 ' O ' ' A' ' 122' ' ' THR . 25.1 mt -106.2 135.78 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.072 -1.018 . . . . 0.0 110.223 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.42 128.5 34.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.323 -0.86 . . . . 0.0 109.451 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.38 125.51 35.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.063 -1.023 . . . . 0.0 110.047 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.451 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.06 155.01 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 110.322 -179.385 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.6 110.48 22.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.603 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.683 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.4 tp -56.5 135.38 54.41 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.269 -0.894 . . . . 0.0 109.976 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.414 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.3 p -134.58 167.47 20.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 110.378 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.05 79.72 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.302 -0.874 . . . . 0.0 109.993 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.621 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 35.8 m -154.14 109.7 3.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.457 -0.777 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.43 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.68 -170.69 29.83 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 118.928 -1.606 . . . . 0.0 111.103 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.33 -22.14 11.5 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.716 -0.873 . . . . 0.0 110.207 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.895 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.83 25.67 Favored Pre-proline 0 N--CA 1.49 1.532 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.738 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.474 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.3 Cg_endo -64.49 131.88 31.36 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.317 1.167 . . . . 0.0 110.805 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.1 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.586 -0.696 . . . . 0.0 110.646 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.703 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.6 m-85 -58.04 81.46 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.397 -0.814 . . . . 0.0 111.342 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.46 47.71 Favored Glycine 0 N--CA 1.493 2.434 0 O-C-N 121.084 -1.01 . . . . 0.0 110.6 179.718 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.683 ' CB ' HD23 ' A' ' 15' ' ' LEU . 16.7 mmtp -130.45 156.8 44.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.957 -1.32 . . . . 0.0 109.309 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.621 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -110.43 107.77 17.56 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.94 -1.1 . . . . 0.0 109.653 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -67.76 113.57 15.25 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.388 -0.82 . . . . 0.0 110.987 -179.25 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.864 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.8 Cg_endo -69.55 127.49 14.84 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 N-CA-C 106.9 -2.0 . . . . 0.0 106.9 175.674 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.608 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.7 mt -55.84 -19.1 10.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.816 -1.178 . . . . 0.0 110.819 -177.49 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -59.86 -16.07 26.06 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.761 -1.212 . . . . 0.0 110.499 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.111 HG23 HG23 ' A' ' 33' ' ' ILE . 15.3 m -91.1 -25.29 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.952 -1.093 . . . . 0.0 110.967 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.111 HG23 HG23 ' A' ' 32' ' ' VAL . 41.3 pt -117.28 -16.48 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.019 -1.051 . . . . 0.0 110.616 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.575 ' HB2' HD11 ' A' ' 60' ' ' ILE . 3.5 tptm -96.33 148.24 22.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.873 -1.142 . . . . 0.0 110.226 179.358 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.43 -3.23 56.41 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.25 -161.35 26.61 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.934 -1.603 . . . . 0.0 110.906 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.15 128.48 44.09 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.531 -0.982 . . . . 0.0 110.521 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.59 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.56 145.11 44.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.035 -1.04 . . . . 0.0 110.771 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.506 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.6 tp -107.19 113.56 27.07 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.369 -0.832 . . . . 0.0 109.979 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.919 HD12 HG12 ' A' ' 83' ' ' VAL . 36.0 mt -96.37 129.28 46.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.251 -0.906 . . . . 0.0 109.452 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.91 123.75 38.56 Favored 'General case' 0 C--N 1.292 -1.917 0 O-C-N 121.136 -0.977 . . . . 0.0 109.74 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.69 159.74 21.79 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.193 -0.942 . . . . 0.0 111.029 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.703 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -112.3 6.83 19.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.482 -0.761 . . . . 0.0 110.057 179.002 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.407 ' OG ' ' HB3' ' A' ' 47' ' ' LYS . 3.9 p -138.18 137.17 37.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.028 -1.045 . . . . 0.0 110.68 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.58 -40.6 69.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.381 -0.824 . . . . 0.0 110.194 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -36.77 79.43 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 110.247 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.421 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -72.24 -35.64 68.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 179.975 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.869 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 5.5 m -60.29 -33.78 72.82 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.434 -0.791 . . . . 0.0 109.55 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.87 -49.05 61.58 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.201 -0.937 . . . . 0.0 110.432 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.64 -43.32 66.32 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.342 -0.849 . . . . 0.0 110.538 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.826 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.5 -41.58 76.89 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.392 -0.818 . . . . 0.0 111.008 -179.047 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.96 -51.33 12.64 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.988 -1.07 . . . . 0.0 110.58 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.59 -42.05 98.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.87 -1.144 . . . . 0.0 109.594 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -57.68 -46.08 84.77 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.86 . . . . 0.0 109.882 179.71 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.741 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.04 -41.51 71.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.473 -0.767 . . . . 0.0 109.607 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.4 t -56.08 -31.19 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.068 -1.02 . . . . 0.0 108.61 178.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.55 -32.92 60.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.561 -0.712 . . . . 0.0 109.97 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.479 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.92 -25.87 62.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.313 -0.867 . . . . 0.0 109.512 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.0 7.32 8.62 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.404 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.608 ' CD1' HD22 ' A' ' 30' ' ' LEU . 34.6 mt -108.83 143.25 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.416 -1.05 . . . . 0.0 110.303 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.586 ' ND2' HD11 ' A' ' 74' ' ' ILE . 24.0 t-20 -86.43 107.0 17.85 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.018 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.619 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.52 143.91 48.32 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.428 -177.589 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.931 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -132.11 150.8 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.848 -0.741 . . . . 0.0 109.176 179.346 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.41 126.51 55.42 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.102 179.37 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.588 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.4 t80 -118.26 122.56 43.25 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.231 -0.918 . . . . 0.0 110.401 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.92 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.76 8.19 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.628 179.643 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.93 125.24 14.73 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.167 -0.958 . . . . 0.0 110.985 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.11 44.69 22.52 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.32 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.926 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.5 tm? -117.72 156.48 28.19 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.089 -1.242 . . . . 0.0 110.127 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.926 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.7 m-20 -94.51 148.98 21.7 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.283 -0.886 . . . . 0.0 110.723 -179.361 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.9 m -62.42 111.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.229 -0.989 . . . . 0.0 109.288 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.507 ' O ' HG23 ' A' ' 74' ' ' ILE . 6.9 m -133.65 -32.63 1.12 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.988 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.931 HG22 ' HB ' ' A' ' 63' ' ' VAL . 30.3 t -56.01 138.73 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.194 -0.941 . . . . 0.0 109.949 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.636 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -137.06 92.12 14.32 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.108 -0.995 . . . . 0.0 111.131 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -87.69 50.91 2.0 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 O-C-N 123.586 1.308 . . . . 0.0 109.738 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -122.47 -25.59 4.74 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.124 -0.985 . . . . 0.0 111.272 -179.026 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.7 m-20 -158.08 160.38 37.3 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.851 -1.156 . . . . 0.0 110.729 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 60.0 160.47 0.07 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -78.26 111.09 13.87 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.058 -1.26 . . . . 0.0 110.097 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.4 p -117.3 133.92 62.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-O 121.961 0.886 . . . . 0.0 110.351 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.591 HG22 HG22 ' A' ' 60' ' ' ILE . 7.8 m -112.67 123.82 68.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 178.818 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.736 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.76 116.46 38.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.1 -1.0 . . . . 0.0 110.353 -177.766 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.919 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -108.97 100.22 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.771 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.475 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.78 162.98 34.13 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.732 -1.23 . . . . 0.0 111.114 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.525 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -92.04 -130.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.537 -0.727 . . . . 0.0 109.47 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.525 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -90.98 34.83 0.91 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.713 -1.242 . . . . 0.0 110.226 179.534 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.43 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 0.0 110.356 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp -62.68 -36.57 83.32 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.132 -0.98 . . . . 0.0 109.099 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.479 ' C ' HG22 ' A' ' 90' ' ' THR . 0.6 OUTLIER 46.07 43.93 11.22 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.538 -0.726 . . . . 0.0 110.664 179.727 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.651 ' OG1' HG22 ' A' ' 93' ' ' THR . 1.8 t 35.39 -119.08 0.11 Allowed 'General case' 0 N--CA 1.504 2.242 0 O-C-N 122.138 -0.351 . . . . 0.0 111.661 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.409 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 79.94 -58.47 4.55 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -179.664 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.3 p90 -122.1 20.18 10.69 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.229 -1.159 . . . . 0.0 110.156 179.643 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.651 HG22 ' OG1' ' A' ' 90' ' ' THR . 8.3 t -94.37 -171.41 2.51 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.217 -0.927 . . . . 0.0 110.204 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 119.58 5.62 11.04 Favored Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.833 -1.175 . . . . 0.0 110.527 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -125.77 58.62 1.32 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.742 -1.446 . . . . 0.0 110.489 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.506 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.51 152.19 38.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.872 -1.143 . . . . 0.0 110.778 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.444 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.56 -28.79 19.35 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.567 -0.708 . . . . 0.0 109.363 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.3 p -161.0 163.77 31.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.34 -0.85 . . . . 0.0 110.758 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.489 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -125.75 119.18 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.251 -0.905 . . . . 0.0 110.292 179.578 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.769 HG21 ' CD1' ' A' ' 28' ' ' ILE . 37.9 mm -95.9 111.26 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 108.859 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.44 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -118.89 161.06 20.81 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.913 -1.117 . . . . 0.0 111.73 -178.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.48 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.3 p -99.96 -0.33 39.6 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 50.52 18.63 0.47 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.341 -0.85 . . . . 0.0 112.175 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.459 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.0 OUTLIER -144.7 120.86 10.81 Favored 'General case' 0 C--N 1.305 -1.349 0 O-C-N 120.729 -1.232 . . . . 0.0 109.407 179.831 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' LYS . 10.3 p -102.45 141.58 35.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 110.277 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t70 52.3 28.32 5.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.263 -0.898 . . . . 0.0 110.536 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.21 -13.26 58.02 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.201 -1.159 . . . . 0.0 110.201 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.459 ' O ' ' HA ' ' A' ' 104' ' ' THR . 14.6 mttt -96.64 156.66 36.4 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 120.952 -1.323 . . . . 0.0 109.973 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.44 130.0 27.01 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.542 1.285 . . . . 0.0 110.639 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -49.24 168.1 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.644 0.735 . . . . 0.0 111.183 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.539 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -102.68 161.56 13.63 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.544 -0.723 . . . . 0.0 110.327 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.644 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -42.28 -56.55 2.9 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.576 -0.702 . . . . 0.0 112.376 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.539 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -64.21 -29.87 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.702 -1.249 . . . . 0.0 111.255 -178.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.403 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.73 -56.32 7.61 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.116 -0.99 . . . . 0.0 110.505 -179.209 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.76 -33.77 76.36 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.159 -0.963 . . . . 0.0 108.851 178.91 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.5 m -60.93 -50.16 74.54 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.061 -1.025 . . . . 0.0 108.357 178.473 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.96 -38.71 64.13 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 mtt-85 -71.85 -44.37 63.94 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.258 -0.901 . . . . 0.0 111.321 -179.181 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.536 ' HD3' ' CE1' ' A' ' 7' ' ' HIS . 6.9 ttp180 -62.12 -40.42 95.85 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.917 -1.114 . . . . 0.0 110.244 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.4 75.26 0.04 OUTLIER Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.533 ' NE ' HG21 ' A' ' 93' ' ' THR . 0.7 OUTLIER -149.05 -47.35 0.14 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.43 -1.041 . . . . 0.0 108.76 179.599 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.555 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.1 t -96.19 143.47 27.27 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.76 17.82 4.55 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.409 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 10.8 mmt180 -91.75 82.8 5.22 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.117 -1.225 . . . . 0.0 109.986 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.92 -31.74 4.84 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.482 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.18 -169.74 0.22 Allowed Pre-proline 0 C--N 1.301 -1.514 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 179.509 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.482 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.5 Cg_endo -85.31 115.0 1.59 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 122.916 0.956 . . . . 0.0 110.466 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.555 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.29 51.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.567 HG21 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 mt -119.99 140.13 45.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.039 -1.271 . . . . 0.0 109.051 179.267 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.489 ' HD1' HG23 ' A' ' 99' ' ' VAL . 6.8 t80 -122.7 114.49 20.65 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 118.965 -1.094 . . . . 0.0 110.218 179.547 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.601 ' HB2' HD13 ' A' ' 100' ' ' ILE . 24.2 mtt180 -108.12 126.87 53.27 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.594 -0.692 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.451 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.8 p90 -126.95 156.94 40.72 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.078 -1.014 . . . . 0.0 110.847 -179.131 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.509 HG21 ' HB2' ' A' ' 24' ' ' TYR . 7.0 t -78.05 -69.31 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.319 -0.863 . . . . 0.0 108.978 178.81 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.436 ' N ' HG12 ' A' ' 133' ' ' VAL . . . 54.49 83.29 0.23 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.71 -0.619 . . . . 0.0 110.853 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -83.41 7.85 4.96 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.714 1.376 . . . . 0.0 110.609 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 132.03 -124.66 4.03 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -161.05 155.23 22.84 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.261 -1.141 . . . . 0.0 110.127 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.265 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.0 t -109.34 141.76 41.23 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.405 -1.056 . . . . 0.0 110.33 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.659 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.6 p -113.46 104.61 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.373 -0.83 . . . . 0.0 109.717 179.537 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.1 p -66.54 145.51 55.54 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.306 -0.871 . . . . 0.0 110.792 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.514 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -72.64 149.9 90.87 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.275 -0.891 . . . . 0.0 109.81 179.599 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.516 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 40.2 Cg_endo -79.59 -64.86 0.02 OUTLIER 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 124.222 1.643 . . . . 0.0 112.547 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.524 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 15.3 p80 42.85 88.8 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.62 0 CA-C-O 121.578 0.704 . . . . 0.0 110.404 -177.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.43 2.41 5.14 Favored 'Trans proline' 0 C--N 1.316 -1.165 0 O-C-N 123.511 1.269 . . . . 0.0 112.326 -178.423 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 24.4 t-20 -51.54 -25.07 6.03 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.647 -1.283 . . . . 0.0 109.302 179.039 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.548 HD12 ' HG2' ' A' ' 119' ' ' ARG . 20.0 mt -105.8 132.99 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.442 -0.786 . . . . 0.0 109.117 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.5 33.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.054 -1.028 . . . . 0.0 109.302 179.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.54 126.43 35.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.176 -0.952 . . . . 0.0 110.021 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.559 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 6.4 t -116.14 154.52 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.334 -0.853 . . . . 0.0 110.4 -179.221 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.88 105.04 15.34 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.339 -0.851 . . . . 0.0 109.639 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.506 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -55.43 132.34 48.08 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.412 -0.805 . . . . 0.0 109.82 -179.828 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.408 ' O ' ' N ' ' A' ' 18' ' ' THR . 70.5 p -135.83 172.29 13.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.212 -0.93 . . . . 0.0 110.314 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.91 78.28 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.22 -0.925 . . . . 0.0 110.202 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.682 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.0 m -151.31 108.54 3.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.206 -0.934 . . . . 0.0 110.687 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.037 -1.554 . . . . 0.0 110.747 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.32 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.649 -0.912 . . . . 0.0 110.326 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.867 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.8 tt -100.53 104.24 29.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.314 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.3 Cg_endo -62.94 148.7 93.17 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.338 1.178 . . . . 0.0 109.894 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.533 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.26 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.174 -0.954 . . . . 0.0 111.127 -178.164 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.5 m-85 59.15 66.78 0.99 Allowed 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.406 -0.809 . . . . 0.0 111.332 179.393 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.87 15.0 11.11 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.62 156.98 43.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.057 -1.261 . . . . 0.0 109.121 179.524 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.682 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -117.2 107.28 14.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.883 -1.135 . . . . 0.0 109.69 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.867 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.6 mt -69.98 114.33 24.4 Favored Pre-proline 0 C--N 1.3 -1.553 0 C-N-CA 119.614 -0.835 . . . . 0.0 109.926 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -69.01 129.72 18.92 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 N-CA-C 107.047 -1.943 . . . . 0.0 107.047 176.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.666 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.9 mt -56.52 -16.92 6.8 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.78 -1.2 . . . . 0.0 110.976 -177.495 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.443 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.03 -15.89 47.83 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.799 -1.188 . . . . 0.0 110.242 179.427 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.053 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -92.6 -25.14 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.986 -1.071 . . . . 0.0 111.212 -179.215 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.053 HG23 HG23 ' A' ' 32' ' ' VAL . 12.0 pt -120.47 -23.25 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.99 -1.069 . . . . 0.0 110.804 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.652 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.04 147.9 22.6 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.954 -1.092 . . . . 0.0 110.692 -179.872 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.413 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.63 -3.48 57.65 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.95 -155.73 13.6 Favored Glycine 0 N--CA 1.494 2.542 0 C-N-CA 119.008 -1.567 . . . . 0.0 110.705 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.98 131.12 52.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.413 -1.051 . . . . 0.0 110.092 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.4 m-70 -140.83 152.38 45.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 111.07 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.459 HD12 ' O ' ' A' ' 82' ' ' VAL . 43.0 tp -112.27 115.67 29.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.361 -0.837 . . . . 0.0 110.321 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.836 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.6 mt -100.34 128.59 52.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 109.823 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.467 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.04 123.66 40.84 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.098 -1.001 . . . . 0.0 110.054 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.52 159.59 21.03 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.278 -0.889 . . . . 0.0 110.55 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.577 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.63 5.11 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.362 -0.836 . . . . 0.0 110.006 179.076 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.08 135.95 37.93 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.127 -0.983 . . . . 0.0 110.607 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.486 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.51 -31.31 66.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.546 -0.721 . . . . 0.0 110.395 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.06 -30.0 66.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.357 -0.84 . . . . 0.0 110.198 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.4 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.1 -36.98 66.87 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.394 -0.816 . . . . 0.0 109.649 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.909 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.3 82.33 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.53 -49.9 73.5 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.103 -0.998 . . . . 0.0 109.955 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.65 -47.01 51.09 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.328 -0.858 . . . . 0.0 110.348 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.684 ' O ' HD13 ' A' ' 51' ' ' LEU . 1.9 tm? -56.53 -40.08 74.48 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.51 -0.744 . . . . 0.0 110.772 -179.298 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.36 13.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.078 -1.014 . . . . 0.0 110.179 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.34 -42.21 98.31 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 109.798 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.523 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.42 -45.25 84.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.459 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.834 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.08 -42.12 72.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.541 -0.725 . . . . 0.0 109.614 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.5 t -56.08 -33.33 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 109.097 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.64 -31.36 59.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.408 -0.807 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.21 -26.39 62.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.339 -0.85 . . . . 0.0 109.456 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.24 5.39 8.75 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.666 ' CD1' HD22 ' A' ' 30' ' ' LEU . 67.9 mt -108.15 143.83 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -1.106 . . . . 0.0 110.358 -179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.72 106.48 18.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 177.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.687 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.47 142.87 46.3 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.883 -177.029 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.88 HG21 ' HA ' ' A' ' 73' ' ' VAL . 84.0 t -122.97 148.81 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.909 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.48 117.17 29.63 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.256 178.226 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.473 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.88 135.37 49.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.294 -0.878 . . . . 0.0 111.02 -179.235 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.977 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 15.4 p90 -167.95 177.36 5.69 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.522 -0.736 . . . . 0.0 109.853 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.1 ttp-105 -51.56 126.06 16.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.07 -1.018 . . . . 0.0 110.683 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.88 45.11 22.44 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.977 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.28 153.61 32.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.04 -1.271 . . . . 0.0 109.836 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.783 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.9 m-20 -91.2 149.46 21.77 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.297 -0.877 . . . . 0.0 110.608 -179.242 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.663 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.9 m -62.42 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.125 179.096 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.674 ' O ' HG23 ' A' ' 74' ' ' ILE . 15.0 m -133.9 -34.37 1.01 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.445 -0.785 . . . . 0.0 110.843 -179.345 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.88 ' HA ' HG21 ' A' ' 63' ' ' VAL . 92.4 t -49.43 129.47 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.098 -1.001 . . . . 0.0 110.106 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.674 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -138.41 94.75 10.58 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.11 -0.994 . . . . 0.0 110.996 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.563 ' HA ' HG11 ' A' ' 80' ' ' VAL . 48.3 Cg_endo -78.75 58.05 6.66 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.675 1.355 . . . . 0.0 110.012 179.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.9 t -165.3 41.87 0.07 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.354 -0.841 . . . . 0.0 110.42 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.441 ' HB2' HD12 ' A' ' 74' ' ' ILE . 5.4 m120 -140.99 29.33 1.86 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.171 -0.956 . . . . 0.0 110.41 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 106.74 -89.0 0.57 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -140.56 102.81 4.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.11 -1.23 . . . . 0.0 110.241 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.563 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.2 p -116.89 135.23 57.91 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 CA-C-O 121.966 0.889 . . . . 0.0 109.912 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 13.7 m -112.62 124.6 69.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 O-C-N 121.282 -0.886 . . . . 0.0 109.373 179.568 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.839 HG11 HD13 ' A' ' 88' ' ' LEU . 13.1 t -97.19 119.14 44.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 O-C-N 120.955 -1.091 . . . . 0.0 110.383 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.836 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.3 m -111.9 99.27 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.015 -1.074 . . . . 0.0 108.771 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.426 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.22 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.587 -1.321 . . . . 0.0 110.811 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.05 -28.56 17.88 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.345 -0.847 . . . . 0.0 110.71 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.89 -31.3 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.079 -1.013 . . . . 0.0 110.762 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.473 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.95 -37.55 9.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.259 -0.901 . . . . 0.0 111.099 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.839 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -70.22 -33.44 71.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.145 -0.972 . . . . 0.0 110.7 -179.708 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 89' ' ' MET . . . . . . . . . . . . . 2.3 tpt 53.43 -144.12 0.68 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.088 -1.007 . . . . 0.0 109.337 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.499 HG23 ' HB ' ' A' ' 93' ' ' THR . 0.5 OUTLIER -155.54 24.84 0.4 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.863 -1.148 . . . . 0.0 110.44 179.463 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.03 -62.41 5.98 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -101.21 36.24 2.05 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.354 -1.086 . . . . 0.0 108.609 178.464 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.642 HG22 ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -133.8 -167.58 1.97 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.742 -0.599 . . . . 0.0 110.063 -179.433 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.417 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 120.68 -24.2 7.65 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.599 -1.401 . . . . 0.0 109.599 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -84.43 73.26 10.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.981 -1.305 . . . . 0.0 110.186 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.642 ' CE2' HG22 ' A' ' 93' ' ' THR . 38.6 m-85 -119.77 152.75 36.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.208 -0.932 . . . . 0.0 110.167 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -84.83 -29.26 25.48 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.505 -0.747 . . . . 0.0 109.735 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.452 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.7 p -161.18 163.47 31.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.166 -0.959 . . . . 0.0 110.843 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.414 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.29 116.32 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.298 -0.876 . . . . 0.0 109.963 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.842 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -94.61 111.3 25.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.07 -1.019 . . . . 0.0 108.974 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.416 ' HB2' ' CE1' ' A' ' 130' ' ' TYR . 3.5 t0 -114.4 161.07 18.42 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.149 -0.97 . . . . 0.0 111.732 -178.369 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.32 9.65 35.81 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.079 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.444 ' CB ' ' HB3' ' A' ' 134' ' ' ALA . 2.7 m120 46.19 27.29 0.53 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.279 -0.888 . . . . 0.0 110.963 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.579 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -144.29 133.45 22.93 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.188 -0.945 . . . . 0.0 110.469 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 62.0 p -113.42 128.66 56.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.323 -0.861 . . . . 0.0 109.394 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.0 t70 55.65 -141.55 0.84 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.037 -1.039 . . . . 0.0 109.555 -179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -88.35 18.46 41.52 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -134.82 156.98 78.1 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.115 -1.227 . . . . 0.0 109.569 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.579 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.0 Cg_endo -63.26 158.37 44.91 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.53 1.279 . . . . 0.0 110.443 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.416 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER -64.85 164.77 11.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.278 -0.889 . . . . 0.0 111.205 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.506 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -100.52 161.78 13.37 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.556 -0.715 . . . . 0.0 110.111 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.465 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.46 -61.56 1.03 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.476 -0.765 . . . . 0.0 112.108 -178.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.506 HG22 ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.79 -28.87 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.71 -1.244 . . . . 0.0 111.435 -178.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.69 -57.19 5.83 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.893 -1.13 . . . . 0.0 110.932 -178.732 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.465 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.46 -34.63 78.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.02 -1.05 . . . . 0.0 108.525 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 49.6 m -59.84 -48.87 79.95 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.28 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.59 -40.1 64.13 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.513 -0.742 . . . . 0.0 110.126 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.467 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.48 -44.61 70.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.984 -1.073 . . . . 0.0 110.31 -179.687 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.548 ' HG2' HD12 ' A' ' 10' ' ' ILE . 41.9 ttp180 -61.54 -36.08 79.58 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.047 -1.033 . . . . 0.0 109.315 179.184 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.05 66.67 0.34 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.7 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.462 -1.022 . . . . 0.0 108.848 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.538 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.3 t -92.12 142.45 27.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.335 -0.853 . . . . 0.0 108.931 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.58 17.07 2.95 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.269 -1.444 . . . . 0.0 110.605 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.417 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.2 mmt180 -95.11 82.37 3.77 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.986 -1.303 . . . . 0.0 110.002 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.39 -51.46 0.76 Allowed Glycine 0 N--CA 1.493 2.483 0 N-CA-C 108.412 -1.875 . . . . 0.0 108.412 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.455 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.84 166.36 21.72 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.3 Cg_endo -63.59 117.73 4.68 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.299 1.157 . . . . 0.0 110.128 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.538 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.85 172.24 54.78 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.424 HG23 ' CG2' ' A' ' 13' ' ' VAL . 5.1 mt -126.15 142.06 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.301 -1.117 . . . . 0.0 108.989 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.416 ' CE1' ' HB2' ' A' ' 101' ' ' ASP . 10.5 t80 -131.13 115.19 16.06 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.292 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.559 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 5.9 mtp180 -99.78 147.71 25.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.497 -0.752 . . . . 0.0 109.365 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.47 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 25.1 p90 -138.14 150.36 46.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.085 -1.01 . . . . 0.0 110.212 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.506 HG22 HD23 ' A' ' 15' ' ' LEU . 34.5 t -87.01 -41.07 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.129 -0.982 . . . . 0.0 109.448 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.444 ' HB3' ' CB ' ' A' ' 103' ' ' ASN . . . -91.17 113.1 57.18 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.357 -0.839 . . . . 0.0 109.947 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.435 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 45.4 Cg_endo -71.52 -22.96 23.94 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.456 1.24 . . . . 0.0 110.756 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 157.31 148.14 5.01 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -90.63 -32.44 16.24 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.272 -1.134 . . . . 0.0 110.223 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.677 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.143 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.376 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.2 m -89.89 105.98 18.16 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.195 -1.179 . . . . 0.0 110.154 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 3' ' ' VAL . 31.3 m -112.87 104.4 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.357 -0.84 . . . . 0.0 109.629 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.474 HG21 ' HD3' ' A' ' 115' ' ' ARG . 43.8 p -90.02 143.35 26.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.202 -0.936 . . . . 0.0 110.785 -179.448 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.471 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.67 148.5 98.05 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.34 -0.85 . . . . 0.0 109.477 179.434 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.471 ' HD2' HG23 ' A' ' 5' ' ' VAL . 39.4 Cg_endo -67.65 -167.01 0.14 Allowed 'Trans proline' 0 C--N 1.307 -1.622 0 O-C-N 124.045 1.55 . . . . 0.0 111.11 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.562 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 176.33 83.23 0.1 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.681 -0.637 . . . . 0.0 109.332 -179.736 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.72 -9.61 26.05 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 O-C-N 123.861 1.453 . . . . 0.0 111.059 -179.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 50.7 t30 -77.96 -29.41 49.82 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.94 -1.1 . . . . 0.0 109.627 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.519 HD13 HG22 ' A' ' 122' ' ' THR . 16.5 mt -106.81 132.43 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.001 -1.062 . . . . 0.0 109.518 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.87 127.26 33.71 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.134 -0.979 . . . . 0.0 109.278 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.66 128.5 36.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.16 -0.962 . . . . 0.0 110.003 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.42 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.49 158.04 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.404 -0.81 . . . . 0.0 110.176 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.98 110.94 21.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.752 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.451 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -53.45 134.5 40.44 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.319 -0.863 . . . . 0.0 110.329 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.6 p -135.49 177.76 7.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 110.142 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.33 65.31 0.42 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.225 -0.922 . . . . 0.0 109.951 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.474 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 22.1 m -137.1 110.57 7.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.339 -0.851 . . . . 0.0 110.353 -179.721 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.0 -163.89 27.98 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.76 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.72 -21.02 7.43 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.675 -0.897 . . . . 0.0 110.327 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.893 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -96.79 108.66 44.44 Favored Pre-proline 0 N--CA 1.488 1.458 0 C-N-CA 118.668 -1.213 . . . . 0.0 110.204 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.437 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.6 Cg_endo -65.48 149.77 87.49 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 O-C-N 123.444 1.234 . . . . 0.0 110.296 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.523 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.3 t80 -169.04 108.21 0.45 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 110.977 -178.778 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.545 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 17.6 m-85 56.25 60.69 3.05 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.234 -0.916 . . . . 0.0 111.171 179.209 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.97 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.523 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.49 157.28 43.1 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.128 -1.219 . . . . 0.0 109.064 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.474 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.79 107.27 14.83 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.811 -1.181 . . . . 0.0 110.239 -179.517 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.893 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.4 mt -68.29 114.5 21.77 Favored Pre-proline 0 C--N 1.301 -1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.8 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -69.16 128.39 16.5 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 N-CA-C 106.579 -2.123 . . . . 0.0 106.579 175.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.64 HD22 ' CD1' ' A' ' 60' ' ' ILE . 11.0 mt -55.82 -17.62 6.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.673 -1.267 . . . . 0.0 111.09 -177.216 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -59.63 -15.98 22.83 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.677 -1.264 . . . . 0.0 110.667 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.084 HG23 HG23 ' A' ' 33' ' ' ILE . 16.4 m -91.37 -25.38 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.024 -1.048 . . . . 0.0 111.187 -179.432 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.084 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -119.84 -16.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.96 -1.087 . . . . 0.0 110.65 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.6 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.9 tptt -98.8 147.86 24.49 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.769 -1.207 . . . . 0.0 110.046 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.84 -5.39 50.63 Favored Glycine 0 N--CA 1.485 1.911 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.576 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.35 -151.17 9.52 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.081 -1.533 . . . . 0.0 110.561 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.442 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.03 131.92 53.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.43 -1.041 . . . . 0.0 110.371 -179.409 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.572 ' HB2' HG12 ' A' ' 81' ' ' VAL . 95.6 m-70 -138.44 151.53 47.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.172 -0.955 . . . . 0.0 110.95 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.578 HD12 ' O ' ' A' ' 82' ' ' VAL . 45.9 tp -111.58 119.29 38.24 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.766 . . . . 0.0 110.025 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.921 HD12 ' CG1' ' A' ' 83' ' ' VAL . 31.6 mt -103.86 126.26 58.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.295 -0.878 . . . . 0.0 109.155 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.96 123.79 38.63 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.177 -0.952 . . . . 0.0 110.329 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.28 160.13 21.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.425 -0.797 . . . . 0.0 110.668 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.545 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 10.6 p80 -105.16 -4.73 21.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.337 -0.852 . . . . 0.0 110.426 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 66.4 p -136.14 145.8 46.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.01 -1.056 . . . . 0.0 111.235 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.477 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 23.7 tttt -72.08 -40.92 67.91 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.673 -0.642 . . . . 0.0 110.669 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.77 -34.98 72.04 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.139 -0.976 . . . . 0.0 110.684 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HA ' ' HD3' ' A' ' 47' ' ' LYS . 12.3 tppt? -71.6 -40.42 69.86 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.077 -1.014 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.888 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 67.3 m -61.83 -37.15 83.37 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 110.06 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.98 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.949 -1.094 . . . . 0.0 110.577 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.414 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -72.28 -44.2 63.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.174 -0.954 . . . . 0.0 110.229 179.908 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.728 HD12 HG11 ' A' ' 83' ' ' VAL . 1.7 tm? -56.58 -42.12 78.1 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.489 -0.757 . . . . 0.0 111.198 -179.102 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.35 -50.88 16.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.897 -1.127 . . . . 0.0 110.375 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.38 -42.09 98.15 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.118 -0.989 . . . . 0.0 109.798 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.504 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.98 -45.78 86.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.901 . . . . 0.0 109.788 179.703 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.644 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -54.54 -42.31 70.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.453 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.5 t -56.79 -30.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.122 -0.986 . . . . 0.0 108.591 178.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.503 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.56 -33.93 60.67 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.597 -0.689 . . . . 0.0 110.021 179.23 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.536 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.48 -25.73 62.4 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.82 0.819 . . . . 0.0 109.556 179.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.56 7.34 9.0 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.64 ' CD1' HD22 ' A' ' 30' ' ' LEU . 40.1 mt -108.01 143.31 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.324 -1.103 . . . . 0.0 109.977 -179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 4.1 t-20 -87.2 107.08 18.32 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.272 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.637 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.91 145.11 48.02 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.409 -177.576 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.887 HG21 ' HA ' ' A' ' 73' ' ' VAL . 6.7 t -133.02 143.1 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.589 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.888 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -107.16 123.45 48.28 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.824 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.492 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.17 119.06 36.47 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.335 -0.853 . . . . 0.0 110.387 -179.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.922 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.8 p90 -146.74 174.48 11.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.608 -0.683 . . . . 0.0 109.753 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.6 5.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.161 -0.962 . . . . 0.0 110.803 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.02 35.73 9.58 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.948 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.0 tm? -117.17 155.84 28.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 110.079 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.948 ' N ' HD13 ' A' ' 69' ' ' LEU . 37.1 m-20 -95.37 149.42 21.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.333 -0.854 . . . . 0.0 110.248 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.672 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.2 m -61.81 110.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.176 179.455 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.401 ' O ' HG23 ' A' ' 74' ' ' ILE . 7.3 m -132.04 -20.82 2.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.486 -0.759 . . . . 0.0 111.068 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.887 ' HA ' HG21 ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.88 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 109.302 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.629 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp -126.25 96.91 35.54 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.241 -0.912 . . . . 0.0 110.969 -179.496 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.542 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.7 Cg_endo -82.26 54.0 4.77 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.689 1.362 . . . . 0.0 109.95 179.164 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.4 t -156.95 42.44 0.35 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.259 -0.901 . . . . 0.0 110.537 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.408 ' CG ' HD13 ' A' ' 74' ' ' ILE . 3.9 m120 -141.5 -164.94 1.87 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.171 -0.956 . . . . 0.0 110.149 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.43 -73.36 0.36 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 -149.93 111.66 4.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.303 -1.116 . . . . 0.0 110.097 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.542 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -117.47 134.58 60.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.074 0.94 . . . . 0.0 110.359 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.647 HG11 ' HB ' ' A' ' 33' ' ' ILE . 5.7 m -113.28 124.67 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 O-C-N 121.413 -0.805 . . . . 0.0 108.901 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.784 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.91 45.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 121.159 -0.963 . . . . 0.0 110.049 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.921 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.8 m -114.48 100.98 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.07 -1.019 . . . . 0.0 108.594 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.492 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.37 164.22 32.16 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.725 -1.234 . . . . 0.0 111.796 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.706 HG23 ' H ' ' A' ' 87' ' ' ALA . 6.4 t -94.28 -147.2 0.26 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.671 -0.643 . . . . 0.0 109.42 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.15 -15.3 56.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.964 -1.085 . . . . 0.0 110.235 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.706 ' H ' HG23 ' A' ' 85' ' ' THR . . . -49.32 -44.64 44.49 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.038 -1.039 . . . . 0.0 110.257 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp -63.56 -26.86 68.89 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 108.985 179.101 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.488 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 5.6 tpt 45.2 32.42 0.95 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.71 -0.619 . . . . 0.0 111.207 179.768 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.447 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 48.1 p 44.13 36.77 1.59 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.706 -0.621 . . . . 0.0 111.22 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.06 -63.98 4.67 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -122.31 41.13 3.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.307 -1.114 . . . . 0.0 109.879 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.52 HG21 ' HD2' ' A' ' 121' ' ' ARG . 15.3 t -91.13 -159.38 0.63 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.342 -0.849 . . . . 0.0 110.777 -179.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.47 -36.9 3.63 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -84.45 55.05 3.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.966 -1.314 . . . . 0.0 110.492 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.461 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 40.9 m-85 -119.92 147.93 44.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.937 -1.102 . . . . 0.0 110.303 179.591 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.481 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.43 -28.77 56.75 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.409 -0.807 . . . . 0.0 110.127 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.2 p -160.38 163.58 33.05 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.256 -0.903 . . . . 0.0 110.752 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.505 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.9 117.86 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.332 -0.855 . . . . 0.0 110.563 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.798 HG21 HD11 ' A' ' 28' ' ' ILE . 4.6 mp -98.24 110.86 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.16 158.88 25.05 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.992 . . . . 0.0 111.773 -178.19 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.84 3.67 53.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.004 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.423 ' CA ' ' OE1' ' A' ' 110' ' ' GLN . 3.2 m-20 52.88 27.72 5.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.239 -0.913 . . . . 0.0 111.087 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p -147.23 130.78 16.8 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.11 -0.994 . . . . 0.0 110.24 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.407 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.1 p -112.86 127.88 56.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.324 -0.86 . . . . 0.0 109.837 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 55.43 26.96 9.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.316 -0.865 . . . . 0.0 110.553 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.15 -37.83 3.31 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.407 ' O ' ' N ' ' A' ' 105' ' ' SER . 15.8 mttt -77.05 156.56 82.06 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.325 -1.103 . . . . 0.0 110.121 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -65.94 132.61 30.78 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.612 1.322 . . . . 0.0 109.887 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.46 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER -49.66 171.15 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.275 -0.891 . . . . 0.0 110.998 -179.046 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.535 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -99.7 160.77 14.05 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.28 179.674 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.31 -53.47 5.21 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.438 -0.789 . . . . 0.0 112.286 -178.76 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.535 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.8 m -69.75 -29.42 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 120.83 -1.169 . . . . 0.0 111.525 -178.683 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.402 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.31 -56.52 6.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.07 -1.019 . . . . 0.0 110.625 -179.114 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.474 ' HD3' HG21 ' A' ' 4' ' ' THR . 1.8 ptm180 -69.07 -34.69 75.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.296 -0.877 . . . . 0.0 108.819 178.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.431 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.8 m -59.52 -49.79 76.42 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.68 -37.53 65.2 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.451 -0.781 . . . . 0.0 110.056 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 36.3 mtt-85 -71.89 -45.63 60.61 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.209 -0.932 . . . . 0.0 111.719 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.562 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 27.6 ttp85 -59.34 -51.65 69.02 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.091 -1.006 . . . . 0.0 109.917 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.429 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.4 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -179.265 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.52 ' HD2' HG21 ' A' ' 93' ' ' THR . 0.0 OUTLIER -45.73 -33.21 2.87 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.283 -1.128 . . . . 0.0 111.632 -179.6 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.519 HG22 HD13 ' A' ' 10' ' ' ILE . 14.9 t -100.65 144.12 30.01 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.884 -1.135 . . . . 0.0 110.884 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.97 14.54 24.51 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.389 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.429 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.59 84.23 0.61 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -1.201 . . . . 0.0 109.794 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.53 -26.34 13.34 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.903 -1.679 . . . . 0.0 108.903 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.499 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.96 -168.7 0.19 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.495 -1.003 . . . . 0.0 108.669 179.653 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.499 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.0 Cg_endo -87.32 110.95 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.14 1.074 . . . . 0.0 110.7 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.48 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -82.42 170.57 50.7 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 49.1 mt -126.48 142.64 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.516 -0.991 . . . . 0.0 108.416 178.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.505 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -128.77 114.75 16.97 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.721 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.444 ' HD3' HG11 ' A' ' 32' ' ' VAL . 18.2 mtp180 -105.27 122.88 46.86 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.437 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.423 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 32.0 p90 -121.72 158.06 29.58 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 110.662 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.623 ' O ' ' HB3' ' A' ' 134' ' ' ALA . 32.1 t -94.69 -56.97 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.623 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 69.08 145.19 0.1 Allowed Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.749 -0.594 . . . . 0.0 110.343 -179.576 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -78.32 -56.02 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.726 1.382 . . . . 0.0 110.506 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 136.85 -32.53 2.43 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.24 -161.12 1.26 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.257 -1.143 . . . . 0.0 110.317 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 9.8 ttt-85 . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 118.049 -0.977 . . . . 0.0 110.149 179.886 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 t -77.36 108.29 10.39 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.204 -1.174 . . . . 0.0 110.302 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 3' ' ' VAL . 19.2 m -113.32 104.26 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.278 -0.889 . . . . 0.0 109.878 179.654 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.2 p -63.59 139.87 58.81 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.382 -0.824 . . . . 0.0 110.497 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.44 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.81 148.38 96.47 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.361 -0.837 . . . . 0.0 109.717 179.677 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.44 ' HD2' HG23 ' A' ' 5' ' ' VAL . 45.6 Cg_endo -71.99 -165.72 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 124.136 1.598 . . . . 0.0 110.887 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.518 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 174.65 80.64 0.06 OUTLIER Pre-proline 0 N--CA 1.499 1.982 0 O-C-N 121.508 -0.745 . . . . 0.0 109.523 -179.617 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -75.18 55.23 3.98 Favored 'Trans proline' 0 C--N 1.313 -1.325 0 O-C-N 123.681 1.359 . . . . 0.0 111.427 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.466 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 -139.04 4.66 2.28 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.028 -1.045 . . . . 0.0 110.968 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.68 HD11 ' O ' ' A' ' 122' ' ' THR . 30.3 mt -129.0 137.28 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.867 -1.146 . . . . 0.0 109.707 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -82.75 127.81 33.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.056 -1.028 . . . . 0.0 109.207 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.89 139.32 30.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.3 -0.875 . . . . 0.0 110.553 -179.089 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.78 HG11 ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.75 156.55 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.215 -0.928 . . . . 0.0 110.14 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.34 109.86 21.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -0.889 . . . . 0.0 110.109 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.708 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.77 141.88 36.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 109.311 179.456 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.33 174.57 10.62 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 110.548 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.58 0.99 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.325 -0.86 . . . . 0.0 110.276 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.732 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.9 m -155.68 109.32 2.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.174 -0.954 . . . . 0.0 110.482 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.421 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.49 -171.35 28.89 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.891 -1.623 . . . . 0.0 111.181 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.54 -22.59 11.57 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.722 -0.87 . . . . 0.0 110.45 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.943 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -95.26 107.12 30.31 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 118.872 -1.131 . . . . 0.0 109.455 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.43 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -63.84 144.67 89.15 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.249 1.131 . . . . 0.0 111.34 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.421 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.73 -166.37 1.85 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.522 -0.736 . . . . 0.0 110.318 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.533 ' CD2' ' HB3' ' A' ' 102' ' ' CYS . 36.8 m-85 -59.92 82.03 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.403 -0.811 . . . . 0.0 111.051 -179.564 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.4 5.85 51.49 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.708 ' CB ' HD23 ' A' ' 15' ' ' LEU . 14.4 mmtm -130.64 156.68 44.47 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.941 -1.329 . . . . 0.0 109.778 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.732 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.64 16.77 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.062 -1.024 . . . . 0.0 109.106 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 1.051 HD11 HG21 ' A' ' 100' ' ' ILE . 6.2 mt -69.12 114.16 21.57 Favored Pre-proline 0 C--N 1.299 -1.596 0 O-C-N 121.367 -0.833 . . . . 0.0 110.798 -179.081 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.736 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.2 Cg_endo -69.73 132.12 22.72 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.13 -1.912 . . . . 0.0 107.13 176.164 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.78 HD11 HD12 ' A' ' 58' ' ' LEU . 13.2 mt -56.95 -14.95 4.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.961 -1.087 . . . . 0.0 111.219 -177.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -63.31 -16.16 59.5 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.539 -1.351 . . . . 0.0 110.51 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 10.6 m -93.86 -24.44 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.052 -1.03 . . . . 0.0 110.87 -179.406 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 48.3 pt -117.16 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.035 -1.041 . . . . 0.0 110.493 -179.328 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.635 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.98 148.41 24.56 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -0.903 . . . . 0.0 110.501 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.74 -5.17 46.99 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.27 -147.68 7.79 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.428 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.8 132.5 53.93 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.406 -1.055 . . . . 0.0 110.473 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.546 ' HB2' HG12 ' A' ' 81' ' ' VAL . 88.2 m-70 -140.77 149.0 41.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 0.0 110.603 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.583 HD12 ' O ' ' A' ' 82' ' ' VAL . 57.3 tp -111.0 113.59 26.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.441 -0.787 . . . . 0.0 109.803 179.548 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.891 HD12 HG12 ' A' ' 83' ' ' VAL . 29.2 mt -96.41 127.38 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.882 . . . . 0.0 109.662 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.51 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.2 m-85 -95.08 122.72 38.03 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.295 -0.878 . . . . 0.0 110.251 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.04 160.16 21.98 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.339 -0.85 . . . . 0.0 110.733 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 5.4 p80 -110.01 4.65 21.55 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.396 -0.815 . . . . 0.0 109.964 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.52 136.41 49.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 110.987 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.498 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.84 69.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.645 -0.66 . . . . 0.0 110.861 -179.866 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.74 -36.75 73.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.28 -0.888 . . . . 0.0 110.917 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.13 -35.39 80.36 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.313 -0.867 . . . . 0.0 109.574 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.923 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 53.2 m -61.48 -33.83 74.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.511 -0.743 . . . . 0.0 109.764 179.231 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.19 -50.22 61.77 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.283 -0.886 . . . . 0.0 110.967 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.22 -44.11 63.44 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.119 -0.988 . . . . 0.0 110.569 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.638 ' CD2' HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -56.99 -38.35 72.91 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.562 -0.711 . . . . 0.0 111.242 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.62 -51.15 13.49 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.871 -1.143 . . . . 0.0 110.633 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.46 -40.04 85.58 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.146 -0.971 . . . . 0.0 110.145 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.695 ' CE ' HD21 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.04 82.99 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.318 -0.864 . . . . 0.0 109.788 179.739 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.902 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.07 -38.92 71.29 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.643 -0.661 . . . . 0.0 110.093 179.818 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.3 t -58.62 -34.38 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.185 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.29 -30.66 60.47 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.436 -0.79 . . . . 0.0 109.965 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.78 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -72.01 -25.71 61.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.437 -0.789 . . . . 0.0 109.773 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.9 10.3 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.323 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.635 HD11 ' HB2' ' A' ' 34' ' ' LYS . 45.9 mt -108.03 143.23 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.298 -1.119 . . . . 0.0 109.75 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 15.2 t-20 -89.84 106.39 18.44 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.698 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.18 142.59 46.62 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.729 -177.07 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.927 HG21 ' HA ' ' A' ' 73' ' ' VAL . 57.4 t -125.56 149.41 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 120.139 -0.624 . . . . 0.0 109.701 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.923 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.69 119.05 34.25 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.433 178.341 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.475 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.42 132.72 55.52 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.216 -0.927 . . . . 0.0 110.839 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.75 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -166.93 176.85 6.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.569 -0.707 . . . . 0.0 109.719 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.15 125.35 15.44 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.069 -1.02 . . . . 0.0 110.707 -179.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.7 37.4 19.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.838 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.44 157.24 26.57 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.031 -1.276 . . . . 0.0 110.12 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.838 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -96.53 149.23 21.98 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.29 -0.881 . . . . 0.0 110.555 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 71' ' ' VAL . 30.3 m -62.66 111.37 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.193 -0.942 . . . . 0.0 109.121 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.82 -35.39 1.09 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.389 -0.819 . . . . 0.0 110.733 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.927 ' HA ' HG21 ' A' ' 63' ' ' VAL . 59.6 t -48.41 120.37 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.391 -0.818 . . . . 0.0 110.294 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.826 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp -137.53 109.99 8.79 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.235 -0.916 . . . . 0.0 110.608 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.638 ' HA ' HG11 ' A' ' 80' ' ' VAL . 50.3 Cg_endo -87.31 40.14 0.63 Allowed 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 123.327 1.172 . . . . 0.0 110.666 179.559 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.3 p -136.42 26.27 3.16 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.081 -1.012 . . . . 0.0 110.143 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.7 m-20 -135.44 27.27 3.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.216 -0.927 . . . . 0.0 110.172 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 111.4 -156.5 15.52 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.369 -1.492 . . . . 0.0 109.369 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.67 112.59 15.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.113 -1.228 . . . . 0.0 110.182 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.638 HG11 ' HA ' ' A' ' 75' ' ' PRO . 5.2 p -116.92 135.56 56.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-O 122.151 0.977 . . . . 0.0 110.568 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 11.9 m -112.88 119.94 61.72 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.072 0 O-C-N 121.228 -0.92 . . . . 0.0 108.844 178.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.662 HG22 HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.84 45.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 120.886 -1.134 . . . . 0.0 110.265 -178.041 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.891 HG12 HD12 ' A' ' 40' ' ' ILE . 3.2 m -109.06 100.53 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.146 -0.971 . . . . 0.0 108.691 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.475 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.36 162.24 35.49 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.765 -1.21 . . . . 0.0 110.979 -178.172 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.513 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -88.26 -131.34 0.07 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.347 -0.846 . . . . 0.0 109.612 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.513 ' N ' HG23 ' A' ' 85' ' ' THR . 44.9 p30 -91.4 29.28 1.49 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.694 -1.254 . . . . 0.0 110.55 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.62 -29.06 12.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.052 -1.03 . . . . 0.0 110.231 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -75.19 -33.49 61.43 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.144 -0.973 . . . . 0.0 109.742 179.674 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.404 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 1.6 mmt 51.1 -106.76 0.26 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.305 -0.872 . . . . 0.0 109.958 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.758 ' CB ' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.75 41.58 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.831 0 O-C-N 120.668 -1.27 . . . . 0.0 110.419 179.739 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.25 -32.4 51.08 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 108.639 -1.784 . . . . 0.0 108.639 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.481 ' N ' ' CD1' ' A' ' 92' ' ' PHE . 14.2 p90 -145.47 38.26 1.13 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.684 -0.892 . . . . 0.0 109.803 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.758 HG22 ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER -126.86 -162.4 1.15 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.323 -0.861 . . . . 0.0 110.209 -179.633 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.696 ' N ' HG23 ' A' ' 93' ' ' THR . . . 123.48 -40.47 1.97 Allowed Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.331 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -84.42 81.05 9.01 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.132 -1.217 . . . . 0.0 110.844 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.492 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 15.1 m-85 -119.77 147.98 43.97 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.111 -0.993 . . . . 0.0 110.115 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.495 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -71.11 -35.1 71.65 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.385 -0.822 . . . . 0.0 109.383 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.434 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.3 p -162.04 163.65 28.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.225 -0.922 . . . . 0.0 111.128 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.713 HG22 HG21 ' A' ' 122' ' ' THR . 1.3 m -129.36 118.1 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.52 -0.737 . . . . 0.0 110.091 179.378 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 1.051 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -92.6 111.98 25.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.481 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.14 160.26 21.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 111.718 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.533 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.23 6.26 38.08 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.159 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.442 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.04 25.43 0.49 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.66 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -147.75 129.38 15.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.294 -0.879 . . . . 0.0 110.396 179.641 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 24.4 p -113.34 132.17 55.69 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.266 -0.896 . . . . 0.0 109.636 179.403 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.404 ' OD1' ' N ' ' A' ' 106' ' ' ASP . 1.5 m-20 54.5 -141.87 0.83 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.053 -1.03 . . . . 0.0 109.669 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.76 17.99 41.88 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.0 mmtp -133.74 156.28 79.59 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.05 -1.264 . . . . 0.0 109.749 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.66 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.4 Cg_endo -64.61 159.82 43.03 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 O-C-N 123.662 1.348 . . . . 0.0 110.198 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.442 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 -57.16 153.33 11.97 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.22 -0.925 . . . . 0.0 110.713 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.543 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -90.73 160.78 15.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.342 -0.849 . . . . 0.0 110.285 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.37 -52.26 4.63 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.544 -0.722 . . . . 0.0 112.34 -178.728 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.543 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.79 -29.27 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.855 -1.153 . . . . 0.0 111.214 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.43 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.39 -56.21 7.37 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.112 -0.993 . . . . 0.0 110.509 -179.377 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.439 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.4 OUTLIER -68.84 -34.5 75.59 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.168 -0.957 . . . . 0.0 108.789 178.685 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.446 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 31.3 m -60.02 -49.92 75.76 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.183 -0.948 . . . . 0.0 108.533 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.64 -39.93 64.13 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.546 -0.721 . . . . 0.0 109.671 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.439 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 4.1 mtt180 -66.21 -44.75 83.01 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 110.018 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.518 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 13.5 ttm180 -64.06 -34.08 77.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.221 -0.925 . . . . 0.0 110.279 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.455 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.33 12.07 1.96 Allowed Glycine 0 N--CA 1.497 2.73 0 O-C-N 121.055 -1.028 . . . . 0.0 112.3 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.498 ' CZ ' HG21 ' A' ' 90' ' ' THR . 1.2 mmt85 -101.32 -5.19 25.76 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.296 -1.708 . . . . 0.0 109.461 178.617 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.713 HG21 HG22 ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.44 142.15 50.31 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.224 -0.923 . . . . 0.0 109.424 179.782 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 78.48 26.5 59.12 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.455 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.3 82.62 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.134 -1.215 . . . . 0.0 110.109 179.908 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.59 24.92 5.45 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.474 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.5 -1.0 . . . . 0.0 109.105 -179.628 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 45.8 Cg_endo -84.47 99.58 0.75 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.187 1.099 . . . . 0.0 109.551 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.436 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.82 176.58 52.18 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.48 143.95 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.45 -1.03 . . . . 0.0 109.968 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.535 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 9.6 t80 -129.4 116.9 19.73 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.176 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.78 ' NE ' HG11 ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.21 137.9 37.07 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.541 -0.725 . . . . 0.0 109.215 179.018 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.458 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.6 p90 -137.8 153.98 49.6 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 110.719 -179.58 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.85 -46.7 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.323 -0.861 . . . . 0.0 109.422 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.2 161.01 38.99 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 110.271 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.45 -27.37 15.94 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 O-C-N 123.776 1.409 . . . . 0.0 110.572 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 137.47 79.84 0.08 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -175.91 143.36 0.57 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.291 -1.123 . . . . 0.0 110.182 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.191 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.5 m -93.04 150.96 20.17 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.232 -1.158 . . . . 0.0 110.382 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 3' ' ' VAL . 21.0 m -113.37 104.73 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.388 -0.82 . . . . 0.0 110.013 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.824 HG22 ' OG1' ' A' ' 116' ' ' THR . 6.1 p -66.09 145.07 56.26 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.358 -0.839 . . . . 0.0 110.331 -179.89 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.683 HG22 ' HD1' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -70.2 147.82 95.58 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.215 -0.928 . . . . 0.0 109.819 179.841 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.519 ' HD2' HG23 ' A' ' 5' ' ' VAL . 38.8 Cg_endo -73.11 -64.67 0.03 OUTLIER 'Trans proline' 0 C--N 1.309 -1.517 0 O-C-N 124.096 1.577 . . . . 0.0 112.445 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.683 ' HD1' HG22 ' A' ' 5' ' ' VAL . 47.8 p-80 41.26 87.24 0.12 Allowed Pre-proline 0 N--CA 1.492 1.652 0 CA-C-O 121.231 0.539 . . . . 0.0 111.294 -178.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.9 0.72 8.51 Favored 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.463 1.244 . . . . 0.0 111.556 -179.211 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 -52.41 -22.13 4.37 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.803 -1.186 . . . . 0.0 110.436 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 31.1 mt -111.86 135.2 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.973 -1.079 . . . . 0.0 110.277 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.19 129.07 34.87 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.188 -0.945 . . . . 0.0 109.726 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.44 33.57 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.077 -1.014 . . . . 0.0 110.501 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.7 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 17.2 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.91 114.93 29.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.15 -0.968 . . . . 0.0 110.371 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.54 HD23 HG22 ' A' ' 133' ' ' VAL . 12.3 tp -63.2 135.65 57.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 109.607 179.561 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.3 p -134.78 171.58 14.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.093 -1.004 . . . . 0.0 110.602 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.532 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -149.21 112.68 5.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.353 -0.842 . . . . 0.0 110.349 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.33 -161.68 27.28 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.674 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -122.05 -22.35 5.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.724 -0.868 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.931 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -93.51 112.82 58.28 Favored Pre-proline 0 N--CA 1.488 1.426 0 C-N-CA 118.598 -1.241 . . . . 0.0 110.335 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -64.85 141.26 70.66 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.597 1.314 . . . . 0.0 109.977 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.459 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.91 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.101 -0.999 . . . . 0.0 111.732 -178.618 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.574 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.08 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.534 -0.729 . . . . 0.0 111.558 178.769 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 12.07 25.88 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.468 ' CB ' HD23 ' A' ' 15' ' ' LEU . 10.2 mmtt -129.91 156.63 44.1 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.055 -1.262 . . . . 0.0 109.235 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.532 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.93 15.11 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.873 -1.142 . . . . 0.0 108.891 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.931 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -70.88 114.97 31.3 Favored Pre-proline 0 C--N 1.296 -1.733 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.045 -179.412 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.845 ' O ' HG22 ' A' ' 32' ' ' VAL . 38.9 Cg_endo -67.51 130.32 22.01 Favored 'Trans proline' 0 C--N 1.302 -1.878 0 N-CA-C 107.465 -1.783 . . . . 0.0 107.465 176.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.769 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.32 -16.41 5.5 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.939 -1.101 . . . . 0.0 110.628 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.21 -16.22 59.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.671 -1.268 . . . . 0.0 110.576 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -92.68 -25.21 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 120.934 -1.104 . . . . 0.0 111.074 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 30.7 pt -116.41 -29.73 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.622 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.35 148.15 24.4 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.294 -0.879 . . . . 0.0 110.385 179.404 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.12 -5.21 49.46 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.09 -152.52 11.25 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.122 -1.514 . . . . 0.0 110.533 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.18 128.61 50.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.469 -1.018 . . . . 0.0 110.436 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.628 ' HB2' HG12 ' A' ' 81' ' ' VAL . 54.6 m80 -139.47 149.93 44.58 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 110.474 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.577 HD12 ' HB ' ' A' ' 82' ' ' VAL . 19.9 tp -111.85 117.26 32.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.403 -0.811 . . . . 0.0 110.403 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.893 ' CG1' HG12 ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.307 -0.871 . . . . 0.0 108.997 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.433 ' CZ ' ' HG2' ' A' ' 118' ' ' ARG . 5.8 m-85 -94.84 122.0 37.02 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.98 -1.075 . . . . 0.0 110.059 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.35 159.37 23.53 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.409 -0.807 . . . . 0.0 110.442 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.574 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.69 18.17 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.413 -0.805 . . . . 0.0 109.617 178.465 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.53 141.35 47.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.093 -1.005 . . . . 0.0 110.476 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.09 -35.69 69.3 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.535 -0.728 . . . . 0.0 110.549 -179.912 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.17 -45.38 88.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.303 -0.873 . . . . 0.0 110.591 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.14 -38.32 85.98 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.409 -0.807 . . . . 0.0 109.613 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.934 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.2 -34.19 74.68 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.488 -0.757 . . . . 0.0 109.56 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.24 -48.68 69.75 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.208 -0.933 . . . . 0.0 110.784 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.427 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.26 -44.61 64.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.204 -0.935 . . . . 0.0 110.472 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 1.044 HD12 HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.64 77.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.319 -0.863 . . . . 0.0 111.002 -179.058 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.434 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.16 -51.41 21.43 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.059 -1.026 . . . . 0.0 110.484 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.09 -43.46 98.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.93 . . . . 0.0 110.039 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.623 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.2 -46.16 83.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.171 -0.956 . . . . 0.0 109.526 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.747 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.76 -40.96 73.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.537 -0.727 . . . . 0.0 110.176 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.0 t -57.33 -35.34 48.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.984 -1.073 . . . . 0.0 108.978 179.425 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -31.26 59.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.352 -0.842 . . . . 0.0 110.243 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.769 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.32 -25.8 62.56 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.94 0.876 . . . . 0.0 109.75 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.41 5.77 10.11 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.321 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.662 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.7 mt -108.03 143.29 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.468 -1.019 . . . . 0.0 110.08 -179.532 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.467 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 14.8 t-20 -89.52 106.64 18.59 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.741 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.77 144.4 46.31 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.708 -177.292 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.928 HG21 ' HA ' ' A' ' 73' ' ' VAL . 48.8 t -127.84 145.91 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.881 -0.727 . . . . 0.0 109.646 179.243 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.934 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -110.09 119.42 39.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.877 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.518 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 4.1 t80 -116.45 127.26 54.43 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.229 -0.92 . . . . 0.0 110.655 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.835 ' CE1' HD23 ' A' ' 69' ' ' LEU . 1.2 p90 -153.22 -171.4 3.91 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.402 -0.811 . . . . 0.0 110.013 179.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.56 126.9 21.03 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.308 -0.87 . . . . 0.0 111.276 -179.129 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.85 48.63 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.835 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.73 155.0 30.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.978 -1.307 . . . . 0.0 109.958 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.818 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.3 m-20 -90.75 149.49 21.99 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.37 -0.832 . . . . 0.0 110.694 -179.18 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.4 m -62.54 110.94 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.145 -0.972 . . . . 0.0 109.586 179.423 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.44 ' O ' HG23 ' A' ' 74' ' ' ILE . 34.5 m -132.11 -23.82 2.16 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.383 -0.823 . . . . 0.0 111.178 -179.552 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.928 ' HA ' HG21 ' A' ' 63' ' ' VAL . 22.6 t -60.1 138.73 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.133 -0.979 . . . . 0.0 110.082 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.459 HD12 ' HB2' ' A' ' 77' ' ' ASN . 1.2 pp -137.11 100.49 9.59 Favored Pre-proline 0 N--CA 1.495 1.797 0 O-C-N 121.203 -0.935 . . . . 0.0 110.541 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.647 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.4 Cg_endo -88.19 36.92 0.43 Allowed 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.608 1.32 . . . . 0.0 110.537 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.47 16.43 6.52 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.099 -1.001 . . . . 0.0 110.655 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.459 ' HB2' HD12 ' A' ' 74' ' ' ILE . 2.7 m120 -116.18 -165.37 1.04 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.023 -1.048 . . . . 0.0 110.042 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.83 -87.56 0.01 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -131.85 115.02 15.39 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.192 -1.181 . . . . 0.0 110.379 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.647 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.1 p -116.88 133.75 62.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.039 0.923 . . . . 0.0 110.425 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.628 HG12 ' HB2' ' A' ' 38' ' ' HIS . 6.1 m -113.54 123.56 69.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 O-C-N 121.502 -0.749 . . . . 0.0 109.021 179.095 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.721 HG22 HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.51 118.04 43.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.958 -1.089 . . . . 0.0 110.649 -177.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.044 HG11 HD12 ' A' ' 51' ' ' LEU . 3.4 m -106.64 100.45 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.009 -1.057 . . . . 0.0 108.634 179.037 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.518 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -144.19 162.39 36.45 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.667 -1.27 . . . . 0.0 111.239 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -92.9 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.476 -0.765 . . . . 0.0 108.988 179.223 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.443 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -86.36 50.06 1.92 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.72 -1.237 . . . . 0.0 109.931 179.416 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.68 -18.63 9.61 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.22 -0.925 . . . . 0.0 110.583 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.462 HD12 ' HA ' ' A' ' 88' ' ' LEU . 14.2 tp -62.43 -23.55 66.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.031 -1.043 . . . . 0.0 109.71 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.542 ' C ' HG22 ' A' ' 90' ' ' THR . 0.4 OUTLIER 46.29 28.35 0.68 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.42 -0.8 . . . . 0.0 110.733 179.736 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.768 ' OG1' HG22 ' A' ' 93' ' ' THR . 5.8 t 35.11 -126.34 0.11 Allowed 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 178.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.446 ' N ' HG23 ' A' ' 90' ' ' THR . . . 90.75 -51.25 3.24 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 -178.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -133.19 23.68 4.15 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.552 -0.97 . . . . 0.0 109.432 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.768 HG22 ' OG1' ' A' ' 90' ' ' THR . 3.7 t -98.95 -156.33 0.54 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.433 -0.792 . . . . 0.0 110.695 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.531 ' N ' HG23 ' A' ' 93' ' ' THR . . . 94.12 -24.99 24.34 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.196 -1.162 . . . . 0.0 110.196 179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -87.15 60.92 6.44 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.024 -1.28 . . . . 0.0 110.844 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.493 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 20.8 m-85 -119.66 146.6 45.43 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.015 -1.053 . . . . 0.0 110.345 179.333 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.33 -34.81 58.98 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.516 -0.74 . . . . 0.0 109.508 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.441 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -160.89 163.02 32.26 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.249 -0.907 . . . . 0.0 110.778 179.784 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.554 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.29 118.15 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.21 -0.931 . . . . 0.0 110.131 179.375 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.71 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -95.96 117.73 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.462 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.427 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 18.8 t0 -124.46 161.36 26.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.137 -0.977 . . . . 0.0 111.851 -178.796 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.91 -6.81 34.84 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.412 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 4.0 m-20 55.7 15.36 1.56 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.319 -0.863 . . . . 0.0 111.654 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.496 HG23 ' C ' ' A' ' 107' ' ' GLY . 1.1 m -143.4 120.15 11.19 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 120.731 -1.231 . . . . 0.0 109.535 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.479 ' N ' ' O ' ' A' ' 108' ' ' LYS . 8.9 p -96.92 121.74 39.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.312 -0.868 . . . . 0.0 110.348 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 13.5 t0 60.78 32.84 20.19 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.311 -0.868 . . . . 0.0 110.736 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.496 ' C ' HG23 ' A' ' 104' ' ' THR . . . 92.34 -28.27 9.23 Favored Glycine 0 N--CA 1.492 2.394 0 C-N-CA 119.907 -1.14 . . . . 0.0 110.262 179.369 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -88.36 155.78 51.37 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.044 -1.268 . . . . 0.0 110.109 -179.765 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.88 128.47 22.07 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.506 1.266 . . . . 0.0 110.777 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER -46.36 168.73 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.588 -0.695 . . . . 0.0 111.163 -179.439 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.523 ' OD1' HG22 ' A' ' 113' ' ' VAL . 3.0 p30 -87.77 160.98 17.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.333 -0.854 . . . . 0.0 110.292 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.15 3.75 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.339 -0.851 . . . . 0.0 111.832 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.523 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.66 -29.76 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.932 -1.105 . . . . 0.0 111.794 -178.345 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.408 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.27 -56.1 7.42 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.083 -1.011 . . . . 0.0 110.426 -179.142 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.471 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.35 -32.87 72.22 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.224 -0.922 . . . . 0.0 108.848 178.808 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.824 ' OG1' HG22 ' A' ' 4' ' ' THR . 25.3 m -61.11 -49.8 75.81 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.109 -0.994 . . . . 0.0 108.409 178.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.97 -36.3 64.56 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.918 -0.713 . . . . 0.0 109.807 178.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HG2' ' CZ ' ' A' ' 41' ' ' PHE . 49.1 mtt-85 -71.68 -44.47 64.19 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.255 -0.903 . . . . 0.0 111.117 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.483 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 19.5 ttm180 -56.7 -41.03 76.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.891 -1.131 . . . . 0.0 109.93 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.06 71.43 0.19 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.456 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.72 -45.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.593 -0.945 . . . . 0.0 108.836 179.488 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.518 HG23 ' HA3' ' A' ' 128' ' ' GLY . 9.2 t -101.14 143.01 31.76 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.598 -0.689 . . . . 0.0 109.393 178.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 4.0 22.02 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.184 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.01 85.38 0.71 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.995 -1.297 . . . . 0.0 109.822 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 104.08 9.79 35.99 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 3.6 pttt -174.96 -173.76 0.22 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.318 -1.107 . . . . 0.0 108.659 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.469 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.0 Cg_endo -88.15 105.33 0.51 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.22 1.116 . . . . 0.0 110.297 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.518 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.42 170.45 53.61 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.706 -1.235 . . . . 0.0 110.102 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -126.79 142.55 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.535 -0.979 . . . . 0.0 108.862 179.167 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.554 ' CD2' HG23 ' A' ' 99' ' ' VAL . 6.3 t80 -129.33 115.18 17.18 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.982 -1.073 . . . . 0.0 110.578 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.7 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.68 122.85 42.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.47 -0.768 . . . . 0.0 109.273 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 24.0 p90 -121.41 148.7 44.05 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.05 -1.031 . . . . 0.0 110.262 -179.495 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.54 HG22 HD23 ' A' ' 15' ' ' LEU . 46.1 t -74.65 -31.69 27.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.524 179.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.412 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -127.69 134.0 25.71 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.142 -0.974 . . . . 0.0 110.076 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -74.45 -18.79 19.93 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.529 1.278 . . . . 0.0 110.707 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.425 ' O ' ' N ' ' A' ' 138' ' ' ARG . . . 108.03 -42.59 1.9 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 55.1 -88.22 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.531 -0.981 . . . . 0.0 110.564 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.425 ' N ' ' O ' ' A' ' 136' ' ' GLY . 9.8 ptt85 . . . . . 0 N--CA 1.492 1.63 0 O-C-N 120.996 -1.065 . . . . 0.0 110.312 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.8 m -117.09 140.1 49.92 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.243 -1.151 . . . . 0.0 110.303 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.628 ' O ' HG13 ' A' ' 3' ' ' VAL . 7.1 p -112.84 104.83 17.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.285 -0.885 . . . . 0.0 109.761 179.657 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 71.7 p -62.87 141.79 58.53 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.336 -0.852 . . . . 0.0 110.337 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.458 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -66.9 148.84 98.74 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.326 -0.859 . . . . 0.0 109.303 179.79 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.458 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.2 Cg_endo -69.07 -172.01 0.47 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 124.057 1.556 . . . . 0.0 110.883 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.51 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.6 OUTLIER 175.68 75.09 0.07 OUTLIER Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.513 -0.742 . . . . 0.0 109.54 -179.718 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.65 -13.51 32.5 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.827 1.436 . . . . 0.0 110.687 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.446 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 40.8 m-20 -59.86 -18.08 41.55 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.062 -1.024 . . . . 0.0 110.19 179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.445 HD11 ' O ' ' A' ' 122' ' ' THR . 40.8 mt -117.52 136.39 54.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 110.533 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.164 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 110.382 -179.013 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.49 156.3 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.439 -0.788 . . . . 0.0 110.05 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.01 111.49 24.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.276 -0.89 . . . . 0.0 110.169 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.438 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.16 136.17 48.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.358 -0.839 . . . . 0.0 109.877 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.97 173.83 11.28 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.132 -0.98 . . . . 0.0 110.22 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.9 p -67.57 74.32 0.16 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 109.814 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.634 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.8 m -145.59 109.55 4.84 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.379 -0.826 . . . . 0.0 110.388 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.7 27.93 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.671 179.567 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.04 -25.01 5.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.696 -0.884 . . . . 0.0 110.561 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.34 52.55 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.172 -179.535 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.438 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -64.79 143.01 78.8 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.5 1.263 . . . . 0.0 110.158 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.5 t80 -155.23 94.84 1.66 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 111.286 -178.602 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.415 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 23.7 m-85 57.66 67.07 1.01 Allowed 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.535 -0.728 . . . . 0.0 111.611 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.5 13.33 16.4 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 22.2 mmtm -130.6 156.99 43.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.142 -1.211 . . . . 0.0 109.185 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.634 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.6 107.52 16.26 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.906 -1.121 . . . . 0.0 109.827 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.5 mt -69.97 113.39 17.28 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 121.372 -0.83 . . . . 0.0 109.894 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.781 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.8 Cg_endo -68.99 128.88 17.41 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 N-CA-C 106.993 -1.964 . . . . 0.0 106.993 176.463 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.59 HD11 HD12 ' A' ' 58' ' ' LEU . 6.2 mt -56.61 -15.98 5.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.854 -1.154 . . . . 0.0 111.137 -177.599 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.425 ' OE2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.43 62.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.65 -1.281 . . . . 0.0 110.869 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.069 HG23 HG23 ' A' ' 33' ' ' ILE . 15.1 m -89.68 -26.5 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.922 -1.111 . . . . 0.0 111.134 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.069 HG23 HG23 ' A' ' 32' ' ' VAL . 43.3 pt -116.94 -23.68 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.165 -0.96 . . . . 0.0 110.048 -179.626 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.597 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.59 148.35 22.15 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.174 -0.954 . . . . 0.0 110.596 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.23 51.73 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.18 -151.61 9.86 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.211 -1.471 . . . . 0.0 110.208 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.57 130.72 54.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -1.078 . . . . 0.0 110.208 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.56 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.9 m80 -140.81 148.81 41.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.117 -0.99 . . . . 0.0 110.983 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 20.2 tp -109.76 123.18 49.09 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.924 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.94 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.8 mt -104.78 128.73 58.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.286 -0.883 . . . . 0.0 108.876 179.225 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.424 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.3 122.86 37.28 Favored 'General case' 0 C--N 1.294 -1.844 0 O-C-N 121.241 -0.912 . . . . 0.0 110.348 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.83 160.05 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.335 -0.853 . . . . 0.0 110.8 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -115.51 5.23 14.39 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.575 -0.703 . . . . 0.0 109.799 178.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.74 138.14 45.61 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.007 . . . . 0.0 110.878 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.509 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.69 -43.35 66.11 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.709 -0.619 . . . . 0.0 110.53 -179.931 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.66 -34.5 74.4 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.325 -0.859 . . . . 0.0 110.564 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.21 -38.19 66.18 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.233 -0.917 . . . . 0.0 109.911 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.942 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 61.5 m -61.4 -34.48 75.43 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.521 -0.737 . . . . 0.0 109.892 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.24 -49.72 58.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 110.381 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.01 -46.38 57.41 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.246 -0.909 . . . . 0.0 110.274 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.798 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -56.92 -42.65 80.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.976 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.475 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -73.38 -50.85 19.74 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.01 -1.056 . . . . 0.0 110.651 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -40.5 97.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.038 -1.039 . . . . 0.0 109.733 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.541 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.24 -43.1 82.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.315 -0.866 . . . . 0.0 109.434 179.394 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.727 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -55.34 -42.87 74.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.39 -0.819 . . . . 0.0 109.749 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.14 -32.58 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -0.966 . . . . 0.0 108.716 179.043 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.52 -32.08 60.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.571 -0.706 . . . . 0.0 110.013 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.59 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.52 -26.26 62.58 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.298 -0.876 . . . . 0.0 109.595 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 5.47 9.45 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.597 HD11 ' HB2' ' A' ' 34' ' ' LYS . 51.8 mt -108.26 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.303 -1.116 . . . . 0.0 110.069 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 7.9 t-20 -86.65 107.04 18.02 Favored 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.387 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.727 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.03 147.74 45.71 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.541 -177.571 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.952 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.8 t -135.73 142.43 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.518 179.278 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.942 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -105.35 135.05 47.44 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.244 -0.983 . . . . 0.0 109.871 179.324 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.447 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.62 131.29 49.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.12 -0.987 . . . . 0.0 110.792 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.685 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.6 p90 -166.25 175.33 8.39 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.66 -0.65 . . . . 0.0 109.515 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.74 114.89 1.41 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.249 -0.907 . . . . 0.0 110.799 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.77 31.45 7.77 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.916 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.53 157.31 26.55 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.064 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.916 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.3 m-20 -96.91 149.45 21.86 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.195 -0.941 . . . . 0.0 110.508 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.677 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.3 m -62.64 111.25 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.189 -0.945 . . . . 0.0 109.162 179.224 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.638 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.6 m -133.63 -32.19 1.15 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.337 -0.852 . . . . 0.0 111.08 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.952 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.4 t -53.73 137.94 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.193 -0.942 . . . . 0.0 109.825 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.638 HG23 ' O ' ' A' ' 72' ' ' SER . 1.2 pp -137.76 101.0 8.87 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.223 -0.923 . . . . 0.0 111.169 -179.453 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -82.1 53.45 4.56 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.462 1.243 . . . . 0.0 110.109 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.8 p -149.63 22.36 0.91 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.047 -1.033 . . . . 0.0 110.918 -179.309 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -123.18 -165.85 1.38 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.021 -1.049 . . . . 0.0 110.135 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.67 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -126.36 113.04 16.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.159 -1.201 . . . . 0.0 110.153 179.561 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 12.0 p -117.86 133.16 65.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.089 0.947 . . . . 0.0 110.111 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.59 HG22 HG22 ' A' ' 60' ' ' ILE . 4.7 m -113.87 125.45 71.16 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.369 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.088 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.681 HG22 HG13 ' A' ' 73' ' ' VAL . 9.1 t -97.18 121.17 47.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 121.008 -1.058 . . . . 0.0 110.133 -178.482 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.94 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.2 m -114.88 100.07 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.706 -1.246 . . . . 0.0 108.586 179.412 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.447 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.27 163.99 33.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.667 -1.271 . . . . 0.0 111.659 -177.64 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.481 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -84.11 -138.56 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.597 -0.689 . . . . 0.0 109.6 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.481 ' N ' HG23 ' A' ' 85' ' ' THR . 0.7 OUTLIER -87.53 14.4 8.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.799 -1.188 . . . . 0.0 110.613 179.817 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.476 ' H ' HG23 ' A' ' 85' ' ' THR . . . -86.54 -21.82 26.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.989 -1.069 . . . . 0.0 110.181 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.55 -24.55 53.61 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.128 -0.983 . . . . 0.0 110.143 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.409 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 52.56 -157.03 0.15 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.354 -179.198 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.617 ' CB ' HG22 ' A' ' 93' ' ' THR . 0.1 OUTLIER -147.72 29.16 0.93 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.035 -1.041 . . . . 0.0 110.071 179.717 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.64 -39.54 61.1 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -130.03 25.16 5.27 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.43 -1.041 . . . . 0.0 110.463 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.617 HG22 ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER -108.31 -171.08 1.79 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.146 -0.971 . . . . 0.0 109.81 179.684 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.557 ' N ' HG23 ' A' ' 93' ' ' THR . . . 121.77 -26.87 6.4 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.964 -1.255 . . . . 0.0 109.964 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -83.94 65.8 8.84 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.927 -1.337 . . . . 0.0 110.201 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.47 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 24.1 m-85 -119.38 144.36 46.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.23 -0.919 . . . . 0.0 110.339 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.424 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 6.5 m-20 -78.95 -31.66 45.18 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.694 179.372 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -161.56 163.15 30.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.294 -0.879 . . . . 0.0 110.768 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.523 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.45 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.271 -0.893 . . . . 0.0 110.08 179.27 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.887 HG21 HD11 ' A' ' 28' ' ' ILE . 3.0 mp -93.41 119.18 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.276 -0.89 . . . . 0.0 109.14 179.349 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' A' ' 41' ' ' PHE . 2.4 t70 -128.47 160.58 31.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.121 -0.987 . . . . 0.0 111.599 -178.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.45 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.96 -5.14 31.14 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 177.452 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.15 14.02 1.38 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.285 -0.884 . . . . 0.0 111.723 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.416 HG23 ' O ' ' A' ' 108' ' ' LYS . 1.3 m -141.61 127.94 19.91 Favored 'General case' 0 C--N 1.307 -1.242 0 O-C-N 120.678 -1.264 . . . . 0.0 109.043 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.478 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -109.18 124.43 50.83 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.304 -0.873 . . . . 0.0 110.657 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 58.23 34.73 24.38 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.348 -0.845 . . . . 0.0 111.262 179.35 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.85 -33.94 4.78 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.841 -1.171 . . . . 0.0 110.342 179.286 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -86.21 155.29 57.6 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.158 -1.201 . . . . 0.0 110.067 -179.858 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -64.91 138.49 57.76 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 123.366 1.193 . . . . 0.0 110.747 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -50.32 156.7 0.8 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.545 -0.722 . . . . 0.0 110.99 -179.439 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.506 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.8 p-10 -73.82 162.88 28.65 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.558 -0.714 . . . . 0.0 110.287 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.449 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.24 -44.8 92.33 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.877 -1.14 . . . . 0.0 111.6 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.506 HG22 ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.76 -30.66 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.716 -1.24 . . . . 0.0 112.74 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 2.6 p -53.6 -55.25 27.39 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.449 -1.407 . . . . 0.0 110.162 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.449 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.64 -35.33 75.92 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.048 178.435 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.415 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 26.2 m -62.07 -50.35 72.32 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 119.369 -0.932 . . . . 0.0 108.581 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.25 -46.83 39.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.322 -0.861 . . . . 0.0 109.982 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 114' ' ' SER . 60.2 mtt180 -61.3 -45.29 95.06 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.268 -0.895 . . . . 0.0 110.967 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.51 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 11.9 ttm180 -55.55 -38.68 69.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.694 -1.254 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.78 0.28 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.61 -50.81 0.24 Allowed 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.468 -1.019 . . . . 0.0 108.632 179.666 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.487 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -94.79 142.35 27.57 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.484 1.891 0 C-N-CA 119.335 -1.412 . . . . 0.0 110.574 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.448 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -62.2 86.19 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.883 -1.363 . . . . 0.0 109.931 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.89 -43.01 1.75 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.344 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.472 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 12.9 mttt -111.0 -171.68 0.22 Allowed Pre-proline 0 N--CA 1.487 1.392 0 O-C-N 121.611 -0.935 . . . . 0.0 109.454 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.457 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.9 Cg_endo -90.75 107.79 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.61 1.321 . . . . 0.0 109.786 179.044 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.487 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.33 166.07 50.92 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.429 ' O ' ' HA ' ' A' ' 98' ' ' SER . 4.0 mt -119.55 140.49 43.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.227 179.2 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.523 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.6 t80 -128.73 114.93 17.21 Favored 'General case' 0 C--N 1.3 -1.585 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.139 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.418 ' NE ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -99.38 134.28 42.48 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 109.665 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.474 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.16 148.26 50.59 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.157 -0.964 . . . . 0.0 109.803 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.45 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.1 t -79.89 -54.16 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.068 -1.02 . . . . 0.0 110.042 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -89.5 134.98 31.52 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.218 -0.926 . . . . 0.0 110.121 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.23 -51.87 0.13 Allowed 'Trans proline' 0 C--N 1.311 -1.398 0 O-C-N 123.533 1.28 . . . . 0.0 110.373 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.31 -69.34 0.42 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 53.47 96.32 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.25 -1.147 . . . . 0.0 110.077 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 117.925 -1.036 . . . . 0.0 110.195 -179.885 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.2 m -115.02 128.33 56.2 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -1.155 . . . . 0.0 110.239 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 63.6 t -113.19 104.21 16.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.262 -0.899 . . . . 0.0 110.174 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.524 HG22 ' OG1' ' A' ' 116' ' ' THR . 69.1 p -72.16 146.1 47.63 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.497 -0.752 . . . . 0.0 110.108 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.606 HG22 ' HD1' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -66.47 148.42 98.61 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.18 -0.95 . . . . 0.0 109.75 -179.867 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.536 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.9 Cg_endo -80.3 -59.74 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.442 0 O-C-N 124.21 1.637 . . . . 0.0 112.392 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.838 ' HE1' ' HD2' ' A' ' 119' ' ' ARG . 50.3 p-80 39.3 89.28 0.08 OUTLIER Pre-proline 0 N--CA 1.492 1.655 0 CA-C-O 121.063 0.458 . . . . 0.0 111.466 -178.347 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -74.7 57.26 4.31 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.289 1.152 . . . . 0.0 110.925 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.8 m120 -119.95 -18.82 8.09 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.264 -0.897 . . . . 0.0 110.29 179.686 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.832 HD13 HG23 ' A' ' 122' ' ' THR . 62.2 mt -108.75 136.64 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.044 -1.035 . . . . 0.0 110.141 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.43 127.94 34.1 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.188 -0.945 . . . . 0.0 109.25 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.72 135.66 33.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.159 -0.963 . . . . 0.0 110.185 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.8 t -137.22 156.41 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.286 -0.884 . . . . 0.0 110.423 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.33 113.83 26.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 0.0 109.83 179.529 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.647 HD23 ' CB ' ' A' ' 26' ' ' LYS . 8.8 tp -52.78 142.58 18.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.161 -0.962 . . . . 0.0 110.111 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 p -138.22 174.36 10.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.262 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.2 71.91 1.71 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.289 -0.882 . . . . 0.0 109.969 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.753 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -144.19 110.15 5.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 110.513 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.77 -171.44 26.75 Favored Glycine 0 N--CA 1.488 2.145 0 C-N-CA 118.876 -1.631 . . . . 0.0 110.859 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -108.95 -26.18 10.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.65 -0.912 . . . . 0.0 110.394 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.979 HD12 HD13 ' A' ' 55' ' ' LEU . 8.0 tt -95.27 101.53 7.69 Favored Pre-proline 0 N--CA 1.487 1.403 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.357 -179.38 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 36.5 Cg_endo -61.29 155.29 52.6 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.516 1.272 . . . . 0.0 110.228 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.589 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.75 94.48 0.5 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.091 -1.005 . . . . 0.0 111.309 -178.024 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.589 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 60.0 68.28 0.79 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.407 -0.808 . . . . 0.0 111.673 178.808 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 14.6 11.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.647 ' CB ' HD23 ' A' ' 15' ' ' LEU . 21.4 mmtt -130.73 156.69 44.52 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.082 -1.246 . . . . 0.0 109.2 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.753 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.24 108.07 16.11 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.986 -1.071 . . . . 0.0 109.086 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 1.088 HD11 HG21 ' A' ' 100' ' ' ILE . 5.1 mt -71.31 113.33 18.47 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.117 -179.384 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.89 ' O ' HG22 ' A' ' 32' ' ' VAL . 43.0 Cg_endo -71.04 129.69 16.64 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.053 -1.941 . . . . 0.0 107.053 176.71 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.489 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.8 mt -55.77 -18.82 9.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.808 -1.182 . . . . 0.0 110.545 -177.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -15.97 23.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.628 -1.295 . . . . 0.0 110.332 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.069 HG23 HG23 ' A' ' 33' ' ' ILE . 16.2 m -93.36 -25.36 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.882 -1.136 . . . . 0.0 111.057 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.069 HG23 HG23 ' A' ' 32' ' ' VAL . 21.4 pt -117.9 -16.17 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.01 -1.056 . . . . 0.0 110.923 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.566 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -97.82 148.49 23.34 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.844 -1.16 . . . . 0.0 110.083 179.534 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.17 -4.14 51.81 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.65 -159.08 23.37 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.347 -1.406 . . . . 0.0 110.082 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.89 133.45 44.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.275 -1.132 . . . . 0.0 110.547 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.76 147.01 40.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.098 -1.001 . . . . 0.0 110.703 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.592 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.2 tp -108.54 113.74 27.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.417 -0.802 . . . . 0.0 109.998 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.784 HD12 HG12 ' A' ' 83' ' ' VAL . 25.9 mt -96.54 126.89 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.341 -0.85 . . . . 0.0 109.409 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.504 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 34.0 m-85 -95.23 123.75 38.9 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.41 -0.806 . . . . 0.0 109.978 -179.587 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.01 160.23 21.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.192 -0.943 . . . . 0.0 110.606 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.422 ' HB3' ' O ' ' A' ' 104' ' ' THR . 7.8 p80 -107.18 -3.81 19.46 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.439 -0.788 . . . . 0.0 110.175 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.65 50.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.066 -1.021 . . . . 0.0 110.779 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.516 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.53 -41.38 69.24 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.81 -0.556 . . . . 0.0 110.646 -179.765 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mttp -58.79 -35.27 72.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.195 -0.941 . . . . 0.0 110.109 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.26 -34.86 66.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.347 -0.846 . . . . 0.0 109.427 179.656 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.811 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 91.9 m -60.7 -34.23 74.05 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.511 -0.743 . . . . 0.0 109.58 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.06 -49.16 63.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.17 -0.956 . . . . 0.0 110.246 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.7 -42.68 67.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.258 -0.901 . . . . 0.0 110.599 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.775 HD12 HG11 ' A' ' 83' ' ' VAL . 1.1 tm? -57.23 -41.1 78.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.427 -0.796 . . . . 0.0 111.295 -179.018 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.95 -51.48 12.33 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.874 -1.141 . . . . 0.0 110.528 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.6 89.78 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.996 -1.065 . . . . 0.0 109.48 179.583 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.531 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.98 -45.77 86.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.475 -0.766 . . . . 0.0 109.559 179.337 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.979 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.83 -42.0 75.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 109.898 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.8 t -56.35 -33.71 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.091 -1.006 . . . . 0.0 109.181 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -32.05 61.01 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.32 -0.862 . . . . 0.0 109.863 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.531 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.69 -26.2 62.41 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.379 -0.826 . . . . 0.0 109.529 179.637 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.52 6.09 8.94 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.618 HG22 HG22 ' A' ' 81' ' ' VAL . 30.6 mt -108.25 143.72 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.254 -1.145 . . . . 0.0 110.143 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.471 ' OD1' HD11 ' A' ' 74' ' ' ILE . 1.5 t-20 -87.07 107.3 18.38 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.302 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.608 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.22 147.33 45.76 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.744 -177.274 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.88 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.6 t -134.75 150.0 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.916 -0.714 . . . . 0.0 109.326 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.811 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.47 136.4 52.83 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.011 179.078 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.577 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.1 t80 -123.47 128.12 49.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.911 . . . . 0.0 110.742 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.849 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.12 -179.94 8.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.515 -0.741 . . . . 0.0 109.858 179.63 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.73 11.0 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.238 -0.913 . . . . 0.0 111.012 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.76 47.73 19.39 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.849 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -116.96 153.02 33.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.058 -1.26 . . . . 0.0 109.608 179.549 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.4 m-20 -89.55 148.25 23.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.219 -0.925 . . . . 0.0 110.994 -178.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.677 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -63.2 111.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.102 -0.999 . . . . 0.0 109.235 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.712 ' O ' HG23 ' A' ' 74' ' ' ILE . 18.1 m -132.58 -38.31 1.03 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.266 -0.896 . . . . 0.0 110.488 -179.486 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.88 HG22 ' HB ' ' A' ' 63' ' ' VAL . 64.6 t -48.19 137.3 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.388 -0.82 . . . . 0.0 110.464 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.712 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -137.0 91.77 14.7 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.305 -0.872 . . . . 0.0 110.298 179.922 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.51 ' HA ' HG11 ' A' ' 80' ' ' VAL . 53.2 Cg_endo -79.83 55.69 5.74 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 O-C-N 123.707 1.372 . . . . 0.0 110.387 179.812 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.8 t -156.13 31.91 0.34 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.171 -0.956 . . . . 0.0 110.46 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -128.95 -164.75 1.43 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.179 -0.95 . . . . 0.0 110.075 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.57 -73.65 0.34 Allowed Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -149.26 109.36 4.12 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.212 -1.169 . . . . 0.0 110.024 179.416 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.555 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -117.06 134.8 59.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 122.014 0.911 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.618 HG22 HG22 ' A' ' 60' ' ' ILE . 11.4 m -112.6 125.76 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.334 -0.854 . . . . 0.0 109.02 179.127 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.795 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -97.39 118.34 43.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 120.935 -1.103 . . . . 0.0 110.037 -178.282 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.784 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -112.64 100.09 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.027 -1.046 . . . . 0.0 108.806 179.571 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.51 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -142.0 162.23 36.0 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.613 -1.304 . . . . 0.0 111.521 -178.079 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.699 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -87.01 -143.95 0.12 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.678 -0.639 . . . . 0.0 109.353 179.39 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.409 ' N ' HG23 ' A' ' 85' ' ' THR . 3.1 p30 -73.9 -4.62 36.12 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.926 -1.109 . . . . 0.0 110.782 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.699 ' H ' HG23 ' A' ' 85' ' ' THR . . . -61.65 -40.05 93.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.144 . . . . 0.0 110.502 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.67 -46.98 64.86 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.107 -0.996 . . . . 0.0 109.844 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.457 ' O ' ' N ' ' A' ' 91' ' ' GLY . 0.4 OUTLIER 53.1 21.91 2.33 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.356 -0.84 . . . . 0.0 110.088 -179.744 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.406 HG22 ' N ' ' A' ' 94' ' ' GLY . 0.2 OUTLIER 62.35 -72.75 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.581 -0.699 . . . . 0.0 110.709 -179.995 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 54.63 -98.65 0.05 OUTLIER Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.529 ' CD2' ' O ' ' A' ' 92' ' ' PHE . 46.6 p90 -88.98 48.43 1.63 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.258 -1.143 . . . . 0.0 109.592 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.424 ' CG2' ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -151.65 -146.16 0.19 Allowed 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.375 -0.828 . . . . 0.0 109.951 -179.628 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.406 ' N ' HG22 ' A' ' 90' ' ' THR . . . 111.51 -30.64 7.71 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.17 80.99 9.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.211 -1.17 . . . . 0.0 110.421 -179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.441 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 21.9 m-85 -119.42 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.109 -0.994 . . . . 0.0 109.726 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.445 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.99 -35.59 80.7 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.142 -0.973 . . . . 0.0 109.067 179.538 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.485 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.59 31.79 Favored 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.741 -0.784 . . . . 0.0 110.863 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.741 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.12 117.6 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.453 -0.78 . . . . 0.0 110.571 179.837 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 1.088 HG21 HD11 ' A' ' 28' ' ' ILE . 2.9 mp -93.1 112.59 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.29 161.1 21.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.115 -0.99 . . . . 0.0 111.912 -178.059 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.506 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.1 p -102.83 6.57 39.29 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.068 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.409 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.2 m120 45.86 25.4 0.29 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.238 -0.913 . . . . 0.0 111.349 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.506 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.9 p -146.91 128.89 15.47 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.921 . . . . 0.0 110.028 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.4 p -114.4 134.6 54.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.073 -1.017 . . . . 0.0 110.381 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 29.0 t0 54.07 26.98 7.01 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.243 -0.911 . . . . 0.0 110.385 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.41 -31.51 6.36 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.73 155.91 77.96 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.136 -1.214 . . . . 0.0 110.115 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.506 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.1 Cg_endo -66.63 133.52 32.23 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 O-C-N 123.637 1.335 . . . . 0.0 110.319 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.7 pp0? -47.91 163.98 0.05 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.318 -0.864 . . . . 0.0 110.709 -179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.512 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -96.36 160.29 14.5 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.298 -0.876 . . . . 0.0 110.397 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.44 -48.26 37.5 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.418 -0.801 . . . . 0.0 112.001 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.512 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -71.17 -29.56 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.769 -1.207 . . . . 0.0 110.836 -178.781 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.48 -56.31 7.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.217 -0.927 . . . . 0.0 110.387 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.426 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.66 -34.82 76.35 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.279 -0.888 . . . . 0.0 108.715 178.705 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.524 ' OG1' HG22 ' A' ' 4' ' ' THR . 42.7 m -59.79 -49.82 76.24 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.064 -1.022 . . . . 0.0 108.608 178.792 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -73.82 -38.89 64.42 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.43 -0.794 . . . . 0.0 109.951 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 82.8 mtt180 -70.18 -44.29 69.05 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.262 -0.899 . . . . 0.0 110.586 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.838 ' HD2' ' HE1' ' A' ' 7' ' ' HIS . 34.5 ttm180 -54.45 -36.58 64.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.222 -0.924 . . . . 0.0 110.577 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.94 -15.85 11.1 Favored Glycine 0 N--CA 1.494 2.527 0 O-C-N 120.959 -1.088 . . . . 0.0 111.524 -179.205 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.73 -3.58 22.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.651 -1.5 . . . . 0.0 111.485 -179.252 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.832 HG23 HD13 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.98 143.53 48.97 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.76 -1.213 . . . . 0.0 110.9 -179.685 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.469 ' N ' ' HA3' ' A' ' 128' ' ' GLY . . . 74.93 12.25 83.32 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.846 178.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.2 mtt180 -61.3 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.048 -1.266 . . . . 0.0 109.022 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.4 16.64 39.46 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -178.516 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.459 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.2 OUTLIER -175.48 -176.48 0.26 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.472 -1.016 . . . . 0.0 108.779 -179.615 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.459 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -88.27 105.39 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.133 1.07 . . . . 0.0 109.983 179.452 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.469 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.23 173.82 25.63 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.529 -1.32 . . . . 0.0 110.198 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.28 142.94 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.486 -1.008 . . . . 0.0 109.572 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.741 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.44 114.93 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.757 -1.215 . . . . 0.0 110.389 179.4 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.441 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.55 145.68 27.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.495 -0.753 . . . . 0.0 109.484 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.7 p90 -137.89 157.08 47.14 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.906 -1.121 . . . . 0.0 110.306 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t -87.03 -34.77 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.142 -0.974 . . . . 0.0 109.656 179.451 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -128.11 159.81 64.97 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.208 -0.932 . . . . 0.0 110.32 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -73.71 -41.0 1.22 Allowed 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.778 1.409 . . . . 0.0 110.415 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 67.09 88.78 0.06 OUTLIER Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -78.47 130.79 36.45 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.242 -1.152 . . . . 0.0 110.307 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.4 mtt-85 . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.293 179.884 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.4 m -111.57 155.35 23.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.3 -1.118 . . . . 0.0 110.189 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.596 HG23 ' O ' ' A' ' 3' ' ' VAL . 27.6 m -113.34 104.01 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.221 -0.924 . . . . 0.0 109.877 179.638 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.548 HG22 ' OG1' ' A' ' 116' ' ' THR . 10.5 p -64.23 138.14 58.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.406 -0.809 . . . . 0.0 110.605 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.432 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.61 147.83 98.66 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.556 179.62 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.432 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.3 Cg_endo -69.91 -169.29 0.33 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 124.089 1.573 . . . . 0.0 111.057 179.512 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.542 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 6.9 p80 -177.42 82.48 0.24 Allowed Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.568 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -63.81 89.25 0.15 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 O-C-N 123.67 1.353 . . . . 0.0 110.471 -179.441 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.509 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 -177.24 -33.94 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.753 -0.592 . . . . 0.0 109.898 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.488 HD13 HG22 ' A' ' 122' ' ' THR . 19.8 mt -105.28 134.83 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.856 -1.153 . . . . 0.0 110.027 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -84.93 128.28 34.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.328 -0.857 . . . . 0.0 108.893 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.43 142.74 27.39 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.043 -1.036 . . . . 0.0 110.245 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.611 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 13.3 t -136.53 157.29 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.943 -179.448 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.35 108.7 19.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.869 179.418 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.586 HD23 HG22 ' A' ' 133' ' ' VAL . 11.2 tp -54.98 134.35 48.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.798 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.0 p -137.97 -179.32 5.7 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.323 -0.861 . . . . 0.0 110.176 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.2 p -74.56 60.78 0.91 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -0.909 . . . . 0.0 109.988 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.456 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.8 m -131.73 111.41 11.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.892 . . . . 0.0 110.227 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.454 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.53 -162.61 27.97 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.977 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.32 -21.63 7.42 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.724 -0.868 . . . . 0.0 110.474 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.896 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.0 tt -97.39 107.1 36.8 Favored Pre-proline 0 N--CA 1.489 1.517 0 C-N-CA 118.796 -1.162 . . . . 0.0 110.24 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.448 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -63.64 155.01 65.62 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 O-C-N 123.385 1.203 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.7 t80 -169.13 91.6 0.25 Allowed 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.056 -1.027 . . . . 0.0 111.563 -178.123 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.501 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.82 67.27 0.89 Allowed 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.473 -0.767 . . . . 0.0 111.38 178.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.68 13.56 18.33 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.632 ' HG3' HG13 ' A' ' 133' ' ' VAL . 6.5 mmtt -130.8 156.23 45.34 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.14 -1.212 . . . . 0.0 109.08 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.456 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.81 106.92 12.56 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.896 -1.127 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.896 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.0 mt -68.47 115.1 26.44 Favored Pre-proline 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.61 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.911 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.1 Cg_endo -68.42 126.74 14.63 Favored 'Trans proline' 0 C--N 1.304 -1.813 0 N-CA-C 107.382 -1.815 . . . . 0.0 107.382 176.261 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.565 HD11 HD12 ' A' ' 58' ' ' LEU . 5.6 mt -56.08 -20.72 18.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.962 -1.086 . . . . 0.0 110.846 -177.474 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -59.95 -16.05 26.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.674 -1.266 . . . . 0.0 110.467 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.109 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.58 -25.33 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.005 -1.059 . . . . 0.0 110.955 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.109 HG23 HG23 ' A' ' 32' ' ' VAL . 14.7 pt -117.86 -15.49 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.963 -1.085 . . . . 0.0 110.951 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.597 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.5 tptm -98.22 147.77 24.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.809 -1.182 . . . . 0.0 110.507 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.35 -3.14 61.43 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.09 -159.45 21.29 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.23 -1.462 . . . . 0.0 110.374 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.375 -1.074 . . . . 0.0 110.543 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.563 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.11 147.86 39.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.225 -0.922 . . . . 0.0 110.918 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.429 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 40.4 tp -109.14 116.24 31.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.38 -0.825 . . . . 0.0 110.291 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.907 HD12 HG12 ' A' ' 83' ' ' VAL . 34.4 mt -99.89 127.77 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.132 -0.98 . . . . 0.0 109.687 179.465 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.05 39.55 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.327 -0.858 . . . . 0.0 109.891 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.71 159.72 21.82 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.821 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.501 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.43 -8.58 19.05 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.557 -0.714 . . . . 0.0 109.942 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.13 138.98 53.27 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.031 -1.043 . . . . 0.0 110.96 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.471 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.95 -40.37 68.73 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.315 0.579 . . . . 0.0 110.774 -179.79 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mttp -59.93 -36.49 77.13 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.369 -0.832 . . . . 0.0 111.028 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.28 71.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 -179.48 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.916 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 84.8 m -61.2 -36.36 79.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.284 -0.885 . . . . 0.0 109.302 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.45 66.85 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.267 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -73.01 -45.99 54.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.234 -0.916 . . . . 0.0 110.283 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.61 ' O ' HD13 ' A' ' 51' ' ' LEU . 3.2 tm? -57.01 -39.72 75.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.591 -0.693 . . . . 0.0 111.267 -179.002 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.477 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.88 -51.17 13.1 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.929 -1.107 . . . . 0.0 110.54 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.127 -0.983 . . . . 0.0 109.677 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.498 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.68 83.89 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.372 -0.83 . . . . 0.0 109.526 179.379 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.873 HD13 HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -54.94 -42.59 72.49 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.491 -0.756 . . . . 0.0 109.489 179.683 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.5 t -56.14 -31.02 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.99 -1.068 . . . . 0.0 108.725 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.03 -32.73 61.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.521 -0.737 . . . . 0.0 109.899 179.35 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.565 HD12 HD11 ' A' ' 30' ' ' LEU . 4.3 mm? -72.1 -26.11 62.01 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-O 121.851 0.834 . . . . 0.0 109.728 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.0 9.17 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.599 HG22 HG22 ' A' ' 81' ' ' VAL . 44.7 mt -107.55 143.24 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.247 -1.149 . . . . 0.0 109.861 -179.818 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.7 t-20 -87.56 106.83 18.27 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.348 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.642 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 118.774 -1.17 . . . . 0.0 111.831 -177.079 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.896 HG21 ' HA ' ' A' ' 73' ' ' VAL . 92.2 t -126.01 148.12 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.697 -0.627 . . . . 0.0 109.828 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.916 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -117.77 117.63 29.85 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.495 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.485 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 3.5 t80 -108.14 131.25 54.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 110.878 -179.264 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.857 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -155.34 -168.72 2.93 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.62 -0.675 . . . . 0.0 109.958 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -55.92 123.66 15.04 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.319 -0.863 . . . . 0.0 111.266 -179.256 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.56 59.02 8.76 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.857 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.66 152.05 35.98 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.074 -1.25 . . . . 0.0 109.712 179.397 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.738 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -85.88 149.03 25.51 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.209 -0.932 . . . . 0.0 110.592 -179.276 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.0 m -62.5 110.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.133 179.178 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.707 ' O ' HG23 ' A' ' 74' ' ' ILE . 68.9 m -131.33 -32.09 1.58 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.372 -0.83 . . . . 0.0 110.656 -179.403 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.896 ' HA ' HG21 ' A' ' 63' ' ' VAL . 94.9 t -53.0 131.25 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.153 -0.967 . . . . 0.0 109.441 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -134.04 103.8 11.72 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.125 -0.984 . . . . 0.0 110.779 -179.263 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -87.05 43.68 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 O-C-N 123.457 1.241 . . . . 0.0 110.294 179.214 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.5 p -136.64 4.52 2.84 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.018 -1.051 . . . . 0.0 111.114 -179.441 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.516 ' HB2' HD12 ' A' ' 74' ' ' ILE . 2.5 m120 -100.74 -169.11 1.66 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.915 -1.116 . . . . 0.0 110.291 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -54.47 -70.47 0.94 Allowed Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -144.85 113.67 6.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.202 -1.175 . . . . 0.0 110.297 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.619 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.43 132.44 67.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 CA-C-O 122.087 0.946 . . . . 0.0 110.456 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.614 HG11 ' HB ' ' A' ' 33' ' ' ILE . 11.4 m -112.45 122.05 65.95 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 121.356 -0.84 . . . . 0.0 108.96 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.839 HG22 HG13 ' A' ' 73' ' ' VAL . 16.1 t -97.01 120.94 46.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.684 0 O-C-N 121.054 -1.029 . . . . 0.0 110.611 -177.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.907 HG12 HD12 ' A' ' 40' ' ' ILE . 3.3 m -112.39 100.39 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.044 -1.035 . . . . 0.0 108.667 179.321 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.485 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.7 34.44 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -177.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.574 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -93.19 -136.68 0.18 Allowed 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.203 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.525 ' N ' HG23 ' A' ' 85' ' ' THR . 3.3 p30 -77.04 -6.16 51.63 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.679 -1.263 . . . . 0.0 111.068 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.574 ' H ' HG23 ' A' ' 85' ' ' THR . . . -60.71 -41.52 95.4 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.849 -1.157 . . . . 0.0 110.066 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.4 tp -64.43 -32.25 73.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 108.577 179.161 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.482 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 43.82 34.82 0.94 Allowed 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 121.244 0.545 . . . . 0.0 110.953 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.567 HG21 ' NH1' ' A' ' 121' ' ' ARG . 22.6 p 47.28 -130.31 1.49 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.708 -0.62 . . . . 0.0 110.392 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 92.98 -85.17 1.13 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 27.0 p90 -94.44 17.06 13.7 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -1.167 . . . . 0.0 109.781 179.307 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.466 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 14.9 t -92.53 -151.22 0.28 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.319 -0.863 . . . . 0.0 110.264 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.458 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 94.08 -31.92 6.28 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.28 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.59 57.3 3.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.977 -1.307 . . . . 0.0 110.304 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.446 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 64.0 m-85 -120.26 152.81 37.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.214 -0.929 . . . . 0.0 110.294 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.478 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.6 -28.35 30.88 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.425 -0.797 . . . . 0.0 109.831 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.503 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.6 p -160.7 163.58 32.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.283 -0.886 . . . . 0.0 110.712 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.503 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.91 128.12 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.345 -0.847 . . . . 0.0 110.138 179.441 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.86 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -105.95 111.11 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.195 -0.94 . . . . 0.0 108.666 178.778 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.418 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.7 t0 -115.85 161.29 18.99 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.052 -1.03 . . . . 0.0 111.96 -178.277 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.468 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.84 -2.91 43.04 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.023 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.423 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 53.89 21.48 2.82 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.007 . . . . 0.0 110.183 -179.098 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.742 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -144.13 125.94 15.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.323 -0.86 . . . . 0.0 110.153 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.1 p -112.59 139.23 48.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.154 -0.966 . . . . 0.0 109.61 179.468 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.5 t70 54.74 -143.54 0.73 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.047 -1.033 . . . . 0.0 109.605 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.76 26.45 12.54 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.594 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.11 156.79 67.92 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.175 -1.191 . . . . 0.0 109.843 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.742 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.1 Cg_endo -65.84 162.1 36.36 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.654 1.344 . . . . 0.0 110.523 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.9 pp0? -64.86 168.1 6.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.308 -0.87 . . . . 0.0 110.873 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.482 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -105.55 161.85 14.0 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.478 -0.764 . . . . 0.0 110.323 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.8 -59.85 1.8 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.315 -0.865 . . . . 0.0 112.156 -178.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.482 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.4 m -64.31 -29.32 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.788 -1.195 . . . . 0.0 111.764 -178.57 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.34 -56.5 6.73 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.009 -1.057 . . . . 0.0 110.63 -179.015 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.47 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.58 -34.75 76.35 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.719 178.933 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.548 ' OG1' HG22 ' A' ' 4' ' ' THR . 29.5 m -59.13 -49.22 78.69 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.984 -1.072 . . . . 0.0 108.301 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.418 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -36.99 65.87 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.508 -0.745 . . . . 0.0 109.9 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.425 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 5.1 mtt180 -71.8 -44.59 63.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.042 -1.036 . . . . 0.0 111.193 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.542 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -57.35 -41.64 80.48 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.848 -1.158 . . . . 0.0 109.834 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.421 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.05 63.88 0.21 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.567 ' NH1' HG21 ' A' ' 90' ' ' THR . 10.9 mmp_? -135.38 -44.69 0.69 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.43 -1.041 . . . . 0.0 108.524 178.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.507 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.0 t -93.58 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.677 -0.639 . . . . 0.0 109.732 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.08 3.23 36.13 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.617 179.058 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.458 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 2.8 mmt180 -62.71 87.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.965 -1.315 . . . . 0.0 109.511 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.51 19.13 33.29 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -178.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.462 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 16.4 ptpt -176.23 -178.31 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.491 -1.005 . . . . 0.0 108.503 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.5 Cg_endo -89.16 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.254 1.134 . . . . 0.0 110.428 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.588 ' C ' HD12 ' A' ' 129' ' ' ILE . . . -80.85 176.72 54.59 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.772 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.588 HD12 ' C ' ' A' ' 128' ' ' GLY . 3.5 mp -132.52 143.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.764 -0.845 . . . . 0.0 109.043 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.503 ' HD1' HG23 ' A' ' 99' ' ' VAL . 9.6 t80 -129.95 115.52 17.28 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.24 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.611 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mtt180 -105.98 131.42 53.29 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.522 -0.736 . . . . 0.0 109.435 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.418 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 46.0 p90 -129.63 157.29 42.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.042 -1.036 . . . . 0.0 110.376 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.632 HG13 ' HG3' ' A' ' 26' ' ' LYS . 42.8 t -76.08 -60.39 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.104 -0.997 . . . . 0.0 109.923 179.757 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.423 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -111.14 146.81 35.29 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.154 -0.967 . . . . 0.0 110.317 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.99 -51.05 0.15 Allowed 'Trans proline' 0 C--N 1.311 -1.4 0 O-C-N 123.81 1.426 . . . . 0.0 110.432 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 62.7 85.6 0.05 OUTLIER Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -94.93 81.99 3.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.23 -1.159 . . . . 0.0 110.326 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.3 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.2 139.3 50.09 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -1.155 . . . . 0.0 110.24 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 59.6 t -112.83 104.28 16.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.239 -0.913 . . . . 0.0 109.822 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.627 HG22 ' OG1' ' A' ' 116' ' ' THR . 18.1 p -69.12 138.23 54.07 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.479 -0.763 . . . . 0.0 110.185 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.82 146.25 98.3 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.257 -0.902 . . . . 0.0 109.523 179.72 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.429 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 46.2 Cg_endo -72.69 -174.28 1.44 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.978 1.515 . . . . 0.0 110.51 179.204 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.512 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 175.85 76.79 0.08 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.481 -0.762 . . . . 0.0 109.887 -179.61 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -75.25 53.98 3.61 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.76 1.4 . . . . 0.0 111.1 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.436 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 11.2 m120 -138.45 8.31 2.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.002 -1.061 . . . . 0.0 110.346 179.562 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.64 HD11 ' O ' ' A' ' 122' ' ' THR . 36.2 mt -128.05 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.187 -0.945 . . . . 0.0 109.413 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.97 128.45 34.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.139 -0.976 . . . . 0.0 109.305 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.06 133.09 34.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.206 -0.933 . . . . 0.0 110.429 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.522 HG11 ' HE ' ' A' ' 131' ' ' ARG . 16.5 t -128.66 156.11 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.403 -0.811 . . . . 0.0 110.021 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.61 110.9 21.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.252 -0.905 . . . . 0.0 109.968 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.718 HD23 HG22 ' A' ' 133' ' ' VAL . 11.7 tp -58.84 134.21 56.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.275 -0.891 . . . . 0.0 109.581 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.9 p -138.78 -175.19 4.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.24 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.5 p -77.75 81.3 4.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.264 -0.897 . . . . 0.0 109.896 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.625 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.8 m -153.64 109.5 3.27 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.297 -0.877 . . . . 0.0 110.656 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.74 -165.08 28.07 Favored Glycine 0 N--CA 1.487 2.044 0 C-N-CA 119.072 -1.537 . . . . 0.0 110.567 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.7 -21.83 8.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.647 -0.914 . . . . 0.0 110.275 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.876 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -96.19 110.69 53.55 Favored Pre-proline 0 N--CA 1.487 1.407 0 C-N-CA 118.8 -1.16 . . . . 0.0 109.91 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.462 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.3 Cg_endo -64.63 155.39 67.07 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.684 1.36 . . . . 0.0 110.285 -179.515 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.4 t80 -169.5 94.06 0.28 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.112 -0.993 . . . . 0.0 111.508 -178.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 24.9 m-85 58.38 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.393 -0.817 . . . . 0.0 111.497 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.44 14.76 9.61 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.431 -1.067 . . . . 0.0 110.431 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.473 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.8 156.8 44.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.041 -1.27 . . . . 0.0 109.418 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.625 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -114.7 107.35 15.34 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 120.967 -1.083 . . . . 0.0 109.5 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.865 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.3 mt -69.56 113.9 20.46 Favored Pre-proline 0 C--N 1.299 -1.6 0 O-C-N 121.383 -0.823 . . . . 0.0 110.215 -179.517 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.917 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.8 Cg_endo -70.27 129.73 17.54 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 N-CA-C 107.189 -1.889 . . . . 0.0 107.189 176.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.818 HD11 HD12 ' A' ' 58' ' ' LEU . 17.6 mt -56.33 -18.19 10.07 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.874 -1.141 . . . . 0.0 110.94 -177.659 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.49 -16.47 24.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.636 -1.29 . . . . 0.0 110.087 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.025 HG23 HG23 ' A' ' 33' ' ' ILE . 14.4 m -93.96 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.155 -0.966 . . . . 0.0 110.981 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.025 HG23 HG23 ' A' ' 32' ' ' VAL . 40.9 pt -118.15 -22.79 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.934 -1.104 . . . . 0.0 110.872 -178.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.596 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.26 22.16 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.506 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.02 -5.27 59.35 Favored Glycine 0 N--CA 1.483 1.82 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.22 -162.58 27.81 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.678 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.22 129.38 44.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.468 -1.019 . . . . 0.0 110.351 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.5 m-70 -138.93 145.59 40.01 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.222 -0.924 . . . . 0.0 110.607 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.593 HD12 ' O ' ' A' ' 82' ' ' VAL . 38.3 tp -108.06 117.17 33.43 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.922 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.5 mm -94.03 125.69 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.275 -0.891 . . . . 0.0 108.601 179.26 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.471 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 11.4 m-85 -94.21 121.81 36.11 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.089 -1.007 . . . . 0.0 109.637 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.46 150.69 39.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.271 -0.893 . . . . 0.0 110.83 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.42 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p80 -103.74 3.59 34.33 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 109.682 178.442 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.55 135.39 45.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.186 -0.946 . . . . 0.0 110.199 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.454 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.4 ttpt -71.28 -37.2 71.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.609 -0.682 . . . . 0.0 110.735 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.7 -37.03 80.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.315 -0.866 . . . . 0.0 110.775 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 4.3 tptm -72.6 -36.33 68.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 110.015 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.725 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 71.1 m -60.4 -34.23 73.63 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.475 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.72 -49.15 56.07 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 110.538 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.445 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.43 -41.71 69.17 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.147 -0.971 . . . . 0.0 110.583 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.919 HD12 HG11 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.9 80.41 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 111.282 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.11 -51.0 43.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.934 -1.104 . . . . 0.0 110.175 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.88 -31.76 65.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.209 -0.932 . . . . 0.0 109.123 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.596 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.83 -47.06 85.05 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 179.358 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.876 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -60.99 -41.42 96.46 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.279 -0.888 . . . . 0.0 111.053 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.0 t -56.38 -33.93 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.868 -1.145 . . . . 0.0 109.227 179.519 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -34.83 60.3 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.318 -0.864 . . . . 0.0 110.482 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.818 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.32 -25.57 62.47 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.409 -0.807 . . . . 0.0 109.833 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.31 8.9 8.25 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.758 ' CD1' HD22 ' A' ' 30' ' ' LEU . 36.5 mt -108.34 143.73 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.338 -1.095 . . . . 0.0 109.666 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 17.1 t-20 -90.07 106.75 18.69 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.23 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.569 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.59 145.96 45.94 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.508 -176.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.877 HG21 ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.64 149.36 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.52 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.725 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.43 128.29 56.4 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.711 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.603 ' CD1' HD12 ' A' ' 69' ' ' LEU . 12.9 t80 -119.96 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.384 -0.823 . . . . 0.0 110.094 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.898 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.7 p90 -167.76 -178.27 3.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.521 -0.737 . . . . 0.0 109.776 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.13 116.78 3.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.175 -0.953 . . . . 0.0 110.617 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.69 36.12 7.5 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.898 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.68 156.88 27.44 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.191 -1.182 . . . . 0.0 110.122 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.782 ' N ' HD13 ' A' ' 69' ' ' LEU . 33.7 m-20 -97.41 149.01 22.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.284 -0.885 . . . . 0.0 110.088 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.681 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.7 m -62.45 111.28 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 C-N-CA 119.261 -0.976 . . . . 0.0 109.207 179.245 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.446 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 27.4 m -130.16 -34.39 1.66 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.366 -0.834 . . . . 0.0 110.731 -179.459 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.877 ' HA ' HG21 ' A' ' 63' ' ' VAL . 50.7 t -49.88 151.77 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.225 -0.922 . . . . 0.0 109.459 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.426 HG13 HG21 ' A' ' 80' ' ' VAL . 1.0 OUTLIER -131.31 100.29 16.91 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 120.781 -1.199 . . . . 0.0 111.523 -178.945 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -81.7 59.83 7.36 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.632 1.332 . . . . 0.0 109.889 179.064 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.432 HG23 ' O ' ' A' ' 76' ' ' THR . 4.7 t -135.88 61.78 1.64 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.463 -0.773 . . . . 0.0 109.311 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.428 ' N ' ' OD1' ' A' ' 77' ' ' ASN . 3.2 m-20 62.74 -154.13 0.34 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.831 -0.543 . . . . 0.0 110.033 -179.33 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 63.68 151.36 0.05 OUTLIER Glycine 0 N--CA 1.489 2.227 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.44 94.04 6.12 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.95 -1.324 . . . . 0.0 110.242 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 4.9 p -117.25 131.07 71.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 122.062 0.935 . . . . 0.0 110.057 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.622 HG11 ' HB ' ' A' ' 33' ' ' ILE . 6.2 m -112.95 121.36 65.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.328 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.725 HG22 HG13 ' A' ' 73' ' ' VAL . 11.1 t -96.76 118.52 43.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.148 -0.97 . . . . 0.0 110.414 -177.647 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.922 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.9 m -109.44 100.34 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.063 -1.023 . . . . 0.0 108.79 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -143.0 161.6 37.69 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.6 -1.313 . . . . 0.0 111.108 -178.31 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.789 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.8 t -85.37 -136.97 0.07 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.493 -0.755 . . . . 0.0 109.147 179.532 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.509 ' N ' HG23 ' A' ' 85' ' ' THR . 6.1 m-20 -82.54 -13.64 56.26 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.723 -1.235 . . . . 0.0 110.404 179.764 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.789 ' H ' HG23 ' A' ' 85' ' ' THR . . . -52.65 -41.96 64.26 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.072 -1.017 . . . . 0.0 110.339 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.434 HD12 ' CD2' ' A' ' 65' ' ' TYR . 2.4 tp -64.07 -47.87 78.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.081 -1.012 . . . . 0.0 109.769 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.446 ' HA ' ' HE2' ' A' ' 89' ' ' MET . 0.0 OUTLIER 54.21 20.61 2.67 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.287 -0.883 . . . . 0.0 109.937 -179.744 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.671 HG22 ' HB ' ' A' ' 93' ' ' THR . 0.1 OUTLIER 46.85 54.69 8.77 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.37 -0.831 . . . . 0.0 110.777 179.834 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.6 -67.92 1.83 Allowed Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -93.1 21.73 5.61 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.322 -1.105 . . . . 0.0 109.643 178.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.671 ' HB ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER -127.98 -167.69 1.79 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.446 -0.784 . . . . 0.0 109.817 -179.91 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.425 ' HA3' ' NH1' ' A' ' 124' ' ' ARG . . . 150.74 -51.0 0.53 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -87.3 97.36 10.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -1.154 . . . . 0.0 110.611 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.539 ' CZ ' HG21 ' A' ' 93' ' ' THR . 10.6 m-85 -116.64 151.69 35.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.331 -0.855 . . . . 0.0 109.494 179.198 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.49 -32.98 72.19 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.342 -0.943 . . . . 0.0 109.327 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.7 p -162.37 163.56 27.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.274 -0.891 . . . . 0.0 111.084 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.604 HG22 HG21 ' A' ' 122' ' ' THR . 0.3 OUTLIER -130.83 112.98 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.52 -0.738 . . . . 0.0 109.886 179.343 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.601 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -94.48 115.32 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.217 -0.927 . . . . 0.0 109.166 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -127.99 161.12 29.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 111.504 -178.484 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 42.7 t -90.94 -9.1 47.36 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.824 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 57.35 13.74 1.88 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.293 -0.879 . . . . 0.0 111.662 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.495 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.2 m -144.06 109.95 5.31 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 120.777 -1.202 . . . . 0.0 108.992 179.541 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.459 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -86.82 128.76 35.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.316 -0.865 . . . . 0.0 111.093 -179.307 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.9 t70 54.34 34.34 20.43 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.425 -0.797 . . . . 0.0 111.272 179.208 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.6 -14.9 54.21 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.314 179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 104' ' ' THR . 10.6 mttt -98.08 156.58 35.74 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 120.929 -1.336 . . . . 0.0 109.743 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -62.51 127.3 20.45 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.524 1.276 . . . . 0.0 110.473 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.48 157.42 0.06 Allowed 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.591 0.71 . . . . 0.0 111.239 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.537 ' OD2' HG22 ' A' ' 113' ' ' VAL . 4.4 p-10 -73.25 162.49 29.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.501 -0.749 . . . . 0.0 109.971 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.16 -42.61 91.15 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.884 -1.135 . . . . 0.0 111.62 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.537 HG22 ' OD2' ' A' ' 111' ' ' ASP . 6.7 m -72.59 -30.86 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 120.784 -1.198 . . . . 0.0 113.031 -178.001 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.74 -55.76 20.44 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.474 -1.391 . . . . 0.0 110.3 -178.766 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.411 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -62.88 -34.71 77.97 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 118.695 -1.202 . . . . 0.0 108.225 178.327 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.627 ' OG1' HG22 ' A' ' 4' ' ' THR . 24.6 m -61.46 -50.7 71.72 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.825 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.89 41.91 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.832 . . . . 0.0 109.6 178.778 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.422 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 25.2 mtt180 -59.59 -45.14 92.78 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.287 -0.883 . . . . 0.0 110.405 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.512 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 20.1 ttm180 -62.68 -34.59 77.41 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.734 -1.229 . . . . 0.0 110.071 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.427 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.78 -5.36 31.06 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 119.998 -1.096 . . . . 0.0 111.12 -179.236 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.515 ' HG3' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -87.95 -4.96 58.77 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.656 -1.496 . . . . 0.0 110.96 -179.823 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.64 ' O ' HD11 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -118.72 140.36 50.06 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.859 -1.151 . . . . 0.0 109.442 179.535 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.01 19.6 39.17 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.427 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 10.2 mmt85 -69.39 85.98 0.42 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.033 -1.275 . . . . 0.0 109.806 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.05 57.82 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.469 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.41 -174.8 0.39 Allowed Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.202 -1.175 . . . . 0.0 109.016 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.469 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -85.22 103.33 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.36 1.19 . . . . 0.0 109.438 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -86.98 173.25 44.72 Favored Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.046 -179.107 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.4 mt -122.18 142.92 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -1.056 . . . . 0.0 109.54 179.778 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.7 t80 -127.02 115.34 19.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.166 -0.959 . . . . 0.0 110.178 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.522 ' HE ' HG11 ' A' ' 13' ' ' VAL . 10.6 mtt85 -105.65 135.26 47.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.353 -0.842 . . . . 0.0 109.476 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.2 147.0 45.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.153 -0.967 . . . . 0.0 110.552 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.718 HG22 HD23 ' A' ' 15' ' ' LEU . 54.4 t -69.22 -55.59 14.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.829 179.735 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -118.85 159.26 45.23 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.217 -0.927 . . . . 0.0 110.312 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.451 ' HG2' ' CB ' ' A' ' 138' ' ' ARG . 44.6 Cg_endo -72.17 -23.11 21.57 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 O-C-N 123.719 1.378 . . . . 0.0 110.374 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 115.47 -64.58 0.31 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -83.65 -48.95 9.65 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.188 -1.184 . . . . 0.0 110.169 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.451 ' CB ' ' HG2' ' A' ' 135' ' ' PRO . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.141 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.3 p -104.04 106.88 17.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 0.0 110.279 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.559 ' O ' HG13 ' A' ' 3' ' ' VAL . 4.7 p -113.32 103.92 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 O-C-N 121.29 -0.881 . . . . 0.0 109.881 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.404 HG22 ' O ' ' A' ' 112' ' ' ALA . 18.1 p -75.19 142.68 43.45 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.222 -0.924 . . . . 0.0 110.324 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.458 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.8 146.91 97.8 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.21 -0.932 . . . . 0.0 109.635 179.604 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.458 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.4 Cg_endo -71.97 -168.58 0.38 Allowed 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.17 1.616 . . . . 0.0 110.456 179.167 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.549 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.6 OUTLIER -173.67 81.87 0.38 Allowed Pre-proline 0 C--N 1.302 -1.457 0 O-C-N 121.531 -0.731 . . . . 0.0 109.547 179.565 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.415 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 39.8 Cg_endo -67.05 87.83 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.387 1.204 . . . . 0.0 110.999 -179.138 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.459 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.8 p30 171.79 -5.76 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.382 0 O-C-N 121.45 -0.781 . . . . 0.0 112.448 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.528 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 12.7 mt -124.32 135.62 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.131 -1.606 . . . . 0.0 109.562 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.88 128.74 34.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.316 -0.865 . . . . 0.0 109.801 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.36 140.93 29.01 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.194 -0.941 . . . . 0.0 109.882 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.408 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 6.5 t -134.78 153.97 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.224 -0.923 . . . . 0.0 110.467 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.59 18.6 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.325 -0.859 . . . . 0.0 109.552 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.501 HD11 HG12 ' A' ' 28' ' ' ILE . 10.8 tp -56.08 136.63 52.29 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.29 -0.881 . . . . 0.0 109.778 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.42 -167.58 1.99 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 110.288 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.2 p -88.3 73.24 8.88 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.636 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.3 m -146.04 112.37 5.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 110.48 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.34 -165.35 27.87 Favored Glycine 0 N--CA 1.489 2.204 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.831 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.59 -21.57 9.08 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.61 -0.936 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.907 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.1 tt -98.85 105.69 32.76 Favored Pre-proline 0 N--CA 1.488 1.46 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.179 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.474 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -62.95 155.0 63.13 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.225 1.118 . . . . 0.0 109.66 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.463 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.2 t80 -167.55 93.61 0.41 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.062 -1.024 . . . . 0.0 111.576 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.427 ' CD2' ' SG ' ' A' ' 102' ' ' CYS . 25.5 m-85 59.38 67.04 0.94 Allowed 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.571 -0.705 . . . . 0.0 111.554 179.06 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.09 13.81 15.82 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.84 156.89 44.25 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.105 -1.233 . . . . 0.0 109.039 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.636 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.06 107.92 14.59 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.789 -1.194 . . . . 0.0 109.675 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.975 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -70.89 114.15 24.6 Favored Pre-proline 0 C--N 1.299 -1.62 0 O-C-N 121.411 -0.806 . . . . 0.0 110.637 -179.415 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.833 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.3 Cg_endo -68.91 128.42 16.79 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 N-CA-C 106.906 -1.998 . . . . 0.0 106.906 176.181 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.55 HD11 HD12 ' A' ' 58' ' ' LEU . 6.9 mt -55.91 -18.94 10.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.914 -1.116 . . . . 0.0 110.678 -177.587 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.51 -16.29 23.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.714 -1.241 . . . . 0.0 110.296 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.121 HG23 HG23 ' A' ' 33' ' ' ILE . 13.1 m -92.24 -25.43 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 120.968 -1.082 . . . . 0.0 111.228 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.121 HG23 HG23 ' A' ' 32' ' ' VAL . 8.9 pt -117.9 -18.53 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.985 -1.072 . . . . 0.0 110.662 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.511 ' HB2' HD11 ' A' ' 60' ' ' ILE . 9.7 tptt -96.24 148.92 22.22 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.931 -1.106 . . . . 0.0 110.417 179.534 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.84 56.7 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.8 -159.22 21.81 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.239 -1.457 . . . . 0.0 110.091 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.447 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.6 mtt85 -100.61 130.65 46.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.404 -1.057 . . . . 0.0 110.603 -179.571 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.2 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 110.505 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.626 HD12 ' HB ' ' A' ' 82' ' ' VAL . 14.0 tp -109.49 120.96 44.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 110.301 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.918 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.3 mm -99.72 125.58 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.194 -0.941 . . . . 0.0 109.283 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.5 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.3 123.05 38.62 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.098 -1.001 . . . . 0.0 109.709 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.24 157.89 25.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.239 -0.913 . . . . 0.0 110.857 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.411 ' HB3' ' O ' ' A' ' 104' ' ' THR . 0.0 OUTLIER -105.75 8.14 32.79 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.412 -0.805 . . . . 0.0 109.967 178.939 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.46 139.65 40.75 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.172 -0.955 . . . . 0.0 110.346 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.459 ' HG2' ' CB ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.93 -38.11 69.92 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 110.783 -179.683 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.93 -37.26 86.74 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.759 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.412 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -64.91 -35.98 82.9 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.765 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.774 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.2 m -60.2 -34.34 73.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.407 -0.808 . . . . 0.0 109.039 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.03 -48.83 64.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.191 -0.943 . . . . 0.0 110.25 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.0 mt-10 -71.46 -45.59 62.18 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.198 -0.939 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.972 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.42 -41.38 76.27 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.373 -0.83 . . . . 0.0 111.338 -178.926 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.443 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.36 -50.92 14.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 110.363 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.73 -41.62 99.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 109.446 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.573 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.4 -46.16 86.95 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.346 -0.846 . . . . 0.0 109.433 179.341 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.41 -42.93 78.81 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.487 -0.758 . . . . 0.0 110.236 179.853 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.9 -33.43 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.073 -1.017 . . . . 0.0 109.166 179.504 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.61 -31.48 59.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.323 -0.861 . . . . 0.0 110.004 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.573 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -72.07 -26.54 62.21 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.893 0.854 . . . . 0.0 109.601 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.03 6.3 8.45 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.603 HG22 HG22 ' A' ' 81' ' ' VAL . 35.1 mt -107.86 143.87 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -1.14 . . . . 0.0 110.144 -179.802 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.625 ' ND2' HD11 ' A' ' 74' ' ' ILE . 15.8 t30 -88.02 106.45 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.364 -1.717 . . . . 0.0 106.364 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.588 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.69 141.67 47.9 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.671 -177.203 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.951 HG21 ' HA ' ' A' ' 73' ' ' VAL . 87.4 t -124.27 147.9 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.998 -0.681 . . . . 0.0 109.69 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.774 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.47 127.04 55.04 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.822 178.503 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.71 31.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 110.57 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.879 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.7 p90 -147.78 175.08 11.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.619 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.69 5.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 110.766 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.9 37.18 10.43 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.879 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.31 155.93 28.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.115 -1.227 . . . . 0.0 109.969 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.856 ' N ' HD13 ' A' ' 69' ' ' LEU . 32.3 m-20 -95.61 149.25 21.66 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.225 -0.922 . . . . 0.0 110.462 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.4 m -61.81 110.08 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 120.939 -1.101 . . . . 0.0 108.969 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.7 m -132.13 -9.69 3.38 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.508 -0.745 . . . . 0.0 110.953 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.951 ' HA ' HG21 ' A' ' 63' ' ' VAL . 40.1 t -72.27 135.12 28.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.082 -1.012 . . . . 0.0 109.305 -179.582 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.884 HD13 ' OD1' ' A' ' 77' ' ' ASN . 1.3 pp -137.14 104.1 8.79 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.155 -0.965 . . . . 0.0 111.235 -178.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -89.35 35.57 0.36 Allowed 'Trans proline' 0 C--N 1.312 -1.378 0 O-C-N 123.7 1.369 . . . . 0.0 110.606 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.705 HG23 ' ND2' ' A' ' 77' ' ' ASN . 6.9 t -127.8 -11.16 5.49 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.908 -1.12 . . . . 0.0 111.5 -179.143 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.884 ' OD1' HD13 ' A' ' 74' ' ' ILE . 8.1 m120 -104.82 -150.37 0.43 Allowed 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.853 -1.154 . . . . 0.0 110.37 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -53.05 174.98 0.23 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -54.86 115.81 2.39 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.133 -1.216 . . . . 0.0 110.141 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.687 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -116.06 135.42 56.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 121.966 0.889 . . . . 0.0 110.302 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.603 HG22 HG22 ' A' ' 60' ' ' ILE . 19.0 m -111.88 126.88 69.31 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 O-C-N 121.464 -0.773 . . . . 0.0 109.236 179.567 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.778 HG22 HG13 ' A' ' 73' ' ' VAL . 7.6 t -97.63 116.91 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.793 -1.192 . . . . 0.0 110.502 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.972 HG11 HD12 ' A' ' 51' ' ' LEU . 3.9 m -110.67 100.07 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.884 -1.135 . . . . 0.0 108.691 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.53 162.48 34.96 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.568 -1.332 . . . . 0.0 111.195 -178.109 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.505 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -90.8 -133.36 0.12 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.524 -0.735 . . . . 0.0 109.112 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.505 ' N ' HG23 ' A' ' 85' ' ' THR . 49.4 p-10 -90.02 41.74 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.583 -1.323 . . . . 0.0 110.147 179.457 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.91 -32.09 6.5 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.62 -34.29 46.72 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.92 . . . . 0.0 108.907 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.418 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 46.44 -96.19 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.767 -0.583 . . . . 0.0 110.526 179.71 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.683 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.09 57.02 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.807 -1.183 . . . . 0.0 110.745 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.05 -50.14 68.39 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 108.459 -1.856 . . . . 0.0 108.459 179.227 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.419 ' CD2' ' O ' ' A' ' 92' ' ' PHE . 51.8 p90 -137.51 38.69 2.45 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.597 -0.943 . . . . 0.0 109.918 179.715 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.694 HG23 ' N ' ' A' ' 94' ' ' GLY . 1.3 t -98.4 -153.77 0.44 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.938 . . . . 0.0 110.634 -179.402 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.694 ' N ' HG23 ' A' ' 93' ' ' THR . . . 109.75 7.56 27.39 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.74 68.87 1.1 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.783 -1.422 . . . . 0.0 110.785 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.505 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 22.6 m-85 -119.39 151.06 39.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.955 -1.09 . . . . 0.0 110.255 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.87 -28.4 20.38 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.348 -0.845 . . . . 0.0 109.417 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.553 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 5.8 p -160.87 163.33 32.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.397 -0.815 . . . . 0.0 110.675 179.795 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.415 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.15 115.39 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 110.093 179.72 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.975 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -95.52 111.29 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.16 -0.962 . . . . 0.0 108.579 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.7 t0 -119.65 161.17 21.13 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.159 -0.963 . . . . 0.0 111.786 -178.48 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.427 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.1 t -101.84 8.5 41.28 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.715 -0.616 . . . . 0.0 109.502 178.191 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.417 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.5 m-20 51.66 23.75 2.09 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.113 -0.992 . . . . 0.0 111.293 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.411 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p -145.13 128.71 17.09 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.17 -0.956 . . . . 0.0 109.972 179.141 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 3.8 p -113.07 134.49 54.51 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.316 -0.865 . . . . 0.0 110.189 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 54.16 41.5 31.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.182 -0.949 . . . . 0.0 110.297 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 65.15 19.77 66.41 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.412 ' HB2' ' O ' ' A' ' 105' ' ' SER . 0.9 OUTLIER -126.56 157.58 70.38 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.245 -1.15 . . . . 0.0 109.694 179.82 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -62.61 123.72 12.87 Favored 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.64 1.337 . . . . 0.0 110.196 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.51 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 -48.71 147.35 2.64 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.488 -0.757 . . . . 0.0 111.053 -179.163 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.436 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.9 p-10 -88.45 161.12 17.21 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.298 -0.876 . . . . 0.0 110.345 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.01 -54.97 7.49 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -178.248 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.476 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.67 -31.89 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 120.585 -1.322 . . . . 0.0 112.685 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.51 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.41 -56.22 8.77 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.96 -1.088 . . . . 0.0 110.434 -179.266 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.485 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.74 -35.54 80.35 Favored 'General case' 0 C--O 1.205 -1.284 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.265 178.781 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.476 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.0 m -58.38 -49.2 78.08 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.541 178.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.08 -35.54 71.9 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.376 -0.827 . . . . 0.0 109.571 178.815 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.5 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.2 -45.18 61.41 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.239 -0.913 . . . . 0.0 110.931 -179.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.549 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 14.4 ttt180 -54.03 -45.17 71.52 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.045 -1.035 . . . . 0.0 109.995 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.58 64.19 0.29 Allowed Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.225 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.434 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.78 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.562 -0.964 . . . . 0.0 108.438 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.508 ' O ' HD11 ' A' ' 10' ' ' ILE . 10.9 t -96.12 142.87 27.79 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.621 -0.674 . . . . 0.0 109.478 178.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.68 33.25 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.47 -1.348 . . . . 0.0 110.94 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.422 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -61.29 87.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.047 -1.266 . . . . 0.0 109.397 179.607 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.87 -8.33 70.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -178.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.471 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.03 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.18 -1.188 . . . . 0.0 109.265 -179.799 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.471 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -89.04 97.46 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.379 1.199 . . . . 0.0 110.601 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.489 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.24 171.09 53.01 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -126.85 142.15 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.488 -1.007 . . . . 0.0 109.305 179.356 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.415 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.4 t80 -128.65 115.27 17.78 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.0 . . . . 0.0 110.314 179.683 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.428 ' HD2' ' HB ' ' A' ' 32' ' ' VAL . 4.1 mtp180 -104.73 122.8 46.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.433 -0.792 . . . . 0.0 109.17 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 29.8 p90 -121.53 157.5 30.55 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 110.415 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.567 ' O ' ' HB3' ' A' ' 134' ' ' ALA . 18.2 t -95.0 -56.01 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.567 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 63.34 146.85 0.09 OUTLIER Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.662 -0.649 . . . . 0.0 110.188 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.22 -52.08 0.19 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 123.768 1.404 . . . . 0.0 110.467 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 160.18 -151.69 22.35 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -86.42 159.19 19.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.268 -1.137 . . . . 0.0 110.173 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.176 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.3 t -83.87 146.48 28.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.199 -1.177 . . . . 0.0 110.368 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.9 p -113.16 104.63 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.293 -0.879 . . . . 0.0 109.571 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 16.4 p -80.11 145.61 32.3 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.32 -0.863 . . . . 0.0 110.775 -179.61 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.561 HG13 HG23 ' A' ' 116' ' ' THR . 0.2 OUTLIER -74.98 148.99 85.02 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.383 -0.823 . . . . 0.0 109.452 179.366 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.53 ' HD2' HG23 ' A' ' 5' ' ' VAL . 40.3 Cg_endo -71.16 -43.61 1.49 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 124.169 1.616 . . . . 0.0 112.839 -179.613 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.525 ' CG ' ' O ' ' A' ' 6' ' ' PRO . 13.5 p-80 41.26 85.39 0.16 Allowed Pre-proline 0 N--CA 1.498 1.94 0 O-C-N 122.128 -0.357 . . . . 0.0 110.774 -177.204 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.466 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 41.6 Cg_endo -68.3 -161.18 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.791 1.416 . . . . 0.0 110.157 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.466 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER 78.11 -35.91 0.2 Allowed 'General case' 0 N--CA 1.508 2.446 0 O-C-N 121.636 -0.665 . . . . 0.0 111.055 -179.192 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.491 HD13 HG22 ' A' ' 122' ' ' THR . 12.5 mt -95.79 124.92 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.574 -1.329 . . . . 0.0 109.892 179.53 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.57 128.02 34.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.138 -0.976 . . . . 0.0 109.554 179.325 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.97 132.95 35.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -0.943 . . . . 0.0 110.005 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.726 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 16.7 t -122.08 149.94 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.24 -0.912 . . . . 0.0 110.419 -179.304 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.85 21.65 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.268 -0.895 . . . . 0.0 109.706 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.885 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.0 tp -53.52 141.1 26.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.278 -0.889 . . . . 0.0 109.881 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.452 ' HA ' ' HD2' ' A' ' 26' ' ' LYS . 28.3 p -136.09 -178.49 5.17 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.253 -0.905 . . . . 0.0 110.526 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.8 p -79.74 71.19 6.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.887 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.689 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.9 m -146.12 112.71 5.94 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.317 -0.865 . . . . 0.0 110.424 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.441 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.81 28.42 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 118.731 -1.7 . . . . 0.0 111.173 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.62 10.4 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.783 -0.834 . . . . 0.0 110.306 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.14 107.94 41.06 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.666 -1.214 . . . . 0.0 110.098 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.446 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.5 Cg_endo -65.05 117.4 4.51 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 O-C-N 123.478 1.251 . . . . 0.0 110.645 -179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.5 -170.79 1.8 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.649 -0.657 . . . . 0.0 110.592 -179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.507 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.5 m-85 -57.73 82.26 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.552 -0.718 . . . . 0.0 111.634 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.15 -1.84 54.16 Favored Glycine 0 N--CA 1.493 2.437 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.684 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.885 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.1 mmtm -130.1 156.18 44.96 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.858 -1.378 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.689 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.83 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.94 -1.1 . . . . 0.0 109.427 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.9 mt -68.38 112.95 12.55 Favored Pre-proline 0 C--N 1.301 -1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 110.779 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.761 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.0 Cg_endo -68.26 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 N-CA-C 106.96 -1.977 . . . . 0.0 106.96 175.718 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.838 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.72 -16.65 6.81 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.826 -1.171 . . . . 0.0 110.652 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.83 -15.97 36.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.686 -1.259 . . . . 0.0 110.268 179.348 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.129 HG23 HG23 ' A' ' 33' ' ' ILE . 12.1 m -91.77 -25.71 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.011 -1.056 . . . . 0.0 111.213 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.129 HG23 HG23 ' A' ' 32' ' ' VAL . 27.7 pt -118.48 -25.33 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.938 -1.101 . . . . 0.0 110.199 -179.496 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.602 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.41 148.18 22.5 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 110.648 179.828 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.87 57.77 Favored Glycine 0 N--CA 1.484 1.891 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.42 -151.27 8.74 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.127 -1.511 . . . . 0.0 110.278 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.45 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.3 mtt85 -109.74 132.37 54.21 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.53 -0.982 . . . . 0.0 110.1 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.551 ' HB2' HG12 ' A' ' 81' ' ' VAL . 90.9 m-70 -140.81 152.94 45.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.087 -1.008 . . . . 0.0 110.993 -179.766 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 54.9 tp -112.03 114.17 26.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.4 -0.812 . . . . 0.0 109.994 179.622 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.85 HD12 ' CG1' ' A' ' 83' ' ' VAL . 32.8 mt -98.37 129.2 48.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.594 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.4 123.82 38.04 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.304 -0.873 . . . . 0.0 109.751 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.86 158.83 23.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 110.801 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.507 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.17 4.28 20.91 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.439 -0.788 . . . . 0.0 110.023 179.203 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.11 137.05 38.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.058 -1.026 . . . . 0.0 110.618 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.481 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.59 -42.82 67.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.485 -0.76 . . . . 0.0 110.219 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.83 -39.21 84.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.882 . . . . 0.0 110.45 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.74 -35.11 76.69 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.906 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.14 -34.1 74.47 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.537 -0.727 . . . . 0.0 109.501 179.212 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.76 -49.43 62.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.235 -0.916 . . . . 0.0 110.255 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.79 -44.64 63.64 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -0.951 . . . . 0.0 110.146 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.716 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.17 -41.65 79.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.819 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.521 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.0 -51.16 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.03 -1.044 . . . . 0.0 110.382 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.08 96.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.12 -0.988 . . . . 0.0 109.675 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.553 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.15 -44.91 83.86 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 179.485 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.7 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -55.1 -42.68 73.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.517 -0.739 . . . . 0.0 109.885 179.956 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.4 -32.09 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.007 -1.058 . . . . 0.0 108.807 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.4 -30.87 60.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.389 -0.82 . . . . 0.0 109.608 179.026 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.838 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.66 -26.17 62.43 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.833 0.825 . . . . 0.0 109.467 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.04 7.44 10.27 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.143 -1.583 . . . . 0.0 109.143 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.602 HD11 ' HB2' ' A' ' 34' ' ' LYS . 56.4 mt -108.26 143.24 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.277 -1.131 . . . . 0.0 110.349 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.93 107.56 17.78 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.924 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.655 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -122.01 144.62 48.78 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.019 -1.072 . . . . 0.0 111.643 -177.558 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.932 HG21 ' HA ' ' A' ' 73' ' ' VAL . 45.2 t -130.3 143.58 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 C-N-CA 119.976 -0.69 . . . . 0.0 109.512 179.083 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.906 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -109.49 118.36 36.41 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.95 179.094 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.462 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.65 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.26 -0.9 . . . . 0.0 110.574 -179.59 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.748 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.2 p90 -167.31 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.544 -0.723 . . . . 0.0 109.757 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.24 127.14 30.6 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.165 -0.96 . . . . 0.0 110.764 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.32 37.77 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.4 tm? -117.09 155.81 28.64 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.156 -1.203 . . . . 0.0 110.101 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.895 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.24 22.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.366 -0.834 . . . . 0.0 110.545 -179.351 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 29.5 m -62.1 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 119.061 -1.055 . . . . 0.0 109.002 179.229 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.72 -15.45 2.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.507 -0.746 . . . . 0.0 111.413 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.932 ' HA ' HG21 ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.06 23.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.072 -1.017 . . . . 0.0 109.471 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.676 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.6 pp -137.33 98.8 9.98 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.261 -0.899 . . . . 0.0 111.004 -179.362 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.658 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.9 Cg_endo -81.55 51.57 3.92 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 O-C-N 123.583 1.307 . . . . 0.0 110.44 179.24 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.9 p -141.89 8.97 1.92 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.943 -1.098 . . . . 0.0 111.089 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -108.64 -165.51 1.04 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.898 -1.126 . . . . 0.0 109.906 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.08 -91.86 0.01 OUTLIER Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.797 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.422 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.7 m-20 -124.23 113.67 18.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.171 -1.193 . . . . 0.0 109.998 179.475 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.658 HG11 ' HA ' ' A' ' 75' ' ' PRO . 8.2 p -115.06 130.91 68.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 122.152 0.977 . . . . 0.0 110.414 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 60' ' ' ILE . 6.9 m -113.0 123.04 68.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 O-C-N 121.351 -0.843 . . . . 0.0 109.104 179.052 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.661 ' O ' HD12 ' A' ' 39' ' ' LEU . 4.7 t -97.06 118.07 42.82 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 O-C-N 121.056 -1.028 . . . . 0.0 110.149 -177.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.85 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.9 m -111.19 100.3 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.809 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.462 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.46 162.64 34.99 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.765 -1.209 . . . . 0.0 111.122 -178.23 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -90.17 -139.26 0.14 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.598 -0.689 . . . . 0.0 109.4 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.41 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -86.01 48.05 1.55 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.806 -1.184 . . . . 0.0 109.99 179.706 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.454 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.24 -19.22 7.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.173 -0.955 . . . . 0.0 110.646 -179.671 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp -62.48 -23.54 66.97 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.671 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.514 ' C ' HG22 ' A' ' 90' ' ' THR . 32.4 mmt 49.89 37.23 13.13 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.412 -0.805 . . . . 0.0 110.923 179.548 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.514 HG22 ' C ' ' A' ' 89' ' ' MET . 3.1 t 32.68 42.7 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.189 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 178.541 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.09 -38.55 88.38 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -136.24 12.42 3.29 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.489 -1.007 . . . . 0.0 110.758 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.489 ' HA ' ' CE2' ' A' ' 96' ' ' PHE . 14.9 t -67.41 -158.98 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.981 -1.074 . . . . 0.0 110.478 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.453 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 90.35 -50.95 3.34 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.06 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -84.2 60.21 5.79 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.993 -1.298 . . . . 0.0 110.965 -179.241 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.489 ' CE2' ' HA ' ' A' ' 93' ' ' THR . 20.3 m-85 -119.74 144.86 47.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.075 -1.016 . . . . 0.0 109.918 178.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.49 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.21 -33.44 63.39 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.502 179.334 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -162.88 163.56 26.35 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.272 -0.892 . . . . 0.0 110.913 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.19 116.58 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.331 -0.855 . . . . 0.0 110.078 179.062 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.865 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -93.37 118.41 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.178 -0.951 . . . . 0.0 109.031 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.402 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.3 t0 -126.85 160.87 29.66 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.119 -0.988 . . . . 0.0 111.454 -178.66 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.412 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 37.0 t -101.59 7.26 42.26 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.685 -0.634 . . . . 0.0 109.393 178.213 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.406 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 49.07 33.2 4.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 111.111 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.441 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p -147.52 130.36 16.14 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.877 -1.139 . . . . 0.0 110.819 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.446 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.6 p -114.0 127.69 56.06 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.253 -0.905 . . . . 0.0 109.907 179.321 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 26.9 t70 54.95 28.99 11.38 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.172 -0.955 . . . . 0.0 110.487 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.92 -36.18 3.91 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.85 156.6 82.48 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.32 -1.106 . . . . 0.0 109.966 179.873 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -64.75 138.96 60.77 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 O-C-N 123.469 1.247 . . . . 0.0 109.962 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.42 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 -49.77 150.64 2.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.276 -0.89 . . . . 0.0 110.837 -179.018 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.5 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.7 p30 -80.74 161.49 24.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -0.954 . . . . 0.0 109.664 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.44 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.32 -57.05 4.29 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.847 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.5 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -66.17 -28.34 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 120.823 -1.173 . . . . 0.0 111.729 -178.77 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.12 -56.27 6.89 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.994 -1.066 . . . . 0.0 110.715 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.457 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.55 -35.91 78.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.108 -0.995 . . . . 0.0 108.836 178.931 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.561 HG23 HG13 ' A' ' 5' ' ' VAL . 88.1 m -59.27 -49.48 77.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.066 -1.021 . . . . 0.0 108.598 178.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.74 -35.52 65.07 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.493 -0.755 . . . . 0.0 109.754 178.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.447 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.58 -44.81 63.81 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 110.844 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.497 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 2.8 ttm180 -55.01 -37.97 67.29 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.9 -1.125 . . . . 0.0 109.721 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.53 77.21 0.13 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -153.38 -49.08 0.1 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.462 -1.022 . . . . 0.0 108.522 179.51 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.542 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.7 t -93.14 143.3 26.38 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.369 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.25 15.96 5.85 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.263 -1.446 . . . . 0.0 110.405 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.453 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 25.4 mmt180 -92.9 83.02 4.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.065 -1.256 . . . . 0.0 110.106 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.12 -26.83 6.01 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.49 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.29 -166.51 0.15 Allowed Pre-proline 0 N--CA 1.488 1.456 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.61 115.02 2.44 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.025 1.013 . . . . 0.0 110.545 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.542 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.99 172.09 55.22 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.409 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mp -132.76 142.6 41.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.283 -1.128 . . . . 0.0 109.432 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.501 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.24 115.21 17.29 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.316 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.726 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.67 122.54 43.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.814 . . . . 0.0 109.213 179.505 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.406 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 50.3 p90 -117.44 149.71 40.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.036 -1.04 . . . . 0.0 110.228 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.412 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 48.8 t -78.43 -61.08 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.207 -0.933 . . . . 0.0 110.079 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.617 ' HB1' ' HD2' ' A' ' 135' ' ' PRO . . . -115.97 170.76 5.35 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.295 -0.878 . . . . 0.0 110.425 -179.72 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.617 ' HD2' ' HB1' ' A' ' 134' ' ' ALA . 48.8 Cg_endo -74.72 -50.33 0.14 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.776 1.408 . . . . 0.0 110.317 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 112.02 87.09 1.67 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -85.08 -164.72 1.03 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.247 -1.149 . . . . 0.0 110.339 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.257 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.27 138.0 31.93 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.245 -1.15 . . . . 0.0 110.0 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 3' ' ' VAL . 8.9 m -113.13 104.09 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.179 -0.95 . . . . 0.0 109.943 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.0 p -73.45 135.81 44.16 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.332 -0.855 . . . . 0.0 110.224 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.414 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.12 147.5 99.02 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.297 -0.877 . . . . 0.0 109.146 179.623 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.442 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 49.9 Cg_endo -73.6 -168.87 0.48 Allowed 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 124.053 1.554 . . . . 0.0 110.644 179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.528 ' CD2' ' HD3' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 173.67 81.27 0.05 OUTLIER Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.644 -0.66 . . . . 0.0 109.226 -179.758 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.52 -5.87 17.95 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.788 1.415 . . . . 0.0 111.187 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.2 m120 -69.56 -14.32 62.79 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.908 -1.12 . . . . 0.0 110.406 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.476 HD13 HG22 ' A' ' 122' ' ' THR . 34.0 mt -119.62 136.17 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.906 -1.121 . . . . 0.0 110.436 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.79 128.89 34.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.319 -0.863 . . . . 0.0 109.543 179.449 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.24 132.42 34.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.226 -0.921 . . . . 0.0 110.339 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.792 HG11 ' NH1' ' A' ' 131' ' ' ARG . 29.5 t -122.64 157.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.45 -0.781 . . . . 0.0 110.246 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.04 110.64 22.82 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.209 -0.932 . . . . 0.0 109.851 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.564 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -62.63 134.77 56.82 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.279 -0.888 . . . . 0.0 109.68 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.68 179.52 6.18 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.911 . . . . 0.0 110.176 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.92 74.47 2.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 109.631 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.692 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -144.55 111.61 5.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 110.576 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.48 -159.35 27.18 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.561 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.94 -24.78 5.99 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.602 -0.94 . . . . 0.0 110.522 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.921 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -95.86 108.76 42.6 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.618 -1.233 . . . . 0.0 110.492 -179.399 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.475 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.33 154.56 70.61 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.341 1.18 . . . . 0.0 109.897 179.79 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.501 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.3 t80 -167.79 95.02 0.42 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 110.891 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.463 ' HH ' ' CE1' ' A' ' 43' ' ' HIS . 66.8 m-85 60.33 65.48 1.07 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.5 -0.75 . . . . 0.0 111.188 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 15.87 16.53 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.56 ' HG3' HG13 ' A' ' 133' ' ' VAL . 3.6 mmtt -130.54 157.26 43.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.182 -1.187 . . . . 0.0 109.389 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.692 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.98 107.39 14.91 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.77 -1.206 . . . . 0.0 109.719 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.989 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -69.84 114.03 21.85 Favored Pre-proline 0 C--N 1.301 -1.523 0 O-C-N 121.294 -0.879 . . . . 0.0 110.461 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.764 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.3 Cg_endo -69.14 130.09 19.45 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 N-CA-C 106.586 -2.121 . . . . 0.0 106.586 175.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.486 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -56.16 -18.32 9.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.734 -1.228 . . . . 0.0 110.528 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.429 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.33 -15.91 19.08 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.662 -1.274 . . . . 0.0 110.693 179.68 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.079 HG23 HG23 ' A' ' 33' ' ' ILE . 12.3 m -92.46 -25.14 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 120.884 -1.135 . . . . 0.0 110.995 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.079 HG23 HG23 ' A' ' 32' ' ' VAL . 10.3 pt -116.89 -22.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 -179.403 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.53 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptt -92.67 148.46 22.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.001 -1.062 . . . . 0.0 109.97 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.71 -5.68 43.76 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.6 -152.66 11.2 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.086 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.46 131.41 52.91 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.314 -1.109 . . . . 0.0 110.292 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.55 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.41 153.73 51.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.154 -0.966 . . . . 0.0 110.943 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.526 ' HB3' HG12 ' A' ' 99' ' ' VAL . 65.5 tp -114.45 118.27 33.33 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.371 -0.83 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.865 HD12 ' CG1' ' A' ' 83' ' ' VAL . 30.2 mt -104.39 127.92 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.127 -0.983 . . . . 0.0 109.673 179.395 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -95.74 122.73 38.82 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.242 -0.911 . . . . 0.0 110.097 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.79 159.01 23.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.523 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.463 ' CE1' ' HH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.31 26.84 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 110.375 179.18 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.74 136.34 37.24 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.09 -1.007 . . . . 0.0 110.916 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.46 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.0 69.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.557 -0.714 . . . . 0.0 110.232 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.31 -36.48 84.26 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.282 -0.886 . . . . 0.0 110.421 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.82 -36.48 75.66 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.233 -0.917 . . . . 0.0 109.513 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.936 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 98.7 m -61.65 -34.05 75.03 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.439 -0.788 . . . . 0.0 109.684 179.465 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.35 -49.42 64.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.175 -0.953 . . . . 0.0 109.957 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.79 -45.66 60.87 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.097 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.668 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.1 tm? -56.49 -41.67 77.01 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.446 -0.784 . . . . 0.0 110.567 -179.411 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.416 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -76.0 -51.43 12.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.092 -1.005 . . . . 0.0 110.236 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.402 ' O ' ' HB ' ' A' ' 56' ' ' VAL . . . -61.44 -42.04 98.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.985 -1.072 . . . . 0.0 109.652 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.528 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.09 -44.39 83.09 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.167 -0.958 . . . . 0.0 109.644 179.614 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.772 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.11 -41.58 71.84 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.345 -0.847 . . . . 0.0 109.612 179.735 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 53' ' ' ALA . 78.6 t -56.27 -33.18 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.146 -0.971 . . . . 0.0 108.815 179.054 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.0 -32.05 59.23 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.5 -0.75 . . . . 0.0 110.131 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.528 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.62 -26.42 62.57 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.332 -0.855 . . . . 0.0 109.712 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.09 8.36 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.702 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.608 HG22 HG22 ' A' ' 81' ' ' VAL . 49.4 mt -108.15 143.94 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.202 -1.175 . . . . 0.0 110.32 -179.677 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 22.2 t-20 -86.84 107.1 18.16 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 178.121 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.577 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.86 147.71 45.03 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.62 -177.274 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.94 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.9 t -136.11 148.71 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.507 179.308 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.936 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.32 126.95 55.45 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.095 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.48 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 5.4 t80 -117.48 125.9 51.69 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 110.713 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.906 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.5 p90 -157.76 -174.85 5.05 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.63 123.64 11.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 0.0 111.26 -179.212 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.65 47.73 32.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.931 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.27 155.7 29.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.07 -1.253 . . . . 0.0 109.807 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.931 ' N ' HD13 ' A' ' 69' ' ' LEU . 7.7 m-20 -92.12 148.6 22.04 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.201 -0.937 . . . . 0.0 110.825 -179.18 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 71' ' ' VAL . 30.4 m -62.8 111.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.055 -1.028 . . . . 0.0 109.336 179.068 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.756 ' O ' HG23 ' A' ' 74' ' ' ILE . 10.6 m -134.58 -35.96 0.88 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.375 -0.828 . . . . 0.0 110.849 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.94 HG22 ' HB ' ' A' ' 63' ' ' VAL . 24.9 t -51.38 135.85 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.032 -1.043 . . . . 0.0 110.055 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.756 HG23 ' O ' ' A' ' 72' ' ' SER . 1.4 pp -136.16 95.06 13.62 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.263 -0.898 . . . . 0.0 110.724 -179.447 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.69 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.3 Cg_endo -81.42 52.83 4.44 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.622 1.327 . . . . 0.0 110.88 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.7 t -149.98 17.73 0.87 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.968 -1.082 . . . . 0.0 110.689 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -112.6 -165.84 1.03 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.099 -1.001 . . . . 0.0 110.169 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.09 -66.29 2.7 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 m-20 -151.84 110.92 3.88 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -1.165 . . . . 0.0 110.211 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.69 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -117.33 133.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 122.003 0.906 . . . . 0.0 110.347 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 60' ' ' ILE . 9.5 m -111.93 124.2 68.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.202 0 O-C-N 121.311 -0.868 . . . . 0.0 108.773 178.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.735 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -97.24 120.99 47.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 110.306 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.865 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.6 m -116.47 100.48 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.971 -1.081 . . . . 0.0 108.7 179.592 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.48 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -138.4 162.22 35.0 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.683 -1.261 . . . . 0.0 111.454 -177.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.605 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.1 t -87.24 -132.27 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.612 -0.68 . . . . 0.0 109.708 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.605 ' N ' HG23 ' A' ' 85' ' ' THR . 3.7 p30 -91.5 32.83 1.04 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.803 -1.186 . . . . 0.0 110.594 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.475 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.49 -32.96 9.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.095 -1.003 . . . . 0.0 109.887 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp -76.23 -45.49 32.65 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.85 . . . . 0.0 109.254 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.433 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.6 OUTLIER 53.23 20.72 1.96 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.563 -0.71 . . . . 0.0 110.717 179.644 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.499 HG23 ' HB ' ' A' ' 93' ' ' THR . 0.7 OUTLIER 48.08 32.67 3.06 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.184 -0.947 . . . . 0.0 110.578 179.584 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.83 -67.85 1.9 Allowed Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.433 ' O ' ' CD1' ' A' ' 92' ' ' PHE . 53.3 p90 -96.72 34.01 1.75 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -1.145 . . . . 0.0 109.136 179.077 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.505 HG21 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -131.23 -151.67 0.47 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.579 -0.701 . . . . 0.0 110.281 -179.351 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 124.42 -35.8 3.09 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.556 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -84.6 80.15 9.34 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.928 -1.337 . . . . 0.0 110.839 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.505 ' CZ ' HG21 ' A' ' 93' ' ' THR . 27.1 m-85 -119.07 148.16 43.34 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.18 -0.95 . . . . 0.0 109.906 178.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.432 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.95 -32.25 61.68 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.272 -0.893 . . . . 0.0 109.486 179.294 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.463 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.0 p -162.51 163.79 27.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.218 -0.927 . . . . 0.0 111.207 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.564 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.47 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.452 -0.78 . . . . 0.0 110.3 179.347 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.989 HG21 HD11 ' A' ' 28' ' ' ILE . 3.1 mp -92.88 117.78 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.893 . . . . 0.0 108.795 179.145 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.19 20.5 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.07 -1.019 . . . . 0.0 112.107 -178.424 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.22 -11.66 34.81 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.412 ' ND2' ' HB2' ' A' ' 132' ' ' PHE . 3.7 m120 55.58 12.37 0.78 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.294 -0.879 . . . . 0.0 112.487 179.091 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.432 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.0 OUTLIER -147.5 122.16 9.85 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 120.491 -1.38 . . . . 0.0 109.495 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.466 ' N ' ' O ' ' A' ' 108' ' ' LYS . 32.7 p -102.59 131.47 49.32 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.296 -0.877 . . . . 0.0 110.248 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 56.04 30.69 16.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.334 -0.854 . . . . 0.0 111.0 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.39 -29.71 8.02 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.338 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.466 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -85.29 154.42 59.91 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.005 -1.291 . . . . 0.0 110.131 -179.937 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.83 139.26 56.45 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.584 1.307 . . . . 0.0 110.256 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.566 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER -48.14 164.69 0.05 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.304 -0.872 . . . . 0.0 110.851 -179.434 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.547 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -88.92 160.36 17.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.9 . . . . 0.0 109.85 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.403 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.85 -51.13 7.66 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.424 -0.798 . . . . 0.0 112.317 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.547 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.44 -29.7 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.795 -1.19 . . . . 0.0 111.447 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.443 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.08 -56.47 6.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.08 -1.013 . . . . 0.0 110.402 -179.204 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.9 OUTLIER -69.49 -34.38 74.24 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.301 -0.874 . . . . 0.0 108.688 178.756 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.458 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 22.5 m -59.22 -50.02 75.6 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.164 -0.96 . . . . 0.0 108.454 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.93 -39.52 63.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.763 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.405 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 2.2 mtt180 -67.47 -44.32 78.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.168 -0.958 . . . . 0.0 110.557 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.528 ' HD3' ' CD2' ' A' ' 7' ' ' HIS . 7.0 ttm180 -60.47 -39.06 86.25 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.026 -1.046 . . . . 0.0 110.057 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.74 66.69 0.44 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.06 -46.6 0.3 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.514 -0.992 . . . . 0.0 108.602 179.471 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.518 HG23 ' HA3' ' A' ' 128' ' ' GLY . 15.0 t -94.45 142.13 27.79 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.375 -0.828 . . . . 0.0 109.136 178.657 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.89 10.03 19.45 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.556 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.0 mmt85 -69.3 86.96 0.42 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.011 -1.288 . . . . 0.0 109.69 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.2 22.17 33.19 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.479 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.85 -178.31 0.29 Allowed Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.514 -0.992 . . . . 0.0 108.717 -179.515 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.3 Cg_endo -89.65 103.94 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.258 1.136 . . . . 0.0 110.126 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.518 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -77.61 156.84 45.09 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.605 -179.303 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 38.8 mt -111.05 142.06 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.479 -1.012 . . . . 0.0 109.046 178.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.564 ' CD2' HG23 ' A' ' 99' ' ' VAL . 5.4 t80 -132.09 118.91 20.27 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.09 -1.006 . . . . 0.0 110.785 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.792 ' NH1' HG11 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -101.51 124.04 46.52 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.454 -0.779 . . . . 0.0 109.477 179.158 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.471 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.6 p90 -118.04 155.87 29.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 110.229 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.564 HG22 HD23 ' A' ' 15' ' ' LEU . 71.1 t -95.36 -24.11 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.168 -0.958 . . . . 0.0 109.869 179.602 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -148.03 124.64 5.48 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.295 -0.878 . . . . 0.0 110.164 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -76.46 -50.76 0.1 Allowed 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.484 1.255 . . . . 0.0 110.358 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 66.73 113.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -100.73 83.89 2.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.188 -1.183 . . . . 0.0 110.295 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 69.5 ttt180 . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.167 -179.931 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.568 ' OG ' ' HB2' ' A' ' 112' ' ' ALA . 2.5 t -84.11 106.31 15.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.197 -1.178 . . . . 0.0 110.313 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 3' ' ' VAL . 19.3 m -113.16 104.36 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.314 -0.866 . . . . 0.0 110.059 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.771 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 50.8 p -88.5 136.34 33.04 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.333 -0.855 . . . . 0.0 110.232 179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.407 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.67 147.25 98.68 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.306 -0.871 . . . . 0.0 109.647 179.639 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.415 ' O ' ' CB ' ' A' ' 7' ' ' HIS . 55.9 Cg_endo -81.96 -169.34 0.74 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 124.102 1.58 . . . . 0.0 110.909 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.534 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 169.75 80.84 0.03 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 N-CA-C 109.074 -0.714 . . . . 0.0 109.074 179.14 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -65.7 108.81 1.31 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.826 1.435 . . . . 0.0 110.875 -179.506 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.454 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.8 t-20 179.69 -32.48 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.789 0 CA-C-O 121.512 0.672 . . . . 0.0 109.424 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.528 HD13 ' CG2' ' A' ' 122' ' ' THR . 33.0 mt -103.48 136.34 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.011 -1.056 . . . . 0.0 110.094 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.9 129.46 35.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 109.322 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.75 34.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.173 -0.954 . . . . 0.0 110.294 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.465 HG11 ' NE ' ' A' ' 131' ' ' ARG . 20.4 t -117.84 155.0 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.641 -0.662 . . . . 0.0 110.026 -179.422 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.19 106.89 17.58 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.669 HD23 HG22 ' A' ' 133' ' ' VAL . 12.5 tp -57.6 132.16 52.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.593 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.8 p -135.84 -166.95 1.94 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.192 -0.942 . . . . 0.0 110.587 -179.516 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.1 p -82.49 83.45 7.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.436 -0.79 . . . . 0.0 109.917 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.701 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 11.0 m -156.9 110.04 2.58 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.302 -0.874 . . . . 0.0 110.541 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.38 28.52 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 118.895 -1.622 . . . . 0.0 110.956 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.417 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -117.49 -24.68 7.23 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.78 -0.835 . . . . 0.0 110.404 -179.906 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.882 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -93.86 103.48 10.4 Favored Pre-proline 0 N--CA 1.485 1.303 0 C-N-CA 118.496 -1.281 . . . . 0.0 109.99 -179.342 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.61 118.76 5.66 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 O-C-N 123.682 1.359 . . . . 0.0 110.558 -179.564 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.62 -168.74 1.39 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.736 -0.602 . . . . 0.0 110.718 -178.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.435 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.09 81.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.592 -0.693 . . . . 0.0 111.71 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.4 -1.68 49.53 Favored Glycine 0 N--CA 1.495 2.625 0 C-N-CA 120.148 -1.025 . . . . 0.0 110.809 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.463 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.13 156.41 44.6 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.899 -1.353 . . . . 0.0 109.304 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.701 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.22 107.09 17.89 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.837 -1.164 . . . . 0.0 108.993 179.401 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.931 HD11 HG21 ' A' ' 100' ' ' ILE . 4.0 mt -67.37 113.58 14.65 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.798 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.3 Cg_endo -68.85 127.36 15.21 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 N-CA-C 106.828 -2.028 . . . . 0.0 106.828 175.819 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.556 HD11 HD12 ' A' ' 58' ' ' LEU . 8.7 mt -55.93 -17.98 7.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.897 -1.127 . . . . 0.0 110.791 -177.538 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.69 -16.36 26.27 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.639 -1.288 . . . . 0.0 110.26 179.666 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.035 HG23 HG23 ' A' ' 33' ' ' ILE . 12.4 m -90.97 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.008 -1.058 . . . . 0.0 110.884 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.035 HG23 HG23 ' A' ' 32' ' ' VAL . 20.3 pt -117.46 -18.64 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.996 -1.065 . . . . 0.0 110.633 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.606 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.65 148.24 23.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.867 -1.146 . . . . 0.0 110.169 179.537 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.97 36.67 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.375 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.2 -143.63 6.08 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.153 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.465 ' HG2' HG12 ' A' ' 80' ' ' VAL . 8.9 mtt85 -111.25 134.57 52.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.396 -1.061 . . . . 0.0 110.313 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.572 ' HB2' HG12 ' A' ' 81' ' ' VAL . 66.4 m80 -141.14 150.73 43.19 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.089 -1.007 . . . . 0.0 111.077 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.7 tp -110.01 115.07 29.11 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.478 -0.764 . . . . 0.0 110.013 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.824 HD12 ' CG1' ' A' ' 83' ' ' VAL . 26.6 mt -98.79 127.27 51.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.113 -0.992 . . . . 0.0 109.821 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.428 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 29.5 m-85 -95.35 124.67 39.5 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.453 -0.78 . . . . 0.0 110.084 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.66 157.77 24.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.163 -0.961 . . . . 0.0 110.642 -179.708 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.435 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 15.0 p80 -101.96 -2.95 28.61 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 110.29 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.55 46.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.111 -0.993 . . . . 0.0 110.288 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -70.59 -37.49 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.47 -0.769 . . . . 0.0 110.757 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.57 -36.06 77.57 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.172 -0.955 . . . . 0.0 110.291 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.42 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -71.63 -32.75 68.3 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.424 -0.798 . . . . 0.0 109.253 179.835 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.703 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.74 74.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.35 -0.844 . . . . 0.0 109.095 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.88 -48.86 64.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.379 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.86 -44.39 63.89 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.236 -0.915 . . . . 0.0 110.631 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.751 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -56.81 -38.94 73.28 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.459 -0.776 . . . . 0.0 111.235 -178.937 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.84 -51.36 12.72 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.868 -1.145 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -40.78 97.26 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.01 -1.056 . . . . 0.0 109.672 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.545 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.94 83.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.522 179.447 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.741 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.37 -40.99 72.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.478 -0.764 . . . . 0.0 109.978 179.937 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.3 -33.81 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.135 -0.978 . . . . 0.0 108.899 179.04 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.88 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.333 -0.854 . . . . 0.0 110.078 179.357 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.556 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.47 -25.94 62.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.426 179.609 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.0 5.67 10.59 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.606 HD11 ' HB2' ' A' ' 34' ' ' LYS . 33.7 mt -108.42 143.46 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.475 -1.015 . . . . 0.0 110.235 -179.572 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 20.3 t-20 -87.98 106.92 18.45 Favored 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.056 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.693 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -118.56 146.97 44.18 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.748 -1.181 . . . . 0.0 111.922 -177.163 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.939 HG21 ' HA ' ' A' ' 73' ' ' VAL . 19.6 t -129.32 149.34 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.706 -0.621 . . . . 0.0 109.884 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.703 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.03 123.84 50.67 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.261 -0.975 . . . . 0.0 109.861 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.45 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -114.04 134.68 54.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.923 . . . . 0.0 111.013 -179.31 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.986 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.1 p90 -171.01 -179.82 2.86 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.381 -0.825 . . . . 0.0 110.174 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.24 126.27 18.39 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.209 -0.932 . . . . 0.0 111.02 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.1 46.5 35.31 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.338 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.986 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.49 154.74 30.91 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.127 -1.219 . . . . 0.0 109.891 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.836 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.1 m-20 -93.16 149.83 20.95 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.271 -0.893 . . . . 0.0 110.651 -179.229 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.69 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.1 m -61.69 111.15 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 119.041 -1.064 . . . . 0.0 108.829 179.104 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.933 ' O ' HG23 ' A' ' 74' ' ' ILE . 74.1 m -132.42 -34.71 1.19 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 110.749 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.939 ' HA ' HG21 ' A' ' 63' ' ' VAL . 58.7 t -47.69 125.18 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.246 -0.909 . . . . 0.0 109.612 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.933 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -136.7 113.33 10.0 Favored Pre-proline 0 N--CA 1.497 1.894 0 O-C-N 121.098 -1.001 . . . . 0.0 111.751 -178.373 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.462 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.1 Cg_endo -89.29 40.96 0.51 Allowed 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.575 1.303 . . . . 0.0 110.343 178.705 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.0 p -142.59 47.7 1.56 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.015 -1.053 . . . . 0.0 110.704 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -148.46 27.38 0.92 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.159 -0.963 . . . . 0.0 110.253 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.7 -94.55 1.39 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -128.31 111.67 13.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.153 -1.204 . . . . 0.0 110.087 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.9 p -117.2 134.96 59.13 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 CA-C-O 122.124 0.964 . . . . 0.0 110.084 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.596 HG22 HG22 ' A' ' 60' ' ' ILE . 5.3 m -113.99 122.05 67.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 O-C-N 121.296 -0.877 . . . . 0.0 109.229 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.766 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -96.84 117.87 42.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 120.916 -1.115 . . . . 0.0 110.308 -178.054 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.824 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -108.81 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.244 -0.982 . . . . 0.0 108.916 179.548 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.444 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.23 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.658 -1.276 . . . . 0.0 110.656 -178.744 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.04 -34.48 15.09 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 110.679 -179.151 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -178.01 -29.57 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.114 -0.991 . . . . 0.0 111.066 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.518 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -44.88 -34.09 2.22 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.178 -0.951 . . . . 0.0 111.073 -179.553 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.445 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.7 tp -66.99 -33.87 76.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.087 -1.008 . . . . 0.0 109.772 179.469 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.548 ' C ' HG22 ' A' ' 90' ' ' THR . 4.4 mmt 55.1 -87.47 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.585 -0.697 . . . . 0.0 110.526 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.548 HG22 ' C ' ' A' ' 89' ' ' MET . 0.0 OUTLIER -179.54 -91.76 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.006 -1.059 . . . . 0.0 110.438 -179.853 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.425 ' H ' HG23 ' A' ' 90' ' ' THR . . . 70.14 -65.42 0.72 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.41 ' N ' ' O ' ' A' ' 90' ' ' THR . 38.0 p90 -128.2 13.94 6.69 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.073 -1.251 . . . . 0.0 110.881 -179.657 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.545 HG22 ' OG1' ' A' ' 90' ' ' THR . 14.6 t -75.49 -167.23 0.63 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.11 -0.994 . . . . 0.0 110.398 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.437 ' O ' ' CD ' ' A' ' 124' ' ' ARG . . . 113.11 -37.58 3.57 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.339 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -84.42 65.4 8.9 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.95 -1.323 . . . . 0.0 110.776 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 22.1 m-85 -119.83 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.055 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.448 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.68 -29.32 27.69 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.492 -0.755 . . . . 0.0 109.976 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.66 163.66 29.71 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -0.975 . . . . 0.0 111.351 -179.643 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.519 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.22 114.4 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.439 -0.788 . . . . 0.0 109.922 179.141 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.931 HG21 HD11 ' A' ' 28' ' ' ILE . 3.7 mp -93.0 115.64 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.244 -0.91 . . . . 0.0 109.297 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.95 160.94 25.17 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.169 -0.957 . . . . 0.0 111.53 -178.582 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.418 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.64 3.75 42.74 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.628 -0.67 . . . . 0.0 109.504 178.15 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.48 23.88 0.66 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.266 -0.896 . . . . 0.0 111.254 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.9 HG22 ' HA ' ' A' ' 109' ' ' PRO . 0.8 OUTLIER -146.76 135.77 22.45 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.959 -1.088 . . . . 0.0 110.476 179.283 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.7 p -114.76 132.69 56.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.262 -0.899 . . . . 0.0 109.908 179.826 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t0 52.55 -142.65 0.75 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.008 -1.058 . . . . 0.0 109.826 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.19 17.29 43.38 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 179.453 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 5.6 mmtp -129.43 156.26 78.82 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.101 -1.235 . . . . 0.0 109.432 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.9 ' HA ' HG22 ' A' ' 104' ' ' THR . 39.0 Cg_endo -64.29 167.07 15.37 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 123.581 1.306 . . . . 0.0 110.48 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.512 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 13.9 tt0 -70.8 154.84 41.47 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.417 -0.802 . . . . 0.0 110.902 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.416 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.3 p-10 -88.27 161.5 17.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.567 -0.708 . . . . 0.0 110.092 179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.771 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -52.31 -61.79 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.346 -0.846 . . . . 0.0 112.29 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.432 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 7.2 m -58.1 -29.79 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.765 -1.209 . . . . 0.0 112.004 -177.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.512 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.82 -56.22 7.95 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.011 -1.055 . . . . 0.0 110.489 -179.293 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.436 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.49 -33.9 76.73 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.207 -0.933 . . . . 0.0 108.941 178.94 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.432 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.0 m -60.29 -49.82 76.1 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 120.999 -1.063 . . . . 0.0 108.452 178.462 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -73.93 -38.02 64.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 178.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 40.6 mtt85 -72.16 -44.85 62.43 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.222 -0.924 . . . . 0.0 111.477 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.534 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -54.59 -45.38 73.58 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.787 -1.195 . . . . 0.0 109.495 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.28 81.71 0.03 OUTLIER Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.73 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 179.606 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.528 ' CG2' HD13 ' A' ' 10' ' ' ILE . 8.7 t -93.13 143.47 26.22 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.56 1.7 19.74 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.646 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.437 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -70.24 85.9 0.57 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.978 -1.307 . . . . 0.0 110.13 -179.801 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.1 -38.04 2.89 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.87 -166.87 0.13 Allowed Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.508 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -86.31 114.81 1.31 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.086 1.045 . . . . 0.0 109.647 179.202 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.522 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.4 167.88 54.81 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.504 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.83 138.74 49.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.451 -1.029 . . . . 0.0 108.62 178.699 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.519 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.26 118.78 22.88 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.218 -0.993 . . . . 0.0 110.581 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.5 ' HD2' HG11 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.31 127.14 53.03 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.487 -0.758 . . . . 0.0 109.879 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' A' ' 134' ' ' ALA . 10.4 p90 -118.84 158.5 25.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.17 -0.956 . . . . 0.0 109.81 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.669 HG22 HD23 ' A' ' 15' ' ' LEU . 7.2 t -82.93 -50.55 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.085 -1.009 . . . . 0.0 110.263 179.76 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.465 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -49.51 162.61 0.42 Allowed Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.35 -0.844 . . . . 0.0 111.553 -178.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -76.38 -53.82 0.08 OUTLIER 'Trans proline' 0 C--N 1.311 -1.4 0 O-C-N 123.617 1.325 . . . . 0.0 110.184 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 117.87 177.68 17.28 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -74.24 -34.41 63.64 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.353 -1.086 . . . . 0.0 110.205 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.215 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.01 106.37 6.48 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.214 -1.168 . . . . 0.0 110.093 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.6 ' O ' HG23 ' A' ' 3' ' ' VAL . 27.5 m -112.97 104.16 16.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.271 -0.893 . . . . 0.0 110.024 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.873 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 17.9 p -66.94 141.21 57.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.317 -0.865 . . . . 0.0 109.922 179.788 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.469 HG13 ' CG2' ' A' ' 116' ' ' THR . 0.2 OUTLIER -66.68 147.59 98.97 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.19 -0.944 . . . . 0.0 109.403 179.839 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.434 ' HD2' HG23 ' A' ' 5' ' ' VAL . 42.3 Cg_endo -67.85 -168.31 0.19 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 124.169 1.615 . . . . 0.0 110.654 179.683 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.529 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -179.83 81.21 0.19 Allowed Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.522 -0.736 . . . . 0.0 109.998 -179.82 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.456 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 42.5 Cg_endo -69.73 -170.74 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.697 1.367 . . . . 0.0 109.821 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.456 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 6.5 m120 76.83 -14.05 0.87 Allowed 'General case' 0 N--CA 1.508 2.462 0 O-C-N 121.816 -0.553 . . . . 0.0 111.239 -179.526 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.499 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.1 mt -116.59 135.38 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.664 -1.273 . . . . 0.0 109.488 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.417 ' N ' ' O ' ' A' ' 128' ' ' GLY . 1.5 tm-20 -86.1 127.15 34.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.8 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.407 ' HG2' ' NH2' ' A' ' 119' ' ' ARG . 47.6 mt-10 -90.43 136.65 32.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.104 -0.997 . . . . 0.0 110.03 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.493 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.2 157.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.193 -0.942 . . . . 0.0 110.044 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.63 112.21 25.2 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.188 -0.945 . . . . 0.0 110.044 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.778 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.5 tp -54.81 147.36 15.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.873 . . . . 0.0 109.282 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.53 7.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.122 -0.987 . . . . 0.0 110.533 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.13 74.62 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.345 -0.847 . . . . 0.0 109.976 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.803 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.4 m -152.41 108.8 3.42 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.322 -0.862 . . . . 0.0 110.741 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.57 -167.16 29.2 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.922 -1.608 . . . . 0.0 110.818 179.214 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.46 ' HB3' HD11 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.26 -24.85 9.58 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.664 -0.904 . . . . 0.0 110.482 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 1.018 HD12 HD13 ' A' ' 55' ' ' LEU . 9.4 tt -95.12 101.89 8.27 Favored Pre-proline 0 C--N 1.305 -1.334 0 C-N-CA 118.734 -1.187 . . . . 0.0 109.743 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.44 127.39 21.73 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.534 1.281 . . . . 0.0 111.074 -178.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 25' ' ' GLY . 6.3 t80 -117.19 -171.91 2.12 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.541 0.686 . . . . 0.0 110.695 -179.062 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.565 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.4 m-85 -57.58 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.434 -0.791 . . . . 0.0 111.688 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.02 -4.62 53.47 Favored Glycine 0 N--CA 1.493 2.495 0 O-C-N 121.229 -0.919 . . . . 0.0 110.911 178.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.778 ' HB2' HD23 ' A' ' 15' ' ' LEU . 28.3 mmtt -130.05 156.34 44.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.826 -1.397 . . . . 0.0 109.908 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.803 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.26 108.07 19.39 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.064 -1.023 . . . . 0.0 108.864 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.917 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.1 mt -68.24 112.99 12.54 Favored Pre-proline 0 C--N 1.3 -1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 110.732 -179.056 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.714 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.3 Cg_endo -68.43 130.05 20.26 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.125 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.576 ' CD2' HD11 ' A' ' 33' ' ' ILE . 12.8 mt -56.64 -17.13 7.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.772 -1.205 . . . . 0.0 110.801 -177.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.438 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.32 -16.05 19.87 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.739 -1.226 . . . . 0.0 110.476 179.955 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.064 HG23 HG23 ' A' ' 33' ' ' ILE . 9.9 m -95.16 -24.24 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.008 -1.057 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.064 HG23 HG23 ' A' ' 32' ' ' VAL . 46.2 pt -116.58 -12.17 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.919 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.643 ' HB2' HD11 ' A' ' 60' ' ' ILE . 8.9 tptm -102.12 148.29 25.57 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.831 -1.168 . . . . 0.0 110.193 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.03 -5.3 36.24 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.74 3.89 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.407 -1.377 . . . . 0.0 110.08 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.54 135.96 53.38 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.313 -1.11 . . . . 0.0 110.363 -179.736 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.576 ' HB2' HG12 ' A' ' 81' ' ' VAL . 93.6 m-70 -140.01 153.42 46.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.254 -0.904 . . . . 0.0 111.196 -179.427 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.622 ' HB3' HG12 ' A' ' 99' ' ' VAL . 60.4 tp -113.5 116.47 29.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.419 -0.801 . . . . 0.0 110.285 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.906 HD12 ' CG1' ' A' ' 83' ' ' VAL . 33.7 mt -100.93 128.1 53.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.194 -0.942 . . . . 0.0 109.568 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -95.08 123.75 38.74 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.441 -0.787 . . . . 0.0 110.238 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.94 159.92 21.71 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.217 -0.927 . . . . 0.0 110.679 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.565 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.2 p80 -105.55 -4.48 21.15 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.381 -0.824 . . . . 0.0 110.395 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.5 p -132.13 138.53 48.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.973 -1.08 . . . . 0.0 110.702 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.509 ' HD2' ' CE1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.25 -41.19 70.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.483 -0.761 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.77 72.1 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.221 -0.924 . . . . 0.0 110.59 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.41 -37.36 65.95 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.379 -0.826 . . . . 0.0 109.949 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.875 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 73.9 m -61.14 -34.35 74.87 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.273 -0.892 . . . . 0.0 109.857 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.413 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.67 -50.08 59.54 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.229 -0.919 . . . . 0.0 110.592 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.404 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 11.7 mt-10 -72.37 -40.54 67.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.191 -0.943 . . . . 0.0 110.374 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.814 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.92 -42.67 98.55 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.616 -0.678 . . . . 0.0 111.567 -178.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.64 -51.16 45.13 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.8 -1.188 . . . . 0.0 110.271 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.15 -34.43 68.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.032 -1.043 . . . . 0.0 109.183 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.532 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.24 -47.95 80.08 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.208 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 1.018 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.02 -42.45 80.43 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.531 -0.731 . . . . 0.0 110.955 -179.994 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -55.67 -28.32 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.925 -1.11 . . . . 0.0 108.753 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.62 -35.37 60.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.516 -0.74 . . . . 0.0 110.266 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.532 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.33 -26.11 61.81 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.06 7.96 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.643 HD11 ' HB2' ' A' ' 34' ' ' LYS . 50.4 mt -106.39 143.0 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.282 -1.128 . . . . 0.0 109.633 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.442 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.7 t30 -87.41 106.56 18.04 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.024 -1.472 . . . . 0.0 107.024 178.401 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.576 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.5 146.07 45.77 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.23 -0.988 . . . . 0.0 111.008 -177.704 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.698 ' HB ' HG13 ' A' ' 73' ' ' VAL . 6.1 t -138.7 149.97 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.823 -0.751 . . . . 0.0 109.303 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.875 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.01 134.84 53.32 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.713 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.657 ' CD1' HD12 ' A' ' 69' ' ' LEU . 20.4 t80 -124.96 129.27 50.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.382 -0.824 . . . . 0.0 110.274 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.814 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -154.73 -171.3 3.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.595 -0.691 . . . . 0.0 109.634 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.8 124.88 22.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.125 -0.984 . . . . 0.0 110.731 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.35 34.02 30.27 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.794 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.937 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.35 157.13 26.67 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.143 -1.21 . . . . 0.0 110.035 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.937 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.15 22.77 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.188 -0.945 . . . . 0.0 110.815 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.679 ' O ' HG23 ' A' ' 71' ' ' VAL . 27.8 m -62.97 111.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.121 -0.987 . . . . 0.0 109.067 178.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.437 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.0 m -131.19 -11.73 3.64 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.166 -0.959 . . . . 0.0 111.494 -179.322 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.955 ' CG1' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.34 136.2 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.737 -1.227 . . . . 0.0 109.509 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.515 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -136.91 92.09 14.65 Favored Pre-proline 0 N--CA 1.497 1.883 0 O-C-N 121.12 -0.987 . . . . 0.0 110.513 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.446 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.3 Cg_endo -77.01 58.1 6.02 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 123.456 1.24 . . . . 0.0 110.491 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.5 p -119.43 -31.99 4.47 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.189 -0.944 . . . . 0.0 110.361 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.7 m-80 -150.81 160.67 43.72 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.229 -0.919 . . . . 0.0 110.179 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 64.99 166.69 1.38 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -89.11 102.95 15.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.042 -1.27 . . . . 0.0 110.181 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.446 HG11 ' HA ' ' A' ' 75' ' ' PRO . 5.8 p -117.06 135.11 58.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 121.904 0.859 . . . . 0.0 110.359 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.593 HG22 HG22 ' A' ' 60' ' ' ILE . 7.1 m -112.95 122.5 67.2 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.955 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.6 t -96.83 117.65 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.019 -1.051 . . . . 0.0 110.097 -177.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.906 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.3 m -111.43 99.74 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.075 -1.016 . . . . 0.0 108.828 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.479 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.13 159.84 41.2 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.646 -1.283 . . . . 0.0 111.27 -178.189 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.509 HG23 ' N ' ' A' ' 86' ' ' ASP . 7.8 t -82.33 -130.45 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.618 -0.676 . . . . 0.0 109.515 179.746 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.509 ' N ' HG23 ' A' ' 85' ' ' THR . 0.3 OUTLIER -93.82 27.82 2.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.595 -1.315 . . . . 0.0 110.225 179.94 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.476 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.11 -35.76 12.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 110.133 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.3 tp -69.37 -32.96 72.34 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.644 179.643 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.402 ' C ' HG22 ' A' ' 90' ' ' THR . 4.2 mmt 54.06 -89.98 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.575 -0.703 . . . . 0.0 110.134 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.535 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.4 OUTLIER 177.84 41.73 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 O-C-N 120.912 -1.118 . . . . 0.0 110.066 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.81 -48.6 79.73 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.593 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -128.57 32.63 4.79 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.481 -1.011 . . . . 0.0 110.502 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.566 HG23 ' N ' ' A' ' 94' ' ' GLY . 5.6 t -95.07 -152.91 0.37 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.097 -1.002 . . . . 0.0 110.219 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.566 ' N ' HG23 ' A' ' 93' ' ' THR . . . 97.34 -10.32 65.21 Favored Glycine 0 N--CA 1.49 2.247 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.618 179.111 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.7 t0 -124.93 64.95 1.12 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.802 -1.41 . . . . 0.0 110.871 -179.633 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -120.05 151.57 38.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.079 -1.013 . . . . 0.0 110.315 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.443 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.42 -30.96 33.36 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.33 178.983 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.457 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.9 163.94 28.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.377 -0.827 . . . . 0.0 111.197 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.628 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.44 115.38 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.557 -0.714 . . . . 0.0 109.796 179.002 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.859 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -93.11 117.62 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.241 -0.912 . . . . 0.0 109.113 179.495 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.439 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.9 t0 -122.5 161.18 24.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.937 . . . . 0.0 111.559 -178.499 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.423 ' HG ' ' CB ' ' A' ' 24' ' ' TYR . 20.7 t -103.47 8.42 37.87 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.257 -0.902 . . . . 0.0 110.713 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.622 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -142.9 133.65 25.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.73 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.4 p -113.83 132.42 55.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.325 -0.86 . . . . 0.0 109.441 179.257 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 54.47 -141.92 0.83 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.991 -1.068 . . . . 0.0 109.513 -179.341 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -90.36 24.69 15.38 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.87 157.2 70.07 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.301 -1.117 . . . . 0.0 109.617 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.622 ' HA ' HG22 ' A' ' 104' ' ' THR . 39.3 Cg_endo -64.61 166.3 18.14 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.547 1.288 . . . . 0.0 110.248 -179.791 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.04 162.91 28.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.186 -0.946 . . . . 0.0 110.826 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.578 ' OD2' HG22 ' A' ' 113' ' ' VAL . 3.6 p-10 -92.73 162.57 14.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.479 -0.763 . . . . 0.0 110.382 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.873 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -50.55 -49.38 56.17 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.831 -1.168 . . . . 0.0 111.868 -178.675 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.578 HG22 ' OD2' ' A' ' 111' ' ' ASP . 5.8 m -72.63 -30.62 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.601 -1.312 . . . . 0.0 113.283 -177.825 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.88 -54.7 34.95 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.293 -1.504 . . . . 0.0 110.096 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.27 -35.97 78.76 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 118.363 -1.335 . . . . 0.0 108.164 178.363 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.469 ' CG2' HG13 ' A' ' 5' ' ' VAL . 83.0 m -60.79 -49.97 75.34 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.77 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.8 tp-100 -73.68 -46.45 46.32 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.86 178.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.0 mtt-85 -58.25 -46.08 86.63 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 110.466 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.529 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 11.1 ttm180 -58.21 -39.85 80.1 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.847 -1.158 . . . . 0.0 109.485 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.56 68.81 0.4 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -146.22 -45.95 0.2 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.425 -1.044 . . . . 0.0 108.743 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.563 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.9 t -94.34 142.33 27.54 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.4 5.7 11.17 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.547 179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.434 ' HD3' ' HA2' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -76.2 84.53 3.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.947 -1.325 . . . . 0.0 110.171 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.93 -43.58 1.66 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.474 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.22 -169.31 0.17 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.499 -1.001 . . . . 0.0 108.662 179.565 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -87.72 110.67 0.73 Allowed 'Trans proline' 0 C--N 1.309 -1.529 0 O-C-N 123.274 1.144 . . . . 0.0 109.452 178.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.563 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.62 146.58 32.89 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.483 HD12 ' N ' ' A' ' 129' ' ' ILE . 2.9 mp -106.35 141.15 22.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.859 -1.377 . . . . 0.0 109.301 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.628 ' CD2' HG23 ' A' ' 99' ' ' VAL . 4.4 t80 -127.87 115.35 18.46 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.105 -0.997 . . . . 0.0 110.41 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.493 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mmt180 -102.06 123.39 45.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.498 -0.752 . . . . 0.0 109.632 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.447 ' CE1' ' HA ' ' A' ' 135' ' ' PRO . 25.7 p90 -115.23 157.84 23.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.022 -1.049 . . . . 0.0 110.059 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t -89.01 -38.98 12.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.09 -1.006 . . . . 0.0 109.76 179.507 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.422 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -96.17 131.71 28.23 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.178 -0.952 . . . . 0.0 110.198 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.447 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 50.0 Cg_endo -76.88 -19.66 13.89 Favored 'Trans proline' 0 C--N 1.314 -1.263 0 O-C-N 123.519 1.273 . . . . 0.0 110.657 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -52.21 105.36 0.24 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -135.02 -166.32 1.81 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.252 -1.146 . . . . 0.0 110.214 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 118.124 -0.941 . . . . 0.0 110.262 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.3 p -115.19 157.2 24.0 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.204 -1.174 . . . . 0.0 110.19 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.94 104.47 17.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.303 -0.873 . . . . 0.0 109.665 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.7 p -66.68 137.0 56.38 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.4 -0.813 . . . . 0.0 110.535 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.443 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -73.04 149.05 89.53 Favored Pre-proline 0 C--N 1.303 -1.432 0 O-C-N 121.315 -0.865 . . . . 0.0 109.297 179.225 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.443 ' HD2' HG23 ' A' ' 5' ' ' VAL . 50.6 Cg_endo -80.28 -165.55 0.35 Allowed 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.992 1.522 . . . . 0.0 111.377 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.495 ' NE2' ' NE ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.07 83.35 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.824 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.14 60.69 0.47 Allowed 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.906 1.477 . . . . 0.0 111.937 -178.337 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 13.2 m120 -131.88 2.57 4.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.49 -0.756 . . . . 0.0 109.931 178.37 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.482 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 11.7 mt -128.44 137.64 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.952 -1.093 . . . . 0.0 109.343 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.67 128.24 34.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.102 -0.999 . . . . 0.0 109.39 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.59 127.99 35.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.109 -0.994 . . . . 0.0 110.198 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.818 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 15.7 t -122.93 155.4 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.286 -0.884 . . . . 0.0 110.206 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.05 110.46 22.59 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.295 -0.878 . . . . 0.0 109.925 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.538 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.67 134.72 54.89 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 110.005 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 17.7 p -135.37 171.5 14.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.256 -0.902 . . . . 0.0 110.214 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.53 69.96 0.17 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 110.153 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.577 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.4 m -140.54 112.29 7.53 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.28 -0.887 . . . . 0.0 110.392 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.74 -163.28 26.94 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.542 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.2 -22.33 7.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.666 -0.902 . . . . 0.0 110.518 179.846 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.914 HD12 HD13 ' A' ' 55' ' ' LEU . 9.0 tt -97.41 107.06 36.64 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 120.839 -1.163 . . . . 0.0 110.28 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.511 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.91 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.318 1.167 . . . . 0.0 110.088 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.55 93.73 0.2 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.191 -0.943 . . . . 0.0 110.96 -178.522 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.25 68.56 0.76 Allowed 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.526 -0.733 . . . . 0.0 111.251 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.76 15.38 9.15 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.538 ' CB ' HD23 ' A' ' 15' ' ' LEU . 5.2 mmpt? -130.67 156.21 45.29 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.028 -1.278 . . . . 0.0 109.243 179.638 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.577 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.79 107.51 15.14 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 109.348 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.913 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -69.83 113.91 20.95 Favored Pre-proline 0 C--N 1.298 -1.654 0 O-C-N 121.474 -0.766 . . . . 0.0 110.688 -179.235 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.8 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.9 Cg_endo -70.18 130.81 19.45 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 106.443 -2.176 . . . . 0.0 106.443 175.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.673 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.1 mt -55.92 -18.41 8.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.718 -1.238 . . . . 0.0 110.518 -177.716 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.489 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -59.75 -16.16 25.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.771 -1.205 . . . . 0.0 110.484 179.655 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.051 HG23 HG23 ' A' ' 33' ' ' ILE . 13.3 m -92.03 -25.04 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.976 -1.078 . . . . 0.0 110.93 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.051 HG23 HG23 ' A' ' 32' ' ' VAL . 42.2 pt -117.06 -17.48 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.079 -1.013 . . . . 0.0 110.622 -179.391 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.569 ' HB2' HD11 ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.49 22.84 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.947 -1.095 . . . . 0.0 110.262 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.05 -7.56 27.24 Favored Glycine 0 N--CA 1.485 1.947 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.02 3.21 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.149 -1.5 . . . . 0.0 110.342 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.435 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -111.99 129.95 56.02 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.353 -1.086 . . . . 0.0 110.232 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.603 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.63 146.94 46.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.06 -1.025 . . . . 0.0 110.953 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 36.8 tp -109.65 115.66 30.3 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.475 -0.765 . . . . 0.0 110.216 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.94 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.8 mt -98.96 127.67 51.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.15 -0.969 . . . . 0.0 109.465 179.284 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.401 ' CE2' ' HA ' ' A' ' 118' ' ' ARG . 4.2 m-85 -94.88 122.62 37.7 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.556 -0.715 . . . . 0.0 110.518 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.2 31.24 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.344 -0.847 . . . . 0.0 110.581 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.3 p80 -109.31 8.17 25.48 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.245 -0.91 . . . . 0.0 109.478 178.363 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.93 135.95 41.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.13 -0.981 . . . . 0.0 110.316 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.531 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.94 -42.37 66.7 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.55 -0.719 . . . . 0.0 110.818 -179.687 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.63 -36.51 74.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.345 -0.847 . . . . 0.0 110.428 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.413 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -72.29 -36.28 68.9 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.482 -0.761 . . . . 0.0 109.809 -179.781 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.83 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 2.2 m -60.89 -34.04 74.03 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.359 -0.838 . . . . 0.0 109.77 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.34 -49.31 56.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.268 -0.895 . . . . 0.0 110.672 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.56 -43.85 65.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.208 -0.933 . . . . 0.0 110.383 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.702 HD12 HG11 ' A' ' 83' ' ' VAL . 1.5 tm? -56.34 -41.14 75.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.422 -0.799 . . . . 0.0 110.909 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.21 -51.41 13.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 110.372 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.75 -43.86 98.02 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.055 -1.028 . . . . 0.0 109.582 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.516 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -56.83 -43.84 81.45 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.309 -0.87 . . . . 0.0 109.549 179.528 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.914 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.46 -42.89 74.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.444 -0.785 . . . . 0.0 109.704 179.592 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.8 t -55.84 -30.78 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.133 -0.98 . . . . 0.0 108.71 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -76.15 -33.32 59.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.574 -0.703 . . . . 0.0 110.121 179.126 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.558 ' HB3' HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.74 -26.37 62.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 109.614 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.97 5.64 8.05 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.673 ' CD1' HD22 ' A' ' 30' ' ' LEU . 19.8 mt -108.29 143.57 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.199 -1.177 . . . . 0.0 110.235 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.5 t30 -86.12 107.34 17.8 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.199 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.628 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.96 146.92 46.67 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.002 -1.079 . . . . 0.0 112.064 -177.151 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.943 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.2 t -135.92 150.29 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.66 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.83 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.69 131.82 55.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.222 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.483 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -120.82 123.42 42.54 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.933 . . . . 0.0 110.731 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.855 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.1 p90 -155.2 178.43 10.22 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.641 179.546 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -52.36 128.17 24.58 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.071 -1.018 . . . . 0.0 110.63 -179.357 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.25 39.27 31.99 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.951 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -117.02 155.63 28.88 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.124 -1.221 . . . . 0.0 109.777 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.951 ' N ' HD13 ' A' ' 69' ' ' LEU . 27.0 m-20 -95.39 149.15 21.7 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.272 -0.893 . . . . 0.0 110.884 -179.125 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.677 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.7 m -62.21 111.4 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.061 -1.024 . . . . 0.0 108.873 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.78 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.2 m -134.33 -36.06 0.9 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.895 . . . . 0.0 110.888 -179.11 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.943 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.6 t -50.91 134.7 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.195 -0.941 . . . . 0.0 109.851 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.78 HG23 ' O ' ' A' ' 72' ' ' SER . 1.8 pp -136.91 109.52 9.17 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.219 -0.926 . . . . 0.0 110.905 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.632 ' HA ' HG11 ' A' ' 80' ' ' VAL . 50.8 Cg_endo -86.93 46.79 1.51 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.485 1.255 . . . . 0.0 110.245 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.5 p -129.87 -9.49 4.42 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.068 -1.02 . . . . 0.0 111.424 -179.286 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -88.9 -171.94 3.49 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.933 -1.104 . . . . 0.0 110.366 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.11 -80.19 0.07 OUTLIER Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 -130.8 114.44 15.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.174 -1.192 . . . . 0.0 110.072 179.584 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.632 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -116.85 134.94 58.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 CA-C-O 121.969 0.89 . . . . 0.0 109.855 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 60' ' ' ILE . 16.0 m -113.34 124.45 69.99 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.341 0 O-C-N 121.422 -0.799 . . . . 0.0 109.484 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.742 HG22 ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.4 117.25 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.096 -1.003 . . . . 0.0 109.934 -178.61 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.94 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -112.08 100.07 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.986 -1.071 . . . . 0.0 108.625 179.697 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.9 162.24 35.64 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.752 -1.218 . . . . 0.0 110.943 -178.149 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.513 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -91.35 -133.15 0.12 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.627 -0.671 . . . . 0.0 109.24 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.513 ' N ' HG23 ' A' ' 85' ' ' THR . 46.5 p-10 -88.42 43.33 1.12 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.663 -1.273 . . . . 0.0 110.342 179.709 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.473 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.79 -30.29 6.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 110.144 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.446 ' O ' ' N ' ' A' ' 90' ' ' THR . 2.2 tp -68.9 -29.13 67.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.041 -1.037 . . . . 0.0 109.28 179.421 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.466 ' C ' HG22 ' A' ' 90' ' ' THR . 0.8 OUTLIER 55.61 -85.9 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.833 -0.542 . . . . 0.0 110.418 179.872 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.561 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.3 OUTLIER 173.61 43.14 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.023 -1.048 . . . . 0.0 110.22 -179.928 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -56.85 -46.87 89.87 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 179.412 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -138.17 28.15 2.57 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.453 -1.028 . . . . 0.0 110.128 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.561 HG22 ' OG1' ' A' ' 90' ' ' THR . 3.1 t -86.26 -160.41 0.55 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.16 -0.963 . . . . 0.0 110.42 -179.656 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.5 ' N ' HG23 ' A' ' 93' ' ' THR . . . 100.53 -31.83 8.08 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.2 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 -107.46 73.89 0.94 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.815 -1.403 . . . . 0.0 111.163 -179.24 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.518 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 25.8 m-85 -119.74 153.18 36.04 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.066 . . . . 0.0 110.139 178.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.91 -26.99 25.26 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.386 -0.821 . . . . 0.0 109.551 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.8 p -162.52 163.63 27.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 111.432 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.485 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -134.0 126.21 49.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.479 -0.763 . . . . 0.0 109.718 179.114 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.913 HG21 HD11 ' A' ' 28' ' ' ILE . 2.8 mp -105.51 111.54 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.088 -1.007 . . . . 0.0 109.117 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.422 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -121.58 161.0 23.17 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.249 -0.907 . . . . 0.0 111.565 -178.864 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.1 t -96.26 -6.91 36.86 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 177.781 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 57.76 11.01 1.21 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.37 -0.831 . . . . 0.0 112.225 179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.566 HG23 ' C ' ' A' ' 107' ' ' GLY . 0.9 OUTLIER -147.35 126.26 12.75 Favored 'General case' 0 C--N 1.31 -1.123 0 O-C-N 120.537 -1.352 . . . . 0.0 109.509 179.819 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 108' ' ' LYS . 24.6 p -100.54 129.27 46.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.918 . . . . 0.0 110.189 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 57.3 29.1 16.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.223 -0.923 . . . . 0.0 110.552 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.566 ' C ' HG23 ' A' ' 104' ' ' THR . . . 94.75 -30.56 7.78 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -82.51 155.36 68.83 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.175 -1.191 . . . . 0.0 110.206 -179.885 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -64.69 137.41 54.08 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 123.552 1.291 . . . . 0.0 110.503 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.427 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 -51.29 163.62 0.24 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.475 -0.766 . . . . 0.0 110.956 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.54 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -83.53 161.4 21.23 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.298 -0.876 . . . . 0.0 110.062 179.69 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.442 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.53 -61.88 1.25 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.435 -0.791 . . . . 0.0 112.172 -178.822 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.54 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.1 m -60.41 -29.31 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.742 -1.224 . . . . 0.0 111.692 -178.652 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.21 -56.49 6.6 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.01 -1.056 . . . . 0.0 110.749 -178.812 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.03 76.88 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.124 -0.985 . . . . 0.0 108.668 178.947 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.2 m -60.49 -50.03 75.18 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.109 -0.995 . . . . 0.0 108.368 178.576 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.24 63.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.477 -0.764 . . . . 0.0 110.184 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.401 ' HA ' ' CE2' ' A' ' 41' ' ' PHE . 10.8 mtt85 -71.2 -44.31 65.68 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.119 -0.988 . . . . 0.0 111.138 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.495 ' NE ' ' NE2' ' A' ' 7' ' ' HIS . 11.8 ttp180 -70.46 -40.0 73.96 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.999 -1.063 . . . . 0.0 109.975 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.96 63.33 0.71 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -137.12 -45.93 0.57 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.144 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.452 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.1 t -95.16 142.29 27.78 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.316 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.467 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.2 17.33 51.01 Favored Glycine 0 N--CA 1.484 1.887 0 C-N-CA 119.528 -1.32 . . . . 0.0 110.356 178.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.437 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -52.07 -37.86 55.21 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.059 -1.26 . . . . 0.0 109.705 179.666 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.0 28.59 2.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.475 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.6 -168.25 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.694 -0.886 . . . . 0.0 109.123 -179.415 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.48 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 49.6 Cg_endo -86.66 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.167 1.088 . . . . 0.0 110.556 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -80.09 157.67 41.35 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -106.85 141.59 21.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.041 -1.27 . . . . 0.0 109.105 178.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.485 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.9 t80 -130.07 114.81 16.23 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.07 -1.052 . . . . 0.0 110.227 179.392 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.818 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -101.5 122.15 43.27 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.428 -0.795 . . . . 0.0 109.656 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.422 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 14.3 p90 -120.24 154.54 34.74 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.896 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.432 HG13 ' HG3' ' A' ' 26' ' ' LYS . 75.4 t -86.67 -41.3 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.205 -0.934 . . . . 0.0 110.235 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -101.45 111.57 63.93 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.16 -0.962 . . . . 0.0 110.336 -179.715 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -71.5 -46.74 0.58 Allowed 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.529 1.279 . . . . 0.0 110.311 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 97.31 129.72 6.38 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 51.8 82.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.245 -1.15 . . . . 0.0 110.407 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.306 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.19 102.59 14.41 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.217 -1.166 . . . . 0.0 110.154 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.671 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.4 p -113.32 104.32 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.283 -0.886 . . . . 0.0 109.689 179.474 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.445 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 18.2 p -100.41 140.44 34.66 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.339 -0.85 . . . . 0.0 110.41 -179.626 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.834 HG13 HG23 ' A' ' 116' ' ' THR . 0.2 OUTLIER -67.21 147.38 98.98 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.343 -0.848 . . . . 0.0 109.101 179.589 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.527 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 45.9 Cg_endo -73.93 -19.54 20.56 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 O-C-N 124.054 1.555 . . . . 0.0 113.113 -178.541 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.527 ' CD2' ' CD ' ' A' ' 119' ' ' ARG . 1.8 p-80 42.73 75.8 0.59 Allowed Pre-proline 0 N--CA 1.502 2.146 0 O-C-N 121.375 -0.828 . . . . 0.0 110.715 -178.011 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.422 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 43.6 Cg_endo -71.02 -175.11 1.34 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.735 1.387 . . . . 0.0 110.145 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 65.77 7.15 4.34 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.685 -0.634 . . . . 0.0 111.221 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.729 HG12 HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.55 126.23 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.674 -1.266 . . . . 0.0 109.313 179.136 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.78 127.59 34.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.942 179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.47 136.18 33.22 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.209 -0.932 . . . . 0.0 110.104 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.462 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.2 t -129.71 154.95 41.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.368 -0.832 . . . . 0.0 109.925 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.5 112.87 25.98 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.109 -0.994 . . . . 0.0 110.389 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.614 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.8 tp -59.31 140.52 55.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.368 -0.833 . . . . 0.0 109.19 179.308 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.33 -178.24 5.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 110.508 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 72.0 p -76.99 59.9 1.73 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.077 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 10.0 m -132.45 109.34 9.74 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.269 -0.895 . . . . 0.0 110.714 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.17 -167.2 28.98 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 118.85 -1.643 . . . . 0.0 110.687 179.204 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.54 -18.86 10.83 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.667 -0.902 . . . . 0.0 110.304 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -99.34 104.51 27.25 Favored Pre-proline 0 N--CA 1.49 1.533 0 C-N-CA 118.771 -1.172 . . . . 0.0 109.876 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.449 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.2 Cg_endo -63.55 128.51 22.54 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.336 1.177 . . . . 0.0 111.009 -179.109 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.442 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.95 1.17 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.779 -0.576 . . . . 0.0 109.882 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.1 m-85 -58.11 82.21 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.219 -0.926 . . . . 0.0 111.605 -179.236 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.12 0.52 52.7 Favored Glycine 0 N--CA 1.494 2.566 0 O-C-N 121.156 -0.965 . . . . 0.0 110.888 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.614 ' HB2' HD23 ' A' ' 15' ' ' LEU . 27.3 mmtp -130.51 156.99 43.88 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.877 -1.367 . . . . 0.0 109.538 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -108.23 107.64 18.34 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 120.977 -1.077 . . . . 0.0 109.474 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.893 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -67.08 113.43 13.42 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.34 -0.85 . . . . 0.0 110.757 -179.344 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.817 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.4 Cg_endo -68.52 130.99 22.01 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 N-CA-C 106.874 -2.01 . . . . 0.0 106.874 176.012 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.747 HD11 HD12 ' A' ' 58' ' ' LEU . 10.7 mt -56.24 -17.61 8.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.816 -1.178 . . . . 0.0 110.728 -177.815 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -59.9 -16.41 29.25 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.64 -1.287 . . . . 0.0 110.518 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.051 HG23 HG23 ' A' ' 33' ' ' ILE . 13.6 m -93.09 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.005 -1.059 . . . . 0.0 111.213 -179.552 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.051 HG23 HG23 ' A' ' 32' ' ' VAL . 18.9 pt -119.45 -21.45 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.031 -1.043 . . . . 0.0 110.639 -179.288 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.566 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.79 148.28 22.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.89 -1.131 . . . . 0.0 110.317 179.46 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.14 -3.9 60.38 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.579 -1.409 . . . . 0.0 109.579 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.3 -158.65 21.45 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.465 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.75 132.38 50.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -1.069 . . . . 0.0 110.654 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.82 147.02 40.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.181 -0.949 . . . . 0.0 110.523 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.08 122.22 46.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.341 -0.849 . . . . 0.0 110.08 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.894 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.3 mm -100.56 126.08 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.271 -0.893 . . . . 0.0 109.186 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.454 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.2 m-85 -96.5 121.41 38.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.105 -0.997 . . . . 0.0 110.025 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.36 28.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.277 -0.889 . . . . 0.0 110.511 179.527 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.1 37.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.284 -0.885 . . . . 0.0 110.079 178.71 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.97 135.39 46.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.067 -1.021 . . . . 0.0 110.459 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.474 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.43 65.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.662 -0.649 . . . . 0.0 110.906 -179.761 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.31 -32.77 73.13 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.36 -0.837 . . . . 0.0 110.843 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.33 65.71 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.399 -0.813 . . . . 0.0 109.9 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.876 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.6 m -61.13 -38.52 86.66 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.592 179.154 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.4 -49.16 70.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.128 -0.983 . . . . 0.0 110.531 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.416 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -72.05 -46.29 57.54 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.239 -0.913 . . . . 0.0 110.608 -179.701 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.776 HD21 HD11 ' A' ' 21' ' ' ILE . 3.0 tm? -56.73 -41.09 76.87 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.459 -0.776 . . . . 0.0 111.42 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.36 -51.08 60.81 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.851 -1.156 . . . . 0.0 109.759 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.8 -32.5 69.4 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.236 -0.915 . . . . 0.0 109.347 179.253 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.849 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -61.72 -33.67 74.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.573 -0.704 . . . . 0.0 109.352 179.63 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.822 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.91 -42.44 57.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.423 -0.798 . . . . 0.0 110.397 -179.911 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.07 -33.03 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.048 -1.033 . . . . 0.0 109.189 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.43 -32.95 60.87 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.502 -0.749 . . . . 0.0 109.918 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.849 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.5 mm? -71.96 -26.37 62.24 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.947 0.88 . . . . 0.0 109.981 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.81 3.06 10.21 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.289 -1.525 . . . . 0.0 109.289 -179.251 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.619 HG22 HG22 ' A' ' 81' ' ' VAL . 31.2 mt -103.88 143.96 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.356 -1.085 . . . . 0.0 109.955 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.477 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 2.2 t-20 -88.68 106.87 18.62 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.178 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.544 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.92 145.28 44.77 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 118.868 -1.133 . . . . 0.0 111.739 -177.2 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.888 HG21 ' HA ' ' A' ' 73' ' ' VAL . 70.5 t -129.22 152.74 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.084 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.876 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -118.67 117.33 28.66 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.156 -1.018 . . . . 0.0 109.237 177.67 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -105.76 127.48 53.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.172 -0.955 . . . . 0.0 110.826 -179.256 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.925 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 10.0 p90 -155.58 -178.66 7.44 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.503 -0.748 . . . . 0.0 110.096 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.35 127.41 22.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.171 -0.956 . . . . 0.0 110.834 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.23 53.1 23.6 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.925 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.42 154.44 31.35 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.211 -1.17 . . . . 0.0 109.794 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.7 m-20 -91.21 149.37 21.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.229 -0.919 . . . . 0.0 110.427 -179.297 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.685 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.2 m -61.69 110.65 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.024 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.771 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.5 m -132.2 -38.72 1.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.759 . . . . 0.0 109.973 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.888 ' HA ' HG21 ' A' ' 63' ' ' VAL . 95.3 t -49.5 133.32 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.39 -0.819 . . . . 0.0 109.484 179.642 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.771 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -133.76 89.95 29.0 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 120.99 -1.069 . . . . 0.0 110.398 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -90.61 53.5 1.11 Allowed 'Trans proline' 0 C--N 1.311 -1.404 0 O-C-N 124.04 1.547 . . . . 0.0 110.584 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.1 t -125.68 -25.98 3.59 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.114 -0.991 . . . . 0.0 111.031 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -155.23 167.69 29.54 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.988 -1.07 . . . . 0.0 110.608 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 54.54 174.72 0.09 OUTLIER Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -94.71 110.16 22.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.058 -1.26 . . . . 0.0 110.206 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 74' ' ' ILE . 6.3 p -116.68 135.13 57.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 122.013 0.911 . . . . 0.0 110.286 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.83 HG11 ' HB ' ' A' ' 33' ' ' ILE . 9.9 m -113.0 121.23 64.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 O-C-N 121.242 -0.911 . . . . 0.0 108.877 179.2 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.753 HG22 HG13 ' A' ' 73' ' ' VAL . 15.1 t -97.82 120.04 46.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 O-C-N 120.788 -1.195 . . . . 0.0 111.257 -177.612 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.894 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.8 m -111.26 99.0 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 122.361 1.077 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.45 155.04 46.35 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 120.514 -1.366 . . . . 0.0 110.526 -178.775 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.53 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.87 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.222 -0.923 . . . . 0.0 110.663 -179.322 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.53 ' N ' HG23 ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.77 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.123 -0.986 . . . . 0.0 110.608 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.587 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -101.04 -33.92 9.96 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.039 179.362 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 5.3 tp -67.48 -42.27 83.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.597 -0.689 . . . . 0.0 109.341 178.805 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.481 ' HA ' ' HE2' ' A' ' 89' ' ' MET . 0.5 OUTLIER 49.74 23.41 0.99 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.55 -0.719 . . . . 0.0 110.462 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.93 HG23 ' HB ' ' A' ' 93' ' ' THR . 89.8 m 53.91 -85.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.445 -0.784 . . . . 0.0 110.719 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 65.11 -83.41 0.07 OUTLIER Glycine 0 N--CA 1.492 2.381 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.42 ' N ' ' O ' ' A' ' 90' ' ' THR . 29.6 p90 -97.87 37.85 1.36 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.371 -1.076 . . . . 0.0 108.587 178.144 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.93 ' HB ' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -137.75 -168.74 2.39 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.714 -0.617 . . . . 0.0 110.311 -179.284 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 133.01 -17.92 4.55 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.34 75.92 3.92 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -1.19 . . . . 0.0 110.643 -179.8 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.401 ' HZ ' HG21 ' A' ' 93' ' ' THR . 27.3 m-85 -113.43 150.89 32.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.172 -0.955 . . . . 0.0 109.81 179.489 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.502 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.2 -32.58 56.07 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.369 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.465 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.2 p -161.45 163.06 30.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.203 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.561 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.29 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.389 -0.819 . . . . 0.0 110.031 179.264 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.893 HG21 HD11 ' A' ' 28' ' ' ILE . 3.3 mp -93.44 112.82 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.264 -0.898 . . . . 0.0 108.584 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.424 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.93 161.35 20.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 111.52 -178.269 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.452 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 58.5 m -88.86 -13.32 39.51 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.15 10.63 1.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.295 -0.878 . . . . 0.0 112.073 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.507 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 0.9 OUTLIER -147.47 130.55 16.36 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 120.755 -1.216 . . . . 0.0 109.133 179.598 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.441 ' N ' ' O ' ' A' ' 108' ' ' LYS . 86.2 p -107.58 134.97 49.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.159 -0.963 . . . . 0.0 110.546 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.6 t0 55.95 32.85 20.6 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.304 -0.873 . . . . 0.0 110.959 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 79.4 12.44 83.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.529 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 104' ' ' THR . 0.1 OUTLIER -123.41 156.06 64.47 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.056 -1.261 . . . . 0.0 109.604 179.705 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -62.88 127.71 21.18 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.543 1.286 . . . . 0.0 110.726 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.472 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 -44.02 160.93 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 CA-C-O 121.366 0.603 . . . . 0.0 111.544 -179.212 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.523 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -87.47 160.78 18.15 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.466 -0.771 . . . . 0.0 110.359 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.445 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -42.02 -55.34 3.21 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.647 -0.658 . . . . 0.0 112.553 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.523 HG22 ' OD1' ' A' ' 111' ' ' ASP . 9.3 m -70.62 -29.64 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.705 -1.247 . . . . 0.0 111.838 -178.197 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.472 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.49 -56.28 7.37 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.129 -0.982 . . . . 0.0 110.553 -179.243 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.426 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.2 -35.08 77.43 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.465 -0.894 . . . . 0.0 108.786 178.905 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.834 HG23 HG13 ' A' ' 5' ' ' VAL . 99.6 m -59.14 -49.8 76.47 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.537 178.832 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.406 ' OE1' ' CE ' ' A' ' 89' ' ' MET . 7.7 tt0 -73.28 -36.04 66.24 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.494 -0.754 . . . . 0.0 109.98 179.022 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.414 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 8.8 mtt85 -71.9 -44.98 62.81 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.262 -0.899 . . . . 0.0 111.118 -179.494 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.527 ' CD ' ' CD2' ' A' ' 7' ' ' HIS . 0.8 OUTLIER -64.36 -36.62 84.71 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.984 -1.072 . . . . 0.0 110.318 -179.873 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.43 0.76 Allowed Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.443 ' HB3' HG11 ' A' ' 99' ' ' VAL . 0.0 OUTLIER -135.51 -43.02 0.69 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.411 -1.053 . . . . 0.0 109.206 179.489 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.729 HG23 HG12 ' A' ' 10' ' ' ILE . 14.8 t -102.32 141.77 34.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.561 -0.712 . . . . 0.0 109.632 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.451 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.16 10.81 14.8 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.502 -1.332 . . . . 0.0 110.15 179.761 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.11 84.71 1.82 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.956 -1.32 . . . . 0.0 109.876 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 96.33 16.13 38.66 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.468 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.89 0.22 Allowed Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.259 -1.142 . . . . 0.0 109.378 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.468 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.2 Cg_endo -88.06 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 O-C-N 123.349 1.183 . . . . 0.0 110.412 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -79.26 160.05 45.64 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.49 142.75 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.417 -1.049 . . . . 0.0 108.779 178.883 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.561 ' CD2' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -129.91 117.27 19.87 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 120.953 -1.092 . . . . 0.0 111.016 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.462 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 22.2 mtt180 -101.42 123.5 45.58 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.548 -0.72 . . . . 0.0 109.331 179.22 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.415 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.19 156.24 26.87 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.041 -1.037 . . . . 0.0 110.533 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.437 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 4.6 t -84.78 -67.44 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.171 -0.956 . . . . 0.0 109.392 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.429 ' N ' HG12 ' A' ' 133' ' ' VAL . . . 52.77 95.24 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.551 -0.718 . . . . 0.0 110.37 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.27 -35.0 7.18 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 O-C-N 123.644 1.339 . . . . 0.0 110.401 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 63.38 -170.03 17.25 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -62.08 121.98 14.4 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.287 -1.126 . . . . 0.0 110.258 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.281 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.454 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.28 133.05 43.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.215 -1.168 . . . . 0.0 110.3 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.604 HG23 ' O ' ' A' ' 3' ' ' VAL . 27.1 m -113.42 104.45 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.25 -0.906 . . . . 0.0 110.175 179.662 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.3 p -65.95 145.07 56.34 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.368 -0.832 . . . . 0.0 110.235 179.813 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.482 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.28 147.22 98.96 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.265 -0.897 . . . . 0.0 109.851 179.926 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.482 ' HD2' HG23 ' A' ' 5' ' ' VAL . 44.8 Cg_endo -71.73 -169.02 0.39 Allowed 'Trans proline' 0 C--N 1.307 -1.634 0 O-C-N 124.15 1.605 . . . . 0.0 111.066 179.248 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.507 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 13.4 p-80 -178.89 82.99 0.21 Allowed Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 179.464 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -65.79 89.64 0.23 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.756 1.398 . . . . 0.0 110.905 -179.17 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 0.3 OUTLIER -179.98 -35.62 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.554 0.692 . . . . 0.0 109.365 179.859 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.485 HD13 HG22 ' A' ' 122' ' ' THR . 14.6 mt -96.73 133.73 37.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.935 -1.103 . . . . 0.0 110.203 179.816 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -84.2 128.14 34.38 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.35 -0.844 . . . . 0.0 109.541 179.19 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -89.4 121.5 31.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.069 -1.02 . . . . 0.0 109.9 -179.573 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.783 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 4.8 t -115.69 156.63 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.368 -0.833 . . . . 0.0 110.222 -179.34 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.77 105.07 15.17 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.281 -0.887 . . . . 0.0 109.625 179.078 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.651 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -54.15 132.51 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.35 -0.844 . . . . 0.0 109.658 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.51 -174.7 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 110.256 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.94 63.43 3.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 110.041 179.835 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.501 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.0 m -132.07 112.08 12.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.337 -0.852 . . . . 0.0 110.244 -179.834 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.21 -163.41 26.72 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 119.158 -1.496 . . . . 0.0 110.455 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.39 -22.5 5.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.525 -0.985 . . . . 0.0 110.729 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.9 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -93.94 113.24 60.04 Favored Pre-proline 0 N--CA 1.487 1.417 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.064 -179.5 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.9 Cg_endo -64.23 150.76 87.68 Favored 'Trans proline' 0 C--N 1.313 -1.309 0 O-C-N 123.519 1.273 . . . . 0.0 110.026 -179.824 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.479 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.95 88.84 0.62 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.137 -0.977 . . . . 0.0 111.374 -178.477 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.514 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.14 67.18 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.349 -0.845 . . . . 0.0 111.26 179.146 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.03 13.75 21.29 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.708 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.36 156.16 45.17 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.063 -1.257 . . . . 0.0 109.366 179.738 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.501 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.47 106.97 15.57 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.918 -1.114 . . . . 0.0 109.279 179.74 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.898 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.47 114.11 21.83 Favored Pre-proline 0 C--N 1.3 -1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 110.384 -179.307 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.881 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.7 Cg_endo -70.67 129.98 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 N-CA-C 107.024 -1.952 . . . . 0.0 107.024 176.364 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.862 HD11 HD12 ' A' ' 58' ' ' LEU . 15.7 mt -56.62 -17.49 8.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.939 -1.101 . . . . 0.0 110.744 -177.942 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.477 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -60.86 -16.19 38.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.817 -1.177 . . . . 0.0 110.347 179.503 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.1 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -93.77 -25.35 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.003 -1.061 . . . . 0.0 111.15 -179.348 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.1 HG23 HG23 ' A' ' 32' ' ' VAL . 46.0 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 110.472 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.03 147.86 24.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.256 -0.902 . . . . 0.0 110.429 179.898 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.36 -5.63 38.49 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.95 -145.62 7.11 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.198 -1.477 . . . . 0.0 110.44 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.1 mtt85 -108.53 132.67 53.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.415 -1.05 . . . . 0.0 110.264 -179.696 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -140.71 150.56 43.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.023 -1.048 . . . . 0.0 111.031 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.591 HD12 ' O ' ' A' ' 82' ' ' VAL . 62.1 tp -110.98 114.29 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.447 -0.783 . . . . 0.0 109.947 179.565 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.919 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.2 mt -98.75 127.15 51.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.131 -0.981 . . . . 0.0 109.493 179.689 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.403 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 6.9 m-85 -95.44 124.01 39.26 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.172 -0.955 . . . . 0.0 110.143 -179.78 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.76 21.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.202 -0.936 . . . . 0.0 110.494 -179.688 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.514 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.2 p80 -107.02 -1.41 22.17 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.352 -0.843 . . . . 0.0 110.073 179.03 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.91 136.8 42.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.1 -1.0 . . . . 0.0 110.465 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.469 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.72 -38.27 70.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.466 -0.771 . . . . 0.0 110.663 -179.848 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.86 -35.6 73.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.333 -0.854 . . . . 0.0 110.453 -179.636 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.43 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.68 -35.83 65.24 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.79 -179.958 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.904 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 76.3 m -61.2 -34.01 74.4 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.415 -0.803 . . . . 0.0 109.757 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.7 -50.17 53.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 110.245 -179.841 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.32 -43.5 64.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.288 -0.882 . . . . 0.0 110.065 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.694 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -57.12 -42.51 81.03 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.602 -0.686 . . . . 0.0 111.248 -178.994 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.03 -51.09 42.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.796 -1.19 . . . . 0.0 110.013 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.24 -34.62 68.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.272 -0.893 . . . . 0.0 109.25 179.462 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.587 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.81 -46.39 84.74 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.274 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.9 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.78 -43.35 94.43 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.39 -0.819 . . . . 0.0 110.999 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.4 t -56.11 -34.14 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.966 -1.084 . . . . 0.0 109.375 179.617 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.51 -34.46 60.82 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.297 -0.877 . . . . 0.0 110.315 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.862 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.35 -25.84 62.56 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.285 -0.884 . . . . 0.0 109.699 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.2 7.86 8.18 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.633 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.622 ' CD1' HD22 ' A' ' 30' ' ' LEU . 47.0 mt -108.47 143.48 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.254 -1.145 . . . . 0.0 110.119 -179.756 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.504 ' OD1' HD11 ' A' ' 74' ' ' ILE . 1.0 OUTLIER -89.25 106.53 18.5 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.168 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.656 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.48 145.21 45.45 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.977 -1.089 . . . . 0.0 111.629 -177.244 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.893 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.95 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.066 -0.653 . . . . 0.0 109.454 179.719 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.904 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.2 122.52 47.09 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.585 178.818 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.475 ' CD1' HD12 ' A' ' 69' ' ' LEU . 0.4 OUTLIER -109.52 131.35 55.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.262 -0.899 . . . . 0.0 110.809 -179.534 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.907 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.24 178.32 5.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.563 -0.711 . . . . 0.0 109.905 179.644 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.55 125.52 20.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.045 -1.035 . . . . 0.0 110.814 -179.366 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.83 40.93 13.44 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.743 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.907 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.38 157.02 26.89 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -1.14 . . . . 0.0 110.322 -179.831 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.884 ' N ' HD13 ' A' ' 69' ' ' LEU . 21.8 m-20 -98.48 149.33 22.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.281 -0.887 . . . . 0.0 110.571 -179.378 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.5 m -62.33 111.36 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.036 . . . . 0.0 109.311 179.123 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.72 ' O ' HG23 ' A' ' 74' ' ' ILE . 43.8 m -134.31 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.52 -0.737 . . . . 0.0 110.368 -179.415 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.909 HG13 HG22 ' A' ' 82' ' ' VAL . 76.9 t -46.47 131.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.489 -0.757 . . . . 0.0 110.685 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.721 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.3 pp -137.75 91.61 13.55 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.166 -0.958 . . . . 0.0 110.659 179.408 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.487 ' HA ' HG11 ' A' ' 80' ' ' VAL . 49.7 Cg_endo -89.32 44.9 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.608 1.32 . . . . 0.0 109.947 178.947 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -124.38 -21.94 4.81 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.285 -0.884 . . . . 0.0 111.255 -179.097 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.6 m-20 -139.8 150.12 44.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.941 -1.099 . . . . 0.0 110.855 -179.385 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 51.79 -177.78 0.08 OUTLIER Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.66 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -94.55 112.31 24.07 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.342 -1.093 . . . . 0.0 109.954 179.848 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.721 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -116.39 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-O 121.899 0.857 . . . . 0.0 110.199 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.613 HG22 HG22 ' A' ' 60' ' ' ILE . 10.1 m -111.91 123.35 67.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.159 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.909 HG22 HG13 ' A' ' 73' ' ' VAL . 33.2 t -96.62 118.11 42.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.061 -1.025 . . . . 0.0 110.612 -178.062 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.919 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.2 m -111.75 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 118.93 -1.108 . . . . 0.0 108.756 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.434 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -131.44 156.46 45.58 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 120.69 -1.256 . . . . 0.0 110.339 -178.606 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.551 HG23 ' OD2' ' A' ' 86' ' ' ASP . 9.0 t -94.07 -30.46 14.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.367 -0.833 . . . . 0.0 111.471 -178.583 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.551 ' OD2' HG23 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.56 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.931 -1.106 . . . . 0.0 111.529 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.616 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.79 -39.95 12.76 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.958 -1.089 . . . . 0.0 110.163 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.9 tp -64.59 -40.34 95.35 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.213 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.475 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 45.09 26.79 0.25 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.864 -0.523 . . . . 0.0 111.219 179.378 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.595 HG21 ' NE ' ' A' ' 121' ' ' ARG . 63.8 p 43.41 -133.45 0.56 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.551 -0.718 . . . . 0.0 110.988 179.616 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.87 -78.07 0.79 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.675 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -95.52 18.34 12.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.275 -1.133 . . . . 0.0 109.812 179.27 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.496 HG23 ' N ' ' A' ' 94' ' ' GLY . 13.3 t -98.88 -148.55 0.34 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.363 -0.836 . . . . 0.0 110.199 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.496 ' N ' HG23 ' A' ' 93' ' ' THR . . . 115.12 18.57 6.25 Favored Glycine 0 N--CA 1.491 2.3 0 C-N-CA 119.835 -1.174 . . . . 0.0 110.171 179.462 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -125.32 59.62 1.25 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.945 -1.326 . . . . 0.0 110.344 179.761 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.48 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 25.2 m-85 -120.22 135.55 54.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.04 -1.037 . . . . 0.0 110.381 179.868 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.508 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.14 -27.75 57.15 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.556 179.22 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.514 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.0 p -160.38 163.0 33.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.29 -0.881 . . . . 0.0 110.54 179.501 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.415 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.82 115.9 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.228 -0.92 . . . . 0.0 110.336 179.66 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.823 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -93.44 114.63 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.6 161.31 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.09 -1.006 . . . . 0.0 111.829 -178.151 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.26 9.09 38.28 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.946 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.421 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 52.35 23.18 2.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.194 -0.941 . . . . 0.0 110.97 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.649 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -144.25 137.94 27.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 110.657 179.584 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.403 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.7 p -111.09 121.91 46.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.369 -0.832 . . . . 0.0 109.495 179.622 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 55.06 -141.61 0.85 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.096 -1.003 . . . . 0.0 109.426 -179.344 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.25 9.6 57.19 Favored Glycine 0 N--CA 1.49 2.288 0 C-N-CA 119.813 -1.185 . . . . 0.0 110.234 179.776 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.403 ' O ' ' N ' ' A' ' 105' ' ' SER . 11.3 mmtt -126.16 155.47 73.62 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 120.857 -1.378 . . . . 0.0 109.868 -179.929 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.649 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.9 Cg_endo -67.48 160.7 46.68 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 O-C-N 123.505 1.266 . . . . 0.0 110.519 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.468 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER -68.12 147.6 52.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.356 -0.84 . . . . 0.0 110.722 -179.473 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.414 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -84.96 161.0 19.96 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.154 -0.966 . . . . 0.0 110.085 179.605 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.417 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.26 -57.45 2.98 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.517 -0.74 . . . . 0.0 112.433 -178.531 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.474 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.2 m -68.6 -29.39 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 120.688 -1.257 . . . . 0.0 111.847 -178.143 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.468 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.21 -56.23 7.07 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.039 -1.038 . . . . 0.0 110.545 -179.263 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.476 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.7 ptm180 -70.43 -35.15 73.22 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.377 -0.929 . . . . 0.0 108.873 179.073 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.474 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.9 m -58.98 -49.55 77.47 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.04 -1.037 . . . . 0.0 108.371 178.637 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.78 -35.85 64.98 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.394 -0.816 . . . . 0.0 109.863 178.704 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.476 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.69 -44.54 64.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.08 -1.013 . . . . 0.0 110.934 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.507 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 17.2 ttm180 -53.12 -41.82 65.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.896 -1.127 . . . . 0.0 109.713 179.587 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.37 63.28 0.26 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.595 ' NE ' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -132.57 -42.71 0.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.449 -1.03 . . . . 0.0 108.658 179.152 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.486 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.9 t -98.17 144.05 28.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.653 -0.654 . . . . 0.0 109.576 179.148 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.24 9.25 36.85 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.692 -1.242 . . . . 0.0 110.32 179.35 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.447 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 2.9 mmt180 -66.29 87.5 0.11 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.99 -1.3 . . . . 0.0 109.52 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.74 23.27 28.65 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -178.772 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.478 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.43 -179.81 0.3 Allowed Pre-proline 0 N--CA 1.492 1.646 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.7 Cg_endo -88.93 105.97 0.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.09 1.047 . . . . 0.0 110.882 -179.939 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.486 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.64 179.47 53.47 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.51 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.468 -1.019 . . . . 0.0 108.951 179.033 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.447 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 11.7 t80 -129.71 115.83 17.9 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.897 -1.121 . . . . 0.0 111.063 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.783 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 1.7 mtt180 -100.58 134.33 43.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.515 -0.74 . . . . 0.0 109.029 179.366 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.4 p90 -126.28 156.73 39.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.931 -1.105 . . . . 0.0 110.582 -179.456 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.651 HG22 HD23 ' A' ' 15' ' ' LEU . 55.9 t -94.28 -46.02 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.287 -0.883 . . . . 0.0 109.9 179.561 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.42 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -119.79 103.77 45.45 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.207 -0.933 . . . . 0.0 110.279 -179.79 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.39 -21.37 22.97 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 O-C-N 123.542 1.285 . . . . 0.0 110.711 -179.733 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -117.45 140.54 15.81 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 -179.966 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -69.56 -29.33 66.88 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.267 -1.137 . . . . 0.0 110.282 179.931 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.231 179.878 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.37 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.8 108.09 4.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -1.131 . . . . 0.0 110.259 -179.984 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.666 HG23 ' O ' ' A' ' 3' ' ' VAL . 31.3 m -113.37 105.22 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.973 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.7 p -63.22 144.89 56.54 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.328 -0.858 . . . . 0.0 110.32 -179.846 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.462 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -70.39 147.23 94.98 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.3 -0.875 . . . . 0.0 110.248 -179.885 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD2' HG23 ' A' ' 5' ' ' VAL . 52.1 Cg_endo -76.4 -173.61 1.78 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 124.203 1.633 . . . . 0.0 110.962 179.609 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 3.9 p80 -177.97 83.66 0.23 Allowed Pre-proline 0 N--CA 1.489 1.499 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.325 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.85 58.54 1.61 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 O-C-N 123.446 1.235 . . . . 0.0 111.6 -178.989 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -148.59 7.98 0.77 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.095 -1.003 . . . . 0.0 111.18 179.475 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.711 HD11 ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.08 137.39 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.832 -1.168 . . . . 0.0 110.62 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.6 128.43 34.51 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 108.866 178.312 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -89.53 142.68 27.45 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.055 -1.028 . . . . 0.0 110.62 -179.007 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.45 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.2 t -137.73 158.02 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.418 -0.802 . . . . 0.0 110.434 -179.694 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.88 109.41 17.58 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.442 -0.786 . . . . 0.0 109.56 179.104 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.732 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.1 tp -53.5 136.85 37.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.279 -0.888 . . . . 0.0 109.964 -179.878 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.1 p -137.38 174.49 10.54 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 110.285 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.8 p -71.63 80.09 0.82 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.196 -0.94 . . . . 0.0 110.067 179.856 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.826 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.8 m -155.53 109.05 2.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.176 -0.953 . . . . 0.0 110.799 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.416 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.33 -170.22 29.6 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.833 -1.651 . . . . 0.0 110.942 179.136 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.22 -20.39 12.34 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.755 -0.85 . . . . 0.0 110.417 -179.792 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -98.85 103.88 21.95 Favored Pre-proline 0 N--CA 1.491 1.592 0 C-N-CA 118.906 -1.118 . . . . 0.0 109.86 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -62.63 124.96 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.32 1.168 . . . . 0.0 110.84 -179.369 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.426 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.49 -166.85 1.13 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.737 -0.602 . . . . 0.0 110.433 -179.239 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.527 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.17 81.77 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.465 -0.772 . . . . 0.0 111.514 -179.451 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.1 2.25 52.27 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.607 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.732 ' HB2' HD23 ' A' ' 15' ' ' LEU . 15.1 mmtp -130.18 156.3 44.81 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.973 -1.31 . . . . 0.0 109.355 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.826 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.69 107.43 18.44 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.961 -1.087 . . . . 0.0 109.078 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 1.007 HD11 HG21 ' A' ' 100' ' ' ILE . 5.2 mt -69.33 112.92 13.42 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.312 -0.867 . . . . 0.0 110.521 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.745 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.1 Cg_endo -68.54 129.62 19.28 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 N-CA-C 107.161 -1.9 . . . . 0.0 107.161 176.282 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.746 HD22 ' CD1' ' A' ' 60' ' ' ILE . 10.9 mt -56.27 -17.78 8.61 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.83 -1.169 . . . . 0.0 110.69 -177.803 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -59.88 -16.05 26.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.677 -1.265 . . . . 0.0 110.575 179.898 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.131 HG23 HG23 ' A' ' 33' ' ' ILE . 10.6 m -93.99 -25.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.982 -1.074 . . . . 0.0 110.775 -179.727 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.131 HG23 HG23 ' A' ' 32' ' ' VAL . 12.3 pt -114.62 -23.27 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.094 -1.004 . . . . 0.0 110.57 -179.508 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.578 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptm -93.81 147.96 22.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.803 -1.185 . . . . 0.0 110.2 179.381 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.77 -3.42 52.85 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.799 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.64 -150.63 8.64 Favored Glycine 0 N--CA 1.494 2.533 0 C-N-CA 118.927 -1.606 . . . . 0.0 110.626 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.451 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.42 129.41 55.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.435 -1.038 . . . . 0.0 109.968 -179.793 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.536 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.1 m-70 -137.8 149.42 46.35 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.982 -1.074 . . . . 0.0 110.963 -179.635 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.656 HD23 ' HG2' ' A' ' 121' ' ' ARG . 34.1 tp -110.82 117.27 32.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.419 -0.8 . . . . 0.0 110.21 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.943 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.1 mm -97.92 125.42 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.293 -0.88 . . . . 0.0 109.471 179.792 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.429 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.67 123.38 42.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.093 -1.004 . . . . 0.0 109.882 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.21 159.39 22.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.545 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.527 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.56 23.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.161 179.373 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.35 141.12 51.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.11 -0.994 . . . . 0.0 110.382 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.445 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.63 -31.82 67.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.478 -0.764 . . . . 0.0 110.58 -179.762 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.47 75.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.183 -0.948 . . . . 0.0 110.54 -179.861 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.434 ' HE2' ' CE1' ' A' ' 24' ' ' TYR . 0.2 OUTLIER -73.83 -34.26 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.873 . . . . 0.0 109.622 179.803 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.707 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 62.7 m -60.52 -35.05 75.04 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.398 -0.814 . . . . 0.0 109.177 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.56 -49.06 65.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 110.304 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.437 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.56 -43.16 66.84 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.165 -0.959 . . . . 0.0 110.778 -179.615 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 1.028 HD12 HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.46 73.92 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.248 -0.907 . . . . 0.0 110.909 -179.057 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.462 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.74 -51.37 12.83 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.974 -1.079 . . . . 0.0 110.281 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.43 99.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.025 -1.047 . . . . 0.0 109.696 179.636 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.568 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.42 -47.41 81.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.422 -0.799 . . . . 0.0 109.468 179.649 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.78 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.89 -43.02 76.83 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.604 -0.685 . . . . 0.0 110.365 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.38 -34.6 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.084 -1.01 . . . . 0.0 109.217 179.614 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.0 59.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.316 -0.865 . . . . 0.0 109.74 179.271 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.568 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.7 mm? -71.52 -26.36 62.63 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-O 121.924 0.869 . . . . 0.0 109.575 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.15 6.3 10.03 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.235 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.746 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.8 mt -108.1 143.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.293 -1.122 . . . . 0.0 110.104 -179.776 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 2.4 t-20 -87.89 106.56 18.19 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 177.953 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.644 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.33 144.26 46.0 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.086 -1.045 . . . . 0.0 111.397 -177.288 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.878 HG21 ' HA ' ' A' ' 73' ' ' VAL . 2.5 t -131.03 142.63 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.807 179.551 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.707 ' HB2' ' O ' ' A' ' 48' ' ' CYS . . . -105.84 118.33 36.31 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.81 178.984 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.7 OUTLIER -105.27 118.43 36.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.857 . . . . 0.0 110.706 -179.43 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.909 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -149.69 -179.88 7.46 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 179.32 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.66 129.37 40.79 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.069 -1.019 . . . . 0.0 110.687 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.96 23.68 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.909 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.22 154.71 30.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.321 -1.105 . . . . 0.0 110.014 -179.765 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.844 ' N ' HD13 ' A' ' 69' ' ' LEU . 23.9 m-20 -94.9 149.78 20.89 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.338 -0.851 . . . . 0.0 110.39 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.674 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 118.934 -1.107 . . . . 0.0 108.99 179.338 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.509 ' O ' HG23 ' A' ' 74' ' ' ILE . 36.7 m -133.09 -33.51 1.14 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.485 -0.759 . . . . 0.0 110.708 -179.234 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.878 ' HA ' HG21 ' A' ' 63' ' ' VAL . 89.6 t -56.49 134.67 20.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.154 -0.966 . . . . 0.0 109.782 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.577 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -137.61 93.61 12.37 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.194 -0.941 . . . . 0.0 110.696 179.873 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -79.63 60.95 8.03 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.784 1.412 . . . . 0.0 110.236 179.436 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.0 t -162.75 40.25 0.11 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.039 -1.038 . . . . 0.0 110.52 -179.743 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -141.53 -163.48 1.57 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.204 -0.935 . . . . 0.0 109.82 179.891 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.37 -73.93 0.31 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -152.26 111.75 3.93 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.156 -1.202 . . . . 0.0 110.313 179.654 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.526 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.6 134.22 61.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 122.052 0.929 . . . . 0.0 110.351 179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.626 HG22 HG22 ' A' ' 60' ' ' ILE . 8.0 m -113.16 124.55 69.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.249 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.009 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.758 HG22 HG13 ' A' ' 73' ' ' VAL . 8.8 t -97.7 118.78 44.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.019 -1.051 . . . . 0.0 110.778 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.028 HG11 HD12 ' A' ' 51' ' ' LEU . 4.1 m -111.87 98.54 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 120.78 -1.2 . . . . 0.0 108.81 179.135 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.92 29.24 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.626 -1.296 . . . . 0.0 110.077 -178.813 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -103.36 -24.73 13.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 111.296 -178.544 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.425 ' O ' ' N ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 179.92 -29.37 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.996 -1.065 . . . . 0.0 111.059 -179.943 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.95 -38.98 24.58 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.013 -1.055 . . . . 0.0 110.278 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.9 tp -63.6 -29.85 71.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.135 -0.978 . . . . 0.0 108.705 178.552 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.502 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 44.19 27.31 0.2 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.754 -0.591 . . . . 0.0 111.426 179.578 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.541 HG21 ' HD3' ' A' ' 121' ' ' ARG . 60.8 p 42.06 52.59 4.35 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.785 -0.572 . . . . 0.0 111.423 179.304 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.53 -66.44 2.29 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -179.834 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -110.15 22.96 14.94 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.246 -1.149 . . . . 0.0 110.269 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.535 HG21 ' CB ' ' A' ' 90' ' ' THR . 14.6 t -78.81 -148.42 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.344 -0.847 . . . . 0.0 110.143 179.974 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.428 ' N ' HG23 ' A' ' 93' ' ' THR . . . 103.54 -43.14 1.73 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.344 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -86.75 66.63 9.54 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.914 -1.345 . . . . 0.0 110.838 -179.354 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.503 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.2 m-85 -119.7 150.67 39.98 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.953 -1.092 . . . . 0.0 110.265 179.284 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.458 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.6 m-20 -76.86 -31.92 57.15 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.459 -0.776 . . . . 0.0 109.898 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.61 163.97 26.92 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.256 -0.977 . . . . 0.0 111.788 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.698 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.98 113.77 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.504 -0.748 . . . . 0.0 110.069 179.064 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 1.007 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -92.74 116.16 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.093 -1.004 . . . . 0.0 108.387 178.863 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.05 31.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.083 -1.011 . . . . 0.0 112.039 -177.895 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.479 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.5 t -95.77 -1.04 50.56 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 177.84 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.549 ' ND2' ' HB2' ' A' ' 132' ' ' PHE . 1.4 m-80 54.89 20.92 3.34 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -0.974 . . . . 0.0 111.168 179.737 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.425 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -143.17 140.54 30.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.974 -1.079 . . . . 0.0 110.659 179.669 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.406 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.5 p -114.32 127.72 56.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.319 -0.863 . . . . 0.0 109.918 179.561 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.0 t0 51.42 30.12 5.9 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.274 -0.891 . . . . 0.0 110.552 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.12 -33.0 5.5 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.406 ' O ' ' N ' ' A' ' 105' ' ' SER . 7.3 mtmt -76.66 156.53 82.88 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.277 -1.131 . . . . 0.0 109.998 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.425 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.4 Cg_endo -65.7 133.27 33.51 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.657 1.346 . . . . 0.0 110.339 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 -47.94 167.02 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.426 -0.796 . . . . 0.0 110.942 -179.301 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.513 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -98.1 160.81 14.06 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.43 -0.794 . . . . 0.0 110.141 179.741 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.51 -50.67 7.06 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.522 -0.736 . . . . 0.0 112.298 -178.681 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.513 HG22 ' OD1' ' A' ' 111' ' ' ASP . 16.2 m -71.25 -29.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 120.699 -1.251 . . . . 0.0 111.446 -178.564 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.418 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.32 -56.01 7.67 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.059 -1.026 . . . . 0.0 110.449 -179.375 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.469 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.17 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.401 -0.92 . . . . 0.0 108.888 178.683 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.468 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.495 -0.882 . . . . 0.0 108.698 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.42 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.27 66.42 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.608 -0.683 . . . . 0.0 109.528 178.984 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.469 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 21.3 mtt85 -68.42 -44.97 73.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.164 -0.96 . . . . 0.0 110.499 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.491 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -59.94 -46.45 89.36 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.23 -0.919 . . . . 0.0 110.332 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.0 -26.37 1.2 Allowed Glycine 0 N--CA 1.499 2.85 0 O-C-N 121.474 -0.766 . . . . 0.0 111.396 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.656 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -48.83 -55.39 11.76 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.882 -1.363 . . . . 0.0 110.858 -179.394 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.711 ' O ' HD11 ' A' ' 10' ' ' ILE . 1.3 t -91.62 142.59 27.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.66 12.54 16.4 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.303 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 6.2 mtt180 -102.47 76.56 1.55 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.953 -1.322 . . . . 0.0 109.951 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.671 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.44 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -145.14 167.11 15.38 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.58 -0.953 . . . . 0.0 108.79 179.779 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.95 111.98 1.71 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.202 1.106 . . . . 0.0 109.637 179.582 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.493 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -87.24 166.16 36.44 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -178.854 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 98' ' ' SER . 2.7 mt -124.3 141.79 43.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.514 -0.992 . . . . 0.0 108.54 178.946 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.698 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.59 115.44 19.5 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.927 179.827 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.45 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.35 121.82 45.34 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.536 -0.728 . . . . 0.0 109.183 179.276 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.549 ' HB2' ' ND2' ' A' ' 103' ' ' ASN . 24.5 p90 -119.52 157.75 27.69 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -0.987 . . . . 0.0 109.991 -179.694 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.7 t -85.92 -42.47 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.189 -0.944 . . . . 0.0 110.005 179.751 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.71 155.1 55.01 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.168 -0.957 . . . . 0.0 110.503 -179.714 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -77.06 -57.32 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.369 0 O-C-N 123.713 1.375 . . . . 0.0 110.542 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 162.64 74.41 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.913 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -78.55 81.35 4.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.221 -1.164 . . . . 0.0 110.306 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 51.8 ttt180 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.274 -179.988 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 39.2 m -87.96 150.69 23.3 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.237 -1.155 . . . . 0.0 110.339 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 3' ' ' VAL . 17.3 m -113.2 104.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 109.831 179.57 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.454 HG23 ' HB1' ' A' ' 112' ' ' ALA . 16.8 p -68.87 138.5 54.76 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.341 -0.85 . . . . 0.0 110.343 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.442 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.17 147.81 98.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.498 179.69 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.442 ' HD2' HG23 ' A' ' 5' ' ' VAL . 45.7 Cg_endo -71.5 -169.3 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 124.082 1.569 . . . . 0.0 111.083 179.793 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.518 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.43 77.62 0.04 OUTLIER Pre-proline 0 N--CA 1.498 1.948 0 O-C-N 121.564 -0.71 . . . . 0.0 109.682 -179.901 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -70.47 -10.64 28.42 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 O-C-N 123.695 1.366 . . . . 0.0 111.178 -179.437 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.4 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 41.6 m-80 -74.91 -11.3 60.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.934 -1.104 . . . . 0.0 110.449 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.659 HG12 HG23 ' A' ' 122' ' ' THR . 1.9 mt -112.8 135.49 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.03 -1.044 . . . . 0.0 109.811 179.898 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.94 125.14 33.13 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.256 -0.902 . . . . 0.0 108.741 178.311 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -89.33 129.53 35.85 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.031 -1.043 . . . . 0.0 110.276 -179.245 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.625 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 12.0 t -125.35 157.88 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.472 -0.767 . . . . 0.0 110.42 -179.193 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.46 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.46 114.15 27.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.292 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.677 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -52.21 143.87 13.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.231 -0.918 . . . . 0.0 109.878 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.8 p -142.06 -178.2 5.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.196 -0.94 . . . . 0.0 110.226 -179.663 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.4 p -80.33 59.16 3.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.302 -0.873 . . . . 0.0 110.097 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.454 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 23.8 m -132.75 109.22 9.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.436 -0.79 . . . . 0.0 110.597 -179.829 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.414 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.35 -171.63 28.73 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 118.81 -1.662 . . . . 0.0 111.139 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.7 -22.82 10.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.703 -0.88 . . . . 0.0 110.473 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.893 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.8 tt -93.48 109.5 41.01 Favored Pre-proline 0 N--CA 1.49 1.538 0 C-N-CA 118.749 -1.18 . . . . 0.0 109.226 -179.923 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.14 145.54 93.73 Favored 'Trans proline' 0 C--N 1.312 -1.354 0 O-C-N 123.423 1.223 . . . . 0.0 111.491 -178.284 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.438 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.83 -165.12 1.68 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.624 -0.673 . . . . 0.0 110.403 -179.311 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.714 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 38.3 m-85 -60.65 79.76 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.507 -0.745 . . . . 0.0 110.688 -179.879 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.99 57.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.485 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.677 ' HB2' HD23 ' A' ' 15' ' ' LEU . 1.3 mmtp -130.19 156.08 45.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.027 -1.278 . . . . 0.0 109.547 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.454 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.08 106.91 16.11 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.989 -1.069 . . . . 0.0 109.054 179.38 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.893 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.32 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 110.819 -179.173 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.799 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.4 Cg_endo -70.31 130.57 18.88 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 N-CA-C 106.668 -2.089 . . . . 0.0 106.668 175.869 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.736 HD11 HD12 ' A' ' 58' ' ' LEU . 14.3 mt -55.99 -17.98 8.16 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.809 -1.182 . . . . 0.0 110.581 -177.784 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -59.35 -16.49 22.85 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.525 -1.359 . . . . 0.0 110.515 179.729 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.02 HG23 HG23 ' A' ' 33' ' ' ILE . 13.4 m -92.73 -24.33 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.002 -1.061 . . . . 0.0 111.038 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.02 HG23 HG23 ' A' ' 32' ' ' VAL . 37.9 pt -117.45 -26.28 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.921 -1.112 . . . . 0.0 110.358 -179.413 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.621 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -90.32 148.79 22.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.057 -1.027 . . . . 0.0 110.058 179.057 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.457 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.81 -4.86 25.92 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.577 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.5 -130.95 2.18 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 119.214 -1.469 . . . . 0.0 110.268 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.2 mtt-85 -115.59 131.0 57.07 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.33 -1.1 . . . . 0.0 110.234 -179.69 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.57 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 74.4 m-70 -140.83 146.4 37.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.111 -0.993 . . . . 0.0 110.879 -179.762 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.517 HD22 ' HG2' ' A' ' 121' ' ' ARG . 20.4 tp -106.79 127.59 53.53 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.534 -0.729 . . . . 0.0 109.942 179.593 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.916 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.1 mt -109.76 128.22 66.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.515 179.388 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -95.09 124.11 38.95 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 109.99 -179.754 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.56 159.9 21.44 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.347 -0.845 . . . . 0.0 110.739 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.714 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -106.81 3.1 26.07 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.492 -0.755 . . . . 0.0 110.206 179.26 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.0 p -136.7 136.74 39.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.957 -1.089 . . . . 0.0 110.834 -179.661 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.483 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.91 -36.98 70.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.551 -0.718 . . . . 0.0 110.628 179.907 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.29 -33.67 76.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.416 -179.738 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.54 -35.51 65.53 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.51 -0.744 . . . . 0.0 109.712 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.784 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 93.1 m -61.11 -36.06 78.68 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.357 -0.839 . . . . 0.0 109.418 179.498 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.54 -49.95 60.92 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.197 -0.939 . . . . 0.0 110.519 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.407 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.4 mm-40 -72.22 -44.81 62.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.209 -0.932 . . . . 0.0 110.267 179.828 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.634 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -56.79 -43.57 81.04 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.661 . . . . 0.0 111.154 -179.12 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.455 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -67.72 -51.16 52.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.872 -1.142 . . . . 0.0 109.821 179.894 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -35.5 69.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.195 -0.941 . . . . 0.0 109.27 179.323 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.668 ' HD3' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.765 . . . . 0.0 108.978 179.235 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.867 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.15 -41.95 84.86 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 110.794 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.5 t -56.15 -32.87 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.07 -1.019 . . . . 0.0 109.156 179.664 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.38 60.15 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.392 -0.818 . . . . 0.0 110.491 179.68 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.736 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.31 -25.44 62.42 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.146 -0.971 . . . . 0.0 109.918 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.78 4.61 9.51 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.329 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.668 ' CD1' HD22 ' A' ' 30' ' ' LEU . 44.7 mt -105.71 143.37 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 121.376 -1.073 . . . . 0.0 109.845 -179.729 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.486 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.9 t-20 -88.58 106.99 18.67 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 178.173 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.572 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.57 146.31 44.69 Favored 'General case' 0 C--N 1.294 -1.812 0 C-N-CA 118.706 -1.197 . . . . 0.0 111.728 -177.084 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.928 HG21 ' HA ' ' A' ' 73' ' ' VAL . 89.8 t -128.2 149.75 33.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.784 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.29 117.74 30.83 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.549 178.412 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.5 142.36 45.16 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.337 -0.852 . . . . 0.0 110.354 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.886 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.9 p90 -175.32 -177.27 1.01 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.399 -0.813 . . . . 0.0 110.034 179.888 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.52 119.8 5.76 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.176 -0.952 . . . . 0.0 111.234 -179.232 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 40.97 11.8 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.13 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.886 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -117.59 155.37 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.052 -1.264 . . . . 0.0 110.223 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.813 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -93.56 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.282 -0.886 . . . . 0.0 110.416 -179.541 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.656 HG23 ' O ' ' A' ' 71' ' ' VAL . 28.2 m -62.55 110.61 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.411 179.384 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.59 -20.95 2.27 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.536 -0.728 . . . . 0.0 111.046 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.928 ' HA ' HG21 ' A' ' 63' ' ' VAL . 54.5 t -63.99 128.15 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.022 -1.049 . . . . 0.0 109.53 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.703 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.4 pp -136.33 98.31 11.39 Favored Pre-proline 0 N--CA 1.495 1.777 0 O-C-N 121.028 -1.045 . . . . 0.0 110.926 -179.647 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.682 ' HA ' HG11 ' A' ' 80' ' ' VAL . 50.7 Cg_endo -78.93 53.27 4.61 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.328 1.173 . . . . 0.0 110.207 179.238 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.625 HG23 ' O ' ' A' ' 75' ' ' PRO . 5.6 p -157.21 40.05 0.31 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.24 -0.913 . . . . 0.0 110.385 -179.471 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -145.21 31.67 1.11 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.171 -0.956 . . . . 0.0 110.343 -179.888 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 108.52 -116.2 4.64 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.812 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -115.86 109.48 17.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -1.144 . . . . 0.0 110.146 179.841 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.682 HG11 ' HA ' ' A' ' 75' ' ' PRO . 6.8 p -116.65 135.38 57.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-O 122.006 0.908 . . . . 0.0 110.721 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 60' ' ' ILE . 9.6 m -113.2 122.81 68.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.611 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.702 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -97.29 118.81 44.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 120.833 -1.167 . . . . 0.0 110.5 -178.118 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.916 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.5 m -109.8 100.64 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.018 -1.051 . . . . 0.0 108.947 179.699 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.21 163.83 31.9 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.602 -1.311 . . . . 0.0 111.38 -177.859 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.494 HG23 ' N ' ' A' ' 86' ' ' ASP . 11.2 t -91.38 -140.76 0.17 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.423 -0.798 . . . . 0.0 109.332 179.757 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.494 ' N ' HG23 ' A' ' 85' ' ' THR . 3.8 p30 -84.43 52.12 2.28 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.806 -1.184 . . . . 0.0 110.248 179.633 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.471 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.43 -19.58 6.36 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.202 -0.936 . . . . 0.0 110.936 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -62.43 -26.97 68.78 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.012 -1.055 . . . . 0.0 109.548 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.545 ' C ' HG22 ' A' ' 90' ' ' THR . 27.4 mmt 47.25 30.82 1.55 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.372 -0.83 . . . . 0.0 110.731 179.61 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.759 ' OG1' HG22 ' A' ' 93' ' ' THR . 5.5 t 35.11 -134.98 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 178.889 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 93.1 -49.61 2.46 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 107.99 -2.044 . . . . 0.0 107.99 -178.786 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -125.27 21.01 8.05 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.632 -0.922 . . . . 0.0 109.374 179.001 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.759 HG22 ' OG1' ' A' ' 90' ' ' THR . 4.9 t -102.82 -155.49 0.53 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.326 -0.859 . . . . 0.0 110.343 -179.702 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.527 ' N ' HG23 ' A' ' 93' ' ' THR . . . 92.39 -33.94 4.7 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.467 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -84.26 59.04 5.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.939 -1.33 . . . . 0.0 110.392 -179.588 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -119.45 153.1 35.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.205 -0.934 . . . . 0.0 110.167 179.433 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.86 -29.24 25.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.396 -0.815 . . . . 0.0 109.513 179.393 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.4 p -161.88 163.7 29.07 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.244 -0.91 . . . . 0.0 111.161 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.492 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.53 125.85 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.389 -0.819 . . . . 0.0 110.094 179.24 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.742 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -102.86 112.15 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.231 -0.918 . . . . 0.0 109.003 179.265 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.417 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.0 t0 -118.09 162.01 18.91 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.184 -0.948 . . . . 0.0 111.869 -178.485 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.523 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.26 9.38 38.13 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.75 -0.594 . . . . 0.0 109.744 178.556 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.523 ' ND2' ' HB2' ' A' ' 132' ' ' PHE . 1.0 OUTLIER 46.58 25.16 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.091 -1.006 . . . . 0.0 111.481 179.933 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -147.04 136.43 22.73 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 110.454 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.42 ' N ' ' O ' ' A' ' 108' ' ' LYS . 60.2 p -113.13 126.66 55.69 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.367 -0.833 . . . . 0.0 110.122 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 52.76 35.63 19.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.279 -0.888 . . . . 0.0 110.762 179.951 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 84.26 -6.02 77.89 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.004 -1.093 . . . . 0.0 110.429 179.573 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.42 ' O ' ' N ' ' A' ' 105' ' ' SER . 72.1 mmtt -100.4 156.35 35.33 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.0 -1.294 . . . . 0.0 110.076 -179.77 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -65.49 129.2 21.91 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 O-C-N 123.74 1.389 . . . . 0.0 110.497 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -51.12 152.85 2.14 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.554 -0.716 . . . . 0.0 110.892 -179.5 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.532 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.5 p30 -93.21 161.09 14.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.384 -0.822 . . . . 0.0 109.719 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.454 ' HB1' HG23 ' A' ' 4' ' ' THR . . . -43.13 -51.75 5.78 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.375 -0.828 . . . . 0.0 112.316 -178.629 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.532 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.6 m -69.74 -29.15 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.76 -1.213 . . . . 0.0 111.382 -178.81 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.47 -56.13 7.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.122 -0.986 . . . . 0.0 110.522 -179.091 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.419 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.3 OUTLIER -68.08 -34.86 77.22 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.066 -1.021 . . . . 0.0 108.658 178.927 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.462 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.95 -49.91 75.83 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.14 -0.975 . . . . 0.0 108.427 178.623 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.8 -36.85 65.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.584 -0.697 . . . . 0.0 109.888 179.078 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.419 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 13.6 mtt180 -71.23 -44.61 65.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.163 -0.96 . . . . 0.0 110.502 -179.727 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.518 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.5 OUTLIER -58.6 -42.19 87.55 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.109 -0.994 . . . . 0.0 109.903 179.734 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.97 89.41 0.02 OUTLIER Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.517 ' HG2' HD22 ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.66 -44.06 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.55 -0.971 . . . . 0.0 108.616 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.659 HG23 HG12 ' A' ' 10' ' ' ILE . 14.6 t -102.07 132.54 47.88 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 178.663 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.44 8.18 3.67 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.015 -1.564 . . . . 0.0 110.845 179.596 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.433 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 18.0 mmt180 -85.39 82.48 8.3 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.853 -1.381 . . . . 0.0 110.269 -179.791 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.67 -52.08 0.71 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.458 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.92 178.74 0.91 Allowed Pre-proline 0 C--N 1.302 -1.489 0 O-C-N 121.579 -0.954 . . . . 0.0 109.332 179.403 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.4 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.8 Cg_endo -77.53 109.53 2.79 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 123.57 1.3 . . . . 0.0 109.39 179.127 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.48 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.57 161.8 52.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.261 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.5 mt -119.64 142.66 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.427 -1.043 . . . . 0.0 109.389 179.491 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.492 ' CD1' HG23 ' A' ' 99' ' ' VAL . 5.5 t80 -130.34 115.47 16.96 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.18 -0.95 . . . . 0.0 110.387 179.899 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.625 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 2.0 mtt180 -103.27 133.95 47.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.432 -0.793 . . . . 0.0 109.892 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.523 ' HB2' ' ND2' ' A' ' 103' ' ' ASN . 8.2 p90 -127.12 152.44 47.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 110.205 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.402 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t -77.46 -46.89 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.183 -0.948 . . . . 0.0 109.859 179.568 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.427 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -65.69 116.38 31.34 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.365 -0.834 . . . . 0.0 110.715 -179.328 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.25 -23.77 15.19 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 O-C-N 123.531 1.28 . . . . 0.0 110.711 179.841 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.59 147.07 29.24 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.979 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -72.53 -51.49 19.7 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.146 -1.208 . . . . 0.0 110.143 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 117.91 -1.043 . . . . 0.0 110.285 179.97 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.04 153.62 22.33 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.336 -1.097 . . . . 0.0 110.308 -179.951 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.667 HG23 ' O ' ' A' ' 3' ' ' VAL . 33.8 m -113.38 104.54 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.278 -0.889 . . . . 0.0 110.037 179.678 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.691 HG22 ' OG1' ' A' ' 116' ' ' THR . 40.6 p -66.05 143.73 57.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 110.026 179.781 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.528 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -74.28 149.06 86.68 Favored Pre-proline 0 C--N 1.302 -1.498 0 O-C-N 121.293 -0.879 . . . . 0.0 109.566 179.673 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.528 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.6 Cg_endo -80.82 -57.95 0.03 OUTLIER 'Trans proline' 0 C--N 1.309 -1.5 0 O-C-N 124.261 1.664 . . . . 0.0 111.681 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.645 ' CD2' ' O ' ' A' ' 7' ' ' HIS . 49.8 p-80 38.37 83.02 0.21 Allowed Pre-proline 0 N--CA 1.491 1.624 0 CA-C-O 121.098 0.475 . . . . 0.0 111.781 -178.796 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.22 58.11 2.88 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.375 1.198 . . . . 0.0 110.876 -179.938 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 -114.22 -28.02 7.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.178 -0.951 . . . . 0.0 109.433 179.315 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.608 HD12 ' HG2' ' A' ' 119' ' ' ARG . 28.4 mt -102.09 136.68 33.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.116 -0.99 . . . . 0.0 109.772 179.452 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.11 34.99 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.132 -0.98 . . . . 0.0 109.576 179.838 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.93 121.54 31.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.237 -0.915 . . . . 0.0 110.206 -179.291 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.537 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 10.8 t -116.45 157.16 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.432 -0.793 . . . . 0.0 110.113 -179.521 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.86 111.29 23.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.165 -0.959 . . . . 0.0 109.91 179.483 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.686 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.9 tp -55.65 139.62 44.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.935 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.72 3.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 110.34 -179.825 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.56 84.38 7.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.17 -0.957 . . . . 0.0 109.867 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.785 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 25.2 m -158.99 109.78 2.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.186 -0.946 . . . . 0.0 110.906 -179.482 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.419 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.32 -174.47 29.71 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.212 178.922 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.02 -19.57 13.46 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.834 -0.803 . . . . 0.0 110.284 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.863 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.3 tt -98.26 106.31 34.56 Favored Pre-proline 0 N--CA 1.489 1.516 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.443 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -62.91 123.38 12.16 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 O-C-N 123.347 1.182 . . . . 0.0 110.776 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.0 t80 -111.5 -167.81 1.23 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.686 -0.634 . . . . 0.0 110.336 -179.185 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.8 m-85 -58.93 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.479 -0.763 . . . . 0.0 111.117 -179.595 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.73 3.83 56.14 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 179.831 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.686 ' CB ' HD23 ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.43 44.28 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.019 -1.283 . . . . 0.0 109.224 179.733 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.785 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.21 106.49 17.02 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.971 -1.08 . . . . 0.0 108.546 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.863 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -69.8 113.44 17.38 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.337 -0.852 . . . . 0.0 110.52 -178.991 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.787 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -69.75 130.77 19.94 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 N-CA-C 107.159 -1.9 . . . . 0.0 107.159 176.347 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.666 HD11 HD12 ' A' ' 58' ' ' LEU . 10.5 mt -56.74 -16.43 6.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.802 -1.186 . . . . 0.0 110.521 -178.313 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.435 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.05 -16.14 49.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.555 -1.341 . . . . 0.0 110.532 179.516 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.042 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -93.39 -25.77 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 120.935 -1.103 . . . . 0.0 111.125 -179.313 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.042 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -115.98 -26.04 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.061 . . . . 0.0 109.954 -179.658 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.21 147.99 22.67 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.224 -0.923 . . . . 0.0 110.435 179.945 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.22 -4.77 41.19 Favored Glycine 0 N--CA 1.484 1.872 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.352 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.63 -149.44 9.32 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.185 -1.483 . . . . 0.0 110.376 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.65 129.95 54.47 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.336 -1.097 . . . . 0.0 110.323 -179.621 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.544 ' HB2' HG12 ' A' ' 81' ' ' VAL . 70.2 m80 -138.43 153.59 48.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.067 -1.02 . . . . 0.0 111.087 -179.508 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.639 HD12 ' O ' ' A' ' 82' ' ' VAL . 24.9 tp -113.23 114.05 26.19 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.41 -0.806 . . . . 0.0 109.81 179.613 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.96 HD12 ' CG1' ' A' ' 83' ' ' VAL . 38.6 mt -97.14 126.75 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.28 -0.887 . . . . 0.0 109.539 179.427 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.465 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 10.5 m-85 -95.0 123.73 38.65 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.402 -0.811 . . . . 0.0 110.196 -179.797 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.2 -0.938 . . . . 0.0 110.885 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.499 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.7 p80 -104.42 -5.47 21.63 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.834 . . . . 0.0 110.128 179.148 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.63 137.4 53.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 110.637 -179.741 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.52 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.8 -43.28 65.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.677 -0.64 . . . . 0.0 110.679 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.17 -36.94 81.18 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.266 -0.896 . . . . 0.0 110.71 -179.632 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.68 -35.38 78.74 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.37 -0.831 . . . . 0.0 109.485 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.869 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.3 m -61.45 -34.84 76.11 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.439 -0.788 . . . . 0.0 109.385 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.61 -49.02 74.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 110.459 179.86 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.76 -40.38 69.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.228 -0.92 . . . . 0.0 110.494 -179.734 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.742 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -57.11 -39.96 76.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.47 -0.769 . . . . 0.0 110.958 -179.354 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.43 -51.36 13.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 110.377 -179.784 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.32 -41.21 93.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.096 -1.002 . . . . 0.0 109.517 179.619 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.553 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.67 -46.88 83.69 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.423 -0.798 . . . . 0.0 109.664 179.47 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.815 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.17 -43.32 78.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.552 -0.718 . . . . 0.0 110.326 179.931 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.3 t -55.7 -33.16 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.04 -1.037 . . . . 0.0 109.166 179.611 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.9 60.85 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.272 -0.892 . . . . 0.0 109.79 179.088 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.666 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -72.05 -26.2 62.09 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.312 -0.867 . . . . 0.0 109.703 179.634 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.46 9.51 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.343 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.62 HD11 ' HB2' ' A' ' 34' ' ' LYS . 48.6 mt -108.3 143.09 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.308 -1.113 . . . . 0.0 110.239 -179.626 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.1 t-20 -86.69 106.66 17.79 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 178.232 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.66 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.84 144.59 48.28 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.506 -177.432 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.974 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.7 t -134.56 145.1 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.79 128.79 55.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.976 -1.09 . . . . 0.0 109.996 179.308 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.474 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.1 53.19 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 110.376 -179.839 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.937 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.4 p90 -170.57 174.62 4.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.473 -0.767 . . . . 0.0 109.655 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.78 120.84 5.68 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 110.766 -179.179 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.27 34.36 14.65 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.531 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.949 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -116.97 156.24 27.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.134 -1.215 . . . . 0.0 110.021 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.949 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.0 m-20 -93.96 148.32 22.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.186 -0.946 . . . . 0.0 110.91 -179.189 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.648 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.8 m -63.26 111.45 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.343 178.884 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.454 ' O ' HG23 ' A' ' 74' ' ' ILE . 5.4 m -134.76 -33.18 0.96 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.419 -0.801 . . . . 0.0 110.921 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.974 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.8 t -53.96 140.1 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.109 -0.995 . . . . 0.0 110.308 -179.418 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.55 ' O ' HG11 ' A' ' 80' ' ' VAL . 0.9 OUTLIER -137.8 91.79 13.33 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.3 -0.875 . . . . 0.0 110.832 179.814 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -86.73 55.51 3.29 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.616 1.324 . . . . 0.0 109.763 179.046 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -129.72 -24.69 2.68 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.207 -0.933 . . . . 0.0 111.547 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -154.39 158.57 40.23 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.842 -1.161 . . . . 0.0 110.894 -179.519 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 59.1 162.33 0.07 OUTLIER Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -80.47 102.92 9.98 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.141 -1.211 . . . . 0.0 109.791 179.704 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.55 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -110.98 134.47 53.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-O 121.928 0.87 . . . . 0.0 110.042 -179.779 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 6.3 m -112.04 125.9 69.38 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.397 -0.814 . . . . 0.0 109.248 179.495 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.721 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.8 t -97.57 116.14 39.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 O-C-N 121.117 -0.99 . . . . 0.0 110.12 -178.303 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.96 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.4 m -110.65 100.21 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.048 -1.032 . . . . 0.0 108.763 179.723 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.474 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.16 33.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.545 -1.347 . . . . 0.0 111.552 -177.891 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.534 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -86.9 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.595 -0.691 . . . . 0.0 109.412 179.6 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.534 ' N ' HG23 ' A' ' 85' ' ' THR . 9.9 p-10 -90.1 42.87 1.12 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.693 -1.255 . . . . 0.0 110.484 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.443 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.96 -26.04 8.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.122 -0.987 . . . . 0.0 110.351 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -76.28 -30.08 57.66 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.089 -1.007 . . . . 0.0 109.977 179.538 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.403 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 5.7 mmt 50.87 -115.49 0.87 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.344 -0.847 . . . . 0.0 109.737 -179.767 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.664 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.05 42.94 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.962 0 O-C-N 120.54 -1.35 . . . . 0.0 110.022 179.806 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -67.27 -29.86 74.81 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.789 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.425 ' CD1' ' N ' ' A' ' 92' ' ' PHE . 36.3 p90 -137.8 21.19 2.87 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.379 -1.071 . . . . 0.0 110.661 -179.742 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.664 HG22 ' OG1' ' A' ' 90' ' ' THR . 0.6 OUTLIER -100.91 -162.39 0.94 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.103 -0.998 . . . . 0.0 110.281 -179.831 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.621 ' N ' HG23 ' A' ' 93' ' ' THR . . . 118.94 11.97 7.34 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.956 -1.116 . . . . 0.0 110.315 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -124.9 65.6 1.11 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.714 -1.462 . . . . 0.0 110.448 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.474 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 51.0 m-85 -119.79 152.85 36.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.08 -1.012 . . . . 0.0 110.507 179.636 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.19 17.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.504 -0.747 . . . . 0.0 109.356 179.213 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.439 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.8 p -160.82 163.04 32.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.421 -0.799 . . . . 0.0 110.294 179.779 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.456 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.36 122.67 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.066 -1.021 . . . . 0.0 110.421 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.827 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.7 mp -97.99 112.68 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.429 -0.795 . . . . 0.0 109.121 179.266 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.419 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 5.2 t0 -121.01 160.74 22.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.114 -0.991 . . . . 0.0 111.589 -178.72 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.66 5.55 43.82 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.688 -0.633 . . . . 0.0 109.47 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.417 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 49.21 24.44 0.98 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 111.064 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -145.41 127.1 15.23 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.081 -1.012 . . . . 0.0 110.316 179.55 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 108' ' ' LYS . 96.2 p -107.66 130.95 54.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.305 -0.872 . . . . 0.0 110.167 179.964 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 25.2 t70 53.79 26.67 6.24 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.184 -0.947 . . . . 0.0 110.131 -179.889 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.8 -33.11 5.38 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.416 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.2 OUTLIER -78.07 157.26 78.81 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.291 -1.123 . . . . 0.0 110.089 179.946 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -62.69 128.69 24.03 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 O-C-N 123.649 1.342 . . . . 0.0 110.304 -179.586 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -46.55 146.69 1.41 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.648 -0.657 . . . . 0.0 111.253 -179.193 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.528 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -77.4 160.57 28.65 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.429 -0.794 . . . . 0.0 110.174 179.85 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.406 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.62 -52.83 12.78 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.348 -0.845 . . . . 0.0 112.058 -178.794 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.528 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.51 -28.95 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 120.838 -1.164 . . . . 0.0 111.466 -178.583 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.05 -56.47 6.43 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.071 -1.018 . . . . 0.0 110.593 -179.289 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.439 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.7 OUTLIER -68.95 -34.61 75.63 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.231 -0.918 . . . . 0.0 108.723 178.961 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.691 ' OG1' HG22 ' A' ' 4' ' ' THR . 41.0 m -59.61 -49.98 75.65 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.174 -0.954 . . . . 0.0 108.482 178.781 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.72 -36.25 65.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.464 -0.772 . . . . 0.0 109.9 178.926 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.439 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.1 mtt180 -71.22 -44.58 65.09 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.179 -0.951 . . . . 0.0 110.723 -179.585 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.632 ' HD2' ' HE1' ' A' ' 7' ' ' HIS . 14.1 ttm180 -56.15 -43.38 78.23 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.912 -1.117 . . . . 0.0 110.415 -179.757 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.69 79.55 0.06 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.478 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -152.08 -43.96 0.11 Allowed 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.296 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.519 HG22 HD13 ' A' ' 10' ' ' ILE . 8.8 t -100.27 144.06 29.73 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.297 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.69 14.63 46.13 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.192 -1.48 . . . . 0.0 110.444 179.425 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.421 ' HD3' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -58.67 -31.79 68.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.127 -1.219 . . . . 0.0 110.032 -179.916 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.89 20.75 4.03 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.333 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.494 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -165.46 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.427 -1.043 . . . . 0.0 108.506 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.494 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 50.2 Cg_endo -85.32 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 122.85 0.921 . . . . 0.0 110.607 179.365 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.503 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.53 176.61 50.25 Favored Glycine 0 N--CA 1.497 2.759 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.439 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mt -131.35 142.87 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.466 -1.02 . . . . 0.0 109.075 179.296 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.476 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 18.6 t80 -131.3 116.03 17.06 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.034 -1.041 . . . . 0.0 110.934 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.537 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.9 mtt180 -101.83 134.86 44.35 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.536 -0.727 . . . . 0.0 109.461 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.449 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.91 148.93 50.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.055 -1.028 . . . . 0.0 110.042 -179.79 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.442 HG22 HD23 ' A' ' 15' ' ' LEU . 54.4 t -73.22 -37.72 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.188 -0.945 . . . . 0.0 109.902 179.75 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.417 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -132.18 143.62 49.69 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.168 -0.958 . . . . 0.0 110.298 -179.799 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -73.59 -50.23 0.19 Allowed 'Trans proline' 0 C--N 1.312 -1.373 0 O-C-N 123.685 1.361 . . . . 0.0 110.251 179.939 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.46 -54.46 0.65 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -90.98 -55.79 3.42 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -1.147 . . . . 0.0 110.258 -179.914 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 23.7 mtt180 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.133 179.971 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.2 p -94.64 109.97 21.84 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.251 -1.146 . . . . 0.0 110.31 -179.778 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.624 ' O ' HG13 ' A' ' 3' ' ' VAL . 7.6 p -113.29 104.05 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.192 -0.942 . . . . 0.0 110.018 179.609 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.508 HG22 ' OG1' ' A' ' 116' ' ' THR . 17.3 p -63.85 145.19 56.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.367 -0.833 . . . . 0.0 110.256 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.411 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.99 146.42 98.21 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.269 -0.895 . . . . 0.0 110.173 -179.9 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.411 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.6 Cg_endo -70.83 -175.86 1.57 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 124.163 1.612 . . . . 0.0 111.05 179.291 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.646 ' CD2' ' HD2' ' A' ' 119' ' ' ARG . 7.5 p-80 -176.55 84.25 0.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.746 -0.596 . . . . 0.0 109.601 179.02 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -66.99 83.21 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.529 0 O-C-N 123.658 1.346 . . . . 0.0 110.604 -179.723 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.3 m-80 -172.74 -37.05 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.647 -0.658 . . . . 0.0 109.736 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.839 HG12 HG23 ' A' ' 122' ' ' THR . 20.8 mt -95.15 128.19 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.428 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.12 128.14 34.37 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.263 -0.898 . . . . 0.0 108.951 178.868 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.3 134.67 33.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.109 -0.994 . . . . 0.0 110.128 -179.303 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.548 HG11 ' HE ' ' A' ' 131' ' ' ARG . 5.5 t -128.66 157.73 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.396 -0.815 . . . . 0.0 110.183 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.43 113.79 27.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.356 -0.84 . . . . 0.0 110.068 179.718 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.746 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.78 143.97 19.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 110.027 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.42 170.17 16.41 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.977 . . . . 0.0 110.397 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.86 81.59 1.18 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.201 -0.937 . . . . 0.0 109.754 179.651 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.829 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.4 m -158.31 111.44 2.39 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.872 -179.502 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.416 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.27 -170.39 30.24 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.139 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.75 -19.08 12.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.787 -0.831 . . . . 0.0 110.0 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -99.92 104.05 26.18 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.833 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.16 125.92 16.8 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.231 1.122 . . . . 0.0 111.008 -179.18 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.0 t80 -112.93 -169.57 1.51 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.738 -0.601 . . . . 0.0 110.352 -179.499 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.524 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.0 m-85 -59.46 82.3 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.269 -0.894 . . . . 0.0 111.377 -179.433 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.19 61.69 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.627 179.274 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.746 ' CB ' HD23 ' A' ' 15' ' ' LEU . 26.6 mmtt -129.86 156.54 44.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.884 -1.362 . . . . 0.0 109.638 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.829 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.34 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.98 -1.075 . . . . 0.0 108.993 179.56 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.4 mt -70.28 113.17 15.95 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.375 -0.828 . . . . 0.0 110.729 -179.122 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.72 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.4 Cg_endo -69.63 130.77 20.09 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 N-CA-C 106.849 -2.02 . . . . 0.0 106.849 175.754 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.577 HD11 HD12 ' A' ' 58' ' ' LEU . 9.7 mt -55.99 -18.68 9.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.784 -1.198 . . . . 0.0 110.507 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.433 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.01 15.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.861 -1.149 . . . . 0.0 110.589 179.728 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.024 HG23 HG23 ' A' ' 33' ' ' ILE . 9.6 m -93.96 -25.3 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.926 -1.109 . . . . 0.0 110.951 -179.735 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.024 HG23 HG23 ' A' ' 32' ' ' VAL . 27.1 pt -117.95 -14.86 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.934 -1.104 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.557 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.64 148.06 24.2 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.849 -1.157 . . . . 0.0 110.383 179.683 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.7 -4.4 50.17 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.629 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.01 7.23 Favored Glycine 0 N--CA 1.492 2.393 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.589 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.05 132.54 54.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -1.018 . . . . 0.0 110.213 -179.602 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -139.93 150.46 44.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.197 -0.939 . . . . 0.0 110.863 -179.759 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.645 HD12 ' O ' ' A' ' 82' ' ' VAL . 51.3 tp -110.99 115.26 29.17 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.466 -0.771 . . . . 0.0 109.996 179.836 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.944 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.4 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.231 -0.918 . . . . 0.0 109.041 179.503 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.55 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.76 37.98 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.866 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.63 159.36 23.06 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.363 -0.836 . . . . 0.0 110.422 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.59 20.31 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.388 -0.82 . . . . 0.0 110.024 179.069 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.2 p -132.8 139.21 47.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.42 ' HE3' ' CE1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.57 -34.09 71.81 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.464 -0.773 . . . . 0.0 110.465 -179.932 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.46 -34.14 76.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.249 -0.907 . . . . 0.0 110.333 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.457 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.09 -36.34 64.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.206 -0.934 . . . . 0.0 109.636 179.818 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.805 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 64.9 m -60.98 -39.2 88.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.563 -0.71 . . . . 0.0 109.469 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.52 -46.59 87.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.915 . . . . 0.0 110.035 179.699 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.439 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.43 -45.47 62.59 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.395 -0.815 . . . . 0.0 110.454 -179.875 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 1.05 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.36 -45.07 80.66 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.36 -0.838 . . . . 0.0 111.149 -178.997 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.47 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.75 -51.57 22.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.001 -1.062 . . . . 0.0 110.366 -179.467 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.16 99.33 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 109.762 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.548 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.54 -46.81 86.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.24 -0.912 . . . . 0.0 109.606 179.591 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.847 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.2 -43.52 78.56 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.636 -0.665 . . . . 0.0 110.147 179.86 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.2 t -55.48 -32.67 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.21 -0.931 . . . . 0.0 109.029 179.7 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.56 -31.05 59.89 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.251 -0.906 . . . . 0.0 109.832 179.071 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.577 HD12 HD11 ' A' ' 30' ' ' LEU . 3.9 mm? -72.19 -26.36 62.03 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.864 0.84 . . . . 0.0 109.837 179.844 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.9 4.58 10.29 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.16 -1.576 . . . . 0.0 109.16 -179.113 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.557 HD11 ' HB2' ' A' ' 34' ' ' LYS . 28.1 mt -105.48 143.34 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.352 -1.087 . . . . 0.0 110.096 -179.748 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.771 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.7 t-20 -88.06 106.07 17.91 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 178.031 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.713 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.288 -177.502 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.924 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.33 139.55 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.806 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.805 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -101.26 122.77 44.27 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.214 178.758 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.496 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.1 134.88 54.78 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.313 -0.867 . . . . 0.0 111.153 -178.925 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.896 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -168.89 170.65 8.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.574 -0.704 . . . . 0.0 109.641 179.506 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.67 118.3 3.27 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.242 -0.912 . . . . 0.0 110.845 -179.439 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.82 37.35 6.44 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.969 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.896 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.42 30.03 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -1.142 . . . . 0.0 110.168 -179.724 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.848 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.3 m-20 -91.84 149.58 21.51 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.36 -0.837 . . . . 0.0 110.596 -179.48 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.7 m -62.15 110.88 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 119.128 -1.029 . . . . 0.0 109.426 179.326 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.715 ' O ' HG23 ' A' ' 74' ' ' ILE . 19.7 m -133.19 -39.33 0.93 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.447 -0.783 . . . . 0.0 110.233 -179.656 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.924 ' HA ' HG21 ' A' ' 63' ' ' VAL . 79.0 t -47.61 133.09 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.42 -0.8 . . . . 0.0 109.993 179.822 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.771 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.0 OUTLIER -136.08 99.09 11.27 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.138 -0.976 . . . . 0.0 110.842 -179.51 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -84.45 48.04 2.34 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 O-C-N 123.788 1.415 . . . . 0.0 109.981 179.056 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.6 p -148.11 40.36 0.96 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.259 -0.901 . . . . 0.0 110.372 -179.218 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.405 ' HB2' HD12 ' A' ' 74' ' ' ILE . 4.0 m120 -143.74 -165.46 2.11 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.109 -0.994 . . . . 0.0 110.298 -179.794 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.42 ' O ' ' NH1' ' A' ' 37' ' ' ARG . . . -50.33 -77.04 0.14 Allowed Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -147.94 113.41 5.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.186 -1.185 . . . . 0.0 110.39 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.644 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.75 134.0 62.73 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 CA-C-O 122.095 0.95 . . . . 0.0 110.05 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.546 HG22 HG22 ' A' ' 60' ' ' ILE . 16.8 m -113.24 122.71 67.89 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.466 -0.771 . . . . 0.0 108.984 179.348 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.998 HG11 HD13 ' A' ' 88' ' ' LEU . 12.2 t -96.95 118.59 43.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.723 -1.235 . . . . 0.0 111.106 -177.686 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.05 HG11 HD12 ' A' ' 51' ' ' LEU . 4.3 m -108.7 99.68 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.034 -1.041 . . . . 0.0 108.852 178.838 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.496 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -135.79 155.93 49.59 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.446 -1.409 . . . . 0.0 110.912 -178.488 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.517 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.17 -42.43 15.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.369 -0.832 . . . . 0.0 110.385 -179.5 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.517 ' N ' HG23 ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.22 32.54 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.69 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -103.16 -30.99 10.35 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.009 . . . . 0.0 110.067 -179.929 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.998 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -69.61 -16.13 63.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 110.067 179.415 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.427 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 16.8 mmt 53.25 -165.07 0.08 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.311 -0.868 . . . . 0.0 109.894 -179.636 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.486 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 0.7 OUTLIER -136.47 30.13 2.93 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.193 -0.942 . . . . 0.0 110.042 179.939 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.4 -42.04 94.09 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.979 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -121.29 14.94 11.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.218 -1.166 . . . . 0.0 110.667 -179.825 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.486 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 6.6 t -80.39 -157.62 0.16 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.062 -1.024 . . . . 0.0 110.174 -179.731 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.425 ' N ' HG23 ' A' ' 93' ' ' THR . . . 102.76 -32.87 7.08 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.306 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.83 56.76 3.8 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.133 -1.216 . . . . 0.0 110.478 -179.528 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.484 ' CE2' ' HB2' ' A' ' 39' ' ' LEU . 16.9 m-85 -119.9 149.75 41.6 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.103 -0.998 . . . . 0.0 110.078 179.399 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.424 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.85 -31.54 25.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.812 . . . . 0.0 109.619 179.554 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.5 p -162.26 163.43 28.15 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.417 -0.913 . . . . 0.0 111.466 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.47 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 117.74 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.455 -0.778 . . . . 0.0 109.614 178.798 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.878 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -97.59 117.18 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.224 -0.923 . . . . 0.0 109.456 179.876 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.429 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.8 t0 -129.84 161.32 31.04 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.107 -0.995 . . . . 0.0 111.634 -178.716 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.436 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 52.8 t -92.03 -7.41 48.87 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.641 -0.662 . . . . 0.0 109.534 178.017 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 57.2 13.44 1.66 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.255 -0.903 . . . . 0.0 111.87 179.704 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.447 HG23 ' O ' ' A' ' 108' ' ' LYS . 1.5 m -143.83 121.72 12.01 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 120.725 -1.234 . . . . 0.0 109.39 -179.888 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.447 ' N ' ' O ' ' A' ' 108' ' ' LYS . 12.5 p -98.85 132.85 43.88 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.184 -0.947 . . . . 0.0 110.416 -179.879 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 t0 51.08 30.24 5.33 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.293 -0.879 . . . . 0.0 110.604 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.91 -28.81 8.76 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.447 ' O ' HG23 ' A' ' 104' ' ' THR . 0.0 OUTLIER -80.89 155.43 72.95 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.024 -1.28 . . . . 0.0 109.99 179.824 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -66.12 136.78 45.63 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.598 1.315 . . . . 0.0 110.666 -179.786 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -49.99 154.87 1.01 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.52 -0.737 . . . . 0.0 110.794 -179.588 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -80.88 159.06 25.12 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.272 -0.892 . . . . 0.0 109.84 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -46.63 -50.92 16.88 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.282 -0.886 . . . . 0.0 111.893 -178.787 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.41 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.792 -1.193 . . . . 0.0 111.444 -178.727 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.423 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.27 -56.6 6.47 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.987 -1.071 . . . . 0.0 110.426 -179.131 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.422 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.73 -35.03 76.61 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.264 -0.898 . . . . 0.0 108.918 178.718 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.508 ' OG1' HG22 ' A' ' 4' ' ' THR . 25.2 m -59.9 -46.69 88.53 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 178.709 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.61 -40.43 63.82 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.671 -0.643 . . . . 0.0 109.767 178.905 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -69.65 -44.23 70.99 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.273 -0.892 . . . . 0.0 110.344 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.646 ' HD2' ' CD2' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -56.54 -43.74 80.16 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.362 -0.836 . . . . 0.0 110.004 179.678 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.01 0.11 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.682 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.457 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.77 -46.41 0.13 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.563 -0.963 . . . . 0.0 108.76 179.622 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.839 HG23 HG12 ' A' ' 10' ' ' ILE . 15.3 t -97.19 141.89 29.77 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.26 17.17 3.34 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.594 179.787 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.499 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.15 81.71 6.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.889 -1.359 . . . . 0.0 109.986 -179.731 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.52 -52.08 0.71 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.477 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.96 176.61 1.49 Allowed Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 121.765 -0.844 . . . . 0.0 109.123 179.308 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.6 Cg_endo -73.21 112.89 3.64 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 N-CA-C 108.806 -1.267 . . . . 0.0 108.806 178.484 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.473 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.01 177.87 41.45 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -178.927 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.2 mt -135.23 142.8 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.239 -1.154 . . . . 0.0 109.652 179.502 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.47 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.87 114.5 19.29 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.051 178.721 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.548 ' HE ' HG11 ' A' ' 13' ' ' VAL . 3.8 mtt85 -105.97 122.77 46.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.515 -0.741 . . . . 0.0 109.297 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 11.0 p90 -122.94 157.81 31.8 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.058 -1.026 . . . . 0.0 110.464 -179.576 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.444 HG22 HD23 ' A' ' 15' ' ' LEU . 37.8 t -77.15 -40.9 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.751 179.555 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -131.37 144.04 51.77 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.317 -0.864 . . . . 0.0 110.07 179.886 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -75.45 -55.7 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.531 1.279 . . . . 0.0 110.612 -179.785 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 124.67 -91.35 0.42 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 54.03 68.12 0.9 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.244 -1.15 . . . . 0.0 110.161 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.173 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.447 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.31 0.576 . . . . 0.0 109.974 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.749 HG12 HG23 ' A' ' 122' ' ' THR . 9.0 mt -106.0 133.3 50.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.043 -1.036 . . . . 0.0 109.901 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.422 ' HB3' HG12 ' A' ' 129' ' ' ILE . 6.4 tp10 -85.67 128.41 34.77 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.383 -0.823 . . . . 0.0 108.946 178.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -89.21 139.24 30.69 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.026 . . . . 0.0 110.328 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.67 155.63 41.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.46 -0.775 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.09 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 110.064 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.68 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.6 tp -54.35 140.0 34.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.324 -0.86 . . . . 0.0 109.889 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.48 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 110.249 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.274 -0.891 . . . . 0.0 110.033 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 31.3 m -146.15 109.29 4.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 110.555 -179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.91 -173.9 28.7 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.294 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.42 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -107.87 -22.75 12.33 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.794 -0.827 . . . . 0.0 110.428 179.994 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -95.11 102.45 9.43 Favored Pre-proline 0 N--CA 1.486 1.345 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.695 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.442 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -61.97 139.97 82.21 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 O-C-N 123.558 1.293 . . . . 0.0 110.603 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.87 -164.08 1.45 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 111.028 -178.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.517 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.4 m-85 -58.07 81.61 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.527 -0.733 . . . . 0.0 111.221 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.05 4.99 38.2 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.68 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.5 mmtm -131.05 155.91 46.08 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.295 . . . . 0.0 109.432 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.92 107.34 16.31 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.063 -1.023 . . . . 0.0 108.918 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.898 ' CD1' HG21 ' A' ' 100' ' ' ILE . 4.5 mt -68.04 114.57 21.51 Favored Pre-proline 0 C--N 1.3 -1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 110.895 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.772 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.0 Cg_endo -70.2 128.28 15.41 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 N-CA-C 106.91 -1.996 . . . . 0.0 106.91 175.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.597 HD11 HD12 ' A' ' 58' ' ' LEU . 9.8 mt -56.22 -18.51 10.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.785 -1.197 . . . . 0.0 110.867 -177.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -59.5 -16.13 22.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.632 -1.293 . . . . 0.0 110.466 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.077 HG23 HG23 ' A' ' 33' ' ' ILE . 9.3 m -91.8 -25.17 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.021 -1.049 . . . . 0.0 110.869 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.077 HG23 HG23 ' A' ' 32' ' ' VAL . 38.0 pt -118.31 -17.15 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.011 -1.056 . . . . 0.0 110.602 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.628 ' HB2' HD11 ' A' ' 60' ' ' ILE . 6.1 tptm -98.66 148.39 23.88 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.987 -1.07 . . . . 0.0 109.847 179.229 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.58 -6.1 33.41 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.98 -136.81 2.97 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.305 -1.426 . . . . 0.0 110.307 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -117.65 132.54 56.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -1.124 . . . . 0.0 110.43 -179.56 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.574 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.83 150.25 44.45 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.244 -0.91 . . . . 0.0 110.806 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.58 HD12 ' HB ' ' A' ' 82' ' ' VAL . 24.3 tp -112.16 114.73 27.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.503 -0.748 . . . . 0.0 110.023 179.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.824 HD12 HG12 ' A' ' 83' ' ' VAL . 43.8 mt -97.6 127.93 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.325 -0.859 . . . . 0.0 109.972 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.418 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.34 123.03 38.65 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.217 -0.927 . . . . 0.0 109.907 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.12 21.68 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.275 -0.891 . . . . 0.0 110.702 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.517 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.7 p80 -107.12 0.46 23.47 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.483 -0.761 . . . . 0.0 110.371 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.24 137.42 44.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.944 -1.098 . . . . 0.0 110.865 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.512 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.51 -39.69 70.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.722 -0.611 . . . . 0.0 110.787 -179.753 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -58.6 -36.71 74.42 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 110.369 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.417 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.4 OUTLIER -73.8 -34.4 64.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 109.59 -179.941 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.888 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.95 73.43 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.46 -0.775 . . . . 0.0 109.461 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.48 -49.58 53.43 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.216 -0.928 . . . . 0.0 110.295 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.421 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.93 -44.38 63.72 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.288 -0.883 . . . . 0.0 110.353 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.749 HD12 HG11 ' A' ' 83' ' ' VAL . 2.0 tm? -56.86 -43.05 80.8 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.441 -0.787 . . . . 0.0 110.773 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.411 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -74.19 -51.84 14.28 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.9 -1.125 . . . . 0.0 110.656 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.69 -38.77 86.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.854 -1.154 . . . . 0.0 109.413 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.57 ' HE3' HD22 ' A' ' 51' ' ' LEU . 2.5 ttmm -59.38 -45.98 89.93 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.36 -0.838 . . . . 0.0 109.493 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.702 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.35 -40.28 71.05 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.418 -0.801 . . . . 0.0 109.763 179.833 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -56.41 -34.49 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.109 -0.995 . . . . 0.0 108.786 178.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.48 -31.2 60.15 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.558 -0.714 . . . . 0.0 110.093 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.597 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.22 -26.13 62.8 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.63 4.77 9.56 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.63 HG22 HG22 ' A' ' 81' ' ' VAL . 58.2 mt -108.09 143.34 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.283 -1.128 . . . . 0.0 110.034 -179.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.495 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 52.4 t30 -86.28 107.6 18.02 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 178.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.534 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . . . -120.9 149.79 42.07 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.947 -1.101 . . . . 0.0 112.095 -176.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.911 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -138.3 152.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.429 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.888 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.45 130.81 56.74 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.076 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.465 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.51 122.24 40.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.29 -0.881 . . . . 0.0 110.441 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.949 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -156.23 176.76 12.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.592 -0.692 . . . . 0.0 109.62 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.31 125.1 16.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.064 -1.023 . . . . 0.0 110.505 -179.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.95 38.57 15.34 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.949 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.5 156.06 28.66 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.152 -1.205 . . . . 0.0 110.147 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.878 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.5 m-20 -96.68 148.96 22.34 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.322 -0.862 . . . . 0.0 110.565 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.662 ' O ' HG23 ' A' ' 71' ' ' VAL . 32.4 m -62.23 110.95 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.054 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.4 m -132.62 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.398 -0.814 . . . . 0.0 110.523 -179.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.911 HG22 ' HB ' ' A' ' 63' ' ' VAL . 58.7 t -52.25 128.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -0.904 . . . . 0.0 110.053 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.874 ' O ' HD12 ' A' ' 74' ' ' ILE . 2.0 pp . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.274 -0.891 . . . . 0.0 110.487 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 121.925 0.869 . . . . 0.0 110.176 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.1 p -116.98 134.46 60.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 122.054 0.93 . . . . 0.0 110.698 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.63 HG22 HG22 ' A' ' 60' ' ' ILE . 13.4 m -112.9 122.3 66.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.092 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.705 HG22 HG13 ' A' ' 73' ' ' VAL . 4.3 t -96.99 119.62 45.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.009 -1.057 . . . . 0.0 110.326 -177.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.824 HG12 HD12 ' A' ' 40' ' ' ILE . 4.5 m -111.36 100.4 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 120.997 -1.065 . . . . 0.0 108.627 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.465 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.45 162.78 34.65 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.731 -1.231 . . . . 0.0 111.602 -177.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.54 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -93.28 -136.0 0.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.524 179.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.54 ' N ' HG23 ' A' ' 85' ' ' THR . 12.3 p-10 -86.42 46.69 1.37 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.734 -1.228 . . . . 0.0 110.623 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.13 -23.09 8.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.931 -1.106 . . . . 0.0 110.405 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.698 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.053 0.454 . . . . 0.0 111.095 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -119.69 146.66 45.39 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.086 -1.008 . . . . 0.0 109.855 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.06 -33.33 67.88 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.352 -0.843 . . . . 0.0 109.856 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.78 163.7 26.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.887 . . . . 0.0 111.078 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.528 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 114.56 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.312 -0.868 . . . . 0.0 109.994 178.811 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.898 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.2 114.7 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.227 -0.92 . . . . 0.0 108.608 179.061 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.418 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.11 160.17 25.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.125 -0.984 . . . . 0.0 111.798 -178.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.94 -7.39 52.24 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.86 18.79 0.55 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 112.247 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.482 HG22 ' O ' ' A' ' 104' ' ' THR . 0.8 OUTLIER . . . . . 0 C--N 1.305 -1.368 0 O-C-N 120.746 -1.221 . . . . 0.0 109.366 179.565 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 121.489 0.662 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -108.01 161.61 14.79 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.6 -0.687 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.52 -55.13 2.95 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.605 -0.684 . . . . 0.0 112.629 -178.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.31 -29.79 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 120.663 -1.273 . . . . 0.0 111.499 -178.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.426 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.78 -57.58 5.41 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.093 -1.005 . . . . 0.0 110.555 -179.037 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.428 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.53 -33.94 77.09 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.198 -0.939 . . . . 0.0 108.819 178.631 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.1 m -60.23 -49.25 78.35 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -41.03 63.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.427 -0.796 . . . . 0.0 110.288 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.426 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.2 mpt_? -69.96 -44.13 70.12 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.049 -1.032 . . . . 0.0 110.732 -179.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.477 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 0.9 OUTLIER -54.18 -38.51 65.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.044 -1.035 . . . . 0.0 110.243 -179.863 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.93 0.06 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.466 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.9 mmt-85 -151.38 -43.55 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.952 . . . . 0.0 108.848 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.749 HG23 HG12 ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.49 39.25 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.522 -0.736 . . . . 0.0 109.345 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.407 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 121.76 19.86 3.28 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.622 179.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.462 ' N ' ' CD ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.42 81.85 4.42 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.033 -1.275 . . . . 0.0 110.034 179.821 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.49 5.39 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.473 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.611 -0.935 . . . . 0.0 108.573 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.473 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.0 Cg_endo -84.08 111.78 1.67 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.12 1.063 . . . . 0.0 109.913 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.46 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.64 168.96 54.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.422 HG12 ' HB3' ' A' ' 11' ' ' GLU . 41.5 mt -127.15 142.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.366 -1.079 . . . . 0.0 109.231 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.528 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.04 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.585 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.403 ' NH2' HG21 ' A' ' 129' ' ' ILE . 6.8 mtt85 -106.47 123.23 47.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.524 -0.735 . . . . 0.0 109.372 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.426 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.93 155.43 31.32 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.167 -0.958 . . . . 0.0 110.559 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.499 HG22 HD23 ' A' ' 15' ' ' LEU . 50.1 t . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.17 -0.956 . . . . 0.0 109.322 179.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.435 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.9 m120 . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.188 0.518 . . . . 0.0 110.399 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.498 HD11 ' O ' ' A' ' 122' ' ' THR . 19.9 mt -107.82 135.4 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 120.946 -1.096 . . . . 0.0 110.383 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.91 128.71 34.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.519 179.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.16 131.82 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.095 -1.003 . . . . 0.0 110.099 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.449 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.7 t -126.62 158.13 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.368 -0.832 . . . . 0.0 110.258 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 108.55 20.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.253 -0.904 . . . . 0.0 109.693 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.555 HD11 HG12 ' A' ' 28' ' ' ILE . 9.7 tp -55.22 138.69 44.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.348 -0.845 . . . . 0.0 109.883 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.0 p -136.41 -179.68 5.83 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.301 -0.874 . . . . 0.0 110.55 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.306 -0.871 . . . . 0.0 109.862 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.742 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 2.6 m -147.66 113.13 5.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.334 -0.854 . . . . 0.0 110.373 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.442 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.45 -162.26 27.95 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.889 -1.624 . . . . 0.0 110.625 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.408 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -118.16 -22.64 7.67 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.78 -0.835 . . . . 0.0 110.497 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.911 HG23 ' HB ' ' A' ' 28' ' ' ILE . 10.0 tt -97.22 100.46 7.83 Favored Pre-proline 0 N--CA 1.485 1.324 0 C-N-CA 118.641 -1.224 . . . . 0.0 110.264 -179.317 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -62.34 147.29 95.19 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.384 1.202 . . . . 0.0 109.649 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.587 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.8 t80 -160.84 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.189 -0.944 . . . . 0.0 111.487 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.587 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 25.9 m-85 59.13 67.32 0.93 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.425 -0.797 . . . . 0.0 111.609 178.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.48 14.35 13.54 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.545 ' CB ' HD23 ' A' ' 15' ' ' LEU . 41.3 mmtm -130.63 156.4 44.95 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.069 -1.254 . . . . 0.0 109.192 179.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.742 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.16 107.1 13.54 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.921 -1.112 . . . . 0.0 109.487 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -71.22 113.79 22.16 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.29 -0.881 . . . . 0.0 110.156 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.834 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.8 Cg_endo -68.69 129.59 19.05 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 N-CA-C 106.877 -2.009 . . . . 0.0 106.877 176.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.635 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.7 mt -55.58 -19.36 9.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.867 -1.146 . . . . 0.0 110.762 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.448 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.06 24.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.753 -1.217 . . . . 0.0 110.434 179.682 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.027 HG23 HG23 ' A' ' 33' ' ' ILE . 12.5 m -91.99 -25.01 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.997 -1.064 . . . . 0.0 111.049 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.027 HG23 HG23 ' A' ' 32' ' ' VAL . 6.2 pt -117.6 -21.09 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.917 -1.115 . . . . 0.0 110.764 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.565 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.0 tptt -94.29 148.44 22.2 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.1 -1.0 . . . . 0.0 110.175 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.38 33.39 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.24 -140.43 4.85 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.113 -1.518 . . . . 0.0 110.266 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.78 131.57 55.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.319 -1.106 . . . . 0.0 110.399 -179.609 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.565 ' HB2' HG12 ' A' ' 81' ' ' VAL . 86.5 m-70 -139.32 151.89 46.77 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.289 -0.882 . . . . 0.0 110.701 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.48 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.3 tp -114.32 122.07 45.56 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.273 -0.892 . . . . 0.0 110.224 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.848 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.5 mt -104.23 129.51 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.248 -0.907 . . . . 0.0 109.451 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.48 123.92 38.2 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.452 -0.78 . . . . 0.0 109.934 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.81 159.18 22.73 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.198 -0.939 . . . . 0.0 110.732 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -108.25 0.4 21.36 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.394 -0.816 . . . . 0.0 110.15 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 30.2 p -136.37 141.39 43.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.523 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.491 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.83 -40.2 69.25 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.538 -0.726 . . . . 0.0 110.6 -179.842 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.88 -34.14 71.29 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.353 -0.842 . . . . 0.0 110.663 -179.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.18 -35.08 68.89 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.891 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -61.3 -33.9 74.34 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.455 -0.778 . . . . 0.0 109.464 179.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -69.15 -50.59 46.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.273 -0.892 . . . . 0.0 110.874 -179.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.71 -47.11 49.88 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.133 -0.979 . . . . 0.0 110.56 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.723 HD13 ' O ' ' A' ' 51' ' ' LEU . 2.6 tm? -56.74 -37.64 71.29 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.585 -0.697 . . . . 0.0 111.256 -178.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.416 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -76.23 -51.36 12.22 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.793 -1.192 . . . . 0.0 110.381 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.57 92.71 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.149 -0.969 . . . . 0.0 110.008 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.561 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.3 OUTLIER -57.3 -44.56 84.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.362 -0.836 . . . . 0.0 109.347 179.598 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.839 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.38 -42.91 74.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.647 -0.658 . . . . 0.0 110.12 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.2 -33.16 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.052 -1.03 . . . . 0.0 108.983 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.7 -31.48 59.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.458 -0.776 . . . . 0.0 110.057 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.561 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -71.65 -26.36 62.51 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.302 -0.874 . . . . 0.0 109.329 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.77 5.47 9.09 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.635 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.6 mt -108.23 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.261 -1.14 . . . . 0.0 110.314 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.653 HD22 HG23 ' A' ' 80' ' ' VAL . 1.4 t30 -88.05 107.08 18.56 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.74 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.03 143.9 45.22 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.912 -1.115 . . . . 0.0 111.893 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.937 HG21 ' HA ' ' A' ' 73' ' ' VAL . 94.8 t -125.05 147.46 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.713 -0.617 . . . . 0.0 109.767 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.891 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.44 123.0 49.0 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.46 -0.896 . . . . 0.0 109.519 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.45 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.3 t80 -117.67 136.36 53.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.124 -0.985 . . . . 0.0 110.743 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.869 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -169.14 176.25 5.35 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.454 -0.779 . . . . 0.0 109.819 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -50.95 122.93 8.2 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 110.876 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.4 38.78 16.7 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.869 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.01 154.82 30.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.06 -1.259 . . . . 0.0 109.923 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.848 ' N ' HD13 ' A' ' 69' ' ' LEU . 10.1 m-20 -94.09 149.12 21.52 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.292 -0.88 . . . . 0.0 110.557 -179.176 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.671 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.8 m -62.58 110.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.212 -0.995 . . . . 0.0 109.501 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.7 m -132.56 -17.54 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.561 -0.712 . . . . 0.0 110.903 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.937 ' HA ' HG21 ' A' ' 63' ' ' VAL . 61.2 t -65.38 141.85 17.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.146 -0.971 . . . . 0.0 109.744 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.756 ' O ' HG11 ' A' ' 80' ' ' VAL . 6.0 pt . . . . . 0 N--CA 1.493 1.703 0 O-C-N 121.239 -0.913 . . . . 0.0 110.436 -179.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 122.072 0.939 . . . . 0.0 109.933 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.756 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.2 p -116.93 134.29 60.95 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 CA-C-O 122.125 0.964 . . . . 0.0 110.339 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.572 HG22 HG22 ' A' ' 60' ' ' ILE . 13.9 m -113.44 124.69 70.34 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.856 HG22 HG13 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.865 -1.147 . . . . 0.0 110.58 -177.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.848 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -112.7 100.6 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.862 -1.149 . . . . 0.0 108.305 179.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.45 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.73 34.7 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.886 -1.134 . . . . 0.0 111.541 -177.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.522 HG23 ' N ' ' A' ' 86' ' ' ASP . 6.3 t -84.17 -126.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.522 ' N ' HG23 ' A' ' 85' ' ' THR . 1.0 OUTLIER -101.37 40.27 1.32 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.474 -1.391 . . . . 0.0 110.211 179.691 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.469 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.72 -34.67 7.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.87 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.663 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.722 0 O-C-N 121.279 -0.888 . . . . 0.0 109.841 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 121.008 0.432 . . . . 0.0 110.567 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.498 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.15 145.71 46.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.039 -1.038 . . . . 0.0 110.161 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.521 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.53 -31.5 42.08 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.725 179.532 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.475 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.1 p -161.56 163.95 29.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.176 -0.953 . . . . 0.0 111.33 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.462 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.89 115.54 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.494 -0.754 . . . . 0.0 110.017 179.291 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.946 HG21 HD11 ' A' ' 28' ' ' ILE . 3.6 mp -93.42 112.56 26.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.165 -0.96 . . . . 0.0 108.859 179.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.8 161.07 19.86 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.125 -0.985 . . . . 0.0 111.765 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.471 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 15.0 t -102.98 8.31 39.0 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.735 -0.603 . . . . 0.0 109.482 178.19 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 47.09 26.16 0.6 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.155 -0.966 . . . . 0.0 111.09 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.492 1.672 0 O-C-N 121.114 -0.991 . . . . 0.0 110.516 179.633 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.447 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 121.293 0.568 . . . . 0.0 110.78 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.555 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -89.06 161.57 16.48 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.402 -0.811 . . . . 0.0 110.442 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.434 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.7 -53.87 3.47 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.469 -0.769 . . . . 0.0 112.375 -178.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.555 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.1 m -68.66 -29.5 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.608 -1.307 . . . . 0.0 111.264 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.447 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.66 -56.48 7.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.078 -1.014 . . . . 0.0 110.549 -179.268 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.44 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.3 OUTLIER -67.6 -34.89 77.92 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.15 -0.969 . . . . 0.0 108.605 178.758 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 13.3 m -59.56 -49.79 76.42 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -74.02 -35.89 64.4 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.592 -0.693 . . . . 0.0 109.871 178.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.44 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 3.3 mtt85 -71.13 -44.83 64.81 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.028 -1.045 . . . . 0.0 110.71 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.476 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 2.7 ttm105 -60.42 -42.56 96.26 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.978 -1.076 . . . . 0.0 110.455 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.58 86.16 0.09 OUTLIER Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.7 -45.4 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.5 -1.0 . . . . 0.0 108.652 179.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.526 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.57 30.03 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.48 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.09 10.45 12.04 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.117 -1.516 . . . . 0.0 110.567 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 5.8 mtt180 -84.88 83.99 7.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.043 -1.269 . . . . 0.0 109.842 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.49 9.46 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 108.916 -1.674 . . . . 0.0 108.916 -179.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.508 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.74 -169.63 0.22 Allowed Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.892 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.508 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.8 Cg_endo -88.0 111.06 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 122.883 0.938 . . . . 0.0 110.047 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.526 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.57 150.93 38.95 Favored Glycine 0 N--CA 1.494 2.563 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.173 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.454 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.43 141.46 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -1.202 . . . . 0.0 109.139 179.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.476 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.89 116.46 17.2 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.882 -1.136 . . . . 0.0 110.725 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.486 ' NH1' HG11 ' A' ' 32' ' ' VAL . 9.6 mtt-85 -105.81 125.78 51.39 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.405 -0.809 . . . . 0.0 109.635 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.7 p90 -114.61 157.92 22.42 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.979 -1.076 . . . . 0.0 110.192 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.471 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t . . . . . 0 N--CA 1.491 1.603 0 O-C-N 121.119 -0.988 . . . . 0.0 109.984 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.35 0.595 . . . . 0.0 109.561 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.503 HD13 HG22 ' A' ' 122' ' ' THR . 13.7 mt -96.24 130.21 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.095 -1.003 . . . . 0.0 110.153 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.416 ' HB3' HG12 ' A' ' 129' ' ' ILE . 18.4 tt0 -84.93 129.44 34.8 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.454 -0.778 . . . . 0.0 109.686 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -88.42 133.04 34.22 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.024 -1.047 . . . . 0.0 109.946 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.557 HG11 ' NE ' ' A' ' 131' ' ' ARG . 12.0 t -126.72 158.0 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.433 -0.792 . . . . 0.0 110.469 -179.016 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.74 110.74 23.0 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.312 -0.867 . . . . 0.0 109.906 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.417 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.7 tp -56.49 140.1 47.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.766 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.9 p -135.36 170.53 15.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.17 -0.956 . . . . 0.0 110.236 -179.682 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.73 63.6 0.29 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.08 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.47 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.3 m -133.91 111.67 10.64 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.35 -0.844 . . . . 0.0 110.399 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.445 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.912 -1.613 . . . . 0.0 110.815 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.4 -19.15 8.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.763 -0.845 . . . . 0.0 110.366 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.904 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.56 113.2 62.21 Favored Pre-proline 0 N--CA 1.485 1.322 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.421 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -65.48 144.22 78.63 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.596 1.314 . . . . 0.0 109.648 179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.506 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.07 98.65 1.06 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.078 -1.049 . . . . 0.0 111.634 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CD1' ' N ' ' A' ' 24' ' ' TYR . 22.7 m-85 55.45 65.24 1.53 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.292 -0.88 . . . . 0.0 111.59 178.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.86 14.59 10.37 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.506 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.91 156.2 45.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.075 -1.25 . . . . 0.0 108.93 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.47 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.39 106.55 14.13 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.916 -1.115 . . . . 0.0 109.465 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.935 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -68.7 114.9 25.48 Favored Pre-proline 0 C--N 1.298 -1.663 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.018 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.766 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.3 Cg_endo -69.54 128.68 16.59 Favored 'Trans proline' 0 C--N 1.303 -1.825 0 N-CA-C 106.587 -2.12 . . . . 0.0 106.587 176.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.756 HD11 HD12 ' A' ' 58' ' ' LEU . 14.0 mt -55.57 -18.85 8.36 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.469 -177.375 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -59.06 -16.52 19.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.721 -1.237 . . . . 0.0 110.574 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.034 HG23 HG23 ' A' ' 33' ' ' ILE . 11.0 m -92.57 -24.1 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 120.921 -1.112 . . . . 0.0 110.925 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.034 HG23 HG23 ' A' ' 32' ' ' VAL . 6.9 pt -119.44 -20.27 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.936 -1.103 . . . . 0.0 110.983 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.556 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.41 22.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.935 -1.103 . . . . 0.0 110.403 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.86 -2.85 66.96 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.66 18.0 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.025 -1.56 . . . . 0.0 110.69 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.46 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.61 132.79 52.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.479 -1.012 . . . . 0.0 110.162 -179.622 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.518 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.14 45.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 110.933 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.621 HD12 ' O ' ' A' ' 82' ' ' VAL . 50.2 tp -113.29 114.44 26.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.411 -0.806 . . . . 0.0 110.241 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.755 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.2 mt -97.31 128.79 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.021 . . . . 0.0 109.549 179.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.401 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 8.0 m-85 -97.54 123.28 41.36 Favored 'General case' 0 C--N 1.292 -1.893 0 O-C-N 121.108 -0.995 . . . . 0.0 110.448 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.39 159.86 22.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.342 -0.849 . . . . 0.0 110.382 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 18.6 p-80 -104.73 -5.61 21.13 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.31 -0.869 . . . . 0.0 110.06 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.7 p -128.15 139.85 52.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.98 -1.075 . . . . 0.0 110.863 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.86 -39.51 69.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.636 -0.665 . . . . 0.0 110.475 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.08 -33.44 70.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.399 -0.813 . . . . 0.0 110.648 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.408 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.67 -37.08 68.02 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.349 -0.844 . . . . 0.0 109.914 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.883 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 69.7 m -62.16 -36.38 81.68 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.364 -0.835 . . . . 0.0 109.651 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.35 -50.28 64.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.027 -1.046 . . . . 0.0 110.231 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.63 -44.81 61.43 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.312 -0.867 . . . . 0.0 110.415 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.897 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -61.29 -36.82 81.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.479 -0.763 . . . . 0.0 111.583 -178.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.417 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.77 -51.68 12.1 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.843 -1.161 . . . . 0.0 110.776 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.78 -38.22 78.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.036 -1.04 . . . . 0.0 109.563 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.806 ' HE2' HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.11 -46.46 82.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.661 -0.649 . . . . 0.0 109.464 179.287 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.742 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.7 -40.23 72.1 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.355 -0.841 . . . . 0.0 110.131 179.897 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.5 t -59.08 -30.91 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.173 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.77 60.17 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.456 -0.778 . . . . 0.0 110.0 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.756 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.27 -25.52 62.49 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.845 0.831 . . . . 0.0 109.739 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.79 7.05 8.97 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.709 ' CD1' HD22 ' A' ' 30' ' ' LEU . 39.4 mt -107.77 142.78 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.31 -1.112 . . . . 0.0 109.821 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.648 ' ND2' HD11 ' A' ' 74' ' ' ILE . 28.5 t30 -88.87 106.52 18.45 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 177.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.679 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -115.95 141.76 47.68 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.521 -177.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.898 HG21 ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.97 143.17 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.704 -0.622 . . . . 0.0 110.007 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.883 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.34 117.82 34.17 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.366 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.28 127.12 53.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.197 -0.939 . . . . 0.0 111.07 -179.235 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.866 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 7.3 p90 -157.59 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.684 -0.635 . . . . 0.0 109.642 179.417 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.19 126.99 25.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.08 -1.012 . . . . 0.0 111.007 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.75 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.866 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -116.59 154.92 29.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.09 -1.241 . . . . 0.0 109.896 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.831 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.7 m-20 -94.84 149.57 21.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.345 -0.847 . . . . 0.0 110.517 -179.201 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.678 ' O ' HG23 ' A' ' 71' ' ' VAL . 31.1 m -61.75 110.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 118.969 -1.092 . . . . 0.0 108.817 179.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.855 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.3 m -130.66 -34.72 1.52 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.438 -0.789 . . . . 0.0 110.283 -179.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.898 ' HA ' HG21 ' A' ' 63' ' ' VAL . 90.9 t -46.86 129.83 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.457 -0.777 . . . . 0.0 109.883 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.855 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 111.18 -179.186 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.898 0.856 . . . . 0.0 110.343 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.618 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.5 p -117.25 133.95 62.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 CA-C-O 121.978 0.894 . . . . 0.0 110.452 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.671 HG11 ' HB ' ' A' ' 33' ' ' ILE . 12.6 m -112.59 122.01 65.99 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.107 0 O-C-N 121.355 -0.841 . . . . 0.0 109.01 179.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.763 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.54 45.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.911 -1.118 . . . . 0.0 110.726 -177.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.755 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -110.16 99.58 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.91 -1.116 . . . . 0.0 108.974 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -132.41 162.09 32.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.698 -1.251 . . . . 0.0 110.326 -178.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.601 HG23 ' OD2' ' A' ' 86' ' ' ASP . 7.2 t -99.1 -27.91 13.62 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.161 -0.962 . . . . 0.0 110.689 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.601 ' OD2' HG23 ' A' ' 85' ' ' THR . 1.3 p30 177.93 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.376 -0.827 . . . . 0.0 110.257 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.499 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.35 -25.57 0.67 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.266 -0.896 . . . . 0.0 110.936 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.441 HD12 ' HA ' ' A' ' 88' ' ' LEU . 14.7 tp . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.184 -0.948 . . . . 0.0 109.791 179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.126 0.488 . . . . 0.0 110.781 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -119.25 149.47 41.72 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -0.988 . . . . 0.0 110.01 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.439 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.6 -30.74 46.78 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.354 -0.841 . . . . 0.0 109.61 179.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -161.65 163.22 30.02 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.231 -0.918 . . . . 0.0 110.925 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.459 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.2 114.37 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.999 0 O-C-N 121.417 -0.802 . . . . 0.0 110.154 179.189 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.935 HG21 HD11 ' A' ' 28' ' ' ILE . 3.8 mp -93.06 112.41 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 108.523 179.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.416 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.82 21.2 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.103 -0.998 . . . . 0.0 111.722 -177.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.447 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 57.0 m -98.45 2.31 47.61 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.658 -0.651 . . . . 0.0 109.293 177.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.415 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 53.86 24.84 4.78 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.149 -0.97 . . . . 0.0 111.172 179.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.489 1.48 0 O-C-N 121.026 -1.046 . . . . 0.0 110.923 179.907 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.428 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 4.2 pt20 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.272 0.558 . . . . 0.0 110.935 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.519 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -85.28 161.46 19.53 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.245 -0.909 . . . . 0.0 110.286 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.67 -57.94 2.13 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.605 -0.685 . . . . 0.0 112.519 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.519 HG22 ' OD1' ' A' ' 111' ' ' ASP . 8.1 m -67.36 -29.6 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 120.68 -1.263 . . . . 0.0 111.532 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.428 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.54 -56.09 7.83 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.111 -0.993 . . . . 0.0 110.437 -179.286 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.463 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.16 -34.06 76.74 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.537 178.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.6 m -59.28 -48.89 79.92 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.049 -1.032 . . . . 0.0 108.404 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.1 -35.7 66.64 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.746 -0.782 . . . . 0.0 109.812 178.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.432 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.58 -45.06 66.1 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.058 -1.026 . . . . 0.0 110.463 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.473 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.1 ttm180 -59.45 -40.79 88.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.003 -1.06 . . . . 0.0 110.004 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.28 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.437 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -149.07 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.515 -0.991 . . . . 0.0 108.625 179.365 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.543 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.8 t -98.16 143.35 28.78 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 12.5 10.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.4 -1.381 . . . . 0.0 110.515 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.5 85.07 5.3 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.009 -1.289 . . . . 0.0 109.877 179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 98.74 17.2 28.94 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.463 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 4.5 pttt -176.98 -177.02 0.25 Allowed Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.48 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.7 Cg_endo -89.01 106.93 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.118 1.062 . . . . 0.0 109.488 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.543 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.01 174.0 49.73 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.321 -179.131 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 20.3 mt -130.22 141.86 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 108.839 179.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 12.8 t80 -132.18 115.95 16.35 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.061 -1.024 . . . . 0.0 110.858 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.557 ' NE ' HG11 ' A' ' 13' ' ' VAL . 0.3 OUTLIER -102.67 122.15 43.86 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.415 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 39.1 p90 -115.17 158.1 22.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.015 -1.053 . . . . 0.0 110.254 -179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.4 t . . . . . 0 N--CA 1.493 1.681 0 O-C-N 121.156 -0.965 . . . . 0.0 110.37 -179.881 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.5 t-20 . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.12 0.486 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.536 HD12 ' HG2' ' A' ' 119' ' ' ARG . 45.0 mt -103.45 128.24 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.919 -1.113 . . . . 0.0 110.218 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.36 127.98 34.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.147 179.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.63 142.02 28.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.049 -1.032 . . . . 0.0 110.365 -179.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.53 HG11 ' NE ' ' A' ' 131' ' ' ARG . 4.8 t -128.97 157.7 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.481 -0.762 . . . . 0.0 109.878 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.66 112.32 25.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.248 -0.907 . . . . 0.0 110.317 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.584 HD23 HG22 ' A' ' 133' ' ' VAL . 13.5 tp -62.9 135.58 57.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -0.922 . . . . 0.0 109.326 179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.5 p -137.15 -178.15 5.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.029 -1.045 . . . . 0.0 110.623 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.29 4.28 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.371 -0.83 . . . . 0.0 109.741 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.673 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 3.6 m -156.68 113.55 3.1 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.898 . . . . 0.0 110.589 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.429 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -168.18 28.25 Favored Glycine 0 N--CA 1.488 2.125 0 C-N-CA 118.836 -1.649 . . . . 0.0 111.081 179.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.42 -20.92 10.06 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.844 -0.798 . . . . 0.0 110.289 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.901 HD12 HD13 ' A' ' 55' ' ' LEU . 9.0 tt -96.78 107.76 38.92 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 118.794 -1.163 . . . . 0.0 109.757 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.2 Cg_endo -64.62 126.97 17.79 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 123.353 1.186 . . . . 0.0 110.887 -178.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.3 -169.82 1.69 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.564 -0.71 . . . . 0.0 110.345 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.3 m-85 -57.4 81.15 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.488 -0.757 . . . . 0.0 111.6 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.84 -1.29 59.23 Favored Glycine 0 N--CA 1.494 2.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.757 179.427 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.404 ' CB ' HD23 ' A' ' 15' ' ' LEU . 0.5 OUTLIER -129.59 156.89 43.46 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.881 -1.364 . . . . 0.0 110.047 -179.903 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.673 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -104.79 106.86 17.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.062 -1.024 . . . . 0.0 108.868 179.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.8 mt -68.34 113.14 13.54 Favored Pre-proline 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 110.677 -179.169 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.893 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -68.97 130.65 20.72 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 107.216 -1.879 . . . . 0.0 107.216 175.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.682 HD11 HD12 ' A' ' 58' ' ' LEU . 13.0 mt -56.3 -18.99 12.34 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.816 -1.178 . . . . 0.0 110.137 -178.09 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.466 ' OE2' HG12 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.69 -16.15 24.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.681 -1.262 . . . . 0.0 110.437 179.687 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.025 HG23 HG23 ' A' ' 33' ' ' ILE . 17.0 m -91.76 -25.02 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.949 -1.094 . . . . 0.0 110.836 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.025 HG23 HG23 ' A' ' 32' ' ' VAL . 38.6 pt -119.4 -20.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.058 -1.026 . . . . 0.0 111.134 -178.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.592 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.2 tptm -92.93 148.33 22.1 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.984 -1.072 . . . . 0.0 110.073 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.93 -5.32 46.44 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 -179.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.87 21.88 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.205 -1.474 . . . . 0.0 110.341 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.1 mtt-85 -97.85 133.01 42.93 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -1.028 . . . . 0.0 110.305 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.572 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.5 m-70 -140.29 149.21 42.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.21 -0.931 . . . . 0.0 110.799 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.464 ' HB3' HG12 ' A' ' 99' ' ' VAL . 26.8 tp -111.41 114.09 26.99 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.371 -0.831 . . . . 0.0 110.061 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.821 HD12 HG12 ' A' ' 83' ' ' VAL . 35.3 mt -96.68 127.76 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.192 -0.943 . . . . 0.0 109.776 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -95.36 123.46 38.9 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.574 -0.704 . . . . 0.0 109.873 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.8 157.07 27.25 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.2 -0.937 . . . . 0.0 110.755 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.2 p80 -104.44 0.92 29.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.374 -0.829 . . . . 0.0 109.976 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 110.255 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.416 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.7 ttpt -71.63 -41.9 68.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.513 -0.742 . . . . 0.0 110.907 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.86 -33.79 72.27 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.251 -0.906 . . . . 0.0 110.812 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.506 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.27 -39.6 82.11 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.926 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.864 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.6 m -61.16 -34.68 75.41 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.253 -0.904 . . . . 0.0 109.768 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.63 -50.36 65.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.241 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.17 53.85 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.213 -0.929 . . . . 0.0 110.377 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.769 ' CD2' HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.03 -36.51 70.55 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.719 -0.613 . . . . 0.0 111.386 -178.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.487 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.84 -51.09 13.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.9 -1.125 . . . . 0.0 110.722 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.14 -39.34 89.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.072 -1.017 . . . . 0.0 109.846 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.545 ' HE3' HD21 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.26 -45.77 83.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.332 -0.855 . . . . 0.0 109.586 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.901 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.32 -39.95 70.57 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.513 -0.742 . . . . 0.0 110.088 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.93 -34.84 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.118 -0.989 . . . . 0.0 108.958 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -30.81 60.64 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.435 -0.79 . . . . 0.0 110.238 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.682 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.6 -25.88 62.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.345 -0.847 . . . . 0.0 109.815 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.11 4.71 10.03 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.669 ' CD1' HD22 ' A' ' 30' ' ' LEU . 45.9 mt -107.57 143.4 18.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.362 -1.081 . . . . 0.0 109.919 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.476 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 55.6 t30 -89.46 106.85 18.72 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 106.476 -1.675 . . . . 0.0 106.476 178.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.676 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.21 143.48 45.82 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.728 -1.189 . . . . 0.0 112.316 -176.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.918 HG21 ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.25 151.88 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.864 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -121.27 118.34 29.31 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.715 178.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.493 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -108.81 133.83 52.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.317 -0.865 . . . . 0.0 110.552 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.977 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.5 p90 -165.81 -173.25 2.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.473 -0.767 . . . . 0.0 110.162 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.91 125.44 23.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.224 -0.923 . . . . 0.0 110.702 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.55 29.2 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.977 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -1.167 . . . . 0.0 109.997 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.826 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.4 m-20 -97.24 149.13 22.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 110.731 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.672 ' O ' HG23 ' A' ' 71' ' ' VAL . 32.9 m -62.9 110.99 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.254 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.7 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.8 m -131.4 -32.53 1.54 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.426 -0.796 . . . . 0.0 110.752 -179.346 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.918 ' HA ' HG21 ' A' ' 63' ' ' VAL . 99.0 t -47.83 134.55 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.44 -0.787 . . . . 0.0 110.19 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.7 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.137 -0.977 . . . . 0.0 111.12 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 121.973 0.892 . . . . 0.0 110.381 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.3 p -116.52 134.69 59.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 122.038 0.923 . . . . 0.0 109.858 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.588 HG22 HG22 ' A' ' 60' ' ' ILE . 16.5 m -112.83 123.53 68.59 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.317 -0.864 . . . . 0.0 109.555 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.762 HG22 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.95 116.46 40.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.842 -1.161 . . . . 0.0 110.595 -178.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.821 HG12 HD12 ' A' ' 40' ' ' ILE . 2.8 m -107.87 100.38 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 0.0 108.559 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.493 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -135.63 162.2 33.37 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.732 -1.23 . . . . 0.0 111.335 -177.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.422 HG22 ' H ' ' A' ' 85' ' ' THR . 5.3 t -91.61 -132.83 0.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.673 -0.642 . . . . 0.0 109.649 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.15 21.35 3.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.752 -1.217 . . . . 0.0 110.59 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.46 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.25 -34.91 15.59 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -0.949 . . . . 0.0 109.646 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp . . . . . 0 N--CA 1.489 1.508 0 O-C-N 121.375 -0.828 . . . . 0.0 109.592 179.461 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.157 0.503 . . . . 0.0 110.717 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -119.21 148.51 43.03 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.112 -0.993 . . . . 0.0 109.964 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.23 59.8 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.351 -0.843 . . . . 0.0 109.237 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.323 -0.861 . . . . 0.0 111.003 179.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.58 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.03 117.54 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.355 -0.841 . . . . 0.0 110.685 179.799 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.868 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.12 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.74 160.71 22.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.174 -0.954 . . . . 0.0 111.517 -178.154 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.475 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 13.7 t -100.01 8.27 44.13 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.649 -0.657 . . . . 0.0 109.588 178.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.402 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.5 m120 46.89 25.95 0.52 Allowed 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.272 -0.893 . . . . 0.0 110.725 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.235 -0.915 . . . . 0.0 110.062 179.53 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.382 0.61 . . . . 0.0 110.797 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.9 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.243 -0.911 . . . . 0.0 110.294 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.16 -53.19 5.15 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.554 -0.716 . . . . 0.0 112.239 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.46 -29.07 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.68 -1.263 . . . . 0.0 111.432 -178.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.404 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.36 -56.46 6.85 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.124 -0.985 . . . . 0.0 110.486 -179.067 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.434 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 16.4 ptp180 -68.9 -35.17 76.54 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.218 -0.926 . . . . 0.0 108.635 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.434 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 26.9 m -59.32 -49.89 76.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.072 -1.017 . . . . 0.0 108.608 178.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -73.75 -38.54 64.7 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.498 -0.752 . . . . 0.0 110.064 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.425 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.43 -44.71 67.31 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.263 -0.898 . . . . 0.0 110.838 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.536 ' HG2' HD12 ' A' ' 10' ' ' ILE . 1.3 ttp180 -55.28 -48.73 73.63 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.27 -0.893 . . . . 0.0 110.507 -179.552 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.18 -18.89 1.41 Allowed Glycine 0 N--CA 1.499 2.834 0 O-C-N 121.526 -0.734 . . . . 0.0 112.343 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.425 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -56.61 -35.55 68.41 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.501 -1.588 . . . . 0.0 112.014 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.481 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.3 t -100.06 144.67 28.82 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.696 -1.252 . . . . 0.0 111.495 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.432 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.63 8.06 62.62 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.578 178.659 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.09 86.83 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.065 -1.256 . . . . 0.0 109.006 179.502 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.8 -21.44 34.2 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -178.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.489 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -138.99 -168.87 0.2 Allowed Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.386 -1.067 . . . . 0.0 109.09 179.924 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.1 Cg_endo -87.87 107.98 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.147 1.077 . . . . 0.0 110.564 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.481 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -84.52 168.36 43.92 Favored Glycine 0 N--CA 1.498 2.777 0 O-C-N 121.047 -1.033 . . . . 0.0 110.973 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.445 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.2 mt -124.87 143.24 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.58 ' CD2' HG23 ' A' ' 99' ' ' VAL . 10.0 t80 -130.22 121.94 27.15 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.693 -1.254 . . . . 0.0 111.771 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.53 ' NE ' HG11 ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.25 124.38 49.67 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.402 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 45.8 p90 -123.27 155.97 36.15 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.954 -1.091 . . . . 0.0 110.888 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.584 HG22 HD23 ' A' ' 15' ' ' LEU . 16.7 t . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.369 -0.832 . . . . 0.0 109.173 178.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.427 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 18.3 m120 . . . . . 0 N--CA 1.494 1.725 0 CA-C-O 121.142 0.496 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.491 HD11 ' O ' ' A' ' 122' ' ' THR . 25.1 mt -106.2 135.78 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.072 -1.018 . . . . 0.0 110.223 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.42 128.5 34.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.323 -0.86 . . . . 0.0 109.451 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.38 125.51 35.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.063 -1.023 . . . . 0.0 110.047 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.451 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.06 155.01 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 110.322 -179.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.6 110.48 22.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.603 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.683 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.4 tp -56.5 135.38 54.41 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.269 -0.894 . . . . 0.0 109.976 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.414 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.3 p -134.58 167.47 20.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 110.378 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.05 79.72 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.302 -0.874 . . . . 0.0 109.993 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.621 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 35.8 m -154.14 109.7 3.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.457 -0.777 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.43 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.68 -170.69 29.83 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 118.928 -1.606 . . . . 0.0 111.103 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.33 -22.14 11.5 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.716 -0.873 . . . . 0.0 110.207 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.895 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.83 25.67 Favored Pre-proline 0 N--CA 1.49 1.532 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.738 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.474 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.3 Cg_endo -64.49 131.88 31.36 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.317 1.167 . . . . 0.0 110.805 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.1 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.586 -0.696 . . . . 0.0 110.646 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.512 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 36.6 m-85 -58.04 81.46 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.397 -0.814 . . . . 0.0 111.342 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.46 47.71 Favored Glycine 0 N--CA 1.493 2.434 0 O-C-N 121.084 -1.01 . . . . 0.0 110.6 179.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.683 ' CB ' HD23 ' A' ' 15' ' ' LEU . 16.7 mmtp -130.45 156.8 44.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.957 -1.32 . . . . 0.0 109.309 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.621 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -110.43 107.77 17.56 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.94 -1.1 . . . . 0.0 109.653 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -67.76 113.57 15.25 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.388 -0.82 . . . . 0.0 110.987 -179.25 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.864 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.8 Cg_endo -69.55 127.49 14.84 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 N-CA-C 106.9 -2.0 . . . . 0.0 106.9 175.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.608 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.7 mt -55.84 -19.1 10.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.816 -1.178 . . . . 0.0 110.819 -177.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -59.86 -16.07 26.06 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.761 -1.212 . . . . 0.0 110.499 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.111 HG23 HG23 ' A' ' 33' ' ' ILE . 15.3 m -91.1 -25.29 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.952 -1.093 . . . . 0.0 110.967 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.111 HG23 HG23 ' A' ' 32' ' ' VAL . 41.3 pt -117.28 -16.48 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.019 -1.051 . . . . 0.0 110.616 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.575 ' HB2' HD11 ' A' ' 60' ' ' ILE . 3.5 tptm -96.33 148.24 22.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.873 -1.142 . . . . 0.0 110.226 179.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.43 -3.23 56.41 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.25 -161.35 26.61 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.934 -1.603 . . . . 0.0 110.906 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.15 128.48 44.09 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.531 -0.982 . . . . 0.0 110.521 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.59 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.56 145.11 44.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.035 -1.04 . . . . 0.0 110.771 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.506 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.6 tp -107.19 113.56 27.07 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.369 -0.832 . . . . 0.0 109.979 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.919 HD12 HG12 ' A' ' 83' ' ' VAL . 36.0 mt -96.37 129.28 46.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.251 -0.906 . . . . 0.0 109.452 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.91 123.75 38.56 Favored 'General case' 0 C--N 1.292 -1.917 0 O-C-N 121.136 -0.977 . . . . 0.0 109.74 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.69 159.74 21.79 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.193 -0.942 . . . . 0.0 111.029 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.512 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -112.3 6.83 19.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.482 -0.761 . . . . 0.0 110.057 179.002 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.407 ' OG ' ' HB3' ' A' ' 47' ' ' LYS . 3.9 p -138.18 137.17 37.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.028 -1.045 . . . . 0.0 110.68 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.58 -40.6 69.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.381 -0.824 . . . . 0.0 110.194 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -36.77 79.43 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 110.247 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.421 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -72.24 -35.64 68.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 179.975 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.869 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 5.5 m -60.29 -33.78 72.82 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.434 -0.791 . . . . 0.0 109.55 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.87 -49.05 61.58 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.201 -0.937 . . . . 0.0 110.432 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.64 -43.32 66.32 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.342 -0.849 . . . . 0.0 110.538 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.826 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.5 -41.58 76.89 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.392 -0.818 . . . . 0.0 111.008 -179.047 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.96 -51.33 12.64 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.988 -1.07 . . . . 0.0 110.58 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.59 -42.05 98.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.87 -1.144 . . . . 0.0 109.594 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -57.68 -46.08 84.77 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.86 . . . . 0.0 109.882 179.71 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.741 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.04 -41.51 71.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.473 -0.767 . . . . 0.0 109.607 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.4 t -56.08 -31.19 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.068 -1.02 . . . . 0.0 108.61 178.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.55 -32.92 60.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.561 -0.712 . . . . 0.0 109.97 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.479 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.92 -25.87 62.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.313 -0.867 . . . . 0.0 109.512 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.0 7.32 8.62 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.608 ' CD1' HD22 ' A' ' 30' ' ' LEU . 34.6 mt -108.83 143.25 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.416 -1.05 . . . . 0.0 110.303 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.586 ' ND2' HD11 ' A' ' 74' ' ' ILE . 24.0 t-20 -86.43 107.0 17.85 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.018 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.619 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.52 143.91 48.32 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.428 -177.589 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.931 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -132.11 150.8 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.848 -0.741 . . . . 0.0 109.176 179.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.41 126.51 55.42 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.102 179.37 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.588 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.4 t80 -118.26 122.56 43.25 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.231 -0.918 . . . . 0.0 110.401 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.92 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.76 8.19 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.628 179.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.93 125.24 14.73 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.167 -0.958 . . . . 0.0 110.985 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.11 44.69 22.52 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.32 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.926 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.5 tm? -117.72 156.48 28.19 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.089 -1.242 . . . . 0.0 110.127 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.926 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.7 m-20 -94.51 148.98 21.7 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.283 -0.886 . . . . 0.0 110.723 -179.361 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.676 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.9 m -62.42 111.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.229 -0.989 . . . . 0.0 109.288 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.507 ' O ' HG23 ' A' ' 74' ' ' ILE . 6.9 m -133.65 -32.63 1.12 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.988 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.931 HG22 ' HB ' ' A' ' 63' ' ' VAL . 30.3 t -56.01 138.73 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.194 -0.941 . . . . 0.0 109.949 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.636 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.496 1.829 0 O-C-N 121.108 -0.995 . . . . 0.0 111.131 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.938 0.875 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.4 p -117.3 133.92 62.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-O 121.961 0.886 . . . . 0.0 110.351 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.591 HG22 HG22 ' A' ' 60' ' ' ILE . 7.8 m -112.67 123.82 68.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 178.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.736 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.76 116.46 38.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.1 -1.0 . . . . 0.0 110.353 -177.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.919 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -108.97 100.22 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.771 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.475 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.78 162.98 34.13 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.732 -1.23 . . . . 0.0 111.114 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.525 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -92.04 -130.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.537 -0.727 . . . . 0.0 109.47 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.525 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -90.98 34.83 0.91 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.713 -1.242 . . . . 0.0 110.226 179.534 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.43 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 0.0 110.356 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.132 -0.98 . . . . 0.0 109.099 179.401 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 120.761 0.315 . . . . 0.0 110.489 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.506 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.51 152.19 38.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.872 -1.143 . . . . 0.0 110.778 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.444 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.56 -28.79 19.35 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.567 -0.708 . . . . 0.0 109.363 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.3 p -161.0 163.77 31.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.34 -0.85 . . . . 0.0 110.758 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.489 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -125.75 119.18 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.251 -0.905 . . . . 0.0 110.292 179.578 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.769 HG21 ' CD1' ' A' ' 28' ' ' ILE . 37.9 mm -95.9 111.26 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 108.859 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.44 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -118.89 161.06 20.81 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.913 -1.117 . . . . 0.0 111.73 -178.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.48 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.3 p -99.96 -0.33 39.6 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 50.52 18.63 0.47 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.341 -0.85 . . . . 0.0 112.175 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.305 -1.349 0 O-C-N 120.729 -1.232 . . . . 0.0 109.407 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.644 0.735 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.539 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -102.68 161.56 13.63 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.544 -0.723 . . . . 0.0 110.327 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.433 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.28 -56.55 2.9 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.576 -0.702 . . . . 0.0 112.376 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.539 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -64.21 -29.87 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.702 -1.249 . . . . 0.0 111.255 -178.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.403 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.73 -56.32 7.61 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.116 -0.99 . . . . 0.0 110.505 -179.209 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.76 -33.77 76.36 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.159 -0.963 . . . . 0.0 108.851 178.91 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.5 m -60.93 -50.16 74.54 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.061 -1.025 . . . . 0.0 108.357 178.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.96 -38.71 64.13 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 mtt-85 -71.85 -44.37 63.94 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.258 -0.901 . . . . 0.0 111.321 -179.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.474 ' O ' ' N ' ' A' ' 121' ' ' ARG . 6.9 ttp180 -62.12 -40.42 95.85 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.917 -1.114 . . . . 0.0 110.244 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.4 75.26 0.04 OUTLIER Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -149.05 -47.35 0.14 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.43 -1.041 . . . . 0.0 108.76 179.599 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.555 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.1 t -96.19 143.47 27.27 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.76 17.82 4.55 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.409 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -91.75 82.8 5.22 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.117 -1.225 . . . . 0.0 109.986 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.92 -31.74 4.84 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.482 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.18 -169.74 0.22 Allowed Pre-proline 0 C--N 1.301 -1.514 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 179.509 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.482 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.5 Cg_endo -85.31 115.0 1.59 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 122.916 0.956 . . . . 0.0 110.466 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.555 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.29 51.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.567 HG21 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 mt -119.99 140.13 45.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.039 -1.271 . . . . 0.0 109.051 179.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.489 ' HD1' HG23 ' A' ' 99' ' ' VAL . 6.8 t80 -122.7 114.49 20.65 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 118.965 -1.094 . . . . 0.0 110.218 179.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.601 ' HB2' HD13 ' A' ' 100' ' ' ILE . 24.2 mtt180 -108.12 126.87 53.27 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.594 -0.692 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.451 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.8 p90 -126.95 156.94 40.72 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.078 -1.014 . . . . 0.0 110.847 -179.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.509 HG21 ' HB2' ' A' ' 24' ' ' TYR . 7.0 t . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.319 -0.863 . . . . 0.0 108.978 178.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 24.4 t-20 . . . . . 0 N--CA 1.496 1.851 0 CA-C-O 121.574 0.702 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.548 HD12 ' HG2' ' A' ' 119' ' ' ARG . 20.0 mt -105.8 132.99 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.442 -0.786 . . . . 0.0 109.117 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.5 33.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.054 -1.028 . . . . 0.0 109.302 179.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.54 126.43 35.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.176 -0.952 . . . . 0.0 110.021 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.559 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 6.4 t -116.14 154.52 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.334 -0.853 . . . . 0.0 110.4 -179.221 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.88 105.04 15.34 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.339 -0.851 . . . . 0.0 109.639 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.506 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -55.43 132.34 48.08 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.412 -0.805 . . . . 0.0 109.82 -179.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.408 ' O ' ' N ' ' A' ' 18' ' ' THR . 70.5 p -135.83 172.29 13.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.212 -0.93 . . . . 0.0 110.314 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.91 78.28 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.22 -0.925 . . . . 0.0 110.202 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.682 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.0 m -151.31 108.54 3.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.206 -0.934 . . . . 0.0 110.687 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.037 -1.554 . . . . 0.0 110.747 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.32 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.649 -0.912 . . . . 0.0 110.326 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.867 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.8 tt -100.53 104.24 29.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.314 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.3 Cg_endo -62.94 148.7 93.17 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.338 1.178 . . . . 0.0 109.894 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.533 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.26 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.174 -0.954 . . . . 0.0 111.127 -178.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.5 m-85 59.15 66.78 0.99 Allowed 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.406 -0.809 . . . . 0.0 111.332 179.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.87 15.0 11.11 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.62 156.98 43.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.057 -1.261 . . . . 0.0 109.121 179.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.682 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -117.2 107.28 14.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.883 -1.135 . . . . 0.0 109.69 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.867 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.6 mt -69.98 114.33 24.4 Favored Pre-proline 0 C--N 1.3 -1.553 0 C-N-CA 119.614 -0.835 . . . . 0.0 109.926 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -69.01 129.72 18.92 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 N-CA-C 107.047 -1.943 . . . . 0.0 107.047 176.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.666 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.9 mt -56.52 -16.92 6.8 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.78 -1.2 . . . . 0.0 110.976 -177.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.443 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.03 -15.89 47.83 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.799 -1.188 . . . . 0.0 110.242 179.427 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.053 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -92.6 -25.14 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.986 -1.071 . . . . 0.0 111.212 -179.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.053 HG23 HG23 ' A' ' 32' ' ' VAL . 12.0 pt -120.47 -23.25 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.99 -1.069 . . . . 0.0 110.804 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.652 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.04 147.9 22.6 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.954 -1.092 . . . . 0.0 110.692 -179.872 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.413 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.63 -3.48 57.65 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.95 -155.73 13.6 Favored Glycine 0 N--CA 1.494 2.542 0 C-N-CA 119.008 -1.567 . . . . 0.0 110.705 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.98 131.12 52.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.413 -1.051 . . . . 0.0 110.092 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.4 m-70 -140.83 152.38 45.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 111.07 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.459 HD12 ' O ' ' A' ' 82' ' ' VAL . 43.0 tp -112.27 115.67 29.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.361 -0.837 . . . . 0.0 110.321 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.836 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.6 mt -100.34 128.59 52.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 109.823 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.467 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.04 123.66 40.84 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.098 -1.001 . . . . 0.0 110.054 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.52 159.59 21.03 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.278 -0.889 . . . . 0.0 110.55 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.577 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.63 5.11 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.362 -0.836 . . . . 0.0 110.006 179.076 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.08 135.95 37.93 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.127 -0.983 . . . . 0.0 110.607 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.486 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.51 -31.31 66.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.546 -0.721 . . . . 0.0 110.395 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.06 -30.0 66.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.357 -0.84 . . . . 0.0 110.198 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.4 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.1 -36.98 66.87 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.394 -0.816 . . . . 0.0 109.649 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.909 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.3 82.33 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.53 -49.9 73.5 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.103 -0.998 . . . . 0.0 109.955 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.65 -47.01 51.09 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.328 -0.858 . . . . 0.0 110.348 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.684 HD13 ' O ' ' A' ' 51' ' ' LEU . 1.9 tm? -56.53 -40.08 74.48 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.51 -0.744 . . . . 0.0 110.772 -179.298 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.36 13.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.078 -1.014 . . . . 0.0 110.179 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.34 -42.21 98.31 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 109.798 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.523 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.42 -45.25 84.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.459 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.834 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.08 -42.12 72.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.541 -0.725 . . . . 0.0 109.614 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.5 t -56.08 -33.33 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 109.097 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.64 -31.36 59.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.408 -0.807 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.21 -26.39 62.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.339 -0.85 . . . . 0.0 109.456 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.24 5.39 8.75 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.666 ' CD1' HD22 ' A' ' 30' ' ' LEU . 67.9 mt -108.15 143.83 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -1.106 . . . . 0.0 110.358 -179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.72 106.48 18.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 177.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.687 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.47 142.87 46.3 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.883 -177.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.88 HG21 ' HA ' ' A' ' 73' ' ' VAL . 84.0 t -122.97 148.81 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.909 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.48 117.17 29.63 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.256 178.226 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.473 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.88 135.37 49.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.294 -0.878 . . . . 0.0 111.02 -179.235 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.977 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 15.4 p90 -167.95 177.36 5.69 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.522 -0.736 . . . . 0.0 109.853 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.1 ttp-105 -51.56 126.06 16.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.07 -1.018 . . . . 0.0 110.683 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.88 45.11 22.44 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.977 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.28 153.61 32.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.04 -1.271 . . . . 0.0 109.836 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.783 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.9 m-20 -91.2 149.46 21.77 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.297 -0.877 . . . . 0.0 110.608 -179.242 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.663 ' O ' HG23 ' A' ' 71' ' ' VAL . 33.9 m -62.42 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.125 179.096 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.674 ' O ' HG23 ' A' ' 74' ' ' ILE . 15.0 m -133.9 -34.37 1.01 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.445 -0.785 . . . . 0.0 110.843 -179.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.88 ' HA ' HG21 ' A' ' 63' ' ' VAL . 92.4 t -49.43 129.47 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.098 -1.001 . . . . 0.0 110.106 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.674 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.11 -0.994 . . . . 0.0 110.996 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 122.103 0.954 . . . . 0.0 110.241 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.485 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.2 p -116.89 135.23 57.91 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 CA-C-O 121.966 0.889 . . . . 0.0 109.912 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 13.7 m -112.62 124.6 69.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 O-C-N 121.282 -0.886 . . . . 0.0 109.373 179.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.839 HG11 HD13 ' A' ' 88' ' ' LEU . 13.1 t -97.19 119.14 44.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 O-C-N 120.955 -1.091 . . . . 0.0 110.383 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.836 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.3 m -111.9 99.27 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.015 -1.074 . . . . 0.0 108.771 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.426 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.22 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.587 -1.321 . . . . 0.0 110.811 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.05 -28.56 17.88 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.345 -0.847 . . . . 0.0 110.71 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.89 -31.3 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.079 -1.013 . . . . 0.0 110.762 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.473 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.95 -37.55 9.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.259 -0.901 . . . . 0.0 111.099 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.839 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.738 0 O-C-N 121.145 -0.972 . . . . 0.0 110.7 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.217 0.532 . . . . 0.0 110.186 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -119.77 152.75 36.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.208 -0.932 . . . . 0.0 110.167 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -84.83 -29.26 25.48 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.505 -0.747 . . . . 0.0 109.735 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.452 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.7 p -161.18 163.47 31.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.166 -0.959 . . . . 0.0 110.843 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.414 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.29 116.32 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.298 -0.876 . . . . 0.0 109.963 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.842 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -94.61 111.3 25.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.07 -1.019 . . . . 0.0 108.974 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.416 ' HB2' ' CE1' ' A' ' 130' ' ' TYR . 3.5 t0 -114.4 161.07 18.42 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.149 -0.97 . . . . 0.0 111.732 -178.369 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.32 9.65 35.81 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.416 ' O ' ' HG2' ' A' ' 110' ' ' GLN . 2.7 m120 46.19 27.29 0.53 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.279 -0.888 . . . . 0.0 110.963 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.4 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.1 p . . . . . 0 N--CA 1.488 1.446 0 O-C-N 121.188 -0.945 . . . . 0.0 110.469 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.416 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.571 0.701 . . . . 0.0 111.205 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.506 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -100.52 161.78 13.37 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.556 -0.715 . . . . 0.0 110.111 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.465 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.46 -61.56 1.03 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.476 -0.765 . . . . 0.0 112.108 -178.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.506 HG22 ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.79 -28.87 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.71 -1.244 . . . . 0.0 111.435 -178.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.69 -57.19 5.83 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.893 -1.13 . . . . 0.0 110.932 -178.732 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.465 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.46 -34.63 78.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.02 -1.05 . . . . 0.0 108.525 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 49.6 m -59.84 -48.87 79.95 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.28 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.59 -40.1 64.13 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.513 -0.742 . . . . 0.0 110.126 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.467 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.48 -44.61 70.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.984 -1.073 . . . . 0.0 110.31 -179.687 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.548 ' HG2' HD12 ' A' ' 10' ' ' ILE . 41.9 ttp180 -61.54 -36.08 79.58 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.047 -1.033 . . . . 0.0 109.315 179.184 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.05 66.67 0.34 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.7 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.462 -1.022 . . . . 0.0 108.848 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.538 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.3 t -92.12 142.45 27.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.335 -0.853 . . . . 0.0 108.931 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.58 17.07 2.95 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.269 -1.444 . . . . 0.0 110.605 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -95.11 82.37 3.77 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.986 -1.303 . . . . 0.0 110.002 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.39 -51.46 0.76 Allowed Glycine 0 N--CA 1.493 2.483 0 N-CA-C 108.412 -1.875 . . . . 0.0 108.412 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.455 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.84 166.36 21.72 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.3 Cg_endo -63.59 117.73 4.68 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.299 1.157 . . . . 0.0 110.128 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.538 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.85 172.24 54.78 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.424 HG23 ' CG2' ' A' ' 13' ' ' VAL . 5.1 mt -126.15 142.06 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.301 -1.117 . . . . 0.0 108.989 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.416 ' CE1' ' HB2' ' A' ' 101' ' ' ASP . 10.5 t80 -131.13 115.19 16.06 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.292 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.559 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 5.9 mtp180 -99.78 147.71 25.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.497 -0.752 . . . . 0.0 109.365 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.47 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 25.1 p90 -138.14 150.36 46.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.085 -1.01 . . . . 0.0 110.212 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.506 HG22 HD23 ' A' ' 15' ' ' LEU . 34.5 t . . . . . 0 N--CA 1.492 1.666 0 O-C-N 121.129 -0.982 . . . . 0.0 109.448 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.9 t-20 . . . . . 0 N--CA 1.493 1.682 0 CA-C-O 121.461 0.648 . . . . 0.0 109.627 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.519 HD13 HG22 ' A' ' 122' ' ' THR . 16.5 mt -106.81 132.43 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.001 -1.062 . . . . 0.0 109.518 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.87 127.26 33.71 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.134 -0.979 . . . . 0.0 109.278 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.66 128.5 36.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.16 -0.962 . . . . 0.0 110.003 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.42 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.49 158.04 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.404 -0.81 . . . . 0.0 110.176 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.98 110.94 21.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.752 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.451 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -53.45 134.5 40.44 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.319 -0.863 . . . . 0.0 110.329 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.6 p -135.49 177.76 7.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 110.142 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.33 65.31 0.42 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.225 -0.922 . . . . 0.0 109.951 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.474 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 22.1 m -137.1 110.57 7.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.339 -0.851 . . . . 0.0 110.353 -179.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.0 -163.89 27.98 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.76 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.72 -21.02 7.43 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.675 -0.897 . . . . 0.0 110.327 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.893 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -96.79 108.66 44.44 Favored Pre-proline 0 N--CA 1.488 1.458 0 C-N-CA 118.668 -1.213 . . . . 0.0 110.204 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.437 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.6 Cg_endo -65.48 149.77 87.49 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 O-C-N 123.444 1.234 . . . . 0.0 110.296 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.523 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.3 t80 -169.04 108.21 0.45 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 110.977 -178.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.478 ' OH ' ' CE1' ' A' ' 43' ' ' HIS . 17.6 m-85 56.25 60.69 3.05 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.234 -0.916 . . . . 0.0 111.171 179.209 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.97 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.523 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.49 157.28 43.1 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.128 -1.219 . . . . 0.0 109.064 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.474 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.79 107.27 14.83 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.811 -1.181 . . . . 0.0 110.239 -179.517 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.893 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.4 mt -68.29 114.5 21.77 Favored Pre-proline 0 C--N 1.301 -1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.8 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -69.16 128.39 16.5 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 N-CA-C 106.579 -2.123 . . . . 0.0 106.579 175.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.64 HD22 ' CD1' ' A' ' 60' ' ' ILE . 11.0 mt -55.82 -17.62 6.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.673 -1.267 . . . . 0.0 111.09 -177.216 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -59.63 -15.98 22.83 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.677 -1.264 . . . . 0.0 110.667 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.084 HG23 HG23 ' A' ' 33' ' ' ILE . 16.4 m -91.37 -25.38 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.024 -1.048 . . . . 0.0 111.187 -179.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.084 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -119.84 -16.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.96 -1.087 . . . . 0.0 110.65 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.6 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.9 tptt -98.8 147.86 24.49 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.769 -1.207 . . . . 0.0 110.046 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.84 -5.39 50.63 Favored Glycine 0 N--CA 1.485 1.911 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.35 -151.17 9.52 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.081 -1.533 . . . . 0.0 110.561 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.442 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.03 131.92 53.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.43 -1.041 . . . . 0.0 110.371 -179.409 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.572 ' HB2' HG12 ' A' ' 81' ' ' VAL . 95.6 m-70 -138.44 151.53 47.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.172 -0.955 . . . . 0.0 110.95 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.578 HD12 ' O ' ' A' ' 82' ' ' VAL . 45.9 tp -111.58 119.29 38.24 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.766 . . . . 0.0 110.025 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.921 HD12 ' CG1' ' A' ' 83' ' ' VAL . 31.6 mt -103.86 126.26 58.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.295 -0.878 . . . . 0.0 109.155 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.96 123.79 38.63 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.177 -0.952 . . . . 0.0 110.329 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.28 160.13 21.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.425 -0.797 . . . . 0.0 110.668 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.478 ' CE1' ' OH ' ' A' ' 24' ' ' TYR . 5.4 p-80 -105.16 -4.73 21.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.337 -0.852 . . . . 0.0 110.426 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.412 ' HB3' ' CD2' ' A' ' 43' ' ' HIS . 66.4 p -136.14 145.8 46.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.01 -1.056 . . . . 0.0 111.235 -179.413 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.477 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 23.7 tttt -72.08 -40.92 67.91 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.673 -0.642 . . . . 0.0 110.669 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.77 -34.98 72.04 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.139 -0.976 . . . . 0.0 110.684 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HA ' ' HD3' ' A' ' 47' ' ' LYS . 12.3 tppt? -71.6 -40.42 69.86 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.077 -1.014 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.888 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 67.3 m -61.83 -37.15 83.37 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 110.06 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.98 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.949 -1.094 . . . . 0.0 110.577 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.414 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -72.28 -44.2 63.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.174 -0.954 . . . . 0.0 110.229 179.908 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.728 HD12 HG11 ' A' ' 83' ' ' VAL . 1.7 tm? -56.58 -42.12 78.1 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.489 -0.757 . . . . 0.0 111.198 -179.102 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.35 -50.88 16.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.897 -1.127 . . . . 0.0 110.375 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.38 -42.09 98.15 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.118 -0.989 . . . . 0.0 109.798 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.504 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.98 -45.78 86.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.901 . . . . 0.0 109.788 179.703 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.644 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -54.54 -42.31 70.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.453 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.5 t -56.79 -30.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.122 -0.986 . . . . 0.0 108.591 178.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.503 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.56 -33.93 60.67 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.597 -0.689 . . . . 0.0 110.021 179.23 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.536 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.48 -25.73 62.4 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.82 0.819 . . . . 0.0 109.556 179.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.56 7.34 9.0 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.64 ' CD1' HD22 ' A' ' 30' ' ' LEU . 40.1 mt -108.01 143.31 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.324 -1.103 . . . . 0.0 109.977 -179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 38.2 t30 -87.2 107.08 18.32 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.272 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.637 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.91 145.11 48.02 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.409 -177.576 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.887 HG21 ' HA ' ' A' ' 73' ' ' VAL . 6.7 t -133.02 143.1 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.589 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.888 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -107.16 123.45 48.28 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.824 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.492 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.17 119.06 36.47 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.335 -0.853 . . . . 0.0 110.387 -179.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.922 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.8 p90 -146.74 174.48 11.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.608 -0.683 . . . . 0.0 109.753 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.6 5.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.161 -0.962 . . . . 0.0 110.803 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.02 35.73 9.58 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.948 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.0 tm? -117.17 155.84 28.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 110.079 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.948 ' N ' HD13 ' A' ' 69' ' ' LEU . 37.1 m-20 -95.37 149.42 21.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.333 -0.854 . . . . 0.0 110.248 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.672 ' O ' HG23 ' A' ' 71' ' ' VAL . 27.2 m -61.81 110.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.176 179.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.401 ' O ' HG23 ' A' ' 74' ' ' ILE . 7.3 m -132.04 -20.82 2.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.486 -0.759 . . . . 0.0 111.068 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.887 ' HA ' HG21 ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.88 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 109.302 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.629 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.496 1.85 0 O-C-N 121.241 -0.912 . . . . 0.0 110.969 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.965 0.888 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.523 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -117.47 134.58 60.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.074 0.94 . . . . 0.0 110.359 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.647 HG11 ' HB ' ' A' ' 33' ' ' ILE . 5.7 m -113.28 124.67 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 O-C-N 121.413 -0.805 . . . . 0.0 108.901 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.784 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.91 45.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 121.159 -0.963 . . . . 0.0 110.049 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.921 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.8 m -114.48 100.98 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.07 -1.019 . . . . 0.0 108.594 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.492 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.37 164.22 32.16 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.725 -1.234 . . . . 0.0 111.796 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.706 HG23 ' H ' ' A' ' 87' ' ' ALA . 6.4 t -94.28 -147.2 0.26 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.671 -0.643 . . . . 0.0 109.42 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.15 -15.3 56.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.964 -1.085 . . . . 0.0 110.235 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.706 ' H ' HG23 ' A' ' 85' ' ' THR . . . -49.32 -44.64 44.49 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.038 -1.039 . . . . 0.0 110.257 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 108.985 179.101 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.11 0.481 . . . . 0.0 110.492 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -119.92 147.93 44.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.937 -1.102 . . . . 0.0 110.303 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.481 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.43 -28.77 56.75 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.409 -0.807 . . . . 0.0 110.127 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.2 p -160.38 163.58 33.05 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.256 -0.903 . . . . 0.0 110.752 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.505 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.9 117.86 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.332 -0.855 . . . . 0.0 110.563 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.798 HG21 HD11 ' A' ' 28' ' ' ILE . 4.6 mp -98.24 110.86 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.16 158.88 25.05 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.992 . . . . 0.0 111.773 -178.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.84 3.67 53.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.423 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.2 m-20 52.88 27.72 5.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.239 -0.913 . . . . 0.0 111.087 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.488 1.455 0 O-C-N 121.11 -0.994 . . . . 0.0 110.24 179.361 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.46 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.195 0.522 . . . . 0.0 110.998 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.535 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -99.7 160.77 14.05 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.28 179.674 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.31 -53.47 5.21 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.438 -0.789 . . . . 0.0 112.286 -178.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.535 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.8 m -69.75 -29.42 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 120.83 -1.169 . . . . 0.0 111.525 -178.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.402 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.31 -56.52 6.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.07 -1.019 . . . . 0.0 110.625 -179.114 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.408 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 1.8 ptm180 -69.07 -34.69 75.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.296 -0.877 . . . . 0.0 108.819 178.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.431 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.8 m -59.52 -49.79 76.42 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.68 -37.53 65.2 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.451 -0.781 . . . . 0.0 110.056 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 36.3 mtt-85 -71.89 -45.63 60.61 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.209 -0.932 . . . . 0.0 111.719 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' NH1' HD12 ' A' ' 10' ' ' ILE . 27.6 ttp85 -59.34 -51.65 69.02 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.091 -1.006 . . . . 0.0 109.917 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.429 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.4 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -179.265 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -45.73 -33.21 2.87 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.283 -1.128 . . . . 0.0 111.632 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.519 HG22 HD13 ' A' ' 10' ' ' ILE . 14.9 t -100.65 144.12 30.01 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.884 -1.135 . . . . 0.0 110.884 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.97 14.54 24.51 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.389 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.429 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.59 84.23 0.61 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -1.201 . . . . 0.0 109.794 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.53 -26.34 13.34 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.903 -1.679 . . . . 0.0 108.903 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.499 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.96 -168.7 0.19 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.495 -1.003 . . . . 0.0 108.669 179.653 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.499 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.0 Cg_endo -87.32 110.95 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.14 1.074 . . . . 0.0 110.7 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.48 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -82.42 170.57 50.7 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 49.1 mt -126.48 142.64 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.516 -0.991 . . . . 0.0 108.416 178.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.505 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -128.77 114.75 16.97 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.721 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.444 ' HD3' HG11 ' A' ' 32' ' ' VAL . 18.2 mtp180 -105.27 122.88 46.86 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.423 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 32.0 p90 -121.72 158.06 29.58 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 110.662 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.451 HG22 HD23 ' A' ' 15' ' ' LEU . 32.1 t . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.466 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 . . . . . 0 N--CA 1.496 1.827 0 CA-C-O 120.971 0.415 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.68 HD11 ' O ' ' A' ' 122' ' ' THR . 30.3 mt -129.0 137.28 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.867 -1.146 . . . . 0.0 109.707 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -82.75 127.81 33.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.056 -1.028 . . . . 0.0 109.207 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.89 139.32 30.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.3 -0.875 . . . . 0.0 110.553 -179.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.78 HG11 ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.75 156.55 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.215 -0.928 . . . . 0.0 110.14 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.34 109.86 21.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -0.889 . . . . 0.0 110.109 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.708 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.77 141.88 36.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 109.311 179.456 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.33 174.57 10.62 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 110.548 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.58 0.99 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.325 -0.86 . . . . 0.0 110.276 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.732 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.9 m -155.68 109.32 2.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.174 -0.954 . . . . 0.0 110.482 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.421 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.49 -171.35 28.89 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.891 -1.623 . . . . 0.0 111.181 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.54 -22.59 11.57 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.722 -0.87 . . . . 0.0 110.45 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.943 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -95.26 107.12 30.31 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 118.872 -1.131 . . . . 0.0 109.455 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.43 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -63.84 144.67 89.15 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.249 1.131 . . . . 0.0 111.34 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.421 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.73 -166.37 1.85 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.522 -0.736 . . . . 0.0 110.318 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.572 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.8 m-85 -59.92 82.03 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.403 -0.811 . . . . 0.0 111.051 -179.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.4 5.85 51.49 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.708 ' CB ' HD23 ' A' ' 15' ' ' LEU . 14.4 mmtm -130.64 156.68 44.47 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.941 -1.329 . . . . 0.0 109.778 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.732 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.64 16.77 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.062 -1.024 . . . . 0.0 109.106 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 1.051 HD11 HG21 ' A' ' 100' ' ' ILE . 6.2 mt -69.12 114.16 21.57 Favored Pre-proline 0 C--N 1.299 -1.596 0 O-C-N 121.367 -0.833 . . . . 0.0 110.798 -179.081 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.736 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.2 Cg_endo -69.73 132.12 22.72 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.13 -1.912 . . . . 0.0 107.13 176.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.78 HD11 HD12 ' A' ' 58' ' ' LEU . 13.2 mt -56.95 -14.95 4.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.961 -1.087 . . . . 0.0 111.219 -177.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -63.31 -16.16 59.5 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.539 -1.351 . . . . 0.0 110.51 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 10.6 m -93.86 -24.44 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.052 -1.03 . . . . 0.0 110.87 -179.406 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 48.3 pt -117.16 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.035 -1.041 . . . . 0.0 110.493 -179.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.635 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.98 148.41 24.56 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -0.903 . . . . 0.0 110.501 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.74 -5.17 46.99 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.27 -147.68 7.79 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.428 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.8 132.5 53.93 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.406 -1.055 . . . . 0.0 110.473 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.546 ' HB2' HG12 ' A' ' 81' ' ' VAL . 88.2 m-70 -140.77 149.0 41.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 0.0 110.603 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.583 HD12 ' O ' ' A' ' 82' ' ' VAL . 57.3 tp -111.0 113.59 26.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.441 -0.787 . . . . 0.0 109.803 179.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.891 HD12 HG12 ' A' ' 83' ' ' VAL . 29.2 mt -96.41 127.38 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.882 . . . . 0.0 109.662 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.51 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.2 m-85 -95.08 122.72 38.03 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.295 -0.878 . . . . 0.0 110.251 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.04 160.16 21.98 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.339 -0.85 . . . . 0.0 110.733 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.572 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p-80 -110.01 4.65 21.55 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.396 -0.815 . . . . 0.0 109.964 178.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.52 136.41 49.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 110.987 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.498 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.84 69.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.645 -0.66 . . . . 0.0 110.861 -179.866 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.74 -36.75 73.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.28 -0.888 . . . . 0.0 110.917 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.13 -35.39 80.36 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.313 -0.867 . . . . 0.0 109.574 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.923 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 53.2 m -61.48 -33.83 74.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.511 -0.743 . . . . 0.0 109.764 179.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.19 -50.22 61.77 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.283 -0.886 . . . . 0.0 110.967 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.22 -44.11 63.44 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.119 -0.988 . . . . 0.0 110.569 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.638 ' CD2' HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -56.99 -38.35 72.91 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.562 -0.711 . . . . 0.0 111.242 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.62 -51.15 13.49 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.871 -1.143 . . . . 0.0 110.633 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.46 -40.04 85.58 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.146 -0.971 . . . . 0.0 110.145 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.695 ' CE ' HD21 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.04 82.99 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.318 -0.864 . . . . 0.0 109.788 179.739 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.902 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.07 -38.92 71.29 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.643 -0.661 . . . . 0.0 110.093 179.818 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.3 t -58.62 -34.38 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.185 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.29 -30.66 60.47 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.436 -0.79 . . . . 0.0 109.965 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.78 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -72.01 -25.71 61.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.437 -0.789 . . . . 0.0 109.773 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.9 10.3 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.635 HD11 ' HB2' ' A' ' 34' ' ' LYS . 45.9 mt -108.03 143.23 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.298 -1.119 . . . . 0.0 109.75 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 51.8 t30 -89.84 106.39 18.44 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.698 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.18 142.59 46.62 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.729 -177.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.927 HG21 ' HA ' ' A' ' 73' ' ' VAL . 57.4 t -125.56 149.41 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 120.139 -0.624 . . . . 0.0 109.701 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.923 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.69 119.05 34.25 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.433 178.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.475 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.42 132.72 55.52 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.216 -0.927 . . . . 0.0 110.839 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.75 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -166.93 176.85 6.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.569 -0.707 . . . . 0.0 109.719 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.15 125.35 15.44 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.069 -1.02 . . . . 0.0 110.707 -179.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.7 37.4 19.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.838 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.44 157.24 26.57 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.031 -1.276 . . . . 0.0 110.12 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.838 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -96.53 149.23 21.98 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.29 -0.881 . . . . 0.0 110.555 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.655 ' O ' HG23 ' A' ' 71' ' ' VAL . 30.3 m -62.66 111.37 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.193 -0.942 . . . . 0.0 109.121 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.82 -35.39 1.09 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.389 -0.819 . . . . 0.0 110.733 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.927 ' HA ' HG21 ' A' ' 63' ' ' VAL . 59.6 t -48.41 120.37 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.391 -0.818 . . . . 0.0 110.294 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.826 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.494 1.762 0 O-C-N 121.235 -0.916 . . . . 0.0 110.608 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.813 0.816 . . . . 0.0 110.182 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 5.2 p -116.92 135.56 56.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-O 122.151 0.977 . . . . 0.0 110.568 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 11.9 m -112.88 119.94 61.72 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.072 0 O-C-N 121.228 -0.92 . . . . 0.0 108.844 178.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.662 HG22 HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.84 45.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 120.886 -1.134 . . . . 0.0 110.265 -178.041 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.891 HG12 HD12 ' A' ' 40' ' ' ILE . 3.2 m -109.06 100.53 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.146 -0.971 . . . . 0.0 108.691 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.475 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.36 162.24 35.49 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.765 -1.21 . . . . 0.0 110.979 -178.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.513 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -88.26 -131.34 0.07 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.347 -0.846 . . . . 0.0 109.612 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.513 ' N ' HG23 ' A' ' 85' ' ' THR . 44.9 p30 -91.4 29.28 1.49 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.694 -1.254 . . . . 0.0 110.55 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.62 -29.06 12.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.052 -1.03 . . . . 0.0 110.231 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.144 -0.973 . . . . 0.0 109.742 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.0 t0 . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.055 0.455 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -119.77 147.98 43.97 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.111 -0.993 . . . . 0.0 110.115 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.495 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -71.11 -35.1 71.65 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.385 -0.822 . . . . 0.0 109.383 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.434 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.3 p -162.04 163.65 28.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.225 -0.922 . . . . 0.0 111.128 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.713 HG22 HG21 ' A' ' 122' ' ' THR . 1.3 m -129.36 118.1 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.52 -0.737 . . . . 0.0 110.091 179.378 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 1.051 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -92.6 111.98 25.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.14 160.26 21.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 111.718 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.533 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.23 6.26 38.08 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.159 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.442 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.04 25.43 0.49 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.406 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 1.3 p . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.294 -0.879 . . . . 0.0 110.396 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.442 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.341 0.591 . . . . 0.0 110.713 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.543 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -90.73 160.78 15.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.342 -0.849 . . . . 0.0 110.285 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.37 -52.26 4.63 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.544 -0.722 . . . . 0.0 112.34 -178.728 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.543 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.79 -29.27 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.855 -1.153 . . . . 0.0 111.214 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.43 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.39 -56.21 7.37 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.112 -0.993 . . . . 0.0 110.509 -179.377 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.439 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.4 OUTLIER -68.84 -34.5 75.59 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.168 -0.957 . . . . 0.0 108.789 178.685 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.446 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 31.3 m -60.02 -49.92 75.76 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.183 -0.948 . . . . 0.0 108.533 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.64 -39.93 64.13 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.546 -0.721 . . . . 0.0 109.671 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.439 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 4.1 mtt180 -66.21 -44.75 83.01 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 110.018 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.47 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 13.5 ttm180 -64.06 -34.08 77.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.221 -0.925 . . . . 0.0 110.279 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.455 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.33 12.07 1.96 Allowed Glycine 0 N--CA 1.497 2.73 0 O-C-N 121.055 -1.028 . . . . 0.0 112.3 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 1.2 mmt85 -101.32 -5.19 25.76 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.296 -1.708 . . . . 0.0 109.461 178.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.713 HG21 HG22 ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.44 142.15 50.31 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.224 -0.923 . . . . 0.0 109.424 179.782 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 78.48 26.5 59.12 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.455 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.3 82.62 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.134 -1.215 . . . . 0.0 110.109 179.908 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.59 24.92 5.45 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.474 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.5 -1.0 . . . . 0.0 109.105 -179.628 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 45.8 Cg_endo -84.47 99.58 0.75 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.187 1.099 . . . . 0.0 109.551 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.436 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.82 176.58 52.18 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.48 143.95 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.45 -1.03 . . . . 0.0 109.968 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.535 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 9.6 t80 -129.4 116.9 19.73 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.176 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.78 ' NE ' HG11 ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.21 137.9 37.07 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.541 -0.725 . . . . 0.0 109.215 179.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.458 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.6 p90 -137.8 153.98 49.6 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 110.719 -179.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.323 -0.861 . . . . 0.0 109.422 179.315 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 . . . . . 0 N--CA 1.494 1.771 0 CA-C-O 121.112 0.482 . . . . 0.0 110.436 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 31.1 mt -111.86 135.2 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.973 -1.079 . . . . 0.0 110.277 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.19 129.07 34.87 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.188 -0.945 . . . . 0.0 109.726 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.44 33.57 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.077 -1.014 . . . . 0.0 110.501 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.7 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 17.2 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.91 114.93 29.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.15 -0.968 . . . . 0.0 110.371 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.54 HD23 HG22 ' A' ' 133' ' ' VAL . 12.3 tp -63.2 135.65 57.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 109.607 179.561 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.3 p -134.78 171.58 14.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.093 -1.004 . . . . 0.0 110.602 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.532 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -149.21 112.68 5.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.353 -0.842 . . . . 0.0 110.349 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.33 -161.68 27.28 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.674 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -122.05 -22.35 5.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.724 -0.868 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.931 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -93.51 112.82 58.28 Favored Pre-proline 0 N--CA 1.488 1.426 0 C-N-CA 118.598 -1.241 . . . . 0.0 110.335 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -64.85 141.26 70.66 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.597 1.314 . . . . 0.0 109.977 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.459 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.91 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.101 -0.999 . . . . 0.0 111.732 -178.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.574 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.08 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.534 -0.729 . . . . 0.0 111.558 178.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 12.07 25.88 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.468 ' CB ' HD23 ' A' ' 15' ' ' LEU . 10.2 mmtt -129.91 156.63 44.1 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.055 -1.262 . . . . 0.0 109.235 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.532 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.93 15.11 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.873 -1.142 . . . . 0.0 108.891 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.931 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -70.88 114.97 31.3 Favored Pre-proline 0 C--N 1.296 -1.733 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.045 -179.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.845 ' O ' HG22 ' A' ' 32' ' ' VAL . 38.9 Cg_endo -67.51 130.32 22.01 Favored 'Trans proline' 0 C--N 1.302 -1.878 0 N-CA-C 107.465 -1.783 . . . . 0.0 107.465 176.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.769 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.32 -16.41 5.5 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.939 -1.101 . . . . 0.0 110.628 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.21 -16.22 59.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.671 -1.268 . . . . 0.0 110.576 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -92.68 -25.21 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 120.934 -1.104 . . . . 0.0 111.074 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 30.7 pt -116.41 -29.73 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.622 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.35 148.15 24.4 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.294 -0.879 . . . . 0.0 110.385 179.404 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.12 -5.21 49.46 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.09 -152.52 11.25 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.122 -1.514 . . . . 0.0 110.533 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.18 128.61 50.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.469 -1.018 . . . . 0.0 110.436 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.628 ' HB2' HG12 ' A' ' 81' ' ' VAL . 54.6 m80 -139.47 149.93 44.58 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 110.474 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.577 HD12 ' HB ' ' A' ' 82' ' ' VAL . 19.9 tp -111.85 117.26 32.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.403 -0.811 . . . . 0.0 110.403 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.893 ' CG1' HG12 ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.307 -0.871 . . . . 0.0 108.997 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.433 ' CZ ' ' HG2' ' A' ' 118' ' ' ARG . 5.8 m-85 -94.84 122.0 37.02 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.98 -1.075 . . . . 0.0 110.059 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.35 159.37 23.53 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.409 -0.807 . . . . 0.0 110.442 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.574 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.69 18.17 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.413 -0.805 . . . . 0.0 109.617 178.465 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.53 141.35 47.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.093 -1.005 . . . . 0.0 110.476 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.09 -35.69 69.3 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.535 -0.728 . . . . 0.0 110.549 -179.912 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.17 -45.38 88.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.303 -0.873 . . . . 0.0 110.591 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.14 -38.32 85.98 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.409 -0.807 . . . . 0.0 109.613 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.934 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.2 -34.19 74.68 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.488 -0.757 . . . . 0.0 109.56 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.24 -48.68 69.75 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.208 -0.933 . . . . 0.0 110.784 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.427 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.26 -44.61 64.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.204 -0.935 . . . . 0.0 110.472 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 1.044 HD12 HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.64 77.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.319 -0.863 . . . . 0.0 111.002 -179.058 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.434 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.16 -51.41 21.43 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.059 -1.026 . . . . 0.0 110.484 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.09 -43.46 98.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.93 . . . . 0.0 110.039 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.623 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.2 -46.16 83.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.171 -0.956 . . . . 0.0 109.526 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.747 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.76 -40.96 73.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.537 -0.727 . . . . 0.0 110.176 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.0 t -57.33 -35.34 48.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.984 -1.073 . . . . 0.0 108.978 179.425 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -31.26 59.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.352 -0.842 . . . . 0.0 110.243 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.769 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.32 -25.8 62.56 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.94 0.876 . . . . 0.0 109.75 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.41 5.77 10.11 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.662 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.7 mt -108.03 143.29 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.468 -1.019 . . . . 0.0 110.08 -179.532 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.508 ' ND2' HD11 ' A' ' 74' ' ' ILE . 45.9 t30 -89.52 106.64 18.59 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.741 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.77 144.4 46.31 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.708 -177.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.928 HG21 ' HA ' ' A' ' 73' ' ' VAL . 48.8 t -127.84 145.91 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.881 -0.727 . . . . 0.0 109.646 179.243 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.934 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -110.09 119.42 39.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.877 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.518 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 4.1 t80 -116.45 127.26 54.43 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.229 -0.92 . . . . 0.0 110.655 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.835 ' CE1' HD23 ' A' ' 69' ' ' LEU . 1.2 p90 -153.22 -171.4 3.91 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.402 -0.811 . . . . 0.0 110.013 179.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.56 126.9 21.03 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.308 -0.87 . . . . 0.0 111.276 -179.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.85 48.63 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.835 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.73 155.0 30.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.978 -1.307 . . . . 0.0 109.958 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.818 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.3 m-20 -90.75 149.49 21.99 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.37 -0.832 . . . . 0.0 110.694 -179.18 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.683 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.4 m -62.54 110.94 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.145 -0.972 . . . . 0.0 109.586 179.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.44 ' O ' HG23 ' A' ' 74' ' ' ILE . 34.5 m -132.11 -23.82 2.16 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.383 -0.823 . . . . 0.0 111.178 -179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.928 ' HA ' HG21 ' A' ' 63' ' ' VAL . 22.6 t -60.1 138.73 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.133 -0.979 . . . . 0.0 110.082 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.508 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.2 pp . . . . . 0 N--CA 1.495 1.797 0 O-C-N 121.203 -0.935 . . . . 0.0 110.541 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 122.036 0.922 . . . . 0.0 110.379 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.1 p -116.88 133.75 62.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.039 0.923 . . . . 0.0 110.425 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.628 HG12 ' HB2' ' A' ' 38' ' ' HIS . 6.1 m -113.54 123.56 69.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 O-C-N 121.502 -0.749 . . . . 0.0 109.021 179.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.721 HG22 HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.51 118.04 43.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.958 -1.089 . . . . 0.0 110.649 -177.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.044 HG11 HD12 ' A' ' 51' ' ' LEU . 3.4 m -106.64 100.45 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.009 -1.057 . . . . 0.0 108.634 179.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.518 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -144.19 162.39 36.45 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.667 -1.27 . . . . 0.0 111.239 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -92.9 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.476 -0.765 . . . . 0.0 108.988 179.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.443 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -86.36 50.06 1.92 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.72 -1.237 . . . . 0.0 109.931 179.416 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.68 -18.63 9.61 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.22 -0.925 . . . . 0.0 110.583 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.462 ' HA ' HD12 ' A' ' 88' ' ' LEU . 14.2 tp . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.031 -1.043 . . . . 0.0 109.71 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 121.007 0.432 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -119.66 146.6 45.43 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.015 -1.053 . . . . 0.0 110.345 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.33 -34.81 58.98 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.516 -0.74 . . . . 0.0 109.508 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.441 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -160.89 163.02 32.26 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.249 -0.907 . . . . 0.0 110.778 179.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.554 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.29 118.15 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.21 -0.931 . . . . 0.0 110.131 179.375 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.71 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -95.96 117.73 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.462 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.427 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 18.8 t0 -124.46 161.36 26.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.137 -0.977 . . . . 0.0 111.851 -178.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.91 -6.81 34.84 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 55.7 15.36 1.56 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.319 -0.863 . . . . 0.0 111.654 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.308 -1.221 0 O-C-N 120.731 -1.231 . . . . 0.0 109.535 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.832 0 CA-C-O 121.357 0.598 . . . . 0.0 111.163 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.523 ' OD1' HG22 ' A' ' 113' ' ' VAL . 3.0 p30 -87.77 160.98 17.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.333 -0.854 . . . . 0.0 110.292 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.15 3.75 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.339 -0.851 . . . . 0.0 111.832 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.523 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.66 -29.76 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.932 -1.105 . . . . 0.0 111.794 -178.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.408 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.27 -56.1 7.42 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.083 -1.011 . . . . 0.0 110.426 -179.142 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.471 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.35 -32.87 72.22 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.224 -0.922 . . . . 0.0 108.848 178.808 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.471 ' N ' ' HG2' ' A' ' 115' ' ' ARG . 25.3 m -61.11 -49.8 75.81 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.109 -0.994 . . . . 0.0 108.409 178.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.97 -36.3 64.56 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.918 -0.713 . . . . 0.0 109.807 178.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HG2' ' CZ ' ' A' ' 41' ' ' PHE . 49.1 mtt-85 -71.68 -44.47 64.19 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.255 -0.903 . . . . 0.0 111.117 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.458 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 19.5 ttm180 -56.7 -41.03 76.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.891 -1.131 . . . . 0.0 109.93 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.06 71.43 0.19 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.456 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.72 -45.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.593 -0.945 . . . . 0.0 108.836 179.488 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.518 HG23 ' HA3' ' A' ' 128' ' ' GLY . 9.2 t -101.14 143.01 31.76 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.598 -0.689 . . . . 0.0 109.393 178.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 4.0 22.02 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.184 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.01 85.38 0.71 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.995 -1.297 . . . . 0.0 109.822 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 104.08 9.79 35.99 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 3.6 pttt -174.96 -173.76 0.22 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.318 -1.107 . . . . 0.0 108.659 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.469 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.0 Cg_endo -88.15 105.33 0.51 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.22 1.116 . . . . 0.0 110.297 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.518 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.42 170.45 53.61 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.706 -1.235 . . . . 0.0 110.102 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -126.79 142.55 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.535 -0.979 . . . . 0.0 108.862 179.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.554 ' CD2' HG23 ' A' ' 99' ' ' VAL . 6.3 t80 -129.33 115.18 17.18 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.982 -1.073 . . . . 0.0 110.578 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.7 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.68 122.85 42.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.47 -0.768 . . . . 0.0 109.273 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 24.0 p90 -121.41 148.7 44.05 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.05 -1.031 . . . . 0.0 110.262 -179.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.54 HG22 HD23 ' A' ' 15' ' ' LEU . 46.1 t . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.524 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.446 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 . . . . . 0 N--CA 1.494 1.749 0 CA-C-O 121.135 0.493 . . . . 0.0 110.19 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.445 HD11 ' O ' ' A' ' 122' ' ' THR . 40.8 mt -117.52 136.39 54.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 110.533 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.164 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 110.382 -179.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.49 156.3 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.439 -0.788 . . . . 0.0 110.05 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.01 111.49 24.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.276 -0.89 . . . . 0.0 110.169 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.438 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.16 136.17 48.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.358 -0.839 . . . . 0.0 109.877 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.97 173.83 11.28 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.132 -0.98 . . . . 0.0 110.22 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.9 p -67.57 74.32 0.16 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 109.814 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.634 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.8 m -145.59 109.55 4.84 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.379 -0.826 . . . . 0.0 110.388 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.7 27.93 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.671 179.567 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.04 -25.01 5.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.696 -0.884 . . . . 0.0 110.561 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.34 52.55 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.172 -179.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.438 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -64.79 143.01 78.8 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.5 1.263 . . . . 0.0 110.158 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.5 t80 -155.23 94.84 1.66 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 111.286 -178.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.433 ' CZ ' ' CE1' ' A' ' 43' ' ' HIS . 23.7 m-85 57.66 67.07 1.01 Allowed 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.535 -0.728 . . . . 0.0 111.611 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.5 13.33 16.4 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 22.2 mmtm -130.6 156.99 43.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.142 -1.211 . . . . 0.0 109.185 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.634 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.6 107.52 16.26 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.906 -1.121 . . . . 0.0 109.827 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.5 mt -69.97 113.39 17.28 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 121.372 -0.83 . . . . 0.0 109.894 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.781 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.8 Cg_endo -68.99 128.88 17.41 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 N-CA-C 106.993 -1.964 . . . . 0.0 106.993 176.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.59 HD11 HD12 ' A' ' 58' ' ' LEU . 6.2 mt -56.61 -15.98 5.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.854 -1.154 . . . . 0.0 111.137 -177.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.425 ' OE2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.43 62.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.65 -1.281 . . . . 0.0 110.869 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.069 HG23 HG23 ' A' ' 33' ' ' ILE . 15.1 m -89.68 -26.5 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.922 -1.111 . . . . 0.0 111.134 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.069 HG23 HG23 ' A' ' 32' ' ' VAL . 43.3 pt -116.94 -23.68 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.165 -0.96 . . . . 0.0 110.048 -179.626 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.597 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.59 148.35 22.15 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.174 -0.954 . . . . 0.0 110.596 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.23 51.73 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.18 -151.61 9.86 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.211 -1.471 . . . . 0.0 110.208 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.57 130.72 54.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -1.078 . . . . 0.0 110.208 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.56 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.9 m80 -140.81 148.81 41.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.117 -0.99 . . . . 0.0 110.983 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 20.2 tp -109.76 123.18 49.09 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.924 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.94 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.8 mt -104.78 128.73 58.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.286 -0.883 . . . . 0.0 108.876 179.225 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.424 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.3 122.86 37.28 Favored 'General case' 0 C--N 1.294 -1.844 0 O-C-N 121.241 -0.912 . . . . 0.0 110.348 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.83 160.05 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.335 -0.853 . . . . 0.0 110.8 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.433 ' CE1' ' CZ ' ' A' ' 24' ' ' TYR . 3.9 p-80 -115.51 5.23 14.39 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.575 -0.703 . . . . 0.0 109.799 178.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.74 138.14 45.61 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.007 . . . . 0.0 110.878 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.509 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.69 -43.35 66.11 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.709 -0.619 . . . . 0.0 110.53 -179.931 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.66 -34.5 74.4 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.325 -0.859 . . . . 0.0 110.564 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.21 -38.19 66.18 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.233 -0.917 . . . . 0.0 109.911 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.942 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 61.5 m -61.4 -34.48 75.43 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.521 -0.737 . . . . 0.0 109.892 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.24 -49.72 58.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 110.381 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.01 -46.38 57.41 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.246 -0.909 . . . . 0.0 110.274 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.798 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -56.92 -42.65 80.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.976 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.475 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -73.38 -50.85 19.74 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.01 -1.056 . . . . 0.0 110.651 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -40.5 97.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.038 -1.039 . . . . 0.0 109.733 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.541 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.24 -43.1 82.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.315 -0.866 . . . . 0.0 109.434 179.394 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.727 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -55.34 -42.87 74.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.39 -0.819 . . . . 0.0 109.749 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.14 -32.58 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -0.966 . . . . 0.0 108.716 179.043 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.52 -32.08 60.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.571 -0.706 . . . . 0.0 110.013 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.59 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.52 -26.26 62.58 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.298 -0.876 . . . . 0.0 109.595 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 5.47 9.45 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.597 HD11 ' HB2' ' A' ' 34' ' ' LYS . 51.8 mt -108.26 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.303 -1.116 . . . . 0.0 110.069 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 36.7 t30 -86.65 107.04 18.02 Favored 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.727 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.03 147.74 45.71 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.541 -177.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.952 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.8 t -135.73 142.43 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.518 179.278 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.942 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -105.35 135.05 47.44 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.244 -0.983 . . . . 0.0 109.871 179.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.447 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.62 131.29 49.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.12 -0.987 . . . . 0.0 110.792 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.685 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.6 p90 -166.25 175.33 8.39 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.66 -0.65 . . . . 0.0 109.515 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.74 114.89 1.41 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.249 -0.907 . . . . 0.0 110.799 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.77 31.45 7.77 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.916 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.53 157.31 26.55 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.064 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.916 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.3 m-20 -96.91 149.45 21.86 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.195 -0.941 . . . . 0.0 110.508 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.677 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.3 m -62.64 111.25 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.189 -0.945 . . . . 0.0 109.162 179.224 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.638 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.6 m -133.63 -32.19 1.15 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.337 -0.852 . . . . 0.0 111.08 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.952 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.4 t -53.73 137.94 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.193 -0.942 . . . . 0.0 109.825 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.638 HG23 ' O ' ' A' ' 72' ' ' SER . 1.2 pp . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.223 -0.923 . . . . 0.0 111.169 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 122.109 0.957 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 12.0 p -117.86 133.16 65.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.089 0.947 . . . . 0.0 110.111 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.59 HG22 HG22 ' A' ' 60' ' ' ILE . 4.7 m -113.87 125.45 71.16 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.369 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.088 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.681 HG22 HG13 ' A' ' 73' ' ' VAL . 9.1 t -97.18 121.17 47.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 121.008 -1.058 . . . . 0.0 110.133 -178.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.94 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.2 m -114.88 100.07 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.706 -1.246 . . . . 0.0 108.586 179.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.447 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.27 163.99 33.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.667 -1.271 . . . . 0.0 111.659 -177.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.481 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -84.11 -138.56 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.597 -0.689 . . . . 0.0 109.6 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.481 ' N ' HG23 ' A' ' 85' ' ' THR . 0.7 OUTLIER -87.53 14.4 8.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.799 -1.188 . . . . 0.0 110.613 179.817 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.476 ' H ' HG23 ' A' ' 85' ' ' THR . . . -86.54 -21.82 26.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.989 -1.069 . . . . 0.0 110.181 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.128 -0.983 . . . . 0.0 110.143 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.3 t0 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.158 0.504 . . . . 0.0 110.201 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -119.38 144.36 46.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.23 -0.919 . . . . 0.0 110.339 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.424 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 6.5 m-20 -78.95 -31.66 45.18 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.694 179.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -161.56 163.15 30.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.294 -0.879 . . . . 0.0 110.768 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.523 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.45 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.271 -0.893 . . . . 0.0 110.08 179.27 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.887 HG21 HD11 ' A' ' 28' ' ' ILE . 3.0 mp -93.41 119.18 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.276 -0.89 . . . . 0.0 109.14 179.349 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' A' ' 41' ' ' PHE . 2.4 t70 -128.47 160.58 31.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.121 -0.987 . . . . 0.0 111.599 -178.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.45 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.96 -5.14 31.14 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 177.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.15 14.02 1.38 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.285 -0.884 . . . . 0.0 111.723 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 C--N 1.307 -1.242 0 O-C-N 120.678 -1.264 . . . . 0.0 109.043 179.585 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.476 0.655 . . . . 0.0 110.99 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.506 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.8 p-10 -73.82 162.88 28.65 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.558 -0.714 . . . . 0.0 110.287 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.449 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.24 -44.8 92.33 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.877 -1.14 . . . . 0.0 111.6 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.506 HG22 ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.76 -30.66 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.716 -1.24 . . . . 0.0 112.74 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 2.6 p -53.6 -55.25 27.39 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.449 -1.407 . . . . 0.0 110.162 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.449 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.64 -35.33 75.92 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.048 178.435 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.415 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 26.2 m -62.07 -50.35 72.32 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 119.369 -0.932 . . . . 0.0 108.581 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.25 -46.83 39.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.322 -0.861 . . . . 0.0 109.982 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 114' ' ' SER . 60.2 mtt180 -61.3 -45.29 95.06 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.268 -0.895 . . . . 0.0 110.967 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.478 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.9 ttm180 -55.55 -38.68 69.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.694 -1.254 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.78 0.28 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.61 -50.81 0.24 Allowed 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.468 -1.019 . . . . 0.0 108.632 179.666 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.487 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -94.79 142.35 27.57 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.484 1.891 0 C-N-CA 119.335 -1.412 . . . . 0.0 110.574 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.2 86.19 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.883 -1.363 . . . . 0.0 109.931 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.89 -43.01 1.75 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.472 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 12.9 mttt -111.0 -171.68 0.22 Allowed Pre-proline 0 N--CA 1.487 1.392 0 O-C-N 121.611 -0.935 . . . . 0.0 109.454 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.457 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.9 Cg_endo -90.75 107.79 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.61 1.321 . . . . 0.0 109.786 179.044 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.487 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.33 166.07 50.92 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.429 ' O ' ' HA ' ' A' ' 98' ' ' SER . 4.0 mt -119.55 140.49 43.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.227 179.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.523 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.6 t80 -128.73 114.93 17.21 Favored 'General case' 0 C--N 1.3 -1.585 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.139 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.418 ' NE ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -99.38 134.28 42.48 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 109.665 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.474 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.16 148.26 50.59 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.157 -0.964 . . . . 0.0 109.803 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.45 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.1 t . . . . . 0 N--CA 1.493 1.682 0 O-C-N 121.068 -1.02 . . . . 0.0 110.042 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.8 m120 . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 121.307 0.575 . . . . 0.0 110.29 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.832 HD13 HG23 ' A' ' 122' ' ' THR . 62.2 mt -108.75 136.64 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.044 -1.035 . . . . 0.0 110.141 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.43 127.94 34.1 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.188 -0.945 . . . . 0.0 109.25 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.72 135.66 33.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.159 -0.963 . . . . 0.0 110.185 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.8 t -137.22 156.41 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.286 -0.884 . . . . 0.0 110.423 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.33 113.83 26.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 0.0 109.83 179.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.647 HD23 ' CB ' ' A' ' 26' ' ' LYS . 8.8 tp -52.78 142.58 18.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.161 -0.962 . . . . 0.0 110.111 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 p -138.22 174.36 10.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.262 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.2 71.91 1.71 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.289 -0.882 . . . . 0.0 109.969 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.753 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -144.19 110.15 5.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 110.513 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.77 -171.44 26.75 Favored Glycine 0 N--CA 1.488 2.145 0 C-N-CA 118.876 -1.631 . . . . 0.0 110.859 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -108.95 -26.18 10.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.65 -0.912 . . . . 0.0 110.394 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.979 HD12 HD13 ' A' ' 55' ' ' LEU . 8.0 tt -95.27 101.53 7.69 Favored Pre-proline 0 N--CA 1.487 1.403 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.357 -179.38 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 36.5 Cg_endo -61.29 155.29 52.6 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.516 1.272 . . . . 0.0 110.228 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.589 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.75 94.48 0.5 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.091 -1.005 . . . . 0.0 111.309 -178.024 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.589 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 60.0 68.28 0.79 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.407 -0.808 . . . . 0.0 111.673 178.808 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 14.6 11.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.647 ' CB ' HD23 ' A' ' 15' ' ' LEU . 21.4 mmtt -130.73 156.69 44.52 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.082 -1.246 . . . . 0.0 109.2 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.753 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.24 108.07 16.11 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.986 -1.071 . . . . 0.0 109.086 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 1.088 HD11 HG21 ' A' ' 100' ' ' ILE . 5.1 mt -71.31 113.33 18.47 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.117 -179.384 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.89 ' O ' HG22 ' A' ' 32' ' ' VAL . 43.0 Cg_endo -71.04 129.69 16.64 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.053 -1.941 . . . . 0.0 107.053 176.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.489 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.8 mt -55.77 -18.82 9.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.808 -1.182 . . . . 0.0 110.545 -177.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -15.97 23.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.628 -1.295 . . . . 0.0 110.332 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.069 HG23 HG23 ' A' ' 33' ' ' ILE . 16.2 m -93.36 -25.36 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.882 -1.136 . . . . 0.0 111.057 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.069 HG23 HG23 ' A' ' 32' ' ' VAL . 21.4 pt -117.9 -16.17 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.01 -1.056 . . . . 0.0 110.923 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.566 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -97.82 148.49 23.34 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.844 -1.16 . . . . 0.0 110.083 179.534 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.17 -4.14 51.81 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.65 -159.08 23.37 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.347 -1.406 . . . . 0.0 110.082 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.89 133.45 44.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.275 -1.132 . . . . 0.0 110.547 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.76 147.01 40.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.098 -1.001 . . . . 0.0 110.703 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.592 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.2 tp -108.54 113.74 27.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.417 -0.802 . . . . 0.0 109.998 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.784 HD12 HG12 ' A' ' 83' ' ' VAL . 25.9 mt -96.54 126.89 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.341 -0.85 . . . . 0.0 109.409 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.504 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 34.0 m-85 -95.23 123.75 38.9 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.41 -0.806 . . . . 0.0 109.978 -179.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.01 160.23 21.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.192 -0.943 . . . . 0.0 110.606 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.545 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 4.3 p-80 -107.18 -3.81 19.46 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.439 -0.788 . . . . 0.0 110.175 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.65 50.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.066 -1.021 . . . . 0.0 110.779 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.516 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.53 -41.38 69.24 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.81 -0.556 . . . . 0.0 110.646 -179.765 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mttp -58.79 -35.27 72.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.195 -0.941 . . . . 0.0 110.109 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.26 -34.86 66.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.347 -0.846 . . . . 0.0 109.427 179.656 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.811 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 91.9 m -60.7 -34.23 74.05 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.511 -0.743 . . . . 0.0 109.58 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.06 -49.16 63.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.17 -0.956 . . . . 0.0 110.246 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.7 -42.68 67.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.258 -0.901 . . . . 0.0 110.599 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.775 HD12 HG11 ' A' ' 83' ' ' VAL . 1.1 tm? -57.23 -41.1 78.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.427 -0.796 . . . . 0.0 111.295 -179.018 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.95 -51.48 12.33 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.874 -1.141 . . . . 0.0 110.528 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.6 89.78 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.996 -1.065 . . . . 0.0 109.48 179.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.531 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.98 -45.77 86.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.475 -0.766 . . . . 0.0 109.559 179.337 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.979 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.83 -42.0 75.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 109.898 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.8 t -56.35 -33.71 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.091 -1.006 . . . . 0.0 109.181 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -32.05 61.01 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.32 -0.862 . . . . 0.0 109.863 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.531 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.69 -26.2 62.41 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.379 -0.826 . . . . 0.0 109.529 179.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.52 6.09 8.94 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.618 HG22 HG22 ' A' ' 81' ' ' VAL . 30.6 mt -108.25 143.72 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.254 -1.145 . . . . 0.0 110.143 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.621 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.3 t30 -87.07 107.3 18.38 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.608 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.22 147.33 45.76 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.744 -177.274 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.88 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.6 t -134.75 150.0 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.916 -0.714 . . . . 0.0 109.326 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.811 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.47 136.4 52.83 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.011 179.078 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.577 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.1 t80 -123.47 128.12 49.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.911 . . . . 0.0 110.742 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.849 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.12 -179.94 8.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.515 -0.741 . . . . 0.0 109.858 179.63 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.73 11.0 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.238 -0.913 . . . . 0.0 111.012 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.76 47.73 19.39 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.849 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -116.96 153.02 33.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.058 -1.26 . . . . 0.0 109.608 179.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.4 m-20 -89.55 148.25 23.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.219 -0.925 . . . . 0.0 110.994 -178.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.677 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.5 m -63.2 111.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.102 -0.999 . . . . 0.0 109.235 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.712 ' O ' HG23 ' A' ' 74' ' ' ILE . 18.1 m -132.58 -38.31 1.03 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.266 -0.896 . . . . 0.0 110.488 -179.486 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.88 HG22 ' HB ' ' A' ' 63' ' ' VAL . 64.6 t -48.19 137.3 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.388 -0.82 . . . . 0.0 110.464 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.712 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.627 0 O-C-N 121.305 -0.872 . . . . 0.0 110.298 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.944 0.878 . . . . 0.0 110.024 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.555 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -117.06 134.8 59.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 122.014 0.911 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.618 HG22 HG22 ' A' ' 60' ' ' ILE . 11.4 m -112.6 125.76 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.334 -0.854 . . . . 0.0 109.02 179.127 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.795 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -97.39 118.34 43.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 120.935 -1.103 . . . . 0.0 110.037 -178.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.784 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -112.64 100.09 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.027 -1.046 . . . . 0.0 108.806 179.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.51 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -142.0 162.23 36.0 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.613 -1.304 . . . . 0.0 111.521 -178.079 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.699 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -87.01 -143.95 0.12 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.678 -0.639 . . . . 0.0 109.353 179.39 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.409 ' N ' HG23 ' A' ' 85' ' ' THR . 3.1 p30 -73.9 -4.62 36.12 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.926 -1.109 . . . . 0.0 110.782 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.699 ' H ' HG23 ' A' ' 85' ' ' THR . . . -61.65 -40.05 93.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.144 . . . . 0.0 110.502 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.107 -0.996 . . . . 0.0 109.844 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.198 0.523 . . . . 0.0 110.421 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.441 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 21.9 m-85 -119.42 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.109 -0.994 . . . . 0.0 109.726 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.445 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.99 -35.59 80.7 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.142 -0.973 . . . . 0.0 109.067 179.538 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.485 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.59 31.79 Favored 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.741 -0.784 . . . . 0.0 110.863 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.741 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.12 117.6 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.453 -0.78 . . . . 0.0 110.571 179.837 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 1.088 HG21 HD11 ' A' ' 28' ' ' ILE . 2.9 mp -93.1 112.59 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.29 161.1 21.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.115 -0.99 . . . . 0.0 111.912 -178.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.506 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.1 p -102.83 6.57 39.29 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.068 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.409 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.2 m120 45.86 25.4 0.29 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.238 -0.913 . . . . 0.0 111.349 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.9 p . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.921 . . . . 0.0 110.028 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.421 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 121.147 0.499 . . . . 0.0 110.709 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.512 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -96.36 160.29 14.5 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.298 -0.876 . . . . 0.0 110.397 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.44 -48.26 37.5 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.418 -0.801 . . . . 0.0 112.001 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.512 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -71.17 -29.56 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.769 -1.207 . . . . 0.0 110.836 -178.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.48 -56.31 7.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.217 -0.927 . . . . 0.0 110.387 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.426 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.66 -34.82 76.35 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.279 -0.888 . . . . 0.0 108.715 178.705 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.459 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 42.7 m -59.79 -49.82 76.24 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.064 -1.022 . . . . 0.0 108.608 178.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -73.82 -38.89 64.42 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.43 -0.794 . . . . 0.0 109.951 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 82.8 mtt180 -70.18 -44.29 69.05 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.262 -0.899 . . . . 0.0 110.586 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.571 ' O ' HG23 ' A' ' 122' ' ' THR . 34.5 ttm180 -54.45 -36.58 64.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.222 -0.924 . . . . 0.0 110.577 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.94 -15.85 11.1 Favored Glycine 0 N--CA 1.494 2.527 0 O-C-N 120.959 -1.088 . . . . 0.0 111.524 -179.205 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.73 -3.58 22.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.651 -1.5 . . . . 0.0 111.485 -179.252 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.832 HG23 HD13 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.98 143.53 48.97 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.76 -1.213 . . . . 0.0 110.9 -179.685 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.469 ' N ' ' HA3' ' A' ' 128' ' ' GLY . . . 74.93 12.25 83.32 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.846 178.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.2 mtt180 -61.3 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.048 -1.266 . . . . 0.0 109.022 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.4 16.64 39.46 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -178.516 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.459 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.2 OUTLIER -175.48 -176.48 0.26 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.472 -1.016 . . . . 0.0 108.779 -179.615 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.459 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -88.27 105.39 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.133 1.07 . . . . 0.0 109.983 179.452 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.469 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.23 173.82 25.63 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.529 -1.32 . . . . 0.0 110.198 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.28 142.94 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.486 -1.008 . . . . 0.0 109.572 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.741 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.44 114.93 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.757 -1.215 . . . . 0.0 110.389 179.4 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.441 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.55 145.68 27.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.495 -0.753 . . . . 0.0 109.484 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.7 p90 -137.89 157.08 47.14 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.906 -1.121 . . . . 0.0 110.306 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 N--CA 1.494 1.752 0 O-C-N 121.142 -0.974 . . . . 0.0 109.656 179.451 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.509 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.279 0.561 . . . . 0.0 109.898 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.488 HD13 HG22 ' A' ' 122' ' ' THR . 19.8 mt -105.28 134.83 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.856 -1.153 . . . . 0.0 110.027 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -84.93 128.28 34.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.328 -0.857 . . . . 0.0 108.893 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.43 142.74 27.39 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.043 -1.036 . . . . 0.0 110.245 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.611 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 13.3 t -136.53 157.29 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.943 -179.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.35 108.7 19.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.869 179.418 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.586 HD23 HG22 ' A' ' 133' ' ' VAL . 11.2 tp -54.98 134.35 48.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.798 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.0 p -137.97 -179.32 5.7 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.323 -0.861 . . . . 0.0 110.176 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.2 p -74.56 60.78 0.91 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -0.909 . . . . 0.0 109.988 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.456 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.8 m -131.73 111.41 11.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.892 . . . . 0.0 110.227 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.454 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.53 -162.61 27.97 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.977 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.32 -21.63 7.42 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.724 -0.868 . . . . 0.0 110.474 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.896 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.0 tt -97.39 107.1 36.8 Favored Pre-proline 0 N--CA 1.489 1.517 0 C-N-CA 118.796 -1.162 . . . . 0.0 110.24 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.448 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -63.64 155.01 65.62 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 O-C-N 123.385 1.203 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.7 t80 -169.13 91.6 0.25 Allowed 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.056 -1.027 . . . . 0.0 111.563 -178.123 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.501 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.82 67.27 0.89 Allowed 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.473 -0.767 . . . . 0.0 111.38 178.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.68 13.56 18.33 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.632 ' HG3' HG13 ' A' ' 133' ' ' VAL . 6.5 mmtt -130.8 156.23 45.34 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.14 -1.212 . . . . 0.0 109.08 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.456 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.81 106.92 12.56 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.896 -1.127 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.896 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.0 mt -68.47 115.1 26.44 Favored Pre-proline 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.61 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.911 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.1 Cg_endo -68.42 126.74 14.63 Favored 'Trans proline' 0 C--N 1.304 -1.813 0 N-CA-C 107.382 -1.815 . . . . 0.0 107.382 176.261 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.565 HD11 HD12 ' A' ' 58' ' ' LEU . 5.6 mt -56.08 -20.72 18.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.962 -1.086 . . . . 0.0 110.846 -177.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -59.95 -16.05 26.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.674 -1.266 . . . . 0.0 110.467 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.109 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.58 -25.33 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.005 -1.059 . . . . 0.0 110.955 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.109 HG23 HG23 ' A' ' 32' ' ' VAL . 14.7 pt -117.86 -15.49 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.963 -1.085 . . . . 0.0 110.951 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.597 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.5 tptm -98.22 147.77 24.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.809 -1.182 . . . . 0.0 110.507 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.35 -3.14 61.43 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.09 -159.45 21.29 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.23 -1.462 . . . . 0.0 110.374 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.375 -1.074 . . . . 0.0 110.543 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.563 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.11 147.86 39.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.225 -0.922 . . . . 0.0 110.918 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.429 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 40.4 tp -109.14 116.24 31.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.38 -0.825 . . . . 0.0 110.291 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.907 HD12 HG12 ' A' ' 83' ' ' VAL . 34.4 mt -99.89 127.77 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.132 -0.98 . . . . 0.0 109.687 179.465 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.05 39.55 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.327 -0.858 . . . . 0.0 109.891 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.71 159.72 21.82 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.821 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.501 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.43 -8.58 19.05 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.557 -0.714 . . . . 0.0 109.942 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.13 138.98 53.27 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.031 -1.043 . . . . 0.0 110.96 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.471 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.95 -40.37 68.73 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.315 0.579 . . . . 0.0 110.774 -179.79 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mttp -59.93 -36.49 77.13 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.369 -0.832 . . . . 0.0 111.028 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.28 71.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 -179.48 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.916 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 84.8 m -61.2 -36.36 79.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.284 -0.885 . . . . 0.0 109.302 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.45 66.85 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.267 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -73.01 -45.99 54.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.234 -0.916 . . . . 0.0 110.283 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.61 HD13 ' O ' ' A' ' 51' ' ' LEU . 3.2 tm? -57.01 -39.72 75.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.591 -0.693 . . . . 0.0 111.267 -179.002 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.477 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.88 -51.17 13.1 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.929 -1.107 . . . . 0.0 110.54 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.127 -0.983 . . . . 0.0 109.677 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.498 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.68 83.89 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.372 -0.83 . . . . 0.0 109.526 179.379 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.873 HD13 HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -54.94 -42.59 72.49 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.491 -0.756 . . . . 0.0 109.489 179.683 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.5 t -56.14 -31.02 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.99 -1.068 . . . . 0.0 108.725 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.03 -32.73 61.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.521 -0.737 . . . . 0.0 109.899 179.35 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.565 HD12 HD11 ' A' ' 30' ' ' LEU . 4.3 mm? -72.1 -26.11 62.01 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-O 121.851 0.834 . . . . 0.0 109.728 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.0 9.17 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.599 HG22 HG22 ' A' ' 81' ' ' VAL . 44.7 mt -107.55 143.24 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.247 -1.149 . . . . 0.0 109.861 -179.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 50.0 t30 -87.56 106.83 18.27 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.348 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.642 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 118.774 -1.17 . . . . 0.0 111.831 -177.079 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.896 HG21 ' HA ' ' A' ' 73' ' ' VAL . 92.2 t -126.01 148.12 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.697 -0.627 . . . . 0.0 109.828 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.916 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -117.77 117.63 29.85 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.495 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.485 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 3.5 t80 -108.14 131.25 54.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 110.878 -179.264 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.857 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -155.34 -168.72 2.93 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.62 -0.675 . . . . 0.0 109.958 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -55.92 123.66 15.04 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.319 -0.863 . . . . 0.0 111.266 -179.256 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.56 59.02 8.76 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.857 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.66 152.05 35.98 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.074 -1.25 . . . . 0.0 109.712 179.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.738 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -85.88 149.03 25.51 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.209 -0.932 . . . . 0.0 110.592 -179.276 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.683 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.0 m -62.5 110.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.133 179.178 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.707 ' O ' HG23 ' A' ' 74' ' ' ILE . 68.9 m -131.33 -32.09 1.58 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.372 -0.83 . . . . 0.0 110.656 -179.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.896 ' HA ' HG21 ' A' ' 63' ' ' VAL . 94.9 t -53.0 131.25 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.153 -0.967 . . . . 0.0 109.441 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 O-C-N 121.125 -0.984 . . . . 0.0 110.779 -179.263 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 122.018 0.914 . . . . 0.0 110.297 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.619 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.43 132.44 67.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 CA-C-O 122.087 0.946 . . . . 0.0 110.456 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.614 HG11 ' HB ' ' A' ' 33' ' ' ILE . 11.4 m -112.45 122.05 65.95 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 121.356 -0.84 . . . . 0.0 108.96 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.839 HG22 HG13 ' A' ' 73' ' ' VAL . 16.1 t -97.01 120.94 46.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.684 0 O-C-N 121.054 -1.029 . . . . 0.0 110.611 -177.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.907 HG12 HD12 ' A' ' 40' ' ' ILE . 3.3 m -112.39 100.39 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.044 -1.035 . . . . 0.0 108.667 179.321 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.485 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.7 34.44 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -177.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.574 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -93.19 -136.68 0.18 Allowed 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.525 ' N ' HG23 ' A' ' 85' ' ' THR . 3.3 p30 -77.04 -6.16 51.63 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.679 -1.263 . . . . 0.0 111.068 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.574 ' H ' HG23 ' A' ' 85' ' ' THR . . . -60.71 -41.52 95.4 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.849 -1.157 . . . . 0.0 110.066 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.4 tp . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 108.577 179.161 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.274 0.559 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -120.26 152.81 37.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.214 -0.929 . . . . 0.0 110.294 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.478 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.6 -28.35 30.88 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.425 -0.797 . . . . 0.0 109.831 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.503 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.6 p -160.7 163.58 32.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.283 -0.886 . . . . 0.0 110.712 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.503 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.91 128.12 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.345 -0.847 . . . . 0.0 110.138 179.441 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.86 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -105.95 111.11 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.195 -0.94 . . . . 0.0 108.666 178.778 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.418 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.7 t0 -115.85 161.29 18.99 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.052 -1.03 . . . . 0.0 111.96 -178.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.468 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.84 -2.91 43.04 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.023 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.411 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 53.89 21.48 2.82 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.007 . . . . 0.0 110.183 -179.098 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.323 -0.86 . . . . 0.0 110.153 179.662 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.408 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.474 0.654 . . . . 0.0 110.873 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.482 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -105.55 161.85 14.0 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.478 -0.764 . . . . 0.0 110.323 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.8 -59.85 1.8 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.315 -0.865 . . . . 0.0 112.156 -178.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.482 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.4 m -64.31 -29.32 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.788 -1.195 . . . . 0.0 111.764 -178.57 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.34 -56.5 6.73 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.009 -1.057 . . . . 0.0 110.63 -179.015 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.47 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.58 -34.75 76.35 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.719 178.933 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.401 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 29.5 m -59.13 -49.22 78.69 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.984 -1.072 . . . . 0.0 108.301 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . 0.418 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -36.99 65.87 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.508 -0.745 . . . . 0.0 109.9 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.425 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 5.1 mtt180 -71.8 -44.59 63.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.042 -1.036 . . . . 0.0 111.193 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.47 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 12.2 ttm180 -57.35 -41.64 80.48 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.848 -1.158 . . . . 0.0 109.834 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.421 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.05 63.88 0.21 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.443 ' N ' ' O ' ' A' ' 119' ' ' ARG . 10.9 mmp_? -135.38 -44.69 0.69 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.43 -1.041 . . . . 0.0 108.524 178.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.507 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.0 t -93.58 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.677 -0.639 . . . . 0.0 109.732 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.08 3.23 36.13 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.617 179.058 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.8 mmt180 -62.71 87.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.965 -1.315 . . . . 0.0 109.511 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.51 19.13 33.29 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -178.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.462 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 16.4 ptpt -176.23 -178.31 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.491 -1.005 . . . . 0.0 108.503 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.5 Cg_endo -89.16 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.254 1.134 . . . . 0.0 110.428 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.588 ' C ' HD12 ' A' ' 129' ' ' ILE . . . -80.85 176.72 54.59 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.772 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.588 HD12 ' C ' ' A' ' 128' ' ' GLY . 3.5 mp -132.52 143.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.764 -0.845 . . . . 0.0 109.043 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.503 ' HD1' HG23 ' A' ' 99' ' ' VAL . 9.6 t80 -129.95 115.52 17.28 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.24 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.611 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mtt180 -105.98 131.42 53.29 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.522 -0.736 . . . . 0.0 109.435 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.418 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 46.0 p90 -129.63 157.29 42.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.042 -1.036 . . . . 0.0 110.376 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.632 HG13 ' HG3' ' A' ' 26' ' ' LYS . 42.8 t . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.104 -0.997 . . . . 0.0 109.923 179.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.436 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.0 m-80 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.142 0.496 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.64 HD11 ' O ' ' A' ' 122' ' ' THR . 36.2 mt -128.05 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.187 -0.945 . . . . 0.0 109.413 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.97 128.45 34.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.139 -0.976 . . . . 0.0 109.305 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.06 133.09 34.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.206 -0.933 . . . . 0.0 110.429 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.522 HG11 ' HE ' ' A' ' 131' ' ' ARG . 16.5 t -128.66 156.11 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.403 -0.811 . . . . 0.0 110.021 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.61 110.9 21.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.252 -0.905 . . . . 0.0 109.968 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.718 HD23 HG22 ' A' ' 133' ' ' VAL . 11.7 tp -58.84 134.21 56.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.275 -0.891 . . . . 0.0 109.581 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.9 p -138.78 -175.19 4.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.24 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.5 p -77.75 81.3 4.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.264 -0.897 . . . . 0.0 109.896 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.625 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.8 m -153.64 109.5 3.27 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.297 -0.877 . . . . 0.0 110.656 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.74 -165.08 28.07 Favored Glycine 0 N--CA 1.487 2.044 0 C-N-CA 119.072 -1.537 . . . . 0.0 110.567 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.7 -21.83 8.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.647 -0.914 . . . . 0.0 110.275 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.876 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -96.19 110.69 53.55 Favored Pre-proline 0 N--CA 1.487 1.407 0 C-N-CA 118.8 -1.16 . . . . 0.0 109.91 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.462 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.3 Cg_endo -64.63 155.39 67.07 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.684 1.36 . . . . 0.0 110.285 -179.515 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.4 t80 -169.5 94.06 0.28 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.112 -0.993 . . . . 0.0 111.508 -178.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.583 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 24.9 m-85 58.38 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.393 -0.817 . . . . 0.0 111.497 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.44 14.76 9.61 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.431 -1.067 . . . . 0.0 110.431 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.473 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.8 156.8 44.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.041 -1.27 . . . . 0.0 109.418 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.625 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -114.7 107.35 15.34 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 120.967 -1.083 . . . . 0.0 109.5 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.865 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.3 mt -69.56 113.9 20.46 Favored Pre-proline 0 C--N 1.299 -1.6 0 O-C-N 121.383 -0.823 . . . . 0.0 110.215 -179.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.917 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.8 Cg_endo -70.27 129.73 17.54 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 N-CA-C 107.189 -1.889 . . . . 0.0 107.189 176.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.818 HD11 HD12 ' A' ' 58' ' ' LEU . 17.6 mt -56.33 -18.19 10.07 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.874 -1.141 . . . . 0.0 110.94 -177.659 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.49 -16.47 24.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.636 -1.29 . . . . 0.0 110.087 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.025 HG23 HG23 ' A' ' 33' ' ' ILE . 14.4 m -93.96 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.155 -0.966 . . . . 0.0 110.981 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.025 HG23 HG23 ' A' ' 32' ' ' VAL . 40.9 pt -118.15 -22.79 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.934 -1.104 . . . . 0.0 110.872 -178.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.596 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.26 22.16 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.506 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.02 -5.27 59.35 Favored Glycine 0 N--CA 1.483 1.82 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.22 -162.58 27.81 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.678 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.22 129.38 44.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.468 -1.019 . . . . 0.0 110.351 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.5 m-70 -138.93 145.59 40.01 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.222 -0.924 . . . . 0.0 110.607 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.593 HD12 ' O ' ' A' ' 82' ' ' VAL . 38.3 tp -108.06 117.17 33.43 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.922 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.5 mm -94.03 125.69 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.275 -0.891 . . . . 0.0 108.601 179.26 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.471 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 11.4 m-85 -94.21 121.81 36.11 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.089 -1.007 . . . . 0.0 109.637 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.46 150.69 39.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.271 -0.893 . . . . 0.0 110.83 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.583 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 2.4 p-80 -103.74 3.59 34.33 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 109.682 178.442 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.55 135.39 45.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.186 -0.946 . . . . 0.0 110.199 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.454 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.4 ttpt -71.28 -37.2 71.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.609 -0.682 . . . . 0.0 110.735 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.7 -37.03 80.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.315 -0.866 . . . . 0.0 110.775 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 4.3 tptm -72.6 -36.33 68.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 110.015 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.725 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 71.1 m -60.4 -34.23 73.63 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.475 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.72 -49.15 56.07 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 110.538 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.445 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.43 -41.71 69.17 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.147 -0.971 . . . . 0.0 110.583 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.919 HD12 HG11 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.9 80.41 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 111.282 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.11 -51.0 43.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.934 -1.104 . . . . 0.0 110.175 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.88 -31.76 65.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.209 -0.932 . . . . 0.0 109.123 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.596 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.83 -47.06 85.05 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 179.358 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.876 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -60.99 -41.42 96.46 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.279 -0.888 . . . . 0.0 111.053 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.0 t -56.38 -33.93 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.868 -1.145 . . . . 0.0 109.227 179.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -34.83 60.3 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.318 -0.864 . . . . 0.0 110.482 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.818 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.32 -25.57 62.47 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.409 -0.807 . . . . 0.0 109.833 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.31 8.9 8.25 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.758 ' CD1' HD22 ' A' ' 30' ' ' LEU . 36.5 mt -108.34 143.73 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.338 -1.095 . . . . 0.0 109.666 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.6 t30 -90.07 106.75 18.69 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.23 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.569 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.59 145.96 45.94 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.508 -176.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.877 HG21 ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.64 149.36 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.52 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.725 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.43 128.29 56.4 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.711 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.603 ' CD1' HD12 ' A' ' 69' ' ' LEU . 12.9 t80 -119.96 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.384 -0.823 . . . . 0.0 110.094 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.898 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.7 p90 -167.76 -178.27 3.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.521 -0.737 . . . . 0.0 109.776 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.13 116.78 3.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.175 -0.953 . . . . 0.0 110.617 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.69 36.12 7.5 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.898 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.68 156.88 27.44 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.191 -1.182 . . . . 0.0 110.122 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.782 ' N ' HD13 ' A' ' 69' ' ' LEU . 33.7 m-20 -97.41 149.01 22.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.284 -0.885 . . . . 0.0 110.088 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.681 ' O ' HG23 ' A' ' 71' ' ' VAL . 33.7 m -62.45 111.28 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 C-N-CA 119.261 -0.976 . . . . 0.0 109.207 179.245 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.446 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 27.4 m -130.16 -34.39 1.66 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.366 -0.834 . . . . 0.0 110.731 -179.459 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.877 ' HA ' HG21 ' A' ' 63' ' ' VAL . 50.7 t -49.88 151.77 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.225 -0.922 . . . . 0.0 109.459 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.426 HG13 HG21 ' A' ' 80' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.78 0 O-C-N 120.781 -1.199 . . . . 0.0 111.523 -178.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 122.059 0.933 . . . . 0.0 110.242 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 4.9 p -117.25 131.07 71.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 122.062 0.935 . . . . 0.0 110.057 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.622 HG11 ' HB ' ' A' ' 33' ' ' ILE . 6.2 m -112.95 121.36 65.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.725 HG22 HG13 ' A' ' 73' ' ' VAL . 11.1 t -96.76 118.52 43.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.148 -0.97 . . . . 0.0 110.414 -177.647 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.922 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.9 m -109.44 100.34 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.063 -1.023 . . . . 0.0 108.79 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -143.0 161.6 37.69 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.6 -1.313 . . . . 0.0 111.108 -178.31 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.789 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.8 t -85.37 -136.97 0.07 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.493 -0.755 . . . . 0.0 109.147 179.532 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.509 ' N ' HG23 ' A' ' 85' ' ' THR . 6.1 m-20 -82.54 -13.64 56.26 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.723 -1.235 . . . . 0.0 110.404 179.764 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.789 ' H ' HG23 ' A' ' 85' ' ' THR . . . -52.65 -41.96 64.26 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.072 -1.017 . . . . 0.0 110.339 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.434 HD12 ' CD2' ' A' ' 65' ' ' TYR . 2.4 tp . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.081 -1.012 . . . . 0.0 109.769 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.314 0.578 . . . . 0.0 110.611 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 10.6 m-85 -116.64 151.69 35.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.331 -0.855 . . . . 0.0 109.494 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.49 -32.98 72.19 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.342 -0.943 . . . . 0.0 109.327 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.7 p -162.37 163.56 27.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.274 -0.891 . . . . 0.0 111.084 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.604 HG22 HG21 ' A' ' 122' ' ' THR . 0.3 OUTLIER -130.83 112.98 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.52 -0.738 . . . . 0.0 109.886 179.343 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.601 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -94.48 115.32 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.217 -0.927 . . . . 0.0 109.166 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -127.99 161.12 29.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 111.504 -178.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 42.7 t -90.94 -9.1 47.36 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 57.35 13.74 1.88 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.293 -0.879 . . . . 0.0 111.662 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.2 m . . . . . 0 C--N 1.306 -1.31 0 O-C-N 120.777 -1.202 . . . . 0.0 108.992 179.541 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.906 0 CA-C-O 121.591 0.71 . . . . 0.0 111.239 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.537 ' OD2' HG22 ' A' ' 113' ' ' VAL . 4.4 p-10 -73.25 162.49 29.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.501 -0.749 . . . . 0.0 109.971 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.16 -42.61 91.15 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.884 -1.135 . . . . 0.0 111.62 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.537 HG22 ' OD2' ' A' ' 111' ' ' ASP . 6.7 m -72.59 -30.86 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 120.784 -1.198 . . . . 0.0 113.031 -178.001 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.74 -55.76 20.44 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.474 -1.391 . . . . 0.0 110.3 -178.766 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.411 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -62.88 -34.71 77.97 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 118.695 -1.202 . . . . 0.0 108.225 178.327 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.408 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 24.6 m -61.46 -50.7 71.72 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.89 41.91 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.832 . . . . 0.0 109.6 178.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.422 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 25.2 mtt180 -59.59 -45.14 92.78 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.287 -0.883 . . . . 0.0 110.405 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.481 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 20.1 ttm180 -62.68 -34.59 77.41 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.734 -1.229 . . . . 0.0 110.071 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.427 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.78 -5.36 31.06 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 119.998 -1.096 . . . . 0.0 111.12 -179.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.95 -4.96 58.77 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.656 -1.496 . . . . 0.0 110.96 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.64 ' O ' HD11 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -118.72 140.36 50.06 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.859 -1.151 . . . . 0.0 109.442 179.535 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.01 19.6 39.17 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.427 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 10.2 mmt85 -69.39 85.98 0.42 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.033 -1.275 . . . . 0.0 109.806 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.05 57.82 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.469 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.41 -174.8 0.39 Allowed Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.202 -1.175 . . . . 0.0 109.016 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.469 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -85.22 103.33 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.36 1.19 . . . . 0.0 109.438 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -86.98 173.25 44.72 Favored Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.046 -179.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.4 mt -122.18 142.92 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -1.056 . . . . 0.0 109.54 179.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.7 t80 -127.02 115.34 19.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.166 -0.959 . . . . 0.0 110.178 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.522 ' HE ' HG11 ' A' ' 13' ' ' VAL . 10.6 mtt85 -105.65 135.26 47.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.353 -0.842 . . . . 0.0 109.476 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.2 147.0 45.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.153 -0.967 . . . . 0.0 110.552 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.718 HG22 HD23 ' A' ' 15' ' ' LEU . 54.4 t . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.829 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.465 ' ND2' ' N ' ' A' ' 9' ' ' ASN . 0.1 OUTLIER . . . . . 0 N--CA 1.507 2.382 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.508 HD11 ' O ' ' A' ' 122' ' ' THR . 12.7 mt -124.32 135.62 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.131 -1.606 . . . . 0.0 109.562 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.88 128.74 34.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.316 -0.865 . . . . 0.0 109.801 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.36 140.93 29.01 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.194 -0.941 . . . . 0.0 109.882 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.408 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 6.5 t -134.78 153.97 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.224 -0.923 . . . . 0.0 110.467 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.59 18.6 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.325 -0.859 . . . . 0.0 109.552 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.501 HD11 HG12 ' A' ' 28' ' ' ILE . 10.8 tp -56.08 136.63 52.29 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.29 -0.881 . . . . 0.0 109.778 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.42 -167.58 1.99 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 110.288 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.2 p -88.3 73.24 8.88 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.636 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.3 m -146.04 112.37 5.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 110.48 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.34 -165.35 27.87 Favored Glycine 0 N--CA 1.489 2.204 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.831 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.59 -21.57 9.08 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.61 -0.936 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.907 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.1 tt -98.85 105.69 32.76 Favored Pre-proline 0 N--CA 1.488 1.46 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.179 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.474 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -62.95 155.0 63.13 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.225 1.118 . . . . 0.0 109.66 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.463 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.2 t80 -167.55 93.61 0.41 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.062 -1.024 . . . . 0.0 111.576 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.479 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 25.5 m-85 59.38 67.04 0.94 Allowed 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.571 -0.705 . . . . 0.0 111.554 179.06 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.09 13.81 15.82 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.84 156.89 44.25 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.105 -1.233 . . . . 0.0 109.039 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.636 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.06 107.92 14.59 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.789 -1.194 . . . . 0.0 109.675 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.975 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -70.89 114.15 24.6 Favored Pre-proline 0 C--N 1.299 -1.62 0 O-C-N 121.411 -0.806 . . . . 0.0 110.637 -179.415 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.833 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.3 Cg_endo -68.91 128.42 16.79 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 N-CA-C 106.906 -1.998 . . . . 0.0 106.906 176.181 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.55 HD11 HD12 ' A' ' 58' ' ' LEU . 6.9 mt -55.91 -18.94 10.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.914 -1.116 . . . . 0.0 110.678 -177.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.51 -16.29 23.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.714 -1.241 . . . . 0.0 110.296 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.121 HG23 HG23 ' A' ' 33' ' ' ILE . 13.1 m -92.24 -25.43 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 120.968 -1.082 . . . . 0.0 111.228 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.121 HG23 HG23 ' A' ' 32' ' ' VAL . 8.9 pt -117.9 -18.53 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.985 -1.072 . . . . 0.0 110.662 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.511 ' HB2' HD11 ' A' ' 60' ' ' ILE . 9.7 tptt -96.24 148.92 22.22 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.931 -1.106 . . . . 0.0 110.417 179.534 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.84 56.7 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.8 -159.22 21.81 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.239 -1.457 . . . . 0.0 110.091 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.447 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.6 mtt85 -100.61 130.65 46.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.404 -1.057 . . . . 0.0 110.603 -179.571 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.2 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 110.505 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.626 HD12 ' HB ' ' A' ' 82' ' ' VAL . 14.0 tp -109.49 120.96 44.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 110.301 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.918 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.3 mm -99.72 125.58 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.194 -0.941 . . . . 0.0 109.283 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.5 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.3 123.05 38.62 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.098 -1.001 . . . . 0.0 109.709 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.24 157.89 25.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.239 -0.913 . . . . 0.0 110.857 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.479 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 0.7 OUTLIER -105.75 8.14 32.79 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.412 -0.805 . . . . 0.0 109.967 178.939 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.46 139.65 40.75 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.172 -0.955 . . . . 0.0 110.346 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.459 ' HG2' ' CB ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.93 -38.11 69.92 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 110.783 -179.683 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.93 -37.26 86.74 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.759 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.412 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -64.91 -35.98 82.9 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.765 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.774 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.2 m -60.2 -34.34 73.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.407 -0.808 . . . . 0.0 109.039 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.03 -48.83 64.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.191 -0.943 . . . . 0.0 110.25 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.0 mt-10 -71.46 -45.59 62.18 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.198 -0.939 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.972 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.42 -41.38 76.27 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.373 -0.83 . . . . 0.0 111.338 -178.926 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.443 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.36 -50.92 14.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 110.363 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.73 -41.62 99.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 109.446 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.573 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.4 -46.16 86.95 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.346 -0.846 . . . . 0.0 109.433 179.341 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.41 -42.93 78.81 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.487 -0.758 . . . . 0.0 110.236 179.853 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.9 -33.43 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.073 -1.017 . . . . 0.0 109.166 179.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.61 -31.48 59.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.323 -0.861 . . . . 0.0 110.004 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.573 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -72.07 -26.54 62.21 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.893 0.854 . . . . 0.0 109.601 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.03 6.3 8.45 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.603 HG22 HG22 ' A' ' 81' ' ' VAL . 35.1 mt -107.86 143.87 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -1.14 . . . . 0.0 110.144 -179.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.625 ' ND2' HD11 ' A' ' 74' ' ' ILE . 15.8 t30 -88.02 106.45 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.364 -1.717 . . . . 0.0 106.364 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.588 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.69 141.67 47.9 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.671 -177.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.951 HG21 ' HA ' ' A' ' 73' ' ' VAL . 87.4 t -124.27 147.9 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.998 -0.681 . . . . 0.0 109.69 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.774 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.47 127.04 55.04 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.822 178.503 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.71 31.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 110.57 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.879 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.7 p90 -147.78 175.08 11.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.619 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.69 5.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 110.766 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.9 37.18 10.43 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.879 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.31 155.93 28.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.115 -1.227 . . . . 0.0 109.969 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.856 ' N ' HD13 ' A' ' 69' ' ' LEU . 32.3 m-20 -95.61 149.25 21.66 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.225 -0.922 . . . . 0.0 110.462 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.679 ' O ' HG23 ' A' ' 71' ' ' VAL . 33.4 m -61.81 110.08 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 120.939 -1.101 . . . . 0.0 108.969 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.7 m -132.13 -9.69 3.38 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.508 -0.745 . . . . 0.0 110.953 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.951 ' HA ' HG21 ' A' ' 63' ' ' VAL . 40.1 t -72.27 135.12 28.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.082 -1.012 . . . . 0.0 109.305 -179.582 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.687 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.3 pp . . . . . 0 N--CA 1.493 1.722 0 O-C-N 121.155 -0.965 . . . . 0.0 111.235 -178.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.965 0.888 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.687 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -116.06 135.42 56.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 121.966 0.889 . . . . 0.0 110.302 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.603 HG22 HG22 ' A' ' 60' ' ' ILE . 19.0 m -111.88 126.88 69.31 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 O-C-N 121.464 -0.773 . . . . 0.0 109.236 179.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.778 HG22 HG13 ' A' ' 73' ' ' VAL . 7.6 t -97.63 116.91 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.793 -1.192 . . . . 0.0 110.502 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.972 HG11 HD12 ' A' ' 51' ' ' LEU . 3.9 m -110.67 100.07 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.884 -1.135 . . . . 0.0 108.691 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.53 162.48 34.96 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.568 -1.332 . . . . 0.0 111.195 -178.109 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.505 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -90.8 -133.36 0.12 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.524 -0.735 . . . . 0.0 109.112 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.505 ' N ' HG23 ' A' ' 85' ' ' THR . 49.4 p-10 -90.02 41.74 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.583 -1.323 . . . . 0.0 110.147 179.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.91 -32.09 6.5 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.92 . . . . 0.0 108.907 178.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.052 0.453 . . . . 0.0 110.785 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -119.39 151.06 39.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.955 -1.09 . . . . 0.0 110.255 179.366 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.87 -28.4 20.38 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.348 -0.845 . . . . 0.0 109.417 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.553 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 5.8 p -160.87 163.33 32.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.397 -0.815 . . . . 0.0 110.675 179.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.415 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.15 115.39 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 110.093 179.72 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.975 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -95.52 111.29 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.16 -0.962 . . . . 0.0 108.579 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.7 t0 -119.65 161.17 21.13 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.159 -0.963 . . . . 0.0 111.786 -178.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.427 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.1 t -101.84 8.5 41.28 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.715 -0.616 . . . . 0.0 109.502 178.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.417 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.5 m-20 51.66 23.75 2.09 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.113 -0.992 . . . . 0.0 111.293 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.411 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p . . . . . 0 N--CA 1.492 1.634 0 O-C-N 121.17 -0.956 . . . . 0.0 109.972 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.51 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.308 0.575 . . . . 0.0 111.053 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.436 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.9 p-10 -88.45 161.12 17.21 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.298 -0.876 . . . . 0.0 110.345 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.01 -54.97 7.49 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -178.248 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.476 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.67 -31.89 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 120.585 -1.322 . . . . 0.0 112.685 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.51 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.41 -56.22 8.77 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.96 -1.088 . . . . 0.0 110.434 -179.266 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.485 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.74 -35.54 80.35 Favored 'General case' 0 C--O 1.205 -1.284 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.265 178.781 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.476 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.0 m -58.38 -49.2 78.08 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.541 178.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.08 -35.54 71.9 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.376 -0.827 . . . . 0.0 109.571 178.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.5 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.2 -45.18 61.41 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.239 -0.913 . . . . 0.0 110.931 -179.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.485 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 14.4 ttt180 -54.03 -45.17 71.52 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.045 -1.035 . . . . 0.0 109.995 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.58 64.19 0.29 Allowed Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.225 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.434 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.78 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.562 -0.964 . . . . 0.0 108.438 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.508 ' O ' HD11 ' A' ' 10' ' ' ILE . 10.9 t -96.12 142.87 27.79 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.621 -0.674 . . . . 0.0 109.478 178.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.68 33.25 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.47 -1.348 . . . . 0.0 110.94 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.29 87.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.047 -1.266 . . . . 0.0 109.397 179.607 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.87 -8.33 70.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -178.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.471 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.03 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.18 -1.188 . . . . 0.0 109.265 -179.799 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.471 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -89.04 97.46 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.379 1.199 . . . . 0.0 110.601 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.489 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.24 171.09 53.01 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -126.85 142.15 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.488 -1.007 . . . . 0.0 109.305 179.356 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.415 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.4 t80 -128.65 115.27 17.78 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.0 . . . . 0.0 110.314 179.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.428 ' HD2' ' HB ' ' A' ' 32' ' ' VAL . 4.1 mtp180 -104.73 122.8 46.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.433 -0.792 . . . . 0.0 109.17 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 29.8 p90 -121.53 157.5 30.55 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 110.415 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.341 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.508 2.446 0 CA-C-O 120.666 0.27 . . . . 0.0 111.055 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.491 HD13 HG22 ' A' ' 122' ' ' THR . 12.5 mt -95.79 124.92 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.574 -1.329 . . . . 0.0 109.892 179.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.57 128.02 34.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.138 -0.976 . . . . 0.0 109.554 179.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.97 132.95 35.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -0.943 . . . . 0.0 110.005 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.726 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 16.7 t -122.08 149.94 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.24 -0.912 . . . . 0.0 110.419 -179.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.85 21.65 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.268 -0.895 . . . . 0.0 109.706 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.885 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.0 tp -53.52 141.1 26.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.278 -0.889 . . . . 0.0 109.881 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.452 ' HA ' ' HD2' ' A' ' 26' ' ' LYS . 28.3 p -136.09 -178.49 5.17 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.253 -0.905 . . . . 0.0 110.526 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.8 p -79.74 71.19 6.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.887 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.689 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.9 m -146.12 112.71 5.94 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.317 -0.865 . . . . 0.0 110.424 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.441 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.81 28.42 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 118.731 -1.7 . . . . 0.0 111.173 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.62 10.4 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.783 -0.834 . . . . 0.0 110.306 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.14 107.94 41.06 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.666 -1.214 . . . . 0.0 110.098 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.446 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.5 Cg_endo -65.05 117.4 4.51 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 O-C-N 123.478 1.251 . . . . 0.0 110.645 -179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.5 -170.79 1.8 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.649 -0.657 . . . . 0.0 110.592 -179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.507 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.5 m-85 -57.73 82.26 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.552 -0.718 . . . . 0.0 111.634 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.15 -1.84 54.16 Favored Glycine 0 N--CA 1.493 2.437 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.684 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.885 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.1 mmtm -130.1 156.18 44.96 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.858 -1.378 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.689 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.83 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.94 -1.1 . . . . 0.0 109.427 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.9 mt -68.38 112.95 12.55 Favored Pre-proline 0 C--N 1.301 -1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 110.779 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.761 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.0 Cg_endo -68.26 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 N-CA-C 106.96 -1.977 . . . . 0.0 106.96 175.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.838 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.72 -16.65 6.81 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.826 -1.171 . . . . 0.0 110.652 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.83 -15.97 36.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.686 -1.259 . . . . 0.0 110.268 179.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.129 HG23 HG23 ' A' ' 33' ' ' ILE . 12.1 m -91.77 -25.71 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.011 -1.056 . . . . 0.0 111.213 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.129 HG23 HG23 ' A' ' 32' ' ' VAL . 27.7 pt -118.48 -25.33 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.938 -1.101 . . . . 0.0 110.199 -179.496 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.602 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.41 148.18 22.5 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 110.648 179.828 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.87 57.77 Favored Glycine 0 N--CA 1.484 1.891 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.42 -151.27 8.74 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.127 -1.511 . . . . 0.0 110.278 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.45 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.3 mtt85 -109.74 132.37 54.21 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.53 -0.982 . . . . 0.0 110.1 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.551 ' HB2' HG12 ' A' ' 81' ' ' VAL . 90.9 m-70 -140.81 152.94 45.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.087 -1.008 . . . . 0.0 110.993 -179.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 54.9 tp -112.03 114.17 26.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.4 -0.812 . . . . 0.0 109.994 179.622 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.85 HD12 ' CG1' ' A' ' 83' ' ' VAL . 32.8 mt -98.37 129.2 48.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.594 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.4 123.82 38.04 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.304 -0.873 . . . . 0.0 109.751 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.86 158.83 23.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 110.801 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.507 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.17 4.28 20.91 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.439 -0.788 . . . . 0.0 110.023 179.203 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.11 137.05 38.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.058 -1.026 . . . . 0.0 110.618 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.481 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.59 -42.82 67.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.485 -0.76 . . . . 0.0 110.219 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.83 -39.21 84.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.882 . . . . 0.0 110.45 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.74 -35.11 76.69 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.906 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.14 -34.1 74.47 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.537 -0.727 . . . . 0.0 109.501 179.212 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.76 -49.43 62.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.235 -0.916 . . . . 0.0 110.255 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.79 -44.64 63.64 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -0.951 . . . . 0.0 110.146 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.716 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.17 -41.65 79.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.819 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.521 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.0 -51.16 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.03 -1.044 . . . . 0.0 110.382 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.08 96.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.12 -0.988 . . . . 0.0 109.675 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.553 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.15 -44.91 83.86 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 179.485 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.7 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -55.1 -42.68 73.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.517 -0.739 . . . . 0.0 109.885 179.956 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.4 -32.09 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.007 -1.058 . . . . 0.0 108.807 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.4 -30.87 60.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.389 -0.82 . . . . 0.0 109.608 179.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.838 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.66 -26.17 62.43 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.833 0.825 . . . . 0.0 109.467 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.04 7.44 10.27 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.143 -1.583 . . . . 0.0 109.143 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.602 HD11 ' HB2' ' A' ' 34' ' ' LYS . 56.4 mt -108.26 143.24 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.277 -1.131 . . . . 0.0 110.349 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.93 107.56 17.78 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.924 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.655 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -122.01 144.62 48.78 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.019 -1.072 . . . . 0.0 111.643 -177.558 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.932 HG21 ' HA ' ' A' ' 73' ' ' VAL . 45.2 t -130.3 143.58 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 C-N-CA 119.976 -0.69 . . . . 0.0 109.512 179.083 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.906 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -109.49 118.36 36.41 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.95 179.094 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.462 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.65 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.26 -0.9 . . . . 0.0 110.574 -179.59 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.748 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.2 p90 -167.31 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.544 -0.723 . . . . 0.0 109.757 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.24 127.14 30.6 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.165 -0.96 . . . . 0.0 110.764 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.32 37.77 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.4 tm? -117.09 155.81 28.64 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.156 -1.203 . . . . 0.0 110.101 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.895 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.24 22.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.366 -0.834 . . . . 0.0 110.545 -179.351 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.679 ' O ' HG23 ' A' ' 71' ' ' VAL . 29.5 m -62.1 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 119.061 -1.055 . . . . 0.0 109.002 179.229 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.72 -15.45 2.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.507 -0.746 . . . . 0.0 111.413 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.932 ' HA ' HG21 ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.06 23.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.072 -1.017 . . . . 0.0 109.471 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.676 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.6 pp . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.261 -0.899 . . . . 0.0 111.004 -179.362 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.422 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.7 m-20 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.873 0.845 . . . . 0.0 109.998 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.485 ' O ' HG13 ' A' ' 80' ' ' VAL . 8.2 p -115.06 130.91 68.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 122.152 0.977 . . . . 0.0 110.414 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 60' ' ' ILE . 6.9 m -113.0 123.04 68.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 O-C-N 121.351 -0.843 . . . . 0.0 109.104 179.052 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.661 ' O ' HD12 ' A' ' 39' ' ' LEU . 4.7 t -97.06 118.07 42.82 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 O-C-N 121.056 -1.028 . . . . 0.0 110.149 -177.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.85 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.9 m -111.19 100.3 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.809 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.462 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.46 162.64 34.99 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.765 -1.209 . . . . 0.0 111.122 -178.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -90.17 -139.26 0.14 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.598 -0.689 . . . . 0.0 109.4 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.41 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -86.01 48.05 1.55 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.806 -1.184 . . . . 0.0 109.99 179.706 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.454 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.24 -19.22 7.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.173 -0.955 . . . . 0.0 110.646 -179.671 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp . . . . . 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.671 179.821 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.104 0.478 . . . . 0.0 110.965 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.3 m-85 -119.74 144.86 47.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.075 -1.016 . . . . 0.0 109.918 178.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.49 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.21 -33.44 63.39 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.502 179.334 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -162.88 163.56 26.35 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.272 -0.892 . . . . 0.0 110.913 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.19 116.58 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.331 -0.855 . . . . 0.0 110.078 179.062 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.865 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -93.37 118.41 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.178 -0.951 . . . . 0.0 109.031 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.402 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.3 t0 -126.85 160.87 29.66 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.119 -0.988 . . . . 0.0 111.454 -178.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.412 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 37.0 t -101.59 7.26 42.26 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.685 -0.634 . . . . 0.0 109.393 178.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.406 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 49.07 33.2 4.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 111.111 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.441 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p . . . . . 0 N--CA 1.492 1.627 0 O-C-N 120.877 -1.139 . . . . 0.0 110.819 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.42 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.511 0.672 . . . . 0.0 110.837 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.5 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.7 p30 -80.74 161.49 24.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -0.954 . . . . 0.0 109.664 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.44 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.32 -57.05 4.29 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.847 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.5 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -66.17 -28.34 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 120.823 -1.173 . . . . 0.0 111.729 -178.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.12 -56.27 6.89 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.994 -1.066 . . . . 0.0 110.715 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.457 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.55 -35.91 78.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.108 -0.995 . . . . 0.0 108.836 178.931 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.467 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.1 m -59.27 -49.48 77.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.066 -1.021 . . . . 0.0 108.598 178.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.74 -35.52 65.07 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.493 -0.755 . . . . 0.0 109.754 178.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.447 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.58 -44.81 63.81 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 110.844 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.457 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 2.8 ttm180 -55.01 -37.97 67.29 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.9 -1.125 . . . . 0.0 109.721 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.53 77.21 0.13 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -153.38 -49.08 0.1 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.462 -1.022 . . . . 0.0 108.522 179.51 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.542 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.7 t -93.14 143.3 26.38 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.369 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.25 15.96 5.85 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.263 -1.446 . . . . 0.0 110.405 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 25.4 mmt180 -92.9 83.02 4.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.065 -1.256 . . . . 0.0 110.106 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.12 -26.83 6.01 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.49 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.29 -166.51 0.15 Allowed Pre-proline 0 N--CA 1.488 1.456 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.61 115.02 2.44 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.025 1.013 . . . . 0.0 110.545 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.542 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.99 172.09 55.22 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.409 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mp -132.76 142.6 41.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.283 -1.128 . . . . 0.0 109.432 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.501 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.24 115.21 17.29 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.316 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.726 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.67 122.54 43.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.814 . . . . 0.0 109.213 179.505 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.406 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 50.3 p90 -117.44 149.71 40.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.036 -1.04 . . . . 0.0 110.228 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.412 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 48.8 t . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.207 -0.933 . . . . 0.0 110.079 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.2 m120 . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.054 0.454 . . . . 0.0 110.406 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.476 HD13 HG22 ' A' ' 122' ' ' THR . 34.0 mt -119.62 136.17 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.906 -1.121 . . . . 0.0 110.436 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.79 128.89 34.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.319 -0.863 . . . . 0.0 109.543 179.449 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.24 132.42 34.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.226 -0.921 . . . . 0.0 110.339 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.792 HG11 ' NH1' ' A' ' 131' ' ' ARG . 29.5 t -122.64 157.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.45 -0.781 . . . . 0.0 110.246 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.04 110.64 22.82 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.209 -0.932 . . . . 0.0 109.851 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.564 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -62.63 134.77 56.82 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.279 -0.888 . . . . 0.0 109.68 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.68 179.52 6.18 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.911 . . . . 0.0 110.176 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.92 74.47 2.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 109.631 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.692 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -144.55 111.61 5.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 110.576 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.48 -159.35 27.18 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.561 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.94 -24.78 5.99 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.602 -0.94 . . . . 0.0 110.522 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.921 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -95.86 108.76 42.6 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.618 -1.233 . . . . 0.0 110.492 -179.399 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.475 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.33 154.56 70.61 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.341 1.18 . . . . 0.0 109.897 179.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.501 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.3 t80 -167.79 95.02 0.42 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 110.891 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.463 ' HH ' ' CE1' ' A' ' 43' ' ' HIS . 66.8 m-85 60.33 65.48 1.07 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.5 -0.75 . . . . 0.0 111.188 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 15.87 16.53 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.56 ' HG3' HG13 ' A' ' 133' ' ' VAL . 3.6 mmtt -130.54 157.26 43.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.182 -1.187 . . . . 0.0 109.389 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.692 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.98 107.39 14.91 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.77 -1.206 . . . . 0.0 109.719 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.989 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -69.84 114.03 21.85 Favored Pre-proline 0 C--N 1.301 -1.523 0 O-C-N 121.294 -0.879 . . . . 0.0 110.461 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.764 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.3 Cg_endo -69.14 130.09 19.45 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 N-CA-C 106.586 -2.121 . . . . 0.0 106.586 175.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.486 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -56.16 -18.32 9.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.734 -1.228 . . . . 0.0 110.528 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.429 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.33 -15.91 19.08 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.662 -1.274 . . . . 0.0 110.693 179.68 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.079 HG23 HG23 ' A' ' 33' ' ' ILE . 12.3 m -92.46 -25.14 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 120.884 -1.135 . . . . 0.0 110.995 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.079 HG23 HG23 ' A' ' 32' ' ' VAL . 10.3 pt -116.89 -22.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 -179.403 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.53 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptt -92.67 148.46 22.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.001 -1.062 . . . . 0.0 109.97 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.71 -5.68 43.76 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.6 -152.66 11.2 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.086 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.46 131.41 52.91 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.314 -1.109 . . . . 0.0 110.292 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.55 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.41 153.73 51.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.154 -0.966 . . . . 0.0 110.943 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.526 ' HB3' HG12 ' A' ' 99' ' ' VAL . 65.5 tp -114.45 118.27 33.33 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.371 -0.83 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.865 HD12 ' CG1' ' A' ' 83' ' ' VAL . 30.2 mt -104.39 127.92 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.127 -0.983 . . . . 0.0 109.673 179.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -95.74 122.73 38.82 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.242 -0.911 . . . . 0.0 110.097 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.79 159.01 23.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.523 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.463 ' CE1' ' HH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.31 26.84 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 110.375 179.18 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.74 136.34 37.24 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.09 -1.007 . . . . 0.0 110.916 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.46 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.0 69.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.557 -0.714 . . . . 0.0 110.232 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.31 -36.48 84.26 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.282 -0.886 . . . . 0.0 110.421 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.82 -36.48 75.66 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.233 -0.917 . . . . 0.0 109.513 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.936 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 98.7 m -61.65 -34.05 75.03 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.439 -0.788 . . . . 0.0 109.684 179.465 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.35 -49.42 64.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.175 -0.953 . . . . 0.0 109.957 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.79 -45.66 60.87 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.097 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.668 HD13 ' O ' ' A' ' 51' ' ' LEU . 2.1 tm? -56.49 -41.67 77.01 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.446 -0.784 . . . . 0.0 110.567 -179.411 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.416 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -76.0 -51.43 12.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.092 -1.005 . . . . 0.0 110.236 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.402 ' O ' ' HB ' ' A' ' 56' ' ' VAL . . . -61.44 -42.04 98.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.985 -1.072 . . . . 0.0 109.652 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.528 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.09 -44.39 83.09 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.167 -0.958 . . . . 0.0 109.644 179.614 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.772 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.11 -41.58 71.84 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.345 -0.847 . . . . 0.0 109.612 179.735 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 53' ' ' ALA . 78.6 t -56.27 -33.18 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.146 -0.971 . . . . 0.0 108.815 179.054 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.0 -32.05 59.23 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.5 -0.75 . . . . 0.0 110.131 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.528 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.62 -26.42 62.57 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.332 -0.855 . . . . 0.0 109.712 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.09 8.36 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.608 HG22 HG22 ' A' ' 81' ' ' VAL . 49.4 mt -108.15 143.94 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.202 -1.175 . . . . 0.0 110.32 -179.677 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.774 HD22 HG23 ' A' ' 80' ' ' VAL . 1.3 t30 -86.84 107.1 18.16 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 178.121 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.577 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.86 147.71 45.03 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.62 -177.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.94 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.9 t -136.11 148.71 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.507 179.308 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.936 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.32 126.95 55.45 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.095 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.48 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 5.4 t80 -117.48 125.9 51.69 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 110.713 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.906 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.5 p90 -157.76 -174.85 5.05 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.63 123.64 11.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 0.0 111.26 -179.212 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.65 47.73 32.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.931 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.27 155.7 29.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.07 -1.253 . . . . 0.0 109.807 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.931 ' N ' HD13 ' A' ' 69' ' ' LEU . 7.7 m-20 -92.12 148.6 22.04 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.201 -0.937 . . . . 0.0 110.825 -179.18 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.662 ' O ' HG23 ' A' ' 71' ' ' VAL . 30.4 m -62.8 111.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.055 -1.028 . . . . 0.0 109.336 179.068 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.756 ' O ' HG23 ' A' ' 74' ' ' ILE . 10.6 m -134.58 -35.96 0.88 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.375 -0.828 . . . . 0.0 110.849 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.94 HG22 ' HB ' ' A' ' 63' ' ' VAL . 24.9 t -51.38 135.85 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.032 -1.043 . . . . 0.0 110.055 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.756 HG23 ' O ' ' A' ' 72' ' ' SER . 1.4 pp . . . . . 0 N--CA 1.495 1.776 0 O-C-N 121.263 -0.898 . . . . 0.0 110.724 -179.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 m-20 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.973 0.892 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.774 HG23 HD22 ' A' ' 61' ' ' ASN . 7.6 p -117.33 133.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 122.003 0.906 . . . . 0.0 110.347 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 60' ' ' ILE . 9.5 m -111.93 124.2 68.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.202 0 O-C-N 121.311 -0.868 . . . . 0.0 108.773 178.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.735 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -97.24 120.99 47.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 110.306 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.865 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.6 m -116.47 100.48 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.971 -1.081 . . . . 0.0 108.7 179.592 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.48 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -138.4 162.22 35.0 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.683 -1.261 . . . . 0.0 111.454 -177.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.605 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.1 t -87.24 -132.27 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.612 -0.68 . . . . 0.0 109.708 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.605 ' N ' HG23 ' A' ' 85' ' ' THR . 3.7 p30 -91.5 32.83 1.04 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.803 -1.186 . . . . 0.0 110.594 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.475 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.49 -32.96 9.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.095 -1.003 . . . . 0.0 109.887 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.85 . . . . 0.0 109.254 179.213 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.129 0.49 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -119.07 148.16 43.34 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.18 -0.95 . . . . 0.0 109.906 178.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.432 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.95 -32.25 61.68 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.272 -0.893 . . . . 0.0 109.486 179.294 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.463 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.0 p -162.51 163.79 27.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.218 -0.927 . . . . 0.0 111.207 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.564 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.47 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.452 -0.78 . . . . 0.0 110.3 179.347 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.989 HG21 HD11 ' A' ' 28' ' ' ILE . 3.1 mp -92.88 117.78 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.893 . . . . 0.0 108.795 179.145 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.19 20.5 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.07 -1.019 . . . . 0.0 112.107 -178.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.22 -11.66 34.81 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.429 ' O ' ' NE2' ' A' ' 110' ' ' GLN . 3.7 m120 55.58 12.37 0.78 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.294 -0.879 . . . . 0.0 112.487 179.091 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.306 -1.295 0 O-C-N 120.491 -1.38 . . . . 0.0 109.495 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.429 ' NE2' ' O ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 121.332 0.587 . . . . 0.0 110.851 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.547 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -88.92 160.36 17.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.9 . . . . 0.0 109.85 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.403 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.85 -51.13 7.66 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.424 -0.798 . . . . 0.0 112.317 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.547 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.44 -29.7 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.795 -1.19 . . . . 0.0 111.447 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.443 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.08 -56.47 6.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.08 -1.013 . . . . 0.0 110.402 -179.204 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.9 OUTLIER -69.49 -34.38 74.24 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.301 -0.874 . . . . 0.0 108.688 178.756 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.458 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 22.5 m -59.22 -50.02 75.6 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.164 -0.96 . . . . 0.0 108.454 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.93 -39.52 63.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.763 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.405 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 2.2 mtt180 -67.47 -44.32 78.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.168 -0.958 . . . . 0.0 110.557 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.485 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 7.0 ttm180 -60.47 -39.06 86.25 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.026 -1.046 . . . . 0.0 110.057 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.74 66.69 0.44 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.06 -46.6 0.3 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.514 -0.992 . . . . 0.0 108.602 179.471 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.518 HG23 ' HA3' ' A' ' 128' ' ' GLY . 15.0 t -94.45 142.13 27.79 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.375 -0.828 . . . . 0.0 109.136 178.657 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.89 10.03 19.45 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.556 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.0 mmt85 -69.3 86.96 0.42 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.011 -1.288 . . . . 0.0 109.69 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.2 22.17 33.19 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.479 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.85 -178.31 0.29 Allowed Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.514 -0.992 . . . . 0.0 108.717 -179.515 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.3 Cg_endo -89.65 103.94 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.258 1.136 . . . . 0.0 110.126 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.518 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -77.61 156.84 45.09 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.605 -179.303 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 38.8 mt -111.05 142.06 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.479 -1.012 . . . . 0.0 109.046 178.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.564 ' CD2' HG23 ' A' ' 99' ' ' VAL . 5.4 t80 -132.09 118.91 20.27 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.09 -1.006 . . . . 0.0 110.785 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.792 ' NH1' HG11 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -101.51 124.04 46.52 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.454 -0.779 . . . . 0.0 109.477 179.158 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.471 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.6 p90 -118.04 155.87 29.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 110.229 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.564 HG22 HD23 ' A' ' 15' ' ' LEU . 71.1 t . . . . . 0 N--CA 1.493 1.722 0 O-C-N 121.168 -0.958 . . . . 0.0 109.869 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.454 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.8 t-20 . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.512 0.672 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.528 HD13 ' CG2' ' A' ' 122' ' ' THR . 33.0 mt -103.48 136.34 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.011 -1.056 . . . . 0.0 110.094 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.9 129.46 35.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 109.322 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.75 34.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.173 -0.954 . . . . 0.0 110.294 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.465 HG11 ' NE ' ' A' ' 131' ' ' ARG . 20.4 t -117.84 155.0 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.641 -0.662 . . . . 0.0 110.026 -179.422 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.19 106.89 17.58 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.669 HD23 HG22 ' A' ' 133' ' ' VAL . 12.5 tp -57.6 132.16 52.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.593 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.8 p -135.84 -166.95 1.94 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.192 -0.942 . . . . 0.0 110.587 -179.516 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.1 p -82.49 83.45 7.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.436 -0.79 . . . . 0.0 109.917 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.701 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 11.0 m -156.9 110.04 2.58 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.302 -0.874 . . . . 0.0 110.541 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.38 28.52 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 118.895 -1.622 . . . . 0.0 110.956 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.417 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -117.49 -24.68 7.23 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.78 -0.835 . . . . 0.0 110.404 -179.906 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.882 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -93.86 103.48 10.4 Favored Pre-proline 0 N--CA 1.485 1.303 0 C-N-CA 118.496 -1.281 . . . . 0.0 109.99 -179.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.61 118.76 5.66 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 O-C-N 123.682 1.359 . . . . 0.0 110.558 -179.564 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.62 -168.74 1.39 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.736 -0.602 . . . . 0.0 110.718 -178.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.435 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.09 81.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.592 -0.693 . . . . 0.0 111.71 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.4 -1.68 49.53 Favored Glycine 0 N--CA 1.495 2.625 0 C-N-CA 120.148 -1.025 . . . . 0.0 110.809 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.463 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.13 156.41 44.6 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.899 -1.353 . . . . 0.0 109.304 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.701 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.22 107.09 17.89 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.837 -1.164 . . . . 0.0 108.993 179.401 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.931 HD11 HG21 ' A' ' 100' ' ' ILE . 4.0 mt -67.37 113.58 14.65 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.798 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.3 Cg_endo -68.85 127.36 15.21 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 N-CA-C 106.828 -2.028 . . . . 0.0 106.828 175.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.556 HD11 HD12 ' A' ' 58' ' ' LEU . 8.7 mt -55.93 -17.98 7.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.897 -1.127 . . . . 0.0 110.791 -177.538 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.69 -16.36 26.27 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.639 -1.288 . . . . 0.0 110.26 179.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.035 HG23 HG23 ' A' ' 33' ' ' ILE . 12.4 m -90.97 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.008 -1.058 . . . . 0.0 110.884 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.035 HG23 HG23 ' A' ' 32' ' ' VAL . 20.3 pt -117.46 -18.64 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.996 -1.065 . . . . 0.0 110.633 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.606 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.65 148.24 23.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.867 -1.146 . . . . 0.0 110.169 179.537 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.97 36.67 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.375 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.2 -143.63 6.08 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.153 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.465 ' HG2' HG12 ' A' ' 80' ' ' VAL . 8.9 mtt85 -111.25 134.57 52.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.396 -1.061 . . . . 0.0 110.313 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.572 ' HB2' HG12 ' A' ' 81' ' ' VAL . 66.4 m80 -141.14 150.73 43.19 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.089 -1.007 . . . . 0.0 111.077 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.7 tp -110.01 115.07 29.11 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.478 -0.764 . . . . 0.0 110.013 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.824 HD12 ' CG1' ' A' ' 83' ' ' VAL . 26.6 mt -98.79 127.27 51.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.113 -0.992 . . . . 0.0 109.821 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.428 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 29.5 m-85 -95.35 124.67 39.5 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.453 -0.78 . . . . 0.0 110.084 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.66 157.77 24.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.163 -0.961 . . . . 0.0 110.642 -179.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.435 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 15.0 p80 -101.96 -2.95 28.61 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 110.29 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.55 46.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.111 -0.993 . . . . 0.0 110.288 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -70.59 -37.49 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.47 -0.769 . . . . 0.0 110.757 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.57 -36.06 77.57 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.172 -0.955 . . . . 0.0 110.291 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.42 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -71.63 -32.75 68.3 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.424 -0.798 . . . . 0.0 109.253 179.835 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.703 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.74 74.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.35 -0.844 . . . . 0.0 109.095 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.88 -48.86 64.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.379 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.86 -44.39 63.89 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.236 -0.915 . . . . 0.0 110.631 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.751 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -56.81 -38.94 73.28 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.459 -0.776 . . . . 0.0 111.235 -178.937 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.84 -51.36 12.72 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.868 -1.145 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -40.78 97.26 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.01 -1.056 . . . . 0.0 109.672 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.545 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.94 83.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.522 179.447 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.741 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.37 -40.99 72.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.478 -0.764 . . . . 0.0 109.978 179.937 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.3 -33.81 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.135 -0.978 . . . . 0.0 108.899 179.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.88 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.333 -0.854 . . . . 0.0 110.078 179.357 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.556 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.47 -25.94 62.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.426 179.609 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.0 5.67 10.59 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.606 HD11 ' HB2' ' A' ' 34' ' ' LYS . 33.7 mt -108.42 143.46 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.475 -1.015 . . . . 0.0 110.235 -179.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.663 HD22 HG23 ' A' ' 80' ' ' VAL . 0.6 OUTLIER -87.98 106.92 18.45 Favored 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.056 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.693 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -118.56 146.97 44.18 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.748 -1.181 . . . . 0.0 111.922 -177.163 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.939 HG21 ' HA ' ' A' ' 73' ' ' VAL . 19.6 t -129.32 149.34 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.706 -0.621 . . . . 0.0 109.884 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.703 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.03 123.84 50.67 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.261 -0.975 . . . . 0.0 109.861 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.45 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -114.04 134.68 54.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.923 . . . . 0.0 111.013 -179.31 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.986 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.1 p90 -171.01 -179.82 2.86 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.381 -0.825 . . . . 0.0 110.174 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.24 126.27 18.39 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.209 -0.932 . . . . 0.0 111.02 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.1 46.5 35.31 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.338 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.986 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.49 154.74 30.91 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.127 -1.219 . . . . 0.0 109.891 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.836 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.1 m-20 -93.16 149.83 20.95 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.271 -0.893 . . . . 0.0 110.651 -179.229 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.69 ' O ' HG23 ' A' ' 71' ' ' VAL . 34.1 m -61.69 111.15 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 119.041 -1.064 . . . . 0.0 108.829 179.104 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.933 ' O ' HG23 ' A' ' 74' ' ' ILE . 74.1 m -132.42 -34.71 1.19 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 110.749 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.939 ' HA ' HG21 ' A' ' 63' ' ' VAL . 58.7 t -47.69 125.18 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.246 -0.909 . . . . 0.0 109.612 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.933 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.497 1.894 0 O-C-N 121.098 -1.001 . . . . 0.0 111.751 -178.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 121.995 0.903 . . . . 0.0 110.087 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.663 HG23 HD22 ' A' ' 61' ' ' ASN . 7.9 p -117.2 134.96 59.13 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 CA-C-O 122.124 0.964 . . . . 0.0 110.084 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.596 HG22 HG22 ' A' ' 60' ' ' ILE . 5.3 m -113.99 122.05 67.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 O-C-N 121.296 -0.877 . . . . 0.0 109.229 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.766 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -96.84 117.87 42.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 120.916 -1.115 . . . . 0.0 110.308 -178.054 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.824 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -108.81 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.244 -0.982 . . . . 0.0 108.916 179.548 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.444 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.23 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.658 -1.276 . . . . 0.0 110.656 -178.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.04 -34.48 15.09 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 110.679 -179.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -178.01 -29.57 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.114 -0.991 . . . . 0.0 111.066 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.518 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -44.88 -34.09 2.22 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.178 -0.951 . . . . 0.0 111.073 -179.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 tp . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.087 -1.008 . . . . 0.0 109.772 179.469 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.157 0.503 . . . . 0.0 110.776 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 22.1 m-85 -119.83 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.055 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.448 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.68 -29.32 27.69 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.492 -0.755 . . . . 0.0 109.976 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.66 163.66 29.71 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -0.975 . . . . 0.0 111.351 -179.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.519 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.22 114.4 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.439 -0.788 . . . . 0.0 109.922 179.141 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.931 HG21 HD11 ' A' ' 28' ' ' ILE . 3.7 mp -93.0 115.64 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.244 -0.91 . . . . 0.0 109.297 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.95 160.94 25.17 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.169 -0.957 . . . . 0.0 111.53 -178.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.418 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.64 3.75 42.74 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.628 -0.67 . . . . 0.0 109.504 178.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.48 23.88 0.66 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.266 -0.896 . . . . 0.0 111.254 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.467 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 O-C-N 120.959 -1.088 . . . . 0.0 110.476 179.283 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.512 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 13.9 tt0 . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 121.62 0.724 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.416 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.3 p-10 -88.27 161.5 17.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.567 -0.708 . . . . 0.0 110.092 179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.404 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -52.31 -61.79 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.346 -0.846 . . . . 0.0 112.29 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.432 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 7.2 m -58.1 -29.79 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.765 -1.209 . . . . 0.0 112.004 -177.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.512 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.82 -56.22 7.95 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.011 -1.055 . . . . 0.0 110.489 -179.293 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.436 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.49 -33.9 76.73 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.207 -0.933 . . . . 0.0 108.941 178.94 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.432 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.0 m -60.29 -49.82 76.1 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 120.999 -1.063 . . . . 0.0 108.452 178.462 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -73.93 -38.02 64.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 178.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 40.6 mtt85 -72.16 -44.85 62.43 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.222 -0.924 . . . . 0.0 111.477 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.483 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.2 ttm180 -54.59 -45.38 73.58 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.787 -1.195 . . . . 0.0 109.495 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.28 81.71 0.03 OUTLIER Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.73 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 179.606 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.528 ' CG2' HD13 ' A' ' 10' ' ' ILE . 8.7 t -93.13 143.47 26.22 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.56 1.7 19.74 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.646 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.24 85.9 0.57 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.978 -1.307 . . . . 0.0 110.13 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.1 -38.04 2.89 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.87 -166.87 0.13 Allowed Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.508 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -86.31 114.81 1.31 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.086 1.045 . . . . 0.0 109.647 179.202 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.522 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.4 167.88 54.81 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.504 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.83 138.74 49.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.451 -1.029 . . . . 0.0 108.62 178.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.519 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.26 118.78 22.88 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.218 -0.993 . . . . 0.0 110.581 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.5 ' HD2' HG11 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.31 127.14 53.03 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.487 -0.758 . . . . 0.0 109.879 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.439 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 10.4 p90 -118.84 158.5 25.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.17 -0.956 . . . . 0.0 109.81 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.669 HG22 HD23 ' A' ' 15' ' ' LEU . 7.2 t . . . . . 0 N--CA 1.493 1.68 0 O-C-N 121.085 -1.009 . . . . 0.0 110.263 179.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.419 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.5 m120 . . . . . 0 N--CA 1.508 2.462 0 CA-C-O 120.547 0.213 . . . . 0.0 111.239 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.499 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.1 mt -116.59 135.38 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.664 -1.273 . . . . 0.0 109.488 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.417 ' N ' ' O ' ' A' ' 128' ' ' GLY . 1.5 tm-20 -86.1 127.15 34.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.8 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.407 ' HG2' ' NH2' ' A' ' 119' ' ' ARG . 47.6 mt-10 -90.43 136.65 32.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.104 -0.997 . . . . 0.0 110.03 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.493 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.2 157.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.193 -0.942 . . . . 0.0 110.044 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.63 112.21 25.2 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.188 -0.945 . . . . 0.0 110.044 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.778 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.5 tp -54.81 147.36 15.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.873 . . . . 0.0 109.282 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.53 7.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.122 -0.987 . . . . 0.0 110.533 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.13 74.62 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.345 -0.847 . . . . 0.0 109.976 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.803 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.4 m -152.41 108.8 3.42 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.322 -0.862 . . . . 0.0 110.741 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.57 -167.16 29.2 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.922 -1.608 . . . . 0.0 110.818 179.214 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.46 ' HB3' HD11 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.26 -24.85 9.58 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.664 -0.904 . . . . 0.0 110.482 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 1.018 HD12 HD13 ' A' ' 55' ' ' LEU . 9.4 tt -95.12 101.89 8.27 Favored Pre-proline 0 C--N 1.305 -1.334 0 C-N-CA 118.734 -1.187 . . . . 0.0 109.743 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.44 127.39 21.73 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.534 1.281 . . . . 0.0 111.074 -178.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 25' ' ' GLY . 6.3 t80 -117.19 -171.91 2.12 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.541 0.686 . . . . 0.0 110.695 -179.062 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.565 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.4 m-85 -57.58 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.434 -0.791 . . . . 0.0 111.688 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.02 -4.62 53.47 Favored Glycine 0 N--CA 1.493 2.495 0 O-C-N 121.229 -0.919 . . . . 0.0 110.911 178.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.778 ' HB2' HD23 ' A' ' 15' ' ' LEU . 28.3 mmtt -130.05 156.34 44.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.826 -1.397 . . . . 0.0 109.908 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.803 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.26 108.07 19.39 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.064 -1.023 . . . . 0.0 108.864 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.917 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.1 mt -68.24 112.99 12.54 Favored Pre-proline 0 C--N 1.3 -1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 110.732 -179.056 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.714 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.3 Cg_endo -68.43 130.05 20.26 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.125 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.576 ' CD2' HD11 ' A' ' 33' ' ' ILE . 12.8 mt -56.64 -17.13 7.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.772 -1.205 . . . . 0.0 110.801 -177.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.438 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.32 -16.05 19.87 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.739 -1.226 . . . . 0.0 110.476 179.955 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.064 HG23 HG23 ' A' ' 33' ' ' ILE . 9.9 m -95.16 -24.24 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.008 -1.057 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.064 HG23 HG23 ' A' ' 32' ' ' VAL . 46.2 pt -116.58 -12.17 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.919 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.643 ' HB2' HD11 ' A' ' 60' ' ' ILE . 8.9 tptm -102.12 148.29 25.57 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.831 -1.168 . . . . 0.0 110.193 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.03 -5.3 36.24 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.74 3.89 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.407 -1.377 . . . . 0.0 110.08 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.54 135.96 53.38 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.313 -1.11 . . . . 0.0 110.363 -179.736 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.576 ' HB2' HG12 ' A' ' 81' ' ' VAL . 93.6 m-70 -140.01 153.42 46.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.254 -0.904 . . . . 0.0 111.196 -179.427 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.622 ' HB3' HG12 ' A' ' 99' ' ' VAL . 60.4 tp -113.5 116.47 29.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.419 -0.801 . . . . 0.0 110.285 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.906 HD12 ' CG1' ' A' ' 83' ' ' VAL . 33.7 mt -100.93 128.1 53.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.194 -0.942 . . . . 0.0 109.568 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -95.08 123.75 38.74 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.441 -0.787 . . . . 0.0 110.238 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.94 159.92 21.71 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.217 -0.927 . . . . 0.0 110.679 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.565 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.2 p80 -105.55 -4.48 21.15 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.381 -0.824 . . . . 0.0 110.395 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.5 p -132.13 138.53 48.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.973 -1.08 . . . . 0.0 110.702 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.509 ' HD2' ' CE1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.25 -41.19 70.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.483 -0.761 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.77 72.1 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.221 -0.924 . . . . 0.0 110.59 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.41 -37.36 65.95 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.379 -0.826 . . . . 0.0 109.949 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.875 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 73.9 m -61.14 -34.35 74.87 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.273 -0.892 . . . . 0.0 109.857 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.413 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.67 -50.08 59.54 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.229 -0.919 . . . . 0.0 110.592 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.404 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 11.7 mt-10 -72.37 -40.54 67.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.191 -0.943 . . . . 0.0 110.374 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.814 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.92 -42.67 98.55 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.616 -0.678 . . . . 0.0 111.567 -178.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.64 -51.16 45.13 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.8 -1.188 . . . . 0.0 110.271 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.15 -34.43 68.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.032 -1.043 . . . . 0.0 109.183 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.532 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.24 -47.95 80.08 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.208 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 1.018 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.02 -42.45 80.43 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.531 -0.731 . . . . 0.0 110.955 -179.994 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -55.67 -28.32 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.925 -1.11 . . . . 0.0 108.753 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.62 -35.37 60.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.516 -0.74 . . . . 0.0 110.266 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.532 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.33 -26.11 61.81 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.06 7.96 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.643 HD11 ' HB2' ' A' ' 34' ' ' LYS . 50.4 mt -106.39 143.0 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.282 -1.128 . . . . 0.0 109.633 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.442 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.7 t30 -87.41 106.56 18.04 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.024 -1.472 . . . . 0.0 107.024 178.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.576 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.5 146.07 45.77 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.23 -0.988 . . . . 0.0 111.008 -177.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.698 ' HB ' HG13 ' A' ' 73' ' ' VAL . 6.1 t -138.7 149.97 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.823 -0.751 . . . . 0.0 109.303 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.875 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.01 134.84 53.32 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.713 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.657 ' CD1' HD12 ' A' ' 69' ' ' LEU . 20.4 t80 -124.96 129.27 50.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.382 -0.824 . . . . 0.0 110.274 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.814 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -154.73 -171.3 3.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.595 -0.691 . . . . 0.0 109.634 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.8 124.88 22.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.125 -0.984 . . . . 0.0 110.731 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.35 34.02 30.27 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.937 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.35 157.13 26.67 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.143 -1.21 . . . . 0.0 110.035 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.937 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.15 22.77 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.188 -0.945 . . . . 0.0 110.815 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.679 ' O ' HG23 ' A' ' 71' ' ' VAL . 27.8 m -62.97 111.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.121 -0.987 . . . . 0.0 109.067 178.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.437 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.0 m -131.19 -11.73 3.64 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.166 -0.959 . . . . 0.0 111.494 -179.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.955 ' CG1' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.34 136.2 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.737 -1.227 . . . . 0.0 109.509 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.515 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.497 1.883 0 O-C-N 121.12 -0.987 . . . . 0.0 110.513 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.953 0.882 . . . . 0.0 110.181 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 5.8 p -117.06 135.11 58.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 121.904 0.859 . . . . 0.0 110.359 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.593 HG22 HG22 ' A' ' 60' ' ' ILE . 7.1 m -112.95 122.5 67.2 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.955 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.6 t -96.83 117.65 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.019 -1.051 . . . . 0.0 110.097 -177.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.906 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.3 m -111.43 99.74 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.075 -1.016 . . . . 0.0 108.828 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.479 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.13 159.84 41.2 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.646 -1.283 . . . . 0.0 111.27 -178.189 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.509 HG23 ' N ' ' A' ' 86' ' ' ASP . 7.8 t -82.33 -130.45 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.618 -0.676 . . . . 0.0 109.515 179.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.509 ' N ' HG23 ' A' ' 85' ' ' THR . 0.3 OUTLIER -93.82 27.82 2.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.595 -1.315 . . . . 0.0 110.225 179.94 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.476 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.11 -35.76 12.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 110.133 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.3 tp . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.644 179.643 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.7 t0 . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 120.974 0.416 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -120.05 151.57 38.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.079 -1.013 . . . . 0.0 110.315 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.443 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.42 -30.96 33.36 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.33 178.983 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.457 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.9 163.94 28.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.377 -0.827 . . . . 0.0 111.197 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.628 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.44 115.38 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.557 -0.714 . . . . 0.0 109.796 179.002 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.859 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -93.11 117.62 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.241 -0.912 . . . . 0.0 109.113 179.495 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.439 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.9 t0 -122.5 161.18 24.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.937 . . . . 0.0 111.559 -178.499 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.423 ' HG ' ' CB ' ' A' ' 24' ' ' TYR . 20.7 t -103.47 8.42 37.87 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.257 -0.902 . . . . 0.0 110.713 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.4 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.73 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.454 0.645 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.578 ' OD2' HG22 ' A' ' 113' ' ' VAL . 3.6 p-10 -92.73 162.57 14.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.479 -0.763 . . . . 0.0 110.382 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -50.55 -49.38 56.17 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.831 -1.168 . . . . 0.0 111.868 -178.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.578 HG22 ' OD2' ' A' ' 111' ' ' ASP . 5.8 m -72.63 -30.62 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.601 -1.312 . . . . 0.0 113.283 -177.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.88 -54.7 34.95 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.293 -1.504 . . . . 0.0 110.096 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.27 -35.97 78.76 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 118.363 -1.335 . . . . 0.0 108.164 178.363 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.411 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 83.0 m -60.79 -49.97 75.34 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . 0.401 ' HA ' ' NE2' ' A' ' 117' ' ' GLN . 7.7 tp60 -73.68 -46.45 46.32 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.86 178.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.0 mtt-85 -58.25 -46.08 86.63 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 110.466 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.478 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.1 ttm180 -58.21 -39.85 80.1 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.847 -1.158 . . . . 0.0 109.485 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.56 68.81 0.4 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -146.22 -45.95 0.2 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.425 -1.044 . . . . 0.0 108.743 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.563 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.9 t -94.34 142.33 27.54 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.4 5.7 11.17 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.547 179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.403 ' CD ' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -76.2 84.53 3.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.947 -1.325 . . . . 0.0 110.171 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.93 -43.58 1.66 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.474 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.22 -169.31 0.17 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.499 -1.001 . . . . 0.0 108.662 179.565 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -87.72 110.67 0.73 Allowed 'Trans proline' 0 C--N 1.309 -1.529 0 O-C-N 123.274 1.144 . . . . 0.0 109.452 178.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.563 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.62 146.58 32.89 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.483 ' N ' HD12 ' A' ' 129' ' ' ILE . 2.9 mp -106.35 141.15 22.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.859 -1.377 . . . . 0.0 109.301 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.628 ' CD2' HG23 ' A' ' 99' ' ' VAL . 4.4 t80 -127.87 115.35 18.46 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.105 -0.997 . . . . 0.0 110.41 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.493 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mmt180 -102.06 123.39 45.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.498 -0.752 . . . . 0.0 109.632 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.439 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 25.7 p90 -115.23 157.84 23.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.022 -1.049 . . . . 0.0 110.059 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.09 -1.006 . . . . 0.0 109.76 179.507 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 19.6 m-80 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.159 0.504 . . . . 0.0 109.931 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.482 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 11.7 mt -128.44 137.64 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.952 -1.093 . . . . 0.0 109.343 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.67 128.24 34.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.102 -0.999 . . . . 0.0 109.39 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.59 127.99 35.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.109 -0.994 . . . . 0.0 110.198 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.818 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 15.7 t -122.93 155.4 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.286 -0.884 . . . . 0.0 110.206 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.05 110.46 22.59 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.295 -0.878 . . . . 0.0 109.925 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.538 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.67 134.72 54.89 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 110.005 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 17.7 p -135.37 171.5 14.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.256 -0.902 . . . . 0.0 110.214 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.53 69.96 0.17 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 110.153 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.577 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.4 m -140.54 112.29 7.53 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.28 -0.887 . . . . 0.0 110.392 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.74 -163.28 26.94 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.542 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.2 -22.33 7.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.666 -0.902 . . . . 0.0 110.518 179.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.914 HD12 HD13 ' A' ' 55' ' ' LEU . 9.0 tt -97.41 107.06 36.64 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 120.839 -1.163 . . . . 0.0 110.28 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.511 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.91 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.318 1.167 . . . . 0.0 110.088 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.55 93.73 0.2 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.191 -0.943 . . . . 0.0 110.96 -178.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.25 68.56 0.76 Allowed 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.526 -0.733 . . . . 0.0 111.251 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.76 15.38 9.15 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.538 ' CB ' HD23 ' A' ' 15' ' ' LEU . 5.2 mmpt? -130.67 156.21 45.29 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.028 -1.278 . . . . 0.0 109.243 179.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.577 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.79 107.51 15.14 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 109.348 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.913 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -69.83 113.91 20.95 Favored Pre-proline 0 C--N 1.298 -1.654 0 O-C-N 121.474 -0.766 . . . . 0.0 110.688 -179.235 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.8 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.9 Cg_endo -70.18 130.81 19.45 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 106.443 -2.176 . . . . 0.0 106.443 175.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.673 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.1 mt -55.92 -18.41 8.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.718 -1.238 . . . . 0.0 110.518 -177.716 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.489 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -59.75 -16.16 25.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.771 -1.205 . . . . 0.0 110.484 179.655 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.051 HG23 HG23 ' A' ' 33' ' ' ILE . 13.3 m -92.03 -25.04 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.976 -1.078 . . . . 0.0 110.93 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.051 HG23 HG23 ' A' ' 32' ' ' VAL . 42.2 pt -117.06 -17.48 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.079 -1.013 . . . . 0.0 110.622 -179.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.569 ' HB2' HD11 ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.49 22.84 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.947 -1.095 . . . . 0.0 110.262 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.05 -7.56 27.24 Favored Glycine 0 N--CA 1.485 1.947 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.02 3.21 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.149 -1.5 . . . . 0.0 110.342 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.435 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -111.99 129.95 56.02 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.353 -1.086 . . . . 0.0 110.232 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.603 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.63 146.94 46.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.06 -1.025 . . . . 0.0 110.953 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 36.8 tp -109.65 115.66 30.3 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.475 -0.765 . . . . 0.0 110.216 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.94 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.8 mt -98.96 127.67 51.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.15 -0.969 . . . . 0.0 109.465 179.284 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.401 ' CE2' ' HA ' ' A' ' 118' ' ' ARG . 4.2 m-85 -94.88 122.62 37.7 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.556 -0.715 . . . . 0.0 110.518 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.2 31.24 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.344 -0.847 . . . . 0.0 110.581 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.3 p80 -109.31 8.17 25.48 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.245 -0.91 . . . . 0.0 109.478 178.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.93 135.95 41.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.13 -0.981 . . . . 0.0 110.316 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.531 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.94 -42.37 66.7 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.55 -0.719 . . . . 0.0 110.818 -179.687 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.63 -36.51 74.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.345 -0.847 . . . . 0.0 110.428 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.413 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -72.29 -36.28 68.9 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.482 -0.761 . . . . 0.0 109.809 -179.781 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.83 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 2.2 m -60.89 -34.04 74.03 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.359 -0.838 . . . . 0.0 109.77 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.34 -49.31 56.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.268 -0.895 . . . . 0.0 110.672 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.56 -43.85 65.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.208 -0.933 . . . . 0.0 110.383 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.702 HD12 HG11 ' A' ' 83' ' ' VAL . 1.5 tm? -56.34 -41.14 75.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.422 -0.799 . . . . 0.0 110.909 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.21 -51.41 13.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 110.372 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.75 -43.86 98.02 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.055 -1.028 . . . . 0.0 109.582 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.516 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -56.83 -43.84 81.45 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.309 -0.87 . . . . 0.0 109.549 179.528 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.914 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.46 -42.89 74.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.444 -0.785 . . . . 0.0 109.704 179.592 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.8 t -55.84 -30.78 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.133 -0.98 . . . . 0.0 108.71 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -76.15 -33.32 59.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.574 -0.703 . . . . 0.0 110.121 179.126 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.558 ' HB3' HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.74 -26.37 62.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 109.614 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.97 5.64 8.05 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.673 ' CD1' HD22 ' A' ' 30' ' ' LEU . 19.8 mt -108.29 143.57 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.199 -1.177 . . . . 0.0 110.235 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.5 t30 -86.12 107.34 17.8 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.199 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.628 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.96 146.92 46.67 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.002 -1.079 . . . . 0.0 112.064 -177.151 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.943 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.2 t -135.92 150.29 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.66 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.83 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.69 131.82 55.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.222 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.483 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -120.82 123.42 42.54 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.933 . . . . 0.0 110.731 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.855 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.1 p90 -155.2 178.43 10.22 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.641 179.546 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -52.36 128.17 24.58 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.071 -1.018 . . . . 0.0 110.63 -179.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.25 39.27 31.99 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.951 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -117.02 155.63 28.88 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.124 -1.221 . . . . 0.0 109.777 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.951 ' N ' HD13 ' A' ' 69' ' ' LEU . 27.0 m-20 -95.39 149.15 21.7 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.272 -0.893 . . . . 0.0 110.884 -179.125 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.677 ' O ' HG23 ' A' ' 71' ' ' VAL . 34.7 m -62.21 111.4 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.061 -1.024 . . . . 0.0 108.873 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.78 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.2 m -134.33 -36.06 0.9 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.895 . . . . 0.0 110.888 -179.11 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.943 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.6 t -50.91 134.7 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.195 -0.941 . . . . 0.0 109.851 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.78 HG23 ' O ' ' A' ' 72' ' ' SER . 1.8 pp . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.219 -0.926 . . . . 0.0 110.905 -179.363 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 122.033 0.921 . . . . 0.0 110.072 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.45 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.6 p -116.85 134.94 58.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 CA-C-O 121.969 0.89 . . . . 0.0 109.855 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 60' ' ' ILE . 16.0 m -113.34 124.45 69.99 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.341 0 O-C-N 121.422 -0.799 . . . . 0.0 109.484 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.742 HG22 ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.4 117.25 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.096 -1.003 . . . . 0.0 109.934 -178.61 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.94 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -112.08 100.07 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.986 -1.071 . . . . 0.0 108.625 179.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.9 162.24 35.64 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.752 -1.218 . . . . 0.0 110.943 -178.149 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.513 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -91.35 -133.15 0.12 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.627 -0.671 . . . . 0.0 109.24 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.513 ' N ' HG23 ' A' ' 85' ' ' THR . 46.5 p-10 -88.42 43.33 1.12 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.663 -1.273 . . . . 0.0 110.342 179.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.473 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.79 -30.29 6.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 110.144 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.041 -1.037 . . . . 0.0 109.28 179.421 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 120.902 0.382 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -119.74 153.18 36.04 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.066 . . . . 0.0 110.139 178.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.91 -26.99 25.26 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.386 -0.821 . . . . 0.0 109.551 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.8 p -162.52 163.63 27.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 111.432 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.485 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -134.0 126.21 49.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.479 -0.763 . . . . 0.0 109.718 179.114 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.913 HG21 HD11 ' A' ' 28' ' ' ILE . 2.8 mp -105.51 111.54 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.088 -1.007 . . . . 0.0 109.117 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.422 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -121.58 161.0 23.17 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.249 -0.907 . . . . 0.0 111.565 -178.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.1 t -96.26 -6.91 36.86 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 177.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.76 11.01 1.21 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.37 -0.831 . . . . 0.0 112.225 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.31 -1.123 0 O-C-N 120.537 -1.352 . . . . 0.0 109.509 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.427 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.315 0.579 . . . . 0.0 110.956 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.54 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -83.53 161.4 21.23 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.298 -0.876 . . . . 0.0 110.062 179.69 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.442 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.53 -61.88 1.25 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.435 -0.791 . . . . 0.0 112.172 -178.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.54 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.1 m -60.41 -29.31 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.742 -1.224 . . . . 0.0 111.692 -178.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.21 -56.49 6.6 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.01 -1.056 . . . . 0.0 110.749 -178.812 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.03 76.88 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.124 -0.985 . . . . 0.0 108.668 178.947 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.2 m -60.49 -50.03 75.18 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.109 -0.995 . . . . 0.0 108.368 178.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.24 63.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.477 -0.764 . . . . 0.0 110.184 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.401 ' HA ' ' CE2' ' A' ' 41' ' ' PHE . 10.8 mtt85 -71.2 -44.31 65.68 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.119 -0.988 . . . . 0.0 111.138 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.462 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 11.8 ttp180 -70.46 -40.0 73.96 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.999 -1.063 . . . . 0.0 109.975 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.96 63.33 0.71 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -137.12 -45.93 0.57 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.144 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.452 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.1 t -95.16 142.29 27.78 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.316 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.467 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.2 17.33 51.01 Favored Glycine 0 N--CA 1.484 1.887 0 C-N-CA 119.528 -1.32 . . . . 0.0 110.356 178.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.07 -37.86 55.21 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.059 -1.26 . . . . 0.0 109.705 179.666 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.0 28.59 2.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.475 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.6 -168.25 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.694 -0.886 . . . . 0.0 109.123 -179.415 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.48 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 49.6 Cg_endo -86.66 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.167 1.088 . . . . 0.0 110.556 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -80.09 157.67 41.35 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -106.85 141.59 21.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.041 -1.27 . . . . 0.0 109.105 178.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.485 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.9 t80 -130.07 114.81 16.23 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.07 -1.052 . . . . 0.0 110.227 179.392 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.818 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -101.5 122.15 43.27 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.428 -0.795 . . . . 0.0 109.656 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.422 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 14.3 p90 -120.24 154.54 34.74 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.896 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.432 HG13 ' HG3' ' A' ' 26' ' ' LYS . 75.4 t . . . . . 0 N--CA 1.492 1.66 0 O-C-N 121.205 -0.934 . . . . 0.0 110.235 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 . . . . . 0 N--CA 1.501 2.108 0 CA-C-O 120.8 0.333 . . . . 0.0 111.221 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.729 HG12 HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.55 126.23 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.674 -1.266 . . . . 0.0 109.313 179.136 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.78 127.59 34.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.942 179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.47 136.18 33.22 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.209 -0.932 . . . . 0.0 110.104 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.462 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.2 t -129.71 154.95 41.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.368 -0.832 . . . . 0.0 109.925 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.5 112.87 25.98 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.109 -0.994 . . . . 0.0 110.389 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.614 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.8 tp -59.31 140.52 55.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.368 -0.833 . . . . 0.0 109.19 179.308 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.33 -178.24 5.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 110.508 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 72.0 p -76.99 59.9 1.73 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.077 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 10.0 m -132.45 109.34 9.74 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.269 -0.895 . . . . 0.0 110.714 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.17 -167.2 28.98 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 118.85 -1.643 . . . . 0.0 110.687 179.204 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.54 -18.86 10.83 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.667 -0.902 . . . . 0.0 110.304 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -99.34 104.51 27.25 Favored Pre-proline 0 N--CA 1.49 1.533 0 C-N-CA 118.771 -1.172 . . . . 0.0 109.876 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.449 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.2 Cg_endo -63.55 128.51 22.54 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.336 1.177 . . . . 0.0 111.009 -179.109 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.442 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.95 1.17 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.779 -0.576 . . . . 0.0 109.882 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.1 m-85 -58.11 82.21 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.219 -0.926 . . . . 0.0 111.605 -179.236 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.12 0.52 52.7 Favored Glycine 0 N--CA 1.494 2.566 0 O-C-N 121.156 -0.965 . . . . 0.0 110.888 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.614 ' HB2' HD23 ' A' ' 15' ' ' LEU . 27.3 mmtp -130.51 156.99 43.88 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.877 -1.367 . . . . 0.0 109.538 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -108.23 107.64 18.34 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 120.977 -1.077 . . . . 0.0 109.474 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.893 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -67.08 113.43 13.42 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.34 -0.85 . . . . 0.0 110.757 -179.344 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.817 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.4 Cg_endo -68.52 130.99 22.01 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 N-CA-C 106.874 -2.01 . . . . 0.0 106.874 176.012 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.747 HD11 HD12 ' A' ' 58' ' ' LEU . 10.7 mt -56.24 -17.61 8.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.816 -1.178 . . . . 0.0 110.728 -177.815 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -59.9 -16.41 29.25 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.64 -1.287 . . . . 0.0 110.518 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.051 HG23 HG23 ' A' ' 33' ' ' ILE . 13.6 m -93.09 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.005 -1.059 . . . . 0.0 111.213 -179.552 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.051 HG23 HG23 ' A' ' 32' ' ' VAL . 18.9 pt -119.45 -21.45 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.031 -1.043 . . . . 0.0 110.639 -179.288 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.566 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.79 148.28 22.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.89 -1.131 . . . . 0.0 110.317 179.46 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.14 -3.9 60.38 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.579 -1.409 . . . . 0.0 109.579 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.3 -158.65 21.45 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.465 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.75 132.38 50.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -1.069 . . . . 0.0 110.654 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.82 147.02 40.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.181 -0.949 . . . . 0.0 110.523 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.08 122.22 46.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.341 -0.849 . . . . 0.0 110.08 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.894 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.3 mm -100.56 126.08 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.271 -0.893 . . . . 0.0 109.186 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.454 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.2 m-85 -96.5 121.41 38.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.105 -0.997 . . . . 0.0 110.025 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.36 28.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.277 -0.889 . . . . 0.0 110.511 179.527 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.1 37.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.284 -0.885 . . . . 0.0 110.079 178.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.97 135.39 46.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.067 -1.021 . . . . 0.0 110.459 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.474 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.43 65.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.662 -0.649 . . . . 0.0 110.906 -179.761 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.31 -32.77 73.13 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.36 -0.837 . . . . 0.0 110.843 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.33 65.71 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.399 -0.813 . . . . 0.0 109.9 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.876 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.6 m -61.13 -38.52 86.66 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.592 179.154 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.4 -49.16 70.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.128 -0.983 . . . . 0.0 110.531 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.416 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -72.05 -46.29 57.54 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.239 -0.913 . . . . 0.0 110.608 -179.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.776 HD21 HD11 ' A' ' 21' ' ' ILE . 3.0 tm? -56.73 -41.09 76.87 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.459 -0.776 . . . . 0.0 111.42 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.36 -51.08 60.81 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.851 -1.156 . . . . 0.0 109.759 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.8 -32.5 69.4 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.236 -0.915 . . . . 0.0 109.347 179.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.849 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -61.72 -33.67 74.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.573 -0.704 . . . . 0.0 109.352 179.63 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.822 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.91 -42.44 57.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.423 -0.798 . . . . 0.0 110.397 -179.911 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.07 -33.03 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.048 -1.033 . . . . 0.0 109.189 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.43 -32.95 60.87 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.502 -0.749 . . . . 0.0 109.918 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.849 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.5 mm? -71.96 -26.37 62.24 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.947 0.88 . . . . 0.0 109.981 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.81 3.06 10.21 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.289 -1.525 . . . . 0.0 109.289 -179.251 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.619 HG22 HG22 ' A' ' 81' ' ' VAL . 31.2 mt -103.88 143.96 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.356 -1.085 . . . . 0.0 109.955 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.555 HD22 HD11 ' A' ' 74' ' ' ILE . 35.1 t30 -88.68 106.87 18.62 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.178 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.544 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.92 145.28 44.77 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 118.868 -1.133 . . . . 0.0 111.739 -177.2 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.888 HG21 ' HA ' ' A' ' 73' ' ' VAL . 70.5 t -129.22 152.74 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.084 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.876 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -118.67 117.33 28.66 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.156 -1.018 . . . . 0.0 109.237 177.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -105.76 127.48 53.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.172 -0.955 . . . . 0.0 110.826 -179.256 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.925 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 10.0 p90 -155.58 -178.66 7.44 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.503 -0.748 . . . . 0.0 110.096 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.35 127.41 22.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.171 -0.956 . . . . 0.0 110.834 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.23 53.1 23.6 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.925 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.42 154.44 31.35 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.211 -1.17 . . . . 0.0 109.794 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.7 m-20 -91.21 149.37 21.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.229 -0.919 . . . . 0.0 110.427 -179.297 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.685 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.2 m -61.69 110.65 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.024 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.771 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.5 m -132.2 -38.72 1.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.759 . . . . 0.0 109.973 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.888 ' HA ' HG21 ' A' ' 63' ' ' VAL . 95.3 t -49.5 133.32 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.39 -0.819 . . . . 0.0 109.484 179.642 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.771 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.493 1.7 0 O-C-N 120.99 -1.069 . . . . 0.0 110.398 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.878 0.846 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 74' ' ' ILE . 6.3 p -116.68 135.13 57.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 122.013 0.911 . . . . 0.0 110.286 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.83 HG11 ' HB ' ' A' ' 33' ' ' ILE . 9.9 m -113.0 121.23 64.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 O-C-N 121.242 -0.911 . . . . 0.0 108.877 179.2 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.753 HG22 HG13 ' A' ' 73' ' ' VAL . 15.1 t -97.82 120.04 46.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 O-C-N 120.788 -1.195 . . . . 0.0 111.257 -177.612 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.894 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.8 m -111.26 99.0 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 122.361 1.077 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.45 155.04 46.35 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 120.514 -1.366 . . . . 0.0 110.526 -178.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.53 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.87 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.222 -0.923 . . . . 0.0 110.663 -179.322 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.53 ' N ' HG23 ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.77 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.123 -0.986 . . . . 0.0 110.608 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.587 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -101.04 -33.92 9.96 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.039 179.362 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 5.3 tp . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.597 -0.689 . . . . 0.0 109.341 178.805 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.163 0.506 . . . . 0.0 110.643 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -113.43 150.89 32.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.172 -0.955 . . . . 0.0 109.81 179.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.502 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.2 -32.58 56.07 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.369 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.465 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.2 p -161.45 163.06 30.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.203 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.561 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.29 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.389 -0.819 . . . . 0.0 110.031 179.264 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.893 HG21 HD11 ' A' ' 28' ' ' ILE . 3.3 mp -93.44 112.82 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.264 -0.898 . . . . 0.0 108.584 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.424 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.93 161.35 20.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 111.52 -178.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.452 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 58.5 m -88.86 -13.32 39.51 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.15 10.63 1.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.295 -0.878 . . . . 0.0 112.073 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.306 -1.297 0 O-C-N 120.755 -1.216 . . . . 0.0 109.133 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.472 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 121.366 0.603 . . . . 0.0 111.544 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.523 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -87.47 160.78 18.15 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.466 -0.771 . . . . 0.0 110.359 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.02 -55.34 3.21 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.647 -0.658 . . . . 0.0 112.553 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.523 HG22 ' OD1' ' A' ' 111' ' ' ASP . 9.3 m -70.62 -29.64 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.705 -1.247 . . . . 0.0 111.838 -178.197 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.472 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.49 -56.28 7.37 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.129 -0.982 . . . . 0.0 110.553 -179.243 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.426 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.2 -35.08 77.43 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.465 -0.894 . . . . 0.0 108.786 178.905 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.507 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 99.6 m -59.14 -49.8 76.47 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.537 178.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -73.28 -36.04 66.24 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.494 -0.754 . . . . 0.0 109.98 179.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.414 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 8.8 mtt85 -71.9 -44.98 62.81 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.262 -0.899 . . . . 0.0 111.118 -179.494 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 0.8 OUTLIER -64.36 -36.62 84.71 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.984 -1.072 . . . . 0.0 110.318 -179.873 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.43 0.76 Allowed Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.443 ' HB3' HG11 ' A' ' 99' ' ' VAL . 0.0 OUTLIER -135.51 -43.02 0.69 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.411 -1.053 . . . . 0.0 109.206 179.489 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.729 HG23 HG12 ' A' ' 10' ' ' ILE . 14.8 t -102.32 141.77 34.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.561 -0.712 . . . . 0.0 109.632 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.451 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.16 10.81 14.8 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.502 -1.332 . . . . 0.0 110.15 179.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.11 84.71 1.82 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.956 -1.32 . . . . 0.0 109.876 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 96.33 16.13 38.66 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.468 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.89 0.22 Allowed Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.259 -1.142 . . . . 0.0 109.378 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.468 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.2 Cg_endo -88.06 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 O-C-N 123.349 1.183 . . . . 0.0 110.412 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -79.26 160.05 45.64 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.49 142.75 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.417 -1.049 . . . . 0.0 108.779 178.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.561 ' CD2' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -129.91 117.27 19.87 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 120.953 -1.092 . . . . 0.0 111.016 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.462 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 22.2 mtt180 -101.42 123.5 45.58 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.548 -0.72 . . . . 0.0 109.331 179.22 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.415 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.19 156.24 26.87 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.041 -1.037 . . . . 0.0 110.533 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.437 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 4.6 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.171 -0.956 . . . . 0.0 109.392 179.451 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.554 0.692 . . . . 0.0 109.365 . . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.485 HD13 HG22 ' A' ' 122' ' ' THR . 14.6 mt -96.73 133.73 37.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.935 -1.103 . . . . 0.0 110.203 179.816 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -84.2 128.14 34.38 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.35 -0.844 . . . . 0.0 109.541 179.19 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -89.4 121.5 31.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.069 -1.02 . . . . 0.0 109.9 -179.573 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.783 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 4.8 t -115.69 156.63 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.368 -0.833 . . . . 0.0 110.222 -179.34 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.77 105.07 15.17 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.281 -0.887 . . . . 0.0 109.625 179.078 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.651 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -54.15 132.51 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.35 -0.844 . . . . 0.0 109.658 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.51 -174.7 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 110.256 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.94 63.43 3.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 110.041 179.835 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.501 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.0 m -132.07 112.08 12.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.337 -0.852 . . . . 0.0 110.244 -179.834 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.21 -163.41 26.72 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 119.158 -1.496 . . . . 0.0 110.455 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.39 -22.5 5.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.525 -0.985 . . . . 0.0 110.729 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.9 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -93.94 113.24 60.04 Favored Pre-proline 0 N--CA 1.487 1.417 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.064 -179.5 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.9 Cg_endo -64.23 150.76 87.68 Favored 'Trans proline' 0 C--N 1.313 -1.309 0 O-C-N 123.519 1.273 . . . . 0.0 110.026 -179.824 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.479 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.95 88.84 0.62 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.137 -0.977 . . . . 0.0 111.374 -178.477 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.514 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.14 67.18 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.349 -0.845 . . . . 0.0 111.26 179.146 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.03 13.75 21.29 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.708 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.36 156.16 45.17 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.063 -1.257 . . . . 0.0 109.366 179.738 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.501 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.47 106.97 15.57 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.918 -1.114 . . . . 0.0 109.279 179.74 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.898 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.47 114.11 21.83 Favored Pre-proline 0 C--N 1.3 -1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 110.384 -179.307 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.881 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.7 Cg_endo -70.67 129.98 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 N-CA-C 107.024 -1.952 . . . . 0.0 107.024 176.364 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.862 HD11 HD12 ' A' ' 58' ' ' LEU . 15.7 mt -56.62 -17.49 8.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.939 -1.101 . . . . 0.0 110.744 -177.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.477 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -60.86 -16.19 38.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.817 -1.177 . . . . 0.0 110.347 179.503 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.1 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -93.77 -25.35 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.003 -1.061 . . . . 0.0 111.15 -179.348 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.1 HG23 HG23 ' A' ' 32' ' ' VAL . 46.0 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 110.472 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.03 147.86 24.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.256 -0.902 . . . . 0.0 110.429 179.898 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.36 -5.63 38.49 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.95 -145.62 7.11 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.198 -1.477 . . . . 0.0 110.44 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.1 mtt85 -108.53 132.67 53.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.415 -1.05 . . . . 0.0 110.264 -179.696 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -140.71 150.56 43.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.023 -1.048 . . . . 0.0 111.031 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.591 HD12 ' O ' ' A' ' 82' ' ' VAL . 62.1 tp -110.98 114.29 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.447 -0.783 . . . . 0.0 109.947 179.565 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.919 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.2 mt -98.75 127.15 51.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.131 -0.981 . . . . 0.0 109.493 179.689 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.403 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 6.9 m-85 -95.44 124.01 39.26 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.172 -0.955 . . . . 0.0 110.143 -179.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.76 21.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.202 -0.936 . . . . 0.0 110.494 -179.688 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.514 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.2 p80 -107.02 -1.41 22.17 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.352 -0.843 . . . . 0.0 110.073 179.03 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.91 136.8 42.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.1 -1.0 . . . . 0.0 110.465 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.469 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.72 -38.27 70.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.466 -0.771 . . . . 0.0 110.663 -179.848 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.86 -35.6 73.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.333 -0.854 . . . . 0.0 110.453 -179.636 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.43 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.68 -35.83 65.24 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.79 -179.958 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.904 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 76.3 m -61.2 -34.01 74.4 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.415 -0.803 . . . . 0.0 109.757 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.7 -50.17 53.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 110.245 -179.841 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.32 -43.5 64.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.288 -0.882 . . . . 0.0 110.065 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.694 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -57.12 -42.51 81.03 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.602 -0.686 . . . . 0.0 111.248 -178.994 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.03 -51.09 42.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.796 -1.19 . . . . 0.0 110.013 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.24 -34.62 68.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.272 -0.893 . . . . 0.0 109.25 179.462 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.587 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.81 -46.39 84.74 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.274 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.9 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.78 -43.35 94.43 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.39 -0.819 . . . . 0.0 110.999 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.4 t -56.11 -34.14 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.966 -1.084 . . . . 0.0 109.375 179.617 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.51 -34.46 60.82 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.297 -0.877 . . . . 0.0 110.315 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.862 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.35 -25.84 62.56 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.285 -0.884 . . . . 0.0 109.699 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.2 7.86 8.18 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.633 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.622 ' CD1' HD22 ' A' ' 30' ' ' LEU . 47.0 mt -108.47 143.48 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.254 -1.145 . . . . 0.0 110.119 -179.756 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.638 ' ND2' HD11 ' A' ' 74' ' ' ILE . 16.7 t30 -89.25 106.53 18.5 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.168 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.656 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.48 145.21 45.45 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.977 -1.089 . . . . 0.0 111.629 -177.244 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.893 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.95 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.066 -0.653 . . . . 0.0 109.454 179.719 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.904 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.2 122.52 47.09 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.585 178.818 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.475 ' CD1' HD12 ' A' ' 69' ' ' LEU . 0.4 OUTLIER -109.52 131.35 55.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.262 -0.899 . . . . 0.0 110.809 -179.534 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.907 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.24 178.32 5.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.563 -0.711 . . . . 0.0 109.905 179.644 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.55 125.52 20.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.045 -1.035 . . . . 0.0 110.814 -179.366 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.83 40.93 13.44 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.743 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.907 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.38 157.02 26.89 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -1.14 . . . . 0.0 110.322 -179.831 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.884 ' N ' HD13 ' A' ' 69' ' ' LEU . 21.8 m-20 -98.48 149.33 22.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.281 -0.887 . . . . 0.0 110.571 -179.378 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.618 ' O ' HG23 ' A' ' 71' ' ' VAL . 31.5 m -62.33 111.36 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.036 . . . . 0.0 109.311 179.123 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.72 ' O ' HG23 ' A' ' 74' ' ' ILE . 43.8 m -134.31 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.52 -0.737 . . . . 0.0 110.368 -179.415 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.909 HG13 HG22 ' A' ' 82' ' ' VAL . 76.9 t -46.47 131.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.489 -0.757 . . . . 0.0 110.685 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.721 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.3 pp . . . . . 0 N--CA 1.495 1.802 0 O-C-N 121.166 -0.958 . . . . 0.0 110.659 179.408 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 122.083 0.944 . . . . 0.0 109.954 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.721 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -116.39 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-O 121.899 0.857 . . . . 0.0 110.199 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.613 HG22 HG22 ' A' ' 60' ' ' ILE . 10.1 m -111.91 123.35 67.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.159 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.909 HG22 HG13 ' A' ' 73' ' ' VAL . 33.2 t -96.62 118.11 42.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.061 -1.025 . . . . 0.0 110.612 -178.062 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.919 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.2 m -111.75 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 118.93 -1.108 . . . . 0.0 108.756 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.434 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -131.44 156.46 45.58 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 120.69 -1.256 . . . . 0.0 110.339 -178.606 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.551 HG23 ' OD2' ' A' ' 86' ' ' ASP . 9.0 t -94.07 -30.46 14.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.367 -0.833 . . . . 0.0 111.471 -178.583 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.551 ' OD2' HG23 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.56 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.931 -1.106 . . . . 0.0 111.529 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.616 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.79 -39.95 12.76 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.958 -1.089 . . . . 0.0 110.163 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.9 tp . . . . . 0 N--CA 1.488 1.45 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.213 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 120.964 0.411 . . . . 0.0 110.344 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -120.22 135.55 54.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.04 -1.037 . . . . 0.0 110.381 179.868 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.508 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.14 -27.75 57.15 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.556 179.22 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.514 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.0 p -160.38 163.0 33.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.29 -0.881 . . . . 0.0 110.54 179.501 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.415 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.82 115.9 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.228 -0.92 . . . . 0.0 110.336 179.66 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.823 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -93.44 114.63 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.6 161.31 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.09 -1.006 . . . . 0.0 111.829 -178.151 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.26 9.09 38.28 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.946 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.421 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 52.35 23.18 2.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.194 -0.941 . . . . 0.0 110.97 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 110.657 179.584 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.468 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.199 0.523 . . . . 0.0 110.722 . . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.414 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -84.96 161.0 19.96 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.154 -0.966 . . . . 0.0 110.085 179.605 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.417 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.26 -57.45 2.98 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.517 -0.74 . . . . 0.0 112.433 -178.531 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.474 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.2 m -68.6 -29.39 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 120.688 -1.257 . . . . 0.0 111.847 -178.143 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.468 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.21 -56.23 7.07 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.039 -1.038 . . . . 0.0 110.545 -179.263 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.476 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.7 ptm180 -70.43 -35.15 73.22 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.377 -0.929 . . . . 0.0 108.873 179.073 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.474 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.9 m -58.98 -49.55 77.47 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.04 -1.037 . . . . 0.0 108.371 178.637 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.78 -35.85 64.98 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.394 -0.816 . . . . 0.0 109.863 178.704 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.476 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.69 -44.54 64.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.08 -1.013 . . . . 0.0 110.934 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.467 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 17.2 ttm180 -53.12 -41.82 65.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.896 -1.127 . . . . 0.0 109.713 179.587 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.37 63.28 0.26 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.452 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -132.57 -42.71 0.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.449 -1.03 . . . . 0.0 108.658 179.152 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.486 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.9 t -98.17 144.05 28.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.653 -0.654 . . . . 0.0 109.576 179.148 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.24 9.25 36.85 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.692 -1.242 . . . . 0.0 110.32 179.35 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -66.29 87.5 0.11 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.99 -1.3 . . . . 0.0 109.52 179.709 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.74 23.27 28.65 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -178.772 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.478 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.43 -179.81 0.3 Allowed Pre-proline 0 N--CA 1.492 1.646 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.7 Cg_endo -88.93 105.97 0.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.09 1.047 . . . . 0.0 110.882 -179.939 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.486 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.64 179.47 53.47 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.51 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.468 -1.019 . . . . 0.0 108.951 179.033 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.447 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 11.7 t80 -129.71 115.83 17.9 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.897 -1.121 . . . . 0.0 111.063 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.783 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 1.7 mtt180 -100.58 134.33 43.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.515 -0.74 . . . . 0.0 109.029 179.366 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.4 p90 -126.28 156.73 39.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.931 -1.105 . . . . 0.0 110.582 -179.456 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.651 HG22 HD23 ' A' ' 15' ' ' LEU . 55.9 t . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.287 -0.883 . . . . 0.0 109.9 179.561 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 . . . . . 0 N--CA 1.494 1.761 0 CA-C-O 120.806 0.336 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.711 HD11 ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.08 137.39 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.832 -1.168 . . . . 0.0 110.62 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.6 128.43 34.51 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 108.866 178.312 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -89.53 142.68 27.45 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.055 -1.028 . . . . 0.0 110.62 -179.007 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.45 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.2 t -137.73 158.02 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.418 -0.802 . . . . 0.0 110.434 -179.694 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.88 109.41 17.58 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.442 -0.786 . . . . 0.0 109.56 179.104 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.732 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.1 tp -53.5 136.85 37.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.279 -0.888 . . . . 0.0 109.964 -179.878 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.1 p -137.38 174.49 10.54 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 110.285 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.8 p -71.63 80.09 0.82 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.196 -0.94 . . . . 0.0 110.067 179.856 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.826 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.8 m -155.53 109.05 2.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.176 -0.953 . . . . 0.0 110.799 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.416 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.33 -170.22 29.6 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.833 -1.651 . . . . 0.0 110.942 179.136 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.22 -20.39 12.34 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.755 -0.85 . . . . 0.0 110.417 -179.792 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -98.85 103.88 21.95 Favored Pre-proline 0 N--CA 1.491 1.592 0 C-N-CA 118.906 -1.118 . . . . 0.0 109.86 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -62.63 124.96 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.32 1.168 . . . . 0.0 110.84 -179.369 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.426 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.49 -166.85 1.13 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.737 -0.602 . . . . 0.0 110.433 -179.239 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.527 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.17 81.77 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.465 -0.772 . . . . 0.0 111.514 -179.451 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.1 2.25 52.27 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.607 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.732 ' HB2' HD23 ' A' ' 15' ' ' LEU . 15.1 mmtp -130.18 156.3 44.81 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.973 -1.31 . . . . 0.0 109.355 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.826 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.69 107.43 18.44 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.961 -1.087 . . . . 0.0 109.078 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 1.007 HD11 HG21 ' A' ' 100' ' ' ILE . 5.2 mt -69.33 112.92 13.42 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.312 -0.867 . . . . 0.0 110.521 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.745 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.1 Cg_endo -68.54 129.62 19.28 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 N-CA-C 107.161 -1.9 . . . . 0.0 107.161 176.282 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.746 HD22 ' CD1' ' A' ' 60' ' ' ILE . 10.9 mt -56.27 -17.78 8.61 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.83 -1.169 . . . . 0.0 110.69 -177.803 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -59.88 -16.05 26.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.677 -1.265 . . . . 0.0 110.575 179.898 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.131 HG23 HG23 ' A' ' 33' ' ' ILE . 10.6 m -93.99 -25.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.982 -1.074 . . . . 0.0 110.775 -179.727 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.131 HG23 HG23 ' A' ' 32' ' ' VAL . 12.3 pt -114.62 -23.27 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.094 -1.004 . . . . 0.0 110.57 -179.508 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.578 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptm -93.81 147.96 22.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.803 -1.185 . . . . 0.0 110.2 179.381 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.77 -3.42 52.85 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.799 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.64 -150.63 8.64 Favored Glycine 0 N--CA 1.494 2.533 0 C-N-CA 118.927 -1.606 . . . . 0.0 110.626 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.451 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.42 129.41 55.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.435 -1.038 . . . . 0.0 109.968 -179.793 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.536 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.1 m-70 -137.8 149.42 46.35 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.982 -1.074 . . . . 0.0 110.963 -179.635 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.656 HD23 ' HG2' ' A' ' 121' ' ' ARG . 34.1 tp -110.82 117.27 32.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.419 -0.8 . . . . 0.0 110.21 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.943 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.1 mm -97.92 125.42 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.293 -0.88 . . . . 0.0 109.471 179.792 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.429 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.67 123.38 42.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.093 -1.004 . . . . 0.0 109.882 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.21 159.39 22.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.545 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.527 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.56 23.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.161 179.373 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.35 141.12 51.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.11 -0.994 . . . . 0.0 110.382 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.445 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.63 -31.82 67.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.478 -0.764 . . . . 0.0 110.58 -179.762 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.47 75.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.183 -0.948 . . . . 0.0 110.54 -179.861 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.434 ' HE2' ' CE1' ' A' ' 24' ' ' TYR . 0.2 OUTLIER -73.83 -34.26 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.873 . . . . 0.0 109.622 179.803 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.707 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 62.7 m -60.52 -35.05 75.04 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.398 -0.814 . . . . 0.0 109.177 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.56 -49.06 65.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 110.304 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.437 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.56 -43.16 66.84 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.165 -0.959 . . . . 0.0 110.778 -179.615 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 1.028 HD12 HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.46 73.92 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.248 -0.907 . . . . 0.0 110.909 -179.057 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.462 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.74 -51.37 12.83 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.974 -1.079 . . . . 0.0 110.281 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.43 99.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.025 -1.047 . . . . 0.0 109.696 179.636 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.568 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.42 -47.41 81.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.422 -0.799 . . . . 0.0 109.468 179.649 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.78 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.89 -43.02 76.83 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.604 -0.685 . . . . 0.0 110.365 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.38 -34.6 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.084 -1.01 . . . . 0.0 109.217 179.614 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.0 59.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.316 -0.865 . . . . 0.0 109.74 179.271 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.568 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.7 mm? -71.52 -26.36 62.63 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-O 121.924 0.869 . . . . 0.0 109.575 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.15 6.3 10.03 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.746 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.8 mt -108.1 143.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.293 -1.122 . . . . 0.0 110.104 -179.776 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 21.0 t30 -87.89 106.56 18.19 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 177.953 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.644 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.33 144.26 46.0 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.086 -1.045 . . . . 0.0 111.397 -177.288 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.878 HG21 ' HA ' ' A' ' 73' ' ' VAL . 2.5 t -131.03 142.63 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.807 179.551 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.707 ' HB2' ' O ' ' A' ' 48' ' ' CYS . . . -105.84 118.33 36.31 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.81 178.984 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.7 OUTLIER -105.27 118.43 36.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.857 . . . . 0.0 110.706 -179.43 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.909 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -149.69 -179.88 7.46 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 179.32 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.66 129.37 40.79 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.069 -1.019 . . . . 0.0 110.687 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.96 23.68 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.909 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.22 154.71 30.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.321 -1.105 . . . . 0.0 110.014 -179.765 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.844 ' N ' HD13 ' A' ' 69' ' ' LEU . 23.9 m-20 -94.9 149.78 20.89 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.338 -0.851 . . . . 0.0 110.39 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.674 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 118.934 -1.107 . . . . 0.0 108.99 179.338 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.509 ' O ' HG23 ' A' ' 74' ' ' ILE . 36.7 m -133.09 -33.51 1.14 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.485 -0.759 . . . . 0.0 110.708 -179.234 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.878 ' HA ' HG21 ' A' ' 63' ' ' VAL . 89.6 t -56.49 134.67 20.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.154 -0.966 . . . . 0.0 109.782 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.577 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.495 1.818 0 O-C-N 121.194 -0.941 . . . . 0.0 110.696 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 121.838 0.828 . . . . 0.0 110.313 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.526 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.6 134.22 61.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 122.052 0.929 . . . . 0.0 110.351 179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.626 HG22 HG22 ' A' ' 60' ' ' ILE . 8.0 m -113.16 124.55 69.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.249 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.009 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.758 HG22 HG13 ' A' ' 73' ' ' VAL . 8.8 t -97.7 118.78 44.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.019 -1.051 . . . . 0.0 110.778 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.028 HG11 HD12 ' A' ' 51' ' ' LEU . 4.1 m -111.87 98.54 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 120.78 -1.2 . . . . 0.0 108.81 179.135 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.92 29.24 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.626 -1.296 . . . . 0.0 110.077 -178.813 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -103.36 -24.73 13.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 111.296 -178.544 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 179.92 -29.37 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.996 -1.065 . . . . 0.0 111.059 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.95 -38.98 24.58 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.013 -1.055 . . . . 0.0 110.278 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.9 tp . . . . . 0 N--CA 1.49 1.532 0 O-C-N 121.135 -0.978 . . . . 0.0 108.705 178.552 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.02 0.438 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.503 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.2 m-85 -119.7 150.67 39.98 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.953 -1.092 . . . . 0.0 110.265 179.284 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.458 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.6 m-20 -76.86 -31.92 57.15 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.459 -0.776 . . . . 0.0 109.898 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.61 163.97 26.92 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.256 -0.977 . . . . 0.0 111.788 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.698 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.98 113.77 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.504 -0.748 . . . . 0.0 110.069 179.064 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 1.007 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -92.74 116.16 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.093 -1.004 . . . . 0.0 108.387 178.863 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.05 31.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.083 -1.011 . . . . 0.0 112.039 -177.895 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.479 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.5 t -95.77 -1.04 50.56 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 177.84 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.403 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 54.89 20.92 3.34 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -0.974 . . . . 0.0 111.168 179.737 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.492 1.635 0 O-C-N 120.974 -1.079 . . . . 0.0 110.659 179.669 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.402 ' OE1' ' ND2' ' A' ' 103' ' ' ASN . 5.7 pt20 . . . . . 0 N--CA 1.494 1.762 0 CA-C-O 121.34 0.59 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.513 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -98.1 160.81 14.06 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.43 -0.794 . . . . 0.0 110.141 179.741 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.51 -50.67 7.06 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.522 -0.736 . . . . 0.0 112.298 -178.681 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.513 HG22 ' OD1' ' A' ' 111' ' ' ASP . 16.2 m -71.25 -29.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 120.699 -1.251 . . . . 0.0 111.446 -178.564 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.418 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.32 -56.01 7.67 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.059 -1.026 . . . . 0.0 110.449 -179.375 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.469 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.17 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.401 -0.92 . . . . 0.0 108.888 178.683 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.468 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.495 -0.882 . . . . 0.0 108.698 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . 0.42 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.27 66.42 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.608 -0.683 . . . . 0.0 109.528 178.984 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.469 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 21.3 mtt85 -68.42 -44.97 73.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.164 -0.96 . . . . 0.0 110.499 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.48 ' HE ' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -59.94 -46.45 89.36 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.23 -0.919 . . . . 0.0 110.332 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.0 -26.37 1.2 Allowed Glycine 0 N--CA 1.499 2.85 0 O-C-N 121.474 -0.766 . . . . 0.0 111.396 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.656 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -48.83 -55.39 11.76 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.882 -1.363 . . . . 0.0 110.858 -179.394 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.711 ' O ' HD11 ' A' ' 10' ' ' ILE . 1.3 t -91.62 142.59 27.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.66 12.54 16.4 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.303 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 6.2 mtt180 -102.47 76.56 1.55 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.953 -1.322 . . . . 0.0 109.951 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.671 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.44 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -145.14 167.11 15.38 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.58 -0.953 . . . . 0.0 108.79 179.779 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.95 111.98 1.71 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.202 1.106 . . . . 0.0 109.637 179.582 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.493 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -87.24 166.16 36.44 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -178.854 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 98' ' ' SER . 2.7 mt -124.3 141.79 43.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.514 -0.992 . . . . 0.0 108.54 178.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.698 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.59 115.44 19.5 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.927 179.827 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.45 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.35 121.82 45.34 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.536 -0.728 . . . . 0.0 109.183 179.276 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.403 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 24.5 p90 -119.52 157.75 27.69 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -0.987 . . . . 0.0 109.991 -179.694 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.7 t . . . . . 0 N--CA 1.493 1.711 0 O-C-N 121.189 -0.944 . . . . 0.0 110.005 179.751 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.4 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 41.6 m-80 . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.114 0.483 . . . . 0.0 110.449 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.659 HG12 HG23 ' A' ' 122' ' ' THR . 1.9 mt -112.8 135.49 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.03 -1.044 . . . . 0.0 109.811 179.898 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.94 125.14 33.13 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.256 -0.902 . . . . 0.0 108.741 178.311 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -89.33 129.53 35.85 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.031 -1.043 . . . . 0.0 110.276 -179.245 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.625 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 12.0 t -125.35 157.88 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.472 -0.767 . . . . 0.0 110.42 -179.193 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.46 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.46 114.15 27.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.292 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.677 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -52.21 143.87 13.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.231 -0.918 . . . . 0.0 109.878 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.8 p -142.06 -178.2 5.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.196 -0.94 . . . . 0.0 110.226 -179.663 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.4 p -80.33 59.16 3.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.302 -0.873 . . . . 0.0 110.097 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.454 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 23.8 m -132.75 109.22 9.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.436 -0.79 . . . . 0.0 110.597 -179.829 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.414 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.35 -171.63 28.73 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 118.81 -1.662 . . . . 0.0 111.139 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.7 -22.82 10.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.703 -0.88 . . . . 0.0 110.473 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.893 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.8 tt -93.48 109.5 41.01 Favored Pre-proline 0 N--CA 1.49 1.538 0 C-N-CA 118.749 -1.18 . . . . 0.0 109.226 -179.923 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.14 145.54 93.73 Favored 'Trans proline' 0 C--N 1.312 -1.354 0 O-C-N 123.423 1.223 . . . . 0.0 111.491 -178.284 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.438 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.83 -165.12 1.68 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.624 -0.673 . . . . 0.0 110.403 -179.311 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.523 ' CD2' ' HB3' ' A' ' 102' ' ' CYS . 38.3 m-85 -60.65 79.76 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.507 -0.745 . . . . 0.0 110.688 -179.879 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.99 57.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.485 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.677 ' HB2' HD23 ' A' ' 15' ' ' LEU . 1.3 mmtp -130.19 156.08 45.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.027 -1.278 . . . . 0.0 109.547 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.454 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.08 106.91 16.11 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.989 -1.069 . . . . 0.0 109.054 179.38 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.893 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.32 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 110.819 -179.173 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.799 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.4 Cg_endo -70.31 130.57 18.88 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 N-CA-C 106.668 -2.089 . . . . 0.0 106.668 175.869 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.736 HD11 HD12 ' A' ' 58' ' ' LEU . 14.3 mt -55.99 -17.98 8.16 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.809 -1.182 . . . . 0.0 110.581 -177.784 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -59.35 -16.49 22.85 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.525 -1.359 . . . . 0.0 110.515 179.729 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.02 HG23 HG23 ' A' ' 33' ' ' ILE . 13.4 m -92.73 -24.33 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.002 -1.061 . . . . 0.0 111.038 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.02 HG23 HG23 ' A' ' 32' ' ' VAL . 37.9 pt -117.45 -26.28 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.921 -1.112 . . . . 0.0 110.358 -179.413 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.621 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -90.32 148.79 22.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.057 -1.027 . . . . 0.0 110.058 179.057 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.457 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.81 -4.86 25.92 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.577 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.5 -130.95 2.18 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 119.214 -1.469 . . . . 0.0 110.268 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.2 mtt-85 -115.59 131.0 57.07 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.33 -1.1 . . . . 0.0 110.234 -179.69 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.57 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 74.4 m-70 -140.83 146.4 37.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.111 -0.993 . . . . 0.0 110.879 -179.762 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.517 HD22 ' HG2' ' A' ' 121' ' ' ARG . 20.4 tp -106.79 127.59 53.53 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.534 -0.729 . . . . 0.0 109.942 179.593 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.916 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.1 mt -109.76 128.22 66.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.515 179.388 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -95.09 124.11 38.95 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 109.99 -179.754 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.56 159.9 21.44 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.347 -0.845 . . . . 0.0 110.739 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.52 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.5 OUTLIER -106.81 3.1 26.07 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.492 -0.755 . . . . 0.0 110.206 179.26 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.0 p -136.7 136.74 39.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.957 -1.089 . . . . 0.0 110.834 -179.661 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.483 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.91 -36.98 70.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.551 -0.718 . . . . 0.0 110.628 179.907 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.29 -33.67 76.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.416 -179.738 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.54 -35.51 65.53 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.51 -0.744 . . . . 0.0 109.712 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.784 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 93.1 m -61.11 -36.06 78.68 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.357 -0.839 . . . . 0.0 109.418 179.498 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.54 -49.95 60.92 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.197 -0.939 . . . . 0.0 110.519 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.407 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.4 mm-40 -72.22 -44.81 62.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.209 -0.932 . . . . 0.0 110.267 179.828 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.634 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -56.79 -43.57 81.04 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.661 . . . . 0.0 111.154 -179.12 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.455 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -67.72 -51.16 52.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.872 -1.142 . . . . 0.0 109.821 179.894 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -35.5 69.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.195 -0.941 . . . . 0.0 109.27 179.323 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.668 ' HD3' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.765 . . . . 0.0 108.978 179.235 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.867 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.15 -41.95 84.86 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 110.794 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.5 t -56.15 -32.87 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.07 -1.019 . . . . 0.0 109.156 179.664 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.38 60.15 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.392 -0.818 . . . . 0.0 110.491 179.68 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.736 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.31 -25.44 62.42 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.146 -0.971 . . . . 0.0 109.918 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.78 4.61 9.51 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.329 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.668 ' CD1' HD22 ' A' ' 30' ' ' LEU . 44.7 mt -105.71 143.37 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 121.376 -1.073 . . . . 0.0 109.845 -179.729 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.556 HD22 HG23 ' A' ' 80' ' ' VAL . 1.9 t30 -88.58 106.99 18.67 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 178.173 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.572 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.57 146.31 44.69 Favored 'General case' 0 C--N 1.294 -1.812 0 C-N-CA 118.706 -1.197 . . . . 0.0 111.728 -177.084 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.928 HG21 ' HA ' ' A' ' 73' ' ' VAL . 89.8 t -128.2 149.75 33.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.784 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.29 117.74 30.83 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.549 178.412 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.5 142.36 45.16 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.337 -0.852 . . . . 0.0 110.354 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.886 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.9 p90 -175.32 -177.27 1.01 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.399 -0.813 . . . . 0.0 110.034 179.888 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.52 119.8 5.76 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.176 -0.952 . . . . 0.0 111.234 -179.232 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 40.97 11.8 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.13 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.886 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -117.59 155.37 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.052 -1.264 . . . . 0.0 110.223 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.813 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -93.56 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.282 -0.886 . . . . 0.0 110.416 -179.541 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.656 ' O ' HG23 ' A' ' 71' ' ' VAL . 28.2 m -62.55 110.61 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.411 179.384 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.59 -20.95 2.27 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.536 -0.728 . . . . 0.0 111.046 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.928 ' HA ' HG21 ' A' ' 63' ' ' VAL . 54.5 t -63.99 128.15 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.022 -1.049 . . . . 0.0 109.53 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.703 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.4 pp . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.028 -1.045 . . . . 0.0 110.926 -179.647 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.873 0.844 . . . . 0.0 110.146 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.556 HG23 HD22 ' A' ' 61' ' ' ASN . 6.8 p -116.65 135.38 57.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-O 122.006 0.908 . . . . 0.0 110.721 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 60' ' ' ILE . 9.6 m -113.2 122.81 68.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.611 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.702 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -97.29 118.81 44.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 120.833 -1.167 . . . . 0.0 110.5 -178.118 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.916 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.5 m -109.8 100.64 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.018 -1.051 . . . . 0.0 108.947 179.699 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.21 163.83 31.9 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.602 -1.311 . . . . 0.0 111.38 -177.859 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.494 HG23 ' N ' ' A' ' 86' ' ' ASP . 11.2 t -91.38 -140.76 0.17 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.423 -0.798 . . . . 0.0 109.332 179.757 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.494 ' N ' HG23 ' A' ' 85' ' ' THR . 3.8 p30 -84.43 52.12 2.28 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.806 -1.184 . . . . 0.0 110.248 179.633 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.471 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.43 -19.58 6.36 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.202 -0.936 . . . . 0.0 110.936 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 O-C-N 121.012 -1.055 . . . . 0.0 109.548 179.922 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.199 0.523 . . . . 0.0 110.392 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -119.45 153.1 35.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.205 -0.934 . . . . 0.0 110.167 179.433 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.86 -29.24 25.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.396 -0.815 . . . . 0.0 109.513 179.393 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.4 p -161.88 163.7 29.07 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.244 -0.91 . . . . 0.0 111.161 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.492 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.53 125.85 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.389 -0.819 . . . . 0.0 110.094 179.24 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.742 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -102.86 112.15 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.231 -0.918 . . . . 0.0 109.003 179.265 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.417 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.0 t0 -118.09 162.01 18.91 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.184 -0.948 . . . . 0.0 111.869 -178.485 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.523 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.26 9.38 38.13 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.75 -0.594 . . . . 0.0 109.744 178.556 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.433 ' ND2' ' NE2' ' A' ' 110' ' ' GLN . 2.8 m-20 46.58 25.16 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.091 -1.006 . . . . 0.0 111.481 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 110.454 179.629 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.433 ' NE2' ' ND2' ' A' ' 103' ' ' ASN . 13.9 pt20 . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.465 0.65 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.532 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.5 p30 -93.21 161.09 14.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.384 -0.822 . . . . 0.0 109.719 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.41 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.13 -51.75 5.78 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.375 -0.828 . . . . 0.0 112.316 -178.629 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.532 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.6 m -69.74 -29.15 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.76 -1.213 . . . . 0.0 111.382 -178.81 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.47 -56.13 7.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.122 -0.986 . . . . 0.0 110.522 -179.091 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.419 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.3 OUTLIER -68.08 -34.86 77.22 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.066 -1.021 . . . . 0.0 108.658 178.927 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.462 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.95 -49.91 75.83 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.14 -0.975 . . . . 0.0 108.427 178.623 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.8 -36.85 65.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.584 -0.697 . . . . 0.0 109.888 179.078 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.419 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 13.6 mtt180 -71.23 -44.61 65.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.163 -0.96 . . . . 0.0 110.502 -179.727 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.448 ' HG2' ' CD1' ' A' ' 10' ' ' ILE . 0.5 OUTLIER -58.6 -42.19 87.55 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.109 -0.994 . . . . 0.0 109.903 179.734 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.97 89.41 0.02 OUTLIER Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.517 ' HG2' HD22 ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.66 -44.06 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.55 -0.971 . . . . 0.0 108.616 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.659 HG23 HG12 ' A' ' 10' ' ' ILE . 14.6 t -102.07 132.54 47.88 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 178.663 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.44 8.18 3.67 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.015 -1.564 . . . . 0.0 110.845 179.596 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -85.39 82.48 8.3 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.853 -1.381 . . . . 0.0 110.269 -179.791 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.67 -52.08 0.71 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.458 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.92 178.74 0.91 Allowed Pre-proline 0 C--N 1.302 -1.489 0 O-C-N 121.579 -0.954 . . . . 0.0 109.332 179.403 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.4 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.8 Cg_endo -77.53 109.53 2.79 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 123.57 1.3 . . . . 0.0 109.39 179.127 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.48 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.57 161.8 52.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.261 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.5 mt -119.64 142.66 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.427 -1.043 . . . . 0.0 109.389 179.491 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.492 ' CD1' HG23 ' A' ' 99' ' ' VAL . 5.5 t80 -130.34 115.47 16.96 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.18 -0.95 . . . . 0.0 110.387 179.899 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.625 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 2.0 mtt180 -103.27 133.95 47.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.432 -0.793 . . . . 0.0 109.892 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.46 ' CE1' ' HA ' ' A' ' 14' ' ' ALA . 8.2 p90 -127.12 152.44 47.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 110.205 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.402 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t . . . . . 0 N--CA 1.493 1.687 0 O-C-N 121.183 -0.948 . . . . 0.0 109.859 179.568 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.639 0.733 . . . . 0.0 109.433 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.608 HD12 ' HG2' ' A' ' 119' ' ' ARG . 28.4 mt -102.09 136.68 33.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.116 -0.99 . . . . 0.0 109.772 179.452 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.11 34.99 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.132 -0.98 . . . . 0.0 109.576 179.838 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.93 121.54 31.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.237 -0.915 . . . . 0.0 110.206 -179.291 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.537 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 10.8 t -116.45 157.16 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.432 -0.793 . . . . 0.0 110.113 -179.521 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.86 111.29 23.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.165 -0.959 . . . . 0.0 109.91 179.483 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.686 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.9 tp -55.65 139.62 44.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.935 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.72 3.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 110.34 -179.825 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.56 84.38 7.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.17 -0.957 . . . . 0.0 109.867 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.785 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 25.2 m -158.99 109.78 2.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.186 -0.946 . . . . 0.0 110.906 -179.482 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.419 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.32 -174.47 29.71 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.212 178.922 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.02 -19.57 13.46 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.834 -0.803 . . . . 0.0 110.284 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.863 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.3 tt -98.26 106.31 34.56 Favored Pre-proline 0 N--CA 1.489 1.516 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.443 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -62.91 123.38 12.16 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 O-C-N 123.347 1.182 . . . . 0.0 110.776 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.0 t80 -111.5 -167.81 1.23 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.686 -0.634 . . . . 0.0 110.336 -179.185 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.8 m-85 -58.93 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.479 -0.763 . . . . 0.0 111.117 -179.595 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.73 3.83 56.14 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 179.831 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.686 ' CB ' HD23 ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.43 44.28 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.019 -1.283 . . . . 0.0 109.224 179.733 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.785 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.21 106.49 17.02 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.971 -1.08 . . . . 0.0 108.546 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.863 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -69.8 113.44 17.38 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.337 -0.852 . . . . 0.0 110.52 -178.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.787 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -69.75 130.77 19.94 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 N-CA-C 107.159 -1.9 . . . . 0.0 107.159 176.347 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.666 HD11 HD12 ' A' ' 58' ' ' LEU . 10.5 mt -56.74 -16.43 6.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.802 -1.186 . . . . 0.0 110.521 -178.313 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.435 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.05 -16.14 49.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.555 -1.341 . . . . 0.0 110.532 179.516 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.042 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -93.39 -25.77 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 120.935 -1.103 . . . . 0.0 111.125 -179.313 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.042 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -115.98 -26.04 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.061 . . . . 0.0 109.954 -179.658 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.21 147.99 22.67 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.224 -0.923 . . . . 0.0 110.435 179.945 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.22 -4.77 41.19 Favored Glycine 0 N--CA 1.484 1.872 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.352 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.63 -149.44 9.32 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.185 -1.483 . . . . 0.0 110.376 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.65 129.95 54.47 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.336 -1.097 . . . . 0.0 110.323 -179.621 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.544 ' HB2' HG12 ' A' ' 81' ' ' VAL . 70.2 m80 -138.43 153.59 48.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.067 -1.02 . . . . 0.0 111.087 -179.508 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.639 HD12 ' O ' ' A' ' 82' ' ' VAL . 24.9 tp -113.23 114.05 26.19 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.41 -0.806 . . . . 0.0 109.81 179.613 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.96 HD12 ' CG1' ' A' ' 83' ' ' VAL . 38.6 mt -97.14 126.75 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.28 -0.887 . . . . 0.0 109.539 179.427 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.465 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 10.5 m-85 -95.0 123.73 38.65 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.402 -0.811 . . . . 0.0 110.196 -179.797 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.2 -0.938 . . . . 0.0 110.885 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.499 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.7 p80 -104.42 -5.47 21.63 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.834 . . . . 0.0 110.128 179.148 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.63 137.4 53.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 110.637 -179.741 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.52 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.8 -43.28 65.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.677 -0.64 . . . . 0.0 110.679 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.17 -36.94 81.18 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.266 -0.896 . . . . 0.0 110.71 -179.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.68 -35.38 78.74 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.37 -0.831 . . . . 0.0 109.485 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.869 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.3 m -61.45 -34.84 76.11 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.439 -0.788 . . . . 0.0 109.385 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.61 -49.02 74.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 110.459 179.86 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.76 -40.38 69.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.228 -0.92 . . . . 0.0 110.494 -179.734 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.742 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -57.11 -39.96 76.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.47 -0.769 . . . . 0.0 110.958 -179.354 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.43 -51.36 13.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 110.377 -179.784 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.32 -41.21 93.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.096 -1.002 . . . . 0.0 109.517 179.619 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.553 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.67 -46.88 83.69 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.423 -0.798 . . . . 0.0 109.664 179.47 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.815 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.17 -43.32 78.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.552 -0.718 . . . . 0.0 110.326 179.931 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.3 t -55.7 -33.16 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.04 -1.037 . . . . 0.0 109.166 179.611 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.9 60.85 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.272 -0.892 . . . . 0.0 109.79 179.088 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.666 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -72.05 -26.2 62.09 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.312 -0.867 . . . . 0.0 109.703 179.634 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.46 9.51 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.343 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.62 HD11 ' HB2' ' A' ' 34' ' ' LYS . 48.6 mt -108.3 143.09 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.308 -1.113 . . . . 0.0 110.239 -179.626 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.572 ' ND2' HD11 ' A' ' 74' ' ' ILE . 17.0 t30 -86.69 106.66 17.79 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 178.232 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.66 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.84 144.59 48.28 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.506 -177.432 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.974 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.7 t -134.56 145.1 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.79 128.79 55.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.976 -1.09 . . . . 0.0 109.996 179.308 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.474 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.1 53.19 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 110.376 -179.839 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.937 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.4 p90 -170.57 174.62 4.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.473 -0.767 . . . . 0.0 109.655 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.78 120.84 5.68 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 110.766 -179.179 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.27 34.36 14.65 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.531 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.949 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -116.97 156.24 27.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.134 -1.215 . . . . 0.0 110.021 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.949 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.0 m-20 -93.96 148.32 22.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.186 -0.946 . . . . 0.0 110.91 -179.189 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.648 ' O ' HG23 ' A' ' 71' ' ' VAL . 27.8 m -63.26 111.45 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.343 178.884 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.454 ' O ' HG23 ' A' ' 74' ' ' ILE . 5.4 m -134.76 -33.18 0.96 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.419 -0.801 . . . . 0.0 110.921 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.974 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.8 t -53.96 140.1 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.109 -0.995 . . . . 0.0 110.308 -179.418 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.572 HD11 ' ND2' ' A' ' 61' ' ' ASN . 0.9 OUTLIER . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.3 -0.875 . . . . 0.0 110.832 179.814 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 122.019 0.914 . . . . 0.0 109.791 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.55 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -110.98 134.47 53.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-O 121.928 0.87 . . . . 0.0 110.042 -179.779 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 6.3 m -112.04 125.9 69.38 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.397 -0.814 . . . . 0.0 109.248 179.495 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.721 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.8 t -97.57 116.14 39.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 O-C-N 121.117 -0.99 . . . . 0.0 110.12 -178.303 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.96 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.4 m -110.65 100.21 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.048 -1.032 . . . . 0.0 108.763 179.723 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.474 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.16 33.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.545 -1.347 . . . . 0.0 111.552 -177.891 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.534 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -86.9 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.595 -0.691 . . . . 0.0 109.412 179.6 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.534 ' N ' HG23 ' A' ' 85' ' ' THR . 9.9 p-10 -90.1 42.87 1.12 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.693 -1.255 . . . . 0.0 110.484 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.443 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.96 -26.04 8.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.122 -0.987 . . . . 0.0 110.351 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.701 0 O-C-N 121.089 -1.007 . . . . 0.0 109.977 179.538 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.049 0.452 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -119.79 152.85 36.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.08 -1.012 . . . . 0.0 110.507 179.636 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.19 17.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.504 -0.747 . . . . 0.0 109.356 179.213 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.439 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.8 p -160.82 163.04 32.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.421 -0.799 . . . . 0.0 110.294 179.779 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.456 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.36 122.67 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.066 -1.021 . . . . 0.0 110.421 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.827 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.7 mp -97.99 112.68 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.429 -0.795 . . . . 0.0 109.121 179.266 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.419 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 5.2 t0 -121.01 160.74 22.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.114 -0.991 . . . . 0.0 111.589 -178.72 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.66 5.55 43.82 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.688 -0.633 . . . . 0.0 109.47 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.413 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 49.21 24.44 0.98 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 111.064 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.081 -1.012 . . . . 0.0 110.316 179.55 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 . . . . . 0 N--CA 1.493 1.703 0 CA-C-O 121.35 0.595 . . . . 0.0 111.253 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.528 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -77.4 160.57 28.65 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.429 -0.794 . . . . 0.0 110.174 179.85 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.406 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.62 -52.83 12.78 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.348 -0.845 . . . . 0.0 112.058 -178.794 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.528 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.51 -28.95 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 120.838 -1.164 . . . . 0.0 111.466 -178.583 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.05 -56.47 6.43 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.071 -1.018 . . . . 0.0 110.593 -179.289 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.439 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.7 OUTLIER -68.95 -34.61 75.63 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.231 -0.918 . . . . 0.0 108.723 178.961 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.442 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 41.0 m -59.61 -49.98 75.65 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.174 -0.954 . . . . 0.0 108.482 178.781 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.72 -36.25 65.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.464 -0.772 . . . . 0.0 109.9 178.926 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.439 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.1 mtt180 -71.22 -44.58 65.09 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.179 -0.951 . . . . 0.0 110.723 -179.585 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.608 ' HG2' HD12 ' A' ' 10' ' ' ILE . 14.1 ttm180 -56.15 -43.38 78.23 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.912 -1.117 . . . . 0.0 110.415 -179.757 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.69 79.55 0.06 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.478 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -152.08 -43.96 0.11 Allowed 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.296 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.519 HG22 HD13 ' A' ' 10' ' ' ILE . 8.8 t -100.27 144.06 29.73 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.297 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.69 14.63 46.13 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.192 -1.48 . . . . 0.0 110.444 179.425 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.421 ' HD3' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -58.67 -31.79 68.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.127 -1.219 . . . . 0.0 110.032 -179.916 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.89 20.75 4.03 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.333 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.494 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -165.46 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.427 -1.043 . . . . 0.0 108.506 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.494 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 50.2 Cg_endo -85.32 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 122.85 0.921 . . . . 0.0 110.607 179.365 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.503 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.53 176.61 50.25 Favored Glycine 0 N--CA 1.497 2.759 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.439 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mt -131.35 142.87 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.466 -1.02 . . . . 0.0 109.075 179.296 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.476 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 18.6 t80 -131.3 116.03 17.06 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.034 -1.041 . . . . 0.0 110.934 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.537 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.9 mtt180 -101.83 134.86 44.35 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.536 -0.727 . . . . 0.0 109.461 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.449 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.91 148.93 50.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.055 -1.028 . . . . 0.0 110.042 -179.79 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.442 HG22 HD23 ' A' ' 15' ' ' LEU . 54.4 t . . . . . 0 N--CA 1.493 1.677 0 O-C-N 121.188 -0.945 . . . . 0.0 109.902 179.75 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.3 m-80 . . . . . 0 N--CA 1.493 1.682 0 CA-C-O 121.245 0.545 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.839 HG12 HG23 ' A' ' 122' ' ' THR . 20.8 mt -95.15 128.19 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.428 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.12 128.14 34.37 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.263 -0.898 . . . . 0.0 108.951 178.868 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.3 134.67 33.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.109 -0.994 . . . . 0.0 110.128 -179.303 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.548 HG11 ' HE ' ' A' ' 131' ' ' ARG . 5.5 t -128.66 157.73 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.396 -0.815 . . . . 0.0 110.183 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.43 113.79 27.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.356 -0.84 . . . . 0.0 110.068 179.718 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.746 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.78 143.97 19.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 110.027 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.42 170.17 16.41 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.977 . . . . 0.0 110.397 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.86 81.59 1.18 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.201 -0.937 . . . . 0.0 109.754 179.651 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.829 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.4 m -158.31 111.44 2.39 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.872 -179.502 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.416 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.27 -170.39 30.24 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.139 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.75 -19.08 12.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.787 -0.831 . . . . 0.0 110.0 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -99.92 104.05 26.18 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.833 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.16 125.92 16.8 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.231 1.122 . . . . 0.0 111.008 -179.18 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.0 t80 -112.93 -169.57 1.51 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.738 -0.601 . . . . 0.0 110.352 -179.499 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.524 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.0 m-85 -59.46 82.3 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.269 -0.894 . . . . 0.0 111.377 -179.433 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.19 61.69 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.627 179.274 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.746 ' CB ' HD23 ' A' ' 15' ' ' LEU . 26.6 mmtt -129.86 156.54 44.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.884 -1.362 . . . . 0.0 109.638 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.829 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.34 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.98 -1.075 . . . . 0.0 108.993 179.56 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.4 mt -70.28 113.17 15.95 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.375 -0.828 . . . . 0.0 110.729 -179.122 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.72 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.4 Cg_endo -69.63 130.77 20.09 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 N-CA-C 106.849 -2.02 . . . . 0.0 106.849 175.754 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.577 HD11 HD12 ' A' ' 58' ' ' LEU . 9.7 mt -55.99 -18.68 9.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.784 -1.198 . . . . 0.0 110.507 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.433 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.01 15.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.861 -1.149 . . . . 0.0 110.589 179.728 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.024 HG23 HG23 ' A' ' 33' ' ' ILE . 9.6 m -93.96 -25.3 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.926 -1.109 . . . . 0.0 110.951 -179.735 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.024 HG23 HG23 ' A' ' 32' ' ' VAL . 27.1 pt -117.95 -14.86 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.934 -1.104 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.557 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.64 148.06 24.2 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.849 -1.157 . . . . 0.0 110.383 179.683 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.7 -4.4 50.17 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.629 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.01 7.23 Favored Glycine 0 N--CA 1.492 2.393 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.589 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.05 132.54 54.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -1.018 . . . . 0.0 110.213 -179.602 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -139.93 150.46 44.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.197 -0.939 . . . . 0.0 110.863 -179.759 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.645 HD12 ' O ' ' A' ' 82' ' ' VAL . 51.3 tp -110.99 115.26 29.17 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.466 -0.771 . . . . 0.0 109.996 179.836 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.944 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.4 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.231 -0.918 . . . . 0.0 109.041 179.503 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.55 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.76 37.98 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.866 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.63 159.36 23.06 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.363 -0.836 . . . . 0.0 110.422 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.59 20.31 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.388 -0.82 . . . . 0.0 110.024 179.069 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.2 p -132.8 139.21 47.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.42 ' HE3' ' CE1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.57 -34.09 71.81 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.464 -0.773 . . . . 0.0 110.465 -179.932 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.46 -34.14 76.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.249 -0.907 . . . . 0.0 110.333 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.457 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.09 -36.34 64.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.206 -0.934 . . . . 0.0 109.636 179.818 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.805 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 64.9 m -60.98 -39.2 88.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.563 -0.71 . . . . 0.0 109.469 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.52 -46.59 87.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.915 . . . . 0.0 110.035 179.699 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.439 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.43 -45.47 62.59 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.395 -0.815 . . . . 0.0 110.454 -179.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 1.05 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.36 -45.07 80.66 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.36 -0.838 . . . . 0.0 111.149 -178.997 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.47 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.75 -51.57 22.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.001 -1.062 . . . . 0.0 110.366 -179.467 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.16 99.33 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 109.762 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.548 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.54 -46.81 86.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.24 -0.912 . . . . 0.0 109.606 179.591 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.847 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.2 -43.52 78.56 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.636 -0.665 . . . . 0.0 110.147 179.86 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.2 t -55.48 -32.67 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.21 -0.931 . . . . 0.0 109.029 179.7 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.56 -31.05 59.89 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.251 -0.906 . . . . 0.0 109.832 179.071 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.577 HD12 HD11 ' A' ' 30' ' ' LEU . 3.9 mm? -72.19 -26.36 62.03 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.864 0.84 . . . . 0.0 109.837 179.844 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.9 4.58 10.29 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.16 -1.576 . . . . 0.0 109.16 -179.113 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.557 HD11 ' HB2' ' A' ' 34' ' ' LYS . 28.1 mt -105.48 143.34 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.352 -1.087 . . . . 0.0 110.096 -179.748 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.771 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.7 t-20 -88.06 106.07 17.91 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 178.031 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.713 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.288 -177.502 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.924 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.33 139.55 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.806 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.805 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -101.26 122.77 44.27 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.214 178.758 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.496 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.1 134.88 54.78 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.313 -0.867 . . . . 0.0 111.153 -178.925 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.896 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -168.89 170.65 8.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.574 -0.704 . . . . 0.0 109.641 179.506 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.67 118.3 3.27 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.242 -0.912 . . . . 0.0 110.845 -179.439 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.82 37.35 6.44 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.969 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.896 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.42 30.03 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -1.142 . . . . 0.0 110.168 -179.724 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.848 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.3 m-20 -91.84 149.58 21.51 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.36 -0.837 . . . . 0.0 110.596 -179.48 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.68 ' O ' HG23 ' A' ' 71' ' ' VAL . 34.7 m -62.15 110.88 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 119.128 -1.029 . . . . 0.0 109.426 179.326 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.715 ' O ' HG23 ' A' ' 74' ' ' ILE . 19.7 m -133.19 -39.33 0.93 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.447 -0.783 . . . . 0.0 110.233 -179.656 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.924 ' HA ' HG21 ' A' ' 63' ' ' VAL . 79.0 t -47.61 133.09 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.42 -0.8 . . . . 0.0 109.993 179.822 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.771 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.776 0 O-C-N 121.138 -0.976 . . . . 0.0 110.842 -179.51 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.925 0.869 . . . . 0.0 110.39 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.644 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.75 134.0 62.73 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 CA-C-O 122.095 0.95 . . . . 0.0 110.05 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.546 HG22 HG22 ' A' ' 60' ' ' ILE . 16.8 m -113.24 122.71 67.89 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.466 -0.771 . . . . 0.0 108.984 179.348 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.998 HG11 HD13 ' A' ' 88' ' ' LEU . 12.2 t -96.95 118.59 43.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.723 -1.235 . . . . 0.0 111.106 -177.686 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.05 HG11 HD12 ' A' ' 51' ' ' LEU . 4.3 m -108.7 99.68 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.034 -1.041 . . . . 0.0 108.852 178.838 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.496 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -135.79 155.93 49.59 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.446 -1.409 . . . . 0.0 110.912 -178.488 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.517 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.17 -42.43 15.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.369 -0.832 . . . . 0.0 110.385 -179.5 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.517 ' N ' HG23 ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.22 32.54 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.69 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -103.16 -30.99 10.35 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.009 . . . . 0.0 110.067 -179.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.998 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 110.067 179.415 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 121.1 0.476 . . . . 0.0 110.478 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.484 ' CE2' ' HB2' ' A' ' 39' ' ' LEU . 16.9 m-85 -119.9 149.75 41.6 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.103 -0.998 . . . . 0.0 110.078 179.399 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.424 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.85 -31.54 25.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.812 . . . . 0.0 109.619 179.554 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.5 p -162.26 163.43 28.15 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.417 -0.913 . . . . 0.0 111.466 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.47 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 117.74 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.455 -0.778 . . . . 0.0 109.614 178.798 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.878 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -97.59 117.18 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.224 -0.923 . . . . 0.0 109.456 179.876 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.429 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.8 t0 -129.84 161.32 31.04 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.107 -0.995 . . . . 0.0 111.634 -178.716 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.436 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 52.8 t -92.03 -7.41 48.87 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.641 -0.662 . . . . 0.0 109.534 178.017 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.2 13.44 1.66 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.255 -0.903 . . . . 0.0 111.87 179.704 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 m . . . . . 0 C--N 1.306 -1.31 0 O-C-N 120.725 -1.234 . . . . 0.0 109.39 -179.888 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.369 0.604 . . . . 0.0 110.794 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -80.88 159.06 25.12 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.272 -0.892 . . . . 0.0 109.84 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -46.63 -50.92 16.88 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.282 -0.886 . . . . 0.0 111.893 -178.787 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.41 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.792 -1.193 . . . . 0.0 111.444 -178.727 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.423 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.27 -56.6 6.47 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.987 -1.071 . . . . 0.0 110.426 -179.131 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.422 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.73 -35.03 76.61 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.264 -0.898 . . . . 0.0 108.918 178.718 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.431 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.2 m -59.9 -46.69 88.53 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 178.709 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.61 -40.43 63.82 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.671 -0.643 . . . . 0.0 109.767 178.905 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -69.65 -44.23 70.99 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.273 -0.892 . . . . 0.0 110.344 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.47 ' HG2' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -56.54 -43.74 80.16 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.362 -0.836 . . . . 0.0 110.004 179.678 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.01 0.11 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.682 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.457 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.77 -46.41 0.13 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.563 -0.963 . . . . 0.0 108.76 179.622 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.839 HG23 HG12 ' A' ' 10' ' ' ILE . 15.3 t -97.19 141.89 29.77 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.26 17.17 3.34 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.594 179.787 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.499 ' N ' ' CD ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.15 81.71 6.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.889 -1.359 . . . . 0.0 109.986 -179.731 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.52 -52.08 0.71 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.477 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.96 176.61 1.49 Allowed Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 121.765 -0.844 . . . . 0.0 109.123 179.308 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.6 Cg_endo -73.21 112.89 3.64 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 N-CA-C 108.806 -1.267 . . . . 0.0 108.806 178.484 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.473 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.01 177.87 41.45 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -178.927 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.2 mt -135.23 142.8 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.239 -1.154 . . . . 0.0 109.652 179.502 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.47 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.87 114.5 19.29 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.051 178.721 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.548 ' HE ' HG11 ' A' ' 13' ' ' VAL . 3.8 mtt85 -105.97 122.77 46.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.515 -0.741 . . . . 0.0 109.297 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 11.0 p90 -122.94 157.81 31.8 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.058 -1.026 . . . . 0.0 110.464 -179.576 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.444 HG22 HD23 ' A' ' 15' ' ' LEU . 37.8 t . . . . . 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.751 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.78 135.42 34.13 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.174 -1.192 . . . . 0.0 110.104 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.675 ' O ' HG13 ' A' ' 3' ' ' VAL . 13.6 p -113.01 104.56 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.154 -0.966 . . . . 0.0 109.929 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.521 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 79.1 p -72.28 144.68 48.29 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.31 -0.869 . . . . 0.0 110.5 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.476 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.45 147.96 98.14 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.295 -0.878 . . . . 0.0 109.683 179.673 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.476 ' HD2' HG23 ' A' ' 5' ' ' VAL . 49.3 Cg_endo -73.37 -173.76 1.4 Allowed 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 124.116 1.588 . . . . 0.0 111.006 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.529 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 1.0 OUTLIER 170.67 76.6 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.782 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.576 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -68.22 -17.38 45.05 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 O-C-N 123.879 1.462 . . . . 0.0 111.022 -179.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.447 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 -57.0 -24.56 54.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.104 -0.997 . . . . 0.0 109.974 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.749 HG12 HG23 ' A' ' 122' ' ' THR . 9.0 mt -106.0 133.3 50.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.043 -1.036 . . . . 0.0 109.901 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.422 ' HB3' HG12 ' A' ' 129' ' ' ILE . 6.4 tp10 -85.67 128.41 34.77 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.383 -0.823 . . . . 0.0 108.946 178.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.2 mt-10 -89.21 139.24 30.69 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.026 . . . . 0.0 110.328 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.67 155.63 41.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.46 -0.775 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.09 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.297 -0.877 . . . . 0.0 110.064 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.68 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.6 tp -54.35 140.0 34.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.324 -0.86 . . . . 0.0 109.889 179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.48 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.225 -0.922 . . . . 0.0 110.249 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.274 -0.891 . . . . 0.0 110.033 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 31.3 m -146.15 109.29 4.65 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 110.555 -179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.91 -173.9 28.7 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.294 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.42 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -107.87 -22.75 12.33 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.794 -0.827 . . . . 0.0 110.428 179.994 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -95.11 102.45 9.43 Favored Pre-proline 0 N--CA 1.486 1.345 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.695 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.442 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -61.97 139.97 82.21 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 O-C-N 123.558 1.293 . . . . 0.0 110.603 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.435 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.87 -164.08 1.45 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 111.028 -178.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.517 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.4 m-85 -58.07 81.61 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.527 -0.733 . . . . 0.0 111.221 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.05 4.99 38.2 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.68 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.5 mmtm -131.05 155.91 46.08 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.295 . . . . 0.0 109.432 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.92 107.34 16.31 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.063 -1.023 . . . . 0.0 108.918 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.898 ' CD1' HG21 ' A' ' 100' ' ' ILE . 4.5 mt -68.04 114.57 21.51 Favored Pre-proline 0 C--N 1.3 -1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 110.895 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.772 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.0 Cg_endo -70.2 128.28 15.41 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 N-CA-C 106.91 -1.996 . . . . 0.0 106.91 175.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.597 HD11 HD12 ' A' ' 58' ' ' LEU . 9.8 mt -56.22 -18.51 10.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.785 -1.197 . . . . 0.0 110.867 -177.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -59.5 -16.13 22.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.632 -1.293 . . . . 0.0 110.466 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.077 HG23 HG23 ' A' ' 33' ' ' ILE . 9.3 m -91.8 -25.17 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.021 -1.049 . . . . 0.0 110.869 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.077 HG23 HG23 ' A' ' 32' ' ' VAL . 38.0 pt -118.31 -17.15 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.011 -1.056 . . . . 0.0 110.602 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.628 ' HB2' HD11 ' A' ' 60' ' ' ILE . 6.1 tptm -98.66 148.39 23.88 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.987 -1.07 . . . . 0.0 109.847 179.229 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.58 -6.1 33.41 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.98 -136.81 2.97 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.305 -1.426 . . . . 0.0 110.307 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -117.65 132.54 56.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -1.124 . . . . 0.0 110.43 -179.56 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.574 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.83 150.25 44.45 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.244 -0.91 . . . . 0.0 110.806 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.58 HD12 ' HB ' ' A' ' 82' ' ' VAL . 24.3 tp -112.16 114.73 27.71 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.503 -0.748 . . . . 0.0 110.023 179.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.824 HD12 HG12 ' A' ' 83' ' ' VAL . 43.8 mt -97.6 127.93 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.325 -0.859 . . . . 0.0 109.972 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.418 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.34 123.03 38.65 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.217 -0.927 . . . . 0.0 109.907 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.12 21.68 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.275 -0.891 . . . . 0.0 110.702 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.517 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.7 p80 -107.12 0.46 23.47 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.483 -0.761 . . . . 0.0 110.371 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.24 137.42 44.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.944 -1.098 . . . . 0.0 110.865 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.512 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.51 -39.69 70.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.722 -0.611 . . . . 0.0 110.787 -179.753 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mttp -58.6 -36.71 74.42 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 110.369 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.417 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.4 OUTLIER -73.8 -34.4 64.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.389 -0.82 . . . . 0.0 109.59 -179.941 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.888 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.95 73.43 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.46 -0.775 . . . . 0.0 109.461 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.48 -49.58 53.43 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.216 -0.928 . . . . 0.0 110.295 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.421 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.93 -44.38 63.72 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.288 -0.883 . . . . 0.0 110.353 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.749 HD12 HG11 ' A' ' 83' ' ' VAL . 2.0 tm? -56.86 -43.05 80.8 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.441 -0.787 . . . . 0.0 110.773 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.411 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -74.19 -51.84 14.28 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.9 -1.125 . . . . 0.0 110.656 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.69 -38.77 86.1 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.854 -1.154 . . . . 0.0 109.413 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.57 ' HE3' HD22 ' A' ' 51' ' ' LEU . 2.5 ttmm -59.38 -45.98 89.93 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.36 -0.838 . . . . 0.0 109.493 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.702 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.35 -40.28 71.05 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.418 -0.801 . . . . 0.0 109.763 179.833 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -56.41 -34.49 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.109 -0.995 . . . . 0.0 108.786 178.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.48 -31.2 60.15 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.558 -0.714 . . . . 0.0 110.093 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.597 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.22 -26.13 62.8 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.63 4.77 9.56 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.63 HG22 HG22 ' A' ' 81' ' ' VAL . 58.2 mt -108.09 143.34 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.283 -1.128 . . . . 0.0 110.034 -179.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.495 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 52.4 t30 -86.28 107.6 18.02 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 178.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.534 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . . . -120.9 149.79 42.07 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.947 -1.101 . . . . 0.0 112.095 -176.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.911 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -138.3 152.39 25.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.429 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.888 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.45 130.81 56.74 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.076 179.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.465 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.51 122.24 40.2 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.29 -0.881 . . . . 0.0 110.441 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.949 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -156.23 176.76 12.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.592 -0.692 . . . . 0.0 109.62 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.31 125.1 16.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.064 -1.023 . . . . 0.0 110.505 -179.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.95 38.57 15.34 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.949 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.5 156.06 28.66 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.152 -1.205 . . . . 0.0 110.147 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.878 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.5 m-20 -96.68 148.96 22.34 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.322 -0.862 . . . . 0.0 110.565 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.662 ' O ' HG23 ' A' ' 71' ' ' VAL . 32.4 m -62.23 110.95 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.054 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.4 m -132.62 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.398 -0.814 . . . . 0.0 110.523 -179.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.911 HG22 ' HB ' ' A' ' 63' ' ' VAL . 58.7 t -52.25 128.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -0.904 . . . . 0.0 110.053 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.874 ' O ' HD12 ' A' ' 74' ' ' ILE . 2.0 pp -137.96 115.73 9.52 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.274 -0.891 . . . . 0.0 110.487 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.735 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.1 Cg_endo -87.35 39.15 0.56 Allowed 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 123.251 1.132 . . . . 0.0 110.952 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.5 p -144.2 46.9 1.42 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.904 -1.122 . . . . 0.0 110.528 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.801 ' ND2' HD13 ' A' ' 74' ' ' ILE . 3.8 m-80 -142.25 26.89 1.79 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.173 -0.954 . . . . 0.0 110.164 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.99 -94.95 1.12 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -128.77 109.04 10.95 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.174 -1.192 . . . . 0.0 110.176 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.735 HG11 ' HA ' ' A' ' 75' ' ' PRO . 6.1 p -116.98 134.46 60.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 122.054 0.93 . . . . 0.0 110.698 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.63 HG22 HG22 ' A' ' 60' ' ' ILE . 13.4 m -112.9 122.3 66.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.092 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.705 HG22 HG13 ' A' ' 73' ' ' VAL . 4.3 t -96.99 119.62 45.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.009 -1.057 . . . . 0.0 110.326 -177.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.824 HG12 HD12 ' A' ' 40' ' ' ILE . 4.5 m -111.36 100.4 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 120.997 -1.065 . . . . 0.0 108.627 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.465 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.45 162.78 34.65 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.731 -1.231 . . . . 0.0 111.602 -177.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.54 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -93.28 -136.0 0.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.524 179.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.54 ' N ' HG23 ' A' ' 85' ' ' THR . 12.3 p-10 -86.42 46.69 1.37 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.734 -1.228 . . . . 0.0 110.623 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.13 -23.09 8.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.931 -1.106 . . . . 0.0 110.405 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -65.79 -29.35 69.83 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.698 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.503 ' C ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER 48.68 44.93 21.69 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.455 -0.778 . . . . 0.0 111.074 179.791 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.642 ' OG1' HG22 ' A' ' 93' ' ' THR . 2.6 t 33.94 -118.86 0.09 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 112.03 0.381 . . . . 0.0 112.03 179.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 86.47 -63.66 4.1 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -119.88 1.83 11.0 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.43 -1.041 . . . . 0.0 110.134 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.642 HG22 ' OG1' ' A' ' 90' ' ' THR . 12.3 t -67.65 -154.43 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.016 -1.052 . . . . 0.0 110.278 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.426 ' N ' HG23 ' A' ' 93' ' ' THR . . . 90.11 -41.52 2.97 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 179.428 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -84.05 57.54 4.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.188 -1.183 . . . . 0.0 111.095 -179.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.459 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 29.8 m-85 -119.69 146.66 45.39 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.086 -1.008 . . . . 0.0 109.855 178.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.06 -33.33 67.88 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.352 -0.843 . . . . 0.0 109.856 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.78 163.7 26.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.887 . . . . 0.0 111.078 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.528 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 114.56 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.312 -0.868 . . . . 0.0 109.994 178.811 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.898 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.2 114.7 30.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.227 -0.92 . . . . 0.0 108.608 179.061 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.418 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.11 160.17 25.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.125 -0.984 . . . . 0.0 111.798 -178.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.94 -7.39 52.24 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.86 18.79 0.55 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 112.247 179.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.526 HG23 ' C ' ' A' ' 107' ' ' GLY . 0.8 OUTLIER -147.4 113.76 5.93 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.746 -1.221 . . . . 0.0 109.366 179.565 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.443 ' N ' ' O ' ' A' ' 108' ' ' LYS . 58.9 p -88.01 140.17 29.76 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.155 -0.966 . . . . 0.0 110.625 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 52.41 28.26 5.68 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.382 -0.823 . . . . 0.0 110.675 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.526 ' C ' HG23 ' A' ' 104' ' ' THR . . . 87.62 -14.86 57.19 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.151 -1.179 . . . . 0.0 110.151 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.496 ' O ' ' HA ' ' A' ' 104' ' ' THR . 8.5 mmtt -96.6 156.65 36.44 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.059 -1.26 . . . . 0.0 109.757 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.65 133.79 41.16 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.661 1.348 . . . . 0.0 110.107 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -57.64 -177.18 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.412 -0.805 . . . . 0.0 111.168 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -108.01 161.61 14.79 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.6 -0.687 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.521 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -41.52 -55.13 2.95 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.605 -0.684 . . . . 0.0 112.629 -178.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.31 -29.79 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 120.663 -1.273 . . . . 0.0 111.499 -178.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.426 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.78 -57.58 5.41 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.093 -1.005 . . . . 0.0 110.555 -179.037 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.428 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.53 -33.94 77.09 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.198 -0.939 . . . . 0.0 108.819 178.631 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.1 m -60.23 -49.25 78.35 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -41.03 63.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.427 -0.796 . . . . 0.0 110.288 179.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.426 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.2 mpt_? -69.96 -44.13 70.12 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.049 -1.032 . . . . 0.0 110.732 -179.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.529 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.9 OUTLIER -54.18 -38.51 65.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.044 -1.035 . . . . 0.0 110.243 -179.863 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.93 0.06 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.466 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.9 mmt-85 -151.38 -43.55 0.11 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.952 . . . . 0.0 108.848 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.749 HG23 HG12 ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.49 39.25 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.522 -0.736 . . . . 0.0 109.345 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.407 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 121.76 19.86 3.28 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.247 -1.454 . . . . 0.0 110.622 179.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.462 ' N ' ' CD ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.42 81.85 4.42 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.033 -1.275 . . . . 0.0 110.034 179.821 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.49 5.39 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.473 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.611 -0.935 . . . . 0.0 108.573 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.473 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.0 Cg_endo -84.08 111.78 1.67 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.12 1.063 . . . . 0.0 109.913 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.46 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.64 168.96 54.82 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.422 HG12 ' HB3' ' A' ' 11' ' ' GLU . 41.5 mt -127.15 142.16 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.366 -1.079 . . . . 0.0 109.231 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.528 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.04 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.585 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.403 ' NH2' HG21 ' A' ' 129' ' ' ILE . 6.8 mtt85 -106.47 123.23 47.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.524 -0.735 . . . . 0.0 109.372 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.426 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.93 155.43 31.32 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.167 -0.958 . . . . 0.0 110.559 -179.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.499 HG22 HD23 ' A' ' 15' ' ' LEU . 50.1 t -72.28 -61.48 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.17 -0.956 . . . . 0.0 109.322 179.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -98.95 147.82 33.74 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.822 . . . . 0.0 109.936 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.33 -47.02 0.43 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.655 1.345 . . . . 0.0 110.494 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.19 -124.4 0.82 Allowed Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -110.71 -62.07 1.58 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.229 -1.16 . . . . 0.0 110.252 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 32.7 ttt85 . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.314 179.975 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.41 ' HB3' ' CB ' ' A' ' 112' ' ' ALA . 0.5 OUTLIER -106.88 125.5 51.08 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.291 -1.123 . . . . 0.0 110.245 179.847 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.618 ' O ' HG23 ' A' ' 3' ' ' VAL . 27.4 m -113.3 104.26 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.37 -0.831 . . . . 0.0 110.006 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.455 HG22 ' OG1' ' A' ' 116' ' ' THR . 13.9 p -78.33 142.97 37.33 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.335 -0.853 . . . . 0.0 110.379 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.471 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -74.63 148.72 85.61 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.29 -0.881 . . . . 0.0 109.506 179.4 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.471 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.8 Cg_endo -69.13 -169.24 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 124.132 1.596 . . . . 0.0 110.762 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.542 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.2 OUTLIER 175.72 79.5 0.08 OUTLIER Pre-proline 0 N--CA 1.499 1.995 0 O-C-N 121.299 -0.876 . . . . 0.0 110.11 -179.549 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.52 -15.35 27.65 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.595 1.313 . . . . 0.0 110.547 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.435 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.9 m120 -65.24 -25.8 67.83 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.086 -1.009 . . . . 0.0 110.399 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.498 HD11 ' O ' ' A' ' 122' ' ' THR . 19.9 mt -107.82 135.4 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 120.946 -1.096 . . . . 0.0 110.383 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.91 128.71 34.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.519 179.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.16 131.82 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.095 -1.003 . . . . 0.0 110.099 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.449 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.7 t -126.62 158.13 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.368 -0.832 . . . . 0.0 110.258 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 108.55 20.12 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.253 -0.904 . . . . 0.0 109.693 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.555 HD11 HG12 ' A' ' 28' ' ' ILE . 9.7 tp -55.22 138.69 44.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.348 -0.845 . . . . 0.0 109.883 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.0 p -136.41 -179.68 5.83 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.301 -0.874 . . . . 0.0 110.55 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.306 -0.871 . . . . 0.0 109.862 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.742 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 2.6 m -147.66 113.13 5.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.334 -0.854 . . . . 0.0 110.373 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.442 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.45 -162.26 27.95 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.889 -1.624 . . . . 0.0 110.625 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.408 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -118.16 -22.64 7.67 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.78 -0.835 . . . . 0.0 110.497 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.911 HG23 ' HB ' ' A' ' 28' ' ' ILE . 10.0 tt -97.22 100.46 7.83 Favored Pre-proline 0 N--CA 1.485 1.324 0 C-N-CA 118.641 -1.224 . . . . 0.0 110.264 -179.317 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -62.34 147.29 95.19 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.384 1.202 . . . . 0.0 109.649 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.587 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.8 t80 -160.84 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.189 -0.944 . . . . 0.0 111.487 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.587 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 25.9 m-85 59.13 67.32 0.93 Allowed 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.425 -0.797 . . . . 0.0 111.609 178.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.48 14.35 13.54 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.545 ' CB ' HD23 ' A' ' 15' ' ' LEU . 41.3 mmtm -130.63 156.4 44.95 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.069 -1.254 . . . . 0.0 109.192 179.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.742 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.16 107.1 13.54 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.921 -1.112 . . . . 0.0 109.487 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -71.22 113.79 22.16 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.29 -0.881 . . . . 0.0 110.156 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.834 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.8 Cg_endo -68.69 129.59 19.05 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 N-CA-C 106.877 -2.009 . . . . 0.0 106.877 176.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.635 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.7 mt -55.58 -19.36 9.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.867 -1.146 . . . . 0.0 110.762 -177.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.448 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.06 24.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.753 -1.217 . . . . 0.0 110.434 179.682 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.027 HG23 HG23 ' A' ' 33' ' ' ILE . 12.5 m -91.99 -25.01 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.997 -1.064 . . . . 0.0 111.049 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.027 HG23 HG23 ' A' ' 32' ' ' VAL . 6.2 pt -117.6 -21.09 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.917 -1.115 . . . . 0.0 110.764 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.565 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.0 tptt -94.29 148.44 22.2 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.1 -1.0 . . . . 0.0 110.175 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.38 33.39 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.24 -140.43 4.85 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 119.113 -1.518 . . . . 0.0 110.266 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.78 131.57 55.24 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.319 -1.106 . . . . 0.0 110.399 -179.609 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.565 ' HB2' HG12 ' A' ' 81' ' ' VAL . 86.5 m-70 -139.32 151.89 46.77 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.289 -0.882 . . . . 0.0 110.701 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.48 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.3 tp -114.32 122.07 45.56 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.273 -0.892 . . . . 0.0 110.224 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.848 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.5 mt -104.23 129.51 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.248 -0.907 . . . . 0.0 109.451 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.48 123.92 38.2 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.452 -0.78 . . . . 0.0 109.934 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.81 159.18 22.73 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.198 -0.939 . . . . 0.0 110.732 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -108.25 0.4 21.36 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.394 -0.816 . . . . 0.0 110.15 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 30.2 p -136.37 141.39 43.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.523 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.491 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.83 -40.2 69.25 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.538 -0.726 . . . . 0.0 110.6 -179.842 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.88 -34.14 71.29 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.353 -0.842 . . . . 0.0 110.663 -179.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.18 -35.08 68.89 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.891 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -61.3 -33.9 74.34 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.455 -0.778 . . . . 0.0 109.464 179.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -69.15 -50.59 46.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.273 -0.892 . . . . 0.0 110.874 -179.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.71 -47.11 49.88 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.133 -0.979 . . . . 0.0 110.56 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.723 HD13 ' O ' ' A' ' 51' ' ' LEU . 2.6 tm? -56.74 -37.64 71.29 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.585 -0.697 . . . . 0.0 111.256 -178.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.416 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -76.23 -51.36 12.22 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.793 -1.192 . . . . 0.0 110.381 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.01 -39.57 92.71 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.149 -0.969 . . . . 0.0 110.008 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.561 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.3 OUTLIER -57.3 -44.56 84.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.362 -0.836 . . . . 0.0 109.347 179.598 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.839 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.38 -42.91 74.64 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.647 -0.658 . . . . 0.0 110.12 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.2 -33.16 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.052 -1.03 . . . . 0.0 108.983 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.7 -31.48 59.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.458 -0.776 . . . . 0.0 110.057 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.561 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -71.65 -26.36 62.51 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.302 -0.874 . . . . 0.0 109.329 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.77 5.47 9.09 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.635 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.6 mt -108.23 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.261 -1.14 . . . . 0.0 110.314 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.653 HD22 HG23 ' A' ' 80' ' ' VAL . 1.4 t30 -88.05 107.08 18.56 Favored 'General case' 0 C--N 1.308 -1.215 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.74 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.03 143.9 45.22 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.912 -1.115 . . . . 0.0 111.893 -176.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.937 HG21 ' HA ' ' A' ' 73' ' ' VAL . 94.8 t -125.05 147.46 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.713 -0.617 . . . . 0.0 109.767 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.891 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.44 123.0 49.0 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.46 -0.896 . . . . 0.0 109.519 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.45 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.3 t80 -117.67 136.36 53.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.124 -0.985 . . . . 0.0 110.743 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.869 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -169.14 176.25 5.35 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.454 -0.779 . . . . 0.0 109.819 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -50.95 122.93 8.2 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 110.876 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.4 38.78 16.7 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.869 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.01 154.82 30.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.06 -1.259 . . . . 0.0 109.923 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.848 ' N ' HD13 ' A' ' 69' ' ' LEU . 10.1 m-20 -94.09 149.12 21.52 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.292 -0.88 . . . . 0.0 110.557 -179.176 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.671 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.8 m -62.58 110.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.212 -0.995 . . . . 0.0 109.501 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.7 m -132.56 -17.54 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.561 -0.712 . . . . 0.0 110.903 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.937 ' HA ' HG21 ' A' ' 63' ' ' VAL . 61.2 t -65.38 141.85 17.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.146 -0.971 . . . . 0.0 109.744 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.756 ' O ' HG11 ' A' ' 80' ' ' VAL . 6.0 pt -136.41 91.3 16.49 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.239 -0.913 . . . . 0.0 110.436 -179.565 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -92.57 42.19 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.71 1.373 . . . . 0.0 110.413 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.6 t -120.32 -24.77 5.82 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.157 -0.964 . . . . 0.0 110.668 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -162.98 162.22 25.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.176 -0.953 . . . . 0.0 110.407 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 64.63 134.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -61.27 106.75 0.66 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.074 -1.251 . . . . 0.0 109.933 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.756 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.2 p -116.93 134.29 60.95 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 CA-C-O 122.125 0.964 . . . . 0.0 110.339 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.572 HG22 HG22 ' A' ' 60' ' ' ILE . 13.9 m -113.44 124.69 70.34 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.223 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.856 HG22 HG13 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.865 -1.147 . . . . 0.0 110.58 -177.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.848 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -112.7 100.6 11.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.862 -1.149 . . . . 0.0 108.305 179.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.45 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.73 34.7 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.886 -1.134 . . . . 0.0 111.541 -177.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.522 HG23 ' N ' ' A' ' 86' ' ' ASP . 6.3 t -84.17 -126.12 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.522 ' N ' HG23 ' A' ' 85' ' ' THR . 1.0 OUTLIER -101.37 40.27 1.32 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.474 -1.391 . . . . 0.0 110.211 179.691 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.469 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.72 -34.67 7.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.87 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.663 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -68.99 -19.89 64.15 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.279 -0.888 . . . . 0.0 109.841 179.518 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.423 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.2 OUTLIER 53.68 -150.5 0.37 Allowed 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.251 -0.906 . . . . 0.0 109.871 -179.788 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.457 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 0.1 OUTLIER -150.62 31.51 0.64 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.272 -0.893 . . . . 0.0 109.975 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.33 -29.44 73.15 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -131.95 19.15 4.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.119 -1.224 . . . . 0.0 110.787 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.457 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 14.5 t -90.56 -154.78 0.36 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.051 -1.031 . . . . 0.0 110.302 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.432 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 103.24 -32.46 7.56 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.236 -1.146 . . . . 0.0 110.236 179.443 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -84.05 53.96 2.77 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.962 -1.317 . . . . 0.0 110.567 -179.597 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.498 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.15 145.71 46.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.039 -1.038 . . . . 0.0 110.161 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.521 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.53 -31.5 42.08 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.725 179.532 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.475 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.1 p -161.56 163.95 29.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.176 -0.953 . . . . 0.0 111.33 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.462 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.89 115.54 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.494 -0.754 . . . . 0.0 110.017 179.291 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.946 HG21 HD11 ' A' ' 28' ' ' ILE . 3.6 mp -93.42 112.56 26.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.165 -0.96 . . . . 0.0 108.859 179.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.8 161.07 19.86 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.125 -0.985 . . . . 0.0 111.765 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.471 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 15.0 t -102.98 8.31 39.0 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.735 -0.603 . . . . 0.0 109.482 178.19 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 47.09 26.16 0.6 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.155 -0.966 . . . . 0.0 111.09 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.451 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.8 p -146.53 132.52 19.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.114 -0.991 . . . . 0.0 110.516 179.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.446 ' N ' ' O ' ' A' ' 108' ' ' LYS . 80.6 p -112.81 134.36 54.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.326 -0.859 . . . . 0.0 109.941 179.536 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.4 t0 49.36 29.1 2.62 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.172 -0.955 . . . . 0.0 110.632 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.03 -33.01 5.47 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.66 157.3 82.3 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.287 -1.125 . . . . 0.0 110.127 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.451 ' HA ' HG22 ' A' ' 104' ' ' THR . 39.7 Cg_endo -65.13 133.74 36.69 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.565 1.297 . . . . 0.0 110.135 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.447 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 -49.21 150.2 1.79 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.254 -0.904 . . . . 0.0 110.78 -179.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.555 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -89.06 161.57 16.48 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.402 -0.811 . . . . 0.0 110.442 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.434 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.7 -53.87 3.47 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.469 -0.769 . . . . 0.0 112.375 -178.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.555 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.1 m -68.66 -29.5 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.608 -1.307 . . . . 0.0 111.264 -178.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.447 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.66 -56.48 7.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.078 -1.014 . . . . 0.0 110.549 -179.268 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.44 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.3 OUTLIER -67.6 -34.89 77.92 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.15 -0.969 . . . . 0.0 108.605 178.758 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.455 ' OG1' HG22 ' A' ' 4' ' ' THR . 13.3 m -59.56 -49.79 76.42 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -74.02 -35.89 64.4 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.592 -0.693 . . . . 0.0 109.871 178.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.44 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 3.3 mtt85 -71.13 -44.83 64.81 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.028 -1.045 . . . . 0.0 110.71 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.542 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 2.7 ttm105 -60.42 -42.56 96.26 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.978 -1.076 . . . . 0.0 110.455 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.58 86.16 0.09 OUTLIER Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.423 ' NH1' ' O ' ' A' ' 89' ' ' MET . 0.0 OUTLIER -164.7 -45.4 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.5 -1.0 . . . . 0.0 108.652 179.502 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.526 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.57 30.03 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.48 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.09 10.45 12.04 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.117 -1.516 . . . . 0.0 110.567 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.432 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 5.8 mtt180 -84.88 83.99 7.86 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.043 -1.269 . . . . 0.0 109.842 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.49 9.46 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 108.916 -1.674 . . . . 0.0 108.916 -179.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.508 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.74 -169.63 0.22 Allowed Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.892 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.508 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.8 Cg_endo -88.0 111.06 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 122.883 0.938 . . . . 0.0 110.047 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.526 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.57 150.93 38.95 Favored Glycine 0 N--CA 1.494 2.563 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.173 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.454 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.43 141.46 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -1.202 . . . . 0.0 109.139 179.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.476 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.89 116.46 17.2 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.882 -1.136 . . . . 0.0 110.725 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.486 ' NH1' HG11 ' A' ' 32' ' ' VAL . 9.6 mtt-85 -105.81 125.78 51.39 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.405 -0.809 . . . . 0.0 109.635 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.7 p90 -114.61 157.92 22.42 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.979 -1.076 . . . . 0.0 110.192 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.471 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t -89.94 -65.76 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.119 -0.988 . . . . 0.0 109.984 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 54.29 96.73 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.594 -0.691 . . . . 0.0 109.952 -179.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.03 -49.51 0.3 Allowed 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.669 1.352 . . . . 0.0 110.408 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -131.21 23.67 4.31 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -110.61 167.14 10.45 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -1.103 . . . . 0.0 110.209 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.027 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.9 p -81.35 106.77 13.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.339 -1.094 . . . . 0.0 110.091 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.675 ' O ' HG13 ' A' ' 3' ' ' VAL . 9.2 p -113.01 104.04 16.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.229 -0.92 . . . . 0.0 110.018 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 7.8 p -73.1 145.28 46.58 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 110.176 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.408 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -81.04 147.04 60.32 Favored Pre-proline 0 C--N 1.302 -1.498 0 O-C-N 121.364 -0.835 . . . . 0.0 109.712 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.408 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.7 Cg_endo -73.19 -165.06 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 124.038 1.546 . . . . 0.0 110.949 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.535 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 1.7 p80 -177.62 82.18 0.24 Allowed Pre-proline 0 C--N 1.302 -1.472 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -64.85 81.32 0.18 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 123.891 1.469 . . . . 0.0 110.74 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 -172.16 -37.4 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 CA-C-O 121.35 0.595 . . . . 0.0 109.561 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.511 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 13.7 mt -96.24 130.21 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.095 -1.003 . . . . 0.0 110.153 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.416 ' HB3' HG12 ' A' ' 129' ' ' ILE . 18.4 tt0 -84.93 129.44 34.8 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.454 -0.778 . . . . 0.0 109.686 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -88.42 133.04 34.22 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.024 -1.047 . . . . 0.0 109.946 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.557 HG11 ' NE ' ' A' ' 131' ' ' ARG . 12.0 t -126.72 158.0 37.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.433 -0.792 . . . . 0.0 110.469 -179.016 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.74 110.74 23.0 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.312 -0.867 . . . . 0.0 109.906 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.417 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.7 tp -56.49 140.1 47.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.766 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.9 p -135.36 170.53 15.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.17 -0.956 . . . . 0.0 110.236 -179.682 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.73 63.6 0.29 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.27 -0.894 . . . . 0.0 110.08 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.47 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.3 m -133.91 111.67 10.64 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.35 -0.844 . . . . 0.0 110.399 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.445 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.912 -1.613 . . . . 0.0 110.815 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.4 -19.15 8.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.763 -0.845 . . . . 0.0 110.366 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.904 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.56 113.2 62.21 Favored Pre-proline 0 N--CA 1.485 1.322 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.421 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.463 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -65.48 144.22 78.63 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.596 1.314 . . . . 0.0 109.648 179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.506 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.07 98.65 1.06 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.078 -1.049 . . . . 0.0 111.634 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CD1' ' N ' ' A' ' 24' ' ' TYR . 22.7 m-85 55.45 65.24 1.53 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.292 -0.88 . . . . 0.0 111.59 178.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.86 14.59 10.37 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.506 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.91 156.2 45.47 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.075 -1.25 . . . . 0.0 108.93 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.47 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.39 106.55 14.13 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.916 -1.115 . . . . 0.0 109.465 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.935 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -68.7 114.9 25.48 Favored Pre-proline 0 C--N 1.298 -1.663 0 C-N-CA 119.726 -0.79 . . . . 0.0 110.018 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.766 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.3 Cg_endo -69.54 128.68 16.59 Favored 'Trans proline' 0 C--N 1.303 -1.825 0 N-CA-C 106.587 -2.12 . . . . 0.0 106.587 176.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.756 HD11 HD12 ' A' ' 58' ' ' LEU . 14.0 mt -55.57 -18.85 8.36 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 118.934 -1.106 . . . . 0.0 110.469 -177.375 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -59.06 -16.52 19.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.721 -1.237 . . . . 0.0 110.574 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.034 HG23 HG23 ' A' ' 33' ' ' ILE . 11.0 m -92.57 -24.1 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 120.921 -1.112 . . . . 0.0 110.925 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.034 HG23 HG23 ' A' ' 32' ' ' VAL . 6.9 pt -119.44 -20.27 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 120.936 -1.103 . . . . 0.0 110.983 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.556 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.41 22.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.935 -1.103 . . . . 0.0 110.403 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.86 -2.85 66.96 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.66 18.0 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 119.025 -1.56 . . . . 0.0 110.69 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.46 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.61 132.79 52.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.479 -1.012 . . . . 0.0 110.162 -179.622 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.518 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.14 45.29 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 110.933 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.621 HD12 ' O ' ' A' ' 82' ' ' VAL . 50.2 tp -113.29 114.44 26.69 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.411 -0.806 . . . . 0.0 110.241 179.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.755 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.2 mt -97.31 128.79 48.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.021 . . . . 0.0 109.549 179.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.401 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 8.0 m-85 -97.54 123.28 41.36 Favored 'General case' 0 C--N 1.292 -1.893 0 O-C-N 121.108 -0.995 . . . . 0.0 110.448 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.39 159.86 22.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.342 -0.849 . . . . 0.0 110.382 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 18.6 p-80 -104.73 -5.61 21.13 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.31 -0.869 . . . . 0.0 110.06 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.7 p -128.15 139.85 52.26 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.98 -1.075 . . . . 0.0 110.863 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.86 -39.51 69.64 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.636 -0.665 . . . . 0.0 110.475 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.08 -33.44 70.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.399 -0.813 . . . . 0.0 110.648 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.408 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.67 -37.08 68.02 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.349 -0.844 . . . . 0.0 109.914 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.883 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 69.7 m -62.16 -36.38 81.68 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.364 -0.835 . . . . 0.0 109.651 179.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.35 -50.28 64.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.027 -1.046 . . . . 0.0 110.231 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.63 -44.81 61.43 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.312 -0.867 . . . . 0.0 110.415 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.897 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -61.29 -36.82 81.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.479 -0.763 . . . . 0.0 111.583 -178.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.417 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.77 -51.68 12.1 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.843 -1.161 . . . . 0.0 110.776 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.78 -38.22 78.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.036 -1.04 . . . . 0.0 109.563 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.806 ' HE2' HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.11 -46.46 82.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.661 -0.649 . . . . 0.0 109.464 179.287 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.742 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.7 -40.23 72.1 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.355 -0.841 . . . . 0.0 110.131 179.897 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.5 t -59.08 -30.91 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.173 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.77 60.17 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.456 -0.778 . . . . 0.0 110.0 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.756 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.27 -25.52 62.49 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.845 0.831 . . . . 0.0 109.739 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.79 7.05 8.97 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.279 -1.529 . . . . 0.0 109.279 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.709 ' CD1' HD22 ' A' ' 30' ' ' LEU . 39.4 mt -107.77 142.78 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.31 -1.112 . . . . 0.0 109.821 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.648 ' ND2' HD11 ' A' ' 74' ' ' ILE . 28.5 t30 -88.87 106.52 18.45 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 177.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.679 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -115.95 141.76 47.68 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 118.78 -1.168 . . . . 0.0 111.521 -177.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.898 HG21 ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.97 143.17 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.704 -0.622 . . . . 0.0 110.007 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.883 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.34 117.82 34.17 Favored 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.366 178.348 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.28 127.12 53.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.197 -0.939 . . . . 0.0 111.07 -179.235 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.866 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 7.3 p90 -157.59 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.684 -0.635 . . . . 0.0 109.642 179.417 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.19 126.99 25.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.08 -1.012 . . . . 0.0 111.007 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.75 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 179.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.866 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -116.59 154.92 29.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.09 -1.241 . . . . 0.0 109.896 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.831 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.7 m-20 -94.84 149.57 21.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.345 -0.847 . . . . 0.0 110.517 -179.201 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.678 ' O ' HG23 ' A' ' 71' ' ' VAL . 31.1 m -61.75 110.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 118.969 -1.092 . . . . 0.0 108.817 179.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.855 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.3 m -130.66 -34.72 1.52 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.438 -0.789 . . . . 0.0 110.283 -179.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.898 ' HA ' HG21 ' A' ' 63' ' ' VAL . 90.9 t -46.86 129.83 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.457 -0.777 . . . . 0.0 109.883 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.855 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -136.14 92.99 15.44 Favored Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 111.18 -179.186 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -82.81 53.35 4.38 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 O-C-N 123.731 1.385 . . . . 0.0 109.589 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.9 p -147.05 19.44 1.25 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.332 -0.855 . . . . 0.0 110.435 -179.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -123.39 -164.49 1.22 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.281 -0.887 . . . . 0.0 109.933 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.79 -77.83 0.11 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -146.79 113.39 6.0 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.111 -1.229 . . . . 0.0 110.343 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.618 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.5 p -117.25 133.95 62.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 CA-C-O 121.978 0.894 . . . . 0.0 110.452 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.671 HG11 ' HB ' ' A' ' 33' ' ' ILE . 12.6 m -112.59 122.01 65.99 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.107 0 O-C-N 121.355 -0.841 . . . . 0.0 109.01 179.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.763 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.54 45.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.911 -1.118 . . . . 0.0 110.726 -177.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.755 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -110.16 99.58 8.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 C-N-CA 118.91 -1.116 . . . . 0.0 108.974 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -132.41 162.09 32.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.698 -1.251 . . . . 0.0 110.326 -178.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.601 HG23 ' OD2' ' A' ' 86' ' ' ASP . 7.2 t -99.1 -27.91 13.62 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.161 -0.962 . . . . 0.0 110.689 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.601 ' OD2' HG23 ' A' ' 85' ' ' THR . 1.3 p30 177.93 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.376 -0.827 . . . . 0.0 110.257 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.499 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.35 -25.57 0.67 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.266 -0.896 . . . . 0.0 110.936 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.462 HD11 ' HZ ' ' A' ' 92' ' ' PHE . 14.7 tp -62.01 -34.44 76.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.184 -0.948 . . . . 0.0 109.791 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.499 ' C ' HG22 ' A' ' 90' ' ' THR . 14.7 mmt 48.24 46.95 19.9 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.482 -0.762 . . . . 0.0 110.877 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.572 ' OG1' HG22 ' A' ' 93' ' ' THR . 2.6 t 34.8 -128.05 0.09 Allowed 'General case' 0 N--CA 1.505 2.32 0 O-C-N 122.03 -0.419 . . . . 0.0 112.012 179.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.429 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 93.63 -61.48 2.05 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 108.383 -1.887 . . . . 0.0 108.383 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.462 ' HZ ' HD11 ' A' ' 88' ' ' LEU . 33.3 p90 -122.0 3.48 9.92 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.457 -1.025 . . . . 0.0 109.923 178.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.572 HG22 ' OG1' ' A' ' 90' ' ' THR . 13.1 t -67.41 -160.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.058 -1.026 . . . . 0.0 109.78 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 91.32 -39.38 3.07 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -84.25 57.01 4.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.144 -1.209 . . . . 0.0 110.781 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.497 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 28.4 m-85 -119.25 149.47 41.72 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -0.988 . . . . 0.0 110.01 179.276 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.439 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.6 -30.74 46.78 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.354 -0.841 . . . . 0.0 109.61 179.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -161.65 163.22 30.02 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.231 -0.918 . . . . 0.0 110.925 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.459 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.2 114.37 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.999 0 O-C-N 121.417 -0.802 . . . . 0.0 110.154 179.189 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.935 HG21 HD11 ' A' ' 28' ' ' ILE . 3.8 mp -93.06 112.41 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 108.523 179.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.416 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.82 21.2 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.103 -0.998 . . . . 0.0 111.722 -177.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.447 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 57.0 m -98.45 2.31 47.61 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.658 -0.651 . . . . 0.0 109.293 177.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.668 ' HB3' ' HB3' ' A' ' 134' ' ' ALA . 2.4 m120 53.86 24.84 4.78 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.149 -0.97 . . . . 0.0 111.172 179.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -147.16 129.58 15.82 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.026 -1.046 . . . . 0.0 110.923 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.9 p -103.35 134.06 47.37 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.361 -0.837 . . . . 0.0 109.336 179.128 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 49.09 27.22 1.65 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.146 -0.971 . . . . 0.0 110.455 -179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.18 -32.72 5.71 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 105' ' ' SER . 9.8 mmpt? -76.68 157.31 82.25 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.318 -1.107 . . . . 0.0 110.142 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -64.44 130.12 25.85 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 123.587 1.309 . . . . 0.0 110.168 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.428 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 4.2 pt20 -51.7 154.0 2.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.478 -0.764 . . . . 0.0 110.935 -179.041 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.519 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -85.28 161.46 19.53 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.245 -0.909 . . . . 0.0 110.286 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.67 -57.94 2.13 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.605 -0.685 . . . . 0.0 112.519 -178.711 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.519 HG22 ' OD1' ' A' ' 111' ' ' ASP . 8.1 m -67.36 -29.6 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 120.68 -1.263 . . . . 0.0 111.532 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.428 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.54 -56.09 7.83 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.111 -0.993 . . . . 0.0 110.437 -179.286 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.463 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.16 -34.06 76.74 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.537 178.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.6 m -59.28 -48.89 79.92 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.049 -1.032 . . . . 0.0 108.404 178.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.1 -35.7 66.64 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.746 -0.782 . . . . 0.0 109.812 178.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.432 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.58 -45.06 66.1 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.058 -1.026 . . . . 0.0 110.463 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.535 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.1 ttm180 -59.45 -40.79 88.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.003 -1.06 . . . . 0.0 110.004 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.28 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.437 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -149.07 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.515 -0.991 . . . . 0.0 108.625 179.365 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.543 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.8 t -98.16 143.35 28.78 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 12.5 10.52 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.4 -1.381 . . . . 0.0 110.515 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.406 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 0.7 OUTLIER -79.5 85.07 5.3 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.009 -1.289 . . . . 0.0 109.877 179.797 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 98.74 17.2 28.94 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -179.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.463 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 4.5 pttt -176.98 -177.02 0.25 Allowed Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 -179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.48 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.7 Cg_endo -89.01 106.93 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.118 1.062 . . . . 0.0 109.488 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.543 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.01 174.0 49.73 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.321 -179.131 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 20.3 mt -130.22 141.86 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 108.839 179.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 12.8 t80 -132.18 115.95 16.35 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.061 -1.024 . . . . 0.0 110.858 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.557 ' NE ' HG11 ' A' ' 13' ' ' VAL . 0.3 OUTLIER -102.67 122.15 43.86 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.209 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.415 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 39.1 p90 -115.17 158.1 22.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.015 -1.053 . . . . 0.0 110.254 -179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.4 t -98.01 -30.78 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.156 -0.965 . . . . 0.0 110.37 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.668 ' HB3' ' HB3' ' A' ' 103' ' ' ASN . . . -95.75 117.76 66.29 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.156 -0.965 . . . . 0.0 110.51 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -85.15 47.31 2.02 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.573 1.302 . . . . 0.0 110.375 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -66.02 -136.46 0.03 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 55.56 34.77 23.82 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.335 -1.097 . . . . 0.0 110.212 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 29.5 ttt85 . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.997 179.834 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 p -77.2 143.42 39.03 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.213 -1.169 . . . . 0.0 110.093 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.624 ' O ' HG23 ' A' ' 3' ' ' VAL . 31.3 m -112.95 103.9 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.2 -0.937 . . . . 0.0 110.009 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.49 HG21 ' HD2' ' A' ' 115' ' ' ARG . 62.5 p -103.39 143.13 33.09 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.352 -0.843 . . . . 0.0 110.353 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.445 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.17 149.43 98.47 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.45 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.445 ' HD2' HG23 ' A' ' 5' ' ' VAL . 40.7 Cg_endo -68.51 -165.35 0.12 Allowed 'Trans proline' 0 C--N 1.307 -1.635 0 O-C-N 123.993 1.523 . . . . 0.0 110.608 179.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.563 ' CE1' ' HD3' ' A' ' 119' ' ' ARG . 0.4 OUTLIER 173.42 82.42 0.05 OUTLIER Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.46 -0.775 . . . . 0.0 109.979 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -69.34 66.47 1.52 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.631 1.332 . . . . 0.0 109.858 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.5 t-20 -153.62 -34.84 0.11 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.564 -0.71 . . . . 0.0 110.618 -179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.536 HD12 ' HG2' ' A' ' 119' ' ' ARG . 45.0 mt -103.45 128.24 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.919 -1.113 . . . . 0.0 110.218 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.36 127.98 34.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.147 179.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.63 142.02 28.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.049 -1.032 . . . . 0.0 110.365 -179.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.53 HG11 ' NE ' ' A' ' 131' ' ' ARG . 4.8 t -128.97 157.7 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.481 -0.762 . . . . 0.0 109.878 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.66 112.32 25.36 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.248 -0.907 . . . . 0.0 110.317 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.584 HD23 HG22 ' A' ' 133' ' ' VAL . 13.5 tp -62.9 135.58 57.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.225 -0.922 . . . . 0.0 109.326 179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.5 p -137.15 -178.15 5.08 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.029 -1.045 . . . . 0.0 110.623 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.29 4.28 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.371 -0.83 . . . . 0.0 109.741 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.673 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 3.6 m -156.68 113.55 3.1 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.264 -0.898 . . . . 0.0 110.589 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.429 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -168.18 28.25 Favored Glycine 0 N--CA 1.488 2.125 0 C-N-CA 118.836 -1.649 . . . . 0.0 111.081 179.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.42 -20.92 10.06 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.844 -0.798 . . . . 0.0 110.289 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.901 HD12 HD13 ' A' ' 55' ' ' LEU . 9.0 tt -96.78 107.76 38.92 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 118.794 -1.163 . . . . 0.0 109.757 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.2 Cg_endo -64.62 126.97 17.79 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 123.353 1.186 . . . . 0.0 110.887 -178.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.3 -169.82 1.69 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.564 -0.71 . . . . 0.0 110.345 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.3 m-85 -57.4 81.15 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.488 -0.757 . . . . 0.0 111.6 -179.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.84 -1.29 59.23 Favored Glycine 0 N--CA 1.494 2.546 0 O-C-N 121.02 -1.05 . . . . 0.0 110.757 179.427 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.404 ' CB ' HD23 ' A' ' 15' ' ' LEU . 0.5 OUTLIER -129.59 156.89 43.46 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.881 -1.364 . . . . 0.0 110.047 -179.903 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.673 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -104.79 106.86 17.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.062 -1.024 . . . . 0.0 108.868 179.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.8 mt -68.34 113.14 13.54 Favored Pre-proline 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 110.677 -179.169 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.893 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -68.97 130.65 20.72 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 107.216 -1.879 . . . . 0.0 107.216 175.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.682 HD11 HD12 ' A' ' 58' ' ' LEU . 13.0 mt -56.3 -18.99 12.34 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.816 -1.178 . . . . 0.0 110.137 -178.09 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.466 ' OE2' HG12 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.69 -16.15 24.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.681 -1.262 . . . . 0.0 110.437 179.687 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.025 HG23 HG23 ' A' ' 33' ' ' ILE . 17.0 m -91.76 -25.02 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.949 -1.094 . . . . 0.0 110.836 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.025 HG23 HG23 ' A' ' 32' ' ' VAL . 38.6 pt -119.4 -20.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.058 -1.026 . . . . 0.0 111.134 -178.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.592 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.2 tptm -92.93 148.33 22.1 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.984 -1.072 . . . . 0.0 110.073 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.93 -5.32 46.44 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 -179.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.87 21.88 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.205 -1.474 . . . . 0.0 110.341 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.1 mtt-85 -97.85 133.01 42.93 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -1.028 . . . . 0.0 110.305 -179.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.572 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.5 m-70 -140.29 149.21 42.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.21 -0.931 . . . . 0.0 110.799 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.464 ' HB3' HG12 ' A' ' 99' ' ' VAL . 26.8 tp -111.41 114.09 26.99 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.371 -0.831 . . . . 0.0 110.061 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.821 HD12 HG12 ' A' ' 83' ' ' VAL . 35.3 mt -96.68 127.76 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.192 -0.943 . . . . 0.0 109.776 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -95.36 123.46 38.9 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.574 -0.704 . . . . 0.0 109.873 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.8 157.07 27.25 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.2 -0.937 . . . . 0.0 110.755 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.2 p80 -104.44 0.92 29.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.374 -0.829 . . . . 0.0 109.976 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 110.255 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.416 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.7 ttpt -71.63 -41.9 68.27 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.513 -0.742 . . . . 0.0 110.907 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.86 -33.79 72.27 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.251 -0.906 . . . . 0.0 110.812 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.506 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.27 -39.6 82.11 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.926 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.864 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.6 m -61.16 -34.68 75.41 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.253 -0.904 . . . . 0.0 109.768 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.63 -50.36 65.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.241 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.17 53.85 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.213 -0.929 . . . . 0.0 110.377 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.769 ' CD2' HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.03 -36.51 70.55 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.719 -0.613 . . . . 0.0 111.386 -178.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.487 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.84 -51.09 13.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.9 -1.125 . . . . 0.0 110.722 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.14 -39.34 89.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.072 -1.017 . . . . 0.0 109.846 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.545 ' HE3' HD21 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.26 -45.77 83.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.332 -0.855 . . . . 0.0 109.586 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.901 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.32 -39.95 70.57 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.513 -0.742 . . . . 0.0 110.088 179.839 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.93 -34.84 49.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.118 -0.989 . . . . 0.0 108.958 179.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -30.81 60.64 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.435 -0.79 . . . . 0.0 110.238 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.682 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.6 -25.88 62.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.345 -0.847 . . . . 0.0 109.815 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.11 4.71 10.03 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.669 ' CD1' HD22 ' A' ' 30' ' ' LEU . 45.9 mt -107.57 143.4 18.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.362 -1.081 . . . . 0.0 109.919 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.476 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 55.6 t30 -89.46 106.85 18.72 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 106.476 -1.675 . . . . 0.0 106.476 178.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.676 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.21 143.48 45.82 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.728 -1.189 . . . . 0.0 112.316 -176.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.918 HG21 ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.25 151.88 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.864 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -121.27 118.34 29.31 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.715 178.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.493 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -108.81 133.83 52.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.317 -0.865 . . . . 0.0 110.552 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.977 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.5 p90 -165.81 -173.25 2.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.473 -0.767 . . . . 0.0 110.162 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.91 125.44 23.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.224 -0.923 . . . . 0.0 110.702 -179.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.55 29.2 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.977 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.3 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.217 -1.167 . . . . 0.0 109.997 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.826 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.4 m-20 -97.24 149.13 22.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 110.731 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.672 ' O ' HG23 ' A' ' 71' ' ' VAL . 32.9 m -62.9 110.99 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.254 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.7 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.8 m -131.4 -32.53 1.54 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.426 -0.796 . . . . 0.0 110.752 -179.346 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.918 ' HA ' HG21 ' A' ' 63' ' ' VAL . 99.0 t -47.83 134.55 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.44 -0.787 . . . . 0.0 110.19 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.7 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -137.0 92.53 14.09 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.137 -0.977 . . . . 0.0 111.12 -179.797 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -83.21 51.47 3.63 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.626 1.329 . . . . 0.0 109.719 178.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -146.25 13.88 1.27 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.213 -0.93 . . . . 0.0 111.04 -178.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -135.85 -149.94 0.35 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.021 -1.049 . . . . 0.0 109.856 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.21 174.64 0.1 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -56.5 114.99 2.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.201 -1.176 . . . . 0.0 110.381 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.3 p -116.52 134.69 59.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 122.038 0.923 . . . . 0.0 109.858 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.588 HG22 HG22 ' A' ' 60' ' ' ILE . 16.5 m -112.83 123.53 68.59 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.317 -0.864 . . . . 0.0 109.555 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.762 HG22 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.95 116.46 40.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 O-C-N 120.842 -1.161 . . . . 0.0 110.595 -178.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.821 HG12 HD12 ' A' ' 40' ' ' ILE . 2.8 m -107.87 100.38 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 0.0 108.559 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.493 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -135.63 162.2 33.37 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.732 -1.23 . . . . 0.0 111.335 -177.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.422 HG22 ' H ' ' A' ' 85' ' ' THR . 5.3 t -91.61 -132.83 0.12 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.673 -0.642 . . . . 0.0 109.649 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.15 21.35 3.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.752 -1.217 . . . . 0.0 110.59 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.46 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.25 -34.91 15.59 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.181 -0.949 . . . . 0.0 109.646 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp -69.72 -46.5 65.81 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.375 -0.828 . . . . 0.0 109.592 179.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.427 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 1.2 mmt 53.32 21.04 2.15 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.361 -0.837 . . . . 0.0 110.204 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.487 HG21 ' HG3' ' A' ' 121' ' ' ARG . 0.3 OUTLIER 45.42 36.25 2.31 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.514 -0.741 . . . . 0.0 110.861 179.826 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.79 -70.88 0.78 Allowed Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -99.54 41.61 1.15 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.251 -1.146 . . . . 0.0 108.908 178.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.425 HG21 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -139.23 -156.66 0.7 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.575 -0.703 . . . . 0.0 110.017 -179.337 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.463 ' N ' HG22 ' A' ' 90' ' ' THR . . . 126.71 -25.92 5.23 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -89.49 80.3 6.75 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.119 -1.224 . . . . 0.0 110.717 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.425 ' CZ ' HG21 ' A' ' 93' ' ' THR . 46.3 m-85 -119.21 148.51 43.03 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.112 -0.993 . . . . 0.0 109.964 179.228 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.23 59.8 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.351 -0.843 . . . . 0.0 109.237 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.323 -0.861 . . . . 0.0 111.003 179.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.58 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.03 117.54 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.355 -0.841 . . . . 0.0 110.685 179.799 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.868 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.12 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.74 160.71 22.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.174 -0.954 . . . . 0.0 111.517 -178.154 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.475 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 13.7 t -100.01 8.27 44.13 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.649 -0.657 . . . . 0.0 109.588 178.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.402 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.5 m120 46.89 25.95 0.52 Allowed 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.272 -0.893 . . . . 0.0 110.725 -179.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.6 p -147.31 129.73 15.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.235 -0.915 . . . . 0.0 110.062 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.434 ' N ' ' O ' ' A' ' 108' ' ' LYS . 5.7 p -114.01 133.7 55.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.163 -0.96 . . . . 0.0 110.147 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.19 28.76 7.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.192 -0.942 . . . . 0.0 110.472 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.06 -35.04 4.25 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.434 ' O ' ' N ' ' A' ' 105' ' ' SER . 1.9 mttm -79.47 156.45 75.83 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.168 -1.195 . . . . 0.0 110.061 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -66.18 135.51 40.53 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 O-C-N 123.622 1.327 . . . . 0.0 110.187 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -49.53 165.74 0.06 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.276 -0.89 . . . . 0.0 110.797 -179.067 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.9 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.243 -0.911 . . . . 0.0 110.294 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.16 -53.19 5.15 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.554 -0.716 . . . . 0.0 112.239 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.46 -29.07 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.68 -1.263 . . . . 0.0 111.432 -178.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.404 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.36 -56.46 6.85 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.124 -0.985 . . . . 0.0 110.486 -179.067 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.49 ' HD2' HG21 ' A' ' 4' ' ' THR . 16.4 ptp180 -68.9 -35.17 76.54 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.218 -0.926 . . . . 0.0 108.635 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.434 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 26.9 m -59.32 -49.89 76.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.072 -1.017 . . . . 0.0 108.608 178.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.6 tt0 -73.75 -38.54 64.7 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.498 -0.752 . . . . 0.0 110.064 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.425 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.43 -44.71 67.31 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.263 -0.898 . . . . 0.0 110.838 -179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.563 ' HD3' ' CE1' ' A' ' 7' ' ' HIS . 1.3 ttp180 -55.28 -48.73 73.63 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.27 -0.893 . . . . 0.0 110.507 -179.552 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.18 -18.89 1.41 Allowed Glycine 0 N--CA 1.499 2.834 0 O-C-N 121.526 -0.734 . . . . 0.0 112.343 -178.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.487 ' HG3' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -56.61 -35.55 68.41 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.501 -1.588 . . . . 0.0 112.014 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.481 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.3 t -100.06 144.67 28.82 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.696 -1.252 . . . . 0.0 111.495 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.432 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.63 8.06 62.62 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.578 178.659 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.419 ' HD2' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -62.09 86.83 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.065 -1.256 . . . . 0.0 109.006 179.502 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.8 -21.44 34.2 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -178.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.489 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -138.99 -168.87 0.2 Allowed Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.386 -1.067 . . . . 0.0 109.09 179.924 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.1 Cg_endo -87.87 107.98 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.147 1.077 . . . . 0.0 110.564 179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.481 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -84.52 168.36 43.92 Favored Glycine 0 N--CA 1.498 2.777 0 O-C-N 121.047 -1.033 . . . . 0.0 110.973 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.445 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.2 mt -124.87 143.24 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.58 ' CD2' HG23 ' A' ' 99' ' ' VAL . 10.0 t80 -130.22 121.94 27.15 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.693 -1.254 . . . . 0.0 111.771 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.53 ' NE ' HG11 ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.25 124.38 49.67 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 178.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.402 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 45.8 p90 -123.27 155.97 36.15 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.954 -1.091 . . . . 0.0 110.888 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.584 HG22 HD23 ' A' ' 15' ' ' LEU . 16.7 t -84.01 -68.77 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.369 -0.832 . . . . 0.0 109.173 178.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 52.12 83.04 0.23 Allowed Pre-proline 0 N--CA 1.487 1.387 0 O-C-N 121.744 -0.598 . . . . 0.0 110.225 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.81 -53.26 0.14 Allowed 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.725 1.381 . . . . 0.0 110.536 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 110.37 135.76 7.1 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.99 -68.2 0.83 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.195 -1.179 . . . . 0.0 110.257 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.6 ttt-85 . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.253 -179.934 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.9 p -91.92 138.01 31.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.241 -1.152 . . . . 0.0 110.212 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.479 ' O ' HG23 ' A' ' 3' ' ' VAL . 14.7 m -113.08 104.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.944 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.644 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 34.9 p -92.62 144.87 24.89 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.474 -0.766 . . . . 0.0 110.097 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.448 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.3 147.03 98.97 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.184 -0.948 . . . . 0.0 109.744 -179.963 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.448 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.9 Cg_endo -71.0 -167.63 0.28 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 124.092 1.575 . . . . 0.0 110.461 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.536 ' CE1' ' HD3' ' A' ' 119' ' ' ARG . 0.5 OUTLIER 173.73 83.11 0.06 OUTLIER Pre-proline 0 N--CA 1.496 1.861 0 O-C-N 121.513 -0.742 . . . . 0.0 109.571 179.621 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.22 -13.6 28.36 Favored 'Trans proline' 0 C--N 1.312 -1.36 0 O-C-N 123.903 1.475 . . . . 0.0 111.126 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.427 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 18.3 m120 -64.99 -31.21 72.34 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.063 -1.023 . . . . 0.0 110.316 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.491 HD11 ' O ' ' A' ' 122' ' ' THR . 25.1 mt -106.2 135.78 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.072 -1.018 . . . . 0.0 110.223 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.42 128.5 34.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.323 -0.86 . . . . 0.0 109.451 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.38 125.51 35.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.063 -1.023 . . . . 0.0 110.047 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.451 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.06 155.01 20.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 110.322 -179.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.6 110.48 22.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.603 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.683 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.4 tp -56.5 135.38 54.41 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.269 -0.894 . . . . 0.0 109.976 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.414 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.3 p -134.58 167.47 20.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 110.378 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.05 79.72 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.302 -0.874 . . . . 0.0 109.993 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.621 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 35.8 m -154.14 109.7 3.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.457 -0.777 . . . . 0.0 110.674 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.43 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.68 -170.69 29.83 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 118.928 -1.606 . . . . 0.0 111.103 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.33 -22.14 11.5 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.716 -0.873 . . . . 0.0 110.207 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.895 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.83 25.67 Favored Pre-proline 0 N--CA 1.49 1.532 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.738 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.474 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.3 Cg_endo -64.49 131.88 31.36 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.317 1.167 . . . . 0.0 110.805 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.1 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.586 -0.696 . . . . 0.0 110.646 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.512 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 36.6 m-85 -58.04 81.46 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.397 -0.814 . . . . 0.0 111.342 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.46 47.71 Favored Glycine 0 N--CA 1.493 2.434 0 O-C-N 121.084 -1.01 . . . . 0.0 110.6 179.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.683 ' CB ' HD23 ' A' ' 15' ' ' LEU . 16.7 mmtp -130.45 156.8 44.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.957 -1.32 . . . . 0.0 109.309 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.621 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -110.43 107.77 17.56 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.94 -1.1 . . . . 0.0 109.653 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -67.76 113.57 15.25 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.388 -0.82 . . . . 0.0 110.987 -179.25 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.864 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.8 Cg_endo -69.55 127.49 14.84 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 N-CA-C 106.9 -2.0 . . . . 0.0 106.9 175.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.608 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.7 mt -55.84 -19.1 10.4 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.816 -1.178 . . . . 0.0 110.819 -177.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -59.86 -16.07 26.06 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.761 -1.212 . . . . 0.0 110.499 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.111 HG23 HG23 ' A' ' 33' ' ' ILE . 15.3 m -91.1 -25.29 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.952 -1.093 . . . . 0.0 110.967 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.111 HG23 HG23 ' A' ' 32' ' ' VAL . 41.3 pt -117.28 -16.48 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.019 -1.051 . . . . 0.0 110.616 -179.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.575 ' HB2' HD11 ' A' ' 60' ' ' ILE . 3.5 tptm -96.33 148.24 22.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.873 -1.142 . . . . 0.0 110.226 179.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.43 -3.23 56.41 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.25 -161.35 26.61 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.934 -1.603 . . . . 0.0 110.906 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.15 128.48 44.09 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.531 -0.982 . . . . 0.0 110.521 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.59 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.56 145.11 44.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.035 -1.04 . . . . 0.0 110.771 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.506 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.6 tp -107.19 113.56 27.07 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.369 -0.832 . . . . 0.0 109.979 179.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.919 HD12 HG12 ' A' ' 83' ' ' VAL . 36.0 mt -96.37 129.28 46.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.251 -0.906 . . . . 0.0 109.452 179.409 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.91 123.75 38.56 Favored 'General case' 0 C--N 1.292 -1.917 0 O-C-N 121.136 -0.977 . . . . 0.0 109.74 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.69 159.74 21.79 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.193 -0.942 . . . . 0.0 111.029 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.512 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -112.3 6.83 19.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.482 -0.761 . . . . 0.0 110.057 179.002 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.407 ' OG ' ' HB3' ' A' ' 47' ' ' LYS . 3.9 p -138.18 137.17 37.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.028 -1.045 . . . . 0.0 110.68 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.58 -40.6 69.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.381 -0.824 . . . . 0.0 110.194 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.62 -36.77 79.43 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 110.247 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.421 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -72.24 -35.64 68.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 179.975 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.869 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 5.5 m -60.29 -33.78 72.82 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.434 -0.791 . . . . 0.0 109.55 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.87 -49.05 61.58 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.201 -0.937 . . . . 0.0 110.432 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.64 -43.32 66.32 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.342 -0.849 . . . . 0.0 110.538 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.826 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.5 -41.58 76.89 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.392 -0.818 . . . . 0.0 111.008 -179.047 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.96 -51.33 12.64 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.988 -1.07 . . . . 0.0 110.58 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.59 -42.05 98.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.87 -1.144 . . . . 0.0 109.594 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -57.68 -46.08 84.77 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.86 . . . . 0.0 109.882 179.71 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.741 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.04 -41.51 71.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.473 -0.767 . . . . 0.0 109.607 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.4 t -56.08 -31.19 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.068 -1.02 . . . . 0.0 108.61 178.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.55 -32.92 60.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.561 -0.712 . . . . 0.0 109.97 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.479 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.92 -25.87 62.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.313 -0.867 . . . . 0.0 109.512 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.0 7.32 8.62 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.608 ' CD1' HD22 ' A' ' 30' ' ' LEU . 34.6 mt -108.83 143.25 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.416 -1.05 . . . . 0.0 110.303 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.586 ' ND2' HD11 ' A' ' 74' ' ' ILE . 24.0 t-20 -86.43 107.0 17.85 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.018 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.619 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.52 143.91 48.32 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 118.908 -1.117 . . . . 0.0 111.428 -177.589 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.931 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -132.11 150.8 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.848 -0.741 . . . . 0.0 109.176 179.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.41 126.51 55.42 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.102 179.37 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.588 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.4 t80 -118.26 122.56 43.25 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.231 -0.918 . . . . 0.0 110.401 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.92 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.76 8.19 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.452 -0.78 . . . . 0.0 109.628 179.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.93 125.24 14.73 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.167 -0.958 . . . . 0.0 110.985 -179.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.11 44.69 22.52 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 179.32 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.926 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.5 tm? -117.72 156.48 28.19 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.089 -1.242 . . . . 0.0 110.127 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.926 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.7 m-20 -94.51 148.98 21.7 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.283 -0.886 . . . . 0.0 110.723 -179.361 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.676 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.9 m -62.42 111.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 119.229 -0.989 . . . . 0.0 109.288 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.507 ' O ' HG23 ' A' ' 74' ' ' ILE . 6.9 m -133.65 -32.63 1.12 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.988 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.931 HG22 ' HB ' ' A' ' 63' ' ' VAL . 30.3 t -56.01 138.73 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.194 -0.941 . . . . 0.0 109.949 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.636 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -137.06 92.12 14.32 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.108 -0.995 . . . . 0.0 111.131 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -87.69 50.91 2.0 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 O-C-N 123.586 1.308 . . . . 0.0 109.738 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -122.47 -25.59 4.74 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.124 -0.985 . . . . 0.0 111.272 -179.026 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.7 m-20 -158.08 160.38 37.3 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.851 -1.156 . . . . 0.0 110.729 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 60.0 160.47 0.07 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -78.26 111.09 13.87 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.058 -1.26 . . . . 0.0 110.097 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.4 p -117.3 133.92 62.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-O 121.961 0.886 . . . . 0.0 110.351 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.591 HG22 HG22 ' A' ' 60' ' ' ILE . 7.8 m -112.67 123.82 68.73 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 178.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.736 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.76 116.46 38.95 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.1 -1.0 . . . . 0.0 110.353 -177.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.919 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -108.97 100.22 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 C-N-CA 118.867 -1.133 . . . . 0.0 108.771 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.475 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.78 162.98 34.13 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.732 -1.23 . . . . 0.0 111.114 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.525 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -92.04 -130.97 0.12 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.537 -0.727 . . . . 0.0 109.47 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.525 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -90.98 34.83 0.91 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.713 -1.242 . . . . 0.0 110.226 179.534 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.43 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 0.0 110.356 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp -62.68 -36.57 83.32 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.132 -0.98 . . . . 0.0 109.099 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.479 ' C ' HG22 ' A' ' 90' ' ' THR . 0.6 OUTLIER 46.07 43.93 11.22 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.538 -0.726 . . . . 0.0 110.664 179.727 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.651 ' OG1' HG22 ' A' ' 93' ' ' THR . 1.8 t 35.39 -119.08 0.11 Allowed 'General case' 0 N--CA 1.504 2.242 0 O-C-N 122.138 -0.351 . . . . 0.0 111.661 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.409 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 79.94 -58.47 4.55 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -179.664 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.3 p90 -122.1 20.18 10.69 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.229 -1.159 . . . . 0.0 110.156 179.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.651 HG22 ' OG1' ' A' ' 90' ' ' THR . 8.3 t -94.37 -171.41 2.51 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.217 -0.927 . . . . 0.0 110.204 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 119.58 5.62 11.04 Favored Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.833 -1.175 . . . . 0.0 110.527 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -125.77 58.62 1.32 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.742 -1.446 . . . . 0.0 110.489 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.506 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.51 152.19 38.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.872 -1.143 . . . . 0.0 110.778 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.444 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.56 -28.79 19.35 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.567 -0.708 . . . . 0.0 109.363 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.3 p -161.0 163.77 31.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.34 -0.85 . . . . 0.0 110.758 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.489 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -125.75 119.18 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.251 -0.905 . . . . 0.0 110.292 179.578 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.769 HG21 ' CD1' ' A' ' 28' ' ' ILE . 37.9 mm -95.9 111.26 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 108.859 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.44 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -118.89 161.06 20.81 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.913 -1.117 . . . . 0.0 111.73 -178.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.48 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.3 p -99.96 -0.33 39.6 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 50.52 18.63 0.47 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.341 -0.85 . . . . 0.0 112.175 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.459 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.0 OUTLIER -144.7 120.86 10.81 Favored 'General case' 0 C--N 1.305 -1.349 0 O-C-N 120.729 -1.232 . . . . 0.0 109.407 179.831 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' LYS . 10.3 p -102.45 141.58 35.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 110.277 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t70 52.3 28.32 5.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.263 -0.898 . . . . 0.0 110.536 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.21 -13.26 58.02 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.201 -1.159 . . . . 0.0 110.201 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.459 ' O ' ' HA ' ' A' ' 104' ' ' THR . 14.6 mttt -96.64 156.66 36.4 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 120.952 -1.323 . . . . 0.0 109.973 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.44 130.0 27.01 Favored 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.542 1.285 . . . . 0.0 110.639 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -49.24 168.1 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.644 0.735 . . . . 0.0 111.183 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.539 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -102.68 161.56 13.63 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.544 -0.723 . . . . 0.0 110.327 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.644 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -42.28 -56.55 2.9 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.576 -0.702 . . . . 0.0 112.376 -178.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.539 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -64.21 -29.87 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.702 -1.249 . . . . 0.0 111.255 -178.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.403 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.73 -56.32 7.61 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.116 -0.99 . . . . 0.0 110.505 -179.209 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.76 -33.77 76.36 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.159 -0.963 . . . . 0.0 108.851 178.91 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.5 m -60.93 -50.16 74.54 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.061 -1.025 . . . . 0.0 108.357 178.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.96 -38.71 64.13 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 mtt-85 -71.85 -44.37 63.94 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.258 -0.901 . . . . 0.0 111.321 -179.181 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.536 ' HD3' ' CE1' ' A' ' 7' ' ' HIS . 6.9 ttp180 -62.12 -40.42 95.85 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.917 -1.114 . . . . 0.0 110.244 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.4 75.26 0.04 OUTLIER Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.533 ' NE ' HG21 ' A' ' 93' ' ' THR . 0.7 OUTLIER -149.05 -47.35 0.14 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.43 -1.041 . . . . 0.0 108.76 179.599 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.555 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.1 t -96.19 143.47 27.27 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.76 17.82 4.55 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.409 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 10.8 mmt180 -91.75 82.8 5.22 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.117 -1.225 . . . . 0.0 109.986 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.92 -31.74 4.84 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.482 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.18 -169.74 0.22 Allowed Pre-proline 0 C--N 1.301 -1.514 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 179.509 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.482 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.5 Cg_endo -85.31 115.0 1.59 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 122.916 0.956 . . . . 0.0 110.466 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.555 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.29 51.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.567 HG21 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 mt -119.99 140.13 45.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.039 -1.271 . . . . 0.0 109.051 179.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.489 ' HD1' HG23 ' A' ' 99' ' ' VAL . 6.8 t80 -122.7 114.49 20.65 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 118.965 -1.094 . . . . 0.0 110.218 179.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.601 ' HB2' HD13 ' A' ' 100' ' ' ILE . 24.2 mtt180 -108.12 126.87 53.27 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.594 -0.692 . . . . 0.0 109.321 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.451 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.8 p90 -126.95 156.94 40.72 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.078 -1.014 . . . . 0.0 110.847 -179.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.509 HG21 ' HB2' ' A' ' 24' ' ' TYR . 7.0 t -78.05 -69.31 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.319 -0.863 . . . . 0.0 108.978 178.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.436 ' N ' HG12 ' A' ' 133' ' ' VAL . . . 54.49 83.29 0.23 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.71 -0.619 . . . . 0.0 110.853 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -83.41 7.85 4.96 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.714 1.376 . . . . 0.0 110.609 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 132.03 -124.66 4.03 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -161.05 155.23 22.84 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.261 -1.141 . . . . 0.0 110.127 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.265 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.0 t -109.34 141.76 41.23 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.405 -1.056 . . . . 0.0 110.33 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.659 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.6 p -113.46 104.61 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.373 -0.83 . . . . 0.0 109.717 179.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.1 p -66.54 145.51 55.54 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.306 -0.871 . . . . 0.0 110.792 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.514 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -72.64 149.9 90.87 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.275 -0.891 . . . . 0.0 109.81 179.599 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.516 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 40.2 Cg_endo -79.59 -64.86 0.02 OUTLIER 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 124.222 1.643 . . . . 0.0 112.547 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.524 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 15.3 p80 42.85 88.8 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.62 0 CA-C-O 121.578 0.704 . . . . 0.0 110.404 -177.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.43 2.41 5.14 Favored 'Trans proline' 0 C--N 1.316 -1.165 0 O-C-N 123.511 1.269 . . . . 0.0 112.326 -178.423 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 24.4 t-20 -51.54 -25.07 6.03 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.647 -1.283 . . . . 0.0 109.302 179.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.548 HD12 ' HG2' ' A' ' 119' ' ' ARG . 20.0 mt -105.8 132.99 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.442 -0.786 . . . . 0.0 109.117 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.5 33.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.054 -1.028 . . . . 0.0 109.302 179.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.54 126.43 35.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.176 -0.952 . . . . 0.0 110.021 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.559 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 6.4 t -116.14 154.52 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.334 -0.853 . . . . 0.0 110.4 -179.221 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.88 105.04 15.34 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.339 -0.851 . . . . 0.0 109.639 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.506 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -55.43 132.34 48.08 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.412 -0.805 . . . . 0.0 109.82 -179.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.408 ' O ' ' N ' ' A' ' 18' ' ' THR . 70.5 p -135.83 172.29 13.22 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.212 -0.93 . . . . 0.0 110.314 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.91 78.28 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.22 -0.925 . . . . 0.0 110.202 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.682 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.0 m -151.31 108.54 3.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.206 -0.934 . . . . 0.0 110.687 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 119.037 -1.554 . . . . 0.0 110.747 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.32 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.649 -0.912 . . . . 0.0 110.326 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.867 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.8 tt -100.53 104.24 29.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.314 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.3 Cg_endo -62.94 148.7 93.17 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.338 1.178 . . . . 0.0 109.894 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.533 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.26 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.174 -0.954 . . . . 0.0 111.127 -178.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.5 m-85 59.15 66.78 0.99 Allowed 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.406 -0.809 . . . . 0.0 111.332 179.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.87 15.0 11.11 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.62 156.98 43.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.057 -1.261 . . . . 0.0 109.121 179.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.682 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -117.2 107.28 14.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.883 -1.135 . . . . 0.0 109.69 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.867 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.6 mt -69.98 114.33 24.4 Favored Pre-proline 0 C--N 1.3 -1.553 0 C-N-CA 119.614 -0.835 . . . . 0.0 109.926 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -69.01 129.72 18.92 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 N-CA-C 107.047 -1.943 . . . . 0.0 107.047 176.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.666 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.9 mt -56.52 -16.92 6.8 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.78 -1.2 . . . . 0.0 110.976 -177.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.443 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.03 -15.89 47.83 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.799 -1.188 . . . . 0.0 110.242 179.427 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.053 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -92.6 -25.14 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.986 -1.071 . . . . 0.0 111.212 -179.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.053 HG23 HG23 ' A' ' 32' ' ' VAL . 12.0 pt -120.47 -23.25 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.99 -1.069 . . . . 0.0 110.804 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.652 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.04 147.9 22.6 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.954 -1.092 . . . . 0.0 110.692 -179.872 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.413 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.63 -3.48 57.65 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.95 -155.73 13.6 Favored Glycine 0 N--CA 1.494 2.542 0 C-N-CA 119.008 -1.567 . . . . 0.0 110.705 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.98 131.12 52.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.413 -1.051 . . . . 0.0 110.092 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.4 m-70 -140.83 152.38 45.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 111.07 -179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.459 HD12 ' O ' ' A' ' 82' ' ' VAL . 43.0 tp -112.27 115.67 29.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.361 -0.837 . . . . 0.0 110.321 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.836 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.6 mt -100.34 128.59 52.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 109.823 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.467 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.04 123.66 40.84 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.098 -1.001 . . . . 0.0 110.054 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.52 159.59 21.03 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.278 -0.889 . . . . 0.0 110.55 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.577 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.63 5.11 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.362 -0.836 . . . . 0.0 110.006 179.076 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.08 135.95 37.93 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.127 -0.983 . . . . 0.0 110.607 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.486 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.51 -31.31 66.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.546 -0.721 . . . . 0.0 110.395 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.06 -30.0 66.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.357 -0.84 . . . . 0.0 110.198 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.4 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.1 -36.98 66.87 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.394 -0.816 . . . . 0.0 109.649 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.909 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.3 82.33 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.284 -0.885 . . . . 0.0 109.399 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.53 -49.9 73.5 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.103 -0.998 . . . . 0.0 109.955 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.65 -47.01 51.09 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.328 -0.858 . . . . 0.0 110.348 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.684 HD13 ' O ' ' A' ' 51' ' ' LEU . 1.9 tm? -56.53 -40.08 74.48 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.51 -0.744 . . . . 0.0 110.772 -179.298 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.36 13.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.078 -1.014 . . . . 0.0 110.179 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.34 -42.21 98.31 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 109.798 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.523 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.42 -45.25 84.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.459 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.834 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.08 -42.12 72.41 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.541 -0.725 . . . . 0.0 109.614 179.941 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.5 t -56.08 -33.33 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 109.097 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.64 -31.36 59.8 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.408 -0.807 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.21 -26.39 62.92 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.339 -0.85 . . . . 0.0 109.456 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.24 5.39 8.75 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.666 ' CD1' HD22 ' A' ' 30' ' ' LEU . 67.9 mt -108.15 143.83 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.321 -1.106 . . . . 0.0 110.358 -179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.72 106.48 18.38 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 177.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.687 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.47 142.87 46.3 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.883 -177.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.88 HG21 ' HA ' ' A' ' 73' ' ' VAL . 84.0 t -122.97 148.81 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.909 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.48 117.17 29.63 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.256 178.226 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.473 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.88 135.37 49.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.294 -0.878 . . . . 0.0 111.02 -179.235 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.977 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 15.4 p90 -167.95 177.36 5.69 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.522 -0.736 . . . . 0.0 109.853 179.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.1 ttp-105 -51.56 126.06 16.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.07 -1.018 . . . . 0.0 110.683 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.88 45.11 22.44 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.977 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.28 153.61 32.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.04 -1.271 . . . . 0.0 109.836 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.783 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.9 m-20 -91.2 149.46 21.77 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.297 -0.877 . . . . 0.0 110.608 -179.242 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.663 ' O ' HG23 ' A' ' 71' ' ' VAL . 33.9 m -62.42 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 C-N-CA 119.22 -0.992 . . . . 0.0 109.125 179.096 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.674 ' O ' HG23 ' A' ' 74' ' ' ILE . 15.0 m -133.9 -34.37 1.01 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.445 -0.785 . . . . 0.0 110.843 -179.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.88 ' HA ' HG21 ' A' ' 63' ' ' VAL . 92.4 t -49.43 129.47 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.098 -1.001 . . . . 0.0 110.106 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.674 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -138.41 94.75 10.58 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.11 -0.994 . . . . 0.0 110.996 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.563 ' HA ' HG11 ' A' ' 80' ' ' VAL . 48.3 Cg_endo -78.75 58.05 6.66 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.675 1.355 . . . . 0.0 110.012 179.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.9 t -165.3 41.87 0.07 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.354 -0.841 . . . . 0.0 110.42 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.441 ' HB2' HD12 ' A' ' 74' ' ' ILE . 5.4 m120 -140.99 29.33 1.86 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.171 -0.956 . . . . 0.0 110.41 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 106.74 -89.0 0.57 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -140.56 102.81 4.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.11 -1.23 . . . . 0.0 110.241 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.563 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.2 p -116.89 135.23 57.91 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.81 0 CA-C-O 121.966 0.889 . . . . 0.0 109.912 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 13.7 m -112.62 124.6 69.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.283 0 O-C-N 121.282 -0.886 . . . . 0.0 109.373 179.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.839 HG11 HD13 ' A' ' 88' ' ' LEU . 13.1 t -97.19 119.14 44.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 O-C-N 120.955 -1.091 . . . . 0.0 110.383 -178.237 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.836 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.3 m -111.9 99.27 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 119.015 -1.074 . . . . 0.0 108.771 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.426 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.22 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.587 -1.321 . . . . 0.0 110.811 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.05 -28.56 17.88 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.345 -0.847 . . . . 0.0 110.71 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.89 -31.3 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.079 -1.013 . . . . 0.0 110.762 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.473 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.95 -37.55 9.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.259 -0.901 . . . . 0.0 111.099 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.839 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -70.22 -33.44 71.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.145 -0.972 . . . . 0.0 110.7 -179.708 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . . . . . . . . . 2.3 tpt 53.43 -144.12 0.68 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.088 -1.007 . . . . 0.0 109.337 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.499 HG23 ' HB ' ' A' ' 93' ' ' THR . 0.5 OUTLIER -155.54 24.84 0.4 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.863 -1.148 . . . . 0.0 110.44 179.463 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.03 -62.41 5.98 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -101.21 36.24 2.05 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.354 -1.086 . . . . 0.0 108.609 178.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.642 HG22 ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -133.8 -167.58 1.97 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.742 -0.599 . . . . 0.0 110.063 -179.433 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.417 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 120.68 -24.2 7.65 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.599 -1.401 . . . . 0.0 109.599 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -84.43 73.26 10.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.981 -1.305 . . . . 0.0 110.186 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.642 ' CE2' HG22 ' A' ' 93' ' ' THR . 38.6 m-85 -119.77 152.75 36.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.208 -0.932 . . . . 0.0 110.167 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -84.83 -29.26 25.48 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.505 -0.747 . . . . 0.0 109.735 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.452 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.7 p -161.18 163.47 31.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.166 -0.959 . . . . 0.0 110.843 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.414 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.29 116.32 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.298 -0.876 . . . . 0.0 109.963 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.842 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -94.61 111.3 25.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.07 -1.019 . . . . 0.0 108.974 179.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.416 ' HB2' ' CE1' ' A' ' 130' ' ' TYR . 3.5 t0 -114.4 161.07 18.42 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.149 -0.97 . . . . 0.0 111.732 -178.369 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.32 9.65 35.81 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.444 ' CB ' ' HB3' ' A' ' 134' ' ' ALA . 2.7 m120 46.19 27.29 0.53 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.279 -0.888 . . . . 0.0 110.963 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.579 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -144.29 133.45 22.93 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.188 -0.945 . . . . 0.0 110.469 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 62.0 p -113.42 128.66 56.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.323 -0.861 . . . . 0.0 109.394 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.0 t70 55.65 -141.55 0.84 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.037 -1.039 . . . . 0.0 109.555 -179.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -88.35 18.46 41.52 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -134.82 156.98 78.1 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.115 -1.227 . . . . 0.0 109.569 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.579 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.0 Cg_endo -63.26 158.37 44.91 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.53 1.279 . . . . 0.0 110.443 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.416 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER -64.85 164.77 11.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.278 -0.889 . . . . 0.0 111.205 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.506 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -100.52 161.78 13.37 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.556 -0.715 . . . . 0.0 110.111 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.465 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.46 -61.56 1.03 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.476 -0.765 . . . . 0.0 112.108 -178.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.506 HG22 ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.79 -28.87 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.71 -1.244 . . . . 0.0 111.435 -178.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.69 -57.19 5.83 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.893 -1.13 . . . . 0.0 110.932 -178.732 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.465 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.46 -34.63 78.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.02 -1.05 . . . . 0.0 108.525 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 49.6 m -59.84 -48.87 79.95 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.28 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.59 -40.1 64.13 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.513 -0.742 . . . . 0.0 110.126 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.467 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.48 -44.61 70.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.984 -1.073 . . . . 0.0 110.31 -179.687 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.548 ' HG2' HD12 ' A' ' 10' ' ' ILE . 41.9 ttp180 -61.54 -36.08 79.58 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.047 -1.033 . . . . 0.0 109.315 179.184 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.05 66.67 0.34 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.7 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.462 -1.022 . . . . 0.0 108.848 179.813 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.538 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.3 t -92.12 142.45 27.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.335 -0.853 . . . . 0.0 108.931 178.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.58 17.07 2.95 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.269 -1.444 . . . . 0.0 110.605 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.417 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.2 mmt180 -95.11 82.37 3.77 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.986 -1.303 . . . . 0.0 110.002 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.39 -51.46 0.76 Allowed Glycine 0 N--CA 1.493 2.483 0 N-CA-C 108.412 -1.875 . . . . 0.0 108.412 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.455 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.84 166.36 21.72 Favored Pre-proline 0 N--CA 1.491 1.588 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.3 Cg_endo -63.59 117.73 4.68 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.299 1.157 . . . . 0.0 110.128 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.538 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.85 172.24 54.78 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.424 HG23 ' CG2' ' A' ' 13' ' ' VAL . 5.1 mt -126.15 142.06 43.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.301 -1.117 . . . . 0.0 108.989 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.416 ' CE1' ' HB2' ' A' ' 101' ' ' ASP . 10.5 t80 -131.13 115.19 16.06 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.292 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.559 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 5.9 mtp180 -99.78 147.71 25.18 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.497 -0.752 . . . . 0.0 109.365 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.47 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 25.1 p90 -138.14 150.36 46.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.085 -1.01 . . . . 0.0 110.212 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.506 HG22 HD23 ' A' ' 15' ' ' LEU . 34.5 t -87.01 -41.07 14.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.129 -0.982 . . . . 0.0 109.448 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.444 ' HB3' ' CB ' ' A' ' 103' ' ' ASN . . . -91.17 113.1 57.18 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.357 -0.839 . . . . 0.0 109.947 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.435 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 45.4 Cg_endo -71.52 -22.96 23.94 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.456 1.24 . . . . 0.0 110.756 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 157.31 148.14 5.01 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -90.63 -32.44 16.24 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.272 -1.134 . . . . 0.0 110.223 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.677 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.143 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.376 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.2 m -89.89 105.98 18.16 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.195 -1.179 . . . . 0.0 110.154 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.678 ' O ' HG23 ' A' ' 3' ' ' VAL . 31.3 m -112.87 104.4 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.357 -0.84 . . . . 0.0 109.629 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.474 HG21 ' HD3' ' A' ' 115' ' ' ARG . 43.8 p -90.02 143.35 26.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.202 -0.936 . . . . 0.0 110.785 -179.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.471 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.67 148.5 98.05 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.34 -0.85 . . . . 0.0 109.477 179.434 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.471 ' HD2' HG23 ' A' ' 5' ' ' VAL . 39.4 Cg_endo -67.65 -167.01 0.14 Allowed 'Trans proline' 0 C--N 1.307 -1.622 0 O-C-N 124.045 1.55 . . . . 0.0 111.11 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.562 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 176.33 83.23 0.1 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.681 -0.637 . . . . 0.0 109.332 -179.736 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.72 -9.61 26.05 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 O-C-N 123.861 1.453 . . . . 0.0 111.059 -179.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.9 t-20 -77.96 -29.41 49.82 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.94 -1.1 . . . . 0.0 109.627 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.519 HD13 HG22 ' A' ' 122' ' ' THR . 16.5 mt -106.81 132.43 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.001 -1.062 . . . . 0.0 109.518 179.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.87 127.26 33.71 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.134 -0.979 . . . . 0.0 109.278 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.66 128.5 36.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.16 -0.962 . . . . 0.0 110.003 -179.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.42 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.49 158.04 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.404 -0.81 . . . . 0.0 110.176 -179.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.98 110.94 21.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.752 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.451 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -53.45 134.5 40.44 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.319 -0.863 . . . . 0.0 110.329 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.6 p -135.49 177.76 7.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.263 -0.898 . . . . 0.0 110.142 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.33 65.31 0.42 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.225 -0.922 . . . . 0.0 109.951 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.474 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 22.1 m -137.1 110.57 7.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.339 -0.851 . . . . 0.0 110.353 -179.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.0 -163.89 27.98 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.76 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.72 -21.02 7.43 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.675 -0.897 . . . . 0.0 110.327 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.893 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -96.79 108.66 44.44 Favored Pre-proline 0 N--CA 1.488 1.458 0 C-N-CA 118.668 -1.213 . . . . 0.0 110.204 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.437 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.6 Cg_endo -65.48 149.77 87.49 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 O-C-N 123.444 1.234 . . . . 0.0 110.296 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.523 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.3 t80 -169.04 108.21 0.45 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 110.977 -178.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.478 ' OH ' ' CE1' ' A' ' 43' ' ' HIS . 17.6 m-85 56.25 60.69 3.05 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.234 -0.916 . . . . 0.0 111.171 179.209 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.97 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.523 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.49 157.28 43.1 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.128 -1.219 . . . . 0.0 109.064 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.474 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.79 107.27 14.83 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 120.811 -1.181 . . . . 0.0 110.239 -179.517 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.893 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.4 mt -68.29 114.5 21.77 Favored Pre-proline 0 C--N 1.301 -1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.8 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -69.16 128.39 16.5 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 N-CA-C 106.579 -2.123 . . . . 0.0 106.579 175.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.64 HD22 ' CD1' ' A' ' 60' ' ' ILE . 11.0 mt -55.82 -17.62 6.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.673 -1.267 . . . . 0.0 111.09 -177.216 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -59.63 -15.98 22.83 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.677 -1.264 . . . . 0.0 110.667 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.084 HG23 HG23 ' A' ' 33' ' ' ILE . 16.4 m -91.37 -25.38 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.024 -1.048 . . . . 0.0 111.187 -179.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.084 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -119.84 -16.97 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.96 -1.087 . . . . 0.0 110.65 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.6 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.9 tptt -98.8 147.86 24.49 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.769 -1.207 . . . . 0.0 110.046 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.84 -5.39 50.63 Favored Glycine 0 N--CA 1.485 1.911 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.35 -151.17 9.52 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.081 -1.533 . . . . 0.0 110.561 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.442 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.03 131.92 53.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.43 -1.041 . . . . 0.0 110.371 -179.409 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.572 ' HB2' HG12 ' A' ' 81' ' ' VAL . 95.6 m-70 -138.44 151.53 47.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.172 -0.955 . . . . 0.0 110.95 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.578 HD12 ' O ' ' A' ' 82' ' ' VAL . 45.9 tp -111.58 119.29 38.24 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.766 . . . . 0.0 110.025 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.921 HD12 ' CG1' ' A' ' 83' ' ' VAL . 31.6 mt -103.86 126.26 58.43 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.295 -0.878 . . . . 0.0 109.155 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.96 123.79 38.63 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.177 -0.952 . . . . 0.0 110.329 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.28 160.13 21.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.425 -0.797 . . . . 0.0 110.668 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.478 ' CE1' ' OH ' ' A' ' 24' ' ' TYR . 5.4 p-80 -105.16 -4.73 21.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.337 -0.852 . . . . 0.0 110.426 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.412 ' HB3' ' CD2' ' A' ' 43' ' ' HIS . 66.4 p -136.14 145.8 46.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.01 -1.056 . . . . 0.0 111.235 -179.413 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.477 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 23.7 tttt -72.08 -40.92 67.91 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.673 -0.642 . . . . 0.0 110.669 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.77 -34.98 72.04 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.139 -0.976 . . . . 0.0 110.684 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HA ' ' HD3' ' A' ' 47' ' ' LYS . 12.3 tppt? -71.6 -40.42 69.86 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.077 -1.014 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.888 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 67.3 m -61.83 -37.15 83.37 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 110.06 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.98 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.949 -1.094 . . . . 0.0 110.577 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.414 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -72.28 -44.2 63.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.174 -0.954 . . . . 0.0 110.229 179.908 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.728 HD12 HG11 ' A' ' 83' ' ' VAL . 1.7 tm? -56.58 -42.12 78.1 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.489 -0.757 . . . . 0.0 111.198 -179.102 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.35 -50.88 16.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.897 -1.127 . . . . 0.0 110.375 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.38 -42.09 98.15 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.118 -0.989 . . . . 0.0 109.798 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.504 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.98 -45.78 86.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.901 . . . . 0.0 109.788 179.703 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.644 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -54.54 -42.31 70.76 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.453 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.5 t -56.79 -30.7 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.122 -0.986 . . . . 0.0 108.591 178.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.503 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.56 -33.93 60.67 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.597 -0.689 . . . . 0.0 110.021 179.23 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.536 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.48 -25.73 62.4 Favored 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.82 0.819 . . . . 0.0 109.556 179.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.56 7.34 9.0 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -179.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.64 ' CD1' HD22 ' A' ' 30' ' ' LEU . 40.1 mt -108.01 143.31 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.324 -1.103 . . . . 0.0 109.977 -179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 38.2 t30 -87.2 107.08 18.32 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.272 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.637 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.91 145.11 48.02 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.409 -177.576 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.887 HG21 ' HA ' ' A' ' 73' ' ' VAL . 6.7 t -133.02 143.1 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.589 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.888 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -107.16 123.45 48.28 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.824 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.492 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.17 119.06 36.47 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.335 -0.853 . . . . 0.0 110.387 -179.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.922 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.8 p90 -146.74 174.48 11.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.608 -0.683 . . . . 0.0 109.753 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.6 5.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.161 -0.962 . . . . 0.0 110.803 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.02 35.73 9.58 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.889 -1.284 . . . . 0.0 109.889 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.948 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.0 tm? -117.17 155.84 28.68 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 110.079 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.948 ' N ' HD13 ' A' ' 69' ' ' LEU . 37.1 m-20 -95.37 149.42 21.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.333 -0.854 . . . . 0.0 110.248 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.672 ' O ' HG23 ' A' ' 71' ' ' VAL . 27.2 m -61.81 110.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.176 179.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.401 ' O ' HG23 ' A' ' 74' ' ' ILE . 7.3 m -132.04 -20.82 2.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.486 -0.759 . . . . 0.0 111.068 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.887 ' HA ' HG21 ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.88 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 109.302 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.629 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp -126.25 96.91 35.54 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.241 -0.912 . . . . 0.0 110.969 -179.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.542 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.7 Cg_endo -82.26 54.0 4.77 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.689 1.362 . . . . 0.0 109.95 179.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.4 t -156.95 42.44 0.35 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.259 -0.901 . . . . 0.0 110.537 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.408 ' CG ' HD13 ' A' ' 74' ' ' ILE . 3.9 m120 -141.5 -164.94 1.87 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.171 -0.956 . . . . 0.0 110.149 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.43 -73.36 0.36 Allowed Glycine 0 N--CA 1.494 2.552 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 -149.93 111.66 4.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.303 -1.116 . . . . 0.0 110.097 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.542 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -117.47 134.58 60.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.074 0.94 . . . . 0.0 110.359 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.647 HG11 ' HB ' ' A' ' 33' ' ' ILE . 5.7 m -113.28 124.67 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 O-C-N 121.413 -0.805 . . . . 0.0 108.901 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.784 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.91 45.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 121.159 -0.963 . . . . 0.0 110.049 -178.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.921 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.8 m -114.48 100.98 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.07 -1.019 . . . . 0.0 108.594 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.492 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.37 164.22 32.16 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.725 -1.234 . . . . 0.0 111.796 -177.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.706 HG23 ' H ' ' A' ' 87' ' ' ALA . 6.4 t -94.28 -147.2 0.26 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.671 -0.643 . . . . 0.0 109.42 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.15 -15.3 56.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.964 -1.085 . . . . 0.0 110.235 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.706 ' H ' HG23 ' A' ' 85' ' ' THR . . . -49.32 -44.64 44.49 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.038 -1.039 . . . . 0.0 110.257 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp -63.56 -26.86 68.89 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.925 . . . . 0.0 108.985 179.101 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.488 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 5.6 tpt 45.2 32.42 0.95 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.71 -0.619 . . . . 0.0 111.207 179.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.447 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 48.1 p 44.13 36.77 1.59 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.706 -0.621 . . . . 0.0 111.22 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.06 -63.98 4.67 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -122.31 41.13 3.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.307 -1.114 . . . . 0.0 109.879 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.52 HG21 ' HD2' ' A' ' 121' ' ' ARG . 15.3 t -91.13 -159.38 0.63 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.342 -0.849 . . . . 0.0 110.777 -179.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.47 -36.9 3.63 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -84.45 55.05 3.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.966 -1.314 . . . . 0.0 110.492 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.461 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 40.9 m-85 -119.92 147.93 44.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.937 -1.102 . . . . 0.0 110.303 179.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.481 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.43 -28.77 56.75 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.409 -0.807 . . . . 0.0 110.127 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.425 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.2 p -160.38 163.58 33.05 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.256 -0.903 . . . . 0.0 110.752 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.505 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.9 117.86 45.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.332 -0.855 . . . . 0.0 110.563 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.798 HG21 HD11 ' A' ' 28' ' ' ILE . 4.6 mp -98.24 110.86 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.16 158.88 25.05 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.992 . . . . 0.0 111.773 -178.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.84 3.67 53.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.423 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.2 m-20 52.88 27.72 5.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.239 -0.913 . . . . 0.0 111.087 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p -147.23 130.78 16.8 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.11 -0.994 . . . . 0.0 110.24 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.407 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.1 p -112.86 127.88 56.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.324 -0.86 . . . . 0.0 109.837 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 55.43 26.96 9.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.316 -0.865 . . . . 0.0 110.553 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.15 -37.83 3.31 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.407 ' O ' ' N ' ' A' ' 105' ' ' SER . 15.8 mttt -77.05 156.56 82.06 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.325 -1.103 . . . . 0.0 110.121 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -65.94 132.61 30.78 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.612 1.322 . . . . 0.0 109.887 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.46 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER -49.66 171.15 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.275 -0.891 . . . . 0.0 110.998 -179.046 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.535 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -99.7 160.77 14.05 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.28 179.674 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.31 -53.47 5.21 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.438 -0.789 . . . . 0.0 112.286 -178.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.535 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.8 m -69.75 -29.42 40.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 120.83 -1.169 . . . . 0.0 111.525 -178.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.402 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.31 -56.52 6.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.07 -1.019 . . . . 0.0 110.625 -179.114 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.474 ' HD3' HG21 ' A' ' 4' ' ' THR . 1.8 ptm180 -69.07 -34.69 75.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.296 -0.877 . . . . 0.0 108.819 178.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.431 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.8 m -59.52 -49.79 76.42 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.68 -37.53 65.2 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.451 -0.781 . . . . 0.0 110.056 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 36.3 mtt-85 -71.89 -45.63 60.61 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.209 -0.932 . . . . 0.0 111.719 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.562 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 27.6 ttp85 -59.34 -51.65 69.02 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.091 -1.006 . . . . 0.0 109.917 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.429 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.4 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -179.265 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.52 ' HD2' HG21 ' A' ' 93' ' ' THR . 0.0 OUTLIER -45.73 -33.21 2.87 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.283 -1.128 . . . . 0.0 111.632 -179.6 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.519 HG22 HD13 ' A' ' 10' ' ' ILE . 14.9 t -100.65 144.12 30.01 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.884 -1.135 . . . . 0.0 110.884 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.97 14.54 24.51 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.389 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.429 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.59 84.23 0.61 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -1.201 . . . . 0.0 109.794 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.53 -26.34 13.34 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 108.903 -1.679 . . . . 0.0 108.903 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.499 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.96 -168.7 0.19 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.495 -1.003 . . . . 0.0 108.669 179.653 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.499 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.0 Cg_endo -87.32 110.95 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.14 1.074 . . . . 0.0 110.7 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.48 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -82.42 170.57 50.7 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' SER . 49.1 mt -126.48 142.64 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.516 -0.991 . . . . 0.0 108.416 178.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.505 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -128.77 114.75 16.97 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.721 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.444 ' HD3' HG11 ' A' ' 32' ' ' VAL . 18.2 mtp180 -105.27 122.88 46.86 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.423 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 32.0 p90 -121.72 158.06 29.58 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 110.662 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.623 ' O ' ' HB3' ' A' ' 134' ' ' ALA . 32.1 t -94.69 -56.97 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.278 -0.889 . . . . 0.0 109.455 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.623 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 69.08 145.19 0.1 Allowed Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.749 -0.594 . . . . 0.0 110.343 -179.576 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -78.32 -56.02 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.726 1.382 . . . . 0.0 110.506 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 136.85 -32.53 2.43 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.24 -161.12 1.26 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.257 -1.143 . . . . 0.0 110.317 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 9.8 ttt-85 . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 118.049 -0.977 . . . . 0.0 110.149 179.886 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 t -77.36 108.29 10.39 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.204 -1.174 . . . . 0.0 110.302 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.535 ' O ' HG23 ' A' ' 3' ' ' VAL . 19.2 m -113.32 104.26 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.278 -0.889 . . . . 0.0 109.878 179.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.2 p -63.59 139.87 58.81 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.382 -0.824 . . . . 0.0 110.497 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.44 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.81 148.38 96.47 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.361 -0.837 . . . . 0.0 109.717 179.677 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.44 ' HD2' HG23 ' A' ' 5' ' ' VAL . 45.6 Cg_endo -71.99 -165.72 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 124.136 1.598 . . . . 0.0 110.887 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.518 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 174.65 80.64 0.06 OUTLIER Pre-proline 0 N--CA 1.499 1.982 0 O-C-N 121.508 -0.745 . . . . 0.0 109.523 -179.617 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -75.18 55.23 3.98 Favored 'Trans proline' 0 C--N 1.313 -1.325 0 O-C-N 123.681 1.359 . . . . 0.0 111.427 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.466 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 -139.04 4.66 2.28 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.028 -1.045 . . . . 0.0 110.968 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.68 HD11 ' O ' ' A' ' 122' ' ' THR . 30.3 mt -129.0 137.28 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.867 -1.146 . . . . 0.0 109.707 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -82.75 127.81 33.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.056 -1.028 . . . . 0.0 109.207 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.89 139.32 30.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.3 -0.875 . . . . 0.0 110.553 -179.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.78 HG11 ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.75 156.55 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.215 -0.928 . . . . 0.0 110.14 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.34 109.86 21.71 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -0.889 . . . . 0.0 110.109 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.708 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.77 141.88 36.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.212 -0.93 . . . . 0.0 109.311 179.456 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.33 174.57 10.62 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 110.548 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.58 0.99 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.325 -0.86 . . . . 0.0 110.276 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.732 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.9 m -155.68 109.32 2.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.174 -0.954 . . . . 0.0 110.482 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.421 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.49 -171.35 28.89 Favored Glycine 0 N--CA 1.488 2.143 0 C-N-CA 118.891 -1.623 . . . . 0.0 111.181 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.54 -22.59 11.57 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.722 -0.87 . . . . 0.0 110.45 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.943 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -95.26 107.12 30.31 Favored Pre-proline 0 N--CA 1.488 1.475 0 C-N-CA 118.872 -1.131 . . . . 0.0 109.455 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.43 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -63.84 144.67 89.15 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.249 1.131 . . . . 0.0 111.34 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.421 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.73 -166.37 1.85 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.522 -0.736 . . . . 0.0 110.318 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.572 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.8 m-85 -59.92 82.03 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.403 -0.811 . . . . 0.0 111.051 -179.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.4 5.85 51.49 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.708 ' CB ' HD23 ' A' ' 15' ' ' LEU . 14.4 mmtm -130.64 156.68 44.47 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.941 -1.329 . . . . 0.0 109.778 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.732 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.64 16.77 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.062 -1.024 . . . . 0.0 109.106 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 1.051 HD11 HG21 ' A' ' 100' ' ' ILE . 6.2 mt -69.12 114.16 21.57 Favored Pre-proline 0 C--N 1.299 -1.596 0 O-C-N 121.367 -0.833 . . . . 0.0 110.798 -179.081 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.736 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.2 Cg_endo -69.73 132.12 22.72 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.13 -1.912 . . . . 0.0 107.13 176.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.78 HD11 HD12 ' A' ' 58' ' ' LEU . 13.2 mt -56.95 -14.95 4.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.961 -1.087 . . . . 0.0 111.219 -177.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -63.31 -16.16 59.5 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.539 -1.351 . . . . 0.0 110.51 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 10.6 m -93.86 -24.44 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.052 -1.03 . . . . 0.0 110.87 -179.406 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 48.3 pt -117.16 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.035 -1.041 . . . . 0.0 110.493 -179.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.635 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.98 148.41 24.56 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -0.903 . . . . 0.0 110.501 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.74 -5.17 46.99 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.27 -147.68 7.79 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.109 -1.52 . . . . 0.0 110.428 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.8 132.5 53.93 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.406 -1.055 . . . . 0.0 110.473 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.546 ' HB2' HG12 ' A' ' 81' ' ' VAL . 88.2 m-70 -140.77 149.0 41.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 0.0 110.603 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.583 HD12 ' O ' ' A' ' 82' ' ' VAL . 57.3 tp -111.0 113.59 26.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.441 -0.787 . . . . 0.0 109.803 179.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.891 HD12 HG12 ' A' ' 83' ' ' VAL . 29.2 mt -96.41 127.38 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.882 . . . . 0.0 109.662 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.51 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.2 m-85 -95.08 122.72 38.03 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.295 -0.878 . . . . 0.0 110.251 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.04 160.16 21.98 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.339 -0.85 . . . . 0.0 110.733 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.572 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p-80 -110.01 4.65 21.55 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.396 -0.815 . . . . 0.0 109.964 178.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.52 136.41 49.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 110.987 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.498 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.84 69.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.645 -0.66 . . . . 0.0 110.861 -179.866 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.74 -36.75 73.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.28 -0.888 . . . . 0.0 110.917 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.13 -35.39 80.36 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.313 -0.867 . . . . 0.0 109.574 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.923 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 53.2 m -61.48 -33.83 74.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.511 -0.743 . . . . 0.0 109.764 179.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.19 -50.22 61.77 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.283 -0.886 . . . . 0.0 110.967 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.22 -44.11 63.44 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.119 -0.988 . . . . 0.0 110.569 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.638 ' CD2' HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -56.99 -38.35 72.91 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.562 -0.711 . . . . 0.0 111.242 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.62 -51.15 13.49 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.871 -1.143 . . . . 0.0 110.633 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.46 -40.04 85.58 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.146 -0.971 . . . . 0.0 110.145 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.695 ' CE ' HD21 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.04 82.99 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.318 -0.864 . . . . 0.0 109.788 179.739 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.902 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.07 -38.92 71.29 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.643 -0.661 . . . . 0.0 110.093 179.818 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.3 t -58.62 -34.38 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.185 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.29 -30.66 60.47 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.436 -0.79 . . . . 0.0 109.965 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.78 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -72.01 -25.71 61.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.437 -0.789 . . . . 0.0 109.773 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.9 10.3 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.635 HD11 ' HB2' ' A' ' 34' ' ' LYS . 45.9 mt -108.03 143.23 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.298 -1.119 . . . . 0.0 109.75 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 51.8 t30 -89.84 106.39 18.44 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.698 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.18 142.59 46.62 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 118.924 -1.11 . . . . 0.0 111.729 -177.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.927 HG21 ' HA ' ' A' ' 73' ' ' VAL . 57.4 t -125.56 149.41 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 120.139 -0.624 . . . . 0.0 109.701 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.923 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.69 119.05 34.25 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.293 -0.963 . . . . 0.0 109.433 178.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.475 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.42 132.72 55.52 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.216 -0.927 . . . . 0.0 110.839 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.75 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -166.93 176.85 6.71 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.569 -0.707 . . . . 0.0 109.719 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.15 125.35 15.44 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.069 -1.02 . . . . 0.0 110.707 -179.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.7 37.4 19.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.838 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.44 157.24 26.57 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.031 -1.276 . . . . 0.0 110.12 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.838 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -96.53 149.23 21.98 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.29 -0.881 . . . . 0.0 110.555 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.655 ' O ' HG23 ' A' ' 71' ' ' VAL . 30.3 m -62.66 111.37 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.193 -0.942 . . . . 0.0 109.121 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.82 -35.39 1.09 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.389 -0.819 . . . . 0.0 110.733 -179.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.927 ' HA ' HG21 ' A' ' 63' ' ' VAL . 59.6 t -48.41 120.37 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.391 -0.818 . . . . 0.0 110.294 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.826 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp -137.53 109.99 8.79 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.235 -0.916 . . . . 0.0 110.608 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.638 ' HA ' HG11 ' A' ' 80' ' ' VAL . 50.3 Cg_endo -87.31 40.14 0.63 Allowed 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 123.327 1.172 . . . . 0.0 110.666 179.559 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.3 p -136.42 26.27 3.16 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.081 -1.012 . . . . 0.0 110.143 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.7 m-20 -135.44 27.27 3.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.216 -0.927 . . . . 0.0 110.172 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 111.4 -156.5 15.52 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.369 -1.492 . . . . 0.0 109.369 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.67 112.59 15.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.113 -1.228 . . . . 0.0 110.182 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.638 HG11 ' HA ' ' A' ' 75' ' ' PRO . 5.2 p -116.92 135.56 56.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-O 122.151 0.977 . . . . 0.0 110.568 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 11.9 m -112.88 119.94 61.72 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.072 0 O-C-N 121.228 -0.92 . . . . 0.0 108.844 178.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.662 HG22 HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.84 45.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 120.886 -1.134 . . . . 0.0 110.265 -178.041 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.891 HG12 HD12 ' A' ' 40' ' ' ILE . 3.2 m -109.06 100.53 10.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.146 -0.971 . . . . 0.0 108.691 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.475 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.36 162.24 35.49 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.765 -1.21 . . . . 0.0 110.979 -178.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.513 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -88.26 -131.34 0.07 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.347 -0.846 . . . . 0.0 109.612 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.513 ' N ' HG23 ' A' ' 85' ' ' THR . 44.9 p30 -91.4 29.28 1.49 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.694 -1.254 . . . . 0.0 110.55 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.62 -29.06 12.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.052 -1.03 . . . . 0.0 110.231 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -75.19 -33.49 61.43 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.144 -0.973 . . . . 0.0 109.742 179.674 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.404 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 1.6 mmt 51.1 -106.76 0.26 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.305 -0.872 . . . . 0.0 109.958 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.758 ' CB ' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.75 41.58 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.831 0 O-C-N 120.668 -1.27 . . . . 0.0 110.419 179.739 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.25 -32.4 51.08 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 108.639 -1.784 . . . . 0.0 108.639 179.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.481 ' CD1' ' N ' ' A' ' 92' ' ' PHE . 14.2 p90 -145.47 38.26 1.13 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.684 -0.892 . . . . 0.0 109.803 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.758 HG22 ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER -126.86 -162.4 1.15 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.323 -0.861 . . . . 0.0 110.209 -179.633 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.696 ' N ' HG23 ' A' ' 93' ' ' THR . . . 123.48 -40.47 1.97 Allowed Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.748 -1.215 . . . . 0.0 110.331 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -84.42 81.05 9.01 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.132 -1.217 . . . . 0.0 110.844 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.492 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 15.1 m-85 -119.77 147.98 43.97 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.111 -0.993 . . . . 0.0 110.115 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.495 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -71.11 -35.1 71.65 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.385 -0.822 . . . . 0.0 109.383 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.434 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.3 p -162.04 163.65 28.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.225 -0.922 . . . . 0.0 111.128 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.713 HG22 HG21 ' A' ' 122' ' ' THR . 1.3 m -129.36 118.1 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.52 -0.737 . . . . 0.0 110.091 179.378 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 1.051 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -92.6 111.98 25.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.14 160.26 21.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.171 -0.956 . . . . 0.0 111.718 -178.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.533 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.23 6.26 38.08 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.159 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.442 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.04 25.43 0.49 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.66 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -147.75 129.38 15.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.294 -0.879 . . . . 0.0 110.396 179.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 24.4 p -113.34 132.17 55.69 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.266 -0.896 . . . . 0.0 109.636 179.403 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.404 ' OD1' ' N ' ' A' ' 106' ' ' ASP . 1.5 m-20 54.5 -141.87 0.83 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.053 -1.03 . . . . 0.0 109.669 -179.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.76 17.99 41.88 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.0 mmtp -133.74 156.28 79.59 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.05 -1.264 . . . . 0.0 109.749 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.66 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.4 Cg_endo -64.61 159.82 43.03 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 O-C-N 123.662 1.348 . . . . 0.0 110.198 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.442 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 -57.16 153.33 11.97 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.22 -0.925 . . . . 0.0 110.713 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.543 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -90.73 160.78 15.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.342 -0.849 . . . . 0.0 110.285 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.37 -52.26 4.63 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.544 -0.722 . . . . 0.0 112.34 -178.728 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.543 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.79 -29.27 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.855 -1.153 . . . . 0.0 111.214 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.43 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.39 -56.21 7.37 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.112 -0.993 . . . . 0.0 110.509 -179.377 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.439 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.4 OUTLIER -68.84 -34.5 75.59 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.168 -0.957 . . . . 0.0 108.789 178.685 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.446 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 31.3 m -60.02 -49.92 75.76 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.183 -0.948 . . . . 0.0 108.533 178.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.64 -39.93 64.13 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.546 -0.721 . . . . 0.0 109.671 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.439 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 4.1 mtt180 -66.21 -44.75 83.01 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.184 -0.948 . . . . 0.0 110.018 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.518 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 13.5 ttm180 -64.06 -34.08 77.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.221 -0.925 . . . . 0.0 110.279 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.455 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.33 12.07 1.96 Allowed Glycine 0 N--CA 1.497 2.73 0 O-C-N 121.055 -1.028 . . . . 0.0 112.3 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.498 ' CZ ' HG21 ' A' ' 90' ' ' THR . 1.2 mmt85 -101.32 -5.19 25.76 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.296 -1.708 . . . . 0.0 109.461 178.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.713 HG21 HG22 ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.44 142.15 50.31 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.224 -0.923 . . . . 0.0 109.424 179.782 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 78.48 26.5 59.12 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.455 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.3 82.62 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.134 -1.215 . . . . 0.0 110.109 179.908 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.59 24.92 5.45 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.474 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.5 -1.0 . . . . 0.0 109.105 -179.628 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 45.8 Cg_endo -84.47 99.58 0.75 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.187 1.099 . . . . 0.0 109.551 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.436 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.82 176.58 52.18 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.48 143.95 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.45 -1.03 . . . . 0.0 109.968 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.535 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 9.6 t80 -129.4 116.9 19.73 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.176 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.78 ' NE ' HG11 ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.21 137.9 37.07 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.541 -0.725 . . . . 0.0 109.215 179.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.458 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.6 p90 -137.8 153.98 49.6 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 110.719 -179.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.85 -46.7 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.323 -0.861 . . . . 0.0 109.422 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.2 161.01 38.99 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 110.271 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.45 -27.37 15.94 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 O-C-N 123.776 1.409 . . . . 0.0 110.572 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 137.47 79.84 0.08 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -175.91 143.36 0.57 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.291 -1.123 . . . . 0.0 110.182 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.191 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.5 m -93.04 150.96 20.17 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.232 -1.158 . . . . 0.0 110.382 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.544 ' O ' HG23 ' A' ' 3' ' ' VAL . 21.0 m -113.37 104.73 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.388 -0.82 . . . . 0.0 110.013 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.824 HG22 ' OG1' ' A' ' 116' ' ' THR . 6.1 p -66.09 145.07 56.26 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.358 -0.839 . . . . 0.0 110.331 -179.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.683 HG22 ' HD1' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -70.2 147.82 95.58 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.215 -0.928 . . . . 0.0 109.819 179.841 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.519 ' HD2' HG23 ' A' ' 5' ' ' VAL . 38.8 Cg_endo -73.11 -64.67 0.03 OUTLIER 'Trans proline' 0 C--N 1.309 -1.517 0 O-C-N 124.096 1.577 . . . . 0.0 112.445 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.683 ' HD1' HG22 ' A' ' 5' ' ' VAL . 47.8 p-80 41.26 87.24 0.12 Allowed Pre-proline 0 N--CA 1.492 1.652 0 CA-C-O 121.231 0.539 . . . . 0.0 111.294 -178.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.9 0.72 8.51 Favored 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.463 1.244 . . . . 0.0 111.556 -179.211 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 -52.41 -22.13 4.37 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.803 -1.186 . . . . 0.0 110.436 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.458 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 31.1 mt -111.86 135.2 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.973 -1.079 . . . . 0.0 110.277 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.19 129.07 34.87 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.188 -0.945 . . . . 0.0 109.726 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.44 33.57 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.077 -1.014 . . . . 0.0 110.501 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.7 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 17.2 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.91 114.93 29.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.15 -0.968 . . . . 0.0 110.371 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.54 HD23 HG22 ' A' ' 133' ' ' VAL . 12.3 tp -63.2 135.65 57.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.151 -0.968 . . . . 0.0 109.607 179.561 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.3 p -134.78 171.58 14.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.093 -1.004 . . . . 0.0 110.602 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.532 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -149.21 112.68 5.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.353 -0.842 . . . . 0.0 110.349 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.33 -161.68 27.28 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.674 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.3 mm-40 -122.05 -22.35 5.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.724 -0.868 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.931 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -93.51 112.82 58.28 Favored Pre-proline 0 N--CA 1.488 1.426 0 C-N-CA 118.598 -1.241 . . . . 0.0 110.335 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -64.85 141.26 70.66 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.597 1.314 . . . . 0.0 109.977 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.459 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.91 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.101 -0.999 . . . . 0.0 111.732 -178.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.574 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.08 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.534 -0.729 . . . . 0.0 111.558 178.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 12.07 25.88 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.468 ' CB ' HD23 ' A' ' 15' ' ' LEU . 10.2 mmtt -129.91 156.63 44.1 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.055 -1.262 . . . . 0.0 109.235 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.532 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.93 15.11 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.873 -1.142 . . . . 0.0 108.891 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.931 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -70.88 114.97 31.3 Favored Pre-proline 0 C--N 1.296 -1.733 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.045 -179.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.845 ' O ' HG22 ' A' ' 32' ' ' VAL . 38.9 Cg_endo -67.51 130.32 22.01 Favored 'Trans proline' 0 C--N 1.302 -1.878 0 N-CA-C 107.465 -1.783 . . . . 0.0 107.465 176.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.769 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.32 -16.41 5.5 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.939 -1.101 . . . . 0.0 110.628 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.21 -16.22 59.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.671 -1.268 . . . . 0.0 110.576 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -92.68 -25.21 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 120.934 -1.104 . . . . 0.0 111.074 -179.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 30.7 pt -116.41 -29.73 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.218 -0.926 . . . . 0.0 109.843 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.622 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.35 148.15 24.4 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.294 -0.879 . . . . 0.0 110.385 179.404 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.12 -5.21 49.46 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.09 -152.52 11.25 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.122 -1.514 . . . . 0.0 110.533 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.18 128.61 50.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.469 -1.018 . . . . 0.0 110.436 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.628 ' HB2' HG12 ' A' ' 81' ' ' VAL . 54.6 m80 -139.47 149.93 44.58 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 110.474 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.577 HD12 ' HB ' ' A' ' 82' ' ' VAL . 19.9 tp -111.85 117.26 32.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.403 -0.811 . . . . 0.0 110.403 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.893 ' CG1' HG12 ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.12 48.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.307 -0.871 . . . . 0.0 108.997 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.433 ' CZ ' ' HG2' ' A' ' 118' ' ' ARG . 5.8 m-85 -94.84 122.0 37.02 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.98 -1.075 . . . . 0.0 110.059 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.35 159.37 23.53 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.409 -0.807 . . . . 0.0 110.442 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.574 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.69 18.17 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.413 -0.805 . . . . 0.0 109.617 178.465 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.53 141.35 47.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.093 -1.005 . . . . 0.0 110.476 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.09 -35.69 69.3 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.535 -0.728 . . . . 0.0 110.549 -179.912 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.17 -45.38 88.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.303 -0.873 . . . . 0.0 110.591 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.14 -38.32 85.98 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.409 -0.807 . . . . 0.0 109.613 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.934 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.2 -34.19 74.68 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.488 -0.757 . . . . 0.0 109.56 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.24 -48.68 69.75 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.208 -0.933 . . . . 0.0 110.784 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.427 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.26 -44.61 64.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.204 -0.935 . . . . 0.0 110.472 -179.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 1.044 HD12 HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.64 77.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.319 -0.863 . . . . 0.0 111.002 -179.058 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.434 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.16 -51.41 21.43 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.059 -1.026 . . . . 0.0 110.484 -179.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.09 -43.46 98.47 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.93 . . . . 0.0 110.039 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.623 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.2 -46.16 83.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.171 -0.956 . . . . 0.0 109.526 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.747 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.76 -40.96 73.3 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.537 -0.727 . . . . 0.0 110.176 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.0 t -57.33 -35.34 48.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.984 -1.073 . . . . 0.0 108.978 179.425 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -31.26 59.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.352 -0.842 . . . . 0.0 110.243 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.769 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.32 -25.8 62.56 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.94 0.876 . . . . 0.0 109.75 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.41 5.77 10.11 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.662 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.7 mt -108.03 143.29 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.468 -1.019 . . . . 0.0 110.08 -179.532 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.508 ' ND2' HD11 ' A' ' 74' ' ' ILE . 45.9 t30 -89.52 106.64 18.59 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.741 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.77 144.4 46.31 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.708 -177.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.928 HG21 ' HA ' ' A' ' 73' ' ' VAL . 48.8 t -127.84 145.91 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.881 -0.727 . . . . 0.0 109.646 179.243 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.934 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -110.09 119.42 39.24 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.877 178.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.518 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 4.1 t80 -116.45 127.26 54.43 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.229 -0.92 . . . . 0.0 110.655 -179.667 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.835 ' CE1' HD23 ' A' ' 69' ' ' LEU . 1.2 p90 -153.22 -171.4 3.91 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.402 -0.811 . . . . 0.0 110.013 179.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.56 126.9 21.03 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.308 -0.87 . . . . 0.0 111.276 -179.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.85 48.63 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.835 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.73 155.0 30.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.978 -1.307 . . . . 0.0 109.958 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.818 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.3 m-20 -90.75 149.49 21.99 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.37 -0.832 . . . . 0.0 110.694 -179.18 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.683 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.4 m -62.54 110.94 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.145 -0.972 . . . . 0.0 109.586 179.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.44 ' O ' HG23 ' A' ' 74' ' ' ILE . 34.5 m -132.11 -23.82 2.16 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.383 -0.823 . . . . 0.0 111.178 -179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.928 ' HA ' HG21 ' A' ' 63' ' ' VAL . 22.6 t -60.1 138.73 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.133 -0.979 . . . . 0.0 110.082 -179.475 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.508 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.2 pp -137.11 100.49 9.59 Favored Pre-proline 0 N--CA 1.495 1.797 0 O-C-N 121.203 -0.935 . . . . 0.0 110.541 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.647 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.4 Cg_endo -88.19 36.92 0.43 Allowed 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.608 1.32 . . . . 0.0 110.537 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.47 16.43 6.52 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.099 -1.001 . . . . 0.0 110.655 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.459 ' HB2' HD12 ' A' ' 74' ' ' ILE . 1.8 m-80 -116.18 -165.37 1.04 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.023 -1.048 . . . . 0.0 110.042 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.83 -87.56 0.01 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -131.85 115.02 15.39 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.192 -1.181 . . . . 0.0 110.379 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.647 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.1 p -116.88 133.75 62.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 CA-C-O 122.039 0.923 . . . . 0.0 110.425 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.628 HG12 ' HB2' ' A' ' 38' ' ' HIS . 6.1 m -113.54 123.56 69.32 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 O-C-N 121.502 -0.749 . . . . 0.0 109.021 179.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.721 HG22 HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.51 118.04 43.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.958 -1.089 . . . . 0.0 110.649 -177.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.044 HG11 HD12 ' A' ' 51' ' ' LEU . 3.4 m -106.64 100.45 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.009 -1.057 . . . . 0.0 108.634 179.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.518 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -144.19 162.39 36.45 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.667 -1.27 . . . . 0.0 111.239 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -92.9 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.476 -0.765 . . . . 0.0 108.988 179.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.443 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -86.36 50.06 1.92 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.72 -1.237 . . . . 0.0 109.931 179.416 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.68 -18.63 9.61 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.22 -0.925 . . . . 0.0 110.583 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.462 ' HA ' HD12 ' A' ' 88' ' ' LEU . 14.2 tp -62.43 -23.55 66.93 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.031 -1.043 . . . . 0.0 109.71 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.542 ' C ' HG22 ' A' ' 90' ' ' THR . 0.4 OUTLIER 46.29 28.35 0.68 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.42 -0.8 . . . . 0.0 110.733 179.736 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.768 ' OG1' HG22 ' A' ' 93' ' ' THR . 5.8 t 35.11 -126.34 0.11 Allowed 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 178.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.446 ' N ' HG23 ' A' ' 90' ' ' THR . . . 90.75 -51.25 3.24 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 -178.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -133.19 23.68 4.15 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.552 -0.97 . . . . 0.0 109.432 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.768 HG22 ' OG1' ' A' ' 90' ' ' THR . 3.7 t -98.95 -156.33 0.54 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.433 -0.792 . . . . 0.0 110.695 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.531 ' N ' HG23 ' A' ' 93' ' ' THR . . . 94.12 -24.99 24.34 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.196 -1.162 . . . . 0.0 110.196 179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -87.15 60.92 6.44 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.024 -1.28 . . . . 0.0 110.844 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.493 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 20.8 m-85 -119.66 146.6 45.43 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.015 -1.053 . . . . 0.0 110.345 179.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.33 -34.81 58.98 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.516 -0.74 . . . . 0.0 109.508 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.441 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -160.89 163.02 32.26 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.249 -0.907 . . . . 0.0 110.778 179.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.554 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.29 118.15 45.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.21 -0.931 . . . . 0.0 110.131 179.375 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.71 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -95.96 117.73 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.462 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.427 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 18.8 t0 -124.46 161.36 26.21 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.137 -0.977 . . . . 0.0 111.851 -178.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.91 -6.81 34.84 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 177.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 55.7 15.36 1.56 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.319 -0.863 . . . . 0.0 111.654 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.496 HG23 ' C ' ' A' ' 107' ' ' GLY . 1.1 m -143.4 120.15 11.19 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 120.731 -1.231 . . . . 0.0 109.535 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.479 ' N ' ' O ' ' A' ' 108' ' ' LYS . 8.9 p -96.92 121.74 39.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.312 -0.868 . . . . 0.0 110.348 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 13.5 t0 60.78 32.84 20.19 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.311 -0.868 . . . . 0.0 110.736 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.496 ' C ' HG23 ' A' ' 104' ' ' THR . . . 92.34 -28.27 9.23 Favored Glycine 0 N--CA 1.492 2.394 0 C-N-CA 119.907 -1.14 . . . . 0.0 110.262 179.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -88.36 155.78 51.37 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.044 -1.268 . . . . 0.0 110.109 -179.765 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.88 128.47 22.07 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.506 1.266 . . . . 0.0 110.777 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER -46.36 168.73 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.588 -0.695 . . . . 0.0 111.163 -179.439 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.523 ' OD1' HG22 ' A' ' 113' ' ' VAL . 3.0 p30 -87.77 160.98 17.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.333 -0.854 . . . . 0.0 110.292 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.15 3.75 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.339 -0.851 . . . . 0.0 111.832 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.523 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.66 -29.76 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.932 -1.105 . . . . 0.0 111.794 -178.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.408 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.27 -56.1 7.42 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.083 -1.011 . . . . 0.0 110.426 -179.142 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.471 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.35 -32.87 72.22 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.224 -0.922 . . . . 0.0 108.848 178.808 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.824 ' OG1' HG22 ' A' ' 4' ' ' THR . 25.3 m -61.11 -49.8 75.81 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.109 -0.994 . . . . 0.0 108.409 178.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.97 -36.3 64.56 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.918 -0.713 . . . . 0.0 109.807 178.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HG2' ' CZ ' ' A' ' 41' ' ' PHE . 49.1 mtt-85 -71.68 -44.47 64.19 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.255 -0.903 . . . . 0.0 111.117 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.483 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 19.5 ttm180 -56.7 -41.03 76.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.891 -1.131 . . . . 0.0 109.93 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.06 71.43 0.19 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.456 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.72 -45.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.593 -0.945 . . . . 0.0 108.836 179.488 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.518 HG23 ' HA3' ' A' ' 128' ' ' GLY . 9.2 t -101.14 143.01 31.76 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.598 -0.689 . . . . 0.0 109.393 178.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.52 4.0 22.02 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.184 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -71.01 85.38 0.71 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.995 -1.297 . . . . 0.0 109.822 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 104.08 9.79 35.99 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 3.6 pttt -174.96 -173.76 0.22 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.318 -1.107 . . . . 0.0 108.659 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.469 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.0 Cg_endo -88.15 105.33 0.51 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.22 1.116 . . . . 0.0 110.297 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.518 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.42 170.45 53.61 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.706 -1.235 . . . . 0.0 110.102 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -126.79 142.55 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.535 -0.979 . . . . 0.0 108.862 179.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.554 ' CD2' HG23 ' A' ' 99' ' ' VAL . 6.3 t80 -129.33 115.18 17.18 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.982 -1.073 . . . . 0.0 110.578 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.7 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.68 122.85 42.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.47 -0.768 . . . . 0.0 109.273 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 24.0 p90 -121.41 148.7 44.05 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.05 -1.031 . . . . 0.0 110.262 -179.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.54 HG22 HD23 ' A' ' 15' ' ' LEU . 46.1 t -74.65 -31.69 27.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.137 -0.977 . . . . 0.0 109.524 179.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -127.69 134.0 25.71 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.142 -0.974 . . . . 0.0 110.076 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -74.45 -18.79 19.93 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.529 1.278 . . . . 0.0 110.707 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.425 ' O ' ' N ' ' A' ' 138' ' ' ARG . . . 108.03 -42.59 1.9 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 55.1 -88.22 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.531 -0.981 . . . . 0.0 110.564 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.425 ' N ' ' O ' ' A' ' 136' ' ' GLY . 9.8 ptt85 . . . . . 0 N--CA 1.492 1.63 0 O-C-N 120.996 -1.065 . . . . 0.0 110.312 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.8 m -117.09 140.1 49.92 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.243 -1.151 . . . . 0.0 110.303 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.628 ' O ' HG13 ' A' ' 3' ' ' VAL . 7.1 p -112.84 104.83 17.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.285 -0.885 . . . . 0.0 109.761 179.657 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 71.7 p -62.87 141.79 58.53 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.336 -0.852 . . . . 0.0 110.337 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.458 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -66.9 148.84 98.74 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.326 -0.859 . . . . 0.0 109.303 179.79 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.458 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.2 Cg_endo -69.07 -172.01 0.47 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 124.057 1.556 . . . . 0.0 110.883 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.533 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.2 OUTLIER 175.68 75.09 0.07 OUTLIER Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.513 -0.742 . . . . 0.0 109.54 -179.718 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.65 -13.51 32.5 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.827 1.436 . . . . 0.0 110.687 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.446 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 -59.86 -18.08 41.55 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.062 -1.024 . . . . 0.0 110.19 179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.445 HD11 ' O ' ' A' ' 122' ' ' THR . 40.8 mt -117.52 136.39 54.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.058 -1.026 . . . . 0.0 110.533 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.164 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 110.382 -179.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.49 156.3 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.439 -0.788 . . . . 0.0 110.05 -179.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.01 111.49 24.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.276 -0.89 . . . . 0.0 110.169 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.438 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.16 136.17 48.71 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.358 -0.839 . . . . 0.0 109.877 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.97 173.83 11.28 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.132 -0.98 . . . . 0.0 110.22 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.9 p -67.57 74.32 0.16 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.17 -0.956 . . . . 0.0 109.814 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.634 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.8 m -145.59 109.55 4.84 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.379 -0.826 . . . . 0.0 110.388 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.7 27.93 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 119.003 -1.57 . . . . 0.0 110.671 179.567 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.04 -25.01 5.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.696 -0.884 . . . . 0.0 110.561 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.34 52.55 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.172 -179.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.438 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -64.79 143.01 78.8 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.5 1.263 . . . . 0.0 110.158 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.5 t80 -155.23 94.84 1.66 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 111.286 -178.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.433 ' CZ ' ' CE1' ' A' ' 43' ' ' HIS . 23.7 m-85 57.66 67.07 1.01 Allowed 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.535 -0.728 . . . . 0.0 111.611 179.058 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.5 13.33 16.4 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 22.2 mmtm -130.6 156.99 43.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.142 -1.211 . . . . 0.0 109.185 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.634 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.6 107.52 16.26 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.906 -1.121 . . . . 0.0 109.827 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.5 mt -69.97 113.39 17.28 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 121.372 -0.83 . . . . 0.0 109.894 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.781 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.8 Cg_endo -68.99 128.88 17.41 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 N-CA-C 106.993 -1.964 . . . . 0.0 106.993 176.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.59 HD11 HD12 ' A' ' 58' ' ' LEU . 6.2 mt -56.61 -15.98 5.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.854 -1.154 . . . . 0.0 111.137 -177.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.425 ' OE2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.43 62.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.65 -1.281 . . . . 0.0 110.869 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.069 HG23 HG23 ' A' ' 33' ' ' ILE . 15.1 m -89.68 -26.5 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.922 -1.111 . . . . 0.0 111.134 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.069 HG23 HG23 ' A' ' 32' ' ' VAL . 43.3 pt -116.94 -23.68 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.165 -0.96 . . . . 0.0 110.048 -179.626 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.597 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.59 148.35 22.15 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.174 -0.954 . . . . 0.0 110.596 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.23 51.73 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.18 -151.61 9.86 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.211 -1.471 . . . . 0.0 110.208 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.57 130.72 54.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -1.078 . . . . 0.0 110.208 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.56 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.9 m80 -140.81 148.81 41.19 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.117 -0.99 . . . . 0.0 110.983 -179.698 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 20.2 tp -109.76 123.18 49.09 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.274 -0.891 . . . . 0.0 109.924 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.94 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.8 mt -104.78 128.73 58.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.286 -0.883 . . . . 0.0 108.876 179.225 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.424 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.3 122.86 37.28 Favored 'General case' 0 C--N 1.294 -1.844 0 O-C-N 121.241 -0.912 . . . . 0.0 110.348 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.83 160.05 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.335 -0.853 . . . . 0.0 110.8 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.433 ' CE1' ' CZ ' ' A' ' 24' ' ' TYR . 3.9 p-80 -115.51 5.23 14.39 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.575 -0.703 . . . . 0.0 109.799 178.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.74 138.14 45.61 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.007 . . . . 0.0 110.878 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.509 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.69 -43.35 66.11 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.709 -0.619 . . . . 0.0 110.53 -179.931 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.66 -34.5 74.4 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.325 -0.859 . . . . 0.0 110.564 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.21 -38.19 66.18 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.233 -0.917 . . . . 0.0 109.911 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.942 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 61.5 m -61.4 -34.48 75.43 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.521 -0.737 . . . . 0.0 109.892 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.24 -49.72 58.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 110.381 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.01 -46.38 57.41 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.246 -0.909 . . . . 0.0 110.274 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.798 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -56.92 -42.65 80.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.976 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.475 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -73.38 -50.85 19.74 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.01 -1.056 . . . . 0.0 110.651 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -40.5 97.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.038 -1.039 . . . . 0.0 109.733 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.541 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.24 -43.1 82.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.315 -0.866 . . . . 0.0 109.434 179.394 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.727 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -55.34 -42.87 74.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.39 -0.819 . . . . 0.0 109.749 179.577 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.14 -32.58 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.155 -0.966 . . . . 0.0 108.716 179.043 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.52 -32.08 60.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.571 -0.706 . . . . 0.0 110.013 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.59 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.52 -26.26 62.58 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.298 -0.876 . . . . 0.0 109.595 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 5.47 9.45 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.597 HD11 ' HB2' ' A' ' 34' ' ' LYS . 51.8 mt -108.26 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.303 -1.116 . . . . 0.0 110.069 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 36.7 t30 -86.65 107.04 18.02 Favored 'General case' 0 N--CA 1.484 1.261 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.727 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.03 147.74 45.71 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.541 -177.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.952 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.8 t -135.73 142.43 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.518 179.278 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.942 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -105.35 135.05 47.44 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.244 -0.983 . . . . 0.0 109.871 179.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.447 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.62 131.29 49.93 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.12 -0.987 . . . . 0.0 110.792 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.685 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.6 p90 -166.25 175.33 8.39 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.66 -0.65 . . . . 0.0 109.515 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.74 114.89 1.41 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.249 -0.907 . . . . 0.0 110.799 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.77 31.45 7.77 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.916 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.53 157.31 26.55 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.064 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.916 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.3 m-20 -96.91 149.45 21.86 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.195 -0.941 . . . . 0.0 110.508 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.677 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.3 m -62.64 111.25 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.189 -0.945 . . . . 0.0 109.162 179.224 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.638 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.6 m -133.63 -32.19 1.15 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.337 -0.852 . . . . 0.0 111.08 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.952 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.4 t -53.73 137.94 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.193 -0.942 . . . . 0.0 109.825 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.638 HG23 ' O ' ' A' ' 72' ' ' SER . 1.2 pp -137.76 101.0 8.87 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.223 -0.923 . . . . 0.0 111.169 -179.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -82.1 53.45 4.56 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.462 1.243 . . . . 0.0 110.109 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.8 p -149.63 22.36 0.91 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.047 -1.033 . . . . 0.0 110.918 -179.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -123.18 -165.85 1.38 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.021 -1.049 . . . . 0.0 110.135 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.67 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -126.36 113.04 16.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.159 -1.201 . . . . 0.0 110.153 179.561 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 12.0 p -117.86 133.16 65.52 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.089 0.947 . . . . 0.0 110.111 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.59 HG22 HG22 ' A' ' 60' ' ' ILE . 4.7 m -113.87 125.45 71.16 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.369 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.088 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.681 HG22 HG13 ' A' ' 73' ' ' VAL . 9.1 t -97.18 121.17 47.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 121.008 -1.058 . . . . 0.0 110.133 -178.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.94 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.2 m -114.88 100.07 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.706 -1.246 . . . . 0.0 108.586 179.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.447 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.27 163.99 33.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.667 -1.271 . . . . 0.0 111.659 -177.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.481 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -84.11 -138.56 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.597 -0.689 . . . . 0.0 109.6 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.481 ' N ' HG23 ' A' ' 85' ' ' THR . 0.7 OUTLIER -87.53 14.4 8.33 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.799 -1.188 . . . . 0.0 110.613 179.817 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.476 ' H ' HG23 ' A' ' 85' ' ' THR . . . -86.54 -21.82 26.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.989 -1.069 . . . . 0.0 110.181 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.55 -24.55 53.61 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.128 -0.983 . . . . 0.0 110.143 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.409 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 52.56 -157.03 0.15 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.354 -179.198 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.617 ' CB ' HG22 ' A' ' 93' ' ' THR . 0.1 OUTLIER -147.72 29.16 0.93 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.035 -1.041 . . . . 0.0 110.071 179.717 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.64 -39.54 61.1 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -130.03 25.16 5.27 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.43 -1.041 . . . . 0.0 110.463 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.617 HG22 ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER -108.31 -171.08 1.79 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.146 -0.971 . . . . 0.0 109.81 179.684 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.557 ' N ' HG23 ' A' ' 93' ' ' THR . . . 121.77 -26.87 6.4 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.964 -1.255 . . . . 0.0 109.964 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -83.94 65.8 8.84 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.927 -1.337 . . . . 0.0 110.201 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.47 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 24.1 m-85 -119.38 144.36 46.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.23 -0.919 . . . . 0.0 110.339 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.424 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 6.5 m-20 -78.95 -31.66 45.18 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.694 179.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -161.56 163.15 30.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.294 -0.879 . . . . 0.0 110.768 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.523 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.45 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.271 -0.893 . . . . 0.0 110.08 179.27 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.887 HG21 HD11 ' A' ' 28' ' ' ILE . 3.0 mp -93.41 119.18 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.276 -0.89 . . . . 0.0 109.14 179.349 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' A' ' 41' ' ' PHE . 2.4 t70 -128.47 160.58 31.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.121 -0.987 . . . . 0.0 111.599 -178.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.45 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.96 -5.14 31.14 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 177.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.15 14.02 1.38 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.285 -0.884 . . . . 0.0 111.723 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.416 HG23 ' O ' ' A' ' 108' ' ' LYS . 1.3 m -141.61 127.94 19.91 Favored 'General case' 0 C--N 1.307 -1.242 0 O-C-N 120.678 -1.264 . . . . 0.0 109.043 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.478 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -109.18 124.43 50.83 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.304 -0.873 . . . . 0.0 110.657 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 58.23 34.73 24.38 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.348 -0.845 . . . . 0.0 111.262 179.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.85 -33.94 4.78 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.841 -1.171 . . . . 0.0 110.342 179.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -86.21 155.29 57.6 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.158 -1.201 . . . . 0.0 110.067 -179.858 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -64.91 138.49 57.76 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 123.366 1.193 . . . . 0.0 110.747 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -50.32 156.7 0.8 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.545 -0.722 . . . . 0.0 110.99 -179.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.506 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.8 p-10 -73.82 162.88 28.65 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.558 -0.714 . . . . 0.0 110.287 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.449 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.24 -44.8 92.33 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.877 -1.14 . . . . 0.0 111.6 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.506 HG22 ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.76 -30.66 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.716 -1.24 . . . . 0.0 112.74 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 2.6 p -53.6 -55.25 27.39 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.449 -1.407 . . . . 0.0 110.162 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.449 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.64 -35.33 75.92 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.048 178.435 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.415 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 26.2 m -62.07 -50.35 72.32 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 119.369 -0.932 . . . . 0.0 108.581 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.25 -46.83 39.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.322 -0.861 . . . . 0.0 109.982 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 114' ' ' SER . 60.2 mtt180 -61.3 -45.29 95.06 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.268 -0.895 . . . . 0.0 110.967 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.533 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 11.9 ttm180 -55.55 -38.68 69.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.694 -1.254 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.78 0.28 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.61 -50.81 0.24 Allowed 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.468 -1.019 . . . . 0.0 108.632 179.666 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.487 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -94.79 142.35 27.57 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.484 1.891 0 C-N-CA 119.335 -1.412 . . . . 0.0 110.574 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.448 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -62.2 86.19 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.883 -1.363 . . . . 0.0 109.931 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.89 -43.01 1.75 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 -179.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.472 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 12.9 mttt -111.0 -171.68 0.22 Allowed Pre-proline 0 N--CA 1.487 1.392 0 O-C-N 121.611 -0.935 . . . . 0.0 109.454 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.457 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.9 Cg_endo -90.75 107.79 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.61 1.321 . . . . 0.0 109.786 179.044 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.487 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.33 166.07 50.92 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 -179.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.429 ' O ' ' HA ' ' A' ' 98' ' ' SER . 4.0 mt -119.55 140.49 43.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.227 179.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.523 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.6 t80 -128.73 114.93 17.21 Favored 'General case' 0 C--N 1.3 -1.585 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.139 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.418 ' NE ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -99.38 134.28 42.48 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 109.665 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.474 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.16 148.26 50.59 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.157 -0.964 . . . . 0.0 109.803 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.45 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.1 t -79.89 -54.16 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.068 -1.02 . . . . 0.0 110.042 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -89.5 134.98 31.52 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.218 -0.926 . . . . 0.0 110.121 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.23 -51.87 0.13 Allowed 'Trans proline' 0 C--N 1.311 -1.398 0 O-C-N 123.533 1.28 . . . . 0.0 110.373 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.31 -69.34 0.42 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 53.47 96.32 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.25 -1.147 . . . . 0.0 110.077 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 117.925 -1.036 . . . . 0.0 110.195 -179.885 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.2 m -115.02 128.33 56.2 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -1.155 . . . . 0.0 110.239 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 63.6 t -113.19 104.21 16.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.262 -0.899 . . . . 0.0 110.174 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.524 HG22 ' OG1' ' A' ' 116' ' ' THR . 69.1 p -72.16 146.1 47.63 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.497 -0.752 . . . . 0.0 110.108 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.649 HG22 ' HD2' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -66.47 148.42 98.61 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.18 -0.95 . . . . 0.0 109.75 -179.867 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.536 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.9 Cg_endo -80.3 -59.74 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.442 0 O-C-N 124.21 1.637 . . . . 0.0 112.392 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.649 ' HD2' HG22 ' A' ' 5' ' ' VAL . 20.4 p80 39.3 89.28 0.08 OUTLIER Pre-proline 0 N--CA 1.492 1.655 0 CA-C-O 121.063 0.458 . . . . 0.0 111.466 -178.347 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -74.7 57.26 4.31 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.289 1.152 . . . . 0.0 110.925 -179.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.8 m120 -119.95 -18.82 8.09 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.264 -0.897 . . . . 0.0 110.29 179.686 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.832 HD13 HG23 ' A' ' 122' ' ' THR . 62.2 mt -108.75 136.64 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.044 -1.035 . . . . 0.0 110.141 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.43 127.94 34.1 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.188 -0.945 . . . . 0.0 109.25 179.152 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.72 135.66 33.49 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.159 -0.963 . . . . 0.0 110.185 -179.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.8 t -137.22 156.41 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.286 -0.884 . . . . 0.0 110.423 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.33 113.83 26.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 0.0 109.83 179.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.647 HD23 ' CB ' ' A' ' 26' ' ' LYS . 8.8 tp -52.78 142.58 18.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.161 -0.962 . . . . 0.0 110.111 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 p -138.22 174.36 10.64 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.262 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.2 71.91 1.71 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.289 -0.882 . . . . 0.0 109.969 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.753 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -144.19 110.15 5.36 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 110.513 -179.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.77 -171.44 26.75 Favored Glycine 0 N--CA 1.488 2.145 0 C-N-CA 118.876 -1.631 . . . . 0.0 110.859 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -108.95 -26.18 10.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.65 -0.912 . . . . 0.0 110.394 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.979 HD12 HD13 ' A' ' 55' ' ' LEU . 8.0 tt -95.27 101.53 7.69 Favored Pre-proline 0 N--CA 1.487 1.403 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.357 -179.38 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 36.5 Cg_endo -61.29 155.29 52.6 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.516 1.272 . . . . 0.0 110.228 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.589 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.75 94.48 0.5 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.091 -1.005 . . . . 0.0 111.309 -178.024 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.589 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 60.0 68.28 0.79 Allowed 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.407 -0.808 . . . . 0.0 111.673 178.808 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 14.6 11.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.647 ' CB ' HD23 ' A' ' 15' ' ' LEU . 21.4 mmtt -130.73 156.69 44.52 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.082 -1.246 . . . . 0.0 109.2 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.753 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.24 108.07 16.11 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.986 -1.071 . . . . 0.0 109.086 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 1.088 HD11 HG21 ' A' ' 100' ' ' ILE . 5.1 mt -71.31 113.33 18.47 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.529 -0.868 . . . . 0.0 110.117 -179.384 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.89 ' O ' HG22 ' A' ' 32' ' ' VAL . 43.0 Cg_endo -71.04 129.69 16.64 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.053 -1.941 . . . . 0.0 107.053 176.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.489 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.8 mt -55.77 -18.82 9.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.808 -1.182 . . . . 0.0 110.545 -177.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.426 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -15.97 23.69 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.628 -1.295 . . . . 0.0 110.332 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.069 HG23 HG23 ' A' ' 33' ' ' ILE . 16.2 m -93.36 -25.36 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.882 -1.136 . . . . 0.0 111.057 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.069 HG23 HG23 ' A' ' 32' ' ' VAL . 21.4 pt -117.9 -16.17 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.01 -1.056 . . . . 0.0 110.923 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.566 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -97.82 148.49 23.34 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.844 -1.16 . . . . 0.0 110.083 179.534 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.17 -4.14 51.81 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.65 -159.08 23.37 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.347 -1.406 . . . . 0.0 110.082 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.89 133.45 44.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.275 -1.132 . . . . 0.0 110.547 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.76 147.01 40.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.098 -1.001 . . . . 0.0 110.703 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.592 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.2 tp -108.54 113.74 27.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.417 -0.802 . . . . 0.0 109.998 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.784 HD12 HG12 ' A' ' 83' ' ' VAL . 25.9 mt -96.54 126.89 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.341 -0.85 . . . . 0.0 109.409 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.504 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 34.0 m-85 -95.23 123.75 38.9 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.41 -0.806 . . . . 0.0 109.978 -179.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.01 160.23 21.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.192 -0.943 . . . . 0.0 110.606 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.545 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 4.3 p-80 -107.18 -3.81 19.46 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.439 -0.788 . . . . 0.0 110.175 179.1 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.65 50.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.066 -1.021 . . . . 0.0 110.779 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.516 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.53 -41.38 69.24 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.81 -0.556 . . . . 0.0 110.646 -179.765 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mttp -58.79 -35.27 72.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.195 -0.941 . . . . 0.0 110.109 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.26 -34.86 66.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.347 -0.846 . . . . 0.0 109.427 179.656 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.811 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 91.9 m -60.7 -34.23 74.05 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.511 -0.743 . . . . 0.0 109.58 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.06 -49.16 63.04 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.17 -0.956 . . . . 0.0 110.246 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.417 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.7 -42.68 67.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.258 -0.901 . . . . 0.0 110.599 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.775 HD12 HG11 ' A' ' 83' ' ' VAL . 1.1 tm? -57.23 -41.1 78.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.427 -0.796 . . . . 0.0 111.295 -179.018 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.95 -51.48 12.33 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.874 -1.141 . . . . 0.0 110.528 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.6 89.78 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.996 -1.065 . . . . 0.0 109.48 179.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.531 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.98 -45.77 86.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.475 -0.766 . . . . 0.0 109.559 179.337 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.979 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.83 -42.0 75.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 109.898 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.8 t -56.35 -33.71 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.091 -1.006 . . . . 0.0 109.181 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.24 -32.05 61.01 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.32 -0.862 . . . . 0.0 109.863 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.531 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.69 -26.2 62.41 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.379 -0.826 . . . . 0.0 109.529 179.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.52 6.09 8.94 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.618 HG22 HG22 ' A' ' 81' ' ' VAL . 30.6 mt -108.25 143.72 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.254 -1.145 . . . . 0.0 110.143 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.621 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.3 t30 -87.07 107.3 18.38 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.608 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.22 147.33 45.76 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.744 -177.274 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.88 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.6 t -134.75 150.0 29.9 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.916 -0.714 . . . . 0.0 109.326 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.811 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.47 136.4 52.83 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.011 179.078 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.577 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.1 t80 -123.47 128.12 49.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.911 . . . . 0.0 110.742 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.849 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.12 -179.94 8.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.515 -0.741 . . . . 0.0 109.858 179.63 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.73 11.0 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.238 -0.913 . . . . 0.0 111.012 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.76 47.73 19.39 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.849 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -116.96 153.02 33.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.058 -1.26 . . . . 0.0 109.608 179.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.4 m-20 -89.55 148.25 23.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.219 -0.925 . . . . 0.0 110.994 -178.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.677 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.5 m -63.2 111.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.102 -0.999 . . . . 0.0 109.235 179.005 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.712 ' O ' HG23 ' A' ' 74' ' ' ILE . 18.1 m -132.58 -38.31 1.03 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.266 -0.896 . . . . 0.0 110.488 -179.486 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.88 HG22 ' HB ' ' A' ' 63' ' ' VAL . 64.6 t -48.19 137.3 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.388 -0.82 . . . . 0.0 110.464 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.712 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -137.0 91.77 14.7 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.305 -0.872 . . . . 0.0 110.298 179.922 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.51 ' HA ' HG11 ' A' ' 80' ' ' VAL . 53.2 Cg_endo -79.83 55.69 5.74 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 O-C-N 123.707 1.372 . . . . 0.0 110.387 179.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.8 t -156.13 31.91 0.34 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.171 -0.956 . . . . 0.0 110.46 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -128.95 -164.75 1.43 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.179 -0.95 . . . . 0.0 110.075 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.57 -73.65 0.34 Allowed Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -149.26 109.36 4.12 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.212 -1.169 . . . . 0.0 110.024 179.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.555 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -117.06 134.8 59.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 122.014 0.911 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.618 HG22 HG22 ' A' ' 60' ' ' ILE . 11.4 m -112.6 125.76 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.205 0 O-C-N 121.334 -0.854 . . . . 0.0 109.02 179.127 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.795 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -97.39 118.34 43.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 120.935 -1.103 . . . . 0.0 110.037 -178.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.784 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -112.64 100.09 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.027 -1.046 . . . . 0.0 108.806 179.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.51 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -142.0 162.23 36.0 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.613 -1.304 . . . . 0.0 111.521 -178.079 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.699 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -87.01 -143.95 0.12 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.678 -0.639 . . . . 0.0 109.353 179.39 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.409 ' N ' HG23 ' A' ' 85' ' ' THR . 3.1 p30 -73.9 -4.62 36.12 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.926 -1.109 . . . . 0.0 110.782 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.699 ' H ' HG23 ' A' ' 85' ' ' THR . . . -61.65 -40.05 93.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.144 . . . . 0.0 110.502 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.67 -46.98 64.86 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.107 -0.996 . . . . 0.0 109.844 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.457 ' O ' ' N ' ' A' ' 91' ' ' GLY . 0.4 OUTLIER 53.1 21.91 2.33 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.356 -0.84 . . . . 0.0 110.088 -179.744 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.406 HG22 ' N ' ' A' ' 94' ' ' GLY . 0.2 OUTLIER 62.35 -72.75 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.581 -0.699 . . . . 0.0 110.709 -179.995 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 54.63 -98.65 0.05 OUTLIER Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.529 ' O ' ' CD2' ' A' ' 92' ' ' PHE . 46.6 p90 -88.98 48.43 1.63 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.258 -1.143 . . . . 0.0 109.592 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.424 ' CG2' ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -151.65 -146.16 0.19 Allowed 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.375 -0.828 . . . . 0.0 109.951 -179.628 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.406 ' N ' HG22 ' A' ' 90' ' ' THR . . . 111.51 -30.64 7.71 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.17 80.99 9.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.211 -1.17 . . . . 0.0 110.421 -179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.441 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 21.9 m-85 -119.42 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.109 -0.994 . . . . 0.0 109.726 179.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.445 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.99 -35.59 80.7 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.142 -0.973 . . . . 0.0 109.067 179.538 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.485 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.59 31.79 Favored 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 119.741 -0.784 . . . . 0.0 110.863 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.741 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.12 117.6 41.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.453 -0.78 . . . . 0.0 110.571 179.837 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 1.088 HG21 HD11 ' A' ' 28' ' ' ILE . 2.9 mp -93.1 112.59 26.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.29 161.1 21.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.115 -0.99 . . . . 0.0 111.912 -178.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.506 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.1 p -102.83 6.57 39.29 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.068 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.409 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.2 m120 45.86 25.4 0.29 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.238 -0.913 . . . . 0.0 111.349 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.506 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.9 p -146.91 128.89 15.47 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.921 . . . . 0.0 110.028 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.4 p -114.4 134.6 54.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.073 -1.017 . . . . 0.0 110.381 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 29.0 t0 54.07 26.98 7.01 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.243 -0.911 . . . . 0.0 110.385 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.41 -31.51 6.36 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.73 155.91 77.96 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.136 -1.214 . . . . 0.0 110.115 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.506 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.1 Cg_endo -66.63 133.52 32.23 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 O-C-N 123.637 1.335 . . . . 0.0 110.319 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.421 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER -47.91 163.98 0.05 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.318 -0.864 . . . . 0.0 110.709 -179.483 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.512 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -96.36 160.29 14.5 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.298 -0.876 . . . . 0.0 110.397 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.44 -48.26 37.5 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.418 -0.801 . . . . 0.0 112.001 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.512 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -71.17 -29.56 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.769 -1.207 . . . . 0.0 110.836 -178.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.48 -56.31 7.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.217 -0.927 . . . . 0.0 110.387 -179.518 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.426 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.66 -34.82 76.35 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.279 -0.888 . . . . 0.0 108.715 178.705 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.524 ' OG1' HG22 ' A' ' 4' ' ' THR . 42.7 m -59.79 -49.82 76.24 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.064 -1.022 . . . . 0.0 108.608 178.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -73.82 -38.89 64.42 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.43 -0.794 . . . . 0.0 109.951 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 82.8 mtt180 -70.18 -44.29 69.05 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.262 -0.899 . . . . 0.0 110.586 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.571 ' O ' HG23 ' A' ' 122' ' ' THR . 34.5 ttm180 -54.45 -36.58 64.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.222 -0.924 . . . . 0.0 110.577 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.94 -15.85 11.1 Favored Glycine 0 N--CA 1.494 2.527 0 O-C-N 120.959 -1.088 . . . . 0.0 111.524 -179.205 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.73 -3.58 22.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.651 -1.5 . . . . 0.0 111.485 -179.252 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.832 HG23 HD13 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.98 143.53 48.97 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.76 -1.213 . . . . 0.0 110.9 -179.685 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.469 ' N ' ' HA3' ' A' ' 128' ' ' GLY . . . 74.93 12.25 83.32 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.846 178.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.2 mtt180 -61.3 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.048 -1.266 . . . . 0.0 109.022 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.4 16.64 39.46 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -178.516 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.459 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.2 OUTLIER -175.48 -176.48 0.26 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.472 -1.016 . . . . 0.0 108.779 -179.615 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.459 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -88.27 105.39 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.133 1.07 . . . . 0.0 109.983 179.452 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.469 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.23 173.82 25.63 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.529 -1.32 . . . . 0.0 110.198 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.28 142.94 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.486 -1.008 . . . . 0.0 109.572 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.741 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.44 114.93 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.757 -1.215 . . . . 0.0 110.389 179.4 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.441 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.55 145.68 27.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.495 -0.753 . . . . 0.0 109.484 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.7 p90 -137.89 157.08 47.14 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.906 -1.121 . . . . 0.0 110.306 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t -87.03 -34.77 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.142 -0.974 . . . . 0.0 109.656 179.451 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -128.11 159.81 64.97 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.208 -0.932 . . . . 0.0 110.32 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -73.71 -41.0 1.22 Allowed 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.778 1.409 . . . . 0.0 110.415 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 67.09 88.78 0.06 OUTLIER Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -78.47 130.79 36.45 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.242 -1.152 . . . . 0.0 110.307 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.4 mtt-85 . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.293 179.884 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.4 m -111.57 155.35 23.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.3 -1.118 . . . . 0.0 110.189 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.596 ' O ' HG23 ' A' ' 3' ' ' VAL . 27.6 m -113.34 104.01 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.221 -0.924 . . . . 0.0 109.877 179.638 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.548 HG22 ' OG1' ' A' ' 116' ' ' THR . 10.5 p -64.23 138.14 58.29 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.406 -0.809 . . . . 0.0 110.605 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.432 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.61 147.83 98.66 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.556 179.62 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.432 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.3 Cg_endo -69.91 -169.29 0.33 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 124.089 1.573 . . . . 0.0 111.057 179.512 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.542 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 6.9 p80 -177.42 82.48 0.24 Allowed Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.568 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -63.81 89.25 0.15 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 O-C-N 123.67 1.353 . . . . 0.0 110.471 -179.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.509 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 -177.24 -33.94 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.753 -0.592 . . . . 0.0 109.898 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.488 HD13 HG22 ' A' ' 122' ' ' THR . 19.8 mt -105.28 134.83 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.856 -1.153 . . . . 0.0 110.027 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -84.93 128.28 34.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.328 -0.857 . . . . 0.0 108.893 178.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.43 142.74 27.39 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.043 -1.036 . . . . 0.0 110.245 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.611 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 13.3 t -136.53 157.29 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.943 -179.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.35 108.7 19.36 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.869 179.418 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.586 HD23 HG22 ' A' ' 133' ' ' VAL . 11.2 tp -54.98 134.35 48.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.315 -0.866 . . . . 0.0 109.798 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.0 p -137.97 -179.32 5.7 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.323 -0.861 . . . . 0.0 110.176 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.2 p -74.56 60.78 0.91 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -0.909 . . . . 0.0 109.988 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.456 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.8 m -131.73 111.41 11.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.892 . . . . 0.0 110.227 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.454 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.53 -162.61 27.97 Favored Glycine 0 N--CA 1.488 2.118 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.977 179.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.32 -21.63 7.42 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.724 -0.868 . . . . 0.0 110.474 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.896 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.0 tt -97.39 107.1 36.8 Favored Pre-proline 0 N--CA 1.489 1.517 0 C-N-CA 118.796 -1.162 . . . . 0.0 110.24 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.448 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -63.64 155.01 65.62 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 O-C-N 123.385 1.203 . . . . 0.0 109.497 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.7 t80 -169.13 91.6 0.25 Allowed 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.056 -1.027 . . . . 0.0 111.563 -178.123 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.501 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.82 67.27 0.89 Allowed 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.473 -0.767 . . . . 0.0 111.38 178.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.68 13.56 18.33 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.632 ' HG3' HG13 ' A' ' 133' ' ' VAL . 6.5 mmtt -130.8 156.23 45.34 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.14 -1.212 . . . . 0.0 109.08 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.456 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.81 106.92 12.56 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.896 -1.127 . . . . 0.0 109.237 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.896 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.0 mt -68.47 115.1 26.44 Favored Pre-proline 0 C--N 1.298 -1.638 0 O-C-N 121.479 -0.763 . . . . 0.0 110.61 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.911 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.1 Cg_endo -68.42 126.74 14.63 Favored 'Trans proline' 0 C--N 1.304 -1.813 0 N-CA-C 107.382 -1.815 . . . . 0.0 107.382 176.261 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.565 HD11 HD12 ' A' ' 58' ' ' LEU . 5.6 mt -56.08 -20.72 18.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.962 -1.086 . . . . 0.0 110.846 -177.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -59.95 -16.05 26.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.674 -1.266 . . . . 0.0 110.467 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.109 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.58 -25.33 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.005 -1.059 . . . . 0.0 110.955 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.109 HG23 HG23 ' A' ' 32' ' ' VAL . 14.7 pt -117.86 -15.49 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.963 -1.085 . . . . 0.0 110.951 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.597 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.5 tptm -98.22 147.77 24.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.809 -1.182 . . . . 0.0 110.507 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.35 -3.14 61.43 Favored Glycine 0 N--CA 1.485 1.951 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.09 -159.45 21.29 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.23 -1.462 . . . . 0.0 110.374 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.375 -1.074 . . . . 0.0 110.543 -179.515 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.563 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.11 147.86 39.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.225 -0.922 . . . . 0.0 110.918 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.429 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 40.4 tp -109.14 116.24 31.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.38 -0.825 . . . . 0.0 110.291 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.907 HD12 HG12 ' A' ' 83' ' ' VAL . 34.4 mt -99.89 127.77 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.132 -0.98 . . . . 0.0 109.687 179.465 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.05 39.55 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.327 -0.858 . . . . 0.0 109.891 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.71 159.72 21.82 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.821 -179.355 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.501 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.43 -8.58 19.05 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.557 -0.714 . . . . 0.0 109.942 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.13 138.98 53.27 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.031 -1.043 . . . . 0.0 110.96 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.471 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.95 -40.37 68.73 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.315 0.579 . . . . 0.0 110.774 -179.79 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mttp -59.93 -36.49 77.13 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.369 -0.832 . . . . 0.0 111.028 -179.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.28 71.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 -179.48 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.916 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 84.8 m -61.2 -36.36 79.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.284 -0.885 . . . . 0.0 109.302 179.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.45 66.85 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.267 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -73.01 -45.99 54.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.234 -0.916 . . . . 0.0 110.283 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.61 HD13 ' O ' ' A' ' 51' ' ' LEU . 3.2 tm? -57.01 -39.72 75.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.591 -0.693 . . . . 0.0 111.267 -179.002 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.477 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.88 -51.17 13.1 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.929 -1.107 . . . . 0.0 110.54 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.127 -0.983 . . . . 0.0 109.677 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.498 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.68 83.89 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.372 -0.83 . . . . 0.0 109.526 179.379 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.873 HD13 HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -54.94 -42.59 72.49 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.491 -0.756 . . . . 0.0 109.489 179.683 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.5 t -56.14 -31.02 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.99 -1.068 . . . . 0.0 108.725 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.03 -32.73 61.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.521 -0.737 . . . . 0.0 109.899 179.35 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.565 HD12 HD11 ' A' ' 30' ' ' LEU . 4.3 mm? -72.1 -26.11 62.01 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-O 121.851 0.834 . . . . 0.0 109.728 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.29 6.0 9.17 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.599 HG22 HG22 ' A' ' 81' ' ' VAL . 44.7 mt -107.55 143.24 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.247 -1.149 . . . . 0.0 109.861 -179.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 50.0 t30 -87.56 106.83 18.27 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 178.348 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.642 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 118.774 -1.17 . . . . 0.0 111.831 -177.079 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.896 HG21 ' HA ' ' A' ' 73' ' ' VAL . 92.2 t -126.01 148.12 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.697 -0.627 . . . . 0.0 109.828 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.916 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -117.77 117.63 29.85 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.495 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.485 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 3.5 t80 -108.14 131.25 54.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 110.878 -179.264 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.857 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -155.34 -168.72 2.93 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.62 -0.675 . . . . 0.0 109.958 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -55.92 123.66 15.04 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.319 -0.863 . . . . 0.0 111.266 -179.256 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.56 59.02 8.76 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 179.138 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.857 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.66 152.05 35.98 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.074 -1.25 . . . . 0.0 109.712 179.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.738 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -85.88 149.03 25.51 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.209 -0.932 . . . . 0.0 110.592 -179.276 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.683 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.0 m -62.5 110.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.133 179.178 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.707 ' O ' HG23 ' A' ' 74' ' ' ILE . 68.9 m -131.33 -32.09 1.58 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.372 -0.83 . . . . 0.0 110.656 -179.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.896 ' HA ' HG21 ' A' ' 63' ' ' VAL . 94.9 t -53.0 131.25 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.153 -0.967 . . . . 0.0 109.441 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -134.04 103.8 11.72 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.125 -0.984 . . . . 0.0 110.779 -179.263 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -87.05 43.68 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 O-C-N 123.457 1.241 . . . . 0.0 110.294 179.214 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.5 p -136.64 4.52 2.84 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.018 -1.051 . . . . 0.0 111.114 -179.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.516 ' HB2' HD12 ' A' ' 74' ' ' ILE . 1.6 m-80 -100.74 -169.11 1.66 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.915 -1.116 . . . . 0.0 110.291 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -54.47 -70.47 0.94 Allowed Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -144.85 113.67 6.8 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.202 -1.175 . . . . 0.0 110.297 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.619 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.43 132.44 67.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 CA-C-O 122.087 0.946 . . . . 0.0 110.456 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.614 HG11 ' HB ' ' A' ' 33' ' ' ILE . 11.4 m -112.45 122.05 65.95 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 121.356 -0.84 . . . . 0.0 108.96 179.049 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.839 HG22 HG13 ' A' ' 73' ' ' VAL . 16.1 t -97.01 120.94 46.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.684 0 O-C-N 121.054 -1.029 . . . . 0.0 110.611 -177.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.907 HG12 HD12 ' A' ' 40' ' ' ILE . 3.3 m -112.39 100.39 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.044 -1.035 . . . . 0.0 108.667 179.321 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.485 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.7 34.44 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -177.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.574 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -93.19 -136.68 0.18 Allowed 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.525 ' N ' HG23 ' A' ' 85' ' ' THR . 3.3 p30 -77.04 -6.16 51.63 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.679 -1.263 . . . . 0.0 111.068 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.574 ' H ' HG23 ' A' ' 85' ' ' THR . . . -60.71 -41.52 95.4 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.849 -1.157 . . . . 0.0 110.066 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.4 tp -64.43 -32.25 73.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 108.577 179.161 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.482 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 43.82 34.82 0.94 Allowed 'General case' 0 N--CA 1.493 1.675 0 CA-C-O 121.244 0.545 . . . . 0.0 110.953 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.567 HG21 ' NH1' ' A' ' 121' ' ' ARG . 22.6 p 47.28 -130.31 1.49 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.708 -0.62 . . . . 0.0 110.392 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 92.98 -85.17 1.13 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 27.0 p90 -94.44 17.06 13.7 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -1.167 . . . . 0.0 109.781 179.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.466 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 14.9 t -92.53 -151.22 0.28 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.319 -0.863 . . . . 0.0 110.264 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.458 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 94.08 -31.92 6.28 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.59 57.3 3.99 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.977 -1.307 . . . . 0.0 110.304 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.446 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 64.0 m-85 -120.26 152.81 37.25 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.214 -0.929 . . . . 0.0 110.294 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.478 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.6 -28.35 30.88 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.425 -0.797 . . . . 0.0 109.831 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.503 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.6 p -160.7 163.58 32.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.283 -0.886 . . . . 0.0 110.712 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.503 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.91 128.12 64.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.345 -0.847 . . . . 0.0 110.138 179.441 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.86 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -105.95 111.11 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.195 -0.94 . . . . 0.0 108.666 178.778 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.418 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.7 t0 -115.85 161.29 18.99 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.052 -1.03 . . . . 0.0 111.96 -178.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.468 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.84 -2.91 43.04 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.023 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.423 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 53.89 21.48 2.82 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.088 -1.007 . . . . 0.0 110.183 -179.098 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.742 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -144.13 125.94 15.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.323 -0.86 . . . . 0.0 110.153 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.1 p -112.59 139.23 48.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.154 -0.966 . . . . 0.0 109.61 179.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.5 t70 54.74 -143.54 0.73 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.047 -1.033 . . . . 0.0 109.605 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.76 26.45 12.54 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.11 156.79 67.92 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.175 -1.191 . . . . 0.0 109.843 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.742 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.1 Cg_endo -65.84 162.1 36.36 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.654 1.344 . . . . 0.0 110.523 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.408 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER -64.86 168.1 6.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.308 -0.87 . . . . 0.0 110.873 -179.329 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.482 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -105.55 161.85 14.0 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.478 -0.764 . . . . 0.0 110.323 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.8 -59.85 1.8 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.315 -0.865 . . . . 0.0 112.156 -178.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.482 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.4 m -64.31 -29.32 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.788 -1.195 . . . . 0.0 111.764 -178.57 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.34 -56.5 6.73 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.009 -1.057 . . . . 0.0 110.63 -179.015 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.47 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.58 -34.75 76.35 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.719 178.933 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.548 ' OG1' HG22 ' A' ' 4' ' ' THR . 29.5 m -59.13 -49.22 78.69 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.984 -1.072 . . . . 0.0 108.301 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.418 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -36.99 65.87 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.508 -0.745 . . . . 0.0 109.9 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.425 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 5.1 mtt180 -71.8 -44.59 63.7 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.042 -1.036 . . . . 0.0 111.193 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.542 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -57.35 -41.64 80.48 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.848 -1.158 . . . . 0.0 109.834 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.421 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.05 63.88 0.21 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.567 ' NH1' HG21 ' A' ' 90' ' ' THR . 10.9 mmp_? -135.38 -44.69 0.69 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.43 -1.041 . . . . 0.0 108.524 178.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.507 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.0 t -93.58 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.677 -0.639 . . . . 0.0 109.732 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.08 3.23 36.13 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.617 179.058 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.458 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 2.8 mmt180 -62.71 87.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.965 -1.315 . . . . 0.0 109.511 179.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.51 19.13 33.29 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -178.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.462 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 16.4 ptpt -176.23 -178.31 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.491 -1.005 . . . . 0.0 108.503 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.5 Cg_endo -89.16 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.254 1.134 . . . . 0.0 110.428 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.588 ' C ' HD12 ' A' ' 129' ' ' ILE . . . -80.85 176.72 54.59 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.772 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.588 HD12 ' C ' ' A' ' 128' ' ' GLY . 3.5 mp -132.52 143.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.764 -0.845 . . . . 0.0 109.043 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.503 ' HD1' HG23 ' A' ' 99' ' ' VAL . 9.6 t80 -129.95 115.52 17.28 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.24 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.611 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mtt180 -105.98 131.42 53.29 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.522 -0.736 . . . . 0.0 109.435 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.418 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 46.0 p90 -129.63 157.29 42.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.042 -1.036 . . . . 0.0 110.376 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.632 HG13 ' HG3' ' A' ' 26' ' ' LYS . 42.8 t -76.08 -60.39 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.104 -0.997 . . . . 0.0 109.923 179.757 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.423 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -111.14 146.81 35.29 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.154 -0.967 . . . . 0.0 110.317 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.99 -51.05 0.15 Allowed 'Trans proline' 0 C--N 1.311 -1.4 0 O-C-N 123.81 1.426 . . . . 0.0 110.432 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 62.7 85.6 0.05 OUTLIER Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -94.93 81.99 3.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.23 -1.159 . . . . 0.0 110.326 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.3 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.2 139.3 50.09 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.236 -1.155 . . . . 0.0 110.24 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 59.6 t -112.83 104.28 16.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.239 -0.913 . . . . 0.0 109.822 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.627 HG22 ' OG1' ' A' ' 116' ' ' THR . 18.1 p -69.12 138.23 54.07 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.479 -0.763 . . . . 0.0 110.185 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.82 146.25 98.3 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.257 -0.902 . . . . 0.0 109.523 179.72 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.429 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 46.2 Cg_endo -72.69 -174.28 1.44 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.978 1.515 . . . . 0.0 110.51 179.204 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.512 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 175.85 76.79 0.08 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.481 -0.762 . . . . 0.0 109.887 -179.61 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -75.25 53.98 3.61 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.76 1.4 . . . . 0.0 111.1 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.436 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.0 m-80 -138.45 8.31 2.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.002 -1.061 . . . . 0.0 110.346 179.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.64 HD11 ' O ' ' A' ' 122' ' ' THR . 36.2 mt -128.05 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.187 -0.945 . . . . 0.0 109.413 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.97 128.45 34.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.139 -0.976 . . . . 0.0 109.305 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.06 133.09 34.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.206 -0.933 . . . . 0.0 110.429 -178.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.522 HG11 ' HE ' ' A' ' 131' ' ' ARG . 16.5 t -128.66 156.11 40.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.403 -0.811 . . . . 0.0 110.021 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.61 110.9 21.78 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.252 -0.905 . . . . 0.0 109.968 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.718 HD23 HG22 ' A' ' 133' ' ' VAL . 11.7 tp -58.84 134.21 56.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.275 -0.891 . . . . 0.0 109.581 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.9 p -138.78 -175.19 4.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.22 -0.925 . . . . 0.0 110.24 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.5 p -77.75 81.3 4.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.264 -0.897 . . . . 0.0 109.896 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.625 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.8 m -153.64 109.5 3.27 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.297 -0.877 . . . . 0.0 110.656 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.74 -165.08 28.07 Favored Glycine 0 N--CA 1.487 2.044 0 C-N-CA 119.072 -1.537 . . . . 0.0 110.567 179.476 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.7 -21.83 8.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.647 -0.914 . . . . 0.0 110.275 179.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.876 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -96.19 110.69 53.55 Favored Pre-proline 0 N--CA 1.487 1.407 0 C-N-CA 118.8 -1.16 . . . . 0.0 109.91 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.462 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.3 Cg_endo -64.63 155.39 67.07 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.684 1.36 . . . . 0.0 110.285 -179.515 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.4 t80 -169.5 94.06 0.28 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.112 -0.993 . . . . 0.0 111.508 -178.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.583 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 24.9 m-85 58.38 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.393 -0.817 . . . . 0.0 111.497 179.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.44 14.76 9.61 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.431 -1.067 . . . . 0.0 110.431 179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.473 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.8 156.8 44.38 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.041 -1.27 . . . . 0.0 109.418 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.625 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -114.7 107.35 15.34 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 120.967 -1.083 . . . . 0.0 109.5 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.865 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.3 mt -69.56 113.9 20.46 Favored Pre-proline 0 C--N 1.299 -1.6 0 O-C-N 121.383 -0.823 . . . . 0.0 110.215 -179.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.917 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.8 Cg_endo -70.27 129.73 17.54 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 N-CA-C 107.189 -1.889 . . . . 0.0 107.189 176.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.818 HD11 HD12 ' A' ' 58' ' ' LEU . 17.6 mt -56.33 -18.19 10.07 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.874 -1.141 . . . . 0.0 110.94 -177.659 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.49 -16.47 24.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.636 -1.29 . . . . 0.0 110.087 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.025 HG23 HG23 ' A' ' 33' ' ' ILE . 14.4 m -93.96 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.155 -0.966 . . . . 0.0 110.981 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.025 HG23 HG23 ' A' ' 32' ' ' VAL . 40.9 pt -118.15 -22.79 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.934 -1.104 . . . . 0.0 110.872 -178.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.596 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.26 22.16 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.506 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.02 -5.27 59.35 Favored Glycine 0 N--CA 1.483 1.82 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.22 -162.58 27.81 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.949 -1.596 . . . . 0.0 110.678 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.22 129.38 44.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.468 -1.019 . . . . 0.0 110.351 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.5 m-70 -138.93 145.59 40.01 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.222 -0.924 . . . . 0.0 110.607 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.593 HD12 ' O ' ' A' ' 82' ' ' VAL . 38.3 tp -108.06 117.17 33.43 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.412 -0.805 . . . . 0.0 110.256 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.922 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.5 mm -94.03 125.69 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.275 -0.891 . . . . 0.0 108.601 179.26 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.471 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 11.4 m-85 -94.21 121.81 36.11 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.089 -1.007 . . . . 0.0 109.637 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.46 150.69 39.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.271 -0.893 . . . . 0.0 110.83 -179.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.583 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 2.4 p-80 -103.74 3.59 34.33 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 109.682 178.442 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.55 135.39 45.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.186 -0.946 . . . . 0.0 110.199 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.454 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.4 ttpt -71.28 -37.2 71.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.609 -0.682 . . . . 0.0 110.735 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.7 -37.03 80.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.315 -0.866 . . . . 0.0 110.775 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 4.3 tptm -72.6 -36.33 68.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 110.015 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.725 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 71.1 m -60.4 -34.23 73.63 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.475 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.72 -49.15 56.07 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 110.538 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.445 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.43 -41.71 69.17 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.147 -0.971 . . . . 0.0 110.583 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.919 HD12 HG11 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.9 80.41 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 111.282 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.11 -51.0 43.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.934 -1.104 . . . . 0.0 110.175 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.88 -31.76 65.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.209 -0.932 . . . . 0.0 109.123 179.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.596 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.83 -47.06 85.05 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.082 -0.711 . . . . 0.0 109.082 179.358 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.876 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -60.99 -41.42 96.46 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.279 -0.888 . . . . 0.0 111.053 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.0 t -56.38 -33.93 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.868 -1.145 . . . . 0.0 109.227 179.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -34.83 60.3 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.318 -0.864 . . . . 0.0 110.482 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.818 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.32 -25.57 62.47 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.409 -0.807 . . . . 0.0 109.833 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.31 8.9 8.25 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.758 ' CD1' HD22 ' A' ' 30' ' ' LEU . 36.5 mt -108.34 143.73 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.338 -1.095 . . . . 0.0 109.666 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.6 t30 -90.07 106.75 18.69 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.23 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.569 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.59 145.96 45.94 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.508 -176.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.877 HG21 ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.64 149.36 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.52 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.725 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.43 128.29 56.4 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.711 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.603 ' CD1' HD12 ' A' ' 69' ' ' LEU . 12.9 t80 -119.96 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.384 -0.823 . . . . 0.0 110.094 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.898 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.7 p90 -167.76 -178.27 3.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.521 -0.737 . . . . 0.0 109.776 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.13 116.78 3.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.175 -0.953 . . . . 0.0 110.617 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.69 36.12 7.5 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.898 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.68 156.88 27.44 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.191 -1.182 . . . . 0.0 110.122 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.782 ' N ' HD13 ' A' ' 69' ' ' LEU . 33.7 m-20 -97.41 149.01 22.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.284 -0.885 . . . . 0.0 110.088 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.681 ' O ' HG23 ' A' ' 71' ' ' VAL . 33.7 m -62.45 111.28 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 C-N-CA 119.261 -0.976 . . . . 0.0 109.207 179.245 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.446 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 27.4 m -130.16 -34.39 1.66 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.366 -0.834 . . . . 0.0 110.731 -179.459 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.877 ' HA ' HG21 ' A' ' 63' ' ' VAL . 50.7 t -49.88 151.77 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.225 -0.922 . . . . 0.0 109.459 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.426 HG13 HG21 ' A' ' 80' ' ' VAL . 1.0 OUTLIER -131.31 100.29 16.91 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 120.781 -1.199 . . . . 0.0 111.523 -178.945 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -81.7 59.83 7.36 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.632 1.332 . . . . 0.0 109.889 179.064 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.432 HG23 ' O ' ' A' ' 76' ' ' THR . 4.7 t -135.88 61.78 1.64 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.463 -0.773 . . . . 0.0 109.311 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.428 ' N ' ' OD1' ' A' ' 77' ' ' ASN . 3.2 m-20 62.74 -154.13 0.34 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.831 -0.543 . . . . 0.0 110.033 -179.33 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 63.68 151.36 0.05 OUTLIER Glycine 0 N--CA 1.489 2.227 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.44 94.04 6.12 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.95 -1.324 . . . . 0.0 110.242 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 4.9 p -117.25 131.07 71.03 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.859 0 CA-C-O 122.062 0.935 . . . . 0.0 110.057 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.622 HG11 ' HB ' ' A' ' 33' ' ' ILE . 6.2 m -112.95 121.36 65.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.725 HG22 HG13 ' A' ' 73' ' ' VAL . 11.1 t -96.76 118.52 43.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.148 -0.97 . . . . 0.0 110.414 -177.647 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.922 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.9 m -109.44 100.34 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.063 -1.023 . . . . 0.0 108.79 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -143.0 161.6 37.69 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.6 -1.313 . . . . 0.0 111.108 -178.31 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.789 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.8 t -85.37 -136.97 0.07 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.493 -0.755 . . . . 0.0 109.147 179.532 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.509 ' N ' HG23 ' A' ' 85' ' ' THR . 6.1 m-20 -82.54 -13.64 56.26 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.723 -1.235 . . . . 0.0 110.404 179.764 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.789 ' H ' HG23 ' A' ' 85' ' ' THR . . . -52.65 -41.96 64.26 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.072 -1.017 . . . . 0.0 110.339 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.434 HD12 ' CD2' ' A' ' 65' ' ' TYR . 2.4 tp -64.07 -47.87 78.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.081 -1.012 . . . . 0.0 109.769 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.446 ' HE2' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 54.21 20.61 2.67 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.287 -0.883 . . . . 0.0 109.937 -179.744 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.671 HG22 ' HB ' ' A' ' 93' ' ' THR . 0.1 OUTLIER 46.85 54.69 8.77 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.37 -0.831 . . . . 0.0 110.777 179.834 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.6 -67.92 1.83 Allowed Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -93.1 21.73 5.61 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.322 -1.105 . . . . 0.0 109.643 178.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.671 ' HB ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER -127.98 -167.69 1.79 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.446 -0.784 . . . . 0.0 109.817 -179.91 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.425 ' HA3' ' NH1' ' A' ' 124' ' ' ARG . . . 150.74 -51.0 0.53 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -87.3 97.36 10.74 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -1.154 . . . . 0.0 110.611 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.539 ' CZ ' HG21 ' A' ' 93' ' ' THR . 10.6 m-85 -116.64 151.69 35.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.331 -0.855 . . . . 0.0 109.494 179.198 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.49 -32.98 72.19 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.342 -0.943 . . . . 0.0 109.327 179.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.7 p -162.37 163.56 27.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.274 -0.891 . . . . 0.0 111.084 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.604 HG22 HG21 ' A' ' 122' ' ' THR . 0.3 OUTLIER -130.83 112.98 23.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.52 -0.738 . . . . 0.0 109.886 179.343 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.601 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -94.48 115.32 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.217 -0.927 . . . . 0.0 109.166 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -127.99 161.12 29.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 111.504 -178.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 42.7 t -90.94 -9.1 47.36 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 57.35 13.74 1.88 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.293 -0.879 . . . . 0.0 111.662 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.495 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.2 m -144.06 109.95 5.31 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 120.777 -1.202 . . . . 0.0 108.992 179.541 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.459 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -86.82 128.76 35.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.316 -0.865 . . . . 0.0 111.093 -179.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.9 t70 54.34 34.34 20.43 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.425 -0.797 . . . . 0.0 111.272 179.208 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.6 -14.9 54.21 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.314 179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 104' ' ' THR . 10.6 mttt -98.08 156.58 35.74 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 120.929 -1.336 . . . . 0.0 109.743 179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -62.51 127.3 20.45 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.524 1.276 . . . . 0.0 110.473 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.48 157.42 0.06 Allowed 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.591 0.71 . . . . 0.0 111.239 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.537 ' OD2' HG22 ' A' ' 113' ' ' VAL . 4.4 p-10 -73.25 162.49 29.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.501 -0.749 . . . . 0.0 109.971 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.16 -42.61 91.15 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.884 -1.135 . . . . 0.0 111.62 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.537 HG22 ' OD2' ' A' ' 111' ' ' ASP . 6.7 m -72.59 -30.86 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 120.784 -1.198 . . . . 0.0 113.031 -178.001 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.74 -55.76 20.44 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.474 -1.391 . . . . 0.0 110.3 -178.766 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.411 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -62.88 -34.71 77.97 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 118.695 -1.202 . . . . 0.0 108.225 178.327 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.627 ' OG1' HG22 ' A' ' 4' ' ' THR . 24.6 m -61.46 -50.7 71.72 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.89 41.91 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.832 . . . . 0.0 109.6 178.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.422 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 25.2 mtt180 -59.59 -45.14 92.78 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.287 -0.883 . . . . 0.0 110.405 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.512 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 20.1 ttm180 -62.68 -34.59 77.41 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.734 -1.229 . . . . 0.0 110.071 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.427 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.78 -5.36 31.06 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 119.998 -1.096 . . . . 0.0 111.12 -179.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.515 ' HG3' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -87.95 -4.96 58.77 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.656 -1.496 . . . . 0.0 110.96 -179.823 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.64 ' O ' HD11 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -118.72 140.36 50.06 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.859 -1.151 . . . . 0.0 109.442 179.535 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.01 19.6 39.17 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.427 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 10.2 mmt85 -69.39 85.98 0.42 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.033 -1.275 . . . . 0.0 109.806 179.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.05 57.82 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.469 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.41 -174.8 0.39 Allowed Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.202 -1.175 . . . . 0.0 109.016 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.469 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.7 Cg_endo -85.22 103.33 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.36 1.19 . . . . 0.0 109.438 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -86.98 173.25 44.72 Favored Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.046 -179.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.4 mt -122.18 142.92 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.405 -1.056 . . . . 0.0 109.54 179.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.7 t80 -127.02 115.34 19.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.166 -0.959 . . . . 0.0 110.178 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.522 ' HE ' HG11 ' A' ' 13' ' ' VAL . 10.6 mtt85 -105.65 135.26 47.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.353 -0.842 . . . . 0.0 109.476 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.2 147.0 45.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.153 -0.967 . . . . 0.0 110.552 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.718 HG22 HD23 ' A' ' 15' ' ' LEU . 54.4 t -69.22 -55.59 14.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.159 -0.963 . . . . 0.0 109.829 179.735 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -118.85 159.26 45.23 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.217 -0.927 . . . . 0.0 110.312 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.451 ' HG2' ' CB ' ' A' ' 138' ' ' ARG . 44.6 Cg_endo -72.17 -23.11 21.57 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 O-C-N 123.719 1.378 . . . . 0.0 110.374 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 115.47 -64.58 0.31 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -83.65 -48.95 9.65 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.188 -1.184 . . . . 0.0 110.169 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.451 ' CB ' ' HG2' ' A' ' 135' ' ' PRO . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.141 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.3 p -104.04 106.88 17.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 0.0 110.279 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.559 ' O ' HG13 ' A' ' 3' ' ' VAL . 4.7 p -113.32 103.92 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 O-C-N 121.29 -0.881 . . . . 0.0 109.881 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.404 HG22 ' O ' ' A' ' 112' ' ' ALA . 18.1 p -75.19 142.68 43.45 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.222 -0.924 . . . . 0.0 110.324 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.458 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.8 146.91 97.8 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.21 -0.932 . . . . 0.0 109.635 179.604 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.458 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.4 Cg_endo -71.97 -168.58 0.38 Allowed 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.17 1.616 . . . . 0.0 110.456 179.167 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.549 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.6 OUTLIER -173.67 81.87 0.38 Allowed Pre-proline 0 C--N 1.302 -1.457 0 O-C-N 121.531 -0.731 . . . . 0.0 109.547 179.565 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.415 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 39.8 Cg_endo -67.05 87.83 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.387 1.204 . . . . 0.0 110.999 -179.138 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.465 ' ND2' ' N ' ' A' ' 9' ' ' ASN . 0.1 OUTLIER 171.79 -5.76 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.382 0 O-C-N 121.45 -0.781 . . . . 0.0 112.448 179.251 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.528 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 12.7 mt -124.32 135.62 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.131 -1.606 . . . . 0.0 109.562 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.88 128.74 34.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.316 -0.865 . . . . 0.0 109.801 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.36 140.93 29.01 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.194 -0.941 . . . . 0.0 109.882 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.408 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 6.5 t -134.78 153.97 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.224 -0.923 . . . . 0.0 110.467 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.59 18.6 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.325 -0.859 . . . . 0.0 109.552 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.501 HD11 HG12 ' A' ' 28' ' ' ILE . 10.8 tp -56.08 136.63 52.29 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.29 -0.881 . . . . 0.0 109.778 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.42 -167.58 1.99 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 0.0 110.288 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.2 p -88.3 73.24 8.88 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.636 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.3 m -146.04 112.37 5.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 110.48 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.34 -165.35 27.87 Favored Glycine 0 N--CA 1.489 2.204 0 C-N-CA 118.883 -1.627 . . . . 0.0 110.831 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.59 -21.57 9.08 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.61 -0.936 . . . . 0.0 110.19 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.907 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.1 tt -98.85 105.69 32.76 Favored Pre-proline 0 N--CA 1.488 1.46 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.179 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.474 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -62.95 155.0 63.13 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.225 1.118 . . . . 0.0 109.66 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.463 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.2 t80 -167.55 93.61 0.41 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.062 -1.024 . . . . 0.0 111.576 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.479 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 25.5 m-85 59.38 67.04 0.94 Allowed 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.571 -0.705 . . . . 0.0 111.554 179.06 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.09 13.81 15.82 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.84 156.89 44.25 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.105 -1.233 . . . . 0.0 109.039 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.636 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.06 107.92 14.59 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.789 -1.194 . . . . 0.0 109.675 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.975 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -70.89 114.15 24.6 Favored Pre-proline 0 C--N 1.299 -1.62 0 O-C-N 121.411 -0.806 . . . . 0.0 110.637 -179.415 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.833 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.3 Cg_endo -68.91 128.42 16.79 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 N-CA-C 106.906 -1.998 . . . . 0.0 106.906 176.181 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.55 HD11 HD12 ' A' ' 58' ' ' LEU . 6.9 mt -55.91 -18.94 10.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.914 -1.116 . . . . 0.0 110.678 -177.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.51 -16.29 23.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.714 -1.241 . . . . 0.0 110.296 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.121 HG23 HG23 ' A' ' 33' ' ' ILE . 13.1 m -92.24 -25.43 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 120.968 -1.082 . . . . 0.0 111.228 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.121 HG23 HG23 ' A' ' 32' ' ' VAL . 8.9 pt -117.9 -18.53 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.985 -1.072 . . . . 0.0 110.662 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.511 ' HB2' HD11 ' A' ' 60' ' ' ILE . 9.7 tptt -96.24 148.92 22.22 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.931 -1.106 . . . . 0.0 110.417 179.534 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.84 56.7 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.8 -159.22 21.81 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.239 -1.457 . . . . 0.0 110.091 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.447 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.6 mtt85 -100.61 130.65 46.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.404 -1.057 . . . . 0.0 110.603 -179.571 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.2 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.208 -0.933 . . . . 0.0 110.505 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.626 HD12 ' HB ' ' A' ' 82' ' ' VAL . 14.0 tp -109.49 120.96 44.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.241 -0.912 . . . . 0.0 110.301 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.918 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.3 mm -99.72 125.58 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.194 -0.941 . . . . 0.0 109.283 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.5 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.3 123.05 38.62 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.098 -1.001 . . . . 0.0 109.709 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.24 157.89 25.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.239 -0.913 . . . . 0.0 110.857 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.479 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 0.7 OUTLIER -105.75 8.14 32.79 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.412 -0.805 . . . . 0.0 109.967 178.939 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.46 139.65 40.75 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.172 -0.955 . . . . 0.0 110.346 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.459 ' HG2' ' CB ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.93 -38.11 69.92 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 110.783 -179.683 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.93 -37.26 86.74 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.759 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.412 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -64.91 -35.98 82.9 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.318 -0.864 . . . . 0.0 109.765 -179.844 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.774 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.2 m -60.2 -34.34 73.49 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.407 -0.808 . . . . 0.0 109.039 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.03 -48.83 64.59 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.191 -0.943 . . . . 0.0 110.25 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.0 mt-10 -71.46 -45.59 62.18 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.198 -0.939 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.972 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.42 -41.38 76.27 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.373 -0.83 . . . . 0.0 111.338 -178.926 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.443 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.36 -50.92 14.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 110.363 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.73 -41.62 99.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 109.446 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.573 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.4 -46.16 86.95 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.346 -0.846 . . . . 0.0 109.433 179.341 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.41 -42.93 78.81 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.487 -0.758 . . . . 0.0 110.236 179.853 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.8 t -55.9 -33.43 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.073 -1.017 . . . . 0.0 109.166 179.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.61 -31.48 59.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.323 -0.861 . . . . 0.0 110.004 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.573 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -72.07 -26.54 62.21 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.893 0.854 . . . . 0.0 109.601 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.03 6.3 8.45 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.603 HG22 HG22 ' A' ' 81' ' ' VAL . 35.1 mt -107.86 143.87 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.262 -1.14 . . . . 0.0 110.144 -179.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.625 ' ND2' HD11 ' A' ' 74' ' ' ILE . 15.8 t30 -88.02 106.45 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.364 -1.717 . . . . 0.0 106.364 177.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.588 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.69 141.67 47.9 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.671 -177.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.951 HG21 ' HA ' ' A' ' 73' ' ' VAL . 87.4 t -124.27 147.9 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.998 -0.681 . . . . 0.0 109.69 179.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.774 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.47 127.04 55.04 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.151 -1.02 . . . . 0.0 109.822 178.503 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.71 31.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 110.57 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.879 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.7 p90 -147.78 175.08 11.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.619 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.69 5.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 110.766 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.9 37.18 10.43 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.879 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.31 155.93 28.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.115 -1.227 . . . . 0.0 109.969 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.856 ' N ' HD13 ' A' ' 69' ' ' LEU . 32.3 m-20 -95.61 149.25 21.66 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.225 -0.922 . . . . 0.0 110.462 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.679 ' O ' HG23 ' A' ' 71' ' ' VAL . 33.4 m -61.81 110.08 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 120.939 -1.101 . . . . 0.0 108.969 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.7 m -132.13 -9.69 3.38 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.508 -0.745 . . . . 0.0 110.953 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.951 ' HA ' HG21 ' A' ' 63' ' ' VAL . 40.1 t -72.27 135.12 28.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.082 -1.012 . . . . 0.0 109.305 -179.582 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.884 HD13 ' OD1' ' A' ' 77' ' ' ASN . 1.3 pp -137.14 104.1 8.79 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.155 -0.965 . . . . 0.0 111.235 -178.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -89.35 35.57 0.36 Allowed 'Trans proline' 0 C--N 1.312 -1.378 0 O-C-N 123.7 1.369 . . . . 0.0 110.606 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.705 HG23 ' ND2' ' A' ' 77' ' ' ASN . 6.9 t -127.8 -11.16 5.49 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.908 -1.12 . . . . 0.0 111.5 -179.143 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.884 ' OD1' HD13 ' A' ' 74' ' ' ILE . 8.1 m120 -104.82 -150.37 0.43 Allowed 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.853 -1.154 . . . . 0.0 110.37 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -53.05 174.98 0.23 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -54.86 115.81 2.39 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.133 -1.216 . . . . 0.0 110.141 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.687 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -116.06 135.42 56.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 121.966 0.889 . . . . 0.0 110.302 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.603 HG22 HG22 ' A' ' 60' ' ' ILE . 19.0 m -111.88 126.88 69.31 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.095 0 O-C-N 121.464 -0.773 . . . . 0.0 109.236 179.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.778 HG22 HG13 ' A' ' 73' ' ' VAL . 7.6 t -97.63 116.91 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.793 -1.192 . . . . 0.0 110.502 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.972 HG11 HD12 ' A' ' 51' ' ' LEU . 3.9 m -110.67 100.07 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.884 -1.135 . . . . 0.0 108.691 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.53 162.48 34.96 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.568 -1.332 . . . . 0.0 111.195 -178.109 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.505 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -90.8 -133.36 0.12 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.524 -0.735 . . . . 0.0 109.112 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.505 ' N ' HG23 ' A' ' 85' ' ' THR . 49.4 p-10 -90.02 41.74 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.583 -1.323 . . . . 0.0 110.147 179.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.91 -32.09 6.5 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.252 -0.905 . . . . 0.0 109.677 179.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.62 -34.29 46.72 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.92 . . . . 0.0 108.907 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.418 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 46.44 -96.19 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.767 -0.583 . . . . 0.0 110.526 179.71 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.683 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.09 57.02 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.807 -1.183 . . . . 0.0 110.745 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.05 -50.14 68.39 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 108.459 -1.856 . . . . 0.0 108.459 179.227 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.419 ' O ' ' CD2' ' A' ' 92' ' ' PHE . 51.8 p90 -137.51 38.69 2.45 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.597 -0.943 . . . . 0.0 109.918 179.715 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.694 HG23 ' N ' ' A' ' 94' ' ' GLY . 1.3 t -98.4 -153.77 0.44 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.938 . . . . 0.0 110.634 -179.402 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.694 ' N ' HG23 ' A' ' 93' ' ' THR . . . 109.75 7.56 27.39 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 179.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.74 68.87 1.1 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.783 -1.422 . . . . 0.0 110.785 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.505 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 22.6 m-85 -119.39 151.06 39.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.955 -1.09 . . . . 0.0 110.255 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.87 -28.4 20.38 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.348 -0.845 . . . . 0.0 109.417 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.553 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 5.8 p -160.87 163.33 32.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.397 -0.815 . . . . 0.0 110.675 179.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.415 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.15 115.39 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.348 -0.845 . . . . 0.0 110.093 179.72 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.975 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -95.52 111.29 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.16 -0.962 . . . . 0.0 108.579 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.7 t0 -119.65 161.17 21.13 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.159 -0.963 . . . . 0.0 111.786 -178.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.427 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.1 t -101.84 8.5 41.28 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.715 -0.616 . . . . 0.0 109.502 178.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.417 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.5 m-20 51.66 23.75 2.09 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.113 -0.992 . . . . 0.0 111.293 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.411 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p -145.13 128.71 17.09 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.17 -0.956 . . . . 0.0 109.972 179.141 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 3.8 p -113.07 134.49 54.51 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.316 -0.865 . . . . 0.0 110.189 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 54.16 41.5 31.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.182 -0.949 . . . . 0.0 110.297 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 65.15 19.77 66.41 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.412 ' HB2' ' O ' ' A' ' 105' ' ' SER . 0.9 OUTLIER -126.56 157.58 70.38 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.245 -1.15 . . . . 0.0 109.694 179.82 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -62.61 123.72 12.87 Favored 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.64 1.337 . . . . 0.0 110.196 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.51 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 -48.71 147.35 2.64 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.488 -0.757 . . . . 0.0 111.053 -179.163 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.436 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.9 p-10 -88.45 161.12 17.21 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.298 -0.876 . . . . 0.0 110.345 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.01 -54.97 7.49 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -178.248 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.476 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.67 -31.89 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 120.585 -1.322 . . . . 0.0 112.685 -177.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.51 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.41 -56.22 8.77 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.96 -1.088 . . . . 0.0 110.434 -179.266 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.485 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.74 -35.54 80.35 Favored 'General case' 0 C--O 1.205 -1.284 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.265 178.781 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.476 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.0 m -58.38 -49.2 78.08 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.353 -0.939 . . . . 0.0 108.541 178.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.08 -35.54 71.9 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.376 -0.827 . . . . 0.0 109.571 178.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.5 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.2 -45.18 61.41 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.239 -0.913 . . . . 0.0 110.931 -179.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.549 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 14.4 ttt180 -54.03 -45.17 71.52 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.045 -1.035 . . . . 0.0 109.995 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.58 64.19 0.29 Allowed Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.225 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.434 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.78 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.562 -0.964 . . . . 0.0 108.438 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.508 ' O ' HD11 ' A' ' 10' ' ' ILE . 10.9 t -96.12 142.87 27.79 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.621 -0.674 . . . . 0.0 109.478 178.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.68 33.25 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.47 -1.348 . . . . 0.0 110.94 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.422 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -61.29 87.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.047 -1.266 . . . . 0.0 109.397 179.607 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.87 -8.33 70.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -178.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.471 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.03 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.18 -1.188 . . . . 0.0 109.265 -179.799 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.471 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -89.04 97.46 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.379 1.199 . . . . 0.0 110.601 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.489 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.24 171.09 53.01 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -126.85 142.15 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.488 -1.007 . . . . 0.0 109.305 179.356 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.415 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.4 t80 -128.65 115.27 17.78 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.0 . . . . 0.0 110.314 179.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.428 ' HD2' ' HB ' ' A' ' 32' ' ' VAL . 4.1 mtp180 -104.73 122.8 46.44 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.433 -0.792 . . . . 0.0 109.17 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 29.8 p90 -121.53 157.5 30.55 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 110.415 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.567 ' O ' ' HB3' ' A' ' 134' ' ' ALA . 18.2 t -95.0 -56.01 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.567 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 63.34 146.85 0.09 OUTLIER Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.662 -0.649 . . . . 0.0 110.188 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.22 -52.08 0.19 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 123.768 1.404 . . . . 0.0 110.467 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 160.18 -151.69 22.35 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -86.42 159.19 19.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.268 -1.137 . . . . 0.0 110.173 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.176 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.3 t -83.87 146.48 28.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.199 -1.177 . . . . 0.0 110.368 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.9 p -113.16 104.63 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.293 -0.879 . . . . 0.0 109.571 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 16.4 p -80.11 145.61 32.3 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.32 -0.863 . . . . 0.0 110.775 -179.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.561 HG13 HG23 ' A' ' 116' ' ' THR . 0.2 OUTLIER -74.98 148.99 85.02 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.383 -0.823 . . . . 0.0 109.452 179.366 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.53 ' HD2' HG23 ' A' ' 5' ' ' VAL . 40.3 Cg_endo -71.16 -43.61 1.49 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 124.169 1.616 . . . . 0.0 112.839 -179.613 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.525 ' CG ' ' O ' ' A' ' 6' ' ' PRO . 13.5 p-80 41.26 85.39 0.16 Allowed Pre-proline 0 N--CA 1.498 1.94 0 O-C-N 122.128 -0.357 . . . . 0.0 110.774 -177.204 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.466 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 41.6 Cg_endo -68.3 -161.18 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.791 1.416 . . . . 0.0 110.157 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.466 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER 78.11 -35.91 0.2 Allowed 'General case' 0 N--CA 1.508 2.446 0 O-C-N 121.636 -0.665 . . . . 0.0 111.055 -179.192 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.491 HD13 HG22 ' A' ' 122' ' ' THR . 12.5 mt -95.79 124.92 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.574 -1.329 . . . . 0.0 109.892 179.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.57 128.02 34.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.138 -0.976 . . . . 0.0 109.554 179.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.97 132.95 35.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -0.943 . . . . 0.0 110.005 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.726 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 16.7 t -122.08 149.94 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.24 -0.912 . . . . 0.0 110.419 -179.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.85 21.65 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.268 -0.895 . . . . 0.0 109.706 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.885 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.0 tp -53.52 141.1 26.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.278 -0.889 . . . . 0.0 109.881 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.452 ' HA ' ' HD2' ' A' ' 26' ' ' LYS . 28.3 p -136.09 -178.49 5.17 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.253 -0.905 . . . . 0.0 110.526 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.8 p -79.74 71.19 6.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.375 -0.828 . . . . 0.0 109.887 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.689 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.9 m -146.12 112.71 5.94 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.317 -0.865 . . . . 0.0 110.424 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.441 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.81 28.42 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 118.731 -1.7 . . . . 0.0 111.173 179.228 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.62 10.4 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.783 -0.834 . . . . 0.0 110.306 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.14 107.94 41.06 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.666 -1.214 . . . . 0.0 110.098 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.446 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.5 Cg_endo -65.05 117.4 4.51 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 O-C-N 123.478 1.251 . . . . 0.0 110.645 -179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.5 -170.79 1.8 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.649 -0.657 . . . . 0.0 110.592 -179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.507 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.5 m-85 -57.73 82.26 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.552 -0.718 . . . . 0.0 111.634 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.15 -1.84 54.16 Favored Glycine 0 N--CA 1.493 2.437 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.684 179.405 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.885 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.1 mmtm -130.1 156.18 44.96 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.858 -1.378 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.689 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.83 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.94 -1.1 . . . . 0.0 109.427 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.9 mt -68.38 112.95 12.55 Favored Pre-proline 0 C--N 1.301 -1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 110.779 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.761 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.0 Cg_endo -68.26 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.564 0 N-CA-C 106.96 -1.977 . . . . 0.0 106.96 175.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.838 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.72 -16.65 6.81 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.826 -1.171 . . . . 0.0 110.652 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.83 -15.97 36.01 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.686 -1.259 . . . . 0.0 110.268 179.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.129 HG23 HG23 ' A' ' 33' ' ' ILE . 12.1 m -91.77 -25.71 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.011 -1.056 . . . . 0.0 111.213 -179.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.129 HG23 HG23 ' A' ' 32' ' ' VAL . 27.7 pt -118.48 -25.33 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.938 -1.101 . . . . 0.0 110.199 -179.496 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.602 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.41 148.18 22.5 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 110.648 179.828 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.87 57.77 Favored Glycine 0 N--CA 1.484 1.891 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.42 -151.27 8.74 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.127 -1.511 . . . . 0.0 110.278 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.45 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.3 mtt85 -109.74 132.37 54.21 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.53 -0.982 . . . . 0.0 110.1 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.551 ' HB2' HG12 ' A' ' 81' ' ' VAL . 90.9 m-70 -140.81 152.94 45.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.087 -1.008 . . . . 0.0 110.993 -179.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 54.9 tp -112.03 114.17 26.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.4 -0.812 . . . . 0.0 109.994 179.622 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.85 HD12 ' CG1' ' A' ' 83' ' ' VAL . 32.8 mt -98.37 129.2 48.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.594 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.4 123.82 38.04 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.304 -0.873 . . . . 0.0 109.751 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.86 158.83 23.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 110.801 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.507 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.17 4.28 20.91 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.439 -0.788 . . . . 0.0 110.023 179.203 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.11 137.05 38.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.058 -1.026 . . . . 0.0 110.618 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.481 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.59 -42.82 67.25 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.485 -0.76 . . . . 0.0 110.219 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.83 -39.21 84.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.882 . . . . 0.0 110.45 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.74 -35.11 76.69 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.352 -0.843 . . . . 0.0 109.344 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.906 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.14 -34.1 74.47 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.537 -0.727 . . . . 0.0 109.501 179.212 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.76 -49.43 62.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.235 -0.916 . . . . 0.0 110.255 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.79 -44.64 63.64 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -0.951 . . . . 0.0 110.146 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.716 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.17 -41.65 79.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.819 -179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.521 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.0 -51.16 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.03 -1.044 . . . . 0.0 110.382 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.08 96.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.12 -0.988 . . . . 0.0 109.675 179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.553 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.15 -44.91 83.86 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 179.485 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.7 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -55.1 -42.68 73.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.517 -0.739 . . . . 0.0 109.885 179.956 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.4 -32.09 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.007 -1.058 . . . . 0.0 108.807 178.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.4 -30.87 60.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.389 -0.82 . . . . 0.0 109.608 179.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.838 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.66 -26.17 62.43 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.833 0.825 . . . . 0.0 109.467 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.04 7.44 10.27 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.143 -1.583 . . . . 0.0 109.143 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.602 HD11 ' HB2' ' A' ' 34' ' ' LYS . 56.4 mt -108.26 143.24 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.277 -1.131 . . . . 0.0 110.349 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.93 107.56 17.78 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.924 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.655 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -122.01 144.62 48.78 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.019 -1.072 . . . . 0.0 111.643 -177.558 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.932 HG21 ' HA ' ' A' ' 73' ' ' VAL . 45.2 t -130.3 143.58 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 C-N-CA 119.976 -0.69 . . . . 0.0 109.512 179.083 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.906 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -109.49 118.36 36.41 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.95 179.094 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.462 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.65 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.26 -0.9 . . . . 0.0 110.574 -179.59 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.748 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.2 p90 -167.31 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.544 -0.723 . . . . 0.0 109.757 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.24 127.14 30.6 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.165 -0.96 . . . . 0.0 110.764 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.32 37.77 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.4 tm? -117.09 155.81 28.64 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.156 -1.203 . . . . 0.0 110.101 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.895 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.24 22.01 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.366 -0.834 . . . . 0.0 110.545 -179.351 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.679 ' O ' HG23 ' A' ' 71' ' ' VAL . 29.5 m -62.1 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 119.061 -1.055 . . . . 0.0 109.002 179.229 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.72 -15.45 2.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.507 -0.746 . . . . 0.0 111.413 -178.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.932 ' HA ' HG21 ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.06 23.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.072 -1.017 . . . . 0.0 109.471 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.676 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.6 pp -137.33 98.8 9.98 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.261 -0.899 . . . . 0.0 111.004 -179.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.658 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.9 Cg_endo -81.55 51.57 3.92 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 O-C-N 123.583 1.307 . . . . 0.0 110.44 179.24 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.9 p -141.89 8.97 1.92 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.943 -1.098 . . . . 0.0 111.089 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -108.64 -165.51 1.04 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.898 -1.126 . . . . 0.0 109.906 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.08 -91.86 0.01 OUTLIER Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.797 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.422 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.7 m-20 -124.23 113.67 18.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.171 -1.193 . . . . 0.0 109.998 179.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.658 HG11 ' HA ' ' A' ' 75' ' ' PRO . 8.2 p -115.06 130.91 68.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 CA-C-O 122.152 0.977 . . . . 0.0 110.414 -179.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 60' ' ' ILE . 6.9 m -113.0 123.04 68.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 O-C-N 121.351 -0.843 . . . . 0.0 109.104 179.052 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.661 ' O ' HD12 ' A' ' 39' ' ' LEU . 4.7 t -97.06 118.07 42.82 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 O-C-N 121.056 -1.028 . . . . 0.0 110.149 -177.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.85 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.9 m -111.19 100.3 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.809 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.462 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.46 162.64 34.99 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.765 -1.209 . . . . 0.0 111.122 -178.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -90.17 -139.26 0.14 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.598 -0.689 . . . . 0.0 109.4 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.41 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -86.01 48.05 1.55 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.806 -1.184 . . . . 0.0 109.99 179.706 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.454 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.24 -19.22 7.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.173 -0.955 . . . . 0.0 110.646 -179.671 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp -62.48 -23.54 66.97 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.671 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.514 ' C ' HG22 ' A' ' 90' ' ' THR . 32.4 mmt 49.89 37.23 13.13 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.412 -0.805 . . . . 0.0 110.923 179.548 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.514 HG22 ' C ' ' A' ' 89' ' ' MET . 3.1 t 32.68 42.7 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.189 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 178.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.09 -38.55 88.38 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -136.24 12.42 3.29 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.489 -1.007 . . . . 0.0 110.758 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.489 ' HA ' ' CE2' ' A' ' 96' ' ' PHE . 14.9 t -67.41 -158.98 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.981 -1.074 . . . . 0.0 110.478 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.453 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 90.35 -50.95 3.34 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.06 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -84.2 60.21 5.79 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.993 -1.298 . . . . 0.0 110.965 -179.241 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.489 ' CE2' ' HA ' ' A' ' 93' ' ' THR . 20.3 m-85 -119.74 144.86 47.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.075 -1.016 . . . . 0.0 109.918 178.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.49 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.21 -33.44 63.39 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.502 179.334 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -162.88 163.56 26.35 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.272 -0.892 . . . . 0.0 110.913 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.19 116.58 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.331 -0.855 . . . . 0.0 110.078 179.062 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.865 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -93.37 118.41 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.178 -0.951 . . . . 0.0 109.031 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.402 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.3 t0 -126.85 160.87 29.66 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.119 -0.988 . . . . 0.0 111.454 -178.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.412 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 37.0 t -101.59 7.26 42.26 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.685 -0.634 . . . . 0.0 109.393 178.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.406 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 49.07 33.2 4.54 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.143 -0.973 . . . . 0.0 111.111 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.441 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p -147.52 130.36 16.14 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.877 -1.139 . . . . 0.0 110.819 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.446 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.6 p -114.0 127.69 56.06 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.253 -0.905 . . . . 0.0 109.907 179.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 26.9 t70 54.95 28.99 11.38 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.172 -0.955 . . . . 0.0 110.487 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.92 -36.18 3.91 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.85 156.6 82.48 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.32 -1.106 . . . . 0.0 109.966 179.873 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -64.75 138.96 60.77 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 O-C-N 123.469 1.247 . . . . 0.0 109.962 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.42 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 -49.77 150.64 2.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.276 -0.89 . . . . 0.0 110.837 -179.018 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.5 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.7 p30 -80.74 161.49 24.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -0.954 . . . . 0.0 109.664 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.44 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.32 -57.05 4.29 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.202 -0.936 . . . . 0.0 111.847 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.5 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -66.17 -28.34 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 120.823 -1.173 . . . . 0.0 111.729 -178.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.12 -56.27 6.89 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.994 -1.066 . . . . 0.0 110.715 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.457 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.55 -35.91 78.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.108 -0.995 . . . . 0.0 108.836 178.931 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.561 HG23 HG13 ' A' ' 5' ' ' VAL . 88.1 m -59.27 -49.48 77.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.066 -1.021 . . . . 0.0 108.598 178.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.74 -35.52 65.07 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.493 -0.755 . . . . 0.0 109.754 178.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.447 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.58 -44.81 63.81 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 110.844 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.497 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 2.8 ttm180 -55.01 -37.97 67.29 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.9 -1.125 . . . . 0.0 109.721 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.419 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.53 77.21 0.13 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.419 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -153.38 -49.08 0.1 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.462 -1.022 . . . . 0.0 108.522 179.51 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.542 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.7 t -93.14 143.3 26.38 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.369 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.25 15.96 5.85 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.263 -1.446 . . . . 0.0 110.405 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.453 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 25.4 mmt180 -92.9 83.02 4.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.065 -1.256 . . . . 0.0 110.106 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.12 -26.83 6.01 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.49 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.29 -166.51 0.15 Allowed Pre-proline 0 N--CA 1.488 1.456 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.61 115.02 2.44 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.025 1.013 . . . . 0.0 110.545 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.542 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.99 172.09 55.22 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.409 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mp -132.76 142.6 41.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.283 -1.128 . . . . 0.0 109.432 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.501 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.24 115.21 17.29 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.316 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.726 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.67 122.54 43.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.398 -0.814 . . . . 0.0 109.213 179.505 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.406 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 50.3 p90 -117.44 149.71 40.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.036 -1.04 . . . . 0.0 110.228 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.412 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 48.8 t -78.43 -61.08 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.207 -0.933 . . . . 0.0 110.079 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.617 ' HB1' ' HD2' ' A' ' 135' ' ' PRO . . . -115.97 170.76 5.35 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.295 -0.878 . . . . 0.0 110.425 -179.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.617 ' HD2' ' HB1' ' A' ' 134' ' ' ALA . 48.8 Cg_endo -74.72 -50.33 0.14 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.776 1.408 . . . . 0.0 110.317 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 112.02 87.09 1.67 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -85.08 -164.72 1.03 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.247 -1.149 . . . . 0.0 110.339 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.257 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.27 138.0 31.93 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.245 -1.15 . . . . 0.0 110.0 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 3' ' ' VAL . 8.9 m -113.13 104.09 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.179 -0.95 . . . . 0.0 109.943 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.0 p -73.45 135.81 44.16 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.332 -0.855 . . . . 0.0 110.224 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.414 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.12 147.5 99.02 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.297 -0.877 . . . . 0.0 109.146 179.623 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.442 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 49.9 Cg_endo -73.6 -168.87 0.48 Allowed 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 124.053 1.554 . . . . 0.0 110.644 179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.528 ' CD2' ' HD3' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 173.67 81.27 0.05 OUTLIER Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.644 -0.66 . . . . 0.0 109.226 -179.758 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.52 -5.87 17.95 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.788 1.415 . . . . 0.0 111.187 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.2 m120 -69.56 -14.32 62.79 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.908 -1.12 . . . . 0.0 110.406 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.476 HD13 HG22 ' A' ' 122' ' ' THR . 34.0 mt -119.62 136.17 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.906 -1.121 . . . . 0.0 110.436 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.79 128.89 34.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.319 -0.863 . . . . 0.0 109.543 179.449 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.24 132.42 34.89 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.226 -0.921 . . . . 0.0 110.339 -179.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.792 HG11 ' NH1' ' A' ' 131' ' ' ARG . 29.5 t -122.64 157.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.45 -0.781 . . . . 0.0 110.246 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.04 110.64 22.82 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.209 -0.932 . . . . 0.0 109.851 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.564 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -62.63 134.77 56.82 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.279 -0.888 . . . . 0.0 109.68 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.68 179.52 6.18 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.911 . . . . 0.0 110.176 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.92 74.47 2.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 109.631 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.692 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -144.55 111.61 5.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.336 -0.853 . . . . 0.0 110.576 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.48 -159.35 27.18 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.561 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.94 -24.78 5.99 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.602 -0.94 . . . . 0.0 110.522 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.921 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -95.86 108.76 42.6 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.618 -1.233 . . . . 0.0 110.492 -179.399 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.475 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.33 154.56 70.61 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.341 1.18 . . . . 0.0 109.897 179.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.501 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.3 t80 -167.79 95.02 0.42 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.147 -0.971 . . . . 0.0 110.891 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.463 ' HH ' ' CE1' ' A' ' 43' ' ' HIS . 66.8 m-85 60.33 65.48 1.07 Allowed 'General case' 0 N--CA 1.502 2.153 0 O-C-N 121.5 -0.75 . . . . 0.0 111.188 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 15.87 16.53 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.56 ' HG3' HG13 ' A' ' 133' ' ' VAL . 3.6 mmtt -130.54 157.26 43.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.182 -1.187 . . . . 0.0 109.389 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.692 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.98 107.39 14.91 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.77 -1.206 . . . . 0.0 109.719 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.989 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -69.84 114.03 21.85 Favored Pre-proline 0 C--N 1.301 -1.523 0 O-C-N 121.294 -0.879 . . . . 0.0 110.461 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.764 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.3 Cg_endo -69.14 130.09 19.45 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 N-CA-C 106.586 -2.121 . . . . 0.0 106.586 175.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.486 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -56.16 -18.32 9.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.734 -1.228 . . . . 0.0 110.528 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.429 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.33 -15.91 19.08 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.662 -1.274 . . . . 0.0 110.693 179.68 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.079 HG23 HG23 ' A' ' 33' ' ' ILE . 12.3 m -92.46 -25.14 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 120.884 -1.135 . . . . 0.0 110.995 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.079 HG23 HG23 ' A' ' 32' ' ' VAL . 10.3 pt -116.89 -22.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 -179.403 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.53 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptt -92.67 148.46 22.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.001 -1.062 . . . . 0.0 109.97 179.208 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.71 -5.68 43.76 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.6 -152.66 11.2 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.086 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.46 131.41 52.91 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.314 -1.109 . . . . 0.0 110.292 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.55 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.41 153.73 51.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.154 -0.966 . . . . 0.0 110.943 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.526 ' HB3' HG12 ' A' ' 99' ' ' VAL . 65.5 tp -114.45 118.27 33.33 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.371 -0.83 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.865 HD12 ' CG1' ' A' ' 83' ' ' VAL . 30.2 mt -104.39 127.92 58.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.127 -0.983 . . . . 0.0 109.673 179.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -95.74 122.73 38.82 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.242 -0.911 . . . . 0.0 110.097 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.79 159.01 23.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.523 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.463 ' CE1' ' HH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.31 26.84 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 110.375 179.18 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.74 136.34 37.24 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.09 -1.007 . . . . 0.0 110.916 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.46 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.0 69.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.557 -0.714 . . . . 0.0 110.232 179.784 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.31 -36.48 84.26 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.282 -0.886 . . . . 0.0 110.421 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.82 -36.48 75.66 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.233 -0.917 . . . . 0.0 109.513 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.936 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 98.7 m -61.65 -34.05 75.03 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.439 -0.788 . . . . 0.0 109.684 179.465 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.35 -49.42 64.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.175 -0.953 . . . . 0.0 109.957 179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.79 -45.66 60.87 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.097 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.668 HD13 ' O ' ' A' ' 51' ' ' LEU . 2.1 tm? -56.49 -41.67 77.01 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.446 -0.784 . . . . 0.0 110.567 -179.411 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.416 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -76.0 -51.43 12.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.092 -1.005 . . . . 0.0 110.236 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.402 ' O ' ' HB ' ' A' ' 56' ' ' VAL . . . -61.44 -42.04 98.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.985 -1.072 . . . . 0.0 109.652 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.528 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.09 -44.39 83.09 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.167 -0.958 . . . . 0.0 109.644 179.614 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.772 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.11 -41.58 71.84 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.345 -0.847 . . . . 0.0 109.612 179.735 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 53' ' ' ALA . 78.6 t -56.27 -33.18 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.146 -0.971 . . . . 0.0 108.815 179.054 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.0 -32.05 59.23 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.5 -0.75 . . . . 0.0 110.131 179.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.528 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.62 -26.42 62.57 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.332 -0.855 . . . . 0.0 109.712 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.09 8.36 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.608 HG22 HG22 ' A' ' 81' ' ' VAL . 49.4 mt -108.15 143.94 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.202 -1.175 . . . . 0.0 110.32 -179.677 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.774 HD22 HG23 ' A' ' 80' ' ' VAL . 1.3 t30 -86.84 107.1 18.16 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 178.121 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.577 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.86 147.71 45.03 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.62 -177.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.94 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.9 t -136.11 148.71 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 C-N-CA 119.671 -0.812 . . . . 0.0 109.507 179.308 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.936 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.32 126.95 55.45 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.321 -0.952 . . . . 0.0 110.095 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.48 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 5.4 t80 -117.48 125.9 51.69 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 110.713 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.906 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.5 p90 -157.76 -174.85 5.05 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.63 123.64 11.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 0.0 111.26 -179.212 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.65 47.73 32.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.931 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.27 155.7 29.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.07 -1.253 . . . . 0.0 109.807 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.931 ' N ' HD13 ' A' ' 69' ' ' LEU . 7.7 m-20 -92.12 148.6 22.04 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.201 -0.937 . . . . 0.0 110.825 -179.18 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.662 ' O ' HG23 ' A' ' 71' ' ' VAL . 30.4 m -62.8 111.22 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.055 -1.028 . . . . 0.0 109.336 179.068 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.756 ' O ' HG23 ' A' ' 74' ' ' ILE . 10.6 m -134.58 -35.96 0.88 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.375 -0.828 . . . . 0.0 110.849 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.94 HG22 ' HB ' ' A' ' 63' ' ' VAL . 24.9 t -51.38 135.85 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.032 -1.043 . . . . 0.0 110.055 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.756 HG23 ' O ' ' A' ' 72' ' ' SER . 1.4 pp -136.16 95.06 13.62 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.263 -0.898 . . . . 0.0 110.724 -179.447 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.69 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.3 Cg_endo -81.42 52.83 4.44 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.622 1.327 . . . . 0.0 110.88 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.7 t -149.98 17.73 0.87 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.968 -1.082 . . . . 0.0 110.689 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -112.6 -165.84 1.03 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.099 -1.001 . . . . 0.0 110.169 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.09 -66.29 2.7 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 m-20 -151.84 110.92 3.88 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.219 -1.165 . . . . 0.0 110.211 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.774 HG23 HD22 ' A' ' 61' ' ' ASN . 7.6 p -117.33 133.27 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 CA-C-O 122.003 0.906 . . . . 0.0 110.347 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 60' ' ' ILE . 9.5 m -111.93 124.2 68.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.202 0 O-C-N 121.311 -0.868 . . . . 0.0 108.773 178.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.735 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -97.24 120.99 47.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 110.306 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.865 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.6 m -116.47 100.48 10.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.971 -1.081 . . . . 0.0 108.7 179.592 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.48 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -138.4 162.22 35.0 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.683 -1.261 . . . . 0.0 111.454 -177.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.605 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.1 t -87.24 -132.27 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.612 -0.68 . . . . 0.0 109.708 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.605 ' N ' HG23 ' A' ' 85' ' ' THR . 3.7 p30 -91.5 32.83 1.04 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.803 -1.186 . . . . 0.0 110.594 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.475 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.49 -32.96 9.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.095 -1.003 . . . . 0.0 109.887 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp -76.23 -45.49 32.65 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.341 -0.85 . . . . 0.0 109.254 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.433 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.6 OUTLIER 53.23 20.72 1.96 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.563 -0.71 . . . . 0.0 110.717 179.644 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.499 HG23 ' HB ' ' A' ' 93' ' ' THR . 0.7 OUTLIER 48.08 32.67 3.06 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.184 -0.947 . . . . 0.0 110.578 179.584 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.83 -67.85 1.9 Allowed Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.433 ' CD1' ' O ' ' A' ' 92' ' ' PHE . 53.3 p90 -96.72 34.01 1.75 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -1.145 . . . . 0.0 109.136 179.077 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.505 HG21 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -131.23 -151.67 0.47 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.579 -0.701 . . . . 0.0 110.281 -179.351 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 124.42 -35.8 3.09 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.556 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -84.6 80.15 9.34 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.928 -1.337 . . . . 0.0 110.839 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.505 ' CZ ' HG21 ' A' ' 93' ' ' THR . 27.1 m-85 -119.07 148.16 43.34 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.18 -0.95 . . . . 0.0 109.906 178.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.432 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.95 -32.25 61.68 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.272 -0.893 . . . . 0.0 109.486 179.294 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.463 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.0 p -162.51 163.79 27.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.218 -0.927 . . . . 0.0 111.207 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.564 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.47 22.97 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.452 -0.78 . . . . 0.0 110.3 179.347 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.989 HG21 HD11 ' A' ' 28' ' ' ILE . 3.1 mp -92.88 117.78 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.893 . . . . 0.0 108.795 179.145 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.19 20.5 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.07 -1.019 . . . . 0.0 112.107 -178.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.22 -11.66 34.81 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.429 ' O ' ' NE2' ' A' ' 110' ' ' GLN . 3.7 m120 55.58 12.37 0.78 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.294 -0.879 . . . . 0.0 112.487 179.091 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.432 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.0 OUTLIER -147.5 122.16 9.85 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 120.491 -1.38 . . . . 0.0 109.495 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.466 ' N ' ' O ' ' A' ' 108' ' ' LYS . 32.7 p -102.59 131.47 49.32 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.296 -0.877 . . . . 0.0 110.248 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 56.04 30.69 16.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.334 -0.854 . . . . 0.0 111.0 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.39 -29.71 8.02 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.466 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -85.29 154.42 59.91 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.005 -1.291 . . . . 0.0 110.131 -179.937 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.83 139.26 56.45 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.584 1.307 . . . . 0.0 110.256 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.429 ' NE2' ' O ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -48.14 164.69 0.05 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.304 -0.872 . . . . 0.0 110.851 -179.434 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.547 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -88.92 160.36 17.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.9 . . . . 0.0 109.85 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.403 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.85 -51.13 7.66 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.424 -0.798 . . . . 0.0 112.317 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.547 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.44 -29.7 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.795 -1.19 . . . . 0.0 111.447 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.443 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.08 -56.47 6.48 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.08 -1.013 . . . . 0.0 110.402 -179.204 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.9 OUTLIER -69.49 -34.38 74.24 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 121.301 -0.874 . . . . 0.0 108.688 178.756 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.458 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 22.5 m -59.22 -50.02 75.6 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.164 -0.96 . . . . 0.0 108.454 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.93 -39.52 63.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.808 -0.757 . . . . 0.0 109.763 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.405 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 2.2 mtt180 -67.47 -44.32 78.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.168 -0.958 . . . . 0.0 110.557 -179.752 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.528 ' HD3' ' CD2' ' A' ' 7' ' ' HIS . 7.0 ttm180 -60.47 -39.06 86.25 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.026 -1.046 . . . . 0.0 110.057 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.74 66.69 0.44 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.06 -46.6 0.3 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.514 -0.992 . . . . 0.0 108.602 179.471 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.518 HG23 ' HA3' ' A' ' 128' ' ' GLY . 15.0 t -94.45 142.13 27.79 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.375 -0.828 . . . . 0.0 109.136 178.657 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.462 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.89 10.03 19.45 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.556 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.0 mmt85 -69.3 86.96 0.42 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.011 -1.288 . . . . 0.0 109.69 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.2 22.17 33.19 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.076 -1.61 . . . . 0.0 109.076 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.479 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.85 -178.31 0.29 Allowed Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.514 -0.992 . . . . 0.0 108.717 -179.515 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.3 Cg_endo -89.65 103.94 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.258 1.136 . . . . 0.0 110.126 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.518 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -77.61 156.84 45.09 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.924 -1.131 . . . . 0.0 110.605 -179.303 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 38.8 mt -111.05 142.06 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.479 -1.012 . . . . 0.0 109.046 178.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.564 ' CD2' HG23 ' A' ' 99' ' ' VAL . 5.4 t80 -132.09 118.91 20.27 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.09 -1.006 . . . . 0.0 110.785 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.792 ' NH1' HG11 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -101.51 124.04 46.52 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.454 -0.779 . . . . 0.0 109.477 179.158 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.471 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.6 p90 -118.04 155.87 29.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 110.229 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.564 HG22 HD23 ' A' ' 15' ' ' LEU . 71.1 t -95.36 -24.11 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.168 -0.958 . . . . 0.0 109.869 179.602 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -148.03 124.64 5.48 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.295 -0.878 . . . . 0.0 110.164 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -76.46 -50.76 0.1 Allowed 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.484 1.255 . . . . 0.0 110.358 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 66.73 113.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -100.73 83.89 2.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.188 -1.183 . . . . 0.0 110.295 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 69.5 ttt180 . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.167 -179.931 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.568 ' OG ' ' HB2' ' A' ' 112' ' ' ALA . 2.5 t -84.11 106.31 15.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.197 -1.178 . . . . 0.0 110.313 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.551 ' O ' HG23 ' A' ' 3' ' ' VAL . 19.3 m -113.16 104.36 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.314 -0.866 . . . . 0.0 110.059 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.771 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 50.8 p -88.5 136.34 33.04 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.333 -0.855 . . . . 0.0 110.232 179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.407 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.67 147.25 98.68 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.306 -0.871 . . . . 0.0 109.647 179.639 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.415 ' O ' ' CB ' ' A' ' 7' ' ' HIS . 55.9 Cg_endo -81.96 -169.34 0.74 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 124.102 1.58 . . . . 0.0 110.909 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.534 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 169.75 80.84 0.03 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 N-CA-C 109.074 -0.714 . . . . 0.0 109.074 179.14 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -65.7 108.81 1.31 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.826 1.435 . . . . 0.0 110.875 -179.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.454 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.8 t-20 179.69 -32.48 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.789 0 CA-C-O 121.512 0.672 . . . . 0.0 109.424 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.528 HD13 ' CG2' ' A' ' 122' ' ' THR . 33.0 mt -103.48 136.34 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.011 -1.056 . . . . 0.0 110.094 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.9 129.46 35.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 109.322 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.75 34.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.173 -0.954 . . . . 0.0 110.294 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.465 HG11 ' NE ' ' A' ' 131' ' ' ARG . 20.4 t -117.84 155.0 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.641 -0.662 . . . . 0.0 110.026 -179.422 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.19 106.89 17.58 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -0.932 . . . . 0.0 109.968 179.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.669 HD23 HG22 ' A' ' 133' ' ' VAL . 12.5 tp -57.6 132.16 52.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.361 -0.837 . . . . 0.0 109.593 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.8 p -135.84 -166.95 1.94 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.192 -0.942 . . . . 0.0 110.587 -179.516 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.1 p -82.49 83.45 7.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.436 -0.79 . . . . 0.0 109.917 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.701 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 11.0 m -156.9 110.04 2.58 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.302 -0.874 . . . . 0.0 110.541 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.38 28.52 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 118.895 -1.622 . . . . 0.0 110.956 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.417 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -117.49 -24.68 7.23 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.78 -0.835 . . . . 0.0 110.404 -179.906 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.882 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -93.86 103.48 10.4 Favored Pre-proline 0 N--CA 1.485 1.303 0 C-N-CA 118.496 -1.281 . . . . 0.0 109.99 -179.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.61 118.76 5.66 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 O-C-N 123.682 1.359 . . . . 0.0 110.558 -179.564 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.62 -168.74 1.39 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.736 -0.602 . . . . 0.0 110.718 -178.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.435 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.09 81.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.592 -0.693 . . . . 0.0 111.71 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.4 -1.68 49.53 Favored Glycine 0 N--CA 1.495 2.625 0 C-N-CA 120.148 -1.025 . . . . 0.0 110.809 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.463 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.13 156.41 44.6 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.899 -1.353 . . . . 0.0 109.304 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.701 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.22 107.09 17.89 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.837 -1.164 . . . . 0.0 108.993 179.401 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.931 HD11 HG21 ' A' ' 100' ' ' ILE . 4.0 mt -67.37 113.58 14.65 Favored Pre-proline 0 C--N 1.302 -1.475 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.798 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.3 Cg_endo -68.85 127.36 15.21 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 N-CA-C 106.828 -2.028 . . . . 0.0 106.828 175.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.556 HD11 HD12 ' A' ' 58' ' ' LEU . 8.7 mt -55.93 -17.98 7.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.897 -1.127 . . . . 0.0 110.791 -177.538 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.69 -16.36 26.27 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.639 -1.288 . . . . 0.0 110.26 179.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.035 HG23 HG23 ' A' ' 33' ' ' ILE . 12.4 m -90.97 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.008 -1.058 . . . . 0.0 110.884 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.035 HG23 HG23 ' A' ' 32' ' ' VAL . 20.3 pt -117.46 -18.64 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.996 -1.065 . . . . 0.0 110.633 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.606 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.65 148.24 23.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.867 -1.146 . . . . 0.0 110.169 179.537 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.97 36.67 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.375 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.2 -143.63 6.08 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.153 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.465 ' HG2' HG12 ' A' ' 80' ' ' VAL . 8.9 mtt85 -111.25 134.57 52.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.396 -1.061 . . . . 0.0 110.313 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.572 ' HB2' HG12 ' A' ' 81' ' ' VAL . 66.4 m80 -141.14 150.73 43.19 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.089 -1.007 . . . . 0.0 111.077 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.7 tp -110.01 115.07 29.11 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.478 -0.764 . . . . 0.0 110.013 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.824 HD12 ' CG1' ' A' ' 83' ' ' VAL . 26.6 mt -98.79 127.27 51.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.113 -0.992 . . . . 0.0 109.821 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.428 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 29.5 m-85 -95.35 124.67 39.5 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.453 -0.78 . . . . 0.0 110.084 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.66 157.77 24.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.163 -0.961 . . . . 0.0 110.642 -179.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.435 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 15.0 p80 -101.96 -2.95 28.61 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 110.29 179.288 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.55 46.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.111 -0.993 . . . . 0.0 110.288 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -70.59 -37.49 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.47 -0.769 . . . . 0.0 110.757 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.57 -36.06 77.57 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.172 -0.955 . . . . 0.0 110.291 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.42 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -71.63 -32.75 68.3 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.424 -0.798 . . . . 0.0 109.253 179.835 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.703 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.74 74.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.35 -0.844 . . . . 0.0 109.095 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.88 -48.86 64.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.379 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.86 -44.39 63.89 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.236 -0.915 . . . . 0.0 110.631 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.751 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -56.81 -38.94 73.28 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.459 -0.776 . . . . 0.0 111.235 -178.937 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.84 -51.36 12.72 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.868 -1.145 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -40.78 97.26 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.01 -1.056 . . . . 0.0 109.672 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.545 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.94 83.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.522 179.447 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.741 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.37 -40.99 72.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.478 -0.764 . . . . 0.0 109.978 179.937 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -56.3 -33.81 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.135 -0.978 . . . . 0.0 108.899 179.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.88 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.333 -0.854 . . . . 0.0 110.078 179.357 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.556 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.47 -25.94 62.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.426 179.609 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.0 5.67 10.59 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.606 HD11 ' HB2' ' A' ' 34' ' ' LYS . 33.7 mt -108.42 143.46 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.475 -1.015 . . . . 0.0 110.235 -179.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.663 HD22 HG23 ' A' ' 80' ' ' VAL . 0.6 OUTLIER -87.98 106.92 18.45 Favored 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.056 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.693 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -118.56 146.97 44.18 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.748 -1.181 . . . . 0.0 111.922 -177.163 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.939 HG21 ' HA ' ' A' ' 73' ' ' VAL . 19.6 t -129.32 149.34 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.706 -0.621 . . . . 0.0 109.884 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.703 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.03 123.84 50.67 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.261 -0.975 . . . . 0.0 109.861 178.652 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.45 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -114.04 134.68 54.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.923 . . . . 0.0 111.013 -179.31 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.986 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.1 p90 -171.01 -179.82 2.86 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.381 -0.825 . . . . 0.0 110.174 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.24 126.27 18.39 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.209 -0.932 . . . . 0.0 111.02 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.1 46.5 35.31 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.338 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.986 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.49 154.74 30.91 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.127 -1.219 . . . . 0.0 109.891 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.836 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.1 m-20 -93.16 149.83 20.95 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.271 -0.893 . . . . 0.0 110.651 -179.229 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.69 ' O ' HG23 ' A' ' 71' ' ' VAL . 34.1 m -61.69 111.15 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 119.041 -1.064 . . . . 0.0 108.829 179.104 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.933 ' O ' HG23 ' A' ' 74' ' ' ILE . 74.1 m -132.42 -34.71 1.19 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 110.749 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.939 ' HA ' HG21 ' A' ' 63' ' ' VAL . 58.7 t -47.69 125.18 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.246 -0.909 . . . . 0.0 109.612 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.933 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -136.7 113.33 10.0 Favored Pre-proline 0 N--CA 1.497 1.894 0 O-C-N 121.098 -1.001 . . . . 0.0 111.751 -178.373 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.462 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.1 Cg_endo -89.29 40.96 0.51 Allowed 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.575 1.303 . . . . 0.0 110.343 178.705 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.0 p -142.59 47.7 1.56 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.015 -1.053 . . . . 0.0 110.704 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.515 ' ND2' HD13 ' A' ' 74' ' ' ILE . 5.5 m-80 -148.46 27.38 0.92 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.159 -0.963 . . . . 0.0 110.253 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.7 -94.55 1.39 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -128.31 111.67 13.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.153 -1.204 . . . . 0.0 110.087 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.663 HG23 HD22 ' A' ' 61' ' ' ASN . 7.9 p -117.2 134.96 59.13 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 CA-C-O 122.124 0.964 . . . . 0.0 110.084 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.596 HG22 HG22 ' A' ' 60' ' ' ILE . 5.3 m -113.99 122.05 67.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.28 0 O-C-N 121.296 -0.877 . . . . 0.0 109.229 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.766 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -96.84 117.87 42.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 120.916 -1.115 . . . . 0.0 110.308 -178.054 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.824 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -108.81 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.244 -0.982 . . . . 0.0 108.916 179.548 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.444 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.23 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.658 -1.276 . . . . 0.0 110.656 -178.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.04 -34.48 15.09 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 110.679 -179.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -178.01 -29.57 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.114 -0.991 . . . . 0.0 111.066 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.518 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -44.88 -34.09 2.22 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.178 -0.951 . . . . 0.0 111.073 -179.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.445 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.7 tp -66.99 -33.87 76.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.087 -1.008 . . . . 0.0 109.772 179.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.548 ' C ' HG22 ' A' ' 90' ' ' THR . 4.4 mmt 55.1 -87.47 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.585 -0.697 . . . . 0.0 110.526 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.548 HG22 ' C ' ' A' ' 89' ' ' MET . 0.0 OUTLIER -179.54 -91.76 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.006 -1.059 . . . . 0.0 110.438 -179.853 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.425 ' H ' HG23 ' A' ' 90' ' ' THR . . . 70.14 -65.42 0.72 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.41 ' N ' ' O ' ' A' ' 90' ' ' THR . 38.0 p90 -128.2 13.94 6.69 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.073 -1.251 . . . . 0.0 110.881 -179.657 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.545 HG22 ' OG1' ' A' ' 90' ' ' THR . 14.6 t -75.49 -167.23 0.63 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.11 -0.994 . . . . 0.0 110.398 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.437 ' O ' ' CD ' ' A' ' 124' ' ' ARG . . . 113.11 -37.58 3.57 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -84.42 65.4 8.9 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.95 -1.323 . . . . 0.0 110.776 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 22.1 m-85 -119.83 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.055 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.448 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.68 -29.32 27.69 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.492 -0.755 . . . . 0.0 109.976 179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.66 163.66 29.71 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.141 -0.975 . . . . 0.0 111.351 -179.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.519 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.22 114.4 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.439 -0.788 . . . . 0.0 109.922 179.141 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.931 HG21 HD11 ' A' ' 28' ' ' ILE . 3.7 mp -93.0 115.64 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.244 -0.91 . . . . 0.0 109.297 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.95 160.94 25.17 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.169 -0.957 . . . . 0.0 111.53 -178.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.418 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.64 3.75 42.74 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.628 -0.67 . . . . 0.0 109.504 178.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.48 23.88 0.66 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.266 -0.896 . . . . 0.0 111.254 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.9 HG22 ' HA ' ' A' ' 109' ' ' PRO . 0.8 OUTLIER -146.76 135.77 22.45 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.959 -1.088 . . . . 0.0 110.476 179.283 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.7 p -114.76 132.69 56.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.262 -0.899 . . . . 0.0 109.908 179.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t0 52.55 -142.65 0.75 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.008 -1.058 . . . . 0.0 109.826 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.19 17.29 43.38 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 179.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 5.6 mmtp -129.43 156.26 78.82 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.101 -1.235 . . . . 0.0 109.432 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.9 ' HA ' HG22 ' A' ' 104' ' ' THR . 39.0 Cg_endo -64.29 167.07 15.37 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 123.581 1.306 . . . . 0.0 110.48 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.512 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 13.9 tt0 -70.8 154.84 41.47 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.417 -0.802 . . . . 0.0 110.902 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.416 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.3 p-10 -88.27 161.5 17.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.567 -0.708 . . . . 0.0 110.092 179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.771 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -52.31 -61.79 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.346 -0.846 . . . . 0.0 112.29 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.432 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 7.2 m -58.1 -29.79 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 120.765 -1.209 . . . . 0.0 112.004 -177.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.512 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.82 -56.22 7.95 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.011 -1.055 . . . . 0.0 110.489 -179.293 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.436 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.49 -33.9 76.73 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.207 -0.933 . . . . 0.0 108.941 178.94 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.432 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.0 m -60.29 -49.82 76.1 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 120.999 -1.063 . . . . 0.0 108.452 178.462 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -73.93 -38.02 64.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 178.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 40.6 mtt85 -72.16 -44.85 62.43 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.222 -0.924 . . . . 0.0 111.477 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.534 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -54.59 -45.38 73.58 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.787 -1.195 . . . . 0.0 109.495 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.28 81.71 0.03 OUTLIER Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.73 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.28 -1.008 . . . . 0.0 108.28 179.606 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.528 ' CG2' HD13 ' A' ' 10' ' ' ILE . 8.7 t -93.13 143.47 26.22 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.56 1.7 19.74 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.646 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.437 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -70.24 85.9 0.57 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.978 -1.307 . . . . 0.0 110.13 -179.801 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.1 -38.04 2.89 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.87 -166.87 0.13 Allowed Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.508 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.0 Cg_endo -86.31 114.81 1.31 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.086 1.045 . . . . 0.0 109.647 179.202 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.522 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.4 167.88 54.81 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.504 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.83 138.74 49.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.451 -1.029 . . . . 0.0 108.62 178.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.519 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.26 118.78 22.88 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.218 -0.993 . . . . 0.0 110.581 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.5 ' HD2' HG11 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.31 127.14 53.03 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.487 -0.758 . . . . 0.0 109.879 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' A' ' 134' ' ' ALA . 10.4 p90 -118.84 158.5 25.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.17 -0.956 . . . . 0.0 109.81 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.669 HG22 HD23 ' A' ' 15' ' ' LEU . 7.2 t -82.93 -50.55 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.085 -1.009 . . . . 0.0 110.263 179.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.465 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -49.51 162.61 0.42 Allowed Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.35 -0.844 . . . . 0.0 111.553 -178.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -76.38 -53.82 0.08 OUTLIER 'Trans proline' 0 C--N 1.311 -1.4 0 O-C-N 123.617 1.325 . . . . 0.0 110.184 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 117.87 177.68 17.28 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -74.24 -34.41 63.64 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.353 -1.086 . . . . 0.0 110.205 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.215 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.01 106.37 6.48 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.214 -1.168 . . . . 0.0 110.093 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.6 ' O ' HG23 ' A' ' 3' ' ' VAL . 27.5 m -112.97 104.16 16.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.271 -0.893 . . . . 0.0 110.024 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.873 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 17.9 p -66.94 141.21 57.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.317 -0.865 . . . . 0.0 109.922 179.788 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.469 HG13 ' CG2' ' A' ' 116' ' ' THR . 0.2 OUTLIER -66.68 147.59 98.97 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.19 -0.944 . . . . 0.0 109.403 179.839 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.434 ' HD2' HG23 ' A' ' 5' ' ' VAL . 42.3 Cg_endo -67.85 -168.31 0.19 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 124.169 1.615 . . . . 0.0 110.654 179.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.529 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -179.83 81.21 0.19 Allowed Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.522 -0.736 . . . . 0.0 109.998 -179.82 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.456 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 42.5 Cg_endo -69.73 -170.74 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.697 1.367 . . . . 0.0 109.821 179.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.456 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 6.5 m120 76.83 -14.05 0.87 Allowed 'General case' 0 N--CA 1.508 2.462 0 O-C-N 121.816 -0.553 . . . . 0.0 111.239 -179.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.499 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.1 mt -116.59 135.38 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.664 -1.273 . . . . 0.0 109.488 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.417 ' N ' ' O ' ' A' ' 128' ' ' GLY . 1.5 tm-20 -86.1 127.15 34.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.8 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.407 ' HG2' ' NH2' ' A' ' 119' ' ' ARG . 47.6 mt-10 -90.43 136.65 32.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.104 -0.997 . . . . 0.0 110.03 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.493 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.2 157.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.193 -0.942 . . . . 0.0 110.044 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.63 112.21 25.2 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.188 -0.945 . . . . 0.0 110.044 179.553 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.778 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.5 tp -54.81 147.36 15.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.873 . . . . 0.0 109.282 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.53 7.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.122 -0.987 . . . . 0.0 110.533 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.13 74.62 4.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.345 -0.847 . . . . 0.0 109.976 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.803 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.4 m -152.41 108.8 3.42 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.322 -0.862 . . . . 0.0 110.741 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.57 -167.16 29.2 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.922 -1.608 . . . . 0.0 110.818 179.214 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.46 ' HB3' HD11 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.26 -24.85 9.58 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.664 -0.904 . . . . 0.0 110.482 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 1.018 HD12 HD13 ' A' ' 55' ' ' LEU . 9.4 tt -95.12 101.89 8.27 Favored Pre-proline 0 C--N 1.305 -1.334 0 C-N-CA 118.734 -1.187 . . . . 0.0 109.743 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.44 127.39 21.73 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.534 1.281 . . . . 0.0 111.074 -178.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 25' ' ' GLY . 6.3 t80 -117.19 -171.91 2.12 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.541 0.686 . . . . 0.0 110.695 -179.062 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.565 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.4 m-85 -57.58 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.434 -0.791 . . . . 0.0 111.688 -179.44 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.02 -4.62 53.47 Favored Glycine 0 N--CA 1.493 2.495 0 O-C-N 121.229 -0.919 . . . . 0.0 110.911 178.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.778 ' HB2' HD23 ' A' ' 15' ' ' LEU . 28.3 mmtt -130.05 156.34 44.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.826 -1.397 . . . . 0.0 109.908 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.803 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.26 108.07 19.39 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.064 -1.023 . . . . 0.0 108.864 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.917 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.1 mt -68.24 112.99 12.54 Favored Pre-proline 0 C--N 1.3 -1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 110.732 -179.056 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.714 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.3 Cg_endo -68.43 130.05 20.26 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.125 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.576 ' CD2' HD11 ' A' ' 33' ' ' ILE . 12.8 mt -56.64 -17.13 7.7 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.772 -1.205 . . . . 0.0 110.801 -177.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.438 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.32 -16.05 19.87 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.739 -1.226 . . . . 0.0 110.476 179.955 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.064 HG23 HG23 ' A' ' 33' ' ' ILE . 9.9 m -95.16 -24.24 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.008 -1.057 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.064 HG23 HG23 ' A' ' 32' ' ' VAL . 46.2 pt -116.58 -12.17 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.919 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.643 ' HB2' HD11 ' A' ' 60' ' ' ILE . 8.9 tptm -102.12 148.29 25.57 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.831 -1.168 . . . . 0.0 110.193 179.685 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.03 -5.3 36.24 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.74 3.89 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.407 -1.377 . . . . 0.0 110.08 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.54 135.96 53.38 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.313 -1.11 . . . . 0.0 110.363 -179.736 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.576 ' HB2' HG12 ' A' ' 81' ' ' VAL . 93.6 m-70 -140.01 153.42 46.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.254 -0.904 . . . . 0.0 111.196 -179.427 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.622 ' HB3' HG12 ' A' ' 99' ' ' VAL . 60.4 tp -113.5 116.47 29.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.419 -0.801 . . . . 0.0 110.285 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.906 HD12 ' CG1' ' A' ' 83' ' ' VAL . 33.7 mt -100.93 128.1 53.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.194 -0.942 . . . . 0.0 109.568 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -95.08 123.75 38.74 Favored 'General case' 0 C--N 1.294 -1.84 0 O-C-N 121.441 -0.787 . . . . 0.0 110.238 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.94 159.92 21.71 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.217 -0.927 . . . . 0.0 110.679 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.565 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.2 p80 -105.55 -4.48 21.15 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.381 -0.824 . . . . 0.0 110.395 179.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.5 p -132.13 138.53 48.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.973 -1.08 . . . . 0.0 110.702 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.509 ' HD2' ' CE1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.25 -41.19 70.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.483 -0.761 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.77 72.1 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.221 -0.924 . . . . 0.0 110.59 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.41 -37.36 65.95 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.379 -0.826 . . . . 0.0 109.949 -179.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.875 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 73.9 m -61.14 -34.35 74.87 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.273 -0.892 . . . . 0.0 109.857 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.413 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.67 -50.08 59.54 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.229 -0.919 . . . . 0.0 110.592 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.404 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 11.7 mt-10 -72.37 -40.54 67.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.191 -0.943 . . . . 0.0 110.374 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.814 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.92 -42.67 98.55 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.616 -0.678 . . . . 0.0 111.567 -178.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.64 -51.16 45.13 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.8 -1.188 . . . . 0.0 110.271 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.15 -34.43 68.4 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.032 -1.043 . . . . 0.0 109.183 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.532 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.24 -47.95 80.08 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.208 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 1.018 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.02 -42.45 80.43 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.531 -0.731 . . . . 0.0 110.955 -179.994 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -55.67 -28.32 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.925 -1.11 . . . . 0.0 108.753 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.62 -35.37 60.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.516 -0.74 . . . . 0.0 110.266 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.532 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.33 -26.11 61.81 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.06 7.96 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.643 HD11 ' HB2' ' A' ' 34' ' ' LYS . 50.4 mt -106.39 143.0 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.282 -1.128 . . . . 0.0 109.633 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.442 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.7 t30 -87.41 106.56 18.04 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 107.024 -1.472 . . . . 0.0 107.024 178.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.576 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.5 146.07 45.77 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.23 -0.988 . . . . 0.0 111.008 -177.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.698 ' HB ' HG13 ' A' ' 73' ' ' VAL . 6.1 t -138.7 149.97 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.823 -0.751 . . . . 0.0 109.303 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.875 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.01 134.84 53.32 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.713 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.657 ' CD1' HD12 ' A' ' 69' ' ' LEU . 20.4 t80 -124.96 129.27 50.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.382 -0.824 . . . . 0.0 110.274 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.814 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -154.73 -171.3 3.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.595 -0.691 . . . . 0.0 109.634 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.8 124.88 22.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.125 -0.984 . . . . 0.0 110.731 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.35 34.02 30.27 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.937 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.35 157.13 26.67 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.143 -1.21 . . . . 0.0 110.035 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.937 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.15 22.77 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.188 -0.945 . . . . 0.0 110.815 -179.318 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.8 m -62.97 111.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.121 -0.987 . . . . 0.0 109.067 178.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.437 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.0 m -131.19 -11.73 3.64 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.166 -0.959 . . . . 0.0 111.494 -179.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.955 ' CG1' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.34 136.2 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.737 -1.227 . . . . 0.0 109.509 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.515 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -136.91 92.09 14.65 Favored Pre-proline 0 N--CA 1.497 1.883 0 O-C-N 121.12 -0.987 . . . . 0.0 110.513 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.446 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.3 Cg_endo -77.01 58.1 6.02 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 123.456 1.24 . . . . 0.0 110.491 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.5 p -119.43 -31.99 4.47 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.189 -0.944 . . . . 0.0 110.361 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.7 m-80 -150.81 160.67 43.72 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.229 -0.919 . . . . 0.0 110.179 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 64.99 166.69 1.38 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -89.11 102.95 15.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.042 -1.27 . . . . 0.0 110.181 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.446 HG11 ' HA ' ' A' ' 75' ' ' PRO . 5.8 p -117.06 135.11 58.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 CA-C-O 121.904 0.859 . . . . 0.0 110.359 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.593 HG22 HG22 ' A' ' 60' ' ' ILE . 7.1 m -112.95 122.5 67.2 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.955 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.6 t -96.83 117.65 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.019 -1.051 . . . . 0.0 110.097 -177.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.906 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.3 m -111.43 99.74 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.075 -1.016 . . . . 0.0 108.828 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.479 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.13 159.84 41.2 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.646 -1.283 . . . . 0.0 111.27 -178.189 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.509 HG23 ' N ' ' A' ' 86' ' ' ASP . 7.8 t -82.33 -130.45 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.618 -0.676 . . . . 0.0 109.515 179.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.509 ' N ' HG23 ' A' ' 85' ' ' THR . 0.3 OUTLIER -93.82 27.82 2.6 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.595 -1.315 . . . . 0.0 110.225 179.94 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.476 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.11 -35.76 12.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 110.133 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.3 tp -69.37 -32.96 72.34 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 0.0 109.644 179.643 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.402 ' C ' HG22 ' A' ' 90' ' ' THR . 4.2 mmt 54.06 -89.98 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.575 -0.703 . . . . 0.0 110.134 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.535 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.4 OUTLIER 177.84 41.73 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 O-C-N 120.912 -1.118 . . . . 0.0 110.066 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.81 -48.6 79.73 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -128.57 32.63 4.79 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.481 -1.011 . . . . 0.0 110.502 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.566 HG23 ' N ' ' A' ' 94' ' ' GLY . 5.6 t -95.07 -152.91 0.37 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.097 -1.002 . . . . 0.0 110.219 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.566 ' N ' HG23 ' A' ' 93' ' ' THR . . . 97.34 -10.32 65.21 Favored Glycine 0 N--CA 1.49 2.247 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.618 179.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.7 t0 -124.93 64.95 1.12 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.802 -1.41 . . . . 0.0 110.871 -179.633 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -120.05 151.57 38.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.079 -1.013 . . . . 0.0 110.315 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.443 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.42 -30.96 33.36 Favored 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.635 -0.826 . . . . 0.0 109.33 178.983 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.457 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.9 163.94 28.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.377 -0.827 . . . . 0.0 111.197 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.628 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.44 115.38 31.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.557 -0.714 . . . . 0.0 109.796 179.002 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.859 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -93.11 117.62 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.241 -0.912 . . . . 0.0 109.113 179.495 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.439 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.9 t0 -122.5 161.18 24.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.937 . . . . 0.0 111.559 -178.499 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.423 ' HG ' ' CB ' ' A' ' 24' ' ' TYR . 20.7 t -103.47 8.42 37.87 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.257 -0.902 . . . . 0.0 110.713 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.622 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -142.9 133.65 25.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.73 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.4 p -113.83 132.42 55.89 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.325 -0.86 . . . . 0.0 109.441 179.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 54.47 -141.92 0.83 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.991 -1.068 . . . . 0.0 109.513 -179.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -90.36 24.69 15.38 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.87 157.2 70.07 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.301 -1.117 . . . . 0.0 109.617 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.622 ' HA ' HG22 ' A' ' 104' ' ' THR . 39.3 Cg_endo -64.61 166.3 18.14 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.547 1.288 . . . . 0.0 110.248 -179.791 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.04 162.91 28.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.186 -0.946 . . . . 0.0 110.826 -179.267 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.578 ' OD2' HG22 ' A' ' 113' ' ' VAL . 3.6 p-10 -92.73 162.57 14.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.479 -0.763 . . . . 0.0 110.382 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.873 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -50.55 -49.38 56.17 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.831 -1.168 . . . . 0.0 111.868 -178.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.578 HG22 ' OD2' ' A' ' 111' ' ' ASP . 5.8 m -72.63 -30.62 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.601 -1.312 . . . . 0.0 113.283 -177.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.88 -54.7 34.95 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.293 -1.504 . . . . 0.0 110.096 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.27 -35.97 78.76 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 118.363 -1.335 . . . . 0.0 108.164 178.363 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.469 ' CG2' HG13 ' A' ' 5' ' ' VAL . 83.0 m -60.79 -49.97 75.34 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.401 ' NE2' ' HA ' ' A' ' 117' ' ' GLN . 7.7 tp60 -73.68 -46.45 46.32 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.86 178.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.0 mtt-85 -58.25 -46.08 86.63 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 110.466 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.529 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 11.1 ttm180 -58.21 -39.85 80.1 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.847 -1.158 . . . . 0.0 109.485 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.56 68.81 0.4 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -146.22 -45.95 0.2 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.425 -1.044 . . . . 0.0 108.743 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.563 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.9 t -94.34 142.33 27.54 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.4 5.7 11.17 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.547 179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.434 ' HD3' ' HA2' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -76.2 84.53 3.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.947 -1.325 . . . . 0.0 110.171 -179.889 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.93 -43.58 1.66 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.474 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.22 -169.31 0.17 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.499 -1.001 . . . . 0.0 108.662 179.565 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -87.72 110.67 0.73 Allowed 'Trans proline' 0 C--N 1.309 -1.529 0 O-C-N 123.274 1.144 . . . . 0.0 109.452 178.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.563 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.62 146.58 32.89 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.483 ' N ' HD12 ' A' ' 129' ' ' ILE . 2.9 mp -106.35 141.15 22.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.859 -1.377 . . . . 0.0 109.301 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.628 ' CD2' HG23 ' A' ' 99' ' ' VAL . 4.4 t80 -127.87 115.35 18.46 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.105 -0.997 . . . . 0.0 110.41 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.493 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mmt180 -102.06 123.39 45.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.498 -0.752 . . . . 0.0 109.632 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.447 ' CE1' ' HA ' ' A' ' 135' ' ' PRO . 25.7 p90 -115.23 157.84 23.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.022 -1.049 . . . . 0.0 110.059 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t -89.01 -38.98 12.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.09 -1.006 . . . . 0.0 109.76 179.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.422 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -96.17 131.71 28.23 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.178 -0.952 . . . . 0.0 110.198 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.447 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 50.0 Cg_endo -76.88 -19.66 13.89 Favored 'Trans proline' 0 C--N 1.314 -1.263 0 O-C-N 123.519 1.273 . . . . 0.0 110.657 -179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -52.21 105.36 0.24 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -135.02 -166.32 1.81 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.252 -1.146 . . . . 0.0 110.214 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 118.124 -0.941 . . . . 0.0 110.262 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.3 p -115.19 157.2 24.0 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.204 -1.174 . . . . 0.0 110.19 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.94 104.47 17.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.303 -0.873 . . . . 0.0 109.665 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.7 p -66.68 137.0 56.38 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.4 -0.813 . . . . 0.0 110.535 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.443 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -73.04 149.05 89.53 Favored Pre-proline 0 C--N 1.303 -1.432 0 O-C-N 121.315 -0.865 . . . . 0.0 109.297 179.225 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.443 ' HD2' HG23 ' A' ' 5' ' ' VAL . 50.6 Cg_endo -80.28 -165.55 0.35 Allowed 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.992 1.522 . . . . 0.0 111.377 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.495 ' NE2' ' NE ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.07 83.35 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.824 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.14 60.69 0.47 Allowed 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.906 1.477 . . . . 0.0 111.937 -178.337 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 19.6 m-80 -131.88 2.57 4.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.49 -0.756 . . . . 0.0 109.931 178.37 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.482 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 11.7 mt -128.44 137.64 56.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.952 -1.093 . . . . 0.0 109.343 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.67 128.24 34.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.102 -0.999 . . . . 0.0 109.39 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.59 127.99 35.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.109 -0.994 . . . . 0.0 110.198 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.818 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 15.7 t -122.93 155.4 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.286 -0.884 . . . . 0.0 110.206 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.05 110.46 22.59 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.295 -0.878 . . . . 0.0 109.925 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.538 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.67 134.72 54.89 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 110.005 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.421 ' O ' ' N ' ' A' ' 18' ' ' THR . 17.7 p -135.37 171.5 14.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.256 -0.902 . . . . 0.0 110.214 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.53 69.96 0.17 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 110.153 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.577 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.4 m -140.54 112.29 7.53 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.28 -0.887 . . . . 0.0 110.392 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.74 -163.28 26.94 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.542 179.451 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.2 -22.33 7.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.666 -0.902 . . . . 0.0 110.518 179.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.914 HD12 HD13 ' A' ' 55' ' ' LEU . 9.0 tt -97.41 107.06 36.64 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 120.839 -1.163 . . . . 0.0 110.28 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.511 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.91 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.318 1.167 . . . . 0.0 110.088 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.55 93.73 0.2 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.191 -0.943 . . . . 0.0 110.96 -178.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.25 68.56 0.76 Allowed 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.526 -0.733 . . . . 0.0 111.251 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.76 15.38 9.15 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.538 ' CB ' HD23 ' A' ' 15' ' ' LEU . 5.2 mmpt? -130.67 156.21 45.29 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.028 -1.278 . . . . 0.0 109.243 179.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.577 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.79 107.51 15.14 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.966 -1.084 . . . . 0.0 109.348 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.913 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -69.83 113.91 20.95 Favored Pre-proline 0 C--N 1.298 -1.654 0 O-C-N 121.474 -0.766 . . . . 0.0 110.688 -179.235 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.8 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.9 Cg_endo -70.18 130.81 19.45 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 106.443 -2.176 . . . . 0.0 106.443 175.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.673 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.1 mt -55.92 -18.41 8.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.718 -1.238 . . . . 0.0 110.518 -177.716 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.489 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -59.75 -16.16 25.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.771 -1.205 . . . . 0.0 110.484 179.655 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.051 HG23 HG23 ' A' ' 33' ' ' ILE . 13.3 m -92.03 -25.04 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.976 -1.078 . . . . 0.0 110.93 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.051 HG23 HG23 ' A' ' 32' ' ' VAL . 42.2 pt -117.06 -17.48 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.079 -1.013 . . . . 0.0 110.622 -179.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.569 ' HB2' HD11 ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.49 22.84 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.947 -1.095 . . . . 0.0 110.262 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.05 -7.56 27.24 Favored Glycine 0 N--CA 1.485 1.947 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.02 3.21 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.149 -1.5 . . . . 0.0 110.342 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.435 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -111.99 129.95 56.02 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.353 -1.086 . . . . 0.0 110.232 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.603 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.63 146.94 46.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.06 -1.025 . . . . 0.0 110.953 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 36.8 tp -109.65 115.66 30.3 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.475 -0.765 . . . . 0.0 110.216 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.94 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.8 mt -98.96 127.67 51.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.15 -0.969 . . . . 0.0 109.465 179.284 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.401 ' CE2' ' HA ' ' A' ' 118' ' ' ARG . 4.2 m-85 -94.88 122.62 37.7 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.556 -0.715 . . . . 0.0 110.518 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.2 31.24 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.344 -0.847 . . . . 0.0 110.581 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.3 p80 -109.31 8.17 25.48 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.245 -0.91 . . . . 0.0 109.478 178.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.93 135.95 41.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.13 -0.981 . . . . 0.0 110.316 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.531 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.94 -42.37 66.7 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.55 -0.719 . . . . 0.0 110.818 -179.687 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.63 -36.51 74.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.345 -0.847 . . . . 0.0 110.428 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.413 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -72.29 -36.28 68.9 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.482 -0.761 . . . . 0.0 109.809 -179.781 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.83 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 2.2 m -60.89 -34.04 74.03 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.359 -0.838 . . . . 0.0 109.77 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.34 -49.31 56.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.268 -0.895 . . . . 0.0 110.672 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.413 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.56 -43.85 65.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.208 -0.933 . . . . 0.0 110.383 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.702 HD12 HG11 ' A' ' 83' ' ' VAL . 1.5 tm? -56.34 -41.14 75.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.422 -0.799 . . . . 0.0 110.909 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.21 -51.41 13.41 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 110.372 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.75 -43.86 98.02 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.055 -1.028 . . . . 0.0 109.582 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.516 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -56.83 -43.84 81.45 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.309 -0.87 . . . . 0.0 109.549 179.528 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.914 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.46 -42.89 74.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.444 -0.785 . . . . 0.0 109.704 179.592 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.8 t -55.84 -30.78 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.133 -0.98 . . . . 0.0 108.71 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -76.15 -33.32 59.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.574 -0.703 . . . . 0.0 110.121 179.126 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.558 ' HB3' HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.74 -26.37 62.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 109.614 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.97 5.64 8.05 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.673 ' CD1' HD22 ' A' ' 30' ' ' LEU . 19.8 mt -108.29 143.57 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.199 -1.177 . . . . 0.0 110.235 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.5 t30 -86.12 107.34 17.8 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.199 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.628 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.96 146.92 46.67 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.002 -1.079 . . . . 0.0 112.064 -177.151 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.943 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.2 t -135.92 150.29 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.66 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.83 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.69 131.82 55.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.222 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.483 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -120.82 123.42 42.54 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.933 . . . . 0.0 110.731 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.855 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.1 p90 -155.2 178.43 10.22 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.641 179.546 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.2 ttt180 -52.36 128.17 24.58 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.071 -1.018 . . . . 0.0 110.63 -179.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.25 39.27 31.99 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.951 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -117.02 155.63 28.88 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.124 -1.221 . . . . 0.0 109.777 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.951 ' N ' HD13 ' A' ' 69' ' ' LEU . 27.0 m-20 -95.39 149.15 21.7 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.272 -0.893 . . . . 0.0 110.884 -179.125 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.677 ' O ' HG23 ' A' ' 71' ' ' VAL . 34.7 m -62.21 111.4 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.061 -1.024 . . . . 0.0 108.873 178.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.78 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.2 m -134.33 -36.06 0.9 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.895 . . . . 0.0 110.888 -179.11 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.943 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.6 t -50.91 134.7 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.195 -0.941 . . . . 0.0 109.851 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.78 HG23 ' O ' ' A' ' 72' ' ' SER . 1.8 pp -136.91 109.52 9.17 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.219 -0.926 . . . . 0.0 110.905 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.632 ' HA ' HG11 ' A' ' 80' ' ' VAL . 50.8 Cg_endo -86.93 46.79 1.51 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 O-C-N 123.485 1.255 . . . . 0.0 110.245 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.5 p -129.87 -9.49 4.42 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.068 -1.02 . . . . 0.0 111.424 -179.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -88.9 -171.94 3.49 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.933 -1.104 . . . . 0.0 110.366 -179.74 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.11 -80.19 0.07 OUTLIER Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.6 m-20 -130.8 114.44 15.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.174 -1.192 . . . . 0.0 110.072 179.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.632 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -116.85 134.94 58.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 CA-C-O 121.969 0.89 . . . . 0.0 109.855 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 60' ' ' ILE . 16.0 m -113.34 124.45 69.99 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.341 0 O-C-N 121.422 -0.799 . . . . 0.0 109.484 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.742 HG22 ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.4 117.25 41.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.096 -1.003 . . . . 0.0 109.934 -178.61 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.94 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -112.08 100.07 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.986 -1.071 . . . . 0.0 108.625 179.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.9 162.24 35.64 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.752 -1.218 . . . . 0.0 110.943 -178.149 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.513 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -91.35 -133.15 0.12 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.627 -0.671 . . . . 0.0 109.24 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.513 ' N ' HG23 ' A' ' 85' ' ' THR . 46.5 p-10 -88.42 43.33 1.12 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.663 -1.273 . . . . 0.0 110.342 179.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.473 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.79 -30.29 6.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 110.144 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.446 ' O ' ' N ' ' A' ' 90' ' ' THR . 2.2 tp -68.9 -29.13 67.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.041 -1.037 . . . . 0.0 109.28 179.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.466 ' C ' HG22 ' A' ' 90' ' ' THR . 0.8 OUTLIER 55.61 -85.9 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.833 -0.542 . . . . 0.0 110.418 179.872 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.561 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.3 OUTLIER 173.61 43.14 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.023 -1.048 . . . . 0.0 110.22 -179.928 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -56.85 -46.87 89.87 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 179.412 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -138.17 28.15 2.57 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.453 -1.028 . . . . 0.0 110.128 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.561 HG22 ' OG1' ' A' ' 90' ' ' THR . 3.1 t -86.26 -160.41 0.55 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.16 -0.963 . . . . 0.0 110.42 -179.656 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.5 ' N ' HG23 ' A' ' 93' ' ' THR . . . 100.53 -31.83 8.08 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 -107.46 73.89 0.94 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.815 -1.403 . . . . 0.0 111.163 -179.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.518 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 25.8 m-85 -119.74 153.18 36.04 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.066 . . . . 0.0 110.139 178.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.91 -26.99 25.26 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.386 -0.821 . . . . 0.0 109.551 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.8 p -162.52 163.63 27.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 111.432 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.485 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -134.0 126.21 49.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.479 -0.763 . . . . 0.0 109.718 179.114 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.913 HG21 HD11 ' A' ' 28' ' ' ILE . 2.8 mp -105.51 111.54 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.088 -1.007 . . . . 0.0 109.117 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.422 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -121.58 161.0 23.17 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.249 -0.907 . . . . 0.0 111.565 -178.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.1 t -96.26 -6.91 36.86 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 177.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.76 11.01 1.21 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.37 -0.831 . . . . 0.0 112.225 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.566 HG23 ' C ' ' A' ' 107' ' ' GLY . 0.9 OUTLIER -147.35 126.26 12.75 Favored 'General case' 0 C--N 1.31 -1.123 0 O-C-N 120.537 -1.352 . . . . 0.0 109.509 179.819 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 108' ' ' LYS . 24.6 p -100.54 129.27 46.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.918 . . . . 0.0 110.189 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 57.3 29.1 16.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.223 -0.923 . . . . 0.0 110.552 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.566 ' C ' HG23 ' A' ' 104' ' ' THR . . . 94.75 -30.56 7.78 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -82.51 155.36 68.83 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.175 -1.191 . . . . 0.0 110.206 -179.885 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -64.69 137.41 54.08 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 123.552 1.291 . . . . 0.0 110.503 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.427 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 -51.29 163.62 0.24 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.475 -0.766 . . . . 0.0 110.956 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.54 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -83.53 161.4 21.23 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.298 -0.876 . . . . 0.0 110.062 179.69 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.442 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.53 -61.88 1.25 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.435 -0.791 . . . . 0.0 112.172 -178.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.54 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.1 m -60.41 -29.31 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.742 -1.224 . . . . 0.0 111.692 -178.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.21 -56.49 6.6 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.01 -1.056 . . . . 0.0 110.749 -178.812 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.03 76.88 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.124 -0.985 . . . . 0.0 108.668 178.947 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.2 m -60.49 -50.03 75.18 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.109 -0.995 . . . . 0.0 108.368 178.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.24 63.38 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.477 -0.764 . . . . 0.0 110.184 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.401 ' HA ' ' CE2' ' A' ' 41' ' ' PHE . 10.8 mtt85 -71.2 -44.31 65.68 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.119 -0.988 . . . . 0.0 111.138 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.495 ' NE ' ' NE2' ' A' ' 7' ' ' HIS . 11.8 ttp180 -70.46 -40.0 73.96 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.999 -1.063 . . . . 0.0 109.975 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.96 63.33 0.71 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -137.12 -45.93 0.57 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.144 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.452 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.1 t -95.16 142.29 27.78 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.316 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.467 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.2 17.33 51.01 Favored Glycine 0 N--CA 1.484 1.887 0 C-N-CA 119.528 -1.32 . . . . 0.0 110.356 178.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.437 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -52.07 -37.86 55.21 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.059 -1.26 . . . . 0.0 109.705 179.666 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.0 28.59 2.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 179.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.475 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.6 -168.25 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.694 -0.886 . . . . 0.0 109.123 -179.415 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.48 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 49.6 Cg_endo -86.66 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.167 1.088 . . . . 0.0 110.556 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -80.09 157.67 41.35 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -106.85 141.59 21.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.041 -1.27 . . . . 0.0 109.105 178.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.485 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.9 t80 -130.07 114.81 16.23 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 119.07 -1.052 . . . . 0.0 110.227 179.392 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.818 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -101.5 122.15 43.27 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.428 -0.795 . . . . 0.0 109.656 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.422 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 14.3 p90 -120.24 154.54 34.74 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.364 -0.835 . . . . 0.0 109.896 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.432 HG13 ' HG3' ' A' ' 26' ' ' LYS . 75.4 t -86.67 -41.3 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.205 -0.934 . . . . 0.0 110.235 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -101.45 111.57 63.93 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.16 -0.962 . . . . 0.0 110.336 -179.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -71.5 -46.74 0.58 Allowed 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.529 1.279 . . . . 0.0 110.311 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 97.31 129.72 6.38 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 51.8 82.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.245 -1.15 . . . . 0.0 110.407 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.306 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.19 102.59 14.41 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.217 -1.166 . . . . 0.0 110.154 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.671 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.4 p -113.32 104.32 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.283 -0.886 . . . . 0.0 109.689 179.474 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.445 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 18.2 p -100.41 140.44 34.66 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.339 -0.85 . . . . 0.0 110.41 -179.626 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.834 HG13 HG23 ' A' ' 116' ' ' THR . 0.2 OUTLIER -67.21 147.38 98.98 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.343 -0.848 . . . . 0.0 109.101 179.589 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.527 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 45.9 Cg_endo -73.93 -19.54 20.56 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 O-C-N 124.054 1.555 . . . . 0.0 113.113 -178.541 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.527 ' CG ' ' C ' ' A' ' 6' ' ' PRO . 1.8 p-80 42.73 75.8 0.59 Allowed Pre-proline 0 N--CA 1.502 2.146 0 O-C-N 121.375 -0.828 . . . . 0.0 110.715 -178.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.422 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 43.6 Cg_endo -71.02 -175.11 1.34 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.735 1.387 . . . . 0.0 110.145 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 65.77 7.15 4.34 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.685 -0.634 . . . . 0.0 111.221 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.729 HG12 HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.55 126.23 74.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.674 -1.266 . . . . 0.0 109.313 179.136 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.78 127.59 34.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.942 179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.47 136.18 33.22 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.209 -0.932 . . . . 0.0 110.104 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.462 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.2 t -129.71 154.95 41.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.368 -0.832 . . . . 0.0 109.925 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.5 112.87 25.98 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.109 -0.994 . . . . 0.0 110.389 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.614 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.8 tp -59.31 140.52 55.97 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.368 -0.833 . . . . 0.0 109.19 179.308 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.33 -178.24 5.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.179 -0.951 . . . . 0.0 110.508 -179.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 72.0 p -76.99 59.9 1.73 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.886 . . . . 0.0 110.077 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 10.0 m -132.45 109.34 9.74 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.269 -0.895 . . . . 0.0 110.714 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.17 -167.2 28.98 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 118.85 -1.643 . . . . 0.0 110.687 179.204 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.54 -18.86 10.83 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.667 -0.902 . . . . 0.0 110.304 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -99.34 104.51 27.25 Favored Pre-proline 0 N--CA 1.49 1.533 0 C-N-CA 118.771 -1.172 . . . . 0.0 109.876 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.449 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.2 Cg_endo -63.55 128.51 22.54 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.336 1.177 . . . . 0.0 111.009 -179.109 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.442 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.95 1.17 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.779 -0.576 . . . . 0.0 109.882 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.1 m-85 -58.11 82.21 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.219 -0.926 . . . . 0.0 111.605 -179.236 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.12 0.52 52.7 Favored Glycine 0 N--CA 1.494 2.566 0 O-C-N 121.156 -0.965 . . . . 0.0 110.888 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.614 ' HB2' HD23 ' A' ' 15' ' ' LEU . 27.3 mmtp -130.51 156.99 43.88 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.877 -1.367 . . . . 0.0 109.538 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -108.23 107.64 18.34 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 120.977 -1.077 . . . . 0.0 109.474 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.893 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -67.08 113.43 13.42 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.34 -0.85 . . . . 0.0 110.757 -179.344 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.817 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.4 Cg_endo -68.52 130.99 22.01 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 N-CA-C 106.874 -2.01 . . . . 0.0 106.874 176.012 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.747 HD11 HD12 ' A' ' 58' ' ' LEU . 10.7 mt -56.24 -17.61 8.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.816 -1.178 . . . . 0.0 110.728 -177.815 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -59.9 -16.41 29.25 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.64 -1.287 . . . . 0.0 110.518 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.051 HG23 HG23 ' A' ' 33' ' ' ILE . 13.6 m -93.09 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.005 -1.059 . . . . 0.0 111.213 -179.552 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.051 HG23 HG23 ' A' ' 32' ' ' VAL . 18.9 pt -119.45 -21.45 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.031 -1.043 . . . . 0.0 110.639 -179.288 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.566 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.79 148.28 22.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.89 -1.131 . . . . 0.0 110.317 179.46 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.14 -3.9 60.38 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.579 -1.409 . . . . 0.0 109.579 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.3 -158.65 21.45 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.465 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.75 132.38 50.06 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.383 -1.069 . . . . 0.0 110.654 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.82 147.02 40.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.181 -0.949 . . . . 0.0 110.523 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.08 122.22 46.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.341 -0.849 . . . . 0.0 110.08 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.894 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.3 mm -100.56 126.08 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.271 -0.893 . . . . 0.0 109.186 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.454 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.2 m-85 -96.5 121.41 38.29 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.105 -0.997 . . . . 0.0 110.025 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.36 28.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.277 -0.889 . . . . 0.0 110.511 179.527 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.518 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.1 37.36 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.284 -0.885 . . . . 0.0 110.079 178.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.97 135.39 46.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.067 -1.021 . . . . 0.0 110.459 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.474 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.43 65.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.662 -0.649 . . . . 0.0 110.906 -179.761 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.31 -32.77 73.13 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.36 -0.837 . . . . 0.0 110.843 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.33 65.71 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.399 -0.813 . . . . 0.0 109.9 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.876 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.6 m -61.13 -38.52 86.66 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.592 179.154 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.4 -49.16 70.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.128 -0.983 . . . . 0.0 110.531 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.416 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -72.05 -46.29 57.54 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.239 -0.913 . . . . 0.0 110.608 -179.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.776 HD21 HD11 ' A' ' 21' ' ' ILE . 3.0 tm? -56.73 -41.09 76.87 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.459 -0.776 . . . . 0.0 111.42 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.36 -51.08 60.81 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.851 -1.156 . . . . 0.0 109.759 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.8 -32.5 69.4 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.236 -0.915 . . . . 0.0 109.347 179.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.849 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -61.72 -33.67 74.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.573 -0.704 . . . . 0.0 109.352 179.63 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.822 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.91 -42.44 57.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.423 -0.798 . . . . 0.0 110.397 -179.911 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.07 -33.03 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.048 -1.033 . . . . 0.0 109.189 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.43 -32.95 60.87 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.502 -0.749 . . . . 0.0 109.918 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.849 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.5 mm? -71.96 -26.37 62.24 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.947 0.88 . . . . 0.0 109.981 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.81 3.06 10.21 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.289 -1.525 . . . . 0.0 109.289 -179.251 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.619 HG22 HG22 ' A' ' 81' ' ' VAL . 31.2 mt -103.88 143.96 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.356 -1.085 . . . . 0.0 109.955 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.555 HD22 HD11 ' A' ' 74' ' ' ILE . 35.1 t30 -88.68 106.87 18.62 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.178 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.544 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.92 145.28 44.77 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 118.868 -1.133 . . . . 0.0 111.739 -177.2 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.888 HG21 ' HA ' ' A' ' 73' ' ' VAL . 70.5 t -129.22 152.74 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.084 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.876 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -118.67 117.33 28.66 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.156 -1.018 . . . . 0.0 109.237 177.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -105.76 127.48 53.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.172 -0.955 . . . . 0.0 110.826 -179.256 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.925 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 10.0 p90 -155.58 -178.66 7.44 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.503 -0.748 . . . . 0.0 110.096 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.35 127.41 22.14 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.171 -0.956 . . . . 0.0 110.834 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.23 53.1 23.6 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.209 -1.156 . . . . 0.0 110.209 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.925 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.42 154.44 31.35 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.211 -1.17 . . . . 0.0 109.794 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.7 m-20 -91.21 149.37 21.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.229 -0.919 . . . . 0.0 110.427 -179.297 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.685 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.2 m -61.69 110.65 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.024 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.771 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.5 m -132.2 -38.72 1.07 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.759 . . . . 0.0 109.973 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.888 ' HA ' HG21 ' A' ' 63' ' ' VAL . 95.3 t -49.5 133.32 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.39 -0.819 . . . . 0.0 109.484 179.642 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.771 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -133.76 89.95 29.0 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 120.99 -1.069 . . . . 0.0 110.398 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -90.61 53.5 1.11 Allowed 'Trans proline' 0 C--N 1.311 -1.404 0 O-C-N 124.04 1.547 . . . . 0.0 110.584 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.1 t -125.68 -25.98 3.59 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.114 -0.991 . . . . 0.0 111.031 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 56.4 m-80 -155.23 167.69 29.54 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.988 -1.07 . . . . 0.0 110.608 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 54.54 174.72 0.09 OUTLIER Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -94.71 110.16 22.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.058 -1.26 . . . . 0.0 110.206 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.556 HG11 ' O ' ' A' ' 74' ' ' ILE . 6.3 p -116.68 135.13 57.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 CA-C-O 122.013 0.911 . . . . 0.0 110.286 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.83 HG11 ' HB ' ' A' ' 33' ' ' ILE . 9.9 m -113.0 121.23 64.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.164 0 O-C-N 121.242 -0.911 . . . . 0.0 108.877 179.2 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.753 HG22 HG13 ' A' ' 73' ' ' VAL . 15.1 t -97.82 120.04 46.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 O-C-N 120.788 -1.195 . . . . 0.0 111.257 -177.612 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.894 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.8 m -111.26 99.0 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 CA-C-O 122.361 1.077 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.46 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.45 155.04 46.35 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 120.514 -1.366 . . . . 0.0 110.526 -178.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.53 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.87 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.222 -0.923 . . . . 0.0 110.663 -179.322 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.53 ' N ' HG23 ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.77 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.123 -0.986 . . . . 0.0 110.608 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.587 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -101.04 -33.92 9.96 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.039 179.362 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 5.3 tp -67.48 -42.27 83.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.597 -0.689 . . . . 0.0 109.341 178.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.481 ' HE2' ' HA ' ' A' ' 89' ' ' MET . 0.5 OUTLIER 49.74 23.41 0.99 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.55 -0.719 . . . . 0.0 110.462 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.93 HG23 ' HB ' ' A' ' 93' ' ' THR . 89.8 m 53.91 -85.44 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.445 -0.784 . . . . 0.0 110.719 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.466 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 65.11 -83.41 0.07 OUTLIER Glycine 0 N--CA 1.492 2.381 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.42 ' N ' ' O ' ' A' ' 90' ' ' THR . 29.6 p90 -97.87 37.85 1.36 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.371 -1.076 . . . . 0.0 108.587 178.144 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.93 ' HB ' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -137.75 -168.74 2.39 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.714 -0.617 . . . . 0.0 110.311 -179.284 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 133.01 -17.92 4.55 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.34 75.92 3.92 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -1.19 . . . . 0.0 110.643 -179.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.401 ' HZ ' HG21 ' A' ' 93' ' ' THR . 27.3 m-85 -113.43 150.89 32.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.172 -0.955 . . . . 0.0 109.81 179.489 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.502 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.2 -32.58 56.07 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.369 179.569 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.465 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.2 p -161.45 163.06 30.69 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.203 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.561 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.29 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.389 -0.819 . . . . 0.0 110.031 179.264 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.893 HG21 HD11 ' A' ' 28' ' ' ILE . 3.3 mp -93.44 112.82 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.264 -0.898 . . . . 0.0 108.584 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.424 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.93 161.35 20.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 111.52 -178.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.452 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 58.5 m -88.86 -13.32 39.51 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.15 10.63 1.29 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.295 -0.878 . . . . 0.0 112.073 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.507 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 0.9 OUTLIER -147.47 130.55 16.36 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 120.755 -1.216 . . . . 0.0 109.133 179.598 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.441 ' N ' ' O ' ' A' ' 108' ' ' LYS . 86.2 p -107.58 134.97 49.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.159 -0.963 . . . . 0.0 110.546 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.6 t0 55.95 32.85 20.6 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.304 -0.873 . . . . 0.0 110.959 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 79.4 12.44 83.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.529 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 104' ' ' THR . 0.1 OUTLIER -123.41 156.06 64.47 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.056 -1.261 . . . . 0.0 109.604 179.705 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -62.88 127.71 21.18 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.543 1.286 . . . . 0.0 110.726 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.472 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 -44.02 160.93 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 CA-C-O 121.366 0.603 . . . . 0.0 111.544 -179.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.523 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -87.47 160.78 18.15 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.466 -0.771 . . . . 0.0 110.359 179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.445 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -42.02 -55.34 3.21 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.647 -0.658 . . . . 0.0 112.553 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.523 HG22 ' OD1' ' A' ' 111' ' ' ASP . 9.3 m -70.62 -29.64 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.705 -1.247 . . . . 0.0 111.838 -178.197 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.472 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.49 -56.28 7.37 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.129 -0.982 . . . . 0.0 110.553 -179.243 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.426 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.2 -35.08 77.43 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.465 -0.894 . . . . 0.0 108.786 178.905 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.834 HG23 HG13 ' A' ' 5' ' ' VAL . 99.6 m -59.14 -49.8 76.47 Favored 'General case' 0 N--CA 1.486 1.364 0 C-N-CA 119.318 -0.953 . . . . 0.0 108.537 178.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.406 ' OE1' ' CE ' ' A' ' 89' ' ' MET . 7.7 tt0 -73.28 -36.04 66.24 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.494 -0.754 . . . . 0.0 109.98 179.022 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.414 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 8.8 mtt85 -71.9 -44.98 62.81 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.262 -0.899 . . . . 0.0 111.118 -179.494 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.527 ' CD ' ' CD2' ' A' ' 7' ' ' HIS . 0.8 OUTLIER -64.36 -36.62 84.71 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.984 -1.072 . . . . 0.0 110.318 -179.873 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.43 0.76 Allowed Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.443 ' HB3' HG11 ' A' ' 99' ' ' VAL . 0.0 OUTLIER -135.51 -43.02 0.69 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.411 -1.053 . . . . 0.0 109.206 179.489 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.729 HG23 HG12 ' A' ' 10' ' ' ILE . 14.8 t -102.32 141.77 34.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.561 -0.712 . . . . 0.0 109.632 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.451 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.16 10.81 14.8 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.502 -1.332 . . . . 0.0 110.15 179.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -74.11 84.71 1.82 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.956 -1.32 . . . . 0.0 109.876 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 96.33 16.13 38.66 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.468 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.89 0.22 Allowed Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.259 -1.142 . . . . 0.0 109.378 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.468 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.2 Cg_endo -88.06 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 O-C-N 123.349 1.183 . . . . 0.0 110.412 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -79.26 160.05 45.64 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.49 142.75 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.417 -1.049 . . . . 0.0 108.779 178.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.561 ' CD2' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -129.91 117.27 19.87 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 120.953 -1.092 . . . . 0.0 111.016 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.462 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 22.2 mtt180 -101.42 123.5 45.58 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.548 -0.72 . . . . 0.0 109.331 179.22 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.415 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.19 156.24 26.87 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.041 -1.037 . . . . 0.0 110.533 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.437 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 4.6 t -84.78 -67.44 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.171 -0.956 . . . . 0.0 109.392 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.429 ' N ' HG12 ' A' ' 133' ' ' VAL . . . 52.77 95.24 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.551 -0.718 . . . . 0.0 110.37 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.27 -35.0 7.18 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 O-C-N 123.644 1.339 . . . . 0.0 110.401 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 63.38 -170.03 17.25 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -62.08 121.98 14.4 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.287 -1.126 . . . . 0.0 110.258 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.281 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.454 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.28 133.05 43.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.215 -1.168 . . . . 0.0 110.3 -179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.604 ' O ' HG23 ' A' ' 3' ' ' VAL . 27.1 m -113.42 104.45 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.25 -0.906 . . . . 0.0 110.175 179.662 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.3 p -65.95 145.07 56.34 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.368 -0.832 . . . . 0.0 110.235 179.813 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.482 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.28 147.22 98.96 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.265 -0.897 . . . . 0.0 109.851 179.926 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.482 ' HD2' HG23 ' A' ' 5' ' ' VAL . 44.8 Cg_endo -71.73 -169.02 0.39 Allowed 'Trans proline' 0 C--N 1.307 -1.634 0 O-C-N 124.15 1.605 . . . . 0.0 111.066 179.248 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.54 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 3.3 p80 -178.89 82.99 0.21 Allowed Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 179.464 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -65.79 89.64 0.23 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.756 1.398 . . . . 0.0 110.905 -179.17 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -179.98 -35.62 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.554 0.692 . . . . 0.0 109.365 179.859 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.501 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 14.6 mt -96.73 133.73 37.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.935 -1.103 . . . . 0.0 110.203 179.816 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -84.2 128.14 34.38 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.35 -0.844 . . . . 0.0 109.541 179.19 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -89.4 121.5 31.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.069 -1.02 . . . . 0.0 109.9 -179.573 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.783 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 4.8 t -115.69 156.63 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.368 -0.833 . . . . 0.0 110.222 -179.34 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.77 105.07 15.17 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.281 -0.887 . . . . 0.0 109.625 179.078 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.651 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -54.15 132.51 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.35 -0.844 . . . . 0.0 109.658 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.51 -174.7 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.241 -0.912 . . . . 0.0 110.256 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.94 63.43 3.63 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 110.041 179.835 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.501 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.0 m -132.07 112.08 12.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.337 -0.852 . . . . 0.0 110.244 -179.834 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.21 -163.41 26.72 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 119.158 -1.496 . . . . 0.0 110.455 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.39 -22.5 5.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.525 -0.985 . . . . 0.0 110.729 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.9 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -93.94 113.24 60.04 Favored Pre-proline 0 N--CA 1.487 1.417 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.064 -179.5 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.9 Cg_endo -64.23 150.76 87.68 Favored 'Trans proline' 0 C--N 1.313 -1.309 0 O-C-N 123.519 1.273 . . . . 0.0 110.026 -179.824 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.479 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.95 88.84 0.62 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.137 -0.977 . . . . 0.0 111.374 -178.477 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.514 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.14 67.18 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.349 -0.845 . . . . 0.0 111.26 179.146 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.03 13.75 21.29 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.708 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.36 156.16 45.17 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.063 -1.257 . . . . 0.0 109.366 179.738 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.501 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.47 106.97 15.57 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.918 -1.114 . . . . 0.0 109.279 179.74 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.898 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.47 114.11 21.83 Favored Pre-proline 0 C--N 1.3 -1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 110.384 -179.307 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.881 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.7 Cg_endo -70.67 129.98 17.49 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 N-CA-C 107.024 -1.952 . . . . 0.0 107.024 176.364 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.862 HD11 HD12 ' A' ' 58' ' ' LEU . 15.7 mt -56.62 -17.49 8.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.939 -1.101 . . . . 0.0 110.744 -177.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.477 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -60.86 -16.19 38.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.817 -1.177 . . . . 0.0 110.347 179.503 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.1 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -93.77 -25.35 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.003 -1.061 . . . . 0.0 111.15 -179.348 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.1 HG23 HG23 ' A' ' 32' ' ' VAL . 46.0 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.002 -1.061 . . . . 0.0 110.472 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.03 147.86 24.79 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.256 -0.902 . . . . 0.0 110.429 179.898 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.36 -5.63 38.49 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.95 -145.62 7.11 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.198 -1.477 . . . . 0.0 110.44 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.1 mtt85 -108.53 132.67 53.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.415 -1.05 . . . . 0.0 110.264 -179.696 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -140.71 150.56 43.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.023 -1.048 . . . . 0.0 111.031 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.591 HD12 ' O ' ' A' ' 82' ' ' VAL . 62.1 tp -110.98 114.29 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.447 -0.783 . . . . 0.0 109.947 179.565 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.919 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.2 mt -98.75 127.15 51.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.131 -0.981 . . . . 0.0 109.493 179.689 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.403 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 6.9 m-85 -95.44 124.01 39.26 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.172 -0.955 . . . . 0.0 110.143 -179.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.76 21.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.202 -0.936 . . . . 0.0 110.494 -179.688 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.514 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.2 p80 -107.02 -1.41 22.17 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.352 -0.843 . . . . 0.0 110.073 179.03 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.91 136.8 42.6 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.1 -1.0 . . . . 0.0 110.465 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.469 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.72 -38.27 70.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.466 -0.771 . . . . 0.0 110.663 -179.848 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.86 -35.6 73.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.333 -0.854 . . . . 0.0 110.453 -179.636 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.43 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.68 -35.83 65.24 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.79 -179.958 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.904 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 76.3 m -61.2 -34.01 74.4 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.415 -0.803 . . . . 0.0 109.757 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.7 -50.17 53.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 110.245 -179.841 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.32 -43.5 64.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.288 -0.882 . . . . 0.0 110.065 179.79 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.694 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -57.12 -42.51 81.03 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.602 -0.686 . . . . 0.0 111.248 -178.994 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.03 -51.09 42.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.796 -1.19 . . . . 0.0 110.013 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.24 -34.62 68.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.272 -0.893 . . . . 0.0 109.25 179.462 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.587 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.81 -46.39 84.74 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.274 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.9 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.78 -43.35 94.43 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.39 -0.819 . . . . 0.0 110.999 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.4 t -56.11 -34.14 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.966 -1.084 . . . . 0.0 109.375 179.617 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.51 -34.46 60.82 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.297 -0.877 . . . . 0.0 110.315 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.862 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.35 -25.84 62.56 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.285 -0.884 . . . . 0.0 109.699 179.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.2 7.86 8.18 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.633 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.622 ' CD1' HD22 ' A' ' 30' ' ' LEU . 47.0 mt -108.47 143.48 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.254 -1.145 . . . . 0.0 110.119 -179.756 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.638 ' ND2' HD11 ' A' ' 74' ' ' ILE . 16.7 t30 -89.25 106.53 18.5 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.168 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.656 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.48 145.21 45.45 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.977 -1.089 . . . . 0.0 111.629 -177.244 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.893 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.95 39.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.066 -0.653 . . . . 0.0 109.454 179.719 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.904 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.2 122.52 47.09 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.017 -1.073 . . . . 0.0 109.585 178.818 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.475 ' CD1' HD12 ' A' ' 69' ' ' LEU . 0.4 OUTLIER -109.52 131.35 55.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.262 -0.899 . . . . 0.0 110.809 -179.534 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.907 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.24 178.32 5.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.563 -0.711 . . . . 0.0 109.905 179.644 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.55 125.52 20.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.045 -1.035 . . . . 0.0 110.814 -179.366 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.83 40.93 13.44 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.743 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.907 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.38 157.02 26.89 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -1.14 . . . . 0.0 110.322 -179.831 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.884 ' N ' HD13 ' A' ' 69' ' ' LEU . 21.8 m-20 -98.48 149.33 22.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.281 -0.887 . . . . 0.0 110.571 -179.378 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.618 ' O ' HG23 ' A' ' 71' ' ' VAL . 31.5 m -62.33 111.36 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.036 . . . . 0.0 109.311 179.123 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.72 ' O ' HG23 ' A' ' 74' ' ' ILE . 43.8 m -134.31 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.52 -0.737 . . . . 0.0 110.368 -179.415 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.909 HG13 HG22 ' A' ' 82' ' ' VAL . 76.9 t -46.47 131.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.489 -0.757 . . . . 0.0 110.685 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.721 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.3 pp -137.75 91.61 13.55 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.166 -0.958 . . . . 0.0 110.659 179.408 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.487 ' HA ' HG11 ' A' ' 80' ' ' VAL . 49.7 Cg_endo -89.32 44.9 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.608 1.32 . . . . 0.0 109.947 178.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -124.38 -21.94 4.81 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.285 -0.884 . . . . 0.0 111.255 -179.097 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.6 m-20 -139.8 150.12 44.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.941 -1.099 . . . . 0.0 110.855 -179.385 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 51.79 -177.78 0.08 OUTLIER Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.66 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -94.55 112.31 24.07 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.342 -1.093 . . . . 0.0 109.954 179.848 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.721 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -116.39 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 CA-C-O 121.899 0.857 . . . . 0.0 110.199 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.613 HG22 HG22 ' A' ' 60' ' ' ILE . 10.1 m -111.91 123.35 67.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.159 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.909 HG22 HG13 ' A' ' 73' ' ' VAL . 33.2 t -96.62 118.11 42.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.061 -1.025 . . . . 0.0 110.612 -178.062 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.919 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.2 m -111.75 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 118.93 -1.108 . . . . 0.0 108.756 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.434 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -131.44 156.46 45.58 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 120.69 -1.256 . . . . 0.0 110.339 -178.606 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.551 HG23 ' OD2' ' A' ' 86' ' ' ASP . 9.0 t -94.07 -30.46 14.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.367 -0.833 . . . . 0.0 111.471 -178.583 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.551 ' OD2' HG23 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.56 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 120.931 -1.106 . . . . 0.0 111.529 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.616 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.79 -39.95 12.76 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.958 -1.089 . . . . 0.0 110.163 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.9 tp -64.59 -40.34 95.35 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.213 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.475 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 45.09 26.79 0.25 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.864 -0.523 . . . . 0.0 111.219 179.378 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.595 HG21 ' NE ' ' A' ' 121' ' ' ARG . 63.8 p 43.41 -133.45 0.56 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.551 -0.718 . . . . 0.0 110.988 179.616 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.87 -78.07 0.79 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.675 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -95.52 18.34 12.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.275 -1.133 . . . . 0.0 109.812 179.27 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.496 HG23 ' N ' ' A' ' 94' ' ' GLY . 13.3 t -98.88 -148.55 0.34 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.363 -0.836 . . . . 0.0 110.199 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.496 ' N ' HG23 ' A' ' 93' ' ' THR . . . 115.12 18.57 6.25 Favored Glycine 0 N--CA 1.491 2.3 0 C-N-CA 119.835 -1.174 . . . . 0.0 110.171 179.462 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -125.32 59.62 1.25 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.945 -1.326 . . . . 0.0 110.344 179.761 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.48 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 25.2 m-85 -120.22 135.55 54.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.04 -1.037 . . . . 0.0 110.381 179.868 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.508 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.14 -27.75 57.15 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.556 179.22 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.514 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.0 p -160.38 163.0 33.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.29 -0.881 . . . . 0.0 110.54 179.501 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.415 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.82 115.9 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.228 -0.92 . . . . 0.0 110.336 179.66 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.823 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -93.44 114.63 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.6 161.31 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.09 -1.006 . . . . 0.0 111.829 -178.151 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.26 9.09 38.28 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.946 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.421 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 52.35 23.18 2.32 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.194 -0.941 . . . . 0.0 110.97 179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.649 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -144.25 137.94 27.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 110.657 179.584 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.403 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.7 p -111.09 121.91 46.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.369 -0.832 . . . . 0.0 109.495 179.622 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 55.06 -141.61 0.85 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.096 -1.003 . . . . 0.0 109.426 -179.344 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.25 9.6 57.19 Favored Glycine 0 N--CA 1.49 2.288 0 C-N-CA 119.813 -1.185 . . . . 0.0 110.234 179.776 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.403 ' O ' ' N ' ' A' ' 105' ' ' SER . 11.3 mmtt -126.16 155.47 73.62 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 120.857 -1.378 . . . . 0.0 109.868 -179.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.649 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.9 Cg_endo -67.48 160.7 46.68 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 O-C-N 123.505 1.266 . . . . 0.0 110.519 179.912 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.468 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER -68.12 147.6 52.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.356 -0.84 . . . . 0.0 110.722 -179.473 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.414 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -84.96 161.0 19.96 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.154 -0.966 . . . . 0.0 110.085 179.605 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.417 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.26 -57.45 2.98 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.517 -0.74 . . . . 0.0 112.433 -178.531 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.474 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.2 m -68.6 -29.39 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 120.688 -1.257 . . . . 0.0 111.847 -178.143 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.468 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.21 -56.23 7.07 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.039 -1.038 . . . . 0.0 110.545 -179.263 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.476 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.7 ptm180 -70.43 -35.15 73.22 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.377 -0.929 . . . . 0.0 108.873 179.073 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.474 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.9 m -58.98 -49.55 77.47 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.04 -1.037 . . . . 0.0 108.371 178.637 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.78 -35.85 64.98 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.394 -0.816 . . . . 0.0 109.863 178.704 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.476 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.69 -44.54 64.05 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.08 -1.013 . . . . 0.0 110.934 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.54 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 17.2 ttm180 -53.12 -41.82 65.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.896 -1.127 . . . . 0.0 109.713 179.587 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.37 63.28 0.26 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.595 ' NE ' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -132.57 -42.71 0.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.449 -1.03 . . . . 0.0 108.658 179.152 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.486 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.9 t -98.17 144.05 28.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.653 -0.654 . . . . 0.0 109.576 179.148 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.24 9.25 36.85 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.692 -1.242 . . . . 0.0 110.32 179.35 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.447 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 2.9 mmt180 -66.29 87.5 0.11 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.99 -1.3 . . . . 0.0 109.52 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.74 23.27 28.65 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -178.772 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.478 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.43 -179.81 0.3 Allowed Pre-proline 0 N--CA 1.492 1.646 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.7 Cg_endo -88.93 105.97 0.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 O-C-N 123.09 1.047 . . . . 0.0 110.882 -179.939 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.486 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.64 179.47 53.47 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.892 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.51 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.468 -1.019 . . . . 0.0 108.951 179.033 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.447 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 11.7 t80 -129.71 115.83 17.9 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.897 -1.121 . . . . 0.0 111.063 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.783 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 1.7 mtt180 -100.58 134.33 43.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.515 -0.74 . . . . 0.0 109.029 179.366 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.4 p90 -126.28 156.73 39.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.931 -1.105 . . . . 0.0 110.582 -179.456 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.651 HG22 HD23 ' A' ' 15' ' ' LEU . 55.9 t -94.28 -46.02 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.287 -0.883 . . . . 0.0 109.9 179.561 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.42 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -119.79 103.77 45.45 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.207 -0.933 . . . . 0.0 110.279 -179.79 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.39 -21.37 22.97 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 O-C-N 123.542 1.285 . . . . 0.0 110.711 -179.733 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -117.45 140.54 15.81 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 -179.966 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -69.56 -29.33 66.88 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.267 -1.137 . . . . 0.0 110.282 179.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.231 179.878 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.37 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.8 108.09 4.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -1.131 . . . . 0.0 110.259 -179.984 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.666 ' O ' HG23 ' A' ' 3' ' ' VAL . 31.3 m -113.37 105.22 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.973 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.7 p -63.22 144.89 56.54 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.328 -0.858 . . . . 0.0 110.32 -179.846 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.462 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -70.39 147.23 94.98 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.3 -0.875 . . . . 0.0 110.248 -179.885 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD2' HG23 ' A' ' 5' ' ' VAL . 52.1 Cg_endo -76.4 -173.61 1.78 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 124.203 1.633 . . . . 0.0 110.962 179.609 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 3.9 p80 -177.97 83.66 0.23 Allowed Pre-proline 0 N--CA 1.489 1.499 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.325 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.85 58.54 1.61 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 O-C-N 123.446 1.235 . . . . 0.0 111.6 -178.989 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -148.59 7.98 0.77 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.095 -1.003 . . . . 0.0 111.18 179.475 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.711 HD11 ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.08 137.39 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.832 -1.168 . . . . 0.0 110.62 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.6 128.43 34.51 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 108.866 178.312 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -89.53 142.68 27.45 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.055 -1.028 . . . . 0.0 110.62 -179.007 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.45 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.2 t -137.73 158.02 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.418 -0.802 . . . . 0.0 110.434 -179.694 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.88 109.41 17.58 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.442 -0.786 . . . . 0.0 109.56 179.104 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.732 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.1 tp -53.5 136.85 37.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.279 -0.888 . . . . 0.0 109.964 -179.878 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.1 p -137.38 174.49 10.54 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 110.285 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.8 p -71.63 80.09 0.82 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.196 -0.94 . . . . 0.0 110.067 179.856 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.826 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.8 m -155.53 109.05 2.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.176 -0.953 . . . . 0.0 110.799 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.416 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.33 -170.22 29.6 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.833 -1.651 . . . . 0.0 110.942 179.136 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.22 -20.39 12.34 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.755 -0.85 . . . . 0.0 110.417 -179.792 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -98.85 103.88 21.95 Favored Pre-proline 0 N--CA 1.491 1.592 0 C-N-CA 118.906 -1.118 . . . . 0.0 109.86 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.4 Cg_endo -62.63 124.96 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 O-C-N 123.32 1.168 . . . . 0.0 110.84 -179.369 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.426 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.49 -166.85 1.13 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.737 -0.602 . . . . 0.0 110.433 -179.239 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.527 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.17 81.77 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.465 -0.772 . . . . 0.0 111.514 -179.451 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.1 2.25 52.27 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.607 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.732 ' HB2' HD23 ' A' ' 15' ' ' LEU . 15.1 mmtp -130.18 156.3 44.81 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.973 -1.31 . . . . 0.0 109.355 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.826 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.69 107.43 18.44 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.961 -1.087 . . . . 0.0 109.078 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 1.007 HD11 HG21 ' A' ' 100' ' ' ILE . 5.2 mt -69.33 112.92 13.42 Favored Pre-proline 0 C--N 1.3 -1.586 0 O-C-N 121.312 -0.867 . . . . 0.0 110.521 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.745 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.1 Cg_endo -68.54 129.62 19.28 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 N-CA-C 107.161 -1.9 . . . . 0.0 107.161 176.282 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.746 HD22 ' CD1' ' A' ' 60' ' ' ILE . 10.9 mt -56.27 -17.78 8.61 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.83 -1.169 . . . . 0.0 110.69 -177.803 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -59.88 -16.05 26.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.677 -1.265 . . . . 0.0 110.575 179.898 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.131 HG23 HG23 ' A' ' 33' ' ' ILE . 10.6 m -93.99 -25.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.982 -1.074 . . . . 0.0 110.775 -179.727 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.131 HG23 HG23 ' A' ' 32' ' ' VAL . 12.3 pt -114.62 -23.27 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.094 -1.004 . . . . 0.0 110.57 -179.508 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.578 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptm -93.81 147.96 22.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.803 -1.185 . . . . 0.0 110.2 179.381 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.77 -3.42 52.85 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.799 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.64 -150.63 8.64 Favored Glycine 0 N--CA 1.494 2.533 0 C-N-CA 118.927 -1.606 . . . . 0.0 110.626 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.451 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.42 129.41 55.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.435 -1.038 . . . . 0.0 109.968 -179.793 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.536 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.1 m-70 -137.8 149.42 46.35 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.982 -1.074 . . . . 0.0 110.963 -179.635 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.656 HD23 ' HG2' ' A' ' 121' ' ' ARG . 34.1 tp -110.82 117.27 32.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.419 -0.8 . . . . 0.0 110.21 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.943 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.1 mm -97.92 125.42 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.293 -0.88 . . . . 0.0 109.471 179.792 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.429 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.67 123.38 42.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.093 -1.004 . . . . 0.0 109.882 179.725 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.21 159.39 22.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.545 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.527 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.56 23.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.161 179.373 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.35 141.12 51.52 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.11 -0.994 . . . . 0.0 110.382 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.445 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.63 -31.82 67.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.478 -0.764 . . . . 0.0 110.58 -179.762 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.47 75.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.183 -0.948 . . . . 0.0 110.54 -179.861 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.434 ' HE2' ' CE1' ' A' ' 24' ' ' TYR . 0.2 OUTLIER -73.83 -34.26 64.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.304 -0.873 . . . . 0.0 109.622 179.803 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.707 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 62.7 m -60.52 -35.05 75.04 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.398 -0.814 . . . . 0.0 109.177 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.56 -49.06 65.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 110.304 179.681 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.437 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.56 -43.16 66.84 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.165 -0.959 . . . . 0.0 110.778 -179.615 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 1.028 HD12 HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.46 73.92 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.248 -0.907 . . . . 0.0 110.909 -179.057 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.462 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.74 -51.37 12.83 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.974 -1.079 . . . . 0.0 110.281 -179.782 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.43 99.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.025 -1.047 . . . . 0.0 109.696 179.636 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.568 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.42 -47.41 81.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.422 -0.799 . . . . 0.0 109.468 179.649 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.78 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.89 -43.02 76.83 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.604 -0.685 . . . . 0.0 110.365 -179.975 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.38 -34.6 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.084 -1.01 . . . . 0.0 109.217 179.614 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.0 59.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.316 -0.865 . . . . 0.0 109.74 179.271 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.568 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.7 mm? -71.52 -26.36 62.63 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-O 121.924 0.869 . . . . 0.0 109.575 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.15 6.3 10.03 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.746 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.8 mt -108.1 143.67 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.293 -1.122 . . . . 0.0 110.104 -179.776 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 21.0 t30 -87.89 106.56 18.19 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 177.953 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.644 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.33 144.26 46.0 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.086 -1.045 . . . . 0.0 111.397 -177.288 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.878 HG21 ' HA ' ' A' ' 73' ' ' VAL . 2.5 t -131.03 142.63 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.807 179.551 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.707 ' HB2' ' O ' ' A' ' 48' ' ' CYS . . . -105.84 118.33 36.31 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.102 -1.039 . . . . 0.0 109.81 178.984 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.7 OUTLIER -105.27 118.43 36.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.857 . . . . 0.0 110.706 -179.43 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.909 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -149.69 -179.88 7.46 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 179.32 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.66 129.37 40.79 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.069 -1.019 . . . . 0.0 110.687 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.96 23.68 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.909 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.22 154.71 30.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.321 -1.105 . . . . 0.0 110.014 -179.765 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.844 ' N ' HD13 ' A' ' 69' ' ' LEU . 23.9 m-20 -94.9 149.78 20.89 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.338 -0.851 . . . . 0.0 110.39 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.674 ' O ' HG23 ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 118.934 -1.107 . . . . 0.0 108.99 179.338 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.509 ' O ' HG23 ' A' ' 74' ' ' ILE . 36.7 m -133.09 -33.51 1.14 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.485 -0.759 . . . . 0.0 110.708 -179.234 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.878 ' HA ' HG21 ' A' ' 63' ' ' VAL . 89.6 t -56.49 134.67 20.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.154 -0.966 . . . . 0.0 109.782 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.577 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -137.61 93.61 12.37 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.194 -0.941 . . . . 0.0 110.696 179.873 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -79.63 60.95 8.03 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.784 1.412 . . . . 0.0 110.236 179.436 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.0 t -162.75 40.25 0.11 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.039 -1.038 . . . . 0.0 110.52 -179.743 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -141.53 -163.48 1.57 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.204 -0.935 . . . . 0.0 109.82 179.891 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.37 -73.93 0.31 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -152.26 111.75 3.93 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.156 -1.202 . . . . 0.0 110.313 179.654 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.526 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.6 134.22 61.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-O 122.052 0.929 . . . . 0.0 110.351 179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.626 HG22 HG22 ' A' ' 60' ' ' ILE . 8.0 m -113.16 124.55 69.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.249 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.009 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.758 HG22 HG13 ' A' ' 73' ' ' VAL . 8.8 t -97.7 118.78 44.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.019 -1.051 . . . . 0.0 110.778 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.028 HG11 HD12 ' A' ' 51' ' ' LEU . 4.1 m -111.87 98.54 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 120.78 -1.2 . . . . 0.0 108.81 179.135 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.92 29.24 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 120.626 -1.296 . . . . 0.0 110.077 -178.813 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -103.36 -24.73 13.47 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 111.296 -178.544 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.425 ' O ' ' N ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 179.92 -29.37 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.996 -1.065 . . . . 0.0 111.059 -179.943 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.95 -38.98 24.58 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.013 -1.055 . . . . 0.0 110.278 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.9 tp -63.6 -29.85 71.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.135 -0.978 . . . . 0.0 108.705 178.552 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.502 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 44.19 27.31 0.2 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.754 -0.591 . . . . 0.0 111.426 179.578 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.541 HG21 ' HD3' ' A' ' 121' ' ' ARG . 60.8 p 42.06 52.59 4.35 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.785 -0.572 . . . . 0.0 111.423 179.304 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.53 -66.44 2.29 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -179.834 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -110.15 22.96 14.94 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.246 -1.149 . . . . 0.0 110.269 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.535 HG21 ' CB ' ' A' ' 90' ' ' THR . 14.6 t -78.81 -148.42 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.344 -0.847 . . . . 0.0 110.143 179.974 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.428 ' N ' HG23 ' A' ' 93' ' ' THR . . . 103.54 -43.14 1.73 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.344 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -86.75 66.63 9.54 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.914 -1.345 . . . . 0.0 110.838 -179.354 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.503 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.2 m-85 -119.7 150.67 39.98 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.953 -1.092 . . . . 0.0 110.265 179.284 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.458 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.6 m-20 -76.86 -31.92 57.15 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.459 -0.776 . . . . 0.0 109.898 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.61 163.97 26.92 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.256 -0.977 . . . . 0.0 111.788 -179.876 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.698 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.98 113.77 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.504 -0.748 . . . . 0.0 110.069 179.064 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 1.007 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -92.74 116.16 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.093 -1.004 . . . . 0.0 108.387 178.863 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.05 31.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.083 -1.011 . . . . 0.0 112.039 -177.895 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.479 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.5 t -95.77 -1.04 50.56 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 177.84 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.403 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 54.89 20.92 3.34 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -0.974 . . . . 0.0 111.168 179.737 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.425 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -143.17 140.54 30.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.974 -1.079 . . . . 0.0 110.659 179.669 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.406 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.5 p -114.32 127.72 56.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.319 -0.863 . . . . 0.0 109.918 179.561 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.0 t0 51.42 30.12 5.9 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.274 -0.891 . . . . 0.0 110.552 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.12 -33.0 5.5 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.406 ' O ' ' N ' ' A' ' 105' ' ' SER . 7.3 mtmt -76.66 156.53 82.88 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.277 -1.131 . . . . 0.0 109.998 179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.425 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.4 Cg_endo -65.7 133.27 33.51 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.657 1.346 . . . . 0.0 110.339 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.402 ' OE1' ' ND2' ' A' ' 103' ' ' ASN . 5.7 pt20 -47.94 167.02 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.426 -0.796 . . . . 0.0 110.942 -179.301 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.513 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -98.1 160.81 14.06 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.43 -0.794 . . . . 0.0 110.141 179.741 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.51 -50.67 7.06 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.522 -0.736 . . . . 0.0 112.298 -178.681 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.513 HG22 ' OD1' ' A' ' 111' ' ' ASP . 16.2 m -71.25 -29.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 120.699 -1.251 . . . . 0.0 111.446 -178.564 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.418 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.32 -56.01 7.67 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.059 -1.026 . . . . 0.0 110.449 -179.375 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.469 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.17 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.401 -0.92 . . . . 0.0 108.888 178.683 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.468 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 119.495 -0.882 . . . . 0.0 108.698 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.42 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.27 66.42 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.608 -0.683 . . . . 0.0 109.528 178.984 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.469 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 21.3 mtt85 -68.42 -44.97 73.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.164 -0.96 . . . . 0.0 110.499 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.491 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -59.94 -46.45 89.36 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.23 -0.919 . . . . 0.0 110.332 -179.99 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.0 -26.37 1.2 Allowed Glycine 0 N--CA 1.499 2.85 0 O-C-N 121.474 -0.766 . . . . 0.0 111.396 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.656 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -48.83 -55.39 11.76 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.882 -1.363 . . . . 0.0 110.858 -179.394 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.711 ' O ' HD11 ' A' ' 10' ' ' ILE . 1.3 t -91.62 142.59 27.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.166 -0.959 . . . . 0.0 109.51 179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.66 12.54 16.4 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.303 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 6.2 mtt180 -102.47 76.56 1.55 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.953 -1.322 . . . . 0.0 109.951 -179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.671 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.44 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -145.14 167.11 15.38 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.58 -0.953 . . . . 0.0 108.79 179.779 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.95 111.98 1.71 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.202 1.106 . . . . 0.0 109.637 179.582 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.493 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -87.24 166.16 36.44 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -178.854 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 98' ' ' SER . 2.7 mt -124.3 141.79 43.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.514 -0.992 . . . . 0.0 108.54 178.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.698 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.59 115.44 19.5 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.927 179.827 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.45 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.35 121.82 45.34 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.536 -0.728 . . . . 0.0 109.183 179.276 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.403 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 24.5 p90 -119.52 157.75 27.69 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -0.987 . . . . 0.0 109.991 -179.694 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.7 t -85.92 -42.47 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.189 -0.944 . . . . 0.0 110.005 179.751 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.71 155.1 55.01 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.168 -0.957 . . . . 0.0 110.503 -179.714 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -77.06 -57.32 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.369 0 O-C-N 123.713 1.375 . . . . 0.0 110.542 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 162.64 74.41 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.913 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -78.55 81.35 4.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.221 -1.164 . . . . 0.0 110.306 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 51.8 ttt180 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.274 -179.988 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 39.2 m -87.96 150.69 23.3 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.237 -1.155 . . . . 0.0 110.339 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.529 ' O ' HG23 ' A' ' 3' ' ' VAL . 17.3 m -113.2 104.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 109.831 179.57 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.454 HG23 ' HB1' ' A' ' 112' ' ' ALA . 16.8 p -68.87 138.5 54.76 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.341 -0.85 . . . . 0.0 110.343 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.442 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.17 147.81 98.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.498 179.69 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.442 ' HD2' HG23 ' A' ' 5' ' ' VAL . 45.7 Cg_endo -71.5 -169.3 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 O-C-N 124.082 1.569 . . . . 0.0 111.083 179.793 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.518 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.43 77.62 0.04 OUTLIER Pre-proline 0 N--CA 1.498 1.948 0 O-C-N 121.564 -0.71 . . . . 0.0 109.682 -179.901 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -70.47 -10.64 28.42 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 O-C-N 123.695 1.366 . . . . 0.0 111.178 -179.437 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.4 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 41.6 m-80 -74.91 -11.3 60.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.934 -1.104 . . . . 0.0 110.449 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.659 HG12 HG23 ' A' ' 122' ' ' THR . 1.9 mt -112.8 135.49 52.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.03 -1.044 . . . . 0.0 109.811 179.898 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.94 125.14 33.13 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.256 -0.902 . . . . 0.0 108.741 178.311 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.2 mt-10 -89.33 129.53 35.85 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.031 -1.043 . . . . 0.0 110.276 -179.245 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.625 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 12.0 t -125.35 157.88 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.472 -0.767 . . . . 0.0 110.42 -179.193 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.46 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.46 114.15 27.07 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.292 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.677 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -52.21 143.87 13.67 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.231 -0.918 . . . . 0.0 109.878 179.961 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.8 p -142.06 -178.2 5.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.196 -0.94 . . . . 0.0 110.226 -179.663 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.4 p -80.33 59.16 3.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.302 -0.873 . . . . 0.0 110.097 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.454 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 23.8 m -132.75 109.22 9.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.436 -0.79 . . . . 0.0 110.597 -179.829 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.414 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.35 -171.63 28.73 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 118.81 -1.662 . . . . 0.0 111.139 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.7 -22.82 10.04 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.703 -0.88 . . . . 0.0 110.473 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.893 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.8 tt -93.48 109.5 41.01 Favored Pre-proline 0 N--CA 1.49 1.538 0 C-N-CA 118.749 -1.18 . . . . 0.0 109.226 -179.923 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.14 145.54 93.73 Favored 'Trans proline' 0 C--N 1.312 -1.354 0 O-C-N 123.423 1.223 . . . . 0.0 111.491 -178.284 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.438 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.83 -165.12 1.68 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.624 -0.673 . . . . 0.0 110.403 -179.311 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.523 ' CD2' ' HB3' ' A' ' 102' ' ' CYS . 38.3 m-85 -60.65 79.76 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.507 -0.745 . . . . 0.0 110.688 -179.879 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.99 57.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.485 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.677 ' HB2' HD23 ' A' ' 15' ' ' LEU . 1.3 mmtp -130.19 156.08 45.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.027 -1.278 . . . . 0.0 109.547 179.955 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.454 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.08 106.91 16.11 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.989 -1.069 . . . . 0.0 109.054 179.38 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.893 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.32 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 110.819 -179.173 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.799 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.4 Cg_endo -70.31 130.57 18.88 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 N-CA-C 106.668 -2.089 . . . . 0.0 106.668 175.869 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.736 HD11 HD12 ' A' ' 58' ' ' LEU . 14.3 mt -55.99 -17.98 8.16 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.809 -1.182 . . . . 0.0 110.581 -177.784 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -59.35 -16.49 22.85 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.525 -1.359 . . . . 0.0 110.515 179.729 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.02 HG23 HG23 ' A' ' 33' ' ' ILE . 13.4 m -92.73 -24.33 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.002 -1.061 . . . . 0.0 111.038 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.02 HG23 HG23 ' A' ' 32' ' ' VAL . 37.9 pt -117.45 -26.28 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.921 -1.112 . . . . 0.0 110.358 -179.413 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.621 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -90.32 148.79 22.64 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.057 -1.027 . . . . 0.0 110.058 179.057 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.457 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.81 -4.86 25.92 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.577 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.5 -130.95 2.18 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 119.214 -1.469 . . . . 0.0 110.268 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.2 mtt-85 -115.59 131.0 57.07 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.33 -1.1 . . . . 0.0 110.234 -179.69 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.57 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 74.4 m-70 -140.83 146.4 37.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.111 -0.993 . . . . 0.0 110.879 -179.762 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.517 HD22 ' HG2' ' A' ' 121' ' ' ARG . 20.4 tp -106.79 127.59 53.53 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.534 -0.729 . . . . 0.0 109.942 179.593 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.916 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.1 mt -109.76 128.22 66.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.293 -0.879 . . . . 0.0 109.515 179.388 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -95.09 124.11 38.95 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 109.99 -179.754 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.56 159.9 21.44 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.347 -0.845 . . . . 0.0 110.739 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.52 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.5 OUTLIER -106.81 3.1 26.07 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.492 -0.755 . . . . 0.0 110.206 179.26 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.0 p -136.7 136.74 39.28 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.957 -1.089 . . . . 0.0 110.834 -179.661 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.483 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.91 -36.98 70.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.551 -0.718 . . . . 0.0 110.628 179.907 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.29 -33.67 76.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.416 -179.738 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.54 -35.51 65.53 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.51 -0.744 . . . . 0.0 109.712 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.784 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 93.1 m -61.11 -36.06 78.68 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.357 -0.839 . . . . 0.0 109.418 179.498 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.54 -49.95 60.92 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.197 -0.939 . . . . 0.0 110.519 -179.945 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.407 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.4 mm-40 -72.22 -44.81 62.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.209 -0.932 . . . . 0.0 110.267 179.828 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.634 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -56.79 -43.57 81.04 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.661 . . . . 0.0 111.154 -179.12 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.455 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -67.72 -51.16 52.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.872 -1.142 . . . . 0.0 109.821 179.894 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -35.5 69.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.195 -0.941 . . . . 0.0 109.27 179.323 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.668 ' HD3' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.22 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.475 -0.765 . . . . 0.0 108.978 179.235 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.867 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.15 -41.95 84.86 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 110.794 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.5 t -56.15 -32.87 35.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.07 -1.019 . . . . 0.0 109.156 179.664 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.79 -33.38 60.15 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.392 -0.818 . . . . 0.0 110.491 179.68 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.736 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.31 -25.44 62.42 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.146 -0.971 . . . . 0.0 109.918 -179.929 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.78 4.61 9.51 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.329 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.668 ' CD1' HD22 ' A' ' 30' ' ' LEU . 44.7 mt -105.71 143.37 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 121.376 -1.073 . . . . 0.0 109.845 -179.729 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.556 HD22 HG23 ' A' ' 80' ' ' VAL . 1.9 t30 -88.58 106.99 18.67 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 106.679 -1.6 . . . . 0.0 106.679 178.173 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.572 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.57 146.31 44.69 Favored 'General case' 0 C--N 1.294 -1.812 0 C-N-CA 118.706 -1.197 . . . . 0.0 111.728 -177.084 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.928 HG21 ' HA ' ' A' ' 73' ' ' VAL . 89.8 t -128.2 149.75 33.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.468 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.784 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.29 117.74 30.83 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.549 178.412 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.5 142.36 45.16 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.337 -0.852 . . . . 0.0 110.354 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.886 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.9 p90 -175.32 -177.27 1.01 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.399 -0.813 . . . . 0.0 110.034 179.888 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.52 119.8 5.76 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.176 -0.952 . . . . 0.0 111.234 -179.232 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 40.97 11.8 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.13 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.886 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -117.59 155.37 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.052 -1.264 . . . . 0.0 110.223 179.853 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.813 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -93.56 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.282 -0.886 . . . . 0.0 110.416 -179.541 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.656 ' O ' HG23 ' A' ' 71' ' ' VAL . 28.2 m -62.55 110.61 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.21 -0.996 . . . . 0.0 109.411 179.384 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.59 -20.95 2.27 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.536 -0.728 . . . . 0.0 111.046 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.928 ' HA ' HG21 ' A' ' 63' ' ' VAL . 54.5 t -63.99 128.15 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.022 -1.049 . . . . 0.0 109.53 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.703 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.4 pp -136.33 98.31 11.39 Favored Pre-proline 0 N--CA 1.495 1.777 0 O-C-N 121.028 -1.045 . . . . 0.0 110.926 -179.647 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.682 ' HA ' HG11 ' A' ' 80' ' ' VAL . 50.7 Cg_endo -78.93 53.27 4.61 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.328 1.173 . . . . 0.0 110.207 179.238 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.625 HG23 ' O ' ' A' ' 75' ' ' PRO . 5.6 p -157.21 40.05 0.31 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.24 -0.913 . . . . 0.0 110.385 -179.471 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -145.21 31.67 1.11 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.171 -0.956 . . . . 0.0 110.343 -179.888 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 108.52 -116.2 4.64 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.812 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -115.86 109.48 17.69 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -1.144 . . . . 0.0 110.146 179.841 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.682 HG11 ' HA ' ' A' ' 75' ' ' PRO . 6.8 p -116.65 135.38 57.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-O 122.006 0.908 . . . . 0.0 110.721 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.612 HG22 HG22 ' A' ' 60' ' ' ILE . 9.6 m -113.2 122.81 68.05 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.611 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.702 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -97.29 118.81 44.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 120.833 -1.167 . . . . 0.0 110.5 -178.118 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.916 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.5 m -109.8 100.64 11.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.018 -1.051 . . . . 0.0 108.947 179.699 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.21 163.83 31.9 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.602 -1.311 . . . . 0.0 111.38 -177.859 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.494 HG23 ' N ' ' A' ' 86' ' ' ASP . 11.2 t -91.38 -140.76 0.17 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.423 -0.798 . . . . 0.0 109.332 179.757 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.494 ' N ' HG23 ' A' ' 85' ' ' THR . 3.8 p30 -84.43 52.12 2.28 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.806 -1.184 . . . . 0.0 110.248 179.633 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.471 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.43 -19.58 6.36 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.202 -0.936 . . . . 0.0 110.936 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -62.43 -26.97 68.78 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.012 -1.055 . . . . 0.0 109.548 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.545 ' C ' HG22 ' A' ' 90' ' ' THR . 27.4 mmt 47.25 30.82 1.55 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.372 -0.83 . . . . 0.0 110.731 179.61 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.759 ' OG1' HG22 ' A' ' 93' ' ' THR . 5.5 t 35.11 -134.98 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 178.889 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 93.1 -49.61 2.46 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 107.99 -2.044 . . . . 0.0 107.99 -178.786 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -125.27 21.01 8.05 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.632 -0.922 . . . . 0.0 109.374 179.001 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.759 HG22 ' OG1' ' A' ' 90' ' ' THR . 4.9 t -102.82 -155.49 0.53 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.326 -0.859 . . . . 0.0 110.343 -179.702 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.527 ' N ' HG23 ' A' ' 93' ' ' THR . . . 92.39 -33.94 4.7 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.467 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -84.26 59.04 5.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.939 -1.33 . . . . 0.0 110.392 -179.588 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -119.45 153.1 35.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.205 -0.934 . . . . 0.0 110.167 179.433 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.86 -29.24 25.44 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.396 -0.815 . . . . 0.0 109.513 179.393 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.4 p -161.88 163.7 29.07 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.244 -0.91 . . . . 0.0 111.161 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.492 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.53 125.85 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.389 -0.819 . . . . 0.0 110.094 179.24 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.742 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -102.86 112.15 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.231 -0.918 . . . . 0.0 109.003 179.265 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.417 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.0 t0 -118.09 162.01 18.91 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.184 -0.948 . . . . 0.0 111.869 -178.485 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.523 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.26 9.38 38.13 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.75 -0.594 . . . . 0.0 109.744 178.556 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.433 ' ND2' ' NE2' ' A' ' 110' ' ' GLN . 2.8 m-20 46.58 25.16 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.091 -1.006 . . . . 0.0 111.481 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -147.04 136.43 22.73 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 110.454 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.42 ' N ' ' O ' ' A' ' 108' ' ' LYS . 60.2 p -113.13 126.66 55.69 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.367 -0.833 . . . . 0.0 110.122 179.823 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 52.76 35.63 19.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.279 -0.888 . . . . 0.0 110.762 179.951 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 84.26 -6.02 77.89 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.004 -1.093 . . . . 0.0 110.429 179.573 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.42 ' O ' ' N ' ' A' ' 105' ' ' SER . 72.1 mmtt -100.4 156.35 35.33 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.0 -1.294 . . . . 0.0 110.076 -179.77 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -65.49 129.2 21.91 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 O-C-N 123.74 1.389 . . . . 0.0 110.497 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.433 ' NE2' ' ND2' ' A' ' 103' ' ' ASN . 13.9 pt20 -51.12 152.85 2.14 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.554 -0.716 . . . . 0.0 110.892 -179.5 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.532 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.5 p30 -93.21 161.09 14.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.384 -0.822 . . . . 0.0 109.719 179.208 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.454 ' HB1' HG23 ' A' ' 4' ' ' THR . . . -43.13 -51.75 5.78 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.375 -0.828 . . . . 0.0 112.316 -178.629 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.532 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.6 m -69.74 -29.15 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.76 -1.213 . . . . 0.0 111.382 -178.81 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.47 -56.13 7.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.122 -0.986 . . . . 0.0 110.522 -179.091 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.419 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.3 OUTLIER -68.08 -34.86 77.22 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.066 -1.021 . . . . 0.0 108.658 178.927 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.462 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.95 -49.91 75.83 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.14 -0.975 . . . . 0.0 108.427 178.623 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.8 -36.85 65.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.584 -0.697 . . . . 0.0 109.888 179.078 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.419 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 13.6 mtt180 -71.23 -44.61 65.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.163 -0.96 . . . . 0.0 110.502 -179.727 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.518 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.5 OUTLIER -58.6 -42.19 87.55 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.109 -0.994 . . . . 0.0 109.903 179.734 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.97 89.41 0.02 OUTLIER Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.517 ' HG2' HD22 ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.66 -44.06 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.55 -0.971 . . . . 0.0 108.616 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.659 HG23 HG12 ' A' ' 10' ' ' ILE . 14.6 t -102.07 132.54 47.88 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 178.663 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.44 8.18 3.67 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.015 -1.564 . . . . 0.0 110.845 179.596 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.433 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 18.0 mmt180 -85.39 82.48 8.3 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.853 -1.381 . . . . 0.0 110.269 -179.791 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.67 -52.08 0.71 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 -179.63 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.458 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.92 178.74 0.91 Allowed Pre-proline 0 C--N 1.302 -1.489 0 O-C-N 121.579 -0.954 . . . . 0.0 109.332 179.403 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.4 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.8 Cg_endo -77.53 109.53 2.79 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 123.57 1.3 . . . . 0.0 109.39 179.127 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.48 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.57 161.8 52.86 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.261 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.5 mt -119.64 142.66 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.427 -1.043 . . . . 0.0 109.389 179.491 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.492 ' CD1' HG23 ' A' ' 99' ' ' VAL . 5.5 t80 -130.34 115.47 16.96 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.18 -0.95 . . . . 0.0 110.387 179.899 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.625 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 2.0 mtt180 -103.27 133.95 47.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.432 -0.793 . . . . 0.0 109.892 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.46 ' CE1' ' HA ' ' A' ' 14' ' ' ALA . 8.2 p90 -127.12 152.44 47.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 110.205 179.984 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.402 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t -77.46 -46.89 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.183 -0.948 . . . . 0.0 109.859 179.568 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.427 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -65.69 116.38 31.34 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.365 -0.834 . . . . 0.0 110.715 -179.328 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.25 -23.77 15.19 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 O-C-N 123.531 1.28 . . . . 0.0 110.711 179.841 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.59 147.07 29.24 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.979 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -72.53 -51.49 19.7 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.146 -1.208 . . . . 0.0 110.143 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 117.91 -1.043 . . . . 0.0 110.285 179.97 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.04 153.62 22.33 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.336 -1.097 . . . . 0.0 110.308 -179.951 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.667 ' O ' HG23 ' A' ' 3' ' ' VAL . 33.8 m -113.38 104.54 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.278 -0.889 . . . . 0.0 110.037 179.678 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.691 HG22 ' OG1' ' A' ' 116' ' ' THR . 40.6 p -66.05 143.73 57.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 110.026 179.781 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.607 HG22 ' HD2' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -74.28 149.06 86.68 Favored Pre-proline 0 C--N 1.302 -1.498 0 O-C-N 121.293 -0.879 . . . . 0.0 109.566 179.673 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.528 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.6 Cg_endo -80.82 -57.95 0.03 OUTLIER 'Trans proline' 0 C--N 1.309 -1.5 0 O-C-N 124.261 1.664 . . . . 0.0 111.681 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.607 ' HD2' HG22 ' A' ' 5' ' ' VAL . 17.3 p80 38.37 83.02 0.21 Allowed Pre-proline 0 N--CA 1.491 1.624 0 CA-C-O 121.098 0.475 . . . . 0.0 111.781 -178.796 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.22 58.11 2.88 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.375 1.198 . . . . 0.0 110.876 -179.938 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 -114.22 -28.02 7.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.178 -0.951 . . . . 0.0 109.433 179.315 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.608 HD12 ' HG2' ' A' ' 119' ' ' ARG . 28.4 mt -102.09 136.68 33.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.116 -0.99 . . . . 0.0 109.772 179.452 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.11 34.99 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.132 -0.98 . . . . 0.0 109.576 179.838 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.93 121.54 31.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.237 -0.915 . . . . 0.0 110.206 -179.291 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.537 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 10.8 t -116.45 157.16 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.432 -0.793 . . . . 0.0 110.113 -179.521 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.86 111.29 23.89 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.165 -0.959 . . . . 0.0 109.91 179.483 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.686 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.9 tp -55.65 139.62 44.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.318 -0.864 . . . . 0.0 109.935 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.72 3.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 110.34 -179.825 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.56 84.38 7.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.17 -0.957 . . . . 0.0 109.867 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.785 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 25.2 m -158.99 109.78 2.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.186 -0.946 . . . . 0.0 110.906 -179.482 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.419 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.32 -174.47 29.71 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 118.797 -1.668 . . . . 0.0 111.212 178.922 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.02 -19.57 13.46 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.834 -0.803 . . . . 0.0 110.284 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.863 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.3 tt -98.26 106.31 34.56 Favored Pre-proline 0 N--CA 1.489 1.516 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.443 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -62.91 123.38 12.16 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 O-C-N 123.347 1.182 . . . . 0.0 110.776 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.0 t80 -111.5 -167.81 1.23 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.686 -0.634 . . . . 0.0 110.336 -179.185 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.8 m-85 -58.93 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.479 -0.763 . . . . 0.0 111.117 -179.595 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.73 3.83 56.14 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 179.831 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.686 ' CB ' HD23 ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.43 44.28 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.019 -1.283 . . . . 0.0 109.224 179.733 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.785 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.21 106.49 17.02 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.971 -1.08 . . . . 0.0 108.546 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.863 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -69.8 113.44 17.38 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.337 -0.852 . . . . 0.0 110.52 -178.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.787 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -69.75 130.77 19.94 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 N-CA-C 107.159 -1.9 . . . . 0.0 107.159 176.347 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.666 HD11 HD12 ' A' ' 58' ' ' LEU . 10.5 mt -56.74 -16.43 6.43 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.802 -1.186 . . . . 0.0 110.521 -178.313 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.435 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.05 -16.14 49.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.555 -1.341 . . . . 0.0 110.532 179.516 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.042 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -93.39 -25.77 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 120.935 -1.103 . . . . 0.0 111.125 -179.313 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.042 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -115.98 -26.04 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.003 -1.061 . . . . 0.0 109.954 -179.658 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.21 147.99 22.67 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.224 -0.923 . . . . 0.0 110.435 179.945 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.22 -4.77 41.19 Favored Glycine 0 N--CA 1.484 1.872 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.352 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.63 -149.44 9.32 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.185 -1.483 . . . . 0.0 110.376 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.65 129.95 54.47 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.336 -1.097 . . . . 0.0 110.323 -179.621 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.544 ' HB2' HG12 ' A' ' 81' ' ' VAL . 70.2 m80 -138.43 153.59 48.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.067 -1.02 . . . . 0.0 111.087 -179.508 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.639 HD12 ' O ' ' A' ' 82' ' ' VAL . 24.9 tp -113.23 114.05 26.19 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.41 -0.806 . . . . 0.0 109.81 179.613 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.96 HD12 ' CG1' ' A' ' 83' ' ' VAL . 38.6 mt -97.14 126.75 49.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.28 -0.887 . . . . 0.0 109.539 179.427 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.465 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 10.5 m-85 -95.0 123.73 38.65 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.402 -0.811 . . . . 0.0 110.196 -179.797 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.2 -0.938 . . . . 0.0 110.885 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.499 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.7 p80 -104.42 -5.47 21.63 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.365 -0.834 . . . . 0.0 110.128 179.148 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.63 137.4 53.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.094 -1.004 . . . . 0.0 110.637 -179.741 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.52 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.8 -43.28 65.91 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.677 -0.64 . . . . 0.0 110.679 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.17 -36.94 81.18 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.266 -0.896 . . . . 0.0 110.71 -179.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.68 -35.38 78.74 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.37 -0.831 . . . . 0.0 109.485 -179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.869 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.3 m -61.45 -34.84 76.11 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.439 -0.788 . . . . 0.0 109.385 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.61 -49.02 74.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 110.459 179.86 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.76 -40.38 69.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.228 -0.92 . . . . 0.0 110.494 -179.734 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.742 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -57.11 -39.96 76.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.47 -0.769 . . . . 0.0 110.958 -179.354 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.43 -51.36 13.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 110.377 -179.784 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.32 -41.21 93.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.096 -1.002 . . . . 0.0 109.517 179.619 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.553 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.67 -46.88 83.69 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.423 -0.798 . . . . 0.0 109.664 179.47 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.815 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.17 -43.32 78.25 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.552 -0.718 . . . . 0.0 110.326 179.931 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.3 t -55.7 -33.16 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.04 -1.037 . . . . 0.0 109.166 179.611 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.9 60.85 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.272 -0.892 . . . . 0.0 109.79 179.088 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.666 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -72.05 -26.2 62.09 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.312 -0.867 . . . . 0.0 109.703 179.634 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.46 9.51 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.343 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.62 HD11 ' HB2' ' A' ' 34' ' ' LYS . 48.6 mt -108.3 143.09 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.308 -1.113 . . . . 0.0 110.239 -179.626 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.572 ' ND2' HD11 ' A' ' 74' ' ' ILE . 17.0 t30 -86.69 106.66 17.79 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 178.232 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.66 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.84 144.59 48.28 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.506 -177.432 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.974 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.7 t -134.56 145.1 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.79 128.79 55.2 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.976 -1.09 . . . . 0.0 109.996 179.308 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.474 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.1 53.19 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 110.376 -179.839 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.937 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.4 p90 -170.57 174.62 4.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.473 -0.767 . . . . 0.0 109.655 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.78 120.84 5.68 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 110.766 -179.179 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.27 34.36 14.65 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.531 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.949 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -116.97 156.24 27.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.134 -1.215 . . . . 0.0 110.021 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.949 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.0 m-20 -93.96 148.32 22.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.186 -0.946 . . . . 0.0 110.91 -179.189 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.648 ' O ' HG23 ' A' ' 71' ' ' VAL . 27.8 m -63.26 111.45 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.188 -0.945 . . . . 0.0 109.343 178.884 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.454 ' O ' HG23 ' A' ' 74' ' ' ILE . 5.4 m -134.76 -33.18 0.96 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.419 -0.801 . . . . 0.0 110.921 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.974 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.8 t -53.96 140.1 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.109 -0.995 . . . . 0.0 110.308 -179.418 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.572 HD11 ' ND2' ' A' ' 61' ' ' ASN . 0.9 OUTLIER -137.8 91.79 13.33 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.3 -0.875 . . . . 0.0 110.832 179.814 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -86.73 55.51 3.29 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 O-C-N 123.616 1.324 . . . . 0.0 109.763 179.046 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -129.72 -24.69 2.68 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.207 -0.933 . . . . 0.0 111.547 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -154.39 158.57 40.23 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.842 -1.161 . . . . 0.0 110.894 -179.519 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 59.1 162.33 0.07 OUTLIER Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -80.47 102.92 9.98 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.141 -1.211 . . . . 0.0 109.791 179.704 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.55 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -110.98 134.47 53.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-O 121.928 0.87 . . . . 0.0 110.042 -179.779 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 6.3 m -112.04 125.9 69.38 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.397 -0.814 . . . . 0.0 109.248 179.495 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.721 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.8 t -97.57 116.14 39.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 O-C-N 121.117 -0.99 . . . . 0.0 110.12 -178.303 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.96 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.4 m -110.65 100.21 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.048 -1.032 . . . . 0.0 108.763 179.723 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.474 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.16 33.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 120.545 -1.347 . . . . 0.0 111.552 -177.891 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.534 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -86.9 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.595 -0.691 . . . . 0.0 109.412 179.6 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.534 ' N ' HG23 ' A' ' 85' ' ' THR . 9.9 p-10 -90.1 42.87 1.12 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.693 -1.255 . . . . 0.0 110.484 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.443 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.96 -26.04 8.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.122 -0.987 . . . . 0.0 110.351 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -76.28 -30.08 57.66 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.089 -1.007 . . . . 0.0 109.977 179.538 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.403 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 5.7 mmt 50.87 -115.49 0.87 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.344 -0.847 . . . . 0.0 109.737 -179.767 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.664 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.05 42.94 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.962 0 O-C-N 120.54 -1.35 . . . . 0.0 110.022 179.806 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -67.27 -29.86 74.81 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.789 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.425 ' CD1' ' N ' ' A' ' 92' ' ' PHE . 36.3 p90 -137.8 21.19 2.87 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.379 -1.071 . . . . 0.0 110.661 -179.742 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.664 HG22 ' OG1' ' A' ' 90' ' ' THR . 0.6 OUTLIER -100.91 -162.39 0.94 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.103 -0.998 . . . . 0.0 110.281 -179.831 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.621 ' N ' HG23 ' A' ' 93' ' ' THR . . . 118.94 11.97 7.34 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.956 -1.116 . . . . 0.0 110.315 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -124.9 65.6 1.11 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.714 -1.462 . . . . 0.0 110.448 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.474 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 51.0 m-85 -119.79 152.85 36.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.08 -1.012 . . . . 0.0 110.507 179.636 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.19 17.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.504 -0.747 . . . . 0.0 109.356 179.213 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.439 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.8 p -160.82 163.04 32.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.421 -0.799 . . . . 0.0 110.294 179.779 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.456 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.36 122.67 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.066 -1.021 . . . . 0.0 110.421 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.827 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.7 mp -97.99 112.68 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.429 -0.795 . . . . 0.0 109.121 179.266 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.419 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 5.2 t0 -121.01 160.74 22.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.114 -0.991 . . . . 0.0 111.589 -178.72 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.446 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.66 5.55 43.82 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.688 -0.633 . . . . 0.0 109.47 178.114 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.417 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 49.21 24.44 0.98 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 111.064 179.986 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -145.41 127.1 15.23 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.081 -1.012 . . . . 0.0 110.316 179.55 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 108' ' ' LYS . 96.2 p -107.66 130.95 54.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.305 -0.872 . . . . 0.0 110.167 179.964 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 25.2 t70 53.79 26.67 6.24 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.184 -0.947 . . . . 0.0 110.131 -179.889 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.8 -33.11 5.38 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.416 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.2 OUTLIER -78.07 157.26 78.81 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.291 -1.123 . . . . 0.0 110.089 179.946 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -62.69 128.69 24.03 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 O-C-N 123.649 1.342 . . . . 0.0 110.304 -179.586 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -46.55 146.69 1.41 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.648 -0.657 . . . . 0.0 111.253 -179.193 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.528 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -77.4 160.57 28.65 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.429 -0.794 . . . . 0.0 110.174 179.85 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.406 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.62 -52.83 12.78 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.348 -0.845 . . . . 0.0 112.058 -178.794 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.528 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.51 -28.95 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 120.838 -1.164 . . . . 0.0 111.466 -178.583 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.429 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.05 -56.47 6.43 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.071 -1.018 . . . . 0.0 110.593 -179.289 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.439 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.7 OUTLIER -68.95 -34.61 75.63 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.231 -0.918 . . . . 0.0 108.723 178.961 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.691 ' OG1' HG22 ' A' ' 4' ' ' THR . 41.0 m -59.61 -49.98 75.65 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.174 -0.954 . . . . 0.0 108.482 178.781 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.72 -36.25 65.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.464 -0.772 . . . . 0.0 109.9 178.926 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.439 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.1 mtt180 -71.22 -44.58 65.09 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.179 -0.951 . . . . 0.0 110.723 -179.585 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.608 ' HG2' HD12 ' A' ' 10' ' ' ILE . 14.1 ttm180 -56.15 -43.38 78.23 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.912 -1.117 . . . . 0.0 110.415 -179.757 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.69 79.55 0.06 OUTLIER Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.478 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -152.08 -43.96 0.11 Allowed 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.296 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.519 HG22 HD13 ' A' ' 10' ' ' ILE . 8.8 t -100.27 144.06 29.73 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.297 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.69 14.63 46.13 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.192 -1.48 . . . . 0.0 110.444 179.425 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.421 ' HD3' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -58.67 -31.79 68.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.127 -1.219 . . . . 0.0 110.032 -179.916 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.89 20.75 4.03 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.333 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.494 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -165.46 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.427 -1.043 . . . . 0.0 108.506 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.494 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 50.2 Cg_endo -85.32 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 122.85 0.921 . . . . 0.0 110.607 179.365 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.503 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.53 176.61 50.25 Favored Glycine 0 N--CA 1.497 2.759 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 -179.906 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.439 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mt -131.35 142.87 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.466 -1.02 . . . . 0.0 109.075 179.296 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.476 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 18.6 t80 -131.3 116.03 17.06 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.034 -1.041 . . . . 0.0 110.934 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.537 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.9 mtt180 -101.83 134.86 44.35 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.536 -0.727 . . . . 0.0 109.461 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.449 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.91 148.93 50.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.055 -1.028 . . . . 0.0 110.042 -179.79 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.442 HG22 HD23 ' A' ' 15' ' ' LEU . 54.4 t -73.22 -37.72 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.188 -0.945 . . . . 0.0 109.902 179.75 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.417 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -132.18 143.62 49.69 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.168 -0.958 . . . . 0.0 110.298 -179.799 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -73.59 -50.23 0.19 Allowed 'Trans proline' 0 C--N 1.312 -1.373 0 O-C-N 123.685 1.361 . . . . 0.0 110.251 179.939 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.46 -54.46 0.65 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -90.98 -55.79 3.42 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -1.147 . . . . 0.0 110.258 -179.914 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 23.7 mtt180 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.133 179.971 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.2 p -94.64 109.97 21.84 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.251 -1.146 . . . . 0.0 110.31 -179.778 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.624 ' O ' HG13 ' A' ' 3' ' ' VAL . 7.6 p -113.29 104.05 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.192 -0.942 . . . . 0.0 110.018 179.609 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.508 HG22 ' OG1' ' A' ' 116' ' ' THR . 17.3 p -63.85 145.19 56.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.367 -0.833 . . . . 0.0 110.256 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.411 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.99 146.42 98.21 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.269 -0.895 . . . . 0.0 110.173 -179.9 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.411 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.6 Cg_endo -70.83 -175.86 1.57 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 124.163 1.612 . . . . 0.0 111.05 179.291 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.525 ' CE1' ' HG3' ' A' ' 119' ' ' ARG . 1.7 p80 -176.55 84.25 0.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.746 -0.596 . . . . 0.0 109.601 179.02 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -66.99 83.21 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.529 0 O-C-N 123.658 1.346 . . . . 0.0 110.604 -179.723 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.3 m-80 -172.74 -37.05 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.647 -0.658 . . . . 0.0 109.736 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.839 HG12 HG23 ' A' ' 122' ' ' THR . 20.8 mt -95.15 128.19 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.542 179.428 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.12 128.14 34.37 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.263 -0.898 . . . . 0.0 108.951 178.868 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.3 134.67 33.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.109 -0.994 . . . . 0.0 110.128 -179.303 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.548 HG11 ' HE ' ' A' ' 131' ' ' ARG . 5.5 t -128.66 157.73 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.396 -0.815 . . . . 0.0 110.183 -179.02 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.43 113.79 27.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.356 -0.84 . . . . 0.0 110.068 179.718 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.746 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.78 143.97 19.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 110.027 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.42 170.17 16.41 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.977 . . . . 0.0 110.397 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.86 81.59 1.18 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.201 -0.937 . . . . 0.0 109.754 179.651 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.829 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.4 m -158.31 111.44 2.39 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.872 -179.502 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.416 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.27 -170.39 30.24 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.139 179.079 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.75 -19.08 12.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.787 -0.831 . . . . 0.0 110.0 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.894 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -99.92 104.05 26.18 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.931 -1.108 . . . . 0.0 109.833 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.16 125.92 16.8 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.231 1.122 . . . . 0.0 111.008 -179.18 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.0 t80 -112.93 -169.57 1.51 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.738 -0.601 . . . . 0.0 110.352 -179.499 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.524 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.0 m-85 -59.46 82.3 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.269 -0.894 . . . . 0.0 111.377 -179.433 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.19 61.69 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.627 179.274 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.746 ' CB ' HD23 ' A' ' 15' ' ' LEU . 26.6 mmtt -129.86 156.54 44.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.884 -1.362 . . . . 0.0 109.638 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.829 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.34 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.98 -1.075 . . . . 0.0 108.993 179.56 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.894 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.4 mt -70.28 113.17 15.95 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.375 -0.828 . . . . 0.0 110.729 -179.122 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.72 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.4 Cg_endo -69.63 130.77 20.09 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 N-CA-C 106.849 -2.02 . . . . 0.0 106.849 175.754 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.577 HD11 HD12 ' A' ' 58' ' ' LEU . 9.7 mt -55.99 -18.68 9.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.784 -1.198 . . . . 0.0 110.507 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.433 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.01 15.93 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.861 -1.149 . . . . 0.0 110.589 179.728 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.024 HG23 HG23 ' A' ' 33' ' ' ILE . 9.6 m -93.96 -25.3 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.926 -1.109 . . . . 0.0 110.951 -179.735 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.024 HG23 HG23 ' A' ' 32' ' ' VAL . 27.1 pt -117.95 -14.86 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.934 -1.104 . . . . 0.0 110.958 -179.552 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.557 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.64 148.06 24.2 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.849 -1.157 . . . . 0.0 110.383 179.683 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.7 -4.4 50.17 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.629 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.01 7.23 Favored Glycine 0 N--CA 1.492 2.393 0 C-N-CA 118.989 -1.577 . . . . 0.0 110.589 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.05 132.54 54.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -1.018 . . . . 0.0 110.213 -179.602 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -139.93 150.46 44.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.197 -0.939 . . . . 0.0 110.863 -179.759 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.645 HD12 ' O ' ' A' ' 82' ' ' VAL . 51.3 tp -110.99 115.26 29.17 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.466 -0.771 . . . . 0.0 109.996 179.836 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.944 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.4 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.231 -0.918 . . . . 0.0 109.041 179.503 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.55 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.76 37.98 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.866 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.63 159.36 23.06 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.363 -0.836 . . . . 0.0 110.422 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.524 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.59 20.31 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.388 -0.82 . . . . 0.0 110.024 179.069 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.2 p -132.8 139.21 47.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.124 -0.985 . . . . 0.0 110.456 179.894 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.42 ' HE3' ' CE1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.57 -34.09 71.81 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.464 -0.773 . . . . 0.0 110.465 -179.932 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.46 -34.14 76.22 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.249 -0.907 . . . . 0.0 110.333 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.457 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.09 -36.34 64.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.206 -0.934 . . . . 0.0 109.636 179.818 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.805 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 64.9 m -60.98 -39.2 88.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.563 -0.71 . . . . 0.0 109.469 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.52 -46.59 87.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.235 -0.915 . . . . 0.0 110.035 179.699 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.439 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.43 -45.47 62.59 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.395 -0.815 . . . . 0.0 110.454 -179.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 1.05 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.36 -45.07 80.66 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.36 -0.838 . . . . 0.0 111.149 -178.997 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.47 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.75 -51.57 22.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.001 -1.062 . . . . 0.0 110.366 -179.467 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.16 99.33 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 109.762 179.813 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.548 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.54 -46.81 86.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.24 -0.912 . . . . 0.0 109.606 179.591 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.847 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.2 -43.52 78.56 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.636 -0.665 . . . . 0.0 110.147 179.86 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.2 t -55.48 -32.67 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.21 -0.931 . . . . 0.0 109.029 179.7 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.56 -31.05 59.89 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.251 -0.906 . . . . 0.0 109.832 179.071 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.577 HD12 HD11 ' A' ' 30' ' ' LEU . 3.9 mm? -72.19 -26.36 62.03 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.864 0.84 . . . . 0.0 109.837 179.844 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.9 4.58 10.29 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.16 -1.576 . . . . 0.0 109.16 -179.113 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.557 HD11 ' HB2' ' A' ' 34' ' ' LYS . 28.1 mt -105.48 143.34 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.352 -1.087 . . . . 0.0 110.096 -179.748 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.771 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.7 t-20 -88.06 106.07 17.91 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 178.031 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.713 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.288 -177.502 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.924 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.33 139.55 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.806 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.805 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -101.26 122.77 44.27 Favored 'General case' 0 C--N 1.301 -1.532 0 C-N-CA 119.086 -1.046 . . . . 0.0 109.214 178.758 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.496 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.1 134.88 54.78 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.313 -0.867 . . . . 0.0 111.153 -178.925 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.896 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -168.89 170.65 8.95 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.574 -0.704 . . . . 0.0 109.641 179.506 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.67 118.3 3.27 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.242 -0.912 . . . . 0.0 110.845 -179.439 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.82 37.35 6.44 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.969 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.896 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.42 30.03 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.259 -1.142 . . . . 0.0 110.168 -179.724 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.848 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.3 m-20 -91.84 149.58 21.51 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.36 -0.837 . . . . 0.0 110.596 -179.48 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.68 ' O ' HG23 ' A' ' 71' ' ' VAL . 34.7 m -62.15 110.88 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 119.128 -1.029 . . . . 0.0 109.426 179.326 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.715 ' O ' HG23 ' A' ' 74' ' ' ILE . 19.7 m -133.19 -39.33 0.93 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.447 -0.783 . . . . 0.0 110.233 -179.656 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.924 ' HA ' HG21 ' A' ' 63' ' ' VAL . 79.0 t -47.61 133.09 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.42 -0.8 . . . . 0.0 109.993 179.822 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.771 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.0 OUTLIER -136.08 99.09 11.27 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.138 -0.976 . . . . 0.0 110.842 -179.51 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -84.45 48.04 2.34 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 O-C-N 123.788 1.415 . . . . 0.0 109.981 179.056 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.6 p -148.11 40.36 0.96 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.259 -0.901 . . . . 0.0 110.372 -179.218 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.405 ' HB2' HD12 ' A' ' 74' ' ' ILE . 4.0 m120 -143.74 -165.46 2.11 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.109 -0.994 . . . . 0.0 110.298 -179.794 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.42 ' O ' ' NH1' ' A' ' 37' ' ' ARG . . . -50.33 -77.04 0.14 Allowed Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 36.9 m-20 -147.94 113.41 5.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.186 -1.185 . . . . 0.0 110.39 179.957 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.644 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.75 134.0 62.73 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 CA-C-O 122.095 0.95 . . . . 0.0 110.05 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.546 HG22 HG22 ' A' ' 60' ' ' ILE . 16.8 m -113.24 122.71 67.89 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.466 -0.771 . . . . 0.0 108.984 179.348 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.998 HG11 HD13 ' A' ' 88' ' ' LEU . 12.2 t -96.95 118.59 43.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.723 -1.235 . . . . 0.0 111.106 -177.686 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.05 HG11 HD12 ' A' ' 51' ' ' LEU . 4.3 m -108.7 99.68 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.034 -1.041 . . . . 0.0 108.852 178.838 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.496 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -135.79 155.93 49.59 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.446 -1.409 . . . . 0.0 110.912 -178.488 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.517 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.17 -42.43 15.98 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.369 -0.832 . . . . 0.0 110.385 -179.5 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.517 ' N ' HG23 ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.22 32.54 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.69 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -103.16 -30.99 10.35 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.009 . . . . 0.0 110.067 -179.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.998 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -69.61 -16.13 63.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 110.067 179.415 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.427 ' HA ' ' CE ' ' A' ' 89' ' ' MET . 16.8 mmt 53.25 -165.07 0.08 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.311 -0.868 . . . . 0.0 109.894 -179.636 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.486 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 0.7 OUTLIER -136.47 30.13 2.93 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.193 -0.942 . . . . 0.0 110.042 179.939 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.4 -42.04 94.09 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.979 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -121.29 14.94 11.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.218 -1.166 . . . . 0.0 110.667 -179.825 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.486 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 6.6 t -80.39 -157.62 0.16 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.062 -1.024 . . . . 0.0 110.174 -179.731 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.425 ' N ' HG23 ' A' ' 93' ' ' THR . . . 102.76 -32.87 7.08 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.306 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.83 56.76 3.8 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.133 -1.216 . . . . 0.0 110.478 -179.528 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.484 ' CE2' ' HB2' ' A' ' 39' ' ' LEU . 16.9 m-85 -119.9 149.75 41.6 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.103 -0.998 . . . . 0.0 110.078 179.399 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.424 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.85 -31.54 25.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.812 . . . . 0.0 109.619 179.554 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.5 p -162.26 163.43 28.15 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.417 -0.913 . . . . 0.0 111.466 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.47 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.68 117.74 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.455 -0.778 . . . . 0.0 109.614 178.798 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.878 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -97.59 117.18 41.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.224 -0.923 . . . . 0.0 109.456 179.876 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.429 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.8 t0 -129.84 161.32 31.04 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.107 -0.995 . . . . 0.0 111.634 -178.716 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.436 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 52.8 t -92.03 -7.41 48.87 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.641 -0.662 . . . . 0.0 109.534 178.017 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.2 13.44 1.66 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.255 -0.903 . . . . 0.0 111.87 179.704 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.447 HG23 ' O ' ' A' ' 108' ' ' LYS . 1.5 m -143.83 121.72 12.01 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 120.725 -1.234 . . . . 0.0 109.39 -179.888 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.447 ' N ' ' O ' ' A' ' 108' ' ' LYS . 12.5 p -98.85 132.85 43.88 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.184 -0.947 . . . . 0.0 110.416 -179.879 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 t0 51.08 30.24 5.33 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.293 -0.879 . . . . 0.0 110.604 179.866 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.91 -28.81 8.76 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.447 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -80.89 155.43 72.95 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.024 -1.28 . . . . 0.0 109.99 179.824 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -66.12 136.78 45.63 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.598 1.315 . . . . 0.0 110.666 -179.786 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -49.99 154.87 1.01 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.52 -0.737 . . . . 0.0 110.794 -179.588 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.515 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -80.88 159.06 25.12 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.272 -0.892 . . . . 0.0 109.84 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -46.63 -50.92 16.88 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.282 -0.886 . . . . 0.0 111.893 -178.787 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.41 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.792 -1.193 . . . . 0.0 111.444 -178.727 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.423 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.27 -56.6 6.47 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.987 -1.071 . . . . 0.0 110.426 -179.131 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.422 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.73 -35.03 76.61 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.264 -0.898 . . . . 0.0 108.918 178.718 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.508 ' OG1' HG22 ' A' ' 4' ' ' THR . 25.2 m -59.9 -46.69 88.53 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 178.709 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.61 -40.43 63.82 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.671 -0.643 . . . . 0.0 109.767 178.905 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -69.65 -44.23 70.99 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.273 -0.892 . . . . 0.0 110.344 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.525 ' HG3' ' CE1' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -56.54 -43.74 80.16 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.362 -0.836 . . . . 0.0 110.004 179.678 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.01 0.11 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.682 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.457 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.77 -46.41 0.13 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.563 -0.963 . . . . 0.0 108.76 179.622 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.839 HG23 HG12 ' A' ' 10' ' ' ILE . 15.3 t -97.19 141.89 29.77 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.26 17.17 3.34 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.594 179.787 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.499 ' N ' ' CD ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.15 81.71 6.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.889 -1.359 . . . . 0.0 109.986 -179.731 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.52 -52.08 0.71 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.477 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.96 176.61 1.49 Allowed Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 121.765 -0.844 . . . . 0.0 109.123 179.308 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.6 Cg_endo -73.21 112.89 3.64 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 N-CA-C 108.806 -1.267 . . . . 0.0 108.806 178.484 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.473 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.01 177.87 41.45 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -178.927 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.2 mt -135.23 142.8 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.239 -1.154 . . . . 0.0 109.652 179.502 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.47 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.87 114.5 19.29 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.051 178.721 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.548 ' HE ' HG11 ' A' ' 13' ' ' VAL . 3.8 mtt85 -105.97 122.77 46.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.515 -0.741 . . . . 0.0 109.297 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 11.0 p90 -122.94 157.81 31.8 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.058 -1.026 . . . . 0.0 110.464 -179.576 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.444 HG22 HD23 ' A' ' 15' ' ' LEU . 37.8 t -77.15 -40.9 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.751 179.555 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -131.37 144.04 51.77 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.317 -0.864 . . . . 0.0 110.07 179.886 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -75.45 -55.7 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.531 1.279 . . . . 0.0 110.612 -179.785 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 124.67 -91.35 0.42 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 54.03 68.12 0.9 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.244 -1.15 . . . . 0.0 110.161 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.173 179.949 . . . . . . . . 1 1 . 1 stop_ save_